"","Rank","NCT.ID","Title","Recruitment","Study.Results","Conditions","Interventions","Sponsors","Gender","Age.Groups","Phases","Enrollment","Funded.Bys","Study.Types","Study.Designs","Other.IDs","First.Received","Start.Date","Completion.Date","Last.Updated","Last.Verified","Acronym","Primary.Completion.Date","Outcome.Measures","URL","study.location"
"104",104,"NCT00097500","Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide|Drug: Insulin glargine","Amylin Pharmaceuticals, Inc.|Eli Lilly and Company","Both","Adult|Senior","Phase III",69,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2993-114","November 24, 2004","01/09/2004",2009-12-01,"December 24, 2010","01/12/2010","",2009-12-01,"Beta-cell Function After 52 Weeks of Therapy|Beta-cell Function 4 Weeks After Cessation of Therapy|Change in First Phase C-peptide Release|Change in Second Phase C-peptide Release|Change in Glycosylated Hemoglobin (HbA1c)|Change in Fasting Plasma Glucose|Seven Point Self Monitored Blood Glucose (SMBG) Measurements|Change in Body Weight|M-value at Baseline, Week 52 and Week 56","http://ClinicalTrials.gov/show/NCT00097500",NA
"154",154,"NCT00184600","Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: biphasic insulin aspart|Drug: insulin detemir|Drug: insulin aspart","Novo Nordisk","Both","Adult|Senior","Phase III",708,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NN304-1613","September 13, 2005","01/11/2004",2009-08-01,"July 16, 2010","01/07/2010","4T",2009-08-01,"Proportion of subjects who achieve HbA1c below or equal to 6.5% without hypoglycaemia|Efficacy and durability of the insulin regimens|Adverse events|Body weight|Quality of Life|Blood glucose|Hypoglycaemia","http://ClinicalTrials.gov/show/NCT00184600",NA
"183",183,"NCT00234000","Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes","Drug: arsenic trioxide|Drug: azacitidine","University of California, Los Angeles|National Cancer Institute (NCI)|Cell Therapeutics|Celgene Corporation","Both","Adult|Senior","Phase I|Phase II",78,"Other|NIH|Industry","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000442931|P30CA016042|UCLA-0408087","October 5, 2005","01/02/2007",2009-02-01,"September 24, 2010","01/09/2010","",2009-02-01,"Safety and tolerability as assessed by NCI CTCAE v3.0 (Phase I)|Transfusion independence (Phase II)|Improvement in peripheral blood counts (Phase II)|Complete or partial remission (Phase II)|Hematologic-platelet and hematologic-neutrophil response|Time to disease progression|Overall and progression-free survival|Cytogenetic response","http://ClinicalTrials.gov/show/NCT00234000",NA
"203",203,"NCT00265200","Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small Cell Lung|Carcinoma, Small Cell Lung|Metastases","Drug: zoledronic acid","James Graham Brown Cancer Center|University of Louisville|Novartis Pharmaceuticals","Both","Adult|Senior","Phase II",28,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","565.04|BCC-LUN-04-002","December 12, 2005","01/02/2005",2009-06-01,"January 11, 2010","01/01/2010","",2009-06-01,"Blood specimens to measure TRAP level|Brief Pain Questionnaire to evaluate subject's pain|Bone imaging tests (bone scan, PET scan, MRI, and/or x-ray) will be done to measure progression of bone metastasis","http://ClinicalTrials.gov/show/NCT00265200",NA
"227",227,"NCT00299000","A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI","Completed","Has Results","Mucopolysaccharidosis VI|Maroteaux-Lamy Syndrome","Drug: Naglazyme","BioMarin Pharmaceutical","Both","Child","Phase IV",4,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","ASB-008","March 2, 2006","01/05/2006",2009-04-01,"September 28, 2010","01/09/2010","",2009-04-01,"Change in Height|Change in Weight|Change in Haed Circumference|Change in Urinary Glycosaminoglycan Levels","http://ClinicalTrials.gov/show/NCT00299000",NA
"241",241,"NCT00262600","Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate","Completed","No Results Available","Atrial Fibrillation|Cerebrovascular Accident","Drug: Dabigatran etex|Drug: Warfarin","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",18115,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention","1160.26|2005-003894-26","December 6, 2005","01/11/2005",NA,"September 1, 2010","01/09/2010","",2009-04-01,"Incidence of stroke (including hemorrhagic) and systemic embolism|Incidence of stroke (including hemorrhagic), systemic embolism, all death Incidence of stroke (including hemorrhagic), systemic embolism, pulmonary embolism, acute myocardial infarction, or vascular deaths (including deaths from bleeding)","http://ClinicalTrials.gov/show/NCT00262600",NA
"284",284,"NCT00386100","A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Metformin 2000 mg (ttd)|Drug: Metformin 500 mg (ttd)|Drug: Avandamet 2 mg/500 mg (ttd)|Drug: Avandamet 8 mg/ 2000 mg (ttd)|Drug: Avandamet 6 mg/1500 mg (ttd)|Drug: Avandamet 4 mg/1000 mg (ttd)|Drug: Metformin 1000 mg (ttd)|Drug: Metformin 1500 mg (ttd)","GlaxoSmithKline","Both","Adult|Senior","Phase IV",688,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AVT105913","October 9, 2006","01/10/2006",2009-09-01,"June 3, 2010","01/06/2010","",2009-09-01,"Percentage change in BMD, as measured by DXA, from baseline to 80 weeks at the lumbar spine (L1-L4) (Bone sub-study)|Mean change in HbA1c from baseline to week 80|Change in adiponectin and C-reactive protein from baseline to week 56 and week 80. Change in total cholesterol, LDL-cholesterol, non-HDL-cholesterol, HDL-cholesterol and triglycerides from baseline to week 80.|Percentage change in BMD at the total hip, femoral neck, trochanter, distal radius, and total body after 80 weeks of treatment (Bone sub-study)|Percentage change in BMD at the lumbar spine (L1-L4), total hip, femoral neck, trochanter, distal radius, and total body over time (Bone sub-study)|Change in biochemical markers of bone turnover at weeks 20, 56 and 80 (Bone sub-study)|Change in estradiol at weeks 20, 56 and 80 (Bone sub-study)|Changes in markers of calcium homeostasis markers at week 80 (Bone sub-study)|Mean change in FPG from baseline to week 80.Change from baseline in HbA1c and FPG by visit (over time).Proportion of subjects achieving recommended glycemic targets.Evaluation of adverse events/safety and tolerability over 80 weeks of treatment.|Change in HbA1c from baseline to week 80 based on last observation carried forward (LOCF) from week 32. Proportion of subjects achieving HbA1c 6.5% and <7% at week 80.|Change in FPG from baseline to week 80. Proportion of subjects achieving FPG 100 mg/dL (5.56 mmol/L), <110mg/dL (6.1 mmol/L) and 126 mg/dL (7 mmol/L) at week 80. Change from baseline in HbA1c and FPG at each visit.|Time from randomization to treatment failure (i.e., HbA1c 7% after week 32 or withdrawal due to ITE). Change in FFA, fasting insulin, C-peptide, HOMA-S and HOMA-B from baseline to week 80 (subset of subjects).|Rate of change (i.e. slope) in -cell function as estimated by the ratio I/G over 80 weeks of treatment (subset of subjects). Proportion of subjects with HbA1c 6.5% and >6.5%, and <7% and 7% at week 32 and at week 80.","http://ClinicalTrials.gov/show/NCT00386100",NA
"299",299,"NCT00296400","Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease","Completed","Has Results","Hyperlipidemia","Drug: Rosuvastatin|Drug: Atorvastatin","AstraZeneca","Both","Adult|Senior","Phase II",237,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","D3569C00011|PLANET II","February 23, 2006","01/02/2006",2009-06-01,"November 30, 2010","01/11/2010","PLANET II",2009-06-01,"Urinary Protein/Creatinine Ratio at Week 52 [LOCF]|Urinary Protein/Creatinine Ratio at Week 26.|Urinary Albumin/Creatinine Ratio at Week 26|Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]|Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26|Change From Baseline in eGFR at Week 52 [LOCF]|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26|Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52","http://ClinicalTrials.gov/show/NCT00296400",NA
"308",308,"NCT00423800","Efficacy and Safety of 24 vs 48 Weeks of Pegetron?ó (Peginterferon Alfa-2b + Ribavirin) in Na??ve Genotype 1 Hepatitis C (Study P05016)(COMPLETED)","Completed","No Results Available","Hepatitis C, Chronic","Drug: Combination of pegylated interferon alfa-2b and ribavirin","Schering-Plough","Both","Adult","Phase III",212,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P05016","January 17, 2007","01/12/2006",2009-10-01,"January 27, 2010","01/01/2010","",2009-10-01,"Sustained virologic response, defined as HCV-RNA negative (below limit of detection) 24 weeks following the completion of therapy|Relapse rate, defined as the percentage of subjects with negative virology at end of treatment, but positive virology at 24 weeks of follow up post treatment.","http://ClinicalTrials.gov/show/NCT00423800",NA
"323",323,"NCT00456300","Role of Exenatide in Type 1 Diabetes","Completed","No Results Available","Type 1 Diabetes","Drug: Exenatide","Baylor College of Medicine|National Institutes of Health (NIH)","Both","Child|Adult","Phase IV",17,"Other|NIH","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","H-16488","April 3, 2007","01/03/2007",2009-03-01,"November 30, 2010","01/11/2010","",2009-03-01,"Area under the curve for glucose","http://ClinicalTrials.gov/show/NCT00456300",NA
"351",351,"NCT00504400","Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)","Completed","No Results Available","Type 2 Idiopathic Macular Telangiectasia","Drug: Intravitreal injection ranibizumab","University Hospital, Bonn|Novartis","Both","Adult|Senior","Phase II",10,"Other|Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRFB002ADE04|EudraCT number 2006-006233-40","July 18, 2007","01/08/2007",2009-09-01,"September 21, 2009","01/09/2009","",2009-06-01,"Best corrected visual acuity|Reading ability|Scotomas measured by means of microperimetry|Changes in retinal thickness assessed by optical coherence tomography (OCT) imaging|Changes in parafoveal leakage assessed by fluorescein angiography|Quality of life","http://ClinicalTrials.gov/show/NCT00504400",NA
"374",374,"NCT00540800","BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: docetaxel|Drug: epirubicin|Drug: capecitabine","National Cancer Institute, Naples","Female","Child|Adult|Senior","Phase III",280,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BREAST-10","October 5, 2007","01/02/2004",2009-12-01,"February 23, 2010","01/02/2010","BREAST-10",2009-09-01,"quality of life|Response rate|Toxicity|overall survival","http://ClinicalTrials.gov/show/NCT00540800",NA
"379",379,"NCT00543400","Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)","Completed","No Results Available","Coronary Artery Disease (CAD)|Percutaneous Coronary Intervention (PCI)","Drug: M118|Drug: Unfractionated Heparin","Momenta Pharmaceuticals, Inc.","Both","Adult|Senior","Phase II",503,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","MOM-M118-006|M118-006a Substudy","October 11, 2007","01/09/2007",2009-05-01,"September 30, 2009","01/09/2009","EMINENCE",2009-04-01,"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding.","http://ClinicalTrials.gov/show/NCT00543400",NA
"423",423,"NCT00625300","Repetitive Transcranial Stimulation (r-TMS) Treatment for Patients With Parkinson's Disease","Completed","No Results Available","Parkinson's Disease","Device: repetitive transcranial stimulation (r-TMS)|Device: Repetitive transcranial stimulation","Sheba Medical Center|Weizmann Institute of Science","Both","Adult|Senior","Phase II",20,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","SHEBA-08-4726-OC-CTIL","February 13, 2008","01/04/2008",2009-07-01,"October 19, 2009","01/10/2009","r-TMS",2009-07-01,"Unified Parkinson Disease Rating Scale (UPDRS)(Motor Part)|Clinical Global Impression of Severity (CGIS)","http://ClinicalTrials.gov/show/NCT00625300",NA
"424",424,"NCT00581100","Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis","Completed","Has Results","Nail Psoriasis|Plaque Psoriasis","Drug: etanercept","Wyeth","Both","Adult|Senior","Phase IV",136,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0881A6-409","December 21, 2007","01/09/2007",2009-10-01,"August 3, 2010","01/08/2010","",2009-08-01,"Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score for Target Fingernail|Change From Baseline in Overall Nail Psoriasis Severity Index (NAPSI) Score|Percent of Participants Who Achieved a 50% Improvement in the Nail Psoriasis Severity Index (NAPSI) Score for Target Fingernail at Week 12 and Week 24|Percent of Participants Who Achieved a 75% Improvement in the Nail Psoriasis Severity Index (NAPSI) Score for Target Fingernail at Week 12 and Week 24|Percent of Participants Who Achieved a 50% Improvement in the Nail Psoriasis Severity Index (NAPSI) for Overall NAPSI Score at Week 12 and Week 24|Percent of Participants Who Achieved a 75% Improvement in the Nail Psoriasis Severity Index (NAPSI) for Overall NAPSI Score at Week 12 and Week 24|Change From Baseline in the Psoriasis Area and Severity Index (PASI) Score|Percent of Participants Achieving a 50% Improvement in the Psoriasis Area and Severity Index (PASI) Score at Week 12 and Week 24|Percent of Participants Achieving a 75% Improvement in the Psoriasis Area and Severity Index (PASI) Score at Week 12 and Week 24|Change From Baseline in Physician Global Assessment (PGA) of Psoriasis|Percent of Participants Achieving a Status on the Physician Global Assessment (PGA) of Psoriasis of Clear or Almost Clear|Percent of Participants Achieving a Status on the Physician Global Assessment (PGA) of Psoriasis of Mild or Better|Change From Baseline in the Dermatology Life Quality Index (DLQI)|Change From Baseline in Physician Assessment of Nail Psoriasis Activity Visual Analog Scale (VAS)|Change From Baseline in Patient Assessment of Nail Psoriasis Activity Visual Analog Scale (VAS)|Change From Baseline in Physician Fingernail Grading Assessment Total Score","http://ClinicalTrials.gov/show/NCT00581100",NA
"431",431,"NCT00630500","Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)","Completed","No Results Available","Dementia Associated With Parkinson's Disease|Dementia With Lewy Bodies","Drug: Memantine|Drug: Placebo","Helse Stavanger HF|King's College London|Lund University","Both","Child|Adult|Senior","Phase II",75,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MEMPDD-130206","February 27, 2008","01/02/2006",2009-03-01,"July 26, 2010","01/02/2009","MEMPDD",2009-02-01,"Clinical Global Impression of Change|MMSE|Alzheimer's QUick Test|Cognitive Drug Research test|Neuropsychiatric Inventory|Unified Parkinson's Disease Rating Scale, part III|Epworth Sleep Scale|Stavanger Sleep Scale","http://ClinicalTrials.gov/show/NCT00630500",NA
"434",434,"NCT00633100","Phase II Clinical Study of E7389 for Advanced or Relapsed Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: E7389","Eisai Limited","Female","Adult|Senior","Phase II",82,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E7389-J081-221","February 4, 2008","01/01/2008",2009-09-01,"February 23, 2010","01/02/2010","",2009-09-01,"Objective response rate as measured by Response Evaluation Criteria In Solid Tumors (RECIST) criteria.|Safety profile|Duration of objective response","http://ClinicalTrials.gov/show/NCT00633100",NA
"454",454,"NCT00666900","A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris","Completed","No Results Available","Acne Vulgaris","Drug: Low Strength IDP-107|Drug: High Strength IDP-107|Drug: Placebo Comparator","Dow Pharmaceutical Sciences","Both","Child|Adult|Senior","Phase II",366,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","DPSI-IDP-107-P2-01","April 23, 2008","01/01/2008",2009-09-01,"September 15, 2010","01/09/2010","",2009-03-01,"Change from baseline in the number of inflammatory lesions|Improvement from baseline in global severity|Change from baseline in the number of non-inflammatory lesions","http://ClinicalTrials.gov/show/NCT00666900",NA
"465",465,"NCT00679900","Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties","Completed","No Results Available","Sleep Initiation and Maintenance Disorders","Drug: eplivanserin (SR46349)|Drug: lormetazepam","Sanofi-Aventis","Both","Adult|Senior","Phase III",283,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC10480|EudraCT 2007-003822-28","May 7, 2008","01/04/2008",2009-03-01,"November 29, 2010","01/11/2010","DREAMS",2009-03-01,"Sleepiness in the morning measured on a visual analog scale of the patient's sleep questionnaire|Other measure of next-day residual effects (ability to concentrate of the patient's sleep questionnaire)|Rebound effect measured by pr-WASO and pr-SOL on patient's sleep questionnaire during the run-out period|Subjective sleep parameters","http://ClinicalTrials.gov/show/NCT00679900",NA
"504",504,"NCT00738400","Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome","Completed","No Results Available","Erectile Dysfunction|Metabolic Syndrome","Drug: Levitra (Vardenafil, BAY38-9456)|Drug: Placebo","Bayer","Male","Adult","Phase IV",150,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","13171|EudraCT No: 2008-002140-41|ED-METABOLIC","August 19, 2008","01/11/2008",2009-10-01,"January 29, 2010","01/01/2010","",2009-10-01,"IIEF-EF Domain score at week 8 or LOCF compared with baseline|Percentage of subjects achieving \back to normal\"" erectile function|All diary questions other than SEP 2 and 3 that concern erectile function that were assessed over the entire treatment period|Percentage of patients who can stay on the initially provided dosage of vardenafil (10 mg PRN)""","http://ClinicalTrials.gov/show/NCT00738400",NA
"518",518,"NCT00765700","Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury","Completed","No Results Available","Sprain|Strain","Drug: ketoprofen|Drug: Placebo","Transdel Pharmaceuticals|Cato Research","Both","Adult|Senior","Phase III",364,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TDLP-110-101","October 1, 2008","01/09/2008",2009-09-01,"May 24, 2010","01/05/2010","",2009-08-01,"Assess the efficacy of ketoprofen 10% cream in subjects with acute pain associated with mild to moderate acute soft tissue injury (acute sprain or strain) of upper and lower extremities on the day 3 visit.|Assess the safety, tolerability and other parameters of ketoprofen 10% cream in subjects with acute pain associated with mild to moderate acute soft tissue injury of upper and lower extremities.","http://ClinicalTrials.gov/show/NCT00765700",NA
"521",521,"NCT00770900","Study to Evaluate the Inflammatory Cells Activity in Patients With Persistent Asthma Treated With Montelukast (0476-403)(COMPLETED)","Completed","No Results Available","Asthma","Drug: montelukast sodium|Drug: Comparator: placebo comparator","University of Brasilia","Both","Child|Adult","Phase IV",83,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2008_563|MK0476-403","October 9, 2008","01/09/2008",2009-12-01,"December 17, 2010","01/01/2010","",2009-12-01,"Verify if the quantitative parameters of the eosinophils activation and phagocyte system function show a predictive value for clinical response and prognostic.","http://ClinicalTrials.gov/show/NCT00770900",NA
"523",523,"NCT00774800","Phase II PK Study With Humalog and Humulin R With and Without rHuPH20 in T1DM","Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: Humalog, Humulin R, rHuPH20","Halozyme Therapeutics","Both","Adult","Phase II",22,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","HZ2-08-05","October 15, 2008","01/10/2008",2009-03-01,"May 7, 2009","01/05/2009","",2009-03-01,"Assess differences between PK and PD properties of two types of insulin (Humalog and Humulin R) when each product is injected SC with and without rHuPH20 following a liquid meal|Various other PK and PD endpoint measures|AEs, hematology, biochemistry, urinalyses, physical examinations, vital signs, ECGs, blood glucose, local tolerability at injection site, and antibody formation to insulin agents and to rHuPH20","http://ClinicalTrials.gov/show/NCT00774800",NA
"525",525,"NCT00778700","A Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis","Completed","No Results Available","Plaque Psoriasis","Drug: INCB018424 Phosphate Cream|Drug: Placebo Cream","Incyte Corporation","Both","Adult|Senior","Phase II",200,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","INCB 18424-203","October 21, 2008","01/10/2008",2009-04-01,"June 17, 2010","01/06/2010","",2009-04-01,"To evaluate the safety and tolerability of 3 different strengths of INCB018424 cream formulation compared with placebo when applied once daily to patients with plaque psoriasis.|Change in total lesion score of all psoriatic lesions|To evaluate the pharmacokinetics of 3 different dose strengths of INCB018424 cream formulation when applied once daily to patients with plaque psoriasis.","http://ClinicalTrials.gov/show/NCT00778700",NA
"529",529,"NCT00783900","Intravenous Administration of Metoprolol Versus Biatrial Pacing in the Prevention of Atrial Fibrillation After Cardiac Surgery","Completed","No Results Available","Atrial Fibrillation|Biatrial Pacing|Metoprolol","Other: metoprolol, biatrial pacing","Kuopio University Hospital|Oulu university hospital, Finland|Hospital Cordia, Kuopio, Finland","Both","Child|Adult|Senior","Phase IV",316,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","KUH5204006|Eudra-CT: 2008-006932-36","October 31, 2008","01/01/2007",2009-12-01,"May 27, 2010","01/05/2010","",2009-12-01,"biatriac pacing|Incidence of atrial fibrillation","http://ClinicalTrials.gov/show/NCT00783900",NA
"542",542,"NCT00802100","Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Olanzapine|Drug: Perphenazine|Drug: Aripiprazole|Behavioral: Behavioral Treatment|Drug: Metformin|Drug: Simvastatin|Drug: Benztropine","National Institute of Mental Health (NIMH)","Both","Adult","Phase IV",60,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","N01 MH090001-02|N01MH90001|DSIR AT","December 3, 2008","01/12/2008",2009-10-01,"November 13, 2009","01/11/2009","",2009-09-01,"Identification of appropriate clinical sites to mount the proposed clinical trial|Feasibility of randomizing a cohort of participants meeting the inclusion and exclusion criteria of the study|Feasibility of protocol implementation with a high level of protocol adherence and low participant attrition. The goal is for fewer than 25% of enrolled participants to be poorly adherent to the protocol interventions.|Antipsychotic efficacy, defined as completion of the trial without psychiatric hospitalization, clinician decision to discontinue treatment, or patient decision to discontinue treatment","http://ClinicalTrials.gov/show/NCT00802100",NA
"551",551,"NCT00820300","A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma","Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Latanoprost-PPDS","QLT Plug Delivery, Inc.","Both","Adult|Senior","Phase II",80,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PPL GLAU 03","January 8, 2009","01/01/2009",2009-12-01,"February 2, 2010","01/02/2010","",2009-12-01,"IOP change from baseline","http://ClinicalTrials.gov/show/NCT00820300",NA
"555",555,"NCT00825500","Staccato Loxapine in Migraine (Out Patient)","Completed","No Results Available","Migraine Headache","Drug: High dose|Drug: Low dose|Drug: Placebo","Alexza Pharmaceuticals, Inc.","Both","Adult","Phase II",366,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","AMDC-104-202|24-October-2008","January 19, 2009","01/01/2009",2009-08-01,"August 28, 2009","01/08/2009","",2009-08-01,"Pain-Relief|Pain free, Nausea, Photophobia, Phonophobia","http://ClinicalTrials.gov/show/NCT00825500",NA
"579",579,"NCT00855400","Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis","Completed","No Results Available","Amyotrophic Lateral Sclerosis","Procedure: Laminectomy and bone marrow stem cells transplantation|Procedure: Autologous bone marrow cells collection","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Carlos III Health Institute|Hospital Universitario Virgen de la Arrixaca|Hospital General Universitario Morales Meseguer|Fundaci??n Di??genes","Both","Adult","Phase I|Phase II",11,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CMN/ELA|EudraCT number: 2006-003096-12|ISCIII: EC07/90762","March 3, 2009","01/02/2007",2010-02-01,"December 1, 2010","01/12/2010","CMN/ELA",2009-10-01,"Forced vital capacity|ALS-FRS, MRC and Norris scales|Absence of adverse events","http://ClinicalTrials.gov/show/NCT00855400",NA
"588",588,"NCT00871000","Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.","Completed","No Results Available","Poliomyelitis|Diphtheria|Pertussis|Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines|Tetanus","Biological: Boostrix Polio?ºÑ 711866|Biological: Priorix Tetra TM 208136|Biological: Tetravac TM","GlaxoSmithKline","Both","Child","Phase III",303,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","111815","March 26, 2009","01/04/2009",2009-11-01,"January 6, 2011","01/01/2011","",2009-11-01,"Immunogenicity of the study vaccine antigens.|Immunogenicity of the study vaccine antigens.|Booster responses to study vaccine antigens.|Occurrence of solicited local and general symptoms.|Occurrence of unsolicited symptoms|Occurrence of serious adverse events (SAEs)","http://ClinicalTrials.gov/show/NCT00871000",NA
"593",593,"NCT00880100","Use of Ultrase MT12 in Young Cystic Fibrosis Children","Completed","No Results Available","Cystic Fibrosis|Pancreatic Insufficiency","Drug: Pancrelipase","Axcan Pharma","Both","Child","Phase III",54,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","UMT12CF08-01","April 9, 2009","01/04/2009",2009-11-01,"May 12, 2010","01/05/2010","",2009-11-01,"Proportion of subjects with control of steatorrhea under Ultrase MT12.|Stool frequency,consistency and characteristics under Ultrase MT12. Abdominal complaints under Ultrase MT12. Tolerability of Ultrase MT12.","http://ClinicalTrials.gov/show/NCT00880100",NA
"607",607,"NCT00902200","A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)","Completed","No Results Available","Elevated Intraocular Pressure","Drug: AR-12286|Drug: AR-12286 vehicle","Aerie Pharmaceuticals","Both","Adult|Senior","Phase II",80,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AR-12286-CS201","May 13, 2009","01/05/2009",2009-09-01,"November 5, 2009","01/11/2009","",2009-09-01,"The primary efficacy endpoint will be mean diurnal IOP on each day at which diurnal IOP is measured at each timepoint.","http://ClinicalTrials.gov/show/NCT00902200",NA
"663",663,"NCT00990600","QoL and Adherence to One-pill Once-a-day HAART","Completed","No Results Available","HIV Infection|HIV Infections","Other: reduced number of pills","Ospedali Riuniti di Bergamo","Both","Adult|Senior","Phase III",212,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ADONE|EUDRACT NUMBER: 2007-007839-33","October 6, 2009","01/04/2008",2009-05-01,"October 28, 2009","01/10/2009","ADONE",2009-05-01,"Proportion of adherence to HAART|QoL (VAS scale) preferences of patients virologic and immunologic outcomes","http://ClinicalTrials.gov/show/NCT00990600",NA
"692",692,"NCT01043900","Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant OCD","Completed","No Results Available","Obsessive-Compulsive Disorder","Procedure: repetitive transcranial magnetic stimulation (rTMS)","University of Sao Paulo General Hospital","Both","Adult","Phase II",30,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","cgmansur01","January 5, 2010","01/08/2003",2009-08-01,"January 6, 2010","01/09/2009","",2009-08-01,"A reduction of at least 30 % in the Yale-Brown Obsessive Compulsive Scale (YBOCS) scores and an \improved\"" or \""much improved\"" score on the Clinical Global Impression (CGI) improvement scale by the end of follow-up""","http://ClinicalTrials.gov/show/NCT01043900",NA
"783",783,"NCT01194700","Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","Completed","No Results Available","Asthma","Drug: Seretide 250(8puffs) via Evohaler actuator|Drug: Seretide 250 (8 puffs)/placebo via Volumatic spacer|Drug: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer|Drug: Seretide 250/placebo via Synchro-Breathe","University of Dundee","Both","Adult","Phase IV",19,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NAI008|2007-003627-20","September 2, 2010","01/11/2009",2009-12-01,"September 17, 2010","01/12/2009","",2009-12-01,"Overnight Urinary Cortisol creatinine ratio|Serum Potassium","http://ClinicalTrials.gov/show/NCT01194700",NA
"869",869,"NCT00006001","SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: semaxanib","University of Chicago|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068009|UCCRC-NCI-52|NCI-52","July 5, 2000","01/08/2000",NA,"February 26, 2009","01/02/2009","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00006001",NA
"907",907,"NCT00064701","Comparative Study of Modified Release (MR) Tacrolimus/MMF in de Novo Kidney Transplant Recipients","Completed","No Results Available","Kidney Transplantation","Drug: Tacrolimus Modified Release (MR)|Drug: Tacrolimus|Drug: cyclosporine microemulsion|Drug: mycophenolate mofetil","Astellas Pharma Inc","Both","Child|Adult|Senior","Phase III",668,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","02-0-158","July 10, 2003","01/06/2003",2009-04-01,"May 17, 2010","01/05/2009","",2009-04-01,"1 yr Efficacy Failure (composite endpoint defined as death, graft loss, having biopsy confirmed acute rejection or lost-to follow up)|1 year patient and graft survival rates|Incidence of biopsy confirmed acute rejection (Banff Grade ??­ 1) at 6 and 12 months, time to first acute rejection episode,|Requirement of anti-lymphocyte antibody therapy for treatment of rejection|Severity of acute rejection|Number of patients experiencing multiple rejection episodes|Number of clinically treated acute rejection episodes|Incidence of crossover for treatment failure,Evaluation of renal function.","http://ClinicalTrials.gov/show/NCT00064701",NA
"1002",1002,"NCT00219401","Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea","Completed","No Results Available","Pneumonia|Meningitis|Otitis Media","Biological: Pneumococcal 7 valent conjugate vaccine (Prevenar?ó)","Papua New Guinea Institute of Medical Research|Telethon Institute for Child Health Research|University of Western Australia","Both","Child","Phase II",313,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","071613/Z/03/Z|303123 NHMRC Australia","September 15, 2005","01/05/2005",2010-05-01,"May 11, 2010","01/05/2010","",2009-05-01,"Immunogenicity and Safety|Immunogenicity|Pneumococcal-specific acquired immunity","http://ClinicalTrials.gov/show/NCT00219401",NA
"1026",1026,"NCT00262301","Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema","Completed","No Results Available","Genetic Disorders","Drug: recombinant human C1 inhibitor","Pharming Technologies B.V.","Both","Child|Adult|Senior","Phase III",75,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C1 1304-01","December 1, 2005","01/06/2004",2009-10-01,"August 30, 2010","01/08/2010","",2009-07-01,"Time to the beginning of relief of angioedema symptoms based on VAS|Time to complete resolution of angioedema symptoms based on VAS","http://ClinicalTrials.gov/show/NCT00262301",NA
"1052",1052,"NCT00279201","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Insulin glargine|Drug: Lispro LM|Drug: Lispro Mid Mix|Drug: Lispro","Eli Lilly and Company","Both","Adult|Senior","Phase IV",2133,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10455|F3Z-US-IOOV","December 15, 2005","01/12/2005",2009-11-01,"January 15, 2010","01/01/2010","IOOV",2009-11-01,"INITIATION: Endpoint Hemoglobin A1c (HbA1c) after 6 months of starter insulin therapy with either insulin lispro low mixture [LM] twice-daily or insulin glargine.|MAINTENANCE: Duration of time that each starter insulin regimen is able to maintain HbA1c at goal.|ADDENDUM: Endpoint HbA1c after 6 months of second step intensification regimens in patients who have not achieved control during 6 months of starter insulin therapy.|INITIATION: Change in HbA1c from baseline to 24 weeks (or endpoint)|INITIATION: Percentage of patients with HbA1c < or = 7.0% and HbA1c < or = 6.5%|INITIATION: HbA1c at each visit|INITIATION: 7-point self-monitored plasma glucose (SMPG) profiles and postprandial excursions from these profiles|INITIATION: 1,5 Anhydroglucitol|INITIATION: Body weight|INITIATION: Incidence of self-reported hypoglycemic episodes|INITIATION: Insulin dose|INITIATION: Baseline and endpoint characteristics of patients who did vs. did not achieve HbA1c goal|MAINTENANCE: HbA1c at specified visits and endpoint|MAINTENANCE: 7-point SMPG profiles and postprandial excursions|MAINTENANCE: Rate of increase in HbA1c|MAINTENANCE: Percentage of patients with HbA1c < or = 7.0% and HbA1c < or = 6.5%|MAINTENANCE: Body weight|MAINTENANCE: Insulin dose|MAINTENANCE: Incidence of self-reported hypoglycemic episodes|MAINTENANCE: 1,5-Anhydroglucitol|MAINTENANCE: Change in HbA1c|MAINTENANCE: Baseline and endpoint characteristics of patients who did vs. did not achieve HbA1c goal|ADDENDUM: Change in HbA1c from point of second randomization to endpoint|ADDENDUM: Percentage of patients with HbA1c < or = 7.0% and < or = 6.5%|ADDENDUM: 7-point SMPG profiles|ADDENDUM: Body weight|ADDENDUM: Insulin dose|ADDENDUM: Incidence of self-reported hypoglycemic episodes|ADDENDUM: 1,5-Anhydroglucitol|ADDENDUM: HbA1c at specified visits and endpoint|INITIATION: Rate of self-reported hypoglycemic episodes|MAINTENANCE: Rate of self-reported hypoglycemic episodes|ADDENDUM: Rate of self-reported hypoglycemic episodes|INITIATION: Incremental weight change|MAINTENANCE: Incremental weight change|ADDENDUM: Incremental weight change","http://ClinicalTrials.gov/show/NCT00279201",NA
"1053",1053,"NCT00309101","An Open Study for Steroid Resistant, Non-Thymectomized MG Patients","Completed","No Results Available","Myasthenia Gravis","Drug: tacrolimus","Astellas Pharma Inc","Both","Child|Adult","Phase III",11,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","F506-CL-0602","March 29, 2006","01/02/2006",2009-02-01,"June 2, 2009","01/06/2009","",2009-02-01,"Improvement of clinical symptoms|Improvement of daily activity","http://ClinicalTrials.gov/show/NCT00309101",NA
"1055",1055,"NCT00306501","Volitional Swallowing in Stroke Patients With Chronic Dysphagia","Completed","No Results Available","Stroke|Dysphagia","Procedure: Swallowing Training","National Institute of Neurological Disorders and Stroke (NINDS)","Both","Adult|Senior","Phase II",34,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","060120|06-N-0120","March 22, 2006","01/03/2006",2009-12-01,"October 30, 2010","01/10/2010","",2009-12-01,"Swallowing safety|SWAL_QUAL Patient questionnaire","http://ClinicalTrials.gov/show/NCT00306501",NA
"1095",1095,"NCT00371501","Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus","Completed","No Results Available","Atherosclerosis|Thromboembolism|Systemic Lupus Erythematosus","Drug: Rosuvastatin|Drug: placebo|Drug: aspirin|Drug: placebo","Tuen Mun Hospital|AstraZeneca","Both","Adult|Senior","Phase IV",72,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","HARECCTR0500059","September 1, 2006","01/06/2006",2009-12-01,"September 15, 2010","01/09/2010","",2009-12-01,"endothelial activation markers|carotid intima media thickness|coronary Agatston score|Thrombotic events|adverse events","http://ClinicalTrials.gov/show/NCT00371501",NA
"1098",1098,"NCT00376701","Combination Therapy for Age-Related Macular Degeneration.","Completed","No Results Available","Age Related Macular Degeneration","Drug: Avastin (Bevacizumab)|Drug: Bevacizumab|Drug: Bevacizumab|Drug: Bevacizumab","Lawson Health Research Institute|QLT Inc|Canadian Retinal Trials Group","Both","Adult|Senior","Phase II",103,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","R-06-441|Health Canada Control #106990|9427-U0207/2-21C","September 14, 2006","01/09/2006",2009-04-01,"July 6, 2009","01/07/2009","",2009-04-01,"To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy.|To compare between treatment groups:|Whether combination therapy with rPDT + iA and rPDT + iAK in patients with sub-foveal CNVM of all types secondary to ARMD will result in a significant improvement in visual acuity defined as 2 or more lines (10+ letters) on a standardized ETDRS chart c|Lesion growth and activity over the study period.|Contrast sensitivity.|The rate of cataract progression.|Central retinal thickness via Optical Coherence Tomography (OCT).","http://ClinicalTrials.gov/show/NCT00376701",NA
"1124",1124,"NCT00418301","Changes in Cerebral Blood Flow in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain","Completed","No Results Available","Pain|Low Back Pain|Leg Pain","Other: Precision Spinal Cord Stimulation and PET Scan","Boston Scientific Corporation","Both","Adult|Senior","Phase IV",15,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","SCS0305","January 2, 2007","01/01/2007",2009-04-01,"July 21, 2009","01/07/2009","",2009-04-01,"Cumulative frequency of adverse events and events per subject|Cerebral blood flow and VAS with optimal paresthesia coverage compared with SCS off|Cerebral blood flow and VAS with partial paresthesia coverage and subthreshold stimulation compared with optimal coverage and with SCS off","http://ClinicalTrials.gov/show/NCT00418301",NA
"1127",1127,"NCT00415701","Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery","Completed","No Results Available","Coronary Artery Disease|Mitral Valve Regurgitation","Drug: Etomidate|Drug: Propofol|Drug: Hydrocortisone|Drug: NaCl 0.9%|Other: Tetracosactin","University Hospital Inselspital, Berne","Both","Adult|Senior","Phase IV",130,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DINA-KEK7406-IBAN-2006-1","December 22, 2006","01/11/2006",2009-12-01,"March 3, 2010","01/03/2010","",2009-12-01,"Incidence of absolute and relative adrenal insufficiency|Cumulative requirements of vasoactive drugs during surgery and in the intensive care unit (ICU)|Incidence of failure to wean off cardiopulmonary bypass on first intention|Serum lactate|Time to extubation|Length of stay (LOS) in the intensive care unit (ICU), intermediate care unit (IMC), and hospital|Association of results with preoperative risk, stress-dose hydrocortisone replacement, type of surgery","http://ClinicalTrials.gov/show/NCT00415701",NA
"1168",1168,"NCT00483301","A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma","Completed","No Results Available","Malignant Melanoma","Drug: Sorafenib (BAY 43-9006)|Drug: ABI-007(Abraxane)","Mt. Sinai Medical Center, Miami|Abraxis BioScience, LLC.|Bayer","Both","Adult|Senior","Phase II",43,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MEL0205","May 30, 2007","01/05/2007",2009-08-01,"September 17, 2009","01/09/2009","",2009-08-01,"","http://ClinicalTrials.gov/show/NCT00483301",NA
"1214",1214,"NCT00549601","Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: rivastigmine transdermal patch|Drug: rivastigmine transdermal patch|Drug: rivastigmine capsules","Novartis","Both","Adult|Senior","Phase IV",142,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CENA713DES07","October 24, 2007","01/11/2007",NA,"June 2, 2009","01/06/2009","KAPA",2009-04-01,"The mean incidence of gastrointestinal adverse events between the two study groups.|The mean incidence of any adverse events between the two study groups.|The mean incidence of skin adverse events between the two study groups.|Caregiver / patient satisfaction with transdermal patch treatment.|Changes in Mini Mental State Examination (MMSE in both transdermal patch treatment groups.","http://ClinicalTrials.gov/show/NCT00549601",NA
"1228",1228,"NCT00575601","Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients","Completed","No Results Available","Polycystic Ovary Syndrome","Drug: SIMVASTATIN","Tehran University of Medical Sciences","Female","Adult","Phase III",120,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","850-39-4796","December 15, 2007","01/08/2007",2009-04-01,"June 30, 2009","01/06/2009","",2009-04-01,"ivf-et outcomes|Biochemical parameters baseline and 8weeks Biochemical parameters","http://ClinicalTrials.gov/show/NCT00575601",NA
"1230",1230,"NCT00576901","A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.","Completed","No Results Available","Breast Cancer","Drug: bevacizumab [Avastin]|Drug: Docetaxel|Drug: Xeloda","Hoffmann-La Roche","Female","Adult|Senior","Phase II",23,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20561","December 18, 2007","",2009-11-01,"March 25, 2010","01/03/2010","",2009-11-01,"Pathological response rate|Clinical response rate, breast-conservative surgery rate, disease-free survival.|AEs, laboratory parameters.","http://ClinicalTrials.gov/show/NCT00576901",NA
"1233",1233,"NCT00543101","Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors","Completed","Has Results","HIV Infections","Drug: Darunavir (DRV/r)|Drug: continue on current dual boosted PI","Community Research Initiative of New England","Both","Adult|Senior","Phase IV",24,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07-142","October 11, 2007","01/10/2007",2009-01-01,"December 6, 2010","01/07/2010","DVD",2009-01-01,"The Percentage of Participants With Successful Virologic Suppression|Economic Impact of a Substitution of Dual Boosted PIs With DRV/r|Lipid Fraction Results, Mean of the Change From Baseline to Week 24.|Treatment Satisfaction (+3, Much More Satisfied Now to -3, Much Less Satisfied Now)","http://ClinicalTrials.gov/show/NCT00543101",NA
"1236",1236,"NCT00584701","Pharmacogenomics in Autism Treatment","Completed","No Results Available","Autism","Drug: risperidone","University of California, San Francisco|Janssen, LP|National Institute of Mental Health (NIMH)","Both","Child|Adult","Phase II|Phase III",54,"Other|Industry|NIH","Interventional","Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200715817-1|R21MH080026","December 22, 2007","01/01/2008",2009-05-01,"November 18, 2010","01/11/2010","PG",2009-05-01,"ABC and CGI|ABC","http://ClinicalTrials.gov/show/NCT00584701",NA
"1262",1262,"NCT00626301","Lopinavir/Ritonavir Monotherapy in Children","Completed","No Results Available","HIV Infections","Drug: LPV/r","The HIV Netherlands Australia Thailand Research Collaboration|Chulalongkorn University|Khon Kaen University","Both","Child|Adult","Phase IV",40,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HIV-NAT 077|IRB# 241/50","February 21, 2008","01/11/2007",2009-09-01,"June 4, 2010","01/06/2010","",2009-09-01,"To evaluate efficacy (clinical, immunological, virological outcome), pharmacokinetics and safety of LPV/r monotherapy maintenance in Thai children after viral load suppression with double boosted PIs","http://ClinicalTrials.gov/show/NCT00626301",NA
"1279",1279,"NCT00654901","Study of the DTacP-IPV-HepB-PRP-T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa?ºÑ","Completed","No Results Available","Diphtheria|Tetanus|Pertussis|Hepatitis B|Poliomyelitis|Haemophilus Influenzae Type B","Biological: DTaP-IPV-HB-PRP~T vaccine","Sanofi-Aventis","Both","Child","Phase III",881,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","A3L21|A3L21","April 3, 2008","01/03/2008",2009-07-01,"January 20, 2010","01/01/2010","",2009-05-01,"To provide information concerning the immunogenicity of DTacP-IPV-HepB-PRP-T.","http://ClinicalTrials.gov/show/NCT00654901",NA
"1297",1297,"NCT00678301","Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix?ºÑ Hib and Polio Sabin?ºÑ","Completed","No Results Available","Pneumococcal Disease","Biological: GSK Biologicals' Zilbrix?ºÑ Hib|Biological: Pneumococcal vaccine GSK1024850A|Biological: GSK Biologicals' Polio Sabin?ºÑ","GlaxoSmithKline","Both","Child","Phase III",357,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","110521","May 13, 2008","01/06/2008",2009-12-01,"January 7, 2010","01/01/2010","",2009-12-01,"Antibody concentrations to pneumococcal serotypes contained in the vaccine|Antibody concentrations to protein D|Opsonophagocytic activity against pneumococcal serotypes contained in the vaccine|Anti-pneumococcal serotypes antibody concentrations|Antibody concentrations against pneumococcal cross-reactive serotypes|Seropositivity status (against protein D and defined pneumococcal serotypes)|Anti-diphtheria and anti-tetanus toxoids, anti-PRP, anti-B. pertussis and anti-HBs antibody concentration.|Seropositivity status (against B. pertussis)|Seroprotection status (against diphtheria toxoid, tetanus toxoid, PRP and HBs).|Occurrence of fever|Occurrence of solicited local symptoms (any and grade 3)|Occurrence of solicited general symptoms (any and grade 3)|Occurrence of unsolicited adverse events|Occurrence of serious adverse events","http://ClinicalTrials.gov/show/NCT00678301",NA
"1298",1298,"NCT00688701","GLP-1 Agonist AVE0010 in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: LIXISENATIDE (AVE0010)|Drug: Placebo","Sanofi-Aventis","Both","Adult|Senior","Phase III",361,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC6018|EudraCT 2007-005887-29","May 7, 2008","01/05/2008",2009-12-01,"November 26, 2010","01/11/2010","GETGOAL-MONO",2009-12-01,"Absolute change from baseline in HbA1c|Change from baseline in body weight|Change from baseline in fasting plasma glucose|Change from baseline in 2-hours post-prandial plasma glucose","http://ClinicalTrials.gov/show/NCT00688701",NA
"1299",1299,"NCT00687401","A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612AM4)(COMPLETED)","Completed","Has Results","Psoriasis","Biological: Infliximab","Schering-Plough|Centocor, Inc.","Both","Adult|Senior","Phase III",215,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P04612","May 27, 2008","01/06/2006",2009-05-01,"December 2, 2010","01/12/2010","ESAQUALITY",2009-05-01,"Number of Participants Who Achieve a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI) Score","http://ClinicalTrials.gov/show/NCT00687401",NA
"1325",1325,"NCT00731601","Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding","Completed","No Results Available","Peptic Ulcer Hemorrhage","Drug: pantoprazole|Drug: pantoprazole","Lotung Poh-Ai Hospital","Both","Adult|Senior","Phase IV",120,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","LotungPAH","August 7, 2008","01/05/2008",2009-04-01,"April 6, 2009","01/04/2009","PPI",2009-03-01,"The primary end point was recurrent bleeding before discharge and within 14 days.|At day 14, volume of blood transfused, number of surgeries performed, and the mortality rates of the two groups are compared.","http://ClinicalTrials.gov/show/NCT00731601",NA
"1393",1393,"NCT00840801","Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children","Completed","No Results Available","Encephalitis, Tick-Borne","Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)","Baxter Healthcare Corporation","Both","Child","Phase III",302,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","700801|EUDRACT NUMBER: 2008-002691-10","February 9, 2009","01/02/2009",2010-08-01,"August 2, 2010","01/08/2010","",2009-05-01,"Seropositivity rate as determined by neutralization test (NT) 28 days after the second vaccination|Seropositivity rate determined by NT 180 days after the first vaccination and 28 days after the third vaccination|Seropositivity rate determined by ELISA 28 days after the second vaccination, 180 days after the first vaccination and 28 days after the third vaccination|Antibody response measured by NT/ELISA 28 days after the second vaccination, 180 days after the first vaccination and 28 days after the third vaccination|Fold increase of antibody response measured by NT/ELISA 28 days after the second vaccination, 180 days after the first vaccination and 28 days after the third vaccination as compared to baseline|Frequency and severity of injection site reactions/systemic reactions occurring after each vaccination|Frequency and severity of adverse experiences (AEs) observed during the entire follow-up period","http://ClinicalTrials.gov/show/NCT00840801",NA
"1396",1396,"NCT00807001","Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Na??ve Subjects","Completed","Has Results","Chronic Hepatitis C","Drug: IDX184","Idenix Pharmaceuticals","Both","Adult","Phase I|Phase II",41,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","IDX-08C-003","December 10, 2008","01/12/2008",2009-12-01,"October 8, 2010","01/10/2010","",2009-06-01,"Safety and Tolerability|Antiviral Activity. Change in Plasma HCV RNA","http://ClinicalTrials.gov/show/NCT00807001",NA
"1407",1407,"NCT00865501","Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease","Completed","No Results Available","Primary Hypertension","Drug: spironolactone|Drug: placebo","University of Erlangen-N??rnberg Medical School","Male","Adult","Phase III",50,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KFO-TP5-I","March 18, 2009","01/03/2008",2009-12-01,"February 1, 2010","01/02/2010","",2009-12-01,"left ventricular mass","http://ClinicalTrials.gov/show/NCT00865501",NA
"1432",1432,"NCT00907101","Evaluate Effectiveness of Epiduo?ó Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes","Completed","No Results Available","P Acnes Colonization","Drug: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo?ó Gel)","Galderma Laboratories, L.P.","Both","Adult|Senior","Phase IV",30,"Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","US10127","May 20, 2009","01/06/2009",2009-07-01,"August 14, 2009","01/08/2009","",2009-07-01,"Change from baseline in quantitative bacteriology measurements at week 4|Tolerability assessments","http://ClinicalTrials.gov/show/NCT00907101",NA
"1436",1436,"NCT00861601","Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease","Completed","Has Results","Thrombocytopenia|Liver Diseases","Drug: eltrombopag 12.5 milligrams (mg) tablet|Drug: eltrombopag 25 mg tablet","GlaxoSmithKline","Both","Adult|Senior","Phase II",38,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","111913","March 5, 2009","01/01/2009",2009-08-01,"October 7, 2010","01/10/2010","",2009-08-01,"Change From Baseline in Platelet Counts on Day 15|Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline Platelet Counts as Covariate)|Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline of Platelet Counts and Child-Pugh Class as Covariates)|Percent Change From Baseline in Platelet Counts on Day 15|Platelet Counts by Treatment Visit|Platelet Counts by Post-Treatment Visit|Platelet Counts at Day 22|Change From Baseline in Platelet Counts by Treatment Visit|Change From Baseline in Platelet Counts by Post-Treatment Visit|Percentage of Responders on Day 15|Percentage of Responders on Day 22|Change From Baseline in Platelet Counts on Day 15 by Child-Pugh Class|Change From Baseline in Platelet Counts on Day 15 by Sex|Change From Baseline in Platelet Counts on Day 15 by Age|Log-transformed Cmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg|Log-transformed Tmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg|Log-transformed AUC(0-t) and AUC(0-24) on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg","http://ClinicalTrials.gov/show/NCT00861601",NA
"1437",1437,"NCT00912301","Cheno Effect on Transit in Health and IBS-C","Completed","No Results Available","Constipation-predominant Irritable Bowel Syndrome","Drug: NaCDC","Mayo Clinic","Both","Adult","Phase II",120,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","08-001003|NIH DK 54681","May 29, 2009","01/04/2009",2009-12-01,"January 18, 2010","01/01/2010","Chenotransit",2009-11-01,"Colonic geometric center at 24 hours (GC24)|Colonic transit GC48 h|Ascending colon emptying T1/2|Stool consistency|Colonic Filling at 6 hours","http://ClinicalTrials.gov/show/NCT00912301",NA
"1446",1446,"NCT00927901","Efficacy, Safety, Tolerability and Pharmacokinetics of Indacaterol Salts in Patients With Asthma","Completed","No Results Available","Asthma","Drug: indacaterol maleate 400 ??g via Concept1 device|Drug: indacaterol xinafoate 400 ??g via Concept1 device|Drug: indacaterol acetate 400 ??g via Concept1 device|Drug: Matching placebo to indacaterol via Concept1 device","Novartis Pharmaceuticals","Both","Adult|Senior","Phase II",27,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CQAB149D2301|EudraCT number: 2009-010589-46","June 24, 2009","01/06/2009",NA,"December 10, 2009","01/12/2009","",2009-11-01,"The primary endpoint is change from baseline to trough FEV1 after 7 days of treatment.|Time to peak FEV1 on Day 7 and Day 1 will be analyzed similarly.|Change from baseline in FEV1, FVC and FEF25-75 on Day 7 will be analyzed at each post dose-time|The incidence of cough within 5 minutes of inhalation will be compared between treatments|PK analysis for AUC0-24h and Cmax|All randomized subjects who received at least one dose of study drug will be included in the safety and tolerability evaluation.","http://ClinicalTrials.gov/show/NCT00927901",NA
"1455",1455,"NCT00944801","Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma","Completed","No Results Available","Glioblastoma","Drug: Pegylated Liposomal Doxorubicine","University of Regensburg|Essex Pharma (Schering-Plough) Germany","Both","Adult|Senior","Phase I|Phase II",63,"Other","Interventional","Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RNOP-09","July 17, 2009","01/07/2002",2009-05-01,"July 21, 2009","01/07/2009","",2009-05-01,"progression free survival probability at 12 months to detect an improvement of the PFS-12 of 15.6% as compared to EORTC26981/NCIC-CE.3 combination arm (PFS-12: 26.9%)|PFS-24, mOS, OS-12, OS-24, mTTP, response rate, rate of stabilizations , and toxicity profile","http://ClinicalTrials.gov/show/NCT00944801",NA
"1470",1470,"NCT00965601","A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia","Completed","No Results Available","Fibromyalgia","Behavioral: Cognitive Behavioral Therapy","Indiana University","Female","Adult","Phase IV",30,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","NFR 080554|IU Internally funded","August 24, 2009","01/07/2008",2009-08-01,"August 24, 2009","01/08/2009","NFR",2009-07-01,"Aim 1: Test the feasibility and subject acceptability of a potentially objective tool (NFR) for measuring pain severity.|Aim 2: Determine the longitudinal relationships of changes in patients' symptoms with changes in plasma levels of neuropeptides and NFR pain threshold.","http://ClinicalTrials.gov/show/NCT00965601",NA
"1498",1498,"NCT01015001","A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine","Completed","No Results Available","Schizophrenia|Auditory Hallucinations","Procedure: Active rTMS x sham (placebo) rTMS|Procedure: sham rTMS|Procedure: (1Hz) rTMS applied over the left temporoparietal cortex","Hospital de Clinicas de Porto Alegre","Both","Adult","Phase III",20,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","6382","November 10, 2009","01/05/2008",2009-12-01,"August 11, 2010","01/08/2010","",2009-12-01,"Evaluate the effects of low frequency repetitive Transcranial Magnetic Stimulation applied over the left temporoparietal cortex of refractory schizophrenic patients on the severity of auditory hallucinations.|The secondary outcomes are to evaluate the effects of the same rTMS protocol on their quality of life, functionality and general psychopathology.","http://ClinicalTrials.gov/show/NCT01015001",NA
"1526",1526,"NCT01060501","Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer","Completed","No Results Available","Rectal Cancer","Drug: Folinic Acid, interferon-alpha","University of Ulm|Medac GmbH (Hamburg, Germany)|Roche (Grenzach-Wyhlen, Germany)","Both","Adult|Senior","Phase III",796,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FOGT1","February 1, 2010","01/07/1992",2009-07-01,"February 1, 2010","01/07/1991","FOGT1",2009-07-01,"overall survival|recurrence-free survival|Toxicity (WHO)","http://ClinicalTrials.gov/show/NCT01060501",NA
"1541",1541,"NCT01087801","A Study of Synthetic Human Secretin (ChiRhoStim?ó) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers","Completed","No Results Available","Pancreatic Disease","Drug: ChiRhoStim|Drug: Placebo","ChiRhoClin, Inc.","Both","Adult|Senior","Phase III",55,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Diagnostic","2006-05","March 15, 2010","01/10/2007",2009-12-01,"March 15, 2010","01/03/2010","CRC2006-05",2009-11-01,"Endoscopic Sample","http://ClinicalTrials.gov/show/NCT01087801",NA
"1556",1556,"NCT01106001","Study to Test the Efficacy of Periarticular Levo Bupivicaine Injection Following Primary Hip Arthroplasty","Completed","No Results Available","Osteoarthritis","Drug: Levobupivacaine|Drug: Saline","Orthopaedic Research and Innovation Foundation","Both","Adult|Senior","Phase IV",91,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","KM-042008-014","April 12, 2010","01/09/2008",2009-09-01,"April 16, 2010","01/07/2008","",2009-09-01,"To determine a significant difference (p>0.05) in morphine consumption between the two treatment groups post-operatively.|To analyse the length of stay for between both treatment groups","http://ClinicalTrials.gov/show/NCT01106001",NA
"1557",1557,"NCT01109901","Comparison of Effect of Anterior Subcutaneous and Submuscular Transposition on Cubital Tunnel Syndrome","Completed","No Results Available","Cubital Tunnel Syndrome","Procedure: anterior subcutaneous transposition|Procedure: Anterior submuscular transposition","Isfahan University of Medical Sciences","Both","Child|Adult|Senior","Phase II",48,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","ASD-1213","April 19, 2010","01/10/2008",2009-03-01,"April 22, 2010","01/10/2008","",2009-03-01,"Pain|sensation|Muscle strength|Muscle atrophy","http://ClinicalTrials.gov/show/NCT01109901",NA
"1560",1560,"NCT01115101","Superiority Study for Pain Treatment After Cesarean","Completed","No Results Available","Pain","Drug: Oral Oxycodon|Drug: Piritramid|Device: intravenous PCA device","University of Rostock","Female","Adult|Senior","Phase IV",239,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KJ-2009-MD","April 27, 2010","01/07/2009",2009-11-01,"May 3, 2010","01/02/2006","",2009-11-01,"Difference of Pain Scores on the Visual Analog Scale|Side effects and limitations","http://ClinicalTrials.gov/show/NCT01115101",NA
"1717",1717,"NCT00028002","Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor","Completed","No Results Available","Gastrointestinal Stromal Tumor","Drug: imatinib mesylate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|American College of Radiology Imaging Network|Eastern Cooperative Oncology Group","Both","Adult|Senior","Phase II",63,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000069111|RTOG-S-0132|ACRIN-6665|RTOG-DEV-1055|ECOG-RTOG-R0132","December 7, 2001","01/02/2002",NA,"July 31, 2010","01/01/2009","",2009-01-01,"Biological effects of imatinib mesylate|Rate of disease recurrence at 2 years|Rates of objective response (complete, partial, and stable)|Major toxicity (i.e., grade ??­ 3)|Correlation of glucose transported expression and positron emission tomography (PET) interpretations|Tumor changes observed on PET and correlation with size changes observed on conventional cross-sectional imaging|Diagnostic accuracy of PET to predict disease recurrence","http://ClinicalTrials.gov/show/NCT00028002",NA
"1722",1722,"NCT00024102","Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: CMF regimen|Drug: capecitabine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Procedure: adjuvant therapy","Cancer and Leukemia Group B|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Southwest Oncology Group|NCIC Clinical Trials Group","Female","Adult|Senior","Phase III",1800,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000068891|CALGB-49907|ECOG-CALGB-49907|CAN-NCIC-MAC1|SWOG-CALGB-49907","September 13, 2001","01/09/2001",NA,"April 10, 2010","01/01/2007","",2009-05-01,"Duration of disease-free survival|Overall survival|Toxicity","http://ClinicalTrials.gov/show/NCT00024102",NA
"1817",1817,"NCT00180102","AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years","Completed","No Results Available","Leukemia, Nonlymphocytic, Acute","Drug: Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone|Procedure: early allogeneic PBSCT within induction therapy|Procedure: autologous PBSCT","Dresden University of Technology","Both","Child|Adult","Phase IV",600,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","MK1-95","September 12, 2005","01/12/2003",2009-11-01,"December 23, 2009","01/12/2009","",2009-11-01,"overall survival|relapse-free survival|complete remission rate after induction therapy|subgroup-analyses within the primary outcomes according to different risk factors|development of explanatory proportional hazard-models","http://ClinicalTrials.gov/show/NCT00180102",NA
"1832",1832,"NCT00141102","Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis","Completed","Has Results","Osteoarthritis|Arthritis, Rheumatoid","Drug: Celecoxib|Drug: Diclofenac + Omeprazole","Pfizer","Both","Adult|Senior","Phase IV",4484,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","A3191084","August 29, 2005","01/10/2005",2009-05-01,"August 20, 2010","01/08/2010","CONDOR",2009-05-01,"Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)|Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs)|Change From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET)|Number of Subjects With SUs|Number of Subjects With CSULGIEs by History of GD Ulceration|Number of Subjects With Moderate to Severe Abdominal Symptoms|Number of Subjects Withdrawn Due to GI Adverse Events (AEs)|Change From Baseline in Hemoglobin at Month 6/ET|Change From Baseline in Hematocrit at Month 6/ET|Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin|Number of Subjects With Hepatic AEs in Gamma Glutamyl-Transferase (GGT), Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) of 3 Times the Upper Limit of Normal (ULN)|Change From Baseline in Hepatic Measures of GGT, AST or ALT to Month 6/ET|Change From Baseline in Iron Binding Capacity to Month 6/ET|Change From Baseline in Ferretin to Month 6/ET|Change From Baseline in C-Reactive Protein to Month 6/ET","http://ClinicalTrials.gov/show/NCT00141102",NA
"1903",1903,"NCT00299702","Evaluation of Effectiveness of Risperdal?ó Consta?ó Compared to Abilify?ó Over a Two-year Period in Patients With Schizophrenia","Completed","Has Results","Schizophrenia|Psychotic Disorders","Drug: Abilify|Drug: Risperidal Consta","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP","Both","Adult|Senior","Phase IV",355,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR006121","March 3, 2006","01/02/2006",2009-01-01,"March 4, 2010","01/03/2010","",2009-01-01,"Time to Relapse|Time in Remission","http://ClinicalTrials.gov/show/NCT00299702",NA
"1910",1910,"NCT00316602","A Phase II Study on Immunogenicity and Safety of MVA-BN?ó (IMVAMUNE?ºÑ) Smallpox Vaccine in Subjects With Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Biological: MVA-BN?ó (IMVAMUNE)|Biological: IMVAMUNE","Bavarian Nordic|National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","Phase II",632,"Industry|NIH","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","POX-MVA-008|DMID 05-0133","April 20, 2006","01/07/2006",2010-04-01,"May 19, 2010","01/05/2010","",2009-11-01,"Seroconversion rate at visit 4 assessed by MVA-BN ELISA|Neutralisation assay specific seroconversion rates and geometric mean titres (at all blood sampling time points)|ELISA specific seroconversion rates and geometric mean titres (at all blood sampling time points)|Occurrence, relationship and intensity of any serious and/or unexpected adverse reaction at any time during the study","http://ClinicalTrials.gov/show/NCT00316602",NA
"1923",1923,"NCT00311402","JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme","Completed","Has Results","Cerebrovascular Accident","Drug: Aggrenox capsule|Other: Acetylsalicylic Acid (ASA)","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",1295,"Industry","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Prevention","9.178","March 28, 2006","01/04/2006",NA,"June 23, 2010","01/06/2010","",2009-03-01,"Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal)|Number of Patients With Brain (Cerebral) Haemorrhage|Number of Patients With Subarachnoid Haemorrhage|Number of Patients With Transient Ischemic Attack (TIA)|Number of Patients With Acute Coronary Syndrome (ACS)|Number of Patients With Other Vascular Events|Number of Patients With Ischemic Vascular Event Composite Endpoint","http://ClinicalTrials.gov/show/NCT00311402",NA
"1935",1935,"NCT00360802","Effectiveness of Cognitive Behavioral Treatment and Mindfulness Based Stress Reduction (MBSR) for Chronic Low Back Pain","Completed","No Results Available","Chronic Low Back Pain","Behavioral: Cognitive Behavioral Treatment|Behavioral: Mindfulness Based Stress Reduction","Kovacs Foundation|Spanish Back Pain Research Network (REIDE)|Fondo de Investigacion Sanitaria|Universitat Autonoma de Barcelona","Both","Adult|Senior","Phase II",330,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)","FK-FIS-22","August 4, 2006","01/05/2006",2009-05-01,"May 27, 2009","01/05/2009","",2009-03-01,"Degree of improvement in: anxiety, quality of life|Degree of improvement in: pain, disability, catastrophizing, depression, anger, analgesic medication, satisfaction with treatment received","http://ClinicalTrials.gov/show/NCT00360802",NA
"1967",1967,"NCT00412802","Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome","Completed","No Results Available","Acute Coronary Syndrome|Renal Failure","Drug: dose adaptation of Enoxaparin|Drug: normal injection of Enoxaparine","French Cardiology Society","Both","Adult|Senior","Phase IV",67,"Other","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-01","December 15, 2006","01/12/2006",2009-03-01,"February 26, 2010","01/02/2010","",2009-03-01,"plasma antiXa levels at peak after the fourth enoxaparine dose administration|residual plasma antiXa level before the fifth enoxaparine dose administration|activated thromboplastin time|thrombotic events|bleeding events","http://ClinicalTrials.gov/show/NCT00412802",NA
"1979",1979,"NCT00424502","A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.","Completed","No Results Available","Rheumatoid Arthritis","Drug: rituximab [MabThera/Rituxan]|Drug: Methotrexate","Hoffmann-La Roche","Both","Adult|Senior","Phase IV",20,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20538","January 18, 2007","",2009-10-01,"January 15, 2010","01/01/2010","",2009-10-01,"DAS 24|ACR 20/50/70 and HAQ|AEs, laboratory parameters","http://ClinicalTrials.gov/show/NCT00424502",NA
"1983",1983,"NCT00429702","Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy in Young Patients With Newly Diagnosed Cancer","Completed","No Results Available","Nausea and Vomiting|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: dexamethasone|Drug: diphenhydramine hydrochloride|Drug: lorazepam|Drug: ondansetron hydrochloride","SunCoast CCOP Research Base at the University of South Florida|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",180,"Other|NIH","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Supportive Care","CDR0000527333|SCUSF-0503|HLMCC-0503","January 31, 2007","01/10/2007",NA,"September 18, 2010","01/09/2010","",2009-08-01,"Efficacy of diphenhydramine hydrochloride, lorazepam, & dexamethasone in preventing chemo-induced nausea & vomiting (CINV) as measured by proportion of patients requiring rescue medication for breakthrough nausea or emesis during inpatient chemotherapy|Efficacy of diphenhydramine hydrochloride, lorazepam, and dexamethasone in preventing CINV for 3 days after completion of the first course of emetogenic chemotherapy|Severity of CINV as measured by the Adapted Rhodes Index of Nausea, Vomiting, and Retching--Measured by Child/Parent questionnaire","http://ClinicalTrials.gov/show/NCT00429702",NA
"1997",1997,"NCT00460902","Evaluation of the Deep TMS H-Coil in the Treatment of Major Depression- Augmentation of Antidepressant Medication","Completed","No Results Available","Major Depression","Device: Transcranial Magnetic Stimulation (TMS)","Hadassah Medical Organization|Brainsway, Beer Yaacov Medical Center","Both","Adult|Senior","Phase I|Phase II",NA,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","395/3.11.06(HMO)","April 15, 2007","01/04/2007",2009-08-01,"February 7, 2010","01/01/2010","",2009-08-01,"HAMILTON RATING SCALE FOR DEPRESSION 24 items|BDI|CGI","http://ClinicalTrials.gov/show/NCT00460902",NA
"2002",2002,"NCT00467402","Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder","Completed","No Results Available","Major Depressive Disorder","Drug: agomelatine|Drug: placebo","Novartis","Both","Adult|Senior","Phase III",644,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CAGO178A2304","April 27, 2007","01/04/2007",NA,"May 10, 2010","01/05/2010","",2009-09-01,"Time to relapse, where relapse is defined by the occurrence of any one of the following:|Hamilton Depression Rating Scale total score ??­16 at two consecutive visits;|hospitalization due to depression;|suicide attempt or suicide;|discontinuation due to lack of efficacy according to Investigator judgment.|Proportion of patients who demonstrate clinical improvement at the end of the double-blind continuation phase, where improvement is defined by a score of 1 or 2 on the Clinical Global Impression Improvement (CGI-I) scale.|Proportion of patients experiencing relapse during the double-blind continuation phase.|Proportion of patients who achieve remission at the end of the double-blind continuation phase, where remission is defined by a total score of ???7 on the HAM-D.|Change from randomization to the end of the double-blind continuation phase, on the Hospital Anxiety and Depression (HAD) total score and subscale scores.","http://ClinicalTrials.gov/show/NCT00467402",NA
"2076",2076,"NCT00593502","Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age","Completed","No Results Available","Influenza","Drug: oseltamivir|Drug: placebo","Hospital District of Southwestern Finland|Hoffmann-La Roche","Both","Child","Phase IV",409,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MV21118|EudraCT 2007-004734-17","January 4, 2008","01/02/2008",2009-06-01,"June 18, 2009","01/06/2009","ETOPOM",2009-06-01,"Percentage of influenza-infected children in whom acute otitis media develops after the start of study medication|Time to resolution of fever and other clinical symptoms","http://ClinicalTrials.gov/show/NCT00593502",NA
"2081",2081,"NCT00603902","BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management","Completed","No Results Available","Obesity","Drug: lorcaserin|Drug: lorcaserin|Drug: placebo","Arena Pharmaceuticals","Both","Adult","Phase III",3000,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APD356-011","January 16, 2008","01/01/2008",2009-08-01,"October 7, 2009","01/10/2009","",2009-07-01,"Proportion (%) of patients achieving > or = 5% weight reduction at Week 52.|Change in body weight (kg) from Baseline to Week 52.|Change in waist and hip measurements from Baseline to Week 52.|Change in blood pressure (systolic and diastolic) from Baseline to Week 52.|Change in lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) from Baseline to Week 52.|Change in Quality of Life measures from Baseline to Week 52.","http://ClinicalTrials.gov/show/NCT00603902",NA
"2082",2082,"NCT00605202","Effect of Licorice and Hydrochlorothiazide on Plasma Potassium","Completed","Has Results","Hypokalemia","Drug: Hydrochlorothiazide|Dietary Supplement: Licorice","University of Oulu","Both","Adult","Phase IV",10,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","Lakritsi ja hypokalemia","January 17, 2008","01/02/2008",2009-01-01,"December 10, 2009","01/12/2009","",2009-01-01,"Plasma Potassium","http://ClinicalTrials.gov/show/NCT00605202",NA
"2095",2095,"NCT00623402","Combined Treatment of Sorafenib and Pegylated Interferon ??2b in Stage IV Metastatic Melanoma","Completed","No Results Available","Melanoma","Drug: Sorafenib|Drug: pegylated interferon ??-2b","University of Schleswig-Holstein|Dermatologic Cooperative Oncology Group","Both","Adult|Senior","Phase II",55,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DeCOG SoraPeg 2007|EudraCT 2007-001918-16","February 1, 2008","01/01/2008",NA,"January 11, 2011","01/02/2008","SoraPeg",2009-10-01,"disease control rate (CR,PR,SD)|Best response|Progression free survival (PFS)|Overall survival|Safety and tolerability of the combined treatment","http://ClinicalTrials.gov/show/NCT00623402",NA
"2100",2100,"NCT00632502","Neutrophilic Asthma Study With SCH 527123 (Study P05365AM2)(COMPLETED)","Completed","No Results Available","Neutrophilic Asthma","Drug: SCH 527123|Drug: Placebo","Schering-Plough","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05365|Doc ID: 3709483","February 29, 2008","01/05/2008",2009-02-01,"September 30, 2009","01/09/2009","",2009-02-01,"The primary endpoint is safety.|Effects of Treatment with SCH 527123: Reducing levels of sputum neutrophils. PK parameters. Asthma symptoms, PFTs, QOL, ECGs, lab assessments, & AEs.","http://ClinicalTrials.gov/show/NCT00632502",NA
"2113",2113,"NCT00650702","Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension","Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Latanoprost-PPDS|Drug: Latanoprost-PPDS|Drug: Latanoprost-PPDS","QLT Plug Delivery, Inc.","Both","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PPL GLAU 02","March 27, 2008","01/03/2008",2009-02-01,"May 19, 2009","01/05/2009","CORE",2009-02-01,"IOP change from baseline","http://ClinicalTrials.gov/show/NCT00650702",NA
"2127",2127,"NCT00667602","Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers","Completed","No Results Available","Meningococcal Meningitis","Biological: MenACWY + Concomitant Vaccination|Biological: 1 dose MenACWY + Concomitant Vaccination|Biological: MenC (12 Month) + Concomitant Vaccination (12 Month)","Novartis|Novartis Vaccines","Both","Child","Phase III",662,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","V59P22|2007-004754-82","April 24, 2008","01/03/2008",2010-10-01,"December 10, 2010","01/12/2010","",2009-07-01,"To assess and compare the immunogenicity of one dose of MenACWY to one dose of Menjugate at one month after vaccination.|To assess and compare the immunogenicity of two doses of MenACWY given to infants at 6 to 8 and 12 months of age to a single dose of Menjugate given to toddlers at 12 months of age.|To evaluate the safety and tolerability of MenACWY and concomitant vaccines in all study subjects","http://ClinicalTrials.gov/show/NCT00667602",NA
"2129",2129,"NCT00671502","A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back","Completed","No Results Available","Lower Back Pain","Drug: Carisoprodol|Drug: Carisoprodol SR|Drug: Placebo","Meda Pharmaceuticals","Both","Adult|Senior","Phase III",840,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP510","May 1, 2008","01/04/2008",2009-02-01,"April 30, 2009","01/04/2009","",2009-02-01,"Subject rating of pain on a 100-point visual analog scale (VAS)|Subject functional assessment based on the Roland-Morris Disability Questionnaire (RMDQ)|Adverse events assessments","http://ClinicalTrials.gov/show/NCT00671502",NA
"2146",2146,"NCT00698802","Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: EX1000|Drug: biphasic human insulin","Novo Nordisk","Both","Adult|Senior","Phase II",397,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EX1000-1919","June 16, 2008","01/06/2008",2009-03-01,"November 5, 2010","01/11/2010","",2009-03-01,"HbA1c|HbA1c|Fructosamine|FPG|4-point SMPG profiles|Incidence of hypoglycaemic episodes|Frequency and severity of adverse events (including injection site reactions)|Laboratory safety parameters (haematology, biochemistry and lipids)|Physical examination and vital signs|Total daily insulin dosages","http://ClinicalTrials.gov/show/NCT00698802",NA
"2155",2155,"NCT00710502","Transvaginal NOTES Cholecystectomy: Phase I/II Mexico Clinical Trial","Completed","No Results Available","Cholelithiasis","Procedure: Transvaginal NOTES cholecystectomy|Procedure: Laparoscopic cholecystectomy","Universidad Juarez Durango|Hospital Universitario La Paz","Female","Adult","Phase I|Phase II",40,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","5626","July 2, 2008","01/01/2009",2009-12-01,"December 14, 2009","01/12/2009","",2009-12-01,"Safety and Efficacy of Transvaginal NOTES cholecystectomy when compared to Laparoscopic cholecystectomy|Short term outcomes of Transvaginal NOTES cholecystectomy when compared to Laparoscopic Cholecystectomy","http://ClinicalTrials.gov/show/NCT00710502",NA
"2164",2164,"NCT00723502","Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients","Completed","No Results Available","Gram-Negative Bacterial Infections|Helicobacter Infections|Dyspepsia","Drug: Finafloxacin + Amoxicillin|Drug: Finafloxacin + Esomeprazole","MerLion Pharmaceuticals GmbH","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FINA-002","July 25, 2008","01/09/2008",2009-04-01,"June 15, 2009","01/10/2008","FLASH",2009-04-01,"Eradication of Helicobacter pylori","http://ClinicalTrials.gov/show/NCT00723502",NA
"2170",2170,"NCT00743002","A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: TT223|Drug: Placebo","Transition Therapeutics","Both","Adult|Senior","Phase II",80,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GIN-201","August 26, 2008","01/08/2008",2009-12-01,"March 29, 2010","01/03/2010","",2009-12-01,"To evaluate the safety and tolerability of TT223 as a treatment for Type 2 diabetes at 1 mg, 2 mg and 3 mg.|To evaluate the efficacy of TT223 as a treatment for Type 2 diabetes by comparing the change in HbA1c value from baseline between the TT223 and placebo groups.|To evaluate the efficacy of TT223 on beta cell function by assessing additional outcome measures including fasting blood glucose levels, and meal tolerance testing.|To determine the pharmacokinetic (PK) parameter profile of TT223 in a subset of patients.","http://ClinicalTrials.gov/show/NCT00743002",NA
"2173",2173,"NCT00733902","Tanezumab in Osteoarthritis of the Knee","Completed","No Results Available","Arthritis|Osteoarthritis","Biological: tanezumab|Biological: tanezumab|Biological: tanezumab|Biological: Placebo","Pfizer","Both","Adult|Senior","Phase III",697,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A4091011","August 11, 2008","01/09/2008",2009-11-01,"January 4, 2011","01/01/2011","",2009-09-01,"WOMAC function|WOMAC pain|Patient Global Assessment of Osteoarthritis|Womac pain, physical function and stiffness at other timepoints|SF-36|Daily NRS scores|Safety (AEs, laboratory, ECGs, physical exam, vital signs)|Time to discontinuation","http://ClinicalTrials.gov/show/NCT00733902",NA
"2194",2194,"NCT00772902","ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial","Completed","No Results Available","HIV-1","Drug: Truvada (emtricitabine 200 mg/tenofovir DF 300 mg) and Kaletra (lopinavir 200 mg/ritonavir|Drug: Kivexa (abacavir (as sulfate) 600 mg/lamivudine and Kaletra (lopinavir 200 mg/ritonavir","Gilead Sciences","Both","Adult|Senior","Phase IV",85,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GS-EU-164-0206","October 13, 2008","01/10/2008",2009-10-01,"November 20, 2009","01/11/2009","ROCKET II",2009-09-01,"The primary objective is to determine if switching the NRTI backbone from Kivexa to Truvada leads to a reduction in fasting total cholesterol at 12 weeks.|Evaluation of fasting metabolic parameters (e.g. LDL, HDL, non-HDL cholesterol, triglycerides and cholesterol ratios).|Evaluation of efficacy and safety by assessing adverse events, clinical laboratory tests, physical examinations and vital signs at every visit.|Evaluation of changes in the 10-year risk factor for coronary heart disease outcomes as measured by total cholesterol, HDL, blood pressure, smoking status, treatment for hypertension, sex, and age.","http://ClinicalTrials.gov/show/NCT00772902",NA
"2221",2221,"NCT00821002","A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)","Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: Latanoprost","QLT Plug Delivery, Inc.|QLT Inc","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PPL GLAU 05","January 8, 2009","01/01/2009",2009-11-01,"November 27, 2009","01/11/2009","",2009-11-01,"Compare intraocular pressure and safety outcomes based on plug placement","http://ClinicalTrials.gov/show/NCT00821002",NA
"2328",2328,"NCT00993902","Double and Single Intrauterine Insemination In Controlled Ovarian Stimulation (COH) Cycles With Multifollicular Development","Completed","No Results Available","Infertility","Procedure: Intrauterine insemination (single)|Procedure: Double intrauterine insemination","Baskent University","Female","Adult","Phase IV",228,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BU1","July 22, 2009","01/05/2008",2009-07-01,"October 13, 2009","01/10/2009","",2009-05-01,"ongoing pregnancy rates|The effects of different coh regimens on outcomes","http://ClinicalTrials.gov/show/NCT00993902",NA
"2341",2341,"NCT01013402","Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia","Completed","No Results Available","Hypoglycemia","Drug: Human insulin|Drug: Human Insulin","Gulhane School of Medicine","Both","Child|Adult|Senior","Phase IV",51,"Other","Interventional","Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research","GSM-012009","November 12, 2009","01/12/2008",2009-08-01,"November 12, 2009","01/11/2009","",2009-04-01,"","http://ClinicalTrials.gov/show/NCT01013402",NA
"2443",2443,"NCT01181102","A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty","Completed","No Results Available","Prevention|Venous Thromboembolism","Drug: edoxaban|Drug: enoxaparin sodium","Daiichi Sankyo Inc.|Daiichi Sankyo, Tokyo, LTD.","Both","Adult|Senior","Phase III",716,"Industry|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DU176b-B-J302","August 12, 2010","01/03/2009",2010-02-01,"August 12, 2010","01/08/2010","",2009-09-01,"Proportion of subjects with venous thromboembolism events.|Proportion of subjects with bleeding events","http://ClinicalTrials.gov/show/NCT01181102",NA
"2459",2459,"NCT01201902","A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine","Completed","No Results Available","Influenza Infection","Biological: Adjuvanted influenza A(H1N1) vaccine|Biological: Adjuvanted influenza A(H1N1) vaccine|Biological: un-adjuvanted influenza A(H1N1) vaccine|Biological: Adjuvanted influenza A(H1N1) vaccine|Biological: Adjuvanted influenza A(H1N1) vaccine","Green Cross Corporation","Both","Adult|Senior","Phase III",592,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","GC1116|??º?????À??º??? - 649¬ß½(2009.9.28)","September 13, 2010","01/10/2009",2010-07-01,"September 17, 2010","01/09/2010","",2009-12-01,"HI antibody responses after 1 and/or 2 vaccinations|Solicited local & general AE, Unsolicited AE, AE until 6 months after last vaccination","http://ClinicalTrials.gov/show/NCT01201902",NA
"2553",2553,"NCT00026403","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Radiation: radiation therapy","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069026|NCCTG-N9942","November 9, 2001","01/09/2001",NA,"August 4, 2009","01/07/2009","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT00026403",NA
"2585",2585,"NCT00078403","Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)","Completed","No Results Available","HIV Infections|Hepatitis C|Liver Disease","Drug: Peginterferon alfa-2a|Drug: Ribavirin","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult|Senior","Phase II",300,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","ACTG A5178|SLAM-C|10008","February 24, 2004","01/07/2004",2009-02-01,"January 20, 2010","01/07/2008","",2009-02-01,"Liver fibrosis (Metavir) score|HCV viral loads|Liver inflammation (Metavir) score|Safety, defined as rates and grades of anemia, neutropenia, thrombocytopenia, depression, and other psychological events, and all other high-grade signs and symptoms and laboratory values|Regimen tolerability, defined as dose modification and temporary and permanent drug discontinuation, increased symptom distress, or decreased quality of life|Adherence to study medication|HCV polymorphisms|HCV-specific immune response in intrahepatic lymphocytes|Noninvasive measures of liver fibrosis, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, albumin, and protein measurements|HIV viral load|Weight|Insulin resistance, defined as fasting glucose|Step 3 end of treatment virologic response and sustained virologic response|Use of antianorexia agents, such as megestrol and dronabinol|Use of hematologic adjuvant therapies, such as erythropoietin, granulocyte colony-stimulating factor, and granulocyte-monocyte colony-stimulating factor","http://ClinicalTrials.gov/show/NCT00078403",NA
"2648",2648,"NCT00172003","Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis","Completed","No Results Available","Renal Cell Cancer|Neoplasm Metastasis","Drug: Zoledronic acid","Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",50,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CZOL446EDE15","September 13, 2005","01/09/2004",NA,"June 11, 2010","01/06/2010","",2009-07-01,"Rate of skeletal complications|Time to first skeletal complication|Bone pain|Time to overall progression of disease|Overall survival|Bone turnover parameters","http://ClinicalTrials.gov/show/NCT00172003",NA
"2661",2661,"NCT00194103","Effectiveness of Extended Telephone Monitoring","Completed","No Results Available","Alcohol Dependence","Behavioral: Telephone Monitoring and Feedback|Behavioral: Telephone Monitoring and Counseling","University of Pennsylvania","Both","Adult|Senior","Phase III",252,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","708753|R01 AA14850","September 12, 2005","01/05/2004",2010-04-01,"June 25, 2010","01/06/2010","ETM",2009-08-01,"TimeLineFollowBack","http://ClinicalTrials.gov/show/NCT00194103",NA
"2689",2689,"NCT00237003","A Brief Alcohol Intervention for Incarcerated Women","Completed","No Results Available","Alcohol Use|Incarceration","Behavioral: motivational interviewing","Butler Hospital|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","Female","Adult|Senior","Phase III",326,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NIAAASTE14495|R01AA014495|NIAAASTE14495","October 11, 2005","01/09/2003",2009-08-01,"May 10, 2010","01/05/2010","",2009-08-01,"alcohol use|HIV risk taking","http://ClinicalTrials.gov/show/NCT00237003",NA
"2716",2716,"NCT00243503","Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer","Completed","Has Results","Breast Neoplasms","Drug: SU011248/Trastuzumab","Pfizer","Both","Adult|Senior","Phase II",61,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181067","October 20, 2005","01/02/2006",2010-07-01,"August 5, 2010","01/08/2010","",2009-04-01,"Number of Subjects With Overall Confirmed Objective Disease Response|Clinical Benefit Rate|Progression Free Survival (PFS)|Duration of Response|Overall Survival|Time to Progression (TTP)|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)|Probability of Survival at One Year|EORTC QLQ Breast Cancer Module (BR23)|Trough Plasma Concentrations (Ctrough) of Sunitinib|Ctrough of SU-012662 (Sunitinib's Metabolite)|Ctrough of Total Drug (Sunitinib + SU-012662)","http://ClinicalTrials.gov/show/NCT00243503",NA
"2725",2725,"NCT00287703","Pulsed Electro Magnetic Fields (PEMF) Treatment in Patients With Treatment-Resistant Major Depression in Ongoing Pharmacological Treatment of Depression","Completed","No Results Available","Depression","Device: Pulsating Electro-Magnetic Fields|Device: Pulsating Electro-Magnetic Fields sham","Hillerod Hospital, Denmark|The Lundbeckfoundation|Biofields","Both","Adult|Senior","Phase III",50,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Final version 26 Oktober 2005","January 31, 2006","01/03/2006",2009-03-01,"May 28, 2009","01/05/2009","",2009-03-01,"Hamilton Depression Rating Scale score (depression)|AQT, measure of concentration","http://ClinicalTrials.gov/show/NCT00287703",NA
"2773",2773,"NCT00377403","Treatment of Acute Sinusitis","Completed","No Results Available","Acute Respiratory Infections|Acute Rhinosinusitis","Drug: Acetaminophen|Drug: Amoxicillin|Drug: Dextromethorphan hydrobromide (10mg/5ml) with guaifenesin (100mg/5ml)|Drug: Mucinex OTC (guaifenesin)|Drug: Pseudoephedrine Sustained Action|Drug: Saline spray (0.65%)","Washington University School of Medicine|National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult|Senior","Phase IV",172,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","05-0140","September 14, 2006","01/10/2006",2010-08-01,"September 27, 2010","01/09/2010","",2009-05-01,"SNOT-16 to measure disease-specific quality of life","http://ClinicalTrials.gov/show/NCT00377403",NA
"2789",2789,"NCT00090103","Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment","Completed","Has Results","Benign Prostatic Hyperplasia","Drug: dutasteride|Drug: tamsulosin","GlaxoSmithKline","Male","Adult|Senior","Phase III",4844,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ARI40005","August 24, 2004","01/11/2003",2009-09-01,"June 17, 2010","01/06/2010","",2009-09-01,"Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.|Number of Participants With AUR or BPH-related Surgery|Number of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4|The Number of Participants With Each of the Five Components of BPH Clinical Progression|Number of Events of Symptom Deterioration at the Indicated Time Periods|Number of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria|Number of Participants With an Event of Post-baseline BPH-related Hematospermia|Adjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12, 24, 36, and 48|Adjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12, 24, 36, and 48|Adjusted Mean Percent Change From Baseline in Prostate Volume at Months 12, 24, 36, and 48|Adjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12, 24, 36, and 48|Number of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit|Number of \Yes\"" Responses to the Question: \""Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned\""?.|Number of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit|Number of \""Yes\"" Responses to the Question: \""Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?\""|Number of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI","http://ClinicalTrials.gov/show/NCT00090103",NA
"2792",2792,"NCT00403403","A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)","Completed","No Results Available","Small Cell Lung Cancer","Drug: bevacizumab|Drug: chemotherapy|Drug: placebo","Genentech","Both","Adult|Senior","Phase II",102,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","AVF3995g","November 21, 2006","01/03/2007",NA,"September 2, 2009","01/09/2009","",2009-02-01,"Progression-free survival|Overall survival|Objective response and duration of response|Serious and select adverse events","http://ClinicalTrials.gov/show/NCT00403403",NA
"2794",2794,"NCT00407303","Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)","Completed","No Results Available","Mantle-Cell Lymphoma","Drug: Obatoclax mesylate (GX15-070MS)|Drug: Obatoclax","Gemin X","Both","Adult|Senior","Phase I|Phase II",24,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEM012","December 1, 2006","01/10/2006",2009-11-01,"September 13, 2010","01/09/2010","",2009-03-01,"Determine the response rate to obatoclax in combination with Bortezomib and characterize the safety profile|Peripheral blood counts; Bone marrow aspirates and biopsies; Transfusion and growth factor requirements","http://ClinicalTrials.gov/show/NCT00407303",NA
"2803",2803,"NCT00415103","AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors","Completed","No Results Available","Leukemia|Lymphoma","Drug: Aprepitant|Drug: Palonosetron|Drug: Granisetron","PETHEMA Foundation|Merck","Both","Adult|Senior","Phase IV",196,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2006-00055-18","December 21, 2006","01/11/2006",2009-09-01,"September 17, 2009","01/09/2009","AMENO-2",2009-09-01,"Determinate the security, tolerability and efficacy of aprepitant plus palonosetron versus granisetron in the prevention of nausea and emesis induced by chemotherapy in patients treated with haematopoietic progenitors transplant","http://ClinicalTrials.gov/show/NCT00415103",NA
"2820",2820,"NCT00448903","Clinical Trial to Evaluate the Efficacy and Safety of Sodium Bemiparin for Treatment of Diabetic Foot Ulcers","Completed","No Results Available","Foot Ulcer, Diabetic","Drug: Bemiparin|Drug: Placebo","Rovi Pharmaceuticals Laboratories","Both","Adult|Senior","Phase III",329,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ROV-BEM-2006-01|2006-005201-60","March 15, 2007","01/03/2007",2010-04-01,"May 13, 2010","01/05/2010","",2009-12-01,"total healing with intact skin or a significant improvement defined as a reduction of ulcer area > or = 50% or one degree reduction on Wagner Classification.|incidence of major bleeding and the incidence of adverse events.","http://ClinicalTrials.gov/show/NCT00448903",NA
"2857",2857,"NCT00507403","Infliximab and Methotrexate in Ankylosing Spondylitis","Completed","No Results Available","Ankylosing Spondylitis","Drug: infliximab","University Hospital, Tours|Institut National de la Sant?¢ Et de la Recherche M?¢dicale, France","Both","Adult","Phase IV",30,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label","PHRR/04/PG-SPAXIM","July 24, 2007","01/10/2007",2009-12-01,"February 2, 2010","01/02/2010","SPAXIM",2009-10-01,"Pharmacokinetic properties of infliximab in AS patients with or without methotrexate|Individual pharmacokinetic modelisation of infliximab","http://ClinicalTrials.gov/show/NCT00507403",NA
"2890",2890,"NCT00560703","Treatment of Patients With Blepharitis and Facial Rosacea","Completed","No Results Available","Blepharitis|Meibomianitis|Dry Eye","Drug: COL-101 (doxycycline, USP) capsules|Drug: placebo","Galderma","Both","Adult|Senior","Phase II",70,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COL-101-BLEPH-201","November 16, 2007","01/11/2007",2009-07-01,"December 2, 2010","01/12/2010","",2009-05-01,"Change in Ocular Surface Disease Index Change in bulbar conjunctival hyperemia|Change in Schirmer tear test at each study visit Change in tear break-up time at each study visit Change in meibum character/fluidity at each study visit Change in meibomian gland inspissation at each study visit","http://ClinicalTrials.gov/show/NCT00560703",NA
"2894",2894,"NCT00537303","Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: insulin detemir|Drug: insulin aspart|Drug: insulin aspart","Novo Nordisk","Both","Adult|Senior","Phase IV",296,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NN304-1833|2007-000123-18","September 28, 2007","01/10/2007",2009-03-01,"October 14, 2010","01/10/2010","",2009-03-01,"Glycosylated Haemoglobin A1c (HbA1c)|Glycosylated Haemoglobin A1c (HbA1c)|Hypoglycaemic Episodes|Biochemistry: Serum Alanine Aminotransferase|Haematology: Haemoglobin Measured in Blood|Cardiovascular Risk Marker: High-sensitivity C-reactive Peptide","http://ClinicalTrials.gov/show/NCT00537303",NA
"2897",2897,"NCT00571103","Acamprosate in the Treatment of Pathological Gambling","Completed","No Results Available","Pathological Gambling Disorder","Drug: acamprosate","University of Iowa|University of Nebraska|Forest Laboratories","Both","Adult|Senior","Phase IV",30,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Black2|IRB 200608747","December 10, 2007","01/10/2007",2009-07-01,"October 1, 2009","01/10/2009","",2009-07-01,"The primary efficacy measure will be be the YBOCS-PG total score.|The secondary efficacy evaluations will include the GSAS, CGI-R, GAS, and the CGI-S.","http://ClinicalTrials.gov/show/NCT00571103",NA
"2901",2901,"NCT00575003","Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis","Completed","No Results Available","Perennial Allergy to House Dust Mite and/or Cat","Drug: CYT003-QbG10","Cytos Biotechnology AG","Both","Adult","Phase II",64,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CYT003-QbG10 08","December 14, 2007","01/12/2007",2009-03-01,"April 24, 2009","01/04/2009","",2009-03-01,"Conjunctival provocation test with allergen and rhinoconjunctivitis symptoms in daily life|Safety and tolerability of the vaccine by collection of adverse events","http://ClinicalTrials.gov/show/NCT00575003",NA
"2906",2906,"NCT00482703","A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia","Completed","Has Results","Myeloid Leukemia, Chronic","Drug: Dasatinib|Drug: dasatinib","Bristol-Myers Squibb","Both","Adult|Senior","Phase I|Phase II",23,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA180-138","June 4, 2007","01/05/2007",2009-05-01,"November 30, 2010","01/11/2010","",2009-05-01,"Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24|Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations, and Deaths During Treatment|Complete Hematologic Response (CHR) in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24|Time to Major Cytogenetic Response (MCyR)|Pharmacokinetics of Dasatinib (BMS-354825) as Characterized by Population Pharmacokinetics|Duration of MCyR|Time to CHR|Duration of CHR|Progression-Free Survival (PFS)|Expression of BCR-ABL Gene Mutations of RNA (mRNA)|Mutational Spectrum of BCR-ABL|Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at End of Study|Hematologic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at End of Study","http://ClinicalTrials.gov/show/NCT00482703",NA
"2913",2913,"NCT00598403","Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis","Completed","No Results Available","Urinary Tract Infections","Drug: cefditoren pivoxil|Drug: Ciprofloxacin","Tedec-Meiji Farma, S.A.","Female","Adult|Senior","Phase III",611,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TM-ME1207/311|2007-001486-15","January 9, 2008","01/11/2007",2010-06-01,"June 28, 2010","01/06/2010","",2009-12-01,"Microbiological efficacy|Clinical efficacy","http://ClinicalTrials.gov/show/NCT00598403",NA
"2950",2950,"NCT00651703","Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients","Completed","No Results Available","Malignant Melanoma","Biological: CYT004-MelQbG10 + Montanide|Biological: CYT004-MelQbG10 + Montanide + Imiquimod|Biological: CYT004-MelQbG10 + Imiquimod|Biological: CYT004-MelQbG10 intra nodal injection","Cytos Biotechnology AG","Both","Adult|Senior","Phase II",21,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CYT004-MelQbG10 04","April 1, 2008","01/04/2008",2010-07-01,"November 11, 2010","01/11/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00651703",NA
"2960",2960,"NCT00673803","Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification","Completed","No Results Available","Cataract","Procedure: cataract surgery","Hospital Hietzing","Both","Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","preloaded 2008","May 6, 2008","01/12/2008",2010-06-01,"August 16, 2010","01/12/2008","",2009-07-01,"PCO rate","http://ClinicalTrials.gov/show/NCT00673803",NA
"2961",2961,"NCT00663403","Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)","Completed","Has Results","Critically Ill|Hemodialysis","Drug: Daptomycin","University of Michigan|Cubist Pharmaceuticals","Both","Adult|Senior","Phase IV",8,"Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label","063940|HUM00005646","April 18, 2008","01/02/2007",2009-04-01,"August 27, 2010","01/05/2009","",2009-04-01,"Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis|Daptomycin Dose Actually Administered|Observed Daptomycin Peak Serum Concentration|Daptomycin Volume of Distribution at Steady State|Daptomycin Total Body Clearance|Daptomycin Half-life|Daptomycin Free Fraction","http://ClinicalTrials.gov/show/NCT00663403",NA
"2962",2962,"NCT00675103","Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients","Completed","No Results Available","Treatment Failure Gout","Drug: pegloticase 8 mg i.v.","Savient Pharmaceuticals","Both","Adult|Senior","Phase III",18,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C0409","May 6, 2008","01/05/2008",2009-04-01,"March 2, 2010","01/03/2010","",2009-01-01,"evaluate the safety profile of pegloticase in this patient population|clinical effect on quality of life, functional improvement,swollen and tender joints, and tophus burden","http://ClinicalTrials.gov/show/NCT00675103",NA
"3016",3016,"NCT00751803","BI 44370 TA in Acute Migraine Attack","Completed","No Results Available","Migraine Disorders","Drug: BI 44370 TA|Drug: Eletriptan","Boehringer Ingelheim Pharmaceuticals","Both","Adult","Phase II",416,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1246.4|EudraCT No : 2008-000079-31","August 25, 2008","01/08/2008",NA,"June 25, 2009","01/06/2009","",2009-05-01,"The primary endpoint is a pain free response, defined as reduction of severe or moderate headache to no headache, 2 hours after dosing.|Efficacy: pain relief, sustain pain free and pain relief, relief of associated migraine symptoms, relapse and recurrence, global evaluation of medication, use of rescue medication, time to meaningful relief Safety: adverse events, laboratory parameters","http://ClinicalTrials.gov/show/NCT00751803",NA
"3026",3026,"NCT00777803","NT 201 in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines","Completed","No Results Available","Glabellar Frown Lines","Drug: NT 201 Botulinum neurotoxin type A, free of complexing proteins|Drug: Botulinum toxin type A","Merz Pharmaceuticals GmbH","Female","Adult","Phase III",380,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","MRZ 60201 GL_3002","October 21, 2008","01/10/2008",2009-05-01,"June 2, 2009","01/06/2009","Head2Head",2009-02-01,"Independent raters assessment|Independent raters assessment","http://ClinicalTrials.gov/show/NCT00777803",NA
"3038",3038,"NCT00794703","A Study to Compare Efficacy and Safety of Mycamine?ó and Itraconazole for Preventing Fungal Infections","Completed","No Results Available","Fungemia|Fungal Infections","Drug: micafungin (Mycamine)|Drug: itraconazole","Astellas Pharma Inc","Both","Adult|Senior","Phase III",288,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","MCFGCN02-0","November 19, 2008","01/11/2008",2009-11-01,"February 8, 2010","01/02/2010","",2009-11-01,"Treatment success rate (fungal breakthrough rate)|Incidence of proven or probable invasive fungal infection|The usage rate of systemic antifungal agents|Time to treatment failure|Assessment of Adverse events, Laboratory examinations and vital signs evaluation","http://ClinicalTrials.gov/show/NCT00794703",NA
"3041",3041,"NCT00801203","A Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects With a History of Stress Urinary Incontinence","Completed","No Results Available","Stress Urinary Incontinence","Procedure: IRCT","Pneumoflex Systems, LLC|Ockham Development Group","Female","Adult|Senior","Phase II|Phase III",180,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)","PNEU-01-004","December 1, 2008","01/12/2008",2009-07-01,"July 17, 2009","01/07/2009","",2009-07-01,"Sensitivity to identify SUI in women with a history of SUI and specificity to not identify SUI in healthy women without a history of SUI|Positive predictive value (PPV) and negative predictive value (NPV) of the IRCT administered with urodynamic testing|Urodynamic parameters after IRCT and VCT in normal healthy women and women with a history of SUI","http://ClinicalTrials.gov/show/NCT00801203",NA
"3050",3050,"NCT00811603","Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery","Completed","No Results Available","Cesarean Section|Infection","Drug: Cefazolin (Timing of Antibiotic Prophylaxis)","MemorialCare|University of California, Irvine","Female","Adult|Senior","Phase III",50,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","474-07","December 17, 2008","01/08/2008",2009-09-01,"September 17, 2009","01/09/2009","",2009-06-01,"To assess the rates of maternal infectious morbidity with preoperative administration of antibiotics when compared to antibiotic prophylaxis given following umbilical cord clamping|To assess incidence of neonatal infectious morbidity (i.e. rates of sepsis work-up, confirmed sepsis, and length of hospital stay) between two study arms","http://ClinicalTrials.gov/show/NCT00811603",NA
"3086",3086,"NCT00870103","Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery","Completed","Has Results","Cataract","Drug: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops","Alcon Research","Both","Adult|Senior","Phase IV",64,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RM-08-05","September 26, 2008","01/09/2008",NA,"March 3, 2010","01/03/2010","",2009-02-01,"The Percentage of Patients With a Score of Zero for Anterior Chamber Cells.|The Percentage of Patients With no Ocular Pain","http://ClinicalTrials.gov/show/NCT00870103",NA
"3143",3143,"NCT00972803","The Effects of Pistacia Mutica on De Novo Dental Plaque Formation, Gingival Inflammation and Oral Microorganisms","Completed","No Results Available","Gingivitis","Drug: pistacia Mutica extract|Drug: Placebo|Drug: Chlorhexidine","Tabriz University","Both","Adult","Phase II",25,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","8660","September 8, 2009","01/05/2008",2009-05-01,"September 8, 2009","01/02/2007","",2009-05-01,"The effects of pistacia Mutica extract (PM) on de novo plaque formation.|staining effects of pistacia Mutica extract in comparison to placebo or Chlorhexidine","http://ClinicalTrials.gov/show/NCT00972803",NA
"3190",3190,"NCT00676403","Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients","Completed","Has Results","Restless Legs Syndrome","Drug: placebo|Drug: Pregabalin|Drug: Pregabalin|Drug: Pregabalin|Drug: Pregabalin|Drug: Pregabalin","Pfizer","Both","Adult","Phase II",137,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A0081183","May 8, 2008","01/04/2008",2009-01-01,"June 28, 2010","01/06/2010","",2009-01-01,"Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6|Number of Subjects Responding to Treatment as Assessed by the Clinical Global Impression - Improvement Scale (CGI-I)|Number of Subjects With Categorical Scores on the Clinical Global Impression - Severity Scale (CGI-S)|Subjective Sleep Questionnaire (SSQ): Latency Subscale; Observed Change From Baseline|Subjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline|Subjective Sleep Questionnaire: Number of Awakenings Subscale; Observed Change From Baseline|Subjective Sleep Questionnaire: Total Wake Time After Sleep Onset Subscale; Observed Change From Baseline|Subjective Sleep Questionnaire: Quality of Sleep Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Disturbance Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Snoring Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Awaken Short of Breath or With Headache Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Somnolence Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Quantity Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): 6-Item Sleep Problems Index; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): 9-Item Sleep Problems Index; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Optimal Sleep; Observed Cases Summarized by Week|Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6|Medical Outcomes Study Short Form 36 (SF-36): Change From Baseline to Week 6|Medical Outcomes Study Short Form 36 (SF-36); Number of Subjects With Self-Evaluated Change in Health Status Scores","http://ClinicalTrials.gov/show/NCT00676403",NA
"3235",3235,"NCT01126203","Randomized Prospective Study of Selective Laser Trabeculoplasty (SLT) Versus Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension","Completed","No Results Available","Exfoliation Syndrome|Ocular Hypertension","Procedure: SLT|Procedure: ALT","University of Calgary|Canadian Glaucoma Clinical Research Council","Both","Adult|Senior","Phase III",25,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SLT1","May 17, 2010","01/09/2006",2009-10-01,"May 21, 2010","01/05/2010","SLT",2009-09-01,"IOP (Intraocular Pressure)","http://ClinicalTrials.gov/show/NCT01126203",NA
"3273",3273,"NCT01184703","Low Glycemic Index Diet in Patients With Type 1 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Low GI food","Steno Diabetes Center","Both","Adult","Phase III",65,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","GI-project_1","August 17, 2010","01/06/2007",2009-12-01,"September 2, 2010","01/08/2010","LGID1",2009-08-01,"HbA1c|LDL-cholesterol","http://ClinicalTrials.gov/show/NCT01184703",NA
"3292",3292,"NCT01215903","Fish Gelatin Supplement and Omega-3 Supplement in Obese or Overweight Subjects With Insulin Resistance","Completed","No Results Available","Insulin Resistance|Type 2 Diabetes","Dietary Supplement: Fish gelatin and omega-3 polyunsaturated fatty acid|Dietary Supplement: Omega-3 polyunsaturated fatty acid","Laval University|Advanced Foods and Materials Network, Canada (funding)|Institut des Nutraceutiques et Aliments fonctionnels, Quebec (Clinical nutrition facilities)|University of Guelph, Ontario (data measurements, analysis and interpretation)|Ocean Nutrition Canada, Halifax (in-kind support: omega-3 supplements)|Kenney & Ross Limited, Nova Scotia (in-kind support: Fish gelatin)","Both","Adult|Senior","Phase II",21,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Prevention","SIRUL-85742","October 5, 2010","01/11/2007",2009-05-01,"October 22, 2010","01/10/2010","",2009-05-01,"Insulin sensitivity|Plasma lipids and lipoproteins|Blood pressure|Plasma and serum inflammatory markers|Glucose tolerance|Energy intake|Fatty acids of phospholipids in skeletal muscle","http://ClinicalTrials.gov/show/NCT01215903",NA
"3297",3297,"NCT01223703","PUFAs and Left Ventricular Function in Heart Failure","Completed","No Results Available","Dilated Cardiomyopathy|Heart Failure","Drug: n-3 PUFAs|Drug: Placebo","Universit?? degli Studi di Brescia","Both","Adult|Senior","Phase III",133,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CS-PUFA-02","October 18, 2010","01/11/2007",2009-06-01,"October 18, 2010","01/09/2007","CS-PUFA-02",2009-06-01,"Improvement in left ventricular systolic function|Left ventricular diastolic function; functional capacity; NYHA functional class","http://ClinicalTrials.gov/show/NCT01223703",NA
"3387",3387,"NCT00019604","Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer","Completed","No Results Available","Liver Cancer|Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Procedure: computed tomography|Procedure: magnetic resonance imaging|Procedure: positron emission tomography|Procedure: radiofrequency ablation|Procedure: radionuclide imaging|Procedure: ultrasound imaging|Radiation: fludeoxyglucose F 18|Radiation: gadopentetate dimeglumine","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",58,"NIH","Interventional","Primary Purpose: Treatment","CDR0000066875|NCI-99-C-0025","July 11, 2001","01/08/1998",NA,"February 20, 2009","01/04/2008","",2009-01-01,"Nature and duration of response|Treatment effects|Response as measured by positron emission tomography with fludeoxyglucose F 18 (FDG-PET) after treatment|Comparison of FDG-PET results with CT scan, biopsy, and serum marker results|Comparison of FDG-PET performance with CT scan and MRI performance in assessing efficacy of study treatment","http://ClinicalTrials.gov/show/NCT00019604",NA
"3412",3412,"NCT00056004","Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia","Completed","No Results Available","Head and Neck Cancer|Lung Cancer","Drug: zileuton","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",134,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Prevention","CDR0000271915|WSU-D-2405|WSU-093201MP4F","March 6, 2003","01/09/2002",NA,"April 13, 2010","01/04/2010","",2009-03-01,"Bronchial dysplasia number and grade at 6 months|Biomarkers (Ki-67, Cyclin D1, bcl-2, bax, caspase-3) by immunohistochemistry at 6 and 12 months|Biomarkers (5-HETE, LTB-4) by blood and BAL levels at 6 and 12 months|Adverse events as measured by number and severity monthly","http://ClinicalTrials.gov/show/NCT00056004",NA
"3494",3494,"NCT00188604","The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer","Completed","No Results Available","Breast Neoplasms|Lymphedema","Drug: sodium selenite","University Health Network, Toronto|Princess Margaret Hospital, Canada","Female","Adult|Senior","Phase II",34,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double-Blind|Primary Purpose: Treatment","UHN REB 03-0741-C","September 12, 2005","01/01/2004",2009-01-01,"August 12, 2010","01/08/2010","",2009-01-01,"To assess the effectiveness of orally administered selenium compared to placebo in reducing arm lymphedema in patients treated with surgery (axiallary nodal dissection) and radiotherapy for breast cancer.|To assess the toxicity of selenium.|To assess the association of selenium, quality of life and limb function.","http://ClinicalTrials.gov/show/NCT00188604",NA
"3504",3504,"NCT00199004","Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab","Completed","No Results Available","Adult Acute Lymphocytic Leukemia","Drug: Cyclophosphamide|Drug: Dexamethasone / Prednisolone|Drug: Vincristine|Drug: Daunorubicin|Drug: Asparaginase|Drug: Methotrexate|Drug: Cytarabine|Drug: Mercaptopurine|Drug: G-CSF|Drug: Vindesine|Drug: VP16|Drug: Adriamycin|Drug: Thioguanine|Drug: VM26|Drug: Rituximab|Procedure: CNS irradiation|Procedure: Mediastinal irradiation (if residual TU)|Procedure: Stem cell transplantation","Johann Wolfgang Goethe University Hospitals","Both","Child|Adult","Phase IV",60,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL03","September 12, 2005","01/04/2004",2009-03-01,"August 20, 2010","01/05/2008","",2009-03-01,"Remission rate (cytologic, Remission rate (molecular), Remission duration, Disease free survival, Overall survival|Dose and time compliance, Toxicity according to WHO, Death in induction and CR, Course of MRD","http://ClinicalTrials.gov/show/NCT00199004",NA
"3532",3532,"NCT00251004","Efficacy and Safety Study of Everolimus Plus Cyclosporine and Mycophenolic Acid Plus Cyclosporine in Kidney Transplants","Completed","No Results Available","Kidney Transplantation|Graft Rejection","Drug: everolimus|Drug: mycophenolate","Novartis","Both","Adult|Senior","Phase III",832,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD001A2309","November 7, 2005","01/09/2005",2009-10-01,"September 2, 2010","01/09/2010","",2009-08-01,"treated biopsy acute rejection, graft loss, and survival|graft loss, survival, and renal function","http://ClinicalTrials.gov/show/NCT00251004",NA
"3544",3544,"NCT00273104","The Effect of Lifestyle Intervention Versus Gastric Bypass on Various Comorbidities in Morbidly Obese Subjects","Completed","No Results Available","Obstructive Sleep Apnea|Diabetes Mellitus|Hypertension","Procedure: Behavior","The Hospital of Vestfold|Health Region South-East","Both","Adult","Phase III",180,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","S-05175","January 5, 2006","01/12/2005",2009-12-01,"January 28, 2009","01/01/2009","",2009-12-01,"Improvement of co-morbidities","http://ClinicalTrials.gov/show/NCT00273104",NA
"3548",3548,"NCT00270504","Memokath?ó 044TW Stent for Treatment of Urethral Stricture","Completed","No Results Available","Urethral Stricture","Device: Memokath stenting","Engineers & Doctors Wallsten Medical Group","Male","Adult|Senior","Phase III",92,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1-044TWUS","December 23, 2005","01/12/2002",2009-11-01,"November 17, 2009","01/12/2008","",2009-10-01,"Stent/control effectiveness - urethral patency|Peak urinary flow rate|Re-intervention|Standard survey instruments (QOL, IPSS etc.)|Stent placement success|Stent removal success","http://ClinicalTrials.gov/show/NCT00270504",NA
"3552",3552,"NCT00283504","A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy","Completed","No Results Available","Allergic Asthma","Drug: ANTI-IGE THERAPY (XOLAIR)","Children's Hospital of The King's Daughters|Novartis|Genentech","Both","Child|Adult","Phase IV",40,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","IRB# 05-08-EX-0247","January 26, 2006","01/01/2006",2009-01-01,"May 25, 2010","01/01/2006","",2009-01-01,"description of sputum inflammatory markers|improvement in lung functions and symptoms scores","http://ClinicalTrials.gov/show/NCT00283504",NA
"3585",3585,"NCT00340704","PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder","Completed","No Results Available","Bladder, Neurogenic","Drug: tamsulosin hydrochloride","Astellas Pharma Inc|Boehringer Ingelheim Pharmaceuticals","Both","Child","Phase II",143,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","527.66","June 19, 2006","01/04/2006",2009-06-01,"July 22, 2009","01/07/2009","",2009-06-01,"Responder rate who achieves a decrease in their detrusor leak point pressure to less than 40cm H2O|Improvement or stabilization of hydronephrosis and/or hydroureter base|Assessment of pharmacokinetics parameters","http://ClinicalTrials.gov/show/NCT00340704",NA
"3605",3605,"NCT00335504","Atorvastatin, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia","Completed","No Results Available","Colorectal Cancer|Precancerous Condition","Dietary Supplement: oligofructose-enriched inulin|Drug: atorvastatin calcium|Drug: sulindac|Other: placebo","Mayo Clinic|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",112,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Prevention","CDR0000467755|MAYO-030103|MAYO-1395-05","June 8, 2006","01/03/2006",NA,"February 1, 2010","01/01/2009","",2009-04-01,"Percent change in number of rectal aberrant cryptic foci (ACF) as measured by magnification chromoendoscopy|Screening for possible phase III testing|Effects on proliferation (Ki67 expression) and apoptosis (caspase-3 expression) as measured by biopsy samples obtained from normal-appearing rectal mucosa at baseline and after completion of study treatment|Correlation of endoscopic features with histologic characteristics of rectal ACF|Observation of the natural history of rectal ACF in patients receiving placebo|Adverse events|Utilization of a biospecimen repository archive","http://ClinicalTrials.gov/show/NCT00335504",NA
"3622",3622,"NCT00401804","Bortezomib-Dexamethasone-Doxorubicin-Study","Completed","No Results Available","Multiple Myeloma|Renal Insuficiency","Drug: Dexamethasone, Bortezomib, Doxorubicin","Austrian Forum Against Cancer","Both","Adult|Senior","Phase II",40,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Eudract Number: 2005-003001-85","November 20, 2006","01/02/2006",2009-11-01,"July 22, 2010","01/07/2010","",2009-11-01,"","http://ClinicalTrials.gov/show/NCT00401804",NA
"3628",3628,"NCT00409604","PROTECT : Pacing to Protect Heart for Damage From Blocked Heart Vessel and From Re-opening Blocked Vessel(s)","Completed","No Results Available","Acute Myocardial Infarction","Device: Temporary RV VVI pacing","Guidant Corporation","Both","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CS1017-001","December 8, 2006","01/12/2006",2009-08-01,"August 30, 2010","01/08/2010","",2009-08-01,"Infarct size (area under the curve of creatine kinase) at baseline compared with MRI at 4 months and at 12 months","http://ClinicalTrials.gov/show/NCT00409604",NA
"3632",3632,"NCT00417404","Vitamin A and Very Low Birthweight Babies (VitAL)","Completed","No Results Available","Preterm Birth|Retinopathy of Prematurity","Drug: Aquasol A|Drug: aquasol A|Other: sham injection","Glasgow Royal Infirmary|Chief Scientist Office of the Scottish Government","Both","Child","Phase IV",94,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","RNO50BO17|CZB/4/316","December 29, 2006","01/01/2007",2009-12-01,"June 24, 2010","01/06/2010","",2009-12-01,"retinal function at 36 corrected weeks|plasma levels of vitamin A at birth, 7 and 28 days|hepatic stores of vitamin A at 36 corrected weeks","http://ClinicalTrials.gov/show/NCT00417404",NA
"3633",3633,"NCT00412204","Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise","Completed","No Results Available","COPD","Drug: tiotropium bromide|Other: Placebo","McMaster University|Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase IV",20,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","205.371","December 14, 2006","01/06/2006",2009-04-01,"October 20, 2009","01/10/2009","",2009-04-01,"Efficiency of gas exchange Ve/VO2 and Ve/VCO2 before and after 3 weeks treatment with tiotropium compared to placebo.|Intensity of dyspnea|Effort during incremental and steady state exercise|Exercise endurance capacity|Dyspnea and leg effort|Ventilatory capacity|Alveolar volume|Kco|Cardiac output at rest and during steady state exercise before and after 3 weeks treatment with tiotropium compared to placebo.|Ventilation/perfusion before and after 3 weeks treatment with tiotropium compared to placebo|Ventilation during incremental and steady state exercise before and after 3 weeks treatment with tiotropium compared to placebo.","http://ClinicalTrials.gov/show/NCT00412204",NA
"3635",3635,"NCT00395304","Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)","Completed","Has Results","Asthma","Drug: fluticasone propionate + montelukast|Drug: fluticasone propionate|Drug: fluticasone propionate + salmeterol","National Heart, Lung, and Blood Institute (NHLBI)","Both","Child|Adult","Phase III",182,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","444|5U10HL064313|5U10HL064288|5U10HL064305|5U10HL064295|5U10HL064287|5U10HL064307","October 31, 2006","01/03/2007",2009-06-01,"September 17, 2010","01/05/2010","BADGER",2009-06-01,"The Number of Participants With a Differential Response to the Three Step-up Therapies Based on Fixed Threshold Criteria for the Following Three Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations, Asthma Control Days and FEV1.|Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1)|Post-bronchodilator Forced FEV1|Forced Vital Capacity (FVC)|FEV1/FVC|Morning Peak Expiratory Flow Rate (PEFR)|Evening PEFR|PEFR Variability|Impulse Oscillometry|Methacholine PC20|Exhaled Nitric Oxide|Asthma Control Test|Asthma Quality of Life|Time Until First Asthma Exacerbation|Adverse Events","http://ClinicalTrials.gov/show/NCT00395304",NA
"3645",3645,"NCT00429104","Herceptin and GM-CSF for Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Herceptin|Drug: GM-CSF","M.D. Anderson Cancer Center|Bayer","Female","Child|Adult|Senior","Phase II",18,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM01-0100","January 29, 2007","01/08/2002",2009-11-01,"September 30, 2010","01/09/2010","",2009-11-01,"To see if Herceptin (trastuzumab) and GM-CSF can help to shrink or slow the growth of breast cancer that has spread outside the breast, which did not respond to earlier treatment with Herceptin.|To study the safety of this treatment.","http://ClinicalTrials.gov/show/NCT00429104",NA
"3658",3658,"NCT00449904","Phase III ALTU-135 Safety Trial","Completed","No Results Available","Cystic Fibrosis|Exocrine Pancreatic Insufficiency","Drug: ALTU-135","Alnara Pharmaceuticals","Both","Child|Adult|Senior","Phase III",215,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","767","March 19, 2007","01/06/2007",2009-06-01,"December 13, 2010","01/12/2010","DIGEST",2009-05-01,"To evaluate the long-term safety and tolerability of ALTU-135 treatment in patients with Cystic Fibrosis-related exocrine pancreatic insufficiency.","http://ClinicalTrials.gov/show/NCT00449904",NA
"3672",3672,"NCT00472004","Study Comparing 17B Estradiol/TMG CC 1mg Vs. Tibolone In Postmenopausal Women","Completed","No Results Available","Vasomotor Symptoms","Drug: 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|Drug: Tibolone (Livial)","Wyeth","Female","Adult","Phase IV",204,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0753T-101800|B2481004","May 8, 2007","01/02/2006",2009-12-01,"October 28, 2010","01/10/2010","",2009-12-01,"Decreased of Vasomotor Symptoms [from baseline to six and twelve months]|Changes in Body Weight (from baseline to six and twelve months)|Quality of Life (from baseline to six and twelve months)|Treatment Adherence (from baseline to six and twelve months)|Breast Tenderness (from baseline to six and twelve months)","http://ClinicalTrials.gov/show/NCT00472004",NA
"3681",3681,"NCT00483704","Acute Treatment of Multiple Migraines With or Without Aura in Adults","Completed","No Results Available","Migraines","Drug: Comparator: MK0974|Drug: Comparator: Placebo","Merck","Both","Adult|Senior","Phase III",1800,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2007_546|MK0974-031","May 15, 2007","01/08/2008",2009-04-01,"September 3, 2009","01/09/2009","",2009-03-01,"Compare the effectiveness, consistency, and safety of two doses of MK0974 with placebo in patients with acute migraine|Sustained pain freedom and total migraine freedom","http://ClinicalTrials.gov/show/NCT00483704",NA
"3709",3709,"NCT00533104","Cell Therapy in Chronic Limb Ischemia","Completed","No Results Available","Peripheral Vascular Diseases","Procedure: BM-MNC preparation|Procedure: PB-MNC preparation","CHU de Reims","Both","Adult|Senior","Phase I|Phase II",40,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PHRC R?¢gion 2003 / R11-05 / 95","September 19, 2007","01/10/2004",2009-02-01,"February 5, 2009","01/02/2009","",2009-02-01,"Survival without major amputation|clinical symptoms and haemodynamic parameters","http://ClinicalTrials.gov/show/NCT00533104",NA
"3716",3716,"NCT00527904","A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)","Completed","Has Results","Gastric Ulcer","Drug: PN400 (VIMOVO)|Drug: PN 400 (VIMOVO)","POZEN","Both","Adult|Senior","Phase III",239,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PN400-304","September 10, 2007","01/03/2007",2009-03-01,"August 27, 2010","01/08/2010","",2009-03-01,"Number of Subjects Monitored for Long-term Safety of PN 400","http://ClinicalTrials.gov/show/NCT00527904",NA
"3759",3759,"NCT00594204","Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking","Completed","Has Results","Smoking Cessation","Drug: varenicline tartrate (CP-526, 555-18)|Drug: Placebo","Pfizer","Both","Adult","Phase IV",593,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","A3051080","January 3, 2008","01/04/2008",2009-08-01,"July 14, 2010","01/07/2010","",2009-06-01,"Number of Participants With 4-week Continuous Abstinence|Number of Participants With Continuous Abstinence|Number of Participants With Seven-day Point Prevalence of Abstinence","http://ClinicalTrials.gov/show/NCT00594204",NA
"3762",3762,"NCT00617604","A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients","Completed","No Results Available","De Novo Kidney Transplantation","Drug: Alefacept|Drug: placebo","Astellas Pharma Inc","Both","Adult","Phase II",221,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","0485-CL-E201|2007-002092-14","February 6, 2008","01/12/2007",2009-09-01,"September 29, 2010","01/09/2010","",2009-09-01,"Occurence of and time to biopsy proven acute rejection at 6 months|Safety","http://ClinicalTrials.gov/show/NCT00617604",NA
"3764",3764,"NCT00434304","Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)","Completed","Has Results","Parkinson Disease|Parkinson's Disease","Drug: Ropinirole prolonged release/extended release(PR/XR)","GlaxoSmithKline","Both","Adult|Senior","Phase II",62,"Industry","Interventional","Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ROP106064","February 9, 2007","01/04/2007",2009-03-01,"November 24, 2010","01/11/2010","",2009-03-01,"Food Effects on Cmax and Cmin of SKF101468 (Ropinirole) and Its Metabolites|Food Effects on AUC0-24 of SKF101468 (Ropinirole) and Its Metabolites|Food Effects on Tmax of SKF101468 (Ropinirole) and Its Metabolites|Plasma Trough Concentrations of SKF101468 (Ropinirole) and Its Metabolites|Total Score in the Japanese UPDRS Part III|Change From Baseline in the Japanese UPDRS Part III|Percent Change From Baseline in the Japanese UPDRS Part III|Percentage of Responders of the Total Score in the Japanese UPDRS Total Score in Part III|Total Score in the Japanese UPDRS Part I|Change From Baseline in the Japanese UPDRS Part I|Percent Change From Baseline in the Japanese UPDRS Part I|Total Score in the Japanese UPDRS Part II|Change From Baseline in the Japanese UPDRS Part II|Percent Change From Baseline in the Japanese UPDRS Part II|Total Score in the Japanese UPDRS Part IV|Change From Baseline in the Japanese UPDRS Part IV|Percent Change From Baseline in the Japanese UPDRS Part IV|Summary of the Modified Hoehn & Yahr Criteria Stages|Number of Participants Scored as Responders on the Clinician's Global Impression (CGI) Scale|Percentage of Participants Who Remained in the Study on the Indicated Days|Change From Baseline in Albumin, Total Protein, and Hemoglobin at Weeks 16 and 52|Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase at Weeks 16 and 52|Change From Baseline in Total Bilirubin, Blood Urea Nitrogen, and Creatinine at Weeks 16 and 52|Change From Baseline in Blood Urea Nitrogen, Cholesterol, Chloride, Potassium, and Sodium at Weeks 16 and 52|Change From Baseline in Prolactin at Weeks 16 and 52|Change From Baseline in Hematocrit at Weeks 16 and 52|Change From Baseline in Platelet Count and White Blood Cell Count at Weeks 16 and 52|Change From Baseline in Red Blood Cell Count at Weeks 16 and 52|Urinalysis Data|Number of Participants With the Indicated Shift From Baseline in 12-Lead Electrocardiogram (ECG) Findings at Weeks 16 and 52|Change From Baseline in Supine and Standing Systolic and Diastolic Blood Pressure at Weeks 16 and 52|Change From Baseline in Supine and Standing Pulse Rate at Weeks 16 and 52","http://ClinicalTrials.gov/show/NCT00434304",NA
"3768",3768,"NCT00629304","Multicenter Assessment of the PDA-FIT System in Type 1 Diabetic Patients","Completed","No Results Available","Type 1 Diabetes","Device: placebo|Device: VISITS + PDA-FIT system|Device: PDA-FIT System + telephone follow-up","Centre d???Etudes et de Recherche pour l???Intensification du Traitement du Diab??te|University Hospital, Grenoble","Both","Adult|Senior","Phase III",180,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","DCIC 07 08","February 26, 2008","01/09/2007",2009-08-01,"August 27, 2009","01/08/2009","TELEDIAB-1",2009-03-01,"Comparison of HbA1c mean between the 3 groups|Absolute HbA1c differences (M0-M6)|HbA1c changes at M0, M3 and M6|Percentage of patients reaching HbA1c <7.5% at 6 months|Mean of blood glucose values as provided by glucose meters during the 14 days prior to inclusion and prior to the 6 months-visit|Frequency of severe hypoglycaemic episodes and ketoacidosis episodes during the study period|Frequency of symptomatic benign hypoglycaemic episodes during the week prior to inclusion and prior to the 6 months-visit|8-point blood glucose profiles at inclusion and 6 months|Quality of life at inclusion and 6 months, using the DHP scale and the Satisfaction item of the DQOL questionnaire|Improvement in diabetes care, as assessed by the change in blood glucose testing frequency, reflected by the glucose meter memory|Time spent by physicians with patients during visits (either face to face visits or phone call visits) and time spent by patients during transport, waiting time and lost working time|Satisfaction of patients and physicians with the system and willingness to carry on the use of the system in routine care|Effective number of patients carrying on the use of the system in routine care, at their own expense and in agreement with their physician","http://ClinicalTrials.gov/show/NCT00629304",NA
"3777",3777,"NCT00646204","Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease","Completed","No Results Available","Parkinson's Disease","Drug: Memantine|Drug: placebo","Baylor College of Medicine|Forest Laboratories","Both","Adult|Senior","Phase IV",40,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H-18912","December 28, 2007","01/04/2006",2009-03-01,"April 30, 2009","01/04/2009","",2009-02-01,"This is an exploratory study. The primary efficacy point will be global impressions.|Analyses will be computed for the categorical dependent variables (DV): spirograph, pouring, subjective ADL, observed tremor, global assessment by examiner, global assessment by patient, and subjective assessment by patient scores.","http://ClinicalTrials.gov/show/NCT00646204",NA
"3789",3789,"NCT00663104","Effect of Exercise and Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause","Completed","No Results Available","Bone Diseases|Metabolic Syndrome X|Coronary Disease","Behavioral: exercise|Behavioral: exercise + cimicifuga racemosa|Behavioral: wellness control, placebo","University of Erlangen-N??rnberg Medical School|Institute of Gynecology, University of Erlangen-Nurnberg|Siemens-Betriebskrankenkasse","Female","Adult","Phase III",126,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Prevention","OFZ-Trace","April 21, 2008","01/04/2008",2009-11-01,"December 2, 2009","01/12/2009","",2009-06-01,"Bone Mineral Density|body composition|blood lipids, glucose|blood pressure|10 year CHD-risk|menopausal complaints","http://ClinicalTrials.gov/show/NCT00663104",NA
"3807",3807,"NCT00650104","Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164","Completed","Has Results","Parkinson's Disease","Drug: Ropinirole XL (formerly CR)","GlaxoSmithKline","Both","Adult|Senior","Phase III",76,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","101468/196","March 27, 2008","01/05/2002",2009-03-01,"April 22, 2010","01/04/2010","",2009-03-01,"Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population)|Number of Participants With the Indicated Number of Adverse Events (AEs)|Unified Parkinson's Disease Rating Scale (UPDRS) Total Activities of Daily Living Score (Responder Population)|Unified Parkinson's Disease Rating Scale (UPDRS) Total Activities of Daily Living Scores (Maintained Responder Population)|Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (ITT Population)|Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (Reponder Population)|Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (Maintained Responder Population)|Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (ITT Population)|Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (Responder Population)|Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (Maintained Responder Population)","http://ClinicalTrials.gov/show/NCT00650104",NA
"3808",3808,"NCT00689104","Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder","Completed","No Results Available","Urinary Bladder, Overactive","Drug: YM178|Drug: Tolterodine 4 mg|Drug: Placebo","Astellas Pharma Inc","Both","Adult|Senior","Phase III",1987,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","178-CL-046|2007-001451-19","May 29, 2008","01/04/2008",2009-03-01,"March 23, 2010","01/03/2010","SCORPIO",2009-03-01,"Change from baseline to end of treatment in mean number of micturitions/24 h.|Change from baseline to end of treatment in mean number of incontinence episodes/24 h.|Change from baseline in mean volume voided per micturition|Change from baseline in mean number of urgency incontinence episodes/24 h.|Change from baseline in mean number of urgency episodes (grade 3 and/or 4) /24 h.","http://ClinicalTrials.gov/show/NCT00689104",NA
"3835",3835,"NCT00733304","An Extension to Study MD7108240","Completed","No Results Available","Macular Degeneration","Drug: Pazopanib","GlaxoSmithKline","Both","Adult|Senior","Phase II",99,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MD7111396","August 12, 2008","01/06/2008",2009-05-01,"October 14, 2010","01/10/2010","",2009-05-01,"Safety and tolerability endpoints include ophthalmic examinations, vital signs (heart|Change in: visual acuity, central retinal thickness retinal morphology measured by OCT an imaging technique measured monthly, neovascular size lesion size, characteristics fibrosis atrophy blood measured fundus photography, fluorescein angiography|Change in visual acuity (number of letters read on standardized ETDRS charts).|Change from baseline in central retinal/lesion thickness and changed in retinal morphology as measured by optical coherence tomography|Change in enovascular size, lesion size and characteristics as measured by flourescein angiography and fundus photography.","http://ClinicalTrials.gov/show/NCT00733304",NA
"3853",3853,"NCT00765804","Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye","Completed","No Results Available","Dry Eye Syndrome","Drug: EGP-437 with EyeGate?ó II System|Drug: Sodium citrate buffer solution with EyeGate?ó II System","Eyegate Pharmaceuticals, Inc.","Both","Child|Adult|Senior","Phase II",89,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EGP-437-002","October 2, 2008","01/10/2008",2009-02-01,"August 27, 2010","01/08/2010","",2009-02-01,"Sign: Corneal fluorescein staining after CAE exposure at Visit 5|Symptom: Ocular discomfort during CAE exposure at Visit 5|Sign: Fluorescein staining at each visit over 3 weeks|Symptom: Ocular discomfort pre and post CAE","http://ClinicalTrials.gov/show/NCT00765804",NA
"3856",3856,"NCT00771004","Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.","Completed","No Results Available","Oxidative Stress|Coronary Artery Disease|Type 2 Diabetes","Drug: Pioglitazone|Drug: Placebo","Takeda Pharma GmbH","Both","Adult|Senior","Phase II",63,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ATS K021|2006-002237-20|D-PIO-111|U1111-1115-9160","October 9, 2008","01/08/2006",2009-02-01,"July 1, 2010","01/07/2010","",2009-02-01,"Incidence of Cardiac Troponin I elevation (greater than 1 upper limit of normal) post-percutaneous coronary intervention with stent implantation.|Incidence of Creatine Kinase (Myocard-type) post-percutaneous coronary intervention with stent implantation.|Mean peak values of Troponin I and Creatine Kinase (Myocard-type) post-percutaneous coronary intervention with stent implantation.|Frequency of Doppler-detected microembolism measured by high intensity transient signals during percutaneous coronary intervention with stent implantation (sub-study Jena only).|Time course of Troponin I Laboratory Procedure.|Time course of high-sensitive-C-Reactive Peptide Laboratory Procedure.|Time course of nitrotyrosine Laboratory Procedure.|Time course of Asymmetric dimethylarginine Laboratory Procedure.|Time course of E-selectin Laboratory Procedure.|Time course of Myoglobin Laboratory Procedure.|Time course of Visfatin Laboratory Procedure.|Time course of Proinsulin intact Laboratory Procedure.|Time course of Adiponectin Laboratory Procedure.","http://ClinicalTrials.gov/show/NCT00771004",NA
"3870",3870,"NCT00799604","Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery","Completed","No Results Available","Hypertension","Drug: Clevidipine butyrate injectable emulsion","The Medicines Company","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TMC-CLV-08-02","November 26, 2008","01/11/2008",NA,"October 27, 2009","01/10/2009","SPRINT",2009-10-01,"The mean maximum absolute and percent change in systolic blood pressure from baseline within 15 minutes from the first bolus dose of clevidipine (pre-anesthesia).|The percentage of patients with systolic blood pressure ???85 mm Hg within 15 minutes from the first bolus dose of clevidipine (pre-anesthesia).|The median time to 5%, 10%, and 15% systolic blood pressure reduction from baseline within 15 minutes from the first bolus dose of clevidipine (pre-anesthesia).|The mean percent change in systolic blood pressure from baseline over time during the first 15 minutes following first bolus dose of clevidipine (pre-anesthesia).|The median time to 50% and, when available, 90% recovery from maximum systolic blood pressure effect following the first bolus dose of clevidipine (pre-anesthesia).|The area under the concentration versus time curve, maximum concentration, elimination half-life, clearance, volume of distribution, and elimination rate constant will be determined, if feasible, for each individual patient.|The following pharmacodynamic parameters will be determined, if feasible, for each individual patient following the first bolus dose of clevidipine: area under the effect-time curve, maximum effect, and time to maximum observed effect.|The relationship between change in systolic blood pressure from baseline and the blood concentration of clevidipine following the first bolus dose.|Incidence of adverse events and serious adverse events.|Change in heart rate.","http://ClinicalTrials.gov/show/NCT00799604",NA
"3881",3881,"NCT00819104","A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components","Completed","No Results Available","Primary Hypertension","Drug: Metoprolol XL 50mg + Amlodipine 5mg|Drug: Metoprolol XL 25 mg + Amlodipine 2.5mg|Drug: Metoprolol XL 50mg|Drug: Metoprolol XL 25 mg|Drug: Amlodipine 5mg","AstraZeneca|St. John's Research Institute","Both","Adult|Senior","Phase IV",402,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D4022L00006","January 7, 2009","01/11/2008",2009-08-01,"September 7, 2009","01/09/2009","MARS",2009-08-01,"Change in BP with Selomax?ºÑ 50/5 at the end of the randomisation treatment period.|Change in BP (SBP,DBP & mean BP) with SelomaxTM 25/2.5 at the end of the randomisation period.|Change in the heart rate,Number of responders & control rates.|Incidence of adverse events (serious and non-serious) in each arm.Change in hemogram, serum chemistry (Liver function tests (LFT), Renal function tests (RFT), plasma lipids, Blood Glucose, HbA1c), and Ur.albumin","http://ClinicalTrials.gov/show/NCT00819104",NA
"3904",3904,"NCT00865904","Study of VX-809 in Cystic Fibrosis Subjects With the ???F508-CFTR Gene Mutation","Completed","No Results Available","Cystic Fibrosis","Drug: VX-809|Drug: VX-809|Drug: VX-809|Drug: VX-809|Drug: VX-809 Placebo","Vertex Pharmaceuticals Incorporated","Both","Adult|Senior","Phase II",90,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","VX08-809-101","March 18, 2009","01/03/2009",2009-12-01,"January 7, 2010","01/01/2010","",2009-12-01,"Safety and tolerability assessments based on adverse events, hematology, clinical chemistry, urinalysis, electrocardiograms (ECGs), vital signs, and physical examinations.|Pharmacodynamic assessments using spirometry (FVC, FEV1, and FEF25-75), sweat chloride, nasal potential difference (NPD), and the CF Questionnaire-Revised (CFQ-R), and evaluation of pharmacokinetic parameters.","http://ClinicalTrials.gov/show/NCT00865904",NA
"3911",3911,"NCT00734604","A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.","Completed","Has Results","Erectile Dysfunction","Drug: tadalafil once a day [T(OaD)]|Drug: sildenafil citrate as needed [S(PRN)]|Drug: tadalafil as needed [T(PRN)]","Eli Lilly and Company","Male","Adult|Senior","Phase III",378,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","12313|H6D-CR-S024","August 12, 2008","01/08/2008",2009-09-01,"October 21, 2010","01/10/2010","",2009-09-01,"Change From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)|Change From Baseline Between Tadalafil Once a Day (OaD) and Tadalafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)|Change From Baseline to Endpoint in the Spontaneity Domain of PAIRS|Change From Baseline to Endpoint in the Time Concerns Domain of PAIRS|Change From Baseline to Endpoint in the Erectile Function Domain of the International Index of Erectile Function (IIEF)|Change From Baseline to Endpoint in the Proportion of Days With at Least One Morning Erection|Change From Baseline to Endpoint in the Intercourse Satisfaction (IS) Domain of the IIEF|Change From Baseline to Endpoint in the Overall Satisfaction (OS) Domain of the IIEF|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Score at Endpoint|Number of Participants With at Least One Serious Adverse Event|Change From Baseline to Endpoint in the Self-Esteem And Relationship (SEAR) Questionnaire Transformed Total Score|Question 1 \I Felt as if I Did Not Have ED\"" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint|Question 2 \""I Felt in Control of my Sex Life\"" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint|Question 3 \""I Felt the Drug Was in Control of my Erections\"" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint|Question 4 \""I Felt Like a Whole Man\"" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint""","http://ClinicalTrials.gov/show/NCT00734604",NA
"3921",3921,"NCT00888004","Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients","Completed","No Results Available","Parkinson's Disease|L-dopa Induced Dyskinesia","Drug: AFQ056|Drug: Placebo","Novartis","Both","Adult|Senior","Phase II",28,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAFQ056A2206|2008-006270-15","April 23, 2009","01/03/2009",NA,"October 22, 2009","01/10/2009","",2009-08-01,"Number and severity of Dyskinesias and the safety and tolerability of administering AFQ056 in combination with L-dopa|Safety and tolerability of administration of AFQ056 in combination with L-dopa","http://ClinicalTrials.gov/show/NCT00888004",NA
"3926",3926,"NCT00904904","Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery","Completed","No Results Available","Cataract|Inflammation","Drug: Indomethacin ophthalmic solution|Drug: Ketorolac Ophthalmic Solution","Bausch & Lomb, Inc.","Both","Adult|Senior","Phase IV",120,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","539|2007-004686-18","May 19, 2009","01/04/2008",2009-09-01,"December 15, 2010","01/12/2010","",2009-06-01,"Aqueous flare|Aqueous flare|Change from baseline of retinal thickness","http://ClinicalTrials.gov/show/NCT00904904",NA
"3946",3946,"NCT00933504","Dermacyd Silver Floral (Lactic Acid) - Compatibility - Stay on Floral","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Both","Adult","Phase III",55,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LACAC_L_04804","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"Evaluation of the absence of primary and accumulated dermical irritability and dermical sensitivity by using International Contact Dermatitis Research Group (ICDRG) scale","http://ClinicalTrials.gov/show/NCT00933504",NA
"3950",3950,"NCT00941304","Study of BEMA?ºÑ Buprenorphine in the Treatment of Dental Pain","Completed","No Results Available","Dental Pain","Drug: oxycodone|Drug: BEMA?ºÑ Buprenorphine|Drug: Placebo","BioDelivery Sciences International","Both","Adult","Phase II",150,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","BUP-201","July 15, 2009","01/07/2009",2009-11-01,"November 24, 2009","01/11/2009","",2009-10-01,"Sum of Pain Intensity Differences (SPID)","http://ClinicalTrials.gov/show/NCT00941304",NA
"3951",3951,"NCT00942604","A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","Completed","No Results Available","Actinic Keratoses","Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel","Peplin","Both","Adult|Senior","Phase III",203,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","PEP005-028","July 19, 2009","01/07/2009",2009-10-01,"October 6, 2010","01/10/2010","",2009-10-01,"Efficacy (complete clearance of AKs)|Efficacy (partial clearance of AKs)","http://ClinicalTrials.gov/show/NCT00942604",NA
"3957",3957,"NCT00949104","Role of Oral Sucrose in Reducing the Pain to Orogastric Tube Insertion in Preterm Neonates","Completed","No Results Available","Pain in Preterm Neonates","Drug: Sucrose|Drug: Double distilled water","Lady Hardinge Medical College","Both","Child","Phase II|Phase III",120,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OGTPAIN","July 29, 2009","01/01/2008",2009-04-01,"July 29, 2009","01/07/2009","",2009-03-01,"Painful response as assessed by PIPP Scale|Maximum heart rate and minimum oxygen saturation","http://ClinicalTrials.gov/show/NCT00949104",NA
"3973",3973,"NCT00972504","723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover","Completed","No Results Available","Allergic Rhinitis","Drug: placebo|Drug: GSK835726 10mg|Drug: GSK1004723 1000mcg|Drug: Cetirizine 10mg","GlaxoSmithKline","Both","Adult","Phase II",54,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","112864","August 27, 2009","01/06/2009",2009-08-01,"February 25, 2010","01/02/2010","",2009-08-01,"Change from baseline in total nasal symptom score 1-7 hours post dose","http://ClinicalTrials.gov/show/NCT00972504",NA
"3989",3989,"NCT00995904","A Study Investigating the Tolerability and Pharmacokinetics of Submicron Budesonide in Children 4 Through 11 Years Old With a History of Mild-To-Moderate Stable Asthma","Completed","No Results Available","Asthma","Drug: submicron budesonide","MAP Pharmaceuticals, Inc.","Both","Child","Phase II",24,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","MAP0020-CL-P201","October 6, 2009","01/09/2009",2009-11-01,"November 25, 2009","01/11/2009","",2009-11-01,"Evaluate the pharmacokinetic profile of submicron budesonide resulting from inhalation aerosol delivery. The following pharmacokinetic parameters computed include Cmax, tmax, AUC0-last, AUC0-12, AUC1-inf, CL, kel, t ?¥, ??, and relative bioavailability.|Evaluate the safety and tolerability (adverse events) of a single dose of submicron budesonide via inhalation aerosol delivery.","http://ClinicalTrials.gov/show/NCT00995904",NA
"4304",4304,"NCT00188305","A Randomized Trial of Cancer Risk and Health Education in Relatives of Colorectal Cancer Patients","Completed","No Results Available","Colon Cancer|Colonic Neoplasms","Behavioral: General health counselling and risk information","University Health Network, Toronto|Canadian Institutes of Health Research (CIHR)","Both","Adult","Phase III",252,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","UHN04-0729-CE","September 9, 2005","01/01/2005",2009-08-01,"August 7, 2009","01/08/2009","",2009-06-01,"Colorectal cancer risk comprehension and screening knowledge|Intent to screen the colon|Colon screening behaviour|Personality|Psychosocial functioning|Satisfaction","http://ClinicalTrials.gov/show/NCT00188305",NA
"4346",4346,"NCT00250705","Trial of Aripiprazole in the Treatment of CD in Adolescents","Completed","No Results Available","Conduct Disorder","Drug: Aripiprazole","University of Iowa|Bristol-Myers Squibb","Male","Child","Phase IV",12,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200306035|B042700","November 4, 2005","01/05/2004",2009-03-01,"January 14, 2010","01/01/2010","",2009-03-01,"The primary outcome efficacy measures will be the Rating of Aggression Against People and/or Property Scale (RAAPP) (Kemph et al 1993), Overt Aggression Scale-Modified (OAS-M) (Kay et al 1988), and Children's Aggression Scale-Parent Version (CAS-P)|The secondary outcome measure will be the CGI severity and improvement scale (NIMH, 1985a).","http://ClinicalTrials.gov/show/NCT00250705",NA
"4364",4364,"NCT00270205","Safety and Tolerability of and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving Anti-HIV Treatment","Completed","No Results Available","HIV Infections","Biological: LC002 standard vaccination|Biological: LC002 high-dose vaccination|Biological: LC002 placebo vaccination","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","Phase I|Phase II",24,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","ACTG A5176","December 21, 2005","01/02/2006",NA,"March 24, 2010","01/01/2010","",2009-02-01,"Occurrence of at least one Grade 3 or higher adverse event, including signs/symptoms, lab toxicities, and/or clinical events possibly or definitely related to study treatment|CD4+ T-cell count/ml in PBMCs|CD8+ T-cell count/ml in PBMCs|T-cell count and percent of HIV-1-specific CD4+ and CD8+ T-cell subsets, based on flow cytometry with CFSE staining to detect antigen-specific lymphocyte proliferation responding to whole HIV-1 antigen, p24 protein, and various HIV-1 peptide antigens|T-cell count and percent of HIV-1-specific CD4+ and CD8+ T-cell subsets, based on flow cytometry to detect antigen-specific IFN-gamma- and IL-2-producing cells responding to whole Zn-finger inactivated virus stimulation and various HIV-1 peptide antigens|Magnitude of HIV-specific immune response, as determined by summing the number of spot-forming cells/10^5 PBMCs observed in each ELISPOT assay for IFN-gamma production for whole HIV-1 antigen, p24 protein, and HIV-1 peptide antigen pools|Breadth of HIV-1-specific immune response, as determined by the number of overlapping HIV-1 peptides for which the ELISPOT assay for IFN-gamma production is observed to have five or more spot-forming cells/ 10^5 PBMCs|Lymphocyte proliferation stimulation Index (SI) in response to whole HIV-1 antigen, p24 antigen, and pooled HIV-1 peptide antigens|Anti-dsDNA antibody response","http://ClinicalTrials.gov/show/NCT00270205",NA
"4401",4401,"NCT00332605","N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence","Completed","No Results Available","Methamphetamine Dependence","Drug: Naltrexone|Drug: Placebo|Drug: N-Acetyl Cysteine","University of Minnesota - Clinical and Translational Science Institute","Both","Adult","Phase II",47,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","0601M80486","May 30, 2006","01/06/2006",2010-01-01,"March 23, 2010","01/03/2010","",2009-12-01,"Penn Craving Scale|Urine toxicology screens","http://ClinicalTrials.gov/show/NCT00332605",NA
"4433",4433,"NCT00388505","Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis","Completed","No Results Available","Cystic Fibrosis","Drug: Tobramycin Inhalation Powder|Drug: Tobramycin Solution","Novartis","Both","Child|Adult|Senior","Phase III",517,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTBM100C2302","October 16, 2006","01/02/2006",2009-03-01,"June 23, 2009","01/06/2009","EAGER",2009-03-01,"Safety assessed by incidence of treatment-emergent adverse events and clinical laboratory results|Serum tobramycin concentrations|Audiology test results (at select CF centers)|Change in forced expiratory volume in one second (FEV1) at baseline and after Week 24|Patient satisfaction, assessed using the Treatment Satisfaction Questionnaire for Medication","http://ClinicalTrials.gov/show/NCT00388505",NA
"4459",4459,"NCT00393705","Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Insulin Biphasic Aspart 30/70|Drug: insulin lispro LM|Drug: insulin lispro MM|Drug: insulin lispro LM","Eli Lilly and Company","Both","Adult|Senior","Phase IV",302,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10916|F3Z-VI-S019","October 26, 2006","01/10/2006",2009-03-01,"July 15, 2010","01/07/2010","S019",2009-03-01,"Hemoglobin A1c (HbA1c) at 16 Week Endpoint|Percentage of Patients Achieving Hemoglobin A1c (HbA1c) <7% and HbA1c ???6.5% at 16 Week Endpoint|Change From Baseline in Hemoglobin A1c (HbA1c) at 16 Week Endpoint|2-hour Postprandial Plasma Glucose Concentrations After the Midday Meal From Self-monitored 7-point Plasma Glucose at 16 Week Endpoint|Mean 2-hour Postprandial Blood Glucose Excursions After Midday Meal at 16 Week Endpoint|Mean Daily Blood Glucose Values at 16 Week Endpoint|Number of Patients With Self-reported Hypoglycemic Episodes|30-Day Adjusted Rate of Hypoglycemic Events|Change From Baseline in Weight at 16 Week Endpoint|Total Daily Insulin Dose at 4 Weeks and 12 Weeks","http://ClinicalTrials.gov/show/NCT00393705",NA
"4478",4478,"NCT00458705","Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: bortezomib|Drug: dexamethasone|Drug: pegylated liposomal doxorubicin hydrochloride|Drug: thalidomide","Memorial Sloan-Kettering Cancer Center","Both","Adult|Senior","Phase II",44,"Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000537583|MSKCC-06067","April 9, 2007","01/11/2006",NA,"December 29, 2009","01/07/2009","",2009-12-01,"Disease response|Toxicity","http://ClinicalTrials.gov/show/NCT00458705",NA
"4487",4487,"NCT00478205","Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: Aricept (donepezil SR 23 mg)|Drug: Aricept (donepezil IR 10 mg)","Eisai Inc.|Eisai Limited","Both","Adult|Senior","Phase III",1200,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E2020-G000-326","May 22, 2007","01/06/2007",NA,"April 25, 2010","01/04/2010","",2009-06-01,"Co-primary parameters: Severe Impairment Battery (SIB); Clinician's Interview-Based Impression of Change (Plus version) (CIBIC); Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL).|Secondary parameters: Mini-Mental State Examination (MMSE), ADCS-ADL, or CIBIC+, depending on region.|Exploratory parameters: Quality of Life in Alzheimer's Disease (QoL-AD), EuroQol-5 Dimensions (EQ-5D), Screen for Caregiver Burden (SCB), Treatment Expectation Scale (TES), Treatment Outcome Scale (TOS), and Goal Attainment Scale (GAtS).|Vital signs, physical and neurological examinations, laboratory screens of blood and urine, and 12-lead electrocardiogram.","http://ClinicalTrials.gov/show/NCT00478205",NA
"4505",4505,"NCT00499005","Carbetocin Versus Syntometrine for the Third Stage of Labour","Completed","No Results Available","Postpartum Haemorrhage","Drug: Syntommetrine and Carbetocin|Drug: Syntommetrine and Carbetocin","National University Hospital, Singapore|National Healthcare Group, Singapore","Female","Adult","Phase IV",720,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)","DSRB Ref: D/04/209|NHG-SIG/07059","July 9, 2007","01/11/2006",2009-07-01,"September 18, 2009","01/09/2009","",2009-04-01,"1. Postpartum haemorrhage (less than or equal to 500 ml) 2. Postpartum haemorrhage (less than or equal to 1000ml) 3. Use of additional uterotonic therapy|1. Adverse effects with the intervention which include headache, nausea, vomiting, elevation of blood pressure and retained placenta 2. Cost effectiveness analysis of the intervention","http://ClinicalTrials.gov/show/NCT00499005",NA
"4513",4513,"NCT00513305","Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide, Compared With Low-Dose Cytarabine Alone, for the Treatment of Elderly Patients With Acute Myeloid Leukemia","Completed","No Results Available","Acute Myeloid Leukemia","Drug: Arsenic Trioxide and Low-Dose Cytarabine|Drug: low-dose cytarabine (LDAC) plus arsenic trioxide","Cephalon","Both","Adult|Senior","Phase III",67,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C18477/3059/AM/US-CA","August 6, 2007","01/10/2007",2009-12-01,"April 23, 2010","01/04/2010","",2009-07-01,"The primary objective is to determine whether low dose cytarabine (LDAC) in combination with arsenic trioxide is more effective than low dose cytarabine alone in achieving complete remission (CR) in elderly patients.|Evaluate the safety of treatment with LDAC in combination with arsenic trioxide","http://ClinicalTrials.gov/show/NCT00513305",NA
"4531",4531,"NCT00545805","Surgical Removal of Visceral Fat Tissue (Omentectomy) Associated to Bariatric Surgery: Effects on Insulin Sensitivity","Completed","No Results Available","Insulin Resistance|Obesity|Metabolic Syndrome X","Procedure: Roux-en-Y Gastric Bypass plus total omentectomy|Procedure: Roux-en-Y Gastric Bypass","University of Campinas, Brazil|Funda????o de Amparo ?? Pesquisa do Estado de S??o Paulo","Female","Adult","Phase II|Phase III",20,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LIMED0001|FAPESP 05/58627-2","October 16, 2007","01/10/2005",2009-06-01,"June 13, 2010","01/06/2010","",2009-06-01,"Increase of insulin sensitivity as measured by euglycemic-hyperinsulinemic clamp.|increase of insulin secretion as measured by intravenous glucose tolerance test|regression of carotid intima-media thickness|Improvement of the insulin cell signalling in the subcutaneous adipose tissue.|increase of adipocytokines linked to greater insulin sensitivity and decrease of others linked to insulin resistance","http://ClinicalTrials.gov/show/NCT00545805",NA
"4534",4534,"NCT00461305","Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea","Completed","Has Results","Dysmenorrhea","Drug: DRSP 3 mg/EE 20 ??g (13 cycles)|Drug: DRSP 3 mg/EE 30 ??g (6 cycles)","Bayer","Female","Adult|Senior","Phase II|Phase III",420,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","91616|310284","April 17, 2007","01/02/2007",2009-08-01,"November 30, 2010","01/11/2010","",2009-01-01,"Number of Participants With Intracyclic Bleeding at Cycle 6|Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 6|Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 13|Distribution of Total Dysmenorrhea Score at Cycle 6|Distribution of Total Dysmenorrhea Score at Cycle 13|Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 6|Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 13|Distribution of Severity of Lumbago During Menstruation at Cycle 6|Distribution of Severity of Lumbago During Menstruation at Cycle 13|Distribution of Severity of Headache During Menstruation at Cycle 6|Distribution of Severity of Headache During Menstruation at Cycle 13|Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 6|Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 13|Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 6|Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 13|Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 6|Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 13|Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 6|Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 13|Number of Any Bleeding Episodes From Cycle 1 to Cycle 6|Number of Any Bleeding Episodes From Cycle 1 to Cycle 13|Number of Any Bleeding Days From Cycle 1 to Cycle 6|Number of Any Bleeding Days From Cycle 1 to Cycle 13|Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 6|Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 13|Number of Participants With Withdrawal Beeding From Cycle 1 to Cycle 6|Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 13|Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 6|Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 13|Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 6|Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 13|Change in Serum Carbohydrate Antigen-125 (CA-125) From Baseline to Cycle 6|Change in Serum CA-125 From Baseline to Cycle 13|Change in Serum C-reactive Protein (CRP) From Baseline to Cycle 6|Change in Serum CRP From Baseline to Cycle 13","http://ClinicalTrials.gov/show/NCT00461305",NA
"4535",4535,"NCT00527605","Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)","Completed","Has Results","Benign Prostatic Hyperplasia|Prostatic Hyperplasia","Drug: Dutasteride 0.5mg capsule|Drug: Dutasteride matched placebo","GlaxoSmithKline","Male","Adult|Senior","Phase III",253,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARI108898","September 10, 2007","01/10/2007",2009-03-01,"October 28, 2010","01/10/2010","",2009-03-01,"Percent Change From Baseline in the Prostate Volume at Month 6|Percent Change From Baseline in the Prostate Volume at Month 3|Change From Baseline in the Prostate Volume at Month 6|Change From Baseline in the Prostate Volume at Month 3|Percent Change From Baseline in the Serum Dihydrotestosterone (DHT) at Month 6|Percent Change From Baseline in the Serum DHT at Month 3|Change From Baseline in the Serum DHT at Month 6|Change From Baseline in the Serum DHT at Month 3|Percent Change From Baseline in the American Urological Association Symptom Index (AUA-SI) Score at Month 6|Percent Change From Baseline in the AUA-SI Score at Month 3|Change From Baseline in the AUA-SI Score at Month 6|Change From Baseline in the AUA-SI Score at Month 3|Percent Change From Baseline in Maximum Urinary Flow Rate (Qmax) at Month 6|Percent Change From Baseline in Qmax at Month 3|Change From Baseline in Qmax at Month 6|Change From Baseline in Qmax at Month 3","http://ClinicalTrials.gov/show/NCT00527605",NA
"4537",4537,"NCT00553605","Efficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic","Completed","No Results Available","Pain","Drug: Ketoprofen 100mg|Drug: Parecoxib 40mg","Pfizer","Both","Adult","Phase IV",336,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A3481065","November 2, 2007","01/06/2007",2009-06-01,"July 2, 2009","01/07/2009","NAP",2009-06-01,"Mean pain intensity difference assessed by VAS between Time 0 and at 30 minutes after the administration of study medication.|Proportion of patients with at least 1 grade improvement in pain relief (PR) 30 minutes after administration of study medication.|Mean pain intensity difference at 120 minutes after the administration of study medication.|Physician's global evaluation of study medication at 30 and 120 minutes after the administration of study medication.|Sum of time interval weighted pain relief scores through the first 2 hours after the administration of study medication (TOTPAR2).|Time to rescue medication up to 120 minutes after the administration of study medication.|Incidence rate of adverse events and serious adverse events.|Time-specific pain intensity VAS scores at 30 and 120 minutes.|Changes in vital signs.|Patient's global evaluation of study medication at 30 and 120 minutes after the administration of study medication.|Pain Relief at all post dose time points.|Time-specific pain intensity difference (PID).","http://ClinicalTrials.gov/show/NCT00553605",NA
"4552",4552,"NCT00535405","A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease","Completed","Has Results","Hypercholesterolemia","Drug: Atorvastatin 10 mg|Drug: Ezetimibe 10 mg/simvastatin 20 mg|Drug: Atorvastatin 20 mg|Drug: Ezetimibe 10 mg/simvastatin 40 mg|Drug: Atorvastatin 40 mg","Merck|Merck Shering-Plough JV Study","Both","Adult|Senior","Phase III",1289,"Industry|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2007_588|MK0653A-128","September 25, 2007","01/11/2007",2009-04-01,"June 3, 2010","01/06/2010","",2009-03-01,"Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12|Percentage of Patients Who Achieved LDL-C <70 mg/dL at Week 12|Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12|Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12|Percentage of Patients With High Risk for CHD Who Achieved LDL-C <70 mg/dL at Week 12|Percentage of Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12","http://ClinicalTrials.gov/show/NCT00535405",NA
"4575",4575,"NCT00612105","Safety/Efficacy Study of Retigabine vs. Placebo in PHN","Completed","No Results Available","Postherpetic Neuralgia","Drug: Retigabine|Drug: Placebo","Valeant Pharmaceuticals North America","Both","Adult|Senior","Phase II",187,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VRX-RET-E22-NP201|VRX-RET-E22-NP201","January 25, 2008","01/10/2007",2009-12-01,"January 7, 2010","01/01/2010","",2009-05-01,"Primary endpoint will be the change from baseline in average pain score over the last 7 days of the Maintenance Phase.","http://ClinicalTrials.gov/show/NCT00612105",NA
"4600",4600,"NCT00651105","Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects","Completed","No Results Available","Type-2 Diabetes|Healthy","Drug: Vildagliptin|Drug: Placebo","Novartis","Both","Adult|Senior","Phase III",63,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLAF237A2347","March 28, 2008","01/02/2008",NA,"November 5, 2009","01/11/2009","",2009-05-01,"GLP-1 and non GLP-1 effects of LAF237 on glucagon secretion in patients with Type-2 diabetes and matching healthy subjects|Effects of LAF237 on prandial glucose profiles, prandial insulin, and gastric-emptying in patients with Type-2 diabetes and in matching healthy subjects.","http://ClinicalTrials.gov/show/NCT00651105",NA
"4603",4603,"NCT00658905","Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Infant Formula for Preterm Infants","Completed","No Results Available","Replacement Therapy in Preterm Infants","Drug: BSSL|Drug: Placebo","Biovitrum","Both","Child","Phase II",33,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BVT.BSSL-020","April 14, 2008","01/04/2008",2009-05-01,"August 4, 2009","01/08/2009","",2009-05-01,"Coefficient of Fat Absorption in stool|Change in length and body weight between the start and end of each treatment period","http://ClinicalTrials.gov/show/NCT00658905",NA
"4632",4632,"NCT00701805","Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)","Completed","No Results Available","Secondary Hyperparathyroidism|Hemodialysis","Drug: paricalcitol","Abbott|Abbott Japan Co.,Ltd","Both","Adult|Senior","Phase II",107,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","M10-312","June 17, 2008","01/07/2008",NA,"January 12, 2010","01/12/2009","",2009-12-01,"The incident rate of hypercalcemia|The incident rate of hyperphosphatemia|The mean change of iPTH|The proportion of subjects with iPTH <= 180 pg/mL, or >= 50% decrease of iPTH|The proportion of subjects with two or more <= 180 pg/mL, or >= 50% decrease of iPTH. The time course change of mean iPTH. The duration of two consecutive iPTH >= 50% decrease or <= 180 pg/mL.|The proportion of subjects whose abnormal alkaline phosphatase or BSAP at baseline was normalized","http://ClinicalTrials.gov/show/NCT00701805",NA
"4662",4662,"NCT00752505","A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.","Completed","No Results Available","Fibromyalgia","Drug: Esreboxetine|Drug: Esreboxetine","Pfizer","Both","Adult","Phase II",89,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A6061061","September 12, 2008","01/08/2008",2009-06-01,"July 9, 2009","01/07/2009","",2009-06-01,"Computer based psychometric tests|A questionnaire to evaluate the subjects cognitive status|A questionnaire to assess the subjects mood|A question to assess the subjects pain at visits|A daily diary to assess the subjects pain|A questionnaire to evaluate the impact the subject perceives fibromyalgia has on their cognitive ability|Two questionnaires to assess change in the subjects cognitive ability|Safety evaluations: medical history, physical and neurological exam, heart rate and blood pressure lying and standing, laboratory tests, electrical heart trace (ECG), adverse event collection, assessment of suicidal risk","http://ClinicalTrials.gov/show/NCT00752505",NA
"4664",4664,"NCT00757705","An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexible Dosed Paliperidone ER in Patients With Schizophrenia (INSTAR)","Completed","No Results Available","Schizophrenia","Drug: Paliperidone ER","Johnson & Johnson Taiwan Ltd","Both","Adult|Senior","Phase IV",299,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR014308","September 19, 2008","01/02/2008",2009-05-01,"April 26, 2010","01/04/2010","",2009-05-01,"The maintained efficacy of flexibly dosed paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with other atypical oral antipsychotics at screening and after 2, 4, 12 and 24 weeks.|To explore the tolerability and safety of flexibly dosed paliperidone ER in patients with schizophrenia previously unsuccessfully treated with other oral atypical antipsychotics at screening and after 2, 4, 12 and 24 weeks.","http://ClinicalTrials.gov/show/NCT00757705",NA
"4693",4693,"NCT00800605","Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection","Completed","No Results Available","Influenza","Biological: Vero cell-derived, trivalent, seasonal influenza vaccine|Biological: Placebo: Phosphate-buffered saline","Baxter Healthcare Corporation","Both","Adult","Phase III",7252,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","720802","December 1, 2008","01/12/2008",2009-06-01,"October 28, 2009","01/10/2009","",2009-05-01,"To demonstrate the efficacy of an investigational Vero cell-derived influenza vaccine to prevent infection with an influenza virus that is antigenically similar to one of the three strains in the vaccine|Rate of subjects with seroconversion at Day 21 after vaccination","http://ClinicalTrials.gov/show/NCT00800605",NA
"4703",4703,"NCT00816205","An Open Label Study to Examine the Effect of Coated Nifedipine Suppositories on Anal Pressure in Healthy Subjects","Completed","No Results Available","Anal Resting Pressure","Drug: Coated Nifedipine Suppositories","RDD Pharma Ltd","Both","Adult","Phase I|Phase II",NA,"Industry","Interventional","Intervention Model: Single Group Assignment","RDD102","December 31, 2008","",2009-04-01,"April 6, 2009","01/04/2009","",2009-04-01,"The primary efficacy parameter is change in Resting Anal Pressure from baseline.","http://ClinicalTrials.gov/show/NCT00816205",NA
"4757",4757,"NCT00905905","Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction","Completed","No Results Available","Myocardial Infarction","Drug: Simvastatin|Drug: Ezetimibe-Simvastatin","Brasilia Heart Study Group","Both","Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","EMI","May 20, 2009","01/05/2009",2010-01-01,"March 23, 2010","01/03/2010","",2009-12-01,"C- reactive Protein (CRP) elevation during the first 7 days after myocardial infarction|Endothelial function 30 days after myocardial infarction|Stress Insulin Resistance","http://ClinicalTrials.gov/show/NCT00905905",NA
"4771",4771,"NCT00926705","Dexmedetomidine Infusion in Hypospadias Surgery","Completed","No Results Available","Pain","Drug: Dexmedetomidine and Fentanyl|Drug: Fentanyl","University of Jordan","Male","Child","Phase III",48,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","alghanem2","June 22, 2009","01/06/2008",2009-01-01,"June 22, 2009","01/06/2009","",2009-01-01,"Intraoperative and postoperative fentanyl requirement (in microg/kg)","http://ClinicalTrials.gov/show/NCT00926705",NA
"4890",4890,"NCT01121705","Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Genotype 3 Patients","Completed","No Results Available","Chronic Hepatitis","Drug: Peg Interferon alpha2b + Ribavirin","Casa Sollievo della Sofferenza IRCCS","Both","Adult","Phase III",360,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","2007-00437470","May 4, 2010","01/01/2007",2009-06-01,"May 10, 2010","01/06/2009","genotype-3",2009-06-01,"SVR","http://ClinicalTrials.gov/show/NCT01121705",NA
"4896",4896,"NCT01073605","Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation","Completed","Has Results","Growth Disorders|Intrauterine Growth Retardation","Drug: Genotonorm|Drug: Genotonorm|Drug: Genotonorm","Pfizer","Both","Child","Phase III",208,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","93-8122-001|A6281186, CTN 93-8122-001","February 22, 2010","01/07/1993",2009-05-01,"November 8, 2010","01/02/2010","",2009-05-01,"Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm|Annual Growth Rate Standard Deviation Score (SDS)|Change From Baseline in Annual Growth Rate SDS|Height (cm)|Change From Baseline in Height (cm)|Height (SDS)|Change From Baseline in Height (SDS)|Body Mass Index (BMI)|Weight|Change From Baseline in Bone Age|Change From Baseline in Bone Age/Change From Baseline in Chronological Age Ratio|Chronological Age at Onset of Puberty|Number of Subjects Reaching Puberty","http://ClinicalTrials.gov/show/NCT01073605",NA
"4960",4960,"NCT01232205","Antioxidant Supplementation in Pregnant Women","Completed","Has Results","Pregnant Women|Preeclampsia","Dietary Supplement: micronutrient antioxidant|Dietary Supplement: Control","Showa University|Indonesia University","Female","Adult","Phase II|Phase III",168,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Prevention","asip02","November 1, 2010","01/06/2001",2010-03-01,"November 2, 2010","01/12/2009","ASIP1",2009-12-01,"Preeclampsia|Preeclampsia|Cell-free mRNA","http://ClinicalTrials.gov/show/NCT01232205",NA
"5052",5052,"NCT00041106","Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: cisplatin|Drug: gefitinib|Drug: gemcitabine hydrochloride","Cancer and Leukemia Group B|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000069443|CALGB-90102","July 8, 2002","01/07/2002",NA,"May 20, 2009","01/11/2004","",2009-05-01,"","http://ClinicalTrials.gov/show/NCT00041106",NA
"5065",5065,"NCT00072306","Neoadjuvant and Adjuvant Pamidronate With Induction and Maintenance Chemotherapy in Treating Patients With Osteosarcoma","Completed","No Results Available","Sarcoma","Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: pamidronate disodium|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI)","Both","Child|Adult|Senior","Phase II",75,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000339591|MSKCC-03074","November 4, 2003","01/07/2003",NA,"December 16, 2009","01/12/2009","",2009-02-01,"Event-free survival 3 years after completion of study treatment|Prosthesis survival as assessed by prosthesis failure when surgery is required|Safety and toxicity as assessed by creatinine and creatinine clearance monthly prior to each course and for 1 year after completion of study treatment|Tumor necrosis as assessed by the Huvos grading system 12 weeks after beginning treatment, at time of definitive surgery after induction chemotherapy|Radiographic response as assessed by RECIST criteria 10 weeks after beginning treatment, after induction chemotherapy, and before definitive surgery|Correlate biological studies with clinical outcome as assessed by protocol 97-094 \Chemotherapy Resistance in Osteogenic Sarcoma) at diagnosis""","http://ClinicalTrials.gov/show/NCT00072306",NA
"5092",5092,"NCT00112606","Lenalidomide in Treating Patients With Stage IV Eye Melanoma","Completed","No Results Available","Intraocular Melanoma","Drug: lenalidomide","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",38,"NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000430670|NCI-05-C-0095|NCI-P6501","June 2, 2005","01/04/2005",NA,"April 21, 2009","01/04/2008","",2009-04-01,"Clinical response rate (complete and partial response)|Toxicity","http://ClinicalTrials.gov/show/NCT00112606",NA
"5181",5181,"NCT00255606","Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: docetaxel|Drug: prednisone","Finnish Uro-Oncological Group 1-2003 at Tampere University Hospital","Male","Adult|Senior","Phase III",360,"Other","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000442891|AVENTIS-FIN-1-2003|FINNISH-URO-OGS-1-2003|PROSTY-FIN-1-2003|ICORG-06-14-Prosty|EU-20891","November 18, 2005","01/08/2005",NA,"January 8, 2011","01/09/2010","",2009-05-01,"Time to treatment failure (TTF)|Quality of life every 6 weeks until TTF|Safety|Overall survival|Response rate|Use of epoetin beta","http://ClinicalTrials.gov/show/NCT00255606",NA
"5256",5256,"NCT00372606","An Evaluation of a Culturally- and Linguistically-Appropriate Online Diet Program for U.S Hispanics","Completed","No Results Available","Obesity","Behavioral: Online MiDieta Diet and Weight Management Program for Hispanics","Robert Wood Johnson Foundation","Both","Adult|Senior","Phase II",1000,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind|Primary Purpose: Prevention","51759","September 6, 2006","01/09/2004",2009-02-01,"October 6, 2009","01/10/2009","",2009-02-01,"Weight loss|Dietary behaviors|Fitness activities|Program acceptability by users","http://ClinicalTrials.gov/show/NCT00372606",NA
"5273",5273,"NCT00399906","A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis","Completed","No Results Available","Psoriasis","Drug: BMS-582949|Drug: Placebo","Bristol-Myers Squibb","Both","Adult|Senior","Phase I|Phase II",99,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","IM119-013","November 14, 2006","01/08/2007",2009-04-01,"January 6, 2011","01/05/2009","",2009-01-01,"The primary endpoint is the proportion of subjects achieving an IGA score of clear or almost clear at Week 12|Proportion of subjects achieving a PASI-50|Proportion of subjects achieving a PASI-75|Proportion of subjects achieving a PASI-90","http://ClinicalTrials.gov/show/NCT00399906",NA
"5291",5291,"NCT00431106","Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Gemcitabine|Drug: Capecitabine|Drug: Vinorelbine","Hellenic Oncology Research Group|University Hospital of Crete","Female","Adult|Senior","Phase III",144,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/02.11","February 2, 2007","01/04/2002",2009-01-01,"September 25, 2009","01/09/2009","",2009-01-01,"Time to tumor progression between the two treatment arms|Overall survival","http://ClinicalTrials.gov/show/NCT00431106",NA
"5294",5294,"NCT00432406","Tumor Necrosis Factors (TNF)-?? Blockade for Psoriatic Arthritis","Completed","No Results Available","Psoriatic Arthritis","Drug: Infliximab|Drug: Etanercept","Chinese University of Hong Kong","Both","Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PSA-2006-002","February 6, 2007","01/05/2006",2009-03-01,"March 10, 2009","01/03/2009","",2009-03-01,"Changes in the degree of inflammation as reflected by the MRI score, cytokines and chemokine levels|Changes in the cardiovascular risk factor levels which are directly mediated by TNF-??|Number of patients who can achieve ACR 20|Correlation of clinical parameter, inflammatory markers and MRI findings","http://ClinicalTrials.gov/show/NCT00432406",NA
"5306",5306,"NCT00459706","Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept","Completed","No Results Available","Active Rheumatoid Arthritis","Device: Etanercept Prefilled Syringe|Device: Etanercept Autoinjector","Wyeth","Both","Adult|Senior","Phase III",534,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0881K1-6000","April 11, 2007","01/09/2007",2009-09-01,"February 23, 2010","01/02/2010","",2009-04-01,"Perception and satisfaction","http://ClinicalTrials.gov/show/NCT00459706",NA
"5307",5307,"NCT00461006","A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: aleglitazar|Drug: Actos","Hoffmann-La Roche","Both","Adult|Senior","Phase II",176,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","BC20653","April 16, 2007","",2009-04-01,"May 13, 2009","01/05/2009","",2009-04-01,"Relative change from baseline in glomerular filtration rate|Relative change from baseline in ERPF and UACR|Absolute change in HbAlc, FPG and FPI.|AEs, laboratory parameters.","http://ClinicalTrials.gov/show/NCT00461006",NA
"5308",5308,"NCT00409006","Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers","Completed","Has Results","Non-small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Gefitinib","Eli Lilly and Company","Both","Adult|Senior","Phase II",70,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10918|H3E-AA-S110","December 6, 2006","01/02/2007",2010-05-01,"August 13, 2010","01/08/2010","",2009-08-01,"Progression-Free Survival (PFS)|Number of Participants With Tumor Response|Duration of Response for Responders|Overall Survival","http://ClinicalTrials.gov/show/NCT00409006",NA
"5339",5339,"NCT00511706","Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-VEGF Treatment in Patients With Age-Related Macular Degeneration","Completed","No Results Available","Choroidal Neovascularization|Age-Related Maculopathy","Drug: Dexamethasone and ranibizumab|Other: Sham injection and ranibizumab","Allergan","Both","Adult|Senior","Phase II",243,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","206207-016","August 2, 2007","01/11/2007",2009-03-01,"April 15, 2010","01/04/2010","",2009-03-01,"Time to retreat with ranibizumab|Visual Acuity|Central Retinal Thickness (OCT)|Lesion size (FA)|Quality of Life questionnaires","http://ClinicalTrials.gov/show/NCT00511706",NA
"5350",5350,"NCT00527306","Prevention of Recurrent Aphthous Stomatitis Using Vitamins","Completed","No Results Available","Aphthous Stomatitis","Dietary Supplement: multivitamin","University of Connecticut Health Center|Donaghue Medical Research Foundation","Both","Adult|Senior","Phase III",160,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","06-022-1|DF 04-005","September 6, 2007","01/12/2005",2009-07-01,"March 30, 2010","01/03/2010","",2009-07-01,"Annual number and average duration of minor recurrent aphthous stomatitis (canker sores) episodes|Pain due to recurrent aphthous stomatitis (canker sores); impact of recurrent aphthous stomatitis on ability to consume a normal diet","http://ClinicalTrials.gov/show/NCT00527306",NA
"5364",5364,"NCT00554606","Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: ACZ885","Novartis","Both","Adult|Senior","Phase II",115,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CACZ885A2211","November 5, 2007","01/10/2007",NA,"November 19, 2009","01/11/2009","",2009-08-01,"??Ñ Adverse events and infections ??Ñ Vital signs and body measurements, hematology, blood chemistry, and urinalysis ??Ñ Physical examination ??Ñ Antinuclear antibody (ANA) assessment ??Ñ Electrocardiogram (ECG) evaluation|??Ñ Response to treatment according to ACR20, ACR50, ACR70, and ACR90 and SDAI and DAS28. ??Ñ Effect on ACR components. ??Ñ Long-term immunogenicity. ??Ñ Long-term pharmacokinetics of ACZ885. ??Ñ Long term maintenance of health-related quality of life","http://ClinicalTrials.gov/show/NCT00554606",NA
"5389",5389,"NCT00596206","Leflunomide EfficAcy Response Related to Dosing Regimen in Early Rheumatoid Arthritis","Completed","No Results Available","Arthritis, Rheumatoid","Drug: leflunomide","Sanofi-Aventis","Both","Adult|Senior","Phase III",124,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","LEFLU_R_01143|Eudract#: 2007-000886-40","January 4, 2008","01/12/2007",2009-10-01,"October 11, 2010","01/10/2010","LEADER",2009-10-01,"Clinical efficacy response rate using ACR 20 criteria in each initial dosing regimen group|Clinical efficacy response rate using ACR 50, ACR 70, DAS 28 efficacy criteria in each group of treatment|Clinical and biological safety using standard blood monitoring, TEAED and SAE in each group of treatment|Measure of acute phase response (ESR, CRP)|Patient and physician global assessment|SF-36 questionnaire","http://ClinicalTrials.gov/show/NCT00596206",NA
"5411",5411,"NCT00635206","Investigation of a Novel Positive Pressure Therapy to Rescue Patients Failing to Tolerate CPAP During an Initial Encounter","Completed","No Results Available","Obstructive Sleep Apnea","Device: BiPap auto with Fi Flex|Device: Standard CPAP","Clayton Sleep Insititute","Both","Adult|Senior","Phase III",51,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","BIPAP Rescue|ABF-2007-MCT-03","March 6, 2008","01/09/2007",2009-05-01,"July 13, 2009","01/07/2009","BIPAP",2009-05-01,"proportion of participants compliant (at least four hours of use per night for all nights) in the Auto Bilevel group compared to the CPAP group after 90 days of treatment during the investigation.|ASdherence to BiPAP?ó Auto with Bi-Flex?ó therapy compared to CPAP therapy will include: compliance, AHI, HRV, FOSQ, Visual Analog Scale for mask comfort & satisfaction, ESS, PVT, Attitudes toward use, Actigraphy & sleep diary, FSS, & DFS","http://ClinicalTrials.gov/show/NCT00635206",NA
"5420",5420,"NCT00646906","Mechanisms of Action of Acetaminophen","Completed","No Results Available","Myocardial Infarction|Arthritis","Drug: Aspirin first|Drug: Aspirin last","University of Pennsylvania","Both","Adult","Phase IV",12,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","708270|0898","March 26, 2008","01/05/2004",2009-03-01,"October 14, 2009","01/10/2009","",2009-03-01,"Serum thromboxane B2 concentration|Arachidonic acid induced platelet aggregation|Urinary 11-dehydro thromboxane B2 concentration|Urinary 2,3 dinor-6 keto PGF1?? concentration|Urinary 8,12-iso-iPF2??-VI concentration","http://ClinicalTrials.gov/show/NCT00646906",NA
"5430",5430,"NCT00658606","Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects","Completed","No Results Available","Plaque Psoriasis","Drug: alefacept|Procedure: Narrow Band UVB Phototherapy","Astellas Pharma Inc|Astellas Pharma Canada, Inc.","Both","Adult|Senior","Phase IV",98,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AME-001","April 10, 2008","01/10/2007",2009-12-01,"January 5, 2010","01/01/2010","",2009-12-01,"Proportion of subjects treated with alefacept and nbUVB who achieve Psoriasis Area and Severity Index (PASI) 75 as compared to subjects treated with alefacept alone|Change in Body Surface Area (BSA) covered with psoriasis for subjects treated with alefacept in combination with nbUVB as compared to subjects treated with alefacept alone","http://ClinicalTrials.gov/show/NCT00658606",NA
"5434",5434,"NCT00666406","Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A","Completed","No Results Available","Hemophilia A","Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)|Drug: Recombinant Factor VIII (rAHF)","Baxter Healthcare Corporation","Both","Child|Adult","Phase IV",9,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","60601","April 22, 2008","01/03/2008",2009-09-01,"September 28, 2009","01/09/2009","",2009-08-01,"Area under the plasma concentration versus time curve from 0 to 48 hours (computed using the linear trapezoidal rule)","http://ClinicalTrials.gov/show/NCT00666406",NA
"5445",5445,"NCT00670306","Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)","Completed","Has Results","Benign Prostatic Hyperplasia (BPH)","Drug: Cetrorelix Pamoate","AEterna Zentaris","Male","Adult|Senior","Phase III",528,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AEZS-102-Z041","April 22, 2008","01/03/2008",2009-08-01,"December 15, 2010","01/12/2010","AEZS-102-Z041",2009-08-01,"IPSS Change From Baseline","http://ClinicalTrials.gov/show/NCT00670306",NA
"5464",5464,"NCT00705406","A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza","Completed","No Results Available","Acute, Uncomplicated Human Influenza","Drug: Peramivir|Drug: Placebo","BioCryst Pharmaceuticals","Both","Adult|Senior","Phase II",320,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","BCX1812-212","June 24, 2008","01/07/2008",2009-04-01,"May 8, 2009","01/05/2009","",2009-04-01,"To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.|To evaluate the safety and tolerability of peramivir administered intramuscularly.|To evaluate changes in influenza virus titer in nasopharyngeal samples (viral shedding) in response to treatment.","http://ClinicalTrials.gov/show/NCT00705406",NA
"5483",5483,"NCT00740506","Behavioral and Environmetal Factors and Time to Delivery","Completed","No Results Available","Pregnancy","Behavioral: Frequency of Intercourse","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child|Adult|Senior","Phase IV",510,"NIH","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","999908199|08-CH-N199","August 22, 2008","01/08/2008",2009-07-01,"August 27, 2009","01/07/2009","",2009-07-01,"Time to delivery|Rate of cesarean delivery","http://ClinicalTrials.gov/show/NCT00740506",NA
"5494",5494,"NCT00723606","A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation","Completed","Has Results","Schizophrenia","Drug: Intramuscular ziprasidone mesylate|Drug: Intramuscular haloperidol","Pfizer","Both","Adult","Phase III",376,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A1281152","July 25, 2008","01/09/2008",2009-07-01,"August 24, 2010","01/08/2010","",2009-07-01,"Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Scores at 72 Hours|BPRS Agitation Subscale Response at 72 Hours|Change From Baseline in BPRS Agitation Subscale Score at 72 Hours|Clinical Global Impression-Improvement (CGI-I) Score at 72 Hours|Change From Baseline in Clinical Global Impressions Severity (CGI-S) Score at 72 Hours|Change From Baseline in Behavioral Activity Rating Scale (BARS) at 72 Hours","http://ClinicalTrials.gov/show/NCT00723606",NA
"5496",5496,"NCT00758706","A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: AZD1236|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase II",55,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","D4260C00007","September 23, 2008","01/09/2008",2009-05-01,"July 15, 2009","01/07/2009","BICO",2009-05-01,"Biomarkers in urine, blood and sputum|Nature and incidence of Adverse Events, vital signs and laboratory safety|Lung Function (Spirometry and PEF)Health status (COPD symptoms, rescue medication use, Clinical COPD questionnaire)|Systemic exposure of AZD1236","http://ClinicalTrials.gov/show/NCT00758706",NA
"5509",5509,"NCT00779506","Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)","Completed","No Results Available","Schizophrenia","Drug: Quetiapine Fumarate XR","AstraZeneca","Both","Adult","Phase IV",100,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D1443L00062","October 22, 2008","01/11/2008",2009-07-01,"July 23, 2009","01/07/2009","QUENCH",2009-07-01,"Change in PANSS total score|Change in PANSS positive scale score|Change in PANSS negative scale score|Change in PANSS general psychopathology score","http://ClinicalTrials.gov/show/NCT00779506",NA
"5512",5512,"NCT00783406","Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: PF-00610355|Drug: PF-00610355|Drug: PF-00610355|Drug: Placebo","Pfizer","Both","Adult|Senior","Phase II",20,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A7881010","October 30, 2008","01/10/2008",2009-03-01,"October 27, 2010","01/10/2010","A7881010",2009-03-01,"To characterize the single dose pharmacokinetics of inhaled PF-00610355 in COPD patients.|To evaluate the safety & toleration of single inhaled doses of PF-00610355 in COPD patients|To investigate the efficacy of a single inhaled dose of PF-00610355 in COPD patients.|To investigate the exposure/response relationship of PF-00610355.","http://ClinicalTrials.gov/show/NCT00783406",NA
"5514",5514,"NCT00786006","Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer","Completed","No Results Available","Metastatic Pancreatic Cancer","Drug: FOLFIRI.3|Drug: FOLFOX","Asan Medical Center","Both","Adult|Senior","Phase II",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC_P_01","November 4, 2008","01/03/2007",2009-09-01,"October 12, 2010","01/11/2008","",2009-03-01,"Progression-free survival|Response rate|Overall survival|Safety","http://ClinicalTrials.gov/show/NCT00786006",NA
"5528",5528,"NCT00812006","A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis","Completed","No Results Available","Migraine","Drug: rizatriptan benzoate|Drug: Comparator: placebo","Merck","Both","Adult|Senior","Phase III",100,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2008_597|MK0462-085","December 17, 2008","01/03/2009",2009-10-01,"November 12, 2009","01/11/2009","",2009-10-01,"Efficacy of rizatriptan compared to placebo in treatment of acute migraine in patients on topiramate for migraine prophylaxis|Sustained Pain Relief (SPR)","http://ClinicalTrials.gov/show/NCT00812006",NA
"5529",5529,"NCT00813306","14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations","Completed","No Results Available","Reflux Episodes","Drug: AZD2066|Drug: Placebo|Drug: AZD2066|Drug: AZD2066|Drug: Placebo","AstraZeneca","Both","Adult","Phase I|Phase II",40,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","D9126C00001","December 22, 2008","01/12/2008",2009-11-01,"December 6, 2010","01/12/2010","",2009-11-01,"Manometry|pH|Impedance|Pharmacokinetic variables","http://ClinicalTrials.gov/show/NCT00813306",NA
"5537",5537,"NCT00828906","DuoTrav?ó Eye Drops As Replacement Therapy Program","Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: DuoTrav","Alcon Research","Both","Adult|Senior","Phase IV",2000,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DART-2","January 23, 2009","01/02/2009",NA,"March 11, 2010","01/03/2010","",2009-11-01,"Intra Ocular Pressure","http://ClinicalTrials.gov/show/NCT00828906",NA
"5544",5544,"NCT00839306","Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)","Completed","No Results Available","Gastroesophageal Reflux Disease (GERD)","Drug: Rabeprazole ER|Drug: Ranitidine","Eisai Inc.","Both","Adult|Senior","Phase III",240,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E3810-G000-306|EudraCT No. 2007-007733-39","February 5, 2009","01/08/2008",2010-01-01,"March 24, 2010","01/03/2010","",2009-08-01,"The primary outcome measure will include: esophagogastroduodenoscopy (EGD), Investigator's assessment of symptoms, quality of life as recorded by subjects and concomitant use of dispensed antacid.|Secondary outcome measures will include: adverse events, electrocardiograms (ECGs), laboratory evaluations (hematology, blood chemistry, urinalysis, gastrin), gastric biopsies, physical exam and vital signs.","http://ClinicalTrials.gov/show/NCT00839306",NA
"5567",5567,"NCT00866606","Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects","Completed","Has Results","Hemophilia B","Biological: Benefix","Wyeth","Both","Child|Adult|Senior","Phase III",35,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3090A1-3305|B1821004","March 19, 2009","01/03/2009",2009-12-01,"January 10, 2011","01/01/2011","",2009-12-01,"Investigator Hemostatic Efficacy Assessment of Participants After 8 Hours Post Infusion|Investigator Hemostatic Efficacy Assessment of Participants After 24 Hours Post Infusion|Percentage of Participants With FIX Inhibitor Development|Number of Infusions Required to Treat Each Bleed|FIX Incremental Recovery|Percentage of Participants With Less Than Expected Therapeutic Effect (LETE)|Percentage of Participants With Allergic-Type Allergic Reactions|Percentage of Participants With Thrombosis|Percentage of Participants With Red Blood Cell (RBC) Agglutination","http://ClinicalTrials.gov/show/NCT00866606",NA
"5591",5591,"NCT00916006","A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","Completed","No Results Available","Actinic Keratosis","Drug: PEP005 Gel|Drug: Vehicle Gel","Peplin","Both","Adult|Senior","Phase III",269,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","PEP005-016","June 4, 2009","01/06/2009",2009-09-01,"October 6, 2010","01/10/2010","",2009-09-01,"Efficacy (complete and partial clearance of AK lesions)|Safety (Incidence of treatment related AEs, local skin reactions and pigmentation and scarring)","http://ClinicalTrials.gov/show/NCT00916006",NA
"5592",5592,"NCT00917306","A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)","Completed","No Results Available","Actinic Keratosis","Drug: PEP005 Gel","Peplin","Both","Adult|Senior","Phase III",102,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PEP005-020","June 8, 2009","01/06/2009",2009-09-01,"October 6, 2010","01/10/2010","",2009-09-01,"Safety (Incidence of treatment related AEs, local skin reactions and pigmentation and scarring)|Efficacy (complete and partial clearance of AK lesions)","http://ClinicalTrials.gov/show/NCT00917306",NA
"5608",5608,"NCT00767806","A Study for Patient With Chronic Low Back Pain","Completed","Has Results","Chronic Low Back Pain","Drug: Duloxetine|Drug: Placebo","Eli Lilly and Company","Both","Adult|Senior","Phase III",401,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12360|F1J-MC-HMGC","October 3, 2008","01/09/2008",2009-07-01,"September 30, 2010","01/09/2010","",2009-07-01,"Change From Baseline to 12 Weeks in Brief Pain Inventory 24-hour Average Pain Score|Change From Baseline to 12 Weeks on the Brief Pain Inventory - Severity (BPI-S) and Interference (BPI-I)|Change From Baseline to 12 Weeks in Weekly Mean of 24-hour Average Pain, Worst Pain, and Night Pain Rating|Number of Responders: 30 Percent (%) or Greater Reduction of the Brief Pain Inventory (BPI) Average Pain Severity Rating at 12 Week Endpoint|Number of Responders: 50 Percent (%) or Greater Reduction of the Brief Pain Inventory (BPI) Average Pain Severity Rating at 12 Week Endpoint|Number of Sustained Responders at 12 Week Endpoint|Number of Participants Reaching Each Threshold of of BPI Average Pain Score Reduction During the Study - Cumulative Distribution|Change From Baseline to 12 Weeks Endpoint in Clinical Global Impressions of Severity (CGI-S)|Patient's Global Impression of Improvement (PGI-I) at 12 Weeks|Change From Baseline to 12 Weeks in Roland Morris Disability Questionnaire|Change From Baseline to 12 Weeks in Profile of Mood States - Brief Form|Change From Baseline to 12 Weeks in 36-item Short-Form (SF-36) Health Survey|Change From Baseline to 12 Weeks in European Quality of Life Questionnaire - 5 Dimension|Change From Baseline to 12 Weeks in Work Productivity and Activity Impairment Instrument (WPAI)|Participants Who Discontinued From Baseline to 12 Weeks|Change From Baseline to 12 Weeks in Uric Acid|Change From Baseline to 12 Week Endpoint in Albumin|Change From Baseline to 12 Week Endpoint in Alkaline Phosphatase|Change From Baseline to 12 Week Endpoint in Alanine Aminotransferase|Change From Baseline to 12 Week Endpoint in Aspartate Aminotransferase|Change From Baseline to 12 Week Endpoint in Creatinine|Change From Baseline to 12 Week Endpoint in Total Protein|Change From Baseline to 12 Weeks in Blood Pressure|Change From Baseline to 12 Week Endpoint in Weight|Change From Baseline to 12 Week Endpoint in Pulse Rate|Number of Participants With Suicidal Ideation or Suicidal Behaviors According to the Columbia Suicide Severity Rating Scale","http://ClinicalTrials.gov/show/NCT00767806",NA
"5621",5621,"NCT00961506","Prospective Evaluation of Laparoendoscopic Single Site Versus Laparoscopic Cholecystectomy","Completed","No Results Available","Gallbladder Disease","Procedure: LESS cholecystectomy|Procedure: Laparoscopic cholecystectomy","University Hospital, Geneva","Both","Adult|Senior","Phase II",40,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CER-08-145a","August 18, 2009","01/03/2009",2009-08-01,"August 18, 2009","01/08/2009","",2009-06-01,"Body image scale|pain VAS|Analgesic requirement|time to return to work|scar scale","http://ClinicalTrials.gov/show/NCT00961506",NA
"5650",5650,"NCT01001806","A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification","Completed","No Results Available","Cataracts","Drug: Ketorolac Tromethamine 0.45%|Drug: bromfenac 0.09%|Drug: nepafenac 0.1%","Bucci Laser Vision Institute|Allergan","Both","Adult|Senior","Phase IV",120,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","2009-0199","October 23, 2009","01/10/2009",2010-01-01,"August 16, 2010","01/08/2010","",2009-12-01,"Aqueous concentrations of drugs tested","http://ClinicalTrials.gov/show/NCT01001806",NA
"5799",5799,"NCT01242306","Comparison of Endothelial Dysfunction (BMS vs SES) in the Same Patient With Multiple Coronary Artery Lesions","Completed","No Results Available","Endothelial Dysfunction","Drug: intracoronary infusion of acetylcholine","Azienda Ospedaliera San Camillo Forlanini","Both","Adult|Senior","Phase I|Phase II",25,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CREDENTIAL","November 16, 2010","01/03/2009",2009-12-01,"November 16, 2010","01/04/2009","CREDENTIAL",2009-11-01,"evaluation of endothelial dysfunction at 6 months follow-up by measuring the change in vessel diameter in 5 points of the stent and peri-stent site after infusion of acetylcholine","http://ClinicalTrials.gov/show/NCT01242306",NA
"5838",5838,"NCT00002807","Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery","Completed","No Results Available","Endometrial Cancer","Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: laparoscopic surgery|Radiation: brachytherapy|Radiation: radiation therapy","NCIC Clinical Trials Group","Female","Child|Adult|Senior","Phase III",400,"Other","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","EN5|CAN-NCIC-EN5|NCI-V96-0945|CDR0000064915","November 1, 1999","01/07/1996",2009-12-01,"November 7, 2010","01/11/2010","",2009-12-01,"Survival (combined with the ASTEC trial)|Progression-free survival","http://ClinicalTrials.gov/show/NCT00002807",NA
"5879",5879,"NCT00030407","Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: celecoxib|Drug: docetaxel","Barbara Ann Karmanos Cancer Institute","Both","Adult|Senior","Phase II",NA,"Other","Interventional","Primary Purpose: Treatment","CDR0000069163|WSU-C-2305|AVENTIS-WSU-C-2305|WSU-06-15-01-M01-FB|NCI-V01-1687","February 14, 2002","01/10/2001",NA,"April 13, 2010","01/01/2005","",2009-04-01,"","http://ClinicalTrials.gov/show/NCT00030407",NA
"5932",5932,"NCT00116207","An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes","Completed","No Results Available","Diabetic Autonomic Neuropathy","Drug: allopurinal, alpha lipoic acid (ALA), nicotinamide","University of Michigan|Juvenile Diabetes Research Foundation","Both","Adult","Phase III",50,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","IRB:2002-0460","June 27, 2005","01/01/2000",2009-12-01,"July 27, 2010","01/07/2010","",2009-09-01,"Retention Index (RI)|Endothelial function|8-epi prostaglandin F2alpha|CRP|Adverse events","http://ClinicalTrials.gov/show/NCT00116207",NA
"5988",5988,"NCT00200707","BONAMI (BOne Marrow in Acute Myocardial Infarction)","Completed","No Results Available","Acute and Severe Myocardial Infarction","Procedure: Intracoronary injection of autologous bone marrow mononuclear cells","Nantes University Hospital","Both","Adult|Senior","Phase II",100,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BRD/03/2-B","September 13, 2005","01/12/2004",2009-04-01,"June 24, 2009","01/06/2009","",2009-01-01,"Change in Myocardial viability evaluated by thallium scintigraphy (3 months and 1 year)|Left ventricle ejection fraction (LVEF) evaluated by radionuclide ventriculography, (3 and 12 months) and by echography (1, 3, 6, and 12 months). Segmental EF and myocardial viability evaluated by MRI (3 months)|Correlation with biological parameters (hematopoietic stem cell number, etc.) at the time of cell injection","http://ClinicalTrials.gov/show/NCT00200707",NA
"6029",6029,"NCT00259207","Pulmonary Valve Replacement in Large Right Ventricular Outflow Tract","Completed","No Results Available","Pulmonary Valve Insufficiency","Procedure: Pulmonary valve insertion|Procedure: medical surgery hybride","Assistance Publique - H??pitaux de Paris|H??pital Necker-Enfants Malades|European Georges Pompidou Hospital","Both","Child|Adult|Senior","Phase III",8,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P040413|AOR04068","November 28, 2005","01/12/2005",2009-05-01,"September 29, 2009","01/03/2007","",2009-05-01,"Right ventricular function|Morbidity and mortality|Length of stay","http://ClinicalTrials.gov/show/NCT00259207",NA
"6049",6049,"NCT00056407","\REDUCE\"" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk""","Completed","Has Results","Neoplasms, Prostate|Prostate Cancer","Drug: Dutasteride|Drug: Placebo","GlaxoSmithKline","Male","Adult|Senior","Phase III",8231,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ARI40006","March 11, 2003","01/03/2003",2009-05-01,"January 6, 2011","01/01/2011","REDUCE",2009-01-01,"Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Crude Rate Approach)|Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Modified Crude Rate Approach)|Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Restricted Crude Rate Approach)|Number of Participants With the Indicated Gleason Score at Diagnosis|Number of Participants With HGPIN, ASAP, and Prostate Cancer at Biopsy|Volume of HGPIN at Biopsy|Percentage of Core Involved at Diagnosis|Number of Cancer-positive Cores|Treatment Alteration Score|Number of Participants Undergoing Intervention (Surgical and Non-surgical) for Prostate Cancer Treatment|Adjusted Mean Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 48|Adjusted Mean Percentage Change From Baseline in Prostate Volume at Months 24 and 48|Adjusted Mean Change From Baseline in Maximum Urinary Flow (Qmax) at Months 12, 24, 36, and 48|Number of Participants Starting Alpha Blockers to Control Benign Prostatic Hyperplasia (BPH) Symptoms|Number of Participants With at Least One Event of Acute Urinary Retention (AUR)|Number of Participants With at Least One Urinary Tract Infection (UTI)|Number of Participants With Post-biopsy Macroscopic Hematuria|Number of Participants With Post-biopsy Macroscopic Hematospermia|Overall Survival|Adjusted Mean Change From Baseline in the Benign Prostatic Hypertrohpy (BPH) Impact Index (BII) at Month 48|Adjusted Mean Change From Baseline in The Medical Outcomes Study Sleep Problems Index 6-item Standard Version (MOS Sleep-6S) at Month 48|Adjusted Mean Change From Baseline in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH CPSI) at Month 48|Adjusted Mean Change From Baseline in Quality of Life Question 8 (QOL Q8) at Month 48|Adjusted Mean Change From Baseline in the Problem Assessment Scale of the Sexual Function Index (PASSFI) at Month 48|Number of Participants With the Indicated Serum Dihydrotestosterone (DHT) Concentration at Month 48|Mean Change From Baseline in Testosterone at Month 48","http://ClinicalTrials.gov/show/NCT00056407",NA
"6050",6050,"NCT00289107","Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA","Completed","Has Results","Total Knee Replacement","Device: Total Knee Arthroplasty|Device: Total knee replacement","DePuy Orthopaedics","Both","Adult|Senior","Phase IV",149,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","SRP-3","February 7, 2006","01/05/2001",2009-09-01,"December 10, 2010","01/12/2010","",2009-09-01,"Knee Society Score|Complications|Revisions|Medical Imaging|SF-12 Patient Outcomes","http://ClinicalTrials.gov/show/NCT00289107",NA
"6127",6127,"NCT00417807","Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors","Completed","No Results Available","Refractory Desmoplastic Small Round Cell Tumors","Drug: Imatinib mesilate","Novartis Pharmaceuticals","Both","Child|Adult|Senior","Phase I|Phase II",9,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CSTI571BIT06","January 2, 2007","01/08/2005",NA,"December 23, 2010","01/12/2010","",2009-06-01,"Overall tumor response rates|Explore how Imatinib cooperated with other treatment modatilities|Safety and tolerability|Conversion rate to surgical resectability|Mutational analysis of molecular targets of imatinib (at any time during the study)","http://ClinicalTrials.gov/show/NCT00417807",NA
"6142",6142,"NCT00438607","Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease","Completed","No Results Available","Parkinson's Disease","Drug: BIIB014|Drug: Placebo","Biogen Idec","Both","Adult|Senior","Phase II",83,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","204PD202|EUDRA CT NO: 2006-003490-27|ISCRTN 12870393","February 20, 2007","01/04/2007",2009-04-01,"July 10, 2009","01/07/2009","",2009-04-01,"Number and proportion of subjects with adverse events|Assessment of clinical laboratory parameters|Assessment of vital signs|Assessment of ECG parameters.|Assess PK by measuring concentrations of BIIB014 and its N-acetyl metabolite in blood plasma.|Explore activity of BIIB014 by evaluating standard Parkinson's disease assessments","http://ClinicalTrials.gov/show/NCT00438607",NA
"6153",6153,"NCT00436007","Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","Completed","No Results Available","Plasmodium Falciparum|Malaria","Biological: Stamaril?ºÑ|Biological: Tritanrix HepB?ºÑ/Hiberix?ºÑ|Biological: Measles vaccine|Biological: Polio Sabin?ºÑ|Biological: GSK Malaria vaccine 257049","GlaxoSmithKline","Both","Child","Phase II",511,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","106369","February 15, 2007","01/04/2007",2009-10-01,"October 15, 2009","01/10/2009","",2009-10-01,"Occurrence of SAEs.|Occurrence of unsolicited AEs.|Occurrence of solicited general and local reactions.|Anti-hepatitis B surface agent (HBs) antibody titers.|Anti-diphtheria antibody titers.|Anti-tetanus antibody titers.|Anti- polyribosyl-ribitol-phosphate (PRP) antibody titers.|Anti-pertussis antibody titers.|Anti-polio type 1 antibody titers.|Anti-polio type 2 antibody titers.|Anti-polio type 3 antibody titers.|Anti-measles antibody titers.|Anti-yellow fever antibody titers.|Anti HBs antibody titers and antibody titers to the P. falciparum circumsporozoite repeat domain (anti-CS) in Group A and C.|Anti HBs and anti-CS antibody titers.|Difference between groups in percent seroprotection to HBs|Difference between groups in percent seroprotection to diphtheria|Difference between groups in percent seroprotection to tetanus|Difference between groups in percent seroprotection to PRP|Ratio of anti-pertussis GMTs between groups|Difference between groups in percent seroprotection to polio virus type 1|Difference between groups in percent seroprotection to polio virus type 2.|Difference between groups in percent seroprotection to polio virus type 3.|Difference between groups in percent seroconversion to measles|Difference between groups in percent seroconversion to yellow fever","http://ClinicalTrials.gov/show/NCT00436007",NA
"6191",6191,"NCT00454207","Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension","Completed","Has Results","Pulmonary Hypertension","Drug: sildenafil citrate (UK-92,480)","Pfizer","Both","Child|Adult|Senior","Phase III",44,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A1481252|JapicCTI-070381","March 28, 2007","01/04/2007",2009-02-01,"August 18, 2010","01/08/2010","",2009-02-01,"Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Mean Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Pulmonary Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Cardiac Output From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the 6-minute Walk Distance From Baseline at Week 8 in Participants Who Entered the Study From Part I|Change in the Systolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Diastolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Systolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Diastolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Mean Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Pulmonary Capillary Wedge Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Right Atrial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Cardiac Index From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Heart Rate From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Pulmonary Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Systemic Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Systemic Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Mixed Venous Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Arterial Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Arterial Oxygen Partial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I|Change in the Partial Pressure of Mixed Venous Oxygen From Baseline at Week 12 in Participants Who Entered the Study From Part I|Changes in the World Health Organization (WHO) Functional Class of Pulmonary Arterial Hypertension From Baseline at Weeks 12 in Participants Who Entered the Study From Part I|Changes in the BORG Dyspnoea Score From Baseline at Week 8 and Week 12 in Participants Who Entered the Study From Part I|Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 4, Week 8 and Week 12 in Participants Who Entered the Study From Part I|Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II|Change in the World Health Organization (WHO) Functional Class From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II|Changes in the BORG Dyspnoea Score From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II|Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 12 in Participants Who Newly Enterd the Study From Part II|Maximum Plasma Concentrations (Cmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320|Time to First Occurrence of Maximum Plasma Concentrations (Tmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320|The Area Under the Curve (AUC) From Time 0 to Time 8 Hour of Sildenafil and Sildenafil's Metabolite, UK-103,320|The Average Plasma Concentration (Css,av) of Sildenafil at Steady State|The Average Plasma Trough Concentration (Ctrough) of Sildenafil|Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)","http://ClinicalTrials.gov/show/NCT00454207",NA
"6197",6197,"NCT00520507","An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients","Completed","No Results Available","Bipolar Disorder|Depression|Depressive Disorder","Drug: Olanzapine|Drug: Placebo","Queen's University|Eli Lilly and Company","Both","Adult|Senior","Phase IV",27,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PSIY-263-07","August 22, 2007","01/10/2007",2009-05-01,"June 8, 2009","01/06/2009","",2009-05-01,"Sleep quality as measured by overnight PSG, defined as the change in time spent in slow wave sleep.|Sleep measures: time in bed, total sleep time, sleep period time, percentage of sleep stages (stage 1, stage 2, slow wave sleep, REM sleep) of sleep period time, sleep latency to stage 1 and 2, REM latency, number of awakenings.|Respiratory events (during PSG): obstructive sleep apneas, mixed apneas, central apneas, total apneas, obstructive hypopneas, mixed hypopneas, central hypopneas, total hypopneas, and apneas + hypopneas (AHI), oxygen saturation, and heart rate.|Subjective sleep experience: visual analogue scale, sleep diary, Epworth Sleep Scale and Pittsburgh Sleep Quality Index.|Changes in weight and blood glucose will be monitored.|Cognition: CANTAB scores|Illness severity: HDRS-17, MADRS, CGI and HamA","http://ClinicalTrials.gov/show/NCT00520507",NA
"6208",6208,"NCT00536107","Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Gefitinib|Procedure: CT or MRI|Drug: Docetaxel","AstraZeneca","Both","Adult|Senior","Phase IV",40,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D7913C00046","September 26, 2007","01/10/2007",2009-08-01,"December 7, 2010","01/12/2010","",2009-08-01,"The primary objective of this study is to compare safety and tolerability between gefitinib and docetaxel|Progression free survival (PFS) and overall survival (OS)|overall objective tumor response rate|Quality of Life","http://ClinicalTrials.gov/show/NCT00536107",NA
"6228",6228,"NCT00567307","Polypill For Prevention of Cardiovascular Disease","Completed","No Results Available","Cardiovascular Disease","Drug: Red Heart Pill 2b (Polypill)|Other: Standard Practice","Wake Forest University|World Health Organization|National Hospital of Sri Lanka","Both","Adult|Senior","Phase II",216,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","WFUBMC-IRB00004134|SLCTR/ 2007/012","November 30, 2007","01/01/2009",2010-01-01,"May 25, 2010","01/02/2009","",2009-12-01,"Reduction of the estimated 10-year total cardiovascular risk score|Adherence|Side effects|Physician and patient acceptability|Recruitment and retention","http://ClinicalTrials.gov/show/NCT00567307",NA
"6233",6233,"NCT00550407","An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients","Completed","Has Results","Bipolar Disorder","Drug: lamotrigine|Drug: Placebo","GlaxoSmithKline","Both","Adult|Senior","Phase III",103,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SCA104779","October 26, 2007","01/11/2007",2009-10-01,"July 1, 2010","01/07/2010","",2009-10-01,"Time to Withdrawal From Study|Time to Intervention for Any Mood Episode (TIME)|Time to Intervention for Depressive Episode (TIDep)|Time to Intervention for Manic, Hypomanic, or Mixed Episode (TIMan)|Clinical Global Impressions of Improvement (CGI-I) at Week 26/Withdrawal (Randomized Phase)|Clinical Global Impressions of Improvement (CGI-I) at Week 16/Withdrawal (Preliminary Phase)|Change From Baseline in Clinical Global Impressions of Severity (CGI-S) Scores at Week 26/Withdrawal (Randomized Phase)|Change From Baseline in Clinical Global Impressions of Severity (CGI-S) Scores at Week 16/Withdrawal (Preliminary Phase)|Change From Baseline in Hamilton Rating Scale for Depression (HAMD-17) Scores at Week 26/Withdrawal (Randomized Phase)|Change From Baseline in Hamilton Rating Scale for Depression (HAMD-17) Scores at Week 16/Withdrawal (Preliminary Phase)|Change From Baseline in Young Mania Rating Scale (YMRS) Total Scores at Week 26/Withdrawal (Randomized Phase)|Change From Baseline in Young Mania Rating Scale (YMRS) Total Scores at Week 16/Withdrawal (Preliminary Phase)","http://ClinicalTrials.gov/show/NCT00550407",NA
"6252",6252,"NCT00601107","A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Patients With Moderate to Severe Psoriasis","Completed","No Results Available","Moderate to Severe Chronic Plaque Psoriasis","Drug: doxercalciferol|Drug: doxercalciferol|Drug: doxercalciferol|Drug: placebo","Genzyme","Both","Adult|Senior","Phase II",136,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HECTPS02507","January 15, 2008","01/04/2008",2009-06-01,"May 4, 2010","01/05/2010","",2009-02-01,"Achievement of at least a 50% reduction in PASI score (PASI 50)|Achievement of PASI 50|Achievement of a static PGA score of clear (0) or almost clear (1)","http://ClinicalTrials.gov/show/NCT00601107",NA
"6259",6259,"NCT00621907","Study : LEVOBUPIVACAINE Versus Placebo","Completed","No Results Available","Pain","Drug: chirocaine (Levobupivacaine)|Drug: sodium chloride","Centre Hospitalier Universitaire de Saint Etienne","Female","Adult","Phase III",140,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0708097|2007-006275-36","February 11, 2008","01/03/2008",2009-05-01,"September 15, 2010","01/09/2010","LEVOBU",2009-05-01,"analgesic consumption of level 3 in the two treated groups|visual analogic scale (VAS) at rest or on rising, early rehabilitation, residual pain 2 months after the operation","http://ClinicalTrials.gov/show/NCT00621907",NA
"6271",6271,"NCT00637507","Study of a Novel Technique of Mechanical Ventilation in Patients With Severe Acute Respiratory Failure","Completed","No Results Available","Respiratory Distress Syndrome","Other: High-frequency Oscillation and Tracheal Gas Insufflation","University of Athens|University of Thessaly","Both","Adult|Senior","Phase II|Phase III",124,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HFO-TGI-728-4-10-07","March 4, 2008","01/03/2008",2009-05-01,"August 18, 2009","01/08/2009","HFO-TGI-2",2009-05-01,"Survival to days 28 and 60 post-randomization, and to Hospital Discharge|Lung recruitment during the study-intervention period|Evolution of Gas-exchange, Hemodynamics, and Respiratory Mechanics during the Study Intervention Period|Ventilator Free Days|Organ or System Failure Free Days|Occurrence of barotrauma (i.e., any new pneumothorax, pneumomediastinum, or subcutaneous emphysema, or pneumatocele > 2 cm)|Occurence of Tracheal Mucosal Injury due to use of Tracheal Gas Insufflation","http://ClinicalTrials.gov/show/NCT00637507",NA
"6295",6295,"NCT00631007","A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: INT131 besylate|Drug: Pioglitazone HCl|Drug: Placebo","InteKrin Therapeutics, Inc.","Both","Adult|Senior","Phase II",367,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INT131-007","February 27, 2008","01/02/2008",2009-09-01,"August 18, 2010","01/08/2010","",2009-08-01,"Change From Baseline in Hemoglobin A1c (HBA1c) at Week 24 With Last Observation Carried Forward|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 With Last Observation Carried Forward.","http://ClinicalTrials.gov/show/NCT00631007",NA
"6297",6297,"NCT00677807","Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","COPD","Drug: Indacaterol 150 ??g o.d.|Drug: Indacaterol 300 ??g o.d.|Drug: Placebo o.d.","Novartis","Both","Adult|Senior","Phase III",415,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CQAB149B2335SE|2008-000663-42","May 13, 2008","01/05/2008",2009-03-01,"February 22, 2010","01/02/2010","",2009-03-01,"Safety profile of two doses of indacaterol compared to placebo over 52 weeks of treatment|Quality of life assessment with St George's Respiratory Questionnaire (SGRQ)","http://ClinicalTrials.gov/show/NCT00677807",NA
"6304",6304,"NCT00690807","A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Drug: PH-10","Provectus Pharmaceuticals","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PH-10-AD-21","June 3, 2008","01/06/2008",2009-09-01,"September 24, 2009","01/09/2009","",2009-08-01,"The primary efficacy endpoint is \Treatment Success","http://ClinicalTrials.gov/show/NCT00690807",NA
"6309",6309,"NCT00694707","Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Placebo|Drug: RGH-188|Drug: RGH-188|Drug: RGH-188|Drug: Risperidone","Forest Laboratories|Gedeon Richter Ltd.","Both","Adult","Phase II",732,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RGH-MD-16","June 6, 2008","01/06/2008",2009-08-01,"May 25, 2010","01/05/2010","",2009-08-01,"PANSS total score|Clinical Global Impression - Severity","http://ClinicalTrials.gov/show/NCT00694707",NA
"6333",6333,"NCT00736307","Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients","Completed","No Results Available","Limbal Stem Cell Deficiency","Procedure: Cultured limbal stem cells Transplantation","Royan Institute|Small Business Developing Center|Labafi Nejad Eye Research Center","Both","Adult|Senior","Phase I|Phase II",10,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ROYAN-EYE-001","August 14, 2008","01/10/2007",2009-10-01,"April 17, 2010","01/04/2010","",2009-07-01,"Snellen visual acuity|corneal epithelial integrity and stability|Impression cytology|Extent of retarding recurrent neovascularisation","http://ClinicalTrials.gov/show/NCT00736307",NA
"6334",6334,"NCT00740207","Pilot Study to Compare ISOVUE?ó-250 and VISIPAQUE?ºÑ 270 for Motion Artifact and Pain in Peripheral (DSA)","Completed","No Results Available","Peripheral Arterial Occlusive Disease","Drug: VISIPAQUE 270|Drug: Isovue 250","Bracco Diagnostics, Inc","Both","Adult|Senior","Phase IV",20,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Diagnostic","IOP-113","August 20, 2008","01/09/2008",2009-07-01,"January 28, 2010","01/01/2010","",2009-07-01,"To compare pain in the lower extremities following intraarterial administration of ISOVUE-250 and VISIPAQUE 270 in peripheral DSA.|To compare the motion artifact and requirement for repeat injection(s) following intraarterial administration of ISOVUE-250 and VISIPAQUE 270 in peripheral DSA.","http://ClinicalTrials.gov/show/NCT00740207",NA
"6341",6341,"NCT00749307","Effects of Docosahexaenoic Acid (DHA) on Heart Rate Variability in Elderly Patients","Completed","No Results Available","Arrhythmia","Dietary Supplement: Docosahexaenoic acid (DHA)|Dietary Supplement: Placebo","Campus Bio-Medico University|IRCCS San Raffaele|Martek Biosciences Corporation|Pharmanutra s.r.l.","Both","Adult|Senior","Phase II|Phase III",50,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ALFAHRV01|EudraCT number 2008-005715-18","September 8, 2008","01/06/2008",2009-11-01,"November 24, 2009","01/11/2009","",2009-09-01,"Heart rate variability (HRV)","http://ClinicalTrials.gov/show/NCT00749307",NA
"6361",6361,"NCT00761007","Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)","Completed","Has Results","Irritable Bowel Syndrome","Drug: Ibodutant|Drug: Ibodutant|Drug: Ibodutant|Drug: Placebo","Menarini Group","Both","Adult|Senior","Phase II",554,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","NAK 03|2008-000214-71","September 25, 2008","01/07/2008",2009-03-01,"October 28, 2010","01/10/2010","IRIS",2009-02-01,"Response of Overall IBS Symptom Relief - 50% Rule|Response of Overall IBS Symptom Relief - 75% Rule|Response of Overall IBS Symptom Relief in the Subgroup of Patients With IBS With Diarrhea (IBS-D) - 75% Rule","http://ClinicalTrials.gov/show/NCT00761007",NA
"6368",6368,"NCT00735007","12-week Study to Evaluate RebiSmart?ºÑ Suitability for Self Injection in Relapsing Multiple Sclerosis.","Completed","Has Results","Multiple Sclerosis","Drug: Rebif?ó New Formulation (RNF) using RebiSmartTM","EMD Serono","Both","Adult","Phase III",106,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","28733","August 12, 2008","01/07/2008",NA,"August 12, 2010","01/08/2010","",2009-01-01,"The Number of Subjects Rating the Suitability of RebiSmart at the End of 12-week Treatment Period for Self-injecting Rebif?ó New Formulation (RNF).|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Items 13-16 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Items 13-16 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Items 13-16 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Site Reaction Score Items 17-20 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Site Reaction Score Items 17-20 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Site Reaction Score Items 17-20 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Global Side Effects Score Items 21-23 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Global Side Effects Score Items 21-23 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Global Side Effects Score Items 21-23 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Issues Score Item 34 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Issues Score Item 34 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Issues Score Item 34 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Benefit Item 35 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Benefit Item 35 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Benefit Item 35 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Scale Item 37 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Scale Item 37 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Scale Item 37 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Grade Item 38 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Grade Item 38 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Grade Item 38 at End Week 12|The Incidence of Predefined Injection Site Reactions, MSTCQ Scores, Side Effects, McGill Pain Questionnaire, Visual Analog Scale, and Rating of Pain Regarding Injection Pain Following RNF Administration With RebiSmart at 12-week Treatment Period.","http://ClinicalTrials.gov/show/NCT00735007",NA
"6374",6374,"NCT00801307","Trial Comparing Effect of He/O2 to Medical Air on Pulmonary Function Disease","Completed","No Results Available","Asthma|Chronic Obstructive Pulmonary Disease|Healthy","Device: spirometer","Air Liquide SA|Inamed","Both","Adult|Senior","Phase I|Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","ALMED-07-C2-012|2007-004158-10","December 2, 2008","01/06/2008",2010-03-01,"April 29, 2010","01/12/2008","",2009-03-01,"Inspiratory Capacity measured by spirometry at rest while breathing each He/O2 mixture compared to its measurement on medical air|Inspiratory Capacity measured by ergospirometry while breathing Pulmonary function parameters at rest, i.e., FEV1, FVC, FEF25-75, PEF and ERV while breathing each He/O2 mixture compared to medical air,","http://ClinicalTrials.gov/show/NCT00801307",NA
"6407",6407,"NCT00859807","A Bioequivalence Study Comparing Camoquin?ó Suspension (Pfizer) To Flavoquine?ó Tablets (Sanofi Aventis) In Healthy Subjects","Completed","No Results Available","Falciparum Malaria","Drug: Flavoquine?ó, Camoquin?ó Suspension|Drug: Flavoquine?ó, Camoquin?ó Suspension","Pfizer","Both","Adult","Phase IV",38,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","B0731001","March 6, 2009","01/05/2009",2009-06-01,"April 20, 2010","01/04/2010","",2009-06-01,"Cmax, AUCtlast and AUCinf for amodiaquine.|Cmax and AUC72 for DesethylAQ","http://ClinicalTrials.gov/show/NCT00859807",NA
"6409",6409,"NCT00863707","A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment","Completed","No Results Available","Kidney Diseases|Coronary Artery Disease","Drug: regadenoson|Drug: Placebo","Astellas Pharma Inc","Both","Adult|Senior","Phase IV",510,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic","3606-CL-3010","March 16, 2009","01/04/2009",2009-12-01,"January 4, 2010","01/01/2010","",2009-12-01,"Frequency of serious adverse events","http://ClinicalTrials.gov/show/NCT00863707",NA
"6417",6417,"NCT00876707","Wavefront Analyzes and Visual Performance of Three Multifocal Intra-ocular Lenses","Completed","No Results Available","Cataract|Astigmatism","Device: Tecnis implant|Device: ReSTOR implant|Device: ReZoom implant","University of Sao Paulo","Both","Adult|Senior","Phase I|Phase II",60,"Other","Interventional","Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","0088/09","April 3, 2009","01/03/2009",2009-11-01,"July 1, 2010","01/04/2009","IOL",2009-11-01,"visual acuity, wavefront data and modulation transfer function|contrast sensitivity","http://ClinicalTrials.gov/show/NCT00876707",NA
"6449",6449,"NCT00927407","Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice","Completed","No Results Available","Pediculosis","Drug: Malathion gel 0.5%|Drug: Malathion lotion 0.5%","Taro Pharmaceuticals USA","Both","Adult|Senior","Phase II",24,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MALG-0603","June 23, 2009","01/07/2009",2009-08-01,"September 8, 2009","01/09/2009","",2009-08-01,"Measurement of blood and urinary levels of malathion and metabolites|Measure cholinesterase levels and compare to malathion metabolite levels","http://ClinicalTrials.gov/show/NCT00927407",NA
"6454",6454,"NCT00933907","Dermacyd PH_DESILSTY_FR (Lactic Acid) - Compatibility - Stay on Frutal","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Both","Adult","Phase III",55,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LACAC_L_04807","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"Evaluation of the absence of primary and accumulated dermical irritability and dermical sensitivity by using International Contact Dermatitis Research Group (ICDRG) scale.","http://ClinicalTrials.gov/show/NCT00933907",NA
"6631",6631,"NCT01234207","Clinical Assessment of a Customized Free-form Progressive Addition Lens Spectacle","Completed","No Results Available","Presbyopia","Device: Standard, non-free-form, non-customized PAL spectacles|Device: Individually customized free-form surfaced PAL spectacles","University of California, Berkeley|Funding by Carl Zeiss Vision, Inc., Germany","Both","Adult|Senior","Phase III",95,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CZV_PAL1","November 3, 2010","01/02/2009",2009-10-01,"November 3, 2010","01/11/2010","CZV_PAL1",2009-10-01,"Visual Acuity, high and low contrast, distance and near charts|30-degree off-axis visual acuity, high and low contrast, distance chart|Horizontal extent of undistorted vision at reading distance|Questionnaire Battery","http://ClinicalTrials.gov/show/NCT01234207",NA
"6647",6647,"NCT01251107","Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP)","Completed","No Results Available","Hodgkin Lymphoma","Drug: Bleomycin|Drug: Etoposide|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Procarbazine|Drug: Prednisone|Drug: Doxorubicin|Drug: Bleomycin|Drug: Vinblastine|Drug: Dacarbazine","Fondazione Michelangelo","Both","Child|Adult","Phase III",331,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","41/99","November 26, 2010","01/03/2000",2009-11-01,"November 30, 2010","01/11/2010","",2009-11-01,"Freedom from first progression at 5 years|Freedom from second progression at 5 years|Overall survival at 5 years|Number of participants with acute adverse events at initial therapy and at salvage therapy as a measure of safety and tolerability|Number of participants long term sequelae","http://ClinicalTrials.gov/show/NCT01251107",NA
"6745",6745,"NCT00074308","Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers","Completed","No Results Available","Melanoma (Skin)|Unspecified Adult Solid Tumor, Protocol Specific","Biological: bevacizumab|Drug: imatinib mesylate","Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI)","Both","Adult|Senior","Phase I|Phase II",64,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000343804|UPCC-03903|NCI-6006","December 10, 2003","01/10/2003",NA,"October 15, 2009","01/11/2008","",2009-10-01,"Toxicity (phase I)|Progression-free survival at 8 weeks (phase II)|Response rate at 8 weeks (phase II)|Overall survival (phase II)","http://ClinicalTrials.gov/show/NCT00074308",NA
"6810",6810,"NCT00171808","Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer","Completed","No Results Available","Endometrial Cancer","Drug: Letrozole","Novartis Pharmaceuticals","Female","Adult|Senior","Phase II",26,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CFEM345ADE08|EudraCT-Number: 2004-003886-34","September 13, 2005","01/04/2005",NA,"March 29, 2010","01/03/2010","deFEND",2009-04-01,"clinical response rate (partial response PR and complete response CR) according to RECIST at least once during the treatment period|Time to progression (TTP)|Overall survival (OS)","http://ClinicalTrials.gov/show/NCT00171808",NA
"6895",6895,"NCT00310908","Comparison Between Tramadol Hcl and Other Analgesics in the Treatment of Renal Colic","Completed","No Results Available","Renal Calculus","Drug: Tramadol Hcl","Hadassah Medical Organization|Grumental","Both","Adult","Phase IV",100,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1234567-HMO-CTIL","April 4, 2006","01/09/2006",2009-02-01,"February 15, 2009","01/09/2006","",2009-02-01,"Pain improvement according to VAS score at 30, 60 and 120 minutes(Stage I)|Need for rescue medication at 30 minutes (Stage I)|Pain improvement according to VAS score at 24 and 48 hrs (Stage II)","http://ClinicalTrials.gov/show/NCT00310908",NA
"6903",6903,"NCT00318708","Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)","Completed","No Results Available","Asthma","Drug: Clarithromycin|Drug: Fluticasone propionate","National Heart, Lung, and Blood Institute (NHLBI)","Both","Adult","Phase III",92,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","377|5U10 HL074231|7U10 HL074206|5U10 HL074208|5U10 HL074073|5U10 HL074227|5U10 HL074225|5U10 HL074204|5U10 HL074218|5U10 HL074212","April 25, 2006","01/06/2006",2009-04-01,"June 23, 2009","01/06/2009","MIA",2009-04-01,"Asthma control questionnaire (ACQ) results|Asthma symptoms|Asthma rescue medication use|AM and PM peak expiratory flow (PEF)|Forced expiratory volume in one second (FEV1)|Asthma-specific quality of life|Methacholine provocative concentration (PC20)|Exhaled nitric oxide (eNO)|Blood cell counts|AM cortisol|Adverse events","http://ClinicalTrials.gov/show/NCT00318708",NA
"6932",6932,"NCT00365508","Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking","Completed","No Results Available","Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Leukemia|Liver Cancer|Lung Cancer|Pancreatic Cancer|Tobacco Use Disorder","Drug: nicotine","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",700,"Other|NIH","Interventional","Allocation: Randomized|Masking: Open Label","CDR0000491296|FCCC-FCRB-04-003-P","August 16, 2006","01/02/2006",NA,"November 5, 2009","01/11/2009","",2009-08-01,"Continuous abstinence assessed by the time-line follow-back method (quit day to 6-month follow up)|Rate of compliance at 24 hours and 30 days","http://ClinicalTrials.gov/show/NCT00365508",NA
"6989",6989,"NCT00451308","Induction of Labor With a Foley Balloon Catheter: Inflation With 30ml Compared to 60ml","Completed","No Results Available","Induction of Labor","Procedure: Induction of labor with foley balloon - 60cc of saline|Procedure: Induction of labor with foley balloon with 30cc","University of California, San Francisco","Female","Child|Adult|Senior","Phase IV",192,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H4114729401-01","March 22, 2007","01/11/2006",2009-07-01,"December 28, 2009","01/07/2009","",2009-07-01,"Rate of vaginal delivery within 24 hours|Cervical dilation after Foley balloon catheter expulsion|Time to catheter expulsion|Duration of the first stage of labor|Time interval from induction to active labor|Induction to delivery interval|Presence of abnormal vaginal bleeding|Peak oxytocin requirement during induction and labor augmentation|Epidural utilization, diagnosis of chorioamnionitis|Meconium stained amniotic fluid, placental abruption|Cesarean delivery rate, operative vaginal delivery rate|Indication for operative vaginal or cesarean delivery|Rate of cervical laceration|Birthweight|5 minute Apgar score|Umbilical cord arterial blood pH analysis","http://ClinicalTrials.gov/show/NCT00451308",NA
"6998",6998,"NCT00469508","Modafinil vs Placebo for the Treatment of Methamphetamine Dependence","Completed","No Results Available","Methamphetamine Dependence","Drug: Modafinil|Drug: Placebo","National Institute on Drug Abuse (NIDA)","Both","Adult|Senior","Phase II",73,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","P50 DA018185-03|P50 DA018185-03|DPMCDA","May 3, 2007","01/04/2007",2009-01-01,"September 3, 2009","01/09/2009","Modafinil",2009-01-01,"Urine toxicology|Beck Depression Inventory|Clinical Global Impressions|Brief Symptom Inventory","http://ClinicalTrials.gov/show/NCT00469508",NA
"7000",7000,"NCT00477308","Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs","Completed","No Results Available","HIV Infections","Procedure: salvage therapy","The HIV Netherlands Australia Thailand Research Collaboration|Swiss Cohort","Both","Child|Adult","Phase IV",95,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","HIV-NAT 013 phase II","May 20, 2007","01/01/2006",2009-04-01,"June 4, 2010","01/06/2010","",2009-04-01,"Clinical, immunologic and virologic outcome of children who had genotyping directed salvage therapy|Comparison outcome of children in the 3 groups,|Changes of mutation in children within the 3 groups, and|Effect of previously unreported mutations, minor and others, on treatment outcome","http://ClinicalTrials.gov/show/NCT00477308",NA
"7013",7013,"NCT00495508","Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy","Completed","No Results Available","Malaria","Drug: Quinine|Drug: artemether / lumefantrine","Epicentre|Medecins Sans Frontieres|University of Cape Town|Sholklo Malaria Research Unit","Female","Child|Adult|Senior","Phase IV",300,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Mba/06/MIP","July 2, 2007","01/10/2006",2009-06-01,"May 12, 2010","01/05/2010","",2009-06-01,"PCR-corrected adequate clinical and parasitological response (ACPR) on Day 42 or at delivery.|Pharmacokinetic parameters|Incidence of adverse events|Pregnancy outcome|Infant development during the first year of life|Histopathological findings in the placenta","http://ClinicalTrials.gov/show/NCT00495508",NA
"7055",7055,"NCT00556608","Efficacy Study of Intra-articular Hyaluronic Acid in the Knee Osteoarthritis","Completed","No Results Available","Osteoarthritis, Knee","Device: Sinovial?ó (syringe containing sodium hyaluronate solution)|Device: Synvisc?ó ( syringe containing Hylan G-F 20 solution)","IBSA Institut Biochimique SA","Both","Adult|Senior","Phase IV",381,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","06CZIFCH/Hai06","November 9, 2007","01/11/2007",2010-05-01,"August 13, 2010","01/08/2010","",2009-07-01,"Improvement in WOMAC pain subscore from baseline|Change in WOMAC OA Index total score and pain, function and stiffness subscores;Change in Lequesne's algofunctional index; Change in global pain (visit assessment); Change in global status by the patient;Change in global status by the Investigator;SPID%","http://ClinicalTrials.gov/show/NCT00556608",NA
"7059",7059,"NCT00567008","Chantix for Treating Cocaine Dependence","Completed","No Results Available","Cocaine Dependence","Drug: varenicline|Drug: placebo","National Institute on Drug Abuse (NIDA)","Both","Adult","Phase II",37,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","806565|NIDA P60DA0005186","December 3, 2007","01/12/2007",2009-09-01,"July 29, 2010","01/06/2010","",2009-09-01,"Evidence of abstinence from cocaine as indicated by qualitative urinalysis for benzoylecgonine.|Evidence of more cocaine non-use days during the medication treatment and decreases in cocaine craving, demonstrated by scores on self-report measures of cocaine craving.","http://ClinicalTrials.gov/show/NCT00567008",NA
"7069",7069,"NCT00560508","A 12-week Study of Pramipexole ER in Patients With Parkinson's Disease, Followed by a 52-week Long-term Treatment Period","Completed","No Results Available","Parkinson Disease","Drug: Placebo|Drug: Placebo|Drug: Pramipexol Extended Release|Drug: Pramipexole Immediate Release","Boehringer Ingelheim Pharmaceuticals","Both","Child|Adult|Senior","Phase II",112,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","248.61","November 16, 2007","01/11/2007",NA,"June 14, 2010","01/06/2010","",2009-11-01,"No primary efficacy endpoints are set up, because the primary objective of this trial is to compare safety, tolerability and trough plasma drug concentration.|Double blind period: Responder rate for Patient Global Impression of Improvement (PGI-I)|Double blind period: the change from baseline to visit 8 in UPDRS parts II+III score.|Double blind period: the change from baseline to visit 8 in percentage off-time during waking hours (diary based).|Double blind period: the change from baseline to visit 8 in percentage on-time: without dyskinesia; with non troublesome dyskinesia; without dyskinesia or with non-troublesome dyskinesia; with troublesome dyskinesia; during waking hours (diary based).|Double blind period: Responder rate for Clinical Global Impression of Improvement (CGI-I)|Double blind period: the change form baseline to visit 8 in total score of each UPDRS I, II, III and IV.|Double blind period: Proportion of patients with at least 20% improvement relative to baseline in the UPDRS II+III total score|Double blind period: the change from baseline to visit 8 in L-DOPA daily dose|Double blind period: Trough plasma concentration at steady state at Visit 3, Visit 4, Visit 5 and Visit 8 after pramipexole ER and IR treatment.|Double blind period: Dose proportionality of trough plasma concentration at steady state after pramipexole ER treatment.|Dose adjustment phase in open label period (To assess the influence of switching to pramipexole ER) : the change from visit 8 to visit 10 in UPDRS parts II+III total score.|Dose adjustment phase in open label period (To assess the influence of switching to pramipexole ER) : Percentage of patients with no worsening of the UPDRS II+III score at visit 10 by more than 15% from Visit 8|Dose adjustment phase in open label period (To assess the influence of switching to pramipexole ER) : Responder rate for Clinical Global Impression of Improvement (CGI-I) at visit 10 compared to Visit 8|Dose adjustment phase in open label period (To assess the influence of switching to pramipexole ER) : Responder rate for Patient Global Impression of Improvement (PGI-I) at visit 10 compared to Visit 8.|Open label period (To assess efficacy for long-term treatment of pramipexole ER) : UPDRS parts II+III total score and UPDRS parts I, II, III, and IV total scores|Open label period (To assess efficacy for long-term treatment of pramipexole ER) : Percentage off-time during waking hours (%)|Open label period (To assess efficacy for long-term treatment of pramipexole ER) : Percentage on-time: without dyskinesia (%); with non troublesome dyskinesia (%); without dyskinesia or with non-troublesome dyskinesia (%); with troublesome dyskinesia (%)|Open label period (To assess efficacy for long-term treatment of pramipexole ER) : L-DOPA daily dose|Open label period (To assess efficacy for long-term treatment of pramipexole ER) : Proportion of patients with at least 20% improvement relative to baseline in the UPDRS II+III total score|Safety endpoint: Incidences of adverse events|Safety endpoint: Proportion of patients with discontinuation due to adverse events (%)|Safety endpoint: change from baseline to visit 15 in vital signs (blood pressure and pulse rate) and body weight.|Safety endpoint: Epworth Sleepiness Scale (ESS)|Safety endpoint: Laboratory parameters","http://ClinicalTrials.gov/show/NCT00560508",NA
"7084",7084,"NCT00548808","A Study for Type 2 Diabetic Patients","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Insulin lispro low mixture|Drug: Insulin glargine|Drug: Insulin lispro","Eli Lilly and Company","Both","Adult|Senior","Phase IV",426,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11541|F3Z-CR-IOPH","October 22, 2007","01/11/2007",2009-08-01,"August 20, 2010","01/08/2010","",2009-08-01,"Change From Baseline to 48 Week Endpoint in Hemoglobin A1c (HbA1c)|Change in Hemoglobin A1c (HbA1c) Over Time|Percentage of Patients Achieving HbA1c <6.5% and <7% Over Time|7-point Self-monitored Blood Glucose Profiles|Change From Baseline in Postprandial Blood Glucose Over Time|Daily Total Insulin Dose (U/Day) at 16, 32, and 48 Weeks|Daily Total Insulin Dose Per Body Weight (U/kg/Day) at 16, 32, and 48 Weeks|Change From Baseline to 48 Week Endpoint in Lipid and Cholesterol Profiles|Safety: Number of Participants With Serious and Non-Serious Adverse Events","http://ClinicalTrials.gov/show/NCT00548808",NA
"7099",7099,"NCT00632008","Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers","Completed","No Results Available","Chronic Diabetic Foot Ulcers","Drug: Soluble beta-glucan (SBG)|Drug: Placebo comparator","Biotec Pharmacon ASA","Both","Adult|Senior","Phase III",122,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SBG-1-12","February 29, 2008","01/03/2007",2009-10-01,"January 25, 2010","01/01/2010","",2009-08-01,"","http://ClinicalTrials.gov/show/NCT00632008",NA
"7117",7117,"NCT00663208","A Multiple Ascending Dose Study of BMS-790052 in Hepatitis C Virus (HCV) Infected Subjects","Completed","No Results Available","Chronic Hepatitis C","Drug: BMS-790052|Drug: Placebo","Bristol-Myers Squibb","Both","Adult","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","AI444-004","April 18, 2008","01/05/2008",2009-06-01,"December 2, 2010","01/12/2010","",2009-06-01,"Pharmacodynamic Measures: Antiviral activity will be assessed by the magnitude and rate of change in plasma HCV RNA levels from baseline|PD-PK Relationship Measures: Assess relationship between antiviral activity and measures of exposure to BMS-790052|Safety Outcome Measures|Pharmacokinetic Measures","http://ClinicalTrials.gov/show/NCT00663208",NA
"7125",7125,"NCT00674908","Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine","Completed","No Results Available","Diphtheria|Tetanus|Pertussis|Hepatitis B|Haemophilus Influenzae Type B","Biological: Shan 5|Biological: Easy Five","Shantha Biotechnics Limited","Both","Child","Phase IV",144,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","SBL/DTPwHB-Hib/INT/2007/0200","May 6, 2008","01/03/2008",2009-05-01,"June 24, 2009","01/06/2009","",2009-03-01,"Seroprotection rates for Diphtheria, Tetanus, Pertussis, Hepatitis B and Hib following 3 doses of the vaccines in a single and mixed sequence regimen.|Solicited and unsolicited local and systemic adverse events following vaccination","http://ClinicalTrials.gov/show/NCT00674908",NA
"7142",7142,"NCT00687908","Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance","Completed","Has Results","Acne","Drug: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Drug: Vehicle Gel","Galderma","Both","Child|Adult","Phase III",243,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RD.03.SPR.29075","May 28, 2008","01/11/2008",2009-07-01,"September 30, 2010","01/09/2010","ACCESS II",2009-07-01,"Maintenance Success for Total Lesions at Week 24|Maintenance Success for Inflamatory Lesions at Week 24|Maintenance Success for Non-inflammatory Lesions at Week 24|Investigator Global Assessment (IGA) Maintenance Success at Week 24|Percent of Subjects With Adverse Events","http://ClinicalTrials.gov/show/NCT00687908",NA
"7143",7143,"NCT00707408","High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)","Completed","No Results Available","AML","Drug: Imatinib","Nantes University Hospital","Both","Adult|Senior","Phase II",15,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BRD 03/3-B","June 26, 2008","01/02/2004",2009-01-01,"January 30, 2009","01/01/2009","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00707408",NA
"7146",7146,"NCT00711308","Tinzaparin in the Treatment of the Acute Pulmonary Embolism","Completed","No Results Available","Acute Pulmonary Embolism","Drug: tinzaparin|Drug: acenocoumarol","Complejo Hospitalario Xeral-Calde|LEO Pharma","Both","Adult|Senior","Phase IV",102,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EX0401ES|eudract-no. 2004-002019-97","July 3, 2008","01/04/2005",2009-02-01,"February 12, 2009","01/02/2009","",2009-01-01,"Feasibility of the secondary prophylaxis of pulmonary embolism with tinzaparin|direct and indirect cost of each treatment regimen|Major haemorrhagic events","http://ClinicalTrials.gov/show/NCT00711308",NA
"7153",7153,"NCT00720408","A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.","Completed","No Results Available","Liver Transplantation|Transplantation Immunology|Host vs Graft Reaction","Drug: Prograf-XL|Drug: Prograf|Drug: MMF","Astellas Pharma Inc|Astellas Pharma Taiwan, Inc.","Both","Adult|Senior","Phase III",48,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PRGXLLTx-0702-TW","July 18, 2008","01/12/2007",2009-09-01,"September 14, 2009","01/09/2009","",2009-09-01,"Incidence of biopsy confirmed acute rejection (local assessment of biopsies performed due to hepatic dysfunction) during the 6 months post-transplant.|Patient and graft survival rates during the 6 and 12 months post-transplant|Incidence of biopsy confirmed acute rejection (local assessment of biopsies performed due to hepatic dysfunction) during the 12 months post-transplant|Incidence of anti-lymphocyte antibody therapy for treatment of rejection during the 6 and 12 months post-transplant","http://ClinicalTrials.gov/show/NCT00720408",NA
"7158",7158,"NCT00729508","Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects","Completed","No Results Available","Cat Allergy","Biological: Cat-PAD|Biological: Cat-PAD|Biological: Cat-PAD|Biological: Cat-PAD|Biological: Cat-PAD","Circassia Limited","Both","Adult","Phase II",120,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CP002","August 4, 2008","01/08/2008",2009-05-01,"July 7, 2009","01/07/2009","",2009-04-01,"Change from baseline in Total Rhinoconjunctivitis Symptom Score (TRSS) using all timepoints during PTC in Cat-PAD treatment groups compared to placebo.|Change from baseline in TRSS in Cat-PAD treatment groups at last two timepoints on third and fourth challenge days compared to placebo.|Change from baseline in individual symptom scores for ocular and nasal symptoms at all timepoints during Exposure Chamber visit in Cat-PAD treatment groups compared to placebo.|Change from baseline in TRSS at all timepoints during Exposure Chamber visit in pooled data from Cat-PAD treatment groups compared to placebo.|Proportion of subjects prematurely leaving the EEC due to intolerable symptoms during Post-Treatment Challenge (PTC) in Cat-PAD treatment groups compared to placebo.|Change from baseline in EEC-Rhinoconjunctivitis Quality of Life Questionnaire (EEC-RQOL) at all timepoints during Exposure Chamber visit in Cat-PAD treatment groups compared to placebo.|Exploratory analyses of change from baseline in asthma symptoms, FEV1 and use of rescue medication in Cat-PAD treatment groups compared to placebo in asthmatic subjects.","http://ClinicalTrials.gov/show/NCT00729508",NA
"7163",7163,"NCT00739908","A Study of CX157 (Tyrima) for the Treatment of Depression","Completed","No Results Available","Major Depressive Disorder","Drug: CX157|Drug: Placebo","CeNeRx BioPharma Inc.","Both","Adult","Phase II",272,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CX157-200","August 20, 2008","01/09/2008",2009-07-01,"July 28, 2010","01/07/2010","CX157-200",2009-07-01,"The primary efficacy measure is the Montgomery-Asberg Depression Rating Scale (MADRS).|Efficacy measures: IDS-SR 30, HADS, CGI-I and CGI-S; Safety measures: PE, clinical laboratory evaluations, 12-lead ECG, AEs, vital signs, and suicidality assessment using the Columbia Suicide Severity Rating Scale (C-SSRS).","http://ClinicalTrials.gov/show/NCT00739908",NA
"7180",7180,"NCT00777608","A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease.","Completed","No Results Available","Alzheimer's Disease","Drug: non-product or non-Merck product|Drug: Comparator: Placebo","Merck","Both","Adult|Senior","Phase II",100,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2008_573|086","October 21, 2008","01/12/2008",2010-04-01,"April 22, 2010","01/04/2010","",2009-10-01,"Evaluate the efficacy of donepezil in improving cognitive function in patients with mild-to-moderate Alzheimer's disease as assessed by the composite score on the CogState computerized neuropsychological battery.|Evaluate the efficacy of donepezil in improving cognitive function in patients with mild-to-moderate Alzheimer's disease as assessed by the total score from the ADAS-Cog.","http://ClinicalTrials.gov/show/NCT00777608",NA
"7194",7194,"NCT00797108","A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization","Completed","No Results Available","Pneumonia, Bacterial","Drug: sulopenem and PF-03709270|Drug: Sulopenem and PF-03709270|Drug: Ceftriaxone and amoxicillin/clavulanate","Pfizer","Both","Adult|Senior","Phase II",35,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A8811020","November 24, 2008","01/01/2009",2009-06-01,"September 21, 2009","01/09/2009","",2009-06-01,"clinical response at the test of cure visit|clinical response at end of treatment and follow-up visit;|microbiological response at test of cure visit|change in Community acquired pneumonia symptom questionnaire.|Safety and tolerability will be measured by adverse event (AE) reporting including mortality, vital signs, physical examinations and safety laboratory results|Population pharmacokinetics|healthcare resource utilization","http://ClinicalTrials.gov/show/NCT00797108",NA
"7202",7202,"NCT00810108","Lopinavir/Ritonavir (Kaletra)PK","Completed","No Results Available","HIV/AIDS Treatment|HIV Infections","Drug: lopinavir/ritonavir (Kaletra?ó) tablets|Drug: lopinavir/ritonavir (Kaletra?ó) tablets","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|American Association of Colleges of Pharmacy","Female","Child","Phase IV",12,"NIH|Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","10894","December 15, 2008","01/06/2006",2009-05-01,"January 9, 2011","01/10/2010","",2009-05-01,"Plasma Sampling (3 mL of blood)|Physical Exam|Clinical Assessment","http://ClinicalTrials.gov/show/NCT00810108",NA
"7221",7221,"NCT00838708","Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus","Completed","No Results Available","Pruritus, Atopic Dermatitis","Drug: SRD174 Cream|Other: vehicle cream","Serentis Ltd.","Both","Adult|Senior","Phase II",62,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P174954201CD","February 5, 2009","01/01/2009",2009-08-01,"October 29, 2009","01/10/2009","",2009-07-01,"Measure of intensity and duration of itch episodes|Safety and local dermal tolerability","http://ClinicalTrials.gov/show/NCT00838708",NA
"7235",7235,"NCT00856908","Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes","Completed","No Results Available","Type II Diabetes","Drug: AZD1656|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase II",20,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","D1020C00020","March 5, 2009","01/02/2009",2009-08-01,"December 6, 2010","01/12/2010","",2009-08-01,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG)|PK variables (Area under the plasma conc vs. time curve (AUC), max plasma conc (Cmax), Plasma conc immediately before the next dose (Ctrough), time to reach max plasma conc (tmax), terminal elimination half-life and apparent oral clearance (CL/F)|Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide)","http://ClinicalTrials.gov/show/NCT00856908",NA
"7280",7280,"NCT00940108","A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children","Completed","No Results Available","Influenza Caused by the Novel Influenza A (H1N1) Virus","Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)|Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)","CSL Limited","Both","Child","Phase II",369,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CSLCT-CAL-09-60","July 13, 2009","01/07/2009",2010-04-01,"May 22, 2010","01/05/2010","",2009-10-01,"Immunogenicity|Frequency,duration and intensity of solicited adverse events|Frequency, duration and intensity of unsolicited adverse events|Incidence of Serious Adverse Events, Adverse Events of Special Interest (AESI's) and new onset of Chronic Illnesses","http://ClinicalTrials.gov/show/NCT00940108",NA
"7290",7290,"NCT00958308","Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection","Completed","No Results Available","Antibiotic-Associated Diarrhea|Clostridium Difficile-Associated Diarrhea","Other: BIO-K+ CL-1285?ó|Other: Placebo","Bio-K Plus International Inc.|SPRIM (CRO)","Both","Adult|Senior","Phase III",255,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","07-SC-9-BIK-01|CL 1285-AAD-CH01","August 12, 2009","01/12/2008",2009-04-01,"August 12, 2009","01/08/2009","",2009-03-01,"To compare the incidence of AAD in hospitalized patients following either BIO-K+CL1285?ó or placebo prophylaxis|To compare the severity of AAD in hospitalized patients following either BIO-K+CL1285?ó or placebo prophylaxis|To compare the incidence of Clostridium difficile in the stool of patients with AAD following BIO-K+CL1285?ó or placebo prophylaxis|To compare the safety profile of BIO-K+CL1285?ó with that of placebo","http://ClinicalTrials.gov/show/NCT00958308",NA
"7311",7311,"NCT00993408","Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)","Completed","No Results Available","Pulmonary Arterial Hypertension","Device: ACT-293987 (NS-304)","Actelion","Both","Adult|Senior","Phase II",43,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment","NS-304/-02","October 9, 2009","01/04/2008",2009-06-01,"October 9, 2009","01/10/2009","",2009-06-01,"Assessment of hemodynamic parameters after single oral dose of ACT-293987.|Proof-of-concept assessment of the efficacy of ACT-293987 in subjects with PAH by measuring the change from baseline in the PVR at Week 17 compared to placebo.|Safety and tolerability of a single oral dose of ACT-293987.|Assessments of preliminary efficacy of ACT-293987 regarding 6 minute walk test (6MWT), proportion of subjects with aggravation of PAH, hemodynamic parameters other than PVR","http://ClinicalTrials.gov/show/NCT00993408",NA
"7535",7535,"NCT00014209","Combination Chemotherapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma That Has Not Responded to Previous Treatment","Completed","No Results Available","Lymphoma","Drug: cisplatin|Drug: dexamethasone|Drug: gemcitabine hydrochloride","NCIC Clinical Trials Group","Both","Child|Adult|Senior","Phase II",NA,"Other","Interventional","Primary Purpose: Treatment","LY10|CAN-NCIC-LY10|LILLY-CAN-NCIC-LY10|CDR0000068518","April 10, 2001","01/12/2000",2009-02-01,"November 7, 2010","01/03/2010","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00014209",NA
"7564",7564,"NCT00053209","Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: gemcitabine hydrochloride|Drug: pemetrexed disodium","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000269302|ECOG-E4802","January 27, 2003","01/04/2004",NA,"May 29, 2009","01/10/2005","",2009-05-01,"Response as measured by RECIST criteria|Time to disease progression|Overall survival","http://ClinicalTrials.gov/show/NCT00053209",NA
"7575",7575,"NCT00084409","Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease","Completed","No Results Available","Lung Cancer|Precancerous Condition","Drug: iloprost|Other: placebo","University of Colorado, Denver|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",152,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Prevention","CDR0000362053|UCHSC-01279","June 10, 2004","01/11/2001",NA,"February 1, 2010","01/04/2008","",2009-01-01,"Measures of improvement in histologic response at baseline and 6 months after completion of treatment|Change in mean, dysplastic index, and worst histologic score|Change in the proliferative intermediate marker Ki-67","http://ClinicalTrials.gov/show/NCT00084409",NA
"7583",7583,"NCT00096109","17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: tanespimycin","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",37,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000391198|WSU-C-2803|NCI-6552","November 9, 2004","01/09/2004",NA,"April 13, 2010","01/04/2010","",2009-11-01,"Response rate|Progression-free survival|Correlation of HER2/neu status with response","http://ClinicalTrials.gov/show/NCT00096109",NA
"7598",7598,"NCT00115609","Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)","Completed","No Results Available","HIV Infections|Tuberculosis","Drug: efavirenz|Drug: tenofovir DF|Drug: emtricitabine","French National Agency for Research on AIDS and Viral Hepatitis","Both","Adult|Senior","Phase III",70,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-002470-30|ANRS129 BKVIR","June 23, 2005","01/01/2006",2009-11-01,"September 16, 2010","01/09/2010","",2009-11-01,"treatment success rate at week 48 (W48)|course of plasma HIV-1 RNA between W0 and W48|tuberculosis cure rate|safety of trial treatments (number of events, description, time to onset, metabolic disorders, immune restoration syndrome)|frequency of treatment changes or discontinuations|clinical progression of HIV infection|course of CD4 and CD8 T lymphocytes|study of resistance in the case of virological failure|study of compliance and quality of life|pharmacokinetic study of tuberculostatic agents|effect of treatment on hepatitis B viral replication","http://ClinicalTrials.gov/show/NCT00115609",NA
"7661",7661,"NCT00201409","A Randomized Trial of GM-CSF in Patients With ALI/ARDS","Completed","No Results Available","Respiratory Distress Syndrome, Adult","Drug: Placebo|Drug: GM-CSF","National Heart, Lung, and Blood Institute (NHLBI)|University of Michigan|Emory University|University of Colorado, Denver","Both","Adult|Senior","Phase II",132,"NIH|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","258|P50 HL074024","September 12, 2005","01/07/2004",2009-06-01,"July 14, 2009","01/07/2009","",2009-05-01,"Ventilator-free days during Days 1-28|Lung epithelial cell integrity|Alveolar macrophage function|Changes in severity of physiologic derangements of respiratory gas exchange|Non-respiratory organ failure|Incidence of ventilator-associated pneumonia","http://ClinicalTrials.gov/show/NCT00201409",NA
"7714",7714,"NCT00289809","TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients","Completed","No Results Available","Sarcoma, Soft Tissue","Drug: combination of TLC D-99 and Ifosfamide","Istituto Clinico Humanitas","Both","Adult|Senior","Phase I|Phase II",36,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ONC-2005-001|EUDRACT 2005-004569-40","February 9, 2006","01/09/2006",2009-12-01,"December 17, 2009","01/12/2009","",2009-12-01,"Phase I: Maximum Tolerated Dose (MTD) of combination of TLC D-99 and Ifosfamide|Phase II: Response rate (CR/PR or SD)|Phase II: time to progression, duration of response, overall survival","http://ClinicalTrials.gov/show/NCT00289809",NA
"7753",7753,"NCT00348309","Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: Rosiglitazone Extended Release 8mg|Drug: Rosiglitazone Extended Release 2mg|Other: Placebo","GlaxoSmithKline","Both","Adult|Senior","Phase III",1496,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AVA102672","June 30, 2006","01/07/2006",2009-01-01,"April 22, 2010","01/04/2010","REFLECT-2",2009-01-01,"Change from baseline in ADAS-Cog total score and CDR-Sum of Boxes score at Week 48, as a function of APOE e4 status.|Assessments of changes in behaviorActivities of daily livingHealthcare resource utilizationSubject and caregiver quality of lifeExploratory pharmacogeneticsProteomicsTranscriptomics|Secondary endpoints include measures of:Cognition and function: MMSE, Neuropsychiatric Inventory (NPI), DAD.|Health Outcomes: Resource Utilization in Dementia (RUD), European Quality of Life -5 Dimensions (EQ-5D), Alzheimer's Carer's Quality of Life Instrument (ACQLI).","http://ClinicalTrials.gov/show/NCT00348309",NA
"7756",7756,"NCT00347009","Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis","Completed","Has Results","Hepatitis B, Chronic|Cirrhosis|Fibrosis|Chronic Hepatitis B","Drug: adefovir dipivoxil","GlaxoSmithKline","Both","Adult|Senior","Phase IV",155,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ADF104070","June 30, 2006","01/05/2005",2009-09-01,"November 4, 2010","01/11/2010","",2009-09-01,"Number of Participants With Histologic Improvement at Month 36 (Intent-to-Treat Population)|Number of Participants With Histologic Improvement at Month 36 (Per Protocol Population)|Number of Participants With a Reduction From Baseline in the Child-Pugh Score by 2 Points or More at Months 12, 24, and 36|Number of Participants With a Reduction From Screening of at Least 2 Points in the Knodell Necroinflammation Score at Month 36|Change From Baseline in Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level at Months 12, 24, and 36|Number of Participants Achieving Virological Response (HBV DNA Level <= 10^3 Copies/ml) at Months 12, 24, and 36|Number of Participants Achieving Virological Response (HBV DNA Level <= 10^4 Copies/ml) at Months 12, 24, and 36|Number of Participants With Undetectable HBV DNA at Months 12, 24, and 36|Number of Participants With Virological Breakthrough at Months 12, 24, and 36|Number of Participants With Alanine Aminotransferase (ALT) Normalization at Months 12, 24, and 36|Number of Participants Who Were Hepatitis B Envelope Antigen (HBeAg) Positive at Baseline and Developed Undetectable Levels of HBeAg at Months 12, 24, and 36|Number of Participants Who Were HBeAg Positive at Baseline, With HBeAg Seroconversion at Months 12, 24, and 36|Number of Participants Who Were Hepatitis B Surface Antigen (HBsAg) Positive at Baseline and Developed Undetectable Levels of HBsAg at Months 12, 24, and 36|Number of Participants Who Were HBsAg Positive at Baseline, With HBsAg Seroconversion at Months 12, 24, and 36","http://ClinicalTrials.gov/show/NCT00347009",NA
"7791",7791,"NCT00414609","Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)","Completed","No Results Available","Myocardial Infarction","Drug: Aliskiren|Drug: placebo","Novartis","Both","Adult|Senior","Phase III",800,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CSPP100A2340","December 19, 2006","01/12/2006",NA,"October 27, 2009","01/10/2009","",2009-09-01,"Change in left ventricular end systolic volume (LVESD) as measured by echocardiography|Cardiovascular-related deaths, hospitalization for heart failure, recurrent myocardial infarction, stroke, and resuscitated sudden deaths|Change in left ventricular end diastolic volume|Change in left ventricular ejection fraction|Overall safety and tolerability","http://ClinicalTrials.gov/show/NCT00414609",NA
"7795",7795,"NCT00417209","Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen","Completed","No Results Available","Pancreatic Neoplasms","Drug: larotaxel (XRP9881)|Drug: 5-Fluorouracil","Sanofi-Aventis","Both","Adult|Senior","Phase III",408,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC6596|EUDRACT: 2006-003086-14","December 28, 2006","01/12/2006",2009-11-01,"August 3, 2010","01/08/2010","PAPRIKA",2009-07-01,"overall survival (OS) defined as the time interval from the date of randomization to the date of death due to any cause|Progression free survival (PFS); Overall Response Rate (proportion of patients with confirmed RECIST-defined complete response (CR) or partial response (PR); clinical benefit based on the measurement of tumor related symptoms;","http://ClinicalTrials.gov/show/NCT00417209",NA
"7811",7811,"NCT00443209","MK0974 Long Term Safety Study","Completed","No Results Available","Migraine","Drug: Comparator: MK0974|Drug: Comparator: rizatriptan|Drug: Comparator: Placebo to MK0974|Drug: Comparator: Placebo to rizatriptan","Merck","Both","Adult|Senior","Phase III",1068,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2006_524|MK0974-012","February 28, 2007","01/02/2007",2009-02-01,"March 17, 2009","01/03/2009","",2009-01-01,"Adverse experiences, laboratory values, ECGs, and vital signs during the study period.|Pain freedom at 2 hours postdose.","http://ClinicalTrials.gov/show/NCT00443209",NA
"7824",7824,"NCT00462709","Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks","Completed","Has Results","Hereditary Angioedema","Biological: C1 esterase inhibitor [human] (C1INH-nf)","ViroPharma","Both","Child|Adult|Senior","Phase III",146,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","LEVP2006-4","April 17, 2007","01/06/2006",2009-03-01,"May 7, 2010","01/05/2010","CHANGE 3",2009-03-01,"Frequency of All HAE Attacks","http://ClinicalTrials.gov/show/NCT00462709",NA
"7830",7830,"NCT00473109","Chronic Hemodialysis Without Systemic Heparinization : a Randomized Study","Completed","No Results Available","Contra-Indication to the Use of Low Molecular Weight Heparin","Procedure: Dialysis without systemic heparinization","Assistance Publique - H??pitaux de Paris","Both","Adult|Senior","Phase III",75,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P050311|CRC05032","May 11, 2007","01/05/2007",2009-05-01,"May 22, 2009","01/05/2007","HDSH",2009-03-01,"Need for stopping the meeting for coagulation of the circuit of dialysis: -either complete coagulation of the circuit|or coagulation partial of the circuit (a clot is noted in the lines or the trap with bubbles|-or increase in the venous pressure (statement) of the circuit of more than 50 that is to say increase in the venous pressure (statement) of the circuit of more than 50 % beyond its initial value|Loss of effectiveness of dialysis? dialysance of urea during the meeting (online measurement carried out by the generator of dialysis)|Loss of effectiveness of dialysis overloads hydro-sodic persistent (weight of the patient at the end of the meeting: + 500 grams compared to the basic weight)|Tolerance of the meeting of dialysis clinical side effects (cephalgias, cramps, arterial hypotension|Tolerance of the meeting of dialysis hemorrhagic accidents to at the time the 48 hours following the meeting of dialysis","http://ClinicalTrials.gov/show/NCT00473109",NA
"7877",7877,"NCT00547209","Effect of Nitrous Oxide on Intravenous Closed-loop Anesthesia","Completed","No Results Available","Anesthesia","Drug: air|Drug: Nitrous oxide","Hopital Foch","Both","Adult|Senior","Phase IV",560,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","2007-08","October 19, 2007","01/10/2007",2009-11-01,"November 22, 2009","01/11/2009","Drone-N2O",2009-11-01,"Measure: influence of nitrous oxide on the automated administration of propofol and remifentanil.|Measure: consequences of the use of nitrous oxide on the performance of the automated administration system.|Influence of Gender","http://ClinicalTrials.gov/show/NCT00547209",NA
"7902",7902,"NCT00586209","L-Glutamine Therapy for Sickle Cell Anemia","Completed","No Results Available","Sickle Cell Anemia|Thalassemia","Drug: L-Glutamine|Drug: Placebo","Los Angeles Biomedical Research Institute|Emmaus Medical, Inc.","Both","Adult|Senior","Phase II",50,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10511-01RY","December 21, 2007","01/01/2003",2009-11-01,"December 2, 2010","01/12/2010","",2009-01-01,"Number of occurrences of painful sickle cell crises|Frequency of hospitalizations for sickle cell pain|Frequency of emergency room visits for sickle cell pain|Number of days patients' usual daily activities are interrupted due to sickle cell pain|Subjective exercise tolerance","http://ClinicalTrials.gov/show/NCT00586209",NA
"7904",7904,"NCT00595309","Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51","Completed","No Results Available","Japanese Encephalitis","Biological: IC51","Intercell AG","Both","Adult|Senior","Phase III",200,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","IC51-311","January 4, 2008","01/12/2007",2009-10-01,"June 2, 2010","01/09/2007","",2009-10-01,"Seroconversion rate|Safety and Adverse Events","http://ClinicalTrials.gov/show/NCT00595309",NA
"7931",7931,"NCT00631709","REmote MOnitoring Transmission Evaluation of IPGs","Completed","No Results Available","Pacemaker","Other: CareLink Remote Monitoring","Medtronic","Both","Child|Adult|Senior","Phase IV",120,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","REMOTE-IPG 2008","March 3, 2008","01/03/2008",2010-02-01,"December 21, 2010","01/12/2010","REMOTE-IPG",2009-11-01,"","http://ClinicalTrials.gov/show/NCT00631709",NA
"7949",7949,"NCT00660309","A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: aliskiren|Drug: irbesartan","Novartis","Both","Adult|Senior","Phase IV",45,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label","CSPP100A2329","April 11, 2008","01/04/2008",NA,"April 26, 2010","01/04/2010","",2009-12-01,"Renal blood flow and glomerular filtration rate at baseline, after 1 and 14 days of treatment with aliskiren or irbesartan and after a single dose of captopril (an angiotensin converting enzyme inhibitor and positive control)|Retinal blood flow at baseline, after 14 days of treatment with aliskiren or irbesartan, after a singe dose of captopril Plasma levels of renin system biomarkers (renin, pro-renin, angiotensin 1, angiotensin 2, angiotensinogen, and aldosterone)","http://ClinicalTrials.gov/show/NCT00660309",NA
"7953",7953,"NCT00662909","Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 in Patients With Symptoms of Overactive Bladder","Completed","No Results Available","Urinary Bladder, Overactive","Drug: YM178|Drug: Placebo","Astellas Pharma Inc","Both","Adult|Senior","Phase III",2190,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","178-CL-047","April 17, 2008","01/04/2008",2009-04-01,"April 15, 2010","01/04/2010","ARIES",2009-04-01,"Change from baseline to end of treatment in mean number of micturitions per 24 hours|Change from baseline to end of treatment in mean number of incontinence episode per 24 hours|Change from baseline in mean volume voided per micturition|Change from baseline in mean number of urgency incontinence episodes per 24 hours|Change from baseline in mean number of urgency episodes (grade 3 and/or 4) per 24 hours","http://ClinicalTrials.gov/show/NCT00662909",NA
"7956",7956,"NCT00669409","A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee","Completed","No Results Available","Osteoarthritis, Knee","Drug: PF-04383119 (tanezumab)|Drug: PF-04383119 (tanezumab)|Drug: PF-04383119 (tanezumab)|Drug: PF-04383119 (tanezumab)|Drug: PF-04383119 (tanezumab)|Drug: PF-04383119 (tanezumab)","Pfizer","Both","Adult|Senior","Phase II",83,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A4091022","April 25, 2008","01/06/2008",2009-12-01,"January 4, 2011","01/01/2011","",2009-12-01,"Safety assessments for the study include AE collection, vital signs, postural vital signs, weight, physical and neurological examinations, ECG, Hopkins Verbal Learning Test -Revised (HVLT-R?ºÑ), and routine laboratory tests.|Western Ontario and McMaster Universities Arthritis (WOMAC 3.1?ºÑ) scale.|VAS for index knee pain during walking in the past 24 hours.|VAS for index knee pain in the past 24 hours.|Visual analogue scale (VAS) for current index knee pain.|Following PK parameters will be determined from the plasma PF-04383119 concentration-time profiles by model-independent analysis: Cmax, Tmax, AUCinf, AUClast, V0, Vss, CL, MRT, and t1/2.|All patients exposed to PF-04383119 will be tested for development of anti-PF-04383119 antibodies.","http://ClinicalTrials.gov/show/NCT00669409",NA
"7958",7958,"NCT00661609","A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer","Completed","Has Results","Bladder Cancer|Transitional Cell Bladder Cancer|Urethra Cancer|Ureter Cancer|Renal Pelvis Cancer","Drug: AZD4877","AstraZeneca","Both","Adult|Senior","Phase II",54,"Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D2782C00010","April 16, 2008","01/05/2008",2009-12-01,"December 13, 2010","01/12/2010","",2009-05-01,"Objective Response Rate (ORR) as Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST)|Disease Control Rate (DCR)|Duration of Objective Tumor Response (OTR)|Progression Free Survival (PFS)|Overall Survival (OS)","http://ClinicalTrials.gov/show/NCT00661609",NA
"7968",7968,"NCT00688909","Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: letrozole","Novartis Pharmaceuticals","Female","Adult|Senior","Phase IV",260,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","CFEM345DUS59","May 29, 2008","01/03/2008",2009-10-01,"November 18, 2009","01/11/2009","REAL",2009-10-01,"Proportion of patients discontinuing due to grade 2 or higher arthralgia-myalgia.|Time to discontinuation due to grade 2 or higher arthralgia- myalgia.|Proportion of patients discontinuing, irrespective of cause.","http://ClinicalTrials.gov/show/NCT00688909",NA
"7974",7974,"NCT00701909","Pain Medicine for Wound Care Procedures","Completed","No Results Available","Wound Care|Pain Intensity|Hyperalgesia|Nausea|Vomiting|Hallucinations","Drug: morphine plus saline|Drug: morphine plus ketamine","University of California, San Francisco","Both","Adult","Phase III",12,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","H2280-32187-01","June 18, 2008","01/06/2008",2009-04-01,"January 15, 2010","01/02/2009","",2009-04-01,"pain intensity|hyperalgesia","http://ClinicalTrials.gov/show/NCT00701909",NA
"7982",7982,"NCT00713609","Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne","Completed","No Results Available","Acne Vulgaris","Drug: Benzoyl peroxide/clindamycin gel + tazarotene cream|Drug: Benzoyl peroxide/clindamycin gel + vehicle cream|Drug: Benzoyl peroxide gel + tazarotene cream|Drug: Clindamycin gel + tazarotene cream|Drug: Vehicle gel+ tazarotene cream|Drug: Vehicle gel + vehicle cream","Stiefel, a GSK Company","Both","Child|Adult","Phase II",591,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","W0259-201","July 7, 2008","01/06/2008",2009-03-01,"September 7, 2010","01/09/2010","",2009-03-01,"The absolute change in lesion counts (total, inflammatory, noninflammatory) from baseline to week 12. The proportion of subjects who have a minimum 2-grade improvement in ISGA score from baseline to week 12.|The percent (%) change in lesion counts (total, inflammatory, noninflammatory) from baseline to week 12. The proportion of subjects who have an ISGA score of 0 or 1 at week 12.","http://ClinicalTrials.gov/show/NCT00713609",NA
"8000",8000,"NCT00735709","Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder","Completed","No Results Available","Major Depressive Disorder","Drug: Lu AA21004|Drug: Lu AA21004|Drug: Lu AA21004|Drug: Placebo","Takeda Global Research & Development Center, Inc.|H. Lundbeck A/S","Both","Adult|Senior","Phase III",560,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","LuAA21004_305|2008-001580-11|U1111-1114-0326","August 14, 2008","01/08/2008",2009-08-01,"April 28, 2010","01/04/2010","",2009-07-01,"The least squares mean change from Baseline in the 24-item Hamilton Depression Scale total score.|The least squares mean change from baseline in the 24-item Hamilton Depression Scale total score.|Response rates ??­50% decrease in the 24-item Hamilton Depression Scale total score from Baseline.|Sustained response from Week 1 for Lu AA21004 compared with placebo (sustained response: at least a 20% decrease from baseline in 24-item HAM-D total score obtained at Week 1 and sustained through Wk 6 and at least 50% decrease from baseline at Wk 8.)|Remission rates using a Montgomery ??sberg Depression Rating Scale total score ???10.|The least squares mean change from Baseline in Montgomery ??sberg Depression Rating Scale total score.|The least squares mean change from Baseline in Hamilton Anxiety Scale total score.|The least squares mean change from Baseline in Clinical Global Impression Scale-Global Improvement|The least squares mean change from Baseline in Clinical Global Impression Scale-Severity of Illness.|The least squares mean change from Baseline in Hospital Anxiety and Depression scale.|Sheehan Disability Scale.|Healthcare resource utilization as assessed by the Health Economic Assessment Questionnaire.|Medical Outcomes Study Short-Form 36, each of the 8 subscales separately.","http://ClinicalTrials.gov/show/NCT00735709",NA
"8007",8007,"NCT00752609","Safety and Efficacy of Peginesatide Injection in Chronic Renal Failure Subjects.","Completed","No Results Available","Anemia","Drug: Peginesatide","Takeda Global Research & Development Center, Inc.|Affymax","Both","Adult|Senior","Phase II",102,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AFX01_202|2008-003459-64|U1111-1114-1500","September 11, 2008","01/10/2008",2009-12-01,"June 2, 2010","01/06/2010","",2009-12-01,"Mean change in hemoglobin between baseline and the evaluation period.|Proportion of subjects who have mean Hemoglobin values within the target range of 10.0 to 12.0 g/dL during the evaluation period|Proportion of subjects with a change in Hemoglobin between Baseline and the evaluation period of less than or equal to ?? 1g/dL|Proportion of subjects who receive red blood cell transfusions.|Mean Hemoglobin during 4-week intervals|Proportion of subjects who maintain a target Hemoglobin of 10.0 to 12.0 g/dL during 4-week intervals.|Proportion of subjects requiring dose adjustments during the study","http://ClinicalTrials.gov/show/NCT00752609",NA
"8010",8010,"NCT00761709","Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension","Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: AL-39256|Drug: Latanoprost Ophthalmic Solution, 0.005%|Drug: Placebo (Vehicle Solution)","Alcon Research","Both","Adult|Senior","Phase II",90,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-08-28","September 25, 2008","01/01/2009",2009-03-01,"March 23, 2009","01/03/2009","",2009-03-01,"Mean IOP from baseline","http://ClinicalTrials.gov/show/NCT00761709",NA
"8012",8012,"NCT00759109","Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (Study P02733AM4)(COMPLETED)","Completed","No Results Available","Carcinoma, Hepatocellular","Biological: Peginterferon alfa-2b, PegIntron, Pegylated Alfa-2b (SCH 054031)|Other: Observation (no treatment)","Schering-Plough","Both","Adult|Senior","Phase III",160,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","P02733","August 26, 2008","01/01/2002",2009-11-01,"December 22, 2010","01/12/2010","",2009-11-01,"Development of hepatocellular carcinoma, measured as the appearance of focal lesion US (FNB), or focal lesion US + AFP >400 ng/mL|Development of hepatic decompensation; Worsening of portal hypertension; Survival; Tolerability of the study treatment|Virologic response rate (HCV-RNA negative)|Alterations of PCNA-LI levels, as measured by liver biopsy","http://ClinicalTrials.gov/show/NCT00759109",NA
"8015",8015,"NCT00772109","Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone?ó in Adults","Completed","No Results Available","Orthomyxoviridae Infection|Influenza|Myxovirus Infection","Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B","Sanofi-Aventis","Both","Adult","Phase III",4300,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","FID31","October 13, 2008","01/10/2008",2009-07-01,"March 31, 2010","01/03/2010","",2009-05-01,"Immunogenicity: To provide information concerning the immunogenicity of an investigational Fluzone vaccine.|Safety: To provide information concerning the safety of an investigational Fluzone vaccine.","http://ClinicalTrials.gov/show/NCT00772109",NA
"8029",8029,"NCT00799409","Lab School Study for CONCERTA","Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Drug: methylphenidate HCl|Drug: methylphenidate HCl","Ortho-McNeil Janssen Scientific Affairs, LLC","Both","Child","Phase IV",78,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR015046|CONCERTAATT4069","November 26, 2008","01/11/2008",2009-06-01,"April 26, 2010","01/04/2010","",2009-06-01,"The primary efficacy variable in this study is the Permanent Product Math Test (PERMP) attempted score.|Secondary Measures include: SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham), tests of inattention, reading fluency and comprehension, and memory.","http://ClinicalTrials.gov/show/NCT00799409",NA
"8031",8031,"NCT00792909","Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A","Completed","No Results Available","Pneumococcal Disease|Streptococcus Pneumoniae Vaccines","Biological: Pneumococcal conjugate vaccine GSK1024850A|Biological: Pneumococcal conjugate vaccine GSK1024850A","GlaxoSmithKline","Both","Child","Phase III",172,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","111736","November 17, 2008","01/12/2008",2009-07-01,"November 4, 2010","01/11/2010","",2009-07-01,"Concentrations of antibodies against vaccine pneumococcal serotypes|Immune responses (= antibody concentrations) against components of the investigational pneumococcal conjugate vaccine|Immune responses (= antibody concentrations) against components of the investigational pneumococcal conjugate vaccine.|Immune responses (= antibody concentrations) against components of investigational pneumococcal conjugate vaccine|In a subset of subjects: immune responses (= antibody concentrations) against components of the investigational pneumococcal conjugate vaccine|Occurrence of solicited adverse events|Occurrence of unsolicited adverse events|Occurrence of serious adverse events","http://ClinicalTrials.gov/show/NCT00792909",NA
"8032",8032,"NCT00805909","NI-0401 in Patients With Acute Renal Allograft Rejection","Completed","No Results Available","Acute Renal Transplant Rejection","Drug: NI-0401","NovImmune SA","Both","Adult|Senior","Phase I|Phase II",12,"Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NI-0401-02","December 8, 2008","01/08/2007",2009-01-01,"June 8, 2009","01/06/2009","",2009-01-01,"Nature,frequency,intensity,causality and seriousness of adverse events","http://ClinicalTrials.gov/show/NCT00805909",NA
"8075",8075,"NCT00872209","Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa","Completed","No Results Available","Otitis Externa|Otorhinolaryngologic Diseases|Ear Diseases|Otitis","Drug: 0.3% Ciprofloxacin Ear Drops|Drug: 0.3% Ciprofloxacin Foam Otic Cipro","Otic Pharma","Both","Adult|Senior","Phase I|Phase II",100,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OP-001-00","March 29, 2009","01/05/2009",2009-11-01,"December 23, 2009","01/12/2009","",2009-10-01,"Clinical cure confirmed by significant reduction or absence of the disease symptoms a) Otalgia, b) tenderness with movement of pinna, and c) edema/ear canal occlusion","http://ClinicalTrials.gov/show/NCT00872209",NA
"8137",8137,"NCT00976209","Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(COMPLETED)","Completed","No Results Available","Vasomotor Rhinitis|Seasonal Allergic Rhinitis","Drug: Phenylephrine Hydrochloride Extended Release Tablets 30 mg|Drug: Phenylephrine Hydrochloride Tablets, 10 mg","Schering-Plough","Both","Adult|Senior","Phase III",288,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","CL2008-15","September 11, 2009","01/08/2009",2009-12-01,"December 10, 2009","01/12/2009","",2009-12-01,"Which product did you prefer for the relief of nasal congestion? Possible answers are: I preferred relief of Treatment A & every 12 hrs white tablet); I preferred relief of Treatment B (every 4 hours red tablet) Or I didn't have preference.|Which product was more convenient? I preferred convenience of Treatment A (every 12 hours white tablet); I preferred convenience of Treatment B (every four hours red tablet: Or, I didn't have a preference.","http://ClinicalTrials.gov/show/NCT00976209",NA
"8262",8262,"NCT01190709","Study of Tibial Shaft Fracture Fixation: Intramedullary Nailing Comparing With Dynamic Compression Plate","Completed","No Results Available","Tibial Shaft Fracture","Procedure: Dynamic Compression Plate|Procedure: Unreamed intramedullary nailing","Isfahan University of Medical Sciences","Both","Child|Adult|Senior","Phase II",100,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","ASD-1213-6","August 27, 2010","01/10/2008",2009-03-01,"August 27, 2010","01/10/2008","",2009-03-01,"time of fracture healing|malunion|nonunion|infection","http://ClinicalTrials.gov/show/NCT01190709",NA
"8400",8400,"NCT00088010","Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer","Completed","No Results Available","Osteoporosis, Postmenopausal","Drug: Arzoxifene|Drug: Placebo","Eli Lilly and Company","Female","Adult|Senior","Phase III",9369,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8536|H4Z-MC-GJAD","July 19, 2004","01/06/2004",2009-11-01,"May 27, 2010","01/05/2010","",2009-06-01,"Effects of arzoxifene on bone fractures and bone mass|Effects of arzoxifene on getting breast cancer|The safety of arzoxifene and any side effects|Effects of arzoxifene on certain types of cardiovascular events|Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health|Effects of arzoxifene on the uterus|Effects of arzoxifene on cognition|Effects of arzoxifene on back pain","http://ClinicalTrials.gov/show/NCT00088010",NA
"8514",8514,"NCT00259610","Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)","Completed","No Results Available","Rheumatoid Arthritis","Drug: methotrexate|Drug: sulfasalazine|Drug: hydroxychloroquine|Drug: etanercept|Drug: MTX + Etanercept|Drug: MTX + SSZ/HCQ|Drug: MTX + Etanercept|Drug: MTX or MTX + SSZ/HCQ|Drug: MTX or MTX + Etanercept","University of Alabama at Birmingham|Amgen|Barr Laboratories|Pfizer","Both","Adult|Senior","Phase IV",750,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","X031030004|20040391","November 28, 2005","01/05/2004",2009-06-01,"September 2, 2009","01/09/2009","TEAR",2009-06-01,"Disease Activity","http://ClinicalTrials.gov/show/NCT00259610",NA
"8538",8538,"NCT00276510","A Study of EGb 761?ó (Tanakan?ó) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints","Completed","No Results Available","Memory Disorders, Age-Related|Retention Disorders, Cognitive","Drug: EGb 761?ó (Tanakan?ó)|Other: Placebo","Ipsen","Both","Senior","Phase IV",2878,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2-31-00240-011","January 12, 2006","01/02/2002",2009-11-01,"December 14, 2009","01/12/2009","",2009-11-01,"EGb 761?ó efficacy on conversion rate of memory complaint to dementia of Alzheimer type by a survival analysis|Efficacy on rate of cognitive abilities decline|Effect on concomitant diseases|Concomitant treatments' reports|Global evaluation of memory complaint by the patient|Clinical safety","http://ClinicalTrials.gov/show/NCT00276510",NA
"8548",8548,"NCT00310310","Effect of Self-Management on Improving Sleep Apnea Outcomes","Completed","No Results Available","Sleep Apnea Syndromes","Behavioral: Sleep Apnea Self-Management Program|Behavioral: Usual care","Department of Veterans Affairs","Both","Adult|Senior","Phase II|Phase III",240,"U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)","IIR 02-275|UCSD HRPP #050717","March 30, 2006","01/04/2006",2009-12-01,"March 2, 2010","01/03/2010","",2009-05-01,"CPAP adherence|Perceived self-efficacy, outcome expectations and reduced sleep apnea symptoms at post-intervention","http://ClinicalTrials.gov/show/NCT00310310",NA
"8583",8583,"NCT00366210","Constraint-Induced Therapy Modified for Rehabilitating Arm Function in Stroke Survivors w/Plegic Hands","Completed","No Results Available","Chronic Stroke Survivors With Plegic Hand","Behavioral: Constraint-Induced Movement (CI) Therapy|Other: Usual & Customary Care|Behavioral: Stretching, Relaxation, & Biofeedback","University of Alabama at Birmingham","Both","Adult|Senior","Phase I|Phase II",21,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","F060112013","August 18, 2006","01/10/2005",2009-09-01,"August 10, 2010","01/08/2010","",2009-09-01,"Motor Activity Log","http://ClinicalTrials.gov/show/NCT00366210",NA
"8650",8650,"NCT00470210","Peginterferon Alfa-2a, Ribavirin and Epoetin ?? in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens","Completed","No Results Available","Hepatitis C|HIV Infections","Drug: Peginterfer??n alfa-2a (40 KD) (Pegasys?ó) 180 ug/week|Drug: Ribavirin (Copegus?ó) 1600 mg/day|Drug: Epoetin ?? (450 UI/kg/week)","Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA","Both","Adult|Senior","Phase IV",10,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MORE|2006-005554-74","May 4, 2007","01/05/2007",2009-06-01,"April 15, 2010","01/04/2010","",2009-06-01,"Rate of sustained virologic response measured as serum HCV-RNA loads of < 50 IU/mL|Changes in serum HCV-RNA titers|Percentage of patients with serum HCV-RNA loads of < 50 IU/mL","http://ClinicalTrials.gov/show/NCT00470210",NA
"8656",8656,"NCT00475410","Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn??s Disease","Completed","No Results Available","Anal Fistula","Drug: ASCs (Cx401, company code)|Drug: Fibrin adhesive","Cellerix","Both","Adult|Senior","Phase III",214,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","Cx401/FATT1|2006-003370-95","May 17, 2007","01/02/2007",2009-08-01,"November 25, 2009","01/11/2009","FATT1",2009-08-01,"Closure of fistulas defined as absence of suppuration and re-epithelization of the external opening and absence of collections>2 cm directly related to the fistula tract treated, as measured by MRI (healing)|??Ñ Clinical complexity of fistula (complexity of fistula score) ??Ñ Safety: Cumulative incidence of adverse effects. ??Ñ Quality of life (SF-36 score) ??Ñ Degree of anal incontinence (Wexner incontinence score)","http://ClinicalTrials.gov/show/NCT00475410",NA
"8703",8703,"NCT00540410","Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks","Completed","No Results Available","Malaria","Drug: Coarsucam?ó (art?¢sunate (AS) + amodiaquine (AQ) as fixed dose combination)|Drug: Coartem?ó (arthemether+ lumefantrine)","Sanofi-Aventis","Both","Child|Adult|Senior","Phase IV",366,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ARAMF_L_02873","October 5, 2007","01/09/2007",2009-02-01,"June 22, 2010","01/06/2010","",2009-02-01,"PCR corrected and uncorrected clinical and parasitological cure rate|PCR corrected and uncorrected clinical and parasitological cure rate|Fever and parasitological clearance|Proportion of afebrile patients and proportion of patients without parasites|Clinical tolerability (incidence and intensity of recorded AE)|Biological tolerability (Hb, bilirubin, ALAT, Creatinine, Leukocytes, Neutrophils and platelets count)|Cardiac tolerability (QTc) for the first attack in patients group aged >= 12 years)|Assessment and evolution of hearing function in patients groupe aged >=12 years","http://ClinicalTrials.gov/show/NCT00540410",NA
"8711",8711,"NCT00559910","A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: PH-797804|Drug: Placebo","Pfizer","Both","Adult|Senior","Phase II",230,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A6631011","November 15, 2007","01/01/2008",2009-12-01,"March 3, 2010","01/03/2010","",2009-12-01,"Safety and tolerability measures (AEs, 12-lead ECG, lab safety) during 6 weeks of treatment and up to 2 weeks post treatment.|Spirometry measures during 6 weeks of treatment and up to 2 weeks post treatment.|Peak expiratory flow rate.|Blood sample for pharmacogenomics|Blood sample for pharmacokinetics|Rescue bronchodilator usage.|Dyspnea index scores.|Global impression of change (patient and clinician).|Symptom scores.|Blood sample for biomarkers","http://ClinicalTrials.gov/show/NCT00559910",NA
"8717",8717,"NCT00567710","A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study","Completed","No Results Available","Schizophrenia","Drug: BL - 1020|Drug: BL - 1020|Drug: Placebo|Drug: Risperidone","BioLineRx, Ltd.","Both","Adult","Phase II",360,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BL - 1020 IIb|BL - 1020 IIb","December 4, 2007","01/07/2008",2009-09-01,"June 27, 2010","01/06/2010","",2009-07-01,"to evaluate the safety and tolerability of two dose ranges|to evaluate the efficacy of two dose ranges","http://ClinicalTrials.gov/show/NCT00567710",NA
"8719",8719,"NCT00569010","Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory AML or High Risk MDS","Completed","No Results Available","Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Leukemia","Drug: Azacitidine|Drug: Ara-C","M.D. Anderson Cancer Center|Celgene Corporation","Both","Adult|Senior","Phase I|Phase II",36,"Other|Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0291","December 5, 2007","01/12/2005",2009-10-01,"October 23, 2009","01/10/2009","",2009-10-01,"Dose limiting toxicity of the combination of azacitidine and Ara-C(ie. recommended Phase II dose)|Clinical Activity","http://ClinicalTrials.gov/show/NCT00569010",NA
"8724",8724,"NCT00546910","Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)","Completed","Has Results","Attention Deficit Hyperactivity Disorder","Drug: Atomoxetine|Drug: Placebo","Eli Lilly and Company","Both","Child","Phase IV",125,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11148|B4Z-SB-LYDV","October 17, 2007","01/10/2007",2009-05-01,"August 4, 2010","01/08/2010","",2009-05-01,"Change From Baseline Computer-based Continuous Performance Test (cb- CPT; Qbtech AB, Sweden), Variable: Hyperactivity (Includes Time Active [TA], Distance [DIS], Area [AR], Microevents [ME], Motion Simplicity [MS]) Q-scores At Week 8|Change From Baseline cb CPT Variable: Inattention (Includes Reaction Time Variation[RTV], Omission Error [OR], Mean Reaction Time [mRT], Normalized Variation Of Reaction Time [nVRT]) Q-scores At Week 8|Change From Baseline cb CPT Variable: Impulsivity (Includes Commission Error [CE], Anticipatory Response [AR]) Q-scores At Week 8|Change From Baseline cb CPT Variable: Other (Includes Error Rate [ER] and Multi Response [MR]) Q-scores At Week 8|Change From Baseline Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered And Scored (ADHDRS-IV-Parent:Inv) Total Score At Week 8|Change From Baseline Clinical Global Impressions-Severity of ADHD (CGI-S-ADHD) Score at Week 8|Change From Baseline Weekly Rating Of Evening and Morning Behavior-Revised-Investigator Rated, Total and Subscores at Week 8","http://ClinicalTrials.gov/show/NCT00546910",NA
"8727",8727,"NCT00576810","Sodium Picosulphate vs. Placebo in Functional Constipation","Completed","No Results Available","Constipation","Drug: sodium picosulphate","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",367,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1062.7|EURDRACT2007-002087-10","October 29, 2007","01/10/2007",NA,"June 23, 2010","01/06/2010","",2009-01-01,"The primary endpoint in this trial is the mean number of complete spontaneous bowel movements (CSBMs) per week, during the 4 week treatment phase of the trial.|Number of CSBMs per week; Number of SBM per week; time to first SBM; number of patients with increase of min. 1CSBM per week; ....","http://ClinicalTrials.gov/show/NCT00576810",NA
"8749",8749,"NCT00615810","ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial","Completed","No Results Available","HIV Infections","Drug: Atripla|Drug: Kivexa plus Sustiva","Gilead Sciences","Both","Adult|Senior","Phase IV",159,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GS-UK-177-0109|2007-003354-28 EudraCT Number","February 1, 2008","01/03/2008",2010-01-01,"July 30, 2010","01/07/2010","ROCKET I",2009-10-01,"Change from baseline in total fasting cholesterol at Week 12.|Change in total fasting cholesterol at Week 24|Changes in fasting LDL, HDL, triglycerides, non-HDL cholesterol and cholesterol ratios","http://ClinicalTrials.gov/show/NCT00615810",NA
"8763",8763,"NCT00410410","A Study of Abatacept in Patients With Active Ulcerative Colitis","Completed","Has Results","Ulcerative Colitis","Drug: abatacept (ABA)|Drug: placebo|Drug: abatacept","Bristol-Myers Squibb","Both","Adult|Senior","Phase III",591,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","IM101-108","December 11, 2006","01/12/2006",2009-11-01,"November 4, 2010","01/11/2010","",2009-06-01,"Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)|Maintenance Period (MP); Number of Participants With Clinical Response (Per Mayo Score) at Month 12|Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation|OL; Number of Participants With AEs of Special Interest|OL; Number of Participants With Physical Examination Findings|OL; Number of Participants With Marked Hematology Laboratory Abnormalities|OL; Number of Participants With Liver and Kidney Function and Electrolyte Laboratory Abnormalities|OL; Number of Participants With Chemistry and Urinalysis Laboratory Abnormalities|IP; Baseline Mayo Score: IP1C|IP; Number of Participants in Clinical Remission (Per Mayo Score) at Week 12: IP1C|IP; Number of Participants in Mucosal Healing (Per Mayo Score) at Week 12: IP1C|IP; Number of Participants With Clinical Response (Per Mayo Score) at Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C|IP; Baseline Inflammatory Bowel Disease Questionnaire (IBDQ) Score: IP1C|IP; Mean Change From Baseline To Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ): IP1C|IP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (???1 Point) at Week 12: IP1C|IP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (???1 Point) at Week 12: IP1C|IP; Number of Participants With Mayo Physician Global Assessment (PGA) Subscores Indicating Mild Disease (???1 Point) at Week 12: IP1C|IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With Clinical Response At Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C|IP; Number of Participants With Clinical Response At Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C|IP; Number of Participants in Clinical Remission at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C|IP; Number of Participants in Mucosal Healing at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C|IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation: IP1C + IP2C|IP; Number of Participants With AEs Of Special Interest: IP1C + IP2C|IP; Number of Participants With Physical Examination Findings: IP1C + IP2C|IP; Number of Participants With Marked Hematology Laboratory Abnormalities: IP1C|IP; Number of Participants With Marked Liver and Kidney Function and Electrolyte Laboratory Abnormalities: IP1C|IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP1C|IP; Number of Participants With Marked Hematology, Liver and Kidney Function, and Electrolyte Laboratory Abnormalities: IP2C|IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP2C|IP; Number of Participants With Abatacept-Induced Antibodies: IP1C + IP2C|MP; Number of Participants in Clinical Remission at Month 12|MP; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (???1 Point) at Month 12|MP; Number of Participants in Clinical Remission at Both Month 6 and Month 12|MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids and Achieved Clinical Remission by Month 12|MP; Mean Change From Baseline to Month 12 in IBDQ|MP; Mean Change From Baseline to Month 12 in Short Form-36 (SF-36)|MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids for 90 Consecutive Days and Achieved Clinical Remission by Month 12|MP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (???1 Point) at Month 12|MP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (???1 Point) at Month 12|MP; Number of Participants With Mayo PGA Subscores Indicating Mild Disease (???1 Point) at Month 12|MP; Number of Participants With Clinical Response at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)|MP; Number of Participants With Clinical Remission at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)|MP; Number of Participants With Clinical Mucosal Healing at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)|MP; Number of Participants With Abatacept-Induced Antibodies|MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation|MP; Number of Participants With AEs of Special Interest|MP; Number of Participants With Physical Examination Findings|MP; Number of Participants With Marked Hematology Laboratory Abnormalities|MP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities|OL; Number of Participants With Clinical Response Over Time|OL; Number of Participants With Clinical Remission Over Time|OL; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (???1 Point) During OL|OL; Number of Participants With Clinical Response or Clinical Remission Upon Retreatment With Abatacept Among Those Who Received Abatacept in the IP or MP Period|OL; Number of Participants With Abatacept-Induced Antibodies|OL; Number of Participants Using Corticosteroids During OL","http://ClinicalTrials.gov/show/NCT00410410",NA
"8794",8794,"NCT00678210","Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","Completed","No Results Available","Psoriasis","Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: Placebo","Pfizer","Both","Adult|Senior","Phase II",197,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A3921047","May 13, 2008","01/07/2008",2009-08-01,"September 14, 2009","01/09/2009","",2009-08-01,"Proportion of subjects achieving a PASI 75 response (ie, at least a 75% reduction in PASI relative to baseline) at Week 12.|Proportion of subjects achieving a PASI 75 response|Proportion of subjects achieving a PASI 50 response (ie, at least a 50% reduction in PASI relative to baseline)|Proportion of subjects achieving a PASI 90 response (ie, at least a 90% reduction in PASI relative to baseline)|Actual and change from baseline in PASI (Psoriasis Area and Severity Index) and PASI component scores|Proportion of subjects with a Physician's Global Assessment (PGA) of \clear\"" or \""almost clear\""""","http://ClinicalTrials.gov/show/NCT00678210",NA
"8816",8816,"NCT00660010","Study of Lupron Depot In The Treatment of Central Precocious Puberty","Completed","Has Results","Puberty, Precocious","Drug: Lupron (leuprolide acetate)","Abbott","Both","Child","Phase III",55,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M90-516","April 15, 2008","01/01/1991",2009-04-01,"November 18, 2010","01/09/2010","",2009-04-01,"Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics Acccording to Tanner Staging (Breast Development in Females)|Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics Acccording to Tanner Staging (Genital Development in Males)|Mean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations|Mean Stimulated Estradiol Concentrations in Females|Mean Stimulated Testosterone Concentrations in Males|Mean Ratio of Bone Age to Chronological Age","http://ClinicalTrials.gov/show/NCT00660010",NA
"8821",8821,"NCT00728910","Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study","Completed","No Results Available","Atherogenic Dyslipidemia","Drug: Lipitor|Drug: ABT335|Drug: Niaspan","University of Pennsylvania|Abbott","Both","Adult|Senior","Phase II",25,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Bio-availability Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","807965 CNTR|CTRC #1123","August 4, 2008","01/06/2008",2009-08-01,"December 14, 2009","01/12/2009","CENTAUR",2009-08-01,"The apolipoprotein AI rate of catabolism and rate of production.|The incremental area under the curve for triglycerides and high-density lipoprotein cholesterol.|Other key outcomes include a. fasting cholesterol efflux, b. HDL cholesterol, apolipoprotein A-I, and enzymes that remodel HDL, c. atherogenic lipoproteins, and d. markers of energy metabolism and e. markers of inflammation.","http://ClinicalTrials.gov/show/NCT00728910",NA
"8831",8831,"NCT00740610","Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)","Completed","No Results Available","Nonalcoholic Steatohepatitis","Drug: GS-9450|Drug: GS-9450|Drug: GS-9450|Drug: GS-9450|Drug: Placebo","Gilead Sciences","Both","Adult|Senior","Phase II",124,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-228-0101","August 21, 2008","01/08/2008",2009-09-01,"August 20, 2010","01/01/2010","",2009-08-01,"Safety and Tolerability|Plasma pharmacokinetic parameters of GS-9450 and metabolites|Change from baseline in ALT levels at Week 4","http://ClinicalTrials.gov/show/NCT00740610",NA
"8903",8903,"NCT00814710","Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age","Completed","Has Results","Streptococcus Pneumoniae|Pneumococcal Disease","Biological: Pneumococcal conjugate vaccine GSK1024850A|Biological: Tritanrix-HepB/Hib|Biological: Hiberix|Biological: Tritanrix-HepB","GlaxoSmithKline","Both","Child","Phase III",360,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","111188","December 23, 2008","01/03/2009",2009-11-01,"November 11, 2010","01/11/2010","",2009-11-01,"Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes|Concentration of Antibody Against Protein D (PD)|Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Serotypes|Number of Subjects With Antibody Concentrations Against Pneumococcal Serotypes Equal to or Above Cut-off Value|Concentrations of Antibodies Against Pneumococcal Cross-reactive Serotypes|Number of Subjects Seropositive for Pneumococcal Serotypes|Number of Subjects Seropositive for Protein D (PD)|Concentration of Antibody Against Polyribosyl-ribitol Phosphate (PRP)|Concentration of Antibodies Against Diphteria (Anti-DT) and Tetanus (Anti-TT)|Concentration of Antibody Against Bordetella Pertussis (B. Pertussis)|Concentration of Antibody Against Hepatitis B (Anti-HBs)|Number of Subjects Seropostive for B. Pertussis|Number of Seroprotected Subjects (Anti-DT, Anti-TT, Anti-PRP, Anti-HBs)|Number of Seroprotected Subjects (Anti-PRP Above the Cut-off of 1.0 ??g/mL)|Number of Subjects With Solicited Local and General Symptoms|Number of Subjects With Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)","http://ClinicalTrials.gov/show/NCT00814710",NA
"8952",8952,"NCT00943410","Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: trastuzumab|Radiation: external beam radiation therapy","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","Child|Adult|Senior","Phase II",40,"Other|NIH","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000649128|UNC-LCCC9925","July 21, 2009","01/03/2000",NA,"August 4, 2009","01/07/2009","",2009-07-01,"Toxicity|Pathologic response rate|Locoregional recurrence rate|Time to locoregional recurrence|Time to local progression (in patients who are deemed to be non-surgical candidates)","http://ClinicalTrials.gov/show/NCT00943410",NA
"9109",9109,"NCT01220310","Doctors and Web-based Self-management Support Pilot Study","Completed","No Results Available","Diabetes Mellitus","Behavioral: We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.","Stanford University|Santa Clara Valley Health & Hospital System|O'Connor Hospital|Alameda County Medical Center","Both","Adult|Senior","Phase III",25,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research","SU-09242008-1309|IRB Protocol ID: 15108","August 12, 2010","01/10/2008",2009-08-01,"October 11, 2010","01/10/2010","",2009-08-01,"Self-Efficacy","http://ClinicalTrials.gov/show/NCT01220310",NA
"9189",9189,"NCT00005811","Topotecan in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment","Completed","No Results Available","Brain and Central Nervous System Tumors|Leukemia|Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: topotecan hydrochloride","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",77,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000067813|COG-P9962|POG-9962|CCG-P9962|NCI-01-C-0123","June 2, 2000","01/04/2000",NA,"November 20, 2010","01/11/2010","",2009-02-01,"Therapeutic activity|Safety and toxicity|Concentration of matrix metalloproteinases in the CSF","http://ClinicalTrials.gov/show/NCT00005811",NA
"9218",9218,"NCT00050011","Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy","Completed","No Results Available","Breast Neoplasms|Osteoporosis","Drug: Zoledronic Acid and Letrozole","Novartis Pharmaceuticals","Female","Adult|Senior","Phase III",602,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","CZOL446EUS32","November 18, 2002","01/09/2002",NA,"May 28, 2010","01/05/2010","",2009-01-01,"Percent change in lumbar spine (L1-L4) bone mineral density (BMD) at 2 years, 3 years and 5 years|Percent change in lumbar spine and total hip BMD over 5 years|Changes in biochemical markers of bone turnover over 5 years|Incidence of fractures at 3 years|Time to disease recurrence/relapse","http://ClinicalTrials.gov/show/NCT00050011",NA
"9236",9236,"NCT00057811","Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","Completed","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Leukemia|Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: methylprednisolone|Drug: prednisone|Drug: rasburicase|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",90,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000271941|COG-ANHL01P1","April 7, 2003","01/06/2004",NA,"November 20, 2010","01/11/2010","",2009-10-01,"Toxicity|Incidence of tumor lysis syndrome|Response rate|Minimal residual disease","http://ClinicalTrials.gov/show/NCT00057811",NA
"9302",9302,"NCT00178711","Effects of Hypothermia Upon Outcomes After Acute Traumatic Brain Injury","Completed","No Results Available","Traumatic Brain Injury","Procedure: Hypothermia","The University of Texas Health Science Center, Houston|National Institute of Neurological Disorders and Stroke (NINDS)","Both","Child|Adult","Phase III",240,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S U01 NS043353-02|Grant# 5 U01 NS043353-05","September 13, 2005","01/11/2005",2009-12-01,"April 12, 2010","01/04/2010","NABIS:HIIR",2009-12-01,"The dichotomized Glasgow Outcome Scale (Good Recovery/Moderate Disability vs. Severe Disability/Vegetative/Dead)","http://ClinicalTrials.gov/show/NCT00178711",NA
"9362",9362,"NCT00272311","Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome","Completed","No Results Available","Cardiovascular Diseases|Metabolic Syndrome X|Atherosclerosis","Drug: Aspirin","Florida Atlantic University|Bayer","Both","Adult|Senior","Phase IV",100,"Other|Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","H07-28","January 3, 2006","01/10/2006",2009-01-01,"April 1, 2009","01/04/2009","PAD",2009-01-01,"inflammatory markers, measured at baseline and 3 months|platelet biomarkers, measured at baseline and 3 months|nitric oxide formation, measured at baseline and 3 months","http://ClinicalTrials.gov/show/NCT00272311",NA
"9378",9378,"NCT00310011","Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Procedure: conventional surgery","Wake Forest University|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",71,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000466059|CCCWFU-88197|CCCWFU-BG98-217|AMGEN-CCCWFU-88197","March 29, 2006","01/06/1998",NA,"September 18, 2009","01/12/2006","",2009-07-01,"Response|Response duration|Freedom from progression|Overall survival|Toxicity","http://ClinicalTrials.gov/show/NCT00310011",NA
"9385",9385,"NCT00319111","Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","Completed","No Results Available","Pulmonary Hypertension","Drug: bosentan","Actelion","Both","Adult|Senior","Phase III",148,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AC-052-370|BENEFIT OL","April 26, 2006","01/01/2006",2009-04-01,"February 11, 2010","01/02/2010","BENEFIT",2009-02-01,"Change from baseline to all assessed time points in 6-minute walk test distance|Change from baseline to all assessed time points in Borg dyspnea index|Change from baseline to all assessed time points in New York Heart Association (NYHA) class|Time to clinical worsening up to end-of-study|Adverse event(s) leading to premature discontinuation of study medication|Serious adverse events up to 28 days after study medication discontinuation|Occurrence of liver function test (ALT and/or AST) abnormality and hemoglobin abnormality","http://ClinicalTrials.gov/show/NCT00319111",NA
"9417",9417,"NCT00372411","Robotic Assisted Upper-Limb Neurorehabilitation in Stroke Patients","Completed","No Results Available","Stroke","Device: Robot-Assisted Therapy - MIT-MANUS System|Other: Intensive Comparison Therapy","Department of Veterans Affairs|Burke Medical Research Institute","Both","Adult|Senior","Phase II",127,"U.S. Fed|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","558","September 5, 2006","01/12/2005",2009-08-01,"November 10, 2010","01/11/2010","VA ROBOTICS",2009-07-01,"Fugl-Meyer Assessment for Motor Recovery (FM) Scale","http://ClinicalTrials.gov/show/NCT00372411",NA
"9419",9419,"NCT00320411","GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer","Completed","Has Results","Metastatic Breast Cancer","Drug: lapatinib","GlaxoSmithKline","Female","Adult|Senior","Phase II",62,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EGF104911","May 1, 2006","01/11/2005",2009-04-01,"March 18, 2010","01/03/2010","",2009-04-01,"Overall Tumor Response|Duration of Response|Time to Progression|Clinical Benefit|Time to Response|4-month Progression Free Survival|6-month Progression Free Survival|Overall Survival|Mean Phosphorylated 58 kDa Serine/Threonine Protein Kinase (p-AKT) H Score for All Participants|Mean p-BAD H Score for All Participants|Mean Bcl-2 H Score for All Participants|Mean Epidermal Growth Factor Receptor 3 (ErbB3) H Score for All Participants|Mean Epidermal Growth Factor Receptor 4 (ErbB4) H Score for All Participants|Mean Phosphorylated Extracellular Signal-regulated Kinase (p-ERK) H Score for All Participants|Mean Heregulin H Score for All Participants|Mean Insulin-like Growth Factor 1 Receptor (IGF1R) H Score for All Participants|Mean Survivin H Score for All Participants|Mean Terminal Deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling (TUNEL) H Score for All Participants","http://ClinicalTrials.gov/show/NCT00320411",NA
"9447",9447,"NCT00417911","Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients","Completed","No Results Available","Multiple Myeloma","Drug: bortezomib","Nordic Myeloma Study Group|Janssen-Cilag Ltd.","Both","Adult|Senior","Phase III",400,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NMSG 15/05|EudraCT No: 2005-002756-18","January 3, 2007","01/12/2005",2010-05-01,"June 17, 2010","01/06/2010","",2009-05-01,"Evaluate the effect on EFS (an event is defined as either progression or death of any cause without preceding progression) of consolidation treatment with bortezomib after ASCT compared to no consolidation|Overall survival from ASCT|Overall survival from start of relapse treatment|Time to need for relapse treatment|Response rate in patients not in CR following ASCT|Toxicity from consolidation treatment|Quality of life|Cost utility|Planned subgroup analysis: comparison of primary and secondary endpoint in patients receiving one vs. two high dose treatments","http://ClinicalTrials.gov/show/NCT00417911",NA
"9448",9448,"NCT00421811","A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan","Completed","No Results Available","Neoplasms","Drug: ADH-1|Drug: melphalan","Adherex Technologies, Inc.","Both","Adult|Senior","Phase I|Phase II",56,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AHX-01-007","January 10, 2007","01/04/2007",2009-03-01,"December 27, 2010","01/12/2010","",2009-03-01,"To tabulate the Best Overall Response according to unconfirmed RECIST, modified for cutaneous lesions","http://ClinicalTrials.gov/show/NCT00421811",NA
"9485",9485,"NCT00485511","A Trial of Hydroxyurea in Spinal Muscular Atrophy","Completed","No Results Available","Spinal Muscular Atrophy","Drug: Hydroxyurea","Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","Child|Adult|Senior","Phase II|Phase III",NA,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind","DOH96-TD-I-111-TM103","June 11, 2007","01/06/2007",2009-06-01,"February 11, 2010","01/02/2010","",2009-06-01,"","http://ClinicalTrials.gov/show/NCT00485511",NA
"9486",9486,"NCT00482911","Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma","Completed","No Results Available","Intraocular Melanoma|Malignant Conjunctival Neoplasm","Drug: cyclophosphamide|Drug: lenalidomide|Drug: sunitinib malate","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",50,"NIH","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Masking: Open Label|Primary Purpose: Treatment","CDR0000546695|NCI-07-C-0134","June 4, 2007","01/04/2007",NA,"April 21, 2009","01/10/2008","",2009-04-01,"Response rate (complete and partial response)|Toxicity|Progression-free survival|Overall survival","http://ClinicalTrials.gov/show/NCT00482911",NA
"9509",9509,"NCT00518011","A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: erlotinib [Tarceva]|Drug: Gemcitabine","Hoffmann-La Roche","Both","Adult|Senior","Phase II",17,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20063","August 16, 2007","",2009-07-01,"November 17, 2009","01/11/2009","",2009-07-01,"Progression free survival|Overall response rate, disease control rate, duration of response, overall survival.|AEs, SAEs, vital signs.","http://ClinicalTrials.gov/show/NCT00518011",NA
"9516",9516,"NCT00528411","A Study of the Onset and Offset of Antiplatelet Effects Comparing AZD6140, Clopidogrel, and Placebo With Aspirin","Completed","No Results Available","Coronary Artery Disease","Drug: AZD6140|Drug: Clopidogrel|Drug: aspirin","AstraZeneca","Both","Adult|Senior","Phase II",112,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5130C00048","September 10, 2007","01/10/2007",2009-03-01,"April 17, 2009","01/04/2009","",2009-03-01,"To determine the onset and offset of antiplatelet effect of AZD6140 compared to clopidogrel by evaluation of the % IPA by LTA and by evaluation of the difference in slope of IPA effect curve by LTA|To evaluate the PK/PD relationship of AZD6140 and its active metabolite; to determine the effect on platelet aggregation of AZD6140 compared to clopidogrel; to assess the overall safety and tolerability of AZD6140 compared to clopidogrel and placebo","http://ClinicalTrials.gov/show/NCT00528411",NA
"9557",9557,"NCT00598611","Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)","Completed","No Results Available","Chronic Urticaria","Drug: desloratadine|Drug: desloratadine","Charite University, Berlin, Germany","Both","Adult|Senior","Phase III",30,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","P04805-V2.0|EudraCT number: 2006-003686-13","January 10, 2008","01/09/2007",2009-08-01,"November 30, 2009","01/11/2009","AUD2OCU",2009-08-01,"Reduction in size of existing spontaneous urticaria lesions (wheal and flare) as assessed by thermography.|Reduction in size of existing spontaneous urticaria lesions (wheal and flare) as assessed by volumetry and digital time lapse photography.","http://ClinicalTrials.gov/show/NCT00598611",NA
"9560",9560,"NCT00599911","Dose-finding Study With Lu AA24530 in Major Depressive Disorder","Completed","No Results Available","Major Depressive Disorder","Drug: Lu AA24530|Drug: Duloxetine|Drug: Placebo","H. Lundbeck A/S","Both","Adult","Phase II",652,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","11918A|2007-001071-11","December 28, 2007","01/10/2007",2009-04-01,"September 24, 2010","01/09/2010","",2009-03-01,"The difference in change from baseline to end of treatment on the Montgomery-??sberg Depression Rating Scale total score|Response rate, remission rate, and safety","http://ClinicalTrials.gov/show/NCT00599911",NA
"9566",9566,"NCT00609011","Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma","Completed","No Results Available","Metastatic Melanoma","Drug: MPC-6827 + Temozolomide","Myrexis Inc.","Both","Adult|Senior","Phase I|Phase II",22,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MPC-6827-07-005","January 23, 2008","01/03/2008",2009-08-01,"August 19, 2010","01/08/2010","",2009-08-01,"Safety and Tolerability; Maximum Tolerated Dose|Pharmacokinetics|Antitumor Activity","http://ClinicalTrials.gov/show/NCT00609011",NA
"9587",9587,"NCT00642811","A Study of the Antiplatelet Effects Comparing AZD6140 With Clopidogrel Responder and Non-Responders","Completed","No Results Available","Stable Coronary Artery Disease","Drug: AZD6140|Drug: Clopidogrel|Drug: Aspirin","AstraZeneca","Both","Adult|Senior","Phase II",80,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5130C00030","March 19, 2008","01/05/2008",2009-03-01,"April 23, 2009","01/04/2009","RESPOND",2009-03-01,"To assess the effect of AZD6140 on inhibition of platelet aggregation compared with clopidogrel in patients previously identified as non-responsive to clopidogrel.|To compare inhibition of platelet aggregation (IPA), platelet aggregation and biomarker expression in clopidogrel responsive patients when directly switched from clopidogrel to AZD6140, in addition, also when switching from AZD6140 to Clopidogrel|To assess the overall safety and tolerability of AZD6140 compared to clopidogrel and placebo","http://ClinicalTrials.gov/show/NCT00642811",NA
"9635",9635,"NCT00719511","Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration","Completed","No Results Available","Allergies","Drug: Purified allergen dose 1 integrated in a Patch system|Drug: Purified allergen dose 2 integrated in a Patch system|Drug: Purified allergen dose 3 integrated in a Patch system|Drug: Purified allergen integrated in a Patch system","University of Zurich","Both","Adult","Phase II",132,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZU-SkinSIT-002","July 17, 2008","01/08/2008",2009-12-01,"April 28, 2010","01/04/2010","",2009-11-01,"Comparison of the efficacy of the placebo with that of three different test doses of the epicutaneous pollen allergen administration evaluated by visual analog scales after the treatment","http://ClinicalTrials.gov/show/NCT00719511",NA
"9657",9657,"NCT00749411","Safety and Tolerabilty of Repeat Dosing of GSK233705/GW642444 in COPD","Completed","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)|Chronic Bronchitis|Emphysema","Drug: Placebo|Drug: GSK233705/GW642444","GlaxoSmithKline","Both","Adult|Senior","Phase II",61,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DB1111581","September 8, 2008","01/11/2008",2009-02-01,"February 5, 2010","01/02/2010","",2009-02-01,"Weight mean heart rate 0-4 hours post dose|adverse events|systolic and diastolic blood pressure|QTc measured by ECG|plasma glucose and serum potassium|Holter monitoring|Forced expiratory volume in one second (FEV1)|Pharmacodynamic assessments","http://ClinicalTrials.gov/show/NCT00749411",NA
"9667",9667,"NCT00770211","Efficacy and Safety of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines","Completed","No Results Available","Moderate to Severe Glabellar Frown Lines","Drug: Clostridium Botulinum neurotoxin type A|Drug: Placebo","Merz Pharmaceuticals GmbH","Both","Adult|Senior","Phase III",271,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MRZ 60201 - 0741 / 1","October 8, 2008","01/10/2008",NA,"March 25, 2010","01/01/2010","",2009-03-01,"Investigator's rating on the Facial Wrinkle Scale and the patient's assessment on a 4-point scale|Percentage of responders by patient assessment on 4-point scale|Percentage of responders by investigator assessment on facial wrinkle scale","http://ClinicalTrials.gov/show/NCT00770211",NA
"9670",9670,"NCT00775411","Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-VEGF in Subjects With Wet Age-Related Macular Degeneration","Completed","No Results Available","Choroidal Neovascularization|Age-Related Maculopathy","Drug: Dexamethasone as adjunctive therapy to Ranibizumab Injection","Allergan","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","206207-019","October 16, 2008","01/11/2008",2010-04-01,"September 24, 2010","01/09/2010","",2009-11-01,"Mean central retinal thickness by OCT|Best corrected visual acuity|Fluorescein leakage","http://ClinicalTrials.gov/show/NCT00775411",NA
"9686",9686,"NCT00797511","Immunogenicity and Safety of Adacel Polio Vaccine","Completed","No Results Available","Diphtheria|Tetanus|Pertussis|Poliomyelitis","Biological: TdcP-IPV vaccine","Sanofi-Aventis","Both","Child","Phase III",132,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","TD525","November 24, 2008","01/11/2008",2009-07-01,"January 26, 2010","01/01/2010","",2009-04-01,"To provide information concerning the immunogenicity of Adacel Polio after booster vaccination.|To provide information concerning the safety of Adacel Polio after booster administration.","http://ClinicalTrials.gov/show/NCT00797511",NA
"9708",9708,"NCT00828711","Misoprostol Vaginal Insert (MVI) 100, 150, 200 Mcg for Cervical Ripening and Induction of Labor","Completed","No Results Available","Cervical Ripening|Induction of Labor","Drug: MVI 100|Drug: MVI 150|Drug: MVI 200","Cytokine PharmaSciences","Female","Adult|Senior","Phase II",370,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Miso-Obs-204","January 22, 2009","01/04/2009",2009-10-01,"December 3, 2009","01/12/2009","",2009-10-01,"Proportion of women delivering vaginally|Time to vaginal delivery|Adverse Events|Proportion of cesarean delivery|Cervical ripening using composite measure of success|Vaginal delivery|Use of oxytocin|pharmacokinetics","http://ClinicalTrials.gov/show/NCT00828711",NA
"9730",9730,"NCT00861211","Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects","Completed","No Results Available","Atopic Asthma","Drug: senicapoc|Drug: Placebo","Icagen","Both","Adult","Phase II",34,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ICA-17043-17","March 12, 2009","01/10/2008",2009-05-01,"November 13, 2009","01/11/2009","",2009-03-01,"Decrease in FEV1 between 4-10 hours (Late Asthmatic Response) after allergen challenge and will compare the active (40 mg QD) vs. placebo treatment groups with respect to change in response to allergen challenge.|Early allergen response to allergen challenge, measure of airway hyperreactivity to methacholine challenge, pulmonary function tests (FEV1 and FVC), fraction of exhaled NO, cell differentials and cytokine measurements from induced sputum samples.","http://ClinicalTrials.gov/show/NCT00861211",NA
"9739",9739,"NCT00883311","A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Device: BRT-FC-83C","Biomed Research & Technologies, Inc.","Both","Adult","Phase II",32,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BRT-C09-C017","April 15, 2009","01/01/2009",2009-07-01,"August 29, 2010","01/08/2010","",2009-07-01,"Change in mean Atopic Dermatitis Severity Index (ADSI) in lesional skin at target site|Change in mean Trans Epidermal Water Loss (TEWL) in lesional skin at target site|Change in mean corneometer measurement in lesional skin at target site|Self assessment of efficacy of BRT-FC-83C on signs and symptoms of atopic dermatitis|Change in Investigator's Global Assessment (IGA) in lesional skin at target site","http://ClinicalTrials.gov/show/NCT00883311",NA
"9758",9758,"NCT00918411","A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome","Completed","No Results Available","Irritable Bowel Syndrome","Drug: Ramosetron|Drug: Placebo","Astellas Pharma Inc","Male","Adult","Phase IV",98,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)","060-CL-500","June 9, 2009","01/06/2009",2009-12-01,"January 21, 2010","01/01/2010","",2009-12-01,"IBS severity index (Japanese version)|Patient reported global assessment of relief of IBS symptoms|Patient reported assessment of relief of abdominal discomfort and/or pain|Patient reported assessment of improvement of abdominal bowel habits","http://ClinicalTrials.gov/show/NCT00918411",NA
"9759",9759,"NCT00917111","The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Nasal CO2|Drug: Inactive Placebo Gas","Capnia, Inc.","Both","Adult","Phase II",33,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C218","June 8, 2009","01/07/2009",2009-11-01,"December 2, 2009","01/12/2009","",2009-10-01,"To assess the efficacy of four times a day treatment with nasal carbon dioxide (CO2) in patients with seasonal allergic rhinitis (SAR).","http://ClinicalTrials.gov/show/NCT00917111",NA
"9769",9769,"NCT00935311","Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction","Completed","No Results Available","Pain","Drug: Hydrocodone/Acetaminophen Extended Release|Drug: Hydrocodone/Acetaminophen|Drug: Placebo","Abbott","Both","Adult","Phase II",122,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M11-063","June 29, 2009","01/06/2009",NA,"November 2, 2010","01/09/2010","",2009-08-01,"Sum of pain intensity difference|Pain relief|Rescue medication use|Adverse Events","http://ClinicalTrials.gov/show/NCT00935311",NA
"9773",9773,"NCT00939211","The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: AZD9164|Drug: Tiotropium|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase II",25,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1882C00003","July 13, 2009","01/06/2009",2009-11-01,"December 4, 2009","01/12/2009","LaCrossE",2009-11-01,"Forced Expiratory Volume in 1 second (FEV1).|Pharmacokinetics|CIinical significant abnormalities in ECG, pulse, blood pressure, laboratory assessments and physical examinations","http://ClinicalTrials.gov/show/NCT00939211",NA
"9788",9788,"NCT00956111","A Clinical Trial With Influenza A/H1N1 Vaccines","Completed","No Results Available","Influenza","Biological: split-virion, adjuvanted H1N1 vaccine of 7.5 ??g per dose|Biological: split-virion, adjuvanted H1N1 vaccine of 15 ??g per dose|Biological: split-virion, non-adjuvanted H1N1 vaccine of 15 ??g per dose|Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 ??g per dose|Biological: whole-virion, adjuvanted H1N1 vaccine of 5 ??g per dose|Biological: whole-virion, adjuvanted H1N1 vaccine of 10 ??g per dose|Biological: placebo control","Sinovac Biotech Co., Ltd","Both","Child|Adult|Senior","Phase IV",1614,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PRO-PanFlu-4001","August 10, 2009","01/07/2009",2009-10-01,"October 28, 2009","01/10/2009","",2009-09-01,"Evaluate immunogenicity and safety of influenza A ???H1N1???vaccines in elders, adults, adolescent and children .|Provide a basis to determine the best type and dose of vaccine and immunization procedures","http://ClinicalTrials.gov/show/NCT00956111",NA
"9803",9803,"NCT00991211","Bendamustine Plus Rituximab Versus CHOP Plus Rituximab","Completed","No Results Available","Non-Hodgkin Lymphomas|Follicular Lymphomas|Immunocytomas|Lymphocytic Lymphomas|Marginal Zone Lymphomas","Drug: Bendamustine|Drug: Standard chemotherapy CHOP + Ritiximab","University of Giessen","Both","Adult|Senior","Phase III",549,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NHL 1-2003","October 6, 2009","01/01/2004",2009-08-01,"October 6, 2009","01/10/2009","",2009-08-01,"Progression free survival|Determination and comparison of remission rates, of toxicity, infectious complications, overall survival, EFS, TTNT, capacity of peripheral blood stem cell mobilization","http://ClinicalTrials.gov/show/NCT00991211",NA
"9827",9827,"NCT01027611","Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections","Completed","No Results Available","Pain","Drug: proparacaine HCL 0.5%|Drug: proparacaine HCL 0.5% + 4% lidocaine solution|Drug: 3.5% viscous lidocaine gel","Illinois Retina Associates","Both","Adult|Senior","Phase III",120,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","jsp-001","December 4, 2009","01/10/2009",2009-12-01,"May 3, 2010","01/12/2009","",2009-11-01,"Injection experience \grade\""|Pain grades for lid speculum","http://ClinicalTrials.gov/show/NCT01027611",NA
"9855",9855,"NCT01071811","The Effect After 12 Weeks of Having Received a Pedometer and a Pedometer Program on Physical Activity and Health","Completed","No Results Available","Physical Inactivity","Behavioral: Pedometer-based intervention","University of Southern Denmark","Both","Adult|Senior","Phase III",668,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","1975","February 18, 2010","01/08/2008",2009-01-01,"February 19, 2010","01/02/2010","",2009-01-01,"Physical activity (walking time, sitting time, physical activity level in leisure time)|Health measurements (blood pressure, weight, fat percentage, and aerobic fitness), self-rated health, stress, and sleep quality","http://ClinicalTrials.gov/show/NCT01071811",NA
"10044",10044,"NCT00027612","Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: carmustine|Drug: irinotecan hydrochloride|Procedure: adjuvant therapy|Radiation: radiation therapy","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase I|Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069048|NCCTG-N997D","December 7, 2001","01/07/2002",NA,"January 14, 2010","01/07/2009","",2009-07-01,"Survival at 52 weeks","http://ClinicalTrials.gov/show/NCT00027612",NA
"10239",10239,"NCT00320112","Improving Insulin Therapy With Enhanced Care Management","Completed","No Results Available","Diabetes","Behavioral: Peer-support telephone calls|Behavioral: group outpatient counseling visits","Department of Veterans Affairs","Both","Adult|Senior","Phase III",324,"U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","IIR 04-239","April 27, 2006","01/02/2007",2010-03-01,"August 18, 2010","01/08/2010","",2009-10-01,"glycemic control (HbA1c)|blood pressure, self-management behavior, perceived social support","http://ClinicalTrials.gov/show/NCT00320112",NA
"10258",10258,"NCT00352612","Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections","Completed","No Results Available","Staphylococcal Infection|Abscess|Staphylococcal Skin Infection|Folliculitis","Drug: clindamycin|Drug: cephalexin","Johns Hopkins University|Thrasher Research Fund","Both","Child|Adult","Phase IV",200,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","NA_00003301","July 13, 2006","01/09/2006",2009-08-01,"August 10, 2009","01/08/2009","",2009-05-01,"Clinical improvement at the 48-72 hour clinical follow-up|Clinical improvement at 7 days|Time to clinical improvement|Time to resolution of disease|Treatment failures|Need for subsequent hospitalization|Need for subsequent procedure","http://ClinicalTrials.gov/show/NCT00352612",NA
"10281",10281,"NCT00386412","TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant","Completed","No Results Available","Cytomegalovirus Infection","Drug: Valganciclovir","PETHEMA Foundation","Both","Child|Adult|Senior","Phase II",132,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-002813-19.|TAMOVALCIR in alogenic","October 9, 2006","01/11/2005",2009-09-01,"September 17, 2009","01/09/2009","",2009-09-01,"To value valganciclovir efficacy in advance treatment of CMV in patients received allogenic transplant with a uniform treatment.|To value valganciclovir security in advance treatment of CMV in in patients received allogenic transplant with a uniform treatment.","http://ClinicalTrials.gov/show/NCT00386412",NA
"10290",10290,"NCT00277212","A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode","Completed","Has Results","Bipolar Disorder","Drug: Lamotrigine + Aripiprazole|Drug: Lamotrigine + Placebo","Bristol-Myers Squibb|Otsuka America Pharmaceutical","Both","Adult|Senior","Phase IV",1169,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CN138-392 ST","January 13, 2006","01/12/2005",2009-07-01,"November 16, 2010","01/11/2010","",2009-07-01,"Proportion of Participants Not Experiencing Relapse Through Week 52 in the Double-Blind Relapse Assessment Phase (Phase 2)|Proportion of Participants Not Experiencing Relapse (Manic, Mixed, Depressive) in the Double-blind Relapse Assessment Phase Phase 2|Proportion of Participants Not Experiencing a Depressive Relapse in the Double-blind Relapse Assessment Phase (Phase 2)|Proportion of Participants Without Discontinuation for Any Reason in the Double-blind Relapse Assessment Phase (Phase 2)|Deaths, Treatment-Emergent Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation of Study Medication, Treatment-Emergent AEs and Treatment-Emergent Extrapyramidal Syndrome (EPS)-Related AEs|Adjusted Mean Change From Baseline in Body Weight, Phase 2|Number of Participants Showing Clinically Relevant Weight Loss by Study Week|Number of Participants Showing Clinically Relevant Weight Gain by Study Week|Adjusted Mean Change From Baseline in BMI by Study Week|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities Occurring During Double-Blind Treatment|Number of Participants With Potentially Clinically Relevant Vital Sign Abnormalities Occurring During Double-Blind Treatment|Number of Participants With Potentially Clinically Relevant Laboratory Abnormalities Occurring During Double-Blind Treatment (Phase 2)|Summary of Concomitant Medications, Phase 1|Summary of Concomitant Medications, Phase 2|Adjusted Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score|Adjusted Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score|Adjusted Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment,","http://ClinicalTrials.gov/show/NCT00277212",NA
"10305",10305,"NCT00429312","A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma","Completed","No Results Available","Melanoma","Biological: JX-594","Jennerex Biotherapeutics","Both","Adult|Senior","Phase I|Phase II",15,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JX594-IT-MEL005","January 29, 2007","01/02/2007",2009-12-01,"March 31, 2010","01/03/2010","",2009-12-01,"Response rate for injected tumor(s)|Safety, as determined by incidence of treatment-related adverse events, serious adverse events (SAEs), and clinically-significant changes from baseline in routine laboratory parameters|Best overall response for entire disease burden (RECIST criteria)|Progression-free survival (PFS)|Response rate of non-injected tumor(s)","http://ClinicalTrials.gov/show/NCT00429312",NA
"10318",10318,"NCT00450112","Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee","Completed","No Results Available","Osteoarthritis of the Knee","Drug: Gel-200","Seikagaku Corporation","Both","Adult|Senior","Phase III",240,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Gel/1132","March 20, 2007","01/03/2007",2009-06-01,"June 28, 2010","01/06/2010","",2009-06-01,"Occurrence of systemic and local adverse events following a single or repeat intra-articular injection of Gel-200|Safety: Examination of the knee, Laboratory tests|Effectiveness: WOMAC VAS scores (Pain subscore, Stiffness subscore, Physical Function subscore, Total WOMAC score), OMERACT-OARSI Response, SF-36, subject and physician global evaluations, acetaminophen consumption","http://ClinicalTrials.gov/show/NCT00450112",NA
"10319",10319,"NCT00451412","A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients","Completed","No Results Available","Thromboembolism","Drug: Certoparin|Drug: unfractionated heparin","Novartis","Both","Senior","Phase III",3254,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CMEX839BDE03","March 21, 2007","01/01/2007",2009-06-01,"July 5, 2010","01/07/2010","",2009-06-01,"Incidence of venous thromboembolism during treatment (proximal deep vein thrombosis, pulmonary embolism, death related to venous thromboembolism)|proximal and distal deep vein thrombosis (DVT) (combined and separate) assessed by ultrasound screening,|symptomatic DVT,|symptomatic non-fatal pulmonary embolism (PE),|combination of proximal DVT, non fatal PE and death from all causes including PE|VTE related death,","http://ClinicalTrials.gov/show/NCT00451412",NA
"10344",10344,"NCT00481312","Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU)","Completed","No Results Available","Continuous Sedation in Initially Sedated Adults in ICU","Drug: Dexmedetomidine|Drug: Midazolam","Orion Corporation, Orion Pharma","Both","Adult|Senior","Phase III",501,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","3005013","May 31, 2007","01/06/2007",2009-10-01,"November 23, 2009","01/11/2009","MIDEX",2009-08-01,"Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required|Duration of mechanical ventilation the number of days the patient receives mechanical ventilation will be recorded|Nurse's assessment of subject communication with visual analogue scales (VAS)Patients rousability and ability to co-operate and communicate will be measured using a visual analogue scale.|Length of ICU stay","http://ClinicalTrials.gov/show/NCT00481312",NA
"10349",10349,"NCT00495612","A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-Induced Asthma","Completed","No Results Available","Asthma","Drug: omalizumab|Drug: placebo","Genentech","Both","Adult","Phase IV",82,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","Q4229n","June 29, 2007","01/09/2007",NA,"January 14, 2010","01/01/2010","AERO",2009-04-01,"Percent change in FEV1|Percent decrease in FEV1|Maximum percent change in FEV1|Duration of cat chamber exposure|Change in chest symptom score|Change in nasal and ocular symptom scores (NOSS)","http://ClinicalTrials.gov/show/NCT00495612",NA
"10352",10352,"NCT00444912","The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)","Completed","Has Results","Non-Hodgkin Lymphoma|Hodgkin Disease","Drug: G-CSF plus plerixafor|Drug: G-CSF plus plerixafor|Biological: rituximab","Genzyme","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AMD31002113","March 7, 2007","01/02/2006",2009-06-01,"August 10, 2010","01/06/2010","",2009-06-01,"Summary of Adverse Events (AEs)|Median Cumulative Number of CD34+ Cells Collected During Apheresis|Median Fold Increase in the Number of CD34+ Cells After Plerixafor Administration|Median Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg|Median Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg|Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment|Median Number of Days to Platelet (PLT) Engraftment|Median Number of Days to Lymphocyte Engraftment|Median Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant|Median Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant|The Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day|Number of Participants With Durable Engraftment 12 Months After Transplantation","http://ClinicalTrials.gov/show/NCT00444912",NA
"10367",10367,"NCT00508612","Effectiveness of an Anger and Stress Management Program on Reducing Blood Pressure Levels in Youth","Completed","No Results Available","Cardiovascular Diseases|Hypertension","Behavioral: Williams LifeSkills Stress and Anger Management Workshop|Behavioral: High school classes","National Heart, Lung, and Blood Institute (NHLBI)","Both","Child|Adult","Phase II",259,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","497|R42 HL072644-02A2","July 27, 2007","01/04/2007",2010-03-01,"June 21, 2010","01/06/2010","",2009-05-01,"Reduction in day-time ambulatory systolic blood pressure","http://ClinicalTrials.gov/show/NCT00508612",NA
"10408",10408,"NCT00577512","UARK 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE","Completed","No Results Available","Multiple Myeloma","Drug: DTPACE","University of Arkansas","Both","Adult|Senior","Phase II",4,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-32","December 18, 2007","01/04/2007",2009-04-01,"May 12, 2009","01/05/2009","",2009-04-01,"To find out how many subjects treated with high dose DTPACE and Etoposide. (HD DTPACE) on this protocol will have a complete response or near complete response that lasts for 6 months or longer.|In subjects achieving a response, to find out how long the response will last.","http://ClinicalTrials.gov/show/NCT00577512",NA
"10416",10416,"NCT00593112","Proton Magnetic Spectroscopy in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) Before and After Treatment With OROS Methylphenidate","Completed","No Results Available","ADHD","Drug: OROS methylphenidate|Other: No intervention","Massachusetts General Hospital","Both","Child|Adult","Phase IV",20,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","2005-P-002180","December 28, 2007","01/11/2006",2009-05-01,"June 21, 2010","01/06/2010","",2009-05-01,"H MRS Scan results","http://ClinicalTrials.gov/show/NCT00593112",NA
"10431",10431,"NCT00617812","Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine","Completed","No Results Available","Diphtheria|Tetanus|Pertussis|Hepatitis B|Haemophilus Influenzae Type B","Biological: Shan5","Shantha Biotechnics Limited","Both","Child","Phase IV",160,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","SBL/DTPwHB-Hib/PMS/2007/0100","February 6, 2008","01/03/2008",2009-05-01,"June 24, 2009","01/06/2009","",2009-04-01,"Seroprotection rates for Diphtheria, Tetanus, Pertussis, Hepatitis B and Hib following 3 doses of the vaccine.|Solicited and unsolicited local and systemic adverse events following vaccination","http://ClinicalTrials.gov/show/NCT00617812",NA
"10477",10477,"NCT00678912","Weaning Children From Mechanical Ventilation:Computer-driven System Versus Usual Care","Completed","No Results Available","Respiratory Failure","Device: Smartcare/PS","University of Montreal|Fonds de la Recherche en Sant?¢ du Qu?¢bec","Both","Child|Adult","Phase III",30,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CHUSJ-2239","May 14, 2008","01/09/2007",2009-07-01,"October 8, 2009","01/10/2009","",2009-06-01,"Length of weaning from mechanical ventilation that corresponds to the time from Time 0 to the first extubation.|Total mechanical ventilation duration|Proportion of time in the acceptable breathing zone|Weaning failure|Number of interventions on the ventilator by a physician or physiotherapist","http://ClinicalTrials.gov/show/NCT00678912",NA
"10479",10479,"NCT00680212","Vitamin A Equivalence of Plant Carotenoids in Children","Completed","No Results Available","Vitamin A Deficiency","Dietary Supplement: dietary carotenoids|Dietary Supplement: spinach, rice, and synthetic beta-carotene","Tufts University","Both","Child","Phase II",72,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Basic Science","IRB 8458|R01DK60021","May 16, 2008","01/07/2008",2009-01-01,"February 17, 2009","01/02/2009","",2009-01-01,"conversion efficiency of b-C to retinol","http://ClinicalTrials.gov/show/NCT00680212",NA
"10484",10484,"NCT00690612","Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years","Completed","No Results Available","Hypertension","Drug: candesartan cilexetil","AstraZeneca","Both","Child","Phase III",35,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D2451C00006","June 2, 2008","01/09/2007",2009-09-01,"December 11, 2009","01/12/2009","HIP",2009-09-01,"systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements|Adverse events, including abnormal physical exam findings,laboratory test abnormalities, adverse events that necessitate drug discontinuation, and serious adverse events.","http://ClinicalTrials.gov/show/NCT00690612",NA
"10491",10491,"NCT00686712","Insulin Glargine at Bedtime or in AM Versus NPH","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Insulin glargine|Drug: Insulin glargine|Drug: NPH insulin","Charles Drew University of Medicine and Science|National Institutes of Health (NIH)","Both","Adult|Senior","Phase IV",108,"Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","03-02-524|U54RR014616","May 27, 2008","01/02/2003",2009-08-01,"September 15, 2010","01/09/2010","",2009-08-01,"Hemoglobin A1c Change From Baseline|Frequency of Glucose Readings < 130 mg/dL|Frequency of Total Hypoglycemic Reactions|Frequency of Severe Hypoglycemic Reactions|Body Mass Index Change From Baseline|Total Daily Insulin Dose|Any Adverse Event Other Than Hypoglycemia","http://ClinicalTrials.gov/show/NCT00686712",NA
"10493",10493,"NCT00702312","A Bengali Dietary Salt Study to Control Blood Pressure","Completed","No Results Available","Hypertension","Behavioral: Low-salt educational programme|Behavioral: Low-salt Bangladeshi educational programme|Behavioral: Low-salt Bangladeshi educational programme","Barts & The London NHS Trust|St. Bartholomew's Hospital","Both","Adult|Senior","Phase III",56,"Other","Interventional","Allocation: Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07/Q0605/13","June 19, 2008","01/06/2008",2009-07-01,"July 28, 2009","01/07/2009","",2009-04-01,"Reduction in blood pressure|Reduction in dietary salt intake","http://ClinicalTrials.gov/show/NCT00702312",NA
"10496",10496,"NCT00708812","Paclitaxel Plus Carboplatin With Endostar in Patients of Advanced Non-small Cell Lung Cancer","Completed","No Results Available","Advanced Non-Small Cell Lung Cancer","Drug: Endostar(Recombinant Human Endostatin Injection)","Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd","Both","Adult|Senior","Phase IV",126,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XYL014","June 21, 2008","01/07/2007",2009-12-01,"February 7, 2010","01/02/2010","",2009-09-01,"Time to Progression.|Progress Free Survival,1 year survival,objective response,clinical benefit rate,median survival time,quality of life and remission rate of clinical symptom","http://ClinicalTrials.gov/show/NCT00708812",NA
"10504",10504,"NCT00724412","Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye","Completed","No Results Available","Dry Eye","Drug: Systane|Drug: Optive","Alcon Research","Both","Adult|Senior","Phase IV",279,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SMA-07-15","July 25, 2008","01/04/2008",NA,"May 13, 2009","01/05/2009","",2009-02-01,"Tear Break-up time","http://ClinicalTrials.gov/show/NCT00724412",NA
"10509",10509,"NCT00725712","Study of GSK1363089 in Metastatic Gastric Cancer","Completed","No Results Available","Gastro Esophageal(GE)Junction Cancer|Neoplasms, Gastrointestinal Tract|Distal Esophageal Adenocarcinoma|Metastatic Gastric Carcinoma","Drug: GSK1363089 (formerly XL880)","GlaxoSmithKline","Both","Adult|Senior","Phase II",74,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MET111643","July 29, 2008","01/03/2007",2009-11-01,"November 4, 2010","01/11/2010","",2009-11-01,"Objective response rate (RECIST) of GSK1363089 on 2 different dosing regimens|Number of subjects with adverse events, and clinically significant changes in vital signs and laboratory values|Median progression free survival (PFS) of GSK1363089|Duration of Stable Disease of GSK1363089|Peak and trough concentrations of GSK1363089 in plasma samples|Disease stabilization rate of GSK 1363089|Median overall survival of GSK1363089|Plasma concentrations of soluble MET, HGF, soluble VEGFR2 and VEGFA","http://ClinicalTrials.gov/show/NCT00725712",NA
"10515",10515,"NCT00737412","Efficacy of BIO-K+ CL1285?ó Prophylaxis in the Prevention of Traveler's Diarrhea in Adults","Completed","No Results Available","Diarrhea","Other: Probiotic: Bio-K+ CL1285|Other: Placebo","Bio-K Plus International Inc.|ethica Clinical Research Inc.","Both","Adult|Senior","Phase III",277,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","CL1285-TD-M02","August 15, 2008","01/04/2008",2010-01-01,"January 19, 2010","01/01/2010","",2009-12-01,"To determine the efficacy of Bio-K+ CL1285 RX?ó in reducing traveler's diarrhea by comparing the incidence of diarrhea in travelers during their stay abroad and upon their return to Canada, following either BIO-K+CL1285 RX?ó or placebo prophylaxis.|To compare the severity of diarrhea in travelers during their stay abroad and upon their return to Canada, following either BIO-K+CL1285 RX?ó or placebo prophylaxis.|To compare the safety profile of BIO-K+CL1285 RX?ó to that of placebo|To compare the physician and traveler satisfaction following daily prophylaxis with either BIO-K+CL1285 RX?ó or placebo|To evaluate and compare the health economic impact of daily prophylaxis with BIO-K+CL1285 RX?ó.","http://ClinicalTrials.gov/show/NCT00737412",NA
"10554",10554,"NCT00785512","A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy","Completed","Has Results","Hypertension","Drug: Nebivolol|Drug: Placebo","Forest Laboratories","Both","Adult|Senior","Phase IV",207,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NEB-MD-17","November 3, 2008","01/11/2008",NA,"August 19, 2010","01/08/2010","",2009-08-01,"Trough Sitting Diastolic Blood Pressure|Trough Sitting Systolic Blood Pressure","http://ClinicalTrials.gov/show/NCT00785512",NA
"10568",10568,"NCT00828412","Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Device: EpiCeram Skin Barrier Emulsion|Drug: Desonide Cream 0.05%","Promius Pharma, LLC","Both","Child","Phase IV",100,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","EPC0801","January 21, 2009","01/03/2009",2009-08-01,"June 28, 2010","01/06/2010","",2009-08-01,"Change from baseline in three item severity score|Change from baseline in SCORAD|Pruritus severity score|Sleep disturbance score|Investigator global assessment|Quality of life index","http://ClinicalTrials.gov/show/NCT00828412",NA
"10582",10582,"NCT00849212","An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)","Completed","No Results Available","Refractory Partial Seizures","Drug: E2007","Eisai Co., Ltd.","Both","Adult","Phase II",30,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E2007-J081-231","February 20, 2009","01/04/2009",2009-11-01,"November 19, 2010","01/11/2010","",2009-11-01,"To investigate maximum tolerated dose.|Percentage change in the seizure frequency.","http://ClinicalTrials.gov/show/NCT00849212",NA
"10588",10588,"NCT00858312","Dairy Foods and Weight Loss","Completed","No Results Available","Overweight and Obesity","Other: high dairy diet|Other: Low Dairy","USDA, Western Human Nutrition Research Center|Iowa State University","Both","Adult","Phase II|Phase III",72,"U.S. Fed|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","FL49|DMI","March 5, 2009","01/10/2006",2009-08-01,"October 22, 2009","01/10/2009","",2009-08-01,"Weight loss, body fat loss, and reduction in intra-abdominal adipose tissue|Changes in metabolic hormones, e.g. leptin, grehlin, amylin PYY, CCK, insulin GLP-1, GIP","http://ClinicalTrials.gov/show/NCT00858312",NA
"10601",10601,"NCT00880412","A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: EHT 0202 etazolate|Drug: Placebo","Exonhit Therapeutics","Both","Adult|Senior","Phase II",197,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EHT0202/002","April 10, 2009","01/04/2008",2009-08-01,"September 18, 2009","01/09/2009","EHT0202/002",2009-06-01,"incidence/frequency and severity of adverse events, relation to treatment start and drug exposure, drop-out rate, including reason for withdrawal, clinical examination, change from screening of biological safety parameters, vital signs, ECG and weight.|Assessment of cognition (ADAS-Cog, Neuropsychological Test Battery, MMSE), patient's global functioning (CDR-SB,CGI), patient's behaviour (NPI), daily living activities (ADCS-ADL) and caregiver's burden. Population PK of EHT 0202 and PK/PD profile.","http://ClinicalTrials.gov/show/NCT00880412",NA
"10612",10612,"NCT00893412","Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis?ó) as Analgesia for Hysterosalpingography","Completed","No Results Available","Infertility|Pain","Drug: Fast-release Orodispersible Tramadol Tablet (Tradonal odis?ó)|Procedure: Hysterosalpingography (HSG)|Drug: Placebo","Universitair Ziekenhuis Brussel","Female","Adult","Phase IV",128,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","2008/191","May 4, 2009","01/11/2008",2009-04-01,"May 4, 2009","01/05/2009","",2009-04-01,"VAS at the six different assessment points|Adverse effects and complications","http://ClinicalTrials.gov/show/NCT00893412",NA
"10615",10615,"NCT00902512","Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations","Completed","No Results Available","Healthy Males","Drug: Treatment A|Drug: Blood samples for the analysis of sildenafil in plasma|Drug: Treatment B|Other: Blood samples for the analysis of sildenafil in plasma|Drug: Treatment C|Other: Blood samples for the analysis of sildenafil in plasma","Pfizer|Investigaci??n Farmacol??gica y Biofarmac?¢utica (IFaB)","Male","Adult","Phase IV",36,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Masking: Open Label","A1481267","May 13, 2009","01/04/2009",2009-04-01,"April 27, 2010","01/04/2010","",2009-04-01,"AUC0-T and Cmax of sildenafil|AUC0-inf of sildenafil|Tmax and half-life of sildenafil|Adverse events and vital signs","http://ClinicalTrials.gov/show/NCT00902512",NA
"10619",10619,"NCT00911612","Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in D-IBS?","Completed","No Results Available","Irritable Bowel Syndrome|Diarrhea","Drug: colesevelam","Mayo Clinic|National Institutes of Health (NIH)","Both","Adult","Phase II",24,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","08-007454|NIH (DK54681)","May 29, 2009","01/01/2009",2009-05-01,"June 1, 2009","01/05/2009","welchol",2009-05-01,"colonic transit, geometric center at 24 hours (GC 24)|ascending colon emptying T1/2|intestinal and colonic permeability in cumulative mannitol urine excretion at 0-2h and 2-24h collections|Colonic GC 48 h|Stool consistency","http://ClinicalTrials.gov/show/NCT00911612",NA
"10630",10630,"NCT00924612","Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation","Completed","No Results Available","Male Hypogonadism","Drug: Oral testosterone undecanoate (containing 300 mg of T)","Clarus Therapeutics, Inc.","Male","Adult","Phase II",16,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","CLAR-09008","June 17, 2009","01/07/2009",2010-07-01,"August 23, 2010","01/08/2010","",2009-09-01,"Serum testosterone Cmax|Serum testosterone Cavg|Serum testosterone Tmax|Serum testosterone AUC|Serum DHT Cmax|Serum DHT Cavg|Serum DHT Tmax|Serum DHT AUC|Serum testosterone undecanoate (TU) Cmax|Serum TU Tmax|Serum TU AUC","http://ClinicalTrials.gov/show/NCT00924612",NA
"10633",10633,"NCT00933712","Dermacyd Silver Floral (Lactic Acid) - Compatibility.","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Both","Adult","Phase III",55,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LACAC_L_04839","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"Evaluation of the absence of primary and accumulated dermical irritability and dermical sensitivity by using International Contact Dermatitis Research Group (ICDRG) scale","http://ClinicalTrials.gov/show/NCT00933712",NA
"10656",10656,"NCT00970112","Dexamethasone and Etoricoxib for Pain Prevention Following Periodontal Surgery","Completed","No Results Available","Pain Control","Procedure: Open Flap Debridement","Universidade Estadual de Ponta Grossa","Both","Adult","Phase II|Phase III",20,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","08169/08|51/2008","August 31, 2009","01/11/2008",2010-03-01,"May 17, 2010","01/03/2010","",2009-09-01,"pain","http://ClinicalTrials.gov/show/NCT00970112",NA
"10674",10674,"NCT00992212","Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10","Completed","No Results Available","Pandemic Influenza Disease","Biological: Monovalent A/H1N1 influenza vaccine","Novartis|Novartis Vaccines","Both","Child|Adult|Senior","Phase II",418,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","V111_04","October 8, 2009","01/08/2009",2009-11-01,"April 7, 2010","01/04/2010","",2009-10-01,"To evaluate the immunogenicity, safety and tolerability of 1 and 2 IM doses of MF59-H1N1sw flu vaccine in adult-elderly subjects previously exposed to 09/10 NH TIV and in those not yet vaccinated against flu season 09/10.","http://ClinicalTrials.gov/show/NCT00992212",NA
"10676",10676,"NCT00994812","The Effects of Metformin on Pregnancy and Miscarriage Rates in Polycystic Ovary Syndrome (PCOS)","Completed","No Results Available","Polycystic Ovary Syndrome|Miscarriage|Infertility|Toxemia|Gestational Diabetes","Drug: metformin","University of Oulu|University of Eastern Finland|Helsinki University|University of Tampere|University of Turku","Female","Adult","Phase III",326,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","T59108","October 9, 2009","01/08/2002",2009-12-01,"February 22, 2010","01/10/2009","",2009-12-01,"Miscarriage rates|Effect of metformin versus placebo on the time to be pregnant|Effect of metformin versus placebo on the rates of toxemia during pregnancy|Effects of metformin versus placebo on the rates of gestational diabetes during pregnancy","http://ClinicalTrials.gov/show/NCT00994812",NA
"10727",10727,"NCT01079312","Patient-controlled Sedation With Propofol and Remifentanyl for Endoscopic Retrograde Cholangiopancreatography (ERCP)","Completed","No Results Available","Endoscopic Retrograde Cholangiopancreatography","Device: infusion pump|Device: infusion pump for patient-controlled sedation|Drug: propofol|Drug: fentanyl|Drug: sedative mixture|Drug: remifentanil hydrochlorid","Helsinki University Central Hospital","Both","Adult|Senior","Phase IV",80,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","a001c|2008-007968-42","March 1, 2010","01/01/2009",2009-04-01,"March 2, 2010","01/12/2008","",2009-04-01,"propofol and opioid consumption|vital signs|patient??s and endoscopist??s satisfaction|sedation level","http://ClinicalTrials.gov/show/NCT01079312",NA
"10737",10737,"NCT01096212","Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia","Completed","No Results Available","General Anesthesia|Sevoflurane|Generic Drugs","Drug: original sevoflurane|Drug: generic sevoflurane","Asan Medical Center|National Clinical Research Coordination Center, Seoul, Korea","Both","Adult|Senior","Phase IV",178,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Asan Medical Center_sevofran_1","March 29, 2010","01/09/2008",2010-03-01,"March 30, 2010","01/03/2010","",2009-09-01,"Comparison of mean minimum alveolar concentration between original and generic sevoflurane|Comparison of secondary efficacy and safety endpoints between two inhalation agents","http://ClinicalTrials.gov/show/NCT01096212",NA
"10758",10758,"NCT01131312","Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)","Completed","No Results Available","Cervical Intraepithelial Neoplasia|Cervical Smears|HPV DNA Probes","Device: HPV Test","National Cancer Institute (NCI)","Female","Adult|Senior","Phase III",5060,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","999908076|08-C-N076","May 25, 2010","01/02/2008",2009-02-01,"December 8, 2010","01/11/2010","",2009-02-01,"Cumulative detection of pathology QC histologically confirmed CIN3 (cervical precancer) over the 2 years of the trial.|Cumulative detection of clinical center histologically confirmed CIN2 and above (high grade lesion) over the 2 years of the trial.","http://ClinicalTrials.gov/show/NCT01131312",NA
"10787",10787,"NCT01179412","Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine","Completed","No Results Available","Viral Conjunctivitis","Drug: 2% povidone-iodine|Drug: 2% povidone-iodine","Mahidol University","Both","Child|Adult|Senior","Phase IV",172,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EKC2004","July 18, 2010","01/07/2004",2009-12-01,"August 10, 2010","01/08/2010","",2009-12-01,"the recovery rate within one week of treatment|drug tolerability","http://ClinicalTrials.gov/show/NCT01179412",NA
"10944",10944,"NCT00087113","Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix","Completed","No Results Available","Cervical Cancer","Drug: pemetrexed disodium","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child|Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000372923|GOG-0127T|LILLY-H3E-US-JMGS","July 8, 2004","01/08/2004",NA,"February 5, 2009","01/04/2006","",2009-01-01,"Antitumor activity|Toxicity","http://ClinicalTrials.gov/show/NCT00087113",NA
"10991",10991,"NCT00161213","Gemcitabine and Imatinib Mesylate as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: gemcitabine hydrochloride|Drug: imatinib mesylate","University of Medicine and Dentistry New Jersey|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",42,"Other|NIH","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Masking: Open Label|Primary Purpose: Treatment","CDR0000539409|P30CA072720|CINJ-070501|CINJ-5324|CINJ-NJ1205","September 8, 2005","01/09/2005",2009-07-01,"November 12, 2009","01/11/2009","",2009-07-01,"Time to disease progression|Response rate|Percentage of patients who survive 1 year or more","http://ClinicalTrials.gov/show/NCT00161213",NA
"11001",11001,"NCT00183313","Improving Primary Care in Patients With Mental Disorders","Completed","No Results Available","Mental Disorders","Behavioral: Nurse case management|Behavioral: Usual care","National Institute of Mental Health (NIMH)","Both","Adult|Senior","Phase III",407,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","R01 MH70437|DSIR 82-SEPC","September 12, 2005","01/07/2004",2009-07-01,"October 22, 2010","01/02/2008","",2009-07-01,"Quality of primary medical care|Health status|Psychiatric symptoms|Costs","http://ClinicalTrials.gov/show/NCT00183313",NA
"11054",11054,"NCT00253513","Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes","Drug: fludarabine|Drug: treosulfan|Procedure: allogeneic blood or bone marrow transplantation","OHSU Knight Cancer Institute|medac GmbH|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",62,"Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000445306|FHCRC-1931.00|MEDAC-FHCRC-1931.00|OHSU-HEM-05107-LM","November 11, 2005","01/06/2005",2009-10-01,"October 5, 2010","01/10/2010","",2009-10-01,"Incidence of severe to fatal regimen-related toxicity to major organ systems (cardiac, bladder/renal, pulmonary, hepatic, neurologic and gastrointestinal) between days -6 and 28|Incidence of graft failure|Incidence of nonrelapse mortality by day 200 (second phase only)|Disease-free survival","http://ClinicalTrials.gov/show/NCT00253513",NA
"11061",11061,"NCT00269113","A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: rituximab [MabThera/Rituxan]|Drug: Standard chemotherapy","Hoffmann-La Roche","Both","Adult|Senior","Phase III",368,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","M39023","December 22, 2005","",2009-04-01,"July 15, 2009","01/07/2009","",2009-04-01,"Clinical response (complete or partial remission).|Duration of response|Adverse drug effects, laboratory parameters, vital signs","http://ClinicalTrials.gov/show/NCT00269113",NA
"11066",11066,"NCT00270413","SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer","Drug: SU11248","University Hospital, Gasthuisberg|Pfizer","Female","Adult|Senior","Phase II",55,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT 2005-004587-23|UZL/MBC SUBE0501","December 23, 2005","01/01/2006",2009-03-01,"November 10, 2009","01/11/2009","",2009-03-01,"Progression Free Survival (PFS) at 5 months (= proportion of patients alive and free of progression 5 months after starting therapy in the sunitinib arm (control arm = only for descriptive purpose)|To compare other measures of antitumor efficacy in both treatment arms of the study|To evaluate the safety and tolerability of SU011248|To explore the correlations of potential biomarkers with clinical outcomes|To confirm efficacy of SU11248 in patients of the control group, who receive delayed|SU11248 treatment at the time progression after taxane chemotherapy.","http://ClinicalTrials.gov/show/NCT00270413",NA
"11073",11073,"NCT00284713","Progenitor Cell Therapy in Dilative Cardiomyopathy","Completed","No Results Available","Heart Failure, Congestive|Cardiomyopathy, Dilated|Stem Cell Transplantation","Procedure: intracoronary infusion of BMC","Johann Wolfgang Goethe University Hospitals","Both","Adult|Senior","Phase I|Phase II",30,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TOPCARE-DCM","January 31, 2006","01/05/2004",2009-01-01,"February 17, 2009","01/02/2009","",2009-01-01,"LV function (Ejection fraction within 3 months) Simpson","http://ClinicalTrials.gov/show/NCT00284713",NA
"11095",11095,"NCT00312013","Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer","Completed","No Results Available","Prostate Cancer|Pancreatic Cancer|Non-Small-Cell Lung Cancer","Drug: Nadroparin","GlaxoSmithKline","Both","Adult|Senior","Phase III",503,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FRX106365","April 5, 2006","01/05/2006",2009-07-01,"May 27, 2010","01/05/2010","",2009-07-01,"Death due to all causes at study end (patients will be followed until at least Week 46 after randomization).|Time to tumor progression","http://ClinicalTrials.gov/show/NCT00312013",NA
"11158",11158,"NCT00418613","A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Drug: MK633|Drug: Comparator: Placebo (unspecified)","Merck","Both","Adult|Senior","Phase II",266,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2006_509|MK0633-009","January 3, 2007","01/10/2006",2009-03-01,"October 6, 2009","01/10/2009","",2009-03-01,"Pulmonary function test data|Overall daytime symptoms score, total daily beta agonist use, and Chronic Respiratory Disease Questionnaire (CRQ) score","http://ClinicalTrials.gov/show/NCT00418613",NA
"11163",11163,"NCT00423813","A Safety and Efficacy Study of Xyrem?ó (Sodium Oxybate) to Treat Fibromyalgia.","Completed","No Results Available","Fibromyalgia","Drug: placebo|Drug: Xyrem?ó","Jazz Pharmaceuticals","Both","Adult|Senior","Phase III",573,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06-009","January 16, 2007","01/12/2006",2009-06-01,"December 18, 2009","01/12/2009","",2009-04-01,"Pain Severity accessby VAS; Fibromyalgia Impact Questionnaire; Patient Global Impression of Change.","http://ClinicalTrials.gov/show/NCT00423813",NA
"11223",11223,"NCT00518713","Clobazam in Patients With Lennox-Gastaut Syndrome","Completed","No Results Available","Epilepsy|Epilepsy, Generalized|Seizures","Drug: Clobazam|Drug: Clobazam|Drug: Clobazam|Drug: Placebo","Lundbeck Inc.","Both","Child|Adult","Phase III",238,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","13110A|OV1012","August 20, 2007","01/08/2007",2010-04-01,"May 27, 2010","01/05/2010","",2009-12-01,"Percent reduction in number of drop seizures (average per week) from the 4-week baseline period compared to the 12-week maintenance period.|Percent reduction in number of drop seizures (average per week) from the 4-week baseline period compared to the first 8 weeks of the maintenance period.|Percent reduction in number of drop seizures (average per week) from the 4-week baseline period compared to the first 4 weeks of the 12-week maintenance period.|Percent reduction in number of drop seizures (average per week) from the 4-week baseline period compared to the middle 4 weeks of the 12-week maintenance period.|Percent reduction in number of drop seizures (average per week) from the 4-week baseline period compared to the last 4 weeks of the 12-week maintenance period.|Percent of patients considered treatment responders defined as those with a >=25%, >=50%, >=75%, 100% reduction in drop seizures (average per week) from the 4-week baseline period compared to the 12-week maintenance period.|Percent of patients considered treatment responders defined as those with a >=25%, >=50%, >=75%, 100% reduction in drop seizures (average per week) from the 4-week baseline period compared to the first 8 weeks of the maintenance period.|Tolerance will be assessed in study responders who have a mean of >=50% improvement in reduction of drop seizures over any 4-week consecutive period during the first 8 weeks of maintenance treatment compared to mean number of drop seizures at baseline.|Investigator global evaluations of the patient's overall change in symptoms.|Parent/caregiver global evaluations of the patient's overall change in symptoms.","http://ClinicalTrials.gov/show/NCT00518713",NA
"11230",11230,"NCT00525213","Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Methotrexate","Completed","No Results Available","Rheumatoid Arthritis","Drug: Rob 803|Drug: Placebo","OxyPharma","Both","Adult|Senior","Phase II",224,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2006-004834-33","September 4, 2007","01/10/2007",2009-08-01,"August 20, 2009","01/08/2009","ROBUST",2009-08-01,"To evaluate the efficacy (ACR20) of Rob 803 administered orally once daily for 12 weeks in combination with a stable dose of methotrexate in subjects with moderate or severe active RA.|Evaluate the safety of Rob 803 administered orally once daily in combination with a stable dose of methotrexate in subjects with moderate or severe active RA","http://ClinicalTrials.gov/show/NCT00525213",NA
"11246",11246,"NCT00551213","A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed or Recurrent Colorectal Cancer (Study P04721AM1)(COMPLETED)","Completed","No Results Available","Colorectal Cancer","Drug: SCH 717454|Drug: Chemotherapy and SCH 717454","Schering-Plough","Both","Adult|Senior","Phase II",59,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P04721","October 29, 2007","01/11/2007",2009-06-01,"September 10, 2009","01/09/2009","",2009-06-01,"Response rate by PET.|Assess Safety and tolerability of SCH 717454.|Tumor response rate, duration of response, and tumor growth rate.","http://ClinicalTrials.gov/show/NCT00551213",NA
"11252",11252,"NCT00560313","Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults","Completed","No Results Available","Meningococcal Disease","Biological: serogroups ACWY meningococcal vaccine|Biological: Serogroup B meningococcal Vaccine","Novartis|Novartis Vaccines","Both","Adult","Phase II",250,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","V72P4|2007-001563-29","November 16, 2007","01/07/2007",2009-11-01,"November 16, 2009","01/11/2009","",2009-11-01,"Immunogenicity as measured by serum bactericidal activity of the Meningococcal B vaccine at one month after completion of immunization schedule|Safety and tolerability of the two Meningococcal vaccines throughout the clinical study|Immunogenicity as measured by serum bactericidal activity of the Meningococcal B vaccine at one month after the first and the second immunization|Immunogenicity as measured by serum bactericidal activity of the Meningococcal ACWY vaccine at one month after the immunization","http://ClinicalTrials.gov/show/NCT00560313",NA
"11261",11261,"NCT00573313","Effects of SAMe in Patients With Alcoholic Liver Disease","Completed","No Results Available","Liver Disease, Alcoholic","Drug: S-adenosylmethionine|Drug: placebo","University of California, Davis|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Abbott|Joint Clinical Research Center|University of Colorado, Denver|University of California, Los Angeles","Both","Adult","Phase III",94,"Other|NIH|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NIAAA_HAL-014562|R01AA014562","December 12, 2007","01/09/2005",2009-09-01,"September 30, 2010","01/09/2010","",2009-06-01,"Liver Histopathology|Liver biochemistry","http://ClinicalTrials.gov/show/NCT00573313",NA
"11270",11270,"NCT00588913","Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases","Completed","No Results Available","Kidney Cancer|Metastatic Cancer","Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: zoledronic acid","Tokyo Women's Medical University","Both","Adult|Senior","Phase I|Phase II",20,"Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000581156|TRIC-CTR-GU-05-01","December 20, 2007","01/01/2006",NA,"August 19, 2009","01/08/2009","",2009-03-01,"Frequency and severity of adverse events based on NCI-CTCAE version 3.0|Proportion of gd T-cells in peripheral blood|Secondary doubling time of tumor growth|Overall response","http://ClinicalTrials.gov/show/NCT00588913",NA
"11274",11274,"NCT00595413","Study of Atacicept in Anti-TNF??-na??ve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate","Completed","No Results Available","Rheumatoid Arthritis","Drug: Atacicept|Drug: Atacicept|Other: Placebo|Biological: Humira","EMD Serono","Both","Adult|Senior","Phase II",311,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","27905|2007-002536-29","January 7, 2008","01/09/2007",2009-08-01,"December 7, 2010","01/12/2010","",2009-05-01,"The proportion of subjects achieving an ACR20 response at Week 26.","http://ClinicalTrials.gov/show/NCT00595413",NA
"11284",11284,"NCT00614913","Proton Beam Therapy for Treatment of Hepatocellular Carcinoma","Completed","No Results Available","Liver Cancer|Hepatocellular Carcinoma","Radiation: Proton radiation therapy","Loma Linda University","Both","Adult|Senior","Phase I|Phase II",86,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSR #48095","December 26, 2007","01/05/1998",2009-02-01,"February 24, 2009","01/02/2009","",2009-02-01,"To determine the over-all survival, disease specific survival, recurrence rates, and toxicities associated with proton treatment.|To determine the response rate of HCC to proton therapy and evaluate its ability to provide bridging therapy for patients receiving liver transplantation.","http://ClinicalTrials.gov/show/NCT00614913",NA
"11288",11288,"NCT00622713","A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)","Completed","No Results Available","Alzheimer's Disease","Drug: Rivastigmine transdermal patch","Novartis","Both","Adult|Senior","Phase IV",218,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CENA713DFRO8|N?? EudraCT : 2007-003405-27","February 14, 2008","01/01/2008",NA,"May 10, 2010","01/05/2010","EXTRA",2009-01-01,"Percentage of patients treated by rivastigmine 10 cm2 patch sizes for at least 8 weeks at week 24 (ITT population)|Mini-Mental State Examination score at baseline, week 8, 24 and premature discontinuation|Clinical Global Impression of Change (week 8, 24 and premature discontinuation)|4 scores from the Activities of Daily Living (budget, transport, drug management, phone) at baseline, week 8 and week 24 or at premature discontinuation|At any time : Adverse events, vital signs, physical examination","http://ClinicalTrials.gov/show/NCT00622713",NA
"11294",11294,"NCT00620113","MK0822 Clinical Study in Patients With Involutional Osteoporosis","Completed","No Results Available","Osteoporosis Postmenopausal","Drug: odanacatib|Dietary Supplement: cholecalciferol|Dietary Supplement: calcium carbonate|Drug: Comparator: Placebo (unspecified)","Merck","Both","Adult|Senior","Phase II",280,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2007_034|MK0822-022","January 29, 2008","01/01/2008",2009-05-01,"November 5, 2009","01/11/2009","",2009-05-01,"Change in lumber spine bone mineral density (BMD) in patients taking MK0822 (Odanacatib) compared to placebo.|Changes in total hip, femoral neck, trochanter bone mineral density (BMD) in patients taking MK0822 (Odanacatib) compared to placebo.","http://ClinicalTrials.gov/show/NCT00620113",NA
"11340",11340,"NCT00700713","Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra?ó Three Years Earlier in Study MTA26","Completed","No Results Available","Meningitis|Meningococcemia","Biological: Meningococcal polysaccharide diphtheria toxoid conjugate|Biological: Meningococcal polysaccharide diphtheria toxoid conjugate|Biological: Meningococcal polysaccharide diphtheria toxoid conjugate","Sanofi-Aventis","Both","Child","Phase II",181,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","MTA62","May 7, 2008","01/06/2008",2009-03-01,"September 2, 2010","01/09/2010","",2009-02-01,"To provide information concerning the immune response to Menactra?ó after booster vaccination.","http://ClinicalTrials.gov/show/NCT00700713",NA
"11377",11377,"NCT00750113","Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.","Completed","No Results Available","Hypertension","Drug: Nifidipine|Drug: Telmisartan|Drug: Nifedipine/Telmisartan","Bayer","Both","Adult|Senior","Phase IV",255,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","12313|EudraCT Nr: 2006-006436-22","September 9, 2008","01/10/2007",2009-08-01,"April 12, 2010","01/04/2010","",2009-07-01,"The primary efficacy parameter will be the 24 hour mean systolic Blood Pressure on Ambulatory Blood Pressure Monitoring (ABPM)|Office blood pressure, response rate (> 10mmHg decrease control rate (< 130/80) mean SBP, mean DBP.|ABPM: % patients achieving BP < 125/80 mmHg morning BP increase/surge,24h mean diastolic BP,day average BP, night average BP,BP variability, pulse pressure through to peak ratio,smoothness index dipping or non dipping|Microalbuminuria in subgroup (any reduction)|Metabolic parameters: fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides|Inflammatory markers: sRAGE (soluble receptors for advanced glycation end products) eotaxin-3, CRP (C-Reactive Protein)","http://ClinicalTrials.gov/show/NCT00750113",NA
"11380",11380,"NCT00770913","Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis","Completed","No Results Available","Refractory Reflux Esophagitis","Drug: E3810|Drug: E3810|Drug: E3810","Eisai Limited","Both","Adult|Senior","Phase II|Phase III",300,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E3810-J081-304","October 9, 2008","01/10/2008",2010-03-01,"June 1, 2010","01/06/2010","",2009-11-01,"Upper gastrointestinal endoscopy.|Adverse events, lab evaluations (hematology, blood chemistry, urinalysis, serum gastrin, etc.)","http://ClinicalTrials.gov/show/NCT00770913",NA
"11435",11435,"NCT00859313","An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement","Completed","No Results Available","Unilateral Knee Replacement","Drug: Sublingual dosage of sufentanil","AcelRx Pharmaceuticals, Inc.","Both","Adult|Senior","Phase II",32,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ARX-C-004","March 9, 2009","01/04/2009",2009-08-01,"August 12, 2009","01/08/2009","",2009-08-01,"To evaluate the functionality of the NanoTab?ºÑ Delivery System for patient self-administration of ARX-F01 NanoTabs?ºÑ to the sublingual cavity.|To evaluate the safety, efficacy, and tolerability of the NanoTab?ºÑ Delivery System /ARX-F01.","http://ClinicalTrials.gov/show/NCT00859313",NA
"11475",11475,"NCT00933413","Dermacyd Silver Frutal (Lactic Acid) - Acceptability.","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Female","Adult","Phase III",30,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","LACAC_L_04841","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"Evaluation of the absence of irritation and the good acceptability by using one specific scale which describes the intensity of the reaction.","http://ClinicalTrials.gov/show/NCT00933413",NA
"11492",11492,"NCT00955513","Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle Sprain","Completed","No Results Available","Grade I/II Ankle Sprain","Drug: diclofenac diethylamine gel 2.32%|Drug: diclofenac diethylamine gel 2.32%|Drug: Placebo","Novartis","Both","Adult|Senior","Phase III",240,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VOPO-P-307","August 7, 2009","01/07/2009",2009-12-01,"December 22, 2009","01/12/2009","",2009-12-01,"Measure: Pain on Movement|Secondary Outcome Measure #1: Measure:POM on VAS|Secondary Outcome Measure #2: Measure: Pain at rest|Secondary Outcome Measure #3: Measure: Tenderness|Secondary Outcome Measure #4: Measure: Ankle Joint Function|Secondary Outcome Measure #5: Measure: Circumference measurement of swelling","http://ClinicalTrials.gov/show/NCT00955513",NA
"11535",11535,"NCT01040013","Gut Oxygenation and Laparoscopy","Completed","No Results Available","Laparoscopy|Laparotomy|Oxygenation,|Ischemia-Reperfusion Injury","Procedure: Laparoscopy|Procedure: left colectomy by laparotomy","University of Milano Bicocca","Both","Adult|Senior","Phase II",40,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","oxylap-2009","December 24, 2009","01/03/2008",2009-09-01,"December 24, 2009","01/11/2009","",2009-03-01,"Intestinal oxygenation|Ischemic reperfusion injury","http://ClinicalTrials.gov/show/NCT01040013",NA
"11538",11538,"NCT01043913","Guarana (Paullinia Cupana) for Breast Cancer Chemotherapy-related Fatigue","Completed","No Results Available","Signs and Symptoms|Neoplasms|Neoplasms by Site|Fatigue|Breast Neoplasms|Breast Diseases","Drug: Guarana extract","Faculdade de Medicina do ABC","Female","Adult|Senior","Phase II",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","mairapaschoin","December 22, 2009","01/02/2008",2009-12-01,"January 6, 2010","01/11/2009","",2009-09-01,"Fatigue improvement between the baseline to D21 or from D21 to D42 measured by Chalder Fatigue Scale, FACT-F and FACT-ES questionnaires|To access the quality of life between the baseline to D21 or from D21 to D42 measured by FACT-F and FACT ES questionnaires","http://ClinicalTrials.gov/show/NCT01043913",NA
"11540",11540,"NCT01045213","Integrated Care Program for Chronic Obstructive Pulmonary Disease","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Other: Integrated Care","University of Colorado, Denver","Both","Adult|Senior","Phase III",100,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09 FLA 000317","January 6, 2010","01/10/2008",2009-06-01,"January 7, 2010","01/01/2010","",2009-03-01,"Quality of Life measured by the St. Georges Respiratory Questionnaire|Guideline-based medical care|Oxygen utilization and pre/post exercise oxygen saturations|Smoking status|Exercise status measured by the 6 minute walk test|Symptoms including cough, sputum production and dyspnea (measured by the modified Medical Research Council (MMRC) dyspnea scale)|Body Mass Index, Obstruction, Dyspnoea, Exercise Capacity (BODE) Index|Healthcare utilization","http://ClinicalTrials.gov/show/NCT01045213",NA
"11671",11671,"NCT01279213","Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia","Completed","No Results Available","Schizophrenia|Schizophrenic Disorders|Psychotic Disorder","Drug: paliperidone clozapine","Universidad Nacional de Rosario","Both","Adult","Phase IV",70,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","109","January 11, 2011","01/01/2009",2009-12-01,"January 18, 2011","01/07/2009","",2009-10-01,"bprs|cgs","http://ClinicalTrials.gov/show/NCT01279213",NA
"11714",11714,"NCT00002514","Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission","Completed","No Results Available","Leukemia","Biological: filgrastim|Biological: sargramostim|Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: imatinib mesylate|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Medical Research Council","Both","Child|Adult","Phase III",590,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000078099|ECOG-2993|MRC-LEUK-UKALL-XII|EST-4491","November 1, 1999","01/04/1993",NA,"April 22, 2010","01/08/2007","",2009-03-01,"Complete remission","http://ClinicalTrials.gov/show/NCT00002514",NA
"11715",11715,"NCT00006014","SU5416 in Treating Patients With Malignant Mesothelioma","Completed","No Results Available","Malignant Mesothelioma","Drug: semaxanib","University of Chicago|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068023|UCCRC-10409|UCCRC-NCI-44|NCI-44","July 5, 2000","01/08/2000",NA,"February 26, 2009","01/02/2009","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00006014",NA
"11743",11743,"NCT00058214","Perifosine in Treating Patients With Recurrent Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: perifosine","California Cancer Consortium|National Cancer Institute (NCI)","Male","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000287195|CCC-PHII-44|CHNMC-PHII-44-02166|NCI-5978","April 7, 2003","01/03/2003",NA,"October 4, 2010","01/10/2010","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00058214",NA
"11796",11796,"NCT00132314","Long-Acting Injectable Risperidone in the Treatment of Schizophrenia","Completed","No Results Available","Schizoaffective Disorder|Schizophrenia","Drug: IM risperidone|Drug: oral antipsychotic medication","Department of Veterans Affairs","Both","Adult|Senior","Phase III",382,"U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","555","August 17, 2005","01/09/2006",2009-09-01,"December 11, 2009","01/12/2009","",2009-09-01,"Time to re-hospitalization","http://ClinicalTrials.gov/show/NCT00132314",NA
"11804",11804,"NCT00145314","FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: FLOX (5-fluorouracil/folinic acid/oxaliplatin)|Drug: FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab|Drug: FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab","The Nordic Colorectal Cancer Biomodulation Group","Both","Adult|Senior","Phase III",571,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Nordic VII|EudraCT no.: 2005-000117-34","September 2, 2005","01/05/2005",2010-08-01,"January 13, 2011","01/01/2011","",2009-05-01,"To compare efficacy, as measured by time to disease progression, of treatment with cetuximab in combination with the FLOX regimen compared to FLOX alone, in first- line treatment of patients with metastatic cororectal cancer|To measure response rates, response duration, secondary surgical curative resection frequency, safety profile, overall survival and quality of life in the treatment groups.","http://ClinicalTrials.gov/show/NCT00145314",NA
"11817",11817,"NCT00166114","Depression, Epinephrine, and Platelet Function","Completed","No Results Available","Major Depressive Disorder","Drug: escitalopram or desipramine","Emory University|National Heart, Lung, and Blood Institute (NHLBI)","Both","Adult","Phase IV",90,"Other|NIH","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1 RO1 HL65523-01A2","September 13, 2005","01/02/2002",2009-01-01,"January 14, 2009","01/01/2009","",2009-01-01,"Study endpoints will include measures of psychiatric function|biologic parameters|Measurement of psychiatric function before and after treatment will include:|Measurement of early life abuse: Early Trauma Inventory, Childhood Trauma Questionnaire|Measurements of mood and anxiety symptoms: Hamilton Depression Rating Scale,|Zung Depression Rating Scale|Measurements of HPA axis activity: adrenocorticotropin and cortisol.|Measurements of immunoinflammatory mediators and lipid metabolism|Measurement of oxidative stress|Measurements of platelet function:|platelet autocrine stimulation release of platelet serotonin (whole blood concentrations) and platelet 5HT2 receptor binding,|adenosine disphosphate (ADP) release, and|thromboxane A2 production (as detected by serum and urine thromboxane B2|increased platelet-surface epitopes, as detected by flow cytometric analysis of:|platelet expression of the GPIIb/IIIa receptor, as detected by the monoclonal antibody (mAb), anti-LIBS binding- measurement taken at pre-treatment, post week 1 treatment, and post-treatment.|platelet aggregation [as detected by diminished half-maximal aggregation concentration (AC50) of platelet agonists - taken at pre-treatment, week 1 of treatment, and post-treatment.|A Holter monitor will be utilized to determine Heart Rate variability- measurement taken pre-treatment and post-treatment.","http://ClinicalTrials.gov/show/NCT00166114",NA
"11826",11826,"NCT00185614","Mixed Chimera Allo Transplantation in Multiple Myeloma","Completed","No Results Available","Blood Cancer|Multiple Myeloma","Procedure: autologous then nonmyeloablative allogeneic transplant","Stanford University","Both","Adult|Senior","Phase II",60,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT109|75190|BMT109","September 12, 2005","01/08/2000",2010-04-01,"December 6, 2010","01/12/2010","",2009-04-01,"Survival, event-free survival and relapse rate with an intent-to-treat analysis. Results will be compared to allogeneic HCT reported results.|Development of Graft Versus Host Disease (GVHD) in vaccinated patients|Development of GVHD in concurrent myeloma patients receiving allogeneic HCT at our institution who are not candidates for vaccination.","http://ClinicalTrials.gov/show/NCT00185614",NA
"11863",11863,"NCT00244114","Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients","Completed","No Results Available","Hemophilia B","Procedure: blood draw|Procedure: Blood draw","Wyeth","Both","Child|Adult|Senior","Phase IV",20,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","3090A1-900|B1821003; 3090A-101795","October 19, 2005","01/02/2006",2009-12-01,"November 30, 2010","01/11/2010","",2009-12-01,"Descriptive presentation of the results of the Basophil histamine release assay for both study and control groups|Collect and evaluate adverse events that occur from the time the subject signs the informed consent form to 15 days following the study visit will be collected|Any serious adverse events and/or adverse events of special interest occurring outside of the predefined study reporting period noted to be possibly, probably or definitely related to treatment with BeneFIX will be reported.","http://ClinicalTrials.gov/show/NCT00244114",NA
"11885",11885,"NCT00276614","Bortezomib in Treating Patients With Metastatic Kidney Cancer","Completed","No Results Available","Kidney Cancer","Drug: bortezomib","University of California, Los Angeles|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",3,"Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000453541|P30CA016042|UCLA-0412011-01|MILLENNIUM-X05145","January 12, 2006","01/04/2006",2009-07-01,"June 3, 2010","01/06/2010","",2009-05-01,"Objective response rate as measured by RECIST criteria after every 2 courses of treatment for up to 6 courses","http://ClinicalTrials.gov/show/NCT00276614",NA
"11886",11886,"NCT00280514","Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration","Completed","No Results Available","Abscess|Cysts","Drug: cefpirome and moxifloxacin administration","Medical University of Vienna","Both","Adult|Senior","Phase IV",20,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study","abscess-cef-moxi|EUdraCT no. 2005-004455-35","January 20, 2006","01/01/2006",2009-12-01,"August 3, 2010","01/11/2005","",2009-12-01,"AUC|AUC0-12/24h|Cmax|Tmax|t1/2?È|Cav(ss)|ratios of AUC and Cav(ss) to MIC|T>MIC","http://ClinicalTrials.gov/show/NCT00280514",NA
"11901",11901,"NCT00309114","Prevention of Urinary Tract Infection (UTI) in Persons With Spinal Cord Injury (SCI)","Completed","No Results Available","Urinary Tract Infections","Procedure: bacterial interference","Baylor College of Medicine","Both","Child|Adult","Phase II",160,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","5R01HD043943-03","March 30, 2006","01/02/2004",2009-11-01,"November 30, 2010","01/11/2010","",2009-11-01,"Putting E. coli 83972 into the bladder of SCI patients reduces the rate of symptomatic UTI.|Study the affect of bladder colonization with E. coli 83972 on the rate of symptom causing UTI in a large group of SCI and Spina Bifida patients.","http://ClinicalTrials.gov/show/NCT00309114",NA
"11903",11903,"NCT00314314","The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder","Completed","No Results Available","Bipolar Disorder","Drug: Intranasal Insulin|Drug: Diluent","University Health Network, Toronto|Hamilton Health Sciences Corporation","Both","Adult","Phase III",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","Insulin","April 11, 2006","01/05/2006",2009-03-01,"July 9, 2009","01/05/2008","",2009-03-01,"Cognitive Tests: CVLT, Process Dissociation Tasks|Cognitive Tests: Trails A","http://ClinicalTrials.gov/show/NCT00314314",NA
"11912",11912,"NCT00326014","A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.","Completed","No Results Available","Open-Angle Glaucoma","Device: iStent","Glaukos Corporation","Both","Adult|Senior","Phase IV",58,"Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GC-002","May 12, 2006","01/04/2003",2009-12-01,"July 2, 2010","01/07/2010","",2009-12-01,"Efficacy","http://ClinicalTrials.gov/show/NCT00326014",NA
"11913",11913,"NCT00316914","Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery","Completed","No Results Available","Colorectal Cancer|Neurotoxicity","Drug: calcium gluconate|Drug: magnesium sulfate|Other: placebo","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",300,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care","CDR0000471238|NCCTG-N04C7","April 19, 2006","01/01/2006",NA,"January 13, 2011","01/07/2009","",2009-07-01,"Percentage of patients with oxaliplatin-induced neurotoxicity as assessed by CTCAE v3.0|Time to onset of grade 2+ chronic neurotoxicity as assessed by CTCAE v3.0|Time to onset of grade 3+ chronic neurotoxicity as assessed by CTCAE v3.0|Average duration of chronic neuropathic toxicity as assessed by CTCAE v3.0|Percentage of patients discontinuing therapy as assessed by CTCAE v3.0|Average cumulative oxaliplatin dose|Average duration of treatment|Percentage of patients with acute neuropathic toxicity|Incidence of calcium magnesium (CaMg)-induced toxicity|Percentage of patients experiencing impact on activities of daily living (ADL)|Average fatigue from baseline to 1 month|Average quality of life from baseline to 1 month|Percentage of patients with grade 2+ chronic neuropathic toxicity who express the GSTP1 1105V polymorphism|Time to onset of grade 2+ chronic neuropathic toxicity comparison between patients who either express or don't express the GSTP1 1105V polymorphism","http://ClinicalTrials.gov/show/NCT00316914",NA
"11970",11970,"NCT00413114","Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)","Completed","No Results Available","Myelodysplastic Syndromes","Drug: Obatoclax mesylate (GX15-070MS)","Gemin X","Both","Adult|Senior","Phase II",24,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEM013","December 18, 2006","01/12/2006",2009-11-01,"September 14, 2010","01/09/2010","",2009-02-01,"Determine the response rate to obatoclax and characterize the safety profile.|Peripheral blood counts; Bone marrow aspirates and biopsies; Transfusions and growth factor requirements","http://ClinicalTrials.gov/show/NCT00413114",NA
"11971",11971,"NCT00414414","A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection","Completed","No Results Available","Tuberculosis|HIV Infections","Drug: Prednisone|Drug: placebo","Ottawa Hospital Research Institute|Ontario Lung Association","Both","Child|Adult|Senior","Phase III",412,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2006301-01H","December 19, 2006","01/02/2007",2009-06-01,"August 19, 2010","01/08/2010","",2009-06-01,"Our primary objective is to determine if 30-day survival will be improved with addition of prednisone to quadruple standard TB therapy. We will measure all cause mortality at 30 days.|Our secondary endpoints will involve the measurement of clinical, laboratory and radiological parameters and adverse reactions.","http://ClinicalTrials.gov/show/NCT00414414",NA
"11991",11991,"NCT00443014","The Dementia Study in Northern Norway","Completed","No Results Available","Alzheimer Disease","Device: Cognitive, physical and social stimulation","University Hospital of North Norway|County Officer of Nordland, Moloveien 2, 8006 Bod?½, Norway|Norwegian Foundation for Health and Rehabilitation|Norwegian Department of Health and Social Affairs","Both","Adult|Senior","Phase IV",187,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","200201054-12/12BMA2/400","March 2, 2007","01/06/2003",2009-06-01,"May 11, 2010","01/05/2010","",2009-06-01,"The cognitive function is measured with the Alzheimer's Disease Assessment|Changes in Activity of Daily Living (ADL) measured by standardized tests.","http://ClinicalTrials.gov/show/NCT00443014",NA
"12031",12031,"NCT00513214","Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus","Completed","No Results Available","Type 2 Diabetes","Drug: XOMA 052|Drug: Placebo","XOMA (US) LLC","Both","Adult|Senior","Phase I|Phase II",72,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","X052073","August 7, 2007","01/07/2007",2010-02-01,"March 12, 2010","01/03/2010","",2009-06-01,"Safety assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and treatment-emergent adverse events.|Pharmacokinetic assessments from serum samples collected at time points specified in the protocol.|Assessment of inflammatory markers CRP and ESR collected at time points specified in the protocol.|Glucose Control assessed by the collection of HbA1c, fructosamine, and fasting plasma glucose (FPG) at time points specified in the protocol.","http://ClinicalTrials.gov/show/NCT00513214",NA
"12080",12080,"NCT00589914","Comparison of Paliperidone Palmitate and Risperdal Consta in Patients With Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: RISPERDAL CONSTA|Drug: Paliperidone Palmitate","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult|Senior","Phase III",1100,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR012289|R092670PSY3006","December 21, 2007","01/03/2007",2009-06-01,"October 28, 2010","01/10/2010","",2009-06-01,"Change from baseline in total PANSS score|Change from baseline in CGI-S, Change from baseline in PSP, Change from baseline in SDS, Change from baseline in PSQI and sleep VAS, Change from baseline in PANSS subscales, Responder rate","http://ClinicalTrials.gov/show/NCT00589914",NA
"12082",12082,"NCT00593814","GORE EXCLUDER?ó Endoprosthesis - Low Permeability in Treatment of Abdominal Aortic Aneurysms","Completed","Has Results","Aortic Aneurysm, Abdominal","Device: GORE EXCLUDER?ó Bifurcated Endoprosthesis-Low Permeability","W.L.Gore & Associates","Both","Adult|Senior","Phase IV",139,"Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AAA 04-04","December 20, 2007","01/06/2005",2009-02-01,"July 13, 2010","01/07/2010","",2009-02-01,"Number of Subjects With Aneurysm Volume Increase Greater Than 10% at 2 Years Post-procedure|Device Efficacy Events","http://ClinicalTrials.gov/show/NCT00593814",NA
"12086",12086,"NCT00488514","Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents","Completed","Has Results","Migraine Disorders","Drug: Combination Tablet of Treximet (sumatriptan/naproxen sodium)","GlaxoSmithKline","Both","Child","Phase III",656,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TXA107977","June 18, 2007","01/07/2007",2009-08-01,"November 4, 2010","01/11/2010","",2009-08-01,"Number of Participants With the Indicated Drug-related Adverse Events|Number of Participants With Any Adverse Event Categorized by Severity|Number of Participants With Any Adverse Event Categorized Over Time|Number of Participants With Any Adverse Event Categorized by Participant Age|Number of Participants With Any Adverse Event Categorized by Participant Race|Number of Participants With Any Adverse Event Categorized by Participant Gender|Number of Participants With Any Adverse Event That Occurred Within 3 or 5 Days of the First Dose of the Combination Tablet|Number of Tablets Taken, After Which at Least One Adverse Event Occurred Within 3 or 5 Days of Dosing With That Combination Tablet|Number of Participants With Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine, Potassium, and Blood Urea Nitrogen (BUN) Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit|Number of Participants With Hematocrit and Hemoglobin Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit|Mean Height for All Study Participants at the Indicated Time Points|Mean Weight for All Study Participants at the Indicated Time Points|Mean Body Mass Index (BMI) for All Study Participants at the Indicated Time Points|Mean Blood Pressure for All Study Participants at the Indicated Time Points|Mean Heart Rate for All Study Participants at the Indicated Time Points|Number of Participants With Abnormal Electrocardiogram Findings at Screening and at the Final Visit as Assessed by the Investigator|Number of Treated Migraine Attacks|Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 24 Hours of Dosing With the Combination Tablet|Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 4 Hours of Dosing With a Combination Tablet|Number of Treated Attacks Classified as Migraine Pain-Free Within 4 Hours That Were Also Pain Free Within 2 Hours of Dosing With the Combination Tablet|Average Number of Headaches, Migraine Attacks, and Treated Migraine Attacks Per Month|Number of Total Migraines Headaches and Migraines Treated With the Combination Tablet|Number of Migraine Attacks Rated With the Indicated Pain Severity|Number of Treated Migraine Attacks With Photophobia, Phonophobia, Nausea, Neck Pain, Sinus Pain, and Vomiting|Mean Change From Baseline in the Migraine Specific Quality of Life (QOL) Questionnaire for Adolescents (MSQ-A) Score at Months 3, 6, 9, and 12|Number of Participants Categorized by Response to Each of the 3 Global Satisification Questions From the Patient Perception Migraine Questionnaire-Revised (PPMQ-R) at the Screening Visit|Number of Participants Categorized by Response to Each of the 3 Global Satisification Questions From the Patient Perception Migraine Questionaire-Revised (PPMQ-R) at Month 12","http://ClinicalTrials.gov/show/NCT00488514",NA
"12090",12090,"NCT00612014","Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis","Completed","No Results Available","Gastroparesis|Diabetes Mellitus","Drug: 5% dextrose in water|Drug: TZP-101|Drug: TZP-101|Drug: TZP-101|Drug: TZP-101|Drug: TZP-101","Tranzyme, Inc.","Both","Adult|Senior","Phase II",78,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","TZP-101-CL-G004|2007-003279-38","January 28, 2008","01/10/2007",2009-03-01,"September 9, 2010","01/09/2010","",2009-02-01,"Change from baseline in the mean Gastroparesis Cardinal Symptom Index score (24 hour recall version) across the four days of dosing. Baseline is the average of the scores collected across the 4 days just prior to admission for dosing.|Cumulative GSA score after each dosing event and after all dosing events","http://ClinicalTrials.gov/show/NCT00612014",NA
"12104",12104,"NCT00632814","Russian Kogenate Pediatric Study","Completed","No Results Available","Hemophilia A","Drug: Kogenate (BAY14-2222)","Bayer","Male","Child","Phase IV",32,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12684","March 4, 2008","01/06/2007",2009-09-01,"September 28, 2009","01/09/2009","",2009-09-01,"Evaluate and compare the effect on frequency of joint bleeding events in severe and moderate pediatric hemophilia A patients using 3 different prophylactic regimens.|To assess the effect of prophylactic treatment on the number of all bleeds|the clinical status|the number of patients in each treatment group|total monthly consumption|evaluate the effect of prophylaxis with rFVIII-FS on QoL in severe and moderate hemophilia A patients, using Haemo-QoL questionnaire","http://ClinicalTrials.gov/show/NCT00632814",NA
"12107",12107,"NCT00640614","Clinical Evaluation of T.R.U.E. TEST?ó : Safety and Efficacy","Completed","No Results Available","Contact Dermatitis","Biological: T.R.U.E. TEST?ó Skin Patch Test: Dose Response Allergens","Allerderm","Both","Adult|Senior","Phase III",235,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","Mekos 07 7P3.2 301|2008-000168-18|WIRB Pr. No.: 20080089","March 3, 2008","01/04/2008",2009-10-01,"May 13, 2010","01/05/2010","",2009-08-01,"The performance of each allergen will be evaluated based on: Calculating concordance/discordance between T.R.U.E. Test Panel 3.2 allergens and their corresponding petrolatum or aqueous-based allergens and calculated sensitivity and specificity.|Evaluations will be based on: Frequency and characterization of late and/or persistent reactions, tape-induced irritation, incomplete panel adhesion, and subject-reported sensations of itching or burning and the frequency of adverse events.","http://ClinicalTrials.gov/show/NCT00640614",NA
"12108",12108,"NCT00638014","Rapid Sternal Closure System (TALON)","Completed","No Results Available","Sternal Wound Infection|Mediastinitis","Device: Rapid Sternal Closure System","Duke University|KLS Martin, L.P.","Both","Adult|Senior","Phase IV",200,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","PRO00006260","March 12, 2008","01/03/2008",2009-07-01,"May 24, 2010","01/05/2010","TALON",2009-07-01,"The primary objective is to establish if the Rapid Sternal Closure System improves early postoperative recovery as manifested by decreased pain and improved pulmonary function.|Evaluation of Rapid Sternal Closure System with regard to sternal wound infection and sternal instability/non-union as outlined in the protocol.","http://ClinicalTrials.gov/show/NCT00638014",NA
"12117",12117,"NCT00652314","Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel?ó Versus Gelfoam-Thrombin","Completed","No Results Available","Surgical Intervention Hemostasis|Comparison of Surgical Hemostats","Device: Thrombi-Gel","Vascular Solutions, Inc|King Pharmaceuticals","Both","Adult|Senior","Phase IV",75,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","0307|The CONTROL Study","March 28, 2008","01/03/2008",2009-10-01,"December 21, 2009","01/12/2009","Control",2009-10-01,"The primary objective of this investigation is to gather information to support the effectiveness of Thrombi-Gel as compared to a gelatin sponge (Gelfoam) plus thrombin as an adjunct to hemostasis in multi-specialty surgical settings.|Effectiveness: Device success (defined as the percentage of first bleeding site applications for which hemostasis was obtained within 6 minutes of study device application without the need for adjunctive treatment)|Effectiveness: Hemostatic handling characteristics (surgeon's questionnaire)|Safety: Incidence rate of device-related adverse events|Safety: Immunological testing for factor Va antibodies and coagulation parameters","http://ClinicalTrials.gov/show/NCT00652314",NA
"12118",12118,"NCT00634114","Reflux Esophagitis Phase III Study (Maintenance Treatment)","Completed","Has Results","Reflux Esophagitis","Drug: Esomeprazole|Drug: Esomeprazole|Drug: Omeprazole","AstraZeneca","Both","Adult|Senior","Phase III",540,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D961HC00006","March 4, 2008","01/01/2008",2009-05-01,"May 18, 2010","01/05/2010","",2009-05-01,"Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period.|Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 4 Weeks After Treatment|Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 12 Weeks After Treatment","http://ClinicalTrials.gov/show/NCT00634114",NA
"12122",12122,"NCT00653614","Cycle Control and Safety of E2-DRSP","Completed","No Results Available","Oral Contraceptive","Drug: E2/DRSP|Drug: E2/DRSP|Drug: E2/DRSP|Drug: E2/DRSP|Drug: E2/DRSP|Drug: E2/DRSP","Bayer","Female","Adult","Phase II",575,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","91765|EudraCT No.: 2007-005258-22|311926","April 2, 2008","01/03/2008",2009-06-01,"April 28, 2010","01/04/2010","",2009-06-01,"Number of intracyclic bleeding episodes during cycles 2 to 7|Assessment of bleeding patterns and cycle control|Comparison of safety of the different treatment regimens","http://ClinicalTrials.gov/show/NCT00653614",NA
"12129",12129,"NCT00669214","A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp","Completed","No Results Available","Psoriasis","Drug: efalizumab|Drug: placebo","Genentech","Both","Adult|Senior","Phase IV",100,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ACD4412n","April 28, 2008","01/02/2008",NA,"July 28, 2009","01/07/2009","SCALP",2009-01-01,"Proportion of patients achieving a ??­ 75% decrease of the PSSI|Proportion of patients achieving a ??­ 75% decrease in the PSSI|Proportion of patients achieving a ??­ 50% decrease in the PSSI|Proportion of patients who achieve a whole body (including the scalp) PGA rating of clear (0), almost clear (1), or mild (2)|Change in the Scalpdex (a quality-of-life instrument for scalp dermatitis)|Change in a VAS of patient reported scalp itch|Change in BSA affected by psoriasis on the entire body","http://ClinicalTrials.gov/show/NCT00669214",NA
"12152",12152,"NCT00699114","Analgesic Effect of Ibuprofen, Paracetamol (Acetaminophen), and Paracetamol (Acetaminophen) Plus Codeine on Acute Pain","Completed","No Results Available","Surgery","Drug: Placebo|Drug: Ibuprofen 400 mg|Drug: Ibuprofen 600 mg|Drug: Ibuprofen 800 mg|Drug: Paracetamol (acetaminophen) 500 mg|Drug: Paracetamol (acetaminophen) 1000 mg|Drug: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg","Ullevaal University Hospital|University of Oslo","Both","Adult","Phase IV",350,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PARIBU-020","June 12, 2008","01/06/2007",2009-12-01,"March 2, 2010","01/02/2009","",2009-12-01,"Sum Pain Intensity Score(SPI)|Sum Pain Intensity Difference Score (SPID)|Sum Pain Intensity Score (SPI)|Sum Pain Intensity Difference Score (SPID)|Maximum Pain Intensity Difference Score (MAXPID)|Time to Maximum Pain Intensity Difference Score|Self-reported Occurrence of Adverse Effects|Self-reported Occurrence of Adverse Effects","http://ClinicalTrials.gov/show/NCT00699114",NA
"12157",12157,"NCT00712114","Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: HE3286|Drug: HE3286|Drug: HE3286","Harbor BioSciences, Inc","Both","Adult|Senior","Phase I|Phase II",18,"Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HE3286-0201","July 6, 2008","01/07/2008",2009-07-01,"May 11, 2010","01/05/2010","",2009-07-01,"Safety and pharmacokinetics|To assess the potential activity of HE3286 to decrease inflammation via evaluation of inflammatory cytokine activity.","http://ClinicalTrials.gov/show/NCT00712114",NA
"12170",12170,"NCT00680914","Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar?ºÑ and Hiberix?ºÑ","Completed","Has Results","Pneumococcal Disease|Streptococcus Pneumoniae Vaccines","Biological: Pneumococcal vaccine GSK1024850A (Synflorix)|Biological: Prevenar|Biological: GSK Biologicals' Hiberix?ºÑ","GlaxoSmithKline","Both","Child","Phase III",503,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","110808","May 16, 2008","01/06/2008",2009-05-01,"November 18, 2010","01/11/2010","",2009-05-01,"Number of Subjects With Vaccine Pneumococcal Serotypes Antibody Concentrations Above the Cut-Off Value|Number of Subjects With a Seropositivity Status Against Protein D and Defined Pneumococcal Serotypes|Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Serotypes Contained in the Vaccine Above the Cut-off Value|Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value|Antibody Concentrations Against Pneumococal Serotypes Contained in the Vaccine|Anti-PD Antibody Concentration|Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes|Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes|Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations|Number of Subjects With Seroprotection Status Against PRP|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects With Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events|Number of Subjects With Serious Adverse Events (SAE)","http://ClinicalTrials.gov/show/NCT00680914",NA
"12191",12191,"NCT00760214","Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension","Completed","No Results Available","Essential Hypertension","Drug: Azilsartan medoxomil|Drug: Azilsartan medoxomil|Drug: Ramipril","Takeda Global Research & Development Centre (Europe) Ltd.","Both","Adult|Senior","Phase III",1227,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01-06-TL-491-020|2007-002583-10|U1111-1113-8982","September 24, 2008","01/01/2008",2009-04-01,"July 15, 2010","01/07/2010","",2009-04-01,"Change from Baseline in the sitting trough clinic systolic blood pressure.|Change from Baseline in the sitting trough clinic diastolic blood pressure.|Change from baseline in the 24-hour mean diastolic blood pressure by ambulatory blood pressure monitor.|Change from baseline in the 24-hour mean systolic blood pressure by ambulatory blood pressure monitor.|Change from baseline for daytime mean (6am to 10pm) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for daytime mean (6am to 10pm) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for peak effect on diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for peak effect on systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough-to-peak ratio for diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough-to-peak ratio for systolic blood pressure by ambulatory blood pressure monitor","http://ClinicalTrials.gov/show/NCT00760214",NA
"12194",12194,"NCT00771914","The Effects of Omega-3 Fatty Acids on Aspirin Resistance","Completed","No Results Available","Aspirin Resistance","Drug: ethyl EPA + DHA","University of Rochester|GlaxoSmithKline|American College of Clinical Pharmacy|Cornell University","Both","Adult","Phase I|Phase II",26,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Study Protocol 112421","October 14, 2008","01/11/2008",2009-01-01,"February 18, 2010","01/02/2010","",2009-01-01,"Platelet Function Analyzer 100 and Thromboxane A2 as measures of platelet aggregation","http://ClinicalTrials.gov/show/NCT00771914",NA
"12209",12209,"NCT00795314","Propofol-butorphanol Anesthesia During Uterine Curettage","Completed","No Results Available","Abortion|Curettage","Drug: Fentanyl Citrate|Drug: Butorphanol Tartrate","Nanjing Medical University","Female","Adult","Phase IV",150,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NMU-2008-FY10MZ31|NJFY0811-MZ02","November 20, 2008","01/11/2008",2009-07-01,"July 14, 2009","01/07/2009","PABADUC",2009-07-01,"Intraoperative awareness|Bispectral Index (BIS) value|Anesthetic consumptions|Postoperative pain|Postoperative bleeding","http://ClinicalTrials.gov/show/NCT00795314",NA
"12211",12211,"NCT00796614","Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder","Completed","No Results Available","Bladder, Neurogenic","Drug: tamsulosin hydrochloride|Drug: Placebo","Astellas Pharma Inc|Boehringer Ingelheim Pharmaceuticals","Both","Child","Phase II|Phase III",231,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","527.51","November 20, 2008","01/09/2007",2009-02-01,"May 26, 2009","01/05/2009","",2009-02-01,"Response to treatment defined as patients who decrease their detrusor leak point pressure to a pre-set value|Change from baseline in detrusor leak point pressure|Improvement or stabilization of hydronephrosis and hydroureter|Assessment of physical examination, vital signs, orthostatic testing, ECG, laboratory values","http://ClinicalTrials.gov/show/NCT00796614",NA
"12212",12212,"NCT00804414","Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers","Completed","No Results Available","Diabetes|Diabetic Ulcer","Drug: SBG|Drug: Placebo Comparator","Biotec Pharmacon ASA","Both","Adult|Senior","Phase III",133,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SBG-1-13","December 5, 2008","01/10/2008",2009-09-01,"January 25, 2010","01/01/2010","",2009-08-01,"Compare the proportion of patients in the two arms who have complete healing of target ulcer","http://ClinicalTrials.gov/show/NCT00804414",NA
"12223",12223,"NCT00817414","An Evaluation of the Effects of LCI699 on Cortisol in Patients With Hypertension","Completed","No Results Available","Hypertension","Drug: Placebo|Drug: LCI699","Novartis|Great Lakes Drug Development, Inc.|Integrium","Both","Adult|Senior","Phase II",63,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CLCI699A2215|EudraCT 2008-007337-49","January 5, 2009","01/12/2008",NA,"February 22, 2010","01/02/2010","",2009-07-01,"To determine the maximum tolerated dose (MTD) of LCI699 with respect to effect on the ACTH-stimulated cortisol response following ACTH stimulation in hypertensive patients.|To characterize the LCI699 exposure-response relationship on cortisol levels following ACTH stimulation in hypertensive patients.|To characterize the pharmacokinetics of LCI699 in hypertensive patients|To assess the safety and tolerability of LCI699 in hypertensive patients|To explore the proportion of patients achieving a successful BP response and BP control in all treatment groups for 23-26 hour post dose (11-14 hour post dose for BID regimen) MSSBP and MSDBP","http://ClinicalTrials.gov/show/NCT00817414",NA
"12227",12227,"NCT00827814","Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction","Completed","No Results Available","Benign Prostatic Hyperplasia","Drug: Dutasteride","Samsung Medical Center|GlaxoSmithKline","Male","Adult|Senior","Phase IV",36,"Other|Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-06-022","January 22, 2009","01/06/2006",2009-04-01,"June 8, 2009","01/06/2009","",2009-04-01,"Percent (numeric) changes in ultrasound-estimated bladder weight (UEBW)|Urodynamic parameters|Micturition diary efficacy parameters|Prostate volume parameters|Quality of life parameters|LUTS Symptom parameters|LUTS outcome score|Patient perceptions|Safety parameters","http://ClinicalTrials.gov/show/NCT00827814",NA
"12267",12267,"NCT00888914","Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","Completed","No Results Available","Lateral Canthal Lines|Crow's Feet|Facial Wrinkles","Drug: RT001|Drug: RT001|Drug: RT001|Drug: RT001|Other: Vehicle Comparator","Revance Therapeutics, Inc.","Both","Adult","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RT001-CL006LCL","April 24, 2009","01/11/2008",2009-02-01,"September 28, 2010","01/09/2010","",2009-01-01,"The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Smile from Baseline (Day 0) to End of Study (Day 28)|The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Rest from Baseline (Day 0) to End of Study (Day 28)|Incidence of treatment-emergent AEs","http://ClinicalTrials.gov/show/NCT00888914",NA
"12300",12300,"NCT00944814","Acceptability of Zinc-fortified Lipid-based Nutrient Supplements","Completed","No Results Available","Malnutrition","Dietary Supplement: LNS with zinc|Dietary Supplement: LNS without zinc","University of California, Davis|Institut de Recherche en Sciences de la Sant?¢, Bobo-Dioulasso|Helen Keller International|Bill and Melinda Gates Foundation","Both","Child","Phase IV",36,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","200917273|iLiNS-ACCEPT-Zinc","July 21, 2009","01/07/2009",2009-08-01,"February 18, 2010","01/02/2010","",2009-08-01,"Amount of each type of LNS formulation consumed by young children|Preference and detection of differences between LNS formulations among mothers|Acceptability of feeding LNS to young children at home","http://ClinicalTrials.gov/show/NCT00944814",NA
"12318",12318,"NCT00974714","L-arginine Effects on Chronic Hypertension in Pregnancy","Completed","No Results Available","Hypertension in Pregnancy","Drug: L-arginine|Other: placebo","University of Modena and Reggio Emilia|University of Modena","Female","Adult","Phase III",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","Facchinetti|Neri Isabella|De Pace Viviana|Monari Francesca|Dante Giulia","September 9, 2009","01/09/2007",2009-12-01,"January 19, 2010","01/09/2009","",2009-06-01,"to evaluate blood pressure changes during oral L-arginine or placebo administration in pregnant women with chronic hypertension at second trimester of gestation|evaluate if is necessary to add a conventional therapy for hypertension, to evaluate pregnancy outcomes and eventual complications, to evaluate safety of oral L-arginine administration","http://ClinicalTrials.gov/show/NCT00974714",NA
"12327",12327,"NCT00989014","Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea","Completed","No Results Available","Erythematotelangiectatic Rosacea","Drug: CD07805/47|Drug: CD07805/47|Drug: CD07805/47|Drug: CD07805/47 placebo","Galderma","Both","Adult|Senior","Phase II",122,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RD.06.SPR.18144","September 30, 2009","01/09/2009",2009-12-01,"December 2, 2010","01/12/2010","",2009-11-01,"Clinician's Erythema Assessment|Patient's Self Assessment","http://ClinicalTrials.gov/show/NCT00989014",NA
"12351",12351,"NCT01025414","Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective Study","Completed","No Results Available","Pancreatic Fistula","Drug: enteral nutrition|Drug: Parenteral nutrition","Jagiellonian University","Both","Adult|Senior","Phase IV",78,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Fistula-1|CMUJ-FIS-1","December 2, 2009","01/07/2006",2009-11-01,"December 2, 2009","01/12/2009","FIS-1",2009-10-01,"The ratio of pancreatic fistula closure after 30 days is selected as the primary outcome measure|Rates of fistula and treatment-related complications, changes in quality of life","http://ClinicalTrials.gov/show/NCT01025414",NA
"12408",12408,"NCT01126814","A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia","Completed","No Results Available","Leukemia","Drug: Imatinib (Gleevec)","University Health Network, Toronto","Both","Adult","Phase I|Phase II",35,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-0147-C","May 3, 2010","01/07/2004",2010-04-01,"May 19, 2010","01/05/2010","",2009-09-01,"Toxicity (hematologic and non-hematologic) of the combination of Imatinib and Chemotherapy consisting of Mitoxantrone, Etoposide and Ara-c|Response rate - CR, MLFS and PR as per section 7.1|Maximum tolerated dose of Imatinib when given in combination with chemotherapy|Toxicity of imatinib maintenance therapy.|Number of Participants with adverse events as a measure of safety and tolerability|Remission-free survival and overall survival.|Total and phosphorylated c-kit activity at Days 1 and 4.|Levels of downstream components of c-kit pathway at Days 1 & 4.","http://ClinicalTrials.gov/show/NCT01126814",NA
"12435",12435,"NCT01171014","Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms","Completed","No Results Available","Gastrointestinal Symptoms","Dietary Supplement: Bifidobacterium lactis HN019|Dietary Supplement: Bifidobacterium lactis HN019|Dietary Supplement: Placebo","Fonterra Research Centre|Danisco|Sprim Advanced Life Sciences","Both","Adult","Phase II|Phase III",100,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","#08???SPUS???o6???FON???01","July 26, 2010","01/06/2009",2009-12-01,"July 27, 2010","01/07/2010","",2009-12-01,"Colonic transit time|Gastrointestinal symptoms","http://ClinicalTrials.gov/show/NCT01171014",NA
"12462",12462,"NCT01210014","Systemic Zinc Sulphate in Treatment of Recurrent Aphthous Ulcerations:A Doubleblind, Placebo Controled Study","Completed","No Results Available","Aphthous Stomatitis","Drug: zinc sulphate 220mg/day in one dosage|Drug: placebo: one dosage","Qazvin University Of Medical Sciences","Both","Child|Adult|Senior","Phase II",14,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","QUMS320","September 2, 2010","01/04/2008",2009-08-01,"September 27, 2010","01/09/2010","",2009-04-01,"improvment of Recurrent Aphthous Ulcerations|Relief sign &symptom|relief clinical features","http://ClinicalTrials.gov/show/NCT01210014",NA
"12548",12548,"NCT00006015","Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Biological: trastuzumab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Cancer and Leukemia Group B|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068024|CALGB-89902","July 5, 2000","01/05/2000",NA,"April 26, 2009","01/04/2009","",2009-01-01,"Response rate after treatment with study regimen|Time to progression|Overall toxicity","http://ClinicalTrials.gov/show/NCT00006015",NA
"12603",12603,"NCT00100815","Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Biological: bevacizumab|Drug: capecitabine|Drug: gemcitabine hydrochloride","Roswell Park Cancer Institute","Both","Adult|Senior","Phase II",35,"Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000409556|RPCI-I-19903|GENENTECH-RPCI-I-19903","January 6, 2005","01/08/2004",NA,"November 17, 2009","01/11/2009","",2009-02-01,"Progression-free survival|Toxicity|Quality of life|Clinical response","http://ClinicalTrials.gov/show/NCT00100815",NA
"12679",12679,"NCT00197015","Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children","Completed","Has Results","Hepatitis A Vaccine|Hepatitis A","Biological: Havrix?ó|Biological: M-M-R?óII|Biological: VARIVAX?ó","GlaxoSmithKline","Both","Child","Phase III",1474,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","208109/231","September 13, 2005","01/10/2003",2009-06-01,"November 30, 2010","01/11/2010","",2009-01-01,"Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups.|Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups|Number of Subjects Seroconverted for Anti-measle, Anti-mumps and Anti-varicella Antibodies in HAV+MMR+V and MMR+V??ÊHAV Groups|Number of Subjects With Vaccine Response for Anti-rubella Antibodies in HAV+MMR+V and MMR+V??ÊHAV Groups|Anti-measles, Anti-mumps, Anti-rubella and Anti-varicella Antibody Titers in HAV+MMR+V and MMR+V??ÊHAV Groups|Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups|Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups|Anti-hepatitis A Virus (HAV) Antibody Concentrations in MMR+V??ÊHAV Group|Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value in MMR+V??ÊHAV Group|Number of Subjects With Vaccine Response to Havrix?ó|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Measles, Mumps, Rubella and Varicella Specific Solicited General Adverse Events|Number of Subjects Reporting Unsolicited Adverse Events (AEs)|Number of Subjects Reporting Serious Adverse Events (SAEs)|Number of Subjects Reporting New Chronic Illnesses|Number of Subjects Reporting Medically Significant Events","http://ClinicalTrials.gov/show/NCT00197015",NA
"12765",12765,"NCT00093015","Trial to Reduce Cardiovascular Events With Aranesp?ó Therapy (TREAT)","Completed","Has Results","Kidney Disease|Diabetes Mellitus|Anemia","Drug: Placebo|Drug: darbepoetin alfa","Amgen","Both","Adult|Senior","Phase III",4038,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20010184|TREAT","September 28, 2004","01/08/2004",2009-08-01,"December 22, 2010","01/12/2010","",2009-07-01,"Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)|Time to All-cause Mortality or End Stage Renal Disease (ESRD)|Time to All-cause Mortality|Time to CV Mortality|Time to MI|Time to CVA|Time to CHF|Time to Hospitalization Due to Acute Myocardial Ischemia|Time to ESRD|Rate of Decline in Estimated Glomerular Filtration Rate (eGFR) Relative to Baseline|Change in Patient Reported Fatigue Relative to Baseline at Week 25","http://ClinicalTrials.gov/show/NCT00093015",NA
"12771",12771,"NCT00353015","Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract","Completed","No Results Available","Gastrointestinal Cancer|Carcinoma, Neuroendocrine","Drug: Cisplatin|Drug: Irinotecan","M.D. Anderson Cancer Center|Pharmacia","Both","Child|Adult|Senior","Phase II",21,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-523","July 13, 2006","01/03/2003",2009-07-01,"August 12, 2009","01/08/2009","",2009-07-01,"Complete blood count (CBC). If platelet count is < 50,000/mm3, frequent platelet counts until the platelet count is > 50,000/mm3 or clearly rising|Prior to each course of chemotherapy (every 3 weeks), CBC, serum chemistries, lactate dehydrogenase (LDH), SGPT, electrolytes|At time of response evaluation, in addition to above. Carcinoembryonic antigen (CEA), chromogranin A|Following the completion of 3 course = 9 weeks of treatment, assess all measurable or evaluable lesions|Chest x-ray will be obtained at the time of response evaluation.","http://ClinicalTrials.gov/show/NCT00353015",NA
"12800",12800,"NCT00397215","Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age","Completed","No Results Available","Pandemic Flu","Biological: Fluarix|Biological: Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)","GlaxoSmithKline","Both","Adult|Senior","Phase II",320,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","108251|108252|111275|111276","November 7, 2006","01/11/2006",2009-09-01,"October 8, 2009","01/10/2009","",2009-09-01,"Humoral immune response in terms of anti-HA antibodies: Geometric mean titres|Humoral immune response in terms of anti-HA antibodies: Seroconversion rates|Humoral immune response in terms of anti-HA antibodies: Seroconversion factors|Humoral immune response in terms of anti-HA antibodies: Seroprotection rates|Humoral immune response in terms of neutralizing antibodies: Geometric mean titres|Humoral immune response in terms of neutralizing antibodies: Seroconversion rates|Percentage, intensity and relationship to vaccination of solicited local and general signs and symptoms|Percentage, intensity and relationship to vaccination of unsolicited local and general signs and symptoms|Occurrence of SAEs|Biochemical assessments and hematological analysis.|Cell-mediated immunity response evaluation: Frequency of influenza-specific CD4/CD8 T-cells tests producing at least two different cytokines|Occurrence of adverse events of specific interest (AESIs)","http://ClinicalTrials.gov/show/NCT00397215",NA
"12822",12822,"NCT00432315","Docetaxel in Non Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Carcinoma, Squamous Cell","Drug: Docetaxel + CDDP|Drug: docetaxel + CDDP","Sanofi-Aventis","Both","Adult|Senior","Phase II",80,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TAX_AT1_203","February 6, 2007","01/05/2001",2009-10-01,"September 13, 2010","01/09/2010","",2009-10-01,"To assess the response rate to induction therapy with docetaxel in combination with CDDP|Resectability after induction therapy|Time to progression|Overall survival|Safety profile|Quality of life","http://ClinicalTrials.gov/show/NCT00432315",NA
"12832",12832,"NCT00438815","Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks","Completed","Has Results","Hereditary Angioedema","Biological: C1 esterase inhibitor [human] (C1INH-nf)","ViroPharma","Both","Child|Adult|Senior","Phase III",113,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LEVP2006-1","February 21, 2007","01/09/2006",2009-03-01,"June 16, 2010","01/06/2010","CHANGE 2",2009-03-01,"Number of Hereditary Angioedema (HAE) Attacks Treated With C1INH-nf|Percent of HAE Attacks With Substantial Relief of the Defining Symptom|Time to Beginning of Substantial Relief of the Defining Symptom|Time to Beginning of Substantial Relief of the Defining Symptom for Subjects Who Received Multiple Treatments|Antigenic C1 Inhibitor (C1INH) Serum Levels|Functional C1INH Serum Levels|Complement C4 Serum Levels","http://ClinicalTrials.gov/show/NCT00438815",NA
"12838",12838,"NCT00450515","Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: capecitabine|Drug: vinflunine|Procedure: quality-of-life assessment","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",48,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000536545|NCCTG-N0632","March 20, 2007","01/03/2007",NA,"April 14, 2009","01/01/2009","",2009-01-01,"Confirmed tumor response|Adverse event profile|Progression-free survival|Overall survival|Duration of response|Time to treatment failure|Quality of life","http://ClinicalTrials.gov/show/NCT00450515",NA
"12841",12841,"NCT00460915","Efficacy and Safety of Lacidipine and Amlodipine on Blood Pressure in Korean ISH Patients Aged 60 to 80 Years","Completed","No Results Available","Hypertension","Drug: Lacidipine & Amlodipine","Korea University Guro Hospital|GlaxoSmithKline","Both","Adult|Senior","Phase IV",204,"Other|Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","COL109776","April 16, 2007","01/01/2007",2010-02-01,"March 1, 2010","01/11/2009","ELDER",2009-07-01,"Change from baseline in the mean SBP at week 12|Change from baseline in the mean DBP at week 12|Change from baseline in the CRP at week 12","http://ClinicalTrials.gov/show/NCT00460915",NA
"12863",12863,"NCT00497315","Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: combination chemotherapy (pemetrexed + cisplatin)|Radiation: thoracic irradiation + pemetrexed","University Hospital, Antwerp|Thoracic Oncology Group Antwerp|Eli Lilly and Company","Both","Adult|Senior","Phase II",30,"Other|Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TOGA 0502|Eudra CT 2005-004030-40","July 4, 2007","01/02/2006",2009-03-01,"April 9, 2009","01/04/2009","PACCORA",2009-03-01,"Response rate|Toxicity|Time to progression|Overall survival","http://ClinicalTrials.gov/show/NCT00497315",NA
"12868",12868,"NCT00502515","Dose-effect of SSR180575 in Diabetic Neuropathy","Completed","No Results Available","Diabetic Neuropathies","Drug: SSR180575|Drug: Placebo","Sanofi-Aventis","Both","Adult","Phase II",309,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PDY5807","July 16, 2007","01/07/2007",2009-02-01,"January 19, 2010","01/01/2010","",2009-02-01,"Rate of epidermal nerve fiber regeneration|Efficacy: change between baseline and 24 weeks of peripheral neuropathy assessed with nerve conduction studies, clinical evaluation, Total Neuropathy Score|Safety: physical examination, clinical laboratories, adverse event reporting","http://ClinicalTrials.gov/show/NCT00502515",NA
"12872",12872,"NCT00496015","Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A","Completed","No Results Available","Pneumococcal and Meningococcal Diseases.","Biological: Infanrix hexa.|Drug: Paracetamol.|Biological: Meningococcal vaccine GSK134612.|Biological: Pneumococcal conjugate vaccine GSK1024850A.","GlaxoSmithKline","Both","Child","Phase III",750,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","107137","July 3, 2007","01/07/2007",2009-02-01,"September 25, 2009","01/09/2009","",2009-02-01,"Occurrence of core fever >= 38??C (rectal temperature) in the AP-AP, AP-NAP and NAP groups.|Occurrence of solicited general adverse events.|Occurrence of unsolicited adverse events.|Occurrence of serious adverse events.|Occurrence of adverse events specific to the meningococcal vaccine: rash, new onset of chronic illness, conditions prompting ER visits, in the unprimed group.|Concentrations of antibodies against vaccine pneumococcal serotypes.|Opsonophagocytic activity against vaccine pneumococcal serotypes.|Concentrations of antibodies against protein D.|Occurrence of core fever > 39.0??C (rectal temperature).|Occurrence of solicited local adverse events.|Concentrations of antibodies against cross-reactive pneumococcal serotypes.|Opsonophagocytic activity against cross-reactive pneumococcal serotypes.|For subjects in the unprimed group, meningococcal serum bactericidal assay (rSBA) titres.|For subjects in the unprimed group, anti-meningococcal polysaccharide concentrations.|For subjects in the unprimed group, anti-tetanus toxoid and anti-hepatitis B surface antigen (HBs) antibody concentrations.|Anti-diphtheria and anti-tetanus toxoids, anti-PRP, anti-pertussis, anti-HBs antibody concentrations and anti-polio type 1, 2 and 3 titres.|Anti-HBs antibody concentration and anti-polio type 1, 2 and 3 titres.|Occurrence of S. pneumoniae and/or H. influenzae in the nasopharynx.|Acquisition of new S. pneumoniae and/or H. influenzae strains in the nasopharynx.","http://ClinicalTrials.gov/show/NCT00496015",NA
"12916",12916,"NCT00585715","Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening","Completed","No Results Available","Cellulite","Device: 1064 nm Nd:YAG laser","University of California, Irvine|Candela Corporation","Both","Adult|Senior","Phase I|Phase II",25,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-5138|No. 062905","December 26, 2007","01/10/2006",2010-01-01,"June 23, 2010","01/01/2010","IH062905",2009-12-01,"Celluite skin tightening|Safety and efficacy of laser with and without cooling","http://ClinicalTrials.gov/show/NCT00585715",NA
"12927",12927,"NCT00598715","Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents","Completed","No Results Available","Coronary Artery Disease","Device: Sirolimus eluting stent|Device: Paclitaxel-eluting stent","Deutsches Herzzentrum Muenchen","Both","Adult|Senior","Phase IV",450,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","GE IDE No. S02407","January 10, 2008","01/10/2007",2009-08-01,"December 16, 2010","01/09/2009","DESIRE-2",2009-08-01,"Late luminal loss at follow-up angiography|Need of target lesion revascularization.|Combined incidence of death or myocardial infarction.|Incidence of stent thrombosis.|Incidence of binary restenosis at follow-up angiography","http://ClinicalTrials.gov/show/NCT00598715",NA
"12953",12953,"NCT00640315","Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.","Completed","No Results Available","Hypertension, Pulmonary|Pulmonary Disease, Chronic Obstructive","Drug: Riociguat (BAY63-2521)","Bayer","Both","Adult|Senior","Phase I|Phase II",23,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","12915|EudraCT: 2007-003919-31","February 29, 2008","01/08/2008",2009-09-01,"September 11, 2009","01/09/2009","",2009-09-01,"Impact of a single dose of BAY 63-2521 on pharmacodynamic parameters of the pulmonary system.","http://ClinicalTrials.gov/show/NCT00640315",NA
"13004",13004,"NCT00724815","The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine","Completed","No Results Available","Migraine Disorders","Drug: NP101|Drug: NP101 placebo","NuPathe Inc.","Both","Adult","Phase III",530,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","PROT-15-NP101-007","July 28, 2008","01/07/2008",2009-07-01,"July 30, 2009","01/07/2009","NP101-007",2009-07-01,"The primary objective of this study is to assess the proportion of subjects who are headache pain free at two hours after patch activation.|To assess the proportion of subjects who are free from nausea, photophobia, phonophobia at two hours after patch activation.","http://ClinicalTrials.gov/show/NCT00724815",NA
"13007",13007,"NCT00730015","Trial of Linaclotide in Patients With Chronic Constipation","Completed","No Results Available","Chronic Constipation","Drug: Matching Placebo|Drug: Linaclotide","Ironwood Pharmaceuticals, Inc.|Forest Laboratories","Both","Adult|Senior","Phase III",643,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MCP-103-303","August 5, 2008","01/08/2008",2009-10-01,"January 26, 2010","01/01/2010","",2009-08-01,"Complete Spontaneous Bowel Movement (CSBM) Overall Responder|Change from Baseline in 12-week CSBM Frequency|Change from Baseline in 12-week Spontaneous Bowel Movement (SBM) Frequency|Change from Baseline in 12-week Stool Consistency|Change from Baseline in 12-week Severity of Straining|Change from Baseline in 12-week Abdominal Discomfort|Change from Baseline in 12-week Bloating|Change from Baseline in 12-week Constipation Severity","http://ClinicalTrials.gov/show/NCT00730015",NA
"13027",13027,"NCT00761215","Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections","Completed","No Results Available","Skin Diseases, Infectious|Skin Structure Infections","Drug: oral TR-701","Trius Therapeutics, Inc.","Both","Adult|Senior","Phase II",180,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TR701-104","September 25, 2008","01/09/2008",2009-05-01,"June 8, 2009","01/06/2009","",2009-05-01,"Clinical response at the early follow-up visit|Clinical outcome at the late follow-up visit|Microbiological response rates|Safety Profiles|Population pharmacokinetic profile of the study drug","http://ClinicalTrials.gov/show/NCT00761215",NA
"13029",13029,"NCT00766415","14729-D9831C00002- 1 Month Biopsy Study","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: AZD1981|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D9831C00002","October 3, 2008","01/10/2008",2009-06-01,"June 24, 2009","01/06/2009","Biopsy",2009-06-01,"Aggregate pathology score|Cell counts|Lung function measurements|Adverse events|Diary card variables (symptoms, PEF)Clinical COPD Questionnaire","http://ClinicalTrials.gov/show/NCT00766415",NA
"13041",13041,"NCT00771615","Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years","Completed","No Results Available","Influenza Disease Caused by an Influenza A Virus With Pandemic Potential, Sub-type H5N1","Biological: GSK influenza virus H5N1 vaccine 1557484A","GlaxoSmithKline","Both","Adult","Phase II",469,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","111729","October 10, 2008","01/10/2008",2009-12-01,"July 2, 2010","01/07/2010","",2009-12-01,"Vaccine-homologous virus antibody response measured by:Seroconversion rate (SCR), proportion of subjects with Hl titer >= 40, Geometric mean titer (GMT)|Vaccine-homologous virus antibody response measured by Seroconversion rate (SCR), proportion of subjects with HI titer >= 40, Geometric mean fold rise (GMFR)|The occurrence of all unsolicited adverse events.|The occurrence of SAEs and medically-attended events|Vaccine-heterologous virus antibody response measured by GMT, SCR, proportion of subjects with HI titer >= 40, GMFR|Homologous and drift variant H5N1 virus immune responses as assessed by reciprocal MN (microneutralization) titer GMT, reciprocal MN titer SCR, proportion of subjects with MN titers >= 40|The occurrence of specifically-solicited local and general safety signs and symptoms","http://ClinicalTrials.gov/show/NCT00771615",NA
"13059",13059,"NCT00789815","Bispectral Index-guided Sedation for Flexible Bronchoscopy","Completed","Has Results","Flexible Bronchoscopy","Device: Bispectral index guide propofol infusion|Drug: Clinical-judged midazolam administration","Chang Gung Memorial Hospital","Both","Adult|Senior","Phase IV",500,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","97-0257B","November 10, 2008","01/04/2008",2009-09-01,"April 1, 2010","01/04/2010","",2009-09-01,"The Number of Participants With Any Hypoxemia Event During Flexible Bronchoscopy|The Number of Participants With Any Hypotension Event During Flexible Bronchoscopy|The Global Tolerance for Flexible Bronchoscopy by Verbal Analogus Scale|The Number of Participants Causing Any Procedure Interference by the Patients' Movement During Flexible Bronchoscocopy|The Number of Participants Causing Any Procedure Interference by Cough|The Recovery Time to Orientation|The Recovery Time to Ambulation|Patients Willing Return if Repeated Bronchoscopy is Indicated.","http://ClinicalTrials.gov/show/NCT00789815",NA
"13060",13060,"NCT00814515","Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome","Completed","No Results Available","Moderate to Severe Dry Eye Syndrome","Drug: NOVA22007 (Ciclosporin 0.1%)|Drug: NOVA22007","Novagali Pharma","Both","Adult|Senior","Phase III",482,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","NVG06C103","December 24, 2008","01/09/2007",2009-09-01,"July 15, 2010","01/07/2010","",2009-09-01,"Corneal fluorescein staining (on modified Oxford scale)|Patient's global score of all symptoms of ocular discomfort unrelated to study medication instillation, using a visual analog scale (VAS) ranging from 0%-100%|??Ñ Ocular Symptom Disease Index?¢ (OSDI?¢) questionnaire ??Ñ Percentage of complete responder to corneal fluorescein staining (on modified Oxford scale), i.e. with corneal staining score =0 ??Ñ Patient's score of each symptom of ocular discomfort unrelated to","http://ClinicalTrials.gov/show/NCT00814515",NA
"13109",13109,"NCT00889915","Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)","Completed","No Results Available","Attention Deficit Disorder With Hyperactivity","Drug: Methylphenidate transdermal system|Drug: Lisdexamfetamine dimesylate|Drug: Osmotic-release oral system methylphenidate (OROS MPH)|Drug: Mixed amphetamine salts extended release","National Institute of Mental Health (NIMH)","Both","Child","Phase IV",228,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P30 MH066386-02|DSIR CTM 4571; Pro00014075","April 27, 2009","01/04/2009",2009-12-01,"February 5, 2010","01/10/2009","",2009-12-01,"Dichotomized Clinical Global Impression-Effectiveness (CGI-E) scale|Clinical Global Impressions-Improvement (CGI-I) scale|Clinical Global Improvements-Acceptability (CGI-A) scale","http://ClinicalTrials.gov/show/NCT00889915",NA
"13155",13155,"NCT00973115","Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia","Completed","No Results Available","Hyperlipidemia","Drug: Simvastatin CR","Hanmi Pharmaceutical Company Limited","Both","Adult|Senior","Phase III",132,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HM-SIM-302","September 6, 2009","01/11/2007",2009-08-01,"September 8, 2009","01/09/2009","",2009-08-01,"the percent change from baseline in LDL cholesterol|the change and the percent change from baseline for total cholesterol, HDL cholesterol, Triglyceride, apolipoprotein A-I, apolipoprotein B, and lipoprotein(a)","http://ClinicalTrials.gov/show/NCT00973115",NA
"13159",13159,"NCT00979615","Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis","Completed","No Results Available","Vasomotor Rhinitis","Drug: Olopatadine HCL (Patanase) Nasal Spray, 0.6%|Drug: Azelastine HCl (Astelin) Nasal Spray, 137 mcg","Alcon Research","Both","Child|Adult|Senior","Phase IV",120,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SMA-09-03","September 17, 2009","01/09/2009",NA,"January 22, 2010","01/01/2010","",2009-11-01,"Total Nasal VMR Symptoms Score|Individual symptom severity scores","http://ClinicalTrials.gov/show/NCT00979615",NA
"13185",13185,"NCT01019915","Effect of Cardiac Resynchronization Therapy (CRT) on Skeletal Muscle Histology, Neuroendocrine Activation and Inflammatory Response","Completed","No Results Available","Skeletal Muscle Changes After Crt","Device: CRT","Helse Stavanger HF|University of Tromso|University of Oslo|The Royal Norwegian Ministry of Health","Both","Adult|Senior","Phase IV",21,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRT-AIL-SUS 2009","November 23, 2009","01/01/2004",2009-11-01,"November 23, 2009","01/11/2009","",2009-11-01,"","http://ClinicalTrials.gov/show/NCT01019915",NA
"13193",13193,"NCT01031615","Evaluation of the Child and Family Traumatic Stress Intervention","Completed","No Results Available","Posttraumatic Stress Disorder","Behavioral: Child and Family Traumatic Stress Interv (CFTSI)|Behavioral: Psychoeducational Comparison","Yale University","Both","Child","Phase I|Phase II",112,"Other","Interventional","Allocation: Randomized|Primary Purpose: Prevention","0504027679|SAMHSA U79SM54318","December 10, 2009","01/10/2005",2009-09-01,"December 11, 2009","01/12/2009","CFTSI",2009-09-01,"UCLA Posttraumatic Reaction Index (PTSD-RI)|Trauma Symptom Checklist for Children (TSCC)","http://ClinicalTrials.gov/show/NCT01031615",NA
"13230",13230,"NCT01094015","Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysteroscopy Practice","Completed","No Results Available","Pain","Drug: lidocaine-prilocaine cream|Other: gel application for the transmission of ultrasound","Consorci Sanitari de Terrassa","Female","Adult|Senior","Phase IV",92,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HISTEROS-07","March 23, 2010","01/07/2007",2009-04-01,"April 8, 2010","01/03/2006","HISTEROS-07",2009-01-01,"pain reduction in the performance of hysteroscopy|sense of discomfort experience during the procedure","http://ClinicalTrials.gov/show/NCT01094015",NA
"13255",13255,"NCT01138215","The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children","Completed","No Results Available","HIV Infections|Varicella-Zoster Virus","Biological: VZV vaccination","The HIV Netherlands Australia Thailand Research Collaboration|Chulalongkorn University","Both","Child","Phase IV",60,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","HIV-NAT 111","June 4, 2010","01/06/2009",2009-08-01,"June 4, 2010","01/06/2010","",2009-08-01,"Proportion of children with protective VZV Antibody in HIV infected children after 2 doses of VZV vaccine.|Adverse events from VZV vaccine.|Compare proportion of children who developed VZV antibody by baseline characteristics e.g. immune status, age, gender.","http://ClinicalTrials.gov/show/NCT01138215",NA
"13513",13513,"NCT00113516","A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer","Completed","Has Results","Non-small Cell Lung Cancer","Drug: carboplatin|Drug: paclitaxel|Drug: sunitinib","Pfizer","Both","Adult|Senior","Phase II",84,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181057","June 8, 2005","01/09/2005",2009-03-01,"May 14, 2010","01/05/2010","",2009-03-01,"Proportion of Subjects Surviving at One Year|Progression-free Survival (PFS)|Time to Tumor Progression (TTP)|Duration of Response (DR)|Number of Subjects With Overall Confirmed Objective Disease Response|Overall Survival (OS)|Trough Plasma Concentration (Ctrough) of Sunitinib|Ctrough of SU-012662 (Sunitinib's Metabolite)|Ctrough of Total Drug (Sunitinib + SU-012662)|Dose-Corrected Ctrough of Sunitinib|Dose-Corrected Ctrough of SU-012662 (Sunitinib's Metabolite)|Dose-Corrected Ctrough of Total Drug (Sunitinib + SU-012662)|Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Concentration at Baseline|VEGFR3 Ratio to Baseline at Each Time Point|VEGF-C Concentration at Baseline|VEGF-C Ratio to Baseline at Each Time Point|Soluble E-Selectin at Baseline|Soluble E-Selectin Ratio to Baseline at Each Time Point|VEGFR3 at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|VEGFR3 Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|VEGF-C at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|VEGF-C Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|Soluble E-Selectin at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|Soluble E-Selectin Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline|Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline|Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline|Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline|Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline|Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline Changes From Baseline|Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline Changes From Baseline|Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline|Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline|Immunohistochemical Staining of Paraffin Embedded Tumor Tissue|Correlation of Polymorphisms in c-Kit, Flt-3 and c-Fms to Safety of Sunitinib|Change From Baseline in Health Related Quality of Life (HRQOL) and Lung Cancer Related Symptoms as Assessed With the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)|Change From Baseline in HRQOL and Lung Cancer Related Symptoms as Assessed With the EORTC QLQ Lung Cancer Module (QLQ-LC13)","http://ClinicalTrials.gov/show/NCT00113516",NA
"13520",13520,"NCT00209716","Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.","Completed","No Results Available","Esophageal Cancer","Drug: Taxotere|Drug: 5-Fluorouracil|Drug: Briplatin","Hokkaido Gastrointestinal Cancer Study Group|Hokkaido University Hospital","Both","Adult|Senior","Phase I|Phase II",30,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HGCSG0305-2|TPF-2","September 13, 2005","01/12/2003",2009-11-01,"May 24, 2010","01/05/2010","",2009-10-01,"Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.|Determine the clinical response rate of patients in Phase I setting.|Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.","http://ClinicalTrials.gov/show/NCT00209716",NA
"13538",13538,"NCT00238316","Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density","Completed","No Results Available","Breast Cancer","Drug: letrozole","NCIC Clinical Trials Group","Female","Child|Adult|Senior","Phase II",120,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Prevention","MAP1|CAN-NCIC-MAP1|CDR0000445442","October 12, 2005","01/12/2000",2009-02-01,"November 7, 2010","01/03/2010","",2009-02-01,"Percentage change of the BMD parameters from baseline BMD values|Percentage change of bone biomarker measurements (serum bone alkaline phosphatase and urine N-telopeptide) from baseline values","http://ClinicalTrials.gov/show/NCT00238316",NA
"13548",13548,"NCT00247416","Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer","Completed","No Results Available","Stage IV Non-small Cell Lung Cancer|Stage IIIB-pleural Effusion","Drug: Gemcitabine|Drug: Dexamethasone|Drug: Carboplatin","University of Kentucky|Kentucky Lung Cancer Research Program","Both","Adult|Senior","Phase II",124,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTN-0501","October 28, 2005","01/08/2005",2009-07-01,"January 27, 2010","01/06/2008","",2009-07-01,"Determine the effect of dexamethasone pre-treatment on response rates, and survival.|Evaluate the effect of dexamethasone on clinically relevant parameters of hematologic, non-hematologic toxicity and quality of life parameters.","http://ClinicalTrials.gov/show/NCT00247416",NA
"13553",13553,"NCT00252616","Timing of Target Enteral Feeding in the Mechanically Ventilated Patient","Completed","No Results Available","Acute Respiratory Failure","Behavioral: trophic enteral feeds","Vanderbilt University|National Institutes of Health (NIH)","Both","Child|Adult|Senior","Phase II|Phase III",200,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20744","November 9, 2005","01/09/2003",2009-10-01,"January 13, 2010","01/01/2010","",2009-10-01,"Ventilator-free days|ICU-free days|Mortality|Incidence of Gastrointestinal intolerances|Organ failure-free days|Changes in inflammation as measured by serum cytokine levels|Changes in levels of nutrition as measured by serum albumin, total protein, and pre-albumin","http://ClinicalTrials.gov/show/NCT00252616",NA
"13582",13582,"NCT00299416","Caffeinol Hypothermia Protocol","Completed","No Results Available","Acute Ischemic Stroke","Drug: Caffeinol|Procedure: hypothermia","The University of Texas Health Science Center, Houston","Both","Adult|Senior","Phase I|Phase II",30,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HSC- MS-02-188|P50NS44277 project #1","March 2, 2006","01/02/2003",2009-08-01,"July 12, 2010","01/07/2010","",2009-01-01,"Safety: symptomatic hemorrhage, catheter-related complications, infections, cardiorespiratory failure, arrhythmias|Feasibility: time required to reach the target core temperature or lowest tolerated temperature, stability of patient temperature, control of rewarming,|achievement of therapeutic serum ethanol and caffeine levels, and amount of sedation needed to suppress shivering.|Efficacy: NIHSS < 2 at 24 hours, mRS < 2 at 3 months, NIHSS < 2 at 3 months, and length of hospital and ICU stay.","http://ClinicalTrials.gov/show/NCT00299416",NA
"13624",13624,"NCT00368316","Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel","Completed","No Results Available","Shigellosis","Drug: Shigella Vaccines","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Child|Adult|Senior","Phase III",6080,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","999900003|OH00-CH-N003","August 22, 2006","01/01/2000",NA,"January 28, 2010","01/04/2009","",2009-04-01,"Reduction in disease incidence","http://ClinicalTrials.gov/show/NCT00368316",NA
"13629",13629,"NCT00372216","CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction","Completed","No Results Available","Myocardial Infarction","Drug: Clopidogrel (Iscover/Plavix)","Stiftung Institut fuer Herzinfarktforschung|Bristol-Myers Squibb|Sanofi-Aventis","Both","Adult|Senior","Phase III",337,"Other|Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CIPAMI","September 4, 2006","01/10/2006",2010-01-01,"November 18, 2010","01/11/2010","",2009-10-01,"TIMI 2/3 patency of the infarct-related artery immediately prior to PCI|TIMI 3 patency before PCI|TIMI 3 patency after PCI|ST resolution immediately before angiography and 60-90 minutes after PCI|Death, re-MI, urgent revascularisation until 48 hours and until hospital discharge|Stroke (hemorrhagic, non-hemorrhagic)|Severe bleeding complications according to the TIMI classification","http://ClinicalTrials.gov/show/NCT00372216",NA
"13641",13641,"NCT00385216","Nicotine as an Adjuvant Analgesic for Third Molar Surgery","Completed","Has Results","Dental Crowding","Drug: Nicotine|Other: Placebo","Columbia University","Both","Adult","Phase IV",20,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAAA6273","October 5, 2006","01/07/2004",2009-06-01,"December 1, 2010","01/12/2010","",2009-05-01,"Pain Reported by Patient|Nausea|hydrocodone5 mg/Acetaminopgen 325 mg Use|Heart Rate|Systolic Blood Pressure|Diastolic Blood Pressure","http://ClinicalTrials.gov/show/NCT00385216",NA
"13650",13650,"NCT00402116","Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients","Completed","No Results Available","Glioblastoma|Glioblastoma Multiforme|Gliosarcoma","Drug: enzastaurin|Drug: temozolomide|Radiation: radiation","Eli Lilly and Company|University of California, San Francisco","Both","Adult|Senior","Phase I|Phase II",72,"Industry|Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9815|H6Q-MC-S008","November 17, 2006","01/09/2006",2009-12-01,"October 25, 2010","01/10/2010","",2009-12-01,"Phase 1 - To determine the maximum tolerated dose (MTD) of enzastaurin in patients with newly diagnosed GBM or GS|Phase 2 - To determine the efficacy of enzastaurin in combination with radiation therapy and temozolomide in patients with newly diagnosed GBM or GS as measured by overall survival (OS)|Phase 1 - To characterize the safety of enzastaurin when combined with temozolomide and radiation therapy in this setting|Phase 1 - To characterize the pharmacokinetics of enzastaurin when administered in combination with temozolomide and radiation therapy|Phase 1 - To assess biomarkers relevant to enzastaurin and disease state, and their correlation to clinical outcome|Phase 1 - To assess for evidence of antitumor activity in this patient population|Phase 2 - To evaluate progression free survival (PFS)|Phase 2 - To evaluate the safety profile of enzastaurin in combination with temozolomide and radiation therapy in this patient population|Phase 2 - To assess biomarkers relevant to enzastaurin and disease state and their correlation to clinical outcome|Phase 2 - To explore the utility of magnetic resonance perfusion techniques to assess treatment with enzastaurin when possible|Phase 2 - To assess changes in health-related quality of life and symptoms in this patient population","http://ClinicalTrials.gov/show/NCT00402116",NA
"13665",13665,"NCT00429416","Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation","Completed","No Results Available","Hematological Malignancies","Drug: L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells","Thomas Jefferson University","Both","Adult|Senior","Phase I|Phase II",22,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04U.115|2003-68","January 29, 2007","01/03/2004",2009-05-01,"August 24, 2010","01/08/2010","",2009-05-01,"","http://ClinicalTrials.gov/show/NCT00429416",NA
"13671",13671,"NCT00365716","Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine","Completed","Has Results","Papillomavirus Infections|Genital Diseases, Female","Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|Biological: Placebo (mcg) (Aluminum Adjuvant)225|Biological: Placebo (mcg) (Aluminum Adjuvant) 450","Merck","Female","Child|Adult","Phase II",1158,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2006_516|V501-007","August 16, 2006","01/05/2000",2009-09-01,"July 6, 2010","01/07/2010","",2009-09-01,"Number of Subjects With Injection Site Adverse Experiences|Incidence of HPV 6-, 11-, 16- or 18-related Persistent Infection or Disease (Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Adenocarcinoma in Situ, Cervical Cancer, and Genital Warts)","http://ClinicalTrials.gov/show/NCT00365716",NA
"13672",13672,"NCT00435916","Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma","Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin","Drug: SGN-40","Seattle Genetics, Inc.|Genentech","Both","Adult|Senior","Phase II",35,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SG040-0004","February 14, 2007","01/12/2006",NA,"September 8, 2009","01/09/2009","",2009-01-01,"Objective response as assessed by CT and PET scans and revised response criteria for malignant lymphoma.|Progression-free survival, disease-free survival, and overall survival.|Adverse events, laboratory values, and anti-drug antibody immune responses.|PK profile.","http://ClinicalTrials.gov/show/NCT00435916",NA
"13680",13680,"NCT00454116","A Phase II, Double Blind Study of 2 Doses of ZACTIMA?ºÑ(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients","Completed","No Results Available","Colorectal Cancer","Drug: Vandetanib|Drug: FOLFIRI","AstraZeneca","Both","Adult|Senior","Phase II",110,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4200C00048","March 28, 2007","01/01/2008",2009-11-01,"May 19, 2010","01/05/2010","",2009-03-01,"","http://ClinicalTrials.gov/show/NCT00454116",NA
"13695",13695,"NCT00474916","Neuropathic Pain in Patients With Cancer","Completed","No Results Available","Neuropathic Pain","Drug: KRN5500|Drug: Placebo","DARA Therapeutics","Both","Adult|Senior","Phase II",19,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DTCL100","May 15, 2007","01/06/2006",2009-04-01,"August 13, 2010","01/08/2010","",2009-03-01,"Average pain intensity over the previous 24 hours as measured by a numeric rating scale (NRS) ranging from 0 to 10 where 0 represents \no pain\"" and 10 represents the \""worst possible pain.\""|Physical Examination","http://ClinicalTrials.gov/show/NCT00474916",NA
"13698",13698,"NCT00478816","Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines","Completed","No Results Available","Prophylaxis of Avian Influenza Vaccine","Biological: Fluad H5N1 Pandemic Influenza Vaccine","Novartis|Novartis Vaccines","Both","Adult","Phase II",58,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","V87P3","May 24, 2007","01/05/2007",2009-02-01,"May 20, 2010","01/05/2010","",2009-02-01,"Cell-mediated immunity, magnitude, breath and kinetics of antibody response to 2 doses of MF59-adjuvanted H5N1 influenza vaccine, in subjects primed by previous vaccination with either MF59-adjuvanted or non-adjuvanted H5N3 influenza vaccine.|Safety Objectives: safety and reactogenicity of the vaccine","http://ClinicalTrials.gov/show/NCT00478816",NA
"13715",13715,"NCT00502216","Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers","Completed","Has Results","Smoking|Nicotine Dependence","Drug: Naltrexone|Drug: Varenicline","Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institute on Drug Abuse (NIDA)","Both","Adult|Senior","Phase I|Phase II",40,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","NIAAA_TOL-AA15632|P50AA015632|NIH Grant P50-AA15632|NIH Grant K12-DA00167","July 13, 2007","01/07/2007",2009-06-01,"August 30, 2010","01/08/2010","",2009-06-01,"Weight Gain in Treatment Completers|Weight Gain in Participants Who Are Continuously Abstinent for the Last 4 Weeks of Treatment|Tolerability of the Combination of 25 mg Naltrexone and 2 mg Varenicline","http://ClinicalTrials.gov/show/NCT00502216",NA
"13749",13749,"NCT00551616","Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception","Completed","No Results Available","Contraception","Drug: CDB-2914|Drug: Levonorgestrel","HRA Pharma","Female","Child|Adult|Senior","Phase III",2321,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","2914-004","October 30, 2007","01/04/2007",2009-04-01,"June 16, 2010","01/06/2010","",2009-04-01,"Pregnancy rate|Prevented fraction (number of prevented pregnancies divided by number of expected pregnancies)|Menstrual bleeding patterns|Frequencies of subjects with treatment emergent adverse events","http://ClinicalTrials.gov/show/NCT00551616",NA
"13751",13751,"NCT00554216","Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults","Completed","No Results Available","Obesity","Drug: VI-0521|Drug: VI-0521|Drug: Placebo matched phentermine/topiramate CR","VIVUS, Inc.|Medpace, Inc.","Both","Adult|Senior","Phase III",1267,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VIVUS OB-302","November 3, 2007","01/11/2007",2009-05-01,"November 30, 2009","01/11/2009","",2009-05-01,"Demonstrate an improvement over placebo in mean percent loss of baseline body weight, and percent of subjects with at least a 5% weight loss.|Demonstrate improvements in obesity-associated comorbidities|Demonstrate an improvement over placebo in absolute weight loss and reduction in waist circumference|Demonstrate an improvement in quality of life","http://ClinicalTrials.gov/show/NCT00554216",NA
"13764",13764,"NCT00568516","Phase II Study of ASP3550 in Patients With Prostate Cancer","Completed","No Results Available","Prostatic Neoplasms","Drug: ASP3550","Astellas Pharma Inc","Male","Adult|Senior","Phase II",273,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3550-CL-0003","December 5, 2007","01/10/2007",2009-10-01,"November 10, 2009","01/11/2009","",2009-10-01,"Proportion of patients with serum testosterone ???0.5 ng/mL from Day 28 to Day 364 of treatment|Proportion of patients with testosterone surge|Percentage change in serum PSA|Changes in serum levels of testosterone, LH, FSH and PSA over time|Time to the recurrence of serum PSA","http://ClinicalTrials.gov/show/NCT00568516",NA
"13798",13798,"NCT00624416","Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas","Completed","No Results Available","Lipoma","Drug: Isoproterenol;Prednisolone","Pennington Biomedical Research Center|Lipothera","Both","Adult","Phase I|Phase II",10,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PBRC27015","February 15, 2008","01/10/2007",2009-03-01,"November 25, 2009","01/11/2009","",2009-03-01,"Lipoma volume at the end of the treatment period compared to baseline.","http://ClinicalTrials.gov/show/NCT00624416",NA
"13811",13811,"NCT00627016","A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn","Completed","Has Results","Gastroesophageal Reflux","Drug: Dexlansoprazole|Drug: Placebo","Takeda Global Research & Development Center, Inc.","Both","Adult","Phase III",305,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","T-GD07-170|U1111-1113-9537","February 21, 2008","01/03/2008",2009-03-01,"May 21, 2010","01/05/2010","",2009-03-01,"Median Percentage of Nights Without Heartburn Over 4 Weeks as Assessed by Daily Diary.|Percent of Subjects With Relief of Night Time Heartburn Over the Last 7 Days of Treatment as Assessed by Daily Diary.|Percentage of Participants With Relief of Gastro-Esophageal Reflux Disease (GERD) Associated Sleep Disturbances Over the Last 7 Days of Treatment as Assessed by Daily Diary.","http://ClinicalTrials.gov/show/NCT00627016",NA
"13833",13833,"NCT00686816","Weight Loss in Pre-diabetic, Obese Women","Completed","No Results Available","Obesity","Dietary Supplement: Low calorie diet|Dietary Supplement: Olestra","Procter and Gamble","Female","Adult","Phase II",80,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2008030","May 27, 2008","01/07/2008",2009-02-01,"October 15, 2009","01/10/2009","",2009-02-01,"weight loss|Weight maintained","http://ClinicalTrials.gov/show/NCT00686816",NA
"13837",13837,"NCT00690716","The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines","Completed","No Results Available","Migraine","Drug: Nasal CO2|Drug: Inactive Placebo","Capnia, Inc.","Both","Adult","Phase II",292,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","C112","June 3, 2008","01/08/2008",2009-06-01,"August 18, 2010","01/09/2009","",2009-06-01,"The proportion of patients who are pain-free","http://ClinicalTrials.gov/show/NCT00690716",NA
"13844",13844,"NCT00701116","Safety Study of Clenbuterol in Combination With Left Ventricular Assist Device to Treat Chronic Heart Failure","Completed","No Results Available","Heart Failure|Nonischemic Cardiomyopathy|Cardiac Disease","Drug: Clenbuterol","Ohio State University|Massachusetts General Hospital|Montefiore Medical Center|Northwestern University|Texas Heart Institute|University of Michigan|Washington Hospital Center","Both","Adult|Senior","Phase I|Phase II",40,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007H0101","June 17, 2008","01/03/2007",2009-08-01,"September 22, 2009","01/09/2009","HARPS",2009-01-01,"To determine if the proportion of subjects treated with the HARPS protocol who Experience LVAD removal and subsequent freedom from mechanical circulatory support or heart transplantation for 1 year post-LVAD removal.|To asses the effect of the HARP regimen on LVAD explantation and the changes to the heart","http://ClinicalTrials.gov/show/NCT00701116",NA
"13848",13848,"NCT00702416","Ultrasound Guidance for Interscalene Brachial Plexus Block","Completed","No Results Available","Shoulder|Orthopedic Surgery|Nerve Block","Procedure: Ultrasound-guided continuous interscalene brachial plexus block|Procedure: Continuous interscalene brachial plexus block using electrical nerve stimulation|Drug: Ropivacaine|Drug: Paracetamol|Drug: Morphine|Drug: Fentanyl|Procedure: General anesthesia","University of Parma","Both","Adult|Senior","Phase IV",50,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","ANEST-ORT-01","June 19, 2008","01/05/2008",2009-11-01,"November 13, 2009","01/11/2009","",2009-11-01,"Onset time of brachial plexus anesthesia|Successful brachial plexus anesthesia|Additional analgesic requirements during surgery|Incidence of paresthesiae during the anesthetic procedure|Incidence of blood aspiration during the anesthetic procedure|Number of needle redirections for the performance of the block|Pain during performance of the block|Pain at rest and on movement (visual analog scale)|Local anesthetic consumption on patient-controlled pump","http://ClinicalTrials.gov/show/NCT00702416",NA
"13853",13853,"NCT00711516","Study to Evaluate the Effects of Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance in Adults With OSAHS Who Use nCPAP Therapy","Completed","No Results Available","Excessive Sleepiness","Drug: Armodafinil|Drug: Placebo","Cephalon","Both","Adult","Phase IV",40,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","C10953/4026/AP/US","July 8, 2008","01/09/2008",2009-10-01,"November 11, 2009","01/11/2009","",2009-09-01,"fMRI activation volume in DLPFC (number of voxels meeting predefined threshold)|Response latency on the 2-back working memory test.|CANTAB, ESS, CGI-C, and MOS-CF6 assessments","http://ClinicalTrials.gov/show/NCT00711516",NA
"13877",13877,"NCT00749216","Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: Solanezumab","Eli Lilly and Company","Both","Adult|Senior","Phase II",33,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12025|H8A-JE-LZAK","September 5, 2008","01/09/2008",2009-07-01,"May 27, 2010","01/05/2010","",2009-07-01,"Adverse events|Changes in the extended ADAS-Cog stand for Alzheimer's Disease Assessment Scale-Cognitive subscale|pharmacodynamic of A??1-40 and A??1-42|Pharmacokinetics","http://ClinicalTrials.gov/show/NCT00749216",NA
"13883",13883,"NCT00762216","Rotational Stability of the AcrySof?ó Toric","Completed","Has Results","Cataract","Device: AcrySof?ó Toric intraocular lens","Alcon Research","Both","Adult|Senior","Phase IV",71,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RM-08-001","September 26, 2008","01/05/2008",NA,"May 10, 2010","01/05/2010","",2009-06-01,"Rotational Stability|Residual Refractive Cylinder","http://ClinicalTrials.gov/show/NCT00762216",NA
"13901",13901,"NCT00785616","A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence","Completed","No Results Available","HIV Infection","Other: MEMS cap monitoring|Other: MEMS cap monitoring|Other: MEMS cap monitoring","Montefiore Medical Center|Abbott","Both","Adult|Senior","Phase IV",55,"Other|Industry","Interventional","Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-03086E","November 4, 2008","01/09/2008",2009-10-01,"July 22, 2010","01/07/2010","",2009-08-01,"Proportion with virologic suppression","http://ClinicalTrials.gov/show/NCT00785616",NA
"13902",13902,"NCT00784316","Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery","Completed","No Results Available","Atrial Fibrillation|Cardiac Surgery","Drug: metoprolol, amiodarone","Kuopio University Hospital|Heart Center, Tampere, Finland|Vaasa Central Hospital, Vaasa, Finland|North-Carelia Central Hospital, Joensuu, Finland","Both","Child|Adult|Senior","Phase IV",316,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","KUH5204005","October 31, 2008","01/08/2007",2009-07-01,"May 27, 2010","01/05/2010","",2009-07-01,"Incidence of atrial fibrillation","http://ClinicalTrials.gov/show/NCT00784316",NA
"13907",13907,"NCT00799916","Saline Solution Versus Voluven?ó: A Controlled Study of Fluid Resuscitation in Severe Sepsis","Completed","No Results Available","Sepsis","Drug: Resuscitation (Voluven)|Drug: Resuscitation (Saline)","Universidad Nacional de La Plata|Cl?¦nica Bazterrica|Sanatorio Otamendi y Miroli|Agencia de Promoci??n Cient?¦fica y Tecnol??gica, Argentina, Proyecto PICT-2007-00912","Both","Adult|Senior","Phase III",30,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEM 001","November 28, 2008","01/01/2006",2009-08-01,"September 14, 2009","01/09/2009","",2009-08-01,"Sublingual microcirculation|Gases, hemoglobin and oxygen saturations|Electrolytes and lactate|Anion gap corrected to albumin","http://ClinicalTrials.gov/show/NCT00799916",NA
"13918",13918,"NCT00814216","Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients","Completed","No Results Available","Asthma","Drug: QAV680|Drug: Matching placebo for QAV680|Drug: Fluticasone Propionate","Novartis","Both","Adult","Phase II",37,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CQAV680A2201|EudraCT number: 2008-005168-15","December 23, 2008","01/12/2008",NA,"September 22, 2010","01/09/2010","",2009-10-01,"Measure: Change in Forced Expiratory Volume in one second (FEV1) as measured by Spirometry.|Measure: Change in Asthma Control Questionnaire (ACQ) score|Measure: Frequency of salbutamol usage|Measure: Change in exhaled Nitric Oxide (NO)|Home Monitoring Of FEV1 By PIKO Monitors","http://ClinicalTrials.gov/show/NCT00814216",NA
"13921",13921,"NCT00797316","Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension","Completed","Has Results","Hypertension","Drug: Aliskiren plus Hydrochlorothiazide|Drug: Aliskiren","Novartis","Both","Adult|Senior","Phase IV",532,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CSPP100A2410","November 24, 2008","01/11/2008",2009-12-01,"December 14, 2010","01/12/2010","AIMS",2009-12-01,"Change From Baseline in msSBP (Mean Sitting Systolic Blood Pressure) at Week 8|Reduction of msDBP at Week 8|Percent With BP Response at Week 8|Percent of Patients Achieving BP Control at Week 8|Change in Pulse Pressure at Week 8","http://ClinicalTrials.gov/show/NCT00797316",NA
"13922",13922,"NCT00818116","Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL","Completed","Has Results","Cataracts","Device: AcrySof ReSTOR Aspheric IOL","Alcon Research","Both","Adult|Senior","Phase IV",34,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-08-001","January 6, 2009","01/12/2008",NA,"June 30, 2010","01/06/2010","",2009-07-01,"Uncorrected and Best Corrected Visual Acuities (Near and Distance)","http://ClinicalTrials.gov/show/NCT00818116",NA
"13923",13923,"NCT00819416","Fluid Resuscitation in Early Septic Shock","Completed","No Results Available","Septic Shock|Sepsis|Severe Sepsis","Drug: 5% albumin|Drug: Normal Saline","Ottawa Hospital Research Institute|Canadian Blood Services|Baxter Healthcare Corporation","Both","Adult|Senior","Phase II",47,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2008640","January 8, 2009","01/02/2009",2010-02-01,"April 13, 2010","01/04/2010","PRECISE",2009-10-01,"Comparison of thrombin generation and protein C and APC levels|Comparison of blood and urine pro and anti-inflammatory cytokine and chemokine levels.Clinical outcomes include mortality, length of stay,organ failure, and organ support measures.","http://ClinicalTrials.gov/show/NCT00819416",NA
"13957",13957,"NCT00867516","Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis","Completed","No Results Available","Arthritis, Rheumatoid","Biological: ALD518|Biological: Infusion without ALD518`","Alder Biopharmaceuticals, Inc.","Both","Adult|Senior","Phase II",127,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALD518-CLIN-003","March 20, 2009","01/10/2008",2009-12-01,"September 10, 2010","01/09/2010","ALD518-003",2009-06-01,"Incidence and severity of AEs and SAEs during the study|To evaluate the difference in treatment with ALD518 relative to treatment with placebo in the proportion of patients achieving a 20% improvement in ACR response (ACR20) at Week 12","http://ClinicalTrials.gov/show/NCT00867516",NA
"14017",14017,"NCT00976716","An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain","Completed","No Results Available","Pain","Drug: Celecoxib","Pfizer","Both","Adult|Senior","Phase III",80,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A3191357","September 11, 2009","01/09/2009",2009-11-01,"November 19, 2009","01/11/2009","",2009-11-01,"Patient Impressions (the proportion of subjects who have rated \worked well\"" and \""worked\"")|Pain intensity (VAS:Visual Analog Scale) of pain at rest (spontaneous pain) and active movement pain|Pain intensity differences in pain at rest (spontaneous pain) and active movement pain|Sum of pain intensity differences in pain at rest (spontaneous pain) and active movement pain until 6 hours after the first dose of study drug|Peak pain intensity difference in pain at rest (spontaneous pain) and active movement pain until 6 hours after the first dose of study drug|Severity of inflammatory symptoms (each of swelling","http://ClinicalTrials.gov/show/NCT00976716",NA
"14049",14049,"NCT01030016","Study of Atenolol Influence on Blood Pressure During Resistance Exercise","Completed","No Results Available","Blood Pressure|Exercise","Drug: atenolol","University of Sao Paulo|Funda????o de Amparo ?? Pesquisa do Estado de S??o Paulo","Both","Adult","Phase IV",10,"Other","Interventional","Allocation: Non-Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","FAPESP-06/06356-8","December 8, 2009","01/05/2007",2009-05-01,"December 14, 2009","01/05/2009","",2009-05-01,"blood pressure during resistance exercise","http://ClinicalTrials.gov/show/NCT01030016",NA
"14072",14072,"NCT01050816","Effects of CHONDRON (Autologous Chondrocytes) With Ankle Cartilage Defect","Completed","Has Results","Articular Cartilage Defects of Ankle Joint","Procedure: Chondron(autologous chondrocyte) Implantation","Sewon Cellontech Co., Ltd.","Both","Child|Adult","Phase III",30,"Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02CON","January 13, 2010","01/01/2006",2009-02-01,"May 6, 2010","01/05/2010","",2009-01-01,"Average Change From Baseline in American Orthopedic Foot and Ankle Society(AOFAS) at 12 Months Post-surgery|Average Change From Baseline in 100mm Visual Analogue Scale(VAS) at 12months Post-surgery|Average Change From Baseline in the Modified Hannover Scoring System at 12 Months Post Surgery","http://ClinicalTrials.gov/show/NCT01050816",NA
"14233",14233,"NCT00003417","Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: carmustine|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase I|Phase II",40,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066432|RTOG-9803","November 1, 1999","01/09/1998",NA,"December 26, 2009","01/09/2003","",2009-03-01,"","http://ClinicalTrials.gov/show/NCT00003417",NA
"14304",14304,"NCT00111917","Beryllium Infliximab Study: Clinical Interventional Trial","Completed","No Results Available","Berylliosis|Beryllium Disease","Drug: Infliximab","Maier, Lisa, M.D.|Centocor, Inc.","Both","Adult|Senior","Phase I|Phase II",13,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NJ202|HS1862","May 26, 2005","01/02/2005",2009-01-01,"February 6, 2009","01/02/2009","BISCIT",2009-01-01,"arterial alveolar oxygen gradient (A-adO2) at end exercise|airflow|lung volume|diffusing capacity (DLCO)|profusion of small opacities on chest x-ray|dyspnea score|quality of life (QOL) questionnaires","http://ClinicalTrials.gov/show/NCT00111917",NA
"14354",14354,"NCT00184717","Subjects Allocated to no Treatment in Trial GHLIQUID-1516 Will Subsequently Receive Growth Hormone for 4 Years.","Completed","No Results Available","Fetal Growth Retardation","Drug: somatropin|Drug: somatropin","Novo Nordisk","Both","Child","Phase III",86,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","GHLIQUID-1517|JAPIC: JapicCTI-050132","September 13, 2005","01/08/2004",2009-12-01,"February 2, 2010","01/02/2010","",2009-12-01,"Change in height SDS for chronological age|Change in height velocity SDS for chronological age|Adverse events|Change in bone age (left hand X-Ray)","http://ClinicalTrials.gov/show/NCT00184717",NA
"14369",14369,"NCT00199017","German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults","Completed","No Results Available","Lymphoma, Lymphoblastic","Drug: Dexamethasone/Prednisolone|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Daunorubicin|Drug: Asparaginase|Drug: G-CSF|Drug: Mercaptopurine|Drug: Cytarabine|Drug: Methotrexate|Drug: VP16|Drug: Vindesine|Drug: Adriamycin|Drug: Thioguanine|Drug: HDARAC|Procedure: CNS irradiation|Procedure: Mediastinal irradiation|Drug: Cladribine","Johann Wolfgang Goethe University Hospitals","Both","Child|Adult","Phase IV",75,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL04","September 12, 2005","01/04/2004",NA,"August 20, 2010","01/05/2008","",2009-03-01,"remission rate, remission duration, disease free survival, overall survival|time and dose compliance, toxicity according to World Health Organization (WHO)","http://ClinicalTrials.gov/show/NCT00199017",NA
"14442",14442,"NCT00323817","To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia","Completed","No Results Available","Functional Dyspepsia","Drug: Z-338","Zeria Pharmaceutical","Both","Adult|Senior","Phase II",282,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","99010206E","May 8, 2006","01/04/2006",2009-10-01,"June 29, 2010","01/06/2010","",2009-04-01,"Global subject Outcome Assessment|Individual symptom","http://ClinicalTrials.gov/show/NCT00323817",NA
"14514",14514,"NCT00433017","Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)","Completed","No Results Available","Macular Degeneration|Choroidal Neovascularization","Drug: ranibizumab|Drug: ranibizumab, verteporfin","Novartis","Both","Adult|Senior","Phase II|Phase III",255,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CBPD952A2309","February 8, 2007","01/05/2007",NA,"May 10, 2010","01/05/2010","",2009-07-01,"Change from baseline in best-corrected visual acuity (BCVA) (letters) at Month 12. Treatment-free interval of at least 3 months duration following Month 2|Retreatment pattern of combination therapy based on the time to first retreatment, the number of retreatments|Safety of combination therapy and monotherapy over 24 months|Changes in Best Corrected Visual Acuity from baseline over 24 months|Angiographic and optical coherence tomography (OCT) outcomes from baseline over 24 months|Onset of effect assessed by change from baseline in BCVA at Months 1, 2 and 3","http://ClinicalTrials.gov/show/NCT00433017",NA
"14517",14517,"NCT00442117","A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)(COMPLETED)","Completed","No Results Available","Asthma","Drug: mometasone furoate dry powder inhaler|Drug: Budesonide DPI","Schering-Plough","Both","Child|Adult|Senior","Phase III",200,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P04880|SCH 900525","February 28, 2007","01/11/2006",2009-07-01,"August 26, 2009","01/08/2009","",2009-07-01,"The primary endpoint for the study is the percent change from baseline in FEV1.|Change from baseline in FVC, FEF(25%-75%), AM PEFR, nocturnal and daytime asthma symptoms based on a 4-point scale, assessment of response to therapy based on a 5-point scale, and the number of puffs of rescue medication.","http://ClinicalTrials.gov/show/NCT00442117",NA
"14522",14522,"NCT00443417","A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: SK-PC-B70M","SK Chemicals Co.,Ltd.","Both","Adult|Senior","Phase II",188,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SMART_II_2006","March 5, 2007","01/04/2007",2009-01-01,"December 8, 2009","01/01/2008","",2009-01-01,"ADAS-cog(Alzheimer's Disease Assessment Scale-Cognitive subscale)|MMSE(Mini Mental State Examination)|CDR-SB(Clinical Dementia Rating Sum of Box)|QOL-AD(Quality of Life in Alzheimer's Disease)|Delayed Word-Recall Task|Symbol Digit Modalities Test|Digit Backward|Maze Task|Digit Cancellation Task|Verbal Fluency-Categories|Concentration / Distractibility|GDS","http://ClinicalTrials.gov/show/NCT00443417",NA
"14554",14554,"NCT00491517","Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety","Completed","No Results Available","Polycystic Kidney","Drug: Sirolimus|Drug: conventional therapy","Mario Negri Institute for Pharmacological Research","Both","Adult|Senior","Phase II",22,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","SIRENA","June 25, 2007","01/03/2007",2009-08-01,"April 28, 2010","01/04/2010","SIRENA",2009-07-01,"Total kidney volume (estimated by computed tomography, CT) in sirolimus and conventional treatment ADPKD groups during 6 month follow-up.|Renal cyst volume, renal parenchymal volume and renal intermediate volume.","http://ClinicalTrials.gov/show/NCT00491517",NA
"14579",14579,"NCT00537017","Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175AM1)(COMPLETED)","Completed","No Results Available","Parkinson Disease|Neurodegenerative Diseases|Central Nervous System Diseases|Movement Disorders|Brain Diseases","Drug: SCH 420814","Schering-Plough","Both","Adult|Senior","Phase II",200,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P05175|Preladenant;|Privadenant","September 27, 2007","01/11/2007",2009-11-01,"December 23, 2009","01/12/2009","",2009-11-01,"Proportion of subjects reporting AEs|Laboratory results, and vital signs assessments. Efficacy data: Hours awake/d in \on\"" state; hours/d in\""off\"" state","http://ClinicalTrials.gov/show/NCT00537017",NA
"14601",14601,"NCT00566917","Comparison Between Transvaginal Mesh and Traditional Surgery for Pelvic Organ Prolapse","Completed","No Results Available","Vaginal Prolapse","Procedure: Anterior colporrhaphy|Procedure: Anterior PROLIFT","Karolinska Institutet|The regional agreement on medical training and clinical research (ALF) between Stockholm county council and Karolinska Institutet.|The Swedish Society of Medicine|Investigators meetings supported by Gynecare Scandinavia.","Female","Adult|Senior","Phase IV",400,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","TVM III-07|.","November 30, 2007","01/12/2007",2010-01-01,"January 28, 2010","01/05/2008","",2009-12-01,"Combined primary outcome measure: anatomical assessment according to the pelvic organ prolapse quantification system and prolapse specific symptom|Quality of life","http://ClinicalTrials.gov/show/NCT00566917",NA
"14609",14609,"NCT00578617","Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial","Completed","No Results Available","Atrial Fibrillation|Arrhythmia|Stroke Prevention|Mortality","Drug: Pharmacologic Therapy Rate and/or Rhythm Control|Device: NAVI-STAR Thermo-cool (Left Atrial Catheter Ablation)","Mayo Clinic|Duke University|St. Jude Medical","Both","Adult|Senior","Phase III",60,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","06-003867|RO1-HL089907","December 14, 2007","01/09/2006",2010-06-01,"November 10, 2010","01/11/2010","CABANA",2009-02-01,"Percutaneous left atrial catheter ablation for the purpose of eliminating AF is superior to current state-of-the-art therapy with either rate or rhythm control drugs for reducing total mortality in patients with untreated or under-treated AF.|A composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest.|Medical costs and resource utilization and cost effectiveness|Composite adverse events|Determine the impact of age, AF type, symptom state, and presence of underlying disease on these outcomes and establish the importance of AF elimination in this population of patients.|Quality of Life","http://ClinicalTrials.gov/show/NCT00578617",NA
"14614",14614,"NCT00560417","Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Insulin Lispro Protamine Suspension|Drug: Insulin Glargine","Eli Lilly and Company","Both","Adult|Senior","Phase III",339,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11647|F3Z-US-IOPB","November 15, 2007","01/11/2007",2009-12-01,"January 12, 2011","01/01/2011","",2009-12-01,"Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])|Actual Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)|Change From Baseline in Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)|Percentage of Participants With Hemoglobin A1C Less Than 7.0% and Hemoglobin A1C Less Than or Equal to 6.5%|7-Point Self-Monitored Blood Glucose (SMBG) Profiles at Baseline and Endpoint (LOCF)|Glycemic Variability at Baseline and Endpoint (LOCF)|Incidence of Self-reported Hypoglycemic Episodes (All, Non-Nocturnal, Nocturnal, and Severe)|Rate of All, Non-Nocturnal, and Nocturnal Self-Reported Hypoglycemic Episodes (Adjusted for One Year)|Actual Body Weight at Baseline and Endpoint (LOCF)|Change From Baseline in Body Weight at Endpoint (LOCF)|Total Daily Insulin Dose at Endpoint (LOCF)","http://ClinicalTrials.gov/show/NCT00560417",NA
"14621",14621,"NCT00595517","Long Term Study to Investigate the Efficacy & Safety of D961H for the Prevention of NSAIDs-induced Ulcer","Completed","No Results Available","Gastric Ulcer|Duodenal Ulcer|Rheumatoid Arthritis|Osteoarthritis|Lumbago","Drug: esomeprazole, 20mg","AstraZeneca","Both","Adult|Senior","Phase III",340,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","D961HC00005","January 7, 2008","01/10/2007",2009-09-01,"September 10, 2009","01/09/2009","",2009-09-01,"To assess the safety & tolerability of D961H 20mg by evaluating AEs, clinical laboratory value and vital signs.|Presence or absence of gastric and/or duodenal ulcers at 4, 12, 24 and 52 weeks. Severity of gastric mucosal lesion evaluated by LANZA score. Presence/absence and severity of NSAID-induced gastrointestinal symptoms","http://ClinicalTrials.gov/show/NCT00595517",NA
"14626",14626,"NCT00596817","Efficacy of Lu AA21004 in the Prevention of Relapse of Major Depressive Episodes","Completed","No Results Available","Major Depressive Disorder","Drug: Lu AA21004|Drug: Placebo","H. Lundbeck A/S","Both","Adult|Senior","Phase III",404,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","11985A|2007-001871-13","January 8, 2008","01/12/2007",2009-10-01,"June 28, 2010","01/06/2010","",2009-09-01,"Time to relapse|To evaluate efficacy of Lu AA21004 during continuation treatment of patients with MDD|To evaluate long-term safety and tolerability of Lu AA21004 in patients with MDD|To evaluate potential discontinuation symptoms after abrupt discontinuation of treatment with Lu AA21004|To evaluate the effect of Lu AA21004 on Health Related Quality of Life, disability and health care resource utilization|To evaluate the effect of the Lu AA21004 on fatigue as assessed by the Fatigue Severity Scale (FSS)|To evaluate the population pharmacokinetics and pharmacodynamics of Lu AA21004 and its metabolites Lu AA34443 and Lu AA39835","http://ClinicalTrials.gov/show/NCT00596817",NA
"14631",14631,"NCT00615017","AZD9773 Dose Escalation Study","Completed","No Results Available","Severe Sepsis","Drug: AZD9773 (CytoFab)","AstraZeneca","Both","Adult|Senior","Phase II",74,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","D0620C00004","January 31, 2008","01/01/2008",2009-07-01,"March 23, 2010","01/03/2010","",2009-07-01,"The primary purpose of the study is to evaluate the safety profile of AZD9773 as evidenced by adverse events, serious adverse events, laboratory safety assessments, vital signs, 12-lead ECG and physical examination.|Additional outcome variables include general assessment of sepsis care, PK, and PD.","http://ClinicalTrials.gov/show/NCT00615017",NA
"14637",14637,"NCT00621517","Bupropion and Restless Legs Syndrome","Completed","No Results Available","Restless Legs Syndrome","Drug: Bupropion|Drug: Placebo","East Tennessee State University","Both","Adult|Senior","Phase II|Phase III",70,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ETSU-07-061f","February 12, 2008","01/02/2008",2009-07-01,"October 1, 2009","01/10/2009","",2009-07-01,"Change in International Restless Legs Syndrome Study Group severity scale|Clinical Global Impression - Improvement Scale|Ordinal Scale(i.e., 1-8)of symptom severity","http://ClinicalTrials.gov/show/NCT00621517",NA
"14641",14641,"NCT00629317","Trial of Methyl Aminolevulinate Plus Aktilite in Facial Photodamage","Completed","No Results Available","Skin Aging","Other: Moisturizer|Drug: Methyl Aminolevulinate","Universidad de Antioquia|Galderma","Female","Adult|Senior","Phase III",49,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","PISUI 2007-031","February 25, 2008","01/02/2008",2009-03-01,"March 13, 2009","01/03/2009","",2009-01-01,"Efficacy in facial global photodamage|Facial fine lines, mottled pigmentation, tactile roughness, sallowness, erythema, telangiectasia|Histological effect of MAL+PDT in fibrosis and new collagen formation|Safety and tolerance","http://ClinicalTrials.gov/show/NCT00629317",NA
"14644",14644,"NCT00631917","A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension","Completed","No Results Available","Hypertension","Drug: Aliskiren|Drug: Ramipril","Novartis","Both","Adult|Senior","Phase IV",774,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSPP100A2404","March 3, 2008","01/02/2008",NA,"July 15, 2010","01/07/2010","",2009-11-01,"Occurrence of colonic pathology as defined by the composite endpoint (hyperplastic polyps, inflammatory polyps, adenomatous polyps or carcinomas) after one year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen|To assess mucosal hyperplasia, dysplasia, and severity of inflammation in rectal and cecal mucosal biopsy specimens obtained at baseline and following one-year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen|To assess the occurrence of the individual components of the composite endpoint following one-year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen.|To assess the number of each component of the composite endpoint following one-year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen.|To evaluate the overall gastrointestinal tolerability following one-year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen.","http://ClinicalTrials.gov/show/NCT00631917",NA
"14651",14651,"NCT00633217","Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)","Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|Drug: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg","GlaxoSmithKline","Both","Adult|Senior","Phase IV",247,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","111117","February 19, 2008","01/03/2008",2009-02-01,"December 7, 2009","01/12/2009","",2009-02-01,"Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug|Mean Change From Baseline in AM Pre-dose FEV1|Mean Change From Baseline in Peak Expiratory Flow","http://ClinicalTrials.gov/show/NCT00633217",NA
"14655",14655,"NCT00647517","Tramadol/Acetaminophen(Ultracet) AS add-on Therapy in the Treatment of Patients With Ankylosing Spondylitis","Completed","No Results Available","Ankylosing Spondylitis","Drug: Ultracet","Chung Shan Medical University","Both","Adult","Phase IV",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","CSH-CMCTC-96-013","March 26, 2008","01/03/2008",2009-07-01,"March 31, 2010","01/01/2008","CS07102",2009-07-01,"The primary endpoint of this study is response defined by ASAS Response at 20% level at week 12. These criteria include measures of pain, function, inflammation, and patient global assessment of disease.|there is no secondary outcome.","http://ClinicalTrials.gov/show/NCT00647517",NA
"14667",14667,"NCT00663117","The Effects of Naltrexone on Active Crohn's Disease","Completed","No Results Available","Inflammation|Crohn's Disease","Drug: Naltrexone|Drug: Placebo","Penn State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|The Broad Foundation","Both","Adult|Senior","Phase II",40,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DK073614 l|NIH 1 R03DK073614 l|IBD-0180R","April 18, 2008","01/09/2006",2009-10-01,"March 30, 2010","01/12/2009","LDN",2009-10-01,"Effects of naltrexone on inflammation of the bowel based upon the following: CDAI scores (Crohn's disease activity index) scores; C-Reactive Protein and ESR; Endoscopic appearance on colonoscopy; Histology biopsies|Quality of life: based upon 2 QOL surveys|Effects of naltrexone on remission of Crohn's disease","http://ClinicalTrials.gov/show/NCT00663117",NA
"14685",14685,"NCT00691717","Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension","Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: Anecortave Acetate|Drug: Placebo","Alcon Research","Both","Adult|Senior","Phase II|Phase III",400,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","C-07-36","June 3, 2008","01/06/2008",NA,"September 30, 2009","01/09/2009","",2009-09-01,"Mean IOP|Percent of patient with a therapeutic benefit.","http://ClinicalTrials.gov/show/NCT00691717",NA
"14705",14705,"NCT00689117","A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel","Completed","Has Results","Acne Vulgaris|Acne","Drug: CT Gel|Drug: Clindamycin Gel (clindamycin )|Drug: Tretinoin Gel (tretinoin)|Drug: Vehicle Gel","Stiefel, a GSK Company","Both","Child|Adult|Senior","Phase III",1649,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","114681|W0265-03","May 24, 2008","01/04/2008",2009-05-01,"December 17, 2010","01/12/2010","",2009-04-01,"Absolute Change From Baseline in Lesion Counts (Total, Inflammatory, and Non-inflammatory) at Week 12 (End of Study)|The Percentage of Participants Who Had a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12|Percent Change From Baseline in Lesion Counts (Inflammatory, Non-inflammatory, and Total) at Week 12|The Percentage of Participants With a Subjects Global Assessment Score of 0 or 1 at Week 12|The Percentage of Participants Who Had ISGA Scores of 0 or 1 at Week 12","http://ClinicalTrials.gov/show/NCT00689117",NA
"14709",14709,"NCT00733317","Budesonide for Emergency Treatment of Acute Wheezing in Children","Completed","No Results Available","Asthma|Acute Asthma","Drug: 0.5 mg/ml budesonide nebules|Drug: Saline","Kecioren Education and Training Hospital","Both","Child","Phase IV",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B.10.0.??EG.0.11.00.01- 1864","August 12, 2008","01/09/2007",2009-12-01,"May 6, 2010","01/09/2009","",2009-12-01,"Pulmonary index score at 2 to 4 hours|Hospital admission rates|Proportion of subjects improving from severe to moderate, severe to mild, and moderate to mild.|Respiratory rate|Oxygen saturation|Time to discharge from the Emergency Department to home|Adverse reactions.","http://ClinicalTrials.gov/show/NCT00733317",NA
"14722",14722,"NCT00755417","Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women","Completed","No Results Available","Hot Flashes","Drug: Gabapentin Extended Release tablets","Depomed","Female","Adult|Senior","Phase III",540,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","BREEZE 1|81-0058","September 17, 2008","01/09/2008",2009-10-01,"November 2, 2009","01/11/2009","",2009-08-01,"Reduction of frequency and severity of hot flashes after 24 weeks of treatment with a stable dose relative to placebo, compared with the baseline week.","http://ClinicalTrials.gov/show/NCT00755417",NA
"14729",14729,"NCT00760617","Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older","Completed","No Results Available","Influenza Disease","Biological: Fluarix|Biological: GSK Bio's influenza vaccine GSK2186877A","GlaxoSmithKline","Both","Adult|Senior","Phase III",526,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","111737","September 25, 2008","01/10/2008",2009-05-01,"September 28, 2009","01/09/2009","",2009-05-01,"Occurrence, intensity and relationship to vaccination of unsolicited AEs|Occurrence and relationship to vaccination of unsolicited AEs with medically attended visit|Occurrence, intensity, duration and relationship to vaccination of solicited local and general AEs|Occurrence and relationship to vaccination of SAEs and AEs of specific interest|Serum haemagglutination-inhibition (HI) antibody titres|Influenza specific CD4 T-cell frequencies","http://ClinicalTrials.gov/show/NCT00760617",NA
"14774",14774,"NCT00700817","The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: liraglutide|Drug: sitagliptin|Drug: metformin|Drug: liraglutide","Novo Nordisk","Both","Adult|Senior","Phase III",665,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NN2211-1860|2007-003937-17","June 18, 2008","01/06/2008",2010-06-01,"August 4, 2010","01/07/2010","",2009-06-01,"Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26|Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 26|Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 26|Mean Change From Baseline in Body Weight at Week 26|Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26|Mean Change From Baseline in Beta-cell Function at Week 26|Mean Change From Baseline in Total Cholesterol at Week 26|Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 26|Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 26|Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 26|Mean Change From Baseline in Triglycerides (TG) at Week 26|Mean Change From Baseline in Free Fatty Acids (FFA) at Week 26|Mean Change From Baseline in Apolipoprotein B at Week 26|Mean Change From Baseline in Highly Sensitive C-reactive Protein (hsCRP) at Week 26|Mean Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at Week 26.|Mean Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 26.|Mean Change From Baseline in Interleukin-6 (IL-6) at Week 26.|Mean Change From Baseline in Adiponectin at Week 26.|Mean Change From Baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 26.|Mean Change From Baseline in Von Willebrand Factor (vWf) at Week 26.|Mean Change From Baseline in Waist to Hip Ratio at Week 26.|Mean Change From Baseline in Waist Circumference at Week 26.|Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 26|Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 26|Mean Change From Baseline in Pulse at Week 26|Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 26|Hypoglyceamic Episodes, Weeks 0-26|Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-26|Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 52|Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 52|Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 52|Mean Change From Baseline in Body Weight at Week 52|Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52|Mean Change From Baseline in Beta-cell Function at Week 52|Mean Change From Baseline in Total Cholesterol at Week 52|Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 52|Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 52|Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 52|Mean Change From Baseline in Triglycerides (TG) at Week 52|Mean Change From Baseline in Free Fatty Acids (FFA) at Week 52|Mean Change From Baseline in Apolipoprotein B at Week 52|Mean Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at Week 52|Mean Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 52|Mean Change From Baseline in Interleukin-6 (IL-6) at Week 52|Mean Change From Baseline in Adiponectin at Week 52|Mean Change From Baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 52|Mean Change From Baseline in Von Willebrand Factor (vWf) at Week 52|Mean Change From Baseline in Waist Circumference at Week 52|Mean Change From Baseline in Waist to Hip Ratio at Week 52|Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 52|Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 52|Mean Change From Baseline in Pulse at Week 52|Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 52|Hypoglyceamic Episodes, Weeks 0-52|Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 78|Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 78|Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 78|Mean Change From Baseline in Body Weight at Week 78|Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 78|Mean Change From Baseline in Beta-cell Function at Week 78|Mean Change From Baseline in Total Cholesterol at Week 78|Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 78|Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 78|Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 78|Mean Change From Baseline in Triglycerides (TG) at Week 26|Mean Change From Baseline in Free Fatty Acids (FFA) at Week 78|Mean Change From Baseline in Apolipoprotein B at Week 78|Mean Change From Baseline in Waist Circumference at Week 78|Mean Change From Baseline in Waist to Hip Ratio at Week 78|Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 78|Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 78|Mean Change From Baseline in Pulse at Week 78|Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 78|Hypoglyceamic Episodes, Weeks 0-78","http://ClinicalTrials.gov/show/NCT00700817",NA
"14817",14817,"NCT00899717","Occlusal Adjustment as Treatment for Chronic Orofacial Pain","Completed","No Results Available","Temporomandibular Joint Disorders|Orofacial Pain","Procedure: Occlusal adjustment|Procedure: Placebo occlusal adjustment","University of Santiago de Compostela","Both","Adult","Phase I|Phase II",20,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2009/017","May 11, 2009","01/05/2009",2010-04-01,"April 7, 2010","01/08/2009","",2009-06-01,"Visual Analogic Scale for pain intensity (0-10)|SCL-90-R quality of life questionary|Preferred chewing side|Condylar paths (axiography)|Lateral dental guidance angle (Gnatography)|Maximum comfortable mouth opening (mm)|Maximum mouth opening (mm)|Handedness","http://ClinicalTrials.gov/show/NCT00899717",NA
"14832",14832,"NCT00930917","Heat Loss Prevention in Delivery Room Using a Polyethylene Cap","Completed","No Results Available","Hypothermia, Preterm Infants","Device: Polyethylene cap|Device: Polyethylene wrap|Other: conventional treatment","University of Padova","Both","Child","Phase III",96,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","NIDA8","June 30, 2009","01/12/2007",2009-02-01,"June 30, 2009","01/06/2009","",2009-02-01,"Axillary temperature taken on admission to the NICU (immediately after cap and wrap removal) and again 1 hour later.|Mortality prior to hospital discharge, presence of major brain injury, tracheal intubation at birth, Apgar scores, delivery to admission time, blood gas analysis and serum glucose concentration on NICU admission.","http://ClinicalTrials.gov/show/NCT00930917",NA
"15097",15097,"NCT00016718","Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs","Completed","No Results Available","HIV Infections","Drug: Didanosine|Drug: Efavirenz|Drug: Emtricitabine","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Child|Adult","Phase I|Phase II",53,"NIH","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACTG P1021|PACTG P1021|IMPAACT P1021|10038","May 31, 2001","01/06/2005",NA,"April 23, 2010","01/09/2008","",2009-01-01,"Development of Grade 3 or 4 adverse events attributed to the study treatment|Suppression of HIV viral load to less than 400 copies/ml and 50 copies/ml at Week 16|Time to virologic failure at or after Week 16","http://ClinicalTrials.gov/show/NCT00016718",NA
"15125",15125,"NCT00054418","Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer","Completed","No Results Available","Breast Cancer|Osteoporosis","Dietary Supplement: calcium carbonate|Dietary Supplement: cholecalciferol|Drug: risedronate sodium","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Female","Adult|Senior","Phase III",NA,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care","CDR0000270449|NCCTG-N02C1","February 5, 2003","01/03/2003",NA,"May 12, 2009","01/05/2006","",2009-03-01,"Average intra-patient change in lumbar spine (L2-L4, PA) bone mineral density (BMD) from baseline to one year after study entry|Average intra-patient change in femoral neck and total hip BMD from baseline to one year after study entry|Incidence of osteopenia in the risedronate vs placebo groups at one year after study entry|Incidence of osteoporosis in the risedronate vs placebo groups at one year after study entry|Incidence of a 5% difference in intra-patient BMD scores at baseline|Serum and urine N-telopeptide and serum alkaline phosphatase at baseline and 6 months|Frequency and severity of toxicity as measured by NCI CTC version 2.0|Menopausal symptoms as measured by the Greene Climacteric Scale (GCS) at baseline, monthly during chemotherapy, at 6 months, 1 year, and 2 years after study entry|Association of baseline serum estradiol levels with permanent cessation of menses|Relationship between the subscales of the GCS (psychological, vasomotor, somatic and sexual) with type of chemotherapy, duration of chemotherapy, and menstrual cycle changes","http://ClinicalTrials.gov/show/NCT00054418",NA
"15175",15175,"NCT00145418","Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Oxaliplatin + Docetaxel","Oncology Specialists, S.C.|Sanofi-Synthelabo","Both","Adult|Senior","Phase II",15,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OX-03-137 (0409)","September 1, 2005","01/02/2005",2010-03-01,"March 3, 2010","01/04/2008","",2009-08-01,"Response rate|Time to progression|Duration of response|Toxicity","http://ClinicalTrials.gov/show/NCT00145418",NA
"15274",15274,"NCT00289718","Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule","Completed","Has Results","Hepatitis A|Hepatitis B","Biological: Twinrix?ºÑ adult","GlaxoSmithKline","Both","Adult|Senior","Phase III",51,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","100556 (Y11)|100557 (Y12)|100558 (Y13)|100559 (Y14)|100560 (Y15)","February 9, 2006","01/11/2004",2009-02-01,"July 29, 2010","01/07/2010","",2009-02-01,"Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration|Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration|Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration|Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration|Number of Subjects Reporting Serious Adverse Events (SAE) Assessed by the Investigators as Related to Vaccination or to Study Procedures or Lack of Efficacy|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Number of Subjects Reporting Serious Adverse Events (SAE)","http://ClinicalTrials.gov/show/NCT00289718",NA
"15307",15307,"NCT00337818","Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women.","Completed","Has Results","Papillomavirus Type 16/18 Infection|Cervical Intraepithelial Neoplasia","Biological: Cervarix?ºÑ","GlaxoSmithKline","Female","Child|Adult","Phase III",770,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","107476 (M18)|107477 (M24)|107479 (M36)|107481 (M48)","June 15, 2006","01/06/2006",2009-01-01,"March 25, 2010","01/03/2010","",2009-01-01,"Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies|Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Cervical Samples|Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies in Blood Samples|Number of Subjects Reporting Pregnancies, New Onset Chronic Diseases (NOCDs) and Other Medically Significant Conditions (MSCs)|Number of Subjects Reporting SAEs","http://ClinicalTrials.gov/show/NCT00337818",NA
"15311",15311,"NCT00359918","Randomized Multicenter Trial of Prehospital Initiated Facilitated Percutaneous Coronary Intervention (PCI) Versus Primary PCI in ST-segment-Elevation MI (STEMI)","Completed","No Results Available","Myocardial Infarction","Drug: fibrinolysis","University of Leipzig","Both","Adult|Senior","Phase IV",162,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Reg.-Nr. 008/2006","August 1, 2006","01/08/2006",2009-08-01,"August 6, 2009","01/08/2009","LIPSIA STEMI",2009-08-01,"Infarct size and microvascular obstruction assessed by MRI|Clinical endpoints (bleeding, death, Re-MI, stroke)|ST-segment resolution","http://ClinicalTrials.gov/show/NCT00359918",NA
"15317",15317,"NCT00369018","A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.","Completed","No Results Available","Cervical Dysplasia","Drug: methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)","PhotoCure","Female","Adult|Senior","Phase I|Phase II",96,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PC CE101/06","August 28, 2006","01/08/2006",2009-07-01,"November 26, 2010","01/11/2010","",2009-07-01,"Lesion eradication|Eradication of lesion and HPV|Safety assessment","http://ClinicalTrials.gov/show/NCT00369018",NA
"15324",15324,"NCT00353418","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection","Completed","Has Results","Hepatitis C, Chronic","Drug: Peginterferon alfa-2a|Drug: Ribavirin|Drug: Ribavirin","Hoffmann-La Roche","Both","Adult|Senior","Phase IV",415,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NV18209","July 17, 2006","01/06/2006",2009-04-01,"July 30, 2010","01/07/2010","",2009-04-01,"Sustained Virological Response (SVR)|Incidence of Adverse Events, Dose Reductions and Withdrawals Due to Anemia|Virological Response at End of Treatment Period|Virological Response at Weeks 4, 12 and 24|Relapse of Virological Response|Rapid Virological Response (RVR) by Week 4|Early Virological Response (EVR), Partial EVR and Complete EVR by Week 12","http://ClinicalTrials.gov/show/NCT00353418",NA
"15399",15399,"NCT00486018","A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)","Completed","No Results Available","Macular Edema|Retinal Vein Occlusion","Drug: ranibizumab|Drug: ranibizumab|Drug: sham","Genentech","Both","Adult|Senior","Phase III",397,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","FVF4165g","June 11, 2007","01/07/2007",2009-11-01,"May 5, 2010","01/05/2010","BRAVO",2009-05-01,"Mean change from baseline in BCVA score|Proportion of subjects who gain at least 15 letters in BCVA score at 6 months compared with baseline|Proportion of subjects who lose fewer than 15 letters in BCVA score at 6 months compared with baseline|Mean change from baseline in BCVA score|Proportion of subjects with a central foveal thickness of ??? 250 ??m, assessed by OCT|Mean absolute change from baseline in central foveal thickness, assessed by OCT|Mean change from baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) near activities subscale|Mean change from baseline in the NEI VFQ-25 distance activities subscale","http://ClinicalTrials.gov/show/NCT00486018",NA
"15401",15401,"NCT00500318","A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe COPD","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: Aclidinium Bromide","Forest Laboratories|Laboratorios Almirall, SA","Both","Adult|Senior","Phase III",NA,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double-Blind","LAS-MD-CL26","July 10, 2007","01/07/2007",NA,"March 30, 2009","01/03/2009","",2009-03-01,"Endurance time (ET) at 75% Wmax|Trough Forced Expiratory Volume in 1 second (FEV1), Inspiratory Capacity (IC), Functional Residual Capacity (FRC), IC/Total Lung Capacity (TLC) ratio, Safety","http://ClinicalTrials.gov/show/NCT00500318",NA
"15417",15417,"NCT00519818","Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia","Completed","No Results Available","Congenital Adrenal Hyperplasia|21-Hydroxylase Deficiency|Adrenogenital Syndrome","Drug: Chronocort for the treatment of CAH","Diurnal Limited|National Institutes of Health Clinical Center (CC)","Both","Child|Adult","Phase I|Phase II",20,"Industry|NIH","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","070211|07-CH-0211","August 22, 2007","01/08/2007",2009-05-01,"October 6, 2010","01/10/2010","",2009-05-01,"Chronocort vs. Cortef cortisol concentrations (max, min, AUC).|Changes in adrenal hormone concentrations, changes in fatigue, changes in weight.","http://ClinicalTrials.gov/show/NCT00519818",NA
"15446",15446,"NCT00565318","Benfotiamine in Diabetic Nephropathy","Completed","No Results Available","Diabetic Nephropathy","Drug: Benfotiamine|Drug: Placebo","University Medical Centre Groningen|Isala Klinieken Hospital|W??rwag Pharma GmbH & Co. KG|Predictions Network","Both","Adult|Senior","Phase IV",86,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","BENFO-1|NL17390.075.07","November 28, 2007","01/12/2007",2009-06-01,"November 13, 2009","01/11/2009","Benfo",2009-06-01,"Change in urinary excretion of: - Kidney injury molecule-1 (KIM-1) - Albumin|Change in urinary excretion of: ??2 microglobulin, macrophage inhibiting factor (MIF), monocyte chemo-attractant protein-1 (MCP-1), and other advanced glycation end-products (AGEs).","http://ClinicalTrials.gov/show/NCT00565318",NA
"15460",15460,"NCT00597818","Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury","Completed","No Results Available","NSAID-induced Gastroduodenal Injury|Ulcers|Rheumatoid Arthritis|Osteoarthritis","Drug: Cobiprostone|Drug: Placebo","Sucampo Pharmaceuticals, Inc.","Both","Adult|Senior","Phase II",120,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SU0621","January 10, 2008","01/08/2007",2009-05-01,"June 2, 2010","01/06/2010","",2009-04-01,"Incidence of gastric ulcers|Proportion of patients developing duodenal and gastroduodenal ulcers|Proportion of patients developing gastric, duodenal, and gastroduodenal ulcers|Change in number of ulcers by patient|Change in number of erosions by patient|Size of ulcers/erosions|Time-to-onset of ulcer/erosion development|Lanza assessment of gastroduodenal injury|Analysis of dyspepsia/dyspeptic symptoms","http://ClinicalTrials.gov/show/NCT00597818",NA
"15463",15463,"NCT00605618","Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors","Completed","No Results Available","Advanced Solid Tumors","Drug: BMS-777607","Bristol-Myers Squibb","Both","Adult|Senior","Phase I|Phase II",8,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA192-002","January 18, 2008","01/03/2008",2009-03-01,"January 6, 2011","01/08/2009","",2009-03-01,"Safety and efficacy assessment including vitals signs, physical assessments, and blood tests|Tumor assessments|Pharmacokinetics (PK) of BMS-777607 and its N-oxide metabolite, BMS-797669|The effects of BMS-777607 on blood pressure (BP), heart rate (HR)|Effects on electrocardiogram (ECG), PR interval|Effects on left ventricular function","http://ClinicalTrials.gov/show/NCT00605618",NA
"15485",15485,"NCT00609518","A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer","Completed","Has Results","Non Small Cell Lung Cancer","Drug: pemetrexed|Dietary Supplement: Folic acid|Dietary Supplement: Folic Acid|Dietary Supplement: Vitamin B12|Drug: dexamethasone|Drug: dexamethasone","Eli Lilly and Company","Both","Adult|Senior","Phase II",111,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11652|H3E-CR-S111","January 23, 2008","01/02/2008",2010-06-01,"December 10, 2010","01/12/2010","",2009-10-01,"Safety: Number of Participants With Drug-Related Grade 3 or 4 Toxicity|Proportion of Participants With Best Overall Tumor Response (Response Rate)|Overall Survival|Progression-free Survival (PFS)","http://ClinicalTrials.gov/show/NCT00609518",NA
"15501",15501,"NCT00662818","Treatment of Migraine in Patients With Stable Vascular Disease","Completed","No Results Available","Migraine Disorders|Heart Disease|Cerebrovascular Accident|TIA (Transient Ischemic Attack)|Vascular Diseases|Peripheral Vascular Diseases","Drug: Comparator: MK0974|Drug: Comparator: acetaminophen|Drug: Comparator: Placebo","Merck","Both","Adult|Senior","Phase III",165,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2007_545|MK0974-034","April 17, 2008","01/03/2008",2009-09-01,"April 28, 2010","01/04/2010","",2009-09-01,"To evaluate the efficacy of MK0974 compared to placebo in the treatment of acute migraine in patients with stable vascular disease, as measured by pain freedom at 2 hours post dose.|Number of confirmed vascular event within 48 hours after any dose of study medication.","http://ClinicalTrials.gov/show/NCT00662818",NA
"15508",15508,"NCT00671918","Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma","Completed","No Results Available","Breast Cancer|Melanoma","Drug: Lymphoseek","Neoprobe Corporation","Both","Adult|Senior","Phase III",238,"Industry","Interventional","Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NEO3-05","April 30, 2008","01/04/2008",2009-07-01,"August 24, 2009","01/08/2009","",2009-06-01,"The primary objective of efficacy is the concordance between Lymphoseek and vital blue dye in the in-vivo detection of the excised lymph node(s) as confirmed by pathology.|The secondary objective is the assessment of the resected lymph node(s) to confirm the presence/absence of tumor metastases.","http://ClinicalTrials.gov/show/NCT00671918",NA
"15510",15510,"NCT00683618","Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia","Completed","No Results Available","Hypercholesterolemia","Drug: rosuvastatin|Drug: Atorvastatin","AstraZeneca","Both","Adult|Senior","Phase IV",438,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D356FC00007","May 21, 2008","01/05/2008",2009-07-01,"December 1, 2009","01/12/2009","",2009-07-01,"low-density lipoprotein cholesterol (LDL-C)|high-density lipoprotein cholesterol (HDL-C),total cholesterol (TC), triglycerides (TG)|Apolipoprotein B (ApoB), Apolipoprotein A-I (ApoA-I)","http://ClinicalTrials.gov/show/NCT00683618",NA
"15512",15512,"NCT00684918","Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)","Completed","No Results Available","AML","Drug: Obatoclax","Gemin X","Both","Senior","Phase II",18,"Industry","Interventional","Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEM016","May 23, 2008","01/04/2008",2009-12-01,"September 13, 2010","01/09/2010","",2009-08-01,"Determine the rate of morphologic CR after treatment in the obatoclax single-agent therapy in older patients with previously untreated AML.","http://ClinicalTrials.gov/show/NCT00684918",NA
"15522",15522,"NCT00697918","Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures","Completed","No Results Available","Seizures","Drug: RWJ-333369","Janssen Pharmaceutical K.K.","Both","Child|Adult|Senior","Phase III",11,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR014287|333369-KJ-03","June 12, 2008","01/09/2007",2009-04-01,"April 26, 2010","01/04/2010","",2009-04-01,"Adverse events (subjective/objective findings), blood pressure, pulse rate, body temperature, weight, 12-lead ECG, laboratory tests, pregnancy test. Time measure is 1 year.|Percent reduction in partial seizure frequency","http://ClinicalTrials.gov/show/NCT00697918",NA
"15524",15524,"NCT00699218","A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression","Completed","No Results Available","Mood Disorder|Bipolar Disorder|Major Depression|Depression","Device: Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.","University of California, Davis|National Alliance for Research on Schizophrenia and Depression","Both","Adult","Phase I|Phase II",15,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200715749-1","June 4, 2008","01/05/2008",2010-04-01,"June 25, 2010","01/06/2010","TMS-BD",2009-07-01,"Hamilton Rating Scale for Depression (HAM-D)|Inventory of Depressive Symptomatology","http://ClinicalTrials.gov/show/NCT00699218",NA
"15547",15547,"NCT00734318","Study of FlutiForm?ó Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma","Completed","No Results Available","Asthma, Bronchial","Drug: FlutiForm?ó (combination product of Fluticasone and Formoterol)","Mundipharma Research Limited","Both","Adult|Senior","Phase III",508,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","FLT3503|2007-001633-34","August 13, 2008","01/09/2008",2009-10-01,"October 8, 2009","01/10/2009","",2009-06-01,"Comparison of FEV1 (Forced expiratory volume in the first second) values.|Other lung function parameters, asthma symptom scores, sleep disturbance due to asthma, rescue medication use, AQLQ, safety assessments.","http://ClinicalTrials.gov/show/NCT00734318",NA
"15578",15578,"NCT00778518","Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).","Completed","No Results Available","Growth Hormone Deficiency","Drug: ARX201|Drug: ARX201|Drug: ARX201","Ambrx, Inc.|Merck Serono International SA","Male","Adult","Phase II",36,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","PRO-ARX201-701|EudraCT: 2007-001746-40","October 22, 2008","01/07/2008",2009-10-01,"October 9, 2009","01/10/2009","",2009-10-01,"Temporal profiling of circulating IGF-1 levels.|Body composition measurements at start of study and end of study","http://ClinicalTrials.gov/show/NCT00778518",NA
"15644",15644,"NCT00885118","4 Weeks Treatment With BI 10773 in Japanese Type 2 Diabetic Patients","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: BI 10773|Drug: placebo","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",100,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1245.15","April 20, 2009","01/04/2009",NA,"November 24, 2009","01/11/2009","",2009-10-01,"Urine glucose excretion Plasma glucose|HbA1c Fructosamine 1.5 anhydroglucitol","http://ClinicalTrials.gov/show/NCT00885118",NA
"15661",15661,"NCT00904618","Safety and Efficacy Study on the Implantation of the Tension-Free Vaginal Tape (TVT-Secur) Under Local Anesthesia","Completed","Has Results","Urinary Stress Incontinence","Procedure: TVT-SECUR - 'Hammock' technique|Procedure: TVT-SECUR - 'U-Method'|Drug: Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).","Universitaire de Sherbrooke|Ethicon, Inc.","Female","Child|Adult|Senior","Phase II",48,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","USherbrooke-001","March 11, 2009","01/01/2007",2009-03-01,"May 18, 2009","01/04/2009","",2009-03-01,"Local Anesthesia Satisfaction|Improvement in Stress Urinary Symptoms.|Safety of the Sling.","http://ClinicalTrials.gov/show/NCT00904618",NA
"15737",15737,"NCT01028118","Violence Against Women and Consequences During Climacteric??s Phase","Completed","No Results Available","Violence|Battered Women|Cognitive Behavior Therapy","Other: Identifying experience with violence","University of Sao Paulo General Hospital|Conselho Nacional de Desenvolvimento Cient?¦fico e Tecnol??gico|N??cleo de Estudos Sobre Viol??ncia e Humaniza????o da Assistencia ?? Sa??de - NEVHAS","Female","Adult","Phase III",300,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","180/09","December 7, 2009","01/04/2009",2009-10-01,"April 7, 2010","01/03/2009","DV",2009-06-01,"Sessions of Cognitive Behavioral Therapy is good for women subject to sexual violence.|PREVENTION OF DOMESTIC VIOLENCE IN CHILDOOD AND/OR ADOLESCENTS: LESSER PREVALENCE OF COMORBIDITIES IN CLIMACTERIC??S PHASE.|Analyzing among women who suffered violence the comorbidities they suffered in climacteric??s phase.|Sessions of Cognitive Behavioral Therapy is good for women subject to sexual violence.","http://ClinicalTrials.gov/show/NCT01028118",NA
"15747",15747,"NCT01045018","A BE Study Comparing Mesalamine 400 mg to ASACOL?ó 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis","Completed","No Results Available","Mild to Moderate Ulcerative Colitis","Drug: Placebo|Drug: Mesalamine|Drug: Mesalamine","EMET Pharmaceuticals, LLC|Eagle Pharmaceuticals, Inc.","Both","Adult|Senior","Phase III",NA,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment","EMET 001","December 17, 2009","01/01/2008",2009-08-01,"January 7, 2010","01/12/2009","",2009-06-01,"Treatment Success: Responders are patients in remission or who do not require use of rescue medication for symptomatic relief of UC at week 6 Treatment benefit: Improvement at endpoint compared to baseline Treatment Failure: Increase or no improvement|Tolerability and safety will be determined by evaluation of AEs, SAEs, hematology, serum chemistry and urinalysis","http://ClinicalTrials.gov/show/NCT01045018",NA
"15770",15770,"NCT01078818","Oral and Intravenous Iron in Patients Postoperative Cardiovascular Surgery Under Extracorporeal Circulation","Completed","No Results Available","Anaemia","Drug: IV trivalent saccharose hydroxide ferrous|Drug: Oral ferrous fumarate|Drug: Oral and intravenous Placebo","Fundaci??n Canaria Rafael Clavijo para la Investigaci??n Biom?¢dica","Both","Adult|Senior","Phase IV",159,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tratamiento con hierro/2007","March 1, 2010","01/05/2007",2009-05-01,"March 2, 2010","01/05/2007","",2009-05-01,"Haemoglobin and Hematocrit values|need for hemoderived blood transfusions, postoperative stay and hospital costs","http://ClinicalTrials.gov/show/NCT01078818",NA
"15777",15777,"NCT01089218","The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines","Completed","No Results Available","Fever|Pneumonia","Drug: oral amoxicillin/clavulanate 1g (875/125mg)|Drug: control","Seoul National University Hospital","Both","Adult|Senior","Phase IV",241,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","postFB fever","March 14, 2010","01/03/2008",2010-02-01,"March 17, 2010","01/03/2010","",2009-01-01,"The incidence of fever|change of serum cytokines level","http://ClinicalTrials.gov/show/NCT01089218",NA
"15791",15791,"NCT01030718","Rollover Study of BMS-354825 in Patients With CML and Ph+ALL","Completed","Has Results","Chronic Myelogenous Leukemia|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","Drug: dasatinib","Bristol-Myers Squibb","Both","Adult|Senior","Phase I|Phase II",54,"Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA180-036","December 10, 2009","01/01/2006",2009-06-01,"November 15, 2010","01/11/2010","",2009-06-01,"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation|Participants With Chronic Phase CML (CML-CP): Percentage of Participants With Cytogenetic Response|Participants With CML-Accelerated or Blast Phase (AP/BP): Percentage of Participants With Cytogenetic Response|Participants With Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL): Percentage of Participants With Cytogenetic Response|Participants With CML-CP: Time to Complete Cytogenetic Response (CCyR)|Participants With CML-AP/BP and Ph+ ALL: Time to Complete Cytogenetic Response (CCyR)|Participants With CML-CP: Duration of Complete Cytogenetic Response (CCyR)|Participants With CML-AP/BP and Ph+ALL: Duration of Complete Cytogenetic Response (CCyR)|Participants With CML-CP: Time to Major Cytogenetic Response (MCyR)|Participants With CML-AP/BP and Ph+ALL: Time to Major Cytogenetic Response (MCyR)|Participants With CML-CP: Duration of Major Cytogenetic Response (MCyR)|Participants With CML-AP/BP and Ph+ ALL: Duration of Major Cytogenetic Response (MCyR)|Participants With CML-CP: Percentage of Participants With Complete Hematologic Response (CHR)|Participants With CML-AP/BP: Percentage of Participants With Hematologic Response|Participants With Ph+ ALL: Percentage of Participants With Hematologic Response|Time to Complete Hematologic Response (CHR) in Chronic Phase CML, Accelerated or Blast Phase CML, and Ph+ALL|Duration of Complete Hematologic Response (CHR) in Chronic Phase CML, Accelerated or Blast Phase CML, and Ph+ALL|Time to Major Hematologic Response (MaHR) in Accelerated or Blast Phase CML, and Ph+ALL|Duration of Major Hematologic Response (MaHR) in Accelerated or Blast Phase CML, and Ph+ALL|Time to Overall Hematologic Response (OHR) in Accelerated or Blast Phase CML, and Ph+ALL|Duration of Overall Hematologic Response (OHR) in Accelerated or Blast Phase CML, and Ph+ALL|Participants With Detectable Mutations of RNA (mRNA) of BCR-ABL at Baseline and at Best Achievement|Status of Point Mutations of BCR-ABL at Baseline (BL) and End of Study (EOS)|Collection of Blood Samples for Pharmacokinetic Analysis of Dasatinib Twice Daily (BID) That Will Contribute to Population Pharmacokinetic Modeling","http://ClinicalTrials.gov/show/NCT01030718",NA
"15851",15851,"NCT01224418","A Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate","Completed","No Results Available","Rheumatoid Arthritis","Drug: Tacrolimus","Astellas Pharma Inc|Astellas Pharma Korea, Inc.","Both","Adult|Senior","Phase IV",50,"Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PRGRA-08-01-KOR","October 14, 2010","01/05/2008",2009-08-01,"October 19, 2010","01/10/2010","",2009-08-01,"ACR20 response rate compared to baseline|ACR50 response rate compared to baseline|ACR70 response rate compared to baseline|Changes from baseline in 100mm pain VAS (Visual Analogue Scale)|Safety assessed by the incidence of adverse event and abnormalities in clinical laboratory test","http://ClinicalTrials.gov/show/NCT01224418",NA
"15980",15980,"NCT00113919","UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex?ó) in Multiple Myeloma Patients","Completed","No Results Available","Multiple Myeloma","Drug: Busulfex?ó","University of Arkansas","Both","Adult|Senior","Phase I|Phase II",14,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-25","June 10, 2005","01/06/2004",2009-10-01,"June 29, 2010","01/06/2010","",2009-10-01,"To determine the maximal dose of Busulfex?ó that can be given in a two, three, or four day periods with acceptable toxicity|To perform pharmacokinetic (PK) studies to evaluate inter-individual variability and relationship to toxicities.","http://ClinicalTrials.gov/show/NCT00113919",NA
"15995",15995,"NCT00130819","Comparison of HIV Clinic-Based Treatment With Buprenorphine Versus Referred Care in Heroin-Dependent Participants","Completed","No Results Available","Opiate Dependence|HIV Seropositivity|HIV Infections","Behavioral: Clinic-based substance abuse treatment with buprenorphine|Behavioral: Case management and referred substance abuse treatment","Johns Hopkins University|The New York Academy of Medicine","Both","Adult|Senior","Phase II",120,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H97HA03794|HRSA-04-078","August 15, 2005","01/11/2005",2009-04-01,"April 28, 2009","01/04/2009","",2009-04-01,"Retention to substance abuse treatment|Visit attendance with primary medical provider|Urine drug screen positivity for opioids and other drugs|Use of and adherence to highly active antiretroviral therapy (HAART)|HIV RNA changes|CD4 cell count changes|Self-reported HIV transmission risk behaviors|Costs and resource utilization","http://ClinicalTrials.gov/show/NCT00130819",NA
"16007",16007,"NCT00152919","Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy","Completed","No Results Available","Prostatic Neoplasms","Drug: Meloxicam","University Health Network, Toronto|Princess Margaret Hospital, Canada","Male","Adult|Senior","Phase III",100,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 03-0840-C","September 8, 2005","01/02/2004",2009-05-01,"August 12, 2010","01/08/2010","",2009-05-01,"To compare 2 schedules of MeloxicamTM given in the peri-operative period to reduce prostate swelling after permanent seed implantation for prostate cancer|To determine the influence of different timing of MeloxicamTM administration on urinary toxicity and biochemical response after permanent seed implantation for prostate cancer","http://ClinicalTrials.gov/show/NCT00152919",NA
"16095",16095,"NCT00276419","Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin","Completed","No Results Available","Breast Pain|Non-cyclical Mastalgia|Surgical Scar-Related Breast Pain","Drug: Compounded topical formulation of diclofenac|Drug: Placebo","Mayo Clinic","Female","Adult|Senior","Phase II|Phase III",27,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","92-05","January 11, 2006","01/06/2005",2009-05-01,"December 4, 2009","01/12/2009","",2009-05-01,"Frequency of breast pain|Severity of breast pain|Side effects|Adherence|Level of anxiety generated by breast symptoms","http://ClinicalTrials.gov/show/NCT00276419",NA
"16118",16118,"NCT00312819","Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: chemotherapy +/- disulfiram","Hadassah Medical Organization|Augusta Hospital, Berlin","Female","Adult|Senior","Phase II|Phase III",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DVC1.03-HMO-CTIL","April 10, 2006","01/03/2006",2009-12-01,"August 30, 2010","01/02/2009","",2009-12-01,"tumor response disease free survival survival|Clinical response|treatment tolerance","http://ClinicalTrials.gov/show/NCT00312819",NA
"16145",16145,"NCT00359619","Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine","Completed","No Results Available","Prophylaxis for HPV Infections and Cervical Neoplasia","Biological: CervarixTM|Biological: HPV investigational vaccine GSK568893A, different formulations","GlaxoSmithKline","Female","Adult","Phase II",166,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","108052 (FU month 18)|107919 (FU month 24)|107921 (FU month 36)|107918 (FU month 48)","July 18, 2006","01/09/2006",2009-08-01,"October 15, 2009","01/10/2009","",2009-08-01,"HPV-16 and -18 seroconversion rates and GMTs|Seroconversion rates and GMTs to other defined HPV serotypes|Occurrence of SAEs|Occurrence of AEs related to NOCDs and other medically significant conditions|Occurrence of pregnancy and pregnancy outcomes","http://ClinicalTrials.gov/show/NCT00359619",NA
"16194",16194,"NCT00423319","Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery","Completed","No Results Available","Deep Vein Thrombosis|Pulmonary Embolism","Drug: Enoxaparin + Placebo|Drug: Apixaban + Placebo","Bristol-Myers Squibb","Both","Adult|Senior","Phase III",5406,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","CV185-035","January 17, 2007","01/03/2007",2009-09-01,"September 17, 2009","01/09/2009","",2009-09-01,"A combination of asymptomatic and symptomatic DVT, non-fatal PE and all-cause death|Combined endpoints: Proximal DVT, non-fatal PE, and VTE-related death|Major & non-major bleeding events","http://ClinicalTrials.gov/show/NCT00423319",NA
"16199",16199,"NCT00437619","A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.","Completed","No Results Available","Psoriasis","Drug: Calcipotriol hydrate [Daivonex]","Hoffmann-La Roche","Both","Adult|Senior","Phase IV",200,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML19876","February 19, 2007","",2009-08-01,"January 15, 2010","01/01/2010","",2009-08-01,"PASI reduction|AEs.","http://ClinicalTrials.gov/show/NCT00437619",NA
"16200",16200,"NCT00438919","A Multi-center Post-Market Surveillance Registry","Completed","No Results Available","Coronary Artery Disease","Device: drug-eluting stent","Cordis Corporation","Both","Child|Adult|Senior","Phase IV",15000,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EC06-01","February 16, 2007","01/05/2006",2009-12-01,"December 2, 2009","01/12/2009","E-SELECT",2009-12-01,"acute, sub-acute and late stent thrombosis; Major Adverse Cardiac Events (MACE)","http://ClinicalTrials.gov/show/NCT00438919",NA
"16213",16213,"NCT00457119","Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients Not Treated Previously With Systemic Therapy","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: RAD001","Novartis Pharmaceuticals","Both","Adult|Senior","Phase I|Phase II",52,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD001C2114","April 4, 2007","01/02/2007",NA,"February 4, 2010","01/02/2010","",2009-11-01,"Establish the feasible doses/regimens of RAD001 in combination with chemotherapy. Primary endpoint is the End-of-cycle DLT rate|Relative dose intensity (RDI) of Carboplatin + Paclitaxel (step 1)|Relative dose intensity (RDI) of Carboplatin + Paclitaxel + bevacizumab (step 2)|PK parameters derived from PK profiles of treatment drugs alone and in combination|Best overall response - measured by CT/MRI scan every 6-8 week","http://ClinicalTrials.gov/show/NCT00457119",NA
"16215",16215,"NCT00459719","A Study to Compare the Efficacy and Safety of FK506MR vs Prograf?ó in Patients Undergoing Liver Transplantation","Completed","No Results Available","Liver Transplantation","Drug: Tacrolimus modified-release|Drug: Prograf","Astellas Pharma Inc","Both","Adult|Senior","Phase III",42,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","MR4LTxCN01","April 10, 2007","01/03/2007",2009-03-01,"March 10, 2009","01/03/2009","",2009-03-01,"Event rate of patients with acute rejections|Incidence of and time to acute rejections|Overall frequency of acute rejections|Rate of patient and graft survival following transplantation.","http://ClinicalTrials.gov/show/NCT00459719",NA
"16219",16219,"NCT00464919","Sorafenib Plus Tegafur/Uracil (UFUR?ó) for Hepatocellular Carcinoma (HCC)","Completed","No Results Available","Hepatocellular Carcinoma","Drug: Sorafenib|Drug: tegafur/uracil (UFUR?ó)","National Taiwan University Hospital","Both","Adult|Senior","Phase II",50,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","950914","April 23, 2007","01/04/2007",2009-03-01,"July 6, 2009","01/06/2009","",2009-03-01,"To determine the progression- free survival of sorafenib plus tegafur/uracil (UFUR?ó) for the treatment of advanced or metastatic HCC.|The 6-month progression-free survival rate.|The objective tumor response rate.|The disease stabilization rate (complete response + partial response + stable disease for at least 2 months).|The overall survival.|The safety profile.|To evaluate the changes of circulating biomarkers indicating the angiogenesis activity and their correlation with objective tumor response.","http://ClinicalTrials.gov/show/NCT00464919",NA
"16229",16229,"NCT00481819","A Study to Compare the Efficacy and Safety of FK506MR vs Prograf?ó in Patients Undergoing Kidney Transplantation","Completed","No Results Available","Kidney Transplantation","Drug: FK506MR|Drug: Prograf|Drug: Mycophenolate Mofetil|Drug: Methylprednisolone|Drug: Prednisolone","Astellas Pharma Inc","Both","Adult|Senior","Phase III",240,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","MR4KTxCN01","May 31, 2007","01/07/2007",2009-03-01,"March 10, 2009","01/03/2009","",2009-03-01,"Event rate of patients with acute rejections|Incidence of and time to acute rejections|Overall frequency of acute rejections|Rate of patient and graft survival following transplantation","http://ClinicalTrials.gov/show/NCT00481819",NA
"16236",16236,"NCT00467519","Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age","Completed","Has Results","Tetanus|Diphtheria|Pertussis","Biological: Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|Biological: DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)","Sanofi-Aventis","Both","Child","Phase III",1045,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TD517","April 27, 2007","01/04/2007",2009-12-01,"November 4, 2010","01/11/2010","",2009-11-01,"Percentage of Participants Who Achieved Seroprotection at Baseline and 30 Days Post-vaccination for Diphtheria and Tetanus at ??­ 0.1 IU/mL Level|Percentage of Participants Who Achieved Serothreshold at Baseline and 30 Days Post Vaccination for Diphtheria and Tetanus at Level ??­ 1.0 IU/mL|Percentage of Participants Who Demostrated Booster Response at 30 Days Post-Vaccination for Pertussis|Percentage of Participants Who Demostrated Booster Response at 30 Days Post-Vaccination for Diphtheria and Tetanus|Geometric Mean Titers (GMTs) at Baseline and 30 Days Post Vaccination for Pertussis","http://ClinicalTrials.gov/show/NCT00467519",NA
"16246",16246,"NCT00513019","Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation","Completed","No Results Available","Neurotic Excoriation|Pathologic Skin Picking|Psychogenic Excoriation|Dermatillomania","Drug: Lamictal (lamotrigine)|Drug: Placebo","University of Minnesota - Clinical and Translational Science Institute","Both","Adult","Phase II",35,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","0703M03384","August 7, 2007","01/08/2007",2009-09-01,"March 23, 2010","01/03/2010","",2009-08-01,"The Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS) will be the primary outcome measure","http://ClinicalTrials.gov/show/NCT00513019",NA
"16254",16254,"NCT00518219","To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)","Completed","No Results Available","Membranous Nephropathy","Drug: TW","Nanjing University School of Medicine","Both","Adult","Phase IV",68,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NJCT-0702","August 16, 2007","01/07/2007",2009-09-01,"May 25, 2010","01/03/2009","",2009-03-01,"To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of membranous nephropathy|To investigate the safety and tolerability of TW vs ARB in treatment of MN","http://ClinicalTrials.gov/show/NCT00518219",NA
"16271",16271,"NCT00549419","Arterial Pressure Based Cardiac Output for Goal-Directed Therapy in Abdominal Surgery","Completed","No Results Available","Major Abdominal Surgery","Drug: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine|Drug: Goal-directed hemodynamic therapy|Drug: Standard of care","Klinikum Ludwigshafen","Both","Adult|Senior","Phase IV",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","2007-06","October 23, 2007","01/10/2007",2009-04-01,"December 21, 2009","01/01/2009","REPEAT",2009-01-01,"The primary endpoint of the study is postoperative renal function, as determined by measurement of the glomerular filtration rate.|Total fluid requirements (type and volume); Drug requirement (type and volume); Other organ function (myocardial function, liver function, endothelial function, degree of inflammation)","http://ClinicalTrials.gov/show/NCT00549419",NA
"16277",16277,"NCT00523419","Chemotherapy for Patients With Osteosarcoma","Completed","Has Results","Osteosarcoma","Drug: Pemetrexed","Eli Lilly and Company","Both","Adult|Senior","Phase II",32,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11814|H3E-EW-S115","August 29, 2007","01/09/2007",2010-04-01,"August 31, 2010","01/08/2010","",2009-06-01,"Percentage of Participants With Complete Response or Partial Response (Tumor Response Rate)|Duration of Response|Progression-free Survival (PFS)|Time to Treatment Failure|Overall Survival Time|Pharmacology Toxicity|Correlation of Disease Outcome With Pharmacogenomic Analysis","http://ClinicalTrials.gov/show/NCT00523419",NA
"16284",16284,"NCT00568919","Armodafinil for Fibromyalgia Fatigue","Completed","No Results Available","Fibromyalgia|Fatigue","Drug: armodafinil|Drug: Placebo","State University of New York - Upstate Medical University|Martin Morell MD Arthritis Associates","Both","Adult","Phase III",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ArmoFibro-001a|001","December 4, 2007","01/09/2007",2009-06-01,"June 29, 2009","01/06/2009","",2009-06-01,"Brief Fatigue Inventory|Fatigue Severity SCale, Fibromylagia Impact Questionairre, Sheehan Disability SCale","http://ClinicalTrials.gov/show/NCT00568919",NA
"16287",16287,"NCT00572819","Hysteroscopy After Pretreatment With Misoprostol and Estradiol Trial","Completed","No Results Available","Cervical Ripening","Drug: Misoprostol|Drug: Placebo","Ullevaal University Hospital|Helse Nord","Female","Adult|Senior","Phase III",100,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","2007-004083-52|2007-004083-52","December 12, 2007","01/01/2008",2009-05-01,"May 22, 2009","01/05/2009","",2009-05-01,"The primary outcome is the preoperative baseline cervical dilatation in the two treatment groups.|Difference between baseline cervical dilatation at recruitment and preoperative dilatation.|Women with cervical dilatation ??­ 5 mm.|Acceptability.|Number of dilatations judged as \difficult.\""|Frequency of complications.""","http://ClinicalTrials.gov/show/NCT00572819",NA
"16302",16302,"NCT00600119","A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)","Completed","No Results Available","Opioid Induced Constipation (OIC)","Drug: placebo|Drug: NKTR-118","Nektar Therapeutics","Both","Adult|Senior","Phase II",224,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","07-IN-NX003","January 11, 2008","01/12/2007",2009-04-01,"June 9, 2009","01/06/2009","",2009-03-01,"Increase in number of spontaneous bowel movements from baseline|Dose-response, safety, tolerability, pharmacokinetics, other symptoms of OBD assessed using the Patient Assessment of Constipation Symptoms (PAC-SYM), QOL, measurements, and maintenance of opioid analgesic effect","http://ClinicalTrials.gov/show/NCT00600119",NA
"16303",16303,"NCT00604019","Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock","Completed","No Results Available","Septic Shock","Drug: Dopamine|Drug: Norepinephrine","Rush University Medical Center","Both","Adult|Senior","Phase III",262,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ORA-02102801","January 3, 2008","01/03/2003",2009-08-01,"September 23, 2010","01/09/2010","",2009-08-01,"Efficacy - dead or alive at 28 days|Safety, arrythmia - yes or no for each group","http://ClinicalTrials.gov/show/NCT00604019",NA
"16306",16306,"NCT00606619","Effects of Early Oral Feeding After Resection of Gastric Cancer","Completed","No Results Available","Gastric Cancer","Other: Conventional feeding|Other: Early oral feeding","The Catholic University of Korea","Both","Adult|Senior","Phase III",58,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SCMC07OT135","January 22, 2008","01/07/2008",2009-02-01,"May 27, 2010","01/02/2009","",2009-02-01,"Days of hospital stay after operation|Day of recovery of bowel sound and flatus: Evidence of recovery of bowel sound by physician's examination and Evidence of first flatus by question to patient|Laboratory findings after operation: Albumin, complete blood count, total cholesterol, cholinesterase and C-reactive protein are measured|Symptom of Patients: Question to patients about symptoms|Cost effectiveness: Total cost duration of hospitalization|Quality of life: EORTC QLQ30, STO22|Immunologic Outcomes : IL-1, IL-2, IL-6, IL-8, TNF-a will by measured by ELISA|Postoperative morbidity rate in hospital days: Clinically definite morbidity confirmed by physicians according to offered protocol","http://ClinicalTrials.gov/show/NCT00606619",NA
"16315",16315,"NCT00619619","Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients With Major Depressive Disorder","Completed","No Results Available","Depression|Major Depressive Disorder","Drug: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)","Wyeth","Both","Child","Phase I|Phase II",64,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label","3151A6-2000","January 28, 2008","01/01/2008",2009-12-01,"June 11, 2010","01/06/2010","",2009-12-01,"1) safety and tolerability of single ascending doses of DVS SR in children and adolescents with MDD and 2) characterization of PK profile of single ascending doses of DVS SR in children and adolescents with MDD|1) characterization of pop PK in children and adolescents with MDD 2) exploratory efficacy evaluation of DVS SR in children and adolescents with MDD. CDRS-R total score will be summarized by mean change from baseline at each time point using LOCF data","http://ClinicalTrials.gov/show/NCT00619619",NA
"16319",16319,"NCT00631319","A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic OA Pain","Completed","No Results Available","Chronic Pain","Drug: OROS HYDROMORPHONE","Neuromed Pharmaceuticals","Both","Adult|Senior","Phase III",400,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NMT 1077-302","February 28, 2008","01/02/2008",2009-06-01,"August 26, 2010","01/08/2010","OA Pain",2009-04-01,"Mean change from baseline to week 12 (or last visit) of the average PI of the DB treatment based on weekly avrg. PI scores from the patient diary.","http://ClinicalTrials.gov/show/NCT00631319",NA
"16332",16332,"NCT00635219","Efficacy and Safety of Lu AA21004 in Acute Treatment of Major Depressive Disorder","Completed","No Results Available","Major Depressive Disorder","Drug: Lu AA21004|Drug: Lu AA21004|Drug: Lu AA21004|Drug: Duloxetine|Drug: Placebo","H. Lundbeck A/S","Both","Adult|Senior","Phase III",776,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","11984A|EudraCT 2007-001870-95","March 3, 2008","01/02/2008",2009-04-01,"June 28, 2010","01/06/2010","",2009-04-01,"To evaluate the efficacy of three fixed dosages of Lu AA21004 versus placebo after 8 weeks of treatment in patients with MDD|To evaluate the safety and tolerability of Lu AA21004 compared to placebo during the course of treatment|To evaluate the proportion of patients who respond to Lu AA21004 treatment at week 8 compared to placebo|To evaluate the proportion of patients who are in remission after 8 weeks of treatment with Lu AA21004 as compared to placebo|To evaluate the efficacy of Lu AA21004 compared to placebo after 1 week of treatment|To evaluate the proportion of patients who are in sustained response after 1 week of treatment with Lu AA21004 compared to placebo|To evaluate the effect of the Lu AA21004 on fatigue as assessed by the Fatigue Severity Scale (FSS)|To evaluate the efficacy and safety of duloxetine versus placebo on the same parameters as mentioned for the Lu AA21004|To evaluate the effect of Lu AA21004 on Health Related Quality of Life, disability and healthcare resource utilisation|To evaluate the population pharmacokinetics of Lu AA21004 and its metabolites Lu AA34443 and Lu AA39835|To evaluate the effect of Lu AA21004 on sexual function as assessed by Arizona Sexual Experiences Scale (ASEX)","http://ClinicalTrials.gov/show/NCT00635219",NA
"16346",16346,"NCT00667719","A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension","Completed","No Results Available","Essential Hypertension","Drug: aliskiren /amlodipine/hydrochlorothiazide","Novartis","Both","Adult|Senior","Phase III",564,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CSAH100A2301","April 24, 2008","01/06/2008",NA,"March 12, 2010","01/03/2010","",2009-10-01,"To assess the long term safety of the combination of aliskiren /amlodipine / hydrochlorothiazide in patients with essential hypertension over 28 weeks to 54 weeks of treatment.|To assess the long-term blood pressure lowering (msDBP and msSBP) efficacy of the combination of aliskiren / amlodipine / hydrochlorothiazide in patients with essential hypertension|To evaluate the proportion of patients achieving the blood pressure control target of < 140/90 mmHg at the end of the study.","http://ClinicalTrials.gov/show/NCT00667719",NA
"16377",16377,"NCT00706719","To Evaluate Fertility in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone","Completed","Has Results","Infertility in Men|Secondary Hypogonadism","Drug: Androxal (enclomiphene citrate)|Drug: topical testosterone gel","Repros Therapeutics Inc.","Male","Adult","Phase II",17,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ZA-201","June 25, 2008","01/06/2008",2009-08-01,"September 21, 2010","01/09/2010","",2009-07-01,"Change in Sperm Concentration From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Sperm Concentration From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Sperm Concentration From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Sperm Count From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Sperm Count From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Sperm Count From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Semen Volume From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Semen Volume From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Semen Volume From Baseline in Men Treated With Androxal?ó Versus Testim|Changes in Follicle Stimulating Hormone(FSH) and Leutinizing Hormone(LH) Levels From Baseline in Men Treated With Androxal?ó Versus Testim","http://ClinicalTrials.gov/show/NCT00706719",NA
"16396",16396,"NCT00754819","Targeting Inflammation in Acute Coronary Syndrome Using Colchicine","Completed","No Results Available","Acute Coronary Syndrome","Drug: Colchicine|Drug: Placebo","Hamilton Health Sciences Corporation","Both","Adult|Senior","Phase II|Phase III",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COL0001","September 16, 2008","01/04/2008",2009-09-01,"October 7, 2009","01/10/2009","COOL",2009-09-01,"To determine the effect of low dose colchicine on hs-CRP.|To determine the effect of colchicine on (a)platelet function and (b)short-term risk (30 days) of cardiovascular events","http://ClinicalTrials.gov/show/NCT00754819",NA
"16397",16397,"NCT00752219","Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections","Completed","No Results Available","Complicated Intra-Abdominal Infections","Drug: ceftazidime/NXL104 + metronidazole|Drug: meropenem","Novexel Inc","Both","Adult","Phase II",200,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NXL104/2002","September 11, 2008","01/03/2009",2009-12-01,"December 1, 2009","01/12/2009","",2009-11-01,"To estimate the efficacy of NXL104/ceftazidime with respect to the clinical response in baseline microbiologically evaluable patients with cIAI at the Test of Cure (TOC) visit|evaluate the safety and tolerability profile of NXL104/ceftazidime in the treatment of cIAI in adults","http://ClinicalTrials.gov/show/NCT00752219",NA
"16400",16400,"NCT00761319","Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health","Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: Travoprost 0.004%, BAC-Free|Drug: Latanoprost 0.005%","Alcon Research","Both","Adult|Senior","Phase III",1100,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-08-47","September 25, 2008","01/10/2008",2009-09-01,"September 30, 2009","01/09/2009","",2009-09-01,"Ocular Surface Disease Index Questionnaire|Corneal fluorescein staining","http://ClinicalTrials.gov/show/NCT00761319",NA
"16405",16405,"NCT00769119","A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis","Completed","No Results Available","Bronchiectasis","Drug: AZD9668|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","D0520C00010","October 6, 2008","01/09/2008",2009-04-01,"November 30, 2010","01/11/2010","NEPAL",2009-04-01,"Absolute and differential neutrophil count in sputum|Signs and symptoms of Bronchiectasis|Safety outcome (AE's, labs, etc)|Pharmacokinetic (AZD9668 concentrations in plasma and sputum)|Pharmacodynamic markers","http://ClinicalTrials.gov/show/NCT00769119",NA
"16412",16412,"NCT00776919","Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne","Completed","No Results Available","Acne Vulgaris","Drug: clindamycin / benzoyl peroxide gel|Drug: clindamycin gel|Drug: BPO gel|Drug: vehicle gel","Stiefel, a GSK Company|Quintiles CRO|RHO CRO","Both","Child|Adult","Phase III",1319,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","W0261-301","October 21, 2008","01/10/2008",2009-10-01,"August 6, 2010","01/08/2010","",2009-09-01,"Acne lesion counts and Investigator's Static Global Assessment (ISGA).|Local tolerability and adverse events","http://ClinicalTrials.gov/show/NCT00776919",NA
"16416",16416,"NCT00784719","A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.","Completed","No Results Available","Dry Eye Syndromes","Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: Cyclosporine|Drug: CP-690,550 Vehicle","Pfizer","Both","Adult|Senior","Phase I|Phase II",412,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A3921034|A3921034","November 3, 2008","01/11/2008",2009-10-01,"January 4, 2010","01/01/2010","",2009-10-01,"Incidence and severity of ocular adverse events|Incidence and severity of systemic adverse events|Tear break up time|Symptom questionnaire|Corneal staining|Conjunctival staining|Schirmer wetting","http://ClinicalTrials.gov/show/NCT00784719",NA
"16417",16417,"NCT00779519","Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss","Completed","No Results Available","Obesity","Drug: TTP435|Drug: Placebo","TransTech Pharma","Both","Adult","Phase II",100,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TTP435-201","October 23, 2008","01/02/2009",NA,"August 25, 2010","01/08/2010","",2009-12-01,"Safety and tolerability of TTP435 when administered for 8 weeks to obese males and females|Change from Baseline Glucose Levels|Absolute Change in Body Weight|Absolute Change in Body Mass Index|Effects on Body Weight|Effect Subject-reported Satiety|Change from Baseline Insulin Levels|Change from Baseline Free Fatty Acid Levels|Change from Baseline Leptin Levels","http://ClinicalTrials.gov/show/NCT00779519",NA
"16421",16421,"NCT00793819","A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia","Completed","No Results Available","Nocturia|Prostatic Hyperplasia","Drug: silodosin","Watson Pharmaceuticals","Male","Adult|Senior","Phase II",215,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SI08005","November 17, 2008","01/01/2009",2009-10-01,"October 26, 2009","01/10/2009","",2009-10-01,"Change in nocturia episodes|Change in quality of life questionnaire responses","http://ClinicalTrials.gov/show/NCT00793819",NA
"16450",16450,"NCT00841919","Insulin Therapy in the Hospital Comparing Two Protocols","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Glargine insulin|Drug: NPH insulin and regular insulin|Drug: lispro insulin","John H. Stroger Hospital|Eli Lilly and Company","Both","Adult|Senior","Phase IV",60,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BBJHS200901","February 9, 2009","01/12/2006",2009-06-01,"September 8, 2009","01/09/2009","",2009-03-01,"The rate of correct timing of insulin and food administration|Pre and post- prandial glucose levels|Length of hospital stay|Nursing staff satisfaction scores for evaluation of the two methods|Hypoglycemia rates.|High excursions of blood sugars (>300 mg/dl).","http://ClinicalTrials.gov/show/NCT00841919",NA
"16472",16472,"NCT00871819","Optimized Programming in Spinal Cord Stimulation (SCS) System","Completed","No Results Available","Neuropathic Pain|Pain","Device: Precision Spinal Cord Stimulation","Boston Scientific Corporation","Both","Adult|Senior","Phase IV",20,"Industry","Interventional","Control: Dose Comparison|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","A2008","March 27, 2009","01/03/2009",2009-09-01,"December 17, 2009","01/12/2009","OP",2009-08-01,"Correlation between dorsal root paresthesia at maximum-comfortable stimulation level and anode-cathode separation distance|Location of dorsal root paresthesia under multipolar stimulation vs. traditional contact combinations","http://ClinicalTrials.gov/show/NCT00871819",NA
"16633",16633,"NCT01155219","Safety, Efficacy Assessment of Geltim LP?ó 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.","Completed","No Results Available","Glaucoma","Drug: Geltim LP 1 mg/g|Drug: Xalatan","Laboratoires Thea|AXONAL|CSD Medical Research|VEEDA","Both","Adult|Senior","Phase IV",151,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LTG1030-PIV-12/07","June 30, 2010","01/07/2008",2009-12-01,"July 1, 2010","01/07/2010","T1030",2009-07-01,"Ocular tolerance|Efficacy on intraocular pressure (IOP)","http://ClinicalTrials.gov/show/NCT01155219",NA
"16692",16692,"NCT01248819","Local Anesthetic Nebulization and Instillation for Pain Control After Laparoscopic Surgery","Completed","No Results Available","Laparoscopic Cholecystectomy","Drug: Ropivacaine 60 mg|Drug: Ropivacaine 100 mg","San Gerardo Hospital|CHU de Hautepierre Strasbourg","Both","Adult|Senior","Phase III",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AR HSG 04-2008","November 24, 2010","01/04/2008",2009-05-01,"November 24, 2010","01/03/2008","",2009-05-01,"Postoperative Pain|Morphine consumption (mg)|Time of unassisted walking|Hospital morbidity|Time to hospital discharge","http://ClinicalTrials.gov/show/NCT01248819",NA
"16757",16757,"NCT00021320","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: paclitaxel|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068769|P30CA006927|FCCC-00003|NCI-G01-1982","July 11, 2001","01/05/2000",2009-04-01,"February 11, 2010","01/02/2010","",2009-04-01,"","http://ClinicalTrials.gov/show/NCT00021320",NA
"16758",16758,"NCT00016120","Vaccine Therapy Plus Biological Therapy in Treating Patients With Relapsed Prostate Cancer","Completed","No Results Available","Prostate Cancer","Biological: Globo H-GM2-Lewis-y-MUC1-32-mer-TF(c)-Tn(c)-KLH conjugate vaccine|Biological: QS21","Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI)","Male","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068596|MSKCC-00064|NCI-G01-1940","May 6, 2001","01/06/2000",NA,"December 13, 2009","01/12/2003","",2009-03-01,"","http://ClinicalTrials.gov/show/NCT00016120",NA
"16781",16781,"NCT00047320","Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor","Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Drug: thiotepa|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",100,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000257664|COG-ACNS0122","October 3, 2002","01/01/2004",NA,"December 17, 2010","01/11/2010","",2009-05-01,"Response (complete and partial response)|Toxic death|Occurrence of nonhematological grade 4 toxicity during chemotherapy|Event-free survival|Progression-free survival|Overall survival","http://ClinicalTrials.gov/show/NCT00047320",NA
"16854",16854,"NCT00163020","17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies","Completed","No Results Available","Preterm Birth","Drug: 17-alpha-hydroxyprogesterone caproate injectable|Drug: Placebo","Obstetrix Medical Group","Female","Adult","Phase II|Phase III",321,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OBX0003|IND # 59-536","September 9, 2005","01/11/2004",2009-08-01,"October 6, 2010","01/10/2010","170HP",2009-08-01,"Respiratory distress syndrome|Use of oxygen therapy at 28 days of newborn life|Neonatal sepsis|Pneumonia|Intraventricular hemorrhage grade 3 or 4|Periventricular leukomalacia|Necrotizing enterocolitis requiring surgery|Retinopathy of prematurity|Newborn asphyxia with ischemic injury of brain, heart, kidneys, or liver|Individual components of neonatal morbidity enumerated above|Twins: Delivery prior to 28 weeks (wks), 32 wks, 37 wks|Triplets: Delivery prior to 28 wks, 32 wks, 35 wks|Gestational age at delivery|Birthweight|Drop-out rates|Side effects requiring cessation of therapy|Specific side effects (such as: nausea, vomiting, injection site soreness, vaginal bleeding, vaginal discharge, decreased fetal movement, rash, pruritis)","http://ClinicalTrials.gov/show/NCT00163020",NA
"16872",16872,"NCT00129220","Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder","Completed","Has Results","Bipolar Disorder","Drug: olanzapine|Drug: haloperidol|Drug: placebo","Eli Lilly and Company","Both","Adult","Phase III",224,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","9636|F1D-JE-BMAC","August 8, 2005","01/07/2005",2009-01-01,"December 10, 2010","01/12/2010","",2009-01-01,"Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score|Change From Baseline to 6 Week Endpoint in Young Mania Rating Scale (YMRS)|Remission Rate of Bipolar Disorder (Olanzapine Versus Haloperidol)|Change From Baseline to 6 Week Endpoint in Clinical Global Impressions - Bipolar Version (CGI-BP), Overall Severity of Illness|Change From Baseline to 3 Week and 6 Week Endpoints in Clinical Global Impression - Bipolar Version (CGI-BP) Mania Subscale|Response Rate of Manic Symptoms at 3 Weeks and 6 Weeks|Remission Rate of Manic Symptoms at 3 Weeks and 6 Weeks|Percentage of Participants Who Switched to Symptomatic Depression|Change From Baseline to 3 Week and 6 Week Endpoints in the Positive Subscore of Positive and Negative Syndrome Scale (PANSS)|Percentage of Participants Who Switched to Syndromic Depression|Maximum Change From Baseline During 6-Week Period in Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Total Score","http://ClinicalTrials.gov/show/NCT00129220",NA
"16972",16972,"NCT00350220","Transfusion Strategies in Pediatric Cardiothoracic Surgery","Completed","Has Results","Congenital Heart Disease","Other: transfusion strategy|Other: Low Hb transfusion group","University of Rochester","Both","Child","Phase II",60,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12408","July 5, 2006","01/07/2006",2009-09-01,"February 11, 2010","01/01/2010","",2009-09-01,"Mean Arterial Lactate Level|Peak Arterial Lactate Level|Oxygen Utilization During the 8 Hour to 72 Hours Post-operative Period.|Length of Mechanical Ventilation|Length of Oxygen Use|Length of Vasoactive Agent Administration|Volume of Blood Transfused|Mortality Before Hospital Discharge","http://ClinicalTrials.gov/show/NCT00350220",NA
"17002",17002,"NCT00404820","Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Post Menopausal Women With Osteoporosis","Completed","No Results Available","Osteoporosis","Drug: Zoledronic acid|Drug: Alendronate","Novartis","Female","Adult|Senior","Phase III",600,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CZOL446HDE31","November 28, 2006","01/10/2006",NA,"May 7, 2009","01/05/2009","",2009-01-01,"Change in bone metabolism marker NTx as measured throughout the 12 month treatment period|Change in bone metabolism marker P1NP throughout the 12 month treatment period|Quality of Life measured on baseline and after 12 month","http://ClinicalTrials.gov/show/NCT00404820",NA
"17008",17008,"NCT00413920","Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients","Completed","No Results Available","Renal Transplantation","Drug: Enteric-coated mycophenolate sodium (EC-MPS)|Drug: EC MPS","Novartis","Both","Adult|Senior","Phase III",220,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CERL080AFR05","December 19, 2006","01/04/2007",NA,"October 30, 2009","01/10/2009","",2009-03-01,"Incidence of treatment failures defined by biopsy-proven acute rejection (BPAR), graft loss, death or loss to follow-up|BPAR, clinical acute rejection (AR) and treated AR and severity|Subclinical histological rejections|Graft and patient survival|Rate of patients requiring steroids in non-steroid treatment group|Safety assessed by adverse events (AEs), serious adverse events (SAEs), infections, premature study treatment discontinuations due to safety reasons (AE, death, graft loss, abnormal laboratory test value) and steroid side effects","http://ClinicalTrials.gov/show/NCT00413920",NA
"17012",17012,"NCT00416520","A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia","Completed","No Results Available","Chronic Kidney Disease|Hyperphosphatemia","Drug: MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE?ó)|Drug: Placebo|Drug: Another phosphate binder","Mitsubishi Tanabe Pharma Corporation","Both","Adult|Senior","Phase III",320,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MCI-196-E07","December 27, 2006","01/06/2007",2009-11-01,"December 11, 2009","01/12/2009","",2009-11-01,"The change in serum phosphorus for MCI-196 and placebo|The change in Total/LDL/HDL-cholesterol, Triglycerides, PTH, Ca, Ca x P ion product|The change in safety parameters","http://ClinicalTrials.gov/show/NCT00416520",NA
"17034",17034,"NCT00452920","Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: docetaxel|Radiation: cesium Cs 137|Radiation: radiation therapy","University of Miami Sylvester Comprehensive Cancer Center","Female","Adult|Senior","Phase I|Phase II",72,"Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","EPROST-20020358|SCCC-2002058|WIRB-20050719","March 27, 2007","01/09/2003",2009-06-01,"January 11, 2010","01/01/2010","",2009-06-01,"Recommended phase II dose (Phase I)|Progression-free survival (Phase II)|Response (Phase II)|Toxicity (Phase II)","http://ClinicalTrials.gov/show/NCT00452920",NA
"17071",17071,"NCT00515320","Study of Fluoxetine in Autism","Completed","No Results Available","Autistic Disorder","Drug: Fluoxetine|Drug: Placebo","Neuropharm|Autism Speaks","Both","Child","Phase III",158,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NPL-2008-4-AUTUS-004","August 10, 2007","01/08/2007",2009-01-01,"February 23, 2009","01/02/2009","SOFIA",2009-01-01,"The percentage change from baseline to the endpoint visit for the CYBOCS-PDD score.|The time and dose related course of therapeutic effects|The inter-relationship between these effects in the context of global clinical changes.|The indirect effects on patient caregivers of the dose regime in these subjects compared to placebo during treatment.|Safety measures will be physical examination, vital signs, EKG/ECG & clinical laboratory tests.","http://ClinicalTrials.gov/show/NCT00515320",NA
"17088",17088,"NCT00536120","The Effects of TYSABRI Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Biological: TYSABRI (natalizumab)","Biogen Idec","Both","Adult","Phase IV",60,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label","101MS404","September 25, 2007","01/01/2008",2010-01-01,"January 6, 2011","01/01/2011","",2009-10-01,"Difference proportion of tetanus responders at Day 28|Difference in proportion of KLH responders at Day 28|Change from baseline Lymphocyte Subset at Month 3|Change from baseline Lymphocyte subset at Month 6","http://ClinicalTrials.gov/show/NCT00536120",NA
"17093",17093,"NCT00542620","Comparison of Insulin Detemir and NPH Insulin in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily. The Pediatric Mixing Trial.","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: insulin detemir|Drug: insulin aspart","Novo Nordisk","Both","Child|Adult","Phase IV",25,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NN304-1813|EudraCT No: 2006-006715-77","October 10, 2007","01/09/2007",2009-03-01,"October 14, 2009","01/10/2009","MIXING",2009-03-01,"HbA1c|Continuous Glucose Monitoring System (CGMS)|Self Measured Plasma Glucose (SMPG)|Fructosamine|Plasma glucose profiles|Pharmacokinetics|Paper Diary","http://ClinicalTrials.gov/show/NCT00542620",NA
"17137",17137,"NCT00602420","Naproxen in Preventing Bone Pain Caused by Pegfilgrastim in Patients With Non-Hematologic Cancer Undergoing Chemotherapy","Completed","No Results Available","Musculoskeletal Complications|Pain|Unspecified Adult Solid Tumor, Protocol Specific","Drug: naproxen|Other: placebo","University of Rochester|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",322,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care","CDR0000584341|U10CA037420|URCC-07079","January 22, 2008","01/06/2008",2010-05-01,"November 8, 2010","01/11/2010","",2009-06-01,"Severity and duration of bone pain from baseline through day 5 (day 1 being the day pegfilgrastim is administered) as measured by a daily diary|Potential risk factors for the development of pegfilgrastim-induced bone pain|Potential clinical predictors for response or failure to respond to treatment|Presence or severity of symptoms prior to study enrollment and at study outcome as measured by the Symptom Inventory|Toxicity","http://ClinicalTrials.gov/show/NCT00602420",NA
"17141",17141,"NCT00610220","Cast Versus Splint in Children With Acceptably Angulated Wrist Fractures","Completed","No Results Available","Distal Radius Fractures","Device: Fiberglass short arm cast|Device: Prefabricated wrist splint","The Hospital for Sick Children","Both","Child","Phase IV",96,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","1000010377","January 24, 2008","01/01/2007",2009-10-01,"October 26, 2010","01/10/2010","",2009-07-01,"Modified performance Activities Scale for Kids (ASKp) score|Changes in Angulation and/or displacement|Pain|Duration of immobilization device|Grip Strength|Range of Motion|Patient Preference for their Device","http://ClinicalTrials.gov/show/NCT00610220",NA
"17164",17164,"NCT00649220","Memantine and Antipsychotics Use","Completed","No Results Available","Alzheimer's Disease","Drug: memantine","Merz Pharmaceuticals GmbH","Both","Adult|Senior","Phase IV",27,"Industry","Interventional","Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MRZ 90001-0716/1|EudraCT No.2007-004489-41","March 27, 2008","01/03/2008",2009-09-01,"September 8, 2009","01/09/2008","MemAP",2009-06-01,"The primary endpoint is the maximum dose reduction of antipsychotics from baseline to a post-baseline visit without significant behavioral change.|The secondary parameter assesses behavior from baseline to a post-baseline visit.","http://ClinicalTrials.gov/show/NCT00649220",NA
"17165",17165,"NCT00651820","Effect of Collagenase on Healing and Scarring","Completed","No Results Available","Healthy","Drug: Collagenase Santyl|Drug: Vehicle","Healthpoint","Both","Adult","Phase IV",30,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","017 101 09 001","March 20, 2008","01/04/2008",2010-03-01,"June 4, 2010","01/06/2010","",2009-11-01,"complete wound closure","http://ClinicalTrials.gov/show/NCT00651820",NA
"17180",17180,"NCT00614120","Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: liraglutide|Drug: placebo|Drug: liraglutide|Drug: liraglutide|Drug: glimepiride|Drug: metformin|Drug: placebo","Novo Nordisk","Both","Adult|Senior","Phase III",929,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NN2211-1796","January 15, 2008","01/01/2008",2009-02-01,"April 16, 2010","01/04/2010","",2009-02-01,"Change in Glycosylated Haemoglobin A1c (HbA1c)|Change in Body Weight|Change in Self-measured Fasting Plasma Glucose|7-point Self-measured Plasma Glucose Profiles|Change in Beta-cell Function|Change in Fasting Lipid Profile|Change in Fasting Lipid Profile, APO-B|Hypoglycaemic Episodes","http://ClinicalTrials.gov/show/NCT00614120",NA
"17195",17195,"NCT00696020","Combination of Orally Inhaled BI1744Cl/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: BI1744/Tiotropium bromide|Drug: Tiotropium bromide","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",360,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1237.4|EudraCT No: 2007-005087-26","June 10, 2008","01/06/2008",NA,"March 3, 2009","01/03/2009","",2009-02-01,"The primary efficacy variable will be forced expiratory volume in one second (FEV1). The primary endpoint is the trough FEV1 response [L] after four weeks of treatment.|FEV1 and FVC responses at different timepoints Weekly mean predose morning and evening PEF Weekly mean number of occations of rescue therapy used per day Patient's Global Rating scale Adverse events Laboratory and Vital signs","http://ClinicalTrials.gov/show/NCT00696020",NA
"17224",17224,"NCT00731120","Efficacy and Safety of Lu AA21004 in Treating Generalized Anxiety Disorder","Completed","No Results Available","Generalized Anxiety Disorder","Drug: Lu AA21004|Drug: Lu AA21004|Drug: Placebo","Takeda Global Research & Development Center, Inc.|H. Lundbeck A/S","Both","Adult|Senior","Phase III",457,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","LuAA21004_309|U1111-1114-2380","August 6, 2008","01/06/2008",2009-02-01,"June 17, 2010","01/06/2010","",2009-01-01,"The least squares mean change from Baseline in the Hamilton Anxiety Scale total score.|The least squares mean change from Baseline in Hamilton Anxiety Scale total score at each week assessed.|Response rates at Week 8, with response defined as a ??­50% decrease in the Hamilton Anxiety Scale total score from Baseline.|Remission rates at Week 8, with remission defined as a Hamilton Anxiety Scale total score ???7.|The least squares mean change from Baseline in Clinical Global Impression Scale-Global Improvement.|The least squares mean change from Baseline in Clinical Global Impression Scale-Severity of Illness.|The least squares mean change from Baseline in Hospital Anxiety and Depression anxiety subscale|Sheehan Disability Scale.|Medical Outcomes Study 36-Item Short-Form Health Survey.|Health care resource utilization as assessed by the Health Economic Assessment Questionnaire.","http://ClinicalTrials.gov/show/NCT00731120",NA
"17234",17234,"NCT00758420","Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Endovenous Microfoam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence","Completed","No Results Available","Varicose Veins","Drug: Varisolve (Polidocanol Endovenous Microfoam)|Drug: Agitated Saline","BTG Ltd.","Both","Adult","Phase II|Phase III",74,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","VAP.VV013","September 22, 2008","01/10/2008",2009-09-01,"November 24, 2009","01/11/2009","Pilot",2009-08-01,"The absolute change from baseline score for the VEINES-Sym questionnaire (overall score) at 8 weeks","http://ClinicalTrials.gov/show/NCT00758420",NA
"17252",17252,"NCT00781820","Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste","Completed","No Results Available","Onychomycosis","Drug: Bifonazole cream 1%|Drug: Placebo cream","Bayer","Both","Adult|Senior","Phase III",693,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","12999|EudraCT: 2008-003215-13","October 28, 2008","01/10/2008",2010-01-01,"March 3, 2010","01/03/2010","",2009-12-01,"Overall cure rate comprising clinical cure and mycological cure microscopy + culture negative|Clinical cure rate|Culture negative|Microscopy negative|Relapse rate (overall cure at visit 3 but positive clinical ormycological findings at visit 4|Mycological cure rate (microscopy + culture negative)|Culture negative|Incidence of adverse events","http://ClinicalTrials.gov/show/NCT00781820",NA
"17265",17265,"NCT00805220","Nordic Walking as Gait Training for Frail Elderly","Completed","No Results Available","Frail Elderly","Other: Nordic Walking","McGill University","Both","Adult|Senior","Phase II",30,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","NWS-001","December 8, 2008","01/12/2008",2009-08-01,"September 1, 2009","01/09/2009","",2009-06-01,"6 Minute Walk Test 5 Meter Walk Test Activities-Specific Balance Confidence (ABC) Scale|Berg Balance Scale; CHAMPS; Lower Extremity Functional Scale; Visual Analogue Scale of Pain; EuroQol 5D.","http://ClinicalTrials.gov/show/NCT00805220",NA
"17286",17286,"NCT00824720","Safety and Efficacy of a Glaucoma Drug Delivery System","Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: bimatoprost|Drug: bimatoprost|Device: punctal plug","Vistakon Pharmaceuticals","Both","Adult|Senior","Phase II",55,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CR-1630","January 9, 2009","01/12/2008",2009-04-01,"April 15, 2010","01/04/2010","",2009-04-01,"Visual Acuity - Right Eye|Visual Acuity - Left Eye|Intraocular Pressure (IOP)","http://ClinicalTrials.gov/show/NCT00824720",NA
"17295",17295,"NCT00868920","Patient-Controlled Sedation Versus Anesthesiologist-Administered Sedation","Completed","No Results Available","Colonoscopy","Other: patient control of pump|Other: anesthesiologist controlled sedation","University of Pennsylvania","Both","Adult|Senior","Phase IV",50,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","806514","March 24, 2009","01/01/2008",2009-03-01,"March 24, 2009","01/03/2009","",2009-01-01,"The primary outcome measure is the depth of sedation,|The secondary outcome measure is rate of respiratory depression","http://ClinicalTrials.gov/show/NCT00868920",NA
"17304",17304,"NCT00874120","Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(COMPLETED)","Completed","Has Results","Blood Pressure|Human Experimentation","Drug: Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|Drug: Placebo","Schering-Plough","Both","Adult|Senior","Phase III",116,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)","CL2007-07","April 1, 2009","01/12/2008",2009-02-01,"August 25, 2010","01/08/2010","",2009-02-01,"Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax).","http://ClinicalTrials.gov/show/NCT00874120",NA
"17309",17309,"NCT00887120","Dose Reduction of Lopinavir in Children","Completed","No Results Available","HIV Infections","Drug: Lopinavir/ritonavir standard dose According to WHO simplified dosing table|Drug: Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)","The HIV Netherlands Australia Thailand Research Collaboration|Commission on Higher Education, Ministry of Education","Both","Child|Adult","Phase II",24,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HIV-NAT045","April 21, 2009","01/04/2007",2009-02-01,"April 22, 2009","01/04/2009","",2009-01-01,"pharmacokinetics of standard vs low dose LPV/r|efficacy and safety of standard and low dose LPV/r","http://ClinicalTrials.gov/show/NCT00887120",NA
"17323",17323,"NCT00917020","The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Nasal CO2|Drug: Inactive Placebo Gas","Capnia, Inc.","Both","Adult","Phase II",32,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C216","June 8, 2009","01/07/2009",2009-11-01,"December 1, 2009","01/12/2009","",2009-10-01,"To assess the efficacy of as-needed treatment with nasal carbon dioxide (CO2) in patients with seasonal allergic rhinitis (SAR).","http://ClinicalTrials.gov/show/NCT00917020",NA
"17340",17340,"NCT00943020","Effects of Glutamine on Gastric Emptying","Completed","No Results Available","Starvation","Dietary Supplement: Nutricia PreOp nutritional supplement|Dietary Supplement: Lipid|Dietary Supplement: Glutamine","University of Nottingham","Male","Adult","Phase IV",15,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Crossover Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Basic Science","9026","July 17, 2009","01/07/2009",2009-11-01,"November 15, 2009","01/11/2009","",2009-11-01,"Gastric emptying time following supplementation of a standardised carbohydrate drink with glutamine.","http://ClinicalTrials.gov/show/NCT00943020",NA
"17537",17537,"NCT01261520","Chinese Women and Mammography Screening","Completed","No Results Available","Study Chinese Women Who Have Not Adhered to American Cancer Society Mammography Screening Guideline","Behavioral: Culturally-tailored video","Georgetown University|American Cancer Society|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation","Female","Adult|Senior","Phase III",671,"Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","GU 2005-167|MRSGT-05-104-01-CPPB|R03CA117552","December 15, 2010","01/07/2005",NA,"December 16, 2010","01/02/2010","",2009-08-01,"Receipt of mammography screening","http://ClinicalTrials.gov/show/NCT01261520",NA
"17566",17566,"NCT01171820","SPIRIT V: A Clinical Evaluation of the XIENCE V?ó Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)","Completed","Has Results","Coronary Disease|Coronary Artery Disease|Coronary Restenosis","Device: TAXUS?ó Libert?¢?ºÑ|Device: XIENCE V?ó EECSS","Abbott Vascular","Both","Adult|Senior","Phase IV",324,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","05-369 Diabetic Sub-study","April 1, 2010","01/11/2006",2010-07-01,"October 1, 2010","01/10/2010","",2009-07-01,"In-stent Late Loss(LL)|Clinical Device Success|Clinical Procedure Success|In-segment Late Loss|Proximal Late Loss|Distal Late Loss|In-stent Angiographic Binary Restenosis Rate|In-segment Angiographic Binary Restenosis Rate|In-stent Percent Diameter Stenosis|In-segment Percent Diameter Stenosis|Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)|Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)|Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)|Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.|Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.|Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.|Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)|Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)|Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)|Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)|Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)|Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)|Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)|Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)|Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)","http://ClinicalTrials.gov/show/NCT01171820",NA
"17660",17660,"NCT00071721","Valproate in Dementia (VALID)","Completed","Has Results","Alzheimer Disease","Drug: Valproate|Drug: Placebo","Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)","Both","Adult|Senior","Phase III",313,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0043|1RC2AG036535|IND 67,222|ADCS Protocol ADC-022-VN","October 29, 2003","01/10/2003",2009-12-01,"September 24, 2010","01/09/2010","",2009-02-01,"Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change Rated by the Study Clinician|Cognitive Performance Assessed by the Alzheimer's Disease Assessment Scale-cognitive Subtest (ADAS-cog)|Functional Performance Assessed by the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory|Global Severity of Dementia Using the CDR Sum of Boxes|Agitation Measured by the Cohen-Mansfield Agitation Inventory (CMAI), Community Version|Participant's Clinical Condition or Endpoint Assessed With the ADCS-Clinical Global Impression of Change (ADCS-CGIC)","http://ClinicalTrials.gov/show/NCT00071721",NA
"17700",17700,"NCT00187421","Using Intraoperative Coronary Bypass Graft Imaging to Improve Graft Patency","Completed","No Results Available","Coronary Disease","Procedure: Indocyanine green intraoperative angiogram and transit-time flowmetry","Sunnybrook Health Sciences Centre|Heart and Stroke Foundation of Ontario","Both","Child|Adult|Senior","Phase III",156,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","HSF NA 5530","September 14, 2005","01/07/2005",2009-08-01,"January 11, 2010","01/01/2010","GRIIP",2009-08-01,"Graft occlusion determined by conventional angiography or CT angiography|50-99% graft stenosis on postoperative graft angiography|Mortality, myocardial infarction, low output syndrome|Major cardiac adverse events","http://ClinicalTrials.gov/show/NCT00187421",NA
"17763",17763,"NCT00282321","High-protein and High-carbohydrate Diets' Effect on Urinary Concentrating Ability","Completed","No Results Available","Healthy","Behavioral: High Protein diet|Behavioral: High carbohydrate diet","Holstebro Hospital","Both","Adult","Phase IV",20,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","MED.RES.HOS.2006.01.TGK","January 24, 2006","01/05/2007",2009-06-01,"February 19, 2010","01/02/2010","",2009-05-01,"u-AQP-2|FeNa+","http://ClinicalTrials.gov/show/NCT00282321",NA
"17765",17765,"NCT00281021","Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small Cell Lung","Drug: Erlotinib plus Digoxin","James Graham Brown Cancer Center|University of Louisville","Both","Adult|Senior","Phase II",26,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","629.05|BCC-LUN-05-001","January 23, 2006","01/02/2006",2009-01-01,"January 11, 2010","01/01/2010","",2009-01-01,"Computed tomography (CT) Scans of chest & abdomen will be done to evaluate therapeutic response","http://ClinicalTrials.gov/show/NCT00281021",NA
"17802",17802,"NCT00343421","Study to Compare Pediacel?ó to Infanrix?ó-IPV+Hib When Both Are Co-Administered With Prevenar?ó in Infants and Toddlers","Completed","No Results Available","Diphtheria|Tetanus|Pertussis|Poliomyelitis|Haemophilus Influenzae Type B","Biological: PEDIACEL?ó and Prevenar?ó|Biological: Infanrix?ó-IPV+Hib and Prevenar?ó","Sanofi-Aventis","Both","Child","Phase III",588,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","A5I16","June 21, 2006","01/07/2006",2009-07-01,"January 20, 2010","01/01/2010","",2009-04-01,"To provide information concerning the immunogenicity of PEDIACEL?ó and Infanrix?ó-IPV+Hib|To provide information concerning the safety after administration of PEDIACEL?ó and Infanrix?ó-IPV+Hib","http://ClinicalTrials.gov/show/NCT00343421",NA
"17806",17806,"NCT00347321","Early Percutaneous Tracheostomy for Cardiac Surgery (ETOC)","Completed","No Results Available","Respiratory Failure|Cardiovascular Surgery","Procedure: Dilatational Percutaneous tracheostomy","Assistance Publique - H??pitaux de Paris|Institut National de la Sant?¢ Et de la Recherche M?¢dicale, France","Both","Adult|Senior","Phase III",212,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P051013","June 29, 2006","01/07/2006",2009-06-01,"December 2, 2009","01/03/2007","ETOC",2009-03-01,"Number of ventilator-free days defined as the number of days between successful weaning from MV and day 60 after study enrolment.|VFDs = 0 if the patient dies before 60days.|VFDs= (60- X) : if the patient is successfully weaned from MV within 60 days, where X is the number of days spent receiving MV|VFDs = 0: if the patient requires MV for 60 days or more|The trial will be considered positive if early tracheostomy increases the number VFDs of at least 7 days (mean)|Other outcomes will be compared between the two arms:|Mortality rate (day 60, in-ICU, in-hospital)|ICU length of stay|Hospital length of stay|Duration of MV in survivors|Organ failure evolution|Infectious complications|Early laryngeal and tracheal complications|Sedation needs|Patient comfort|Outcome on day 90","http://ClinicalTrials.gov/show/NCT00347321",NA
"17809",17809,"NCT00355121","Study of Menactra?ó in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL?ó","Completed","No Results Available","Meningococcal Meningitis|Tetanus|Diphtheria|Pertussis|Poliomyelitis","Biological: Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Biological: Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Biological: Polysaccharide Diphtheria Toxoid Conjugate Vaccine","Sanofi-Aventis","Both","Child","Phase II",882,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MTA43","July 20, 2006","01/10/2006",2009-07-01,"September 2, 2010","01/09/2010","",2009-06-01,"To provide information concerning the immune response of DAPTACEL?ó.|To provide information concerning the safety after concomitant administration of DAPTACEL?ó and Menactra?ó vaccines.","http://ClinicalTrials.gov/show/NCT00355121",NA
"17825",17825,"NCT00379821","Chloroquine Alone or in Combination for Malaria in Children in Malawi","Completed","No Results Available","Plasmodium Falciparum Malaria","Drug: Artesunate|Drug: Chloroquine|Drug: Atovaquone-proguanil|Drug: Azithromycin","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Child","Phase III",640,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","06-0022","September 21, 2006","01/02/2007",2009-08-01,"December 23, 2010","01/09/2009","",2009-08-01,"The number of clinical malaria episodes.|Effect of each treatment arm on anemia: Hemoglobin level without parasitemia at close of study.|Effect of population movements on the risk of malaria infection - Time to malaria illness after baseline in children who travelled outside the city vs those that did not|Spatial patterns and the environmental determinants of malaria infection: Location of new malarial infections after initial treatment to create spatial point pattern.|Safety of repeated use of the drugs in each of the study arms: Renal and hepatic function labs and neurological examination.|Prevalence of chloroquine resistant parasites, by treatment arm: prevalence of parasites with the mutation pfcrt 76T on Day 0 of each episode of malaria, and in cases of recurrent parasitemia after therapy.|Incidence of subsequent episodes of severe malaria.|Antimalarial drug efficacy during subsequent episodes of malaria, by treatment arm: Rate of adequate clinical and parasitologic response 28 days after subsequent new episodes of malaria, and incidence of new infections and recrudescent infections.|Antimalarial drug efficacy at first administration, by treatment arm: Rate of adequate clinical and parasitologic response 28 days after initial malaria, and incidence of new infections and recrudescent infections after initial treatment.|Determine the chloroquine blood levels at which chloroquine sensitive and resistant parasites are able to cause infection: Chloroquin pharmacokinetic curve for the population and drug levels at the time of parasitemia.","http://ClinicalTrials.gov/show/NCT00379821",NA
"17848",17848,"NCT00424021","Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension","Completed","No Results Available","Pulmonary Hypertension","Drug: ambrisentan","Gilead Sciences","Both","Adult|Senior","Phase II",54,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMB-220-E","January 17, 2007","01/04/2003",2009-12-01,"June 21, 2010","01/06/2010","",2009-12-01,"Incidence and severity of adverse events associated with long-term exposure of ambrisentan in patients with PAH who have completed the Phase II AMB-220 study.|Change from baseline in exercise capacity as measured by the 6-minute walk test distance; Borg Dyspnea Index; WHO Functional Classification, Subject Global Assessment; clinical worsening of PAH; failure-free treatment status|and long-term survival.","http://ClinicalTrials.gov/show/NCT00424021",NA
"17866",17866,"NCT00437021","MVA Post-Event: Administration Timing and Boost Study","Completed","No Results Available","Variola Major (Smallpox)","Biological: Dryvax?ó|Biological: IMVAMUNE?ó|Drug: Placebo (subcutaneous)|Drug: Placebo (scarification)","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","Phase I|Phase II",206,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","06-0012|N01AI80003C|POX-MVA-009","February 16, 2007","01/04/2007",2009-04-01,"January 13, 2011","01/03/2010","",2009-04-01,"Safety: adverse events and reactogenicity to the vaccine.|Determine whether the Geometric Mean Titer (GMT) of neutralizing antibody, among subjects receiving 2 doses of IMVAMUNE?ó (Days 0 and 7, Group A) is noninferior to that among subjects receiving 2 doses of IMVAMUNE?ó (Days 0 and 28, Group B).|Using enzyme linked immunosorbent assay results, determine whether the GMT among subjects receiving a 2 dose regimen of IMVAMUNE?ó (Days 0 and 7, Group A) is noninferior to that among subjects receiving 2 doses of IMVAMUNE?ó (Days 0 and 28, Group B).","http://ClinicalTrials.gov/show/NCT00437021",NA
"17905",17905,"NCT00505921","Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma","Completed","No Results Available","Lymphoma","Drug: Campath-1H","M.D. Anderson Cancer Center|Bayer","Both","Child|Adult|Senior","Phase II",28,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-645","July 20, 2007","01/03/2003",2009-11-01,"July 26, 2010","01/07/2010","",2009-11-01,"Full disease staging","http://ClinicalTrials.gov/show/NCT00505921",NA
"17915",17915,"NCT00525421","A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus","Completed","No Results Available","Oral Lichen Planus","Drug: Curcuminoids|Drug: Placebo","University of California, San Francisco","Both","Adult|Senior","Phase II",26,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H1113-30233-01","September 4, 2007","01/09/2007",2009-02-01,"March 2, 2009","01/02/2009","",2009-02-01,"Change in symptoms of oral lichen planus|Change in clinical signs, occurrence of side-effects, change in serum C-reactive protein and serum interleukin-6 levels","http://ClinicalTrials.gov/show/NCT00525421",NA
"17936",17936,"NCT00546221","Promoting Wellbeing for Women With Depression: A Pragmatic Randomised Controlled Trial (RCT) of an Exercise Programme","Completed","No Results Available","Depression","Behavioral: Psychosocial support exercise programme|Behavioral: Prescribed exercise","University of Nottingham|Burdett Trust for Nursing|Nottinghamshire Healthcare NHS Trust|Nottingham City Primary Care Trust|Nottinghamshire County Teaching Primary Care Trust","Female","Adult|Senior","Phase II",43,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","A925R9|Funder's ID: 293/350|Ethics ref ID: 07/H0401/110","October 17, 2007","01/11/2007",2009-05-01,"May 28, 2010","01/05/2010","",2009-05-01,"The primary outcome measure is score on the BDI??ÊII (Beck Depression Inventory version 2).|Resting heart rate.|GHQ12.|The SF??Ê12vII.|The Rosenberg self??Êesteem scale.|Quality of life in depression scale.|The multidimensional scale of perceived social support.","http://ClinicalTrials.gov/show/NCT00546221",NA
"17945",17945,"NCT00561821","Efficacy and Safety Study of Org 50081 in Elderly Patients (21108AM1)(P05709)(COMPLETED)","Completed","No Results Available","Insomnia|Sleep Initiation and Maintenance Disorders|Mental Disorders|Dyssomnias|Sleep Disorders","Drug: Org 50081|Drug: Org 50081|Drug: Org 50081|Drug: Placebo","Schering-Plough","Both","Adult|Senior","Phase III",520,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21108|P05709","November 19, 2007","01/11/2007",2009-12-01,"February 3, 2010","01/02/2010","",2009-12-01,"Primary efficacy variable is Wake time After Sleep Onset (WASO), averaged over all in-treatment time points and measured by polysomnography (PSG).|To investigate PSG defined latency to persistent sleep (LPS); to investigate subjective reports of efficacy, using electronic diaries; to investigate the safety and tolerability of Org 50081 in elderly subjects;","http://ClinicalTrials.gov/show/NCT00561821",NA
"17973",17973,"NCT00616421","Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children","Completed","No Results Available","Meningococcal Infections","Biological: Novartis MenACWY Conjugate Vaccine|Biological: Novartis MenACWY Conjugate Vaccine|Biological: Licensed meningococcal ACWY vaccine","Novartis|Novartis Vaccines and Diagnostics","Both","Child","Phase III",2907,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","V59P20|11278","January 31, 2008","01/03/2008",2009-10-01,"November 30, 2010","01/11/2010","",2009-04-01,"Percentage of Participants With At Least a 4-fold Rise in Meningococcal Antibody Titer after 1 dose of MenACWY or Licensed Vaccine in 2-5-year-old children|Percentage of Participants With At Least a 4-fold Rise in Meningococcal Antibody Titer after 1 dose of MenACWY or Licensed Vaccines in 6-10-year-old children|Percentage of Subjects With At Least a 4-Fold Rise in Meningococcal Antibody Titer, hSBA Titer of >= 1:4, hSBA Titer of >=1:8 in Healthy 2-5-year-old children|Percentage of Subjects With At Least a 4-Fold Rise in Meningococcal Antibody Titer, hSBA >=1:4, hSBA >=1:8, in 2-10-year-old children","http://ClinicalTrials.gov/show/NCT00616421",NA
"18009",18009,"NCT00681421","Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Biological: URLC10, VEGFR1 and VEGFR2","Tokyo University|Human Genome Center, Institute of Medical Science, University of Tokyo","Both","Adult|Senior","Phase I|Phase II",14,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMS-OKA0201","May 19, 2008","01/05/2008",2009-04-01,"November 18, 2009","01/11/2009","",2009-04-01,"Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST)|To evaluate immunological responses","http://ClinicalTrials.gov/show/NCT00681421",NA
"18024",18024,"NCT00707421","Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes","Completed","No Results Available","Glaucoma|Trabeculectomy|Fibrosis|Intraocular Pressure","Drug: ketorolac acetate|Drug: fluorometholone|Drug: artificial lacrimal tears","Universitaire Ziekenhuizen Leuven|Funding for Research in Ophthalmology (FRO)","Both","Adult|Senior","Phase III",62,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","FRO Pre-op Med Trab","June 24, 2008","01/07/2005",2009-05-01,"May 28, 2009","01/05/2009","",2009-05-01,"Incidence of additional IOP-lowering procedures or postoperative medication; Intraocular pressure evolution","http://ClinicalTrials.gov/show/NCT00707421",NA
"18058",18058,"NCT00733421","The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery","Completed","Has Results","Postoperative Pain","Drug: etoricoxib|Drug: tramadol","Karolinska Institutet","Female","Adult","Phase IV",100,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","2008HV001|EudraCT number 2008-000791-24","August 12, 2008","01/10/2008",2009-08-01,"January 15, 2010","01/08/2009","",2009-06-01,"Number of Patients Requiring Rescue Medication|Summary of Pain Scores, Day 1-7 of Visual Analogue Scale Grading of Pain|Compliance to Base Medication|Gastro-intestinal Symptoms|Dizziness/Sleepiness|Wound Healing|Satisfaction With Pain Medication|Patient Assessed Overall Satisfaction With Surgery/Outcome|Patient Assessed Quality of Life","http://ClinicalTrials.gov/show/NCT00733421",NA
"18060",18060,"NCT00763321","Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP).","Completed","No Results Available","Chronic Low Back Pain","Drug: ABT-712|Drug: ABT-712 placebo","Abbott","Both","Adult|Senior","Phase III",287,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-277","September 26, 2008","01/08/2008",NA,"December 30, 2010","01/12/2010","",2009-04-01,"Visual Analog Scale (VAS)for pain intensity|Chronic Pain Sleep Inventory (CPSI)","http://ClinicalTrials.gov/show/NCT00763321",NA
"18071",18071,"NCT00778921","Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone","Completed","No Results Available","Hypertension","Drug: Amlodipine 10 mg|Drug: Aliskiren/Amlodipine 150/10 mg|Drug: Aliskiren/Amlodipine 300/10 mg","Novartis","Both","Adult|Senior","Phase III",849,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CSPA100A2304","October 23, 2008","01/10/2008",NA,"October 15, 2009","01/10/2009","",2009-07-01,"Vital signs at every visit|Vital signs at every visit|Adverse event at every visit|Biomarker assessment at visit 2 (single blind run in), visit 5 (randomization), and visit 9 (EOS)","http://ClinicalTrials.gov/show/NCT00778921",NA
"18073",18073,"NCT00785421","Chemotherapy With or Without Enoxaparin in Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: enoxaparin|Drug: chemotherapy with LMWH - enoxaparin|Drug: only chemotherapy","CONKO-Studiengruppe|Sanofi-Aventis|Amgen|Eli Lilly and Company","Both","Adult|Senior","Phase II|Phase III",540,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CONKO 004|CCT-NAPN-16752","November 4, 2008","01/04/2004",2009-06-01,"June 12, 2009","01/06/2009","PROSPECT",2009-01-01,"DVT/TVE event rate|TTP, OS, side effects","http://ClinicalTrials.gov/show/NCT00785421",NA
"18088",18088,"NCT00810121","Study of Non Inferiority Bi-Profenid?ó 200mg Versus Bi-Profenid?ó 300mg Among Patients Presenting of the Post-traumatic or Rheumatologic Acute Affections of the Locomotor Apparatus (BIPROPAIN)","Completed","No Results Available","Pain","Drug: ketoprofen 100 mg|Drug: ketoprofen","Sanofi-Aventis","Both","Adult","Phase III",409,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","KETOP_L_03948|2008-003375-41","December 16, 2008","01/11/2008",2009-06-01,"September 24, 2009","01/09/2009","",2009-06-01,"Resting pain intensity measured using the numeric scale (NS) at the end of the day, and total intake of concomitant analgesics over 5 days. For these two parameters, the maximum value will be assigned to patients who used step II or III analgesics","http://ClinicalTrials.gov/show/NCT00810121",NA
"18131",18131,"NCT00890721","Study of Pain Control in Hemorrhoidectomy","Completed","No Results Available","Hemorrhoid","Drug: SKY0402|Drug: Placebo","Pacira Pharmaceuticals, Inc","Both","Adult|Senior","Phase III",189,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","SKY0402C316","April 28, 2009","01/05/2009",2009-11-01,"August 31, 2010","01/08/2010","",2009-11-01,"The area under the curve (AUC) of the numeric rating scale (NRS-R) pain intensity scores through 24 hours for subjects receiving SKY0402 vs. placebo.","http://ClinicalTrials.gov/show/NCT00890721",NA
"18138",18138,"NCT00902421","Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients","Completed","No Results Available","Overactive Bladder","Drug: Selective serotonin reuptake inhibitors|Drug: Antimuscarinics","Samsung Medical Center","Female","Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-08-047","May 14, 2009","01/01/2007",2009-07-01,"August 24, 2010","01/08/2010","",2009-07-01,"Percentage change in urgency episodes/24 hrs|Micturition diary efficacy parameters|Quality of life parameters|Patient perceptions|Psychologic parameters","http://ClinicalTrials.gov/show/NCT00902421",NA
"18153",18153,"NCT00928421","An Open-label, Single-dose Pilot Study to Evaluate Varisolve?ó (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins","Completed","No Results Available","Varicose Veins","Drug: Polidocanol Endovenous Microfoam 0.125%","BTG Ltd.","Both","Adult|Senior","Phase II",16,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VAP.VV014","June 24, 2009","01/06/2009",2010-01-01,"September 8, 2010","01/09/2010","",2009-12-01,"Physician determined evaluation of PEM and EMA characteristics|Elimination of reflux through the SFJ.|Complete occlusion of the GSV","http://ClinicalTrials.gov/show/NCT00928421",NA
"18202",18202,"NCT00997321","Propofol Versus Ketamine for Moderate Procedural Sedation in the Emergency Department (ED)","Completed","No Results Available","Sedation","Drug: propofol|Drug: Ketamine","Minneapolis Medical Research Foundation","Both","Adult|Senior","Phase IV",100,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MMRF062661","October 12, 2009","01/07/2007",2009-10-01,"October 16, 2009","01/10/2009","",2009-10-01,"respiratory depression (sub-clinical and clinical signs)|time to return of baseline mental status|patient reported pain and recall of the procedure|depth of sedation","http://ClinicalTrials.gov/show/NCT00997321",NA
"18205",18205,"NCT00999921","Effects of Tamoxifen in Women With Benign Breast Disease Not Having Any Risks of Developing Breast Cancer","Completed","No Results Available","Benign Breast Disease|Fibrocystic Disease of Breast|Fibroadenoma|Mastalgia","Drug: Tamoxifen|Drug: Evening Primrose Oil","Medical College and Hospital Kolkata","Female","Child|Adult|Senior","Phase IV",256,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","MSVP-107/08","October 21, 2009","01/01/2008",2009-10-01,"November 19, 2009","01/11/2009","",2009-08-01,"Reduction of Lump Size.|Reduction in Mastalgia (Cardiff Breast Pain Score).|Response of Cyclical Mastalgia.","http://ClinicalTrials.gov/show/NCT00999921",NA
"18215",18215,"NCT01018121","Behavioral Rx & Nutrition in Pediatric Chronic Disease","Completed","No Results Available","Pediatric Obesity","Behavioral: LAUNCH|Other: Pediatrician Counseling","Children's Hospital Medical Center, Cincinnati|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)","Both","Child","Phase I|Phase II",18,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","103254|K24DK059492","November 19, 2009","01/11/2007",2009-09-01,"November 20, 2009","01/11/2009","LAUNCH",2009-09-01,"BMI z score|Parent weight loss|Child caloric intake|Home food and activity environment|Child physical activity|Parent-child mealtime interactions","http://ClinicalTrials.gov/show/NCT01018121",NA
"18235",18235,"NCT01049321","The Effect of DASH Diet on the Cardiometabolic Risks and Hepatic Function Among Type 2 Diabetic Patients","Completed","No Results Available","Type 2 Diabetic Patients","Dietary Supplement: DASH diet|Dietary Supplement: a usual diabetic diet","Isfahan University of Medical Sciences|Shahid Motahari Hospital of Fooladshahr, Isfahan Steel Company, Isfahan","Both","Adult|Senior","Phase IV",36,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DASH and cardiovascular risks","January 13, 2010","01/12/2008",2009-12-01,"January 13, 2010","01/03/2008","",2009-06-01,"Cardio-metabolic risks|Hepatic function","http://ClinicalTrials.gov/show/NCT01049321",NA
"18243",18243,"NCT01061021","HIV Prevention Intervention for People Living With HIV/AIDS","Completed","No Results Available","HIV Infections","Behavioral: In The Mix|Behavioral: Information Support Group","University of Connecticut|National Institute of Mental Health (NIMH)","Both","Adult|Senior","Phase II",490,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","H06-113|R01MH071164-04","February 1, 2010","01/03/2005",2010-08-01,"November 15, 2010","01/11/2010","",2009-10-01,"Computerized Interview or Sexual Transmission Risk Behavior|Unannounced Phone Based Pill Counts for Medication Adherence|Infectiousness Beliefs","http://ClinicalTrials.gov/show/NCT01061021",NA
"18340",18340,"NCT01219621","Comparison of AAIsafeR and DDD Modes in Non-selected Patients","Completed","No Results Available","Any Patient Who Fulfills the Inclusion Criteria to be Implanted With a Dual Chamber Pacemaker Maybe Included in the Study as Per ACC/AHA Guidelines","Procedure: Symphony Dual Chamber Rate Responsive Device","Sorin Group Canada","Both","Adult|Senior","Phase III",450,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","IGXD04","October 12, 2010","01/04/2006",2009-04-01,"October 12, 2010","01/09/2006","CAN-SAVE R",2009-04-01,"Percentage of ventricular pacing|Atrial Fibrillation/Atrial Arrhythmia Evolution|Cardiac Function Evolution|Congestive Hear Failure and Atrial Fibrillation Clinical Events|Evolution of conduction Disturbances|Safety Analysis","http://ClinicalTrials.gov/show/NCT01219621",NA
"18449",18449,"NCT00063622","Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)","Completed","No Results Available","Liver Diseases","Drug: Pioglitazone|Dietary Supplement: Vitamin E|Drug: Matching placebo","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Adult|Senior","Phase III",247,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","NASH - ADULT (IND)","July 1, 2003","01/11/2004",2009-09-01,"January 12, 2010","01/01/2010","",2009-06-01,"Improvement in NASH activity defined by change in standardized scoring of liver biopsies at baseline and after 96 weeks of treatment.|Liver fibrosis","http://ClinicalTrials.gov/show/NCT00063622",NA
"18505",18505,"NCT00145522","Study to Compare the Effect of Hormone Replacement Therapy (HRT) on Breast and Cardiovascular Metabolic Markers in Postmenopausal Women","Completed","No Results Available","Menopause","Drug: 17?È-Estradiol/Dydrogesterone|Drug: Tibolone","Solvay Pharmaceuticals","Female","Adult","Phase IV",135,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","S102.4.103|2004-001829-22","September 2, 2005","01/11/2005",2009-03-01,"March 31, 2009","01/03/2009","",2009-03-01,"IGF1 values after 12 cycles of 28 days|after 12 cycles of 28 days: other breast metabolic markers [IGFBP 1 and 3, SHBG, free estradiol, fasting insulin], breast tenderness and breast density, cardiovascular metabolic markers, menopausal symptoms and bleeding pattern","http://ClinicalTrials.gov/show/NCT00145522",NA
"18521",18521,"NCT00167622","Early Mechanical Ventilation for Guillain Barr?¢ Syndrome","Completed","No Results Available","Guillain Barr?¢ Syndrome|Acute Respiratory Failure","Procedure: mechanical ventilation|Procedure: physiotherapy and oxygen if needed","University of Versailles|Assistance Publique - H??pitaux de Paris","Both","Adult|Senior","Phase II",50,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","P050103|PS050103","September 10, 2005","01/04/2005",2009-02-01,"February 17, 2009","01/02/2009","",2009-01-01,"Rate of hospital acquired pneumonia from randomization to study day 90|Time on a ventilator|Intensive care unit lenght of stay|Hospital length of stay|Tolerance","http://ClinicalTrials.gov/show/NCT00167622",NA
"18557",18557,"NCT00226122","The Effect of Indomethacin in Monosymptomatic Enuresis Nocturnal","Completed","No Results Available","Enuresis","Drug: Indomethacin","University of Aarhus","Both","Child","Phase IV",56,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","INDO181202|01","September 23, 2005","01/01/2003",2009-12-01,"June 24, 2010","01/06/2010","",2009-12-01,"Enuresis episodes|Urine production, electrolyte excretion, hormonal changes","http://ClinicalTrials.gov/show/NCT00226122",NA
"18569",18569,"NCT00248222","Early Aerobic Training Program After Ischemic Stroke","Completed","No Results Available","Stroke|Cerebrovascular Accident","Behavioral: Supervised aerobic training","Sheba Medical Center","Both","Adult|Senior","Phase II",NA,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SHEBA-05-3840-DT-CTIL","November 2, 2005","01/10/2005",2009-06-01,"October 26, 2009","01/10/2009","",2009-06-01,"6 Minute Walk Test at 6 weeks|Modified Bruce Exercise Test at 6 weeks|Activity by Ankle accelerometer at 6 weeks|Recurrent vascular events at 6 weeks|METS at 6 weeks|Stair climbing ascend and descend test at 6 weeks|Four Square Step Test at 6 weeks|Gait symmetry by SmartStep at 6 weeks|Walking Impairment Questionnaire at 6 weeks|Rivermead Mobility Index at 6 weeks|Similar outcome measures 3 months later","http://ClinicalTrials.gov/show/NCT00248222",NA
"18604",18604,"NCT00302822","Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)","Completed","No Results Available","HIV Infections|AIDS","Drug: enfuvirtide|Drug: emtricitabine/tenofovir disoproxil fumarate|Drug: efavirenz or lopinavir/r","French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche|Gilead Sciences","Both","Adult|Senior","Phase III",195,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-004722-12|ANRS 130 APOLLO","March 14, 2006","01/04/2006",2009-12-01,"September 16, 2010","01/09/2010","",2009-12-01,"Immunological success defined as a CD4 cell count above 200 cells per mm3 after 24 weeks of initial antiretroviral treatment|Virological response, clinical progression, tolerance,toxicity, quality of life under therapy, adherence and resistance mutations emerging in case of virological failure.","http://ClinicalTrials.gov/show/NCT00302822",NA
"18633",18633,"NCT00347022","A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications","Completed","No Results Available","Diagnostic Imaging","Drug: Xenetix","Guerbet","Both","Child","Phase IV",128,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","ISO-44-008","June 30, 2006","01/05/2006",2009-06-01,"June 4, 2009","01/06/2009","",2009-04-01,"","http://ClinicalTrials.gov/show/NCT00347022",NA
"18701",18701,"NCT00391222","A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder","Completed","Has Results","Bipolar Disorder","Drug: Olanzapine|Drug: Placebo|Drug: Risperidone Long Acting Injectable (LAI)","Janssen Pharmaceutica N.V., Belgium","Both","Adult","Phase III",586,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CR012145","October 20, 2006","01/11/2006",2009-04-01,"October 7, 2010","01/10/2010","",2009-04-01,"Time to Recurrence of a Mood Episode (Risperidone LAI Versus Placebo)|Time to Recurrence of an Elevated Mood (Hypomanic, Manic, or Mixed) Episode|Time to Recurrence of a Depressive Episode|Time to Early Study Discontinuation for Any Reason|Change From Double-blind Baseline to Endpoint in Young Mania Rating Scale (YMRS)|Change From Double-blind Baseline to Endpoint in Montgomery ??sberg Depression Rating Scale (MADRS)|Time to Recurrence of a Mood Episode (Exploratory/Olanzapine)","http://ClinicalTrials.gov/show/NCT00391222",NA
"18713",18713,"NCT00466622","Uterine Artery Blood Flow in Pregnant Women With PCOS Treated With Metformin","Completed","No Results Available","Polycystic Ovary Syndrome","Drug: Metformin|Drug: Placebo","Norwegian University of Science and Technology|St. Olavs Hospital","Female","Adult","Phase III",48,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2004-000792-33","April 26, 2007","01/04/2007",2010-02-01,"March 16, 2010","01/03/2010","FlowMet",2009-08-01,"Pulsatility index of the uterine artery before and 3h after first medicine intake|Pulsatility index of the uterine artery 10-14 days after inclusion, and ongoing medication|Blood flow in the umbilical artery and fetal cerebral artery at gestational week 24","http://ClinicalTrials.gov/show/NCT00466622",NA
"18715",18715,"NCT00467922","An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy","Completed","No Results Available","Crohn's Disease|Ulcerative Colitis|Rectal Cancer|Colon Cancer|Colon Polyps|Rectal Polyps|Diverticulitis","Drug: Hextend|Drug: Lactated Ringers","Spectrum Health Hospitals|Deltex Medical, Inc.","Both","Adult|Senior","Phase III",69,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2007-109|2007-109","April 27, 2007","01/05/2007",2009-10-01,"October 20, 2009","01/10/2009","",2009-09-01,"Determine the relative effects of a standard, colloid or crystalloid based strategy for hand-assisted laparoscopic colectomy surgery on decreasing length of stay|1. Determine the effects of the three fluid management strategies on post-operative fluid requirements in colorectal surgery. on the incidence and severity of post-operative complications. on return of gastrointestinal function.","http://ClinicalTrials.gov/show/NCT00467922",NA
"18732",18732,"NCT00490022","DHT-3-Effect of Dihydrotestosterone (DHT) on Prostate Tissue","Completed","No Results Available","Healthy","Drug: Dihydrotestosterone (DHT) gel (0.7%)|Drug: Placebo gel","University of Washington|National Institute on Aging (NIA)|ASCEND Therapeutics","Male","Adult","Phase I|Phase II",43,"Other|NIH|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","31866-A|AGO27238-01 A1","June 20, 2007","01/06/2007",2009-01-01,"July 9, 2009","01/07/2009","DHT-3",2009-01-01,"Prostate tissue hormone levels at 28 days of treatment|Prostate epithelial cell gene and protein expression","http://ClinicalTrials.gov/show/NCT00490022",NA
"18743",18743,"NCT00506922","Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT","Completed","No Results Available","Leukemia|Lymphoma","Drug: Pentostatin|Drug: Tacrolimus|Drug: Methotrexate","M.D. Anderson Cancer Center|SuperGen","Both","Child|Adult|Senior","Phase I|Phase II",150,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID00-132","July 20, 2007","01/09/2000",2009-11-01,"April 26, 2010","01/04/2010","",2009-11-01,"Number of Patients without GVHD at 100 days","http://ClinicalTrials.gov/show/NCT00506922",NA
"18755",18755,"NCT00531622","An Eight-Week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder","Completed","No Results Available","Major Depressive Disorder","Drug: saredutant (SR48968)|Drug: escitalopram|Drug: placebo","Sanofi-Aventis","Both","Adult","Phase III",615,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC10290|EudraCT 2007-003159-36","September 18, 2007","01/09/2007",2009-01-01,"February 13, 2009","01/02/2009","",2009-01-01,"Change from baseline in Hamilton Depression Rating Scale total score|Change from baseline in the Changes in Sexual Functioning Questionnaire total score|Change from baseline in the Clinical Global Impression severity of illness score","http://ClinicalTrials.gov/show/NCT00531622",NA
"18805",18805,"NCT00566722","Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy","Completed","Has Results","Psoriasis","Biological: adalimumab","Abbott","Both","Adult|Senior","Phase III",152,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M10-238","December 1, 2007","01/01/2008",2009-04-01,"June 17, 2010","01/06/2010","",2009-04-01,"Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16|Number of Participants Achieving a PGA of Clear (0) at Week 16|Number of Participants Achieving at Least 1 Grade of Improvement in PGA at Week 16 Compared to Screening|Number of Participants Achieving 0 or 1 on Patient's Global Assessment at Weeks 2, 4, and 8|Dermatology Life Quality Index (DLQI) Total Score|Number of Participants Achieving DLQI Total Score of 0 at Week 4 and Week 16|Psoriasis-related Pruritus Assessment|Visual Analog Scale (VAS) for Pain Involving Psoriatic Plaques and/or Psoriatic Arthritis|Percent Work Time Missed Due to Psoriasis|Percent Overall Work Impairment Due to Psoriasis|Percent Impairment While Working Due to Psoriasis|Percent Activity Impairment Due to Psoriasis|Sleep Problems Index II","http://ClinicalTrials.gov/show/NCT00566722",NA
"18806",18806,"NCT00620022","The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Indacaterol 300 ??g delivered via SDDPI|Drug: Placebo to indacaterol delivered via SDDPI","Novartis","Both","Adult|Senior","Phase III",90,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CQAB149B2311","February 8, 2008","01/04/2008",NA,"December 16, 2009","01/12/2009","",2009-05-01,"Exercise endurance time after 3 weeks of treatment.|Trough inspiratory capacity after 3 weeks of treatment","http://ClinicalTrials.gov/show/NCT00620022",NA
"18811",18811,"NCT00621322","Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults","Completed","No Results Available","Tuberculosis (TB) Infection","Biological: Control vaccine with physiological saline|Biological: GSK Biologicals' Candidate Tuberculosis Vaccines (692342) - different formulations|Biological: Control vaccine with the adjuvant system.","GlaxoSmithKline","Both","Adult","Phase II",181,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","110345","February 12, 2008","01/04/2008",2009-04-01,"September 3, 2009","01/09/2009","",2009-04-01,"Haematological and biochemical levels in each group.|Occurrence, intensity and relationship to vaccination of any solicited local and general symptoms in each group.|Occurrence, intensity and relationship to vaccination of any unsolicited symptoms in each group.|Occurrence and relationship to vaccination of any serious adverse events in each group.|Analysis of cytokines expression by M72-specific CD4+/CD8+ T cells by means of in vitro flow cytometry|Antibody titres to M72 as measured by ELISA","http://ClinicalTrials.gov/show/NCT00621322",NA
"18812",18812,"NCT00629122","Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation","Completed","No Results Available","Kidney Failure, Chronic","Drug: Tacrolimus/Clotrimazole Troche|Drug: Tacrolimus/Nystatin Suspension","Weill Medical College of Cornell University","Both","Adult|Senior","Phase IV",20,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Health Services Research","710009492","February 12, 2008","01/02/2008",2009-12-01,"November 4, 2010","01/11/2010","",2009-12-01,"Pharmacokinetic evaluation (absorption, distribution, elimination, area under the curve) between sublingual and oral administration routes.|Impact of drug interaction between tacrolimus and clotrimazole troche vs. nystatin suspension. Evaluate genotype polymorphisms that influence CYP3A4, CYP3A5, and p-glycoprotein expression to determine impact on sublingual and oral tacrolimus delivery.","http://ClinicalTrials.gov/show/NCT00629122",NA
"18818",18818,"NCT00633022","A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging","Completed","No Results Available","Atherosclerosis","Drug: GW856553 7.5 mg once a day|Drug: placebo|Drug: GW856553 7.5 mg twice a day","GlaxoSmithKline","Both","Adult|Senior","Phase II",102,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","PM1111138","February 13, 2008","01/06/2008",2009-12-01,"December 23, 2009","01/12/2009","",2009-12-01,"con't -following 12 weeks of treatment with GW856553 (7.5mg once daily or 7.5mg twice daily), in the setting of chronic statin therapy, as compared to placebo|Change in mean standard uptake values of FDG in aortic and carotid arteries, as assessed by PET/CT (TBR),|Baseline corrected blood concentration of biomarkers.|Safety and tolerability parameters, including physical examination, blood pressure, heart rate, 12-lead electrocardiogram (ECGs) recordings, clinical laboratory tests, and adverse event reporting|Change in mean standard uptake values of FDG in aortic and carotid arteries, as assessed by PET/CT (TBR) .|con't - following 12 weeks of treatment with GW856553 7.5mg once daily, versus a 12 week treatment with GW856553 7.5mg twice daily, in the setting of chronic statin therapy","http://ClinicalTrials.gov/show/NCT00633022",NA
"18820",18820,"NCT00644722","Out-of-Hospital Intubation With Metal Single Use Laryngoscope Blades","Completed","No Results Available","Cardiac Arrest|Coma|Major Trauma|Respiratory Distress|Shock","Device: MacIntosh Green Lite (metal single use laryngoscope blades)|Device: MacIntosh Green Spec II (metal reusable laryngoscope blades)","Henri Mondor University Hospital|SFMU","Both","Adult|Senior","Phase IV",800,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","N?? 2007-A00350-53","March 24, 2008","01/04/2008",2009-01-01,"January 27, 2009","01/01/2009","LAMETA",2009-01-01,"Intubation success rate during at the first laryngoscopy|glottis exposure assessed by Cormack and Lehane classification|difficult intubation rate assessed by the Intubation Difficult Score (IDS)|the need for alternative airway techniques and the immediate post intubation complications rate","http://ClinicalTrials.gov/show/NCT00644722",NA
"18821",18821,"NCT00635622","Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis","Completed","No Results Available","Bacterial Vaginosis","Drug: LACTIN-V|Drug: Placebo control substance","Osel, Inc.|University of California, San Francisco","Female","Adult","Phase II",40,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","LV-006","March 10, 2008","01/04/2008",2009-01-01,"July 9, 2009","01/03/2009","",2009-01-01,"To evaluate the vaginal colonization efficiency of L. crispatus CTV-05 after vaginal administration of LACTIN-V at 2 x 10^9 cfu/dose (600 mg) daily for 5 days followed by weekly applications over 2 additional weeks|To evaluate the safety of L. crispatus, LACTIN-V in otherwise healthy pre-menopausal women with BV, immediately after standardized antibiotic treatment with 0.75% topical metronidazole|To evaluate the tolerability and acceptability of LACTIN-V as a powder in a pre-filled applicator|To evaluate and compare vaginal flora by Gram stain before and after receipt of LACTIN-V or placebo.|To identify and compare bacteria colonizing the vagina at screening in women with bacterial vaginosis and after antibiotic and probiotic treatment.|To measure and compare the 4 week cure rate of BV after receipt of MetroGel in women who receive LACTIN-V or placebo.|To measure the rate of vaginal colonization by Candida sp. and symptomatic vaginal candidiasis after receiving LACTIN-V or placebo","http://ClinicalTrials.gov/show/NCT00635622",NA
"18828",18828,"NCT00640822","Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds","Completed","Has Results","Psoriasis Vulgaris","Drug: Calcipotriol plus hydrocortisone ointment vehicle|Drug: Tacalcitol Ointment|Drug: Calcipotriol plus hydrocortisone ointment","LEO Pharma","Both","Adult|Senior","Phase III",782,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","LEO 80190-O22","March 18, 2008","01/02/2008",2009-07-01,"January 12, 2011","01/01/2011","",2009-06-01,"Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8|Overall Disease Severity of the Face According to the Investigator's Assessment|Total Sign Score of the Face|Severity Scores for Redness, Thickness and Scaliness of the Face|Overall Disease Severity of the Intertriginous Areas According to the Investigator's Assessment|Total Sign Score of the Intertriginous Areas|Patients With Relapse During the Study and Time to Relapse|Patients With Rebound During the Study","http://ClinicalTrials.gov/show/NCT00640822",NA
"18850",18850,"NCT00696722","Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction","Completed","No Results Available","Type 2 Diabetes Mellitus Related Endothelial Dysfunction","Drug: placebo + atazanavir|Drug: atazanavir + placebo","Radboud University|Dutch Diabetes Research Foundation","Both","Adult|Senior","Phase II",16,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DM2ATV|2006.00.055","June 11, 2008","01/06/2008",2009-03-01,"January 24, 2010","01/01/2009","DM2ATV",2009-03-01,"Acetylcholine induced vasodilation|heme oxygenase expression and activity|assessment of vascular inflammation by determination of adhesion molecule levels","http://ClinicalTrials.gov/show/NCT00696722",NA
"18853",18853,"NCT00698022","A 4-Week Study of Mifepristone in the Prevention of Risperidone-Induced Weight Gain in Healthy Male Volunteers","Completed","No Results Available","Healthy","Drug: risperidone plus mifepristone|Drug: risperidone plus placebo|Drug: risperidone-matched placebo plus mifepristone","Corcept Therapeutics","Male","Adult","Phase II",100,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","C-1073-205","June 12, 2008","01/11/2008",2009-02-01,"February 2, 2009","01/02/2009","",2009-02-01,"The primary study objective is to determine the mean change in absolute weight at Day 28 compared to baseline in normal healthy male volunteers treated with risperidone plus mifepristone or risperidone alone.|The secondary study objectives are to determine the mean percent change in baseline body weight; and the proportion of subjects that gain less than 5% and less than 7% of their baseline body in the treatment groups.|The safety objective is to evaluate the safety and tolerability of mifepristone in combination with risperidone in healthy male volunteers.","http://ClinicalTrials.gov/show/NCT00698022",NA
"18854",18854,"NCT00700622","Safety and Efficacy of Technosphere?ó Insulin Inhalation Powder and Lantus?ó Compared to Humalog?ó and Lantus?ó Over 16-Weeks","Completed","No Results Available","Diabetes Type 1","Drug: Technosphere Insulin|Drug: Lantus|Drug: Humalog","Mannkind Corporation","Both","Adult|Senior","Phase III",137,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MKC-TI-117","June 16, 2008","01/05/2008",2010-03-01,"August 3, 2010","01/08/2010","",2009-11-01,"efficacy endpoint is the change from Visit 5 to Visit 14 in A1c|Proportion of subjects who achieve an A1c of less than or equal to 6.5%|Proportion of subjects who achieve an A1c of less than or equal to 7.0 %|Proportion of subjects who achieve an A1c of less than or equal to 7.0%, AND do not have any episodes of severe hypoglycemia|Area under the glucose concentration curve (AUC0-240 min), based on plasma glucose concentrations measured at -30, 0, 30, 60, 90, 105, 120, 180, and 240 min following the Meal Challenge(s)|Responder rate as measured by the number of subjects who attain 2-hour PPG levels of < 180 mg/dL (10.0 mmol/L), and < 140 mg/dL (7.8 mmol/L) following Meal Challenges|7-point blood glucose (BG) profiles at regular intervals|CGM parameters|Body weight|Subject treatment satisfaction","http://ClinicalTrials.gov/show/NCT00700622",NA
"18857",18857,"NCT00708422","Ocular Surface Effects of Prostaglandin Analogues (PGAs)","Completed","No Results Available","Glaucoma","Drug: Travoprost eye drop|Drug: Latanoprost","Alcon Research","Both","Adult|Senior","Phase IV",110,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","SMA-08-07","June 30, 2008","01/07/2008",NA,"October 2, 2009","01/10/2009","",2009-08-01,"Measuring TBUT|Change in OSDI score","http://ClinicalTrials.gov/show/NCT00708422",NA
"18866",18866,"NCT00717522","Efficacy and Safety Study of CC-4047 to Treat Advanced Soft Tissue Sarcoma","Completed","No Results Available","Soft Tissue Sarcoma","Drug: CC-4047","Celgene Corporation","Both","Adult|Senior","Phase II",7,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CC-4047-STSAR-001","July 16, 2008","01/05/2008",2009-04-01,"September 18, 2009","01/09/2009","",2009-04-01,"Safety (type, frequency, and severity of adverse events (AEs) and relationship of AEs to CC-4047)|Tumor response (Response Evaluation Criteria in Solid Tumors [RECIST])","http://ClinicalTrials.gov/show/NCT00717522",NA
"18870",18870,"NCT00729222","Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure","Completed","No Results Available","Heart Failure","Drug: Comparator: Placebo|Drug: rolofylline","Merck|NovoCardia, Inc., a wholly owned subsidiary of Merck & Co., Inc.","Both","Adult|Senior","Phase II",60,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2008_532|MK7418-503","August 5, 2008","01/09/2008",2009-04-01,"May 28, 2009","01/05/2009","",2009-04-01,"change in pulmonary capillary wedge pressure|Change in cardiac output, systemic vascular resistance, pulmonary vascular resistance, pulmonary pressure and right atrial pressure","http://ClinicalTrials.gov/show/NCT00729222",NA
"18887",18887,"NCT00755222","The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease","Completed","No Results Available","Peyronie's Disease","Biological: AA4500|Biological: Placebo","Auxilium Pharmaceuticals","Male","Adult|Senior","Phase II",120,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AUX-CC-801","September 16, 2008","01/08/2008",2009-12-01,"June 17, 2010","01/06/2010","",2009-12-01,"Total scores and change from baseline total scores for each of the four scales of the Peyronie's PRO questionnaire|Change from baseline and percent change from baseline in penile curvature","http://ClinicalTrials.gov/show/NCT00755222",NA
"18893",18893,"NCT00768222","Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery","Completed","No Results Available","Breast Cancer","Device: silk suture|Device: VICRYL* Plus suture","Ethicon, Inc.|Johnson & Johnson Medical, China","Both","Adult|Senior","Phase IV",101,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","200-08-002","October 7, 2008","01/10/2008",2009-05-01,"December 2, 2009","01/12/2009","",2009-03-01,"Post-operative cosmetic outcome at Day 30 assessed by an independent blinded central assessor on a validated analog using surgical site photographs|Cosmetic outcome using modified Hollander Scale|Modified ASEPSIS score to identify SSI","http://ClinicalTrials.gov/show/NCT00768222",NA
"18925",18925,"NCT00812422","The Efficacy and Safety of Dexibuprofen Syrup","Completed","No Results Available","Fever|Respiratory Tract Infection","Drug: Dexibuprofen|Drug: Dexibuprofen|Drug: Ibuprofen","Inje University","Both","Child","Phase III",260,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","AG_DIBU_2007","December 19, 2008","01/02/2008",2009-05-01,"January 15, 2010","01/01/2010","",2009-05-01,"measure reduction in fever|determine safety of dexibuprofen by unwanted reaction, clinical laboratory test and physical examination.","http://ClinicalTrials.gov/show/NCT00812422",NA
"18928",18928,"NCT00817622","Effects of EPA and Vitamin E on Leptin, Adiponectin and Enzymatic Antioxidants in Type 2 DM","Completed","No Results Available","Diabetes Mellitus","Dietary Supplement: EPA, Vitamin E","Tehran University of Medical Sciences","Both","Adult","Phase IV",129,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","27-4955","January 3, 2009","01/01/2007",2009-09-01,"November 17, 2009","01/11/2009","EPA",2009-06-01,"Changes in leptin and adiponectin after 12 Weeks","http://ClinicalTrials.gov/show/NCT00817622",NA
"18994",18994,"NCT00934622","Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL","Completed","Has Results","Cataract","Device: AcrySof?ó ReSTOR?ó Aspheric IOL","Alcon Research","Both","Adult|Senior","Phase IV",76,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ALCONsur002.07","July 7, 2009","01/11/2007",NA,"May 5, 2010","01/05/2010","",2009-03-01,"Visual Acuity|Spectacle Independence","http://ClinicalTrials.gov/show/NCT00934622",NA
"19009",19009,"NCT00960622","Switch From Combivir to Truvada - Mitochondrial Effects","Completed","No Results Available","HIV|HIV Infections","Drug: Truvada vs Combivir","St. Luke's-Roosevelt Hospital Center|Gilead Sciences","Both","Adult|Senior","Phase IV",NA,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TRU1","August 17, 2009","01/08/2006",2009-07-01,"September 28, 2009","01/08/2009","TRU",2009-07-01,"VO2 max","http://ClinicalTrials.gov/show/NCT00960622",NA
"19031",19031,"NCT00984022","Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage","Completed","Has Results","Abscess|Cellulitis","Device: Type of dressing - Iodoform|Device: Type of dressing - Aquacel","Maricopa Integrated Health System","Both","Adult","Phase II",92,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-003","September 22, 2009","01/03/2008",2009-09-01,"October 27, 2010","01/10/2010","",2009-09-01,"Number of Participants Who Experienced a 30% or Greater Reduction in Surface Area of Abscess|Change in Patient Rating of Pain|Number of Participants Who Experienced a 30% or Greater Reduction in Surface Area of Cellulitis.","http://ClinicalTrials.gov/show/NCT00984022",NA
"19032",19032,"NCT00994422","Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects","Completed","No Results Available","Head Lice","Drug: Ivermectin cream|Drug: vehicle control","Topaz Pharmaceuticals Inc","Both","Child|Adult|Senior","Phase II",250,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TOP010","October 9, 2009","01/10/2009",2009-12-01,"November 30, 2010","01/12/2009","",2009-12-01,"The proportion within each treatment group of all subjects who are lice free (without live lice)","http://ClinicalTrials.gov/show/NCT00994422",NA
"19043",19043,"NCT01012622","FOSCO Study (Functional Outcomes Study of OROS (Osmotic-controlled Release Oral Delivery System) Methylphenidate","Completed","No Results Available","Attention Deficit Disorder With Hyperactivity","Drug: OROS methylphenidate hydrochloride","Janssen Korea, Ltd., Korea","Both","Child","Phase IV",140,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR015481|CON-KOR-4020","November 5, 2009","01/08/2008",2009-08-01,"April 26, 2010","01/04/2010","",2009-08-01,"Treatment effectiveness will be assessed by evaluating response rate defined as a decrease in total K-ARS (Korean ADHD Rating Scale) score by more than 25% and by evaluating the remission rate defined as total K-ARS score and CGI-S scale.|The changes in Child Health and Illness Profile-Child Edition (CHIP-CE) total and subdomains|Comprehensive Attention Test (CAT) measures across the trial|Academic Performance Rating Scale(APRS)|Beck Depression Inventory (BDI)|Parenting Stress Index (PSI)","http://ClinicalTrials.gov/show/NCT01012622",NA
"19187",19187,"NCT01238822","Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)","Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Drug: Low Dose|Drug: placebo|Drug: Medium Dosage|Drug: methylphenidate","Children's Hospital Medical Center, Cincinnati","Both","Child","Phase IV",89,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","R01MH074770","November 9, 2010","01/06/2006",2009-06-01,"November 10, 2010","01/11/2010","",2009-06-01,"ADHD symptoms|Side effects","http://ClinicalTrials.gov/show/NCT01238822",NA
"19336",19336,"NCT00130923","Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder","Completed","No Results Available","Schizophrenia|Psychotic Disorders|Substance Abuse|Alcohol Abuse","Drug: risperidone long-acting|Drug: oral risperidone","Dartmouth-Hitchcock Medical Center|Janssen, LP","Both","Adult","Phase IV",95,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","17359|RIS-EMR-4032","August 15, 2005","01/09/2005",2010-07-01,"November 2, 2010","01/11/2010","",2009-06-01,"Alcohol use assessed by the Timeline Followback scale|Other substance use as assessed by the Timeline Followback scale|Clinical symptoms, global functioning, cognition, and extrapyramidal system effects","http://ClinicalTrials.gov/show/NCT00130923",NA
"19367",19367,"NCT00185523","Allogeneic Transplantation for Patients With Acute Leukemia or CML","Completed","No Results Available","Leukemia, Lymphocytic, Acute|Leukemia|Leukemia Acute Promyelocytic Leukemia (APL)|Leukemia Acute Lymphoid Leukemia (ALL)|Leukemia Chronic Myelogenous Leukemia (CML)|Leukemia Acute Myeloid Leukemia (AML)|Leukemia Chronic Lymphocytic Leukemia (CLL)","Procedure: Allogeneic hematopoietic cell transplantation","Stanford University","Both","Child|Adult","Phase II",175,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT142|78149|BMT142","September 12, 2005","01/05/2002",2009-04-01,"July 23, 2010","01/07/2010","",2009-04-01,"To evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stemcells from their donors.","http://ClinicalTrials.gov/show/NCT00185523",NA
"19397",19397,"NCT00228423","Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)","Completed","No Results Available","Atherosclerosis","Drug: Clopidogrel 75 mg daily","University of Ottawa Heart Institute|Sanofi-Aventis|Bristol-Myers Squibb","Both","Adult|Senior","Phase II",92,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","UOHI 2006-111","September 26, 2005","01/05/2006",2009-07-01,"June 25, 2010","01/06/2010","",2009-06-01,"Vein graft intimal area, one year following surgery|Vein graft angiographic patency, one year following surgery|Incidence of major adverse coronary events within one year following surgery|Incidence of major bleeding events within one year following surgery","http://ClinicalTrials.gov/show/NCT00228423",NA
"19589",19589,"NCT00528723","Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma","Completed","No Results Available","Bronchial Asthma","Drug: salbutamol 100 mcg|Drug: BDP/salbutamol HFA pMDI|Drug: BDP/salbutamol CFC pMDI","Chiesi Farmaceutici S.p.A.","Both","Adult","Phase III",180,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MC/PR/033004/002/06","September 11, 2007","01/11/2007",2009-01-01,"April 21, 2010","01/04/2010","",2009-01-01,"Mean value of morning PEF (daily measured by the patient)|Morning PEF daily measured by the patient at any other time point|Evening PEF, and morning and evening FEV1 daily measured by the patient|Pulmonary function parameters (FEV1, FVC, PEF and FEF25-75%)|Changes from pre-dosing of pulmonary function parameters measured at in the interval 0-60 minutes (pre-dose and 5, 15, 30 and 60 minutes post-dose);|Rates of asthma exacerbations (in total and by severity)|Time to first asthma exacerbation|Night-time and daytime use of relief salbutamol, and number of days (both day and night) without intake of salbutamol|Nighttime and daytime symptoms scores, and number of symptoms-free days (both day and night)","http://ClinicalTrials.gov/show/NCT00528723",NA
"19609",19609,"NCT00518323","A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients","Completed","Has Results","Schizophrenia","Drug: Paliperidone ER|Drug: Placebo|Drug: Paliperidone ER|Drug: Paliperidone ER","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Child","Phase III",201,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR002368|R076477PSZ3001","August 16, 2007","01/08/2007",2009-03-01,"November 17, 2010","01/11/2010","",2009-03-01,"Change in the PANSS Total Score From Baseline to the Last Postrandomization Assessment in the Double-blind Period of the Study.|Change From Baseline to End Point in Clinical Global Impression-Severity (CGI-S) Scale|Change From Baseline to End Point in Children's Global Assessment (CGAS) Score|Change From Baseline to End Point in Sleep Visual Analog Scale (VAS) for Quality of Sleep.|Change From Baseline to End Point in Sleep VAS for Daytime Drowsiness","http://ClinicalTrials.gov/show/NCT00518323",NA
"19611",19611,"NCT00574223","A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis","Completed","No Results Available","Perennial Allergic Rhinoconjunctivitis|House Dust Mite Allergy","Drug: CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|Drug: House dust mite allergen extract in combination with CYT003-QbG10-placebo","Cytos Biotechnology AG","Both","Adult","Phase II",100,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CYT005-AllQbG10 04","December 14, 2007","01/11/2007",2009-03-01,"April 24, 2009","01/04/2009","",2009-03-01,"Conjunctival provocation test with allergen and rhinoconjunctivitis symptoms in daily life|Safety and tolerability of the study treatment by collection of adverse events","http://ClinicalTrials.gov/show/NCT00574223",NA
"19615",19615,"NCT00580723","Effects of PRK 124 Lotion in Acne Rosacea","Completed","No Results Available","Acne Rosacea","Other: PRK 124","University of California, Irvine|SenetekPLC","Both","Adult|Senior","Phase I|Phase II",24,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-5307|Contract SPLC-41239","December 21, 2007","01/04/2007",2009-02-01,"March 12, 2009","01/03/2009","",2009-02-01,"Inflammatory lesion count, erythema and telangiectasia|Skin Tolerance|Skin photodamage|Transepidermal water loss (TEWL)|Cosmetic acceptability","http://ClinicalTrials.gov/show/NCT00580723",NA
"19617",19617,"NCT00576823","Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology","Completed","No Results Available","Hydronephrosis|Neurogenic Bladder","Drug: Alfuzosin","Sanofi-Aventis","Both","Child","Phase III",25,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC6269|SL770499|2004-002397-38","December 18, 2007","01/12/2007",2009-10-01,"November 26, 2010","01/11/2010","Alfahydro",2009-01-01,"Change From Baseline in Grade of Hydronephrosis|Symptomatic Urinary Tract Infection (UTI) Episodes|Symptomatic Urinary Tract Infection (UTI) Episodes","http://ClinicalTrials.gov/show/NCT00576823",NA
"19619",19619,"NCT00589823","Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids","Completed","No Results Available","Cancers, Pain","Drug: Fentanyl citrate|Drug: Immediate release morphine sulphate","Archimedes Development Ltd","Both","Adult|Senior","Phase III",135,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","CPO44/06/FCNS","December 27, 2007","01/06/2007",2009-03-01,"January 20, 2010","01/01/2010","",2009-03-01,"Pain Relief|Pain Relief at various time points","http://ClinicalTrials.gov/show/NCT00589823",NA
"19667",19667,"NCT00658723","The Fibrin Patch Soft Tissue Study","Completed","No Results Available","Hemostasis","Drug: Fibrin Pad|Device: SURGICEL?ºÑ","Ethicon, Inc.|OMRIX Biopharmaceuticals","Both","Adult|Senior","Phase II",141,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","400-07-002","April 11, 2008","01/03/2008",2009-05-01,"August 30, 2010","01/08/2010","",2009-04-01,"Proportion of subjects achieving hemostatic success|Proportion of subjects achieving hemostatic success|Incidence of treatment failures|Incidence of adverse events that are potentially related to bleeding|Incidence of adverse events that are potentially related to thrombotic events|Incidence of adverse events potentially related to transfusion exposure|Incidence of re-treatment|Incidence of adverse events","http://ClinicalTrials.gov/show/NCT00658723",NA
"19670",19670,"NCT00653523","Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)(COMPLETED)","Completed","Has Results","Hypercholesterolemia","Drug: Ezetimibe|Drug: Simvastatin","Schering-Plough","Both","Adult|Senior","Phase III",151,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P05457","April 1, 2008","01/12/2007",2009-06-01,"August 12, 2010","01/08/2010","",2009-06-01,"Number of Participants With Adverse Events and Adverse Reactions","http://ClinicalTrials.gov/show/NCT00653523",NA
"19678",19678,"NCT00674323","Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy","Completed","No Results Available","Polypoidal Choroidal Vasculopathy","Drug: verteporfin, ranibizumab|Drug: verteporfin|Drug: Ranibizumab","Novartis","Both","Adult|Senior","Phase IV",61,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","CBPD952A2209","May 5, 2008","01/04/2008",NA,"May 10, 2010","01/05/2010","PCV",2009-05-01,"Complete regression (CR) of polyps measured by indocyanine green angiography (ICGA)|Eff?ócacy: CR of polyps assessed by ICGA at Months 3,4,and 5 and proportion of patients with at least one CR of polyps assessed by ICGA during 6 month.|Changes in central retinal thickness measured by optic coherence tomography (OCT)|Best-Corrected Visual Acuity (BCVA) assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) chart.|Time to first re-treatment and number of re-treatments as per re-treatment criteria|Safety: AE, ophthalmic exams, vital signs","http://ClinicalTrials.gov/show/NCT00674323",NA
"19682",19682,"NCT00683423","BMS-741672 for Diabetic Neuropathic Pain","Completed","No Results Available","Neuropathic Pain","Drug: BMS-741672|Drug: Placebo","Bristol-Myers Squibb","Both","Adult|Senior","Phase II",50,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MB114-006","May 21, 2008","01/07/2008",2009-02-01,"January 6, 2011","01/07/2009","",2009-01-01,"Reduction in weekly average pain score for BMS drug vs. placebo, computed from diary scores|Other glycemic, vascular, and mechanism-based biomarkers will be measured","http://ClinicalTrials.gov/show/NCT00683423",NA
"19690",19690,"NCT00699023","Ezetimibe and Statins on Postprandial Lipemia in Type 2 Diabetes","Completed","No Results Available","Postprandial Lipemia|Type 2 Diabetes","Drug: ezetimibe tablets|Drug: simvastatin tablets|Drug: placebo","Federico II University","Both","Adult","Phase IV",13,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","239/07","June 13, 2008","01/06/2008",2009-10-01,"November 3, 2009","01/11/2009","EZE",2009-10-01,"Incremental AUC after a fat-rich meal of cholesterol concentration in chylomicron and VLDL fractions|Incremental AUC after a fat rich-meal of apo B48 concentration- marker of the number of intestinally derived lipoproteins- in chylomicron and VLDL|Fasting LDL concentration|Cholesterol/triglyceride ratio in postprandial chylomicrons and VLDL fractions.|Postprandial LDL size|Concentration and Composition of different lipoprotein subclasses in the fasting condition.","http://ClinicalTrials.gov/show/NCT00699023",NA
"19715",19715,"NCT00740623","A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.","Completed","No Results Available","Epilepsy, Partial, Motor|Epilepsy, Complex Partial|Epilepsy, Simple Partial|Focal Motor Epilepsy","Drug: Carisbamate|Drug: Carisbamate|Drug: placebo","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Child|Adult|Senior","Phase III",548,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR015463|CARISEPY3013","August 21, 2008","01/01/2009",2010-04-01,"October 18, 2010","01/10/2010","",2009-10-01,"Primary efficacy endpoints are percent reduction in partial onset seizure frequency in the US and the rest of the world (excluding Europe, Australia, New Zealand, S Africa), and responder rate for Europe, Australia, New Zealand, S Africa|Secondary endpoints are percent reduction in partial onset seizure frequency for EuropeAustraliaNew Zealand S Africa, percent reduction in secondarily generalized seizure and time to onset of treatment effect on partial onset seizure frequency reduction","http://ClinicalTrials.gov/show/NCT00740623",NA
"19716",19716,"NCT00747123","A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma","Completed","No Results Available","Osteolytic Lesions of Multiple Myeloma","Biological: ACE-011|Biological: Placebo","Celgene Corporation","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A011-04","September 3, 2008","01/09/2008",2009-10-01,"September 28, 2010","01/09/2010","",2009-10-01,"To evaluate the safety and tolerability of multiple doses of ACE-011 in patients with multiple myeloma and determine the effect of ACE-011 on biochemical markers of bone formation and resorption.|To determine the pharmacokinetics (PK) of multiple doses of ACE-011 in patients with multiple myeloma, assess skeletal-related events and evaluate bone pain.","http://ClinicalTrials.gov/show/NCT00747123",NA
"19728",19728,"NCT00757523","Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris","Completed","No Results Available","Acne Vulgaris","Drug: Epiduo Gel|Drug: Duac Gel","Stiefel, a GSK Company","Both","Child|Adult","Phase IV",400,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","S194 -401|Eudract No 2008-002359-26|The 'Duetta' study","September 21, 2008","01/09/2008",2009-06-01,"August 25, 2010","01/08/2010","",2009-04-01,"Outcome Measure: To evaluate the efficacy of Duac Akne Gel compared with Epiduo Gel in the treatment of facial acne vulgaris.|Outcome Measure: To evaluate the safety and tolerability of Duac Akne Gel compared with Epiduo Gel.","http://ClinicalTrials.gov/show/NCT00757523",NA
"19730",19730,"NCT00761423","The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial","Completed","No Results Available","Achilles Tendinopathy","Biological: PRP Injection with eccentric exercises|Biological: Placebo Injection with eccentric exercises","Biomet, Inc.|Erasmus Medical Center","Both","Adult|Senior","Phase IV",81,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","BMET NL 02|NTR1420","September 25, 2008","01/08/2008",2009-08-01,"September 20, 2010","01/09/2010","PRICT",2009-02-01,"VISA-A Score|Ultrasonographic Tissue Characterization|Complications|Power doppler sound|Patient satisfaction|Return to sport","http://ClinicalTrials.gov/show/NCT00761423",NA
"19736",19736,"NCT00777023","Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.","Completed","No Results Available","Hot Flashes","Drug: Gabapentin","Depomed","Female","Adult|Senior","Phase III",540,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","BREEZE 2|81-0059","October 21, 2008","01/10/2008",2009-10-01,"November 2, 2009","01/11/2009","",2009-07-01,"Reduction of frequency and severity of hot flashes after 12 weeks of treatment with a stable dose relative to placebo, compared with the baseline week.","http://ClinicalTrials.gov/show/NCT00777023",NA
"19740",19740,"NCT00784823","Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Bortezomib|Drug: Melphalan","Hackensack University Medical Center","Both","Adult|Senior","Phase I|Phase II",24,"Other","Interventional","Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","06.05.109B","October 31, 2008","01/01/2007",2009-12-01,"November 15, 2010","01/11/2010","Mel-Vel",2009-12-01,"Maximum Tolerated Dose The maximum tolerated dose of bortezomib (MTD) will be defined as the dose level prior to that resulting in two out of six patients experiencing a DLT","http://ClinicalTrials.gov/show/NCT00784823",NA
"19744",19744,"NCT00795223","Comparative Pain Control Between 0.2 or 0.3 Spinal Morphine and 0.25 or 0.5 % Bupivacaine for FNB After TKA","Completed","No Results Available","Post Operative Pain|Total Knee Replacement","Drug: morphine and bupivacaine|Drug: spinal morphine and marcaine|Drug: morphine and bupivacaine|Drug: morphine and bupivacaine","Mahidol University|Siriraj Hospital","Both","Adult|Senior","Phase IV",160,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","461/2551(EC1)|Grant by the siriraj Hospital","November 20, 2008","01/10/2008",2009-05-01,"September 28, 2009","01/09/2009","",2009-05-01,"Global assessment in post operative pain control|Global assessment of post operative pain in 48 HOURS AND SIDE EFFECTS","http://ClinicalTrials.gov/show/NCT00795223",NA
"19746",19746,"NCT00790023","Clinical Trial to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: 80 mcg Ciclesonide|Drug: 160 mcg Ciclesonide|Drug: Placebo","Sunovion","Both","Child|Adult|Senior","Phase III",660,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","060-622","November 11, 2008","01/11/2008",2009-02-01,"August 7, 2009","01/08/2009","",2009-02-01,"Change from baseline in subject-reported AM and PM reflective TNSS averaged over the two-week treatment period|Change from baseline in subject-reported AM and PM instantaneous TNSS averaged over the two-week treatment period.|Change from baseline in subject-reported AM and PM reflective TOSS averaged over the two-week treatment period in subjects.|Change from baseline in subject-reported AM reflective TNSS, PM reflective TNSS, AM and PM reflective TNSS at each day, averaged over each week, and averaged over the two-week treatment period.|Change from baseline in subject-reported AM instantaneous TNSS, PM instantaneous TNSS, AM and PM instantaneous TNSS at each day, averaged over each week, and averaged over the two-week treatment period.|Change from baseline in subject-reported AM reflective TOSS, PM reflective TOSS, AM and PM reflective TOSS at each day, averaged over each week, and averaged over the two-week treatment period in subjects.|Change from baseline in subject-reported AM instantaneous TOSS, PM instantaneous TOSS, AM and PM instantaneous TOSS at each day, averaged over each week, and averaged over the two-week treatment period in subjects.|Change from baseline in subject-reported individual AM reflective NSS, individual PM reflective NSS, individual AM and PM reflective NSS at each day, averaged over each week, and averaged over the two-week treatment period.|Change from baseline in subject-reported individual AM reflective OSS, individual PM reflective OSS, individual AM and PM reflective OSS at each day, averaged over each week, and averaged over the two-week treatment period in subjects.|Change from baseline in subject-reported individual AM instantaneous OSS, individual PM instantaneous OSS, individual AM and PM instantaneous OSS at each day, averaged over each week, and averaged over the two-week treatment period in subjects.|Change from baseline in Rhinoconjunctivitis Quality of Life Questionnaire with Standardised Activities (RQLQ(S)) total and individual items at each day, averaged over each week, and averaged over the two-week treatment period in impaired patients.|Time to Onset of nasal improvement, defined as the first assessment at which instantaneous TNSS for active treatment demonstrates an improvement over placebo from baseline with one-sided p-value of ???0.025.|Time to Onset of ocular improvement, defined: first assessment where instantaneous TOSS for active treatment demonstrates an improvement over placebo from baseline in subjects with baseline TOSS ??­5.0|Time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between Ciclesonide HFA and placebo is at least 90% of the largest estimated difference.","http://ClinicalTrials.gov/show/NCT00790023",NA
"19776",19776,"NCT00845923","Evaluation of Civamide Patch in Treatment of Postherpetic Neuralgia and Post-Incisional Neuralgia","Completed","No Results Available","Postherpetic Neuralgia","Drug: Civamide Patch","Winston Laboratories","Both","Adult|Senior","Phase I|Phase II",22,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","WL-1001-04-03","February 16, 2009","01/03/2009",2009-10-01,"October 16, 2009","01/10/2009","",2009-09-01,"Change in Average Daily Pain Score from the Baseline Period to the Average Daily Pain Score of the last week of the Treatment Period.|Average Daily Sleep Score","http://ClinicalTrials.gov/show/NCT00845923",NA
"19787",19787,"NCT00857623","Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy","Completed","No Results Available","Pain|Diabetic Neuropathy","Drug: AZD2066|Drug: Placebo","AstraZeneca|anders.neijber@astrazeneca.com","Both","Adult|Senior","Phase II",334,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D0475C00009","February 27, 2009","01/02/2009",2009-08-01,"June 2, 2010","01/06/2010","",2009-08-01,"Change in mean numerical rating scale (NRS) score from baseline to last 5 days of treatment|Patients with Patient Global Impression of Change (PGIC) socre of at least \much improved\"" (responder rate) at Day 28|Patients with >=30% reduction from baseline in NRS pain intensity score (responder rate) at Day 28|Patients with >=50% reduction from baseline in NRS pain intensity score (responder rate) at Day 28""","http://ClinicalTrials.gov/show/NCT00857623",NA
"19791",19791,"NCT00864123","D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder","Completed","No Results Available","Obsessive-Compulsive Disorder","Behavioral: Cognitive-behavioral therapy|Drug: D-cycloserine","University of South Florida","Both","Child","Phase II",40,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MH076775|MH076775","March 17, 2009","01/01/2008",2009-11-01,"August 5, 2010","01/08/2010","",2009-11-01,"Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS; Scahill et al., 1997). The CY-BOCS is a 10-item semi-structured measure of obsession and compulsion severity over the previous week. This measure will serve as the primary outcome index.|Clinical Global Impression - Severity (CGI-S; National Institute of Mental Health, 1985). The CGI-S is a 7-point clinician rating of severity of psychopathology.|Adverse Symptom Checklist (ASC; Goodman, 2005). This index assesses adverse side effects that have been associated with DCS, as well as other commonly used psychotropic agents (e.g., SRIs).","http://ClinicalTrials.gov/show/NCT00864123",NA
"19793",19793,"NCT00868023","Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients","Completed","No Results Available","Asthma","Drug: CHF 1535 Next DPI|Drug: Foster BDP/Formoterol|Drug: CHF 1535 Next DPI|Drug: Foster BDP/Formoterol|Drug: Placebo","Chiesi Farmaceutici S.p.A.","Both","Adult|Senior","Phase II",69,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CCD-0809-PR-0038","March 23, 2009","01/02/2009",2009-10-01,"December 22, 2010","01/12/2010","",2009-07-01,"FEV1 AUC0-12h|FVC as assessed at the same time points as for FEV1; Peak FEV1 in terms of absolute values and % of change from baseline Safety evaluation","http://ClinicalTrials.gov/show/NCT00868023",NA
"19798",19798,"NCT00816023","A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume","Completed","Has Results","Bloodloss|Surgical Procedures, Operative","Drug: ecallantide|Drug: placebo","Cubist Pharmaceuticals","Both","Adult|Senior","Phase II",276,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ECAL-PCPB-08-02","December 29, 2008","01/03/2009",2010-01-01,"December 14, 2010","01/12/2010","CONSERV-1",2009-12-01,"Cumulative Volume of Packed Red Blood Cells Transfused at 12 Hours Post Surgery|Treatment-emergent Adverse Events","http://ClinicalTrials.gov/show/NCT00816023",NA
"19799",19799,"NCT00877123","Effect of Vitamin D Supplementation on Fasting Glucose and Interleukin-10 (IL-10) in Arab Women With Impaired Fasting Glucose","Completed","No Results Available","Obesity","Drug: Oral vitamin D 100,000 IU|Drug: Placebo","Clalit Health Services|Rambam Health Care Campus","Female","Adult","Phase IV",80,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","K-09-43-CTIL","April 6, 2009","01/06/2009",2009-10-01,"October 28, 2009","01/10/2009","",2009-10-01,"fasting glucose|interleukin-10 level|hs-CRP level","http://ClinicalTrials.gov/show/NCT00877123",NA
"19843",19843,"NCT00952523","Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face","Completed","Has Results","Acne Vulgaris","Drug: Tretinoin Facial Gel|Drug: Adapalene/Benzoyl Peroxide Facial Gel","Johnson & Johnson Consumer & Personal Products Worldwide","Both","Adult","Phase IV",162,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","CA-P-7190","August 4, 2009","01/07/2009",2009-10-01,"April 8, 2010","01/04/2010","",2009-10-01,"Facial Irritation and Cutaneous Effects","http://ClinicalTrials.gov/show/NCT00952523",NA
"19846",19846,"NCT00964223","A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne","Completed","No Results Available","Acne Vulgaris","Drug: clindamycin and benzoyl peroxide gel (Duac?ó Topical Gel)|Drug: benzoyl peroxide and adapalene gel (EPIDUO?ºÑ Gel)","Stiefel, a GSK Company","Both","Adult|Senior","Phase IV",28,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","C0000-410","August 20, 2009","01/07/2009",2010-02-01,"April 21, 2010","01/04/2010","",2009-12-01,"To compare the tolerability of clindamycin and benzoyl peroxide gel to benzoyl peroxide/adapalene gel in the treatment of facial acne during the first 2 weeks of treatment.|To evaluate efficacy, tolerability, safety and subject satisfaction of clindamycin and benzoyl peroxide gel in the treatment of acne vulgaris. To evaluate the influence of acne on subjects' quality of life.","http://ClinicalTrials.gov/show/NCT00964223",NA
"19927",19927,"NCT01090323","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and the Effects on Liver Iron Concentration of Repeated Doses of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis","Completed","No Results Available","Transfusional Hemosiderosis in Sickle Cell Disease","Drug: ICL670","Novartis Pharmaceuticals","Both","Child|Adult|Senior","Phase II",185,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CICL670A0109E1|EudraCT no. 2004-000597-31","March 15, 2010","01/07/2004",NA,"March 19, 2010","01/03/2010","",2009-07-01,"To evaluate the long-term safety and tolerability profile of ICL670 in sickle cell disease patients with transfusional iron overload requiring chelation therapy|To allow patients treated with either ICL670 or deferoxamine (DFO) satisfactorily completing the week 52 assessment of the core protocol ICL670A0109 to continue iron chelation therapy with ICL670|Change in serum ferritin over time in response to therapy with ICL670|To determine liver iron concentration (LIC) by MRI in a subset of patients (Although it was specified as a secondary objective in the protocol, MRI data were not collected in the extension phase of the trial).|Determinations relative to iron metabolism (serum ferritin, total iron, transferrin and transferrin saturation)","http://ClinicalTrials.gov/show/NCT01090323",NA
"20013",20013,"NCT01235923","Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants","Completed","No Results Available","Preterm Infants","Drug: Epoetin Alfa","University of New Mexico|National Center for Research Resources (NCRR)","Both","Child","Phase II",20,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","05-380|M01RR000997","November 4, 2010","01/04/2006",2009-12-01,"November 5, 2010","01/10/2010","",2009-03-01,"reticulocyte count","http://ClinicalTrials.gov/show/NCT01235923",NA
"20135",20135,"NCT00085124","Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","Completed","No Results Available","Leukemia","Biological: oblimersen sodium|Drug: cytarabine|Drug: daunorubicin hydrochloride","Cancer and Leukemia Group B|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",500,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000367323|CALGB-10201","June 10, 2004","01/12/2003",NA,"February 6, 2010","01/10/2006","",2009-12-01,"Overall survival|Complete remission during remission induction therapy|Disease-free survival|Event-free survival","http://ClinicalTrials.gov/show/NCT00085124",NA
"20158",20158,"NCT00137124","L-Arginine Metabolism in Essential Hypertension","Completed","No Results Available","Essential Hypertension","Drug: L-Arginine","University of Erlangen-N??rnberg Medical School","Both","Adult","Phase II|Phase III",120,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","KFO 106 TP8","August 26, 2005","01/05/2006",2009-12-01,"February 1, 2010","01/02/2010","",2009-12-01,"meaning of L-arginine transport and metabolism on endothelial function","http://ClinicalTrials.gov/show/NCT00137124",NA
"20228",20228,"NCT00246324","Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Drug: Doxycycline","Louisiana State University - Shreveport|Biogen Idec","Both","Adult","Phase IV",NA,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H04-090","October 27, 2005","01/12/2003",2009-08-01,"July 1, 2010","01/12/2004","",2009-08-01,"to determine whether the combination of doxycycline with Avonex will reduce the mean number of new GD+ lesions|to determine pre- and on-treatment relapse rate,proportion relapse free, %free of new MRI activity, and % experencing greater than 25% reduction in new MRI activity|determine safety and tolerability of combination therapy with Avonex plus doxycycline|determine pre- and on-treatment cytokine ELISA, MMP ELISA and bioassay","http://ClinicalTrials.gov/show/NCT00246324",NA
"20237",20237,"NCT00251524","A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Bevacizumab, Oxaliplatin, Pemetrexed","Veeda Oncology|Sanofi-Aventis|Eli Lilly and Company|Genentech","Both","Adult|Senior","Phase II",69,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I-04-015","November 8, 2005","01/11/2005",2009-05-01,"November 30, 2010","01/08/2008","",2009-05-01,"To determine the median progression-free survival in patients with advanced non-squamous non-small cell lung cancer (NSCLC) receiving Eloxatin and Alimta in combination with Bevacizumab as first-line treatment|To evaluate the median and the 1-year and 2-year survival in patients with advanced NSCLC receiving Eloxatin and Alimta in combination with Bevacizumab as first-line treatment.|To determine the overall objective response and the duration of response in patients with advanced NSCLC receiving Eloxatin and Alimta in combination with Bevacizumab as first-line treatment.|To evaluate the safety of Eloxatin and Alimta in combination with Bevacizumab in patients with advanced NSCLC as first-line treatment.","http://ClinicalTrials.gov/show/NCT00251524",NA
"20241",20241,"NCT00261924","Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days","Completed","No Results Available","Thrombocytopenia","Device: Transfusion of Pathogen Inactivated Platelets stored for 6-7 days","Cerus Corporation","Both","Child|Adult|Senior","Phase III",211,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","451-P-A-NIV","December 5, 2005","01/10/2005",2009-07-01,"April 13, 2010","01/12/2005","TESSI",2009-07-01,"1 hour corrected count increment for platelets|Transfusion related adverse events","http://ClinicalTrials.gov/show/NCT00261924",NA
"20288",20288,"NCT00341224","Steppin' Up: Positive Youth Development Program","Completed","No Results Available","Mentoring","Behavioral: Group-mentoring intervention","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Child|Adult|Senior","Phase II",NA,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","999903261|03-CH-N261","June 19, 2006","01/07/2003",2009-12-01,"December 11, 2009","01/12/2009","",2009-12-01,"Student fighting|Academic engagement","http://ClinicalTrials.gov/show/NCT00341224",NA
"20331",20331,"NCT00411424","Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: ASK8007|Drug: Placebo","Astellas Pharma Inc","Both","Adult|Senior","Phase I|Phase II",54,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8007-CL-0001|EudraCT number: 2006-000172-33","December 12, 2006","01/09/2007",2009-06-01,"July 31, 2009","01/07/2009","",2009-06-01,"Safety and tolerability MD ASK8007|DAS28+CD68","http://ClinicalTrials.gov/show/NCT00411424",NA
"20344",20344,"NCT00430924","Inhibition of Aldosterone in Patients With Chronic Renal Disease","Completed","No Results Available","Kidney Failure, Chronic","Drug: Eplerenone","Herlev Hospital|Rigshospitalet, Denmark","Both","Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Prevention","B109LB1|2006-004411-21","February 1, 2007","01/03/2007",2009-08-01,"August 10, 2009","01/08/2009","",2009-08-01,"Proteinuria reduction|Evaluating blood pressure response and hyperkalaemia after aldosterone inhibition.","http://ClinicalTrials.gov/show/NCT00430924",NA
"20377",20377,"NCT00481624","Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia","Completed","No Results Available","Advanced Lung Cancer|Chemotherapy Induced Anemia","Drug: Epoetin Alfa plus Iron","James Graham Brown Cancer Center","Both","Adult|Senior","Phase II",25,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","7.021","June 1, 2007","01/05/2007",2009-11-01,"January 11, 2010","01/01/2010","Procrit",2009-11-01,"Achieve hemoglobin responses > 2g/dl in at least 70% of patients|Descriptive evaluation of adverse effects of parenteral iron and epoetin alfa 120,000 units given every three weeks","http://ClinicalTrials.gov/show/NCT00481624",NA
"20389",20389,"NCT00480324","Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants","Completed","Has Results","Gastroenteritis Caused by Rotavirus|Rotavirus Vaccines","Biological: Rotarix|Biological: Placebo","GlaxoSmithKline","Both","Child","Phase III",765,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","107625","May 29, 2007","01/06/2007",2009-11-01,"October 21, 2010","01/10/2010","",2009-11-01,"Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains|Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains|Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type|Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types|Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains|Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains|Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration|Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies|Number of Subjects Reporting Solicited Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AEs)|Number of Subjects Reporting Serious Adverse Events (SAEs)","http://ClinicalTrials.gov/show/NCT00480324",NA
"20393",20393,"NCT00510224","Sandostatin for Patients With Androgen Independent Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: Sandostatin","University of California, San Francisco|Novartis","Male","Child|Adult|Senior","Phase II",27,"Other|Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCSF055514","July 30, 2007","01/07/2007",2009-08-01,"September 3, 2009","01/09/2009","",2009-08-01,"To evaluate changes in prostate specific antigen (PSA) in patients with androgen independent prostate cancer who are treated with Sandostatin LAR.|To evaluate the effects of Sandostatin LAR on circulating levels of IGF-1 and IGF-Binding Protein 1. To evaluate the safety of Sandostatin. To evaluate the pre versus post treatment mitogenic effects.","http://ClinicalTrials.gov/show/NCT00510224",NA
"20402",20402,"NCT00519324","Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer","Completed","No Results Available","Advanced Gastric Cancer","Drug: Everolimus","Novartis Pharmaceuticals","Both","Adult|Senior","Phase II",54,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD001C1201","August 21, 2007","01/08/2007",NA,"February 8, 2010","01/02/2010","",2009-01-01,"To Assess disease control rate (DCR) as defined CR + PR + SD assessed by RECIST criteria|Objective response rate (ORR) assessed by RECIST criteria|To assess progression free survival (PFS) and overall survival (OS)|To describe the safety profile (incidence and severity of adverse events, serious adverse events) assessed by NCI CTCAE version 3.0","http://ClinicalTrials.gov/show/NCT00519324",NA
"20429",20429,"NCT00564824","The Impact of Caffeine on Brachial Endothelial Function in Healthy Subjects and in Patients With Ischemic Heart Disease","Completed","No Results Available","Coronary Disease","Drug: Caffeine|Drug: Placebo","Sheba Medical Center","Both","Adult|Senior","Phase III",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","SHEBA-07-4913-MS-CTIL","November 27, 2007","01/11/2007",2010-01-01,"February 24, 2010","01/02/2010","",2009-09-01,"Flow-mediated dilation (FMD) as surrogate of brachial artery endothelial function|Markers of inflammation such as hs-CRP, Il6, homocysteine, serum caffeine level","http://ClinicalTrials.gov/show/NCT00564824",NA
"20435",20435,"NCT00575224","Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9","Completed","No Results Available","Chronic Hepatitis C|Asian Americans|Novel Genotypes|Treatment","Drug: Pegylated interferon and ribavirin","Pacific Health Foundation|Hoffmann-La Roche","Both","Adult|Senior","Phase IV",60,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PEG-183|IRB Protocol #20041038|IRB Study #1059635","December 15, 2007","01/10/2004",2009-09-01,"November 23, 2009","01/11/2009","",2009-09-01,"Sustained virologic response","http://ClinicalTrials.gov/show/NCT00575224",NA
"20471",20471,"NCT00629824","Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: pegylated interferon alpha and plus ribavirin|Drug: pegylated interferon alpha and plus ribavirin|Drug: pegylated interferon alpha and plus ribavirin","Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","Adult|Senior","Phase IV",250,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KMUH-IRB- 960047","February 26, 2008","01/02/2007",2009-04-01,"September 6, 2010","01/02/2007","",2009-04-01,"Efficacy: Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.|RVR, rapid virological response, defined as HCV RNA < 50 IU/mL at treatment week 4","http://ClinicalTrials.gov/show/NCT00629824",NA
"20512",20512,"NCT00698724","Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care","Completed","No Results Available","Cataracts","Drug: Xibrom, and Optive|Drug: Xibrom and Pred Forte","Bp Consulting, Inc","Both","Adult|Senior","Phase IV",200,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","5359","June 13, 2008","01/06/2008",2009-06-01,"June 8, 2009","01/06/2009","",2009-06-01,"OCT|Visual Acuity","http://ClinicalTrials.gov/show/NCT00698724",NA
"20525",20525,"NCT00718224","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery","Completed","No Results Available","Venous Thromboembolism","Drug: Semuloparin sodium (AVE5026)|Drug: Enoxaparin|Drug: Placebo","Sanofi-Aventis","Both","Adult|Senior","Phase III",1150,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","EFC10571|2007-007946-37","July 17, 2008","01/07/2008",2009-05-01,"December 20, 2010","01/12/2010","SAVE-KNEE",2009-04-01,"Occurence of the composite endpoint of any VTE confirmed by a blinded Central Independent Adjudication Committee (CIAC) and deaths from any cause|Occurence of the composite endpoint of any proximal Deep Vein Thrombosis (DVT), symptomatic distal DVT, non-fatal Pulmonary Embolism (PE), and all cause deaths|Number of patients with major bleedings and clinically relevant non-major bleedings as confirmed by the CIAC","http://ClinicalTrials.gov/show/NCT00718224",NA
"20534",20534,"NCT00739024","A Study of a Melatonin Receptor Agonist to Prevent Migraine","Completed","No Results Available","Migraine|Migraine With Aura|Migraine Without Aura","Drug: ramelteon","Swedish Medical Center|Takeda Global Research & Development Center, Inc.","Both","Adult","Phase II",30,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","CRC 0690","August 19, 2008","01/04/2008",2010-09-01,"October 5, 2010","01/10/2010","",2009-04-01,"The primary efficacy variable is the percent reduction in the average monthly migraine/probable migraine frequency from the baseline period to the entire double-blind treatment phase of the study quantified by the number of attacks.","http://ClinicalTrials.gov/show/NCT00739024",NA
"20535",20535,"NCT00740324","Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men","Completed","No Results Available","Healthy","Drug: NPO-11|Drug: NPO-11|Drug: NPO-11","Nihon Pharmaceutical Co., Ltd","Male","Adult","Phase III",30,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NPO-11-01/SE-02","August 21, 2008","01/08/2008",2009-07-01,"November 8, 2010","01/11/2010","",2009-03-01,"[Safety] (Evaluation by investigator or subinvestigator) Adverse events and ADRs observed between administration and 7 ?? 3 days after administration|[Efficacy] (Central evaluation by independent evaluator) (1) Change in the frequency of gastric peristalsis classification (2) Presence or absence of gastric peristalsis at each evaluation point","http://ClinicalTrials.gov/show/NCT00740324",NA
"20543",20543,"NCT00750724","Efficacy Study of \Go On\"" in Magnetic Resonance Imaging (MRI) Improvement in Osteoarthritis (OA) Knee""","Completed","No Results Available","Osteoarthritis","Drug: 25 mg sodium hyaluronate \GO ON\""|Drug: normal saline","Khon Kaen University","Both","Adult|Senior","Phase III",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","Faculty of Medicine, Khon Kaen","September 9, 2008","01/07/2008",2009-10-01,"May 25, 2010","01/07/2009","GoOn MRI",2009-09-01,"","http://ClinicalTrials.gov/show/NCT00750724",NA
"20552",20552,"NCT00758524","A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699, a New Experimental Antihypertensive Drug, in Patients With Essential Hypertension","Completed","No Results Available","Essential Hypertension","Drug: LCI699|Drug: Eplerenone|Drug: Placebo","Novartis Pharmaceuticals","Both","Adult|Senior","Phase II",526,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLCI699A2201","September 23, 2008","01/09/2008",NA,"February 22, 2010","01/02/2010","",2009-07-01,"Mean sitting diastolic blood pressure reduction|Efficacy of mean sitting systolic blood pressure","http://ClinicalTrials.gov/show/NCT00758524",NA
"20569",20569,"NCT00792324","Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125","Completed","No Results Available","HIV","Drug: Etravirine|Drug: Efavirenz","St Stephens Aids Trust","Both","Adult|Senior","Phase III",24,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","SSAT 029","November 14, 2008","01/06/2008",2009-08-01,"November 17, 2009","01/11/2009","",2009-08-01,"The rate of neuropsychiatric and central nervous system (CNS) toxicity as measured by the proportion of patients experiencing grade 2-4 neuropsychiatric and CNS toxicity after 12 weeks (as defined by the ACTG adverse event scale).|The rate of neuropsychiatric and central nervous system (CNS) toxicity after 12 and 24 weeks as measured by the change from baseline by the Hospital Anxiety and Depression Scale (HADS).|Proportion of patients with viral load below 50 copies/mL at weeks 12 and 24|Proportion of patients with viral load below 400 copies/mL at weeks 12 and 24|Change from baseline in CD4+ count at weeks 12 and 24|Change from baseline in laboratory parameters at weeks 12 and 24|Proportion of patients with non-CNS adverse events at weeks 12 and 24|Change from baseline in adherence at weeks 12 and 24 as measured by the adherence questionnaire: Medication Adherence Self- Report Inventory (M-MASRI)|Change from baseline in patient-perceived distress associated with tolerability problems at weeks 12 and 24 as determined by tolerability index questionnaire (HIV patients symptoms profile)","http://ClinicalTrials.gov/show/NCT00792324",NA
"20571",20571,"NCT00789724","Anakinra to Prevent Post-infarction Remodeling","Completed","Has Results","ST Segment Elevation Acute Myocardial Infarction","Drug: Anakinra|Drug: Placebo","Virginia Commonwealth University","Both","Adult|Senior","Phase III",10,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VCU-ART","November 11, 2008","01/11/2008",2009-08-01,"September 1, 2010","01/09/2010","VCU-ART",2009-08-01,"Difference Between the Anakinra Arm and Placebo Arm in Change in End-systolic Volume Indices From Baseline to Follow up Exam 10-14 Weeks Later at Cardiac Magnetic Resonance Imaging.|Difference Between the 2 Arms in Change in End-diastolic Volume Indices and Ejection Fraction Values From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging|Difference Between the 2 Arms in Change in E/E' Ratios and Myocardial Performance (Tei) Indices From Baseline to Follow up Exam at Transthoracic Echo-color-Doppler Cardiac Exam|Difference Between the 2 Arms in the Percentage of Patients With Any of the Following : a) End-systolic or End-diastolic Volume Index Increase >10%; b) Ejection Fraction Decrease >10%; c) E/E'>15 at Follow up|Difference Between the 2 Arms in Change in Oxygen Uptake Kinetics From Baseline to Follow up Exam at Submaximal Cardiopulmonary Exercise Test|Difference Between the 2 Arms in Change in the Number of Circulating Endothelial Progenitor Cells From Baseline to Follow up Exam|Difference Between the 2 Arms in Change in Serum BNP Levels, C-reactive Protein, and Hemoglobin A1c% From Baseline to Follow up|Difference Between the 2 Arms in the Incidence of Significant Cardiac Arrhythmias in the Acute Phase|Difference Between the 2 Arms in the Number of Adverse Effects Including a) All Events; b) All Events Requiring Unblinding of the Treatment; c) All Events Requiring Early Termination of the Intervention","http://ClinicalTrials.gov/show/NCT00789724",NA
"20588",20588,"NCT00796224","Pharmacokinetics Of Azithromycin Immediate Release And Extended Release Formulation In Kids With Acute Otitis Media","Completed","Has Results","Acute Otitis Media","Drug: 60 mg/kg azithromycin ER|Drug: 30 mg/kg azithromycin IR","Pfizer","Both","Child","Phase II",38,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A0661190","November 18, 2008","01/12/2008",2009-02-01,"February 1, 2010","01/02/2010","",2009-02-01,"Area Under the Curve From Time Zero to 72 Hours (AUC72Hours)|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Inf)|Maximum Observed Plasma Concentration (Cmax) of Azithromycin|Time to Reach Maximum Observed Plasma Concentration (Tmax) and Plasma Decay Half Life (t1/2) of Azithromycin|Serum Concentrations of Azithromycin ER (Test) and Azithromycin IR (Reference)|Number of Participants With a Clinical Response|Adverse Events (AEs) and Serious AEs (SAEs)","http://ClinicalTrials.gov/show/NCT00796224",NA
"20647",20647,"NCT00909324","Efficacy, Tolerability and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery","Completed","No Results Available","Dry Eye","Drug: 0.3% hypromellose|Drug: 0.3% hypromellose","Novartis","Both","Adult","Phase IV",160,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CGET980AIN03","May 26, 2009","01/07/2009",NA,"June 6, 2010","01/06/2010","",2009-12-01,"Subjective post-operative comfort level using global visual analog scale (VAS)|Objective post-operative parameters of invasive tear break up time.|Objective post-operative parameters of Schirmer's test.","http://ClinicalTrials.gov/show/NCT00909324",NA
"20706",20706,"NCT00995124","Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion?ó, NeutraLice Advance?ó and Moov Head Lice Solution?ó) After a Single Application","Completed","No Results Available","Head Lice","Drug: NeutraLice Lotion|Drug: NeutraLice Advance Solution|Drug: Moov Head Lice Solution","Altman Biomedical Consulting Pty. Ltd.","Both","Child","Phase IV",90,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","KEY/NL/003","October 13, 2009","01/10/2009",2009-12-01,"July 26, 2010","01/07/2010","",2009-12-01,"Ovicidal efficacy index (OEI) The proportion of treated eggs hatched in-vitro divided by the proportion of pre-treated eggs hatched in-vitro expressed as a percentage up to and including 14 days after collection and incubation.","http://ClinicalTrials.gov/show/NCT00995124",NA
"20718",20718,"NCT01018524","Open Mesh Versus Suture Repair in Treatment of Abdominal Wall Hernias","Completed","No Results Available","Abdominal Hernia","Procedure: abdominal wall reconstruction","Hungarian Surgical Society","Both","Adult|Senior","Phase IV",2,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","HSS-AHS 02-09","October 13, 2009","01/03/2002",2009-03-01,"March 7, 2010","01/03/2010","HSS-AHS",2009-03-01,"recurrence rate after hernia surgery|chronic pain after hernia surgery|complications after hernia surgery","http://ClinicalTrials.gov/show/NCT01018524",NA
"20806",20806,"NCT01164124","Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants","Completed","No Results Available","Low Birth Weight","Dietary Supplement: Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)|Other: Placebo","Vermont Oxford Network|University of Vermont|St. Louis University|Cardinal Glennon Children's Hospital|Saint John Hospital & Medical Center","Both","Child","Phase II|Phase III",101,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHRMS 08-019","July 14, 2010","01/02/2008",2009-08-01,"July 15, 2010","01/07/2010","PAS",2009-05-01,"Growth|Growth|Feeding Tolerance|Antimicrobial therapy|Complications of prematurity","http://ClinicalTrials.gov/show/NCT01164124",NA
"20954",20954,"NCT00054925","Weight Loss Maintenance (WLM)","Completed","No Results Available","Cardiovascular Diseases|Heart Diseases|Obesity|Diabetes Mellitus, Non-insulin Dependent|Hypertension","Behavioral: Personal Contact|Device: Interactive Web-based technology","National Heart, Lung, and Blood Institute (NHLBI)","Both","Adult|Senior","Phase III",NA,"NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind|Primary Purpose: Prevention","156","February 13, 2003","01/01/2003",2009-10-01,"March 16, 2010","01/10/2008","",2009-10-01,"","http://ClinicalTrials.gov/show/NCT00054925",NA
"21017",21017,"NCT00138125","Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Faslodex|Biological: Herceptin","Translational Oncology Research International|University of California, Los Angeles|Genentech|AstraZeneca","Female","Adult|Senior","Phase II",3,"Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000439421|UCLA-0502057-01|TORI-B-04|441350-RI-78322","August 29, 2005","01/04/2005",2009-12-01,"September 1, 2010","01/09/2010","",2009-09-01,"Progression-free survival|overall objective response rate|time to tumor progression|duration of response|overall survival|clinical benefit (CR + PR + SD > 6 months)","http://ClinicalTrials.gov/show/NCT00138125",NA
"21091",21091,"NCT00255125","Role of Soy Supplementation in Prostate Cancer Development","Completed","No Results Available","Prostate Neoplasm","Drug: Soy Supplement|Drug: Placebo","Department of Veterans Affairs","Male","Adult|Senior","Phase III",87,"U.S. Fed","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CLIN-006-05S","November 15, 2005","01/09/2005",2009-10-01,"October 2, 2009","01/10/2009","",2009-04-01,"1.Effect of Soy Isoflavones on serum hormonal serum levels.|2.Effect of Soy Isoflavones on estrogen receptor status.|Molecular Effects of Soy Isoflavones.","http://ClinicalTrials.gov/show/NCT00255125",NA
"21151",21151,"NCT00316225","Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen","Completed","Has Results","Non-small Cell Lung Cancer|Mesothelioma|Lung Neoplasms","Drug: pemetrexed","Eli Lilly and Company","Both","Adult|Senior","Phase II",31,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10426|H3E-MC-JMHX","April 18, 2006","01/12/2006",2009-03-01,"June 10, 2010","01/06/2010","",2009-03-01,"Overview of Adverse Events|Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities|Pemetrexed Population Pharmacokinetics (PK): Clearance|Pemetrexed Population Pharmacokinetics: Volume of Distribution|Discontinuations Due to Adverse Events","http://ClinicalTrials.gov/show/NCT00316225",NA
"21179",21179,"NCT00396825","Video-Based Coping Skills Training for Caregivers","Completed","No Results Available","Caregivers","Behavioral: Video-based coping skills training with telephone coaching","Williams LifeSkills|National Institute on Aging (NIA)","Both","Child|Adult|Senior","Phase II",116,"Industry|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Prevention","2R44AG025593-04A;|2R44AG025593","November 6, 2006","01/01/2007",2009-05-01,"March 31, 2010","01/03/2010","",2009-05-01,"Center for Epidemiological Studies Depression scale|Spielberger State-Trait Anger and Anxiety Scales|Perceived Stress Scale|Pittsburgh Sleep Quality Index|Heart rate and blood pressure at rest and during recall of caregiver situation|Salivary cortisol upon awakening, 30 minutes later, and prior to going to bed at night","http://ClinicalTrials.gov/show/NCT00396825",NA
"21186",21186,"NCT00405925","FREE Study: Efficacy and Toxicity of Trizivir","Completed","No Results Available","HIV Infections","Drug: Trizivir|Drug: zidovudine,lamivudine,abacavir","Rijnstate Hospital|GlaxoSmithKline","Both","Adult|Senior","Phase III",207,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LTC-184-010403","November 29, 2006","01/03/2003",2009-09-01,"May 31, 2010","01/05/2010","",2009-08-01,"Plasma HIV-RNA < 400 cop/ml at week 96 for the Intent- To-Treat (ITT).|HIV-RNA <50 cop at week 96|HIV-RNA <400 and <50 cop/ml at week 48|Time to virological failure|Immunological efficacy at week 48 and 96 measured by absolute change from baseline in CD4 cell counts|Duration of change in CD4 cell count from baseline to >200,|Proportion of subjects experiencing one or more predefined values of fasting glucose and triglycerides, LDL and LDL/HDL ratio|Development of adverse events","http://ClinicalTrials.gov/show/NCT00405925",NA
"21191",21191,"NCT00412425","Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting","Completed","No Results Available","Melanoma","Drug: Palonosetron","M.D. Anderson Cancer Center|Eisai Inc.","Both","Adult","Phase I|Phase II",30,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0506","December 14, 2006","01/11/2006",2009-05-01,"October 22, 2009","01/10/2009","",2009-05-01,"Patient Response to Palonosetron","http://ClinicalTrials.gov/show/NCT00412425",NA
"21197",21197,"NCT00421525","Phase I/II Study of hLL1 in Multiple Myeloma","Completed","No Results Available","Multiple Myeloma|Myeloma, Plasma-Cell|Plasmacytoma","Biological: milatuzumab","Immunomedics, Inc.","Both","Adult|Senior","Phase I|Phase II",66,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PROTOCOL: IMMU-115-01","January 11, 2007","01/01/2007",NA,"December 1, 2009","01/12/2009","",2009-08-01,"safety and tolerability of hLL1 administered twice weekly for 4 consecutive weeks|The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.","http://ClinicalTrials.gov/show/NCT00421525",NA
"21203",21203,"NCT00434525","Laparoscopic Sleeve Gastrectomy With and Without Omentectomy","Completed","No Results Available","Morbid Obesity","Procedure: Laparoscopic restrictive procedure|Procedure: Sleeve gastrectomy","North Texas Veterans Healthcare System","Both","Adult","Phase III",30,"U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07-011","February 9, 2007","01/01/2008",2009-12-01,"December 14, 2009","01/08/2009","",2009-12-01,"Weight loss|Metabolic outcomes|Diabetes resolution","http://ClinicalTrials.gov/show/NCT00434525",NA
"21206",21206,"NCT00430625","A Study of Gene-Activated?ó Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease","Completed","Has Results","Gaucher Disease, Type 1","Biological: VPRIV ?ó,","Shire Human Genetic Therapies, Inc.","Both","Child|Adult|Senior","Phase III",25,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TKT032","February 1, 2007","01/01/2007",2009-05-01,"August 19, 2010","01/08/2010","",2009-04-01,"Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group.|Change From Baseline to 12 Months in Hemoglobin Concentration in 45 U/kg Treatment Group|Change From Baseline to 12 Months in Platelet Counts for Each Treatment Group.|Change From Baseline to 12 Months in Normalized Liver Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI)|Change From Baseline to 12 Months in Normalized Spleen Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI))|Percent Change From Baseline to 12 Months in Plasma Chitotriosidase for Each Treatment Group|Percent Change From Baseline to 12 Months in Chemokine (C-C Motif) Ligand 18 (CCL18)","http://ClinicalTrials.gov/show/NCT00430625",NA
"21210",21210,"NCT00439725","Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study","Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Placebo","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult|Senior","Phase III",1193,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","11899|EudraCT No: 2006-004494-96","February 23, 2007","01/02/2007",2009-09-01,"November 18, 2010","01/11/2010","",2009-08-01,"Symptomatic recurrent VTE, i.e., the composite of recurrent DVT or fatal or non-fatal PE|Time-to-first major bleeding|Clinically relevant bleeding|All death and other vascular events","http://ClinicalTrials.gov/show/NCT00439725",NA
"21211",21211,"NCT00437125","Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease","Completed","Has Results","Major Depressive Disorder|Idiopathic Parkinson Disease","Drug: Duloxetine hydrochloride","Eli Lilly and Company","Both","Adult|Senior","Phase IV",151,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11127|F1J-IT-HMFQ","February 16, 2007","01/03/2007",2009-07-01,"September 1, 2010","01/09/2010","",2009-07-01,"Number of Participants Reporting Serious Adverse Events or Other Adverse Events Leading Either to Discontinuation or to Death|Change From Baseline to 12 Weeks on the Unified Parkinson's Disease Rating Scale (UPDRS) Total Score|Change From Baseline to 12 Weeks on the UKU (Udvalg for Kliniske Undersogelser: Committee for Clinical Investigations) Side Effect Rating Scale|Change From Baseline on the Pittsburgh Sleep Quality Index (PSQI)|Change From Baseline to 12 Weeks on the 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score|Change From Baseline to 12 Weeks on the Clinical Global Impression-Severity Scale|Patient's Global Impression-Improvement at Week 12|Change From Baseline to 12 Weeks in Beck Depression Inventory (BDI) Total Score|Change From Baseline to 12 Weeks in Visual Analog Scale (VAS)|Change From Baseline to 12 Weeks in Parkinson Disease Questionnaire - 39 Item Version (PDQ-39) Total Score|Average Change From Baseline to 12 Weeks in Blood Pressure|Average Change From Baseline to 12 Weeks in Heart Rate|Number of Participants With Abnormal Electrocardiograms (ECG) During the 12 Week Study|Laboratory Analytes|Number of Participants Who Responded to Treatment by 12 Weeks|Number of Participants Who Reached Remission by 12 Weeks","http://ClinicalTrials.gov/show/NCT00437125",NA
"21215",21215,"NCT00386425","Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)","Completed","Has Results","Severe Sepsis","Drug: Drotrecogin alfa (activated)","Eli Lilly and Company","Both","Adult|Senior","Phase II",486,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","10553|F1K-MC-EVDK","October 6, 2006","01/11/2006",2009-08-01,"November 18, 2010","01/11/2010","",2009-08-01,"Mean Change in Protein C Levels From Day 1 to Day 7|Mean Change in Protein C Level From Study Day 1 to Study Day 7 in Patients With Moderate and Severe Protein C Deficiency|Day 28 All-Cause Mortality|Hospital Mortality (up to Day 90)|28-Day Time Averaged Sequential Organ Failure (SOFA) Score|Number of Participants With Serious Adverse Events (SAE) and Serious Bleeding Events (SBE) by Time Period|Mortality by Protein C Normalized Versus Not-normalized","http://ClinicalTrials.gov/show/NCT00386425",NA
"21250",21250,"NCT00460525","Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali","Completed","Has Results","Plasmodium Falciparum Malaria","Biological: FMP2.1/AS02A|Biological: Rabies Vaccine","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Child","Phase II",400,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","07-0003|2U01AI065683-06|Malaria-056 (110060)","April 12, 2007","01/05/2007",2009-07-01,"January 13, 2011","01/08/2009","",2009-07-01,"Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination|Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Second Vaccination.|Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Third Vaccination.|Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the First Vaccination|Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Second Vaccination|Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Third Vaccination|Time to First Clinical Malaria Episode With Significant Parasitemia (2500/mm^3) and Temperature of Greater Than or Equal to 37.5 Degrees C.|Number of Subjects Reporting Serious Adverse Events|Incidence Density of Clinical Malaria Episode|Time to First Clinical Malaria Episode With Parasites With AMA-1 Genotype Homologous to the 3D7 Strain of P. Falciparum With Respect to Entire AMA-1 Sequence and With Respect to Key Amino Acid Residues.|Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by Enzyme Linked ImmunoSorbent Assay (ELISA) at Day 0|Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 30.|Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 60.|Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 90.|Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 150.|Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 240.|Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 364|Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 547|Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 730","http://ClinicalTrials.gov/show/NCT00460525",NA
"21278",21278,"NCT00546325","REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Rimonabant|Drug: Placebo","Sanofi-Aventis","Both","Adult|Senior","Phase III",358,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RIMON_L_01661","October 17, 2007","01/10/2007",2009-02-01,"December 9, 2010","01/12/2010","REASSURE",2009-02-01,"Absolute change in HbA1c between both placebo and rimonabant group.|Percentage of participants reaching the treat-to-target objective of HbA1c ??? 6.5% and ??? 7.0%|Percentage of participants responding to treatment|Rate of asymptomatic, symptomatic, and severe hypoglycaemia|Change in physical examinations, vital signs, laboratory parameters, adverse events|Change in insulin sensitivity, fasting plasma glucose, hypoglycaemia rate.|Change in BMI, waist and hip circumference, waist/hip ratio, weight|Changes in Quality of Life|Change in lipid measures: HDL (High Density Lipoprotein), LDL (Low-Density Lipoprotein), TG (Triglycerides), TC (Total Cholesterol), ApoB (Apolipoprotein B)|Change in adiponectin, fasting insulin, Blood Pressure, concomitant medications, health resource use, CRP (C Reactive Protein), ALT (Alanine Aminotransferase), albumin/creatinine ratio","http://ClinicalTrials.gov/show/NCT00546325",NA
"21294",21294,"NCT00542425","Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis","Completed","Has Results","Osteoporosis","Drug: teriparatide|Drug: Placebo|Drug: BA058 20 ??g|Drug: BA058 40 ??g|Drug: BA058 80 ??g","Radius Health","Female","Adult|Senior","Phase II",222,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","BA058-05-002","October 10, 2007","01/04/2007",2009-06-01,"June 30, 2010","01/06/2010","",2009-06-01,"Change in Marker of Bone Metabolism, PINP|Change in Bone Mineral Density, Total Spine.|Change in Bone Mineral Density, Femoral Neck.|Change in Bone Mineral Density, Total Hip.|Change in Bone Mineral Density, Total Spine.","http://ClinicalTrials.gov/show/NCT00542425",NA
"21312",21312,"NCT00600925","A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection","Completed","No Results Available","Colorectal Surgery|Surgical Wound Infection","Drug: gentamicin-collagen sponge dipped in saline","Innocoll Technologies|Duke University|Premier Research Group plc","Both","Adult|Senior","Phase III",600,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","INN-SWI-002","January 14, 2008","01/01/2008",2010-09-01,"October 18, 2010","01/07/2010","",2009-03-01,"Primarily, efficacy will be evaluated by a comparison between the 2 study groups of the incidence of surgical wound infections (involving the laparotomy incision) that occur within the period from surgery through postop day 60.|The effect of the gentamicin-collagen sponge on the proportion of patients with surgically treated surgical wound infections adjudicated by an independent blinded committee|The effect of the gentamicin-collagen sponge on the proportion of patients with deep incisional surgical wound infection based on CDC criteria adjudicated by an independent blinded committee.|The effect of the gentamicin-collagen sponge on the proportion of patients with superficial incisional surgical wound infection based on CDC criteria adjudicated by an independent blinded committee.|The effect of the gentamicin-collagen sponge on type of pathogen/bacteriology|The effect of the gentamicin-collagen sponge on the ASEPSIS score|The effect of the gentamicin-collagen sponge on length of hospital stay postoperatively.|The effect of the gentamicin-collagen sponge on rehospitalization for surgical wound infection.|The effect of the gentamicin-collagen sponge on the total hospitalization related costs.|Serum gentamicin levels in subjects receiving gentamicin-collagen sponge.|Serum gentamicin levels in subjects receiving reapplication of gentamicin-collagen sponge in cases of early reoperation.|Subject self-reported assessment of pain and wound healing based on a structured wound healing questionnaire.|Change in serum creatinine from baseline to peak.|Incidence of reported serious and nonserious AEs, including, but not limited to, development of renal failure, ileus, anastomitic leakage, and small-bowel obstruction.|All-cause mortality|Emergency Room and/or surgical office visits secondary to wound complaints.|The amount of pain medications administered","http://ClinicalTrials.gov/show/NCT00600925",NA
"21329",21329,"NCT00630825","A Study of Dose Titration of LY2189265 in Overweight Patients With Type 2 Diabetes Mellitus","Completed","No Results Available","Diabetes Mellitus Type 2","Drug: Placebo|Drug: LY2189265|Drug: LY2189265|Drug: LY2189265","Eli Lilly and Company","Both","Adult|Senior","Phase II",266,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","12068|H9X-MC-GBCJ","February 28, 2008","01/04/2008",2009-01-01,"December 9, 2009","01/12/2009","EGO",2009-01-01,"Evaluate once weekly injections of LY2189265 (adjusted and non-adjusted doses) compared to placebo on blood glucose as measured by HbA1C change from baseline in overweight patients with Type 2 Diabetes Mellitus|Fasting blood glucose|Meal test glucose excursion (change in blood glucose to test meal)|Self-monitoring of blood glucose (SMBG) 8-point profile|Body weight and waist circumference|B-cell function and insulin sensitivity as estimated by the updated Homeostasis Model Assessment tool (HOMA2)|Percentage of Patients achieving an HbA1C of < 7% and <, equal to 6.5%|Evaluate safety/tolerability of LY2189265 compared to placebo; Evaluate symptoms of nausea,vomiting,diarrhea,dyspepsia measured by Visual Analog Scale and Gastroparesis Cardinal Symptom Index questionnaire; Evaluate hypoglycemia, hyperglycemia,lipids|To characterize the pharmacokinetics (PK) of LY2189265 and the relationship between LY2189265 exposure and safety measures.|To measure and evaluate patient perception of medication effectiveness using the Perceptions about Medications - Diabetes (PAM-D-S) questionnaire.|To test the psychometric properties of the PAM-D-S and to validate its use for future clinical trials.","http://ClinicalTrials.gov/show/NCT00630825",NA
"21349",21349,"NCT00664625","A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects","Completed","No Results Available","Chronic Hepatitis C","Drug: BMS-791325|Drug: Placebo","Bristol-Myers Squibb","Both","Adult","Phase I|Phase II",24,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","AI443-002","April 18, 2008","01/05/2008",2009-06-01,"January 6, 2011","01/12/2009","",2009-06-01,"Safety Outcome Measures|Pharmacokinetic Measures|Pharmacodynamic Measures","http://ClinicalTrials.gov/show/NCT00664625",NA
"21352",21352,"NCT00665925","Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: Fostamatinib disodium (R935788)","Rigel Pharmaceuticals","Both","Adult|Senior","Phase II",420,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-935788-010","April 22, 2008","01/05/2008",2009-06-01,"September 15, 2009","01/09/2009","Taski-2",2009-06-01,"confirm the efficacy of R788 100 mg PO bid as determined by ACR20 responder rates at 6 months.|compare response rates for R788 100 mg PO bid and R788 150 mg PO qd as determined by ACR20, ACR50, ACR70, ACRn, DAS28-CRP and DAS28-ESR response rates over 6 months|To assess the rapidity of onset of clinical effect among the R788 100 mg PO bid, R788 150 mg PO qd, and placebo groups as determined by ACR20 response rates at Weeks 1 and 2|To compare changes for R788 100 mg PO bid and R788 150 mg PO qd in the FACIT-fatigue and SF-36 from baseline to 6 months|To assess and compare the safety profiles for R788 100 mg bid and R788 150 mg qd compared with placebo for effects on liver function tests, clinically significant reductions in peripheral neutrophil counts, G-I side effects and other adverse effect","http://ClinicalTrials.gov/show/NCT00665925",NA
"21362",21362,"NCT00668525","Escitalopram in Adult Patients With Major Depressive Disorder","Completed","Has Results","Major Depressive Disorder","Drug: Escitalopram|Drug: Placebo|Drug: Escitalopram","Forest Laboratories","Both","Adult","Phase III",877,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SCT-MD-49","April 28, 2008","01/04/2008",NA,"May 7, 2010","01/05/2010","",2009-02-01,"Change From Baseline in Total Montgomery Asberg Depression Rating Scale (MADRS) at 8 Weeks.|Change From Baseline in Hamiltion Rating Scale for Depression (HAM-D) at Week 8","http://ClinicalTrials.gov/show/NCT00668525",NA
"21370",21370,"NCT00702325","Phase4/Symbicort Versus Pulmicort Flexhaler in African Americans","Completed","No Results Available","Asthma","Drug: Budesonide /formoterol fumarate|Drug: Budesonide","AstraZeneca","Both","Child|Adult|Senior","Phase IV",300,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D589BL00003","June 19, 2008","01/06/2008",2009-09-01,"November 11, 2009","01/11/2009","Titan",2009-09-01,"change from baseline in the pre-dose forced expiratory volume in one second (FEV1) averaged over the double-blind treatment period|AM Peak Expiratory Flow (PEF)|PM Peak Expiratory Flow (PEF)|Spirometry Measures [forced vital capacity (FVC), forced expiratory flow (FEF)]","http://ClinicalTrials.gov/show/NCT00702325",NA
"21404",21404,"NCT00759525","The Role of Mineralocorticoid Receptors in Vascular Function","Completed","No Results Available","Apparent Mineralocorticoid Excess (AME)","Drug: Glycyrrhetic Acid|Drug: Placebo","Brigham and Women's Hospital","Both","Adult|Senior","Phase II|Phase III",20,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2001-P-001404","September 24, 2008","01/02/2002",2009-09-01,"October 16, 2009","01/10/2009","",2009-09-01,"To determine that inhibition of the enzyme 11-beta hydroxysteroid dehydrogenase (11-beta-HSD) will impair vascular smooth muscle function and endothelial function","http://ClinicalTrials.gov/show/NCT00759525",NA
"21414",21414,"NCT00772525","Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis|Optic Nerve|Neuritis","Drug: nerispirdine (HP184)|Drug: Placebo","Sanofi-Aventis","Both","Adult|Senior","Phase II",31,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","ACT10573","October 13, 2008","01/09/2008",2009-06-01,"December 18, 2009","01/12/2009","",2009-06-01,"Visual Evoked Potential (P100) - Latency|Contrast sensitivity score|ETDRS chart score|Visual Evoked Potentials (VEP) amplitude","http://ClinicalTrials.gov/show/NCT00772525",NA
"21428",21428,"NCT00797225","Efficacy and Safety Study in Endometriosis With NBI-56418; Placebo and Active Controlled","Completed","No Results Available","Endometriosis","Drug: NBI-56418 or placebo tablet ; leuprorelin or placebo injection","Neurocrine Biosciences","Female","Adult","Phase II",174,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NBI-56418-0703","November 21, 2008","01/11/2008",2010-05-01,"June 14, 2010","01/06/2010","Tulip Petal",2009-10-01,"Pain associated with endometriosis|Quality of life, patient impression of change. Safety measure: Laboratory testing including assessment of bone mineral density","http://ClinicalTrials.gov/show/NCT00797225",NA
"21432",21432,"NCT00805025","Evaluation of the Quality of Life Questionnaire-Bronchiectasis in Patients With Bronchiectasis","Completed","No Results Available","Bronchiectasis","Drug: aztreonam for inhalation solution","Gilead Sciences","Both","Adult|Senior","Phase II",92,"Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GS-US-219-0102","December 5, 2008","01/12/2008",2009-12-01,"February 24, 2010","01/02/2010","",2009-10-01,"The primary objective is to determine the reliability and validity of the QOL-B.|The secondary objective is to evaluate the responsiveness of the QOL-B to perceived changes in respiratory symptoms.","http://ClinicalTrials.gov/show/NCT00805025",NA
"21468",21468,"NCT00712725","MK3207 for Treatment of Acute Migraines (3207-005)(COMPLETED)","Completed","Has Results","Migraine","Drug: MK3207- 2.5 mg|Drug: MK3207- 5 mg|Drug: MK3207- 10 mg|Drug: MK3207- 20 mg|Drug: MK3207- 50 mg|Drug: MK3207- 100 mg|Drug: Comparator: placebo (unspecified)","Merck","Both","Adult","Phase II",676,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MK-3207-005|2008_536","July 8, 2008","01/07/2008",2009-02-01,"December 17, 2010","01/12/2010","",2009-01-01,"Pain Freedom (PF)|Pain Relief (PR)|Absence of Photophobia|Absence of Phonophobia|Absence of Nausea|Sustained Pain Freedom (SPF)","http://ClinicalTrials.gov/show/NCT00712725",NA
"21471",21471,"NCT00860925","PeriOperative ISchemic Evaluation-2 Pilot","Completed","No Results Available","Cardiovascular Disease","Drug: active clonidine|Drug: active ASA|Drug: Clonidine Placebo|Drug: ASA Placebo","McMaster University|The Physicians' Services Incorporated Foundation|Canadian Network and Centre for Trials Internationally","Both","Adult|Senior","Phase IV",90,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","POISE-2 01 2009","March 12, 2009","01/05/2009",2010-01-01,"March 8, 2010","01/03/2010","POISE2-pilot",2009-12-01,"Feasibility of recruiting 90 patients in 6 months|Feasibility of administering pre-operative ASA and clonidine|Preliminary estimate of major bleeding and clinically significant hypotension|Preliminary estimate of the composite of vascular death and non-fatal myocardial infarction.","http://ClinicalTrials.gov/show/NCT00860925",NA
"21473",21473,"NCT00871325","Effect of TU-100 on Gastrointestinal and Colonic Transit in Humans","Completed","No Results Available","Postoperative Ileus","Drug: TU-100","Tsumura USA","Both","Adult","Phase I|Phase II",60,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","TU100CPT1","March 26, 2009","01/06/2009",2010-01-01,"February 2, 2010","01/02/2010","",2009-12-01,"Gastric emptying of solid|Colonic geometric center at 24 hours|Ascending colon emptying|Colonic geometric center at 4 hours and 48 hours|Colonic filling at 6 hours|Stool frequency|Stool consistency","http://ClinicalTrials.gov/show/NCT00871325",NA
"21485",21485,"NCT00893425","Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria","Completed","No Results Available","Proteinuria|Diabetic Nephropathy|Chronic Kidney Disease","Drug: ramipril","Gulhane School of Medicine","Both","Adult","Phase IV",78,"Other","Interventional","Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind|Primary Purpose: Treatment","GATARAMCD9509","April 28, 2009","01/01/2008",2009-04-01,"June 2, 2009","01/06/2009","",2009-03-01,"Flow mediated dilatation|ADMA CD95","http://ClinicalTrials.gov/show/NCT00893425",NA
"21502",21502,"NCT00927225","Local Infiltration Analgesia in Bilateral Knee Arthroplasty - Efficacy of Subcutaneous Wound Infiltration With Local Anesthetic","Completed","No Results Available","Pain, Postoperative","Drug: ropivacaine 0.2%, 50 mL|Drug: normal saline","Hvidovre University Hospital|Lundbeck Foundation","Both","Adult|Senior","Phase IV",16,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H-D-2008-104","June 23, 2009","01/09/2008",2009-06-01,"June 23, 2009","01/06/2009","",2009-06-01,"Postoperative pain","http://ClinicalTrials.gov/show/NCT00927225",NA
"21526",21526,"NCT00955825","Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis","Completed","No Results Available","Grass Pollen-related Allergic Rhinoconjunctivitis","Biological: Grass pollen allergen extract|Drug: Placebo tablet","Stallergenes","Both","Adult","Phase III",473,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VO61.08 USA","August 3, 2009","01/10/2008",2009-08-01,"December 31, 2009","01/12/2009","",2009-08-01,"Average Combined Score (ACS): combined score will be calculated taking into account patient's daily RTSS ane RMS assuming equal weight for both scores. ACS will be calculated as the average of daily CS during the pollen period|Average Rhinoconjunctivitis Total Symptom Score (ARTSS): severity of the six rhinoconjunctivitis symptoms are evaluated daily and the daily total score recorded. ARTSS will be calculated as the average of all valid data during the pollen period.|Average Rescue Medication Score (ARMS): daily rescue medication use and corresponding score will be recorded. ARMS will be calculated as the average of all valid data during the pollen period|Proportion of Symptom-controlled Days (PSCD): Symptom-controlled days are days where RMS is equal to 0 and RTSS under a pre-defined threshold.|Average Adjusted Symptom Score (AASS): score taking account RTSS and rescue medication use. Symptom score will be adjusted according to the rescue medication use. AASS is calculated as the average of valid data during the pollen period.","http://ClinicalTrials.gov/show/NCT00955825",NA
"21532",21532,"NCT00968825","Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","Completed","No Results Available","Lateral Canthal Lines|Crow's Feet|Facial Wrinkles","Drug: Botulinum Toxin Type A|Drug: Placebo","Revance Therapeutics, Inc.","Both","Adult","Phase II",72,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RT001-CL012LCL","August 27, 2009","01/07/2009",2009-10-01,"November 16, 2009","01/11/2009","",2009-10-01,"The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line Severity at Rest from Baseline (Day 0) to Week 4; incidence of treatment emergent AEs|The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line Severity at Rest and Smile from Baseline (Day 0) to Week 4 and Baseline (Day 0) to Week 6; incidence of treatment emergent AEs","http://ClinicalTrials.gov/show/NCT00968825",NA
"21622",21622,"NCT01115725","A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f?ó (Filled-by-mass in a Prefilled Pen)","Completed","No Results Available","Infertility","Drug: Gonal-f (follitropin alfa)","Merck KGaA","Female","Adult","Phase IV",76,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMP25404","April 30, 2010","01/11/2005",2010-04-01,"May 3, 2010","01/04/2010","",2009-02-01,"Convenience assessment|Efficacy assessments|Safety and tolerance assessments","http://ClinicalTrials.gov/show/NCT01115725",NA
"21669",21669,"NCT01185925","Exercise Oscillatory Breathing and Sildenafil in Heart Failure","Completed","No Results Available","Heart Failure","Drug: Sildenafil","University of Milan","Male","Adult|Senior","Phase II",32,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","444-14|14a","August 19, 2010","01/04/2008",2010-06-01,"August 19, 2010","01/05/2008","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT01185925",NA
"21692",21692,"NCT01223625","Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function","Completed","No Results Available","Endothelial Dysfunction|Atherosclerosis","Drug: Rosuvastatin 5mg/day|Drug: Rosuvastatin 40mg/day","Odense University Hospital","Both","Adult|Senior","Phase IV",87,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","VF-200600","October 18, 2010","01/11/2007",2010-06-01,"October 18, 2010","01/07/2007","",2009-06-01,"The change from baseline in endothelium-dependent flow mediated vasodilatation of the brachial artery.|The change from baseline in endothelium independent flow mediated vasodilatation of the brachial artery","http://ClinicalTrials.gov/show/NCT01223625",NA
"21809",21809,"NCT00067626","Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes","Completed","No Results Available","Obesity|Pre-diabetes|Insulin Resistance|Impaired Glucose Tolerance|Impaired Fasting Glucose","Dietary Supplement: Chromium","Griffin Hospital|National Center for Complementary and Alternative Medicine (NCCAM)|Yale University","Both","Adult|Senior","Phase II",60,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R21 AT001332|R21AT001332","August 25, 2003","01/04/2005",2009-03-01,"October 14, 2010","01/10/2010","",2009-03-01,"Serum Insulin|2-hour Oral Glucose Tolerance Test|Homeostasis Model Assessment for Insulin Resistance (HOMA-IR)|HbA1C|blood pressure|lipid profile (total cholesterol, LDL, HDL, TG)|BMI|urine albumin:creatinine ratio|endothelial function measures as percent flow-mediated dilitation (FMD).","http://ClinicalTrials.gov/show/NCT00067626",NA
"21813",21813,"NCT00074126","CC-5013 in Treating Patients With Red Blood Cell Transfusion-Dependent Myelodysplastic Syndromes and a Cytogenetic Abnormality","Completed","No Results Available","Myelodysplastic Syndromes","Drug: lenalidomide","Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000343384|MSKCC-03085|CELGENE-CC-5013-MDS-003","December 10, 2003","01/07/2003",NA,"August 6, 2009","01/08/2009","",2009-05-01,"","http://ClinicalTrials.gov/show/NCT00074126",NA
"21880",21880,"NCT00170326","Progressive Ventricular Dysfunction Prevention in Pacemaker Patients","Completed","No Results Available","Cardiac Pacing Indication classI/IIa According AHA/ACC","Device: Biventricular Pacing","Medtronic Bakken Research Center|Medtronic","Both","Adult|Senior","Phase IV",108,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","PreVent-HF","September 13, 2005","01/01/2002",2009-03-01,"April 21, 2009","01/04/2009","Prevent-HF",2009-03-01,"Evolution of the ejection fraction (EF) of the left ventricle (LV) and the ventricular volumes.|Combined endpoint of cardiac mortality, appearance of HF and hospitalization due to cardiovascular problems. Morbidity.","http://ClinicalTrials.gov/show/NCT00170326",NA
"21911",21911,"NCT00228826","GVH 0313: Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies at High Risk for Transplant Related Mortality With Standard Transplantation","Completed","No Results Available","Graft vs Host Disease","Drug: Pentostatin","Emory University","Both","Child|Adult","Phase II",NA,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","045-2004","September 27, 2005","01/02/2004",2009-06-01,"June 29, 2009","01/09/2005","",2009-06-01,"","http://ClinicalTrials.gov/show/NCT00228826",NA
"21954",21954,"NCT00291226","Glycine vs Placebo for the Schizophrenia Prodrome","Completed","No Results Available","Schizophrenia Prodrome","Drug: Glycine|Drug: Placebo","Yale University|Glytech, Inc|National Alliance for Research on Schizophrenia and Depression","Both","Child|Adult","Phase II|Phase III",8,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Glytech|NARSAD Distinguished 2005","February 10, 2006","01/03/2006",2009-07-01,"January 13, 2010","01/01/2010","",2009-07-01,"Scale of Prodromal Symptoms total score","http://ClinicalTrials.gov/show/NCT00291226",NA
"21996",21996,"NCT00354926","Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma","Completed","No Results Available","Non-Hodgkin's Lymphoma","Biological: AME-133v (LY2469298)","Applied Molecular Evolution","Both","Adult|Senior","Phase I|Phase II",80,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AME 06.133v.A","July 18, 2006","01/07/2006",2009-01-01,"August 11, 2010","01/08/2010","",2009-01-01,"Adverse events and laboratory evaluations|Pharmacokinetic analysis and tumor evaluation by International Workshop criteria","http://ClinicalTrials.gov/show/NCT00354926",NA
"22018",22018,"NCT00383526","Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip?ó in the Elderly","Completed","No Results Available","Orthomyxoviridae Infection|Influenza|Myxovirus Infection","Biological: Inactivated, split-virion influenza vaccine|Biological: Inactivated, split-virion influenza vaccine","Sanofi-Aventis","Both","Adult|Senior","Phase III",3707,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","GID17","September 29, 2006","01/09/2006",2009-09-01,"February 9, 2010","01/02/2010","",2009-06-01,"To provide information concerning the immunogenicity of Inactivated, Split-Virion Influenza vaccine|To provide information concerning the safety of Inactivated, Split-Virion Influenza vaccine","http://ClinicalTrials.gov/show/NCT00383526",NA
"22035",22035,"NCT00417326","Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia","Completed","No Results Available","Community-Acquired Pneumonia","Drug: ONO-5046Na|Drug: ONO-5046Na","Ono Pharma","Both","Adult|Senior","Phase II",174,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ONO-5046Na-14","December 28, 2006","01/12/2006",NA,"December 11, 2009","01/12/2009","",2009-08-01,"pulmonary function|mortality|ventilator status","http://ClinicalTrials.gov/show/NCT00417326",NA
"22044",22044,"NCT00430326","Juvista (Avotermin) in Scars Following Varicose Vein Removal","Completed","No Results Available","Varicose Veins|Cicatrix","Drug: Avotermin","Renovo|ICON Clinical Research","Both","Adult|Senior","Phase II",156,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","RN1001-0042","January 31, 2007","01/11/2006",2009-04-01,"March 8, 2010","01/03/2010","",2009-01-01,"Investigator scar assessment|Patient scar assessment|Independent scar assessment|Local tolerance|Adverse events","http://ClinicalTrials.gov/show/NCT00430326",NA
"22054",22054,"NCT00419926","Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients","Completed","Has Results","Kidney Transplantation","Drug: Enteric-coated mycophenolate sodium (EC-MPS)","Novartis","Both","Adult","Phase IV",313,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CERL080A2419","January 8, 2007","01/12/2006",2009-06-01,"December 14, 2010","01/12/2010","",2009-06-01,"(ITT Analysis) Proportion of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death.|(PP Analysis) Proportion of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death.|(ITT Analysis) Comparison of Overall Treatment Failure at Days 21 and 84 Post-transplantation Assessed by Biopsy Proven Acute Rejection (BPAR), GFL, and Death.|(PP Analysis) Comparison of Overall Treatment Failure at Days 21 and 84 Post-transplantation Assessed by Biopsy Proven Acute Rejection (BPAR), GFL, and Death.|Renal Function Assessed by Glomerular Filtration Rate at Each Visit|Renal Function Assessed by Serum Creatinine at Each Visits.","http://ClinicalTrials.gov/show/NCT00419926",NA
"22094",22094,"NCT00496626","An Immunogenicity and Safety Study of Gardasil?ó in Chinese Subjects","Completed","Has Results","Papillomavirus Infections","Biological: Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil?ó)|Biological: Comparator: Placebo","Merck","Both","Child|Adult","Phase III",600,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2007_021|V501-030","July 3, 2007","01/07/2008",2009-06-01,"June 8, 2010","01/06/2010","",2009-02-01,"Geometric Mean Titer (GMT) of Anti-HPV 6, 11, 16 , 18 at Day 1 and Month 7 (1 Month After Completion of Administration of a 6-month 3-dose Regimen of Vaccines)|Number of Subjects Who Were Seronegative at Baseline and Developed Seropositive at Month 7|Serious Adverse Experiences and Systemic Adverse Experiences Occurring Within 14 Days After Each Vaccination, and Injection-site Complaints Occurring Day 1 Through Day 5 After Each Vaccination","http://ClinicalTrials.gov/show/NCT00496626",NA
"22107",22107,"NCT00492726","Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem","Completed","Has Results","Infection","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Ertapenem intravenous","Bayer","Both","Adult|Senior","Phase III",804,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","11976|EudraCT 2006-000874-56","June 26, 2007","01/07/2006",2009-02-01,"April 6, 2010","01/04/2010","",2009-02-01,"Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population|Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population|Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)|Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population|Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)|Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)|Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)|Number of Subjects Who Died Due to Intra-abdominal Infections|Duration of Hospitalization|Duration of Hospitalization Postoperatively","http://ClinicalTrials.gov/show/NCT00492726",NA
"22114",22114,"NCT00543426","Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis","Completed","No Results Available","Posthepatitic Cirrhosis","Drug: Fuzheng Huayu Tablets|Drug: sham Fuzheng Huayu Tablets (placebo)","Shanghai University of Traditional Chinese Medicine","Both","Adult","Phase IV",200,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06DZ19728","October 12, 2007","01/09/2007",2009-06-01,"June 2, 2009","01/06/2009","",2009-05-01,"the value of Child-Pugh and symptoms scale for Posthepatitic Cirrhosis|hepatic function; blood test; blood ammonia and blood sugar determination","http://ClinicalTrials.gov/show/NCT00543426",NA
"22126",22126,"NCT00564226","SSR240600C Treatment in Women With Overactive Bladder","Completed","No Results Available","Overactive Bladder","Drug: SSR240600C|Drug: tolterodine|Drug: placebo","Sanofi-Aventis","Female","Adult|Senior","Phase II",345,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","DRI6271|EudraCT 2007-004126-24","November 26, 2007","01/11/2007",2009-02-01,"September 22, 2009","01/09/2009","BILADY",2009-02-01,"Change from baseline in the number of micturitions per 24 hours|Changes from baseline in number of urge urinary incontinence episodes, in number of urgency episodes, in number of nocturia episodes, in volume of urine per void|Safety of SSR240600|Quality of life","http://ClinicalTrials.gov/show/NCT00564226",NA
"22143",22143,"NCT00587626","Proposal to Evaluate the Efficacy of the InterX 5000 in the Treatment of Chronic Neck and Shoulder Pain","Completed","No Results Available","Neck Pain|Shoulder Pain|Cervical Pain","Device: Inactive InterX 5000|Device: InterX 5000 Treatment","Hamilton Health Sciences Corporation|Canadian Memorial Chiropractic College|Neuro Resource Group","Both","Adult|Senior","Phase II",80,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","NRG","December 21, 2007","01/08/2007",2009-12-01,"June 24, 2010","01/06/2010","",2009-08-01,"Visual Analog Scale|Neck Disability Index (NDI)|Medical Outcomes Study Short-Form 36 (SF-36) Health Survey|Short-Form McGill Questionnaire|Biomarkers (inflammatory cytokines and SP)|Functional Impairment Test-Hand, and Neck, Shoulder, Arm (FIT-HaNSA)|Cervical Range of Motion (CROM)|Grip strength|Vibration threshold|Pain Tolerance and Threshold - Pressure|Pain Threshold and Tolerance - Current Perception|Current Perception Threshold|Neck Walk Index (NWI)|Muscle Fatigue","http://ClinicalTrials.gov/show/NCT00587626",NA
"22149",22149,"NCT00595426","A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery","Completed","No Results Available","Arthroplasty, Replacement, Knee","Drug: YM150|Drug: Warfarin","Astellas Pharma Inc","Both","Adult|Senior","Phase II",685,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","150-CL-033","January 7, 2008","01/05/2008",2009-05-01,"May 26, 2010","01/05/2010","PEARL",2009-05-01,"The incidence of total venous thromboembolisms (VTE).|The incidence of bleeding events classified as major by the Adjudication Committee|Evaluation of efficacy variables including: Proximal VTE, Distal VTE, Confirmed symptomatic VTE, death due to any cause|Incidence of the bleeding types: major, clinically relevant nonmajor, minor","http://ClinicalTrials.gov/show/NCT00595426",NA
"22158",22158,"NCT00527826","Influence Of Salmeterol/Fluticasone (50/500 BD)On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV","Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Salmeterol / Fluticasone (50/500 mcg ) BD fixed combination|Drug: Salmeterol / Fluticasone (50/500 mcg ) BD separate Inhalers","GlaxoSmithKline","Both","Adult|Senior","Phase IV",214,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SCO107227","September 10, 2007","01/11/2007",2009-07-01,"May 27, 2010","01/05/2010","",2009-07-01,"Mean Number of Exacerbations Per Year: Negative Binomial Model|Mean Number of Exacerbations Per Year: Poisson Model|Compliance and Adherence to Study Medication|Mean Number of COPD-related Visits at/by Physician|Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU)|Number of Participants With the Indicated Number of Hospital Stays|Mean Number of Days Rescue Medication Was Used|Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52|Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52|Mean Change From Baseline in the Tiffeaneau Index at Week 52|Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52|Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52|Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52|Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52|Mean Total Costs (Related to COPD) Per Participant","http://ClinicalTrials.gov/show/NCT00527826",NA
"22188",22188,"NCT00640926","Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia","Completed","Has Results","Community-Acquired Pneumonia (CAP)","Drug: Radezolid|Drug: Radezolid|Drug: Radezolid","Rib-X Pharmaceuticals, Inc.","Both","Adult","Phase II",158,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RX-1741-201","March 18, 2008","01/10/2007",2009-04-01,"February 11, 2010","01/02/2010","",2009-03-01,"Clinical Cure in the Clinically Evaluable (CE) Population at Test of Cure (TOC)","http://ClinicalTrials.gov/show/NCT00640926",NA
"22194",22194,"NCT00665626","Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)","Completed","No Results Available","Rheumatoid Arthritis","Drug: Fostamatinib disodium (R935788)","Rigel Pharmaceuticals","Both","Adult|Senior","Phase II",195,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-935788-011","April 22, 2008","01/05/2008",2009-06-01,"June 17, 2009","01/06/2009","Taski-3",2009-06-01,"The primary objective of this study is to assess the efficacy of R788 100 mg PO bid compared with placebo, as determined by ACR20 responder rates at Month 3.|To assess the response rate of R788 100 mg PO bid as determined by ACR50, ACR70, ACRn, DAS28-CRP, and DAS28-ESR at Month 3|To assess the rapidity of onset of clinical effect of R788 100 mg PO bid compared with placebo as determined by ACR20 response rates at Weeks 1 and 2|To assess the radiologic response of R788 100 mg PO bid compared with placebo as determined by Magnetic Resonance Imaging (MRI) using the modified RAMRIS scoring system of hands and wrists at baseline and Month 3|To assess and compare the safety profiles of R788 100 mg PO bid dose with placebo for effects on liver function tests, clinically significant reduction in peripheral neutrophil counts, G-I side effects and other adverse effects as they may appear.","http://ClinicalTrials.gov/show/NCT00665626",NA
"22214",22214,"NCT00699426","The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes","Completed","No Results Available","Type 2 Diabetes","Drug: nexium|Drug: nexium|Dietary Supplement: Yoghurt|Drug: placebo+placebo","Steno Diabetes Center|Novo Nordisk|Chr-Hansen|Statens Serum Institut","Both","Adult|Senior","Phase III",41,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EudraCT: 2007-00405237","June 16, 2008","01/06/2008",2009-06-01,"March 10, 2010","01/06/2008","Nexium",2009-06-01,"insulin secretion|blood pressure","http://ClinicalTrials.gov/show/NCT00699426",NA
"22229",22229,"NCT00724126","Rifaximin 3 Times/Day for Non-constipation IBS","Completed","No Results Available","Non-constipation Irritable Bowel Syndrome","Drug: Rifaximin|Drug: Placebo","Salix Pharmaceuticals","Both","Adult|Senior","Phase III",600,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RFIB3008","July 26, 2008","01/07/2008",2009-09-01,"December 21, 2009","01/12/2009","TARGET 2",2009-08-01,"Proportion of subjects achieving adequate relief of IBS symptoms","http://ClinicalTrials.gov/show/NCT00724126",NA
"22231",22231,"NCT00729326","Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: exenatide|Drug: sitagliptin|Drug: placebo|Drug: placebo","Amylin Pharmaceuticals, Inc.|Eli Lilly and Company","Both","Adult|Senior","Phase IV",64,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","H8O-US-GWCV","August 4, 2008","01/08/2008",2009-10-01,"February 8, 2010","01/08/2008","",2009-10-01,"Test the hypothesis that twice daily exenatide will result in a lower time-averaged glucose during a 24-hour period, compared with once daily oral sitagliptin, in patients with type 2 diabetes inadequately controlled on metformin or a TZD.|Compare exenatide and sitagliptin with respect to various pharmacodynamic measurements in subjects with type 2 diabetes mellitus.","http://ClinicalTrials.gov/show/NCT00729326",NA
"22261",22261,"NCT00768326","Efficacy of Lu 31-130 in Patients With Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Zicronapine|Drug: Zicronapine|Drug: Zicronapine|Drug: Zicronapine|Drug: Zicronapine|Drug: Placebo","H. Lundbeck A/S","Both","Adult","Phase II",280,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","11613A|EudraCT 2006-003739-57","October 7, 2008","01/03/2007",2009-11-01,"July 1, 2010","01/07/2010","",2009-10-01,"Safety: Adverse events, clinical safety laboratory tests (including liver biochemistry tests), metabolic parameters (including blood lipids, blood glucose weight, waist circumference), abnormal movements|Efficacy: Change in the Positive and Negative Syndrome Scale (PANSS) score from baseline to Week 8 as compared to placebo, change from baseline in Clinical Global Impression/Improvement (CGI-S/I) scores as compared to placebo","http://ClinicalTrials.gov/show/NCT00768326",NA
"22270",22270,"NCT00611026","Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.","Completed","Has Results","Overactive Bladder","Drug: Tolterodine ER|Drug: Placebo|Drug: Fesoterodine","Pfizer","Both","Adult|Senior","Phase III",2417,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","A0221046","January 28, 2008","01/02/2008",2009-10-01,"December 13, 2010","01/12/2010","",2009-10-01,"Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12|Change From Baseline in Mean Voided Volume Per Micturition|Change From Baseline in Mean Number of Micturitions Per 24 Hours|Percent Change From Baseline of Micturitions Per 24 Hours|Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours|Percent Change From Baseline of Nocturnal Micturitions Per 24 Hours|Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 1 and Week 4|Percent Change From Baseline of UUI Episodes Per 24 Hours|Change From Baseline in Mean Number of Urgency Urinary Episodes Per 24 Hours (Urinary Sensation Scale ??­3 in the Diary)|Percent Change From Baseline in Mean Number of Urgency Urinary Episodes Per 24 Hours (Urinary Sensation Scale ??­3 in the Diary)|Change From Baseline in Mean Number of Severe Urgency Episodes Per 24 Hours|Percent Change From Baseline of Severe Urgency Episodes Per 24 Hours|Change From Baseline in Mean Urinary Sensation Scale (USS) Rating Per Micturition Per 24 Hours.|Change From Baseline in Frequency-Urgency Sum (FUS) Per 24 Hours (Synonymous With USS Sum in the Study Protocol)|Diary Dry Rate: Percentage of Participants With no Urgency Urinary Incontinence (UUI) in the 3-day Bladder Diary|Change From Baseline in Patient Perception of Bladder Condition (PPBC)|Change From Baseline in Urgency Perception Scale (UPS). UPS Formerly Known as Patient Perception of Urgency Scale (PPUS) in the Protocol.|Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Symptom Bother Score at Week 12|Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Health Related Quality of Life (HRQL) at Week 12","http://ClinicalTrials.gov/show/NCT00611026",NA
"22285",22285,"NCT00809926","8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension","Completed","No Results Available","Stage 2 Hypertension","Drug: Valsartan/aliskiren|Drug: Valsartan","Novartis","Both","Adult|Senior","Phase IV",449,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","CSPV100AUS01","December 16, 2008","01/01/2009",NA,"October 15, 2009","01/10/2009","VANTAGE",2009-07-01,"Change in mean sitting systolic blood pressure (MSSBP)|Change in mean sitting diastolic blood pressure (MSDBP)|Percentage of patients achieving blood pressure control (defined as patients achieving a MSSBP <140 mmHg and MSDBP <90 mmHg)|Percentage of responders (defined as patients with MSSBP <140 mmHg or a decrease from baseline ??­20 mmHg)|Change from baseline in plasma renin activity (PRA) and plasma renin concentration (PRC)|Safety and tolerability of the valsartan and aliskiren combination (160/150 mg, 320/300 mg) compared to valsartan monotherapy (160 mg, 320 mg)","http://ClinicalTrials.gov/show/NCT00809926",NA
"22288",22288,"NCT00807326","A Comparison of Three Medications to Treat Diarrhea in Adults.","Completed","No Results Available","Diarrhea","Drug: Loperamide/simeticone 2 mg/125 mg caplets|Drug: Loperamide/simeticone 2 mg/125 mg chewable tablets|Drug: Probiotic Saccharomyces boulardii 250 mg capsules","Johnson & Johnson Consumer & Personal Products Worldwide","Both","Adult|Senior","Phase IV",415,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","LOPDIR4002","December 9, 2008","01/11/2008",2009-11-01,"February 23, 2010","01/02/2010","",2009-08-01,"Number of unformed stools|Number of unformed stools|Time to last unformed stool|Time to complete relief of abdominal discomfort|Time to complete relief of diarrhea|Proportion of subjects with complete relief of diarrhea|Gas-related abdominal discomfort ratings - change from baseline at subsequent time points|Proportions of subjects with complete well-being|Subject's evaluation of treatment effectiveness for overall illness relief, diarrhea relief and abdominal discomfort relief|Number of loperamide/simeticone 2 mg/125 mg caplets or chewable tablets or probiotic (Saccharomyces boulardii) 250 mg capsules used during the study|Frequency of complete well-being following diarrhea illness|Stool frequency|Frequency of diarrhea relapse|Safety Assessments will consist of monitoring and recording all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product.","http://ClinicalTrials.gov/show/NCT00807326",NA
"22301",22301,"NCT00838526","Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)","Completed","No Results Available","Gastroesophageal Reflux Disease (GERD)","Drug: Rabeprazole ER|Drug: Ranitidine","Eisai Inc.","Both","Adult|Senior","Phase III",240,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","E3810-G000-305|EudraCT No. 2007-007732-26","February 5, 2009","01/08/2008",2009-12-01,"March 17, 2010","01/03/2010","",2009-07-01,"The primary outcome measure will include: esophagogastroduodenoscopy (EGD), Investigator's assessment of symptoms, quality of life as recorded by subjects and concomitant use of dispensed antacid.|Secondary outcome measures will include: adverse events, electrocardiograms (ECGs), laboratory evaluations (hematology, blood chemistry, urinalysis, gastrin), gastric biopsies, physical exam and vital signs.","http://ClinicalTrials.gov/show/NCT00838526",NA
"22324",22324,"NCT00869726","A Study for Patients With Secondary Progressive Multiple Sclerosis","Completed","No Results Available","Secondary Progressive Multiple Sclerosis","Drug: dirucotide|Drug: Placebo","Eli Lilly and Company|BioMS Technology Corp.","Both","Adult","Phase II|Phase III",596,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12788|I3E-BM-MSAB|MBP8298-01","March 24, 2009","01/12/2004",2009-05-01,"May 27, 2010","01/05/2010","MAESTRO-01",2009-05-01,"Increase in the time to worsening of disability by Kurtzke Expended Disability Status (EDSS).|degree of change in EDSS|Brain Atrophy by MRI|Activity analysis of T2 and Gadolinium enhancing lesions|Lesion burden|Degree of change in MS Functional Composite Index (MSFC)|Relapse rates|Quality of life as measured by Short Form 36 (SF-36) or MSQoL54","http://ClinicalTrials.gov/show/NCT00869726",NA
"22326",22326,"NCT00872326","Autologous Bone Marrow Derived Mononuclear Cells in Treating Diabetic Patients With Critical Limb Ischemia","Completed","No Results Available","Peripheral Vascular Diseases|Diabetic Foot","Procedure: Autologous Bone Marrow Mononuclear Cells","Fundacion Progreso y Salud, Spain|Carlos III Health Institute","Both","Adult|Senior","Phase I|Phase II",20,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C/ICPD/2007|FPS C/ICPD/2007","March 30, 2009","01/12/2007",2009-05-01,"September 17, 2009","01/09/2009","",2009-04-01,"Angiographic evaluation of angiogenesis and vasculogenesis at target limb|Ankle-Brachial pressure index","http://ClinicalTrials.gov/show/NCT00872326",NA
"22341",22341,"NCT00902226","Safety of Escitalopram in Patients With Social Anxiety Disorder","Completed","No Results Available","Social Anxiety Disorder","Drug: Escitalopram","H. Lundbeck A/S","Both","Adult","Phase IV",30,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12133A","May 14, 2009","01/03/2009",2010-03-01,"March 30, 2010","01/03/2010","",2009-12-01,"Efficacy of escitalopram after 12 weeks of treatment in patients with SAD using Clinical Global Impression (CGI), Sheehan Disability Scale (SDS)|Evaluation of proportion of patients who responded to escitalopram during 12 weeks of treatment using the CGI-I definition|To evaluate safety in patients with SAD treated with escitalopram","http://ClinicalTrials.gov/show/NCT00902226",NA
"22356",22356,"NCT00920426","Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)","Completed","No Results Available","Infection, Human Immunodeficiency Virus","Drug: GSK1265744|Drug: Placebo","GlaxoSmithKline|Shionogi","Both","Adult","Phase II",9,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","112929","June 12, 2009","01/06/2009",2009-08-01,"September 23, 2010","01/09/2010","",2009-08-01,"Change from plasma HIV-1 ribonucleic acid (RNA) to Day 1|GSK1265744 PK parameters following dose administration on Day 1 and 10: AUC(0-24), Cmax, tmax, concentration at 24 hrs post dose(C24), terminal half-life(t1/2), absorption lag time(tlag), and apparent clearance(CL/F)|GSK1265744 PK parameters following last repeat administration on Day 10:AUC(0-tau), predose concentration(C0), concentration at end of dosing interval(Ctau), minimum observed concentration during one dosing interval(Cmin), Cmax, tmax, t1/2, and CL/F|Safety and tolerability: adverse events (AEs)|Safety and tolerability: clinical laboratory results|Safety and tolerability: vital signs|Safety and tolerability: electrocardiogram (ECG) assessments|Change from baseline in plasma HIV-1 RNA|Change from baseline in plasma HIV-1 RNA to nadir (maximum change) over 11 days|Plasma HIV-1 RNA rate of decline (slope)|Proportion of subjects with HIV-1 RNA<400 copies/mL|Proportion of subjects with HIV-1 RNA<50 copies/mL|Change from baseline in CD4+ cell count to Day 11|Emergence of drug resistance mutations, if appropriate|GSK1265744 Day 10 AUC(0-tau), Cmax, and Ctau compared to Day 1 AUC(0-24), Cmax, and C24, respectively, to estimate accumulation ratios (R) for AUC, Cmax, and Ctau|Pre-morning dose concentrations (C0) on Day 2 through 10 to assess the achievement of steady state of GSK1265744 following repeat administration","http://ClinicalTrials.gov/show/NCT00920426",NA
"22376",22376,"NCT00958126","A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA","Completed","No Results Available","Influenza","Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)|Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)|Biological: Placebo","CSL Limited","Both","Adult|Senior","Phase II",1313,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CSLCT-CAL-09-61","August 12, 2009","01/08/2009",2010-04-01,"May 17, 2010","01/05/2010","",2009-11-01,"Immunogenicity|Frequency, duration and intensity of solicited adverse events|Frequency, duration and intensity of unsolicited adverse events|Incidence of serious adverse events, adverse events of special interest and new onset of chronic illness","http://ClinicalTrials.gov/show/NCT00958126",NA
"22452",22452,"NCT01084226","Rye Bread Trial; Antioxidative and Cholesterol Lowering Effects","Completed","No Results Available","Hypercholesterol","Dietary Supplement: Rye-2008","Helsinki University|Samfundet Folkh??lsan|Sigrid Jus?¢lius Foundation|Fazer Bakeries","Both","Adult","Phase II",68,"Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)","1/13/03/00/08","March 9, 2010","01/02/2008",2010-02-01,"March 9, 2010","01/03/2010","Rye-2008",2009-04-01,"","http://ClinicalTrials.gov/show/NCT01084226",NA
"22466",22466,"NCT01099826","Increasing Colorectal Cancer (CRC) Screening In Primary Care","Completed","No Results Available","Colorectal Cancer Screening","Behavioral: Tailored counseling|Behavioral: Motivational Interview|Behavioral: control","Arizona State University|University of Illinois|Jesse Brown Veteran's Administration Medical Center|University of Utah|Vanderbilt University|Penn State University|Portland State University","Both","Adult|Senior","Phase III",511,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","R01NR8425","April 6, 2010","01/10/2004",2010-01-01,"April 7, 2010","01/04/2010","",2009-11-01,"completing CRC screening test","http://ClinicalTrials.gov/show/NCT01099826",NA
"22529",22529,"NCT01199926","Effect of Vitamin D Supplementation on Muscle Mass and Function","Completed","No Results Available","Vitamin D|Exercise|Muscles|Inflammation","Dietary Supplement: cholecalciferol|Drug: Placebo","Purdue University|Gatorade Sports Science Institute","Both","Adult","Phase IV",34,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","GSSI-VitD (0801006402)","September 9, 2010","01/08/2008",2010-02-01,"September 10, 2010","01/09/2010","",2009-07-01,"Muscle function, glucose tolerance, and inflammation","http://ClinicalTrials.gov/show/NCT01199926",NA
"22550",22550,"NCT01231126","Evaluation the Blood Loss in Pregnancies With Misoprostol-induced Labour","Completed","No Results Available","Pregnancy|Induced Labor","Drug: Misoprostol","Maternidade Escola Assis Chateaubriand","Female","Child|Adult","Phase IV",161,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","051/09","October 29, 2010","01/02/2008",2009-01-01,"November 15, 2010","01/01/2009","",2009-01-01,"Vaginal delivery|blood loss","http://ClinicalTrials.gov/show/NCT01231126",NA
"22646",22646,"NCT00053027","Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cladribine","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000269055|NCCTG-N0189","January 27, 2003","01/02/2003",NA,"December 2, 2009","01/09/2005","",2009-11-01,"Complete remission (CR) and complete remission unconfirmed (CRu) rate at the close of study therapy assessment (after 2, 4, or 6 courses)|Progression at any time after therapy","http://ClinicalTrials.gov/show/NCT00053027",NA
"22677",22677,"NCT00101127","Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma","Completed","No Results Available","Sarcoma","Biological: filgrastim|Biological: pegfilgrastim|Drug: docetaxel|Drug: gemcitabine hydrochloride","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000405892|GOG-0087L","January 7, 2005","01/12/2003",NA,"February 13, 2009","01/06/2006","",2009-01-01,"Antitumor activity|Toxicity","http://ClinicalTrials.gov/show/NCT00101127",NA
"22678",22678,"NCT00103727","Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Talnetant","GlaxoSmithKline","Both","Adult","Phase II",NA,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SB-223412/093","February 14, 2005","01/12/2004",2009-01-01,"January 6, 2011","01/01/2011","",2009-01-01,"The primary outcome measure is change in the Positive and Negative Syndrome Scale (PANSS) at Week 6 compared to baseline values.|The secondary measures assess both efficacy (cognition, depression) as well as a variety of safety/tolerability endpoints (adverse events, motor function, laboratory measures).","http://ClinicalTrials.gov/show/NCT00103727",NA
"22683",22683,"NCT00110227","Tai Chi Mind-Body Therapy for Chronic Heart Failure","Completed","No Results Available","Heart Failure","Behavioral: 12-week Tai Chi Program|Behavioral: 12-week Education Program","National Center for Complementary and Alternative Medicine (NCCAM)","Both","Adult|Senior","Phase III",100,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","R01 AT002454","May 4, 2005","01/09/2005",2009-07-01,"August 17, 2009","01/08/2009","NEXT-Heart",2009-01-01,"HF-specific quality of life|functional capacity|Walking Test|General quality of life|mood and emotional status|exercise self-efficacy|sense of coherence|utility assessment|beliefs, attitudes, and expectations|physical activity level|perceived social support|neurohormonal status|autonomic tone, heart rate variability|echocardiography|costs and use of HF services","http://ClinicalTrials.gov/show/NCT00110227",NA
"22684",22684,"NCT00111527","APAF: Assessment of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation","Completed","No Results Available","Congestive Heart Failure|Atrial Fibrillation","Other: Optimized echo-guided CRT pacing|Other: normal RV pacing","Arcispedale Santa Maria Nuova|Medtronic","Both","Adult|Senior","Phase III",458,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","1893A","May 20, 2005","01/05/2005",2010-03-01,"March 22, 2010","01/03/2010","",2009-08-01,"Short-term clinical study (6 months): Quality of life (measured as Minnesota Living with Heart Failure Questionnaire, Specific Symptom Scale and New York Heart Association classification) and exercise capacity at 6 months in the 2 study groups|Long-term clinical study (24 months): Composite end-point of: death due to cardiovascular cause, hospitalisation for worsening heart failure, worsening heart failure or failure to achieve a persistent subjective symptom improvement (clinical failure)|The evaluation of the predictive value of echo desynchronisation indexes (inter and intra-LV delays) for identification of clinical failure (see above)|Cost-benefit comparison of the 2 pacing strategies","http://ClinicalTrials.gov/show/NCT00111527",NA
"22696",22696,"NCT00129727","Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)","Completed","No Results Available","Ovarian Cancer","Drug: Paclitaxel|Drug: Carboplatin|Drug: bevacizumab","Massachusetts General Hospital|Women and Infants Hospital of Rhode Island","Female","Adult|Senior","Phase II",51,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-247","August 10, 2005","01/06/2005",2009-02-01,"August 7, 2009","01/08/2009","",2009-02-01,"To examine the toxicity, estimate the objective response rate, and progression free survival of carboplatin, paclitaxel, and bevacizumab followed by single agent bevacizumab as consolidation for advanced mullerian cancer|To estimate the objective response rate of carboplatin, paclitaxel, and bevacizumab","http://ClinicalTrials.gov/show/NCT00129727",NA
"22703",22703,"NCT00144027","Patient-Centered Medication Adherence Intervention for Schizophrenia","Completed","No Results Available","Schizophrenia","Behavioral: Antipsychotic medication adherence intervention","Department of Veterans Affairs","Both","Adult|Senior","Phase IV",120,"U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)","IIR 03-257","September 1, 2005","01/12/2004",2009-07-01,"May 6, 2010","01/09/2009","AMAIS",2009-06-01,"Antipsychotic medication adherence, psychosis symptom severity, and health related quality of life at baseline and 6-months|Cost-effectiveness analysis of intervention versus usual care","http://ClinicalTrials.gov/show/NCT00144027",NA
"22767",22767,"NCT00251927","Nexium vs. Surgery","Completed","No Results Available","Gastroesophageal Reflux","Drug: esomeprazole|Procedure: Laparoscopic fundoplication (surgery)","AstraZeneca","Both","Adult|Senior","Phase III",626,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D9612C00003|SH-NEG-0003","November 9, 2005","01/10/2001",2009-04-01,"January 7, 2010","01/01/2010","LOTUS",2009-04-01,"Time to treatment failure defined as need for medical treatment other than esomeprazole for control of reflux disease symptom|Efficacy endpoints including histopathological changes, scores of symptom variables, endoscopic assessments, assessment of 24h pH & Safety variables including lab tests, & all serious adverse events|Quality of life including patient reported outcomes assessed by GSRS & QOLRAD","http://ClinicalTrials.gov/show/NCT00251927",NA
"22801",22801,"NCT00105027","The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study","Completed","Has Results","Macular Edema, Cystoid|Retinal Vein Occlusion","Other: Standard Care|Drug: intravitreal triamcinolone injection|Drug: intravitreal triamcinolone injection","Allergan|National Eye Institute (NEI)","Both","Adult|Senior","Phase III",682,"Industry|NIH","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NEI-99|5U10EY014351-05|5U10EY014404|5U10EY014352","March 3, 2005","01/10/2004",2009-02-01,"December 16, 2010","01/12/2010","SCORE",2009-02-01,"The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit|Changes From Baseline in Best-corrected ETDRS Visual Acuity Score|Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography|Adverse Ocular Outcomes","http://ClinicalTrials.gov/show/NCT00105027",NA
"22821",22821,"NCT00335127","Chemotherapy and Total-Body Irradiation Followed By Autologous Lymphocyte Infusion, Aldesleukin, and Autologous Stem Cell Transplant in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)|Non-Melanomatous Skin Cancer","Biological: aldesleukin|Biological: filgrastim|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: autologous bone marrow transplantation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",108,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000480141|NCI-06-C-0136|NCI-P6763","June 7, 2006","01/04/2006",NA,"March 24, 2009","01/11/2008","",2009-03-01,"Complete tumor regression|Safety|Cell survival","http://ClinicalTrials.gov/show/NCT00335127",NA
"22830",22830,"NCT00350727","Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma","Completed","No Results Available","Glioma|Malignant Disease","Drug: lapatinib|Drug: pazopanib","GlaxoSmithKline","Both","Adult|Senior","Phase II",75,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VEG102857","July 10, 2006","01/12/2006",2009-12-01,"July 1, 2010","01/07/2010","VEG102857",2009-12-01,"Adverse events. Changes in vital signs. Changes in laboratory values.|Phase I: Pharmacokinetic parameters including AUC(0-24), [AUC(0-12) for patients on twice daily administration], Cmax, the time to maximum observed concentration (tmax) and C24 of pazopanib and lapatinib when administered in combination with EIAC.|Phase II: Pharmacokinetic parameters including AUC(0-24), [AUC(0-12) for patients on twice daily administration], Cmax, tmax, and C24 of pazopanib and lapatinib, as appropriate, when administered together in combination with non-EIAC.|Phase II: Plasma concentrations of the circulating biomarkers VEGF, sVEGFR-1, and sVEGFR-2.","http://ClinicalTrials.gov/show/NCT00350727",NA
"22834",22834,"NCT00362427","Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar?ó","Completed","No Results Available","Diphtheria|Pertussis|Polio|Hepatitis B|Tetanus","Biological: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|Biological: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|Biological: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC","Sanofi-Aventis|Merck","Both","Child","Phase II",460,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","PR504","August 9, 2006","01/08/2006",2009-03-01,"February 22, 2010","01/02/2010","",2009-02-01,"To provide information concerning the immune response of subjects that received PR5I concomitantly with Prevnar","http://ClinicalTrials.gov/show/NCT00362427",NA
"22856",22856,"NCT00393627","Behavioral Sleep Intervention in Adult Family Homes","Completed","No Results Available","Dementia","Behavioral: Sleep Education Program","University of Washington|Alzheimer's Association","Both","Child|Adult|Senior","Phase II",47,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","24091-G|03-7612-G 04","October 26, 2006","01/06/2006",2009-08-01,"June 25, 2010","01/06/2010","",2009-08-01,"Actigraphy sleep estimates","http://ClinicalTrials.gov/show/NCT00393627",NA
"22873",22873,"NCT00423527","Levetiracetam in Central Pain in Multiple Sclerosis(MS)","Completed","No Results Available","Multiple Sclerosis","Drug: levetiracetam","Odense University Hospital","Both","Adult|Senior","Phase IV",30,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","keppra3","January 16, 2007","01/01/2007",2009-01-01,"December 17, 2009","01/01/2007","",2009-01-01,"Pain relief rated on a 0 to 10 point numeric rating scale (median value for last treatment week of each period)|Pain rated on a 0 to 10 point numeric rating scale|Pain subtypes rated on the same scale.|Brush-evoked pain|Pin-prick-evoked pain|Cold-evoked pain|Health related quality of life (SF36)|Pain related sleep disturbance|Use of escape medication|Muscle spasms as measured on 2 different scales","http://ClinicalTrials.gov/show/NCT00423527",NA
"22890",22890,"NCT00422227","Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region","Completed","Has Results","Rheumatoid Arthritis","Drug: Etanercept , Methotrexate|Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide","Wyeth","Both","Adult|Senior","Phase IV",300,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0881A1-408","January 11, 2007","01/06/2007",2009-03-01,"July 28, 2010","01/07/2010","",2009-03-01,"Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks|Percentage of Participants Achieving ACR 20, 50, and 70 Responses|Percentage of Participants Achieving DAS28 <3.2 (Low Disease Activity) and <2.6 (Remission)|Percent Change From Baseline in DAS28 at Week 16|Percentage of Participants Achieving European League Against Rheumatism (EULAR) Moderate or Good Response|Percentage of Participants With DAS28 Improvement of ??­0.6 and ??­1.2|Percent Change From Baseline in Painful and Swollen Joint Counts|Percent Change From Baseline in Physician And Subject Global Assessments|Percent Change From Baseline in Duration (Minutes) of Morning Stiffness|Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales","http://ClinicalTrials.gov/show/NCT00422227",NA
"22901",22901,"NCT00463827","Effect of Statins on Asthma Control in Smokers With Asthma","Completed","No Results Available","Asthma|COPD|Smoking","Drug: Atorvastatin|Drug: atorvastatin|Drug: matched placebo","NHS Greater Clyde and Glasgow|University of Glasgow|Medical Research Council","Both","Adult","Phase II",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","AR 003","April 18, 2007","01/08/2007",2009-06-01,"January 15, 2010","01/10/2007","",2009-06-01,"Change in peak flow data|sputum cell counts|spirometry|airway responsiveness to methacholine|symptom scores|Exhaled and alveolar NO|Exacerbation rates|immunological tests in blood|ACQ score|AQLQ score","http://ClinicalTrials.gov/show/NCT00463827",NA
"22929",22929,"NCT00501527","Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense","Completed","No Results Available","Rhinitis, Allergic, Seasonal|Conjunctivitis, Allergic|Asthma","Biological: Immunotherapy with modified extract of P. pratense pollen|Other: Placebo","Laboratorios Leti, S.L.","Both","Child|Adult","Phase II",80,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2006-001437-18|6078-PG-OSL-145","July 13, 2007","01/09/2007",2009-10-01,"December 16, 2010","01/12/2010","",2009-10-01,"Symptom scores|Nasal provocation test|Dose-response skin prick-test|Asthma quality of life questionnaire (AQLQ)/Rhinoconjunctivitis quality of life questionnaire (RQLQ)|Medication scores|Visual scales|\In vitro\"" immunological tests|Record of adverse events""","http://ClinicalTrials.gov/show/NCT00501527",NA
"22941",22941,"NCT00524927","Safety and Efficacy of Methoxyflurane for Treatment of Incident Pain","Completed","No Results Available","Pain Measurement","Drug: Methoxyflurane|Drug: Normal Saline","Medical Developments International Limited|Australian Department of Industry, Tourism and Resources","Both","Adult|Senior","Phase IV",110,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Jun-61","September 2, 2007","01/09/2007",2009-11-01,"January 27, 2010","01/01/2010","",2009-11-01,"Determine where there is a difference in efficacy between Methoxyflurane and placebo for control of pain in participants undergoing a Bone Marrow Biopsy|Determine the safety of Methoxyflurane","http://ClinicalTrials.gov/show/NCT00524927",NA
"22945",22945,"NCT00530127","A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia","Completed","No Results Available","Friedreich's Ataxia","Drug: placebo|Drug: deferiprone|Drug: deferiprone|Drug: placebo|Drug: deferiprone","ApoPharma","Both","Child|Adult","Phase I|Phase II",80,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","LA29-0207","September 13, 2007","01/04/2008",2009-07-01,"May 31, 2010","01/05/2010","",2009-07-01,"The patient's tolerance of treatment will be determined, as assessed by the occurrence of adverse events|The efficacy endpoints will be change in the score for 9-Hole Peg Test (9HPT), Timed 25-Foot Walk (T25FW), Low-Contrast Letter Acuity test (LCLA), International Cooperative Ataxia Rating Scale (ICARS), and Friedreich's Ataxia Rating Scale (FARS).","http://ClinicalTrials.gov/show/NCT00530127",NA
"22965",22965,"NCT00562627","Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty","Completed","No Results Available","Osteoarthritis of the Knee","Drug: ropivacaine|Drug: adrenaline|Drug: ketorolac|Drug: morphine|Drug: fentanyl|Drug: bupivacaine","Asker & Baerum Hospital","Both","Adult|Senior","Phase IV",102,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007-003030-41|EudraCT 2007-003030-41|REK 1.2007.1603","November 21, 2007","01/11/2007",2009-07-01,"July 20, 2009","01/07/2009","",2009-06-01,"opioid use|Pain|time to discharge|Knee injury and osteoarthritis score|side effects and complications","http://ClinicalTrials.gov/show/NCT00562627",NA
"22972",22972,"NCT00531427","Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee","Completed","Has Results","Chronic Pain|Osteoarthritis of the Knee","Drug: Buprenorphine|Drug: Placebo","Purdue Pharma LP","Both","Adult|Senior","Phase III",567,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","BUP3025","September 17, 2007","01/09/2007",2009-11-01,"August 24, 2010","01/08/2010","",2009-04-01,"\Average Pain Over the Last 24 Hours\"" Score of the Study Knee at Week 12 of the Double Blind Phase.|Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Used From Week 2 to 12 of the Double-blind Phase.|Sleep Disturbance Subscale of the MOS-Sleep Scale at Weeks 4","http://ClinicalTrials.gov/show/NCT00531427",NA
"22977",22977,"NCT00589927","Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent","Completed","No Results Available","Coronary Artery Disease","Drug: cilostazol|Drug: placebo","CardioVascular Research Foundation, Korea|Otsuka Korea","Both","Adult|Senior","Phase IV",486,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007-0003","December 31, 2007","01/12/2007",2010-02-01,"March 17, 2010","01/07/2009","DECLARELONG",2009-12-01,"Angiographic in-stent late loss|Composite of death, MI, and target lesion or vessel revascularization at 12 months, In-stent and in-stent restenosis at 8 months, In-segment late loss at 8 months Adverse side effects during treatment","http://ClinicalTrials.gov/show/NCT00589927",NA
"22978",22978,"NCT00591227","Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: insulins aspart and detemir","Rush University Medical Center|Novo Nordisk","Both","Adult|Senior","Phase IV",176,"Other|Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","7070902","December 27, 2007","01/05/2008",2009-07-01,"September 27, 2010","01/09/2010","",2009-07-01,"length of stay in the hospital|average blood glucose during the hospital admission|frequency of hypoglycemia|efficacy of blood glucose lowering during the emergency room stay|frequency of hypoglycemia during emergency room therapy with insulin","http://ClinicalTrials.gov/show/NCT00591227",NA
"22988",22988,"NCT00599027","An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma","Completed","Has Results","Allergic Rhinitis|Asthma","Drug: Mometasone furoate nasal spray (MFNS)|Drug: Placebo nasal spray","Schering-Plough","Both","Adult|Senior","Phase III",51,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05277","January 10, 2008","01/05/2008",2009-05-01,"May 13, 2010","01/05/2010","",2009-05-01,"The Change of the Rhinasthma Global Summary Score From Baseline to Endpoint After 28 Days of Treatment.","http://ClinicalTrials.gov/show/NCT00599027",NA
"23001",23001,"NCT00578227","Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects","Completed","Has Results","Human Papillomavirus (HPV) Infection","Biological: Twinrix ?ºÑ Paediatric|Biological: Cervarix?ºÑ","GlaxoSmithKline","Female","Child","Phase III",814,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","110886","December 20, 2007","01/12/2007",2009-04-01,"March 25, 2010","01/03/2010","",2009-04-01,"Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies|Anti-Heptatis A (HAV) Antibody Titers.|Number of Subjects Seroprotected for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies|Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies|Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers|Anti-HBs Antibody Titers|Number of Subjects Seroconverted for Anti-HBs Antibodies|Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Vaccine Recipients Aged 9 Years|Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers in Vaccine Recipients Aged 9 Years|Number of Subjects Seroconverted for Anti-HAV Antibodies|Anti-HAV Antibody Titers|Number of Subjects Seroconverted and Number of Subjects Seroprotected for Anti-HBs Antibodies|Anti-HBs Antibody Titers|Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies|Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Medically Significant Conditions|Number of Subjects Reporting Medically Significant Conditions|Number of Subjects Reporting Unsolicited Adverse Events|Number of Subjects Reporting Serious Adverse Events (SAE)","http://ClinicalTrials.gov/show/NCT00578227",NA
"23004",23004,"NCT00630227","Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study","Completed","No Results Available","Homogeneous Emphysema","Biological: Biologic Lung Volume Reduction","Aeris Therapeutics","Both","Adult|Senior","Phase II",33,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-C07-002","February 27, 2008","01/02/2008",2009-12-01,"January 14, 2010","01/01/2010","",2009-12-01,"reduction in gas trapping|improvement in exercise capacity|improvement in expiratory flow|improvement in vital capacity|improvement in dyspnea sysmptoms|improvemnet in respiratory quality of life|serious adverse events","http://ClinicalTrials.gov/show/NCT00630227",NA
"23052",23052,"NCT00701727","Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study","Completed","No Results Available","Hypercholesterolemia","Drug: ezetimibe|Drug: Placebo","Radiant Research","Both","Adult|Senior","Phase IV",30,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","Ezetimibe RCT-001","June 17, 2008","01/06/2008",2009-03-01,"October 8, 2009","01/10/2009","",2009-03-01,"fecal excretion of plasma-derived cholesterol|de novo cholesterol synthesis (DNC)|Cholesterol efflux rate (Ra cholesterol|RCT efflux|Fasting lipid levels","http://ClinicalTrials.gov/show/NCT00701727",NA
"23073",23073,"NCT00735527","Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children","Completed","No Results Available","Status Epilepticus|Seizures","Drug: Lorazepam|Drug: Lorazepam","All India Institute of Medical Sciences, New Delhi","Both","Child","Phase III",140,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","INLOR","August 12, 2008","01/05/2008",2009-04-01,"May 4, 2009","01/05/2009","INLOR",2009-04-01,"Cessation of all clinical seizure activity within 10 min of drug administration|Persistent cessation of seizure activity for 1 hr|Patients requiring rescue medication within 1 hr|Time to achieve intra-venous access after arrival in casualty|Time from drug administration to termination of seizure(s)|Development of hypotension (fall of >/= 20 mmHg systolic and/ or >/= 10 mmHg diastolic pressure) within 1 hr of drug administration|Development of significant respiratory depression requiring assisted ventilation","http://ClinicalTrials.gov/show/NCT00735527",NA
"23091",23091,"NCT00744627","Efficacy and Safety of Lu AA21004 for Treatment of Generalized Anxiety Disorder in Adults.","Completed","No Results Available","Generalized Anxiety Disorder","Drug: Lu AA21004|Drug: Placebo","Takeda Global Research & Development Centre (Europe) Ltd.|H. Lundbeck A/S","Both","Adult|Senior","Phase III",301,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LuAA21004_311|2008-001766-90|U1111-1112-3487","August 29, 2008","01/09/2008",2009-07-01,"June 17, 2010","01/06/2010","",2009-07-01,"Least Squares Mean Change from Baseline in the 14-item Hamilton Anxiety Scale Total Score at Week 8.|Mean Change from Baseline in Hospital Anxiety and Depression Scale Anxiety Sub-Score at Week 8.|Mean Clinical Global Impression Scale-Global Improvement Scale at Week 8.|Mean Change from Baseline in Sheehan Disability Scale Total Score at Week 8.|Response Rates at Week 8, with response defined as a greater than or equal to 50% decrease in the Hamilton Anxiety Scale Total Score from Baseline.|Mean Change from Baseline in Hamilton Anxiety Scale Total Score in subjects with Baseline Hamilton Anxiety Scale greater than or equal to 25 at Week 8.|Mean Change from Baseline in 36-Item Short-Form Health Survey Social Functioning Sub-Score at Week 8.|Mean Change from Baseline in Hamilton Anxiety Scale Total Score at Week 1.|Mean Change from Baseline in Hamilton Anxiety Scale Total Score at Week 2.|Mean Change from Baseline in Hamilton Anxiety Scale Total Score at Week 4.|Mean Change from Baseline in Hamilton Anxiety Scale Total Score at Week 6.|Mean Change from Baseline in Hospital Anxiety and Depression Scale Anxiety Sub-Score at Week 1.|Mean Change from Baseline in Hospital Anxiety and Depression Scale Anxiety Sub-Score at Week 4.|Mean Clinical Global Impression Scale-Global Improvement Scale at Week 1.|Mean Clinical Global Impression Scale-Global Improvement Scale at Week 2.|Mean Clinical Global Impression Scale-Global Improvement Scale at Week 4.|Mean Clinical Global Impression Scale-Global Improvement Scale at Week 6.|Mean Change from Baseline in Sheehan Disability Scale Total Score at Week 1.|Mean Change from Baseline in Sheehan Disability Scale Total Score at Week 2.|Mean Change from Baseline in Sheehan Disability Scale Total Score at Week 4.|Response Rates at Week 1, with response defined as a ??­50% decrease in the Hamilton Anxiety Scale Total Score from Baseline.|Response Rates at Week 2, with response defined as a ??­50% decrease in the Hamilton Anxiety Scale Total Score from Baseline.|Response Rates at Week 4, with response defined as a ??­50% decrease in the Hamilton Anxiety Scale Total Score from Baseline.|Response Rates at Week 6, with response defined as a ??­50% decrease in the Hamilton Anxiety Scale Total Score from Baseline.|Mean Change from Baseline in Hamilton Anxiety Scale Total Score in subjects with Baseline Hamilton Anxiety Scale greater than or equal to 25 at Week 1.|Mean Change from Baseline in Hamilton Anxiety Scale Total Score in subjects with Baseline Hamilton Anxiety Scale greater than or equal to 25 at Week 2.|Mean Change from Baseline in Hamilton Anxiety Scale Total Score in subjects with Baseline Hamilton Anxiety Scale greater than or equal to 25 at Week 4.|Mean Change from Baseline in Hamilton Anxiety Scale Total Score in subjects with Baseline Hamilton Anxiety Scale greater than or equal to 25 at Week 6.|Remission Rates at Week 1, with remission defined as a Hamilton Anxiety Scale Total Score less than or equal to 7.|Remission Rates at Week 2, with remission defined as a Hamilton Anxiety Scale Total Score less than or equal to 7.|Remission Rates at Week 4, with remission defined as a Hamilton Anxiety Scale Total Score less than or equal to 7.|Remission Rates at Week 6, with remission defined as a Hamilton Anxiety Scale Total Score less than or equal to 7.|Remission Rates at Week 8, with remission defined as a Hamilton Anxiety Scale Total Score less than or equal to 7.|Mean Change from Baseline in Clinical Global Impression Scale-Severity of Illness Scale at Week 1.|Mean Change from Baseline in Clinical Global Impression Scale-Severity of Illness Scale at Week 2.|Mean Change from Baseline in Clinical Global Impression Scale-Severity of Illness Scale at Week 4.|Mean Change from Baseline in Clinical Global Impression Scale-Severity of Illness Scale at Week 6.|Mean Change from Baseline in Clinical Global Impression Scale-Severity of Illness Scale at Week 8.|Mean Change from Baseline in Hospital Anxiety and Depression Scale Sub-Score at Week 1.|Mean Change from Baseline in Hospital Anxiety and Depression Scale Sub-Score at Week 4.|Mean Change from Baseline in Hospital Anxiety and Depression Scale Sub-Score at Week 8.|Mean Change from Baseline in 36-Item Short-Form Health Survey Social Functioning Sub-Score at Week 2.|Mean Change from Baseline in 36-Item Short-Form Health Survey Social Functioning Sub-Score at Week 4.|Mean Change from Baseline in 36-Item Short-Form Health Survey Physical Functioning Sub-Score at Week 2.|Mean Change from Baseline in 36-Item Short-Form Health Survey Physical Functioning Sub-Score at Week 4.|Mean Change from Baseline in 36-Item Short-Form Health Survey Physical Functioning Sub-Score at Week 8.|Mean Change from Baseline in 36-Item Short-Form Health Survey Role-Physical Sub-Score at Week 2.|Mean Change from Baseline in 36-Item Short-Form Health Survey Role-Physical Sub-Score at Week 4.|Mean Change from Baseline in 36-Item Short-Form Health Survey Role-Physical Sub-Score at Week 8.|Mean Change from Baseline in 36-Item Short-Form Health Survey Bodily Pain Sub-Score at Week 2.|Mean Change from Baseline in 36-Item Short-Form Health Survey Bodily Pain Sub-Score at Week 4.|Mean Change from Baseline in 36-Item Short-Form Health Survey Bodily Pain Sub-Score at Week 8.|Mean Change from Baseline in 36-Item Short-Form Health Survey General Health Sub-Score at Week 2.|Mean Change from Baseline in 36-Item Short-Form Health Survey General Health Sub-Score at Week 4.|Mean Change from Baseline in 36-Item Short-Form Health Survey General Health Sub-Score at Week 8.|Mean Change from Baseline in 36-Item Short-Form Health Survey Vitality Sub-Score at Week 2.|Mean Change from Baseline in 36-Item Short-Form Health Survey Vitality Sub-Score at Week 4.|Mean Change from Baseline in 36-Item Short-Form Health Survey Vitality Sub-Score at Week 8.|Mean Change from Baseline in 36-Item Short-Form Health Survey Role-Emotional Sub-Score at Week 2.|Mean Change from Baseline in 36-Item Short-Form Health Survey Role-Emotional Sub-Score at Week 4.|Mean Change from Baseline in 36-Item Short-Form Health Survey Role-Emotional Sub-Score at Week 8.|Mean Change from Baseline in 36-Item Short-Form Health Survey Mental Health Sub-Score at Week 2.|Mean Change from Baseline in 36-Item Short-Form Health Survey Mental Health Sub-Score at Week 4.|Mean Change from Baseline in 36-Item Short-Form Health Survey Mental Health Sub-Score at Week 8.|Change from Baseline in Healthcare Resource Utilization as assessed by the Health Economic Assessment Questionnaire at Week 8.","http://ClinicalTrials.gov/show/NCT00744627",NA
"23109",23109,"NCT00795327","Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring","Completed","No Results Available","Acne Vulgaris","Device: Sculptra (Poly-L-Lactic Acid Dermal Implant)","Sanofi-Aventis","Both","Adult|Senior","Phase IV",22,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","POLYL_L_02508","November 20, 2008","01/10/2008",2009-09-01,"October 1, 2010","01/10/2010","",2009-09-01,"Physician Scar Improvement Scale (PSIS)|Self-Assessed Scar Improvement Scale (SASIS).|Degree of subject satisfaction with treatment|Adverse events","http://ClinicalTrials.gov/show/NCT00795327",NA
"23110",23110,"NCT00797927","Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: quetiapine|Other: no intervention","National Taiwan University Hospital|National Science Council, Taiwan","Both","Adult","Phase IV",30,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","200702010M","November 24, 2008","01/01/2007",2009-04-01,"April 27, 2009","01/04/2009","",2009-03-01,"The change from baseline in neurochemical peak area ratios (NAA/CRE, NAA/CHO, CHO/CRE) at the end of study|changes from baseline in PANSS","http://ClinicalTrials.gov/show/NCT00797927",NA
"23116",23116,"NCT00799227","Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema","Completed","No Results Available","Diabetic Macular Edema|Vitrectomy","Drug: Dexamethasone","Allergan","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","206207-018","November 26, 2008","01/01/2009",2009-12-01,"September 24, 2010","01/09/2010","",2009-12-01,"Change from baseline in mean central retinal thickness by optical coherence tomography (OCT)|Proportion of patients with at least 10 letters of improvement from baseline in best corrected visual acuity (BCVA)|Change from baseline in fluorescein leakage assessed by fluorescein angiography (FA)|Change from baseline in the scales of the NEI-VFQ-25","http://ClinicalTrials.gov/show/NCT00799227",NA
"23137",23137,"NCT00833027","ALPHA Sitagliptin Add on to Metformin","Completed","Has Results","Diabetes Mellitus","Drug: sitagliptin phosphate","Merck","Both","Adult|Senior","Phase IV",608,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009_527|MK0431-103","January 28, 2009","01/03/2008",2009-10-01,"August 26, 2010","01/08/2010","",2009-10-01,"Change From Baseline in HbA1c at Week 24|Change From Baseline in HbA1c at Week 12","http://ClinicalTrials.gov/show/NCT00833027",NA
"23180",23180,"NCT00913627","Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain","Completed","No Results Available","Pain","Drug: ibuprofen|Drug: ibuprofen|Drug: naproxen|Drug: Placebo","Wyeth","Both","Child|Adult","Phase II",196,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","AK-09-07","May 29, 2009","01/05/2009",2009-08-01,"August 12, 2009","01/08/2009","",2009-08-01,"SPID 0-12 (time weighted sum of pain intensity difference scores from 0-12 hrs) AND SPID 8-12 (time-weighted sum of pain intensity difference scores from 8-12 hrs)|Time to first perceptible relief confirmed by meaningful relief (onset) AND Time to treatment failure (time to first rescue medication or discontinuation due to lack of efficacy) AND Percentage of treatment failures by 8, 9, 10, 11 and 12 hours","http://ClinicalTrials.gov/show/NCT00913627",NA
"23198",23198,"NCT00944827","Combination Treatment With Green Tea Extract and Statins in Patients With Hypercholesterolemia","Completed","No Results Available","Hypercholesterolemia","Dietary Supplement: Green Tea Extract - Catechins|Dietary Supplement: Placebo","University of Thessaly|Center for Research and Technology Thessaly|General Hospital of Trikala, Dept of Internal Medicine|University General Hospital of Larissa, Dept of Medicine","Both","Adult","Phase II",40,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Supportive Care","3-22/846/06-2007|22/08-06-2007|no3/10-01-2007|846/22/15-06-2007","July 21, 2009","01/09/2007",2009-10-01,"December 2, 2010","01/07/2009","GTE-Stat",2009-10-01,"Reduction in Total CHO and LDH|lipids profile, body composition, visceral adiposity, Redox status, glucose disposal, Insulin sensitivity index, liver fat infiltration, quality of life parameters","http://ClinicalTrials.gov/show/NCT00944827",NA
"23224",23224,"NCT00981227","Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia","Completed","No Results Available","Postherpetic Neuralgia","Drug: Eslicarbazepine acetate|Drug: Placebo","Bial - Portela C S.A.","Both","Adult|Senior","Phase II",568,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BIA-2093-207","September 18, 2009","01/11/2007",2009-01-01,"September 21, 2009","01/09/2009","",2009-01-01,"The primary efficacy variable will be the change from baseline to endpoint in mean pain, recorded daily by the patient on a numerical scale.|responder rates (defined as a reduction in endpoint mean pain by at least 30% or at least 50% with respect to baseline)|daily mean pain intensity|weekly mean pain intensity|onset of therapeutic effect|pain assessed via the sensory portion of the Short-Form McGill Pain Questionnaire (SF-MPQ)|Patient Global Impression of Change (PGIC)|the dynamic allodynia (evoked pain) assessed by the Allodynia Severity Rating Scale,|sleep interference assessed by the Chronic Pain Sleep Inventory (CPSI?ó)|quality of life assessed by the SF-36 Health Survey|intake of rescue medication|adverse events (AEs), standard laboratory safety data (haematology, biochemistry), 12-lead electrocardiogram (ECG), vital signs (blood pressure, heart rate), physical and neurological examinations","http://ClinicalTrials.gov/show/NCT00981227",NA
"23237",23237,"NCT01005927","Fructooligosaccharide and Calcium Absorption in Adolescent Girls","Completed","No Results Available","Osteoporosis","Dietary Supplement: Fructooligosaccharide","Purdue University|Abbott Nutrition|GTC Nutrition","Female","Child","Phase I|Phase II",26,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","GTC Study","October 30, 2009","01/01/2009",2009-06-01,"July 27, 2010","01/07/2010","",2009-06-01,"Fractional Calcium Absorption|Bone density and geometry measured with peripheral quantitative computed tomography (pQCT)","http://ClinicalTrials.gov/show/NCT01005927",NA
"23251",23251,"NCT01031927","N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD)","Completed","No Results Available","Obsessive Compulsive Disorder","Drug: N-methyl glycine","China Medical University Hospital|Taipei City Hospital","Both","Adult","Phase II",30,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DMR96-IRB-75","December 13, 2009","01/06/2007",NA,"December 24, 2009","01/12/2009","",2009-02-01,"Yale-Brown Obsessive Compulsive Scale|Hamilton Anxiety Rating scale","http://ClinicalTrials.gov/show/NCT01031927",NA
"23258",23258,"NCT01042327","Study to Assess Clearances and Bio-compatibility of ELISIO Dialyzer","Completed","No Results Available","Chronic Kidney Disease","Device: ELISIO dialyzer","Royal Free Hampstead NHS Trust","Both","Adult|Senior","Phase IV",15,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","08/H0724/11","January 4, 2010","01/02/2009",2009-11-01,"January 4, 2010","01/02/2009","",2009-11-01,"solute clearances|erythropoietin requirements|effect on inflammatory markers|clotting potential","http://ClinicalTrials.gov/show/NCT01042327",NA
"23274",23274,"NCT01078727","Safety Study of Thermal Stimulation on Upper Extremity Motor Recovery to Stroke","Completed","No Results Available","Stroke","Device: A custom-made constant temperature thermal stimulation system (FIRSTEK, Model-B401L, B-300, local company, Taiwan).","Kaohsiung Medical University Chung-Ho Memorial Hospital|National Science Council, Taiwan|National Health Research Institutes, Taiwan|National Taiwan University|Kaohsiung Medical University","Both","Adult|Senior","Phase I|Phase II",25,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","KMUH-IRB-950320","February 11, 2010","01/08/2007",2010-01-01,"March 1, 2010","01/02/2008","",2009-07-01,"Stroke Rehabilitation Assessment of Movement|Action Research Arm Test|Barthel Index|Modified Ashworth Scale","http://ClinicalTrials.gov/show/NCT01078727",NA
"23283",23283,"NCT01091727","Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity","Completed","No Results Available","Neurogenic Detrusor Overactivity","Drug: Botulinum toxin A","Sunnybrook Health Sciences Centre|ethica Clinical Research Inc.","Both","Adult|Senior","Phase III",57,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","922006","March 22, 2010","01/10/2006",2009-04-01,"March 22, 2010","01/03/2010","",2009-04-01,"Efficacy|Efficacy","http://ClinicalTrials.gov/show/NCT01091727",NA
"23292",23292,"NCT01111227","Inflammatory Cytokines Profile in Individuals Subjected to Surgical Procedures Using Propofol or Isoflurane","Completed","No Results Available","Patients in Good Health","Drug: Propofol and isoflurane","UPECLIN HC FM Botucatu Unesp|Funda????o de Amparo ?? Pesquisa do Estado de S??o Paulo","Both","Adult","Phase IV",40,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","upeclin/HC/FMB-Unesp-40","March 11, 2010","01/03/2008",2009-12-01,"April 26, 2010","01/04/2010","",2009-12-01,"Evaluation of cytokines profile|Evaluation of pro and anti-inflammatory cytokines","http://ClinicalTrials.gov/show/NCT01111227",NA
"23302",23302,"NCT01125527","Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children","Completed","No Results Available","Haemophilus Influenzae Type b (Hib) Infection","Biological: Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)|Biological: Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)","Novartis|Novartis Vaccines","Both","Child","Phase III",700,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind|Primary Purpose: Prevention","V37_06","May 14, 2010","01/08/2009",2010-04-01,"May 17, 2010","01/05/2010","",2009-10-01,"Anti-PRP antibody levels at day 31 post last vaccination|Solicited local and systemic reactions, AEs, and SAEs","http://ClinicalTrials.gov/show/NCT01125527",NA
"23419",23419,"NCT00003128","Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus","Completed","No Results Available","Sarcoma","Biological: filgrastim|Drug: ifosfamide|Drug: paclitaxel","Gynecologic Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Female","Adult|Senior","Phase III",166,"Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065891|GOG-0161|ECOG-G0161","November 1, 1999","01/11/1997",NA,"February 13, 2009","01/05/2004","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00003128",NA
"23438",23438,"NCT00006228","Trastuzumab Plus Interleukin-2 in Treating Patients With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: aldesleukin|Biological: trastuzumab","Arthur G. James Cancer Hospital & Richard J. Solove Research Institute|National Cancer Institute (NCI)","Both","Child|Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068150|OSU-99H0192|OSU-9945|NCI-195","September 11, 2000","01/01/2001",NA,"February 6, 2010","01/12/2003","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT00006228",NA
"23474",23474,"NCT00060528","Sequential Vaccinations in Prostate Cancer Patients","Completed","No Results Available","Prostatic Neoplasms","Drug: Recombinant Vaccinia-PSA(L155)-TRICOM (PROSTVAC-V/TRICOM)|Drug: Recombinant Fowlpox-PSA(L155)-TRICOM (PRSTVAC-F/TRICOM)|Drug: Recombinant Fowlpox-GM-CSF","National Cancer Institute (NCI)","Male","Adult|Senior","Phase II",47,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","030176|03-C-0176","May 7, 2003","01/05/2003",2009-10-01,"September 17, 2010","01/07/2010","",2009-10-01,"T cell precursor frequency as measured by Enzyme-linked ImmunoSpot Assay (ELISPOT) assay.|Clinical response","http://ClinicalTrials.gov/show/NCT00060528",NA
"23519",23519,"NCT00129428","Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix","Completed","No Results Available","Keloid|Scleroderma, Localized|Acne Keloidalis|Scars|Granuloma Annulare","Procedure: UVB Irradiation","University of Michigan","Both","Child|Adult|Senior","Phase I|Phase II",50,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","Derm 447","August 9, 2005","01/08/2002",2009-01-01,"July 29, 2009","01/07/2009","",2009-01-01,"Improvement in appearance of keloids (hypertrophic scars), scleroderma, acne keloidalis nuchae,old burn scars, granuloma annulare, and related conditions with altered dermal matrix|Assays to be performed on biopsy specimens may include any or all of the following assays: in situ hybridization, immunohistologic analysis, in situ zymography, radioimmunoassay, and Western blot analysis|Photographs will also be taken.","http://ClinicalTrials.gov/show/NCT00129428",NA
"23578",23578,"NCT00213928","Horse Chestnut Seed Extract for Lymphedema","Completed","No Results Available","#NAME?","Drug: horse chestnut seed extract","University of Wisconsin, Madison","Female","Child|Adult|Senior","Phase II",48,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Factorial Assignment|Masking: Single Blind","2004-050|CC 01106","September 13, 2005","01/05/2002",2005-12-01,"December 21, 2007","01/09/2005","",2009-12-01,"Reduction of arm lymphedema|- comparison of bioelectric impedance to measure lymphedema changes|- validation of bioelectric impedance to measure lymphedema changes|- validation of lymphedema questionnaire","http://ClinicalTrials.gov/show/NCT00213928",NA
"23647",23647,"NCT00312728","A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","Completed","No Results Available","Non-small Cell Lung Cancer|Brain Neoplasms","Drug: bevacizumab|Drug: erlotinib HCl|Drug: chemotherapy","Genentech","Both","Adult|Senior","Phase II",115,"Industry","Interventional","Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AVF3752g","April 7, 2006","01/03/2006",NA,"August 26, 2009","01/08/2009","",2009-06-01,"Symptomatic Grade ??­2 CNS hemorrhage|Overall survival|Serious and selected adverse events","http://ClinicalTrials.gov/show/NCT00312728",NA
"23672",23672,"NCT00353028","Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents","Completed","No Results Available","Major Depressive Disorder","Drug: Fluvoxamine maleate|Drug: Placebo","Solvay Pharmaceuticals","Both","Child|Adult","Phase IV",90,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","S114.3.117","July 14, 2006","01/10/2006",2009-07-01,"March 3, 2010","01/03/2010","",2009-07-01,"the time of onset of 50% decrease from baseline in the Japanese Version of the Structured Interview Guide for the Hamilton Depression Rating Scale (JSIGH-D) 17-item total score|The Clinical Global Impression(CGI) improvement at Week 8","http://ClinicalTrials.gov/show/NCT00353028",NA
"23696",23696,"NCT00388128","Caffeine and Intermittent Claudication","Completed","No Results Available","Intermittent Claudication","Drug: Caffeine 6mg/kg","University of Aarhus|Herning Hospital|Viborg Hospital","Both","Adult|Senior","Phase III",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2006-001902-10|2006/168","October 12, 2006","01/09/2006",2009-09-01,"October 22, 2009","01/10/2009","",2009-05-01,"Quality of life|Maximum walking distance|Painfree Walking Distance|Max muscle strength (MVC) of kneeextension|Endurance of 50%MVC kneeextension|Postural stability|Reaction speed|Cognitive function|Walking Impairment Questionnaire|vascular endothelian growth factors VGF. FGF","http://ClinicalTrials.gov/show/NCT00388128",NA
"23698",23698,"NCT00386828","Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial","Completed","No Results Available","Advanced Colorectal Cancer","Drug: Bevacizumab:","British Columbia Cancer Agency","Both","Adult|Senior","Phase II",43,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PROTOCOL NUMBER: OZM-004|A-CORRECT Study","October 11, 2006","01/10/2006",2009-05-01,"November 24, 2010","01/11/2010","",2009-05-01,"The primary endpoint is pathologic complete response (pCR) rate|Rate of Sphincter Sparing Surgery:|Complete Resection Rate|Post-Surgical Complication Rates:","http://ClinicalTrials.gov/show/NCT00386828",NA
"23711",23711,"NCT00402428","Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients","Completed","No Results Available","Chronic Hepatitis C","Drug: albumin interferon alfa-2b|Drug: peginterferon alfa-2a|Drug: Ribavirin","Human Genome Sciences|Novartis","Both","Adult|Senior","Phase III",1331,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HGS1008-C1060|ACHIEVE-1","November 20, 2006","01/12/2006",2009-02-01,"September 17, 2009","01/09/2009","",2009-02-01,"Sustained virologic response (SVR)|Rapid virologic response|Early virologic response|Undetectable HCV RNA|Normalization of ALT (a liver enzyme)|Quality of life evaluation|Safety assessments (physical exams, AE reporting, lab testing/analysis, HADS and Immunogenicity testing)","http://ClinicalTrials.gov/show/NCT00402428",NA
"23715",23715,"NCT00423228","Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease","Completed","No Results Available","Moderate Alzheimer's Disease","Drug: ZT-1|Drug: Donepezil","Debiopharm S.A.","Both","Adult|Senior","Phase II",128,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DEB-ZTSR-201|EUDRACT no. 2006-005161-18","January 17, 2007","01/02/2007",2009-09-01,"September 15, 2009","01/09/2009","BRAINz",2009-04-01,"Change in the MMSE score from baseline to week 25|Responder rate as defined by at least 2 points improvement in the MMSE score;|Change on the ADAS-Cog 11 items subscale;|Change in the NPI-Q;|Change on the IADL scale;|Patient's convenience questionnaire.","http://ClinicalTrials.gov/show/NCT00423228",NA
"23718",23718,"NCT00420628","Pediatric Zylet Safety and Efficacy Study","Completed","Has Results","Chalazion|Hordeolum","Drug: loteprednol etabonate/tobramycin opthalmic suspension|Drug: vehicle","Bausch & Lomb, Inc.","Both","Child","Phase IV",108,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","459","January 8, 2007","01/11/2006",2009-06-01,"August 27, 2010","01/08/2010","",2009-01-01,"Treatment Emergent Adverse Events|Investigators Global Assessment of the Clinical Condition|Assessment of Ocular Signs in the Study Eye - Visit 1|Assessment of Ocular Signs in the Study Eye - Visit 2|Assessment of Ocular Signs in the Study Eye - Visit 3","http://ClinicalTrials.gov/show/NCT00420628",NA
"23730",23730,"NCT00458328","The Effect of Z-338 in Subjects With Functional Dyspepsia","Completed","No Results Available","Functioanl Dyspepsia","Drug: Z-338","Zeria Pharmaceutical","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","99010208","April 9, 2007","01/04/2007",2010-07-01,"November 21, 2010","01/11/2010","",2009-09-01,"Distal stomach square, Gastric emptying, Motility index, Duodenogastric reflux index","http://ClinicalTrials.gov/show/NCT00458328",NA
"23732",23732,"NCT00460928","Preventive IVIG Therapy for Congenital Heart Block","Completed","No Results Available","Congenital Heart Block|Neonatal Lupus|Autoantibody-Associated Heart Block","Drug: intravenous immune globulin (IVIG)","New York University School of Medicine|Alliance for Lupus Research","Female","Adult","Phase II|Phase III",54,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","H-07-045","April 13, 2007","01/04/2007",2009-06-01,"June 23, 2009","01/06/2009","PITCH",2009-06-01,"2nd or 3rd degree heart block|Prolonged PR interval (>0.150 sec)|Sign of myocardial injury, w/o change in heart rate/rhythm|Echocardiographic density consistent with EFE|Fetal death|Rash consistent w neonatal lupus|Gestational age at birth|Birth weight|Abnormal fluid collection","http://ClinicalTrials.gov/show/NCT00460928",NA
"23738",23738,"NCT00468728","PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","Completed","No Results Available","Clostridium Infections|Diarrhea","Drug: PAR-101/OPT-80|Drug: Vancomycin","Optimer Pharmaceuticals","Both","Child|Adult|Senior","Phase III",536,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","101.1.C.004|101.1.C.004","May 1, 2007","01/04/2007",2009-12-01,"August 30, 2010","01/08/2010","",2009-11-01,"Cure rate at end of therapy|Recurrence","http://ClinicalTrials.gov/show/NCT00468728",NA
"23761",23761,"NCT00503828","Derris Scandens Benth Extract VS Naproxen in Knee OA","Completed","No Results Available","Knee Osteoarthritis","Drug: Derris scandens Benth extracts|Drug: naproxen","Mahidol University|Ministry of Health, Thailand","Both","Adult|Senior","Phase III",120,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind|Primary Purpose: Treatment","Siriraj CEU 50-001","July 18, 2007","01/07/2007",2009-03-01,"January 11, 2010","01/06/2009","",2009-03-01,"WOMAC score|6-minute walk, Quality of Life, adverse event","http://ClinicalTrials.gov/show/NCT00503828",NA
"23764",23764,"NCT00498628","Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency","Completed","No Results Available","Alcoholism|Alcohol Abuse","Drug: Quetiapine fumarate|Other: Placebo","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Department of Veterans Affairs|National Institute on Drug Abuse (NIDA)|AstraZeneca","Both","Adult","Phase II",224,"NIH|U.S. Fed|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","NIAAA_DTRR-2007-LITTEN-01","July 6, 2007","01/12/2007",2009-11-01,"February 2, 2010","01/02/2010","",2009-08-01,"Percentage of Days of Heavy Drinking","http://ClinicalTrials.gov/show/NCT00498628",NA
"23779",23779,"NCT00528528","VX-950-TiDP24-C208: An Open-label Study of Telaprevir Administered Every 12 or Every 8 Hours in Combination With Standard Treatment in Treatment Naive Patients With Chronic Genotype 1 Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic","Drug: Telaprevir","Tibotec BVBA","Both","Adult","Phase II",164,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR013516","September 10, 2007","01/11/2007",2009-09-01,"December 16, 2010","01/12/2010","",2009-07-01,"This is an exploratory study. Effectiveness, viral characteristics, safety and the pharmacokinetic/pharmacodynamic relationship will be studied|Effectiveness, viral characteristics, safety and the pharmacokinetic/pharmacodynamic relationship will be studied","http://ClinicalTrials.gov/show/NCT00528528",NA
"23825",23825,"NCT00597428","Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone","Completed","No Results Available","Opioid-Induced Bowel Dysfunction","Drug: Lubiprostone|Drug: Placebo","Sucampo Pharmaceuticals, Inc.|Takeda Pharmaceutical Company Limited","Both","Adult|Senior","Phase III",420,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OBD0632","January 9, 2008","01/08/2007",2009-03-01,"December 10, 2009","01/12/2009","OPAL",2009-03-01,"Change from baseline in SBM frequency|Change from baseline in SBM frequency|First post-dose SBM (percentage of patients)|Responder rate|Mean changes from baseline in straining, stool consistency, constipation severity, abdominal bloating, abdominal discomfort, and bowel habit regularity|Treatment effectiveness","http://ClinicalTrials.gov/show/NCT00597428",NA
"23850",23850,"NCT00642928","Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients","Completed","No Results Available","Excessive Daytime Sleepiness|Parkinson's Disease","Drug: Placebo|Drug: BF 2.649 5 mg|Drug: BF 2.649 10 mg|Drug: BF 2.649 20 mg|Drug: BF 2.649 40 mg","Bioprojet","Both","Adult|Senior","Phase II",108,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","P07-02/BF 2.649|Eudract number:2007-003512-57","March 21, 2008","01/10/2007",2009-06-01,"August 6, 2009","01/08/2009","",2009-03-01,"Epworth Sleepiness Scale scores (ESS)|Mean number of daytime sleep or sleepiness episodes and their duration|frequency of sleep attacks|UPDRS III for motor function|Clinical global impression scale","http://ClinicalTrials.gov/show/NCT00642928",NA
"23859",23859,"NCT00658528","Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)","Completed","No Results Available","Gastroesophageal Reflux Disease (GERD)","Drug: Rabeprazole sodium|Drug: Esomeprazole","Eisai Inc.","Both","Adult|Senior","Phase III",1060,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E3810-G000-301","April 9, 2008","01/02/2008",2010-01-01,"March 10, 2010","01/03/2010","",2009-09-01,"Upper GI endoscopy (EGD), symptoms based on subject's daily diary and Investigator's assessment.|Adverse events, Electrocardiograms (ECGs), laboratory evaluations (hematology, blood chemistry, urinalysis, serum gastrin), physical examinations, vital signs.","http://ClinicalTrials.gov/show/NCT00658528",NA
"23866",23866,"NCT00654628","Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)","Completed","Has Results","Hypercholesterolemia","Drug: ezetimibe (+) simvastatin","Merck","Both","Adult|Senior","Phase IV",173,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MK 0653A-172|2008_010","April 2, 2008","01/08/2007",2009-07-01,"October 28, 2010","01/10/2010","BRAVO",2009-07-01,"The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment.|The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 12-week Treatment.|Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6|Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 6|Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 6|Mean Percent Change of Triglycerides From Baseline at Week 6|Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12|Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 12|Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 12|Mean Percent Change of Triglycerides From Baseline at Week 12","http://ClinicalTrials.gov/show/NCT00654628",NA
"23885",23885,"NCT00694928","Vaginal Infection Study 2","Completed","No Results Available","Vaginal Infection","Drug: clindamycin phosphate/butoconazole nitrate|Drug: butoconazole nitrate","KV Pharmaceutical Company","Female","Child|Adult|Senior","Phase III",843,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CBC-303-603-622467","June 9, 2008","01/05/2008",2009-11-01,"November 30, 2009","01/11/2009","",2009-11-01,"The primary outcome measure of the study will be clinical symptom resolution|Secondary outcome measures will include laboratory assessments of presence or absence of vaginal infection.","http://ClinicalTrials.gov/show/NCT00694928",NA
"23889",23889,"NCT00698828","SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Cachexia","Drug: Placebo comparator|Drug: SUN11031","Asubio Pharmaceuticals, Inc.","Both","Adult|Senior","Phase II",225,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ASBI 307","May 1, 2008","01/03/2008",2009-10-01,"January 20, 2010","01/01/2010","",2009-09-01,"The physical performance|Safety and tolerability data as measured by adverse events, electrocardiograms, physical exams, clinical laboratory tests, vital signs, and lung function|Evaluate the effect of SUN11031 on body composition data","http://ClinicalTrials.gov/show/NCT00698828",NA
"23900",23900,"NCT00723528","A Verification Study of CNTO 1275 in Patients With Plaque Psoriasis","Completed","No Results Available","Psoriasis","Drug: CNTO 1275|Drug: CNTO 1275|Drug: Placebo|Drug: CNTO 1275","Janssen Pharmaceutical K.K.","Both","Adult|Senior","Phase III",158,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","CR015166|JNS009-JPN-02","July 24, 2008","01/03/2008",2010-03-01,"March 25, 2010","01/03/2010","",2009-01-01,"The proportion of patients who achieved >=75% improvement in Psoriasis Area and Severity Index (PASI) at Week 12.|The proportion of patients judged as","http://ClinicalTrials.gov/show/NCT00723528",NA
"23916",23916,"NCT00758628","Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.","Completed","No Results Available","Diabetic Macular Edema","Drug: Bromefenac|Drug: Blink","Bp Consulting, Inc","Both","Adult|Senior","Phase IV",50,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","1","September 22, 2008","01/08/2008",2009-05-01,"September 3, 2009","01/09/2009","",2009-05-01,"Macular/Foveal Thickness (on OCT) v/s Control Arm, compared to baseline evaluation.|Re-treatment rate and interval between successive sessions of ALT v/s Control Arm.","http://ClinicalTrials.gov/show/NCT00758628",NA
"23934",23934,"NCT00775528","Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis","Completed","Has Results","Cystic Fibrosis|Pancreatic Exocrine Insufficiency","Drug: Pancrelipase Delayed Release","Solvay Pharmaceuticals","Both","Child","Phase III",19,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S245.3.128","October 17, 2008","01/04/2009",2009-06-01,"October 25, 2010","01/10/2010","",2009-06-01,"Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE)|Stool Fat (% Fat)|Fat Intake (g)|Total Calorie Intake (kcal)","http://ClinicalTrials.gov/show/NCT00775528",NA
"23941",23941,"NCT00796328","Up-Down Determination of the ED90 of Phenylephrine for Hypotension Prophylaxis in Cesarean Delivery","Completed","No Results Available","Spinal Induced Hypotension in Cesarean Delivery","Drug: Phenylephrine infusion","IWK Health Centre","Female","Adult|Senior","Phase IV",40,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IWK-4462-2008","November 19, 2008","01/11/2008",2009-07-01,"August 7, 2009","01/11/2008","",2009-02-01,"The ED90 of phenylephrine infused intravenously from the time the spinal is administered until delivery to prevent the subjects systolic blood pressure from decreasing by 20% or below an absolute value (90 mmHg)","http://ClinicalTrials.gov/show/NCT00796328",NA
"23962",23962,"NCT00822328","Fermented Milk Drink on Human Intestinal Microflora","Completed","Has Results","Signs and Symptoms, Digestive","Dietary Supplement: Yakult?ó300|Dietary Supplement: Lactobacillus casei strain Shirota","Cheng Hsin Rehabilitation Medical Center","Both","Adult","Phase II",24,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CHGH-IRB(173)97B-13-1","January 9, 2009","01/01/2009",2009-03-01,"August 27, 2009","01/08/2009","",2009-03-01,"Modification of the Composition of the Intestinal Microflora: Bifidobacterium|Modification of the Composition of the Intestinal Microflora: Clostridium Perfringens|Modification of the Composition of the Intestinal Microflora: Escherichia Coli, Lactobacillus Spp., Lactobacillus Casei Shirota","http://ClinicalTrials.gov/show/NCT00822328",NA
"23988",23988,"NCT00871728","SCIO(Scoring Clinical Index for Onychomycosis) in Onychomycosis Treating With ITRACONOZOLE","Completed","No Results Available","Toenail Onychomychsis","Drug: anti-fungal drug within 3 month prior to study medication administration; Naillacquer within 1 month prior to study medication administration","Janssen Korea, Ltd., Korea","Both","Adult|Senior","Phase IV",131,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR013837","February 13, 2009","01/09/2007",2009-05-01,"April 26, 2010","01/04/2010","",2009-05-01,"Change in Scoring Clinical Index for Onychomycosis (SCIO) score|Mycological cure rate (KOH smear and culture test) and clinical cure rate (by appearance)","http://ClinicalTrials.gov/show/NCT00871728",NA
"24003",24003,"NCT00901628","Periarticular Multimodal Drug Injections in Total Knee Arthroplasty","Completed","No Results Available","Postoperative Pain After TKA","Drug: ropivacaine|Other: No-PMDI|Drug: morphine sulfate|Drug: ketorolac|Drug: epinephrine|Drug: cefuroxime","Seoul National University Hospital","Both","Adult|Senior","Phase IV",87,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","B-0804/056-021","May 13, 2009","01/04/2008",2009-04-01,"May 13, 2009","01/05/2009","",2009-03-01,"pain(VAS)|patient satisfaction|incidence of side effects & complications|PCA & acute pain rescuer consumption|ability to SLR|ROM","http://ClinicalTrials.gov/show/NCT00901628",NA
"24005",24005,"NCT00906828","Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors","Completed","No Results Available","Parkinson Disease","Drug: levodopa/carbidopa|Drug: entacapone|Drug: tolcapone","Uppsala University|Swedish Parkinson's Disease Foundation|Swedish Society for Medical Research","Both","Adult|Senior","Phase IV",10,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","DuoCOMT","May 19, 2009","01/10/2008",2009-11-01,"January 15, 2010","01/01/2010","DuoCOMT",2009-11-01,"Difference in coefficient of variation of levodopa in plasma between baseline (day 1) and each of the days on COMT inhibitors.|Difference in Treatment Response Scale between the treatments.","http://ClinicalTrials.gov/show/NCT00906828",NA
"24018",24018,"NCT00928928","Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer","Completed","No Results Available","Colorectal Cancer","Procedure: Open colectomy|Procedure: laparoscopic colectomy","G. Hatzikosta General Hospital|University of Ioannina","Both","Child|Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)","GH-1948-03|GHDS-12345-3","June 25, 2009","01/01/2008",NA,"June 25, 2009","01/06/2009","",2009-06-01,"Oxidative stress markers in patients with colorectal cancer operated with open or laparoscopic approach","http://ClinicalTrials.gov/show/NCT00928928",NA
"24033",24033,"NCT00948428","Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara?ºÑ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis","Completed","No Results Available","Actinic Keratoses","Drug: imiquimod|Drug: Aldara?ºÑ|Drug: Vehicle Cream","Actavis Mid-Atlantic LLC","Both","Adult|Senior","Phase III",462,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D94-3101-07","July 28, 2009","01/05/2008",2009-04-01,"August 13, 2010","01/08/2010","",2009-03-01,"Primary - Proportion of subjects in each treatment group with Complete Clearance of AK lesions.|The Partial Clearance rates, defined as the proportion of subjects with at least a 75% reduction in the number of AK lesions counted at Baseline and the proportion of subjects with Complete Clearance of AK lesions.","http://ClinicalTrials.gov/show/NCT00948428",NA
"24121",24121,"NCT01113528","Omega-3 and Aspirin in Periodontal Regeneration","Completed","No Results Available","Periodontal Disease","Other: Regenerative therapy (omega 3 PUFA plus low dose aspirin)|Drug: Sugar pill","October 6 University|Cairo University","Both","Adult","Phase II",40,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","HHDA-1962|October 6 U 196222","April 23, 2010","01/11/2009",2010-05-01,"May 13, 2010","01/05/2010","PR",2009-12-01,"Cytokine levels|Gingival inflammation|Healing after regenerative therapy","http://ClinicalTrials.gov/show/NCT01113528",NA
"24158",24158,"NCT01169428","Engaging Motivation for the Prevention of Weight Regain","Completed","No Results Available","Obesity","Behavioral: Mindfulness Based Weight Loss Management (MBWLM)|Behavioral: Behavioral: Standard Behavioral Weight-Loss Maintenence","Duke University|University of Pennsylvania|National Center for Complementary and Alternative Medicine (NCCAM)","Both","Adult|Senior","Phase II",95,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","Pro00013688|U01AT004159","July 22, 2010","01/07/2007",2010-06-01,"July 22, 2010","01/07/2010","EMPOWER",2009-07-01,"Weight Loss Maintenance|Body Mass Index|Waist circumference|Percent Body Fat|Psychological outcomes and lifestyle behavior|Biological markers of appetite|Glucose metabolism|Biological markers of inflammation","http://ClinicalTrials.gov/show/NCT01169428",NA
"24268",24268,"NCT00006229","Paclitaxel and Carboplatin With or Without BMS-275291 in Treating Patients With Advanced or Metastatic Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: paclitaxel|Drug: rebimastat","NCIC Clinical Trials Group","Both","Adult|Senior","Phase II|Phase III",NA,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Treatment","BR18|CAN-NCIC-BR18|BMS-CA161-003|CDR0000068153","September 11, 2000","01/04/2000",2009-02-01,"November 7, 2010","01/03/2010","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00006229",NA
"24291",24291,"NCT00031629","Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus","Completed","No Results Available","Sarcoma","Biological: filgrastim|Biological: pegfilgrastim|Drug: docetaxel|Drug: gemcitabine hydrochloride","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",51,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000069206|GOG-0131G","March 8, 2002","01/01/2002",NA,"February 5, 2009","01/12/2006","",2009-01-01,"Antitumor activity|Toxicity","http://ClinicalTrials.gov/show/NCT00031629",NA
"24294",24294,"NCT00047229","Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)","Completed","No Results Available","Liver Cancer","Biological: oblimersen sodium|Drug: doxorubicin hydrochloride","Princess Margaret Hospital, Canada|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000257565|PMH-PHL-011|NCI-5798","October 3, 2002","01/10/2002",NA,"April 4, 2009","01/08/2005","",2009-01-01,"Rate of objective response (complete and partial)|Stable disease rate|Duration of response|Progression-free survival rate|Median survival rate|Overall survival rate|Safety and tolerability","http://ClinicalTrials.gov/show/NCT00047229",NA
"24343",24343,"NCT00123929","Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: docetaxel|Drug: doxorubicin","Hospital San Carlos, Madrid|UNC Lineberger Comprehensive Cancer Center","Female","Adult|Senior","Phase II",250,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","05/117","July 22, 2005","01/01/2005",2009-05-01,"August 3, 2009","01/08/2009","",2009-05-01,"correlation of genetic tumoral pattern with response to docetaxel versus doxorubicin|response rate to doxorubicin versus docetaxel","http://ClinicalTrials.gov/show/NCT00123929",NA
"24384",24384,"NCT00188929","Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma, Non-Hodgkin","Procedure: PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)","University Health Network, Toronto|Princess Margaret Hospital, Canada","Both","Adult|Senior","Phase II",10,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","UHN REB 05-0339-C","September 12, 2005","01/08/2005",2009-07-01,"August 12, 2010","01/08/2010","",2009-07-01,"To quantify spatial and temporal treatment response to radiation therapy in patients with NHL using the co-registered CT and FDG-PET images and assess this response with temporal geometric models.|To assess the feasibility to spatially correlate the abnormalities on the CT image to the FDG uptake on the co-registered PET image using the geometric models.|To determine if the inclusion of a GTV based upon PET images alters (1) the treatment plan based on the initial planning CT; and (2) if GTVs based on CT or PET differ for adaptive plans.|To assess tumor metabolic activity in non-irradiated areas, if detected, and study its temporal changes during a course of radiation treatment (abscopal response).|To link the concentration of the biochemical marker lactate dehydrogenase (LDH) to treatment response.","http://ClinicalTrials.gov/show/NCT00188929",NA
"24403",24403,"NCT00222729","Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer","Completed","No Results Available","Cancer","Drug: Pemetrexed|Drug: Bevacizumab","University of Pittsburgh|Eli Lilly and Company|Genentech","Both","Adult|Senior","Phase II",20,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-002|12,158","September 16, 2005","01/11/2005",2009-09-01,"April 30, 2010","01/04/2010","",2009-09-01,"To evaluate the time to progression (primary endpoint) with the combination of pemetrexed and bevacizumab in recurrent or metastatic head and neck cancer.|To evaluate the objective response rate, duration of response, overall survival, and toxicities associated with the above therapy.|A secondary endpoint will be the objective response rate.A secondary endpoint will be the objective response rate. The target response rate for the combination is 40%, and if the target is in fact observed, its 95% confidence interval will be 30%.","http://ClinicalTrials.gov/show/NCT00222729",NA
"24419",24419,"NCT00243529","Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients","Completed","No Results Available","Melanoma Stage III or IV","Biological: autologous dendritic cell vaccine","Radboud University|Dutch Cancer Society","Both","Adult|Senior","Phase I|Phase II",64,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-2917|KWF 2003-2917","October 21, 2005","01/04/2004",NA,"September 28, 2009","01/02/2009","",2009-02-01,"Immune response|Safety","http://ClinicalTrials.gov/show/NCT00243529",NA
"24481",24481,"NCT00338429","Better Days, Better Nights: Treatment for Sleep Difficulties","Completed","No Results Available","Sleep Onset Latency and/or Bedtime Resistance","Behavioral: FHP Sleep Program","IWK Health Centre","Both","Child","Phase II",80,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","3104|NSHRF grant","June 15, 2006","01/04/2005",2009-05-01,"February 15, 2010","01/02/2010","",2009-05-01,"Child Sleep Habits Questionnaire|Sleep diary|Actigraph recordings","http://ClinicalTrials.gov/show/NCT00338429",NA
"24517",24517,"NCT00395629","Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis","Completed","No Results Available","Iron Overload in Hereditary Hemochromatosis","Drug: deferasirox","Novartis Pharmaceuticals","Both","Adult|Senior","Phase II",49,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CICL670A2202|EudraCT no. 2006-002102-57","November 1, 2006","01/08/2006",NA,"January 20, 2010","01/01/2010","",2009-03-01,"To explore the safety of ICL670 (dose range 5 to 20 mg/kg PO per day) in adult hemochromatosis patients homozygous for the C282Y mutation, with iron overload|To explore the effect of ICL670 on serum ferritin|To characterize the pharmacokinetics of ICL670 in patients with hereditary hemochromatosis","http://ClinicalTrials.gov/show/NCT00395629",NA
"24540",24540,"NCT00417729","Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DM","Completed","No Results Available","Diabetes Mellitus","Drug: Acarbose","Taichung Veterans General Hospital|Taipei Veterans General Hospital,Taiwan|Changhua Christian Hospital","Both","Adult|Senior","Phase IV",51,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB951004/C06211","January 1, 2007","01/01/2007",2009-01-01,"May 11, 2010","01/05/2010","",2009-01-01,"Mean Amplitude Glycemic Excursion|Oxidative stress|HbA1c|fasting glucose|Insulin response|Fasting lipids|hsCRP|oxLDL|Adiponectin","http://ClinicalTrials.gov/show/NCT00417729",NA
"24565",24565,"NCT00450229","Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer","Completed","No Results Available","Prostate Cancer","Dietary Supplement: DIM 200 mg daily|Other: Placebo|Dietary Supplement: 400mg DIM","University of Wisconsin, Madison|National Cancer Institute (NCI)","Male","Adult|Senior","Phase I|Phase II",45,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","CDR0000534115|P30CA014520|WCCC-CO05186|WCCC-H2006-0255|WCCC-06-1270-02","March 20, 2007","01/10/2006",2009-02-01,"March 23, 2010","01/03/2010","",2009-02-01,"Tissue levels of diindolylmethane (DIM) as measured by liquid chromatography/mass spectrometry (LC/MS) assay after completion of study treatment|Ratio of urinary 2-hydroxyestrone:16-hydroxyestrone as measured by LC/MS assay at 2 weeks and after completion of study treatment|Ratio of plasma insulin-like growth factor (IGF)-1:IGF binding protein-3 and plasma total prostate-specific antigen (PSA) as measured by ELISA at 2 weeks and after completion of study treatment|Serum testosterone as measured at 2 weeks and after completion of study treatment|mRNA expression of CYP1A1, CYP1A2, CYP2B1, and CYP3A enzymes in serum and fresh frozen tissue as measured by semiquantitative real-time polymerase chain reaction|Polymorphisms of CYP1A1, CYP1A2, CYP2B1, and CYP3A enzymes in polymorphonuclear leukocytes (PMNs) as measured by genotyping at 2 weeks and after completion of study treatment|DIM blood steady-state concentrations as measured by LC/MS at 2 weeks and after completion of study treatment|PSA, androgen receptor, Ki-67, and caspase 3 as measured by immunohistochemistry at 2 weeks and after completion of study treatment|Safety as measured by NCI CTCAE v3.0","http://ClinicalTrials.gov/show/NCT00450229",NA
"24578",24578,"NCT00485329","Assessment of the Safety and Efficacy of DERMASTREAM?ºÑ - ENZYSTREAM?ºÑ System for the Treatment of Chronic Venous Ulcers","Completed","No Results Available","Lower Extremity Chronic Venous Ulcers","Other: Papain|Other: Papain|Other: Papain","EnzySurge","Both","Adult|Senior","Phase I|Phase II",48,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","ENZ-DER-002-IL","June 10, 2007","01/07/2007",2009-03-01,"May 24, 2010","01/05/2010","ENZ-DER-002-IL",2009-03-01,"To demonstrate Dermastream-Enzystream safety|To demonstrate Dermastream-Enzystream safety|To demonstrate Dermastream-Enzystream safety|??ÑAssessment of changes in wound debridement status during treatment period|Assessment of wound closure|Assessment of wound closure|Assessment of wound closure","http://ClinicalTrials.gov/show/NCT00485329",NA
"24591",24591,"NCT00491829","Flibanserin Versus Placebo in Premenopausal Women With HSDD","Completed","No Results Available","Sexual Dysfunctions, Psychological","Drug: BIMT 17 BS 50 mg|Drug: BIMT 17 BS 100 mg","Boehringer Ingelheim Pharmaceuticals","Female","Adult|Senior","Phase III",949,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","511.77","June 25, 2007","01/06/2007",NA,"October 6, 2009","01/10/2009","",2009-03-01,"The primary endpoint is the change from baseline in the frequency of satisfying sexual events as measured by the eDiary. The comparison will be made between the four week baseline period and Week 21 to 24.|The first key secondary endpoint is the change from baseline in the monthly sum of responses to the eDiary daily desire question.|The second key secondary endpoint is the FSDS R.","http://ClinicalTrials.gov/show/NCT00491829",NA
"24610",24610,"NCT00530829","Impact of Home Zinc Treatment for Acute Diarrhea in Children","Completed","No Results Available","Diarrhea","Drug: zinc","Centers for Disease Control and Prevention|Kenya Medical Research Institute|International Centre for Diarrhoeal Disease Research, Bangladesh","Both","Child","Phase III",3000,"U.S. Fed|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDC-NCPDCID-4678","September 17, 2007","01/10/2007",2009-04-01,"March 8, 2010","01/03/2010","",2009-04-01,"To assess if access to zinc treatment for diarrhea in the home in addition to zinc treatment of diarrhea in the clinic leads to a greater reduction in the prevalence of diarrhea than giving zinc for treatment of diarrhea in the clinic only|To assess if access to zinc treatment for diarrhea in the home in addition to zinc treatment of diarrhea in the clinic decreases the likelihood of recurrent diarrhea episodes, acute respiratory infections, and antimicrobial use","http://ClinicalTrials.gov/show/NCT00530829",NA
"24615",24615,"NCT00533429","Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Patients With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: enzastaurin|Drug: pemetrexed|Drug: carboplatin|Drug: bevacizumab|Drug: Placebo","Eli Lilly and Company|Genentech","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","11398|H6Q-MC-S034","September 19, 2007","01/10/2007",2009-02-01,"February 16, 2010","01/02/2010","",2009-02-01,"Progression-free survival|Response rate|Overall survival|Time to progressive disease|Duration of response|Pharmacology toxicity","http://ClinicalTrials.gov/show/NCT00533429",NA
"24618",24618,"NCT00546429","DePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial","Completed","Has Results","Femoral Fracture (Proximal)","Device: Intramedullary nailing","DePuy Orthopaedics","Both","Adult|Senior","Phase IV",62,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4077","October 17, 2007","01/09/2006",2009-09-01,"December 9, 2010","01/12/2010","ATN",2009-09-01,"Success in Terms of the Merle D'Aubigne Score|Lower Extremity Measure (LEM)|Medical Imaging|Six Item Screener and Ambulatory Status|SF-12|Merle d'Aubigne and Postel","http://ClinicalTrials.gov/show/NCT00546429",NA
"24630",24630,"NCT00567229","Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: rituximab|Drug: lenalidomide|Genetic: microarray analysis|Other: flow cytometry|Other: laboratory biomarker analysis","Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",41,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000576698|MSKCC-07070","December 1, 2007","01/11/2007",NA,"March 7, 2009","01/12/2008","",2009-02-01,"Final response rate after 4 courses of treatment|Pre- and post-treatment analyses of peripheral blood and bone marrow lymphocyte subsets, NK cell phenotype, and ex vivo antibody-dependent cellular cytotoxicity","http://ClinicalTrials.gov/show/NCT00567229",NA
"24642",24642,"NCT00537329","Anidulafungin In Treatment Of Candidemia In Asian Subjects","Completed","Has Results","Candidemia","Drug: Anidulafungin","Pfizer","Both","Adult|Senior","Phase III",43,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A8851016|PF-03910960","September 25, 2007","01/01/2008",2009-03-01,"March 4, 2010","01/03/2010","",2009-03-01,"Number of Subjects With Global Response of Success at End of Treatment|Number of Subjects With Global Response of Success at Endpoints|Number of Subjects With Clinical Response of Success at Endpoints|Number of Subjects With Microbiological Response of Success at Endpoints|Time to Death From Any Cause|Time to Death Due to Candidemia|Absolute Values for ??-D-glucan Assay Results at Endpoints in Relation to Clinical Response Status of Success or Status of Failure at End of All Treatment|Change From Baseline for ??-D-glucan Assay Results at Endpoints in Relation to Clinical Response Status of Success or Status of Failure at End of All Treatment|Absolute Values for ??-D-glucan Assay Results at Endpoints in Relation to Microbiological Response Status of Success or Status of Failure at End of All Treatment|Change From Baseline for ??-D-glucan Assay Results at Endpoints in Relation to Microbiological Response of Status of Success or Status of Failure at EOT|Number of Subjects With Global Response of Success at EOT in Relation to Subject Subgroups","http://ClinicalTrials.gov/show/NCT00537329",NA
"24659",24659,"NCT00612729","Light Filters in Intraocular Lenses (IOLs) and Its Influence on Colour and Contrast Vision.","Completed","No Results Available","Cataract","Procedure: Polylens Y30 intraocular lens|Procedure: Orange Series Model PC 440 Y intraocular lens","Hospital Hietzing","Both","Adult|Senior","Phase IV",32,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","Ye-Or 2008","January 29, 2008","01/05/2008",2010-06-01,"August 16, 2010","01/12/2008","",2009-11-01,"contrast acuity|visual acuity and color vision|colour perception","http://ClinicalTrials.gov/show/NCT00612729",NA
"24677",24677,"NCT00641329","CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD","Completed","No Results Available","ADHD","Drug: CLONICEL (clonidine HCl sustained release)|Drug: Placebo","Addrenex Pharmaceuticals, Inc.","Both","Child","Phase III",198,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLON-302","March 19, 2008","01/02/2008",2009-02-01,"April 8, 2010","01/03/2009","",2009-02-01,"ADHDRS-IV Total Score|Treatment Emergent Adverse Events, Laboratory Tests, Vital Signs, and ECGs","http://ClinicalTrials.gov/show/NCT00641329",NA
"24690",24690,"NCT00655629","Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.","Completed","No Results Available","Erectile Dysfunction","Drug: Vardenafil ODT (BAY 38-9456)|Drug: Placebo","Bayer|GlaxoSmithKline|Schering-Plough","Male","Adult|Senior","Phase III",339,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","12094","April 4, 2008","01/04/2008",2009-02-01,"February 8, 2010","01/02/2010","",2009-02-01,"Positive change in IIEF-EF domain scores. Statistically significant simultaneous change from baseline for both SEP-2, and SEP-3|Percentage of subjects achieving \back to normal\"" erectile function (IIEF-EF > / = 26) at visit 4 (week 12) or LOCF;|All diary questions other than SEP 2 and 3 concerning erectile function administered over the entire treatment period;|Treatment Satisfaction Scale (TSS) to be administered at the randomization visit and the final visit (or at Premature Discontinuation).|A Global Assessment Question (GAQ) concerning the overall effect on erectile function to be administered at the final visit only.|Safety laboratory examinations","http://ClinicalTrials.gov/show/NCT00655629",NA
"24699",24699,"NCT00677729","Hypertonic Saline to Reduce Hospital Admissions in Bronchiolitis","Completed","No Results Available","Viral Bronchiolitis","Drug: solution contains 1 mg salbutamol plus 3% hypertonic saline|Drug: solution contains 1 mg salbutamol plus 0.9% saline","Queen's University|Kingston General Hospital|Religious Hospitallers of Saint Joseph of the Hotel Dieu of Kingston|Royal Victoria Hospital Of Barrie","Both","Child","Phase II",81,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","HSERFLA|PAED-214-08","May 2, 2008","01/11/2008",2009-05-01,"November 2, 2010","01/11/2010","",2009-04-01,"compare the rate of admission to hospital between the study and control groups|change in the RDAI between study entry and post-treatment.","http://ClinicalTrials.gov/show/NCT00677729",NA
"24701",24701,"NCT00680329","A Pilot Study of Travalert on Compliance in Patients Using Duotrav","Completed","No Results Available","Physician and Patient Estimation of Adherence|Influence of TravAlert on General Well-being|Assessment of TravAlert's Reinforcement of Patient Adherence","Device: TravAlert Dosing Aid","Alcon Research","Both","Adult|Senior","Phase IV",50,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","EMD-07-02","May 16, 2008","01/05/2008",NA,"January 15, 2010","01/01/2010","",2009-07-01,"General compliance measures for once daily dosing with TravAlert","http://ClinicalTrials.gov/show/NCT00680329",NA
"24738",24738,"NCT00734929","Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy","Completed","No Results Available","Postoperative Nausea and Vomiting","Drug: Aprepitant + Dexamethasone|Drug: Ondansetron + Dexamethasone","Duke University|Merck","Both","Adult|Senior","Phase IV",110,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1404","August 13, 2008","01/09/2007",2009-06-01,"October 6, 2010","01/10/2010","",2009-06-01,"cumulative incidence of emesis|Incidence of nausea|Incidence of nausea|Incidence if nausea|Incidence of vomiting|Incidence of vomiting|Use of rescue antiemetics|Use of rescue antiemetics|Use of rescue antiemetics|Complete response rate|Nausea scores|number of vomiting episodes|Time to first vomiting|Patient satisfaction","http://ClinicalTrials.gov/show/NCT00734929",NA
"24748",24748,"NCT00754429","The Effect of Losartan Versus Amlodipine-based Therapy in Ischemic Stroke","Completed","No Results Available","Ischemic Stroke","Drug: losartan|Drug: amlodipine","Merck","Both","Adult|Senior","Phase IV",40,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008_025|MK0954-338","September 16, 2008","01/06/2004",2009-07-01,"July 29, 2009","01/07/2009","",2009-06-01,"MCAFV and TCD for measuring cerebral autoregulatory indices at week 0, week 6, week 18 and week 30.","http://ClinicalTrials.gov/show/NCT00754429",NA
"24759",24759,"NCT00770029","Efficacy and Safety of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines No. 2","Completed","No Results Available","Moderate to Severe Glabellar Frown Lines","Drug: Clostridium Botulinum neurotoxin type A|Drug: Placebo","Merz Pharmaceuticals GmbH","Both","Adult|Senior","Phase III",276,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MRZ 60201 - 0724 / 1","October 8, 2008","01/10/2008",NA,"March 25, 2010","01/01/2010","",2009-03-01,"Investigator's rating on the Facial Wrinkle Scale and the patient's assessment on a 4-point scale|Percentage of responders by patient assessment on 4-point scale|Percentage of responders by investigator assessment on facial wrinkle scale","http://ClinicalTrials.gov/show/NCT00770029",NA
"24772",24772,"NCT00788229","Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome","Completed","No Results Available","Dry Eye Syndromes|Keratoconjunctivitis Sicca","Drug: AT01|Drug: AT02|Drug: AT03|Drug: AT04","Dhp Korea Co., Ltd.","Both","Adult|Senior","Phase II",72,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","dhpat02","November 7, 2008","01/11/2008",2009-08-01,"April 1, 2010","01/04/2010","",2009-08-01,"Tear Break Up Time (TBUT)|Fluorescein staining, schirmer test, OSDI, VAS","http://ClinicalTrials.gov/show/NCT00788229",NA
"24785",24785,"NCT00812929","A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise","Completed","No Results Available","Asthma","Drug: Placebo|Drug: GSK2190915","GlaxoSmithKline","Both","Adult","Phase II",47,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","112025","December 18, 2008","01/12/2008",2009-06-01,"February 5, 2010","01/02/2010","",2009-06-01,"Maximal percentage change from pre-exercise baseline FEV1 to the minimum FEV1 at 24 hours post dose.|Weighted Mean (WM) for FEV1 percentage change from baseline recorded.|Time to FEV1 recovery to within 5% of baseline following exercise challenge.|Proportion of subjects using a short acting beta-2 agonist (rescue medication).|Safety assessments: vital signs, ECG, safety laboratory parameters, adverse events.|Leukotriene biomarkers LTB4 and LTE4 in blood and urine samples, respectively.|Derived PK parameters for GSK2190915.|Maximal percentage change from pre-exercise baseline FEV1 to the minimum FEV1 at 2 and 9.5 hours post dose.","http://ClinicalTrials.gov/show/NCT00812929",NA
"24806",24806,"NCT00848029","Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Shedules","Completed","No Results Available","Prepandemic Influenza Vaccine","Biological: Monovalent inactivated influenza vaccine","Novartis|Novartis Vaccines","Both","Adult","Phase III",240,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","V87P12|2008-003008-72","February 19, 2009","01/11/2008",2009-06-01,"September 30, 2009","01/09/2009","",2009-06-01,"Evaluation of antibody response to a monovalent inactivated influenza vaccine adjuvanted with MF59 and uses a surface antigen from a potential pandemic homologus virus strain candidate (H5N1).|Evaluation of safety of the monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a surface antigen from a potential pandemic virus strain candidate (H5N1) in Adult Subjects.","http://ClinicalTrials.gov/show/NCT00848029",NA
"24859",24859,"NCT00924729","Study of Ocular Penetration of Topically Administered Fluoroquinolones","Completed","Has Results","Cataract Extraction","Drug: Moxifloxacin 0.5% ophthalmic solution|Drug: Besifloxacin 0.6% ophthalmic suspension","Johns Hopkins University","Both","Adult|Senior","Phase IV",50,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","NA_28692","June 5, 2009","01/09/2009",2009-11-01,"May 25, 2010","01/11/2009","",2009-10-01,"Aqueous Humor Concentration of Study Drug|Disk Diffusion Assay of Collected Aqueous Humor","http://ClinicalTrials.gov/show/NCT00924729",NA
"24884",24884,"NCT00968929","Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)","Completed","No Results Available","Pulmonary Embolism|Pulmonary Thromboembolism","Drug: Recombinant Streptokinase|Drug: Urokinase","Beijing Chao Yang Hospital|The Affiliated Hospital of Medical College Qingdao University|Tianjin Medical University General Hospital|The General Hospital of Shenyang Military Command|Guangdong Institute of Respiratory Disease|The First Affiliated Hospital Shanxi Medical University|Shenzhen People's Hospital|Ningxia Medical University","Both","Adult|Senior","Phase IV",83,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006BAI01A06","August 28, 2009","01/06/2006",2009-05-01,"August 31, 2009","01/08/2009","RESUPEC",2009-05-01,"The improvement of the right ventricular function on echocardiogram|Quantitative computed tomographic pulmonary angiography (CTPA) score|The relief of symptoms|Major or minor bleeding|Pulmonary embolism recurrence|Death","http://ClinicalTrials.gov/show/NCT00968929",NA
"24929",24929,"NCT01041729","Long-term Pleiotropic Effect of Statins in Patients With Peripheral Arterial Disease","Completed","No Results Available","Peripheral Arterial Disease","Drug: Atorvastatin|Drug: Standard Medical Treatment","Hospital Universitario Getafe","Both","Adult|Senior","Phase IV",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Basic Science","STA-2009 NO-CRP","December 31, 2009","01/01/2008",2009-06-01,"January 4, 2010","01/12/2009","",2009-03-01,"High-sensitivity C-Reactive Protein (hsCRP) and nitrites plasma levels at baseline and after one month and one year of inclusion.|Lipid profile","http://ClinicalTrials.gov/show/NCT01041729",NA
"24957",24957,"NCT01085929","Incision and Drainage Versus Needle Aspiration in Soft Tissue Abscesses","Completed","No Results Available","Abscess|Cellulitis","Procedure: Incision and Drainage|Procedure: Ultrasound Guided Aspiration","University of Massachusetts, Worcester|Beth Israel Deaconess Medical Center","Both","Adult|Senior","Phase III",101,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","UMass12522","March 10, 2010","01/08/2008",2009-12-01,"March 11, 2010","01/03/2010","",2009-11-01,"Successful drainage of abscess|Successful drainage of abscess|Ability to evacuate purulence from abscess","http://ClinicalTrials.gov/show/NCT01085929",NA
"25142",25142,"NCT00045630","Combination Chemotherapy Followed By Observation or Surgery in Treating Patients With Stage II or Stage III Cancer of the Urothelium","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: carboplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Southwest Oncology Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",95,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000256921|SWOG-S0219","September 6, 2002","01/01/2003",NA,"April 21, 2009","01/12/2006","",2009-01-01,"Pathologic complete response rate by transurethral resection of bladder tumor (TURBT) and imaging studies after chemotherapy","http://ClinicalTrials.gov/show/NCT00045630",NA
"25186",25186,"NCT00113230","Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer","Completed","Has Results","Rectal Cancer","Drug: Avastin (Bevacizumab, RHUMAB VEGF)|Drug: Capecitabine|Radiation: Radiation Therapy","M.D. Anderson Cancer Center|Genentech","Both","Adult|Senior","Phase II",25,"Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0832","June 6, 2005","01/02/2005",2009-01-01,"October 13, 2009","01/10/2009","",2009-01-01,"Pathologic Local Tumor Response","http://ClinicalTrials.gov/show/NCT00113230",NA
"25211",25211,"NCT00153530","Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)","Completed","No Results Available","Central Nervous System Lymphoma","Drug: methotrexate|Radiation: radiotherapy","Charite University, Berlin, Germany|University Hospital Tuebingen","Both","Adult|Senior","Phase IV",604,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","G-PCNSL-SG1","September 8, 2005","01/05/2000",2009-05-01,"December 23, 2009","01/07/2009","",2009-05-01,"overall survival|progression-free survival","http://ClinicalTrials.gov/show/NCT00153530",NA
"25231",25231,"NCT00046930","Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia","Completed","Has Results","Leukemia|Myelodysplastic Syndromes","Biological: filgrastim|Biological: sargramostim|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: zosuquidar trihydrochloride|Drug: Placebo","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Eli Lilly and Company|Kanisa Pharmaceuticals","Both","Adult|Senior","Phase III",449,"Other|NIH|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CDR0000257122|E3999|U10CA021115","October 3, 2002","01/07/2002",NA,"August 17, 2010","01/08/2010","",2009-06-01,"Overall Survival|Progression-free Survival|Response","http://ClinicalTrials.gov/show/NCT00046930",NA
"25257",25257,"NCT00215930","The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Vinorelbine|Drug: Docetaxel|Drug: Gemcitabine|Drug: Carboplatin","H. Lee Moffitt Cancer Center and Research Institute|Eli Lilly and Company|Aventis Pharmaceuticals","Both","Adult|Senior","Phase II",72,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-13208","September 15, 2005","01/02/2004",2009-10-01,"September 17, 2010","01/09/2010","",2009-10-01,"response rates(RR)|progression free survival (PFS)|median survival(MS)|1-yr survival(1-yr S)","http://ClinicalTrials.gov/show/NCT00215930",NA
"25264",25264,"NCT00232830","The Study to Assess AMI Treated With Balloon Angioplasty.","Completed","No Results Available","Coronary Artery Disease","Device: drug-eluting stent|Device: bare-metal stent","Cordis Corporation","Both","Adult|Senior","Phase III",715,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","EC03-03","October 4, 2005","01/10/2003",2009-04-01,"September 15, 2009","01/04/2009","TYPHOON",2009-02-01,"Composite of target vessel failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vesselpost-procedure.|cardiac death|recurrence of myocardial infarction|revascularization of the target vessel (TVR)|recurrence of ischemia","http://ClinicalTrials.gov/show/NCT00232830",NA
"25265",25265,"NCT00238030","Thyroxine Replacement in Organ Donors","Completed","No Results Available","Brain Death","Drug: L-thryoxine|Drug: iv thryoxine","Lawson Health Research Institute","Both","Child|Adult|Senior","Phase I|Phase II",34,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R-04-298","October 12, 2005","01/12/2004",2010-10-01,"January 4, 2011","01/01/2011","",2009-05-01,"Percentage of time patients require inotropic support prior to organ procurement.|pharmacokinetic profiles of oral vs iv T3,T4|number of organs donated|thyroid function derangements at time of brain death","http://ClinicalTrials.gov/show/NCT00238030",NA
"25285",25285,"NCT00262730","Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: poly ICLC|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",96,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000454915|NABTT-0501","December 6, 2005","01/01/2006",NA,"July 15, 2010","01/01/2007","",2009-08-01,"Survival","http://ClinicalTrials.gov/show/NCT00262730",NA
"25310",25310,"NCT00291330","Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism","Completed","No Results Available","Thromboembolism","Drug: Dabigatran etexilate|Drug: Warfarin","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",2564,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1160.53|2005-001999-12","February 13, 2006","01/02/2006",NA,"May 27, 2009","01/05/2009","",2009-05-01,"Composite of recurrent symptomatic venous thromboembolism (VTE) and deaths related to VTE within 6 months. VTE is defined as the composite incidence of deep vein thrombosis (DVT) of the leg and pulmonary embolism (PE).|Composite of recurrent symptomatic VTE and all deaths, symptomatic DVT, symptomatic PE, deaths related to VTE and all deaths. Bleeds, adverse events (AEs), discontinuation due to AEs, laboratory measures, Acute Coronary Syndromes, ECG and vital signs.","http://ClinicalTrials.gov/show/NCT00291330",NA
"25311",25311,"NCT00266630","Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder","Completed","Has Results","Manic or Mixed Episode Associated With Bipolar I Disorder","Drug: olanzapine|Drug: lithium|Drug: valproate|Drug: carbamazepine","Eli Lilly and Company","Both","Adult","Phase III",139,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9637|F1D-JE-BMEX","December 15, 2005","01/11/2005",2009-05-01,"December 10, 2010","01/12/2010","",2009-05-01,"Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Scores - Olanzapine Monotherapy Arm Only|Number of Participants With Response of Manic Symptoms - Olanzapine Monotherapy Arm Only|Number of Participants With Remission of Mania - Olanzapine Monotherapy Arm Only|Number of Participants With Relapse of Manic Symptoms - Olanzapine Monotherapy Arm Only|Change From Baseline to Endpoint on the YMRS Total Score - Olanzapine + Mood Stabilizer Only|Clinical Global Impressions - Bipolar Version, Severity of Illness (CGI-BP) Overall, Visit Data|Number of Participants Who Experienced Switch to Symptomatic Depression as Measured by the Hamilton Depression Scale - 17 Item Version (HAMD-17)|Number of Participants With Relapse of Depressive Symptoms|Number of Participants Who Experienced Remission of Bipolar Disorder|Positive and Negative Syndrome Scale Positive Scores - Visit Data|Number of Participants Who Switched to Syndromic Depression|Maximum Change From Baseline to Endpoint on the Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS) - Total Score|Number of Participants With Treatment-Emergent Parkinsonism Based on DIEPSS Scores|Number of Participants With Treatment-Emergent Akathisia Based on DIEPSS Scores|Number of Participants With Treatment-Emergent Dystonia Based on DIEPSS Scores|Number of Participants With Treatment-Emergent Dyskenisia Based on DIEPSS Scores|Number of Participants With Potentially Clinically Significant Changes in Laboratory Analytes|Number of Participants With Potentially Clinically Significant Changes in Vital Signs and Weight|Number of Participants With Potentially Clinically Significant Changes in Electrocardiograms - High Fridericia Corrected QT Interval (QTcF)|Number of Participants With Treatment-emergent Abnormal, High, or Low Laboratory Values","http://ClinicalTrials.gov/show/NCT00266630",NA
"25370",25370,"NCT00397930","Yoga in Treating Sleep Disturbance in Cancer Survivors","Completed","No Results Available","Cancer Survivor|Fatigue|Psychosocial Effects of Cancer and Its Treatment|Sleep Disorders","Procedure: fatigue assessment and management|Procedure: management of therapy complications|Procedure: quality-of-life assessment|Procedure: sleep disorder therapy|Procedure: yoga therapy","University of Rochester|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",400,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Supportive Care","CDR0000515123|U10CA037420|URCC-U3905|URCC-04-01","November 9, 2006","01/10/2006",2010-04-01,"November 8, 2010","01/11/2010","",2009-06-01,"Efficacy of Hatha yoga in improving sleep quality as measured by Pittsburgh Sleep Quality Inventory and Insomnia Severity Index|Efficacy of yoga in improving fatigue and quality of life (QOL) as measured by Functional Assessment of Chronic Illness Therapy-Fatigue and Sleep Medication and Complimentary and Alternative Medicine Usage questionnaires|Efficacy of yoga in improving fatigue and QOL as measured by Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Profile of Mood States, and Aerobic Center Longitudinal Study Physical Activity questionnaires","http://ClinicalTrials.gov/show/NCT00397930",NA
"25383",25383,"NCT00420030","Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock","Completed","No Results Available","Shock, Cardiogenic","Drug: Abciximab","Charles University, Czech Republic|Eli Lilly and Company","Both","Adult|Senior","Phase IV",80,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Charles University, Prague|MSM 0021620817","January 8, 2007","01/09/2006",2009-06-01,"June 22, 2009","01/06/2009","",2009-06-01,"Combined end-point death/reinfarction/stroke/TIMI-flow <3/EF <30% on day 30.|Left ventricular EF assessed by echocardiography on the day 30 (in deceased pts. EF assumed to be 0%)|Rate of major bleeding complication|Myocardial blush score after PCI|TIMI-flow after PCI","http://ClinicalTrials.gov/show/NCT00420030",NA
"25404",25404,"NCT00453830","Laparoscopic Versus Open Sigmoid Colectomy for Diverticular Disease","Completed","No Results Available","Diverticulitis","Procedure: laparoscopic sigmoid resection","University Hospital, Geneva","Both","Adult|Senior","Phase IV",100,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","CER 04-179","March 28, 2007","01/01/2005",2009-02-01,"February 17, 2009","01/02/2009","",2009-02-01,"Postoperative pain at days 1, 2 and 3|Morphine requirements at days 1, 2 and 3|Duration of postoperative ileus|Medical complications|Surgical complications|Duration of surgical procedure|Duration of hospital stay","http://ClinicalTrials.gov/show/NCT00453830",NA
"25405",25405,"NCT00452530","Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery","Completed","No Results Available","Deep Vein Thrombosis|Pulmonary Embolism","Drug: Enoxaparin + Placebo|Drug: Apixaban + Placebo","Bristol-Myers Squibb","Both","Adult|Senior","Phase III",3054,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CV185-047|EUdraCT: 2006-006896-19","March 23, 2007","01/06/2007",2009-01-01,"January 6, 2011","01/04/2009","ADVANCE-2",2009-01-01,"A combination of adjudicated asymptomatic and symptomatic DVT, non-fatal PE and all-cause death|A combination of adjudicated asymptomatic and symptomatic proximal DVT, non-fatal PE, & VTE-related death","http://ClinicalTrials.gov/show/NCT00452530",NA
"25418",25418,"NCT00474630","A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Type 2 Diabetics","Completed","No Results Available","Obesity|Diabetes Mellitus, Type 2","Drug: Naltrexone SR/Bupropion SR|Other: Placebo","Orexigen Therapeutics, Inc","Both","Adult|Senior","Phase III",525,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NB-304","May 15, 2007","01/05/2007",2009-05-01,"January 22, 2010","01/01/2010","",2009-05-01,"Change from baseline in percentage of total body weight lost and percentage of subjects who achieve a weight decrease of ??­ 5%|Proportion of subjects who lose at least 10% of baseline body weight and who achieve a HbA1c value < 7%; Change in HbA1c; Effects on selected obesity-associated risk factors","http://ClinicalTrials.gov/show/NCT00474630",NA
"25443",25443,"NCT00522730","Safety and Tolerance on Lipids of Parenteral and Enteral Nutrition in Critically Ill Patients With Liver Failure","Completed","No Results Available","Liver Failure|Critical Illness","Other: Parenteral nutrition|Other: Enteral nutrition","Cliniques universitaires Saint-Luc- Universit?¢ Catholique de Louvain","Both","Adult|Senior","Phase IV",45,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SELLIFA-02|B40320072194|EudraCT n??2007-002940-86","August 29, 2007","01/08/2007",2009-08-01,"September 2, 2009","01/09/2009","SELLIFA",2009-08-01,"Change in plasma concentration of triglycerides, total cholesterol, HDL-cholesterol, free fatty acids, apolipoproteins, lipoprotein (a)|Incidence of hyperglycaemia|Alteration of liver function|Gastrointestinal intolerance|Gastrointestinal bleeding|Septic complications|Occurence of new organ dysfunction|Length of stay in the intensive care unit (ICU)|Mortality","http://ClinicalTrials.gov/show/NCT00522730",NA
"25445",25445,"NCT00526630","Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease","Completed","No Results Available","Parkinson's Disease|Gait Impairment","Drug: Methylphenidate (MPD)|Drug: Placebo","University of Cincinnati|Michael J. Fox Foundation for Parkinson's Research","Both","Adult|Senior","Phase IV",20,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","07-06-19-07","September 5, 2007","01/12/2007",2009-10-01,"October 27, 2009","01/10/2009","",2009-10-01,"The primary outcome measures will be the change in the gait composite score between the MPD and Placebo groups, at week 12 after completion of each study arm, immediately before and at the end of the cross-over period.|Secondary outcome measures include changes in gait diary (number of freezing episodes and falls), static posturography, FOGQ (total score), MADRS, EQ-5D, and the ESS between days 1 and 56, that is, at the end of week 12 for each study arm.","http://ClinicalTrials.gov/show/NCT00526630",NA
"25449",25449,"NCT00530530","ASP8825 - Study in Patients With Restless Legs Syndrome","Completed","No Results Available","Restless Legs Syndrome","Drug: ASP8825|Drug: Placebo","Astellas Pharma Inc","Both","Adult|Senior","Phase II",474,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8825-CL-0003","September 13, 2007","01/09/2007",2009-01-01,"March 10, 2009","01/03/2009","",2009-01-01,"The change of the International Restless Legs Syndrome rating scale score|Investigator-related Clinical Global Impression of Improvement|Patient- related Clinical Global Impression of Improvement|The Pittsburgh sleep quality index|The SF-36 Health Survey|The Restless Legs Syndrome QOL Questionnaire|The Medical Outcomes Study sleep scale","http://ClinicalTrials.gov/show/NCT00530530",NA
"25465",25465,"NCT00560430","Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients","Completed","No Results Available","Hypertension|Metabolic Syndrome|Hypertriglyceridemia","Drug: telmisartan|Drug: telmisartan|Drug: placebo","Ludwig-Maximilians - University of Munich|Bayer","Both","Adult","Phase III",56,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","KPUK0106|EudraCT 2006-003567-31","November 16, 2007","01/11/2007",2009-10-01,"July 14, 2010","01/05/2008","METATEL",2009-09-01,"change in IL-6|change in fasting lipids;|change in postprandial lipid metabolism|change in inflammatory parameters|change in glucose metabolism","http://ClinicalTrials.gov/show/NCT00560430",NA
"25474",25474,"NCT00573430","ARIA(Atacand Renoprotection In NephropAthy Pt.)","Completed","No Results Available","Non-diabetic Nephropathy With Hypertension","Drug: Candesartan Cilexetil|Drug: Candesartan Cilexetil|Drug: Candesartan Cilexetil 32mg","AstraZeneca","Both","Adult|Senior","Phase IV",128,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D2452L00015","December 13, 2007","01/12/2007",2009-08-01,"October 27, 2009","01/10/2009","PCR",2009-08-01,"Change in urinary protein/creatinine ratio|Systolic and diastolic blood pressure|Inflammatory marker (hs-CRP)|Estimated GFR predicted from the Modification of Diet in Renal Disease (MDRD) equation|Safety","http://ClinicalTrials.gov/show/NCT00573430",NA
"25508",25508,"NCT00616330","Vaginal Infection Study","Completed","No Results Available","Vulvovaginitis|Vaginitis","Drug: clindamycin phosphate/butoconazole nitrate|Drug: clindamycin phosphate|Drug: butoconazole nitrate","KV Pharmaceutical Company","Female","Child|Adult|Senior","Phase III",1443,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CBC-302-602-622467","February 4, 2008","01/01/2008",2009-12-01,"May 3, 2010","01/05/2010","",2009-12-01,"The primary outcome measure of the study will be clinical symptom resolution.|Secondary outcome measures will include laboratory assessments of presence or absence of vaginal infection.","http://ClinicalTrials.gov/show/NCT00616330",NA
"25529",25529,"NCT00654030","Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: 1650-G Vaccine","University of Kentucky|Kentucky Lung Cancer Research Program","Both","Adult|Senior","Phase II",12,"Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CTN-0505|UKIRB 06-0716-F3R|ULIRB 065.07|CIRB 1079747","April 2, 2008","01/10/2006",2009-11-01,"January 15, 2010","01/01/2010","",2009-11-01,"Primary Outcome Measure: Immunological Response","http://ClinicalTrials.gov/show/NCT00654030",NA
"25548",25548,"NCT00681330","Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Biological: URC10, TTK, KOC1","Tokyo University|Human Genome Center, Institute of Medical Science, University of Tokyo","Both","Adult|Senior","Phase I|Phase II",14,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMS-OKA2402","May 19, 2008","01/05/2008",2009-04-01,"November 18, 2009","01/11/2009","",2009-04-01,"Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST)|To evaluate immunological responses","http://ClinicalTrials.gov/show/NCT00681330",NA
"25551",25551,"NCT00687830","Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.","Completed","No Results Available","Colon Cancer","Drug: Polythylene Glycol|Drug: Polythylene Glycol|Drug: Polyethylene glycol|Drug: Polyethylene glycol","Cleveland Clinic Florida","Both","Child|Adult|Senior","Phase III",192,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Treatment","CCFL-8964","May 28, 2008","01/02/2008",2009-11-01,"January 27, 2010","01/01/2009","CCF",2009-07-01,"Bowel cleansing effect as measured by the Ottawa scale: Evening v Morning|Patient satisfaction with the bowel prep: Evening v Morning","http://ClinicalTrials.gov/show/NCT00687830",NA
"25558",25558,"NCT00698230","Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics","Completed","No Results Available","Type 2 Diabetes","Drug: INCB013739|Drug: Placebo","Incyte Corporation","Both","Adult|Senior","Phase II",300,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","INCB 13739-202","June 13, 2008","01/05/2008",2009-05-01,"June 17, 2010","01/06/2010","",2009-04-01,"Change from baseline in hemoglobin A1c (HbA1c) and safety and tolerability data.|Change from baseline in fasting plasma glucose (FPG) and proportion of subjects meeting HbA1c goal.","http://ClinicalTrials.gov/show/NCT00698230",NA
"25582",25582,"NCT00732030","Low Cylinder Toric","Completed","Has Results","Cataracts","Device: Toric IOL (SN60T3)","Alcon Research","Both","Adult|Senior","Phase IV",26,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M07-005","August 7, 2008","01/06/2007",NA,"March 25, 2010","01/03/2010","",2009-03-01,"Uncorrected Distance Visual Acuity|Best Corrected Distance Visual Acuity|Residual Refractive Cylinder|Patient Satisfaction Survey","http://ClinicalTrials.gov/show/NCT00732030",NA
"25633",25633,"NCT00810030","FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR","Completed","No Results Available","Inflammatory Bowel Disease|Anemia|Iron Deficiency|Iron-Deficiency Anemia|Crohn's Disease|Ulcerative Colitis","Drug: Ferric carboxymaltose|Drug: Iron Sucrose","Vifor Inc.|Parexel|ClinStar","Both","Adult|Senior","Phase III",484,"Industry|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FER-IBD-07-COR","December 16, 2008","01/10/2008",2010-04-01,"April 8, 2010","01/04/2010","FER-IBD-COR",2009-12-01,"Number of responders with respect to the baseline Hb value.|Number of patients whose Hb increased ??­2 g/dL or who reached normal Hb levels at Week 12.|Change in disease activity (CDAI, CAI, C-reactive protein [CRP]).|The number of patients at Week 12: TfS: 20 to 50%.|The number of non-anaemic patients at Week 12|The number of patients with ferritin >100 ??g/L at Week 12.|Maximum increase in Hb, serum ferritin and TfS.|The number of patients at achieving Hb ??­12 (female) or ??­13 (male) g/dL and ferritin >100 ??g/L at Week 12.|The number of patients withdrawal from study due to protocol procedure.|The number of responders (Hb increase ??­2 g/dL) with respect to treatment of underlying disease.|The number of patients with Hb baseline value ???10 g/dL who achieved Hb increase ??­2 g/dL and the number of patients with Hb baseline value >10 g/dL who achieved Hb increase ??­2 g/dL.|Change in health-related quality of life (QoL) from baseline to Week 12 using the Short Form (SF)-36, version 2 and IBDQ.|The number of patients out of work due to anaemia or IBD.|Days out of hospital.|Hospitalisation rate|Adverse events: type, nature, incidence and outcome.|Vital signs (blood pressure, pulse rate and bw).|Electrocardiogram.|Change in laboratory parameters (haematology, clinical chemistry, iron status, urinalysis).|Physical examination.|The number of responders (Hb increase ??­2 g/dL) with respect to the baseline Hb value.","http://ClinicalTrials.gov/show/NCT00810030",NA
"25636",25636,"NCT00825630","13-C Urea Breath Test Using BreathID System and PPIs","Completed","No Results Available","Helicobacter Pylori Infection","Drug: PPI1|Drug: PPI2|Drug: PPI3|Drug: PPI4","Exalenz Bioscience LTD.|Rabin Medical Center","Both","Adult|Senior","Phase IV",200,"Industry|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","HP-BID 608","January 19, 2009","01/11/2008",2009-11-01,"November 26, 2009","01/11/2009","",2009-11-01,"Delta Over Baseline will be measured using a 13C Urea breath test","http://ClinicalTrials.gov/show/NCT00825630",NA
"25642",25642,"NCT00841230","Deanxit and Rivotril in Tinnitus Patients","Completed","No Results Available","Tinnitus","Drug: Deanxit|Drug: Lactose placebo","University Hospital, Antwerp","Both","Adult|Senior","Phase IV",50,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","8/46/260","January 30, 2009","01/02/2009",2009-07-01,"August 10, 2009","01/08/2009","",2009-07-01,"Visual Analogue Scale","http://ClinicalTrials.gov/show/NCT00841230",NA
"25649",25649,"NCT00847730","Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negatvie Pressure Wound Therapy","Completed","No Results Available","Diabetic Foot Ulcers","Device: V.A.C. Negative Pressure Wound Therapy System","KCI USA, Inc.","Both","Adult|Senior","Phase II",75,"Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","VACDrsg 2008-37","February 17, 2009","01/02/2009",2009-09-01,"December 7, 2009","01/12/2009","",2009-06-01,"Percentage of subjects with satisfactory performace, defined as a cumulative eas of use score >6 and a munimum score of >2 on each indiviual charecteristic|Percentage of subjects with a score of >2 on the patient comfort during wear assessment","http://ClinicalTrials.gov/show/NCT00847730",NA
"25657",25657,"NCT00858130","Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome","Completed","No Results Available","Post Thrombotic Syndrome|Deep Vein Thrombosis|Venous Stasis Syndrome|Venous Insufficiency Syndrome|Postphlebitic Syndrome","Device: VeinOPlus","University of North Carolina, Chapel Hill|Clinical and Translational Research Center at UNC Hospitals|VeinoPlus USA","Both","Adult|Senior","Phase II|Phase III",12,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Veinoplus08-2143","March 5, 2009","01/03/2009",2009-11-01,"January 7, 2010","01/01/2010","VeinoPlus",2009-11-01,"Estimate the optimal electrical stimulation intensity level at which patients using the portable electrical muscle stimulator (VeinoPlus?ó) have the largest benefit for relief of symptoms.|Estimate whether use of the device was a \clinical success\"" as defined by the patient reporting benefit by the improvement of symptoms after having used the device","http://ClinicalTrials.gov/show/NCT00858130",NA
"25662",25662,"NCT00868530","Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects","Completed","No Results Available","Hemophilia A","Biological: Xyntha","Wyeth","Both","Child|Adult|Senior","Phase III",53,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3082B2-3316|B1831015","March 19, 2009","01/02/2009",2009-12-01,"November 5, 2010","01/11/2010","",2009-12-01,"the response of bleeding episodes to Xyntha treatment|the number of infusions required to resolve bleeding episodes|the average dose of infusions required to resolve bleeding episodes|the incidence of less than expected therapeutic effect (LETE)|the recovery of Factor VIII activity in response to Xyntha treatment|the incidence of AEs (by severity and relationship to Xyntha)|the incidence of FVIII inhibitors|the incidence of allergic reactions|the incidence of thrombogenicity","http://ClinicalTrials.gov/show/NCT00868530",NA
"25665",25665,"NCT00875030","A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets (Pfizer) Versus Single-Dose Administration Of Arsuamoon?ó Tablets (Guilin-China) In Healthy Subjects","Completed","No Results Available","Healthy Volunteers","Drug: artesunate sachets|Drug: Arsuamoon","Pfizer","Both","Adult","Phase IV",40,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Masking: Open Label","B0551002","April 2, 2009","01/06/2009",2009-06-01,"June 7, 2010","01/06/2010","",2009-06-01,"Cmax, AUCinf and AUClast, for DHA|Tmax and t1/2 for DHA; Cmax, AUCinf, AUClast, Tmax and t1/2 for artesunate.|Safety laboratory tests, vital signs, and adverse events.","http://ClinicalTrials.gov/show/NCT00875030",NA
"25671",25671,"NCT00889330","A Study of an Anti-allergy Eye-drop","Completed","No Results Available","Allergic Conjunctivitis","Drug: alcaftadine|Drug: Placebo","Vistakon Pharmaceuticals","Both","Child|Adult|Senior","Phase III",60,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","09-003-05","April 24, 2009","01/04/2009",NA,"June 1, 2010","01/06/2010","",2009-05-01,"Ocular Itching|Conjunctival Redness|ETDRS Visual Acuity|Slit Lamp Biomicroscopy|Undilated Fundoscopy|Ocular Symptoms|Nasal Symptoms","http://ClinicalTrials.gov/show/NCT00889330",NA
"25675",25675,"NCT00894530","The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period","Completed","No Results Available","Blepharitis","Drug: Azithromycin ophthalmic solution, 1%|Drug: Placebo","Inspire Pharmaceuticals","Both","Adult|Senior","Phase II",314,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","044-102","May 5, 2009","01/05/2009",2009-12-01,"October 29, 2010","01/10/2010","",2009-12-01,"Eyelid margin erythema|Signs and symptoms of Blepharitis","http://ClinicalTrials.gov/show/NCT00894530",NA
"25677",25677,"NCT00895830","Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)","Completed","No Results Available","Postoperative Nausea and Vomiting","Drug: APD405|Drug: Placebo","Acacia Pharma Ltd","Both","Adult|Senior","Phase II",260,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DP10002","May 7, 2009","01/05/2009",2009-11-01,"December 22, 2009","01/12/2009","",2009-11-01,"Post-operative nausea or vomiting","http://ClinicalTrials.gov/show/NCT00895830",NA
"25863",25863,"NCT01213030","Clinical Evaluation of the New Hypoxia Imaging Agent HX4","Completed","No Results Available","Head and Neck Cancer|Lung Cancer|Liver Cancer","Drug: [F-18] FMISO|Drug: [F-18] HX4","Siemens Molecular Imaging|PET Center, Huanshan Hosptial, Fudan University, Shanghai, China","Both","Adult|Senior","Phase I|Phase II",12,"Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","HX4-FMISO","August 14, 2009","01/06/2009",2009-12-01,"October 1, 2010","01/10/2010","",2009-12-01,"Efficacy of a hypoxia imaging agent, HX4, in patients with solitary tumors (i.e., locally advanced head and neck cancer)|Resolution, signal to background ratio, and tumor/blood ratio of PET images with [F-18] FMISO and [F-18]HX4","http://ClinicalTrials.gov/show/NCT01213030",NA
"25969",25969,"NCT00018031","Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients","Completed","No Results Available","Hepatitis C|HIV Infections","Drug: Peginterferon alpha-2b|Drug: Ribavirin","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult|Senior","Phase II",180,"NIH","Interventional","Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","010194|01-I-0194","June 27, 2001","01/06/2001",2009-04-01,"November 12, 2010","01/11/2010","",2009-04-01,"Correlation of HCV viral kinetics to treatment response rates.|Gene an proteomics expression in PBMC and liver and their relationship to the treatment response rates.","http://ClinicalTrials.gov/show/NCT00018031",NA
"25995",25995,"NCT00072631","Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","Advanced Non Small Cell Lung Cancer|Failed Prior Chemotherapy","Drug: Tarceva (Trademark) (erlotinib HCl, OSI-774)","OSI Pharmaceuticals","Both","Adult|Senior","Phase II",50,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSI-774-202|Dose to Rash","November 5, 2003","01/08/2003",2009-10-01,"November 3, 2009","01/10/2009","",2009-10-01,"Feasibility of intrapatient dose escalation of erlotinib HCI to introduce a characteristic, target rash, and evaluate the effect on objective response rate|Feasibility of correlating objective response rate and duration of response to grade of rash","http://ClinicalTrials.gov/show/NCT00072631",NA
"26010",26010,"NCT00093431","Sorafenib in Treating Patients With Metastatic Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: sorafenib tosylate","National Cancer Institute (NCI)","Male","Adult|Senior","Phase II",46,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000387958|NCI-04-C-0262|NCI-6594","October 6, 2004","01/09/2004",NA,"December 5, 2009","01/01/2009","",2009-04-01,"Progression-free survival at 4 months by clinical, radiographic, and prostate-specific antigen (PSA) criteria|Proteomics|PSA|Pharmacokinetics|Molecular effects","http://ClinicalTrials.gov/show/NCT00093431",NA
"26060",26060,"NCT00167531","The Efficacy of Treadmill Training in Establishing Walking After Stroke","Completed","No Results Available","Stroke","Behavioral: treadmill walking with partial weight support|Behavioral: assisted overground walking","University of Sydney","Both","Adult|Senior","Phase II",126,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind|Primary Purpose: Treatment","02/06/2009","September 12, 2005","01/08/2002",2009-07-01,"October 1, 2009","01/09/2006","",2009-04-01,"Proportion of participants walking independently (defined for the purposes of this study as'being able to walk 15 m continuously across flat ground without any aids').|Quality of walking: measured by quantifying parameters such as speed, affected and intact step length, step width, and cadence during 10 m walk test.|Walking capacity at six months measured by 10 m and 6 minute walk tests. Walking participation measured using the Adelaide Activity Profile.","http://ClinicalTrials.gov/show/NCT00167531",NA
"26174",26174,"NCT00361231","Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer","Completed","No Results Available","Biliary Tract Adenocarcinoma|Gallbladder Adenocarcinoma","Drug: Bevacizumab|Drug: Gemcitabine|Drug: Oxaliplatin","Massachusetts General Hospital|Genentech|Sanofi-Aventis|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana-Farber Cancer Institute","Both","Adult|Senior","Phase II",37,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-349","August 4, 2006","01/05/2006",NA,"August 7, 2009","01/08/2009","",2009-05-01,"To assess the progression free survival of GEMOX-B regimen in patients with unresectable or metastatic biliary tract and gallbladder adenocarcinoma.|To evaluate the toxicities of the GEMOX-B regimen in this population of patients|to assess the response rate, the duration of response and median survival of GEMOX-B in this patient population|to evaluate changes on PET scans with treatment and correlation of PET scan change with PFS, response and OS.","http://ClinicalTrials.gov/show/NCT00361231",NA
"26192",26192,"NCT00391131","Subcutaneous Ig NextGen 16% in PID Patients","Completed","No Results Available","Primary Immunodeficiency (PID)","Drug: IgNextGen 16%","CSL Limited","Both","Child|Adult|Senior","Phase III",40,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CSLCT-SCIG-05-23","October 20, 2006","01/01/2007",2009-10-01,"November 5, 2009","01/11/2009","",2009-10-01,"Efficacy|Safety, Tolerability, Quality of Life, Pharmacokinetics","http://ClinicalTrials.gov/show/NCT00391131",NA
"26210",26210,"NCT00414531","Investigations on Differences in Atorvastatin Metabolites Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity","Completed","No Results Available","Myotoxicity of Atorvastatin Treatment","Drug: Atorvastatin","University of Oslo School of Pharmacy","Both","Adult|Senior","Phase IV",53,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Diagnostic","AVALIP05","December 20, 2006","01/05/2005",2009-06-01,"August 11, 2009","01/08/2009","",2009-06-01,"ratio of p-hydroxyatorvastatin to atorvastatin vs. myopathy|ratio of atorvastatin lactone to atorvastatin vs. myopathy","http://ClinicalTrials.gov/show/NCT00414531",NA
"26239",26239,"NCT00396331","AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts","Completed","Has Results","Autologous Stem Cell Transplantation","Drug: G-CSF plus plerixafor","Genzyme","Both","Adult|Senior","Phase II",100,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMD31002112","November 2, 2006","01/10/2005",2009-12-01,"December 1, 2010","01/12/2010","",2009-12-01,"Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment Period|Proportion of Participants Who Achieved ??­2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF|Proportion of Participants Who Achieved ??­5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF|Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment|Median Number of Days to Platelet (PLT) Engraftment|Number of Participants With Durable Engraftment 12 Months After Autologous Transplantation|Number of Participants With Non-Hodgkin's Lymphoma (NHL) Who Had Evidence of Tumor Cell Mobilization After G-CSF or Plerixafor Administration|Number of Participants Who Achieved ??­2*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF|Number of Participants Who Achieved ??­5*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF|Maximum Observed Plasma Concentration (Cmax) on Day 4|Maximum Observed Plasma Concentration (Cmax) on Day 7|Time to Maximum Plasma Concentration (Tmax) on Day 4|Time to Maximum Plasma Concentration (Tmax) on Day 7|Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 4|Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 7","http://ClinicalTrials.gov/show/NCT00396331",NA
"26296",26296,"NCT00548431","NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia","Completed","Has Results","Leukemia, Lymphocytic, Acute","Drug: 6-mercaptopurine","Rigshospitalet, Denmark","Both","Child|Adult","Phase II",38,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NOPHO HDM-6MP pilot study","October 23, 2007","01/12/2007",2009-05-01,"November 9, 2010","01/11/2010","",2009-01-01,"Toxicity of Treatment in Terms of Number of Participants With Serious Adverse Events or Adverse Events, Reported|Incorporation of 6-thioguanine Nucleotides (6TGN) Into Leukocyte DNA, Development of Asparaginase Antibody Production","http://ClinicalTrials.gov/show/NCT00548431",NA
"26309",26309,"NCT00553631","Study of Gene-Activated?ó Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease","Completed","Has Results","Gaucher Disease, Type 1","Biological: velaglucerase alfa|Biological: imiglucerase","Shire Human Genetic Therapies, Inc.","Both","Child|Adult|Senior","Phase III",34,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HGT-GCB-039","November 1, 2007","01/01/2008",2009-06-01,"December 3, 2010","01/12/2010","",2009-05-01,"Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group.|Change From Baseline to Month 9 in Platelet Counts for Each Treatment Group.|Change From Baseline to Month 9 in Normalized Liver Volume (Percent (%) Body Weight) for Each Treatment Group.|Change From Baseline to Month 9 in Normalized Spleen Volume (Percent (%) Body Weight) for Each Treatment Group.|Change From Baseline to Month 9 in Plasma Chitotriosidase for Each Treatment Group.|Change From Baseline to Month 9 in Plasma Chemokine (C-C Motif) Ligand 18 (CCL18) for Each Treatment Group.|Number of Patients Who Developed Antibody for Each Treatment Group.|Time to Response- Comparison of GA-GCB and Imiglucerase on the Earliest Time to Respond as Assesed Via Hemoglobin Concentration","http://ClinicalTrials.gov/show/NCT00553631",NA
"26318",26318,"NCT00590031","Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.","Completed","No Results Available","Esophageal Carcinoma","Drug: Cisplatin|Drug: Irinotecan|Radiation: External Beam Radiation Therapy","Memorial Sloan-Kettering Cancer Center","Both","Adult|Senior","Phase II",61,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-045|IND 65889","December 26, 2007","01/11/2002",2009-12-01,"December 23, 2009","01/12/2009","",2009-12-01,"Determine pathologic complete response rate for subjects on study|Evaluate toxicity and tolerability including surgical morbidity and mortality|Determine overall survival, disease free survival, and pattern of failure.|Assess parameters of quality of life using the Dysphagia scale, and FACT-E questionnaires","http://ClinicalTrials.gov/show/NCT00590031",NA
"26328",26328,"NCT00604331","Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation","Completed","No Results Available","Shock, Cardiogenic|Heart Failure|Acute Myocardial Infarction","Drug: Pyruvate","Herzzentrum Goettingen","Both","Adult|Senior","Phase II",8,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PYR-2008-01|12/10/00","January 17, 2008","01/08/2008",2009-07-01,"December 7, 2010","01/12/2010","",2009-07-01,"Cardiac Output|Cardiac Index|Arterial Pressure|Pulmonary capillary wedge pressure|Pulmonary artery pressure|systemic vascular resistance|pulmonary vascular resistance|heart rate|stroke volume|catecholamine need|safety","http://ClinicalTrials.gov/show/NCT00604331",NA
"26341",26341,"NCT00627731","Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients","Completed","No Results Available","Asthma","Drug: methylprednisolone sodium succinate (mPSL)|Drug: prednisolone (PSL)","Hamamatsu University","Both","Child|Adult|Senior","Phase IV",50,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Hamamatsu-18-68|Hamamatsu-1968","February 22, 2008","01/06/2007",2009-10-01,"October 5, 2009","01/10/2009","",2009-10-01,"Efficacy of oral prednisolone for the treatment of acute asthma|The safety of oral prednisolone for the treatment of acute asthma","http://ClinicalTrials.gov/show/NCT00627731",NA
"26379",26379,"NCT00679731","A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis","Completed","No Results Available","Psoriasis","Drug: ABT-874|Drug: Methotrexate","Abbott","Both","Adult|Senior","Phase III",317,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","M10-255|2007-004687-47","May 15, 2008","01/06/2008",NA,"November 11, 2010","01/09/2010","",2009-11-01,"Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 24|The proportion of subjects who achieve a PGA score of 0 or 1 at Week 24|Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 52|The proportion of subjects who achieve a PGA score of 0 or 1 at Week 52|Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 24|Changes from Baseline in the DLQI total score at Week 24|Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 52|Changes from Baseline in the DLQI total score at Week 52","http://ClinicalTrials.gov/show/NCT00679731",NA
"26413",26413,"NCT00626431","A Study of Leuprolide to Treat Prostate Cancer","Completed","Has Results","Prostate Cancer","Drug: Leuprolide acetate - Formulation A|Drug: Leuprolide acetate - Formulation B","Abbott","Male","Adult|Senior","Phase III",310,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","L-PC07-169","February 20, 2008","01/02/2008",2009-09-01,"October 7, 2010","01/10/2010","",2009-08-01,"Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary Endpoint.|Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation B: ITT Population for the Primary Endpoint|Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation A: ITT Population|Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation B: ITT Population|Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation A: ITT Population|Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation B: ITT Population|Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation A: ITT Population|Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation B: ITT Population|Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation A: ITT Population|Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation B: ITT Population","http://ClinicalTrials.gov/show/NCT00626431",NA
"26418",26418,"NCT00747331","Fenoldopam and Splanchnic Perfusion During Cardiopulmonary Bypass","Completed","No Results Available","Cardiac Complications|Cardiopulmonary Bypass","Drug: Fenoldopam mesilate|Drug: Placebo","IRCCS Policlinico S. Donato","Both","Adult|Senior","Phase IV",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","FenoldopamCPB","September 4, 2008","01/09/2008",2009-04-01,"April 10, 2009","01/04/2009","",2009-04-01,"Peak blood lactate levels during CPB|Urine output during CPB|Peak blood lactate levels during the postoperative period|Peak serum creatinine level during the postoperative period","http://ClinicalTrials.gov/show/NCT00747331",NA
"26459",26459,"NCT00812331","TMC435350-TiDP16-C202: A Study to Assess the Activity of TMC435 on Hepatitis C Virus in Patients Who Have Never Received Treatment for Their Hepatitis C Infection.","Completed","No Results Available","Hepatitis C, Chronic|Hepatitis C|Infection","Drug: TMC435","Tibotec Pharmaceuticals, Ireland","Both","Adult|Senior","Phase II",37,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR012604","December 18, 2008","01/02/2009",2009-11-01,"April 26, 2010","01/04/2010","",2009-11-01,"Determine the antiviral effect of TMC435 during 7 days once daily dosing at 200mg orally (by mouth) as monotherapy in treatment na??ve, genotype 2 to 6 HCV-infected patients.|Determine the safety, tolerability and PK profile of TMC435 during 7 days once daily dosing at 200mg as monotherapy in treatment na??ve, genotype 2 to 6 HCV-infected patients.","http://ClinicalTrials.gov/show/NCT00812331",NA
"26493",26493,"NCT00868231","Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients","Completed","No Results Available","COPD","Drug: Aclidinium bromide|Drug: Tiotropium|Drug: Placebo","Almirall, S.A.|Forest Laboratories","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","M/34273/23","March 23, 2009","01/03/2009",2009-07-01,"July 9, 2010","01/07/2010","",2009-07-01,"Change from baseline in FEV1 at Day 15 on treatment.|Changes from baseline in FVC, FEV1 and AUC.|AEs, laboratory, ECG and vital signs","http://ClinicalTrials.gov/show/NCT00868231",NA
"26504",26504,"NCT00882531","Isotretinoin in Papular-Pustular Rosacea","Completed","No Results Available","Papular-pustular Rosacea","Drug: isotretinoin|Drug: placebo","Laboratoires Bailleul-Biorga|Quanta Medical","Both","Adult|Senior","Phase III",156,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ISOROS","April 15, 2009","01/02/2007",2009-09-01,"November 16, 2009","01/11/2009","ISOROS",2009-08-01,"To determine numbers of patients responding to treatment for 4 months with isotretinoin (patients were considered as responders if their number of papular-pustular lesions fell by at least 90% after 4 months of treatment)|Improvement in patients' quality of life using the reduced Skindex-France QoL scale (30 items)|Change in severity of other symptoms of rosacea (burning sensation, erythema, telangiectasia, vasomotor flush, etc)|Patient satisfaction (on a visual analogue scale)|Global treatment efficacy (global assessment)|Relapse rates at 8 months (after start of treatment)|Safety","http://ClinicalTrials.gov/show/NCT00882531",NA
"26509",26509,"NCT00894231","Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis","Completed","No Results Available","Perennial Allergic Rhinitis","Drug: levocetirizine (Xyzal)|Drug: placebo","AAADRS Clinical Research Center|UCB, Inc.","Both","Child|Adult","Phase IV",30,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IIS071108","April 17, 2009","01/01/2009",2009-08-01,"September 3, 2009","01/09/2009","",2009-08-01,"The change in objective measure of inflammation nasal NO after LC treatment.|The change in nasal eosinophils, QOL and diary scores after LC treatment.","http://ClinicalTrials.gov/show/NCT00894231",NA
"26547",26547,"NCT00929331","Immunogenicity & Safety Study of Fluviral?ó (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years","Completed","Has Results","Influenza|Influenza, Human","Biological: Fluviral?ó","GlaxoSmithKline","Both","Adult|Senior","Phase III",110,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","110586","June 25, 2009","01/07/2009",2009-08-01,"December 2, 2010","01/12/2010","",2009-08-01,"Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibodies|GMTs of HI Antibodies|Number of Subjects With a Serum HI Titer Equal to or Above the Cut-off Value|Number of Subjects With a Serum HI Titer Equal to or Above the Cut-off Value|Number of Seroconverted Subjects|Seroconversion Factors|Number of Subjects With a Pre-vaccination Titer Below the Cut-off Value and a Post-vaccination Titer Equal to or Above the Cut-off Value|Number of Subjects Reporting Any Solicited Local Symptoms|Number of Subjects Reporting Grade 3 Solicited Local Symptoms|Number of Subjects Reporting Any Solicited General Symptoms|Number of Subjects Reporting Grade 3 Solicited General Symptoms|Number of Subjects Reporting Related Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events","http://ClinicalTrials.gov/show/NCT00929331",NA
"26554",26554,"NCT00964431","Phase 2 Study of Indomethacin Capsules to Treat Dental Pain","Completed","No Results Available","Analgesia","Drug: Celecoxib|Drug: Placebo|Drug: Indomethacin Test (lower dose)|Drug: Indomethacin Test (upper dose)","Iroko Pharmaceuticals, LLC","Both","Adult","Phase II",200,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IND2-08-03","August 24, 2009","01/08/2009",2009-12-01,"January 4, 2010","01/01/2010","",2009-12-01,"TOTPAR","http://ClinicalTrials.gov/show/NCT00964431",NA
"26563",26563,"NCT00974831","Glucose Tolerance in Healthy Overweight Adults","Completed","No Results Available","Overweight","Other: Amino Acid Drink Mixture|Other: Glucose drink","Abbott Nutrition","Both","Adult","Phase II",24,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BK51","September 9, 2009","01/07/2009",2009-10-01,"November 24, 2010","01/11/2009","",2009-10-01,"The primary variable is the positive area under the curve from 0 to 180 minutes for plasma glucose.|Plasma glucose, insulin, C-peptide, free fatty acids, and glucagon concentration data over time","http://ClinicalTrials.gov/show/NCT00974831",NA
"26574",26574,"NCT00990431","Ablative Fractional Lasers to Treat Peri-orbital Rhytides","Completed","No Results Available","Peri-orbital Rhytides","Procedure: Fractional carbon dioxide laser treatment|Procedure: Fractional erbium:YAG laser treatment","Laserklinik Karlsruhe","Both","Adult","Phase IV",28,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LK_05_2009","October 5, 2009","01/08/2008",2009-02-01,"October 13, 2009","01/10/2009","",2009-02-01,"Objective wrinkle depth|Wrinkle severity (according to Fitzpatrick??s wrinkle score)|Patient satisfaction","http://ClinicalTrials.gov/show/NCT00990431",NA
"26595",26595,"NCT01020331","Memantine Therapy in Amyotrophic Lateral Sclerosis","Completed","No Results Available","Amyotrophic Lateral Sclerosis","Drug: Memantine","Phoenix Neurological Associates, LTD|Forest Laboratories","Both","Adult|Senior","Phase II",20,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Memantine in ALS","November 20, 2009","01/06/2005",2009-10-01,"November 23, 2009","01/11/2009","TAME",2009-07-01,"Standardized assessment of ALS disease progression through the ALS Functional Rating Scale (ALSFRS) and compare the levels of Tau at baseline, 6 and 12 months|Change in muscle strength as measured by quantitative dynamometry (baseline vs 18 months)","http://ClinicalTrials.gov/show/NCT01020331",NA
"26637",26637,"NCT01093131","Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy","Completed","No Results Available","Contrast Induced Nephropathy","Other: Oral hydration|Drug: Oral sodium bicarbonate|Other: Intravenous Hydration|Drug: Intravenous sodium bicarbonate","The Western Pennsylvania Hospital|Western Pennsylvania Allegheny Health System","Both","Adult|Senior","Phase IV",91,"Other","Interventional","Allocation: Randomized|Control: Historical Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Prevention","04-11-097-DT / WPCI 2009-28","February 25, 2010","01/02/2005",2010-02-01,"June 22, 2010","01/06/2010","HYDRATE",2009-09-01,"Contrast Induced Nephropathy|Length of Hospital Stay|In-Hospital Mortality|Aspiration|Hypotension","http://ClinicalTrials.gov/show/NCT01093131",NA
"26743",26743,"NCT01273831","Effect of Cisatracurium Versus Atracurium on Intraocular Pressure in Patients Underwent General Anesthesia","Completed","No Results Available","Intraocular Pressure","Drug: atracurium|Drug: cisatracurium","Isfahan University of Medical Sciences","Both","Child|Adult|Senior","Phase II",90,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)","ASD-1213-10","January 10, 2011","01/07/2009",2009-12-01,"January 10, 2011","01/07/2009","",2009-12-01,"intraocular pressure|systolic blood pressure","http://ClinicalTrials.gov/show/NCT01273831",NA
"26771",26771,"NCT00003232","Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic Prostate Cancer","Completed","No Results Available","Pain|Prostate Cancer|Quality of Life","Drug: clodronate disodium|Drug: mitoxantrone hydrochloride|Drug: prednisone|Procedure: quality-of-life assessment","NCIC Clinical Trials Group","Male","Child|Adult|Senior","Phase III",204,"Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","PR6|CAN-NCIC-PR6|CDR0000066102","November 1, 1999","01/11/1997",2009-02-01,"November 7, 2010","01/11/2010","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00003232",NA
"26813",26813,"NCT00048932","A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: Abatacept|Drug: Placebo|Drug: Abatacept","Bristol-Myers Squibb","Both","Adult|Senior","Phase III",1795,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","IM101-031","November 11, 2002","01/12/2002",2009-10-01,"October 6, 2009","01/10/2009","",2009-10-01,"incidence of AE, SAE, discontinuation due to AE","http://ClinicalTrials.gov/show/NCT00048932",NA
"26839",26839,"NCT00085332","Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)","Completed","No Results Available","Endometrial Cancer","Drug: docetaxel","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child|Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000368634|GOG-0129N","June 10, 2004","01/07/2004",NA,"February 5, 2009","01/09/2004","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00085332",NA
"26879",26879,"NCT00145132","Beta-CIT-SPECT and Neurophysiology in Depression","Completed","No Results Available","Depression","Procedure: ??-CIT-SPECT, Neurophysiology","Ludwig-Maximilians - University of Munich|H. Lundbeck A/S","Both","Adult|Senior","Phase IV",30,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","ESCIT-SPECT-Pogarell|EK287/98","September 1, 2005","01/06/2005",2009-12-01,"June 1, 2010","01/05/2010","",2009-12-01,"changes in ??-CIT/neurophysiological measurements from baseline to week 4","http://ClinicalTrials.gov/show/NCT00145132",NA
"26889",26889,"NCT00159432","Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: bevacizumab, capecitabine, oxaliplatin","USC/Norris Comprehensive Cancer Center|Hoffmann-La Roche|Genentech","Both","Adult|Senior","Phase II",53,"Other|Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-04-10","September 7, 2005","01/02/2005",NA,"July 23, 2010","01/07/2010","",2009-06-01,"To determine the median time for progression free survival in patients with advanced colorectal cancer treated with a combination of capecitabine, oxaliplatin and bevacizumab.|To assess the toxicity of this regimen.|To confirm the association of TS, TP, DPD, and ERCC1 expression levels in tumor tissue with clinical outcome.|To identify other molecular predictors of response, survival, and toxicity to this combination of chemotherapy.|Confirm the association between TS, TP, DPD, and ERCC1 mRNA expression levels in tumor tissue and progression free survival, time to progression on this regimen, response, and overall survival","http://ClinicalTrials.gov/show/NCT00159432",NA
"26948",26948,"NCT00255632","Transdermal Estradiol in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy and Chemotherapy","Completed","No Results Available","Prostate Cancer","Biological: therapeutic estradiol","University of Medicine and Dentistry New Jersey|National Cancer Institute (NCI)","Male","Adult|Senior","Phase II",33,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","080419; CDR0000445280|P30CA072720|CINJ-080419-5247","November 18, 2005","01/05/2005",2009-11-01,"March 8, 2010","01/03/2010","",2009-11-01,"Decrease of 50% in PSA","http://ClinicalTrials.gov/show/NCT00255632",NA
"27001",27001,"NCT00332332","Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel in Psoriasis","Completed","No Results Available","Psoriasis","Biological: ENBREL|Drug: Enbrel|Biological: ENBREL","Amgen|Wyeth","Both","Adult|Senior","Phase IV",231,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20050180","May 30, 2006","01/03/2006",2010-02-01,"March 11, 2010","01/03/2010","",2009-07-01,"PHYSICIAN GLOBAL ASSESSMENT|QOL, Safety","http://ClinicalTrials.gov/show/NCT00332332",NA
"27037",27037,"NCT00390832","Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3)","Completed","No Results Available","Myocardial Infarction|Angioplasty, Transluminal, Percutaneous Coronary","Drug: Erythropoietin|Other: Placebo","Deutsches Herzzentrum Muenchen","Both","Adult|Senior","Phase III",138,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GE IDE No. I01106","October 19, 2006","01/12/2006",2009-03-01,"December 16, 2010","01/03/2009","REVIVAL-3",2009-03-01,"Left ventricular ejection fraction measured by magnetic resonance imaging|Changes in left ventricular ejection fraction and infarct size|Death, recurrent myocardial infarction, IRA-revascularization and stroke","http://ClinicalTrials.gov/show/NCT00390832",NA
"27050",27050,"NCT00415532","AMG 531 Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura","Completed","No Results Available","Thrombocytopenic Purpura|Idiopathic Thrombocytopenic Purpura|Thrombocytopenia|Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","Biological: AMG531|Drug: Medical Standard of Care for ITP","Amgen","Both","Adult|Senior","Phase III",131,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20060131","December 21, 2006","01/11/2006",2009-07-01,"September 23, 2010","01/09/2010","",2009-05-01,"Number of subjects undergoing a splenectomy by treatment group during the 52-week treatment period.|Number of subjects with a treatment failure during the 52-week treatment period.|Time to splenectomy.|Platelet response.|Change in the ITP-PAQ (Patient reported outcome scale) Physical Health domains.","http://ClinicalTrials.gov/show/NCT00415532",NA
"27068",27068,"NCT00435032","Early Versus Interval Appendectomy for Ruptured Appendicitis in Children","Completed","No Results Available","Ruptured Appendicitis","Procedure: early appendectomy|Procedure: interval appendectomy","University of Tennessee","Both","Child|Adult","Phase III",128,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","R073223335","February 12, 2007","01/10/2006",NA,"January 11, 2010","01/01/2010","RAPTOR",2009-09-01,"time (days) away from normal activities (or time until returns to normal activities)|complication rates of each treatment arm:|Wound infection or dehiscence|Intra-abdominal abscess|Requires reoperation|Bowel obstruction|central venous catheter-related infection|interventional radiology-related complication|Total hospital length of stay|# patients with central venous line|# with interventional radiology drainage|# of return visits to pediatrician, ED, surgery office|Other complication|quality of life questionnaire (SF10)|hospital costs","http://ClinicalTrials.gov/show/NCT00435032",NA
"27088",27088,"NCT00445432","A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease","Completed","Has Results","Crohn's Disease","Biological: adalimumab|Biological: Placebo","Abbott|Abbott Japan Co.,Ltd|Eisai Co., Ltd.","Both","Child|Adult|Senior","Phase II|Phase III",82,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M06-837","March 7, 2007","01/03/2007",2010-11-01,"January 4, 2011","01/12/2010","",2009-03-01,"Number of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment|Number of Participants Who Had Clinical Response 70 (CR-70) at Week 52 of Double-blind Treatment|Number of Participants Who Had Clinical Response 100 (CR-100) at Week 52 of Double-blind (DB) Treatment|Change in Crohn's Disease Activity Index From Baseline of lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment|Number of Participants With Clinical Remission at Week 52 of Open-label Treatment|Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment|Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment|Change in Physical Component of the Short Form-36 Health Survey From Baseline of the lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment|Change in Mental Component of the Short Form-36 Health Survey From Baseline of the lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment","http://ClinicalTrials.gov/show/NCT00445432",NA
"27095",27095,"NCT00487032","Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation","Completed","No Results Available","Allergic Rhinitis|Tachyphylaxis|Rhinitis Medicamentosa","Drug: Oxymetazoline 0.05% w/v|Drug: Fluticasone propionate 50 micrograms per actuation|Drug: Prazosin hydrochloride|Drug: Placebo to Prazosin","University of Dundee","Both","Adult","Phase IV",19,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VAI03|2007??Ê003194??Ê82","June 14, 2007","01/05/2008",2009-05-01,"July 28, 2009","01/07/2009","",2009-05-01,"The primary endpoint will be the difference in peak PNIF response to incremental doses of Oxymetazoline [i.e. as a dose response]|Active Anterior Rhinomanometry|Nasal oscillometric indices|Laser Doppler Flowmetry to measure nasal blood flow|Systolic, Diastolic blood pressure(measure of alpha blockade)","http://ClinicalTrials.gov/show/NCT00487032",NA
"27109",27109,"NCT00507832","Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease","Completed","No Results Available","Prurigo Nodularis","Drug: Pimecrolimus|Drug: Hydrocortisone|Drug: Pimecrolimus","University Hospital Muenster|Novartis Pharmaceuticals","Both","Adult|Senior","Phase II",30,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SST-Pr-2-2005","July 26, 2007","01/04/2007",2009-10-01,"July 6, 2010","01/02/2009","CASM981CDE21",2009-06-01,"Hypothesis: pimecrolimus is superior in the reduction of the itch intensity on a visual analogue scale (VAS) compared to hydrocortisone cream 1%. H1: mean value VAS pimecrolimus < mean value VAS hydrocortisone|Improvement of total symptom score (papule, nodules, excoriations, crusting, erythema) scored from 0-3 for each single symptom|Change of skin neuropeptide content in suction blisters","http://ClinicalTrials.gov/show/NCT00507832",NA
"27113",27113,"NCT00515632","Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Balaglitazone","Rheoscience A/S","Both","Adult|Senior","Phase III",409,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","DRF2593-307|EudraCT No. 2007-002088-29","August 13, 2007","01/07/2007",2009-10-01,"July 22, 2010","01/07/2010","BALLET",2009-07-01,"HbA1c, fasting plasma glucose and 7-point plasma glucose profiles, weight gain, lower leg oedema and safety parameters.|Waist and hip circumferences, plasmaNT-proBNP, ECG, body composition as measured by DXA, blood lipid profiles, plasma insulin","http://ClinicalTrials.gov/show/NCT00515632",NA
"27122",27122,"NCT00234832","A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients","Completed","Has Results","Obesity","Drug: Sibutramine hydrochloride|Drug: Placebo|Drug: Sibutramine hydrochloride","Abbott","Both","Adult|Senior","Phase III",10777,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","M01-392","September 13, 2005","01/01/2003",2009-11-01,"May 6, 2010","01/05/2010","SCOUT",2009-03-01,"Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)|Risk of Death From Any Cause (All-cause Mortality)|Risk of Experiencing a POE or a Revascularization Procedure|Risk of Experiencing a Nonfatal MI Included in the POE|Risk of Experiencing a Nonfatal Stroke Included in the POE|Risk of Experiencing a Resuscitated Cardiac Arrest Included in the POE|Risk of Experiencing Cardiovascular Death Included in the POE","http://ClinicalTrials.gov/show/NCT00234832",NA
"27137",27137,"NCT00552032","Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy. SNORE Study (Study P05155)(COMPLETED)","Completed","No Results Available","Adenoid Hypertrophy","Drug: Mometasone Furoate nasal spray|Drug: Placebo","Schering-Plough","Both","Child","Phase III",144,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","P05155","October 31, 2007","01/08/2007",2009-12-01,"February 24, 2010","01/02/2010","SNORE",2009-12-01,"Size reduction of the adenoids from Baseline as graded by Nasopharyngoscopic evaluation (Adenoid/Choana A/C Index)|Improvement in AM and PM Symptoms Score (snoring, nasal obstruction, oral breathing, ear pain, nasal discharge and difficulty breathing) as evaluated by the parent or patient.|Improvement in the Rhinomanometry, Pure Tone Audiogram and Acoustic Rhinometry measurements in children ages 7 to 11 years old from baseline to end of treatment (week 8) and end of follow up (week 24).|Pediatric Sleep Questionnaire (PSQ, Spanish) improvement from baseline to end of treatment (week 8) and end of follow up (week 24).|Pediatric QOL Questionnaire (PedsQL, Spanish) and Pediatric OSA-18 improvement from baseline to end of treatment (week 8) and end of follow up (week 24).|Improvement in the Otoscopic and Rhinoscopic examination.|Improvement in measures of Bilateral Tympanogram in children 2 to 11 years old from baseline to end of treatment (week 8) and end of follow up (week 24).|Adverse events (related and concurrent) incidence.|Incidence of adenoid hypertrophy recurrence during blinded follow-up extension period via Nasopharyngoscopic evaluation every 2 months.","http://ClinicalTrials.gov/show/NCT00552032",NA
"27153",27153,"NCT00589732","Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent","Completed","No Results Available","Coronary Artery Disease","Drug: Valsartan","CardioVascular Research Foundation, Korea|Novartis","Both","Adult|Senior","Phase IV",300,"Other|Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0077","December 31, 2007","01/09/2006",2009-06-01,"August 17, 2010","01/07/2010","VAL-SUPPRES",2009-06-01,"Angiographic in-stent late-loss|-Percent atheroma volume of 10mm length (non-target vessel) -Major cardiac adverse events including death, Q-MI, Non Q-MI, and target lesion or vessel revascularization -Delta change in percent atheroma area and volume","http://ClinicalTrials.gov/show/NCT00589732",NA
"27177",27177,"NCT00624832","A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels","Completed","No Results Available","Asthma","Drug: Xolair|Drug: Xolair|Drug: Placebo","Novartis|Genentech|Tanox","Both","Adult","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CIGE025A2210","February 18, 2008","01/02/2008",2009-01-01,"September 1, 2010","01/09/2010","",2009-01-01,"Change in early phase allergic response after treatment with study drug in active vs. placebo patients|Change in late phase allergic response after treatment with study drug in active vs. placebo patients","http://ClinicalTrials.gov/show/NCT00624832",NA
"27184",27184,"NCT00576732","A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder","Completed","Has Results","Autistic Disorder|Autism","Drug: Risperidone high dose|Drug: Placebo|Drug: Risperidone low dose","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Child","Phase IV",96,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CR014740|RISAUT4002","December 17, 2007","01/12/2007",2010-03-01,"December 23, 2010","01/12/2010","",2009-09-01,"Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale|Number of Participants Who Had at Least 25% Improvement in ABC-I|Change in Clinical Global Impression Severity (CGI-S)|Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.|Change in Fasting Glucose (mg/dL) at 6 Weeks|Change in Insulin Resistance (IR) at 6 Weeks|Change in Fasting Glucose (mg/dL) at 6 Months|Change in Insulin Resistance (IR) at 6 Months","http://ClinicalTrials.gov/show/NCT00576732",NA
"27203",27203,"NCT00658632","Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)","Completed","No Results Available","Gastroesophageal Reflux Disease (GERD)","Drug: Rabeprazole sodium|Drug: Esomeprazole","Eisai Inc.","Both","Adult|Senior","Phase III",1320,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E3810-G000-303","April 9, 2008","01/02/2008",2009-09-01,"March 10, 2010","01/03/2010","",2009-04-01,"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment.|Adverse events, electrocardiograms (ECGs), lab evaluations (hematology, blood chemistry, urinalysis, serum gastrin), physical exams, vital signs.","http://ClinicalTrials.gov/show/NCT00658632",NA
"27204",27204,"NCT00669032","Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid in Patients With OA of the Knee","Completed","No Results Available","Osteoarthritis of the Knee","Device: Hyaluronic acid|Other: Placebo","Tedec-Meiji Farma, S.A.","Both","Adult|Senior","Phase IV",306,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TM-ME3710/304|2006-001854-28","April 25, 2008","01/10/2003",2009-12-01,"February 24, 2010","01/02/2010","",2009-07-01,"The main objective of this study is maximum overall pain in the knee during the week prior to the evaluation, measured by the Visual Analogue Scale 100mm. The basal score will be compared with the scoring obtained in each follow-up visit.","http://ClinicalTrials.gov/show/NCT00669032",NA
"27205",27205,"NCT00667732","How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics","Completed","No Results Available","Type 2 Diabetes","Drug: exenatide|Drug: placebo","Oregon Health and Science University|Amylin Pharmaceuticals, Inc.|Eli Lilly and Company","Both","Adult|Senior","Phase IV",75,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","IND 75,235","April 24, 2008","01/03/2007",2010-04-01,"August 17, 2010","01/08/2010","MEXELIN",2009-10-01,"The hemoglobin A1c test, which measures the blood glucose level over a 2-month period, will be looking at glucose control.|The hemoglobin A1c test, which measures the blood glucose level over a 2-month period, will be looking at glucose control.|The hemoglobin A1c test, which measures the blood glucose level over a 2-month period, will be looking at glucose control.|Participants' changes in weight will also be closely examined, since one of the primary objectives of this study was to look at the effect of this regimen of drugs to control blood sugar levels as well as weight.|Participants' changes in weight will also be closely examined, since one of the primary objectives of this study was to look at the effect of this regimen of|Participants' changes in weight will also be closely examined, since one of the primary objectives of this study was to look at the effect of this regimen of","http://ClinicalTrials.gov/show/NCT00667732",NA
"27209",27209,"NCT00662532","Antibiotic Study for Dental Implants","Completed","Has Results","Periodontitis","Drug: Minocycline HCl","Johnson & Johnson Consumer & Personal Products Worldwide","Both","Adult|Senior","Phase III",44,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","OP-P-5265-1","April 17, 2008","01/04/2008",2009-04-01,"July 22, 2010","01/07/2010","",2009-04-01,"Overall PD Reduction|Initial PD Reduction|BOP Percent Reduction From Baseline","http://ClinicalTrials.gov/show/NCT00662532",NA
"27213",27213,"NCT00676832","Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis","Completed","No Results Available","Colitis, Ulcerative","Drug: Placebo|Drug: COLAL-PRED","Prometheus Laboratories","Both","Adult|Senior","Phase II",190,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","08CP01","May 9, 2008","01/05/2008",2009-10-01,"September 27, 2010","01/09/2010","",2009-10-01,"The proportion of patients with Complete Response at Week 4 defined as a decrease from baseline in the DAI score by ??­ 30% or ??­ 3 points, and with a decrease in the rectal bleeding subscore of ??­ 1 or an absolute rectal bleeding sub-score of 0 or 1.|The proportion of patients in Clinical Remission defined as a DAI score of ??? 2 points, with no-individual DAI sub-score > 1 at Week 4. Patients in remission by this definition will have a rectal bleeding DAI sub-score of either 0 or 1.","http://ClinicalTrials.gov/show/NCT00676832",NA
"27217",27217,"NCT00684632","A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients","Completed","No Results Available","Pain, Cancer","Drug: Placebo|Drug: KW-2246 (fentanyl citrate)","Kyowa Hakko Kirin Company, Limited","Both","Adult|Senior","Phase III",48,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2246-0702","May 22, 2008","01/03/2008",2009-05-01,"July 6, 2009","01/07/2009","",2009-05-01,"","http://ClinicalTrials.gov/show/NCT00684632",NA
"27224",27224,"NCT00698932","Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control","Completed","No Results Available","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo","AstraZeneca|Bristol-Myers Squibb","Both","Adult|Senior","Phase III",530,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1680C00005","June 16, 2008","01/06/2008",2009-10-01,"November 1, 2009","01/11/2009","",2009-10-01,"Absolute change from baseline in glycosylated haemoglobin A1c (HbA1c) after 24 weeks oral administration|Compare the effects of Saxagliptin versus placebo after 24 weeks double-blind treatment","http://ClinicalTrials.gov/show/NCT00698932",NA
"27239",27239,"NCT00719732","Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3","Completed","Has Results","Cataract","Device: ReSTOR","Alcon Research","Both","Adult|Senior","Phase IV",218,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M07-001","July 21, 2008","01/09/2007",2009-05-01,"March 4, 2010","01/03/2010","",2009-05-01,"Uncorrected Visual Acuity (UCVA)","http://ClinicalTrials.gov/show/NCT00719732",NA
"27245",27245,"NCT00734032","A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients","Completed","No Results Available","Dyslipidaemia","Drug: SB480848 80mg EC Tablet|Drug: SB480848 160mg EC Tablet|Drug: SB480848 40mg EC Tablet|Drug: SB480848 Placebo Tablet","GlaxoSmithKline","Both","Adult|Senior","Phase II",107,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","LPL110118","August 12, 2008","01/08/2008",2009-01-01,"April 8, 2010","01/04/2010","",2009-01-01,"Change from baseline to week 4 in plasma Lp-PLA2 activity|??ÑPercent inhibition of Lp-PLA2 activity in plasma at week 4??ÑOvertime changes of Lp-PLA2 activity and the inhibition rate of Lp-PLA2 activity in plasma from baseline","http://ClinicalTrials.gov/show/NCT00734032",NA
"27247",27247,"NCT00724932","Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (Study 19.4.318AM2)(P05699)(COMPLETED)","Completed","No Results Available","Anesthesia, General","Drug: sugammadex (Org 25969)|Drug: neostigmine","Schering-Plough","Both","Adult|Senior","Phase III",140,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","19.4.318|P05699","July 28, 2008","01/08/2008",2009-03-01,"October 2, 2009","01/10/2009","",2009-03-01,"Time from start of administration of IMP to recovery of the T4/T1 ratio to 0.9.|Neuromuscular assessments: Time from start of administration of IMP to recovery of the T4/T1 ratio to 0.5, 0.6, 0.7 and 0.8|Neuromuscular assessments: Time from start of administration of the last dose of rocuronium to recovery of the T4/T1 ratio to 0.5, 0.6, 0.7, 0.8 and 0.9|Time from start of administration of the last dose of rocuronium to the time of 1-2 PTC in the 4.0 mg.kg-1 sugammadex group.|Time from start of administration of the last dose of rocuronium to the time of reappearance of T2 in the 50 ??g.kg-1 neostigmine group.|Vital signs, i.e. heart rate and blood pressure|Physical examination|Pre-treatment (serious) events (from signing informed consent until administration of IMP) and (serious) adverse events (S)AEs|TOF-Watch?ó SX and arm board related adverse events|Reoccurrence of neuromuscular blockade based on the TOF-Watch?ó SX recording i.e. a decline in T4/T1 ratio from >=0.9 to <0.8 in at least three consecutive TOF values|Clinical evidence of reoccurrence of neuromuscular blockade or residual neuromuscular blockade (routine oxygen saturation by pulse oximetry and breath frequency measurement)|Events due to a possible interaction of sugammadex with endogenous compounds or with exogenous compounds other than rocuronium|Monitoring of Clinical signs of recovery according to routine anesthetic procedures at the trial sites|Pregnancy follow up|Time from OR admission (physical placement of subject into the OR) to OR discharge ready|Time from OR admission (physical placement of subject into the OR) to actual OR discharge|Time from OR discharge ready to actual OR discharge|Time from start of IMP administration to tracheal extubation|Time from start of IMP administration to T4/T1 ratio of <=0.60, >0.60 - <=0.70, >0.70 - <=0.80, >0.80 - <0.90 and >=0.90|Time from start of IMP administration to OR discharge ready|Time from start of IMP administration to actual OR discharge|Time from tracheal extubation to OR discharge ready|Time from tracheal extubation to actual OR discharge|Time from OR discharge ready to PACU discharge ready (a Modified Aldrete Score of >=9 is required for discharge from the PACU)|Time from OR discharge ready to actual PACU discharge|Time from actual OR discharge to PACU discharge ready (a Modified Aldrete Score of >=9 is required for discharge from the PACU)|Time from actual OR discharge to actual PACU discharge|Time from PACU admit to PACU discharge ready (a Modified Aldrete Score of >=9 is required for discharge from the PACU)|Time from PACU admit to actual PACU discharge","http://ClinicalTrials.gov/show/NCT00724932",NA
"27290",27290,"NCT00810732","Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects","Completed","No Results Available","Chronic Kidney Disease|CRD","Drug: Open|Drug: Nifedipine|Drug: Placebo","Pfizer","Both","Adult|Senior","Phase II",27,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","B1321005|B1321005","December 17, 2008","01/05/2007",2009-03-01,"September 8, 2010","01/09/2010","FCRD01",2009-03-01,"The primary efficacy endpoint is the mean 24-hour urine total protein level change from baseline at week 6.|The secondary efficacy endpoints include the changes from Baseline to week 6 in total 24-hour ambulatory monitoring of systemic arterial BP, Absolute values of the carotid-femoral PWV.","http://ClinicalTrials.gov/show/NCT00810732",NA
"27296",27296,"NCT00817232","Effectiveness of Microcurrent for Treatment of Tennis Elbow","Completed","No Results Available","Tennis Elbow","Device: Microcurrent (Elexoma Medic)","University of Hertfordshire","Both","Adult|Senior","Phase II|Phase III",24,"Other","Interventional","Allocation: Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HEPEC/10/08/05","January 5, 2009","01/12/2008",2009-12-01,"June 18, 2010","01/08/2009","",2009-12-01,"Tendon pathology as indicated by sonography|Patient-Rated Global Change Score|Pain Free Grip Strength|Patient-rated Tennis Elbow Questionnaire|Patient-Specific Functional Scale|Adverse events","http://ClinicalTrials.gov/show/NCT00817232",NA
"27372",27372,"NCT00945932","A Study to Evaluate the Effect of Repeat Doses of GW870086X in Mild to Moderate Asthmatics","Completed","No Results Available","Mild Asthma|Moderate Asthma","Drug: GW870086X|Drug: Placebo","GlaxoSmithKline","Both","Adult","Phase II",37,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","112851","July 16, 2009","01/07/2009",2009-12-01,"February 18, 2010","01/02/2010","",2009-12-01,"Lung function as measured by FEV1|Lung function as measured by FEV1|Lung function as measured by PEFR|Rescue medication usage|Assess safety and tolerability","http://ClinicalTrials.gov/show/NCT00945932",NA
"27397",27397,"NCT00984932","Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension","Completed","No Results Available","Systemic Sclerosis","Drug: Rosuvastatin","Faculty of Medicine, University of Alexandria","Both","Child|Adult|Senior","Phase III",40,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","alexmed116613963","September 24, 2009","01/09/2008",2009-07-01,"September 24, 2009","01/09/2009","",2009-07-01,"exercise capacity measured by the SMWT, mPAP and WHO functional class change","http://ClinicalTrials.gov/show/NCT00984932",NA
"27414",27414,"NCT01012232","Local Anesthetic in Total Knee Arthroplasty (TKA): Volume Versus Concentration","Completed","No Results Available","Postoperative Pain|Analgesic Efficacy","Drug: 20 mL ropivacaine 5 mg/mL|Drug: 10 mL ropivacaine 10 mg/mL","Lundbeck Foundation","Both","Child|Adult|Senior","Phase IV",48,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H-D-2009-016","November 10, 2009","01/06/2009",2009-10-01,"November 10, 2009","01/11/2009","",2009-10-01,"postoperative pain","http://ClinicalTrials.gov/show/NCT01012232",NA
"27458",27458,"NCT01085032","Nicotine Patch Trial in Syrian Primary Care Settings","Completed","No Results Available","Smoking Cessation","Drug: Transdermal Nicotine|Drug: Placebo nicotine patch","University of Memphis","Both","Adult","Phase II",269,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R01DA024876","March 10, 2010","01/08/2006",2009-07-01,"March 10, 2010","01/02/2010","",2009-07-01,"Prolonged Abstinence|7 day point prevalent abstinence|Withdrawal symptoms|Depressive symptomatology","http://ClinicalTrials.gov/show/NCT01085032",NA
"27625",27625,"NCT00025233","Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix","Completed","No Results Available","Cervical Cancer","Biological: bevacizumab","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",51,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000068940|GOG-0227C","October 11, 2001","01/04/2002",NA,"August 8, 2009","01/10/2006","",2009-07-01,"Progression-free survival at 6 months|Frequency and severity of adverse effects as assessed by CTC|Duration of progression-free survival and overall survival|Frequency of clinical response (partial and complete response) as assessed by RECIST criteria|Prognostic factors, including initial performance status and age","http://ClinicalTrials.gov/show/NCT00025233",NA
"27632",27632,"NCT00036933","Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer","Completed","No Results Available","Prostate Cancer","Biological: MUC-2-Globo H-KLH conjugate vaccine|Biological: QS21","Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI)","Male","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069342|MSKCC-01140|NCI-G02-2064","May 13, 2002","01/03/2002",NA,"December 3, 2009","01/03/2003","",2009-03-01,"","http://ClinicalTrials.gov/show/NCT00036933",NA
"27688",27688,"NCT00127933","XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: capecitabine [Xeloda]|Drug: Taxotere|Drug: Herceptin","Hoffmann-La Roche","Female","Adult|Senior","Phase IV",157,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18530","August 5, 2005","",2009-07-01,"November 16, 2009","01/11/2009","",2009-07-01,"Pathological complete response in primary breast tumor at time of definitive surgery|Complete pathological response, overall clinical response, local recurrence, disease-free and overall survival.|AEs, laboratory parameters","http://ClinicalTrials.gov/show/NCT00127933",NA
"27750",27750,"NCT00237133","Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women","Completed","No Results Available","Locally Advanced Breast Cancer","Drug: Letrozole","Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",112,"Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CFEM345EBR01","October 9, 2005","01/03/2003",NA,"December 13, 2010","01/12/2010","PREDICT",2009-01-01,"Safety and tolerability of Letrozole","http://ClinicalTrials.gov/show/NCT00237133",NA
"27760",27760,"NCT00244933","Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer","Dietary Supplement: genistein|Drug: gemcitabine hydrochloride|Procedure: complementary or alternative medicine procedure","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",36,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000446089|WSU-C-2597","October 25, 2005","01/02/2004",NA,"April 13, 2010","01/04/2010","",2009-10-01,"Objective response rate by RECIST criteria following every 2 courses until disease progression or death|Duration of response|Overall survival|Time to disease progression|Duration of survival at 1 year following study treatment|Qualitative and quantitative toxicities from treatment initiation until 30 days following treatment|Correlate responses with plasma genistein levels at course 1 day -7, course 1 day -1 (before and 4 hours after dose), course 2 day 1 (before and 4 hours after dose)|In vivo effects of genistein in breast cancer tissue biomarkers (Ki67, TUNEL assay, p-Akt, NF-kB, immunohistochemistry and cDNA microarray analysis) at baseline (pre-genistein treatment) and 7 days following genistein treatment","http://ClinicalTrials.gov/show/NCT00244933",NA
"27813",27813,"NCT00334633","Treatment of BV With Tinidazole","Completed","No Results Available","Bacterial Vaginosis","Drug: tinidazole","University of Alabama at Birmingham|National Institute of Allergy and Infectious Diseases (NIAID)","Female","Adult","Phase IV",500,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","F040329003|R01AI058033","June 7, 2006","01/11/2004",2009-12-01,"July 28, 2010","01/07/2010","",2009-12-01,"cure of BV|recurrence of BV","http://ClinicalTrials.gov/show/NCT00334633",NA
"27891",27891,"NCT00421733","The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors","Completed","Has Results","Diabetic Nephropathy|Chronic Kidney Disease","Drug: Zemplar (paricalcitol ) capsules|Drug: Zemplar (paricalcitol) capsules|Drug: Placebo","Abbott","Both","Adult|Senior","Phase II",281,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M05-741|2006-001363-31","January 10, 2007","01/12/2006",2009-06-01,"September 27, 2010","01/09/2010","VITAL",2009-06-01,"Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine Collections Comparing Placebo to the Combined Paricalcitol Treatment Groups (1 Mcg and 2 Mcg).|Number of Participants Achieving a 15% or Greater Reduction From Baseline to Last On-treatment Urine Albumin to Creatinine Ratio (UACR) Levels.|Change From Baseline to the Last On-treatment Measurement in Albumin Levels Determined From 24-hour Urine Collection.|Change From Baseline to the Last On-treatment Observation in Intact Parathyroid Hormone (iPTH) Levels.","http://ClinicalTrials.gov/show/NCT00421733",NA
"27893",27893,"NCT00455533","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Ixabepilone|Drug: Paclitaxel|Drug: Cyclophosphamide|Drug: Doxorubicin","Bristol-Myers Squibb","Female","Adult|Senior","Phase II",294,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA163-100|EUDRACT 2006-003047-24","April 2, 2007","01/10/2007",2009-12-01,"January 6, 2011","01/06/2010","",2009-12-01,"Estimate the pathologic complete response (pCR) rate in the two arms|Estimate pCR rate in a biomarker predefined population|Estimate the sensitivity and specificity for each of the predictive models|Explore other gene expression and protein expression that may be predictive of pCR in the two arms|Estimate the clinical objective response rates in the two arms|Determine the rate of breast conservation surgery achieved by subjects in each treatment arm|Evaluate the safety of AC followed by ixabepilone in subjects with early stage breast cancer|Determine the combined pCR and minimum residual cancer burden 1 rates in the two arms","http://ClinicalTrials.gov/show/NCT00455533",NA
"27907",27907,"NCT00477633","Study of Safety and Efficacy of an Oral Contraceptive","Completed","No Results Available","Contraception","Drug: Norethindrone/ethinyl estradiol|Drug: norethindrone / ethinyl estradiol","Warner Chilcott","Female","Adult","Phase III",1702,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","PR-00207","May 22, 2007","01/06/2007",2009-02-01,"May 6, 2009","01/05/2009","",2009-01-01,"Pregnancy rate among women 18-35 years old, expressed in terms of the Pearl Index defined as the number of pregnancies per 100 women-years of treatment|Descriptive parameters of bleeding/spotting, safety and tolerability.","http://ClinicalTrials.gov/show/NCT00477633",NA
"27934",27934,"NCT00517933","Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis","Completed","No Results Available","Pulmonary Fibrosis|Hypertension, Pulmonary","Drug: Sildenafil Citrate|Other: Placebo","National Heart, Lung, and Blood Institute (NHLBI)|Pfizer","Both","Adult|Senior","Phase III",180,"NIH|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","507|5 U10 HL080413-01","August 15, 2007","01/08/2007",2009-10-01,"February 19, 2010","01/02/2010","STEP-IPF",2009-05-01,"Change in 6-minute walk distance (defined as greater than or equal to 20% improvement or less than 20% improvement)|Change in dyspnea|Change in oxygen desaturation measures (time, distance, recovery time) during 6-minute walk test|Change in forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO)|Change in quality of life|Change in 6-minute walk distance","http://ClinicalTrials.gov/show/NCT00517933",NA
"27936",27936,"NCT00527033","A Study of YM178 in Patients With Symptomatic Overactive Bladder","Completed","No Results Available","Urinary Bladder, Overactive","Drug: YM178|Drug: Placebo","Astellas Pharma Inc","Both","Adult|Senior","Phase II",842,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","178-CL-045","September 6, 2007","01/09/2007",2009-01-01,"March 10, 2009","01/03/2009","",2009-01-01,"Overactive bladder symptoms|Overactive bladder symptoms (QOL)","http://ClinicalTrials.gov/show/NCT00527033",NA
"27943",27943,"NCT00532233","Clinical Study With QAX576 in Patients With Idiopathic Pulmonary Fibrosis","Completed","No Results Available","Idiopathic Pulmonary Fibrosis","Drug: QAX576","Novartis","Both","Adult|Senior","Phase II",31,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CQAX576A2202","September 19, 2007","01/10/2007",NA,"August 27, 2010","01/08/2010","",2009-06-01,"-To investigate the possibility that some IPF patients experience increased IL-13 production. Blood samples to be collected pre-dose and weekly after dosing. -To investigate the hypothesis that QAX576 will neutralize IL-13 in patients with IPF|-To evaluat","http://ClinicalTrials.gov/show/NCT00532233",NA
"27977",27977,"NCT00582933","Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor","Completed","No Results Available","Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma|Allogeneic Marrow Transplant","Drug: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|Drug: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|Drug: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF","Memorial Sloan-Kettering Cancer Center","Both","Child|Adult","Phase II",96,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-055|CA23766","December 21, 2007","01/05/2001",2009-04-01,"July 9, 2009","01/07/2009","",2009-04-01,"To establish 1-the incidence and quality of engraftment and hematopoietic reconstitution, 2- the early transplant-related severe morbidity and mortality and 3-the incidence and severity of GvHD.|To establish initial estimates of 1-the incidence of overall survival and disease-free survival at 2 years and 2- the quality of immune reconstitution following transplantation.","http://ClinicalTrials.gov/show/NCT00582933",NA
"27995",27995,"NCT00605033","A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)","Completed","Has Results","Opiate Dependence|Drug Dependence","Drug: Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Drug: Subutex, Buprenorphine Hydrochloride, SCH 28444","Schering-Plough","Both","Child|Adult|Senior","Phase IV",241,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P04843|SWITCH","January 17, 2008","01/03/2008",2009-05-01,"September 14, 2010","01/09/2010","",2009-04-01,"Response Rate","http://ClinicalTrials.gov/show/NCT00605033",NA
"27997",27997,"NCT00615433","Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Lurasidone|Drug: Lurasidone|Drug: Olanzapine|Drug: Sugar Pill","Dainippon Sumitomo Pharma America","Both","Adult|Senior","Phase III",478,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","D1050231","February 1, 2008","01/01/2008",2010-03-01,"March 15, 2010","01/03/2010","",2009-12-01,"Change in total PANSS score from baseline to the end of the double blind treatment period.|CGI-S from baseline to the end of the double-blind treatment.","http://ClinicalTrials.gov/show/NCT00615433",NA
"28006",28006,"NCT00628433","Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis","Completed","No Results Available","Ulcerative Colitis","Drug: Placebo|Drug: HE3286","Harbor BioSciences, Inc","Both","Adult","Phase I|Phase II",36,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HE3286-0301","February 25, 2008","01/02/2008",2009-05-01,"June 15, 2009","01/06/2009","",2009-05-01,"safety and pharmacokinetics|assess activity on the signs and symptoms of active mild-to-moderate ulcerative colitis","http://ClinicalTrials.gov/show/NCT00628433",NA
"28021",28021,"NCT00653133","Multicenter Continuous Peripheral Nerve Block Surveillance Study","Completed","No Results Available","Postoperative Pain","Device: Ultrasound imaging plus ON-Q Cbloc|Device: Peripheral nerve stimulator plus ON-Q Cbloc","I-Flow","Both","Adult|Senior","Phase IV",3400,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","iflocpnb2007","March 28, 2008","01/05/2007",2009-03-01,"September 27, 2009","01/09/2009","cpnb",2009-03-01,"complications of peripheral nerve block","http://ClinicalTrials.gov/show/NCT00653133",NA
"28059",28059,"NCT00710333","Safety of Juvista When Administered Following Excision of Ear Lobe Keloids","Completed","No Results Available","Keloid","Drug: Avotermin|Drug: placebo","Renovo","Both","Adult|Senior","Phase I|Phase II",10,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RN1001-0093","July 3, 2008","01/07/2008",2009-12-01,"March 8, 2010","01/03/2010","RN1001-0093",2009-10-01,"Frequency of Adverse events|Keliod recurrence","http://ClinicalTrials.gov/show/NCT00710333",NA
"28081",28081,"NCT00750633","A Phase III Study of an Otic Formulation in Acute Otitis Externa","Completed","No Results Available","Acute Otitis Externa","Drug: AL-15469A/AL-38905|Drug: AL-15469A|Drug: AL-38905","Alcon Research","Both","Child|Adult|Senior","Phase III",1500,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","C-07-13","September 8, 2008","01/06/2008",NA,"January 27, 2009","01/01/2009","",2009-01-01,"Clinical cure|Microbiological success","http://ClinicalTrials.gov/show/NCT00750633",NA
"28087",28087,"NCT00475033","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants","Completed","Has Results","Vaccines, Pneumococcal Conjugate Vaccine","Biological: 13-valent Pneumococcal Conjugate Vaccine|Biological: 7-valent pneumococcal conjugate vaccine","Wyeth","Both","Child","Phase III",603,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","6096A1-3008","May 15, 2007","01/06/2007",2009-05-01,"December 20, 2010","01/12/2010","",2009-05-01,"Percentage of Subjects Achieving Predefined Antibody Level ??­1:8 for Meningococcal C Serum Bactericidal Assay (SBA) in the 13vPnC Group Relative to 7vPnC Group After 2 Doses of NeisVac-C?ó in the Infant Series|Geometric Mean Titer (GMT) of Meningococcal C Antigen in the 13vPnC Group Relative to 7vPnC Group After 2 Doses of NeisVac-C?ó in the Infant Series|Percentage of Subjects Achieving Predefined Antibody Level to Pertussis Antigens in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series|Geometric Mean Concentration (GMC) of Pertussis Antigens in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series|Percentage of Subjects Achieving Predefined Antibody Level ??­0.15 Micrograms Per mL (??g/mL) for Polyribosylribitol Phosphate (PRP) in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series|Geometric Mean Concentration (GMC) of PRP in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series|Percentage of Subjects Achieving Predefined Antibody Level ??­1:8 for Meningococcal C SBA in the 13vPnC Group Relative to 7vPnC Group After the Toddler Dose of NeisVac-C?ó|Geometric Mean Titer (GMT) of Meningococcal C Antigen in the 13vPnC Group Relative to 7vPnC Group After the Toddler Dose|Percentage of Subjects Achieving Predefined Antibody Level ??­1.0 ??g/mL for PRP in Hib in the 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series","http://ClinicalTrials.gov/show/NCT00475033",NA
"28136",28136,"NCT00848133","A Comparison of Subvastus and Midvastus Approaches in Minimally-Invasive Total Knee Arthroplasty","Completed","No Results Available","Total Knee Arthroplasty","Procedure: mini-midvastus surgical approach for total knee arthroplasty|Procedure: mini-subvastus surgical approach for total knee arthroplasty","Sinai Hospital of Baltimore|Bonutti Clinic","Both","Adult|Senior","Phase IV",51,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","Bonutti_SV_MV_001","February 19, 2009","01/07/2004",2009-02-01,"February 19, 2009","01/02/2009","",2009-02-01,"Knee Society Score|Radiographic alignment and fixation","http://ClinicalTrials.gov/show/NCT00848133",NA
"28166",28166,"NCT00883233","Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris","Completed","Has Results","Acne","Drug: Adapalene BPO Gel standard daily overnight application|Drug: Adapalene-BPO 3-hour daily application before bedtime|Drug: Adapalene-BPO Gel every other day application|Drug: Adapalene-BPO Gel standard+Cetaphil?ó Moisturizing Lotion","Galderma","Both","Child|Adult","Phase III",123,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","RD.03.SPR.29085","April 16, 2009","01/04/2009",2009-09-01,"November 11, 2010","01/11/2010","FREE",2009-09-01,"Local Tolerability Was Analyzed in Terms of Worst Score Post-Baseline.","http://ClinicalTrials.gov/show/NCT00883233",NA
"28170",28170,"NCT00917033","Tracheal Intubation of Morbidly Obese Patients. GlideScope Versus Direct Laryngoscopy","Completed","No Results Available","Intubation, Endotracheal|Anesthesia, General|Obesity","Device: GlideScope|Device: Macintosh direct laryngoscope","Glostrup University Hospital, Copenhagen","Both","Adult","Phase IV",100,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LHA GS 01","June 9, 2009","01/09/2008",2009-10-01,"February 23, 2010","01/02/2010","",2009-10-01,"Time to intubate|Number of intubation attempts|Lowest arterial oxygen saturation during intubation|Subjective difficulty of intubation|Cormack-Lehane Score|Airway mucosal trauma|Dental injury|Post-procedure sore throat|Post-procedure hoarseness of voice","http://ClinicalTrials.gov/show/NCT00917033",NA
"28171",28171,"NCT00915733","Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism","Completed","No Results Available","Myocardial Infarction","Drug: cilostazol|Drug: clopidogrel (Plavix)|Genetic: CYP2C19|Drug: aspirin (Acetylsalicylic acid)","Gyeongsang National University Hospital","Both","Adult|Senior","Phase IV",80,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ACCEL-AMI-2C19","June 5, 2009","01/05/2009",2009-11-01,"November 9, 2009","01/11/2009","ACCELAMI2C19",2009-10-01,"Absolute reduction of maximal platelet aggregation (Aggmax) by 5 & 20 ??M ADP induced LTA|Absolute reduction of late platelet aggregation (Agglate) by 5 & 20 ??M ADP induced LTA|Absolute reduction of P2Y12 reaction unit (PRU)|The rate of high post-treatment platelet reactivity","http://ClinicalTrials.gov/show/NCT00915733",NA
"28172",28172,"NCT00920933","Effect of AIN457 on Ozone-induced Airway Neutrophilia Compared to Placebo and Corticosteroid in Healthy Subjects","Completed","No Results Available","Healthy","Biological: AIN457|Other: Placebo|Drug: prednisolone","Novartis Pharmaceuticals","Both","Adult","Phase I|Phase II",24,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science","CAIN457A2104|2008-002854-39","June 12, 2009","01/01/2009",NA,"April 8, 2010","01/04/2010","",2009-11-01,"Total neutrophil cell count in 106/mL in induced sputum|Serum total IL-17A|Percentage neutrophil cell count in induced sputum|Safety and tolerability. Safety assessments will include vital signs, electrocardiograms (ECG), spirometry, pulse oximetry, immunogenicity and adverse events (AEs)|Airway function (FEV1, FVC, and FEF25-75)|Serum AIN457 pharmacokinetics (PK)","http://ClinicalTrials.gov/show/NCT00920933",NA
"28198",28198,"NCT00933933","Evaluation of Diagnostic HIV Ag/Ab Combo Assay","Completed","Has Results","Human Immunodeficiency Viruses","Device: ARCHITECT HIV Ag/Ab Combo|Device: ARCHITECT HIV Ag/Ab Combo","Abbott Diagnostics Division","Both","Child|Adult|Senior","Phase III",635,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","7B5-02-06R01","July 2, 2009","01/06/2009",2009-11-01,"September 17, 2010","01/09/2010","",2009-10-01,"Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection|Architect HIV Combo Test Data for Clinical Sensitivity in HIV Positive Specimens|Architect HIV Combo Test Data for Specificity and Sensitivity in Pregnant Female Population|Architect HIV Combo Test Data for Specificity and Sensitivity in Pediatric Population (From 2 up to 21 Years of Age)|Architect HIV Combo Test Data for Reactivity of Architect HIV Combo in Increased HIV Risk Populations","http://ClinicalTrials.gov/show/NCT00933933",NA
"28248",28248,"NCT01037933","Comedy in Chemotherapy (COMIC) Study","Completed","No Results Available","Cancer|Chemotherapy","Other: Humor intervention|Other: Non-humor intervention (distraction)","Queen's Medical Centre|Queen Emma Nursing Research Institute|University of Hawaii School of Nursing","Both","Adult|Senior","Phase II",50,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","RA2007020|Hob Osterlund","December 21, 2009","01/02/2007",2009-01-01,"December 22, 2009","01/12/2009","COMIC",2009-01-01,"To compare changes in symptoms related to cancer and chemotherapy after a humor vs. non-humor intervention|To compare changes in a marker of immune function (salivary immunoglobulin A), and a hormonal marker of emotional stress (salivary cortisol) between two groups of patients who view a humorous or non-humorous DVD.","http://ClinicalTrials.gov/show/NCT01037933",NA
"28295",28295,"NCT01125033","To Study the Effect of Vitamin E and Vitamin C on Restless Leg Syndrome in Hemodialysis Patients","Completed","No Results Available","Kidney Disease","Drug: Vitamin C|Drug: Vitamin E|Drug: Vitamin C and Vitamin E|Other: Placebo","Shiraz University of Medical Sciences","Both","Adult|Senior","Phase II|Phase III",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","86-3893","May 14, 2010","01/03/2008",2009-02-01,"May 17, 2010","01/03/2008","ShirazUMS",2009-01-01,"To diagnosis hemodialysis patients with RLS according to 4 criteria in IRLSSG|To assay frequency and density of RLS in patients pre and post treatment","http://ClinicalTrials.gov/show/NCT01125033",NA
"28368",28368,"NCT01251133","Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study","Completed","No Results Available","Infectious Disease by Haemophilus Influenzae Type b","Biological: LBVH0101 (Hib vaccine)|Biological: Hiberix?ºÑ Vaccine","LG Life Sciences","Both","Child","Phase III",122,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","LG-VHCL004","November 30, 2010","01/07/2008",2009-03-01,"November 30, 2010","01/11/2010","",2009-03-01,"Percentage of the subjects who obtained protective Ab response with anti-PRP Ab titer ??­ 1 ???/mL after 4th vaccination|Percentage of the subjects who maintained preventive Ab response with anti-PRP Ab titer ??­ 1???/mL prior to 4th vaccination|Percentage of the subjects who maintained preventive Ab response with anti-PRP Ab titer ??­ 0.15???/mL prior to 4th vaccination|Percentage of the subjects who obtained preventive Ab response with anti-PRP Ab titer ??­ 0.15???/mL after 4th vaccination","http://ClinicalTrials.gov/show/NCT01251133",NA
"28378",28378,"NCT01266733","Improvement of the Health-related Quality of Life of Patients With Fibromyalgia Using Multidisciplinary Treatment","Completed","No Results Available","Fibromyalgia","Behavioral: Interdisciplinary treatment|Behavioral: Interdisciplinary treatment of fibromyalgia","Hospital Galdakao-Usansolo","Both","Adult|Senior","Phase II",153,"U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006111057","December 23, 2010","01/02/2007",2010-02-01,"December 23, 2010","01/12/2010","",2009-12-01,"Health-related quality of life among patients with fibromyalgia (FIQ: Fibromyalgia Impact Questionnaire)|Anxiety and depressive symptoms (HADS: The Hospital Anxiety and Depression Scale)","http://ClinicalTrials.gov/show/NCT01266733",NA
"28407",28407,"NCT00003134","Irinotecan in Treating Patients With Recurrent Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: irinotecan hydrochloride","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",60,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065900|NCCTG-967251","November 1, 1999","01/01/1998",NA,"January 27, 2009","01/01/2009","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00003134",NA
"28415",28415,"NCT00004234","Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx","Completed","No Results Available","Head and Neck Cancer|Oral Complications","Procedure: management of therapy complications|Radiation: radiation therapy","NCIC Clinical Trials Group","Both","Child|Adult|Senior","Phase III",NA,"Other","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Supportive Care","HN3|CAN-NCIC-HN3|CDR0000067478","January 28, 2000","01/08/1999",2009-02-01,"November 7, 2010","01/03/2010","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00004234",NA
"28441",28441,"NCT00006734","Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor","Completed","No Results Available","Sarcoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: brachytherapy|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group","Both","Child|Adult","Phase III",NA,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000068323|COG-AEWS0031|CCG-A7983|SWOG-COG-AEWS0031","December 6, 2000","01/05/2001",NA,"December 16, 2010","01/11/2010","",2009-08-01,"Event-free survival","http://ClinicalTrials.gov/show/NCT00006734",NA
"28487",28487,"NCT00096434","Sorafenib in Treating Patients With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: sorafenib tosylate","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000393224|NCCTG-N0336","November 9, 2004","01/09/2004",NA,"February 21, 2009","01/02/2009","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00096434",NA
"28494",28494,"NCT00114634","Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome","Completed","No Results Available","Smith-Lemli-Opitz Syndrome","Drug: Cholesterol Suspension","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Child","Phase II",13,"NIH","Interventional","Primary Purpose: Treatment","050168|05-CH-0168","June 15, 2005","01/06/2005",2009-02-01,"November 25, 2009","01/11/2009","",2009-02-01,"Hyperactivity subscale of the Abberrant Behavior Checklist (ABC).|ABC subscales - inappropriate speech, lethargy, stereotypy, and irritability; Time of caretake tolerance.","http://ClinicalTrials.gov/show/NCT00114634",NA
"28544",28544,"NCT00182234","SONICS - Effectiveness of Specialist Oncology Nursing","Completed","No Results Available","Continuity of Care|Quality of Life","Behavioral: Community Interlink Program","McMaster University|Canadian Institutes of Health Research (CIHR)|Ontario Ministry of Health and Long Term Care","Both","Adult|Senior","Phase III",183,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","74867|CIHR - 74867|MOHLTC - 04171","September 13, 2005","01/12/2005",2009-03-01,"June 17, 2009","01/06/2009","",2009-03-01,"Difference in unmet supportive care needs between intervention and control group|Difference in continuity of care between intervention and control group|Difference in quality of life between intervention and control group|Difference in uncertainty in illness between intervention and control group|Difference in use of resources between intervention and control group|Acute stress following surgery","http://ClinicalTrials.gov/show/NCT00182234",NA
"28565",28565,"NCT00222534","Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis","Completed","No Results Available","Respiratory Insufficiency|Alkalosis","Drug: Acetazolamide","University of Oslo School of Pharmacy","Both","Adult|Senior","Phase IV",90,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","AREMA","September 14, 2005","01/01/2002",2009-12-01,"March 4, 2010","01/03/2010","",2009-12-01,"Partial pressure of oxygen in arterial blood on the 5th day of treatment (without extra oxygen)|Change in partial pressure of oxygen from start of treatment to the fifth day of treatment|Partial pressure of carbon dioxide in arterial blood on the 5th day of treatment.|Change in partial pressure of carbon dioxide from start of treatment to the fifth day of treatment|Intrahospital deaths|Use of mechanical ventilation|Length of stay|Side effects","http://ClinicalTrials.gov/show/NCT00222534",NA
"28607",28607,"NCT00270634","Study of ISA247 in De Novo Renal Transplantation","Completed","No Results Available","Kidney Diseases","Drug: Voclosporin|Drug: tacrolimus","Isotechnika","Both","Adult","Phase II",334,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ISA05-01","December 23, 2005","01/01/2006",2009-07-01,"July 29, 2009","01/07/2009","PROMISE",2009-07-01,"Biopsy proven acute rejection (BPAR)|To demonstrate a 5% improvement in renal function as measured by Iothalamate glomerular filtration rate (GFR)|To determine the pharmacokinetic-pharmacodynamic relationship between ISA247 and calcineurin inhibition, or tacrolimus and calcineurin inhibition|To determine patient survival|To determine graft survival|To determine the proportion of patients with hypertension, hyperlipidemia, or hyperglycemia|A composite of biopsy-proven chronic rejection graft loss, death, or lost to follow up.|A composite of biopsy-proven acute rejections, graft loss or death|To establish the safety of voclosporin","http://ClinicalTrials.gov/show/NCT00270634",NA
"28684",28684,"NCT00404534","Helicobacter Eradication Relief of Dyspeptic Symptoms","Completed","No Results Available","Functional Dyspepsia","Drug: Amoxicillin, Clarythromycin, Omeprazole for ten days","Hospital de Clinicas de Porto Alegre|Ach?¢ Laborat??rios Farmac??uticos Ltda","Both","Adult|Senior","Phase III",407,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","05-422","November 27, 2006","01/11/2006",2009-06-01,"March 29, 2010","01/03/2010","HEROES-12",2009-06-01,"Proportion of patients with 50% reduction of baseline symptoms score measured by the validated Porto Alegre Dyspeptic Symptoms Questionnaire|Proportion of patients with 100% reduction of baseline symptoms score measured by the validated Porto Alegre Dyspeptic Symptoms Questionnaire|Need of rescue medication|Median difference of score between groups|Mean SF-36 scores evolution between groups|Lost of productivity measured by WPAI between groups|Adverse Events","http://ClinicalTrials.gov/show/NCT00404534",NA
"28690",28690,"NCT00420134","Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial","Completed","No Results Available","Liver Failure|Cirrhosis","Procedure: injection of progenitor of hepatocyte drived from Mesenchymal stem cell","Shaheed Beheshti Medical University|Tarbiat Modarres University: Department of Hematology","Both","Adult|Senior","Phase I|Phase II",30,"Other","Interventional","Allocation: Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind|Primary Purpose: Treatment","348","January 8, 2007","01/02/2006",2009-06-01,"September 15, 2009","01/09/2009","",2009-05-01,"Liver function test|MELD score|Cirrhosis mortality after 6 months","http://ClinicalTrials.gov/show/NCT00420134",NA
"28699",28699,"NCT00434434","A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma","Completed","Has Results","Allergic Asthma","Drug: omalizumab|Drug: omalizumab|Drug: placebo","Genentech","Both","Adult","Phase II",61,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","Q4160g","February 11, 2007","01/10/2007",2009-06-01,"April 30, 2010","01/04/2010","AQUA",2009-02-01,"Change in Logarithmically Transformed (log2) Allergen PC15 Concentration (Allergen Concentration Required to Evoke a 15% Decrease in FEV1)|Ratio of the Allergen Forced Expiratory Volume at One Second (FEV1) Two-point Slope at the Week 16 Allergen Challenge to the Allergen FEV1 Two-point Slope at the Baseline Allergen Challenge","http://ClinicalTrials.gov/show/NCT00434434",NA
"28713",28713,"NCT00452634","Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)","Completed","No Results Available","Small Cell Lung Cancer","Drug: Irinotecan|Drug: Cisplatin|Drug: Simvastatin","National Cancer Center, Korea","Both","Adult|Senior","Phase II",62,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-06-176","March 26, 2007","01/04/2006",2010-05-01,"October 22, 2010","01/10/2009","",2009-11-01,"1-year survival & overall survival|Tumor response rate|Time to progression|Toxicity","http://ClinicalTrials.gov/show/NCT00452634",NA
"28723",28723,"NCT00473434","An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Paliperidone","Janssen-Cilag Pty Ltd","Both","Adult","Phase III",64,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR013213|R076477SCH3021","May 11, 2007","01/04/2007",2009-08-01,"April 26, 2010","01/04/2010","",2009-08-01,"The primary endpoint is the mean modal prescribed daily dose of paliperidone from Day 1 to Day 84 inclusive of the study.|To assess the clinical efficacy (CGI and GAF) of Paliperidone ER over the duration of the study.To evaluate the safety of Paliperidone ER over the duration of the study.To assess the long-term (2-year) treatment outcomes of Paliperidone ER.","http://ClinicalTrials.gov/show/NCT00473434",NA
"28725",28725,"NCT00477334","Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients","Completed","No Results Available","Genital Herpes","Drug: Famciclovir|Drug: Placebo","Novartis","Both","Adult|Senior","Phase IV",463,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CFAM810A2310","May 22, 2007","01/06/2007",NA,"March 12, 2010","01/03/2010","",2009-03-01,"Time to healing of non-aborted genital herpes lesions|Safety as assessed by adverse events and laboratory abnormalities","http://ClinicalTrials.gov/show/NCT00477334",NA
"28729",28729,"NCT00485134","Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection","Completed","No Results Available","Shigellosis","Biological: Invaplex 50 Vaccine","Department of Defense|U.S. Army Office of the Surgeon General","Both","Adult","Phase I|Phase II",NA,"U.S. Fed","Interventional","Allocation: Randomized|Control: Dose Comparison|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","NMRC.2006.0007|A-14057|WRAIR 1328","June 11, 2007","01/05/2007",2009-07-01,"December 1, 2010","01/12/2010","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT00485134",NA
"28738",28738,"NCT00494234","Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-Positive Advanced Breast Cancer","Completed","No Results Available","Breast Neoplasms","Drug: KU-0059436 (AZD2281)(PARP inhibitor)","AstraZeneca|KuDOS Pharmaceuticals Limited","Female","Adult|Senior","Phase II",54,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KU36-44|D0810C00008","June 27, 2007","01/06/2007",2009-02-01,"May 14, 2009","01/05/2009","ICEBERG 1",2009-02-01,"Objective tumour response rate|Clinical benefit rate|Safety and tolerability profile","http://ClinicalTrials.gov/show/NCT00494234",NA
"28755",28755,"NCT00496834","LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)","Completed","Has Results","Hypertension","Drug: losartan potassium|Drug: Comparator: carvedilol|Drug: Comparator: losartan (+) hydrochlorothiazide (HCTZ)|Drug: Comparator: carvedilol (+) hydrochlorothiazide","Merck","Both","Adult|Senior","Phase IV",201,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MK-0954-330|2007_015","July 3, 2007","01/02/2008",2009-09-01,"November 18, 2010","01/11/2010","",2009-09-01,"Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug|PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug|Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug|Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug","http://ClinicalTrials.gov/show/NCT00496834",NA
"28763",28763,"NCT00538434","Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years","Completed","No Results Available","Eosinophilic Esophagitis","Biological: Reslizumab|Other: Saline","Ception Therapeutics","Both","Child|Adult","Phase II|Phase III",226,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Res-05-0002","October 1, 2007","01/02/2008",2009-10-01,"February 2, 2010","01/01/2010","",2009-10-01,"esophageal eosinophil counts (co-primary)|EE Global Assessment (co-primary)|EE Predominant Symptom Assessment|Child Health Questionnaire","http://ClinicalTrials.gov/show/NCT00538434",NA
"28770",28770,"NCT00547534","Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: bortezomib|Drug: bendamustine|Drug: rituximab","University of Rochester|Millennium Pharmaceuticals, Inc.|Cephalon","Both","Adult|Senior","Phase II",30,"Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ULYM07054","October 18, 2007","01/10/2007",2009-10-01,"January 8, 2010","01/01/2010","",2009-06-01,"To determine the progression-free survival following treatment with the BVR combination in patients with relapsed or refractory indolent and mantle cell non-Hodgkin lymphoma.|??Ñ Determine safety and toxicity of BVR combination in patients with relapsed or refractory indolent and mantle cell NHL ??Ñ Determine ORR following BVR combination therapy in patients with relapsed or refractory indolent or mantle cell NHL","http://ClinicalTrials.gov/show/NCT00547534",NA
"28773",28773,"NCT00554034","Effect of Herbal Extracts on Gingival Inflammation","Completed","No Results Available","Gingivitis","Drug: periopatch","Shaare Zedek Medical Center","Both","Adult|Senior","Phase II",60,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Protocol C-4","October 15, 2007","01/11/2007",2009-03-01,"December 19, 2010","01/04/2009","",2009-03-01,"To determine the correct dosing of the herbal Patch [THPP]|To demonstarte the safety of THPP on the gingival tissue and in the oral cavity","http://ClinicalTrials.gov/show/NCT00554034",NA
"28798",28798,"NCT00596934","Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)","Completed","No Results Available","Fatty Liver Disease, Nonalcoholic","Drug: metreleptin","University of Michigan|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Male","Adult","Phase II",10,"Other|NIH","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","R03 DK74488|R03DK074488|Protocol 2145 (MCRU)|Amylin Protocol 20050119|DRDA 643938K3","January 8, 2008","01/02/2006",2009-03-01,"March 1, 2010","01/03/2010","",2009-03-01,"Liver histopathology|Body weight|Liver fat by MRI and MR spectroscopy|Liver function tests|Fasting lipids|Fasting glucose|Insulin sensitivity","http://ClinicalTrials.gov/show/NCT00596934",NA
"28799",28799,"NCT00598234","Perioperative Pain Control With Celecoxib (Celebrex) in Total Knee Arthroplasty","Completed","No Results Available","Osteoarthritis","Drug: Celecoxib (Celebrex)","National Taiwan University Hospital","Both","Adult|Senior","Phase IV",120,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","950704","January 10, 2008","01/09/2006",2009-08-01,"June 20, 2010","01/06/2010","",2009-08-01,"VAS pain scores, range-of-motion, narcotics usage","http://ClinicalTrials.gov/show/NCT00598234",NA
"28825",28825,"NCT00635934","A-MAV?ºÑ Anterior Motion Segment Replacement","Completed","No Results Available","Spinal Diseases","Device: A-MAV?ºÑ disc","Medtronic Spinal and Biologics","Both","Adult|Senior","Phase III",53,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","G040135","March 7, 2008","01/12/2005",2010-05-01,"January 5, 2011","01/01/2011","",2009-10-01,"Overall Success= Oswestry Disability Index success; Maintenance or improvement in neurological status; No serious AE classified as implant or implant/surgical procedure associated; No additional surgical procedure classified as a failure|Disc height; SF-36; Back Pain Status; Leg Pain Status; Patient Satisfaction; Patient Global Perceived Effect; Other Measurements-Radiographic; Return to Work; Doctor's Perception of Results","http://ClinicalTrials.gov/show/NCT00635934",NA
"28852",28852,"NCT00676234","Recombinant Human Erythropoietin Use in Intensive Care Unit (ICU) Patients: Does it Prevent Acute Renal Failure","Completed","No Results Available","Acute Renal Failure","Drug: epoetinum","University Hospital, Geneva","Both","Adult|Senior","Phase II",80,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-11021991","May 7, 2008","01/05/2008",2009-06-01,"June 26, 2009","01/06/2009","",2009-06-01,"mean change (%) from baseline in urinary NGAL concentration at 96 hr after rhu EPO injection|mean change (%) from baseline in serum Cystatin C concentration at 96 hr after rhu EPO injection","http://ClinicalTrials.gov/show/NCT00676234",NA
"28872",28872,"NCT00706134","Efficacy and Safety of Aliskiren 75mg, 150mg and 300mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-Controlled Study","Completed","No Results Available","Hypertension","Drug: Aliskiren|Drug: Placebo|Drug: Aliskiren 150 mg|Drug: Aliskiren 300 mg","Novartis","Both","Adult|Senior","Phase III",755,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSPP100A2405","June 25, 2008","01/05/2008",NA,"May 5, 2009","01/05/2009","",2009-04-01,"Reduction in mean sitting systolic blood pressure (msSBP) from baseline to study end comparing aliskiren 975, 150 and 300 mg to placebo|Reduction in mean sitting diastolic blood pressure (msDBP) from baseline to study end comparing aliskiren (75, 150 and 300 mg)to placebo|Change from baseline in mean 24 hour ambulatory systolic blood pressure and ambulatory diastolic blood pressure in a subset of patients comparing aliskiren (75, 150 and 300 mg) to placebo|Change in smoothness index, trough to peak ratio and morning surge of ambulatory systolic blood pressure and ambulatory diastolic blood pressure in a subset of patients comparing aliskiren (75, 150 and 300 mg) to placebo|Proportion of patients achieving blood pressure response rate as defined by msSBP < 140 mmHg and/or a ??­ 20 mmHg decrease in msSBP from baseline to end of study in aliskiren (75, 150 and 300 mg) and placebo.|Safety and tolerability of aliskiren 75 mg, 150 mg and 300 mg","http://ClinicalTrials.gov/show/NCT00706134",NA
"28874",28874,"NCT00713934","Autologous Bone Marrow Stem Cells in Cirrhosis Patients","Completed","No Results Available","Stem Cell Transplantation|Cirrhosis","Biological: CD133|Biological: BM-MNC","Royan Institute|Small Business Developing Center|Shiraz University of Medical Sciences","Both","Adult|Senior","Phase I|Phase II",7,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","Liver-001","July 9, 2008","01/01/2008",2009-02-01,"March 1, 2010","01/03/2010","",2009-01-01,"Liver function test|MELD score|Cirrhosis mortality","http://ClinicalTrials.gov/show/NCT00713934",NA
"28891",28891,"NCT00736034","The Efficacy of Phosphatidylserine-Omega3 in Elderly Subjects With Memory Impairment","Completed","Has Results","Memory Impairment","Dietary Supplement: Phosphatidylserine-Omega3 (SharpPS?ºÑ-Gold)","Enzymotec","Both","Adult|Senior","Phase IV",18,"Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SharpPS?ºÑ-Gold 001","August 14, 2008","01/09/2008",2009-04-01,"March 26, 2010","01/04/2009","",2009-03-01,"Change From Baseline in Neuropsychological Computerized Test|Clinical Global Impression of Change (CGI-C)Scale","http://ClinicalTrials.gov/show/NCT00736034",NA
"28892",28892,"NCT00739934","Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection","Completed","No Results Available","Candidiasis|Candidemia","Drug: Voriconazole","Pfizer","Both","Child","Phase II",40,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A1501088","August 20, 2008","01/12/2008",2009-10-01,"August 9, 2010","01/08/2010","",2009-10-01,"Steady-state pharmacokinetic parameters of voriconazole following oral administration: AUC12,ss, Cmax,ss and Tmax.|Steady-state pharmacokinetic parameters of voriconazole following IV administration: area under the curve over dosing interval at steady state (AUC12,ss), peak plasma concentration at steady state (Cmax,ss) and time to reach Cmax (Tmax).|Pharmacokinetic parameters of voriconazole following a single IV dose on Day 1: AUC12, Cmax and Tmax.|Trough concentrations (Cmin) of voriconazole following IV or oral administration.|Steady-state pharmacokinetic parameters of the N-oxide metabolite (UK-121, 265): AUC12,ss, Cmax,ss and Tmax for information disclosure.|To evaluate the safety and tolerability of voriconazole following an IV to oral switch regimen in immunocompromised children aged 2 to <12 years who are at high risk for systemic fungal infection.","http://ClinicalTrials.gov/show/NCT00739934",NA
"28905",28905,"NCT00758134","Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Trastuzumab (Herceptin)","Istituto Clinico Humanitas","Both","Adult|Senior","Phase II",35,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ONC-2007-001|2007-003709-29","September 22, 2008","01/07/2008",2009-12-01,"October 14, 2010","01/10/2010","",2009-07-01,"Response rate|Time to disease progression, overall survival, safety and assessment of biomarkers potentially implicated in trastuzumab sensitivity/resistance","http://ClinicalTrials.gov/show/NCT00758134",NA
"28916",28916,"NCT00785434","Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD","Completed","No Results Available","Major Depressive Disorder","Drug: escitalopram","Community Pharmacology Services Ltd","Both","Adult","Phase IV",60,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CPS/04/2008","November 4, 2008","01/10/2008",2009-12-01,"January 12, 2010","01/01/2010","",2009-12-01,"The number of patients achieving remission (MADRS<9).","http://ClinicalTrials.gov/show/NCT00785434",NA
"28942",28942,"NCT00820534","A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers","Completed","Has Results","Cold Sore","Drug: Penciclovir|Drug: Placebo","Novartis","Both","Adult|Senior","Phase IV",126,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","FPP4-DE-401","January 9, 2009","01/12/2008",2009-11-01,"December 16, 2010","01/12/2010","",2009-11-01,"Clinical Assessment Performed by the Investigator and Skin Temperature at the Cold Sore.|Size of the Cold Sore","http://ClinicalTrials.gov/show/NCT00820534",NA
"28943",28943,"NCT00824434","A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element?ºÑ)","Completed","No Results Available","Atherosclerosis|Coronary Artery Disease","Device: PROMUS Element?ºÑ","Boston Scientific Corporation","Both","Adult|Senior","Phase III",100,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S2051","January 15, 2009","01/03/2009",2010-08-01,"November 10, 2010","01/11/2010","PLATINUM QCA",2009-09-01,"Cardiac events at 30 days post-index procedure: myocardial infarction rate, cardiac death rate, target lesion failure, target lesion revascularization, stent thrombosis|in-stent late loss and post procedure incomplete apposition|Clinical endpoints: MI rate, cardiac death rate, TLF rate, TLR rate, stent thrombosis rate, target vessel failure rate, target vessel revascularization rate, noncardiac death rate, all death rate, All death or MI rate, All death/MI/TVR rate|Angiographic endpoints: In-stent and in-segment percent diameter stenosis, In-segment late loss, In-stent and in-segment binary restenosis rate, In-stent and in-segment minimum lumen diameter (MLD), Stent fracture|IVUS endpoints: Incomplete apposition, Percent net volume obstruction|Periprocedural endpoints:Technical success rate, Clinical procedural success MLD (QCA), Acute gain (QCA)","http://ClinicalTrials.gov/show/NCT00824434",NA
"28962",28962,"NCT00859534","Phase II Solar Urticaria (SU) Pilot Study","Completed","No Results Available","Solar Urticaria","Drug: afamelanotide","Clinuvel Pharmaceuticals Limited","Both","Adult|Senior","Phase II",5,"Industry","Interventional","Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CUV016","March 5, 2009","01/12/2008",2009-07-01,"September 13, 2009","01/09/2009","",2009-06-01,"To determine whether a CUV1647 (synthetic alpha-MSH analogue) bioresorbable implant can reduce the susceptibility of patients with Solar Urticaria to provocation with a standardized light source (measured as a change in minimum urticarial dose, (MUD)).|To evaluate the safety/tolerability of CUV1647 by measuring treatment-emergent adverse events.|To determine the effect of CUV1647 on melanin density at several specified body sites.|To evaluate a change in the MUD between Days 30 and 60.","http://ClinicalTrials.gov/show/NCT00859534",NA
"28973",28973,"NCT00872534","Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers","Completed","No Results Available","Upper Gastrointestinal Mucosal Damage","Drug: acetylsalicylic acid","PLx Pharma","Both","Adult|Senior","Phase I|Phase II",164,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","PL-ASA-002","March 10, 2009","01/01/2009",2009-07-01,"July 28, 2009","01/05/2009","",2009-07-01,"Incidence of subjects with gastroduodenal erosions and ulcers.|Incidence of subjects with ulcers (ulcers 3mm or greater in length with unequivocal depth).|Mean number of erosions in the duodenum and stomach.","http://ClinicalTrials.gov/show/NCT00872534",NA
"28976",28976,"NCT00879034","A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria","Completed","No Results Available","Progeria","Drug: Lonafarnib|Drug: Zoledronic Acid|Drug: Pravastatin","Children's Hospital Boston|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Schering-Plough","Both","Child|Adult|Senior","Phase II",5,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-02-0074","April 8, 2009","01/03/2009",2009-04-01,"April 20, 2010","01/04/2010","",2009-04-01,"The primary objective of this study is to evaluate the feasibility of administering intravenous zoledronic acid, oral pravastatin and oral lonafarnib, to patients with Progeria for a minimum of 4 weeks|To describe any acute and chronic toxicities associated with treating progeria patients with the combination of zoledronic acid, pravastatin and lonafarnib|To investigate which clinical and laboratory studies are needed to monitor or alter therapy to prevent unacceptable toxicity|To assess the pharmacokinetics of lonafarnib in patients with progeria.|To assay for the inhibition of HDJ-2 farnesylation in Peripheral Blood Leukocytes (PBL)|To obtain baseline clinical and laboratory data so that longer-term measures of efficacy will be achievable if treatment continues beyond the 4-week feasibility study period.","http://ClinicalTrials.gov/show/NCT00879034",NA
"28982",28982,"NCT00884234","Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","Completed","No Results Available","Lateral Canthal Lines","Other: Vehicle Control|Drug: RT001 (Botulinum Toxin Type A Topical Gel)","Revance Therapeutics, Inc.","Both","Adult","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RT001-CL011LCL","April 17, 2009","01/02/2009",2009-06-01,"September 23, 2010","01/09/2010","",2009-04-01,"The number of subjects classified as exhibiting improvement via the Investigator Global Assessment from Baseline (Day 0) to End of Study (Week 6).|Incidence of treatment emergent AEs.","http://ClinicalTrials.gov/show/NCT00884234",NA
"28999",28999,"NCT00911534","Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)","Completed","No Results Available","Symptomatic Gastroesophageal Reflux Disease (sGERD)","Drug: rabeprazole sodium|Drug: Placebo","Eisai Inc.","Both","Adult|Senior","Phase III",304,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E3810-A001-307","May 29, 2009","01/01/2009",2009-10-01,"March 17, 2010","01/03/2010","",2009-07-01,"Time to achieve first 24-hour period without heartburn. Assessment based on subject daily symptom diary.|Percentage of subjects with complete heartburn relief; percentage of heartburn-free time period (daytime or nighttime); change from baseline in average daily severity score of GERD-related symptoms. Assessments based on subject daily symptom diary.","http://ClinicalTrials.gov/show/NCT00911534",NA
"29064",29064,"NCT01015534","Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment","Completed","No Results Available","Brain Neoplasms","Drug: Temozolomide|Radiation: Whole brain radiotherapy","Instituto Nacional de Cancerologia de Mexico","Both","Adult|Senior","Phase II",55,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","006/004/TEI","November 17, 2009","01/01/2006",2009-10-01,"November 17, 2009","01/11/2009","",2009-10-01,"Objective Response Rates. Assessed with IRM/CT Scan|Survival Free of Brain Metastases progression|Overall Survival|Side effects","http://ClinicalTrials.gov/show/NCT01015534",NA
"29066",29066,"NCT01022034","Pexy Versus Non-pexy for Full Thickness Rectal Prolapse","Completed","No Results Available","Rectal Prolapse","Procedure: sacral rectopexy with sutures or meshes|Procedure: full rectal mobilization from the sacrum without sacral rectopexy","Societa Italiana di Chirurgia ColoRettale","Both","Adult|Senior","Phase III",180,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","Berg.2007","November 25, 2009","01/01/2003",2009-10-01,"December 1, 2009","01/12/2009","Bergamaschi",2009-01-01,"long term recurrence of the rectal prolapse","http://ClinicalTrials.gov/show/NCT01022034",NA
"29117",29117,"NCT01109134","Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients","Completed","No Results Available","Acute Myocardial Infarction","Drug: tirofiban intracoronary bolus-only|Drug: tirofiban intravenous bolus plus infusion","Kosuyolu Heart Hospital|The Society of Cardiac Health Protection","Both","Adult|Senior","Phase III",49,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","33","April 21, 2010","01/09/2008",2009-08-01,"April 21, 2010","01/03/2010","",2009-02-01,"Indices of microvascular perfusion|ST segment resolution|corrected TIMI frame count|Myocardial Blush Grade|Scintigraphic infarct size|Changes in left ventricular volume|Composite of major adverse cardiovascular events","http://ClinicalTrials.gov/show/NCT01109134",NA
"29135",29135,"NCT01145534","Evaluation of Cissus Verticillata L. Infusion in Controlling Type 2 Diabetes","Completed","No Results Available","Diabetes","Drug: glibenclamide|Other: medicinal plant infusion","Federal University of Para?¦ba|Brazil: National Council for Scientific and Technological Development","Both","Adult|Senior","Phase I|Phase II",15,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UFPB-0346","June 15, 2010","01/01/2009",2009-10-01,"June 15, 2010","01/08/2008","",2009-08-01,"blood glucose|Salivary glucose level","http://ClinicalTrials.gov/show/NCT01145534",NA
"29296",29296,"NCT00045435","Peripheral Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia","Completed","No Results Available","Leukemia","Biological: therapeutic allogeneic lymphocytes|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",40,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","1654.00|FHCRC-1654.00|CDR0000256466","September 6, 2002","01/04/2002",NA,"September 20, 2010","01/09/2010","",2009-06-01,"Disease-free survival 1 year post-transplant|Nonrelapse mortality on day 200 post-transplant","http://ClinicalTrials.gov/show/NCT00045435",NA
"29315",29315,"NCT00079235","CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: temsirolimus","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",55,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000355117|NCCTG-N0323","March 8, 2004","01/02/2004",NA,"December 3, 2009","01/11/2009","",2009-11-01,"Confirmed response|Progression-free survival at 24 weeks|Survival time|Time to disease progression|Effects of CCI-779 on mTOR","http://ClinicalTrials.gov/show/NCT00079235",NA
"29357",29357,"NCT00145535","SOLX Titanium Sapphire Laser for Trabeculoplasty","Completed","No Results Available","Glaucoma|Glaucoma, Open Angle","Device: SOLX Titanium Sapphire Laser (TiSaLT)|Device: Argon Laser Trabeculoplasty (ALT)","SOLX, Inc.","Both","Adult|Senior","Phase III",120,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SLX41","September 1, 2005","01/05/2004",2009-06-01,"January 28, 2010","01/07/2009","",2009-06-01,"Intraocular Pressure (IOP)|Adverse event frequency","http://ClinicalTrials.gov/show/NCT00145535",NA
"29472",29472,"NCT00319735","Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas","Completed","No Results Available","Esophageal Cancer","Procedure: Radiation Therapy|Procedure: Surgery|Procedure: Tissue Sample","Hoosier Oncology Group|Bristol-Myers Squibb|Walther Cancer Institute","Both","Adult|Senior","Phase II",41,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HOG GI05-92","April 27, 2006","01/04/2006",2009-01-01,"January 22, 2009","01/01/2009","",2009-01-01,"?? To evaluate complete pathologic response rate in patients with esophageal and GE junction carcinomas|To evaluate complete and partial response rate of preoperative radiation and cetuximab in patients with esophageal and GE junction carcinomas|To evaluate time to relief of dysphagia in patients with esophageal and GE junction carcinomas receiving preoperative radiation and cetuximab|To evaluate the overall toxicities of preoperative radiation and cetuximab in patients with esophageal and GE junction carcinomas|To perform exploratory molecular correlates to determine the mechanisms of response and resistance to cetuximab and radiation therapy.","http://ClinicalTrials.gov/show/NCT00319735",NA
"29481",29481,"NCT00337935","A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.","Completed","No Results Available","Renal Failure , Chronic|Anemia","Drug: epoetin alfa","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho Biotech Clinical Affairs, L.L.C.","Both","Adult|Senior","Phase II",157,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","CR012229","June 16, 2006","01/06/2006",2009-07-01,"August 20, 2009","01/08/2009","",2009-07-01,"The primary endpoint is hemoglobin change from baseline to the end of study (26 weeks).|The proportion of patients receiving PROCRIT (Epoetin alfa) vs. control who achieve a Hemoglobin (Hb) response; the time to Hb response; transfusion use; the ability to meet the criteria to convert to Q4W dosing; and the ability to remain on Q4W dosing.","http://ClinicalTrials.gov/show/NCT00337935",NA
"29511",29511,"NCT00395135","BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management","Completed","No Results Available","Obesity","Drug: lorcaserin|Drug: matching placebo","Arena Pharmaceuticals","Both","Adult","Phase III",3182,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APD356-009","October 31, 2006","01/11/2006",2009-02-01,"July 27, 2009","01/07/2009","",2009-02-01,"Year 1: Proportion (%) of patients achieving > or = 5% weight reduction at the end of the first year of treatment (Week 52)|Year 2: Proportion of patients maintaining > or = 5% weight reduction at the end of Year 2 (Week 104)|Change in body weight at the end of Year 1|Additional body weight change during Year 2|Change in waist and hip measurements|Change in cardiovascular risk factors|Change in use of concomitant medications for comorbidities (i.e., hypertension, dyslipidemia)|Change in Quality of Life measures","http://ClinicalTrials.gov/show/NCT00395135",NA
"29517",29517,"NCT00396435","Correction of Anaemia and Progression of Renal Failure on Transplanted Patients","Completed","No Results Available","Anaemia|Renal Transplantation|Kidney Failure","Drug: Neorecormon","Centre Hospitalier Universitaire, Amiens|Roche Pharma AG","Both","Adult|Senior","Phase IV",128,"Other|Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CAPRIT","November 3, 2006","01/04/2004",2010-05-01,"May 26, 2010","01/05/2010","",2009-04-01,"eClcr by Cockcroft formula|Measure CDG by the clearance of Iohexol|1/Scr at J0, 6 months, 12 months, 18 months and 24 months Scr with J0, 6, 12, 18 and 24 months|Proteinuria and micro-albuminuria at J0, 12 and 24 months|Evaluation of the quality of life in the 2 groups of patients per self-evaluation at J0 and 6 months|Adverse events, in particular cardiovascular events: MI, AIT, Arteritis of lower limb, revascularisation,|Biological tolerance: Albuminemia, pre-albuminemia, CRP, plasmatic Cholesterol, HDL and LDL|Level of blood pressure at the beginning and the end of the study and comparison of the number of antihypertensive drugs received by patients before and after the 24 months of follow-up|Number of units of beta-EPO managed in the 2 groups|Number of patients receiving blood transfusions","http://ClinicalTrials.gov/show/NCT00396435",NA
"29526",29526,"NCT00418535","Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma","Completed","No Results Available","Lymphoma, T-Cell","Drug: Concurrent Radiotherapy (RT)/cisplatin, VIPD","Samsung Medical Center|Korea University Anam Hospital|Asan Medical Center|Gyeongsang National University Hospital","Both","Adult|Senior","Phase II",NA,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08/10/2004","January 3, 2007","01/04/2006",2009-07-01,"October 20, 2009","01/01/2007","",2009-03-01,"","http://ClinicalTrials.gov/show/NCT00418535",NA
"29543",29543,"NCT00427635","Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients","Completed","Has Results","GERD","Drug: Esomeprazole","AstraZeneca","Both","Child","Phase III",32,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","D9614C00004","January 25, 2007","01/10/2006",2009-04-01,"December 2, 2010","01/12/2010","",2009-04-01,"Change From Baseline in Normalized Number of GERD Events Observed From Video and Cardiorespiratory Monitoring|Change From Baseline in Normalized Number of GERD Events During Video and Cardiorespiratory Monitoring Associated With Acid Reflux|Change From Baseline in Number of Reflux Episodes (Acid or Non-acid)|Change From Baseline in Number of Acidic Reflux Episodes|Change From Baseline in Number of Weakly Acidic Reflux Episodes|Change From Baseline in Number of Non Acidic Reflux Episodes|Change From Baseline in Number of Liquid Acidic Reflux Episodes|Change From Baseline in Number of Mixed Gas/Liquid Acidic Reflux Episodes|Change From Baseline in Mean Bolus Clearance Time|Change From Baseline in Mean Acid Clearance Time|Change From Baseline in Percentage Time With pH<4.0|Change From Baseline in Percentage Time With pH Within 4.0-6.9","http://ClinicalTrials.gov/show/NCT00427635",NA
"29557",29557,"NCT00469235","Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars","Completed","No Results Available","Keloid","Drug: Avotermin","Renovo","Both","Adult|Senior","Phase I|Phase II",20,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RN1001-0064","May 3, 2007","01/06/2007",2009-05-01,"September 15, 2009","01/09/2009","",2009-03-01,"Frequency of adverse events|Keloid reoccurrence","http://ClinicalTrials.gov/show/NCT00469235",NA
"29558",29558,"NCT00470535","Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: erlotinib hydrochloride|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Roswell Park Cancer Institute","Both","Adult|Senior","Phase II",17,"Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000543406|RPCI-I-87106","May 3, 2007","01/01/2007",2010-09-01,"September 28, 2010","01/09/2010","",2009-01-01,"Progression-free survival|Clinical response (complete and partial response) as measured by RECIST criteria|Median overall survival|Change in quality of life (QOL) as measured by EORTC PAN26 every 3 weeks during study therapy and after completion of study therapy|Correlation of smoking status with overall survival|Correlation of response, QOL, and survival with EGFR, E-cadherin, P-cadherin, vimentin, cytokeratin, ki67, and fibronectin and with other prognostic variables, such as age and tumor grade","http://ClinicalTrials.gov/show/NCT00470535",NA
"29575",29575,"NCT00490035","Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","Completed","No Results Available","Epilepsy","Other: Placebo|Drug: Brivaracetam|Drug: Brivaracetam|Drug: Brivaracetam","UCB, Inc.","Both","Child|Adult|Senior","Phase III",399,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","N01252|2006-006344-59","June 21, 2007","01/09/2007",2009-02-01,"October 15, 2010","01/10/2010","",2009-02-01,"Partial onset seizure (Type I) frequency per week over the 12-week Treatment Period|Responder rate for partial onset seizures (Type I) frequency per week over the 12-week Treatment period|All seizure frequency (Type I+II+III) per week over the 12-week Treatment Period|Percent change from baseline to the 12-week treatment period in partial onset seizure (Type I) frequency per week|Categorized percentage change from Baseline in seizure frequency for partial onset seizure (Type I)over the 12-week Treatment Period|Seizure freedom rate (all seizure types) over the 12-week Treatment Period|Time to first Type I seizure during the 12-week Treatment Period|Time to fifth Type I seizure during the 12-week Treatment Period|Time to tenth Type I seizure during the 12-week Treatment Period|Reduction of Type IC/Type I seizure frequency ratio from baseline to the 12- week treatment period.|Change from baseline to the 12-week treatment period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score|Change from baseline to the12-week treatment period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score|Change from baseline to the 12-week treatment period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score|Change from baseline to the 12-week treatment period in Hospital Anxiety score|Change from baseline to the 12-week treatment period in Hospital Depression score|Patient's Global Evaluation Scale (P-GES) evaluated at last visit or early discontinuation visit|Investigator's Global Evaluation Scale (I-GES) evaluated at last visit or early discontinuation visit","http://ClinicalTrials.gov/show/NCT00490035",NA
"29576",29576,"NCT00487435","An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain","Completed","Has Results","Pain|Osteoarthritis|Low Back Pain","Drug: Tapentadol (CG5503) Extended Release (ER)","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Gr??nenthal GmbH","Both","Adult|Senior","Phase III",1166,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR013567|R331333PAI3010|KF18","June 14, 2007","01/02/2007",2009-06-01,"June 24, 2010","01/06/2010","",2009-06-01,"Number of Subjects With Treatment-emergent Adverse Events (TEAE)|Change From Baseline in Average Pain Intensity Scores at Week 52 Using the Numerical Rating Scale (NRS)","http://ClinicalTrials.gov/show/NCT00487435",NA
"29584",29584,"NCT00512135","Safety and Efficacy of NT 201 in the Treatment of Glabellar Frown Lines","Completed","No Results Available","Glabellar Lines","Drug: Injection of: NT 201, a Botulinum neurotoxin type A, free of complexing proteins","Merz Pharmaceuticals GmbH","Both","Adult|Senior","Phase III",796,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MRZ 60201-0609/1","August 6, 2007","01/06/2007",NA,"January 21, 2010","01/01/2010","",2009-12-01,"- Safety endpoints - Investigator's assessment - Patient's assessment","http://ClinicalTrials.gov/show/NCT00512135",NA
"29615",29615,"NCT00532935","MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)(COMPLETED)","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: sitagliptin phosphate (+) metformin hydrochloride|Drug: Comparator: pioglitazone","Merck","Both","Adult|Senior","Phase III",517,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MK-0431A-066|2007_510","September 19, 2007","01/01/2008",2009-10-01,"January 5, 2011","01/01/2011","",2009-10-01,"Change From Baseline in A1C at Week 32|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 1|Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 32|Change From Baseline in FPG at Week 32|Percent of Participants With A1C <7.0% at Week 32","http://ClinicalTrials.gov/show/NCT00532935",NA
"29623",29623,"NCT00570635","A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib","Completed","No Results Available","Gastrointestinal Stromal Tumors|Gastrointestinal Neoplasms","Drug: XL820|Drug: XL820","Exelixis","Both","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XL820-201","December 7, 2007","01/12/2007",2009-05-01,"August 9, 2010","01/08/2010","",2009-05-01,"Clinical benefit, defined as either confirmed complete response, confirmed partial response, or evidence of stable disease lasting ??­16 weeks, in subjects with advanced GIST resistant to/intolerant of imatinib and/or sunitinib|Safety and tolerability of XL820|Progression-free survival, duration of response, and overall survival|Further characterize the pharmacokinetic and pharmacodynamic parameters of XL820 in subjects with advanced GIST","http://ClinicalTrials.gov/show/NCT00570635",NA
"29641",29641,"NCT00605735","PoC in Rheumatoid Arthritis With Methotrexate","Completed","No Results Available","Rheumatoid Arthritis, NOS","Drug: BMS-582949|Drug: Placebo","Bristol-Myers Squibb","Both","Adult|Senior","Phase II",121,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","IM119-015","January 18, 2008","01/03/2008",2009-09-01,"January 6, 2011","01/10/2009","",2009-08-01,"The primary endpoint is the proportion of subjects achieving an ACR 20 at Week 12|Proportion of subjects achieving an ACR 20|Proportion of subjects schieving and ACR 50|Proportion of subjects schieving and ACR 70|Percent change from baseline to each scheduled visit in DAS28 score|Percent change from baseline to each scheduled visit in ACR scores|Proportion of subjects schieving a 20% change in assessment of pain, disease activity and fatigue|Percent change from baseline to each scheduled visit in HAQ score","http://ClinicalTrials.gov/show/NCT00605735",NA
"29674",29674,"NCT00660335","Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas","Completed","No Results Available","Pancreatitis","Drug: RG1068 (synthetic human secretin)","Repligen Corporation","Both","Adult|Senior","Phase III",258,"Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","RG1068-16","April 15, 2008","01/03/2008",2009-10-01,"December 2, 2009","01/12/2009","",2009-10-01,"The primary outcome measure will be assessed by comparing baseline MRCP images and RG1068-enhanced MRCP images for the presence or absence of pancreatic abnormalities.|The secondary outcome measure will assess safety","http://ClinicalTrials.gov/show/NCT00660335",NA
"29681",29681,"NCT00675935","Falls - Tailoring Interventions for Patient Safety","Completed","No Results Available","Patient Falls","Other: Fall Prevention Tool Kit prototype using a randomized design","Brigham and Women's Hospital|Robert Wood Johnson Foundation|Massachusetts General Hospital|Faulkner Hospital|North Shore Medical Center","Both","Child|Adult|Senior","Phase I|Phase II",2000,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","62572","May 8, 2008","01/09/2007",2009-08-01,"July 22, 2010","01/07/2010","Falls TIPS",2009-06-01,"The outcome measure will be rate of patients falls per 1000 patient days|Falls with injury as a secondary outcome measure.|To evaluate the effectiveness of the FPTK prototype on documentation of planned and completed tailored interventions","http://ClinicalTrials.gov/show/NCT00675935",NA
"29694",29694,"NCT00687635","Efficacy and Safety Study of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment","Completed","No Results Available","Attention Impairment","Drug: Donepezil hydrochloride|Drug: Placebo","Eisai Inc.|Eisai Limited","Both","Child","Phase III",300,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E2020-G000-334","May 28, 2008","01/08/2008",2009-09-01,"September 22, 2009","01/09/2009","",2009-06-01,"Change in the TOVA-CPT (Test of Variables in Attention - Continuous Performance Test) reaction time variability measure (administered to subjects).|Paired Assoc. Learning Test, Woodcock Johnson Decision Speed Test, Woodcock Johnson Mathematics Fluency; Go/No-Go Task (for subjects); Conners' Parent Rating Scale-Revised (S); Behavioral Rating Inventory of Executive Functioning (parent/legal guardian).","http://ClinicalTrials.gov/show/NCT00687635",NA
"29702",29702,"NCT00694135","Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis","Completed","No Results Available","Uveitis, Anterior","Drug: EGP-437 1.6 mA-min at 0.4 with EyeGate?ó II System|Drug: EGP-437 4.8 mA-min at 1.2 mA with EyeGate?ó II System|Drug: EGP-437 10.0 mA-min at 2.5 mA with EyeGate?ó II System|Drug: EGP-437 14.0 mA-min at 3.5 mA with EyeGate?ó II System","Eyegate Pharmaceuticals, Inc.","Both","Child|Adult|Senior","Phase II",40,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EGP-437-001","June 5, 2008","01/06/2008",2009-08-01,"August 27, 2010","01/08/2010","",2009-07-01,"Proportion of subjects with an ACC score of zero at Days 14 and 28|Time to ACC score of zero|Proportion of subjects with a reduction of one full ACC score or more from baseline at Day 28|Change from baseline in ACC score at Day 28|Treatment emergent adverse events","http://ClinicalTrials.gov/show/NCT00694135",NA
"29711",29711,"NCT00700635","Dose Comparison Study of Menactra?ó in US Children","Completed","Has Results","Meningitis|Meningococcal Infection|Neisseria Meningitidis","Biological: Menactra?ó: Meningococcal Polysaccharide Diphtheria Conjugate|Biological: Menactra?ó: Meningococcal Polysaccharide Diphtheria Conjugate|Biological: Menactra?ó: Meningococcal Polysaccharide Diphtheria Conjugate","Sanofi-Aventis","Both","Child","Phase II",333,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","MTA61","May 7, 2008","01/06/2008",2009-10-01,"December 22, 2010","01/12/2010","",2009-05-01,"Percentage of Participants With Meningococcal Antibody Titers ??­ 8 After Each Vaccination|Percentage of Participants With Meningococcal Antibody Titers at ??­ 4 After Each Vaccination|Geometric Mean Titers (GMTs) of Meningococcal Antibodies After Each Menactra?ó Vaccination.|Percentage of Participants Reporting Solicited Injection Site and Solicited Systemic Reactions After Dose 1 Vaccination|Percentage of Participants Reporting Solicited Injection Site and Solicited Systemic Reactions After Dose 2 Vaccination","http://ClinicalTrials.gov/show/NCT00700635",NA
"29713",29713,"NCT00722735","Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)","Completed","No Results Available","Urinary Tract Infections","Drug: Finafloxacin|Drug: Ciprofloxacin","MerLion Pharmaceuticals GmbH","Female","Adult","Phase II",36,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FINA-003","July 25, 2008","01/10/2008",2009-04-01,"June 10, 2009","01/10/2008","FLUT",2009-04-01,"Bacteriological eradication of the initial pathogen.|Clinical cure: Absence of signs or symptoms of uUTI.","http://ClinicalTrials.gov/show/NCT00722735",NA
"29718",29718,"NCT00724035","Ultrasound-Guided Axillary or Infraclavicular Nerve Block for Upper Limb Surgery","Completed","No Results Available","Upper Extremity|Orthopedic Surgery|Trauma|Forearm Injuries|Nerve Block","Drug: Midazolam|Drug: Ropivacaine|Drug: Fentanyl|Procedure: General anesthesia|Procedure: Axillary brachial plexus nerve block|Procedure: Infraclavicular brachial plexus block","University of Parma","Both","Adult|Senior","Phase IV",52,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","ANEST-ORT-02","July 25, 2008","01/05/2008",2009-07-01,"July 14, 2009","01/07/2009","",2009-06-01,"Onset time of brachial plexus sensory block|Onset of brachial plexus motor block|Patient satisfaction (3-point scale)|Anesthesia-related procedural pain (0-10 numerical rating scale)|Rescue analgesic requirements during surgery","http://ClinicalTrials.gov/show/NCT00724035",NA
"29739",29739,"NCT00757835","24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG","Completed","No Results Available","Glaucoma","Drug: treatment with latanoprost/timolol fixed combination|Drug: latanoprost/timolol fixed combination drops","Aristotle University Of Thessaloniki|Alcon Research","Both","Adult|Senior","Phase IV",40,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","A6219","September 19, 2008","01/05/2008",2009-03-01,"September 29, 2010","01/09/2010","",2009-03-01,"Travoprost/timolol fixed combination will demonstrate better quality of 24-hour IOP control than latanoprost/timolol|Incidence of side effects with the two medications","http://ClinicalTrials.gov/show/NCT00757835",NA
"29756",29756,"NCT00782535","Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: CHF 4226 pMDI|Drug: CHF 4226 pMDI|Drug: Placebo","Chiesi Pharmaceuticals Inc.","Both","Adult|Senior","Phase II",20,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCD-0810-PR-0001","October 29, 2008","01/12/2008",2009-03-01,"August 18, 2010","01/08/2010","",2009-03-01,"FEV1|serum potassium|serum glucose|plasma concentrations of CHF 4226|urinary excretion of CHF 4226|FVC","http://ClinicalTrials.gov/show/NCT00782535",NA
"29758",29758,"NCT00789035","12 Weeks Treatement With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: BI 10773|Drug: placebo|Drug: metformin","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",408,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1245.9|EudraCT No 2008-000640-14","October 13, 2008","01/10/2008",NA,"October 12, 2009","01/10/2009","",2009-10-01,"The primary endpoint is change in HbA1c from baseline after 12 weeks of treatment|The main secondary endpoints are: 1. Change in FPG from baseline through 12 weeks of treatment 2. Change in HbA1c from baseline over time 3. Pharmocokinetics of BI 10773","http://ClinicalTrials.gov/show/NCT00789035",NA
"29760",29760,"NCT00794235","Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine","Completed","No Results Available","Melanoma Stage III or IV|No Prior Chemotherapy","Drug: Sorafenib (Nexavar), Dacarbazine (DTIC)","University of Zurich","Both","Adult|Senior","Phase II",12,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Sorafenib and Dacarbazine","November 19, 2008","01/12/2008",2010-01-01,"January 7, 2010","01/01/2010","",2009-11-01,"1) Metabolic activity (glucose-uptake) in vivo, standardised uptake value (SUV) in FDG-PET/CT. 2) Quantification of soluble S100 serum and LDH. 3) Gene expression profile of cutaneous melanoma metastasis","http://ClinicalTrials.gov/show/NCT00794235",NA
"29772",29772,"NCT00813735","Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder","Completed","No Results Available","Insomnia","Drug: Eszopiclone|Drug: Placebo|Drug: Escitalopram","Lehigh Center for Clinical Research|Sunovion","Both","Adult|Senior","Phase IV",60,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ESRCO66","December 22, 2008","01/09/2006",2009-04-01,"October 8, 2009","01/10/2009","",2009-03-01,"Change in total sleep time from baseline to final visit|change in sleep latency from baseline to final visit|Change in HAMD from baseline to final visit|Change in ISI from baseline to final visit|Change in CGI-S, CGI-I from baseline to final visit|labs (CBC,urinalysis,TSH,Chemprofile,drugscreen),height|vitals: BP,pulse,temperature,weight,assess AE's/SAE's","http://ClinicalTrials.gov/show/NCT00813735",NA
"29778",29778,"NCT00817635","A Study to Evaluate the Effects of LCI699 on Safety and Efficacy in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic","Completed","No Results Available","Hypertension","Drug: LCI699|Drug: Placebo|Drug: Eplerenone","Novartis|Great Lakes Drug Development, Inc.|Integrium","Both","Adult|Senior","Phase II",150,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CLCI699A2216|EudraCT 2008-007338-23","January 5, 2009","01/12/2008",NA,"February 22, 2010","01/02/2010","",2009-12-01,"Change in mean sitting systolic blood pressure (MSSBP) as measured by office blood pressure (OBP)|Change in mean sitting diastolic blood pressure (MSDBP) at 8 weeks as measured by OBP|Proportion of patients achieving a successful BP response and BP control (MSSBP and MSDBP), as measured by OBP|Dose/exposure BP response relationship of LCI699, as measured by OBP|Changes from baseline in mean 24 hours, mean daytime and mean nighttime SBP and DBP, as measured by ABPM|To evaluate safety and tolerability of LCI699","http://ClinicalTrials.gov/show/NCT00817635",NA
"29790",29790,"NCT00846235","Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis","Completed","No Results Available","Dermatitis, Atopic","Other: Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%","Orion Corporation, Orion Pharma","Both","Adult","Phase IV",24,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2934004","February 13, 2009","01/12/2008",2009-05-01,"October 7, 2009","01/10/2009","",2009-03-01,"Skin hydratation and transepidermal water loss.","http://ClinicalTrials.gov/show/NCT00846235",NA
"29795",29795,"NCT00851435","Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa","Completed","No Results Available","Pneumonia|Ventilator Associated Pneumonia","Biological: KBPA-101","Kenta Biotech Ltd","Both","Adult|Senior","Phase I|Phase II",15,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KB-101-002","February 25, 2009","01/02/2008",2009-07-01,"July 29, 2009","01/07/2009","",2009-07-01,"Assessment of physical examination, laboratory parameters, vital signs, ECG and any adverse at repeated times since the screening phase till the end of the study.|To confirm the therapeutic plasma concentration of KBPA-101|To ascertain the therapeutic efficacy of KBPA-101 given in addition to standard care for hospital acquired pneumonia","http://ClinicalTrials.gov/show/NCT00851435",NA
"29805",29805,"NCT00551135","Surgical Pain After Inguinal Hernia Repair (SPAIHR)","Completed","Has Results","Pain, Postoperative|Hernia, Inguinal","Drug: Pregabalin|Drug: placebo|Drug: Pregabalin|Drug: Pregabalin","Pfizer","Male","Child|Adult|Senior","Phase III",425,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A0081171","October 26, 2007","01/01/2008",2009-09-01,"June 8, 2010","01/06/2010","",2009-06-01,"Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery|Numeric Rating Scale (NRS): Current Pain With Movement - Sitting|Numeric Rating Scale (NRS): Current Pain With Movement - Walking|Numeric Rating Scale (NRS): Current Pain With Movement - Coughing|Numeric Rating Scale (NRS): Current Pain With Movement - Area Under the Curve (AUC) for Sitting, Walking, and Coughing|Numerical Rating Scale (NRS): Current Pain at Rest|Numeric Rating Scale (NRS): Current Pain at Rest - Area Under the Curve (AUC)|Numeric Rating Scale (NRS): Average Pain|Time From End of Surgery to First Rescue Medication|Time From End of Surgery to Reach a Total Score of at Least 9 on the Post-Anesthetic Discharge Scoring System (PADS)|Time From End of Surgery to Discharge From Post-Anesthesia Care Unit (PACU)|Daily Sleep Interference Rating Scale (DSIRS) Score|Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery|Amount of Non-opioid Rescue Medication (Naproxen and Antiemetic Medications) Used During the Study|Total Clinically Meaningful Event (CME) Score and Cumulative Total Distinct CME Score Using the Opioid-Related Symptom Distress Scale (OR-SDS)|Participants With Clinically Meaningful Events (CMEs) for Individual Symptoms Using the Opioid-Related Symptom Distress Scale (OR-SDS)|Subject Global Evaluation of Study Medication (GESM)|Participants With Wound Healing Complications|Participants With Physician Contacts Post-discharge|Baseline and Change From Baseline in Anxiety Visual Analog Scale (VAS) Score|Baseline and Change From Baseline in EuroQol (EQ-5D) Health State Profile Score|Change From Baseline in Pain Catastrophizing Scale (PCS) Total Score and Subscales|Relationship Between Baseline and Postoperative Pain Catastrophizing Scale (PCS) Score and Severity of Acute Pain and to Response to Therapy|Baseline and Change From Baseline in Short Form Acute Health Survey 12-Item Version (SF-12v2) Physical Component Summary Score (PCSS) and Mental Component Summary Score (MCSS)|Participants With Chronic Postoperative Pain|Chronic Postoperative Pain: Pain Severity Index Score and Pain Interference Index Score on the Modified Brief Pain Inventory-Short Form (mBPI-sf)|Chronic Postoperative Pain: Total Score and Subscale Scores Using the Neuropathic Pain Symptom Inventory (NPSI)","http://ClinicalTrials.gov/show/NCT00551135",NA
"29827",29827,"NCT00907335","A Study of Acne Treatment in Children Ages 9 to 11","Completed","No Results Available","Acne Vulgaris","Drug: Retin-A Micro 0.04% facial acne treatment|Drug: Vehicle control","Johnson & Johnson Consumer & Personal Products Worldwide","Both","Child","Phase II",110,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CA-P-6397","May 20, 2009","01/02/2009",2009-12-01,"January 14, 2010","01/01/2010","",2009-12-01,"Change from baseline in total non-inflammatory lesions.|Change from baseline and percent change from baseline in each lesion type|Change from baseline for each visit in Investigator's Global Assessment of Acne Severity (IGA #1 and IGA #2) score|Measurement of success according to dichotomized IGA scores (IGA #1 And IGA #2) using criteria of improvement of 2 grades from baseline score or clear or almost clear grades (grades 0 or 1)|Improvement from baseline in Investigator Global Assessment score (IGA # 3)","http://ClinicalTrials.gov/show/NCT00907335",NA
"29842",29842,"NCT00933335","Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab","Completed","No Results Available","Non-Hodgkin's Lymphoma","Biological: Tositumomab and Iodine I 131 Tositumomab","GlaxoSmithKline","Both","Adult|Senior","Phase II",38,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","393229/023|CP-98-025","July 2, 2009","01/08/1998",2009-12-01,"May 13, 2010","01/05/2010","",2009-12-01,"To evaluate the safety of combining fludarabine with Iodine I 131 Tostiumomab in a sequential fashion in patients with untreated low-grade, transformed low-grade and follicular lymphoma|To evaluate the efficacy (response rate, CR rate, duration of response and detection of residual disease) of fludarabine combined with Iodine I 131 Tositumomab therapy","http://ClinicalTrials.gov/show/NCT00933335",NA
"29848",29848,"NCT00947635","Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention","Completed","No Results Available","Immunosuppression|Hyperlipidemias|Diabetes Mellitus, Type 1","Dietary Supplement: Dietary intervention - supplements","University of Alberta|Canandian Institutes of Health Research","Both","Adult|Senior","Phase I|Phase II",46,"Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Islet-Liver-MTC","July 22, 2009","01/11/2005",2009-06-01,"July 24, 2009","01/07/2009","",2009-06-01,"Cholesterol and fatty acid synthesis|Blood lipid levels","http://ClinicalTrials.gov/show/NCT00947635",NA
"29875",29875,"NCT00989235","Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: Abatacept|Drug: Abatacept","Bristol-Myers Squibb","Both","Adult|Senior","Phase III",124,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","IM101-023 LT (Sub study)|Eudrac # 2002-000784-26","October 2, 2009","01/04/2007",2009-10-01,"May 24, 2010","01/05/2010","",2009-10-01,"The primary objective is to assess the time to disease relapse for the abatacept 10 mg/kg and 5 mg/kg doses in subjects with early RA in remission (DAS 28 ESR < 2.6) who have received treatment with abatacept 10 mg/kg for at least one year|Assess disease activity as measured by DAS28 CRP score monthly|Assess proportion of subjects who in the 1st year modify therapy and/or have 2 consecutive DAS 28 CRP scores ??­ 3.2 for Additional DMARD therapy given; Two or more course of high dose steroids given; Return to abatacept 10 mg/kg (rescue medication given)|Assess the proportion of subjects who at any time in the 1st year lose remission status|Assess the steady-state trough serum concentration of abatacept in the two dose groups|Determine the safety and tolerability of abatacept in this subject population|Evaluation of immunogenicity of abatacept","http://ClinicalTrials.gov/show/NCT00989235",NA
"30037",30037,"NCT01268735","The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye","Completed","No Results Available","Dry Eye Syndromes","Drug: Lubricating eyedrops containing hydroxypropyl-guar","University of Zagreb","Both","Adult|Senior","Phase IV",229,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LIPCOF Petricek","December 30, 2010","01/04/2009",2010-02-01,"December 30, 2010","01/12/2010","LIPCOF",2009-09-01,"Lid-parallel conjunctival folds (LIPCOF)|Signs and symptoms of dry eye","http://ClinicalTrials.gov/show/NCT01268735",NA
"30081",30081,"NCT00005036","Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","North Central Cancer Treatment Group|National Cancer Institute (NCI)|Southwest Oncology Group|Eastern Cooperative Oncology Group","Both","Adult|Senior","Phase III",NA,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000067623|NCCTG-N9841|ECOG-N9841|SWOG-N9841","April 6, 2000","01/11/1999",NA,"October 15, 2009","01/02/2004","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00005036",NA
"30113",30113,"NCT00049036","Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab","AIDS Malignancy Clinical Trials Consortium|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Both","Adult|Senior","Phase II",70,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment","CDR0000257660|U01CA070019|AMC-034|ECOG-AMC34","November 12, 2002","01/01/2003",NA,"November 3, 2010","01/11/2010","",2009-05-01,"Complete response as measured by tumor response after completion of study treatment","http://ClinicalTrials.gov/show/NCT00049036",NA
"30126",30126,"NCT00076336","Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis","Completed","No Results Available","Hepatitis|Hepatitis B, Chronic|Cirrhosis","Drug: telbivudine|Drug: lamivudine","Novartis Pharmaceuticals","Both","Child|Adult|Senior","Phase III",232,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLDT600A2301","January 20, 2004","01/12/2003",NA,"March 24, 2010","01/03/2010","",2009-12-01,"Primary Outcome is a composite endpoint termed Clinical Response, defined as achievement of the following three efficacy criteria: Serum HBV DNA < 4 log10 copies/mL, Normal ALT level, Improvement or stabilization in CTP score|Time to Clinical Response; Duration of Clinical Response; Improvement, Stabilization, and Worsening in CTP score; Improvement, Stabilization, and Worsening in a modified (3-component) CTP score","http://ClinicalTrials.gov/show/NCT00076336",NA
"30146",30146,"NCT00101036","Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer","Drug: lapatinib ditosylate","California Cancer Consortium|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000406604|CCC-PHII-53|NCI-6674|PCI-04091","January 7, 2005","01/01/2005",2009-01-01,"October 11, 2010","01/10/2010","",2009-01-01,"Anti-tumor activity by response rate based on tumor measurements every 8 weeks|Overall survival every 4 weeks during study treatment|Time to progression every 4 weeks during study treatment|Disease control rate every 4 weeks during study treatment","http://ClinicalTrials.gov/show/NCT00101036",NA
"30157",30157,"NCT00121836","A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: capecitabine [Xeloda]|Drug: Avastin","Hoffmann-La Roche","Female","Adult|Senior","Phase IV",108,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18527","July 18, 2005","",2009-07-01,"October 15, 2009","01/10/2009","",2009-07-01,"Overall survival, defined as the time from date of first study medication to death, across the study phases|Safety profile, using NCI CTCAE version 3.0 (AEs, laboratory parameters, vital signs, premature withdrawals)","http://ClinicalTrials.gov/show/NCT00121836",NA
"30172",30172,"NCT00143936","The Safety and Efficacy of Low and High Carbohydrate Diets","Completed","No Results Available","Obesity","Behavioral: Low- Carbohydrate -Atkins Diet|Behavioral: Low Calorie Diet","Temple University|National Center for Complementary and Alternative Medicine (NCCAM)|National Institutes of Health (NIH)","Both","Adult","Phase IV",360,"Other|NIH","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","R01 AT 001103|1 R01 AT01103-01","September 1, 2005","01/04/2003",2009-02-01,"January 14, 2010","01/01/2008","",2009-02-01,"Weight loss","http://ClinicalTrials.gov/show/NCT00143936",NA
"30180",30180,"NCT00159536","Metformin in Pregnant PCOS Women","Completed","No Results Available","Polycystic Ovary Syndrome","Drug: Metformin|Drug: Placebo|Dietary Supplement: Diet and lifestyle advices","Norwegian University of Science and Technology|St. Olavs Hospital","Female","Adult","Phase III",300,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PregMet","September 8, 2005","01/02/2005",2009-10-01,"March 16, 2010","01/03/2010","PregMet",2009-10-01,"To investigate the incidence of pregnancy complications and pregnancy outcome in PCOS women with special focus on|a)Gestational diabetes, b)Preterm delivery, c)Preeclampsia.|To register the incidence of metabolic syndrome and neurophysiologic parameters in offspring|To investigate: 1)emesis and hyperemesis in pregnancy, 2) weight development, blood pressure in participants during pregnancy, 3)Incident of instrumental deliveries, 4)Hormone levels in mother and offspring, 5)Snoring and sleep quality|6)Breastfeeding","http://ClinicalTrials.gov/show/NCT00159536",NA
"30199",30199,"NCT00189436","Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children","Completed","No Results Available","Asthma","Drug: Nebulized Budesonide|Drug: Usual care (albuterol with or without oral steroid)","West Penn Allegheny Health System|AstraZeneca","Both","Child","Phase IV",61,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","BUD ER 3425|RC - 3425","September 12, 2005","01/03/2003",2009-01-01,"May 28, 2009","01/05/2009","BudER",2009-01-01,"Wheezing/Asthma/Bronchospasm relapse rate|Urinary Cortisol|Spirometry readings","http://ClinicalTrials.gov/show/NCT00189436",NA
"30277",30277,"NCT00310336","Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine","Completed","No Results Available","Hepatitis C","Drug: S-adenosyl-L-methionine|Drug: betaine|Drug: pegylated interferon alpha2b|Drug: ribavirin","University Hospital, Basel, Switzerland","Both","Adult","Phase II|Phase III",30,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EKBB 37/06","March 31, 2006","01/08/2006",2009-09-01,"October 27, 2010","01/10/2010","",2009-08-01,"Sustained response rate|Early virologic response after 12 weeks of therapy with PegIntron, Rebetol, AdoMet and betaine.","http://ClinicalTrials.gov/show/NCT00310336",NA
"30287",30287,"NCT00318136","A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)","Completed","Has Results","Non-small Cell Lung Cancer","Drug: Bevacizumab|Drug: Carboplatin|Drug: Paclitaxel","Genentech","Both","Adult|Senior","Phase II",47,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AVF3744g","April 24, 2006","01/09/2005",2009-07-01,"May 5, 2010","01/05/2010","",2009-07-01,"Incidence of Grade ??­3 Pulmonary Hemorrhage Adverse Events|Selected Adverse Events|Adverse Events That Led to Discontinuation of Bevacizumab|Progression-free Survival","http://ClinicalTrials.gov/show/NCT00318136",NA
"30356",30356,"NCT00385736","Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis","Completed","Has Results","Ulcerative Colitis","Biological: adalimumab|Biological: adalimumab|Biological: placebo","Abbott","Both","Adult|Senior","Phase III",576,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M06-826|2006-002781-20","October 9, 2006","01/11/2006",2010-03-01,"June 17, 2010","01/06/2010","",2009-04-01,"Proportion of Participants With Remission Per Mayo Score at Week 8|Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 80/40 Versus Placebo).|Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 80/40 Versus Placebo).|Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).|Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).|Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).|Proportion of IBDQ Responders at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of IBDQ Responders at Week 8 (Adalimumab 80/40 Versus Placebo).","http://ClinicalTrials.gov/show/NCT00385736",NA
"30357",30357,"NCT00433836","Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure","Completed","No Results Available","Hypertension","Drug: Valsartan|Drug: Enalapril","Novartis Pharmaceuticals","Both","Child","Phase III",300,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CVAL489K2302","February 8, 2007","01/02/2007",2009-03-01,"October 23, 2009","01/10/2009","",2009-02-01,"Reduction of mean sitting systolic blood pressure (MSSBP)|Reduction of mean sitting diastolic blood pressure (MSDBP)|Decrease in MSSBP to < 95th percentile for age, gender and height|Change in mean ambulatory systolic blood pressure and mean ambulatory diastolic blood pressure over 24 hours in subset of patients|Safety and tolerability of valsartan compared to enalapril","http://ClinicalTrials.gov/show/NCT00433836",NA
"30376",30376,"NCT00455936","First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker","Completed","No Results Available","Lung Cancer","Drug: Gefitinib|Procedure: chemotherapy","National Cancer Center, Korea|AstraZeneca","Both","Adult|Senior","Phase III",315,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-05-126|D7913L00054","April 3, 2007","01/10/2005",2010-03-01,"October 22, 2010","01/03/2010","",2009-11-01,"overall survival|To compare Progression-Free survival|To compare the quality of life|To compare safety profile|To collect the tissue samples for the study of predictors of gefitinib (optional)|To compare the objective response rate (CR+PR)","http://ClinicalTrials.gov/show/NCT00455936",NA
"30378",30378,"NCT00462436","Innovative Strategies For Risk Reduction Following CABG","Completed","No Results Available","Coronary Artery Disease|Type II Diabetes Mellitus","Behavioral: Consumption of Dietary Portfolio","St. Michael's Hospital, Toronto|Canadian Diabetes Association","Both","Adult|Senior","Phase II",35,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","REB06-179C","April 17, 2007","01/02/2007",2010-05-01,"July 21, 2010","01/02/2009","",2009-12-01,"Primary Outcome: Reduction of total and LDL cholesterol|Improvement in endothelial function and EPC counts|Reduction in CRP|Feasibility and tolerability|Reduction in markers of inflammation ie TNF, IL-6|Improved markers of glycemic control - fructosamine, HOMA","http://ClinicalTrials.gov/show/NCT00462436",NA
"30386",30386,"NCT00479336","A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema","Completed","No Results Available","Cirrhosis","Drug: OPC-41061 7.5mg|Drug: OPC-41061 placebo|Drug: OPC-41061 15mg|Drug: OPC-41601 30mg","Otsuka Pharmaceutical Co., Ltd.","Both","Adult|Senior","Phase II",100,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","156-06-005","May 25, 2007","01/06/2007",2009-01-01,"September 9, 2010","01/09/2010","",2009-01-01,"Body weight (amount of change)|Body weight (% change from baseline), Abdominal circumference, Ascites, Lower-limb edema, Pleural effusion","http://ClinicalTrials.gov/show/NCT00479336",NA
"30393",30393,"NCT00485836","A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)","Completed","No Results Available","Macular Edema|Retinal Vein Occlusion","Drug: ranibizumab|Drug: sham","Genentech","Both","Adult|Senior","Phase III",392,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","FVF4166g","June 11, 2007","01/07/2007",2009-12-01,"May 5, 2010","01/05/2010","CRUISE",2009-06-01,"Mean change from baseline in BCVA score|Proportion of subjects who gain at least 15 letters in BCVA score at 6 months compared with baseline|Proportion of subjects who lose fewer than 15 letters in BCVA score at 6 months compared with baseline|Mean change from baseline in BCVA score|Proportion of subjects with a central foveal thickness of ??? 250 ??m, assessed on OCT|Mean absolute change from baseline in central foveal thickness, assessed on OCT|Mean change from baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) near activities subscale over time up to 6 months|Mean change from baseline in the NEI VFQ-25 distance activities subscale over time up to 6 months","http://ClinicalTrials.gov/show/NCT00485836",NA
"30399",30399,"NCT00502736","A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.","Completed","No Results Available","Pain; Bone Neoplasms; Neoplasm Metastasis","Drug: ibandronate [Bondronat]","Hoffmann-La Roche","Female","Adult|Senior","Phase II",13,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20684","July 17, 2007","",2009-03-01,"September 16, 2009","01/09/2009","",2009-03-01,"Pain and analgesic consumption|AEs and laboratory parameters|Serum creatinine|Karnofsky index","http://ClinicalTrials.gov/show/NCT00502736",NA
"30424",30424,"NCT00511836","ALK21-018: Effects of Medisorb?ó Naltrexone (VIVITROL?ó) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults","Completed","Has Results","Alcohol Dependence","Drug: VIVITROL 380 mg|Drug: Placebo","Alkermes","Both","Adult","Phase IV",31,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALK21-018","August 2, 2007","01/07/2007",2009-10-01,"December 9, 2010","01/12/2010","",2009-06-01,"Change From Baseline in Blood Oxygen-level-dependent (BOLD) Signal Activation Values Detected in the Reward Circuitry of the Brain in Alcohol-dependent Subjects After Presentation of Alcohol-related Cues.|Change From Baseline in BOLD Signal Activation Values for the Inferior Frontal Gyrus|Change From Baseline in BOLD Signal Activation Values in the Reward Circuitry|Change From Baseline in Obsessive-Compulsive Drinking Scale (OCDS) Score in Alcohol-dependent Subjects|Change From Baseline in Daily Craving Score in Alcohol-dependent Subjects (Actiwatch Data)","http://ClinicalTrials.gov/show/NCT00511836",NA
"30437",30437,"NCT00540436","Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension","Completed","Has Results","Pulmonary Arterial Hypertension|Hypertension, Pulmonary","Drug: GSK1325760A","GlaxoSmithKline","Both","Adult|Senior","Phase II",25,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMB107816","October 5, 2007","01/08/2007",2009-01-01,"October 28, 2010","01/10/2010","",2009-01-01,"Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at Week 12|Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at Week 24/Withdrawal|Mean Change From Baseline in the Borg Dyspnea Index (BDI) at Weeks 12 and 24|Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24|Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) at Week 24, Assessed as the First Occurrence of a Particular Event|Mean Change From Baseline in Mean Pulmonary Atery Pressure (mPAP) and Mean Right Atrial Pressure (mRAP) at Weeks 12 and 24|Mean Change From Baseline in Cardiac Index (CI) at Weeks 12 and 24|Mean Change From Baseline in Cardiac Output (CO) at Weeks 12 and 24|Mean Change From Baseline in Pulmonary Vascular Resistance (PVR) at Weeks 12 and 24|Mean Change From Baseline in B-type Natriuretic Peptide (BNP) Values at Weeks 12 and 24","http://ClinicalTrials.gov/show/NCT00540436",NA
"30443",30443,"NCT00567736","Efficacy of Disci/Rhus Toxicodendron Comp.?ó, in Patients With Chronic Low Back Pain","Completed","No Results Available","Chronic Low Back Pain","Drug: Disci/Rhus toxicodendron comp.?ó|Drug: placebo solution","Charite University, Berlin, Germany|WALA Heilmittel GmbH","Both","Adult|Senior","Phase III",150,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","DISCI-07|EudraCT-Nr. 2006-006390-24","December 4, 2007","01/08/2007",2009-01-01,"August 14, 2009","01/08/2009","DISCI",2009-01-01,"Visual analogue scale (0-100 mm) low back pain|Back function (back function scale FFbHR)|visual analogue scale (0-100 mm) low back pain|days with medication|quality of life (SF-36)|pain disability scale (PDI)|emotional pain scale (SES)|influence of patient expectancy|influence of physician expectancy|Responder rate 36% VAS pain intensity|numbers of days with absence from work|days with physician visits because of low back pain","http://ClinicalTrials.gov/show/NCT00567736",NA
"30447",30447,"NCT00572936","Circadian Rhythms of Aqueous Humor Dynamics in Humans","Completed","No Results Available","Glaucoma","Drug: prostaglandin","University of Nebraska|Pfizer","Both","Adult|Senior","Phase II",30,"Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","405-05-FB","December 7, 2007","01/11/2005",2009-11-01,"January 29, 2010","01/01/2010","",2009-11-01,"Observed patterns of normal, healthy eyes during daytime and nighttime hours.","http://ClinicalTrials.gov/show/NCT00572936",NA
"30450",30450,"NCT00570336","Study of CTS-1027 in Hepatitis C Patients","Completed","No Results Available","Chronic Hepatitis C Virus Infection","Drug: CTS-1027|Other: Placebo","Conatus Pharmaceuticals Inc.|FGK Clinical Research GmbH","Both","Adult|Senior","Phase II",87,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTS-1027-01","December 6, 2007","01/12/2007",2009-07-01,"September 14, 2010","01/09/2010","",2009-07-01,"Number of adverse events at each dose level|Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels at each dose|Peak and trough levels of CTS-1027 in plasma","http://ClinicalTrials.gov/show/NCT00570336",NA
"30459",30459,"NCT00595036","The Impact of Lubiprostone on Mucus Secretion in Asymptomatic Volunteers and Patients With Chronic Constipation","Completed","No Results Available","Constipation","Drug: Lubiprostone|Drug: Placebo","University of Kansas|Takeda Global Research & Development Center, Inc.","Both","Adult","Phase II",40,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)","11029","January 7, 2008","01/01/2008",2009-09-01,"September 14, 2009","01/09/2009","",2009-09-01,"Effect of gastric mucus and mucin production before and after stimulation with lubiprostone in healthy and constipated subjects|Viscosity of gastric secretion before and after lubiprostone in healthy and constipated subjects","http://ClinicalTrials.gov/show/NCT00595036",NA
"30479",30479,"NCT00626236","Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems","Completed","No Results Available","Attention Deficit Disorder With Hyperactivity|Conduct Disorder","Drug: SPN-810","Supernus Pharmaceuticals, Inc.","Both","Child","Phase II",72,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","810P201","February 20, 2008","01/09/2008",2009-10-01,"January 14, 2010","01/01/2010","",2009-09-01,"safety scales (Simpson-Angus, Barnes Akathisia, AIMS)|Nisonger Child Behavior Rating Form - TIQ","http://ClinicalTrials.gov/show/NCT00626236",NA
"30484",30484,"NCT00636636","Safety and Efficacy of Gabapentin in Postherpetic Neuralgia","Completed","No Results Available","Neuralgia,Postherpetic","Drug: Gabapentin Extended Release tablets","Depomed","Both","Adult|Senior","Phase III",450,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","81-0062","February 21, 2008","01/03/2008",2009-09-01,"November 2, 2009","01/11/2009","",2009-08-01,"The primary study objective is to assess the relative efficacy of G-ER versus placebo in reducing the average daily pain score from the baseline week to the final week of the efficacy treatment period (Treatment Week 10) in patients with PHN|Daily pain scores will be measured using an electronic diary.|Secondary objectives include assessment of changes from baseline in average daily sleep interference scores","http://ClinicalTrials.gov/show/NCT00636636",NA
"30505",30505,"NCT00671736","Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis","Completed","No Results Available","Cystic Fibrosis","Drug: Moli1901|Drug: Moli1901 placebo","AOP Orphan Pharmaceuticals AG","Both","Child|Adult|Senior","Phase II",160,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Moli1901-010B|EudraCT No 2006-006693-24","April 30, 2008","01/10/2007",2009-07-01,"August 26, 2009","01/08/2009","",2009-07-01,"The change in the percentage of the predicted FEV1 (forced expiratory volume in first second) value|The ensemble of two subject reported clinical scores, which are physical dimensions of the self-report, disease-specific quality of life test, the cystic fibrosis questionnaire in the revised version","http://ClinicalTrials.gov/show/NCT00671736",NA
"30514",30514,"NCT00666536","The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy","Completed","Has Results","Hypertension","Drug: valsartan and amlodipine|Drug: valsartan and amlodipine","Novartis","Both","Adult|Senior","Phase IV",728,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CVAA489AUS02","April 23, 2008","01/03/2008",NA,"November 17, 2010","01/11/2010","EXTRA",2009-01-01,"Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 4 Weeks|Proportion of Patients Achieving Blood Pressure Goal (<140/90 mmHg)|Change in Mean Sitting Diastolic Blood Pressure (MSDBP) After 4 Weeks|Change in MSSBP After 2, 8 and 12 Weeks|Change in MSDBP After 2, 8 and 12 Weeks|Proportion of Patients Achieving BP Goal of MSSBP < 140mmHg","http://ClinicalTrials.gov/show/NCT00666536",NA
"30535",30535,"NCT00696436","An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Subjects With Essential Hypertension.","Completed","No Results Available","Essential Hypertension","Drug: Azilsartan medoxomil|Drug: Azilsartan medoxomil|Drug: Valsartan|Drug: Olmesartan|Drug: Placebo","Takeda Global Research & Development Center, Inc.","Both","Adult|Senior","Phase III",1291,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01-06-TL-491-019|U1111-1113-9161","June 10, 2008","01/04/2008",2009-08-01,"July 14, 2010","01/07/2010","",2009-08-01,"Change from baseline in the 24-hour mean systolic blood pressure by ambulatory blood pressure monitoring.|Change from baseline in trough sitting systolic blood pressure taken in the clinic|Change from baseline for 24-hour mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline in trough sitting diastolic blood pressure taken in the clinic|Change from baseline for daytime mean (6am to 10pm) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for daytime mean (6am to 10pm) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) diastolic blood pressure by ambulatory blood pressure monitor|Proportion of subjects who achieve a Clinic Diastolic Blood Pressure Response, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg|Proportion of subjects who achieve a Clinic Systolic Blood Pressure Response, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg|Proportion of subjects who achieve both clinic Diastolic and Systolic Blood Pressure Response","http://ClinicalTrials.gov/show/NCT00696436",NA
"30537",30537,"NCT00718536","Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy","Completed","No Results Available","HIV Infections","Drug: Addition of raltegravir 800 mg QD to HAART","Germans Trias i Pujol Hospital","Both","Adult","Phase IV",15,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RALqd-ATV","July 16, 2008","01/08/2008",2009-01-01,"April 8, 2009","01/04/2009","",2009-01-01,"Raltegravir area under the curve (AUC) 24 hours and Cmin|Adverse events|Adherence","http://ClinicalTrials.gov/show/NCT00718536",NA
"30552",30552,"NCT00741936","An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation","Completed","No Results Available","Functional Gastrointestinal Disorders|Constipation","Drug: MaZiRenWan (MZRW)|Drug: Placebo","Hong Kong Baptist University|Health, Welfare and Food Bureau (Health and Health Services Research Fund)|PuraPharm International (H.K.) Ltd","Both","Adult","Phase II",120,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PID-002","August 25, 2008","01/07/2008",2010-01-01,"January 25, 2010","01/01/2010","",2009-11-01,"Responder rate for complete spontaneous bowel movement (CSBM). Patients with a mean increase of ???1 CSBM/wk compared with the baseline(wk1-2) will be defined as responders.|Responder rate for CSBM|Global symptoms improvement|Changes on individual symptom scores|Changes of quality of life evaluated by SF-36 questionnaire|Changes of stool frequency|Changes of Bristol stool form scale|Adverse effects (e.g. renal and liver function tests)","http://ClinicalTrials.gov/show/NCT00741936",NA
"30554",30554,"NCT00743236","Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer","Completed","No Results Available","Kidney Cancer|Long-term Effects Secondary to Cancer Therapy in Adults|Perioperative/Postoperative Complications|Urinary Complications","Procedure: cold ischemia procedure|Procedure: warm ischemia procedure","Wake Forest University|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",176,"Other|NIH","Interventional","Allocation: Randomized|Masking: Single Blind|Primary Purpose: Treatment","CDR0000612519|CCCWFU-89108","August 27, 2008","01/08/2008",NA,"October 21, 2009","01/10/2009","",2009-10-01,"Creatinine clearance at 1 year|Estimated glomerular filtration rate (GFR) at 1 year|Evidence of local or metastatic recurrence|Cancer-specific survival|Overall survival","http://ClinicalTrials.gov/show/NCT00743236",NA
"30561",30561,"NCT00748436","Efficacy Study of Betahistine on Body Weight in Obese Female Subjects","Completed","No Results Available","Obesity","Drug: betahistine dihydrochloride|Drug: betahistine dihydrochloride|Drug: placebo","OBEcure Ltd.|International Antiviral Therapy Evaluation Center","Female","Adult","Phase II",187,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BET207|2008-001840-38|S51130|ML5059","September 5, 2008","01/09/2008",2009-04-01,"May 6, 2009","01/05/2009","",2009-04-01,"change in body weight in Kg or % of initial body weight and/or proportion of subjects achieving > 2.5% and/or >5.0 % weight loss.|Change in obesity associated conditions|Safety parameters","http://ClinicalTrials.gov/show/NCT00748436",NA
"30568",30568,"NCT00758836","A Study to Test the Safety and Effectiveness of MK0974 Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura.","Completed","No Results Available","Migraine","Drug: telcagepant|Drug: Comparator: MK0974 + Ibuprofen|Drug: Comparator: MK0974 + Acetaminophen|Drug: Comparator: placebo (unspecified)","Merck","Both","Adult|Senior","Phase II",628,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2008_551|MK0974-046","September 23, 2008","01/12/2008",2009-08-01,"April 12, 2010","01/04/2010","",2009-08-01,"Evaluate the efficacy of MK0974 in the treatment of migraine when co-administered with acetaminophen or ibuprofen compared to MK0974 alone and compared to placebo.|Test the safety and tolerability of MK0974 when co-administered with acetaminophen or ibuprofen in the treatment of acute migraine.","http://ClinicalTrials.gov/show/NCT00758836",NA
"30610",30610,"NCT00831636","A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer","Completed","No Results Available","Ovarian Cancer","Drug: CP-4055|Drug: CP-4055","Clavis Pharma","Female","Adult|Senior","Phase I|Phase II",28,"Industry","Interventional","Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CP4055-204","January 28, 2009","01/04/2008",2010-04-01,"September 3, 2010","01/09/2010","",2009-11-01,"Phase I: Determine recommended dose for phase II studies of CP-4055 when given five consecutive days twice in a 4 week schedule, D1-5 and D8(+2)-12(+2) q4w|Phase II: Determine the antitumour activity of CP-4055|Determine pharmacokinetic (PK) parameters|Explore the time to progression (TTP)|Investigate the duration of tumour response|Determine the nature and degree of toxicity of CP-4055 in this patient population","http://ClinicalTrials.gov/show/NCT00831636",NA
"30616",30616,"NCT00842036","CRAFT Behavior Therapy: Treatment Entry Component","Completed","No Results Available","Drug Addiction|Stimulant Dependence|Opiate Dependence|Alcohol Dependence|Substance Abuse","Behavioral: Community Reinforcement and Family Training|Behavioral: Treatment Entry Training|Behavioral: 12- step Al/Nar- Anon Facilitation","Treatment Research Institute","Both","Adult|Senior","Phase II",180,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0406|5R01DA018696","February 11, 2009","01/01/2006",2009-12-01,"June 24, 2010","01/06/2010","",2009-12-01,"Treatment entry of the drug user|Reduction in drug use|Improvements in mood and functioning","http://ClinicalTrials.gov/show/NCT00842036",NA
"30636",30636,"NCT00792636","A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period","Completed","Has Results","Migraine With or Without Aura|Migraine Disorders|Migraine, Acute|Migraine Headaches","Drug: sumatriptan and naproxen sodium combination tablet|Drug: sumatriptan tablet|Drug: naproxen sodium tablet","GlaxoSmithKline","Both","Adult","Phase IV",407,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","110948","November 17, 2008","01/11/2008",2009-11-01,"November 11, 2010","01/11/2010","",2009-11-01,"Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen|Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan and Naproxen|Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Sumatriptan|Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Naproxen|Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <4 Migraines Per Month, 4-6 Migraines Per Month, >=4 Migraines Per Month, and >6 Migrain|Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <1.3 Times Per Migraine, 1.3-1.7 Times Per Migraine, and >1.7 Times Per Migraine|Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, With <6, 6-10, >=6, 10-14, and >14 Doses Per Month|Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating With <30 Total Doses, 30-60 Total Doses, >=30, 60-90 Total Doses, and >90 Total Doses|Number of Participants With an Increase of >=5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements|Number of Participants With an Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements|Number of Participants With a Consecutive 2-day Average Systolic Blood Pressure of >=140 mmHg During the Study|Number of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of >=90 mmHg|Time to the First Day With an Average Systolic Blood Pressure Increase of >=5 mmHg From the Baseline Systolic Blood Pressure|Time to the First Day With an Average Diastolic Blood Pressure Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure|Number of Participants Withdrawn From the Study Due to Blood Pressure Changes","http://ClinicalTrials.gov/show/NCT00792636",NA
"30637",30637,"NCT00871936","A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes","Completed","No Results Available","Type 2 Diabetes","Drug: SLx-4090|Other: Placebo","Surface Logix","Both","Adult|Senior","Phase II",82,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SLx-4090-09-07","March 26, 2009","01/04/2009",2009-10-01,"December 14, 2009","01/08/2009","",2009-10-01,"Reduction in HbA1c|Adverse Events","http://ClinicalTrials.gov/show/NCT00871936",NA
"30638",30638,"NCT00869336","Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)","Completed","No Results Available","Tinea Pedis","Drug: Luliconazole Cream 1% - 2 wks|Drug: Placebo Comparator -2 wks|Drug: Luliconazole Cream 1% - 4 wks|Drug: Placebo Comparator - 4 wks","Tinea Pharmaceuticals","Both","Child|Adult|Senior","Phase II",150,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TP-0801","March 25, 2009","01/03/2009",2009-09-01,"November 22, 2010","01/11/2010","",2009-09-01,"Proportion of subjects who achieve complete clearance at 2 weeks post treatment|Proportion of subjects who achieve effective treatment at 2 and 4 weeks post treatment","http://ClinicalTrials.gov/show/NCT00869336",NA
"30651",30651,"NCT00905736","Influence of Microcurrent Parameters on Effectiveness in Treatment of Chronic Tennis Elbow","Completed","No Results Available","Tennis Elbow","Procedure: Microcurrent treatment (controlled current)|Procedure: Micocurrent treatment (controlled voltage)","University of Hertfordshire","Both","Adult|Senior","Phase II|Phase III",24,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HEPEC/03/09/74","May 20, 2009","01/04/2009",2009-12-01,"June 18, 2010","01/08/2009","",2009-12-01,"Tissue healing as indicated by sonography|Patient rating global change|Pain free grip strength|Patient rated tennis elbow questionnaire|Adverse events","http://ClinicalTrials.gov/show/NCT00905736",NA
"30759",30759,"NCT01068236","Primary Care Treatment for Overweight Adolescent Females (SHINE)","Completed","No Results Available","Obesity","Behavioral: Healthy lifestyle managment","Kaiser Permanente","Female","Child","Phase II",215,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","5R01 HD050931-04","February 11, 2010","01/08/2005",2009-12-01,"March 23, 2010","01/03/2010","SHINE",2009-12-01,"BMI z-score|Blood pressure|Fasting lipid profile|Fasting glucose","http://ClinicalTrials.gov/show/NCT01068236",NA
"30810",30810,"NCT01156636","Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure","Completed","No Results Available","Pulmonary Hypertension|Diastolic Heart Failure","Drug: sildenafil","University of Milan","Male","Child|Adult|Senior","Phase II|Phase III",44,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","444-10","July 2, 2010","01/01/2006",2009-12-01,"July 2, 2010","01/06/2009","",2009-09-01,"Pulmonary hemodynamics","http://ClinicalTrials.gov/show/NCT01156636",NA
"30854",30854,"NCT01222936","LBH Phase II in Small Cell Lung Cancer (SCLC)","Completed","No Results Available","Small Cell Lung Carcinoma","Drug: LBH581","Southern Europe New Drug Organization|Novartis Pharmaceuticals","Both","Adult|Senior","Phase II",21,"Other|Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S075LBH501","October 11, 2010","01/05/2008",2010-08-01,"October 14, 2010","01/10/2010","",2009-06-01,"Objective response rate|Duration of antitumor activity|Drug safety profile","http://ClinicalTrials.gov/show/NCT01222936",NA
"30960",30960,"NCT00022737","Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Drug: asparaginase|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: ifosfamide|Drug: imatinib mesylate|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",220,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068859|COG-AALL0031","August 10, 2001","01/10/2002",NA,"November 20, 2010","01/11/2010","",2009-07-01,"Feasibility, in terms of toxicity and patient accrual|Safety|Event-free survival|Feasibility of administering hematopoietic stem cell transplantation after the second consolidation block of chemotherapy|Prognostic effect of minimal residual disease assays","http://ClinicalTrials.gov/show/NCT00022737",NA
"30992",30992,"NCT00098137","Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation","Completed","No Results Available","Heart Disease|Arrhythmia|Atrial Fibrillation","Drug: olmesartanmedoxomil","German Atrial Fibrillation Network|Daiichi Sankyo Inc.","Both","Adult|Senior","Phase III",422,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AFNET-B10|BMBF; Grant No 01GI0204","December 3, 2004","01/01/2005",2009-05-01,"May 28, 2009","01/05/2009","",2009-05-01,"Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele-ECG recording)|Time to first occurrence of a documented relapse of atrial fibrillation|Time to first occurrence of a symptomatic documented episode of AF|Time to persistent atrial fibrillation|Time to prescription of the recovery-medication|Number of hospitalizations for cardiovascular reasons (-> Endpoint review)|Number of intermediate medical visits for cardiovascular reasons (-> Endpoint review) without hospitalization|Number of cerebrovascular events|Quality of life","http://ClinicalTrials.gov/show/NCT00098137",NA
"31042",31042,"NCT00139737","Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia","Completed","Has Results","Schizophrenia","Drug: Ziprasidone","Pfizer","Both","Adult","Phase III",344,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A1281061","August 29, 2005","01/03/2002",2009-06-01,"August 2, 2010","01/08/2010","",2009-06-01,"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","http://ClinicalTrials.gov/show/NCT00139737",NA
"31074",31074,"NCT00211237","CAFE Study - Cancer Patient Fracture Evaluation","Completed","Has Results","Cancer|Spinal Fractures","Device: Balloon Kyphoplasty|Other: Non Surgical Management","Medtronic Spine LLC","Both","Adult|Senior","Phase IV",134,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","SP0401 - CAFE Study","September 13, 2005","01/05/2005",2009-12-01,"May 18, 2010","01/05/2010","CAFE",2009-04-01,"The Functional Status, as Measured by the Roland-Morris Disability Questionnaire (RDQ) at 1 Month|Study Treatment-related Adverse Events and Change in Neurological Status|Clinical: Change in Functional Status (as Assessed With the Roland-Morris Disability Questionnaire and the Karnofsky Performance Scale)|Change in Quality of Life (as Assessed by the SF-36v2?ºÑ Health Survey)|Change in Back Pain (as Measured by a 10-point Numerical Rating Scale)|Radiographic: Change in Spinal Deformity, Defined as the Degree of Spine Angulation (as Assessed by an Independent Radiologist at the Core Laboratory)|Radiographic: Rate of Subsequent Vertebral Body Fractures (as Assessed by Independent Radiologists at the Core Laboratory)","http://ClinicalTrials.gov/show/NCT00211237",NA
"31077",31077,"NCT00196937","Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18","Completed","Has Results","Cervical Intraepithelial Neoplasia|Human Papillomavirus Infection","Biological: Cervarix?ºÑ","GlaxoSmithKline","Female","Child|Adult","Phase III",667,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","103514|105879 (Month 18)|105880 (Month 24)|105881 (Month 36)|105882 (Month 48)","September 13, 2005","01/10/2004",2009-02-01,"July 8, 2010","01/07/2010","",2009-02-01,"Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies, in Women 15 to 25 Years of Age and Women 26 to 45 Years of Age|Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies|Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies in Cervical Samples|Number of Subjects Seropositive for Total Immunoglobulin-G (IgG) in Blood (Serum) and in Cervical Samples (Secretion)|Number of Subjects Seroconverted for Anti-HPV-16 and Anti-HPV-18 Antibodies, in Women 46 - 55 Years of Age|Number of Subjects Seroconverted for Anti-HPV-16 and Anti-HPV-18 Antibodies After 2 Vaccine Doses and 6 Months Following the Complete Vaccination Course|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Number of Subjects Reporting Serious Adverse Events (SAE)|Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSAEs)","http://ClinicalTrials.gov/show/NCT00196937",NA
"31108",31108,"NCT00272337","Aspirin Dose and Atherosclerosis in Patients With Heart Disease","Completed","No Results Available","Cardiovascular Diseases|Atherosclerosis|Myocardial Infarction","Drug: Aspirin","Florida Atlantic University|Bayer","Both","Adult|Senior","Phase IV",70,"Other|Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H07-29","January 3, 2006","01/10/2006",2009-01-01,"April 1, 2009","01/04/2009","TAD",2009-01-01,"inflammatory markers, at baseline and 3 months.|platelet biomarkers, at baseline and 3 months.|nitric oxide formation, at baseline and 3 months.|endothelial function, at baseline and 3 months","http://ClinicalTrials.gov/show/NCT00272337",NA
"31123",31123,"NCT00297037","Pimecrolimus Cream for Oral Lichen Planus","Completed","No Results Available","Oral Lichen Planus","Drug: Pimecrolimus cream","University of Utah|Novartis","Both","Adult|Senior","Phase II",22,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","12589","February 23, 2006","01/08/2005",2009-02-01,"February 9, 2009","01/02/2009","",2009-02-01,"The primary efficacy variable will be change in the Investigator's Global Assessment of the overall severity of disease from baseline to week 6.|The secondary efficacy variables will be changes in the size of the target erosion in millimeters, erythema and assessment of spontaneous pain on a visual analog scale (0-10).","http://ClinicalTrials.gov/show/NCT00297037",NA
"31158",31158,"NCT00355537","Testosterone Replacement in Diabetes With Vascular Disease (Version 2)","Completed","No Results Available","Diabetes Mellitus|Peripheral Vascular Disease","Drug: Testosterone|Drug: 0.9% saline","Barnsley Hospital","Male","Adult|Senior","Phase IV",19,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BDGH 237","July 21, 2006","01/02/2006",2009-12-01,"March 29, 2010","01/03/2010","",2009-12-01,"The effect of testosterone replacement on arterial stiffness measured by ultrasound derived index B of the femoral artery in men with a combination of DM, PVD and hypogonadism.|The effect of testosterone on intima-media thickness of the femoral artery measured by ultrasound .|The effect of testosterone on peripheral circulation in legs affected by PVD as measured by transcutaneous oxygen saturation in the feet of the study population.|The effect of testosterone on PVD as measured by ankle-brachial-pressure-indices (ABPI) .|The effect of testosterone on markers of vascular risk; blood pressure, serum-lipid levels, weight, waist circumference, body fat percentage, urinary micro-albumin concentration and C reactive protein levels.","http://ClinicalTrials.gov/show/NCT00355537",NA
"31192",31192,"NCT00407537","Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors","Completed","No Results Available","Hypertension|Hypercholesterolemia","Drug: Amlodipine besylate/atorvastatin calcium single pill combination","Pfizer","Both","Adult|Senior","Phase IV",1531,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A3841047","December 1, 2006","01/03/2007",2009-10-01,"September 30, 2010","01/12/2009","CRUCIAL",2009-10-01,"The primary efficacy endpoint is the 10-year risk of developing total coronary heart disease using the Framingham Model at the end of 12 months.|Blood pressure and lipid parameters at 4 and 12 months.|10 year risk of developing stroke using the Framingham model for stroke at 4 and 12 months.|10-year risk of developing fatal CHD using the European SCORE model at 4 and 12 months.|10-year risk of developing total CHD using the Framingham Model at 4 months.","http://ClinicalTrials.gov/show/NCT00407537",NA
"31225",31225,"NCT00459537","Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis","Completed","No Results Available","Onychomycosis","Drug: terbinafine hydrogen chloride|Drug: amorolfine nail lacquer","Novartis","Both","Child|Adult|Senior","Phase III",1029,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSFO327N2303","April 10, 2007","01/03/2007",2009-01-01,"February 5, 2009","01/02/2009","",2009-01-01,"Efficacy assessed by complete cure rate (negative culture, negative KOH microscopy and no residual disease involvement) at the end of study (week 52) after treating patients for 48 weeks.|Efficacy assessed by mycological cure (negative culture and negative KOH microscopy) and clinical efficacy (less than 10% residual disease involvement) at the end of study after treating patients for 48 weeks.|Safety and tolerability assessed by adverse events and laboratory values.|Explore patient's satisfaction with medication using a validated questionnaire.","http://ClinicalTrials.gov/show/NCT00459537",NA
"31235",31235,"NCT00479037","Effect of PTH(1-84)or Strontium Ranelate in Postmenopausal Women w/Primary Osteoporosis (FP-006-IM)","Completed","No Results Available","Osteoporosis","Drug: Parathyroid hormone (PTH)","Nycomed","Female","Adult|Senior","Phase IV",70,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FP-006-IM|2006-006065-16","May 23, 2007","01/04/2007",2009-07-01,"October 19, 2010","01/10/2010","",2009-02-01,"Change in N-terminal Propeptides of Human Pro-collagen type I (P1NP) from baseline to end of treatment|Change in bone specific alkaline phosphatase (BSAP) from baseline to end of treatment|Change in C-telopeptide cross-links (CTX) from baseline to end of treatment","http://ClinicalTrials.gov/show/NCT00479037",NA
"31286",31286,"NCT00557037","A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: Phenoxodiol","Marshall Edwards, Inc","Male","Adult|Senior","Phase II",60,"Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Yale 0703002467","November 8, 2007","01/11/2007",2009-11-01,"April 6, 2010","01/04/2010","",2009-11-01,"The proportion of patients that have a 50% post-therapy PSA decline at 12 weeks in patients with: a)Chemotherapy na??ve androgen independent disease (Group A) b)Rising PSA after radical prostatectomy or radiotherapy that are androgen dependent (Group B)|To determine the proportion of patients treated with Phenoxodiol that has measurable disease regression at 12 weeks in patients with chemotherapy na??ve androgen independent disease.","http://ClinicalTrials.gov/show/NCT00557037",NA
"31319",31319,"NCT00607737","Applications Site Reactions After Injection of Insulin Detemir and Saline in Subjects With Diabetes","Completed","No Results Available","Diabetes Mellitus","Drug: insulin detemir|Drug: saline","Steno Diabetes Center|Novo Nordisk","Both","Adult","Phase IV",100,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","APPLY|EudraCT 2007-005677-59","January 23, 2008","01/01/2008",2010-07-01,"July 30, 2010","01/01/2008","APPLY",2009-06-01,"laser doppler blood flow|clinical signs|insulin detemir specific antibodies","http://ClinicalTrials.gov/show/NCT00607737",NA
"31351",31351,"NCT00658437","CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy","Completed","No Results Available","Melanoma","Drug: CY-503","Cytavis Biopharma GmbH","Both","Adult|Senior","Phase II",31,"Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CY503C1|EudraCT no. 2007-000427-17","April 9, 2008","01/04/2008",NA,"August 27, 2009","01/08/2009","",2009-08-01,"Tumor assessment by CT and MRT|Immunological response (e.g. measurement of cytokines in serum)|Assessment of quality of life using a standardized questionnaire","http://ClinicalTrials.gov/show/NCT00658437",NA
"31359",31359,"NCT00546637","Fesoterodine \add-on\"" Male Overactive Bladder Study""","Completed","Has Results","Overactive Bladder Syndrome","Drug: Fesoterodine|Drug: Placebo","Pfizer","Male","Adult|Senior","Phase III",947,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A0221009","October 18, 2007","01/11/2007",2009-02-01,"October 22, 2010","01/10/2010","",2009-02-01,"Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12|Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 4|Percentage Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12|Percentage Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12|Percentage Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12|Percentage Change From Baseline in UUI Episodes Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Severe Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12|Percentage Change From Baseline in Severe Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Nocturnal Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12|Percentage Change From Baseline in Nocturnal Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Urinary Sensation Scale (USS) Sum Rating Per 24 Hours at Week 4 and 12|Change From Baseline in International Prostate Symptom Score (IPSS) Total Score (Sum Question 1 [Q1] to Q7) Per 24 Hours at Week 4 and 12|Change From Baseline in IPSS Storage Domain (Sum Q2, Q4, and Q7) Per 24 Hours at Week 4 and 12|Change From Baseline in IPSS Voiding Domain (Sum Q1, Q3, Q5, and Q6) Per 24 Hours at Week 4 and 12|Change From Baseline in IPSS Quality of Life (QoL) Score (Q8) Per 24 Hours at Week 4 and 12|Change From Baseline in IPSS Individual Item Scores (Q1, Q2, Q3, Q4, Q5, Q6, and Q7) Per 24 Hours at Week 4|Change From Baseline in IPSS Individual Item Scores (Q1, Q2,Q3, Q4, Q5, Q6, and Q7) Per 24 Hours at Week 12|Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) Per 24 Hours at Week 4|Number of Participants With Change From Baseline in PPBC Per 24 Hours at Week 12|Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) Per 24 Hours at Week 4|Number of Participants With Change From Baseline in Change From Baseline in UPS Per 24 Hours at Week 12.|Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Per 24 Hours at Week 4 and 12|Change From Baseline in Total Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12|Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Concern Domain)|Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Coping Domain)|Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Sleep Domain)|Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Social Interaction Domain)|Change From Baseline in Post Void Residual (PVR) Urine Volume Per 24 Hours at Week 4, 8 and 12|Change From Baseline in Maximum Urinary Flow Rate (QMAX) Per 24 Hours at Week 12|Number of Participants Reporting Urinary Retention Requiring Catheterization (All Causalities)|Number of Participants Experiencing Adverse Events Related to Increased Voiding Difficulty (All Causalities)","http://ClinicalTrials.gov/show/NCT00546637",NA
"31379",31379,"NCT00696137","Long-term Extension Study of BEMA?ºÑ Fentanyl","Completed","No Results Available","Cancer|Pain","Drug: BEMA Fentanyl","BioDelivery Sciences International","Both","Adult|Senior","Phase III",5,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FEN-290","June 10, 2008","01/06/2008",2009-07-01,"July 29, 2009","01/07/2009","",2009-07-01,"Safety and tolerability of BEMA Fentanyl (any dose) as demonstrated by the occurrence of drug-related SAEs.","http://ClinicalTrials.gov/show/NCT00696137",NA
"31383",31383,"NCT00703937","Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia","Completed","No Results Available","Anemia","Drug: Ferric Carboxymaltose","Luitpold Pharmaceuticals","Both","Adult|Senior","Phase III",NA,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1VIT08019","June 20, 2008","01/06/2008",NA,"August 30, 2010","01/08/2010","",2009-08-01,"Safety and Tolerability","http://ClinicalTrials.gov/show/NCT00703937",NA
"31409",31409,"NCT00718237","Phase III Placebo-controlled Study of V260 (RotaTeq?ºÑ) in Japanese Healthy Infants (V260-029)(COMPLETED)","Completed","Has Results","Rotavirus|Gastroenteritis","Biological: Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq?ºÑ)|Biological: Comparator: Comparator: Placebo (unspecified)","Merck","Both","Child","Phase III",762,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2008_014|V260-029","July 16, 2008","01/08/2008",2009-09-01,"September 23, 2010","01/09/2010","",2009-09-01,"Efficacy Against Rotavirus Gastroenteritis of Any Severity Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1|Efficacy Against Moderate to Severe Rotavirus Gastroenteritis Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1A.|Efficacy Against Severe Rotavirus Gastroenteritis Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1A","http://ClinicalTrials.gov/show/NCT00718237",NA
"31439",31439,"NCT00792337","The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma","Completed","No Results Available","Asthma","Drug: simvastatin|Drug: B1-6-12","Mahidol University","Both","Adult|Senior","Phase III",53,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","004(II)/51","November 14, 2008","01/12/2008",2009-09-01,"September 17, 2009","01/09/2009","",2009-08-01,"Sputum eosinophil|FEV1|PC20","http://ClinicalTrials.gov/show/NCT00792337",NA
"31453",31453,"NCT00818337","Aspirin Responsiveness in Women at Risk for Cardiac Events","Completed","No Results Available","Heart Disease","Drug: Aspirin","Creighton University","Female","Adult|Senior","Phase IV",125,"Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","08-14888","January 6, 2009","01/11/2008",2009-06-01,"November 27, 2009","01/11/2009","",2009-06-01,"Primary outcome is percentage of women that are asa resistant","http://ClinicalTrials.gov/show/NCT00818337",NA
"31458",31458,"NCT00822237","Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process)","Completed","No Results Available","Varicella","Biological: Varicella Virus Vaccine Live (Oka-Merck)|Biological: Comparator: Varicella Virus Vaccine Live (1999) (Oka-Merck)|Biological: Comparator: measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live","Merck","Both","Child","Phase III",600,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2009_510|V210-057","January 9, 2009","01/01/2009",2009-12-01,"December 17, 2009","01/12/2009","",2009-10-01,"Varicella antibody levels post dose 1 of VARIVAX 2007 process","http://ClinicalTrials.gov/show/NCT00822237",NA
"31468",31468,"NCT00807937","Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325","Completed","Has Results","Anxiety Disorders","Drug: AZD7325|Drug: AZD7325|Drug: Lorazepam|Drug: Placebo","AstraZeneca","Both","Adult","Phase II",369,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1140C00014","December 12, 2008","01/12/2008",2009-05-01,"September 16, 2010","01/09/2010","",2009-05-01,"Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Change in Hospital Anxiety and Depression Scale for Anxiety (HADS-A) Total Score|Change in Psychic Anxiety Factor as Measured by HAM-A Psychic Cluster Score|Change in Somatic Symptoms as Measured by HAM-A Somatic Cluster Score|Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Percent Maximum Total Score","http://ClinicalTrials.gov/show/NCT00807937",NA
"31470",31470,"NCT00837837","Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents","Completed","No Results Available","Allergic Reactions","Drug: Chlorpheniramine","Wyeth","Both","Child","Phase II",36,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CF-08-01","February 4, 2009","01/12/2008",2009-02-01,"February 4, 2009","01/02/2009","",2009-02-01,"AUC and Cmax|Oral clearance (CL) and volume of distribution (Vd); time to reach Cmax (tmax), and apparent elimination constant (Kel) and half-life (t1/2).","http://ClinicalTrials.gov/show/NCT00837837",NA
"31478",31478,"NCT00852137","A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis","Completed","No Results Available","Actinic Keratosis","Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle Gel","Peplin","Both","Adult|Senior","Phase II",16,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","PEP005-017","February 22, 2009","01/03/2009",2009-06-01,"July 18, 2010","01/07/2010","",2009-06-01,"Cmax for ingenol mebutate, PEP015 and PEP025 levels|Tmax for ingenol mebutate, PEP015 and PEP025 levels|AUC(0-24) for ingenol mebutate, PEP015 and PEP025 levels|Incidence rate of AEs, serious adverse events (SAEs) and AEs leading to discontinuation of study medication throughout the study|Complete clearance rate; and % reduction in AK lesions, in a 25 cm2 area within the selected treatment area|Incidence rate and grade of LSRs, pigmentation and scarring following study medication application","http://ClinicalTrials.gov/show/NCT00852137",NA
"31507",31507,"NCT00835237","Evaluation of GlaxoSmithKline Biologicals' Boostrix?ó Vaccine in Comparison With Decavac?ºÑ Vaccine.","Completed","Has Results","Diphtheria|Pertussis|Diphtheria-Tetanus-acellular Pertussis Vaccines|Tetanus","Biological: Boostrix?ó|Biological: Decavac?ºÑ","GlaxoSmithKline","Both","Adult|Senior","Phase III",1332,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","111413","February 2, 2009","01/02/2009",2009-07-01,"December 2, 2010","01/12/2010","",2009-07-01,"Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value|Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration|Anti-T and Anti-D Antibody Concentrations|Number of Subjects With Vaccine Response for Anti-T and Anti-D Antibodies Concentrations Above the Cut-off|Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off|Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off, Using Alternative Definitions.|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Number of Subjects Reporting Serious Adverse Events (SAE)","http://ClinicalTrials.gov/show/NCT00835237",NA
"31543",31543,"NCT00961337","Evaluation of a School-based Influenza Vaccination Program","Completed","No Results Available","Influenza|Influenza Vaccines","Biological: Trivalent inactivated influenza vaccine","Centers for Disease Control, Taiwan|Public Health Bureau,Taoyan County Governmnet, Taiwan|Education Department,Taoyan County Governmnet, Taiwan","Both","Child","Phase IV",7854,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","DOH97-DC-2003","August 10, 2009","01/10/2008",2009-05-01,"August 17, 2009","01/08/2009","",2009-03-01,"Influenza attack rate|Children's absenteeism|Vaccine effectiveness|Side effects after vaccination","http://ClinicalTrials.gov/show/NCT00961337",NA
"31546",31546,"NCT00965237","Multifocal Pilot Study: Refitting Drop Outs","Completed","No Results Available","Presbyopia","Device: lotrafilcon B|Device: lotrafilcon B","Novartis","Both","Child|Adult|Senior","Phase IV",20,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","P-368-C-101","August 24, 2009","01/08/2009",2009-11-01,"February 2, 2010","01/02/2010","GARM",2009-11-01,"success rate of AIR OPTIX Multifocal lenses as determined by purchase intent","http://ClinicalTrials.gov/show/NCT00965237",NA
"31610",31610,"NCT01065337","Induced Wound Healing by Application of Expanded Bone Marrow Stem Cells in Diabetic Patients With Critical Limb Ischemia","Completed","No Results Available","Diabetic Foot","Biological: tissue repair cells (TRC)|Biological: bone marrow stem cells (BMC)","Ruhr University of Bochum","Both","Adult|Senior","Phase II",30,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HDZ-SBE-2004","February 8, 2010","01/08/2005",2009-02-01,"February 9, 2010","01/09/2006","",2009-02-01,"The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred|Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ankle brachial index (ABI) Improvement of transcutaneous oxygen partial pressure (TcPO2) Improvement of local perfusion","http://ClinicalTrials.gov/show/NCT01065337",NA
"31612",31612,"NCT01070537","Evaluation of the Bonfils Fiberscope for Predicted Difficult Intubation in Awake Patients With Ear, Nose, and Throat (ENT) Cancer (INVIBO)","Completed","No Results Available","Carcinoma","Device: Bonfils fiberscope intubation","Centre Leon Berard","Both","Adult|Senior","Phase II",41,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment","INVIBO|ET2007-036","February 15, 2010","01/02/2008",2009-04-01,"February 17, 2010","01/02/2010","INVIBO",2009-04-01,"The rate of BFI meeting quality requirements: the procedure must be successful on the one hand (??? 2 attempts and duration < 180 sec); and well tolerated on the other hand (Fahey score < 2).|Number of well-tolerated BFI procedures|Duration of the intubation procedure among patients with a successful BFI (??? 2 attempts and duration < 180 sec)|Frequency and type of difficulties met by the operator|Frequency and type of adverse events experienced by the patient|Patient's perception of the intubation procedure","http://ClinicalTrials.gov/show/NCT01070537",NA
"31623",31623,"NCT01091337","Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room","Completed","No Results Available","Asthma","Drug: Procaterol|Drug: Salbutamol","Otsuka Pharmaceutical, Inc., Philippines","Both","Adult|Senior","Phase IV",96,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KOIAA-MPT-2005-01","March 5, 2010","01/05/2006",2009-09-01,"March 22, 2010","01/03/2010","",2009-09-01,"To evaluate the bronchodilator efficacy of inhaled procaterol (Meptin Air) vs. inhaled salbutamol used as MDI reliever of acute exacerbation of asthma in the ER.|To evaluate the safety of procaterol MDI (Meptin Air) versus salbutamol MDI in the management of acute exacerbation of asthma in terms of adverse side effects such as palpitations, tachycardia, tremor, and hypokalemia.","http://ClinicalTrials.gov/show/NCT01091337",NA
"31634",31634,"NCT01112137","Effects of Clopidogrel on Blood Pressure","Completed","No Results Available","Blood Pressure|Endothelial Function|Platelet Function","Drug: Clopidogrel|Drug: Clopidogrel|Drug: Clopidogrel|Drug: Clopidogrel","University of Cologne","Both","Adult|Senior","Phase IV",46,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","NLN5031","April 26, 2010","01/01/2005",2010-04-01,"April 27, 2010","01/04/2010","",2009-12-01,"blood pressure|markers of platelet and endothelial function","http://ClinicalTrials.gov/show/NCT01112137",NA
"31698",31698,"NCT01218737","Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation","Completed","No Results Available","Infection and Inflammation After Refractive Surgery (Lasik).","Drug: 0.3% gatifloxacin and 1.0% prednisolone acetate association|Drug: isolated 0.3% gatifloxacin and 1.0% prednisolone acetate","Federal University of S??o Paulo|Allergan","Both","Adult","Phase III",101,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG9890X-001","October 8, 2010","01/01/2009",2009-06-01,"October 14, 2010","01/10/2010","-",2009-06-01,"Percentage of eyes with absence of signs/symptoms of ocular infection/inflammation after surgery.","http://ClinicalTrials.gov/show/NCT01218737",NA
"31799",31799,"NCT00026338","Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: erlotinib hydrochloride|Drug: gemcitabine hydrochloride","NCIC Clinical Trials Group","Both","Adult|Senior","Phase III",NA,"Other","Interventional","Primary Purpose: Treatment","PA3|CAN-NCIC-PA3|OSI-CAN-NCIC-PA3|CDR0000069020","November 9, 2001","01/08/2001",2009-02-01,"November 7, 2010","01/03/2010","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00026338",NA
"31820",31820,"NCT00062738","Treatment of Depression in Parkinson's Disease Trial","Completed","No Results Available","Parkinson Disease|Depression","Drug: paroxetine|Drug: nortirptyline","University of Medicine and Dentistry New Jersey|GlaxoSmithKline","Both","Adult|Senior","Phase II",52,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","4381","June 12, 2003","01/06/2003",2009-01-01,"September 9, 2009","01/04/2009","",2009-01-01,"Hamilton Depression Scale|Percent responders","http://ClinicalTrials.gov/show/NCT00062738",NA
"31948",31948,"NCT00260338","Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia","Completed","No Results Available","Myocardial Ischemia|Coronary Heart Disease","Drug: stem cell","Rigshospitalet, Denmark","Both","Adult|Senior","Phase I|Phase II",40,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Jens Kastrup","November 29, 2005","01/12/2005",2009-02-01,"July 7, 2009","01/07/2009","",2009-02-01,"Improvement in myocardial perfusion measured by SPECT|Safety|Improvement in myocardial perfusion and function measured by PET and MR|Exercise time|Clinical angina status","http://ClinicalTrials.gov/show/NCT00260338",NA
"32007",32007,"NCT00352638","Educational Intervention With or Without Telephone Counseling in Increasing Colorectal Cancer Screening Compliance in Brothers and Sisters of Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Other: counseling intervention|Other: educational intervention|Other: study of socioeconomic and demographic variables","Fox Chase Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",660,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control","CDR0000485294|FCCC-FCRB-04-004-P|FCCC-00-841","July 13, 2006","01/08/2005",NA,"July 9, 2009","01/05/2007","",2009-03-01,"Colorectal cancer screening compliance|Impact on movement in stage of adoption|Increased knowledge and attitudes|Cost","http://ClinicalTrials.gov/show/NCT00352638",NA
"32028",32028,"NCT00381238","Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: rosiglitazone maleate","GlaxoSmithKline","Both","Adult|Senior","Phase II",33,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AVA104617","September 26, 2006","01/06/2006",2009-02-01,"September 3, 2010","01/09/2010","",2009-02-01,"Long term safety and tolerability of rosiglitazone (RSG) XR.|Long-term efficacy of RSG XR in terms of orientation, memory (recent and immediate), concentration, language and praxis.|Frequency of serious adverse events.|Percentage of subjects with adverse event of edema|Change from baseline in vital signs. Frequency of vital signs of clinical concern.|Change from baseline in weight.|Frequency of clinical chemistry (including lipids) and hematology parameters of clinical concern.","http://ClinicalTrials.gov/show/NCT00381238",NA
"32045",32045,"NCT00413738","Prevention of Catheter-Related Bloodstream Infection in Patients With Hemato-Oncological Disease","Completed","No Results Available","Infection","Device: Antiseptic-coated central venous catheters","Centre National de Greffe de Moelle Osseuse","Both","Child|Adult","Phase III",NA,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","Catheters04","December 19, 2006","01/12/2006",2009-01-01,"January 26, 2009","01/01/2009","",2009-01-01,"The primary outcome of this prospective randomised controlled trial is to compare the incidence of catheter-related bloodstream infection in 2 groups of patients with hemato-oncological disease:|Group A: heparin-coated central venous catheters (Control Group)|Group B: antiseptic-coated (chlorhexidine-silver sulfadiazine) central venous catheters|Analysis of variables that may be significant for the development of CRBI (age, gender, underlying disease...)","http://ClinicalTrials.gov/show/NCT00413738",NA
"32110",32110,"NCT00520338","Celecoxib for Reducing Morphine Requirement After Thyroid Surgery: A Randomized Controlled Trial","Completed","No Results Available","Postoperative Pain|Thyroidectomy|Cyclooxygenase 2 Inhibitors","Drug: celecoxib","Mahidol University","Both","Adult|Senior","Phase IV",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Si 117/2007","August 22, 2007","01/08/2007",2009-12-01,"November 6, 2010","01/11/2010","",2009-12-01,"The patients' total amount of morphine requirement in the first 24 hour.","http://ClinicalTrials.gov/show/NCT00520338",NA
"32171",32171,"NCT00420238","Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis","Completed","Has Results","Ankylosing Spondylitis","Drug: Etanercept (Enbrel)|Other: Placebo","Wyeth","Both","Adult|Senior","Phase IV",82,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","0881A3-403","January 8, 2007","01/01/2007",2009-05-01,"June 24, 2010","01/06/2010","",2009-02-01,"Normalized Net Incremental Area Under the Curve (AUC) for the Bath Ankylosing Spondylitis Disease Activities Index (BASDAI) Between Randomization and Week 12|Percent of Subjects Achieving Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response|Percent of Subjects Achieving Assessment Ankylosing Spondylitis (ASAS) 20 at Weeks 2, 4, 8, 12|Percent of Subjects Acheiving Assessment Ankylosing Spondylitis (ASAS) 20 at Weeks 14, 18, 24|Percent of Subjects Achieving Assessment Ankylosing Spondylitis (ASAS) 50 at Weeks 2, 4, 8, 12|Percent of Subjects Achieving Assessment Ankylosing Spondylitis (ASAS) 50 at Weeks 14, 18, 24|Percent of Subjects Achieving Assessment Ankylosing Spondylitis (ASAS) 70 at Weeks 2, 4, 8, 12|Percent of Subjects Achieiving Assessment Ankylosing Spondylitis (ASAS) 70 at Weeks 14, 18, 24|Percent of Subjects Achieving Partial Remission at Weeks 2, 4, 8, 12|Percent of Subjects Achieving Partial Remission at Weeks 14, 18, 24|Normalized Net Incremental Area Under the Curve (AUC) for Patient Global Assessment (PGA) Between Baseline and Week 12|Change From Baseline in Patient Global Assessment Visual Analog Scale (VAS) at Weeks 2, 4, 8, 12|Change From Baseline in Patient Global Assessment at Weeks 14, 18, 24|Normalized Net Incremental Area Under the Curve (AUC) for Physician Global Assessment (PGA) Between Baseline and Week 12|Change From Baseline in Physician Global Assessment Visual Analog Scale at Weeks 2, 4, 8, 12|Change From Baseline in Physician Global Assessment at Weeks 14, 18, 24|Normalized Net Incremental Area Under the Curve (AUC) for Nocturnal Back Pain Between Baseline and Week 12|Change From Baseline in Nocturnal Back Pain at Weeks 2, 4, 8, 12|Change From Baseline in Nocturnal Back Pain at Weeks 14, 18, 24|Normalized Net Incremental Area Under the Curve (AUC) for Total Back Pain Between Baseline and Week 12|Change From Baseline in Total Back Pain at Weeks 2, 4, 8, 12|Change From Baseline in Total Back Pain at Weeks 14, 18, 24|Normalized Net Incremental Area Under the Curve (AUC) for the Bath Ankylosing Spondylitis Functional Index (BASFI) Between Baseline and Week 12|Change From Baseline in the Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, 8, 12|Bath Ankylosing Functional Index (BASFI): Independent Components at Weeks 2, 4, 8, 12|Bath Ankylosing Functional Index (BASFI) Independent Components at Weeks 14, 18, 24|Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Weeks 2, 4, 8, 12|Change From Baseline in the Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI) at Weeks 14, 18, 24|Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI) Independent Components at Weeks 2, 4, 8, 12|Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI) Independent Components at Weeks 14, 18, 24|Normalized Net Incremental Area Under the Curve (AUC) for Bath Ankylosing Spondylitis-Global Score (BAS-G) Visual Analog Scale Between Baseline and Week 12|Change From Baseline in the Bath Ankylosing Spondylitis-Global Score (BAS-G) at Weeks 2, 4, 8, 12|Change From Baseline in the Bath Ankylosing Spondylitis-Global Score (BAS-G) at Weeks 14, 18, 24|Bath Ankylosing Spondylitis Global Score (BAS-G) Independent Component: Effect of Disease on Well-being at Weeks 2, 4, 8, 12|Change From Baseline to Week 12 in Forced Vital Capacity (FVC), Vital Capacity (VC), and Forced Expiratory Volume in One Second (FEV1)|Change From Baseline to Week 12 in Ratio Forced Expitatory Volume in One Second (FEV1)/Forced Vital Capacity (FVC) (%)|Normalized Net Incremental Area Under the Curve (AUC) for the Bath Ankylosing Spondylitis Metrology Index (BASMI) Between Baseline and Week 12|Change From Baseline in Spinal Mobility Measured With the Bath Ankylosing Spondylitis Metrology Index (BASMI) at Weeks 2, 4, 8, 12|Change From Baseline in Spinal Mobility Measured With the Bath Ankylosing Spondylitis Metrology Index (BASMI) at Weeks 14, 18, 24|Bath Ankylosing Spondylitis Metrology Index (BASMI) Independent Component: Cervical Rotation at Weeks 2, 4, 8, 12|Bath Ankylosing Spondylitis Metrology Index (BASMI): Spinal Mobility Measured With Cervical Rotation at Weeks 14, 18, 24|Bath Ankylosing Spondylitis Metrology Index (BASMI) Independent Component: Spinal Mobility Measured With Tragus-to-wall Distance at Baseline and Weeks 2, 4, 8, 12|Bath Ankylosing Spondylitis Metrology Index (BASMI): Spinal Mobility Measured With Tragus-to-wall Measurement at Weeks 14, 18, 24|Bath Ankylosing Spondylitis Metrology Index (BASMI) Independent Component: Spinal Mobility Measured With Lateral Flexion at Baseline and Weeks 2, 4, 8, and 12|Bath Ankylosing Spondylitis Metrology Index (BASMI): Spinal Mobility Measured With Lateral Flexion at Weeks 14, 18, 24|Bath Ankylosing Spondylitis Metrology Index (BASMI) Independent Component: Spinal Mobility Measured With Modified Schober's Test at Baseline and Weeks 2, 4, 8, 12|Bath Ankylosing Spondylitis Metrology Index (BASMI): Spinal Mobility Measured With Modified Schober's Test at Weeks 14, 18, 24|Bath Ankylosing Spondylitis Metrology Index (BASMI) Independent Component: Spinal Mobility Measured With Intermalleolar Distance at Baseline and Weeks 2, 4, 8, 12|Bath Ankylosing Spondylitis Metrology Index (BASMI): Spinal Mobility Measured With Intermalleolar Distance at Weeks 14, 18, 24|Normalized Net Incremental Area Under the Curve (AUC) for the Chest Expansion Test Between Baseline and Week 12|Change From Baseline in the Chest Expansion Test at Weeks 2, 4, 8, 12|Change From Baseline in the Chest Expansion Test at Weeks 14, 18, 24|Change From Baseline in Level of Difficulty to Perform Physically Demanding Activities Due to Ankylosing Spondylitis at Weeks 2, 4, 8, 12|Change From Baseline in Self Assessment of Ability and or Easiness to Perform Physically Demanding Activities at Weeks 14, 18, 24|Normalized Net Incremental Area Under the Curve (AUC) for Erythtocyte Sedimentation Rate Between Baseline and Week 12|Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Weeks 2, 4, 8, 12|Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Weeks 14, 18, 24|Normalized Net Incremental Area Under the Curve (AUC) for C-reactive Protein Between Baseline and Week 12|Change From Baseline in C-reactive Protein (CRP) at Weeks 2, 4, 8, 12|Change From Baseline in C-reactive Protein (CRP) at Weeks 14, 18, 24|Percent of Subjects With Normal and Abnormal C-Reactive Protein at Weeks 14, 18, 24|Percent of Subjects With Patient Acceptable and Unacceptable Symptom State (PASS) at Weeks 2, 4, 8, 12|Percent of Subjects With Patient Acceptable and Unacceptable Symptom State (PASS) at Weeks 14, 18, 24|Percent of Subjects With Minimum Clinically Important Improvement (MCII) in Pain Rating at Weeks 2, 4, 8, 12|Percent of Subjects With Minimum Clinially Important Improvement (MCII) at Weeks 14, 18, 24","http://ClinicalTrials.gov/show/NCT00420238",NA
"32212",32212,"NCT00681538","A Study of the Safety and Effectiveness of Sativex?ó, for the Relief of Symptoms of Spasticity in Subjects With Multiple Sclerosis (MS)","Completed","No Results Available","Spasticity|Multiple Sclerosis","Drug: Sativex?ó|Drug: Placebo","GW Pharmaceuticals Ltd.","Both","Adult|Senior","Phase III",488,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","GWSP0604","May 19, 2008","01/01/2008",2009-01-01,"March 1, 2010","01/03/2010","",2009-01-01,"The mean spasticity NRS score over the last seven days of the evaluable period.|Proportion of subjects showing an improvement of 30% or more and 50% or more in their primary endpoint from baseline.|Spasm frequency (number of spasms per day).|Sleep disruption (daily 11-point NRS).|Modified Ashworth Scale.|Motricity Index|Timed 10-metre walk.|Barthel Activities of Daily Living (ADL) Index.|Carer, Physician and Subject global impressions of change.|Carer global impressions of change for ease of transfer.|Spasm frequency (number of spasms per day).|Adverse events (AEs).|Clinical laboratory tests.|Vital signs.|Oral Examination.|QOL Assessments: EuroQoL quality of life questionnaire (EQ-5D); Short Form 36 Health Survey (SF-36).|Mood Assessment: Beck Depression Inventory - II (BDI-II)","http://ClinicalTrials.gov/show/NCT00681538",NA
"32224",32224,"NCT00704938","Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer","Completed","No Results Available","Kidney Cancer|Melanoma (Skin)|Unspecified Adult Solid Tumor, Protocol Specific","Biological: aldesleukin|Biological: anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Biological: autologous dendritic cell-adenovirus p53 vaccine|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",82,"NIH","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Masking: Open Label|Primary Purpose: Treatment","CDR0000598419|NCI-08-C-0155|NCI-P07215","June 24, 2008","01/06/2008",NA,"September 4, 2009","01/10/2008","",2009-08-01,"Clinical tumor regression|In vivo survival of T-cell receptor (TCR) gene-engineered cells|Ability of a dendritic cell vaccine to restimulate TCR gene-engineered cells in vivo|Toxicity","http://ClinicalTrials.gov/show/NCT00704938",NA
"32251",32251,"NCT00652938","Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects","Completed","Has Results","Papillomavirus Vaccines|Human Papillomavirus Infection","Biological: HPV Vaccine (GSK580299) Cervarix TM|Biological: Engerix B","GlaxoSmithKline","Female","Child","Phase III",744,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","111507","March 27, 2008","01/04/2008",2009-08-01,"January 6, 2011","01/01/2011","",2009-08-01,"Number of Subjects With Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above the Cut-off Value for Seroprotection|Number of Subjects With Anti-human Papillomavirus 16 and 18 (Anti-HPV-16 and Anti-HPV-18) Antibody Concentrations Above the Cut-off Value for Seroconversion|Anti-HPV-16/18 Antibody Titres|Number of Subjects With Anti-HBs Antibody Concentrations Above the Cut-off Value for Seroconversion|Anti-HBs Antibody Titres|Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations Above the Cut-off Value for Seroconversion|Anti-HPV-16/18 Antibody Titres|Number of Subjects With Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above the Cut-off Value for Seroconversion|Number of Subjects With Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above the Cut-off Value for Seroprotection|Anti-HBs Antibody Titers|Number of Subjects Reporting Any Solicited Local Symptoms|Number of Subjects Reporting Grade 3 Solicited Local Symptoms|Number of Subjects Reporting Any Solicited General Symptoms|Number of Subjects Reporting Grade 3 Solicited General Symptoms|Number of Subjects Reporting Related Solicited General Symptoms|Number of Subjects Reporting Any, Grade 3 and Causally Related to Vaccination Unsolicited Adverse Events (AEs)|Number of Subjects Reporting Any and Causally Related to Vaccination Serious Adverse Events (SAEs)|Number of Subjects Reporting Any and Causally Related to Vaccination SAEs|Number of Subjects Reporting Medically Significant Conditions|Number of Subjects Reporting Medically Significant Conditions","http://ClinicalTrials.gov/show/NCT00652938",NA
"32271",32271,"NCT00776438","Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines","Completed","No Results Available","Influenza|Orthomyxovirus Infections|Myxovirus Infection","Biological: Inactivated, split-virion, influenza vaccine|Biological: Inactivated, split-virion, influenza vaccine|Biological: Inactivated, split-virion influenza vaccine|Biological: Inactivated, split-virion influenza vaccine","Sanofi-Aventis","Both","Adult|Senior","Phase II",160,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","GID25","October 17, 2008","01/09/2007",2009-04-01,"February 9, 2010","01/02/2010","",2009-02-01,"To provide information concerning immune response to an inactivated, split-virion, influenza vaccine.|To provide information concerning the safety of inactivated, split-virion, influenza vaccine.","http://ClinicalTrials.gov/show/NCT00776438",NA
"32273",32273,"NCT00775138","A Study to Determine the Safety and Tolerability of Arikace?ºÑ Versus Placebo in Patients Who Have Bronchiectasis.","Completed","No Results Available","Bronchiectasis","Drug: Arikace 280 mg|Drug: Arikace 560 mg|Drug: Matching Placebo","Insmed","Both","Adult|Senior","Phase I|Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","TR02-107","October 15, 2008","01/06/2008",2009-05-01,"July 14, 2009","01/07/2009","",2009-05-01,"Treatment emergent adverse events up to end of treatment|Treatment emergent marked laboratory abnormalities up to 28 days after study medication discontinuation|Treatment emergent pulmonary function test (PFT) abnormalities post-dose for acute tolerability assessment|Treatment emergent pulmonary function test (PFT) abnormalities up to end of treatment|Adverse events leading to permanent discontinuation of study medication|Serious adverse events up to 28 days after study medication discontinuation|To access pharmacokinetics (PK) of Arikace?ºÑ in serum and urine, and evaluate sputum amikacin levels|To evaluate change in Pulmonary function|To evaluate change in density of Pseudomonas aeruginosa in sputum|To evaluate time to and duration of systemic anti-Pseudomonal rescue therapy|To evaluate change in St. George's Respiratory Questionnaire measurements","http://ClinicalTrials.gov/show/NCT00775138",NA
"32277",32277,"NCT00786838","A Placebo-Controlled Study Evaluating the Potential Effects of Trabectedin on the Heart in Patients With Advanced Cancer","Completed","No Results Available","Neoplasm Metastases","Drug: Trabectedin, YONDELIS?ó","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar","Both","Adult","Phase I|Phase II",76,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Single Blind|Primary Purpose: Treatment","CR014917","November 4, 2008","01/10/2008",2009-12-01,"September 23, 2010","01/09/2010","",2009-12-01,"The purpose of the study is to determine the effects of trabectedin on the heart's electrical cycle as measured by electrocardiograms (ECGs) in patients with advanced cancer.|Assess the safety and pharmacokinetics of trabectedin.","http://ClinicalTrials.gov/show/NCT00786838",NA
"32310",32310,"NCT00841438","Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction","Completed","No Results Available","Myocardial Infarction","Drug: Clotinab|Drug: Clotinab","Yonsei University|ISU ABXIS (Korea pharmaceutical company)","Both","Adult|Senior","Phase IV",786,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","ISU-CLT-07001","February 10, 2009","01/07/2007",2009-12-01,"May 3, 2010","01/02/2009","ECLAT-STEMI",2009-12-01,"MACCE (death, MI, TVR, cerebrovascular event)|MACCE (death, MI, TVR, cerebrovascular event)|TIMI flow at before and after PCI|Corrected TIMI frame count after PCI","http://ClinicalTrials.gov/show/NCT00841438",NA
"32311",32311,"NCT00846638","Women's Health Habits Study","Completed","No Results Available","Risk Drinking,Diabetes, Hypertension, Osteoporosis, Infertility","Behavioral: Brief Intervention|Behavioral: Diagnostic assessment","Brigham and Women's Hospital|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Office of Research on Women's Health (ORWH)","Female","Adult|Senior","Phase III",611,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","NIAAA-Chang-AA014678|R01AA014678|NIH Grant R01AA014678","February 18, 2009","01/01/2005",2009-05-01,"May 6, 2010","01/05/2010","WHHS",2009-05-01,"Drinking outcome","http://ClinicalTrials.gov/show/NCT00846638",NA
"32313",32313,"NCT00847938","Comparision of Different Dose of Neostigmine at Advanced Decurarization","Completed","No Results Available","Anesthesia","Drug: neostigmine|Drug: neostigmine|Drug: neostigmine","Centre Hospitalier Departemental Vendee","Both","Adult|Senior","Phase III",72,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHD066-08","February 18, 2009","01/03/2009",2009-11-01,"November 30, 2009","01/11/2009","NEODEC",2009-10-01,"mesure of the train of four, vitals signs, electrocardiogramm, bispectral index of Electro-encephalogram measuring the depth of anesthesia","http://ClinicalTrials.gov/show/NCT00847938",NA
"32322",32322,"NCT00864838","Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab","Completed","No Results Available","Age Related Macular Degeneration|Diabetic Retinopathy","Drug: Acetazolamide|Drug: Brimonidine tartarate|Procedure: Anterior chamber paracentesis","University of Sao Paulo|Funda????o de Apoio ao Ensino Pesquisa e Assit??ncia do HCFMRPUSP","Both","Adult|Senior","Phase II",56,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","4429/2008","March 18, 2009","01/06/2008",2009-03-01,"March 18, 2009","01/03/2009","",2009-02-01,"Intraocular pressure (mmHg)","http://ClinicalTrials.gov/show/NCT00864838",NA
"32345",32345,"NCT00901238","Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma","Completed","No Results Available","Retinoblastoma","Procedure: Intra-arterial Chemotherapy","Weill Medical College of Cornell University|Memorial Sloan-Kettering Cancer Center","Both","Child|Adult|Senior","Phase I|Phase II",100,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTB1","May 12, 2009","01/05/2006",2009-07-01,"December 16, 2009","01/12/2009","Chemosurgery",2009-07-01,"tumor control|tumor control with vision","http://ClinicalTrials.gov/show/NCT00901238",NA
"32353",32353,"NCT00855738","A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice","Completed","Has Results","Focal Epilepsy","Drug: Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide","Pfizer","Both","Adult|Senior","Phase IV",111,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A0081144|LICEO STUDY","March 3, 2009","01/05/2007",2009-06-01,"November 23, 2010","01/11/2010","",2009-06-01,"Percent of Participants Classified as Responders|Percent of Participants With Reduction in Number of Seizures >=25% and >=75% During the Last 3 Months of Treatment|Percent of Seizure-free Participants During the Last 3 Months Before Discontinuation|Percent Change From Baseline in the Median Number of Seizures During the Last 3 Months of Treatment|Percent of Days Without Crisis During the Study|Time to First Seizure|Percent of Participants Who Continued on Study Medication to Month 6|Time to Discontinuation Due to Lack of Efficacy|Time to Discontinuation Due to Safety, Tolerability, or Treatment Compliance|Time to Discontinuation Due to Other Reasons|Treatment Satisfaction Evaluated by Patient Global Impression of Change Visual Analog Scale (VAS)|Percent of Participants Reaching Monotherapy|Percent of Participants That Reduced, Maintained and Increased Their Doses of New Antiepileptic Drugs (AED)|Percent of Participants That Reduced, Maintained and Increased the Doses of the Initial Treatment Administered in Monotherapy|Change From Baseline to Month 6 in the Hospital Anxiety and Depression Scale (HADS)|Change From Baseline to Month 6 in Quality of Life 10 Domains (QOLIE-10)|Change From Baseline to Months 3 and 6 in Health Condition: Euro Quality of Life Scale (EQ-5D) Visual Analog Scale (VAS)|Change in Sleep Disturbances From Baseline to Month 6: Medical Outcomes Study Sleep Scale (MOS-SS)|Percent of Participants Indicating Optimal Sleep on the Optimal Sleep Subscale: Medical Outcomes Study Sleep Scale (MOS-SS)|Change From Baseline to Month 6 in Visits to a Specialist or the Emergency Room Because of Epilepsy|Change From Baseline to Month 6 in Total Number of Days Hospitalized Because of Epilepsy|Percent of Participants With Cessation of Occupation, Requirement of Caregiver, or Admission to Intensive Care Unit","http://ClinicalTrials.gov/show/NCT00855738",NA
"32359",32359,"NCT00833638","A Study in Erectile Dysfunction","Completed","Has Results","Erectile Dysfunction","Drug: Placebo|Drug: Tadalafil","Eli Lilly and Company","Male","Adult|Senior","Phase IV",372,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","12719|H6D-US-LVHZ","January 30, 2009","01/02/2009",2009-06-01,"August 18, 2010","01/08/2010","",2009-06-01,"Earliest Onset Day Measured by Cumulative Percentage of Participants With Yes Response to Sexual Encounter Profile Diary Question 3|Sexual Encounter Profile Diary Question Number 1, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses|Sexual Encounter Profile Diary Question Number 2, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses|Sexual Encounter Profile Diary Question Number 3, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses|Sexual Encounter Profile Diary Question Number 4, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses|Sexual Encounter Profile Diary Question Number 5, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses|Sexual Encounter Profile Diary Question 3, the Overall Distribution of Time to Onset by Yes Responses|Sexual Encounter Profile Diary Question 3, Daily Cumulative Percentage of Successful Intercourse Attempts|Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind and Open-label Periods for Participants Who Were Assigned to Placebo in the Double-blind Treatment Period|Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 2.5 mg in the Double-blind Treatment Period|Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 5 mg in the Double-blind Treatment Period|Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind Period and the Open-label Period for Participants Who Didn't Respond to Tadalafil 2.5 mg During Double-blind Period","http://ClinicalTrials.gov/show/NCT00833638",NA
"32373",32373,"NCT00944138","8-week Pilot Study of Relaxation for Weight Loss in Adults With Chronic Kidney Disease","Completed","No Results Available","Obesity","Behavioral: Relaxation methods","Edward Hines Jr. VA Hospital","Both","Adult|Senior","Phase III",20,"U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PROMISE#0001","July 21, 2009","01/07/2009",2009-10-01,"July 26, 2010","01/07/2009","",2009-10-01,"weight, waist circumference, measures of stress and mood and overall satisfaction","http://ClinicalTrials.gov/show/NCT00944138",NA
"32374",32374,"NCT00945438","Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)","Completed","No Results Available","Influenza","Biological: Influenza virus vaccine 2009-2010 formulation|Biological: Influenza virus vaccine 2009-2010 formulation","Sanofi-Aventis","Both","Adult|Senior","Phase II",131,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","GID29","July 22, 2009","01/05/2009",2009-07-01,"July 23, 2009","01/07/2009","",2009-06-01,"To provide information concerning the immunogenicity of Intradermal (ID) Influenza vaccine (split virion, inactivated), NH 2009-2010 formulation.|To provide information concerning the safety of Intradermal (ID) Influenza vaccine (split virion, inactivated), NH 2009-2010 formulation.","http://ClinicalTrials.gov/show/NCT00945438",NA
"32422",32422,"NCT01015638","Study to Compare the Tolerance of Clindamycin 1% and Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2% and BPO 2.5% Topical Acne Medications","Completed","No Results Available","Acne Vulgaris","Drug: clindamycin and benzoyl peroxide 5% gel|Drug: clindamycin phosphate and benzoyl peroxide 2.5% gel.","Stiefel, a GSK Company","Both","Adult","Phase IV",36,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","C0000-409","November 17, 2009","01/08/2009",2009-09-01,"November 17, 2009","01/11/2009","",2009-09-01,"To determine and compare the tolerability and irritation potential of clindamycin and benzoyl peroxide 5%) and clindamycin phosphate and benzoyl peroxide 2.5% using visual assessments by an independent blinded grader.|To assess potential changes in the integrity of stratum corneum barrier and skin surface hydration and to assess subject tolerability through a skin assessment questionnaire and the Product Acceptability and Preference Questionnaire.","http://ClinicalTrials.gov/show/NCT01015638",NA
"32637",32637,"NCT00022139","Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: carboplatin|Drug: fluorouracil|Drug: paclitaxel|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000068789|NCCTG-N0044","August 10, 2001","01/01/2002",NA,"February 4, 2009","01/09/2007","",2009-01-01,"Proportion of successes|Toxicity-free rate|Clinical tumor response|Pathologic tumor response|Time to disease progression|Surgical outcome|Survival|Time to treatment failure|Quality of life","http://ClinicalTrials.gov/show/NCT00022139",NA
"32663",32663,"NCT00059839","Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma","Completed","No Results Available","Lymphoma","Drug: doxorubicin hydrochloride|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: vinblastine sulfate|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase III",200,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000298777|COG-ANHL0131","May 6, 2003","01/11/2003",NA,"November 20, 2010","01/11/2010","",2009-12-01,"Event-free survival|Toxicity|Overall survival|Disease response","http://ClinicalTrials.gov/show/NCT00059839",NA
"32707",32707,"NCT00130039","Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II","Completed","Has Results","Cerebral Infarction|Atherosclerosis","Drug: clopidogrel|Drug: Cilostazol","Asan Medical Center|Korea Otsuka International Asia Arab","Both","Adult|Senior","Phase IV",457,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TOSS-2","August 11, 2005","01/08/2005",2009-01-01,"January 4, 2010","01/11/2009","TOSS-2",2009-01-01,"Number of Participants With Progression of Symptomatic Intracranial Stenosis|Number of Participants With New MRI (Magnetic Resonance Image) Lesions on Follow-up MRI|Number of Participants With Stroke Events|Number of Participants With Overall Cardiovascular Events|Number of Patients With Ipsilateral Ischemic Stroke Rate|Numbers of Fatal or Major Bleeding Complications","http://ClinicalTrials.gov/show/NCT00130039",NA
"32762",32762,"NCT00221039","Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A","Completed","No Results Available","Cutaneous T Cell Lymphoma|Mycosis Fungoides","Drug: UVADEX (methoxsalen) Solution with UVAR XTS Photopheresis","Therakos|Departments of Dermatology University of Texas M D Anderson Cancer Center|Boston Medical Center|University of Pittsburgh|Case Western Reserve University|Vanderbilt University|University of Minnesota - Clinical and Translational Science Institute|Rush Medical Center","Both","Adult|Senior","Phase IV",19,"Industry|Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ECTCL1","September 13, 2005","01/09/2004",2009-02-01,"March 31, 2010","01/03/2010","",2009-02-01,"The primary endpoint will be the overall response based on skin-weighted assessment.|Time to response|Duration of response|Quality of life","http://ClinicalTrials.gov/show/NCT00221039",NA
"32778",32778,"NCT00245739","TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (\TMC114/r\"") With Other Antiretrovirals","Completed","No Results Available","HIV Infections","Drug: TMC-114","Tibotec Pharmaceuticals, Ireland","Both","Adult|Senior","Phase III",2960,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR006304|0034476","October 27, 2005","01/10/2005",2009-09-01,"January 21, 2010","01/01/2010","",2009-09-01,"Evaluation of safety and tolerability of TMC114/r with other antiretrovirals|The secondary objective is to gather information on the safety and tolerability of TMC114 in combination with low-dose RTV and other ARVs during the course of this study.","http://ClinicalTrials.gov/show/NCT00245739",NA
"32838",32838,"NCT00334139","Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer","Completed","No Results Available","Prostate Cancer|Breast Cancer|Bone Metastasis","Drug: Zoledronic Acid","Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",411,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CZOL446EDE28","June 2, 2006","01/06/2006",NA,"February 15, 2010","01/02/2010","",2009-07-01,"Bone turnover assessed by bone turnover parameters|Pain|Change in prostate specific antigen|Quality of Life|Correlation between pain and bone turnover|Correlation between bone complications and bone turnover","http://ClinicalTrials.gov/show/NCT00334139",NA
"32869",32869,"NCT00384839","Vidaza to Restore Hormone Thx Prostate","Completed","No Results Available","Prostate Cancer","Drug: azacitidine for injectable suspension","US Oncology Research|Celgene Corporation|USC/Norris Comprehensive Cancer Center","Male","Adult|Senior","Phase II",36,"Industry|Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","5015","October 4, 2006","01/04/2006",2009-11-01,"April 5, 2010","01/04/2010","",2009-11-01,"To determine if Vidaza can convert hormone-refractory prostate cancer to a hormone-responsive state","http://ClinicalTrials.gov/show/NCT00384839",NA
"32876",32876,"NCT00392639","Clinical and Economical Interest of Endovascular Cooling in the Management of Cardiac Arrest (ICEREA Study)","Completed","No Results Available","Hypothermia|Heart Arrest","Procedure: Comparison of 2 cooling procedures","Assistance Publique - H??pitaux de Paris|Alsius Corporation|distributed in France by|IST Cardiology (Le Fresne Camilly, France)","Both","Adult|Senior","Phase IV",389,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Treatment","P051038","October 25, 2006","01/11/2006",2009-11-01,"November 30, 2009","01/07/2007","",2009-11-01,"Clinical interest of endovascular cooling versus conventional external cooling for the management of cardiac arrest from cardiac origin|Cost/efficiency ratio (endovascular versus conventional cooling)|Evaluation of the paramedical burden of work|Evaluation of the nurse's satisfaction index|Evaluation of treatment costs: global costs and costs within the first 48 hours of hospitalization|Time necessary to reach the target temperature (33??C): mean speed of temperature decrease|deviations of more than 1??C compared with the target temperature during the 24 hours (24H) after reaching that target temperature|mean speed of rewarming|Safety of the method (type of adverse events)|Analysis according to the type and the cause of the cardiac arrest, duration of resuscitation maneuvers, success of coronary angioplasty, number of organ failures (Logistic Organ Dysfunction System [LODS]|Sequential Organ Failure Assessment [SOFA]|and Organ Dysfunctions and/or Infection [ODIN] scores|Simplified Acute Physiology [SAPS II]), duration of Intensive Care Unit (ICU) stay and duration of mechanical ventilation|The efficiency is measured on survival and on better neurological outcome, as defined by CPC 1 or 2 on the Pittsburgh cerebral performance categories (CPC), with an expected 12% improvement of the survival without major sequels at day 28 after inclusion.","http://ClinicalTrials.gov/show/NCT00392639",NA
"32883",32883,"NCT00408239","Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement","Completed","No Results Available","Thromboembolism","Drug: YM150|Drug: enoxaparin","Astellas Pharma Inc","Both","Adult|Senior","Phase II",367,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","150-CL-029","December 4, 2006","01/12/2006",2009-03-01,"April 20, 2009","01/04/2009","PEARL-1",2009-03-01,"All clinically relevant bleeds during treatment rated as major or clinically relevant non-major, and/or incidence of death due to any cause during study treatment|Venous thromboembolism and/or bleeds|Other safety assessments|PK, PD variables","http://ClinicalTrials.gov/show/NCT00408239",NA
"32898",32898,"NCT00435539","A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)","Completed","No Results Available","Vitreomacular Traction","Drug: Microplasmin|Drug: Microplasmin|Drug: Microplasmin","ThromboGenics","Both","Adult|Senior","Phase II",90,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TG-MV-004|MIVI-IIT","February 14, 2007","01/02/2007",2009-02-01,"April 30, 2009","01/04/2009","",2009-01-01,"Proportion of patients with total PVD|History/full ophthalmologic examination","http://ClinicalTrials.gov/show/NCT00435539",NA
"32907",32907,"NCT00442039","Lithium for the Treatment of Pediatric Mania","Completed","No Results Available","Bipolar I Disorder Without Psychotic Symptoms","Drug: Lithium Carbonate","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Child","Phase II",61,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NICHD-2005-07-01|DUNS No. 07-775-8407","February 27, 2007","01/12/2006",2009-09-01,"May 12, 2010","01/05/2009","",2009-04-01,"To describe evidence-based dosing strategies for lithium in children and adolescents|To characterize the pharmacokinetics/biodisposition of lithium in pediatric patients|To examine the effectiveness and safety of lithium as a maintenance treatment for children and adolescents with bipolar I disorder|To examine the long-term and short-term safety and tolerability of lithium in pediatric bipolar disorder|To describe and compare the pharmacokinetic profile and systemic exposure of lithium after single and multiple doses in children and adolescents|To evaluate the influence of intrinsic factors (e.g. age, gender, race, renal function, height (measured by stadiometer) and weight) on lithium exposure|To describe lithium exposure in the pediatric population in comparison to what is known in adults|To examine the relationship between the systemic exposure and effectiveness and toxicity|To examine the long-term safety and tolerability of combination therapy, lithium plus other psychotropic agents, in pediatric bipolar disorder|To critically assess the efficacy of lithium for prophylaxis against recurrence of mood episodes in children and adolescents|In those patients who discontinue treatment with lithium and experience a mood relapse, to determine the duration of lithium treatment necessary before re-stabilization is achieved","http://ClinicalTrials.gov/show/NCT00442039",NA
"32910",32910,"NCT00455039","INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients","Completed","No Results Available","Breast Cancer","Drug: GW572016","University of New Mexico","Female","Child|Adult|Senior","Phase I|Phase II",55,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INST 0514C","March 30, 2007","01/07/2005",2009-10-01,"June 23, 2010","01/10/2009","",2009-10-01,"The primary end point of this study is clinical efficacy of GW572016 in treatment na??ve patients with locally advanced breast cancer.|The secondary end points would be the biologic correlative of relevant biomarkers.","http://ClinicalTrials.gov/show/NCT00455039",NA
"32923",32923,"NCT00474539","Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants","Completed","No Results Available","Vaccines, Pneumococcal","Biological: 13 valent pneumococcal conjugate vaccine|Biological: 7 valent pneumococcal conjugate vaccine","Wyeth","Both","Child","Phase III",440,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","6096A1-3007","May 15, 2007","01/06/2007",2009-03-01,"June 9, 2009","01/06/2009","",2009-03-01,"To assess immunogenicity of 13vPnC using serotype specific serum IgG antibody levels; to evaluate immunogenicity of antigens in concomitant vaccines; to assess safety by local injection site reactions and systemic events, and adverse events.","http://ClinicalTrials.gov/show/NCT00474539",NA
"32947",32947,"NCT00520039","Osteopathic Otitis Media Research Study","Completed","No Results Available","Otitis Media With Effusion","Procedure: osteopathic manipulative medicine (OMM)","West Virginia School of Osteopathic Medicine|University of New England|American Academy of Osteopathy|Osteopathic Research Center","Both","Child","Phase I|Phase II",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","KS5172007","August 22, 2007","01/09/2007",2009-08-01,"November 18, 2009","01/11/2009","OOMRS",2009-08-01,"Duration of middle ear effusion following a single episode of acute otitis media|Changes in tympanogram and acoustic reflectometer readings immediately following one osteopathic manipulative treatment protocol","http://ClinicalTrials.gov/show/NCT00520039",NA
"32955",32955,"NCT00531739","SurgiWrapTM to Reduce Soft Tissue Attachment & Incidence Early Post-Operative Bowel Obstruction in Colorectal Surgery","Completed","No Results Available","Adhesions|Colectomy","Other: Polylactic Acid Sheet","Cytori Therapeutics","Both","Adult|Senior","Phase IV",60,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","SURGIWRAP(TM)","September 18, 2007","01/03/2006",2009-07-01,"October 5, 2010","01/10/2010","",2009-07-01,"Assess the efficacy of SurgiWrapTM in the prevention/reduction of Grade 2 or higher soft tissue attachments under the abdominal incision made during colorectal surgery|Clinical and radiographic evidence of bowel obstruction|The incidence and extent of soft tissue attachments under the abdominal incision and on the pelvic floor after colorectal surgery","http://ClinicalTrials.gov/show/NCT00531739",NA
"32956",32956,"NCT00521339","Phase 2, Open-label Study to Evaluate Apremilast Recalcitrant (Not Responded to Therapy) Plaque-type Psoriasis","Completed","No Results Available","Psoriasis","Drug: apremilast","Celgene Corporation","Both","Adult|Senior","Phase II",31,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CC-10004-PSOR-004","August 24, 2007","01/08/2007",2009-05-01,"August 24, 2010","01/08/2010","",2009-04-01,"To evaluate the safety and tolerability of CC-10004, twice per day (BID) for 84 days in subjects with recalcitrant plaque-type psoriasis.|To evaluate the pharmacodynamic(PD)effects of CC-10004 in plaque-type; characterize PK effects and evaluate clinical efficacy;and determine the effect on quality of life;","http://ClinicalTrials.gov/show/NCT00521339",NA
"32959",32959,"NCT00533039","sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial","Completed","No Results Available","Coronary Artery Disease","Drug: Varespladib (A-002)|Drug: placebo","University Health Network, Toronto|Anthera Pharmaceuticals","Both","Adult|Senior","Phase II",164,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SPIDER001|A Sub-study of SPIDER-PCI","September 19, 2007","01/10/2007",2009-06-01,"October 8, 2009","01/06/2008","SPIDER-PCI",2009-06-01,"The primary endpoint will be incidence of myocardial injury as evidenced by elevation of CK-MB or troponin I above the upper limit of normal.|A secondary endpoint will be occurrence of elevation of CK-MB or troponin I above the upper limit of normal.|A secondary endpoint will be occurrence of any major adverse cardiac events (MACE).|A secondary outcome will be serum sPLA2 activity.","http://ClinicalTrials.gov/show/NCT00533039",NA
"32961",32961,"NCT00539539","Automated Real-time Feedback on CPR Study","Completed","No Results Available","Heart Arrest","Other: Laerdal Q-CPR /technology","University of Washington|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Neurological Disorders and Stroke (NINDS)|The Institute of Circulatory and Respiratory Health (ICRH)|Defence Research and Development Canada","Both","Adult|Senior","Phase III",1586,"Other|NIH","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","30707-A|91-6001537;|06-3100-A 02","October 2, 2007","01/02/2007",2009-09-01,"July 20, 2010","01/07/2010","",2009-06-01,"Rate of ROSC during the prehospital resuscitation|The presence of spontaneous circulation upon arrival at the hospital, survival to hospital discharge, and adherence to guidelines for CPR fraction, rate and depth of chest compression, complete release of compression, and rate of ventilation.","http://ClinicalTrials.gov/show/NCT00539539",NA
"32973",32973,"NCT00549939","Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction","Completed","No Results Available","Neurogenic Urinary Bladder","Drug: Alfuzosin|Drug: Placebo","Sanofi-Aventis","Both","Child","Phase III",172,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC5722|2004-002397-38","October 25, 2007","01/10/2007",2009-12-01,"December 17, 2010","01/12/2010","ALFACHIN",2009-03-01,"Number of patients with detrusor Leak Point Pressure (LPP) < 40 cm H2O|Baseline and 12-week detrusor Leak Point Pressure (LPP)|Absolute change in detrusor Leak Point Pressure (LPP)|Relative change in detrusor Leak Point Pressure (LPP)|Baseline and 12-week detrusor compliance|Relative change in detrusor compliance|Symptomatic Urinary Tract Infection (UTI) Episodes|Symptomatic Urinary Tract Infection (UTI) Episodes","http://ClinicalTrials.gov/show/NCT00549939",NA
"32975",32975,"NCT00562939","Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults","Completed","No Results Available","HIV Infections","Biological: Pneumococcal vaccines + CPG 7909|Biological: Pneumococcal vaccines","University of Aarhus|Aarhus University Hospital","Both","Adult|Senior","Phase I|Phase II",97,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2007-001588-31","November 23, 2007","01/01/2008",2009-01-01,"January 20, 2009","01/01/2009","ITAP",2009-01-01,"Numbers of vaccine high responders - defined as 2-fold increase and IgG levels ??­1 ??g/mL to at least 5 of 7 pneumococcal serotypes (by quantitative IgG measurements) - in the CpG 7909 group vs. the control group|Functional activity of anticapsular antibodies measured by OPA|Safety/Tolerability|Nasopharyngeal pneumococcal colonization|Predictors of antibody response, i.e. CD4+ cell count and sCD163|Numbers of vaccine high responders - defined as 2-fold increase and IgG levels ??­1 ??g/mL to at least 5 of 7 pneumococcal serotypes (by quantitative IgG measurements) - in the CpG 7909 group vs. the control group|Quantity and differentiation of IgG subtypes for HAART-experienced and HAART-naive individuals|Cytokine response to various antigens by in vitro cell stimulation for HAART-experienced and HAART-naive individuals","http://ClinicalTrials.gov/show/NCT00562939",NA
"32988",32988,"NCT00585039","Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED)","Completed","No Results Available","Asthma","Drug: xopenex","Phoenix Children's Hospital","Both","Child","Phase IV",300,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SRC176","December 20, 2007","01/09/2005",2009-03-01,"September 17, 2009","01/02/2009","Xopenex",2009-03-01,"FEV1|Plasma R and S isomer levels|clinical asthma scores","http://ClinicalTrials.gov/show/NCT00585039",NA
"32993",32993,"NCT00592839","Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women","Completed","Has Results","Nocturnal Vasomotor Symptoms","Drug: SCE-B|Drug: Placebo","Duramed Research","Female","Adult","Phase IV",157,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","DR-ENJ-401","December 20, 2007","01/12/2007",2009-02-01,"March 16, 2010","01/03/2010","",2009-02-01,"Mean Change in Average Frequency of Awakenings Due to Sleep-time Hot Flashes|Mean Change in Individual Sleep Parameters on a Three-point Scale|Mean Change in Stanford Sleepiness Scale|Mean Change in Biochemical Markers of Bone Metabolism (N-telopeptide).|Mean Change in Biochemical Markers of Bone Metabolism (Osteocalcin)|Mean Change in Biochemical Markers of Bone Metabolism (Sex Hormone Binding Globulin).","http://ClinicalTrials.gov/show/NCT00592839",NA
"32997",32997,"NCT00604539","Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee","Completed","No Results Available","Synovitis|Osteoarthritis|Joint Diseases|Muskuloskeletal Diseases","Drug: Chondroitin sulphate (Condrosan)|Drug: Placebo","Bioiberica","Both","Adult|Senior","Phase III",70,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CS/IV-SIN-01|CS/IV-SIN-01","January 17, 2008","01/02/2008",NA,"November 20, 2009","01/11/2009","",2009-11-01,"Evaluation of the change in the severity of synovitis measured by MRI according to the modified methods of Loeuille et al. after chondroitin sulphate treatment in patients with knee OA and clinical signs of synovitis|Changes of cartilage volume and subchondral bone lesions|Pain measured by VAS|WOMAC index|SF-36 Health Questionaire|Assessment of joint swelling, effusion|Use of rescue medication|Tolerability|Adverse events","http://ClinicalTrials.gov/show/NCT00604539",NA
"33001",33001,"NCT00603239","Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide|Drug: placebo","Amylin Pharmaceuticals, Inc.|Eli Lilly and Company","Both","Adult|Senior","Phase III",165,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","H8O-MC-GWCG","January 17, 2008","01/01/2008",2009-07-01,"September 2, 2010","01/09/2010","",2009-07-01,"Change in Glycosylated Hemoglobin (HbA1c)|Percentage of Patients Achieving HbA1c <= 7%|Percentage of Patients Achieving HbA1c <= 6.5%|Change in Fasting Serum Glucose (FSG)|Change in Body Weight|Change in Waist Circumference|Change in Beta-cell Function|Change in Insulin Sensitivity.|Number of Subjects Who Experienced an Episode of Minor Hypoglycemia|Change in Impact of Weight on Quality of Life (IWQOL)-Lite Score|Change in Euroqol - 5 Domain Quality of Life (EQ-5D) Score","http://ClinicalTrials.gov/show/NCT00603239",NA
"33002",33002,"NCT00611039","Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy","Completed","No Results Available","HIV Infections","Drug: Darunavir 900mg + ritonavir 100 mg once a day|Drug: Darunavir 600mg + ritonavir 100mg twice day","Germans Trias i Pujol Hospital","Both","Adult|Senior","Phase IV",30,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DRV 900100 QD","January 28, 2008","01/02/2008",2009-07-01,"October 5, 2009","01/10/2009","DRV900100QD",2009-07-01,"Proportion of patients with HIV-1 viral load < 50 copies /mL|DRV plasma trough concentration|DRV Virtual inhibitory quotient (vIQ)|CD4 and CD8 lymphocytes count|Physical examination including weight and height|Karnofsky index|Adverse events|Lipid profile (total cholesterol, HDL-cholesterol. LDL-cholesterol and triglycerides)|Treatment adherence (assessed by the physician, but not recovered in the data base)|Genotype, if virological failure occurs","http://ClinicalTrials.gov/show/NCT00611039",NA
"33009",33009,"NCT00622739","Ziprasidone in Pediatric Bipolar Disorder","Completed","No Results Available","Bipolar Disorder","Drug: Ziprasidone|Drug: Ziprasidone","University of Texas Southwestern Medical Center|Stanley Medical Research Institute|Pfizer|Children's Medical Center Dallas","Both","Child","Phase IV",45,"Other|Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SaxenaZiprasidone","February 13, 2008","01/02/2007",2009-11-01,"January 11, 2010","01/10/2008","",2009-09-01,"Young Mania Rating Scale (YMRS)|Clinical Global Impressions (CGI) Scale|SAFTEE (Side effects rating scale)|AIMS (Abnormal Involuntary Movement Scale)|Children's Depression Rating Scale","http://ClinicalTrials.gov/show/NCT00622739",NA
"33014",33014,"NCT00614939","Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment","Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo","AstraZeneca|Bristol-Myers Squibb","Both","Adult|Senior","Phase III",572,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","D1680C00007|EudraCT number 2007-004951-12","January 31, 2008","01/01/2008",2010-03-01,"June 7, 2010","01/06/2010","",2009-06-01,"Absolute Change From Baseline in Glucosylated Haemoglobin A1c (HbA1c) (%) Level to Week 12|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) (mg/dL) to Week 12 - Moderate Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) (mg/dL) to Week 12 - Severe Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (mg/dL) - End-Stage Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) (mmol/L) to Week 12 - Moderate Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (mmol/L) - Severe Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (mmol/L) - End-Stage Renal Impairment Subgroup","http://ClinicalTrials.gov/show/NCT00614939",NA
"33040",33040,"NCT00674739","Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts","Completed","No Results Available","Genital Warts","Drug: Imiquimod A|Drug: Imiquimod B|Drug: Placebo","Graceway Pharmaceuticals, LLC","Both","Child|Adult|Senior","Phase III",450,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GW01-0801","May 7, 2008","01/05/2008",2009-07-01,"January 26, 2010","01/01/2010","",2009-07-01,"The primary efficacy endpoint is the proportion of subjects achieving complete clearance of all warts (baseline and new) at the EOS.|Safety variables include adverse reactions (AEs), local skin reactions (LSRs), and number and duration of rest periods during the Treatment Period.","http://ClinicalTrials.gov/show/NCT00674739",NA
"33044",33044,"NCT00681239","Atkins Plus KetoCal for Childhood Epilepsy","Completed","No Results Available","Epilepsy","Dietary Supplement: Modified Atkins diet and KetoCal","Johns Hopkins University|Nutricia, Inc.","Both","Child","Phase III",30,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NA_00017953","May 19, 2008","01/05/2008",2009-12-01,"December 30, 2009","01/12/2009","",2009-07-01,"Seizure reduction|Ketosis|Tolerability and taste","http://ClinicalTrials.gov/show/NCT00681239",NA
"33077",33077,"NCT00729339","Role of Mosapride in Patients With Gastroesophageal Reflux Disease","Completed","No Results Available","Gastroesophageal Reflux Disease","Drug: mosapride for the first month and placebo for the 2nd month|Drug: placebo for the first and mosapride for the second month","Lotung Poh-Ai Hospital|Tomorrow Medical Foundation","Both","Adult|Senior","Phase IV",114,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","OMCP-97-011","July 31, 2008","01/06/2008",2009-05-01,"May 12, 2009","01/05/2009","",2009-04-01,"Symptom improvement evaluated by frequent scale for the symptoms of gastroesophageal reflux disease (FSSG)","http://ClinicalTrials.gov/show/NCT00729339",NA
"33078",33078,"NCT00731939","Titan One Touch Release Inflatable Penile Prosthesis","Completed","No Results Available","Erectile Dysfunction","Device: Inflatable Penile Prosthesis","Coloplast A/S","Male","Adult|Senior","Phase IV",123,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DK057CC","August 7, 2008","01/11/2007",2010-04-01,"January 5, 2011","01/01/2011","",2009-10-01,"Assess the ease of deflation of the Titan OTR pump|Evaluate user acceptance of Titan OTR|Assess the ease of implant of the Titan OTR|Assess the ease of training for Titan OTR|Assess partner satisfaction (where applicable)|Summarize all device and procedure related adverse events","http://ClinicalTrials.gov/show/NCT00731939",NA
"33092",33092,"NCT00750139","Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis","Completed","No Results Available","Tinea Pedis|Athlete's Foot","Drug: NAFT-500|Drug: Placebo|Drug: topical allylamine cream|Drug: placebo","Merz Pharmaceuticals, LLC","Both","Child|Adult|Senior","Phase III",709,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MUS 90200-0736/1","September 8, 2008","01/08/2008",2009-12-01,"August 20, 2010","01/08/2010","",2009-08-01,"NAFT-500 cream to placebo at the 2 week time point post treatment with complete cure defined as negative mycology results from the central laboratory and negative signs and symptoms.|Treatment Effectiveness;Mycological Cure;Clinical Success;Clinical Cure;Physicians Global Evaluation;Subject Satisfaction Assessment","http://ClinicalTrials.gov/show/NCT00750139",NA
"33114",33114,"NCT00570739","Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.","Completed","Has Results","Type 2 Diabetes Mellitus|Hypercholesterolemia|Pre-diabetes","Drug: Metformin HCl and Colesevelam Placebo|Drug: Metformin HCl tablets and Colesevelam tablets|Drug: Colesevelam placebo|Drug: Colesevelam","Daiichi Sankyo Inc.","Both","Adult|Senior","Phase III",502,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","WEL-411|IND 68,466","December 10, 2007","01/11/2007",2009-05-01,"July 19, 2010","01/07/2010","",2009-04-01,"Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-na??ve, Diabetic Subjects.|Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-na??ve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks.|Fasting Plasma Glucose When Given to Drug-na??ve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Fasting Insulin When Given to Drug-na??ve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Fasting C-Peptide Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|30 Minute Post-Meal Glucose Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|1 Hour Post-Meal Glucose Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|2 Hour Post-Meal Glucose Levels to in Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|2 Hour Post-Meal Insulin Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|2 Hour Post-Meal C-Peptide Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|The Percent Change of Low Density Lipoprotein Cholesterol (LDL-C) When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Non-High Density Lipoprotein (Non-HDL) Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of High Density Lipoprotein Cholesterol(HDL-C) When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Total Cholesterol (TC) When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Triglycerides (TG)When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Apolipoprotein A-1 (Apo A-1) When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Apolipoprotein B (Apo B)When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Apolipoprotein C3 (Apo C3)When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Change in the Levels of Various Lipoprotein Particles When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Size of Various Lipoprotein Particles When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Calculated Total Triglycerides When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Calculated Very Low Density Lipoprotein Triglycerides When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Calculated High Density Lipoprotein Cholesterol When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Percent of Subjects Achieving HbA1c Goal of <7.0% at Weeks 4, 8, 12, and 16 if Baseline HbA1c Was > or = to 7.0% When Given to Drug-na??ve, Diabetics|Percent of Subject Achieving HbA1c Goal of <6.5% at Weeks 4, 8, 12, and 16 When Given to Drug-na??ve, Diabetic Subjects|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <100 mg/dL at Weeks 8, 16 When Given to Drug-na??ve, Diabetic Subjects|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol Goal of <70 mg/dL at Weeks 8, 16 When Given as to Drug-na??ve, Diabetics|Change in Body Weight When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Change in Waist-to-Hip Ratio When Given to Drug-Naive Diabetic Subjects From Baseline to 16 Weeks|Change in Plasma Glucose Area Under the Curve (0 to 120 Minutes) From the Baseline Glucose Tolerance Test (GTT) to the 16 Week GTT|Percent Change of Various Calculated Lipid Parameters When Given as Initial Therapy to Drug-na??ve, Diabetic From Baseline to 16 Weeks Subjects|Percent of Subjects Achieving 2-Hr. Post Meal Glucose Goal of <180 mg/dL When Given to Drug-na??ve, Diabetic Subjects From Baseline to Week 16|Percent of Subjects Achieving Hs-C-Reactive Protein Goal of <2.0 mg/L When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Percent Change in Low Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Non-High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Total Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Apolipoprotein A-1 in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Apolipoprotein B in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Apolipoprotein CIII in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Triglycerides in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Hs-C-Reactive Protein in Pre-Diabetic Subjects From Baseline to 16 Weeks|Level of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks|Particle Size of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Various Calculated Lipid Parameters in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Change of HbA1c in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Percent Change of Fasting Plasma Glucose in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Percent Change of Fasting Insulin in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Change of Fasting C-peptide Levels in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Glucose Levels 30 Minutes Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Glucose Levels 1 Hour Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Glucose Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Insulin Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of C-Peptide Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <100 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <70 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects|Change in Body Weight in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change in Waist-to-Hip Ratio in Pre-Diabetic Subjects From Baseline to 16 Weeks|Area Under the Curve for Plasma Glucose From 0 to 120 Minutes During the Oral Glucose Tolerance Tests in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Achievement of <140 mg/dL Plasma Glucose 2 Hours Post the Oral Glucose Tolerance Test in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was >or= to 140 mg/dL From Baseline to 16 Weeks|Percent Achievement of <110 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 110 mg/dL From Baseline to 4, 8, 12, and 16 Weeks|Percent Achievement of <100 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 100 mg/dL From Baseline to 4, 8, 12 and 16 Weeks|Percent Achievement of <140 mg/dL Plasma Glucose Post 2 Hour Glucose Tolerance Test and Fasting Plasma Glucose <110 mg/dL in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Achievement of Hs-C-Reactive Protein <2.0 mg/L in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 2.0 mg/L From Baseline to 16 Weeks|Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose >or= to 126 mg/dL or Plasma Glucose >or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks","http://ClinicalTrials.gov/show/NCT00570739",NA
"33116",33116,"NCT00791739","Trazodone and Its Augmentation With Pregabalin in the Treatment of Fibromyalgia","Completed","No Results Available","Fibromyalgia","Drug: trazodone, pregabalin","Universidad de Granada","Both","Adult|Senior","Phase IV",66,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TZD-PGB-2008","November 12, 2008","01/04/2008",2009-10-01,"January 10, 2011","01/10/2010","",2009-07-01,"Mean decrease, from baseline to endpoint, in the Fibromyalgia Impact Questionnaire|Change from baseline to endpoint in the scores of the Pittsburgh Sleep Quality Inventory, the Brief Pain Inventory, the Beck Depression Inventory, and the Hospital Anxiety and Depression Scale|Discontinuation rates due to treatment-related adverse events, proportion of patients experiencing any adverse event, proportion of patients experiencing serious adverse events","http://ClinicalTrials.gov/show/NCT00791739",NA
"33121",33121,"NCT00802139","Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin","Completed","No Results Available","Iron Deficiency Anemia","Drug: venoferrum(iron sucrose)|Drug: Bolgre (Iron acetyl-transferase)","ChoongWae Pharma Corporation","Female","Adult|Senior","Phase IV",58,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CWP-VNF-402","December 3, 2008","01/02/2008",2010-10-01,"November 3, 2010","01/11/2010","",2009-06-01,"Change of plasma hemoglobin level|Target Hb achievement rate(11g/dL), Transferrin saturation(%), Ferritin(ng/mL), TIBC(ug/dL), MCV(fl), MCH(pg) and change in reticulocyte counts","http://ClinicalTrials.gov/show/NCT00802139",NA
"33168",33168,"NCT00868439","Evaluation of RLY5016 in Heart Failure Patients","Completed","No Results Available","Hyperkalemia|Heart Failure","Drug: Spironolactone + RLY5016|Drug: Spironolactone + Placebo","Relypsa, Inc.|Medpace, Inc.","Both","Adult|Senior","Phase II",105,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","RLY5016-202","March 23, 2009","01/04/2009",NA,"February 4, 2010","01/02/2010","PEARL-HF",2009-11-01,"Change from baseline in serum potassium|Safety and tolerability","http://ClinicalTrials.gov/show/NCT00868439",NA
"33180",33180,"NCT00864539","Comparison of the Efficacy of Calcium-cholecalciferol Foodstuffs and Calcium-cholecalciferol Supplement","Completed","Has Results","Vitamin D Status|Healthy","Dietary Supplement: fortified milk|Dietary Supplement: plain milk|Dietary Supplement: fortified orange juice|Dietary Supplement: plain orange juice|Dietary Supplement: calcium-vitamin D supplement|Dietary Supplement: Placebo","National Nutrition and Food Technology Institute","Both","Child","Phase II|Phase III",585,"Other","Interventional","Allocation: Non-Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","P/25/47/2027","March 17, 2009","01/11/2007",2010-06-01,"October 4, 2010","01/09/2010","",2009-02-01,"Serum Levels of 25hydroxy Vitamin D(25(OH)D)Compared to the Due Control Group","http://ClinicalTrials.gov/show/NCT00864539",NA
"33193",33193,"NCT00920439","Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers.","Completed","No Results Available","Poliomyelitis","Biological: PoliorixTM","GlaxoSmithKline","Both","Child","Phase III",26,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","112683","June 12, 2009","01/06/2009",2009-08-01,"September 18, 2009","01/09/2009","",2009-08-01,"Occurrence of solicited local and general symptoms.|Occurrence of unsolicited symptoms.|Occurrence of serious adverse events (SAEs).","http://ClinicalTrials.gov/show/NCT00920439",NA
"33205",33205,"NCT00938639","A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults","Completed","No Results Available","Influenza Caused by the Novel Influenza A (H1N1) Virus","Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)|Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)","CSL Limited","Both","Adult","Phase II",240,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CSLCT-CAL-09-59","July 13, 2009","01/07/2009",2010-03-01,"May 22, 2010","01/05/2010","",2009-09-01,"Immunogenicity|Frequency, duration and intensity of solicited adverse events|Frequency, duration, and intensity of unsolicited adverse events|Incidence of Serious Adverse Events, Adverse Events of Special Interest (AESI's) and new onset of Chronic Illnesses","http://ClinicalTrials.gov/show/NCT00938639",NA
"33234",33234,"NCT00985439","Study of Diclofenac Capsules to Treat Dental Pain","Completed","No Results Available","Dental Pain","Drug: Diclofenac Test (lower dose)|Drug: Diclofenac Test (upper dose)|Drug: Celecoxib|Drug: Placebo","Iroko Pharmaceuticals, LLC","Both","Adult","Phase II",200,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DIC2-08-03","September 25, 2009","01/09/2009",2009-12-01,"January 4, 2010","01/01/2010","",2009-12-01,"Total Pain Relief (TOTPAR)","http://ClinicalTrials.gov/show/NCT00985439",NA
"33291",33291,"NCT01075139","Brief Motivational Intervention to Increase Physical Activity and Fruit/Vegetable Intake","Completed","No Results Available","Physical Inactivity|Poor Diet","Behavioral: Brief Motivational Intervention|Behavioral: Educational information","University of Missouri-Columbia","Both","Adult|Senior","Phase II",70,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","N/A (unfunded trial)","February 23, 2010","01/10/2008",2009-10-01,"February 23, 2010","01/02/2010","",2009-10-01,"Vigorous physical activity minutes per week.|Moderate physical activity minutes per week.|Fruit and vegetable intake per week","http://ClinicalTrials.gov/show/NCT01075139",NA
"33368",33368,"NCT01186939","An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)","Completed","Has Results","Myelodysplastic Syndromes","Drug: Azacitidine","Celgene Corporation","Both","Adult|Senior","Phase III",40,"Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AZA PH GL 2003 CL 001 E","August 20, 2010","01/04/2007",2009-09-01,"September 27, 2010","01/09/2010","",2009-09-01,"Number of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period","http://ClinicalTrials.gov/show/NCT01186939",NA
"33385",33385,"NCT01235039","A Study Evaluating the Bioequivalence of VIAject?ó7 Compared to VIAject?ó25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject?ó7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus","Completed","No Results Available","Diabetes Mellitus","Drug: VIAject?ó25|Drug: VIAject?ó7|Drug: Insulin Lispro","Biodel","Both","Adult","Phase I|Phase II",43,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","VIAject -030J","November 2, 2010","01/07/2009",2009-09-01,"November 19, 2010","01/11/2010","",2009-09-01,"Serum insulin concentration|Serum insulin concentration|Glucose infusion rate","http://ClinicalTrials.gov/show/NCT01235039",NA
"33504",33504,"NCT00079040","Cisplatin, Etoposide & Bevacizumab in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer","Completed","Has Results","Lung Cancer","Biological: bevacizumab|Drug: cisplatin|Drug: etoposide","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",65,"Other|NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000353484|ECOG-E3501","March 8, 2004","01/06/2004",2009-01-01,"February 3, 2010","01/02/2010","",2009-01-01,"Percentage of Participants Alive and Progression-free (PF) at 6 Months|Overall Survival|Best Objective Response","http://ClinicalTrials.gov/show/NCT00079040",NA
"33590",33590,"NCT00232440","Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma","Completed","No Results Available","Hodgkin's Disease|Lymphoma, Non-Hodgkin","Device: BodyFIX","University Health Network, Toronto|Princess Margaret Hospital, Canada","Both","Adult|Senior","Phase I|Phase II",20,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 02-0526-C","October 3, 2005","01/01/2003",2009-06-01,"August 10, 2010","01/08/2010","",2009-06-01,"The primary outcome for the study is the average deviation in set-up.","http://ClinicalTrials.gov/show/NCT00232440",NA
"33637",33637,"NCT00254540","Study of SU011248 in Patients With Advanced Kidney Cancer","Completed","Has Results","Carcinoma, Renal Cell","Drug: SU011248 capsule","Pfizer","Both","Adult|Senior","Phase II",51,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181072","November 14, 2005","01/12/2005",2009-02-01,"February 17, 2010","01/02/2010","",2009-02-01,"Number of Subjects With Objective Response|Progression-Free Survival (PFS)|Time To Tumor Progression (TTP)|Duration of Response (DR)|Time to Tumor Response (TTR)|Overall Survival Time|Change From Baseline of European Quality of Life Questionnaire- 5 Dimensions(EQ-5D) Questionnaires Health State Index Score|Change From Baseline of European Quality of Life Questionnaire- 5 Dimensions(EQ-5D) Questionnaires Visual Analog Scale (VAS)|Trough Plasma Concentration (Ctrough) of SU-011248 in First-line Treatment Population|Trough Plasma Concentration (Ctrough) of SU-011248 in Pretreated Population|Trough Plasma Concentration (Ctrough) of SU-012662 in First-line Treatment Population|Trough Plasma Concentration (Ctrough) of SU-012662 in Pretreated Population|Trough Plasma Concentration (Ctrough) of SU-011248+SU-012662 in First-line Treatment Population|Trough Plasma Concentration (Ctrough) of SU-011248+SU-012662 in Pretreated Population|Plasma Concentrations of Vascular Endothelial Growth Factor (VEGF)|Plasma Concentrations of Soluble Vascular Endothelial Growth Factor Type 2 Receptors (sVEGFR2)","http://ClinicalTrials.gov/show/NCT00254540",NA
"33640",33640,"NCT00309140","An Open Label Study of Oral Enzastaurin in Patients With Cancer","Completed","No Results Available","Neoplasms|Cancer","Drug: enzastaurin","Eli Lilly and Company","Both","Adult|Senior","Phase II",23,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10287|H6Q-MC-S001","March 29, 2006","01/03/2006",2009-07-01,"May 27, 2010","01/05/2010","",2009-07-01,"This study will collect basic safety data on patients cancer treated with enzastaurin.|This study will document antitumor activity that may be observed with enzastaurin.","http://ClinicalTrials.gov/show/NCT00309140",NA
"33642",33642,"NCT00315640","Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation","Completed","No Results Available","Eye Diseases","Drug: Anecortave Acetate","Alcon Research","Both","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","C-05-03|2005-001598-93","April 17, 2006","01/12/2005",NA,"January 27, 2010","01/01/2010","",2009-08-01,"Mean IOP","http://ClinicalTrials.gov/show/NCT00315640",NA
"33663",33663,"NCT00339040","Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children","Completed","No Results Available","HIV Infections|Sexually Transmitted Diseases","Biological: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP)|Other: Placebo","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Child","Phase II",120,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","PACTG P1047","June 19, 2006","01/10/2006",NA,"August 31, 2010","01/05/2008","",2009-08-01,"Safety, as determined by development of Grade 3 or 4 adverse events (AEs)|safety, as determined by development of Grade 3 or 4 AEs attributed to study treatment|immunogenicity, as determined by anti-HPV 6, 11, 16, 18 responses measured by Clinical Laboratory Improvement Act (CLIA)|serum antibody titers|Change in CD4 count and percent|change in viral load (HIV-1 RNA copies/ml)","http://ClinicalTrials.gov/show/NCT00339040",NA
"33685",33685,"NCT00348140","Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: Rosiglitazone Extended Release 2mg|Drug: Rosiglitazone Extended Release 8mg|Other: Placebo","GlaxoSmithKline","Both","Adult|Senior","Phase III",1450,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AVA102670","June 30, 2006","01/07/2006",2009-03-01,"April 22, 2010","01/04/2010","REFLECT-3",2009-03-01,"Change from baseline in ADAS-Cog total score and CDR-Sum of Boxes score at Week 48, as a function of APOE e4 status.|At visits between Week 4 and 24: Assessments of changes in behavior, activities of daily living, healthcare resource utilization, subject and caregiver quality of life, pharmacokinetics, exploratory pharmacogenetics, proteomics, and transcriptomics.|Assessments of changes in behavior, activities of daily living, healthcare resource utilization, subject and caregiver quality of life, pharmacokinetics, exploratory pharmacogenetics, proteomics, and transcriptomics.|Secondary endpoints include measures of: Cognition and function: MMSE, Neuropsychiatric Inventory (NPI), DAD.|Health Outcomes: Resource Utilization in Dementia (RUD), European Quality of Life -5 Dimensions (EQ-5D), Alzheimer's Carer's Quality of Life Instrument (ACQLI).","http://ClinicalTrials.gov/show/NCT00348140",NA
"33696",33696,"NCT00381940","Bortezomib, Ifosfamide, and Vinorelbine in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: bortezomib|Drug: ifosfamide|Drug: vinorelbine ditartrate","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",48,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000500142|COG-AHOD0521","September 26, 2006","01/01/2007",NA,"December 14, 2010","01/11/2010","",2009-10-01,"Toxicity|Complete response after 2 or 4 courses of treatment|Overall tumor response|Proportion of patients able to mobilize sufficient hematopoietic stem cells|Overall response rate after 2 or 4 courses of treatment|Induction success rate","http://ClinicalTrials.gov/show/NCT00381940",NA
"33718",33718,"NCT00420940","The Influence of Vibration on Bone Mineral Density in Women Who Have Weak Bones After Menopause","Completed","No Results Available","Bone Density|Osteopenia|Osteoporosis|Post-Menopause","Device: Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Device: Juvent 1000 Dynamic Motion Therapy (DMT) Platform","University Health Network, Toronto|The Physicians' Services Incorporated Foundation","Female","Child|Adult|Senior","Phase III",202,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","06-0332-AE|PSI 06-28","January 9, 2007","01/11/2006",2009-12-01,"April 7, 2010","01/10/2008","",2009-12-01,"Trabecul volumetric bone mineral density (BMD) of the lower tibia (using peripheral quantitative computed tomography; pQCT))|Total BMD of the lower tibia (using pQCT)|Cortical BMD and cortical thickness of the lower tibia (using pQCT)|Trabecular thickness, separation, and number of the lower tibia (using pQCT)|Total BMD of the distal radius (using pQCT)|Cortical BMD and cortical thickness of the distal radius (using pQCT)|Trabecular BMD and thickness, separation, and number of the distal radius (using pQCT)|BMD at the total hip (using dual x-ray absorptiometry; DXA)|BMD at the femoral neck (using DXA)|BMD lumbar spine (using DXA)|BMD at the calcaneus (using quantitative ultrasound; QUS)|Speed of sound and broadband ultrasound attenuation at the calcaneus (QUS)","http://ClinicalTrials.gov/show/NCT00420940",NA
"33751",33751,"NCT00466440","A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients","Completed","No Results Available","Prostate Cancer","Drug: enzastaurin|Drug: placebo|Drug: docetaxel|Drug: prednisone","Eli Lilly and Company","Male","Adult|Senior","Phase II",101,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11311|H6Q-MC-S032","April 25, 2007","01/06/2007",2010-06-01,"November 23, 2010","01/11/2010","",2009-08-01,"To determine response rate of enzastaurin given with chemotherapy in prostate cancer patients when they have taken enzastaurin for a maximum of 3 years|To assess rate of PSA level decline of greater than or equal to 30%|Progression free survival|Adverse events and safety|To characterize the pharmacokinetics of enzastaurin|Assess tumor biomarkers","http://ClinicalTrials.gov/show/NCT00466440",NA
"33769",33769,"NCT00501540","Lithium for Low-Grade Neuroendocrine Tumors","Completed","No Results Available","Neuroendocrine Tumors","Drug: Lithium Carbonate","University of Wisconsin, Madison|National Institutes of Health (NIH)","Both","Adult|Senior","Phase II",15,"Other|NIH","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CO07203|R21CA117117-01A2","July 13, 2007","01/07/2007",2009-06-01,"October 15, 2010","01/10/2010","",2009-06-01,"tumor response rate of patients with low-grade neuroendocrine tumors treated with lithium","http://ClinicalTrials.gov/show/NCT00501540",NA
"33774",33774,"NCT00504140","Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma","Completed","No Results Available","Osteosarcoma","Drug: Etoposide|Drug: Interferon Alpha","M.D. Anderson Cancer Center|Schering-Plough","Both","Child|Adult|Senior","Phase II",30,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P96-221","July 17, 2007","01/11/1996",2009-03-01,"August 18, 2009","01/08/2009","",2009-03-01,"Efficacy of combining IFN with etoposide for the treatment of relapsed osteosarcoma.","http://ClinicalTrials.gov/show/NCT00504140",NA
"33810",33810,"NCT00549640","Testing Methylphenidate for Smoking Abstinence","Completed","Has Results","Smoking","Drug: Methylphenidate|Drug: Placebo","Mayo Clinic|Ortho-McNeil Janssen Scientific Affairs, LLC","Both","Adult","Phase II",80,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06-005407|06-006284","October 24, 2007","01/01/2008",2009-05-01,"November 29, 2010","01/11/2010","",2009-01-01,"Number of Subjects Biochemically Confirmed to be Abstinent From Smoking at End of Treatment.|Number of Subjects Biochemically Confirmed to be Abstinent From Smoking at End of Study|The Change in the Average Nicotine Withdrawal Symptom Score From Baseline to 14 Days Post Target Quit Date.","http://ClinicalTrials.gov/show/NCT00549640",NA
"33813",33813,"NCT00566540","Cisplatin, Paclitaxel, Radiation Therapy, and Surgery in Treating Patients With Advanced Cancer of the Oral Cavity, Oropharynx, or Hypopharynx That Can Be Removed by Surgery","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: paclitaxel|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: intensity-modulated radiation therapy|Radiation: intraoperative radiation therapy","Arthur G. James Cancer Hospital & Richard J. Solove Research Institute|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",50,"Other|NIH","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000576461|OSU-06026|OSU-2007C0056","November 30, 2007","01/12/2007",NA,"February 6, 2010","01/06/2009","",2009-01-01,"Feasibility of treatment|Disease-free interval and failure sites|Correlation of molecular markers with treatment outcome|Correlation of quality of life with treatment outcome|Frequency and severity of toxicities|Treatment completion","http://ClinicalTrials.gov/show/NCT00566540",NA
"33824",33824,"NCT00586040","Photochemical Tissue Bonding","Completed","No Results Available","Basal Cell Carcinoma|Squamous Cell Carcinoma|Atypical Nevus","Procedure: tissue bonding|Procedure: sutures","Massachusetts General Hospital","Both","Adult","Phase II",40,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","2006p001528","December 21, 2007","01/09/2007",2009-04-01,"April 9, 2009","01/04/2009","PTB",2009-04-01,"scar appearance|patient satisfaction","http://ClinicalTrials.gov/show/NCT00586040",NA
"33848",33848,"NCT00621140","Efficacy and Safety of BI 1356 Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: BI 1356|Drug: placebo","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",503,"Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1218.16|Eudract 2007-002448-10","January 14, 2008","01/02/2008",NA,"May 28, 2009","01/05/2009","",2009-05-01,"The primary endpoint in this study is the change from baseline in HbA1c (HbA1c after 24 weeks of treatment).|Other HbA1c related parameters fasting plasma glucose. 2 hour post prandial glucose","http://ClinicalTrials.gov/show/NCT00621140",NA
"33853",33853,"NCT00636740","Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients","Completed","No Results Available","Hormone-Refractory Prostate Cancer","Drug: Zoledronic Acid 20mg Tablets|Drug: Zoledronic Acid|Drug: Zoledronic Acid 20mg Tablets","Merrion Pharmaceuticals, LLC","Male","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MER-101-03","March 7, 2008","01/02/2008",2009-02-01,"February 19, 2009","01/02/2009","",2009-02-01,"Effects on 4 markers of bone metabolism|Brief Pain Inventory","http://ClinicalTrials.gov/show/NCT00636740",NA
"33859",33859,"NCT00645840","Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes","Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: Anakinra","University of Texas Southwestern Medical Center|Children's Medical Center Foundation","Both","Child|Adult","Phase I|Phase II",15,"Other","Interventional","Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UTSW 112007-037","March 25, 2008","01/03/2008",2009-09-01,"June 28, 2010","01/06/2010","",2009-09-01,"Change in EGR2 expression in PBMCs upon treatment with anakinra in subjects with newly diagnosed type 1 diabetes|Effect size on preservation of C-peptide secretory capacity","http://ClinicalTrials.gov/show/NCT00645840",NA
"33894",33894,"NCT00700440","Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy","Completed","Has Results","Nasopharyngeal Carcinoma","Drug: C225 (cetuximab)","Sun Yat-sen University|Cancer Institute Hospital, Chinese Academy of Medical Sciences|Sichuan Cancer Hospital|Fujian Cancer Hospital|Fudan University Shanghai Cancer Center|Guizhou Cancer Hospital|The First Affiliated Hospital of Guangxi Medical University|Central South University","Both","Adult|Senior","Phase II",100,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR62202-770|PPRA-RTOG 0001","June 17, 2008","01/07/2008",2009-04-01,"March 9, 2010","01/02/2009","ENCORE",2009-04-01,"3 Month Loco-regional Control After Cetuximab With Concurrent Chemoradiotherapy|1,3,5 Year Loco-regional Control Rate, 1 Year Progression-free Survival and Metastasis-free Survival, 3 and 5 Year Overall Survival","http://ClinicalTrials.gov/show/NCT00700440",NA
"33908",33908,"NCT00704340","DuraSeal Sealant Post Market Study","Completed","Has Results","Elective Cranial Procedures With Dural Incision","Device: DuraSeal Dural Sealant System|Other: Standard of Care","Confluent Surgical|Covidien","Both","Adult|Senior","Phase IV",237,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","DRS-05-002","June 23, 2008","01/09/2005",2009-05-01,"July 27, 2010","01/07/2010","",2009-05-01,"Percentage of Subjects With Surgical Wound Complications, Central Nervous System Events, and Neurosurgical Complications Related to Unplanned Intervention or Return to the Operating Room.|Percentage of Subjects With Post-operative Surgical Site Infections|Percentage of Subjects With a Cerebrospinal Fluid (CSF) Leak","http://ClinicalTrials.gov/show/NCT00704340",NA
"33921",33921,"NCT00744640","Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma","Completed","No Results Available","Locally Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer","Drug: gemcitabine, oxaliplatin, capecitabine","University Hospital, Basel, Switzerland|Swiss National Science Foundation|Swiss Cancer League|Roche Pharma AG|Sanofi-Aventis","Both","Adult|Senior","Phase I|Phase II",46,"Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EK-Nr. 92/05|2005DR2296","August 29, 2008","01/10/2005",2009-12-01,"January 11, 2010","01/01/2010","GEMOXEL",2009-02-01,"Response rate|Progression-free survival and overall survival","http://ClinicalTrials.gov/show/NCT00744640",NA
"33988",33988,"NCT00848640","Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma","Completed","No Results Available","Metastatic Renal Cell Carcinoma","Drug: Sorafenib","Egyptian Foundation For Cancer Research","Both","Adult","Phase II",75,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12594","February 19, 2009","01/10/2008",2010-03-01,"May 25, 2010","01/09/2009","MERITS",2009-12-01,"evaluate the efficacy by evaluating the disease control rate (DCR) and safety of Sorafenib for first line patients unsuitable for another approved first line therapy with advanced RCC in the Middle East region.|Quality of life of patient with RCC and Progression Free Survival","http://ClinicalTrials.gov/show/NCT00848640",NA
"33999",33999,"NCT00862940","A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: Memantine|Drug: Placebo","H. Lundbeck A/S","Both","Adult|Senior","Phase IV",278,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","10112|2004-002614-10","March 16, 2009","01/09/2005",2009-04-01,"March 10, 2010","01/03/2010","",2009-02-01,"To evaluate the effects of memantine on the rate of total brain atrophy in patients with probable AD, using MRI technology|To evaluate the effects of memantine on additional MRI measures|To evaluate the effects of memantine on cognitive and behavioural outcomes|To explore associations between changes in clinical and MRI outcomes|To evaluate the safety and tolerability of memantine","http://ClinicalTrials.gov/show/NCT00862940",NA
"34002",34002,"NCT00869440","Dose-Finding Safety Study Evaluating CNS 7056 in Patients Undergoing Diagnostic Upper GI Endoscopy","Completed","No Results Available","Procedural Sedation|Endoscopy","Drug: CNS 7056|Drug: Midazolam","Paion UK Ltd.","Both","Adult","Phase II",102,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CNS 7056-003","March 25, 2009","01/03/2009",2009-09-01,"September 8, 2010","01/09/2010","",2009-09-01,"MOAA/S scores ???4 on three consecutive measurements after administration of study drug AND completion of the endoscopy procedure without requiring rescue sedative medication AND without requiring manual or mechanical ventilation|Time to fully alert (time to first of 3 consecutive MOAA/S scores of 5)|Time to ready for discharge (time to first of 3 consecutive Aldrete scores ??­9)|No requirement for rescue sedative medication|No manual or mechanical ventilation|MOAA/S score at specified time points|Drowsiness intensity rating on VAS at specified time points|HVLT-R Score|Brice Questionnaire","http://ClinicalTrials.gov/show/NCT00869440",NA
"34022",34022,"NCT00888940","Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery","Completed","Has Results","Bloodloss|Surgical Procedures, Operative","Drug: Ecallantide|Drug: Cyklokapron(R)","Cubist Pharmaceuticals","Both","Adult|Senior","Phase II",243,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ECAL-CCPB-08-07","April 26, 2009","01/06/2009",2010-01-01,"December 14, 2010","01/12/2010","CONSERV-2",2009-12-01,"Cumulative Volume of Packed Red Blood Cells Transfused|Treatment-emergent Adverse Events.","http://ClinicalTrials.gov/show/NCT00888940",NA
"34041",34041,"NCT00944840","Intermittent Preventive Treatment (IPTc) and Home Based Management of Malaria (HMM)in The Gambia","Completed","No Results Available","Malaria","Drug: SP plus amodiaquine|Drug: SP placebo plus amodiaquine placebo","Gates Malaria Partnership|London School of Hygiene and Tropical Medicine","Both","Child","Phase III",1312,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","SCC 1124","July 22, 2009","01/09/2008",2009-08-01,"July 1, 2010","01/07/2010","",2009-07-01,"Malaria incidence (the number of study subjects seen at the OPD clinic with clinical malaria during the surveillance period).|prevalence of parasitaemia at the end of malaria transmission season in December 2008","http://ClinicalTrials.gov/show/NCT00944840",NA
"34183",34183,"NCT01180140","Use of Seamguard to Prevent Leak and Bleeding in Gastrointestinal Surgery","Completed","No Results Available","Leak on Lineal Stapled Anastomoses|Bleeding on Lineal Stapled Anastomoses","Device: Seamguard","Hospital Universitario de Canarias|Unidad mixta de Investigaci??n HUC-ULL|Universidad de La Laguna","Both","Adult|Senior","Phase IV",113,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","Seamguard Study","July 18, 2010","01/03/2006",2010-06-01,"August 10, 2010","01/08/2010","",2009-08-01,"","http://ClinicalTrials.gov/show/NCT01180140",NA
"34318",34318,"NCT00041041","Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer","Completed","No Results Available","Ovarian Cancer|Peritoneal Cavity Cancer","Drug: imatinib mesylate","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000069438|GOG-0170E","July 8, 2002","01/06/2002",NA,"February 5, 2009","01/09/2004","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00041041",NA
"34323",34323,"NCT00039741","Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","Completed","No Results Available","HIV Infections","Drug: Highly active antiretroviral therapy","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|PENTA Foundation","Both","Child|Adult","Phase II|Phase III",256,"NIH|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","PENTA 9/PACTG 390|PENPACT-1B","June 7, 2002","01/10/2005",2010-04-01,"August 17, 2010","01/06/2008","",2009-08-01,"Change in viral load measured in log10 HIV-1 RNA copies/ml|Number of Grade 3 or higher signs, symptoms, or laboratory abnormalities experienced|Change in immunologic outcome, defined as the change in CD4% from baseline to 4 years|Time to a significant HIV-related clinical event, defined as the time to first new CDC Category diagnosis (except for recurrent bacterial infections)|Whether or not a child switched regimens|Time to HIV-1 RNA of 400 copies/ml or greater during first-line therapy or permanent discontinuation of first-line therapy|Time to HIV-1 RNA of 30,000 copies/ml or greater during second-line therapy or permanent discontinuation of second-line therapy|Whether or not a child has an HIV-1 RNA level of less than 400 copies/ml at Week 24 and has not permanently discontinued first-line therapy prior to that week|Whether or not a child has a HIV-1 RNA level less than 400 copies/ml regardless of therapy at that time","http://ClinicalTrials.gov/show/NCT00039741",NA
"34383",34383,"NCT00139841","Safety and Efficacy of Treanda?ºÑ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: Bendamustine HCl","Cephalon","Both","Adult|Senior","Phase III",103,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SDX-105-03","August 18, 2005","01/10/2005",2009-10-01,"May 31, 2010","01/05/2010","",2009-05-01,"Assess the overall response rate (ORR = CR + CRu + PR) and duration of response (DR) to a regimen of bendamustine in patients who are refractory to rituximab therapy.|??Ñ assess the safety profile of Treanda in this patient population. ??Ñ assess the duration of progression-free survival (PFS). ??Ñ estimate the basic pharmacokinetic parameters ??Ñ assess the effects of plasma concentrations","http://ClinicalTrials.gov/show/NCT00139841",NA
"34472",34472,"NCT00275041","Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: cetuximab|Drug: irinotecan hydrochloride","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",38,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000456255|NCCTG-N0436","January 10, 2006","01/02/2006",NA,"June 26, 2009","01/02/2009","",2009-02-01,"Confirmed tumor response (complete or partial)|Time to disease progression|Survival time|Progression-free survival at 6 months","http://ClinicalTrials.gov/show/NCT00275041",NA
"34473",34473,"NCT00277641","Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity","Completed","No Results Available","Binge Eating Disorder|Obesity","Drug: Lamotrigine|Drug: placebo","Lindner Center of HOPE|GlaxoSmithKline|University of Cincinnati","Both","Adult","Phase III",70,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","106531","January 12, 2006","01/03/2006",2009-01-01,"March 12, 2009","01/03/2009","",2009-01-01,"The specific aims of this study are to examine the efficacy and safety of lamotrigine compared with placebo in outpatients with binge eating disorder associated with obesity.","http://ClinicalTrials.gov/show/NCT00277641",NA
"34512",34512,"NCT00336141","Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Suberoylanilide hydroxamic acid","USC/Norris Comprehensive Cancer Center|Merck","Both","Adult|Senior","Phase I|Phase II",77,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3C-05-3","June 9, 2006","01/06/2006",2009-04-01,"September 23, 2010","01/09/2010","",2009-04-01,"Toxicity|Response","http://ClinicalTrials.gov/show/NCT00336141",NA
"34541",34541,"NCT00386841","Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major Depression","Completed","No Results Available","Healthy","Drug: Escitalopram|Drug: Placebo","University of Copenhagen","Both","Adult","Phase IV",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","AGENDA","October 11, 2006","01/04/2007",2009-06-01,"June 29, 2009","01/06/2009","",2009-06-01,"Changes in the response on the combined dexamethasone corticotropin-releasing hormone test before and after 4 weeks treatment with escitalopram or placebo.|Changes in scores before and after 4 weeks treatment with escitalopram or placebo on: Cognition|Social function|Neuroticism|Subjective; sleep, pain, aggression, depression, anxiety, quality of life, perceived stress and side-effects|Receptor status by PET-scans|Inflammatory parameters|Paraclinical measures|MR and fMRI","http://ClinicalTrials.gov/show/NCT00386841",NA
"34544",34544,"NCT00392041","Eszopiclone in the Treatment of Insomnia and Fibromyalgia","Completed","No Results Available","Fibromyalgia|Insomnia","Drug: Eszopiclone|Drug: placebo","University of Medicine and Dentistry New Jersey|Sunovion","Both","Adult","Phase IV",95,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","220060122","October 24, 2006","01/08/2006",2009-03-01,"February 3, 2010","01/02/2010","",2009-03-01,"Total sleep time (TST) as recorded in patient diaries|Wake time after sleep onset (WASO)|Sleep quality|Clinician-rated overall severity of fibromyalgia|Fibromyalgia Impact Questionnaire","http://ClinicalTrials.gov/show/NCT00392041",NA
"34608",34608,"NCT00480441","Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal","Completed","No Results Available","Marijuana Dependence","Drug: Dronabinol|Behavioral: BRENDA therapy|Drug: Placebo","National Institute on Drug Abuse (NIDA)","Both","Adult","Phase II",61,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","5-P60-DA-005186-19","May 30, 2007","01/08/2006",2009-07-01,"June 29, 2010","01/06/2010","",2009-06-01,"Cannabis dependent patients will be able to tolerate dronabinol.|Dronabinol will attenuate cannabis withdrawal.|The quantitative THC and self-report measurements will decrease over the time of study.|Cannabis dependent patients will complete neurocognitive assessments with dronabinol improving performance in certain spheres of function.|Cannabis dependent patients will demonstrate physiological changes in response to cue-induced craving which will be attenuated by dronabinol treatment.|Select group of cannabis dependent patients will complete fMRI scans with demonstrable dronabinol related changes in brain activation.|Structural and perfusion brain differences will be correlated with performance on neurocognitive tasks","http://ClinicalTrials.gov/show/NCT00480441",NA
"34615",34615,"NCT00492141","Aerosol L9-NC and Temozolomide in Ewing's Sarcoma","Completed","No Results Available","Ewing's Sarcoma","Drug: Temozolomide|Drug: L9-NC","M.D. Anderson Cancer Center","Both","Child|Adult|Senior","Phase I|Phase II",10,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0889","June 26, 2007","01/06/2006",2009-09-01,"October 7, 2009","01/10/2009","",2009-09-01,"To learn if liposomal 9-nitro-20(S)-camptothecin (L9-NC) given alone and given in combination with Temodar (temozolomide) can help to control Ewing's sarcoma or another type of cancer that has spread to the lungs.","http://ClinicalTrials.gov/show/NCT00492141",NA
"34624",34624,"NCT00506441","A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia","Completed","No Results Available","Chronic Kidney Disease|Dialysis|Hyperphosphatemia","Drug: MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE?ó)|Drug: Placebo","Mitsubishi Tanabe Pharma Corporation","Both","Adult|Senior","Phase III",245,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MCI-196-A05","July 24, 2007","01/09/2007",2009-09-01,"June 27, 2010","01/06/2010","",2009-09-01,"The change in serum phosphorus levels for MCI-196 and placebo|Change from baseline in serum phosphorus|Change from baseline in PTH|Change from baseline in Calcium|Change from baseline in Calcium x phosphorus ion product|Change from baseline in Total cholesterol|Change from baseline in LDL cholesterol|Change from baseline in HDL cholesterol|Change from baseline in VLDL cholesterol|Change from baseline in Triglyceride|Incidence of adverse events","http://ClinicalTrials.gov/show/NCT00506441",NA
"34667",34667,"NCT00570141","OASIS Wound Matrix (Oasis) Mechanism of Action","Completed","Has Results","Diabetic Foot Ulcers (DFU)|Venous Stasis Ulcers (VSU)","Device: OASIS Wound Matrix","Healthpoint","Both","Adult|Senior","Phase IV",13,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","9310-002-004","December 6, 2007","01/10/2007",2010-04-01,"August 12, 2010","01/08/2010","",2009-04-01,"Decrease in Wound Area From Baseline After 12 Weeks of Treatment or Until Wound Closure, Whichever Occurred First.|Percent Wounds Closed","http://ClinicalTrials.gov/show/NCT00570141",NA
"34670",34670,"NCT00588341","Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection","Completed","No Results Available","Melanoma|Skin Cancer|Cancer","Drug: Temozolomide","Memorial Sloan-Kettering Cancer Center|Schering-Plough","Both","Adult|Senior","Phase II",24,"Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-076","December 26, 2007","01/09/2005",2009-03-01,"March 18, 2009","01/03/2009","",2009-03-01,"Overall objective response rate (CR and PR)|Correlation of oligonucleotide array pattern and of methylation of the MGMT promoter and MGMT expression level with response to treatment; of volumetric tumor measurements with standard response criteria and with final pathological findings; Toxicity","http://ClinicalTrials.gov/show/NCT00588341",NA
"34683",34683,"NCT00607841","A Study of Ispinesib in Metastatic Breast Cancer","Completed","No Results Available","Breast Neoplasms","Drug: Ispinesib (SB-715992)|Drug: Ispinesib (SB-715992)","Cytokinetics","Female","Adult|Senior","Phase I|Phase II",100,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CY 3121","January 22, 2008","01/12/2007",NA,"January 14, 2010","01/01/2010","",2009-11-01,"Safety and tolerability in patients with metastatic breast cancer.|Assessment of response rate based on RECIST in patients with metastatic breast cancer","http://ClinicalTrials.gov/show/NCT00607841",NA
"34685",34685,"NCT00610441","Dose Finding Study in Adults With Attention Deficit Hyperactivity Disorder (ADHD)(174007)(COMPLETED)(P05805)","Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Drug: ORG 26576|Drug: Placebo","Schering-Plough","Both","Adult","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","174007|P05805","January 28, 2008","01/04/2008",2009-03-01,"September 30, 2009","01/09/2009","",2009-03-01,"The primary efficacy outcome measure is the change from baseline in weekly ADHD symptomatology score, assessed by the 18-point Adult ADHD Investigator Symptom Rating Scale (AISRS)|Evaluating treatment effects of Org 26576 compared to placebo to explore safety & tolerability, optimal dose for efficacy of Org 26576 in adult subjects with ADHD, onset of action, depressive symptom changes, cognitive function","http://ClinicalTrials.gov/show/NCT00610441",NA
"34700",34700,"NCT00637741","DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions","Completed","No Results Available","Peripheral Vascular Disease|Intermittent Claudication|Critical Limb Ischemia","Device: Everflex 200","Flanders Medical Research Program","Both","Adult|Senior","Phase IV",100,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FMRP-004","March 12, 2008","01/03/2008",2010-11-01,"November 30, 2010","01/11/2010","",2009-09-01,"Primary patency defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (systolic velocity ratio no greater than 2.4) and without TLR|Technical success, defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30% and residual stenosis less than 50% by duplex imaging.|Primary patency defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (systolic velocity ratio no greater than 2.4) and without TLR|Clinical success at follow-up defined as an improvement of Rutherford classification of one class or more as compared to the pre-procedure|Stent fracture rate determined on x-ray (Mild - single strut fracture; Moderate - fracture of more than one strut but without complete separation; Severe - complete separation)|Serious adverse events","http://ClinicalTrials.gov/show/NCT00637741",NA
"34726",34726,"NCT00670241","Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris","Completed","No Results Available","Psoriasis Vulgaris","Drug: calcipotriol and betamethasone (LEO 80185 gel)|Drug: LEO 80185 vehicle|Drug: Tacalcitol ointment","LEO Pharma","Both","Adult|Senior","Phase III",458,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","LEO 80185-G21","April 29, 2008","01/04/2008",2009-04-01,"August 11, 2009","01/08/2009","",2009-02-01,"Subjects with \Controlled disease\"" (\""Clear\"" or \""Almost Clear\"" disease) according to Investigator's global assessment of disease severity at week 8|Subjects with \""controlled disease\"" according to the Investigator's global assessment of disease severity at week 4|The percentage change in PASI from baseline to week 4 and 8|Subjects with relapse during the study and time to relapse|Subjects with rebound during the study""","http://ClinicalTrials.gov/show/NCT00670241",NA
"34744",34744,"NCT00698841","Study to Evaluate the Effect of Cetuximab on Corrected QT Interval Changes in Patients With Advanced Malignancies From Solid Tumors","Completed","No Results Available","Advanced Cancer IV, NOS","Drug: cetuximab","Bristol-Myers Squibb|ImClone LLC","Both","Adult|Senior","Phase II",3,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA225-315","June 16, 2008","01/02/2009",2009-12-01,"July 26, 2010","01/02/2010","",2009-12-01,"Average maximum change from time-matched baseline in QTc interval in study population|To assess the safety and tolerability of cetuximab administration in the study population","http://ClinicalTrials.gov/show/NCT00698841",NA
"34754",34754,"NCT00718341","Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients","Completed","No Results Available","Fragile X Syndrome","Drug: AF056|Drug: Placebo","Novartis","Male","Adult","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAFQ056A2204","July 17, 2008","01/06/2008",NA,"May 5, 2010","01/05/2010","",2009-02-01,"Aberrant-Behavior Checklist- Community Edition|28 days treatment with AFQ056 on behavior (communication, socialization, daily living, repetitive behaviors, anxiety/avoidance, clinical global improvement)|28 days treatment with AFQ056 on cognition (receptive language, attention, vigilance???)","http://ClinicalTrials.gov/show/NCT00718341",NA
"34763",34763,"NCT00715741","Does High Intraoperative Inspired Oxygen Reduce Postoperative Arterial Oxygen Saturation?","Completed","Has Results","Atelectasis","Other: FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water|Other: FiO2 0.3 without PEEP|Other: FiO2 >0.9 with 3-5 cm water PEEP|Other: FiO2 >0.9 without PEEP","University of Utah","Both","Adult|Senior","Phase II|Phase III",100,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic","29830","July 10, 2008","01/06/2008",2009-07-01,"February 2, 2010","01/02/2010","",2009-07-01,"Oxygen Requirement to Maintain SpO2>90%|Oxygen Requirement|Arterial Oxygen Saturation by Pulse Oximetry \(SpO2)\""|SpO2 Postoperatively""","http://ClinicalTrials.gov/show/NCT00715741",NA
"34782",34782,"NCT00759941","A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated IOP on a Prostaglandin","Completed","No Results Available","Glaucoma","Drug: AZOPT Solution|Drug: Placebo Eye Drops","Alcon Research","Both","Adult|Senior","Phase IV",90,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SMA-07-08","September 24, 2008","01/10/2007",NA,"January 27, 2010","01/01/2010","",2009-07-01,"Intraocular Pressure|Safety","http://ClinicalTrials.gov/show/NCT00759941",NA
"34802",34802,"NCT00788541","A Dose-volume Study of a Treatment for Elevated IOP Due to Open-angle Glaucoma or Ocular Hypertension","Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: Anecortave Acetate|Drug: Vehicle|Drug: Vehicle|Drug: Anecortave Acetate|Drug: Anecortave Acetate|Drug: Anecortave Acetate","Alcon Research","Both","Adult|Senior","Phase II",300,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","C-08-049","November 7, 2008","01/11/2008",NA,"September 30, 2009","01/09/2009","",2009-09-01,"Mean Intraocular Pressure|Percent of patients who remain rescue-medication free","http://ClinicalTrials.gov/show/NCT00788541",NA
"34809",34809,"NCT00805441","A Study in the Treatment of Alcohol Dependence.","Completed","No Results Available","Alcohol Dependence","Drug: LY686017|Drug: Placebo","Eli Lilly and Company","Both","Adult","Phase II",190,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12422|H8R-MC-HJAQ","December 5, 2008","01/12/2008",2009-07-01,"May 27, 2010","01/05/2010","",2009-07-01,"Percent reduction in heavy drinking days.|Percent days abstinent per month.|Number of drinks per drinking day during a month.|Drinker inventory of Consequences (DrInC)|Alcohol Urge questionnaire - change from baseline.|Penn Alcohol Craving Scale - change from baseline.|Beck Depression Inventory II (BDI-II) - change from baseline.|Beck Anxiety Index - change from baseline.|Gamma-glutamyl transferase -change from baseline.|Plasma carbohydrate deficient transferring (CDT) - change from baseline.|Health outcomes (Short Form 12)","http://ClinicalTrials.gov/show/NCT00805441",NA
"34829",34829,"NCT00819741","Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: repaglinide|Drug: metformin|Drug: repaglinide","Novo Nordisk","Both","Adult|Senior","Phase IV",433,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AGEE-3705","January 8, 2009","01/02/2009",2009-11-01,"January 6, 2011","01/01/2011","",2009-11-01,"Change in Glycosylated Haemoglobin A1c (HbA1c)|Change in Fasting Plasma Glucose|Change in 2-hour Postprandial Plasma Glucose|Change in 7-point Plasma Glucose Profile|Change in Fasting Serum Insulin|Change in 2-hour Postprandial Serum Insulin|Change in Fasting Serum C-peptide|Change in 2-hour Postprandial Serum C-peptide|Hypoglycaemic Episodes|Change in Blood Pressure|Physical Examinations|ECG (ElectroCardioGram)|Biochemistry: Alanine Aminotransferase (ALAT)|Biochemistry: Alanine Aminotransferase (ASAT)|Haematology: Haemoglobin","http://ClinicalTrials.gov/show/NCT00819741",NA
"34863",34863,"NCT00862641","A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease","Completed","Has Results","Asthma|Coronary Artery Disease|Pulmonary Disease, Chronic Obstructive","Drug: Regadenoson|Drug: Placebo","Astellas Pharma Inc","Both","Adult|Senior","Phase IV",1009,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic","3606-CL-3001","March 15, 2009","01/04/2009",2009-10-01,"January 11, 2011","01/01/2011","",2009-10-01,"Percentage of Subjects Who Had a >15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline Assessment|Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration|Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration|Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Absolute Values|Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Percent Predicted|Change From Baseline to the 2 Hour Post-dose Assessment for Forced Vital Capacity (FVC)|Change From Baseline to the 2 Hour Post-dose Assessment for FEV1/ FVC Ratio|Change From Baseline to the 2 Hour Post-dose Assessment for Oxygen Saturation Measured by Pulse Oximetry|Percentage of Selected Respiratory Adverse Events","http://ClinicalTrials.gov/show/NCT00862641",NA
"34872",34872,"NCT00922441","A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657??ÑK) During 24 Hours in Patients With Mild to Moderate Essential Hypertension","Completed","No Results Available","Essential Hypertension","Drug: Fimasartan 60 mg group|Drug: Fimasartan 120 mg group|Drug: Reference (Valsartan 80 mg) group","Boryung Pharmaceutical Co., Ltd|Seoul National University Hospital|Kyungpook National University|Catholic Medical Center|Inje University|Chonnam National University Hospital","Both","Adult|Senior","Phase II",92,"Industry|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A657-BR-CT-203","June 16, 2009","01/12/2008",2009-08-01,"December 14, 2010","01/12/2010","",2009-08-01,"Diastolic Blood Pressure","http://ClinicalTrials.gov/show/NCT00922441",NA
"34889",34889,"NCT00945841","Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010","Completed","No Results Available","Seasonal Influenza","Biological: inactivated split influenza vaccine","Novartis|Novartis Vaccines","Both","Adult|Senior","Phase III",126,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","V44_13S|2009-010565-23","July 22, 2009","01/06/2009",2009-06-01,"July 23, 2009","01/07/2009","",2009-06-01,"Evaluation of antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21|Evaluation of safety of inactivated split influenza vaccine","http://ClinicalTrials.gov/show/NCT00945841",NA
"34900",34900,"NCT00966641","Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults","Completed","No Results Available","Healthy Volunteers","Drug: Naproxen|Drug: PL 3100","PLx Pharma|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","Both","Adult|Senior","Phase I|Phase II",28,"Industry|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PL-NAP-001|NIH Grant 1R44AR056529-01","August 25, 2009","01/08/2009",2009-10-01,"May 10, 2010","01/05/2010","",2009-10-01,"Pharmacokinetic measures of plasma naproxen|Pharmacokinetic bioequivalence of PL 3100 and comparator naproxen","http://ClinicalTrials.gov/show/NCT00966641",NA
"34922",34922,"NCT00995241","Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV","Completed","No Results Available","HIV Infections","Drug: Raltegravir","Germans Trias i Pujol Hospital","Both","Adult","Phase IV",5,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RAL-IC","October 7, 2009","01/11/2009",2009-12-01,"September 9, 2010","01/09/2010","",2009-12-01,"Plasmatic and intracellular concentration of raltegravir|Clearance, CL/F|Volume of distribution, V/F|Elimination half-life, t1/2|Area under the plasma concentration-time curve during the dosing interval AUC0-24|Maximum concentration|Time to maximum concentration, Tmax|Minimum concentration","http://ClinicalTrials.gov/show/NCT00995241",NA
"34924",34924,"NCT00999141","Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy","Completed","No Results Available","Face-lift|Facial Rhytidectomy","Procedure: FS VH S/D 4 s-apr","Baxter Healthcare Corporation","Both","Adult|Senior","Phase III",75,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","550901","October 20, 2009","01/09/2009",2010-02-01,"December 17, 2010","01/12/2010","",2009-12-01,"The primary efficacy endpoint of this clinical study is the total drainage volume collected from each side of the face at 24 hours (?? 4h) after surgery.|The primary safety endpoint is the incidence of AEs related to the investigational product throughout the study period.","http://ClinicalTrials.gov/show/NCT00999141",NA
"34952",34952,"NCT01039441","The Effect of Local Anesthesia and Simple Maneuver on Shoulder Pain After Gynecologic Laparoscopy","Completed","No Results Available","Gynecologic Laparoscopic Surgery for Benign Adnexa Disease","Procedure: Intraperitoneal instillation of bupivacaine|Procedure: CO2 removal by means of a pulmonary recruitment maneuver|Procedure: Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver|Other: normal saline","Samsung Medical Center","Female","Child|Adult","Phase II",291,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2008-07-071","December 23, 2009","01/12/2008",2009-07-01,"December 23, 2009","01/10/2008","",2009-03-01,"The degree of shoulder pain after gynecologic laparoscopy","http://ClinicalTrials.gov/show/NCT01039441",NA
"34953",34953,"NCT01043341","Knowledge and Attitude About HPV Vaccines","Completed","No Results Available","Knowledge|Attitude|Behavior","Behavioral: educative folder","Universidade Cidade de Sao Paulo","Female","Adult","Phase IV",200,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Health Services Research","HPV vaccines","January 5, 2010","01/10/2006",2009-10-01,"January 8, 2010","01/01/2010","",2009-10-01,"Incorrect knowledge about HPV vaccines was detected on more than 50% women, however the attitude to accept the HPV vaccine was improved after educative intervention.|The acceptance of HPV vaccines by the women was depended on the sponsor by the public heath services","http://ClinicalTrials.gov/show/NCT01043341",NA
"35041",35041,"NCT01181141","Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery","Completed","No Results Available","Venous Thromboembolism","Drug: DU-176b (edoxaban)|Drug: Enoxaparin sodium 20mg","Daiichi Sankyo Inc.|Daiichi Sankyo, Tokyo, LTD.","Both","Adult|Senior","Phase III",92,"Industry|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","DU176b-B-J303","August 12, 2010","01/10/2008",2010-02-01,"August 12, 2010","01/08/2010","",2009-08-01,"Proportion of subjects with bleeding events|Proportion of subjects with venous thromboembolism events.","http://ClinicalTrials.gov/show/NCT01181141",NA
"35170",35170,"NCT00039442","Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: capecitabine","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child|Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069384|GOG-0128G","June 6, 2002","01/06/2002",NA,"February 13, 2009","01/07/2005","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00039442",NA
"35174",35174,"NCT00049842","Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)","Completed","No Results Available","Chronic Hepatitis C|Liver Fibrosis","Biological: peginterferon alfa-2b (SCH 54031)","Schering-Plough","Both","Adult","Phase III",700,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P02570","November 14, 2002","01/10/2002",2009-10-01,"October 29, 2009","01/10/2009","",2009-10-01,"To compare the PegIntron-treated group vs untreated control with respect to the fibrosis response status (ie, either improving the fibrosis score or preventing the worsening of the fibrosis score in subjects with METAVIR fibrosis score of F2 or F3).|For subjects with paired biopsies: the change in METAVIR fibrosis score between baseline and at the end of the 36-month treatment. The proportion of subjects whose METAVIR fibrosis score did not worsen during treatment compared to baseline.","http://ClinicalTrials.gov/show/NCT00049842",NA
"35177",35177,"NCT00052442","10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: pralatrexate","Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000258425|MSKCC-02078|NCI-H02-0100","January 24, 2003","01/08/2002",NA,"December 13, 2009","01/12/2009","",2009-03-01,"","http://ClinicalTrials.gov/show/NCT00052442",NA
"35187",35187,"NCT00066742","Tirapazamine Combined With Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: tirapazamine|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",85,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000318805|SWOG-S0222","August 6, 2003","01/09/2003",NA,"April 18, 2009","01/08/2006","",2009-01-01,"Measurability of lesions|Objective response|Best response|Performance status|Time to treatment failure|Survival","http://ClinicalTrials.gov/show/NCT00066742",NA
"35197",35197,"NCT00082342","Transcranial Electrical Polarization to Treat Symptoms of Parkinson's Disease","Completed","No Results Available","Parkinson Disease","Device: Phoressor II (IOMED)","National Institute of Neurological Disorders and Stroke (NINDS)","Both","Adult|Senior","Phase II",46,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","030116|03-N-0116","May 6, 2004","01/03/2003",NA,"January 28, 2010","01/02/2009","",2009-02-01,"Gait speed before and after real and placebo TEP course.|UPDRS total scores before and after real TEP course and after sham TEP course. UPDRS motor scores before and after real TEP course and after sham TEP course. Rigidity scores before and after real TEP course and after placebo TEP course.","http://ClinicalTrials.gov/show/NCT00082342",NA
"35213",35213,"NCT00065442","Provenge?ó (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy","Completed","Has Results","Prostate Cancer","Biological: Sipuleucel-T|Biological: APC-Placebo","Dendreon","Male","Adult|Senior","Phase III",512,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","D9902B","July 23, 2003","01/07/2003",2009-01-01,"September 2, 2010","01/09/2010","",2009-01-01,"Overall Survival|Time to Objective Disease Progression","http://ClinicalTrials.gov/show/NCT00065442",NA
"35223",35223,"NCT00122642","Alcohol Locks for the Prevention of Tunneled Catheter-related Infections","Completed","No Results Available","Bacteremia","Procedure: Alcohol-lock|Drug: placebo-lock","Erasmus Medical Center|Stichting Nuts Ohra","Both","Adult|Senior","Phase II|Phase III",440,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AL-01|SNO-T-07-57","July 19, 2005","01/08/2005",2009-09-01,"September 24, 2009","01/09/2009","",2009-06-01,"Endoluminal catheter related bacteremia|All catheter-related bacteremias with differential time to positivity (DTTP) > 2 hours|Catheter survival time|Vancomycin and linezolid use|Incidence of positive catheter tip cultures|Incidence of bacteremia/fungemia (catheter-related or not)","http://ClinicalTrials.gov/show/NCT00122642",NA
"35289",35289,"NCT00233142","Expressive Writing for Reducing Stress and Diabetic Symptoms in Diabetes Patients","Completed","No Results Available","Diabetes Mellitus|Stress|Depression","Behavioral: Expressive writing|Behavioral: Neutral writing","Syracuse University|National Center for Complementary and Alternative Medicine (NCCAM)","Both","Adult|Senior","Phase II",225,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","R01 AT002477|R01AT002477","September 13, 2005","01/09/2005",2009-02-01,"November 24, 2009","01/11/2009","",2009-02-01,"hemoglobin A1C (indicator of blood glucose)|Diabetes symptoms|stress levels|depression|cognitive function|quality of life","http://ClinicalTrials.gov/show/NCT00233142",NA
"35292",35292,"NCT00239642","Safety Efficacy of Iron Sucrose in Children","Completed","No Results Available","Anemia|Chronic Kidney Disease","Drug: iron sucrose injection","Luitpold Pharmaceuticals","Both","Child|Adult","Phase IV",120,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","1VEN03017","October 13, 2005","01/07/2005",2010-04-01,"August 24, 2010","01/08/2010","",2009-01-01,"Safety - incidence of adverse advents|Clinical success","http://ClinicalTrials.gov/show/NCT00239642",NA
"35334",35334,"NCT00295542","Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy","Completed","No Results Available","Hypertension","Device: Ambulatory blood pressure monitoring|Procedure: Chronotherapy, timing of antihypertensive medication|Drug: ACEI (including spirapril, enalapril, quinapril, lisinopril)|Drug: ARB (including valsartan, telmisartan, olmesartan)|Drug: beta blockers (including nebivolol, atenolol, carvedilol)|Drug: diuretics (torasemide, indapamide, HTCZ) and doxazosin|Procedure: Combination therapy in essential hypertension","University of Vigo|Hospital Clinico Universitario de Santiago|Xunta de Galicia|Ministerio de Educacion y Ciencia, Spain","Both","Adult|Senior","Phase IV",3344,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PGIDIT03-PXIB-32201PR|SAF2006-6254|INCITE07-PXI-322003ES","February 21, 2006","01/03/2000",2009-04-01,"April 27, 2009","01/04/2009","MAPEC",2009-04-01,"Prognostic value of ABPM, impact of changes in ambulatory BP and impact of circadian time of antihypertensive treatment in cardiovascular, cerebrovascular and renal risk assessment.|Influence of circadian time of antihypertensive treatment in BP control and the remodeling of the circadian BP pattern of hypertensive patients.|Prevalence of an altered BP profile as a function of the circadian time of treatment.","http://ClinicalTrials.gov/show/NCT00295542",NA
"35340",35340,"NCT00303342","Neuroendocrine Mechanisms in Behavioral Treatment of Insomnia","Completed","No Results Available","Insomnia","Behavioral: mind body treatment|Behavioral: desensitization","Brigham and Women's Hospital|National Center for Complementary and Alternative Medicine (NCCAM)","Both","Adult","Phase II",60,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","R01 AT002490|R01AT002490|R01 AT002490","March 14, 2006","01/03/2006",2009-06-01,"January 12, 2010","01/01/2010","",2009-06-01,"plasma cortisol|plasma melatonin|urinary catecholamines|heart rate variability|subjective sleep efficiency|objective sleep efficiency|actigraphy|EEG|subjective mood|depression|anxiety","http://ClinicalTrials.gov/show/NCT00303342",NA
"35341",35341,"NCT00305942","Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Small Cell","Drug: Topotecan|Drug: carboplatin","Sarah Cannon Research Institute|GlaxoSmithKline","Both","Adult|Senior","Phase II",60,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI LUN 117|105118","March 20, 2006","01/03/2006",2009-11-01,"November 1, 2010","01/11/2010","",2009-04-01,"Overall response rate","http://ClinicalTrials.gov/show/NCT00305942",NA
"35347",35347,"NCT00320242","Laser Light Cues for Gait Freezing in Parkinson's Disease","Completed","No Results Available","Parkinson's Disease","Device: Laser Cane and U-Step Walker with Laser Accessory","Beth Israel Deaconess Medical Center","Both","Adult|Senior","Phase III",26,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-P-000085","April 28, 2006","01/04/2006",2009-06-01,"July 31, 2009","01/07/2009","",2009-06-01,"Mean change from baseline (visit 1 until visit 2) to endpoint (after visit 2 until visit 3) in the freezing of gait questionnaire score.|Mean change in time to perform the timed gait test with versus without the laser feature from visit 1 to visit 3.|Mean change in falls per month for the period between visit 1 and visit 2 (without laser) compared to the period between visit 2 and visit 3 (with the laser).|Comparison of the changes in falls and the Freezing of Gait Questionnaire scores for group 1 versus group 2 based on the change from the first month after baseline visit to the second month after the baseline visit.","http://ClinicalTrials.gov/show/NCT00320242",NA
"35356",35356,"NCT00334542","Simvastatin in Preventing a New Breast Cancer in Women Who Are at High Risk for a New Breast Cancer After Undergoing Surgery for Ductal Carcinoma in Situ or Stage I, Stage II, or Stage III Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: simvastatin|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: radiomammography","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",50,"Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","JHOC-J0485, CDR0000477214|P50CA088843|P30CA006973|JHOC-J0485|JHOC-SKCCC-J0485|JHOC-04100404","June 7, 2006","01/03/2006",NA,"August 9, 2010","01/08/2010","",2009-06-01,"Change in a panel of biomarkers (high-sensitivity C-reactive protein [hsCRP], lipid profile, circulating estrogens, and contralateral breast density) from baseline|Prevalence of breast gene (estrogen receptor [ER]-?? and ER-??, cyclin D2, RAR-??, Twist, RASSF1A, and HIN-1) hypermethylation|Prevalence of Akt and p-Akt activation by contralateral core breast biopsies","http://ClinicalTrials.gov/show/NCT00334542",NA
"35390",35390,"NCT00386542","Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children","Completed","No Results Available","Influenza","Biological: Vaxigrip?ó trivalent inactivated influenza vaccine|Device: Intradermal spacer on Biojector?ó 2000 jet injector","Centers for Disease Control and Prevention|Fundaci??n Dominicana de Infectolog?¦a, Santo Domingo, Dominican Republic|Hospital Infant?¦l Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic|World Health Organization|Pan American Health Organization|PATH (Program for Appropriate Technology in Health), Seattle, WA, USA|Bioject Medical Technologies, Inc. [jet injector donor]|Sanofi Pasteur MSD","Both","Child","Phase I|Phase II",450,"U.S. Fed|Other|Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CDC-ISO-4785","October 10, 2006","01/10/2006",2010-05-01,"June 8, 2010","01/06/2010","",2009-11-01,"Rates of seroconversion (SC) on HI assay 1 month after dose 2. SC defined as titer >= 40 among initial-seronegatives (titer < 8 on day 0); OR, a followup titer which rises >= 4-fold.|Rates of local and systemic reactions|Seroprotection (SP) on HI assay, defined as >= 40 regardless of baseline|Geometric mean titers (GMT) on HI|Geometric mean increase (GMI) on HI","http://ClinicalTrials.gov/show/NCT00386542",NA
"35391",35391,"NCT00393042","Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR","Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Drug: Dexmethylphenidate XR|Drug: Mixed Amphetamine Salts, ER|Drug: placebo","University of Illinois|Novartis","Both","Child","Phase III",77,"Other|Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","CRIT124E US15|2006-0423|2006-04","October 25, 2006","01/01/2006",2009-02-01,"September 27, 2010","01/09/2010","",2009-02-01,"Number of minutes to sleep onset as determined by actigraph and sleep diary over 8 weeks.Ratings of side effects, mood.|Ratings of ADHD symptoms along with parent, self report and clinician ratings of mood, tolerability, stimulant side effects, functional outcomes (e.g. family conflicts), and vital signs over a period of 8 weeks.|The number of 10 repeat alleles of DAT1 as correlated with ADHD symptoms and CGI-S ratings.|Family Conflicts|ADHD Symptoms","http://ClinicalTrials.gov/show/NCT00393042",NA
"35396",35396,"NCT00400842","A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency","Completed","No Results Available","Exocrine Pancreatic Insufficiency|Chronic Pancreatitis","Drug: SA-001|Drug: SA-001|Drug: Placebo","Solvay Pharmaceuticals","Both","Adult|Senior","Phase III",274,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","S245.3.122","November 16, 2006","01/05/2007",2009-08-01,"September 29, 2009","01/09/2009","",2009-08-01,"Change in CFA from baseline to the end of double-blind treatment|Stool fat excretion, stool weight, stool frequency, nutritional parameters","http://ClinicalTrials.gov/show/NCT00400842",NA
"35402",35402,"NCT00409942","Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.","Completed","No Results Available","Congestive Heart Failure","Drug: Torasemide Prolonged Release|Drug: Furosemide","Ferrer Internacional S.A.","Both","Adult|Senior","Phase IV",142,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","N/GF-TORAFIC-06|EudraCT number 2006-001446-14","December 11, 2006","01/03/2007",2009-06-01,"July 14, 2009","01/06/2009","TORAFIC",2009-06-01,"Myocardial fibrosis reduction:measure of Serum carboxy-terminal peptide of procollagen type 1.|Clinical improvement (New York Heart Association classification, signs and symptoms of heart failure)|Cardiovascular events|NT-proBNP (Brain Natriuretic Peptide)|Hospitalizations, home care due to cardiovascular causes related to heart failure|Safety and tolerability|Quality of Life (Minnesota Test)","http://ClinicalTrials.gov/show/NCT00409942",NA
"35408",35408,"NCT00412542","Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas","Completed","No Results Available","Glioblastoma Multiforme|Glioma","Drug: Thalidomide|Drug: CPT-11|Procedure: MRI Scan|Procedure: Quantitative Sensory Tests (QST)","M.D. Anderson Cancer Center|Celgene Corporation","Both","Child|Adult|Senior","Phase II",78,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM02-595","December 15, 2006","01/10/2003",2009-10-01,"October 8, 2009","01/10/2009","",2009-10-01,"To study if the drug Thalomid (thalidomide) when combined with CPT-11 is effective in the treatment of brain cancer.|To learn if a special MRI technique is useful in observing the effect of treatment on the tumor","http://ClinicalTrials.gov/show/NCT00412542",NA
"35436",35436,"NCT00463242","A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)","Completed","No Results Available","Major Depressive Disorder","Drug: agomelatine|Drug: paroxetine|Drug: placebo","Novartis","Both","Adult|Senior","Phase III",501,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAGO178A2303","April 19, 2007","01/03/2007",NA,"November 8, 2010","01/11/2010","",2009-06-01,"Change from Baseline to Week 8 on the total score Hamilton Depression Rating Scale|To demonstrate less sexual dysfunction in patients with MDD receiving agomelatine compared to paroxetine, as measured by the change from baseline to Week 8 on the total score of the Arizona Sexual Experience Scale (ASEX).|Proportion of patients who demonstrate clinical improvement where improvement is defined by a score of 1 or 2 on the Clinical Global Impression Improvement (CGI-I) scale at Week 8.|Proportion of patients with MDD who achieve remission,|Change from baseline to Week 8 on the total score and Anxiety subscale of the Hospital Anxiety and Depression Scale (HAD).","http://ClinicalTrials.gov/show/NCT00463242",NA
"35451",35451,"NCT00490542","Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State","Completed","No Results Available","Bipolar Disorder|Bipolar Depression|Depression","Drug: ziprasidone (Geodon)|Drug: placebo","Tufts Medical Center|Pfizer","Both","Adult","Phase II",100,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","GA128000","June 20, 2007","01/12/2006",2009-08-01,"November 13, 2009","01/11/2009","",2009-08-01,"To determine if ziprasidone is effective for the depressive mixed state in bipolar and unipolar depression.","http://ClinicalTrials.gov/show/NCT00490542",NA
"35454",35454,"NCT00494442","Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-Positive Advanced Ovarian Cancer","Completed","No Results Available","Ovarian Neoplasm","Drug: KU-0059436 (AZD2281)(PARP inhibitor)","AstraZeneca|KuDOS Pharmaceuticals Limited","Female","Adult|Senior","Phase II",57,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KU36-58|D0810C00009","June 27, 2007","01/06/2007",2009-03-01,"May 14, 2009","01/05/2009","ICEBERG 2",2009-03-01,"Objective tumour response rate|Clinical benefit rate|Safety and tolerability","http://ClinicalTrials.gov/show/NCT00494442",NA
"35465",35465,"NCT00511342","Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)","Completed","No Results Available","Contraception","Drug: NOMAC-E2|Drug: LNG/EE","Schering-Plough","Female","Adult","Phase III",110,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","Protocol No. 292005|P05765","August 2, 2007","01/09/2006",2009-06-01,"October 2, 2009","01/10/2009","",2009-06-01,"Bone Mineral Density (BMD) of the lumbar spine (L2-L4) and femoral neck. BMD will be measured by DEXA scans. In addition to the BMD value (g/cm2), the \z-score\"" will also be determined.|Contraceptive efficacy as determined by serum HCG pregnancy test (or home pregnancy test).|Drug safety as determined by [S]AE monitoring","http://ClinicalTrials.gov/show/NCT00511342",NA
"35478",35478,"NCT00532142","The ROVO Study: Radial Optic Neurotomy for CVO","Completed","No Results Available","Central Retinal Vein Occlusion","Drug: Intravitreal Triamcinolone|Procedure: Radial Optic Neurotomy|Other: Placebo - Sham Intravitreal Injection","Rudolf Foundation Clinic","Both","Adult|Senior","Phase II|Phase III",NA,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","EK-04-010-0204","September 18, 2007","01/04/2005",2009-08-01,"October 29, 2009","01/10/2009","",2009-08-01,"Proportion of eyes with an improvement of more than 15 letters (approximately > 3 lines of visual acuity gain) after one year as compared to baseline","http://ClinicalTrials.gov/show/NCT00532142",NA
"35482",35482,"NCT00537342","Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)","Completed","No Results Available","Allergy|Rhinoconjunctivitis","Biological: Immunotherapy with modified extract of O. europaea pollen","Laboratorios Leti, S.L.","Both","Adult","Phase III",83,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2006-001130-41|6018-PG-OSL-142","September 28, 2007","01/10/2007",2009-12-01,"December 16, 2010","01/12/2010","",2009-09-01,"Symptom score|Dose-response skin prick-test|Medication score|Rhinoconjunctivitis quality of life questionnaire|Analogical visual scale|Serology|Record of adverse events","http://ClinicalTrials.gov/show/NCT00537342",NA
"35488",35488,"NCT00550342","Rituximab Treatment of Focal Segmental Glomerulosclerosis","Completed","No Results Available","Focal Segmental Glomerulosclerosis (FSGS)","Drug: rituximab","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Genentech","Both","Child|Adult","Phase II",10,"NIH|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","R21 DK77329 (completed)|1 R21 DK077329-01A1","October 26, 2007","01/01/2008",2009-12-01,"September 2, 2010","01/09/2010","",2009-12-01,"The primary endpoint will be resolution of proteinuria defined as a Up/C ratio of <0.2.|Number of subjects who achieve partial remission defined at a fall of 50% or more in the Up/C ratio from the pre-treatment baseline|Number of subjects who develop a recurrence or increase of proteinuria on samples obtained at least 4 weeks apart|Effect of treatment on PF levels|Safety as measured by infections and drug infusion reactions.","http://ClinicalTrials.gov/show/NCT00550342",NA
"35489",35489,"NCT00549042","Study to Test the Effectiveness of Controlled-Release OROS?ó Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain","Completed","No Results Available","Chronic Low Back Pain","Drug: Drug: OROS?ó hydromorphone at 4, 8, 16, and 32 mg tablets will be used to provide doses of 12-64mg.","Neuromed Pharmaceuticals","Both","Adult|Senior","Phase III",450,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NMT 1077-301","October 23, 2007","01/09/2007",2009-01-01,"March 12, 2009","01/03/2009","",2009-01-01,"The primary efficacy variable is the mean change from baseline to week 12 (or last visit) average pain intensity of double-blind treatment phase based on the weekly pain intensity scores obtained from patient diary entry, as compared to placebo.|Additional analyses on pain intensity.","http://ClinicalTrials.gov/show/NCT00549042",NA
"35520",35520,"NCT00598442","Safety and Efficacy of Hematide?ºÑ for the Correction of Anemia in Patients With Chronic Renal Failure (PEARL 2)","Completed","No Results Available","Chronic Renal Failure|Anemia","Drug: Hematide?ºÑ|Drug: Darbepoetin Alfa","Affymax","Both","Adult|Senior","Phase III",493,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AFX01-13","January 10, 2008","01/12/2007",2009-12-01,"October 7, 2010","01/10/2010","PEARL 2",2009-12-01,"Mean change in Hgb between baseline and the Evaluation Period.|Proportion of patients who received RBC transfusions during the Correction and Evaluation Periods.|Proportion of patients achieving Hgb response during the Correction and Evaluation Periods.","http://ClinicalTrials.gov/show/NCT00598442",NA
"35525",35525,"NCT00530842","Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD","Completed","Has Results","Pulmonary Disease, Chronic Obstructive","Drug: Tiotropium plus Salmeterol|Drug: Fluticasone/Salmeterol","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase IV",344,"Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment","205.334","September 17, 2007","01/09/2007",NA,"March 30, 2010","01/03/2010","",2009-01-01,"Post-dose TGV(FRC) (After 8 Weeks)|Endurance Time (After 8 Weeks)|Post-dose TGV(FRC) (After 4 Weeks)|Endurance Time (After 4 Weeks)|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes|Static Lung Volumes (Percent)|Static Lung Volumes (Percent)|Static Lung Volumes (Percent)|Static Lung Volumes (Percent)|Static Lung Volumes (Percent)|Static Lung Volumes (Percent)|Static Lung Volumes (Percent)|Static Lung Volumes (Percent)|Slow Vital Capacity (SVC)|Slow Vital Capacity (SVC)|Slow Vital Capacity (SVC)|Slow Vital Capacity (SVC)|Forced Expiratory Volume in 1 Second (FEV1)|Forced Expiratory Volume in 1 Second (FEV1)|Forced Expiratory Volume in 1 Second (FEV1)|Forced Expiratory Volume in 1 Second (FEV1)|Forced Expiratory Volume in 1 Second (FEV1)|Forced Expiratory Volume in 1 Second (FEV1)|Forced Expiratory Volume in 1 Second (FEV1)|Forced Expiratory Volume in 1 Second (FEV1)|Forced Vital Capacity (FVC)|Forced Vital Capacity (FVC)|Forced Vital Capacity (FVC)|Forced Vital Capacity (FVC)|FEV1 Over FVC (Percent)|FEV1 Over FVC (Percent)|FEV1 Over FVC (Percent)|FEV1 Over FVC (Percent)|Symptom Intensity During Exercise|Symptom Intensity During Exercise|Symptom Intensity During Exercise|Symptom Intensity During Exercise|Dyspnea and Leg Discomfort|Locus of Symptom Limitation at Peak Exercise During Exercise|Locus of Symptom Limitation at Peak Exercise During Exercise|Locus of Symptom Limitation at Peak Exercise During Exercise","http://ClinicalTrials.gov/show/NCT00530842",NA
"35535",35535,"NCT00603642","P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura","Completed","Has Results","Idiopathic Thrombocytopenic Purpura","Drug: Placebo|Drug: AMG 531","Amgen","Both","Adult|Senior","Phase III",34,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060216","January 17, 2008","01/10/2007",2009-04-01,"November 18, 2010","01/11/2010","",2009-03-01,"Weeks With Weekly Platelet Response|Participants With Increased Platelet Count From Baseline of at Least 20 x 10^9/L|Change From Baseline in Mean of Last 4 Weekly Platelet Counts|Weeks With Platelet Count Between 50 and 200|Participants Requiring Rescue Medications","http://ClinicalTrials.gov/show/NCT00603642",NA
"35538",35538,"NCT00621842","Lamotrigine for Symptoms of Geriatric Bipolar Depression","Completed","No Results Available","Bipolar Disorder|Depression, Bipolar","Drug: Lamotrigine regular tablet formulation|Drug: Lamotrigine novel formulation","University Hospitals of Cleveland|GlaxoSmithKline","Both","Adult|Senior","Phase III",60,"Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","L0971|GSK110720|IND 78,081","February 12, 2008","01/01/2008",2009-12-01,"January 26, 2010","01/01/2010","Geri-BD SAD",2009-12-01,"Assessment of change in depressive symptoms from baseline on the Montgomery Asberg Depression Rating Scale (MADRS)|Assessment of adverse effects with standardized rating scales and Udvalg fur Kliniske Undersogelser (UKU)|Change in depressive symptoms from baseline using the Hamilton Depression Rating Scale (GRID-HAM-D)|Change in manic symptoms from baseline using the Young Mania Rating Scale (YMRS)|Change from baseline in overall clinical diagnosis using the CGI-BP|Change in or appearance of extrapyramidal symptoms from baseline using the SAS, BAS, and AIMS scales.|Change in body weight from baseline|Spontaneous reports of adverse effects","http://ClinicalTrials.gov/show/NCT00621842",NA
"35550",35550,"NCT00642642","Safety and Efficacy Study of Isolagen Therapy in the Treatment of Severe Facial Acne Scarring","Completed","No Results Available","Acne Scarring of the Face","Biological: Autologous Human Fibroblasts (Isolagen TherapyTM)|Biological: Placebo","Isolagen Technologies, Inc.","Both","Adult","Phase II|Phase III",120,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IT-A-008","March 19, 2008","01/11/2007",NA,"October 22, 2009","01/10/2009","",2009-03-01,"Change from baseline of Investigator assessment of acne scarring severity|Change from baseline of subject assessment of appearance|Adverse Events, vital signs and physical examination|Change from baseline of subject and Investigator assessments of scarring","http://ClinicalTrials.gov/show/NCT00642642",NA
"35568",35568,"NCT00624442","A Study of CK-1827452 Infusion in Stable Heart Failure","Completed","Has Results","Heart Failure","Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: Placebo|Drug: Placebo|Drug: CK-1827452|Drug: Placebo|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452","Cytokinetics","Both","Adult|Senior","Phase II",45,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CY 1121","December 21, 2007","01/04/2007",2009-02-01,"July 16, 2010","01/07/2010","",2009-02-01,"Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations|Change From Baseline of Fractional Shortening at Various CK-1827452 Plasma Concentrations|Pharmacokinetics of CK-1827452 Injection in Stable Heart Failure Patients","http://ClinicalTrials.gov/show/NCT00624442",NA
"35577",35577,"NCT00685542","Effect of Diacerein on Hand Osteoarthritis","Completed","No Results Available","Osteoarthritis","Drug: diacerein|Drug: placebo","Seoul National University Hospital|Myungmoon Pharm. Co.","Both","Adult|Senior","Phase IV",86,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H-081-043-232","May 24, 2008","01/06/2008",2009-12-01,"December 2, 2010","01/12/2010","",2009-10-01,"Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain score at 4 week point|AUSCAN stiffness score at 4 week point|AUSCAN pain score at 12 week point","http://ClinicalTrials.gov/show/NCT00685542",NA
"35593",35593,"NCT00710242","Study to Assess Safety and Efficacy of DF01 in Reducing Prolonged Labor","Completed","No Results Available","Pregnancy|Labor","Drug: DF01|Drug: Placebo","Dilafor AB","Female","Adult","Phase II",263,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PPL02","July 1, 2008","01/04/2007",2009-05-01,"May 18, 2009","01/05/2009","",2009-03-01,"Time from the time of at least 3 cm cervix dilatation and 3 contractions of minimum one minute's duration/10 minutes until partus in women with vaginal delivery|Complications of labor","http://ClinicalTrials.gov/show/NCT00710242",NA
"35611",35611,"NCT00741442","A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout","Completed","No Results Available","Hyperuricemia","Drug: RDEA806|Drug: Placebo","Ardea Biosciences, Inc.","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RDEA806-501","August 25, 2008","01/07/2008",2009-09-01,"October 12, 2009","01/10/2009","",2009-04-01,"To compare the proportion of subjects whose serum uric acid (sUA) level is <6.0 mg/dL following 4 weeks of continuous treatment with RDEA806.|To evaluate the proportion of subjects whose sUA levels are <6.0 mg/dL, <5.0 mg/dL and <4.0 mg/dL, at each visit.|To evaluate the absolute and percent reduction from baseline in sUA levels|To evaluate percent change in 24-hour urine uric acid level","http://ClinicalTrials.gov/show/NCT00741442",NA
"35629",35629,"NCT00771342","Efficacy Study to Evaluate the Effect of Nitric Oxide on the Treatment of Tinea Pedis (Athlete's Foot)","Completed","No Results Available","Tinea","Drug: Nitric Oxide|Drug: Nitrogen","Nitric BioTherapeutics, Inc","Both","Adult|Senior","Phase II",50,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","CTP 6","October 10, 2008","01/12/2008",2009-08-01,"February 2, 2010","01/02/2010","",2009-06-01,"Evidence of fungicidal activity as confirmed by mycological culture or microscopic evaluation and improvement in Clinical Symptom Severity Score|Incidence of adverse events","http://ClinicalTrials.gov/show/NCT00771342",NA
"35650",35650,"NCT00805142","Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain","Completed","No Results Available","Pain|Analgesics","Drug: Tapentadol","Janssen Pharmaceutical K.K.|Gr??nenthal GmbH","Both","Adult|Senior","Phase II",78,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR015532","December 8, 2008","01/10/2008",2009-07-01,"April 26, 2010","01/04/2010","",2009-07-01,"The proportion of patients with \sustained pain control\"" for the 5-day fixed-dose phase phase determined by numeric rating scale and the number of rescue dose prescribed at fixed dose period.|24-hour numeric rating scale; visual analogue scale; rescue dose; proportion of patient achieved dose adjustment; sleep questionnaire; patient's global impression of change; adverse event; vital signs; ECG examinations;serum tapentadol concentration","http://ClinicalTrials.gov/show/NCT00805142",NA
"35682",35682,"NCT00853242","Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis","Completed","No Results Available","Kidney Failure, Chronic","Drug: Genz-644470|Drug: Genz-644470|Drug: Genz-644470|Drug: Placebo|Drug: Sevelamer carbonate, Renvela|Drug: Sevelamer carbonate, Renvela|Drug: Sevelamer carbonate, Renvela","Genzyme","Both","Adult|Senior","Phase II",349,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APB00108","February 27, 2009","01/02/2009",2009-09-01,"October 2, 2010","01/10/2010","LEAP",2009-09-01,"Change from baseline in serum phosphorus (Genz-644470 and placebo)|Evaluation of safety and tolerability|Change from baseline in serum phosphorus (Genz-644470 and sevelamer carbonate)|Change from baseline in serum calcium-phosphorus product|Change from baseline in serum lipids","http://ClinicalTrials.gov/show/NCT00853242",NA
"35696",35696,"NCT00881842","Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season","Completed","No Results Available","Influenza","Biological: Trivalent influenza subunit vaccine Influvac","Solvay Biologicals","Both","Adult|Senior","Phase III",120,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","S201.3.128|2009-010900-27","April 14, 2009","01/06/2009",2009-07-01,"October 8, 2009","01/10/2009","",2009-07-01,"HI titers and its derived parameters after 2 weeks (seroprotection, seroconversion and mean fold increase), reactogenicity and inconvenience of Influvac?ó 2008/2009 as defined by the CHMP guideline for influenza vaccines.|HI titers and its derived parameters after 3 weeks (seroprotection, seroconversion and mean fold increase), reactogenicity and inconvenience of Influvac?ó 2008/2009 as defined by the CHMP guideline for influenza vaccines.","http://ClinicalTrials.gov/show/NCT00881842",NA
"35701",35701,"NCT00827242","Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily","Completed","Has Results","Benign Prostatic Hyperplasia","Drug: Placebo|Drug: tadalafil","Eli Lilly and Company","Male","Adult|Senior","Phase III",325,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","10893|H6D-MC-LVHJ","January 20, 2009","01/01/2009",2009-11-01,"October 19, 2010","01/10/2010","",2009-11-01,"Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS)|Change From Baseline to 4 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index|Change From Baseline to 12 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index|Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore|Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore|Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Nocturia Question|Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index|Patient Global Impression of Improvement (PGI-I), Number of Participants in 7 Response Categories|Clinical Global Impression of Improvement (CGI-I), Number of Participants in 7 Response Categories|Change From Baseline to 1 Week, International Prostate Symptom Score (IPSS)|Change From Baseline to 4 Weeks, International Prostate Symptom Score (IPSS)|Change From Baseline to 12 Weeks, International Index of Erectile Function (IIEF)- Erectile Function (EF) Domain Scores|Change From Baseline to 12 Weeks, Peak Flow Rate (Qmax) by Uroflowmetry|Change From Baseline to 12 Weeks, Mean Flow Rate (Qmean) by Uroflowmetry|Change From Baseline to 12 Weeks, Voided Volume (Vcomp) by Uroflowmetry|Change From Baseline to 12 Weeks, Postvoid Residual (PVR) Volume","http://ClinicalTrials.gov/show/NCT00827242",NA
"35706",35706,"NCT00889642","Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers","Completed","No Results Available","Local Anesthesia","Device: Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Device: Iontophoretic Drug Delivery System with Epinephrine","Dharma Therapeutics Inc.","Both","Adult|Senior","Phase II",90,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dharma-NSCO3","April 27, 2009","01/05/2009",2009-06-01,"June 22, 2009","01/06/2009","",2009-05-01,"Following the iontophoresis treatment an IV will be inserted into the treatment area and the amount of pain will be assessed using the median visual analog pain scale (VAS).|Monitor the nature and frequency of adverse events associated with the iontophoretic device through observation during treatment.|Determining the duration of anesthesia through standard pin prick testing.","http://ClinicalTrials.gov/show/NCT00889642",NA
"35715",35715,"NCT00916942","Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)","Completed","No Results Available","Postherpetic Neuralgia","Drug: capsaicin 8%|Drug: Lidocaine (2.5%)/Prilocaine (2.5%) Cream","NeurogesX","Both","Adult|Senior","Phase II",20,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C123","June 8, 2009","01/06/2009",2009-07-01,"September 3, 2009","01/09/2009","",2009-06-01,"Duration of patch application|Mean change in NPRS scores from pre-treatment values to subsequent time points on the day of treatment","http://ClinicalTrials.gov/show/NCT00916942",NA
"35722",35722,"NCT00933842","Dermacyd PH_DESILSTY_FL (Lactic Acid) - Photo Evaluation - Stay on Floral","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Both","Adult","Phase III",27,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LACAC_L_04805","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"Measure of the photo irritation test and the photosensitivity by using UVA irradiation and evaluation according to International Contact Dermatitis Research Group (ICDRG) scale. Evaluation of the sensibility according to the skin type.","http://ClinicalTrials.gov/show/NCT00933842",NA
"35749",35749,"NCT00968942","Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","Completed","No Results Available","Lateral Canthal Lines|Crow's Feet|Facial Wrinkles","Drug: Botulinum Toxin Type A|Drug: Placebo","Revance Therapeutics, Inc.","Both","Adult","Phase II",36,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RT001-CL015LCL","August 28, 2009","01/08/2009",2009-10-01,"November 16, 2009","01/11/2009","",2009-10-01,"The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line-Rest Severity Scale of the LCA at Baseline compared to Week 8; incidence of treatment emergent AEs|The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line Severity at Smile and at Rest from Baseline to Weeks 2, 4, 6, 8; incidence of treatment emergent AEs","http://ClinicalTrials.gov/show/NCT00968942",NA
"35798",35798,"NCT01039142","Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis","Completed","No Results Available","Psoriasis","Drug: Acitretin","Postgraduate Institute of Medical Education and Research","Both","Adult","Phase IV",61,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12345","December 23, 2009","01/03/2008",2009-03-01,"December 23, 2009","01/02/2008","",2009-02-01,"Change in Psoriasis area severity index from baseline to 12 weeks after acitretin therapy|Frequency of adverse effects at 3 different doses of acitretin","http://ClinicalTrials.gov/show/NCT01039142",NA
"35803",35803,"NCT01048242","Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)","Completed","No Results Available","Insomnia|Obstructive Sleep Apnea","Drug: rozerem|Drug: Placebo","University of Pennsylvania|Takeda Global Research & Development Center, Inc.","Both","Adult|Senior","Phase III",29,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","804640","April 15, 2009","01/07/2006",2009-03-01,"January 11, 2010","01/01/2010","",2009-03-01,"Sleep onset latency","http://ClinicalTrials.gov/show/NCT01048242",NA
"35878",35878,"NCT01182142","Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients","Completed","No Results Available","Metastatic Renal Cell Carcinoma","Drug: Capecitabine","Kidney Cancer Research Bureau","Both","Adult|Senior","Phase II",51,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRT-06.CAP","August 11, 2010","01/09/2007",2010-08-01,"August 22, 2010","01/08/2010","",2009-09-01,"Overall response rate|Overall survival Progression-free survival","http://ClinicalTrials.gov/show/NCT01182142",NA
"35937",35937,"NCT01278342","Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients","Completed","No Results Available","Acromegaly","Drug: Sandostatin LAR|Drug: pegvisomant|Drug: cabergoline","Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",65,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSMS995BIC03|2005-005852-42","January 14, 2011","01/09/2006",NA,"January 14, 2011","01/01/2011","HOSCAR",2009-11-01,"Growth Hormone (GH) and insulin-like growth factor-I (IGF l) control|biochemical control on high dose SandostatinLAR in mono treatment|partial biochemical control under combination of high dose of Sandostatin + combination partner","http://ClinicalTrials.gov/show/NCT01278342",NA
"36001",36001,"NCT00020943","Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Cancer and Leukemia Group B|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000068732|CALGB-59909","July 11, 2001","01/06/2001",NA,"November 19, 2009","01/09/2004","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT00020943",NA
"36062",36062,"NCT00134043","Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: vorinostat","Arthur G. James Cancer Hospital & Richard J. Solove Research Institute|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",25,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000439450|OSU-04110|NCI-6902","August 22, 2005","01/12/2005",NA,"February 6, 2010","01/01/2007","",2009-03-01,"Objective response rate|Toxicity","http://ClinicalTrials.gov/show/NCT00134043",NA
"36134",36134,"NCT00232843","The Study to Treat Superficial Femoral Artery Occlusions.","Completed","No Results Available","Arterial Occlusive Diseases","Device: stent|Device: angioplasty","Cordis Corporation","Both","Adult|Senior","Phase IV",150,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EE04-01UK","October 4, 2005","01/03/2005",2009-05-01,"June 2, 2009","01/06/2009","SUPER UK",2009-04-01,"Binary restenosis as demonstrated by Duplex Ultrasound.|Device success.|Procedural success: defined as successful recanalization, without the occurrence of a SAE event.|Ankle Brachial Index|Restenosis measured by Duplex Ultrasound","http://ClinicalTrials.gov/show/NCT00232843",NA
"36155",36155,"NCT00261443","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania","Completed","No Results Available","Bipolar Disorder","Drug: Lithium or Valproate with PBO|Drug: Lithium or Valproate with Aripiprazole","Bristol-Myers Squibb|Otsuka America Pharmaceutical","Both","Adult|Senior","Phase IV",1300,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CN138-189","December 1, 2005","01/09/2005",2009-10-01,"April 27, 2010","01/04/2010","",2009-06-01,"Any mood episode|Mean change in the Clinical Global Impression Scale for Bipolar Disorder (CGI-BP) Severity of Illness Score (mania)","http://ClinicalTrials.gov/show/NCT00261443",NA
"36195",36195,"NCT00327743","Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer|Cancer","Drug: larotaxel (XRP9881)|Drug: capecitabine","Sanofi-Aventis","Female","Adult|Senior","Phase I|Phase II",34,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TCD6511|EudraCT:2006-006474-21","May 4, 2006","01/08/2006",2009-03-01,"August 3, 2010","01/08/2010","",2009-03-01,"Safety, tolerability, and maximum tolerated dose (MTD) of XRP9881 when given in combination with capecitabine|Response in patients with measurable disease","http://ClinicalTrials.gov/show/NCT00327743",NA
"36204",36204,"NCT00331643","Ixabepilone in Treating Young Patients With Refractory Solid Tumors","Completed","No Results Available","Kidney Cancer|Neuroblastoma|Sarcoma","Drug: ixabepilone","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",120,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000472912|COG-ADVL0524|NCI-06-C-0146|NCI-P6451","May 30, 2006","01/04/2006",NA,"November 20, 2010","01/11/2010","",2009-01-01,"Time to progression as measured by the product-limit method of Kaplan-Meier|Progression-free survival at 6 months|Response rates (complete response and partial response)|Toxicity|Correlate tumor burden and change in tumor burden by RECIST, WHO, and volumetric analysis","http://ClinicalTrials.gov/show/NCT00331643",NA
"36247",36247,"NCT00405743","A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies","Completed","No Results Available","Hematologic Malignancies|AML","Drug: CP-4055|Drug: CP-4055","Clavis Pharma","Both","Adult|Senior","Phase I|Phase II",153,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CP4055-106","November 29, 2006","01/05/2006",2010-05-01,"September 3, 2010","01/09/2010","",2009-05-01,"Phase I: Determine the MTD and PK properties of CP-4055 single agent.|Phase II: Determine the efficacy of CP-4055 single agent in AML|Phase I: Evaluate the safety profile of CP-4055 single agent.|Determine the MTD and PK of CP-4055 in combination with idarubicin.|Phase II: Extended evaluation of the safety profile of CP-4055 single agent in AML","http://ClinicalTrials.gov/show/NCT00405743",NA
"36259",36259,"NCT00429143","Haploidentical Transplant for Hematological Malignancies","Completed","No Results Available","Hematologic Malignancies","Procedure: Haploidentical Allogeneic Transplantation","Thomas Jefferson University","Both","Adult|Senior","Phase I|Phase II",27,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06U.20|2005-84","January 29, 2007","01/01/2006",2010-06-01,"July 21, 2010","01/07/2010","",2009-08-01,"Overall Survival|Engraftment, Immune Reconstitution, GVHD","http://ClinicalTrials.gov/show/NCT00429143",NA
"36285",36285,"NCT00468143","A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall","Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Drug: Adderall ?ó and Adderall XR ?ó","New York University School of Medicine","Both","Adult","Phase IV",49,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","IR v XR","April 30, 2007","01/08/2007",2009-01-01,"September 22, 2009","01/09/2009","",2009-01-01,"Medication Event Monitoring System (MEMS?ó). Dosage adherence (MEMSd) is the number of bottle openings divided by number of doses prescribed.|Medication Event Monitoring System (MEMS?ó). Regimen adherence (MEMSr) is a percentage of the number of days in which the complete dose regimen was taken as prescribed.|Medication Event Monitoring System (MEMS?ó). Time adherence (MEMSt) is the percentage of doses taken within an interval compared to the total number of dosing intervals.|Dichotomous Measure of Nonadherence|Pill count|self report","http://ClinicalTrials.gov/show/NCT00468143",NA
"36355",36355,"NCT00573443","Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS","Completed","No Results Available","Pseudobulbar Affect (PBA)","Drug: AVP-923","Avanir Pharmaceuticals|Kendle International","Both","Adult|Senior","Phase III",326,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","07-AVR-123","December 13, 2007","01/12/2007",2009-09-01,"October 3, 2010","01/10/2010","STAR",2009-06-01,"The primary efficacy endpoint is the number of laughing and/or crying episodes as recorded in the patient diary.|The main secondary endpoint is the mean change in CNS-LS score.","http://ClinicalTrials.gov/show/NCT00573443",NA
"36364",36364,"NCT00595543","Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%","Completed","No Results Available","Acute Pseudophakic Cystoid Macular Edema","Drug: Bromfenac|Drug: Ketorolac|Drug: Diclofenac","Bp Consulting, Inc","Both","Adult|Senior","Phase IV",166,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","5349","January 7, 2008","01/01/2008",2009-03-01,"March 17, 2009","01/03/2009","",2009-03-01,"Acute Pseudophakic Cystoid Macular Edema|Visual Acuity","http://ClinicalTrials.gov/show/NCT00595543",NA
"36368",36368,"NCT00600743","Effect of a CCK-1R Agonist on Food Intake in Humans","Completed","No Results Available","Bulimia Nervosa|Normal Subjects Eating to Satiation|Normal Subjects Overeating","Drug: GSKI181771X (CCK-1R agonist)|Drug: GSKI181771X (CCK-1R agonist)","St. Luke's-Roosevelt Hospital Center|GlaxoSmithKline","Female","Adult","Phase II",40,"Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science","07-101","January 14, 2008","01/01/2008",2009-02-01,"March 3, 2010","01/03/2010","GSK",2009-02-01,"Significant reduction in food intake by drug compared to placebo|Significant increase in satiation after drug compared to placebo","http://ClinicalTrials.gov/show/NCT00600743",NA
"36379",36379,"NCT00617643","Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis","Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Nevirapine without dose escalation|Drug: Nevirapine initiation with dose escalation","Makerere University|University of Liverpool","Both","Adult","Phase IV",18,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CPR 004","February 5, 2008","01/05/2008",2010-12-01,"December 3, 2010","01/12/2010","",2009-06-01,"To compare the pharmacokinetics of nevirapine with dose escalation and without dose escalation of nevirapine on day 7, 14 and 21 in patients who are on rifampicin therapy.|Safety and tolerability of nevirapine when administered in HIV-TB coinfected patients receiving rifampicin","http://ClinicalTrials.gov/show/NCT00617643",NA
"36385",36385,"NCT00628043","Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients","Completed","No Results Available","Anemia","Drug: epoetin beta|Drug: placebo","Chugai Pharmaceutical","Both","Adult|Senior","Phase III",160,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","EPO316 JP","February 24, 2008","01/05/2008",2009-09-01,"September 17, 2009","01/09/2009","",2009-05-01,"The proportion of the subjects who receive red blood cell (RBC) transfusion and/or hemoglobin (Hb) concentration < 8.0 g/dL|Change in Hb|Change in FACT- total Fatigue Subscale score (FSS)|Requirement for RBC transfusion","http://ClinicalTrials.gov/show/NCT00628043",NA
"36400",36400,"NCT00641043","Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: BI 1356|Drug: Placebo|Drug: Pioglitazone","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",389,"Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1218.15|EudraCT 2007-002456-41","February 29, 2008","01/03/2008",NA,"June 24, 2009","01/06/2009","",2009-06-01,"Change from baseline in HbA1c (HbA1c after 24 weeks of treatment).|Secondary endpoints are the change from baseline in fasting plasma glucose (FPG) after 24 weeks of treatment. The occurrence of a treat to target response that is an HbA1c under treatment of < or = to 7%.","http://ClinicalTrials.gov/show/NCT00641043",NA
"36412",36412,"NCT00667043","Remifentanil and Propofol Versus Fentanyl and Midazolam for Sedation During Therapeutic Hypothermia. A Randomised, Controlled Trial","Completed","No Results Available","Hypothermia","Drug: remifentanil and propofol|Drug: fentanyl and midazolam","Norwegian University of Science and Technology|St. Olavs Hospital","Both","Adult|Senior","Phase IV",60,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","OPI 07 001","April 23, 2008","01/04/2008",NA,"June 11, 2010","01/06/2010","Cool Sedation",2009-05-01,"time from termination of sedation to extubation in patients treated with therapeutic hypothermia, after treatment with the combination remifentanil and propofol versus that of fentanyl and midazolam.","http://ClinicalTrials.gov/show/NCT00667043",NA
"36417",36417,"NCT00672243","Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme","Completed","No Results Available","Glioblastoma|Gliosarcoma","Drug: Erlotinib, Sirolimus","Duke University|Genentech|OSI Pharmaceuticals","Both","Adult|Senior","Phase II",20,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","345","January 29, 2008","01/04/2007",2009-12-01,"January 9, 2011","01/01/2011","",2009-04-01,"6 month progression-free survival.|a.Median PFS, radiographic response & overall survival b.Correlation of clinical response & pathological findings of EGFR expression, amplification, PTEN gene copy number & EGFR-vIII expression|Gr 3 or greater, treatment related, non-hematologic toxicities","http://ClinicalTrials.gov/show/NCT00672243",NA
"36420",36420,"NCT00680043","Safety Study of Hematide to Correct Anemia in Hemodialysis Patients","Completed","No Results Available","Anemia|Chronic Renal Failure","Drug: Hematide|Drug: Hematide|Drug: Epoetin Alfa","Affymax","Both","Adult|Senior","Phase II",114,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AFX01-15","May 15, 2008","01/05/2008",2009-08-01,"November 9, 2010","01/11/2010","",2009-08-01,"Mean change in Hgb between baseline and the Evaluation Period.|Proportion of patients who received RBC or whole blood transfusions during the Correction and Evaluation Periods.|Proportion of patients achieving Hgb response during the Correction and Evaluation Periods.","http://ClinicalTrials.gov/show/NCT00680043",NA
"36439",36439,"NCT00712543","A Preference Study Comparing Kristalose?ó and Liquid Lactulose","Completed","No Results Available","Constipation","Drug: lactulose (Kristalose?ó)|Drug: liquid lactulose","Cumberland Pharmaceuticals","Both","Adult|Senior","Phase IV",50,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","KR-001","July 8, 2008","01/06/2009",2009-09-01,"September 29, 2009","01/09/2009","",2009-09-01,"To determine patient preference for the powder or liquid form of lactulose, as demonstrated by patients responses on a questionnaire.|To determine patient preference for the taste of the powder or liquid form of lactulose, as demonstrated by patients responses on a questionnaire.|To determine patient preference for the consistency of the powder or liquid form of lactulose, as demonstrated by patients responses on a questionnaire.|To determine patient preference for the portability of the powder or liquid form of lactulose, as demonstrated by patients responses on a questionnaire.","http://ClinicalTrials.gov/show/NCT00712543",NA
"36477",36477,"NCT00778843","Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Dietary Supplement: Viusid|Other: Placebo","Catalysis SL","Both","Adult","Phase III",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VIU-CHC-08","October 21, 2008","01/10/2008",2009-05-01,"May 15, 2009","01/05/2009","",2009-05-01,"The improvement of serum parameters related to oxidative stress (SOD, AT, MDA, MDA/HNE, GPx, GR, AOP, MPO, PAOP, GSH) at 24 weeks (end of the treatment).|The improvement of serum parameters related to immune response (IFN alpha, IFN gamma, IL-1 alpha, IL-2, IL-6, IL-10, IL-12, TNF alpha, Anti TNF alpha, Cathepsin L) at 24 weeks (end of the treatment).|Improvement of aminotransferase levels (ALAT and ASAT) at 24 weeks (end of the treatment).|Improvement of clinical symptoms and signs at 24 weeks (end of the treatment).","http://ClinicalTrials.gov/show/NCT00778843",NA
"36478",36478,"NCT00781443","A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma","Completed","No Results Available","Allergic Asthma","Drug: lebrikizumab (MILR1444A)|Drug: placebo","Genentech","Both","Adult","Phase II",29,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","ILR4544g","October 27, 2008","01/12/2008",NA,"May 4, 2010","01/05/2010","",2009-11-01,"Late asthmatic response (LAR)|Early asthmatic response (EAR)","http://ClinicalTrials.gov/show/NCT00781443",NA
"36479",36479,"NCT00686543","Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115AM1)(COMPLETED)","Completed","Has Results","Fungal Infection|Acute Myelogenous Leukemia|Neutropenia","Drug: Posaconazole","Schering-Plough","Both","Adult|Senior","Phase IV",75,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","P05115|EudraCT No. 2007-003148-31","May 27, 2008","01/12/2007",2009-04-01,"July 2, 2010","01/07/2010","",2009-04-01,"Mean POS Plasma Concentrations on Days 2, 3, and 8.|Mean POS Plasma Concentrations on Days 8 and 15 Stratified by Randomized Dosing Regimen|Participants With a Mean POS Plasma Concentration ??­/<250 ng/mL on Day 3 and ??­/<500 ng/mL on Day 8|Participants With a Mean POS Plasma Concentration ??­/<350 ng/mL on Day 3 and ??­/<700 ng/mL on Day 8|Participants With a Mean POS Plasma Concentration ??­/<250 ng/mL on Day 8 and ??­/<500 ng/mL on Day 15|Participants With a Mean POS Plasma Concentration ??­/<350 ng/mL on Day 8 and ??­/<700 ng/mL on Day 15","http://ClinicalTrials.gov/show/NCT00686543",NA
"36537",36537,"NCT00856843","BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects","Completed","Has Results","Colonoscopy","Drug: BLI800|Drug: Polyethylene glycol 3350 based bowel preparation","Braintree Laboratories","Both","Adult|Senior","Phase III",136,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","BLI800-303","March 5, 2009","01/02/2009",NA,"October 15, 2010","01/10/2010","",2009-05-01,"Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale|Assessment of Residual Stool - Cecum|Assessment of Residual Stool - Ascending Colon|Assessment of Residual Stool - Transverse Colon|Assessment of Residual Stool - Descending Colon|Assessment of Residual Stool - Sigmoid Colon/Rectum|Assessment of Residual Fluid - Cecum|Assessment of Residual Fluid - Ascending Colon|Assessment of Residual Fluid - Transverse Colon|Assessment of Residual Fluid - Descending Colon|Assessment of Residual Fluid - Sigmoid Colon/Rectum|Subject Symptom Scores|Mean Change in Serum Chemistry (mg/dL)|Mean Change in Serum Chemistry (mEq/L)","http://ClinicalTrials.gov/show/NCT00856843",NA
"36575",36575,"NCT00953043","Lubiprostone, Colonic Motility and Sensation","Completed","No Results Available","Healthy","Drug: lubiprostone","Mayo Clinic","Both","Adult","Phase IV",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","07-001438","August 4, 2009","",2009-03-01,"February 5, 2010","01/01/2010","",2009-03-01,"Colonic compliance|Fasting colonic tone|Postprandial colonic tone|Pain sensation ratings in response to colonic distensions|Gas sensation ratings in response to colonic distensions|Thresholds for colonic first, gas and pain sensation","http://ClinicalTrials.gov/show/NCT00953043",NA
"36581",36581,"NCT00958243","A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA","Completed","No Results Available","Influenza","Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)|Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)|Biological: Placebo","CSL Limited","Both","Child","Phase II",473,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CSLCT-CAL-09-62","August 12, 2009","01/08/2009",2010-04-01,"May 17, 2010","01/05/2010","",2009-11-01,"Immunogenicity|Frequency, duration and intensity of solicited adverse events|Frequency, duration and intensity of unsolicited adverse events|Incidence of serious adverse events, adverse events of special interest and new onset of chronic illness","http://ClinicalTrials.gov/show/NCT00958243",NA
"36600",36600,"NCT00988143","A Study of Influenza Virus Vaccines in Children and Adults","Completed","No Results Available","Influenza","Biological: Quadrivalent Influenza Virus Vaccine|Biological: 2009-2010 Trivalent Influenza Virus Vaccine|Biological: 2008-2009 Trivalent Influenza Virus Vaccine","Sanofi-Aventis","Both","Child|Adult|Senior","Phase II",570,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","GRC43|UTN: U1111-1111-5427","October 1, 2009","01/10/2009",2010-03-01,"January 3, 2011","01/01/2011","",2009-12-01,"To provide information concerning the immunogenicity Quadrivalent Influenza Vaccine|To provide information concerning the safety of the Quadrivalent Influenza Vaccine.","http://ClinicalTrials.gov/show/NCT00988143",NA
"36645",36645,"NCT01060943","An Efficacy and Safety Study of TheraFill?ó Versus KOKEN for 3 Months on Nasolabial Folds","Completed","No Results Available","Nasolabial Folds","Device: KOKEN|Device: Atelocollagen Filler","Sewon Cellontech Co., Ltd.","Both","Adult|Senior","Phase III",73,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","01TRF","January 21, 2010","01/05/2008",2009-01-01,"February 1, 2010","01/02/2010","",2009-01-01,"Efficacy: Wrinkle Severity Rating Scale - Primary endpoint|Efficacy: An assessment of the degree of improvement based on the judgement of patients|Efficacy: An assessment of the degree of improvement based on the judgement of the Investigators","http://ClinicalTrials.gov/show/NCT01060943",NA
"36681",36681,"NCT01115543","Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism","Completed","No Results Available","Secondary Hyperparathyroidism|End Stage Renal Disease","Drug: alfacalcidol and calcitriol","Mahidol University","Both","Adult|Senior","Phase IV",32,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","358/2551","May 1, 2010","01/08/2008",2009-08-01,"May 1, 2010","01/05/2010","",2009-08-01,"Reduction of intact parathyroid hormone levels|hypercalcemia and hyperphosphatemia","http://ClinicalTrials.gov/show/NCT01115543",NA
"36698",36698,"NCT01142843","Preliminary Evidence of the Efficacy of a Mouthwash Containing 5% Propolis for the Control of Plaque and Gingivitis","Completed","No Results Available","Dental Plaque|Gingivitis","Drug: green propolis mouthwash","Federal University of Minas Gerais|Conselho Nacional de Desenvolvimento Cient?¦fico e Tecnol??gico|Funda????o de Amparo ?? Pesquisa do Estado de Minas Gerais","Both","Adult","Phase II",25,"Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VSantos-UFMG","June 10, 2010","01/08/2009",2010-03-01,"July 1, 2010","01/05/2009","MGP",2009-10-01,"Efficacy of a mouthwash containing 5% propolis for the control of gingivitis|Efficacy of a mouthwash containing 5% propolis for the control of plaque","http://ClinicalTrials.gov/show/NCT01142843",NA
"36914",36914,"NCT00167544","Randomized Trial of Hydrocortisone in Very Preterm High-Risk Infants","Completed","No Results Available","Bronchopulmonary Dysplasia|Encephalomalacia|Premature Birth","Drug: Hydrocortisone|Drug: Placebo","The University of Texas Health Science Center, Houston|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)","Both","Child","Phase II",64,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","K23NS048152-2|1 K23NS 048152-01A1|HSC-MS-05-0218","September 9, 2005","01/11/2005",2009-04-01,"April 29, 2009","01/04/2009","",2009-01-01,"Total cerebral volume as measured by volumetric brain MRI|Regional brain volumes|Duration of mechanical ventilation|Duration of oxygen requirement|Diagnosis of BPD","http://ClinicalTrials.gov/show/NCT00167544",NA
"36919",36919,"NCT00176644","Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: Transdermal Estradiol","University of Medicine and Dentistry New Jersey","Male","Adult|Senior","Phase II",33,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","5247|CINJ 080419","September 13, 2005","01/05/2005",2009-10-01,"December 10, 2009","01/12/2009","",2009-10-01,"To evaluate the antitumor activity, as measured by PSA response rate in patients with hormone and chemotherapy refractory prostate cancer.|To evaluate the toxicities of the use of transdermal estradiol in patients with HRPC after initial chemotherapy. To measure quality of life of patients receiving therapy with the Functional Assessment of Cancer Therapy-Prostate scale (FACT-P).|To evaluate measurable disease response in patients with hormone and chemotherapy refractory prostate cancer.|To evaluate time to progression.|To assess the plateau level of estradiol that is attained with the dose of 0.4mg/day given via transdermal estradiol patch and in addition, assess the response on testosterone in the androgen resistant population.","http://ClinicalTrials.gov/show/NCT00176644",NA
"36948",36948,"NCT00216944","Balanced Anesthesia for Intubation of Premature Infants","Completed","No Results Available","Premature Birth","Procedure: Tracheal intubation for respiratory care in preterm infants|Procedure: Tracheal intubation for respiratory care in preterm infants","Lund University Hospital","Both","Child|Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","EUDRACT EU 2004-001583-52","September 15, 2005","01/08/2005",2009-10-01,"February 12, 2010","01/12/2010","",2009-10-01,"Success of intubation according to a specific score including duration of the procedure and changes in oxygen saturation, blood pressure and heart rate during the intubation|Pain score at intubation|Biochemical stress/pain response|Physiological stress/pain response|Behavioural stress/pain response|Neurophysiological stress/pain response (aEEG)","http://ClinicalTrials.gov/show/NCT00216944",NA
"37019",37019,"NCT00327444","Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites","Completed","No Results Available","Ovarian Neoplasms|Ascites","Drug: aflibercept (AVE0005 / VEGF Trap)|Drug: placebo","Sanofi-Aventis|Regeneron Pharmaceuticals","Female","Adult|Senior","Phase II|Phase III",58,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","EFC6125|EudraCT : 2005-005026-31|AVE0005A /3001","May 16, 2006","01/07/2006",2009-10-01,"August 3, 2010","01/08/2010","",2009-10-01,"Time to repeat paracentesis|Ascites Impact Measure (patient questionnaire)|60-Day frequency of paracentesis","http://ClinicalTrials.gov/show/NCT00327444",NA
"37024",37024,"NCT00335244","Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery","Completed","No Results Available","Heart Defects, Congenital|Hypertension, Pulmonary","Drug: L-citrulline|Drug: Placebo of intravenous L-citrulline","Asklepion Pharmaceuticals, LLC|Vanderbilt University","Both","Child","Phase III",77,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","409|R01 HL73317-01|IRB# 060197","June 7, 2006","01/05/2006",2009-12-01,"January 19, 2010","01/01/2010","",2009-12-01,"Duration of postoperative mechanical ventilation in hours compared between treatment groups.|Incidence of increased PVT (defined as a sustained mean pulmonary artery pressure greater than 20 mm Hg for at least 2 hours, measured during the first 48 hours|Postoperative intravenous inotrope score|Length and volume of chest tube drainage|Length of ICU stay|Length of hospitalization|Survival","http://ClinicalTrials.gov/show/NCT00335244",NA
"37027",37027,"NCT00345644","Risedronate in Osteopenic Postmenopausal Women","Completed","No Results Available","Osteoporosis","Drug: risedronate|Drug: risedronate placebo","Sanofi-Aventis|Procter and Gamble","Female","Adult|Senior","Phase III",156,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","HMR4003B_3507|EudraCT # :2005-005598-30","March 20, 2006","01/03/2006",2009-06-01,"December 4, 2009","01/12/2009","OSMAUSE",2009-06-01,"Efficacy data : 3-D-pQCT Data??©Microarchitectural Parameters (Distal Radius BV/TV Measurements)|Tolerance data :collection of AEs, with special interest for upper gastrointestinal (UGI) AEs and clinical fractures","http://ClinicalTrials.gov/show/NCT00345644",NA
"37108",37108,"NCT00419744","A Comparison of SYMBICORT?ó pMDI With Formoterol Turbuhaler?ó in Subjects With COPD","Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Budesonide/formoterol (SYMBICORT) pMDI|Drug: Formoterol Turbuhaler","AstraZeneca","Both","Adult|Senior","Phase III",1200,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","D589CC00003","January 5, 2007","01/01/2007",2009-08-01,"August 18, 2010","01/08/2010","",2009-08-01,"Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year|Rate of Exacerbations Per Subject-year|Pre-dose Forced Expiratory Volume in 1 Second (FEV1)|Morning Peak Expiratory Flow (PEF)|Evening PEF|Dyspnea Symptom Scores|Use of Rescue Medication|St. George's Respiratory Questionnaire (SGRQ) Score","http://ClinicalTrials.gov/show/NCT00419744",NA
"37123",37123,"NCT00486044","Evaluating Simvastatin's Potential Role in Therapy","Completed","No Results Available","Alzheimer Disease","Drug: Simvastatin|Drug: Placebo","University of Wisconsin, Madison|National Institute on Aging (NIA)|Paul Beeson Faculty Scholars Program|The John A. Hartford Foundation|The Atlantic Philanthropies|Starr Foundation|American Federation for Aging Research|Merck","Both","Adult|Senior","Phase II",100,"Other|NIH|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0116|1K23AG026752-01","June 12, 2007","01/02/2005",2009-06-01,"September 27, 2010","01/09/2010","ESPRIT",2009-06-01,"Changes in cerebrospinal fluid beta-amyloid levels|Changes in biomarkers of CNS cholesterol metabolism, inflammatory markers, and cerebral perfusion|Changes in cognitive function","http://ClinicalTrials.gov/show/NCT00486044",NA
"37134",37134,"NCT00501644","Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer","Completed","Has Results","Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cavity Cancer","Drug: Carboplatin|Drug: GM-CSF (Sargramostim)|Drug: Interferon Gamma","M.D. Anderson Cancer Center|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Bristol-Myers Squibb|InterMune","Female","Child|Adult|Senior","Phase II",59,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-231","July 12, 2007","01/01/2003",2009-01-01,"December 23, 2010","01/12/2010","",2009-01-01,"Number of Patients With Response","http://ClinicalTrials.gov/show/NCT00501644",NA
"37173",37173,"NCT00558844","Multidose Safety and Tolerability Study of (Arikace?ºÑ) for Inhalation In Cystic Fibrosis Patients","Completed","No Results Available","Cystic Fibrosis","Drug: Arikace?ºÑ","Insmed","Both","Child|Adult|Senior","Phase I|Phase II",40,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TR02-106","November 13, 2007","01/06/2007",2009-06-01,"July 14, 2009","01/07/2009","",2009-06-01,"To evaluate the safety and tolerability of 28 days of daily dosing of nebulized Arikace?ºÑ, liposomal amikacin for inhalation.|To access pharmacokinetics (PK) of Arikace?ºÑ in serum and urine, and evaluate sputum amikacin levels|To evaluate change in Pulmonary function|To evaluate change in density of Pseudomonas aeruginosa in sputum|To evaluate time to and duration of systemic anti-Pseudomonal rescue therapy|To evaluate change in CFQ-R measurements|Exploratory evaluation of a Cystic Fibrosis Symptom Diary (CFSD)|Exploratory evaluation of durability of clinical benefit","http://ClinicalTrials.gov/show/NCT00558844",NA
"37179",37179,"NCT00569244","SH T00186 in the Treatment of Primary Dysmenorrhea","Completed","No Results Available","Primary Dysmenorrhea","Drug: YAZ flex (SH T00186D)|Drug: YAZ (SH T00186D)","Bayer","Female","Adult","Phase III",223,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","91587|EudraCT No.: 2006-004899-13|310882","December 5, 2007","01/12/2007",2009-12-01,"January 22, 2010","01/01/2010","",2009-12-01,"Number of days with dysmenorrheic pain|Use of rescue medication|Interference with daily activity|Number of days: with at least moderate dysmenorrheic pain;|Number of days with pelvic pain|Number of days with dysmenorrheic pain associated with withdrawal bleeding|Number of days with dysmenorrheic pain associated with unscheduled bleeding|Bleeding patterns|Assessment of treatment","http://ClinicalTrials.gov/show/NCT00569244",NA
"37212",37212,"NCT00617344","Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US","Completed","No Results Available","Dengue Fever|Dengue Hemorrhagic Fever|Dengue Virus","Biological: ChimeriVax?ºÑ Tetravalent Dengue Vaccine|Biological: ChimeriVax?ºÑ Tetravalent Dengue Vaccine|Biological: ChimeriVax?ºÑ Tetravalent Dengue Vaccine","Sanofi-Aventis","Both","Adult","Phase II",260,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CYD12","February 6, 2008","01/04/2008",2010-02-01,"May 18, 2010","01/05/2010","",2009-12-01,"Neutralizing antibody titers to each of four dengue virus serotypes in 2 groups of subjects after the second vaccination|Safety: Adverse events in the first 28 days after each injection and SAEs during the entire trial. Immunogenicity: Neutralizing antibody titers to each of the dengue virus serotypes for each vaccine at baseline and 30 days after vaccinations","http://ClinicalTrials.gov/show/NCT00617344",NA
"37269",37269,"NCT00708344","ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination","Completed","No Results Available","Hypertension","Drug: Irbesartan - Hydrochlorothiazide|Drug: Irbesartan - Hydrochlorothiazide","Sanofi-Aventis","Both","Adult|Senior","Phase IV",832,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IRBEH_R_02931","June 27, 2008","01/06/2008",2009-07-01,"July 15, 2010","01/07/2010","ACTUAL",2009-07-01,"Change in mean Systolic Blood Pressure|Change in mean Diastolic Blood Pressure","http://ClinicalTrials.gov/show/NCT00708344",NA
"37270",37270,"NCT00713544","A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: AZD5672|Drug: Etanercept|Drug: Placebo|Drug: AZD5672|Drug: AZD5672|Drug: AZD5672","AstraZeneca","Both","Adult|Senior","Phase II",360,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1710C00009","July 9, 2008","01/07/2008",2009-04-01,"August 24, 2009","01/08/2009","ESCAPE",2009-04-01,"ACR20|ACR50, ACR70, Hybrid ACR response, Individual ACR components, DAS 28|ESR|Safety outcomes","http://ClinicalTrials.gov/show/NCT00713544",NA
"37283",37283,"NCT00735644","Study of ChimeriVax?ºÑ-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines","Completed","No Results Available","Japanese Encephalitis|Hepatitis A","Biological: Japanese encephalitis vaccine|Biological: Japanese encephalitis vaccine|Biological: Japanese encephalitis vaccine|Biological: Japanese encephalitis vaccine (Acambis)|Biological: Hepatitis A vaccine","Sanofi-Aventis","Both","Child","Phase III",1199,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","JEC02","August 14, 2008","01/08/2008",2009-10-01,"October 23, 2009","01/10/2009","",2009-09-01,"Immunogenicity: To provide information concerning the immunogenicity of ChimeriVax?ºÑ-Japanese Encephalitis Vaccine.","http://ClinicalTrials.gov/show/NCT00735644",NA
"37290",37290,"NCT00747344","A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis","Completed","No Results Available","Psoriasis","Drug: CNTO 1275; Ustekinumab","Centocor, Inc.","Both","Adult|Senior","Phase III",121,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","CR015313","September 4, 2008","01/12/2008",2010-03-01,"September 30, 2010","01/09/2010","",2009-09-01,"The primary endpoints is the proportion of patients who achieve a Psoriasis Area and Severity Index (PASI) 75 respone at week 12.|The proportion of patients with a Physician's Global Assessment (PGA) score of cleared (0) or minimal (1) at Week 12 will be compared between the ustekinumab 45 mg group and the placebo group.","http://ClinicalTrials.gov/show/NCT00747344",NA
"37294",37294,"NCT00712244","DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus","Completed","Has Results","Cataract","Device: DisCoVisc|Device: DuoVisc|Device: Healon5|Device: Amvisc Plus","Alcon Research","Both","Adult|Senior","Phase IV",112,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","M07-014","July 7, 2008","01/10/2007",NA,"September 10, 2010","01/09/2010","",2009-04-01,"Corneal Endothelial Cell Loss|Percent Gain in Corneal Thickness.|Aqueous Signs - Corneal Edema|Aqueous Signs - Aqueous Flare|Aqueous Signs - Aqueous Cells|Intraocular Pressure (IOP)|Surgeon Survey - Anterior Chamber Dome Maintenance During Anterior Capsulotomy|Surgeon Surgey - Anterior Dome Maintenance During Phacoemulsification|Surgeon Surgey - Anterior Dome Maintenance During Intraocular Lens (IOL) Insertion","http://ClinicalTrials.gov/show/NCT00712244",NA
"37298",37298,"NCT00764244","Laser Versus Vitrectomy Versus Intravitreal Triamcinolone Injection for Diabetic Macular Edema","Completed","No Results Available","Diffuse Diabetic Macular Edema|Diabetes","Procedure: Vitrectomy|Drug: Intravitreal triamcinolone injections|Procedure: Laser photocoagulation","Assistance Publique - H??pitaux de Paris","Both","Adult|Senior","Phase III",72,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P030426|MUL03010","September 30, 2008","01/01/2005",2009-12-01,"June 3, 2010","01/05/2010","VITRILASE",2009-12-01,"Percentage of patients with visual gain ??­ 3 ETDRS lines at 2 years|Central macular thickness on OCT|Percentage of patients with visual gain ??­ 3 ETDRS lines|Progression of lens opacities|Frequency of complications|Results analysis according to preoperative vitreous detachment, honeycomb macular edema on fluorescein angiography|Evolution of visual fiends and posterior vitreous detachment|Percentage of patients presenting an increase of 2 line or more of best corrected visual acuity on ETDRS charts|Percentage of patients presenting an decrease of 2 line or more of best corrected visual acuity on ETDRS charts|Scores ETDRS|Mean best corrected visual acuity during follow-up period|Progression of retinopathy diabetic in each group|Outcome in respect to posterior vitreal detachment (PVD) stage|PVD stage evolution during the follow-yp in laser and triamcinolone group|Evolution of visual field in each group","http://ClinicalTrials.gov/show/NCT00764244",NA
"37303",37303,"NCT00770744","Efficacy of Lu 31-130 in Patients With Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Zicronapine|Drug: Olanzapine","H. Lundbeck A/S","Both","Adult","Phase II",93,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","12396A|2008-000479-11","October 9, 2008","01/09/2008",2009-11-01,"July 1, 2010","01/07/2010","",2009-10-01,"Change in the Positive and Negative Syndrome Scale (PANSS) score from Baseline to Week 12|Change in cognitive symptoms using Assessment of Cognition in Schizophrenia (BACS) test battery. Change in Clinical Global Impression/Improvement (CGI-S/I) scores. Change in Calgary Depression Scale for Schizophrenia (CDSS) score. Safety assessments.","http://ClinicalTrials.gov/show/NCT00770744",NA
"37304",37304,"NCT00772044","Randomized Study of Provent Versus Sham Device to Treat Obstructive Sleep Apnea","Completed","No Results Available","Obstructive Sleep Apnea Hypopnea|OSA|OSAH","Device: Provent Professional Sleep Apnea Therapy Device|Device: Sham Device","Ventus Medical, Inc.","Both","Adult|Senior","Phase IV",250,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","C009","October 13, 2008","01/11/2008",2009-12-01,"March 31, 2010","01/03/2010","AERO",2009-09-01,"Comparison of difference in AHI at one-week in-lab polysomnography between \device on\"" and \""device off\"" nights","http://ClinicalTrials.gov/show/NCT00772044",NA
"37306",37306,"NCT00773344","Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin","Completed","No Results Available","Solid Tumors|Breast Cancer","Drug: Tanespimycin","Bristol-Myers Squibb","Both","Adult|Senior","Phase I|Phase II",25,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA200-001|KAG 122","October 15, 2008","01/12/2005",2009-08-01,"December 6, 2010","01/12/2010","",2009-05-01,"Objective tumor response rate (RECIST complete response, or partial response ) confirmed by CT and MRI as the preferred methods for tumor assessments and Chest x-ray is acceptable for pulmonary lesions|Kaplan-Meier estimates duration of response and time-to-event variables will be used (time to progression, progression-free survival, time to response, duration of response, time to treatment failure and overall survival)|Kaplan-Meier estimates duration of response and time-to-event variables will be used (time to progression, progression-free survival, time to response, duration of response, time to treatment failure and overall survival)|Kaplan-Meier estimates duration of response and time-to-event variables will be used (time to progression, progression-free survival, time to response, duration of response, time to treatment failure and overall survival)","http://ClinicalTrials.gov/show/NCT00773344",NA
"37318",37318,"NCT00788944","Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl","Completed","No Results Available","Depression","Procedure: blood draw","Wyeth","Both","Adult|Senior","Phase IV",971,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research","0600B1-4433|B2411001","November 7, 2008","01/10/2008",2009-07-01,"January 5, 2011","01/01/2011","",2009-07-01,"0-desmethyl venlafaxine/venlafaxine ratio (levels of the drug in the blood)|Determine the percentage of patients treated with extended-release venlafaxine HCl who are genotypic Poor Metabolizers.","http://ClinicalTrials.gov/show/NCT00788944",NA
"37329",37329,"NCT00814944","A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model","Completed","No Results Available","Dry Eye","Drug: Sirolimus|Drug: Sirolimus|Drug: Sirolimus|Drug: Sirolimus","Santen Inc.|MacuSight, Inc.","Both","Adult|Senior","Phase II",150,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DES-001","December 23, 2008","01/04/2009",2009-10-01,"July 22, 2010","01/07/2010","",2009-10-01,"Mean corneal fluorescein staining (inferior region) after CAE exposure.|Mean ocular discomfort during CAE exposure.|Safety across treatment groups.|Additional evaluations of dry eye including fluorescein staining, lissamine green staining, conjunctival redness, tear film break-up time, blink rate, ocular protection index, Schirmer's Test, and corneal sensitivity.","http://ClinicalTrials.gov/show/NCT00814944",NA
"37361",37361,"NCT00808444","Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age","Completed","Has Results","Pneumococcal Disease|Streptococcus Pneumoniae Vaccines","Biological: Pneumococcal conjugate vaccine GSK1024850A (different lots)|Biological: Infanrix hexa|Biological: Infanrix-IPV/Hib|Biological: Rotarix","GlaxoSmithKline","Both","Child","Phase III",466,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Outcomes Assessor)|Primary Purpose: Prevention","111654","December 11, 2008","01/01/2009",2009-11-01,"January 6, 2011","01/01/2011","",2009-11-01,"Concentrations of Antibodies Against Vaccine Components of the Pneumococcal Vaccine|Concentration of Antibody Against Protein D (PD)|Number of Subjects With Anti-pneumococcal Vaccine Serotype Antibody Concentrations Equal to or Above 0.20 ??g/mL|Number of Subjects With Anti-pneumococcal Cross-reactive Serotype Concentrations Equal to or Above 0.20 ??g/mL|Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes|Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes|Opsonophagocytic Titers of Cross-reactive Pneumococcal Serotypes|Poliovirus Types 1, 2 and 3 Titers|Concentrations of Antibodies Against Diphteria Toxoid (DT) and Tetanus Toxoid (TT)|Concentration of Antibody Against Hepatitis B Surface Antigen (HBs)|Concentration of Antibody Against Rotavirus Immunoglobulin A (IgA)|Occurrence of Serious Adverse Events|Opsonophagocytic Titers of Vaccine Pneumococcal Serotypes|Number of Subjects With Solicited Local and General Symptoms.|Concentrations of Antibodies Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), Pertactin (PRN)|Concentration of Antibody Against Polyribosyl-ribitol Phosphate (PRP)|Occurrence of Unsolicited Adverse Events","http://ClinicalTrials.gov/show/NCT00808444",NA
"37396",37396,"NCT00921544","Sucrose Analgesia for the Reduction of Pain During Retinopathy of Prematurity Screening","Completed","No Results Available","Retinopathy of Prematurity","Other: Sucrose|Other: Sterile water","Coombe Women and Infants University Hospital","Both","Child|Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Coombesucrose","June 10, 2009","01/08/2008",2009-03-01,"June 15, 2009","01/06/2009","",2009-03-01,"Pain profile score as assessed by NPASS|Number of adverse events","http://ClinicalTrials.gov/show/NCT00921544",NA
"37437",37437,"NCT00749944","Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo","Completed","Has Results","Smoking Cessation","Drug: varenicline|Drug: placebo","Pfizer","Both","Adult|Senior","Phase IV",110,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","A3051115","September 9, 2008","01/09/2008",2009-08-01,"August 24, 2010","01/08/2010","",2009-07-01,"Change From Baseline in the Profile of Mood States (POMS): Total Mood Disturbance (TMD)|Change From Baseline in the Profile of Mood States (POMS): Tension-Anxiety Subscale|Change From Baseline in the Profile of Mood States (POMS): Depression-Dejection Subscale|Change From Baseline in the Profile of Mood States (POMS): Anger-Hostility Subscale|Change From Baseline in the Profile of Mood States (POMS): Vigor Subscale|Change From Baseline in the Profile of Mood States (POMS): Fatigue Subscale|Change From Baseline in the Profile of Mood States (POMS): Confusion Subscale|Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score|Change From Baseline in the Hamilton Anxiety Scale (HAM-A): Total Score|Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Aggression Total Score|Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score|Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score|Change From Baseline in the Social Dysfunction and Aggression Scale (SDAS): Total Score|Change From Baseline in the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Total Score|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Negative Affect Domain Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Insomnia Domain Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Urge to Smoke Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Restlessness Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Increased Appetite Subscale|Number of Participants Exceeding Thresholds for the Profile of Mood States (POMS): Total Score|Number of Participants Exceeding Thresholds for the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score|Number of Participants Exceeding Thresholds for the Hamilton Anxiety Scale (HAM-A): Total Score|Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Agression Total Score|Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score|Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score|Number of Participants Exceeding Thresholds for the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score|Number of Participants Exceeding Thresholds for the Social Dysfunction and Aggression Scale (SDAS): Total Score|Number of Participants With Carbon Monoxide Confirmed Daily Smoking Cessation|Number of Participants With 7-day Point Prevalence of Abstinence (Smoking Cessation)|Change From Baseline in the Number of Cigarettes Smoked Per Day","http://ClinicalTrials.gov/show/NCT00749944",NA
"37455",37455,"NCT01025544","Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China","Completed","No Results Available","Haemophilus Influenzae Type b (Hib) Infection","Biological: Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Biological: Hiberix (Haemophilus influenzae type b (Hib) vaccine)","Novartis|Novartis Vaccines","Both","Child","Phase III",846,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","M37P2E1","December 2, 2009","01/09/2009",2010-04-01,"July 29, 2010","01/07/2010","",2009-12-01,"Anti-PRP antibody levels at day 31 post booster|Solicited local and systemic reactions, AEs, and SAEs","http://ClinicalTrials.gov/show/NCT01025544",NA
"37458",37458,"NCT01028144","The Active by Choice Today (ACT) Trial to Increase Physical Activity","Completed","No Results Available","Exercise|Physical Activity|Obesity","Behavioral: Physical Activity Program|Behavioral: General Health Program","University of South Carolina|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Child","Phase I|Phase II",1422,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","Project ACT|R01HD045693","December 1, 2009","01/07/2004",2009-05-01,"December 9, 2009","01/12/2009","ACT",2009-05-01,"moderate to vigorous physical activity (based on accelerometry estimates)|moderate to vigorous physical activity during the intervention (based on accelerometry estimates)","http://ClinicalTrials.gov/show/NCT01028144",NA
"37557",37557,"NCT01185444","Efficacy of Three Weekly Injections of a Bacterial-- Sourced Hyaluronate on Pain and Function in Patients With Knee Osteoarthritis (OA)","Completed","No Results Available","Hyaluronate|Osteoarthritis|Knee","Procedure: Hya-Joint|Procedure: Hyalgan","Kaohsiung Veterans General Hospital.","Both","Adult|Senior","Phase II",89,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","VGHKS97-CT9-12","August 13, 2010","01/02/2009",2009-12-01,"August 19, 2010","01/12/2008","",2009-12-01,"visual analog scale|Lequesne index|Timed \ Up-and-Go\"" test|the level of global satisfaction""","http://ClinicalTrials.gov/show/NCT01185444",NA
"37592",37592,"NCT01242644","Comparison of a Pain Pump Versus Injectable Medication for Analgesia in Knee Arthroscopy","Completed","No Results Available","Pain","Device: pain pump containing ropivacaine|Device: saline pain pump with injectable medication|Drug: ropivacaine, ketorolac , morphine sulfate","University of South Alabama","Both","Adult|Senior","Phase II",49,"Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","06-230","November 11, 2010","01/10/2006",2010-06-01,"November 15, 2010","01/11/2010","",2009-10-01,"VAS Pain Score|Radiographic Arthritis","http://ClinicalTrials.gov/show/NCT01242644",NA
"37603",37603,"NCT01259544","BreathID?ó Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency","Completed","No Results Available","Chronic Pancreatitis|Healthy Volunteers","Drug: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|Drug: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)","Exalenz Bioscience LTD.|Virginia Commonwealth University Medical Center, Richmond, VA, USA|Asian Institute of Gastroenterology, Hyderabad, India","Both","Adult|Senior","Phase II",33,"Industry|Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","CP-EX-110","December 12, 2010","01/01/2009",2009-03-01,"December 13, 2010","01/12/2010","",2009-02-01,"To assess the pancreatic exocrine insufficiency using a 13C labeled di-peptide breath tests in patients with chronic pancreatitis(CP) and show correlation with secretin stimulated endoscopic Pancreatic Function Test (ePFT).|To assess the ability to differentiate between non patients with chronic pancreatitis and those without.","http://ClinicalTrials.gov/show/NCT01259544",NA
"37685",37685,"NCT00052845","Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","Completed","No Results Available","Prostate Cancer","Drug: docetaxel|Drug: estramustine phosphate sodium|Drug: exisulind","Cancer and Leukemia Group B|National Cancer Institute (NCI)","Male","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000258766|CALGB-90004","January 24, 2003","01/11/2002",NA,"November 16, 2009","01/12/2003","",2009-08-01,"","http://ClinicalTrials.gov/show/NCT00052845",NA
"37696",37696,"NCT00077545","3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: triapine","University of Chicago|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000352307|UCCRC-12765A|NCI-6285","February 10, 2004","01/01/2004",NA,"July 21, 2009","01/12/2005","",2009-07-01,"Objective response rate (complete and partial)|Duration of response|Progression-free survival|Overall survival|Toxicity|Improvement in dysphagia","http://ClinicalTrials.gov/show/NCT00077545",NA
"37712",37712,"NCT00100945","Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: gefitinib|Procedure: adjuvant therapy","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",72,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000407534|NCCTG-N0342","January 7, 2005","01/07/2005",NA,"October 13, 2009","01/10/2009","",2009-10-01,"1-year overall survival rate|Survival time|Disease-free survival|Time to disease recurrence|Time to treatment failure|Quality of life|Toxicity","http://ClinicalTrials.gov/show/NCT00100945",NA
"37795",37795,"NCT00150345","Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients","Completed","Has Results","Possible Fungal Infection","Drug: voriconazole (Vfend)|Drug: voriconazole (Vfend)","Pfizer|Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","Both","Adult|Senior","Phase III",147,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A1501029","September 6, 2005","01/01/2005",2009-04-01,"August 26, 2010","01/08/2010","IDEA",2009-04-01,"Number of Subjects With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis|Number of Subjects With Defervescence Day 5 (4 Days After Initiation of Study Treatment)|Number of Subjects With Defervescence Day 9 (8 Days After Initiation of Study Treatment)|Time to Continuous Defervescence|Number of Subjects Per Reason for Lack of Defervescence|Number of Subjects That Died on or Before Day 28 (Mortality)|Time to Negative Panfungal Polymerase Chain Reaction (PCR)|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (Yes)|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (No)|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Age|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Gender|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Primary Underlying Neoplastic Disease|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Planned Allogeneic Transplants|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Concomitant Fluconazole|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Neutrophil Count >500 uL|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With C-reactive Protein Level >1.25 Times the Upper Limit of Normal (x ULN)|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified (Aspergillus Spp=Yes)|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Proven or Probable IFI (Complete Cases) Between Day 2 and Day 28|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence Day 5 (4 Days After Initiation of Study Treatment)|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (Yes) by Day 9 (8 Days After Initiation of Study Treatment)|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (No) by Day 9 (8 Days After Initiation of Study Treatment)|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Time to Defervescence|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence (No)|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence: Unknown Infection (Yes)|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Alive)|Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Died)|Number of Subjects Assessed as Needing Further Antineoplastic Therapy as Planned|Number of Subjects With Reasons Why Antineoplastic Therapy Not Continued as Planned","http://ClinicalTrials.gov/show/NCT00150345",NA
"37890",37890,"NCT00366145","Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Patients Who Have Failed to Respond to Steroid Treatment for Acute Graft Versus Host Disease (GVHD)","Completed","No Results Available","Graft Versus Host Disease","Biological: Mesenchymal Stem Cells|Biological: placebo","Osiris Therapeutics","Both","Child|Adult|Senior","Phase III",240,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","280","August 17, 2006","01/07/2006",2009-05-01,"August 26, 2009","01/08/2009","",2009-05-01,"Complete Response of greater than or equal to 28 days duration|Survival at 180 days post first infusion","http://ClinicalTrials.gov/show/NCT00366145",NA
"37898",37898,"NCT00385645","Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis","Completed","No Results Available","HIV Infections","Drug: Combivir+Kaletra|Drug: Combivir+Reyataz","Hospital Clinic of Barcelona","Both","Adult|Senior","Phase IV",255,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","DATEM-PEP","October 10, 2006","01/05/2006",2009-08-01,"March 30, 2010","01/03/2010","",2009-08-01,"Proportions of patients completing 28-day antiretroviral treatment (ARVT)|Proportion of HIV-seropositive at 6 months|Incidence of adverse effects (clinical and laboratory) during ARVT|Adherence to ARVT, time to adherence loss.","http://ClinicalTrials.gov/show/NCT00385645",NA
"37912",37912,"NCT00397345","TroVax Renal Immunotherapy Survival Trial","Completed","No Results Available","Clear Cell Renal Carcinoma","Biological: Trovax","Oxford BioMedica","Both","Adult|Senior","Phase III",700,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","TV3/001/06","November 8, 2006","01/09/2006",2009-12-01,"June 4, 2010","01/06/2010","",2009-12-01,"overall survival","http://ClinicalTrials.gov/show/NCT00397345",NA
"37921",37921,"NCT00371345","Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer","Completed","Has Results","Breast Cancer|Metastasis","Drug: Dasatinib|Drug: Dasatinib 100 mg","Bristol-Myers Squibb","Female","Adult|Senior","Phase II",92,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA180-088","September 1, 2006","01/12/2006",2009-05-01,"October 7, 2010","01/10/2010","",2009-03-01,"Number of Participants With Objective Response|Percentage of Participants With Objective Response|Best Overall Response|Number of Response-evaluable Participants With Disease Control (DCR)|Percentage of Response-evaluable Participants With Disease Control (DCR)|Number of Participants Who Progressed|Median Progression Free Survival (PFS)|Percentage of Participants With Progression-free Survival (PFS) at Weeks 9, 17, and 25|Duration Of Objective Response|Number of Participants With Death, Adverse Events (AEs), and AEs Leading to Discontinuation|Number of Participants With On-study CTCAE Version 3.0 Grade 3-4 Laboratory Abnormalities|Number of Participants With Serious AEs (SAEs), Drug-related AEs, Drug-related SAEs, and Drug-Related Grade 3 AEs|Number Of Participants With Notable Drug-related AEs|Pharmacokinetics (PK): Plasma Concentration of Dasatinib at Week 3|PK: Plasma Concentration of Dasatinib at Week 7 or Week 9|Pharmacodynamics: Percent Change From Baseline In Plasma Level of Collagen Type IV at Week 3 in Participants With and Without DCR|Pharmacodynamics: Percent Change From Baseline In Plasma Level of Collagen Type IV at Week 5 in Participants With and Without DCR|Pharmacodynamics: Percent Change From Baseline In Plasma Level of VEGFR2 at Week 3 in Participants With and Without DCR|Pharmacodynamics: Percent Change From Baseline In Plasma Level of VEGFR2 at Week 5 in Participants With and Without DCR","http://ClinicalTrials.gov/show/NCT00371345",NA
"37932",37932,"NCT00433745","Vaccination for Patients With High Risk Cancers of the Blood","Completed","No Results Available","Myelodysplastic Syndrome|Acute Myeloid Leukemia (AML)|Chronic Myeloid Leukemia (CML)","Drug: WR 1 and PR 1 Peptide Vaccine","National Heart, Lung, and Blood Institute (NHLBI)","Both","Adult|Senior","Phase II",4,"NIH","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","070091|07-H-0091","February 9, 2007","01/02/2007",2009-11-01,"March 26, 2010","01/11/2009","",2009-11-01,"The primary objectives will to evaluate the efficacy and toxicity associated with the immunotherapy approach of lymphodepletion, lymphocyte infusion, and WT1 vaccination in selected patients with hematological malignancies.|Secondary objectives will include evaluation of disease response by following the numbers of WT1 expressing cells in blood, hematological measurements (reduction in marrow blast cells, changes in blood counts), transfusion dependence, and time t...","http://ClinicalTrials.gov/show/NCT00433745",NA
"37937",37937,"NCT00444145","Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?","Completed","No Results Available","Larynx Disease|Gastroesophageal Reflux","Drug: Lansoprazole Tablet|Procedure: Esophageal and Laryngeal Biopsies","Vanderbilt University","Both","Adult|Senior","Phase IV",30,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","61244","March 5, 2007","01/03/2007",2009-12-01,"November 12, 2010","01/11/2010","biopsy II",2009-03-01,"Dilation of intracellular spaces 3 months after therapy","http://ClinicalTrials.gov/show/NCT00444145",NA
"37948",37948,"NCT00462345","A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.","Completed","No Results Available","Rheumatoid Arthritis","Drug: rituximab [MabThera/Rituxan]|Drug: Methotrexate","Hoffmann-La Roche","Both","Adult|Senior","Phase IV",40,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20934","April 18, 2007","",2009-07-01,"October 15, 2009","01/10/2009","",2009-07-01,"Percentage of patients with ACR 20 response|ACR 50/70; change in DAS; EULAR response; changes in ACR core set; SF-36; radiographic analysis.|AEs, laboratory parameters, immunology parameters","http://ClinicalTrials.gov/show/NCT00462345",NA
"37959",37959,"NCT00476645","Fulvestrant in Hormone Refractory Prostate Cancer","Completed","No Results Available","Prostatic Neoplasms|Prostate Cancer|Prostate Cancer Localized Disease|Prostate Cancer Metastatic Disease","Drug: Fulvestrant","Stanford University|AstraZeneca","Male","Adult|Senior","Phase II",20,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PROS0010|96025|PROS0010","May 18, 2007","01/09/2006",2009-12-01,"July 23, 2010","01/07/2010","",2009-09-01,"Efficacy, defined as the first evidence of a total serum PSA decline of >50% from baseline maintained for at least 28 days and confirmed with two consecutive measurements taken two weeks apart|Time to progression, defined as the time from first administration of study drug to the first observation of disease progression|Disease progression, defined as an increase of >25% over the baseline PSA on two consecutive measurements two weeks apart, need for palliative therapy, or a decline in at least 20% in KPS|Time to sustained biochemical response, defined as the time from first administration of drug to first evidence of sustained response|Duration of sustained response, defined as time from PSA decrease of >50% from baseline to the first evidence of disease progression","http://ClinicalTrials.gov/show/NCT00476645",NA
"37968",37968,"NCT00488345","Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age","Completed","No Results Available","Bacterial Infections|Intra-abdominal Infection|Pneumonia, Bacterial|Skin Diseases, Bacterial|Skin Diseases, Infectious","Drug: Tygacil","Wyeth","Both","Child","Phase II",59,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3074K4-2207","June 18, 2007","01/12/2007",2009-09-01,"September 22, 2009","01/09/2009","",2009-09-01,"Six samples. Serum Tigecycline concentrations to determine individual PK parameters using noncompartmental methods including Cmax, tmax, AUC and clearance. Population PK methods to investigate the impact of covariates: age, weight and height|Tolerability and safety: Vital signs, adverse events, laboratory. Interim safety data reviews planned to validate escalation to the next dose cohort.Clinical response: cure, failure, or indeterminate.","http://ClinicalTrials.gov/show/NCT00488345",NA
"37989",37989,"NCT00523445","The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Varenicline(Chantix)|Drug: Placebo","Inje University|Stanley Medical Research Institute","Both","Adult","Phase III",120,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","Varenicline07|07TAS-1051","August 30, 2007","01/09/2007",2009-07-01,"August 3, 2009","01/08/2009","",2009-06-01,"To examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia.|To evaluate the effect of this combination therapy on smoking in people with schizophrenia.","http://ClinicalTrials.gov/show/NCT00523445",NA
"37991",37991,"NCT00522145","Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: XL647","Symphony Evolution, Inc.","Both","Adult|Senior","Phase II",41,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XL647-203","August 27, 2007","01/05/2007",2010-02-01,"February 18, 2010","01/02/2010","",2009-10-01,"Determine the best confirmed response rate|Safety and tolerability of XL647 administered daily|Progression-free survival, duration of response, and overall survival|Further characterize the pharmacokinetic (PK) parameters","http://ClinicalTrials.gov/show/NCT00522145",NA
"37999",37999,"NCT00535145","Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease","Completed","No Results Available","Schizophrenia|Schizoaffective Disorder|Psychotic Disorders","Drug: Treatment as usual (TAU), Paliperidone ER","Ortho-McNeil Janssen Scientific Affairs, LLC","Both","Adult|Senior","Phase III",121,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR014341|R076477SCH4005","September 24, 2007","01/10/2007",2009-02-01,"October 28, 2010","01/10/2010","",2009-02-01,"The primary safety outcome of the trial is the difference in the incidence of any adverse events when patients switch their antipsychotic from TAU to paliperidone ER.|Various measures of efficacy and safety including PANSS, CGI, MSQ, sleep VAS, SF-36, and PSP will be assessed at different visits throughout the course of the study.","http://ClinicalTrials.gov/show/NCT00535145",NA
"38000",38000,"NCT00537745","Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders","Completed","No Results Available","Alcohol Consumption","Drug: Vivitrol (Medication Therapy)|Other: Individual Compliance Enhancement (Medication Management Therapy)","Pacific Institute for Research and Evaluation|Cephalon","Both","Adult|Senior","Phase IV",14,"Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C18816/6075/DP/US|0328.01.01","September 28, 2007","01/04/2007",2009-05-01,"May 6, 2009","01/05/2009","",2009-05-01,"Evidence of attempts to drive after drinking","http://ClinicalTrials.gov/show/NCT00537745",NA
"38004",38004,"NCT00545545","Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma","Completed","No Results Available","Recurrent Colorectal Carcinoma|Progressive Colorectal Carcinoma","Biological: Safety and efficacy of escalating doses|Biological: Safety and efficacy of escalating doses.","Biothera","Both","Adult|Senior","Phase I|Phase II",48,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BT-CL-PGG-CRC0713","October 16, 2007","01/10/2007",2009-12-01,"March 30, 2010","01/03/2010","",2009-12-01,"To determine safety and maximum tolerated dosage of Imprime PGGwhen used in combination with cetuximab with and without irinotecan therapy in patients with recurrent/progressive colorectal carcinoma previously treated with a 5-FU regimen.|To determine the pharmacokinetic (PK) profile of Imprime PGG administered in combination with cetuximab with concomitant irinotecan therapy in patients with colorectal cancer.|To determine the tumor response rates (complete response, partial response, stable disease, overall response rate), time to progression, duration of overall tumor response, and the duration of stable disease in patients receiving the combination therapy.","http://ClinicalTrials.gov/show/NCT00545545",NA
"38047",38047,"NCT00614445","The Efficacy Of Diclectin?ó For Nausea And Vomiting Of Pregnancy","Completed","No Results Available","Nausea and Vomiting of Pregnancy","Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|Drug: Placebo","Duchesnay Inc.|Premier Research Group plc","Female","Adult|Senior","Phase III",280,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","DIC-301","January 29, 2008","01/01/2008",2009-12-01,"February 3, 2010","01/02/2010","",2009-07-01,"The change in the Pregnancy Unique Quantification of Emesis (PUQE) score from baseline between Diclectin?ó and placebo.","http://ClinicalTrials.gov/show/NCT00614445",NA
"38057",38057,"NCT00624845","Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy","Completed","No Results Available","Postoperative Pain","Drug: OMS103HP|Drug: Vehicle","Omeros Corporation","Both","Adult|Senior","Phase II|Phase III",200,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C07-004","February 19, 2008","01/12/2007",2009-05-01,"April 28, 2010","01/04/2010","C07-004",2009-05-01,"The primary efficacy endpoint is the mean VAS at 24 hours postoperatively.","http://ClinicalTrials.gov/show/NCT00624845",NA
"38077",38077,"NCT00550745","ZOSTAVAX?ºÑ Safety Study in Subjects ??­ 60 Years of Age","Completed","Has Results","Herpes Zoster","Biological: Zoster Vaccine, Live|Biological: Comparator: placebo","Merck","Both","Adult|Senior","Phase IV",11999,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2007_606|V211-020","October 29, 2007","01/09/2007",2009-01-01,"April 20, 2010","01/04/2010","",2009-01-01,"Serious Adverse Events Reported Within 42 Days Postvaccination|Serious Adverse Events Reported Within 6 Months (Day 1 to 182) Postvaccination","http://ClinicalTrials.gov/show/NCT00550745",NA
"38080",38080,"NCT00665145","Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509","Completed","No Results Available","Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Diabetic Polyneuropathy","Drug: SB-509|Drug: SB-509|Drug: Placebo|Drug: SB-509","Sangamo Biosciences","Both","Adult|Senior","Phase II",23,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","SB-509-0703","April 21, 2008","01/01/2008",2009-10-01,"February 25, 2010","01/02/2010","",2009-10-01,"Stem cells circulating in peripheral blood|Safety and Efficacy of SB-509","http://ClinicalTrials.gov/show/NCT00665145",NA
"38081",38081,"NCT00627445","Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: biphasic insulin aspart 30|Drug: metformin|Drug: biphasic insulin aspart 50|Drug: biphasic insulin aspart 30","Novo Nordisk","Both","Adult|Senior","Phase III",441,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BIASP-1858","February 22, 2008","01/02/2008",2009-01-01,"April 6, 2010","01/04/2010","",2009-01-01,"Change in Glycosylated Haemoglobin A1c (HbA1c)|The Percentage of Subjects Achieving HbA1c Treatment Targets|Change and Daily Average in 8-point Plasma Glucose|Change and Daily Average in Prandial Plasma Glucose Increment|The Total Increase in Total Daily Insulin Dose Per Body Weight|Change in Body Weight|Number of Hypoglycaemic Episodes|Number of Nocturnal Hypoglycaemic Episodes","http://ClinicalTrials.gov/show/NCT00627445",NA
"38094",38094,"NCT00680745","Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","Completed","No Results Available","Type 2 Diabetes","Drug: dapagliflozin|Drug: Glimepiride|Drug: metformin hydrochloride|Drug: pioglitazone hydrochloride|Drug: Rosiglitazone","AstraZeneca|Bristol-Myers Squibb","Both","Adult|Senior","Phase III",597,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00005","May 16, 2008","01/04/2008",2010-05-01,"June 1, 2010","01/06/2010","",2009-11-01,"To assess the efficacy of dapagliflozin compared to placebo as add-on therapy to glimepiride in improving glycaemic control in subjects with type 2 diabetes, as determined by the change in A1C levels from baseline to Week 24|To show that dapagliflozin plus glimepiride results in greater reductions in body weight or less weight gain after 24 weeks of treatment when compared to placebo plus glimepiride.|To show that dapagliflozin plus glimepiride results in greater reductions in the 2-h post-challenge plasma glucose level as a response to an oral glucose tolerance test (OGTT) from baseline to Week 24.|To show that dapagliflozin plus glimepiride results in a larger proportion of subjects achieving a therapeutic glycaemic response, defined as A1C < 7% after 24 weeks of treatment, compared to placebo plus glimepiride.","http://ClinicalTrials.gov/show/NCT00680745",NA
"38097",38097,"NCT00692445","TC-5214 as add-on the Treatment of Major Depressive Disorder","Completed","No Results Available","Major Depressive Disorder|Depression","Drug: TC-5214|Drug: Placebo","Targacept Inc.","Both","Adult|Senior","Phase II",574,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TC-5214-23-CRD-001","June 4, 2008","01/06/2008",2009-07-01,"July 28, 2009","01/07/2009","",2009-05-01,"Mean change between TC-5214 and placebo from DB baseline (Week 8) of the HAMD-17 score, at Week 16.|Safety and Pharmacokinetic Endpoints","http://ClinicalTrials.gov/show/NCT00692445",NA
"38103",38103,"NCT00704145","Optical Coherence Tomography Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease","Completed","No Results Available","Coronary Artery Disease","Device: Taxus Libert???ºÑ paclitaxel drug-eluting stent","Ospedali Riuniti di Bergamo|Case Western Reserve University|Boston Scientific Corporation","Both","Adult|Senior","Phase IV",30,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1087/2007","June 20, 2008","01/11/2007",2009-11-01,"February 5, 2010","01/02/2010","OCTAXUS",2009-08-01,"Proportion of uncovered and/or malapposed Taxus Libert?? struts at different time point after the implant, as measured by OCT|% Incomplete apposition at different point of FU (3-6-9 months)|Proportion of neointima disomogeneity around struts at different point of FU (3-6-9 months)|OCT Neointima thickness overtime|Ischemia Driven Target Vessel Failure (ID-TVF) rate at 12 months|Adjudicated MACE rate at 30 days and 12 months","http://ClinicalTrials.gov/show/NCT00704145",NA
"38127",38127,"NCT00743145","Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana","Completed","No Results Available","Marijuana Smoking","Drug: Naltrexone|Drug: Smoked marijuana","New York State Psychiatric Institute|Research Foundation for Mental Hygiene|National Institute on Drug Abuse (NIDA)","Both","Adult","Phase II",48,"Other|NIH","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind|Primary Purpose: Treatment","5693","August 26, 2008","01/05/2008",2009-09-01,"September 22, 2009","01/09/2009","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT00743145",NA
"38149",38149,"NCT00654745","18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics","Completed","Has Results","Type 2 Diabetes|Hypertension","Drug: Amlodipine|Drug: amlodipine / olmesartan medoxomil combination|Drug: Hydrochlorothiazide","Daiichi Sankyo Inc.","Both","Adult|Senior","Phase IV",207,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CS-8663-403","April 4, 2008","01/05/2008",2009-06-01,"July 9, 2010","01/07/2010","",2009-04-01,"Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment|Change From Week 0 (Baseline) in Mean ABPM Diastolic Blood Pressure (DBP) After 12 Weeks of Active Treatment|Change From Week 0 (Baseline) in Mean ABPM SBP After 12 Weeks of Active Treatment|Change in Mean Seated Systolic Blood Pressure (SeSBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks|Change in Mean Seated Diastolic Blood Pressure (SeDBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks|Number of Participants Achieving Mean 24-hour Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Mean Daytime Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Mean Nighttime Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Mean Last 6 Hour Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Mean Last 4 Hour Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Mean Last 2 Hour Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 3|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 6|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 9|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 12|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 15|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 18|Number of Participants Achieving Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Daytime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Nighttime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Last 6 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Last 4 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions|Number of Participants Achieving Mean Last 2 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 3|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 6|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 9|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 15|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 18","http://ClinicalTrials.gov/show/NCT00654745",NA
"38189",38189,"NCT00838045","Evaluation of the Safety & Effectiveness of the Bausch & Lomb AKREOS?ó TL Intraocular Lens","Completed","No Results Available","Cataract","Device: The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL","Bausch & Lomb, Inc.","Both","Adult|Senior","Phase IV",125,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","451","February 5, 2009","01/07/2006",2010-02-01,"August 4, 2010","01/08/2010","",2009-12-01,"Safety and effectiveness of the Bausch & Lomb Akreos TL intraocular lens.","http://ClinicalTrials.gov/show/NCT00838045",NA
"38214",38214,"NCT00882245","Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Other: Vehicle ointment|Drug: Ointment","Serentis Ltd.","Both","Adult|Senior","Phase II",93,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P441201CD","April 15, 2009","01/04/2009",2009-10-01,"October 29, 2009","01/10/2009","",2009-08-01,"Measure efficacy in treating acute exacerbations|Safety and local dermal tolerability","http://ClinicalTrials.gov/show/NCT00882245",NA
"38244",38244,"NCT00932945","Dermacyd PH_DESILSTY_FR (Lactic Acid) - Acceptability - Stay on Frutal","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Female","Adult","Phase III",32,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","LACAC_L_04806","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"Evaluation of the absence of irritation and the good acceptability by using one specific scale which describes the intensity of the reaction.","http://ClinicalTrials.gov/show/NCT00932945",NA
"38297",38297,"NCT01008345","Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol","Completed","No Results Available","Coronary Artery Disease|Diabetes","Drug: ezetimibe","Hotel Dieu de France Hospital|Pharmaline, Lebanon","Both","Adult|Senior","Phase IV",100,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","pharmaline1","November 4, 2009","01/09/2008",2009-06-01,"November 5, 2009","01/11/2009","",2009-06-01,"level of oxidized LDL cholesterol at end of study|small dense LDL level","http://ClinicalTrials.gov/show/NCT01008345",NA
"38301",38301,"NCT01014845","Clinical Trial of Recombinant Hepatitis E Vaccine","Completed","No Results Available","Hepatitis E","Biological: hepatitis E vaccine","Xiamen University|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd|National Institute of Diagnostics and Vaccine Development in infectious disease","Both","Child|Adult","Phase III",122179,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pro-HE-003|2006AA02A209","November 13, 2009","01/08/2007",2009-06-01,"November 16, 2009","01/11/2009","",2009-06-01,"Rate of confirmed hepatitis E cases|IgG anti-HEV seroconversion rate|Persistency of IgG anti-HEV","http://ClinicalTrials.gov/show/NCT01014845",NA
"38336",38336,"NCT01074645","Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure","Completed","No Results Available","Acute on Chronic Liver Failure|Hepatitis B","Drug: Tenofovir disoproxil fumarate (TDF)","Govind Ballabh Pant Hospital","Both","Child|Adult|Senior","Phase IV",27,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","Hitendra garg","February 22, 2010","01/11/2007",2009-10-01,"February 23, 2010","01/10/2009","ACLF",2009-06-01,"Reduction in HBV DNA levels, survival|Improvement in CTP, MELD scores","http://ClinicalTrials.gov/show/NCT01074645",NA
"38366",38366,"NCT01125345","Posterior Capsule Opacification (PCO) With Single Piece Hydrophobic Versus Hydrophillic Intraocular Lens (IOL)","Completed","No Results Available","Posterior Capsule Opacification","Procedure: Phacoemulsification","Iladevi Cataract and IOL Research Center","Both","Adult|Senior","Phase IV",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","06-009","May 17, 2010","01/01/2006",2009-12-01,"June 3, 2010","01/05/2010","",2009-12-01,"posterior capsule evaluation|ND-Yag capsulotomy rate","http://ClinicalTrials.gov/show/NCT01125345",NA
"38386",38386,"NCT01163045","Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerve Versus Neurostimulation","Completed","No Results Available","Thyroidectomy","Procedure: thyroidectomy","University of Bologna","Both","Adult|Senior","Phase II",250,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","2 - Cavicchi","July 13, 2010","01/01/2008",2010-01-01,"July 14, 2010","01/06/2010","",2009-02-01,"recurrent laryngeal nerve paralysis","http://ClinicalTrials.gov/show/NCT01163045",NA
"38435",38435,"NCT01254045","Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome","Completed","No Results Available","Fragile X Syndrome","Drug: Oxytocin","Stanford University","Male","Child|Adult","Phase II",12,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SU-11182010-7215|8618","December 2, 2010","01/02/2007",2010-01-01,"December 14, 2010","01/12/2010","",2009-11-01,"Eye contact|Social Responsiveness Scale","http://ClinicalTrials.gov/show/NCT01254045",NA
"38477",38477,"NCT00002546","Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus","Completed","No Results Available","Sarcoma","Drug: cisplatin|Drug: ifosfamide|Procedure: adjuvant therapy|Radiation: radiation therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Female","Adult|Senior","Phase III",216,"Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000063303|GOG-0150|ECOG-G150","November 1, 1999","01/12/1993",NA,"February 13, 2009","01/11/2005","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00002546",NA
"38514",38514,"NCT00023946","BMS-247550 in Treating Patients With Liver or Gallbladder Cancer","Completed","No Results Available","Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer","Drug: ixabepilone","University of Chicago|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068878|UCCRC-11045|NCI-3656","September 13, 2001","01/10/2001",NA,"December 2, 2009","01/06/2005","",2009-11-01,"","http://ClinicalTrials.gov/show/NCT00023946",NA
"38520",38520,"NCT00030446","Erlotinib and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Drug: carboplatin|Drug: erlotinib hydrochloride","NCIC Clinical Trials Group","Female","Adult|Senior","Phase II",NA,"Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","I149|CAN-NCIC-IND149|CAN-NCIC-149|CDR0000069166","February 14, 2002","01/01/2002",2009-12-01,"November 7, 2010","01/03/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00030446",NA
"38566",38566,"NCT00109746","Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults","Completed","No Results Available","Insulin Resistance|HIV Infections","Dietary Supplement: Chromium piccolinate|Dietary Supplement: Chromium Picolinate|Dietary Supplement: Chromium Picolinate","National Center for Complementary and Alternative Medicine (NCCAM)|Office of Dietary Supplements (ODS)","Both","Adult|Senior","Phase I|Phase II",40,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","R21 AT002499-01A1","May 2, 2005","01/11/2005",2010-05-01,"August 23, 2010","01/08/2010","NT",2009-05-01,"Improvement in insulin sensitivity","http://ClinicalTrials.gov/show/NCT00109746",NA
"38594",38594,"NCT00147446","Stress Management for Patients With Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Behavioral: Cognitive Behavioral Stress Management for MS|Behavioral: Wait List Control","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Adult|Senior","Phase II",120,"NIH","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","SIMS|R01 HD043323","September 2, 2005","01/05/2005",2009-01-01,"January 9, 2011","01/09/2005","",2009-01-01,"MRI|Exacerbation rate based on patient report and verification by neurologist.|EDSS & MSFC|Quality of Life|Interaction between stress and MRI outcomes|Interaction between stress and clinical (EDSS, exacerbation) outcomes","http://ClinicalTrials.gov/show/NCT00147446",NA
"38607",38607,"NCT00170846","ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients","Completed","No Results Available","Renal Transplantation","Drug: Everolimus (RAD001)","Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",NA,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD001A2413","September 9, 2005","01/02/2005",2009-10-01,"July 21, 2010","01/07/2010","",2009-10-01,"","http://ClinicalTrials.gov/show/NCT00170846",NA
"38643",38643,"NCT00230646","Promoting Physical Activity After Colorectal Cancer","Completed","No Results Available","Colon Cancer|Rectal Cancer","Behavioral: Exercise counseling","The Miriam Hospital","Both","Adult|Senior","Phase III",46,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)","CA101770","September 29, 2005","01/07/2005",2009-11-01,"October 4, 2010","01/09/2005","",2009-11-01,"Minutes of moderate-intensity physical activity (PA) at 3 months among 134 sedentary patients who have completed treatment for colorectal cancer (CRC).|Examine the effects of the intervention on survivors' physical functioning, fitness, vigor, fatigue and body esteem at 3 months.|Examine the maintenance of outcomes (minutes of moderate intensity activity, physical functioning, vigor, fatigue and body esteem) at 6 and 12 months.","http://ClinicalTrials.gov/show/NCT00230646",NA
"38701",38701,"NCT00303446","Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)","Completed","Has Results","Kennedy's Disease|Spinal and Bulbar Muscular Atrophy","Drug: Dutasteride|Drug: Placebo","National Institute of Neurological Disorders and Stroke (NINDS)","Male","Adult|Senior","Phase II",57,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","060113|06-N-0113","March 15, 2006","01/03/2006",2009-12-01,"June 21, 2010","01/06/2010","",2009-12-01,"Muscle Strength Change From Baseline|Creatine Kinase, Change From Baseline|Manual Muscle Testing, Change From Baseline.|Adult Myopathy Assessment Tool, Change From Baseline|Timed 2-minute Walk, Change From Baseline|Swallow Score Average, Change From Baseline|Bulbar Rating Scale, Change From Baseline|Sensory Nerve Action Potential Average, Change From Baseline|Median Compound Muscle Action Potential, Change From Baseline|Peroneal Compound Muscle Action Potential, Change From Baseline|Motor Unit Nerve Estimation, Change From Baseline|Activities of Daily Living, Change From Baseline|Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Physical Component Summary, Change From Baseline|Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Mental Component Summary, Percent Change From Baseline|International Index for Erectile Function (IIEF), Change From Baseline","http://ClinicalTrials.gov/show/NCT00303446",NA
"38710",38710,"NCT00333346","Tramadol iv. : Influence of Dose and Dose Intervals on Therapeutic Accuracy and Side Effects When Used for Postoperative Pain Relief in Ambulatory Surgery","Completed","No Results Available","Ambulatory Surgery","Drug: Administration of tramadol intravenously","University Hospital, Ghent","Both","Adult|Senior","Phase II",200,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006/195","June 2, 2006","01/09/2006",2009-04-01,"August 30, 2010","01/08/2010","",2009-04-01,"Time course of pain relief|Accuracy of pain relief|Onset of side-effects|Duration of side-effects","http://ClinicalTrials.gov/show/NCT00333346",NA
"38717",38717,"NCT00350246","Long-term Effects of Laser Refractive Surgery","Completed","No Results Available","Myopia","Procedure: Laser Refractive Surgery","Mayo Clinic|National Institutes of Health (NIH)","Both","Adult|Senior","Phase IV",62,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","66-04","July 7, 2006","01/07/2004",2009-01-01,"January 27, 2010","01/01/2010","",2009-01-01,"keratocyte density at 5 years|nerve density at 5 years","http://ClinicalTrials.gov/show/NCT00350246",NA
"38722",38722,"NCT00191646","An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy","Completed","Has Results","Genital Neoplasms, Female|Fallopian Tube Neoplasms|Ovarian Neoplasms|Pelvic Neoplasms|Peritoneal Neoplasms","Drug: Gemcitabine|Drug: Paclitaxel|Drug: Carboplatin","Eli Lilly and Company","Female","Adult|Senior","Phase III",919,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","6891|B9E-US-S302","September 12, 2005","01/10/2002",2009-08-01,"October 13, 2010","01/10/2010","",2009-08-01,"Progression Free Survival (PFS)|Proportion of Participants With Response (Response Rate)|Time to Treatment Failure|Overall Survival","http://ClinicalTrials.gov/show/NCT00191646",NA
"38731",38731,"NCT00373646","Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients","Completed","No Results Available","MALT Lymphoma","Drug: Thalidomide, Pharmion","Medical University of Vienna","Both","Adult|Senior","Phase II",8,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Thalidomide-MALT|Eudract number 2005-000008-14","September 7, 2006","01/06/2006",2009-01-01,"June 17, 2009","01/06/2009","",2009-01-01,"To evaluate the clinical potential of thalidomide to induce objective/histologic responses in patients with MALT lymphoma|To evaluate the safety of thalidomide in this patient population and to evaluate|The impact of thalidomide on progression free survival","http://ClinicalTrials.gov/show/NCT00373646",NA
"38734",38734,"NCT00369746","STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse","Completed","No Results Available","Non-Psychotic Major Depressive Disorder|Alcohol Use Disorder","Drug: citalopram","National Institute on Alcohol Abuse and Alcoholism (NIAAA)","Both","Adult","Phase IV",60,"NIH","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NIAAA-GRE-13303-01|NIH Grant RO1 AA13303-01","August 24, 2006","01/09/2006",2009-02-01,"February 23, 2009","01/02/2009","",2009-02-01,"Quick Inventory of Depression - Clinician 16 (QIDS-C 16)|Quick Inventory of Depression- Self Report 16 (QIDS-SR 16)|Hamilton Depression Scale 17 (HAM-D 17)|Timeline Follow Back (TLFB)|Quantitative Substance Use Inventory ((SUI)|Treatment Services Review (TSR)","http://ClinicalTrials.gov/show/NCT00369746",NA
"38746",38746,"NCT00391846","Evaluation of Heart Failure Treatment Guided by NTproBNP vs Clinical Symptoms and Signs Alone","Completed","No Results Available","Heart Failure|Ventricular Dysfunction, Left","Drug: Captopril|Drug: Enalapril|Drug: Lisinopril|Drug: Ramipril|Drug: Trandolapril|Drug: Bisoprolol|Drug: Carvedilol|Drug: Metoprolol succinate|Drug: Candesartan|Drug: Valsartan|Drug: Eplerenone|Drug: Spironolactone|Drug: Diuretics|Drug: HF treatment according to Swedish guidelines|Procedure: Blood samples|Procedure: KCCQ Questionnaire","AstraZeneca","Both","Adult|Senior","Phase IV",250,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","D2452L00010|EUDRACT No. 2006-001259-36|SIGNAL HF","October 19, 2006","01/10/2006",2009-01-01,"March 4, 2009","01/03/2009","",2009-01-01,"The primary variable is a composite endpoint of days alive, days out of hospital and symptoms|Number of deaths|Changes in NTproBNP over time amd related to NYHA class|Changes in KCCQ (overall, symptom score subset, related to NTproBNP)|Changes in HFstatus and vital signs|Number of SAEs|Number of DAEs","http://ClinicalTrials.gov/show/NCT00391846",NA
"38826",38826,"NCT00516646","The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure","Completed","No Results Available","Heart Failure","Drug: ALT-711|Drug: Placebo","Synvista Therapeutics, Inc","Both","Adult|Senior","Phase II",100,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALT-711-0527","August 13, 2007","01/08/2007",2009-10-01,"January 12, 2010","01/04/2009","BENEFICIAL",2009-08-01,"The primary end-point of the study will be aerobic capacity (VO2max) measured at exercise testing|Changes in systolic function, diastolic function, advanced glycation end-products (AGE) measurements, changes in Minnesota Living with Heart Failure score, NYHA heart failure score, patient's and physician's global assessment, and NT-pro-BNP","http://ClinicalTrials.gov/show/NCT00516646",NA
"38863",38863,"NCT00568646","Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: MKC-1","EntreMed","Both","Adult|Senior","Phase II",33,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MKC-105","December 4, 2007","01/11/2007",2009-05-01,"May 4, 2009","01/05/2009","",2009-04-01,"Objective tumor response rate based on tumor measurements according to the RECIST","http://ClinicalTrials.gov/show/NCT00568646",NA
"38864",38864,"NCT00550446","A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis","Completed","No Results Available","Arthritis, Rheumatoid","Drug: Adalimumab|Drug: CP-690-550|Drug: CP-690-550|Drug: CP-690-550|Drug: CP-690,550|Drug: CP-690,550|Drug: Placebo","Pfizer","Both","Adult|Senior","Phase II",350,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A3921035","October 25, 2007","01/09/2007",2009-01-01,"October 7, 2009","01/10/2009","",2009-01-01,"American College of Rheumatology 20 (ACR 20) responder rate at the Week 12 visit.|Incidence and severity of adverse events after switch from adalimumab to CP- 690,550 compared to CP-690,550 alone|Categorical summary of absolute vital signs and vital signs changes compared to baseline by subject|The ACR 20 Responder rate (in addition to week 12)|ACR 50 Responder rate|ACR 90 Responder rate|Area under the ACR n curve|Actual and change from baseline in FACS lymphocyte biomarkers.|Mean change from baseline in vital signs (blood pressure, heart rate, and oral or tympanic temperature) measurements|Actual and change from baseline in the FACIT Fatigue Scale|Actual and change from baseline in the Medical Outcomes Study (MOS) Sleep Scale|Actual and change from baseline in serum IgG, IgM and IgA levels|Actual and change from baseline in disease activity, assessed as the|ACR 70 Responder rate|Actual and change from baseline in the SF 36 Health Questionnaire|Actual and change from baseline in the EuroQol EQ 5D|Actual and change from baseline of the 7 individual components of the ACR 20, 50, 70, and 90 response criteria|Actual and change from baseline in the Health Assessment Questionnaire (HAQ DI)|Incidence and severity of adverse events|Incidence and severity of clinical laboratory abnormalities","http://ClinicalTrials.gov/show/NCT00550446",NA
"38874",38874,"NCT00586846","Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma","Completed","No Results Available","Osteosarcoma","Drug: Cisplatin|Drug: Doxorubicin|Drug: Methotrexate","Memorial Sloan-Kettering Cancer Center","Both","Child|Adult|Senior","Phase II",40,"Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","03-074","December 21, 2007","01/07/2003",2009-02-01,"February 12, 2009","01/02/2009","",2009-02-01,"Determine the safety and feasibility of administration of pamidronate with conventional chemotherapy for osteosarcoma.","http://ClinicalTrials.gov/show/NCT00586846",NA
"38882",38882,"NCT00595946","Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone","Completed","No Results Available","Opioid-Induced Bowel Dysfunction","Drug: Lubiprostone|Drug: Placebo","Sucampo Pharmaceuticals, Inc.|Takeda Pharmaceutical Company Limited","Both","Adult|Senior","Phase III",420,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OBD0631","January 4, 2008","01/08/2007",2009-03-01,"December 10, 2009","01/12/2009","OPAL",2009-03-01,"Change from baseline in SBM frequency|Change from baseline in SBM frequency|First post-dose SBM (percentage of patients)|Responder rate|Mean changes from baseline in straining, stool consistency, constipation severity, abdominal bloating, abdominal discomfort, and bowel habit regularity|Treatment effectiveness","http://ClinicalTrials.gov/show/NCT00595946",NA
"38903",38903,"NCT00634946","SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation","Completed","No Results Available","Lumbar Vertebra Hernia","Drug: SI-6603|Drug: Placebo","Seikagaku Corporation","Both","Adult|Senior","Phase II|Phase III",195,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6603/1021|6603/1021","February 27, 2008","01/01/2008",2010-08-01,"August 26, 2010","01/08/2010","",2009-11-01,"Changes in leg pain from baseline.|The leg pain","http://ClinicalTrials.gov/show/NCT00634946",NA
"38918",38918,"NCT00657046","Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension","Completed","No Results Available","Intradialytic Hypotension","Drug: Droxidopa 400 mg|Drug: Droxidopa 600 mg|Drug: Placebo","Chelsea Therapeutics","Both","Adult|Senior","Phase II",75,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Droxidopa IDH201","April 8, 2008","01/12/2007",2009-01-01,"July 30, 2010","01/07/2010","IDH201",2009-01-01,"Determine the efficacy of droxidopa in the treatment of intradialytic hypotension as measured by the change between baseline (visits 2-7) and treatment (visits 14-19) in average mean arterial blood pressure during hemodialysis|Evaluate the efficacy of droxidopa in the treatment of intradialytic hypotension as measured by the change between baseline (visits 2-7) and treatment (visits 14-19) in average mean nadir systolic and diastolic blood pressures during hemodialysis;|Evaluate the efficacy of droxidopa as measured by the number of hypotension-induced interventions during hemodialysis (HD) sessions;|Evaluate the effect of droxidopa on hypotension-induced symptoms measured during hemodialysis|Evaluate the effect of droxidopa on daily symptoms associated with hemodialysis|Evaluate the effect of droxidopa on fatigue using the Multidimensional Fatigue Inventory (MFI-20)|Evaluate the dose-response relationship for droxidopa between the doses of 400 mg and 600 mg in the treatment of intradialytic hypotension|Evaluate the safety of droxidopa based on the occurrence of treatment-emergent adverse events (AE) and specific evaluation of blood pressure, heart rate, ECG, and laboratory findings across the study.","http://ClinicalTrials.gov/show/NCT00657046",NA
"38921",38921,"NCT00659646","The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers","Completed","No Results Available","Diabetic Foot Ulcer","Drug: gentamicin-collagen sponge and levofloxacin|Drug: Levofloxacin only","Innocoll Technologies|Premier Research Group plc","Both","Adult|Senior","Phase II",56,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","INN-TOP-003","April 11, 2008","01/04/2008",2010-02-01,"July 22, 2010","01/07/2010","",2009-05-01,"The percent of patients with a clinical outcome of \clinical cure\"" in each treatment group at Visit 3|The percent of patients with a positive clinical response at each time point|The percent of patients with a \""clinical cure\""|The percent of patients with pathogen eradication|Absolute change in total wound surface area in each treatment group|Time to clinical cure|Time to positive clinical response|Time on parenteral antimicrobial therapy|Visual Analog Scale (VAS) for pain assessment|Lipsky wound score|Treatment emergent adverse events""","http://ClinicalTrials.gov/show/NCT00659646",NA
"38930",38930,"NCT00679146","Efficacy Safety of a Combination Thiocolchicoside+Ketoprofen Compared to Thiocolchicoside Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain","Completed","No Results Available","Low Back Pain","Drug: Thiocolchicoside+Ketoprofen|Drug: Thiocolchicoside","Sanofi-Aventis","Both","Adult","Phase III",334,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","KETOP_R_02693","May 6, 2008","01/04/2008",2009-06-01,"June 10, 2010","01/06/2010","TIOKET",2009-06-01,"Average pain within the last 24 hours (VAS)|Average pain within the last 24 hours (VAS)","http://ClinicalTrials.gov/show/NCT00679146",NA
"38953",38953,"NCT00698646","Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.","Completed","Has Results","Hypertension","Drug: Valsartan + HCTZ|Drug: Valsartan|Drug: HCTZ","Novartis Pharmaceuticals","Both","Senior","Phase IV",384,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CVAH631BUS08","June 13, 2008","01/04/2008",2009-06-01,"November 16, 2010","01/11/2010","",2009-06-01,"Change in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP)|Change in Office Cuff Mean Sitting Diastolic Blood Pressure (MSDBP)|Change in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8, 12 and 16|Proportion of Subjects Achieving Blood Pressure (BP) Control (Defined as BP < 140/90 mmHg)|Proportion of Patients Achieving BP Goal (MSSBP < 140 mmHg)|Time to Achieving the First Treatment Success (Defined as the Time of the First Achievement of the Target Blood Pressure Goal [MSSBP/MSDBP <140/90 mmHg])","http://ClinicalTrials.gov/show/NCT00698646",NA
"38970",38970,"NCT00668746","Long-term Safety of Minocycline in Patients With Gum Disease","Completed","Has Results","Periodontitis","Drug: Minocycline HCl microspheres","Johnson & Johnson Consumer & Personal Products Worldwide","Both","Adult|Senior","Phase IV",35,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","OP-P-5756-1","April 24, 2008","01/12/2007",2009-02-01,"April 1, 2010","01/04/2010","",2009-02-01,"Change in Percent of Minocycline-Resistant Bacteria Using Bacterial Culture|Micocycline-Resistance From Plaque Samples|Micocycline-Resistance From Saliva Sample","http://ClinicalTrials.gov/show/NCT00668746",NA
"38984",38984,"NCT00771446","Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patient With Hepatic Insufficiency","Completed","No Results Available","Acute Hepatitis|Chronic Hepatitis","Other: Standard of care","Vital Therapies, Inc.","Both","Adult|Senior","Phase I|Phase II",18,"Industry","Interventional","Allocation: Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VTI-201","October 9, 2008","01/10/2008",NA,"May 25, 2010","01/08/2009","ELAD",2009-04-01,"To provide preliminary evidence of (1) the effect of ELAD?ó therapy on 30-day transplant-free survival in subjects with AOCH, and (2) its safety when used for a minimum of 3 days or up to a maximum of 10 days of treatment.","http://ClinicalTrials.gov/show/NCT00771446",NA
"38990",38990,"NCT00777946","Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone","Completed","No Results Available","Hypertension","Drug: Aliskiren 300 mg|Drug: Aliskiren/Amlodipine 300/5 mg|Drug: Aliskiren/Amlodipine 300/10 mg","Novartis","Both","Adult|Senior","Phase III",818,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CSPA100A2303","October 20, 2008","01/11/2008",NA,"February 6, 2010","01/02/2010","",2009-05-01,"Vital signs at every visit|Vital signs at every visit|Adverse event at every visit","http://ClinicalTrials.gov/show/NCT00777946",NA
"39023",39023,"NCT00841646","Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects","Completed","No Results Available","Prepandemic Influenza Vaccine","Biological: Monovalent inactivated influenza vaccine","Novartis|Novartis Vaccines","Both","Adult|Senior","Phase II",334,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","V87P11|2008-000895-25","February 10, 2009","01/12/2008",2009-11-01,"November 16, 2009","01/11/2009","",2009-07-01,"Evaluation of antibody response to a monovalent inactivated flu vaccine adjuvanted with MF59 and uses a surface antigen from a potential pandemic homologous virus strain candidate (H5N1), as measured by HI test,MN test,SRH test,on day 0,21,42 and 201|Evaluation of safety of the monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a surface antigen from a potential pandemic virus strain candidate (H5N1) in Adult and Elderly Subjects.","http://ClinicalTrials.gov/show/NCT00841646",NA
"39080",39080,"NCT00933946","Dermacyd Silver Frutal (Lactic Acid) - Compatibility.","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Both","Adult","Phase III",55,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LACAC_L_04842","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"Evaluation of the absence of primary and accumulated dermical irritability and dermical sensitivity by using International Contact Dermatitis Research Group (ICDRG) scale.","http://ClinicalTrials.gov/show/NCT00933946",NA
"39090",39090,"NCT00928746","Actuation Indicator Trial in Patients With COPD","Completed","Has Results","Pulmonary Disease, Chronic Obstructive","Device: Ipratropium bromide","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",142,"Industry","Interventional","Endpoint Classification: Efficacy Study|Primary Purpose: Treatment","244.2507","June 25, 2009","01/06/2009",NA,"September 28, 2010","01/09/2010","",2009-08-01,"Actuations Registered by the Actuation Indicator|Actuations Dispensed|Difference Between the Number of Actuations Registered by Actuation Indicator Versus Actuations Dispensed|Actuations Recorded on Patient Diary|Actuations Based on Advancing the Actuation Indicator|Actuations Registered by the Actuation Indicator and Read by Site Coordinator|Difference Between the Number of Actuations Recorded on Patient Diary Versus Actuations Dispensed|Difference Between the Number of Actuations Based on Advancing Actuation Indicator Versus Actuations Dispensed|Difference Between the Number of Actuations Registered by the Actuation Indicator and Read by Site Coordinator Versus Actuations Dispensed|Number of Participants Who Reported Problems With Use of Inhaler With Integrated Dose Counter According to Patient Handling Questionnaire|Number of Participants Who Reported Problems With Seeing Red Warning Indicating Inhaler Near End of Recommended Doses According to Patient Handling Questionnaire|Number of Participants Who Reported Problems With Inhaler and Dose Counter Performing as Expected Based on Instructions According to Patient Handling Questionnaire|Number of Participants Who Reported Satisfaction With Performance of the Dose Counter for Indicating Approximately How Many Doses Remain in Inhaler According to Patient Handling Questionnaire|Number of Participants Who Reported Satisfaction That the Dose Counter Worked Reliably According to Patient Handling Questionnaire|Number of Participants Who Reported Satisfaction With Ease of Use of the Dose Counter According to Patient Handling Questionnaire|Number of Participants Who Reported Satisfaction With Dose Counter in the Mouthpiece of the Inhaler According to Patient Handling Questionnaire|Number of Participants Having Any Additional Comments According to Patient Handling Questionnaire","http://ClinicalTrials.gov/show/NCT00928746",NA
"39101",39101,"NCT00961246","Web-Based Active Balance Childhood Study in Chinese-American","Completed","No Results Available","Healthy","Behavioral: general health information|Behavioral: individually-tailored intervention","University of California, San Francisco|UCSF Hellman Junior Faculty development award","Both","Child","Phase II",70,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","H11584-31742|KL2RR024130","August 16, 2009","01/03/2008",2009-05-01,"September 2, 2009","01/08/2009","WEBABC",2009-05-01,"BMI|physical activity, dietary intake, coping strategy","http://ClinicalTrials.gov/show/NCT00961246",NA
"39115",39115,"NCT00987246","Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis","Completed","No Results Available","Actinic Keratosis","Drug: Placebo Gel|Drug: LAS41005|Drug: LAS106521","Almirall, S.A.","Both","Adult|Senior","Phase III",470,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H 1005 6002 - 0702|EudraCT: 2007-003889-18","September 29, 2009","01/06/2008",NA,"July 9, 2010","01/07/2010","",2009-06-01,"Histological status of AK target lesion","http://ClinicalTrials.gov/show/NCT00987246",NA
"39215",39215,"NCT01144546","Passive Leg Raising Test to Predict Hypotension During Induction of Anesthesia in Patients Undergoing Cardiac Surgery","Completed","No Results Available","Ischemic Heart Disease|Cardiac Valve Disease","Procedure: passive leg raising (45 degree leg elevation for 1-2 min)","Seoul National University Hospital","Both","Adult|Senior","Phase II",42,"Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","H-0809-037-256","June 8, 2010","01/08/2009",2009-09-01,"June 14, 2010","01/06/2010","",2009-09-01,"The area under ROC curve to predict hypotension and refractory hypotension","http://ClinicalTrials.gov/show/NCT01144546",NA
"39232",39232,"NCT01167946","Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata","Completed","No Results Available","Alopecia Totalis|Alopecia Universalis|Ophiasic Alopecia","Drug: methylprednisolone sodium succinate|Drug: methylprednisolone sodium succinate|Drug: methylprednisolone sodium succinate","King Saud University|Saudi Society of Dermatology and Dermatologic surgery","Both","Child|Adult|Senior","Phase IV",42,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","03-451","July 21, 2010","01/01/2003",2010-07-01,"July 21, 2010","01/01/2003","",2009-12-01,"hair regrowth|Safety of the protocol|Factors affect the response to treatment","http://ClinicalTrials.gov/show/NCT01167946",NA
"39328",39328,"NCT00004547","Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy","Completed","No Results Available","Abdominal Neoplasm|Colonic Neoplasm|Mesothelioma|Peritoneal Neoplasm","Procedure: Adjuvant therapy|Procedure: Conventional therapy|Drug: Cisplatin|Drug: fluorouracil|Drug: Paclitaxel|Procedure: Hyperthermia treatment","National Cancer Institute (NCI)","Both","Child|Adult","Phase II",188,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","000069|00-C-0069","February 3, 2000","01/01/2000",2009-08-01,"September 17, 2010","01/05/2010","",2009-08-01,"Disease-free survival at 6 or 12 months.","http://ClinicalTrials.gov/show/NCT00004547",NA
"39392",39392,"NCT00093847","Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression","Completed","No Results Available","Depression","Drug: S-adenosyl methione (SAMe)|Drug: Placebo","National Institute of Mental Health (NIMH)","Both","Adult|Senior","Phase III",80,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","K23 MH069629|DATR AK-TNET1","October 6, 2004","01/05/2004",2009-02-01,"March 10, 2009","01/03/2009","",2009-02-01,"Depressive scales|Self-report depression questionnaires","http://ClinicalTrials.gov/show/NCT00093847",NA
"39395",39395,"NCT00095147","Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: Abatacept + Methotrexate|Drug: Infliximab + Methotrexate|Drug: Placebo + Methotrexate|Drug: Abatacept","Bristol-Myers Squibb","Both","Adult|Senior","Phase III",400,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IM101-043","November 1, 2004","01/02/2005",2009-07-01,"June 17, 2010","01/06/2010","",2009-07-01,"To demonstrate that the Abatacept in combination with Methotraexate will demonstrate a greater reduction in disease activity than placebo in combination with methotrexate as measured by the Disease Activity Score (das28)|Assess the safety and long-term tolerability of Abatacept in subjects who will continue in the long-term extention|To demonstrate that infliximab in combination with methotrexate will demonstrate a greater reduction in disease activity than placebo in combination with methotrexate (mtx) as measured by the disease activity score (DASE28)|Assess the immunogenicity of abatacept in combionation with methotrexate","http://ClinicalTrials.gov/show/NCT00095147",NA
"39479",39479,"NCT00225147","Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema","Completed","No Results Available","Hereditary Angioedema|Angioneurotic Edema","Drug: Recombinant Human C1 Inhibitor","Pharming Technologies B.V.|FDA Office of Orphan Products Development","Both","Child|Adult|Senior","Phase II",77,"Industry|U.S. Fed","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C1 1205-01|3086","September 20, 2005","01/07/2005",2010-01-01,"August 30, 2010","01/08/2010","",2009-10-01,"Relief of angioedema symptoms|Safety and tolerability; pharmacokinetics/pharmacodynamics","http://ClinicalTrials.gov/show/NCT00225147",NA
"39500",39500,"NCT00252447","Preop Conformal Radiotherapy - Prostate","Completed","No Results Available","Prostatic Neoplasm","Procedure: Pre-Operative Conformal Radiotherapy","University Health Network, Toronto|Princess Margaret Hospital, Canada","Male","Adult|Senior","Phase I|Phase II",15,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 01-0483-C","November 9, 2005","01/05/2000",2009-03-01,"August 10, 2010","01/08/2010","",2009-03-01,"To document the feasibility of pre-operative conformal radiation therapy in patients undergoing radical prostatectomy for localized prostate cancer who are at high risk for having local extra-prostatic disease at time of surgery.","http://ClinicalTrials.gov/show/NCT00252447",NA
"39528",39528,"NCT00297947","High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder","Completed","No Results Available","Schizophrenia|Schizoaffective Disorder","Drug: quetiapine|Drug: quetiapine","Manhattan Psychiatric Center|Nathan Kline Institute for Psychiatric Research","Both","Adult","Phase II|Phase III",60,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRUSQUET0348","February 27, 2006","01/12/2004",NA,"August 9, 2010","01/08/2010","HDQ",2009-10-01,"To see if mean extrapyramidal symptoms measure will change significantly from baseline to endpoint for the whole group and if the mean change in EPS measure is significantly different between quetiapine 1200mg daily group and quetiapine 600mg daily group|To see if treatment with quetiapine 1200 mg per day will improve total PANSS more robustly than quetiapine 600 mg per day","http://ClinicalTrials.gov/show/NCT00297947",NA
"39592",39592,"NCT00395447","REPLACE: Implantable Cardiac Pulse Generator Replacement Registry","Completed","Has Results","Device Replacement|Elective Replacement (ERI)|Device Advisory|Device Upgrade|Postoperative Complications","Procedure: Pulse generator replacement or upgrade|Device: Pacemaker, ICD or CRT system","Biotronik, Inc.","Both","Adult|Senior","Phase IV",1744,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research","REPLACE","November 1, 2006","01/07/2007",2009-06-01,"November 29, 2010","01/11/2010","REPLACE",2009-06-01,"Percentage of Subjects Experiencing a Complication During Generator Replacement Without a Planned Lead Revision or Addition (Straight-forward Device Replacment) or With a Planned Lead Revision or Addition (Planned System Modification)|Baseline Variables for Subjects Undergoing Generator Replacement Without a Planned Lead Revision or Addition (Straight-forward Device Replacment) or With a Planned Lead Revision or Addition (Planned System Modification)","http://ClinicalTrials.gov/show/NCT00395447",NA
"39613",39613,"NCT00434447","Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases","Completed","No Results Available","Bone Neoplasms","Drug: Zoledronic acid","Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",73,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","CZOL446EAU22","February 9, 2007","01/12/2006",NA,"October 21, 2010","01/10/2010","",2009-09-01,"Safety assessed by incidence of renal impairment, osteonecrosis of the Jaw (ONJ), adverse events and serious adverse events. Efficacy assessed by incidence of skeletal related events (SREs).","http://ClinicalTrials.gov/show/NCT00434447",NA
"39614",39614,"NCT00426647","Norspan?ó Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip Knee and/or Lumbar Spine","Completed","No Results Available","Osteoarthritis|Pain","Drug: Buprenorphine|Drug: Tramadol","Norpharma A/S|Mundipharma Finland","Both","Adult|Senior","Phase IV",120,"Industry|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","BUP4006|NORTOP","January 23, 2007","01/02/2007",2009-08-01,"January 29, 2010","01/01/2010","",2009-07-01,"Equivalence study to evaluate the efficacy of Norspan?ó patches versus Tramadol in subjects with chronic, moderate to severe osteoarthritis pain of the hip, knee and/or lumber spine.|To evaluate the safety and general satisfaction for the patients in the two treatment groups.","http://ClinicalTrials.gov/show/NCT00426647",NA
"39631",39631,"NCT00465647","An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain","Completed","No Results Available","Acute Pain","Drug: Hydromorphone HCl","Purdue Pharma LP","Both","Child","Phase IV",116,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HMP4009","April 24, 2007","01/04/2007",2010-04-01,"May 6, 2010","01/05/2010","",2009-05-01,"Population Pharmacokinetic/Pharmacodynamic (PK/PD) analysis|Faces Pain Scale-Revised (FPS-R)|Visual Analog Scale (VAS)|The Faces, Legs, Activity, Cry, Consolability (FLACC) Scale","http://ClinicalTrials.gov/show/NCT00465647",NA
"39645",39645,"NCT00478647","Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase","Completed","Has Results","Gaucher Disease, Type 1","Biological: GA-GCB (velaglucerase alfa)","Shire Human Genetic Therapies, Inc.","Both","Child|Adult|Senior","Phase II|Phase III",40,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TKT034","May 23, 2007","01/07/2007",2009-08-01,"September 20, 2010","01/09/2010","",2009-07-01,"Patients Which Experienced at Least One Adverse Event|Change From Baseline to Week 53 in Hemoglobin Concentration|Percent Change From Baseline to Week 53 in Platelet Count|Percent Change From Baseline to Week 51 in Normalized Liver Volume|Percent Change From Baseline to Week 51 in Normalized Spleen Volume","http://ClinicalTrials.gov/show/NCT00478647",NA
"39648",39648,"NCT00487747","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.","Completed","No Results Available","Hepatitis B, Chronic","Drug: peginterferon alfa-2a [Pegasys]","Hoffmann-La Roche","Both","Adult|Senior","Phase IV",19,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20003","June 18, 2007","",2009-10-01,"February 15, 2010","01/02/2010","",2009-10-01,"HBV DNA <100,000 copies/mL (HBeAg positive patients)|HBV DNA <20,000 copies/mL (HBeAg negative patients)|HBV DNA <400 copies/mL, HbsAg seroconversion, ALT normalization, sustained HBe seroconversion in HBeAg positive patients.|AEs and laboratory parameters","http://ClinicalTrials.gov/show/NCT00487747",NA
"39650",39650,"NCT00494247","Endothelial Progenitor Cells-capture Stents in Acute Coronary Syndromes","Completed","No Results Available","Acute Coronary Syndromes|Coronary Heart Disease","Device: coronary stent (Genous, OrbusNeich) with immobilised anti-CD34 antibody to capture circulating endothelial progenitor cells","Silesian School of Medicine|Ministry of Science and Higher Education, Poland","Both","Adult|Senior","Phase IV",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","N40202932/0651|0651/P01/2007/32","June 28, 2007","01/10/2007",2009-08-01,"June 18, 2010","01/11/2009","JACK-EPC",2009-06-01,"Safety: MACE (composite CV death, myocardial infarction, heart failure, target vessel revascularization, target lesion revascularization)|Neointima volume measured by IVUS|In-stent late lumen loss and binary restenosis measured by QCA|In stent thrombosis (angiographic, clinical)|Clinical status (treadmill stress test)|Number, function (migration, eNOS expression), transcriptional activity of circulating EPCs|In segment late lumen loss, EEM area (QCA, IVUS)|Reactivity of target vessel to adenosine and nitroglycerine (QCA, Doppler)|Stent apposition/complete stent expansion (IVUS)|Plasma levels of inflammatory/hematopoietic cytokines","http://ClinicalTrials.gov/show/NCT00494247",NA
"39657",39657,"NCT00463047","Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain","Completed","Has Results","Chronic Pain","Drug: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone","Cephalon","Both","Adult|Senior","Phase III",323,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","C25608/3055/BP/MN","February 8, 2007","01/07/2007",2009-02-01,"November 16, 2010","01/11/2010","",2009-02-01,"Pain Intensity Difference (PID15) At 15 Minutes|Pain Intensity Difference (PID 5) at 5 Minutes|Pain Intensity Difference (PID 10) at 10 Minutes|Pain Intensity Difference (PID 30) at 30 Minutes|Pain Intensity Difference (PID 45) at 45 Minutes|Pain Intensity Difference (PID 60) at 60 Minutes|Percentage Change in Pain Intensity Difference (% PID) at 5 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (%PID) at 10 Minutes|Percentage Change in Pain Intensity Difference (%PID) at 15 Minutes|Percentage Change in Pain Intensity Difference (%PID) at 30 Minutes|Percentage Change in Pain Intensity Difference (% PID) at 45 Minutes|Percentage Change in Pain Intensity Difference (%PID) at 60 Minutes|Sum of Pain Intensity Difference at 30 Minutes Post-treatment (SPID30)|Sum of Pain Intensity Difference at 60 Minutes Post-treatment (SPID60)|Pain Relief (PR) Score at 5 Minutes|Pain Relief Score (PR) at 10 Minutes|Pain Relief Score (PR) at 15 Minutes|Pain Relief Score (PR) at 30 Minutes|Pain Relief Score (PR) at 45 Minutes|Pain Relief Score (PR) at 60 Minutes|Total Pain Relief (TOTPAR60) at 60 Minutes|Percent Total Pain Relief at 60 Minutes Posttreatment (%TOTPAR)|Time to Any Pain Relief (APR) by Treatment - <= 5 Minutes|Time to Any Pain Relief (APR) by Treatment <=10 Minutes|Time to Any Pain Relief (APR) by Treatment <=15 Minutes|Time to Any Pain Relief (APR) by Treatment <=30 Minutes|Time to Any Pain Relief (APR) by Treatment <=45 Minutes|Time to Any Pain Relief (APR) by Treatment <=60 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment - <= 5 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=10 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=15 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=30 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=45 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=60 Minutes|Standard Rescue Medication Usage|Medication Performance Assessment 30 Minutes After-treatment|Medication Performance Assessment 60 Minutes After-treatment|Breakthrough Pain Preference Questionnaire|Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at the End of the First Double-blind Treatment Period (Visit 5)|Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at the End of the Second Double-blind Treatment Period (Visit 6)|Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at Endpoint (End of Second Double-blind Treatment Period or Last Observation After Start of Treatment Period)","http://ClinicalTrials.gov/show/NCT00463047",NA
"39738",39738,"NCT00633347","Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation","Completed","No Results Available","Infertility","Drug: Antagonist GnRH Cetrotide|Drug: Agonist GnRH Acetate Triptoreline","Instituto Valenciano de Infertilidad, Spain","Female","Adult","Phase IV",400,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VLC-CV-1006-02","February 21, 2008","01/01/2007",2009-10-01,"October 1, 2009","01/10/2009","",2009-10-01,"clinical pregnancy rate|implantation rate","http://ClinicalTrials.gov/show/NCT00633347",NA
"39756",39756,"NCT00658047","A Study to Assess CH-1504 in Patients With Active Rheumatoid Arthritis","Completed","No Results Available","Arthritis, Rheumatoid","Drug: CH-1504|Drug: Methotrexate","Chelsea Therapeutics","Both","Adult|Senior","Phase II",200,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CH-1504-201","April 8, 2008","01/04/2008",2009-06-01,"January 27, 2010","01/01/2010","",2009-02-01,"Assess the clinical effect of CH-1504 (0.25, 0.5, and 1.0 mg po daily) by determining the proportion of patients achieving an ACR20 response.|Assess the clinical efficacy of CH-1504 by proportion of patients achieving ACR50 and ACR70 responses.|Assess the clinical efficacy of CH-1504 using EULAR \good\"" and \""moderate\"" response criteria.|Assess the clinical efficacy of CH-1504 using the difference from baseline of ACR core set and DAS28 of measures.|Evaluate the safety and tolerability of CH-1504 in RA patients as determined by the frequency and severity of adverse events","http://ClinicalTrials.gov/show/NCT00658047",NA
"39793",39793,"NCT00716547","Safety and Efficacy of Two Dosages of Diractin?ó in Osteoarthritis (OA)","Completed","No Results Available","Osteoarthritis of the Knee","Drug: ketoprofen in Diractin?ó|Drug: ketoprofen in Diractin?ó|Drug: Placebo|Drug: celecoxib","IDEA AG","Both","Adult|Senior","Phase III",1399,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CL-033-III-03","July 14, 2008","01/05/2008",2009-05-01,"October 15, 2009","01/10/2009","",2009-03-01,"pain subscale of the WOMAC|Patient global assessment of response to therapy|function subscale of the WOMAC","http://ClinicalTrials.gov/show/NCT00716547",NA
"39806",39806,"NCT00736047","Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100??g NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.","Completed","No Results Available","Smokers","Biological: NIC002|Biological: Placebo","Novartis","Both","Adult","Phase II",200,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CNIC002A2201","August 14, 2008","01/08/2008",NA,"October 29, 2009","01/10/2009","",2009-10-01,"Smoking status|Exhaled carbon monoxide|Smoking status at various time intervals from target quit date to the end of the study|Safety and tolerability|Immunogenicity (specific anti-nicotine antibodies in serum)","http://ClinicalTrials.gov/show/NCT00736047",NA
"39812",39812,"NCT00745147","Comparison of TCM and Laxatives for Adults With Chronic Constipation","Completed","No Results Available","Chronic Constipation","Drug: Chinese herbal formula (CCH1)|Drug: Duphalac","National Taiwan University Hospital","Both","Adult|Senior","Phase III",93,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","200803029M","August 31, 2008","01/07/2008",2010-04-01,"May 3, 2010","01/04/2010","",2009-10-01,"frequency of spontaneous bowel movement|amount of rescue laxative use|stool consistency|stool amount|global assessment of efficacy|safety evaluation|frequency of enema/suppository use/digital maneuver|medical cost per spontaneous bowel movement","http://ClinicalTrials.gov/show/NCT00745147",NA
"39831",39831,"NCT00765947","Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension","Completed","Has Results","Essential Hypertension ( Mild to Moderate)","Drug: Aliskiren","Novartis","Both","Adult|Senior","Phase IV",256,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CSPP100A2360","October 2, 2008","01/09/2008",2009-08-01,"December 13, 2010","01/12/2010","",2009-08-01,"Percentage of Patients (Defined as Estimated Cumulative Control Rate) Reaching BP Target in a Stepped Care, Aliskiren-based Regimen|Percentage of Patients (Defined as Estimated Cumulative Control Rate) Reaching BP Target in a Stepped-care, Aliskiren-based Regimen|BP-lowering Effect in msSBP and msDBP in a Stepped-care, Aliskiren-based Regimen|Responder Rate (Defined as Estimated Cumulative Response Rate) for msSBP and for msDBP in a Stepped-care, Aliskiren-based Regimen|Overall Safety and Tolerability of Aliskiren Monotherapy and in Combination Treatment","http://ClinicalTrials.gov/show/NCT00765947",NA
"39880",39880,"NCT00855647","Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)","Completed","No Results Available","Prostatic Neoplasms","Procedure: Hypo-fractionated Radiotherapy","Stanford University","Male","Adult|Senior","Phase II",99999,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SU-11022007-792|79432|PROS0020","March 2, 2009","01/08/2003",2009-07-01,"June 1, 2010","01/06/2010","",2009-03-01,"PSA response that achieves a stable nadir over time.","http://ClinicalTrials.gov/show/NCT00855647",NA
"39915",39915,"NCT00921947","Comparative Safety and Immunogenicity of 1.0 ??g Intramuscular (i.m.) and 2.0 ??g Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults","Completed","No Results Available","Influenza","Biological: VAX102","VaxInnate Corporation","Both","Adult","Phase I|Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","VAX102-09","June 15, 2009","01/06/2009",2009-08-01,"February 4, 2010","01/02/2010","",2009-07-01,"To assess the safety, reactogenicity, tolerability, and adverse events (AEs) of the VAX102 vaccine in a two dose regimen (Day 0 and Day 28) at the 1.0 ??g dose level delivered i.m., or the 2.0 ??g dose level delivered s.c. in a healthy adult population.|To assess the anti-M2e serum antibody concentration after VAX102 vaccine in a two dose regimen (Day 0 and Day 28) at the 1.0 ??g dose level delivered i.m., or the 2.0 ??g dose level delivered s.c.","http://ClinicalTrials.gov/show/NCT00921947",NA
"39923",39923,"NCT00928447","Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis","Completed","No Results Available","Dermatitis, Allergic Contact","Drug: rHuPH20","Halozyme Therapeutics","Female","Adult","Phase II",22,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","HALO-114-201","June 25, 2009","01/06/2009",2009-10-01,"August 27, 2010","01/08/2010","",2009-09-01,"Determine the treatment effect of rHuPH20 or placebo control injection on the exposure to topical nickel allergen|Determine the time to onset and severity of the cutaneous reaction to nickel allergen after pre-treatment with rHuPH20 or placebo control|Assess the safety and tolerability of the rHuPH20 injection","http://ClinicalTrials.gov/show/NCT00928447",NA
"39956",39956,"NCT00980447","Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults","Completed","No Results Available","Influenza|Virus Diseases","Biological: UMN-0501|Biological: UMN-0501|Biological: UMN-0501","UMN Pharma Inc.","Both","Adult","Phase II",90,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","JPIP501-01a","September 17, 2009","01/10/2009",2009-12-01,"February 5, 2010","01/02/2010","",2009-12-01,"Number of subjects who achieve seroconversion, seroprotection, GMTs and GMT ratio to baseline, 21 days after the 2nd vaccination defined by serum neutralizing and HAI titers against the influenza H5N1 A/Vietnam/1203/2004 virus.|Frequencies of AEs including vaccine-related reactogenicity events.|To explore T-cell response in the subset of subjects after each vaccination as determined by proliferation and cytokine production capacity of T-cells re-stimulate by H5N1 A/Vietnam/1203/2004 recombinant virus antigens.","http://ClinicalTrials.gov/show/NCT00980447",NA
"40000",40000,"NCT01053247","Study of 0416 Ointment in the Treatment of Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Drug: 0416|Drug: Vehicle of 0416 test product|Drug: tacrolimus ointment 0.1%","Nycomed US Inc.","Both","Adult|Senior","Phase III",793,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","416","December 9, 2009","01/01/2008",2009-08-01,"January 20, 2010","01/01/2010","",2009-08-01,"Incidence of success based on the investigator's global evaluation at the end of treatment|The mean change from baseline in the total individual clinical signs and symptoms per body region, the mean change from baseline in pruritus and mean change from baseline in the percentage total body surface affected (%BSA).","http://ClinicalTrials.gov/show/NCT01053247",NA
"40096",40096,"NCT01213147","Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders","Completed","No Results Available","Pregnancy","Drug: clomiphene citrate|Drug: buserelin","Yazd Medical University|Yazd Research & Clinical Center for Infertility","Female","Adult","Phase IV",159,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","2063","September 30, 2010","01/04/2009",2010-05-01,"September 30, 2010","01/09/2010","",2009-08-01,"clinical pregnancy rate|and implantation rate","http://ClinicalTrials.gov/show/NCT01213147",NA
"40212",40212,"NCT00033748","Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: monoclonal antibody 11D10 anti-idiotype vaccine|Biological: monoclonal antibody 3H1 anti-idiotype vaccine|Procedure: adjuvant therapy","Cancer and Leukemia Group B|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000069324|CALGB-89903","April 9, 2002","01/12/2001",NA,"August 27, 2009","01/07/2004","",2009-08-01,"","http://ClinicalTrials.gov/show/NCT00033748",NA
"40284",40284,"NCT00146848","PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy","Completed","Has Results","Heart Failure","Device: Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices","Boston Scientific Corporation","Both","Adult|Senior","Phase IV",1742,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","CR-CA-100604-H|PEGASUS","September 2, 2005","01/12/2004",2009-02-01,"September 21, 2010","01/09/2010","PEGASUS CRT",2009-01-01,"Clinical Composite Score|Change in Quality of Life|Change in Self Assessed Physical Activity","http://ClinicalTrials.gov/show/NCT00146848",NA
"40358",40358,"NCT00272948","Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide","Completed","No Results Available","Hepatic Veno-Occlusive Disease","Drug: Defibrotide|Drug: Defibrotide|Drug: Defibrotide","European Group for Blood and Marrow Transplantation|Gentium SpA|Deutsche Krebshilfe e.V., Bonn (Germany)","Both","Child|Adult","Phase II|Phase III",360,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","EudraCT Number:2004-000592-33|EBMT-PD-200601","January 4, 2006","01/12/2005",2009-07-01,"June 21, 2010","01/06/2010","VOD-DF",2009-01-01,"The primary objective is to evaluate if prophylactic DF has an impact on the incidence of VOD|Occurrence of Multi-System Organ Failure and Survival (all causes of mortality)","http://ClinicalTrials.gov/show/NCT00272948",NA
"40359",40359,"NCT00275548","Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C","Completed","No Results Available","Liver Transplant|Hepatitis C","Drug: Pagssys and Copegus","Mayo Clinic|Roche Pharma AG","Both","Adult|Senior","Phase IV",12,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","1404-04","January 10, 2006","01/07/2004",2009-04-01,"January 19, 2010","01/01/2010","",2009-04-01,"The proportion of patients in each group who experienced histologically confirmed recurrence of HCV at 120 weeks post randomization.|The proportion of patients who have non-detectable serum HCV-RNA measured by Quanta Sure plus HCV test and HCV RNA negative by quantative PCR at week 12, 24, and 48 following initiation of treatment or on observation.|Virological response rate to antiviral therapy at week 12, week 24, and week 48 of therapy among patients who received antiviral therapy in either study arm.|Sustained virological response rate: the virological response at the conclusion of the 24 weeks treatment free follow-up period or 72 weeks on observation (for patients who received no treatment).|The virological response at the conclusion of the 24 weeks treatment-free follow-up period among patients who received antiviral therapy in either arm of the study.|Patient death or graft failure (as indicated by retransplantation).","http://ClinicalTrials.gov/show/NCT00275548",NA
"40362",40362,"NCT00280748","Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer|Metastatic Cancer","Drug: pemetrexed disodium|Radiation: radiation therapy","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",30,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000551069|UNC-LCCC-0409","January 19, 2006","01/05/2005",NA,"August 29, 2009","01/06/2009","",2009-06-01,"Response of intracranial metastases (complete and partial response)","http://ClinicalTrials.gov/show/NCT00280748",NA
"40365",40365,"NCT00282048","Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer","Completed","No Results Available","Kidney Neoplasms|Carcinoma, Renal Cell","Drug: AG-013736 (axitinib)","Pfizer","Both","Adult|Senior","Phase II",62,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A4061023","January 23, 2006","01/03/2006",2009-08-01,"November 13, 2009","01/11/2009","",2009-02-01,"Measured by overall objective response rate, CR and PR, by RECIST.|To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer|Progression-free survival|Duration of response|Explore effects of treatment on patient reported outcomes|Cancer related symptoms (FKSI)|Overall survival|Explore PK correlates with response or adverse events.|Safety profile of AG-013736","http://ClinicalTrials.gov/show/NCT00282048",NA
"40387",40387,"NCT00322348","Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women","Completed","No Results Available","Advanced Breast Cancer","Drug: Goserelin acetate|Drug: Goserelin acetate","AstraZeneca","Female","Adult|Senior","Phase II",98,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D8664C00008|Zoladex ABC Study","May 3, 2006","01/04/2006",2009-11-01,"December 3, 2009","01/12/2009","",2009-11-01,"Evaluate whether Zoladex 10.8 mg (12-weekly) is non-inferior to Zoladex 3.6 mg (4-weekly) in pre-menopausal women with oestrogen receptor positive advanced breast cancer by assessment of progression-free survival|Provide supporting data confirming that Zoladex 10.8 mg/12 weeks is non-inferior to Zoladex 3.8 mg/4 weeks|Compare safety and tolerability of both doses|Assess goserelin pharmacokinetics (PK) in Japanese and non-Japanese patients who have received Zoladex 10.8 mg","http://ClinicalTrials.gov/show/NCT00322348",NA
"40410",40410,"NCT00344448","Raptiva to Treat Sjogren's Syndrome","Completed","No Results Available","Sjogren's Syndrome","Drug: Raptiva","National Institute of Dental and Craniofacial Research (NIDCR)","Both","Adult|Senior","Phase II",10,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","060181|06-D-0181","June 23, 2006","01/06/2006",2009-01-01,"February 20, 2010","01/12/2009","",2009-01-01,"Improvement in exocrine function|Response defined by a composite criteria","http://ClinicalTrials.gov/show/NCT00344448",NA
"40444",40444,"NCT00404248","Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: terameprocol|Other: pharmacological study","National Cancer Institute (NCI)","Both","Adult|Senior","Phase I|Phase II",50,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000515952|NABTT-0503","November 27, 2006","01/01/2007",NA,"June 23, 2009","01/06/2009","",2009-06-01,"Maximum tolerated dose (Phase I)|Response rate (Phase II)|Pharmacokinetics (Phase I)|Toxicity (Phase I)|Effects of hepatic enzyme-inducing anticonvulsants on the pharmacokinetic profile (Phase I)|Safety (Phase II)|Tolerability (Phase I and II)|Overall survival (Phase I and II)|Treatment response (complete and partial remission and stable disease) (Phase II)","http://ClinicalTrials.gov/show/NCT00404248",NA
"40460",40460,"NCT00362648","Developing World Study for RotaTeq?ºÑ","Completed","Has Results","Vomiting|Diarrhea|Fever","Biological: RotaTeq?ºÑ - Rotavirus Vaccine, Live, Oral, Pentavalent|Biological: Comparator: Placebo","Merck","Both","Child","Phase III",7504,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2006_027|V260-015","August 8, 2006","01/03/2007",2009-03-01,"April 26, 2010","01/04/2010","",2009-03-01,"Occurrence of Severe Clinical Rotavirus Disease Caused by Any Rotavirus Serotype More Than 14 Days Following the Third Dose|Africa - Serum Anti-rotavirus IgA Responses and Serum Neutralizing Antibody (SNA) Responses Against Rotavirus Serotypes G1, G2, G3, G4, and P1A[8]|Asia - Serum Anti-rotavirus IgA Responses and Serum Neutralizing Antibody (SNA) Responses Against Rotavirus Serotypes G1, G2, G3, G4, and P1A[8]","http://ClinicalTrials.gov/show/NCT00362648",NA
"40472",40472,"NCT00449748","Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis","Completed","No Results Available","Systemic Mastocytosis","Drug: RAD001","M.D. Anderson Cancer Center|Novartis Pharmaceuticals","Both","Adult|Senior","Phase II",10,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0759","March 19, 2007","01/04/2007",2009-10-01,"October 23, 2009","01/10/2009","",2009-10-01,"Patients with Improvement in Objective Response over 30%","http://ClinicalTrials.gov/show/NCT00449748",NA
"40473",40473,"NCT00451048","Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes","Drug: sunitinib malate","University Health Network, Toronto|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",32,"Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000535656|PMH-PHL-063","March 20, 2007","01/02/2007",NA,"October 27, 2010","01/10/2010","",2009-05-01,"Overall response rate (complete response, partial response, or hematologic improvement) defined by the International Working Group Criteria|Duration of response|Overall survival and progression-free survival at 6 months and 1 year|Time to progression at 6 months and 1 year|Toxicity and safety","http://ClinicalTrials.gov/show/NCT00451048",NA
"40479",40479,"NCT00452348","A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg Twice Daily In Symptomatic Patients With Asthma","Completed","Has Results","Asthma","Drug: Fluticasone propionate 250 mcg BID|Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID","GlaxoSmithKline","Both","Child|Adult|Senior","Phase IV",628,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADA109057","March 26, 2007","01/05/2007",2009-05-01,"March 4, 2010","01/03/2010","",2009-05-01,"Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52|Mean Change From Baseline in AM PEF Over Weeks 1-52|Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52|Rate of Asthma Attacks Per Participant Per Year","http://ClinicalTrials.gov/show/NCT00452348",NA
"40502",40502,"NCT00406848","A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients","Completed","Has Results","Major Depressive Disorder","Drug: duloxetine hydrochloride|Drug: placebo","Eli Lilly and Company|Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase IV",370,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10815|F1J-US-HMFA","November 29, 2006","01/11/2006",2009-11-01,"September 13, 2010","01/09/2010","",2009-07-01,"Change From Baseline to 13 Weeks in Hamilton Depression Rating Scale (HAMD-17) Maier Subscale|Change From Baseline on the 30-item Geriatric Depression Scale (GDS)|Change From Baseline in the HAMD-17 Total Score, Subscales, and Individual Items|Change From Baseline in the Brief Pain Inventory (BPI) Severity and Interference Scores|Change From Baseline in the Numeric Rating Scales (NRS) for Pain Item Scores|Patient's Global Impression of Improvement (PGI-I) at 13 Weeks and 25 Weeks|Change From Baseline in the Clinical Global Impression-Severity (CGI-S)|Change From Baseline in the Mini-Mental State Exam (MMSE)|Change From Baseline in the Quality of Life, Enjoyment, and Satisfaction Questionnaire (Q-LES-Q-SF)|Probability of Remission as Measured by the HAMD-17 Total Score ???7 and ???10|Probability of Response at Endpoint as Measured by ??­50% Improvement in the HAMD-17 Total Score|Probability of Remission as Measured by the HAMD-17 Total Score ???7 and ???10 by Medical Comorbidity Severity as Assessed by the Cumulative Illness Rating Scale-Geriatric Version (CIRS-G)|Probability of Efficacy Onset as Measured by at Least 20% Sustained Reduction From Baseline in the HAMD-17 Maier Subscale at Week 3|Change From Baseline in Supine Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Pulse Rate|Change From Baseline in Weight|Number of Participants With Abnormal Vital Signs and Weight at Any Time During the Study|Number of Participants Experiencing Sustained Hypertension (SH) or Orthostatic Hypotension (OH)|Summary of Adverse Events and Serious Adverse Events Leading to Discontinuation|Change From Baseline in Laboratory Values - Platelet Count|Change From Baseline in Laboratory Values - Uric Acid|Change From Baseline in Laboratory Values - Erythrocyte Count|Change From Baseline in Laboratory Values - Hemoglobin, Mean Cell Hemoglobin Concentration (MCHC)|Change From Baseline in Laboratory Values - Chloride and Fasting Glucose|Number of Participants With Abnormal Laboratory Values - Low Leukocyte Count|Change From Baseline in Electrocardiograms|Number of Participants With Successful Treatment Outcome|Change From Baseline on Cognitive Test Scores: Verbal Learning and Recall Test (VLRT), Symbol Digit Substitution Test (SDST), Trail Making Test (Part B), 2-Digit Cancellation Test (2DCT), and the Composite Cognitive Score Derived From the Above Scores","http://ClinicalTrials.gov/show/NCT00406848",NA
"40540",40540,"NCT00542048","A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG?ó-1 in Tumor Patients With Hepatic Metastases","Completed","No Results Available","Liver Cancer|Neoplasm Metastasis","Drug: EndoTAG?ó-1","MediGene","Both","Adult|Senior","Phase II",20,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","CT 4003","October 9, 2007","01/11/2007",2009-09-01,"February 8, 2010","01/11/2009","",2009-09-01,"Pharmacokinetic profile|Tumor response, Tumor perfusion, Soluble markers of angiogenesis, Pharmacodynamics, Safety","http://ClinicalTrials.gov/show/NCT00542048",NA
"40575",40575,"NCT00600548","Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)","Completed","No Results Available","Treatment of Cutaneous Leishmaniasis in Brazil.","Drug: Miltefosine.|Drug: Meglumine antimoniate.|Drug: Miltefosine.|Drug: Meglumine antimoniate.","Hospital Universit?ªrio Professor Edgard Santos|Conselho Nacional de Desenvolvimento Cient?¦fico e Tecnol??gico|Minist?¢rio de Ci??ncia e Tecnologia|Minist?¢rio da Sa??de|Zentaris Gmb H","Both","Child|Adult","Phase II",180,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D-18506|410559/2006-7","January 2, 2008","01/07/2007",2009-07-01,"April 14, 2010","01/03/2010","",2009-03-01,"Cure rate or complete cicatrization of the ulcer.|Inicial cure rate or complete cicatrization of the ulcer.","http://ClinicalTrials.gov/show/NCT00600548",NA
"40603",40603,"NCT00642148","A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive|Chronic Obstructive Pulmonary Disease (COPD)","Drug: GW856553|Drug: Placebo|Drug: Seretide","GlaxoSmithKline","Both","Adult|Senior","Phase II",306,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MKI102428","March 17, 2008","01/02/2008",2009-09-01,"October 14, 2010","01/10/2010","",2009-09-01,"To evaluate the effects if 12 wks of treatment with GW856553 7.5 mg BID compared with placebo on the percentage of sputum neutrophils at 12 weeks|To evaluate the effects if 12 wks of treatment with GW856553 7.5 mg BID compared with placebo on pulmonary function assesses by body plethysmography, by spirometry and by impulse oscillometry|Plethysmography measures: IC, RV, TGV at FRC, TLC, SVC.|Spirometry measures: FVC, FEV1, FEV1/FVC.|Impulse oscillometry (Jaeger IOS).Peripheral airway resistance (R5 - R15).Total resistance (R5) and large airway resistance (R25).|Resonant frequency, X5 and low-frequency reactance area (AX) as indicators of the reactive capacitance properties of the lung.|Serum fibrinogen and additional systemic inflammation biomarkers (e.g. serum IL1??, clara cell protein 16, SP-D, MMP9, CXCL5, and CXCL8).|Levels of ex vivo lipopolysaccharide (LPS) induced tumour necrosis factor (TNF-alpha) in whole blood pre-dose and 2 h post-dose at selected centres.|Levels of ex vivo sorbitol induced phosphorylation of heat shock protein 27 (pHSP27) in whole blood pre-dose and 2 h post-dose at selected centres.|Parameters measured in induced sputum:?©?Total cell count (cells/mL) ?©? Macrophages, lymphocytes and eosinophils as a percentage of total cells. ?©? Neutrophils, macrophages, lymphocytes and eosinophils as absolute inflammatory cell numbers.|?©? Sputum weight and volume (Exploratory) ?©? The concentration of inflammatory biomarkers (including but not limited to myeloperoxidase and total protein)","http://ClinicalTrials.gov/show/NCT00642148",NA
"40634",40634,"NCT00694148","Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines","Completed","No Results Available","Healthy","Drug: NT 201","Merz Pharmaceuticals GmbH","Both","Adult","Phase III",108,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MRZ 60201 GL_3001","June 2, 2008","01/05/2008",2009-01-01,"December 6, 2010","01/12/2010","",2009-01-01,"Investigator`s assessment","http://ClinicalTrials.gov/show/NCT00694148",NA
"40653",40653,"NCT00726648","CDP323 Biomarker Study","Completed","No Results Available","Relapsing Multiple Sclerosis","Drug: CDP323|Drug: CDP323|Drug: CDP323|Drug: CDP323|Drug: Placebo","UCB, Inc.|Biogen Idec","Both","Adult","Phase I|Phase II",71,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science","C32325|EudraCT 2008-000147-34|IND 74863","July 29, 2008","01/07/2008",2009-03-01,"August 26, 2009","01/08/2009","",2009-03-01,"Pharmacodynamic parameters related to leukocyte trafficking|Standard and disease-related safety variables|Class-related safety parameters","http://ClinicalTrials.gov/show/NCT00726648",NA
"40669",40669,"NCT00744848","Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy","Completed","No Results Available","Hemorrhoids","Drug: Bupivacaine HCl|Drug: SKY0402","Pacira Pharmaceuticals, Inc","Both","Adult|Senior","Phase III",220,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Investigator)|Primary Purpose: Supportive Care","SIMPLE Hemorrhoidectomy 312","August 28, 2008","01/08/2008",2009-02-01,"August 27, 2010","01/08/2010","",2009-02-01,"Area under the curve (AUC) of NRS-R|AEs through Day 3 and SAEs through Day 30","http://ClinicalTrials.gov/show/NCT00744848",NA
"40675",40675,"NCT00757848","A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis","Completed","No Results Available","Cystic Fibrosis","Drug: AZD9668|Drug: AZD9668 Placebo equivalent","AstraZeneca","Both","Child|Adult|Senior","Phase II",70,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","D0520C00009","September 22, 2008","01/10/2008",2009-08-01,"November 4, 2009","01/11/2009","INCA",2009-08-01,"Absolute and differential neutrophil count in sputum|Signs and symptoms of CF|Safety outcome|Pharmacokinetic (AZD9668 concentrations in plasma and sputum)|Pharmacodynamic markers","http://ClinicalTrials.gov/show/NCT00757848",NA
"40678",40678,"NCT00761748","Comparasion of Two Urostomy Bags (2-Piece).","Completed","No Results Available","Urostomy","Device: Convatec Uro 2-piece Combihesive Natura?ó with a Durahesive Convex-It?ó base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape.|Device: SenSura Uro 2-piece","Coloplast A/S","Both","Adult|Senior","Phase III",30,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label","DK189OS","September 26, 2008","01/09/2008",2009-02-01,"February 4, 2009","01/02/2009","",2009-01-01,"preference of the two urostomy products|Reason for change of product","http://ClinicalTrials.gov/show/NCT00761748",NA
"40703",40703,"NCT00807248","Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder","Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram and Gaboxadol|Drug: Escitalopram and Gaboxadol|Drug: Escitalopram and Placebo|Drug: Placebo","H. Lundbeck A/S","Both","Adult","Phase II",490,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","12213A|2008-000506-36","December 10, 2008","01/11/2008",2010-02-01,"April 6, 2010","01/04/2010","",2009-12-01,"Montgomery and Asberg Depression Rating Scale (MADRS)|Clinical Global Impression: - Global Improvement (CGI-I) and - Severity of Illness (CGI-S); Sheehan Disability Scale (SDS); Hospital Anxiety and Depression (HAD); Insomnia Severity Index (ISI)","http://ClinicalTrials.gov/show/NCT00807248",NA
"40704",40704,"NCT00809848","Safety and Efficacy of AGN 210699 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma","Completed","No Results Available","Ocular Hypertension|Glaucoma","Drug: AGN 210669 non-preserved ophthalmic solution|Drug: AGN 210669 non-preserved ophthalmic solution|Drug: AGN 210669 non-preserved ophthalmic solution|Drug: AGN 210669 vehicle ophthalmic solution|Drug: bimatoprost ophthalmic solution","Allergan","Both","Adult|Senior","Phase I|Phase II",150,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","210669-003","December 16, 2008","01/02/2009",2009-10-01,"September 8, 2010","01/09/2010","",2009-10-01,"IOP change from Baseline|Mean intraocular pressure","http://ClinicalTrials.gov/show/NCT00809848",NA
"40717",40717,"NCT00830648","Safety of a Second Dose of Biken's Varicella Vaccine","Completed","No Results Available","Varicella","Biological: Live Attenuated Varicella Virus Vaccine","Sanofi-Aventis","Both","Child","Phase IV",122,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","VBK12","January 27, 2009","01/01/2009",2009-12-01,"April 8, 2010","01/04/2010","",2009-10-01,"To provide information concerning the safety after administration of Varicella vaccine","http://ClinicalTrials.gov/show/NCT00830648",NA
"40730",40730,"NCT00857948","Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation","Completed","No Results Available","Pediculus Humanus Capitis (Head Lice)","Drug: ivermectin treatment conditioner|Drug: Placebo, vehicle control","Topaz Pharmaceuticals Inc","Both","Child|Adult|Senior","Phase II",78,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TOP003","March 6, 2009","01/03/2009",2009-04-01,"September 30, 2010","01/09/2010","",2009-04-01,"Presence or absence of live lice after final study drug application|Evaluation of safety based on reported adverse events.","http://ClinicalTrials.gov/show/NCT00857948",NA
"40739",40739,"NCT00877448","A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)","Completed","No Results Available","Healthy","Biological: Montanide isa 51 vg","BiondVax Pharmaceuticals ltd.","Both","Adult","Phase I|Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","BVX002","January 28, 2009","01/06/2009",2009-11-01,"February 14, 2010","01/02/2010","",2009-10-01,"Vital signs (systolic/diastolic blood pressure and heart rate), ECG, physical examination, local tolerance (Draize score and subject diary), routine safety lab tests, observed and spontaneously reported adverse events (AEs) and SAEs.","http://ClinicalTrials.gov/show/NCT00877448",NA
"40742",40742,"NCT00881348","Dermacyd Infantile (Lactic Acid) - Photo Evaluation.","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Both","Adult","Phase IV",25,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","LACAC_L_04680","April 10, 2009","01/02/2009",2009-03-01,"April 14, 2009","01/04/2009","",2009-03-01,"The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. The sensibility will be evaluated according to the skin type.","http://ClinicalTrials.gov/show/NCT00881348",NA
"40747",40747,"NCT00891748","Safety Study on AdCD40L Gene Therapy for Bladder Cancer","Completed","No Results Available","Bladder Cancer","Genetic: AdCD40L","Uppsala University|Uppsala University Hospital","Both","Adult|Senior","Phase I|Phase II",12,"Other","Interventional","Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","001:CD40L|2006-000985-34","April 30, 2009","01/11/2006",2009-10-01,"January 15, 2010","01/04/2009","",2009-10-01,"Toxicity|Inflammation","http://ClinicalTrials.gov/show/NCT00891748",NA
"40756",40756,"NCT00903448","Comparison of Prilosec Over-the-counter (OTC)?ó Versus Prevacid?ó for Gastric Acid Suppression","Completed","Has Results","Healthy","Drug: Prilosec OTC (omeprazole-magnesium)|Drug: Prevacid","Procter and Gamble","Both","Adult","Phase IV",40,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2009010","May 14, 2009","01/04/2009",2009-06-01,"December 22, 2010","01/12/2010","",2009-06-01,"Mean Percent Time That Gastric pH > 4.0 on Day 5","http://ClinicalTrials.gov/show/NCT00903448",NA
"40773",40773,"NCT00941148","Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin","Completed","No Results Available","Type 2 Diabetic Patients|Insufficient Metabolic Control|OAD Treatment","Drug: Insulin Glargin|Drug: NPH insulin|Drug: Insulin detemir|Drug: metformin","ikfe-CRO GmbH|IKFE Institute for Clinical Research and Development","Both","Adult|Senior","Phase IV",30,"Industry|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LANT_001|EudraCT Number: 2007-006109-26","July 16, 2009","01/04/2008",2009-03-01,"July 16, 2009","01/07/2009","",2009-03-01,"postprandial dynamics of intact proinsulin secretion after standardized test meals (AUC for two hours after dinner)|AUC for intact proinsulin levels for two hours after a standardized test meal (breakfast and lunch)|increase of intact proinsulin after breakfast (BF), lunch (LU) and dinner (DI)|Ratio of exogenous insulin vs. endogenous insulin (measurements of glargine, NPH Insulin, detemir and human insulin levels)|Postprandial endothelial function measured as postischaemic response in LDF measurements (after BF, LU, DI)|Postprandial change in and AUC for hs CRP (after BF, LU, DI)|Postprandial change in and AUC for ADMA (after BF, LU, DI)|Postprandial increase in and AUC for glucose levels (after BF, LU, DI)|Changes in FBG|Changes in 8-point BG profiles|Percentage of patients reaching the treatment goal|Insulin dosage per kg body weight to reach treatment goal","http://ClinicalTrials.gov/show/NCT00941148",NA
"40776",40776,"NCT00938548","Perioperative Administration of Pregabalin for Pain After Mastectomy","Completed","Has Results","Pain, Postoperative","Drug: Pregabalin|Drug: Vitamin Complex (placebo)","Severance Hospital","Female","Adult|Senior","Phase IV",70,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","IRB 4-2009-0186","July 13, 2009","01/06/2009",2010-01-01,"May 17, 2010","01/07/2009","",2009-12-01,"Pain Scores (Verbal Numerical Rating Scale;VNRS) During Postoperative Hours.|Number of Participants With the Indicated Side Effects - Nausea & Vomiting, Sedation, Headache, Dizziness Etc.|Pain Scores (VNRS) at 1 Week and 1 Month After Operation","http://ClinicalTrials.gov/show/NCT00938548",NA
"40787",40787,"NCT00964548","Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage","Completed","No Results Available","Cerebral Vasospasm After Subarachnoid Hemorrhage","Drug: Dantrolene|Drug: Dantrolene","University of Massachusetts, Worcester|Massachusetts General Hospital","Both","Adult|Senior","Phase I|Phase II",15,"Other","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-13076","August 23, 2009","01/07/2007",2009-10-01,"November 11, 2009","01/11/2009","",2009-10-01,"Hemodynamic parameters (compare before, during and 45 min after infusion) and Laboratory values (up to 24 hrs after infusion)|Transcranial Doppler peak systolic and mean flow velocities of vessel in vasospasm","http://ClinicalTrials.gov/show/NCT00964548",NA
"40850",40850,"NCT01081548","A Clinical Trial Study to Evaluate Efficacy and Safety of Atorvastatin in Korean Patients With Hypercholesterolemia","Completed","No Results Available","Hypercholesterolemia","Drug: atorvastatin|Drug: atorvastatin","Yonsei University","Both","Child|Adult|Senior","Phase IV",17,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","4-2008-0288","March 4, 2010","01/08/2008",2009-07-01,"March 4, 2010","01/01/2010","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT01081548",NA
"40852",40852,"NCT01084148","Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis","Completed","No Results Available","Uremic Xerosis","Drug: V0034CR01B|Drug: V0034CR01B vehicle","Orfagen","Both","Adult|Senior","Phase III",236,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","V00034 CR 308 ORF","March 9, 2010","01/01/2007",2009-03-01,"March 9, 2010","01/03/2010","",2009-03-01,"Long-term efficacy of V0034 CR 01B cream on uraemic xerosis in the real-life setting.|Local tolerance of V0034 CR 01B after long-term use and patient's benefit and acceptability of V0034 CR 01B","http://ClinicalTrials.gov/show/NCT01084148",NA
"40977",40977,"NCT01270048","The Effect of Bunsimgieum on the Chest Discomfort of Hwa-byung's Major Symptom","Completed","No Results Available","Hwa-byung (Disorder)","Drug: mild-ex-gwarip|Other: Placebo","Korea Health Industry Development Institute","Both","Adult","Phase III",144,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","B070057","January 4, 2011","01/05/2008",2009-08-01,"January 4, 2011","01/09/2009","",2009-03-01,"","http://ClinicalTrials.gov/show/NCT01270048",NA
"41060",41060,"NCT00072449","Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",25,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","NABTT-2201 CDR0000339737|U01CA062475|NABTT-2201","November 4, 2003","01/05/2004",NA,"October 1, 2010","01/10/2010","",2009-03-01,"Radiographic response|Progression-free survival|Overall survival|Toxicity","http://ClinicalTrials.gov/show/NCT00072449",NA
"41087",41087,"NCT00112749","Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer","Completed","No Results Available","Breast Cancer|Fatigue","Biological: infliximab|Other: Clinical Assessment|Other: Self-report questionnaires|Other: Immune Assessment","University of California, Los Angeles|National Cancer Institute (NCI)|American Cancer Society","Female","Adult","Phase II",6,"Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CDR0000428460|P30CA016042|UCLA-0410033-01","June 2, 2005","01/02/2005",2009-01-01,"November 5, 2010","01/11/2010","",2009-01-01,"Fatigue as measured by the fatigue symptom inventory (FSI) at baseline and after completion of study treatment|Fatigue as measured by multidimensional fatigue symptom inventory (MFSI) at baseline and after completion of study|Proinflammatory cytokines as measured by interleukin-1 receptor antagonist, interleukin 6, and tumor necrosis factor at baseline and after completion of study treatment","http://ClinicalTrials.gov/show/NCT00112749",NA
"41198",41198,"NCT00289549","Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)","Completed","No Results Available","Leukemia, Lymphocytic, Chronic","Drug: forodesine hydrochloride (BCX-1777)","BioCryst Pharmaceuticals","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BCX1777-Bo-05-204","February 8, 2006","01/06/2005",2009-01-01,"December 2, 2009","01/12/2009","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00289549",NA
"41219",41219,"NCT00322049","A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants","Completed","No Results Available","Dengue","Biological: Tetravalent live attenuated dengue vaccine","U.S. Army Office of the Surgeon General|GlaxoSmithKline","Both","Child","Phase I|Phase II",51,"U.S. Fed|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Prevention","WRAIR 824|HSRRB Log A-10064|GSK CPMS7663310/001(Dengue-001","May 3, 2006","01/02/2004",2009-06-01,"September 15, 2010","01/09/2010","",2009-06-01,"Compare the reactogenicity in terms of solicited symptoms within the 21-day follow-up period after Dose 1 of the dengue vaccine vs. control vaccine.|Assess the immunogenicity of the dengue vaccine in terms of seroconversion 30 days post-Dose 2 of dengue vaccine for all four serotypes.|Neutralizing (N) antibody titers >= 1:10 to each DEN serotype, one year and four years after the second dose of dengue/control vaccine.|Neutralizing (N) antibody titers >=1:10 to each DEN serotype, at booster visit prior to vaccination and one month after the booster dose, and Year 4 after primary vaccination (dengue group only).|Assess the safety and reactogenicity of two doses of the dengue vaccine;|Assess the immunogenicity of the dengue vaccine in terms of appearance of neutralizing antibodies to each of four dengue virus serotypes and Japanese encephalitis (JE), 30 days after each dose of dengue vaccine and 30 days after the second dose of JE;|Assess the immunogenicity of the dengue vaccine in terms of appearance of neutralizing antibodies to all dengue virus serotypes 30 days after Dose 1 of dengue vaccine;|Explore the effect of prior dengue vaccination on immunogenicity of two (of three required) doses of JE vaccine given four and six weeks after completion of the dengue vaccination course.|Explore the effect of prior dengue vaccination on reactogenicity of two doses of JE vaccine given four and six weeks after completion of the dengue vaccination course.|Occurrence, intensity and relationship to vaccination of solicited adverse events (AE) within 21 days and unsolicited AEs within 31 days (days 0-30) follow-up after the dengue vaccine booster dose.|Occurrence, intensity and relationship to vaccination of unsolicited AEs within 31 days (days 0-30) after the dengue vaccine booster dose|Occurrence and relationship to vaccination of all serious adverse events (SAEs) occurring throughout the study period.|Occurrence of hematological and biochemical values within or outside the normal ranges at booster visit, 10 days post booster dose and one month post booster dose.|Occurrence of alert values for safety laboratory determinations within 31 days post booster dose.|Occurence of suspected and confirmed dengue within 31 days post booster dose.|Occurence of dengue viremia 10.","http://ClinicalTrials.gov/show/NCT00322049",NA
"41260",41260,"NCT00384449","Lucentis (Ranibizumab) for Eales' Disease","Completed","No Results Available","Eales' Disease","Drug: Ranibizumab","Oregon Health and Science University|Genentech","Both","Adult|Senior","Phase II|Phase III",5,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FVF3849s","October 5, 2006","01/10/2006",2009-04-01,"April 2, 2009","01/04/2009","",2009-04-01,"Change in OCT thickness.|Incidence and severity of ocular adverse events, as identified by eye examination (including visual acuity testing)|Incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs|BCVA, as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters.|Incidence of ocular and non-ocular adverse events evaluated through month 6.","http://ClinicalTrials.gov/show/NCT00384449",NA
"41275",41275,"NCT00366249","Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.","Completed","Has Results","Bacterial Infections|Diabetic Foot|Osteomyelitis","Drug: Tigecycline|Drug: Ertapenem","Wyeth","Both","Adult|Senior","Phase III",1061,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","3074K5-319","August 17, 2006","01/01/2007",2009-03-01,"April 22, 2010","01/04/2010","",2009-03-01,"Number of Patients With Clinical Response of Cure Vs. Failure.|Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.|Number of Patients With Clinical Response of Cure Vs. Failure Assessed at Least 25 - 27 Weeks Post Last Dose.|Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate Assessed at Least 25 - 27 Weeks Post Last Dose.|Number of Patients With Microbiologic Response of Eradication.","http://ClinicalTrials.gov/show/NCT00366249",NA
"41276",41276,"NCT00411749","V501 Immunogenicity Study in Females Age 9 to 17 Years","Completed","Has Results","HPV Infections","Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)|Biological: Comparator: Placebo (unspecified)","Merck","Female","Child","Phase II",107,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2006_052|V501-028","December 14, 2006","01/12/2006",2009-09-01,"July 19, 2010","01/07/2010","",2009-09-01,"Human Papilloma Virus (HPV) 6 Serum Antibody Titer at One Month After Completed Vaccination Series|Human Papilloma Virus (HPV) 11 Serum Antibody Titer at One Month After Completed Vaccination Series|Human Papilloma Virus (HPV) 16 Serum Antibody Titer at One Month After Completed Vaccination Series|Human Papilloma Virus (HPV) 18 Serum Antibody Titer at One Month After Completed Vaccination Series|HPV 6, 11, 16 and 18 Serum Antibody Titer at 24 Month After Completed Vaccination Series","http://ClinicalTrials.gov/show/NCT00411749",NA
"41299",41299,"NCT00448149","Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer","Completed","No Results Available","Carcinoma, Renal Cell","Drug: RAD001|Drug: Sorafenib","The Methodist Hospital System|Novartis Pharmaceuticals","Both","Adult|Senior","Phase I|Phase II",55,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RCC-06-102|1006-0152","March 15, 2007","01/12/2006",NA,"November 3, 2009","01/01/2009","",2009-06-01,"Phase I: To establish the maximally tolerated dose (MTD) and safety profile of RAD001 in combination with Nexavar?ó in patients with metastatic renal cell carcinoma (MRCC).|Phase II: Study the anti-tumor effects of RAD001 plus Nexavar?ó|Phase II: Response rate|Duration of tumor response|Progression free survival|Overall survival|Study the safety of RAD001 plus Nexavar?ó given at MTD.","http://ClinicalTrials.gov/show/NCT00448149",NA
"41301",41301,"NCT00445549","Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Completed","No Results Available","Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms","Drug: Zactima (Vandetanib)(ZD6474)","National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",12,"NIH","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","070061|07-C-0061","March 7, 2007","01/01/2007",2009-10-01,"January 11, 2011","01/07/2010","",2009-10-01,"Clinical outcome (complete response, partial response, or disease stabilization lasting 6 months or longer)|Biochemical modulation of activated (phosphorylated) vascular endothelial growth factor receptor 2, epidermal growth factor receptor, extracellular signal-regulated kinase, and AKT|Toxicity|Quality of life|Progression-free survival","http://ClinicalTrials.gov/show/NCT00445549",NA
"41302",41302,"NCT00383149","A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer","Completed","Has Results","Metastatic Pancreatic Cancer","Drug: Ixabepilone + Cetuximab","Bristol-Myers Squibb","Both","Adult|Senior","Phase II",58,"Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA163-116","September 28, 2006","01/01/2007",2009-06-01,"September 24, 2010","01/09/2010","",2009-06-01,"Percentage of Participants Surviving at 6 Months|Best Overall Tumor Response|Percentage of Participants With Objective Tumor Response|Median Progression Free Survival Time|Median Overall Survival Time|Median Duration of Response|Median Time to Response|Number of Participants With Death Within 30 Days of Last Dose, Any Serious Adverse Event (SAE), Any Adverse Event (AE) Leading to Discontinuation (DC), or Any Treatment-related AEs By Common Terminology Criteria Version 3.0 (CTC v3) Grade (Gr)|Most Common Treatment-related Nonhematologic AE (>25%) By CTC v3 Grade (Gr)|Number of Participants With Hematology, Liver Function, and Renal Laboratory Abnormalities By CTC v3 Grade (Gr)|Number of Participants With Dose Reduction, Dose Delay, or Dose Interruption|Percentage of Participants With Baseline Epidermal Growth Factor Receptor (EGFR) Tumor Expression|Change From Baseline in FHSI-8 Total Score by Time-point","http://ClinicalTrials.gov/show/NCT00383149",NA
"41303",41303,"NCT00446849","Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)","Completed","Has Results","Ulcerative Colitis","Drug: MMX Mesalamine","Shire Pharmaceutical Development","Both","Adult|Senior","Phase IV",290,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SPD476-404","March 12, 2007","01/05/2007",2009-07-01,"August 3, 2010","01/08/2010","",2009-07-01,"Clinical Recurrence of Ulcerative Colitis (UC) During the Maintenance Phase at 6 Months|Clinical Recurrence of UC During the Maintenance Phase at 12 Months|Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 6 Months|Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 12 Months|Quiescent UC During the Maintenance Phase at 12 Months|Endoscopic Remission of UC During the Maintenance Phase at 12 Months","http://ClinicalTrials.gov/show/NCT00446849",NA
"41317",41317,"NCT00478049","Iressa as Second Line Therapy in Advanced NSCLC-Asia","Completed","No Results Available","NSCLC","Drug: Gefitinib|Drug: Docetaxel","AstraZeneca","Both","Adult|Senior","Phase III",163,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D7913L00039","May 23, 2007","01/09/2005",2009-02-01,"April 22, 2009","01/04/2009","ISTANA",2009-02-01,"Compare progression free survival between patients on gefitinib or on docetaxel by Progression as per Response Evaluation Criteria In Solid Tumors|To compare the overall objective tumor response rates between patients on gefitinib or on docetaxel by overall objective tumor response (complete response (CR) + partial response (PR)) using RECIST criteria.|To compare changes in quality of life (QoL) between patients on gefitinib or on docetaxel by QoL as measured by the FACT-L total score|For those patients who are symptomatic at baseline to compare improvement in symptom control between patients on gefitinib or on docetaxel by the FACT-L LCS (Functional Assessment of Cancer Therapy - Lung Lung Cancer Subscale).|To compare the safety and tolerability of gefitinib and of docetaxel by Frequency and severity of adverse events (AEs) and laboratory parameters.","http://ClinicalTrials.gov/show/NCT00478049",NA
"41345",41345,"NCT00517049","A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: PRO95780|Drug: rituximab","Genentech","Both","Adult|Senior","Phase II",49,"Industry","Interventional","Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","APM4083g","August 14, 2007","01/03/2008",2009-12-01,"June 18, 2010","01/06/2010","",2009-12-01,"Objective response, as determined by independent review facility|Progression-free survival, as determined by independent review facility|Duration of objective response, as determined by independent review facility|Overall survival|Objective response, PFS, and duration of objective response, as determined by the investigator","http://ClinicalTrials.gov/show/NCT00517049",NA
"41364",41364,"NCT00548249","Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With ESRD Receiving Chronic Hemodialysis","Completed","No Results Available","End-Stage Renal Disease","Drug: Soluble Ferric Pyrophosphate","Rockwell Medical Technologies, Inc.","Both","Adult|Senior","Phase II",131,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RMTI-SFP-2","October 19, 2007","01/09/2007",2010-01-01,"June 21, 2010","01/06/2010","",2009-10-01,"Efficacy of an SFP-containing dialysate solution in maintaining physiological iron levels during chronic HD, as measured by the percent of subjects whose hgb decreases by a total of 1.0 g/dL (or more) from baseline on each of two successive measurements.|Safety of an SFP-containing dialysate solution, measured by AEs, physical examination, vital signs, ECGs, lab measures (complete blood count, coagulation, blood chemistries including liver function tests),Transferrin Saturation,UIBC, and ferritin levels.|Efficacy of SFP as measured by time in days for hgb to decrease by a total of > = 1.0 g/dL from baseline on each of two successive measurements in each treatment group. The mean change from baseline in hgb will also be compared across treatment groups.|Efficacy of SFP administration in dialysate solution as measured by reticulocyte hemoglobin values every four weeks, and at the end of the subject's treatment.|The incidence of infection episodes requiring antibiotic or anti-fungal therapy in each treatment group.|Estimate the amount of SFP transferred from the dialysate to the blood during a dialysis session.|Incidence rate of subjects with a rise in hemoglobin to 12.6 g/dL or more on two separate occasions measured one week apart.","http://ClinicalTrials.gov/show/NCT00548249",NA
"41367",41367,"NCT00549549","Celebrex In Acute Gouty Arthritis Study","Completed","No Results Available","Arthritis, Gouty","Drug: Indomethacin|Drug: Celecoxib|Drug: Celecoxib|Drug: Celecoxib","Pfizer","Both","Adult|Senior","Phase III",402,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A3191219","October 24, 2007","01/02/2008",2009-12-01,"January 21, 2010","01/01/2010","",2009-12-01,"The primary endpoint of the study will be the Change from Baseline to Day 2 (24-hour recall of pain experienced during Day 2 assessed on the morning of Day 3) in the Patient's Assessment of Pain Intensity in the index joint.|Time weighted average change from Baseline in the Patient's Assessment of Pain Intensity over 8 (TWA-8), 12 (TWA-12) and 24 (TWA-24) hours post first dose of study medication on Day 1|Incidence of at least a 30% and 50% reduction from Baseline in the Patient's Assessment of Pain Intensity on Day 2 (24-hour recall of pain experienced during Day 2 assessed on the morning of Day 3)|Change from Baseline to in the Patient's Assessment of Pain Intensity (24-hour recall of pain experienced during prior day as assessed on the next morning for each day), and average change in this measure over Days 2-5 and Days 2-8|Incidence of withdrawal due to lack of efficacy on Day 1 and over Days 1-8|Patient's Global Evaluation of Study Medication score on Day 8 and Day 14|Physician's Assessment of the Index Joint on : change from Baseline to each post-baseline assessment for \tenderness\"" and \""swelling\""","http://ClinicalTrials.gov/show/NCT00549549",NA
"41415",41415,"NCT00635349","A Comparative Study on Tramadol 37.5mg/Acetaminophen 325mg Tablets Maintenance Versus Non-steroidal Anti-inflammatory Drugs(NSAIDs) Maintenance in Patients With Knee Osteoarthritis","Completed","No Results Available","Osteoarthritis","Drug: tramadol hydrochloride, acetaminophen, meloxicam, aceclofenac","Janssen Korea, Ltd., Korea","Both","Adult|Senior","Phase IV",98,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR012964","March 6, 2008","01/05/2007",2009-04-01,"April 26, 2010","01/04/2010","",2009-04-01,"WOMAC total score: Day 85 - Day 29 (randomization)|Pain intensity, pain relief, subject's and investigator's overall evaluation on the study medication, swelling and tenderness","http://ClinicalTrials.gov/show/NCT00635349",NA
"41417",41417,"NCT00639249","Safety and Preliminary Efficacy Study of SA4503 in Subjects Recovering From Ischemic Stroke","Completed","No Results Available","Ischemic Stroke","Drug: placebo|Drug: SA4503 Low|Drug: SA4503 High","M's Science Corporation","Both","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ME1-2|EudraCT number: 2007-004840-60","March 14, 2008","01/02/2008",NA,"July 28, 2009","01/07/2009","",2009-06-01,"Safety and tolerability|NIHSS","http://ClinicalTrials.gov/show/NCT00639249",NA
"41449",41449,"NCT00688649","Nutritional Supplement Compliance Study","Completed","No Results Available","Undernutrition","Dietary Supplement: Standard Oral Nutritional Supplement (ONS)|Dietary Supplement: High energy Oral Nutritional Supplement (ONS)","Nutricia UK Ltd","Both","Adult|Senior","Phase III",80,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","NCC200","May 27, 2008","01/05/2008",2009-01-01,"February 3, 2009","01/02/2009","NSCS",2009-01-01,"Nutrient intake (energy, protein and micronutrients)|Compliance with ONS","http://ClinicalTrials.gov/show/NCT00688649",NA
"41462",41462,"NCT00701649","Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension","Completed","No Results Available","Hypertension","Biological: CYT006-AngQb|Biological: Placebo","Cytos Biotechnology AG","Both","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CYT006-AngQb 02|Eudract No. 2007-005843-93","June 18, 2008","01/03/2008",2009-11-01,"December 1, 2009","01/12/2009","",2009-03-01,"Adverse events: quality, quantity, severity|Change in daytime, nighttime and 24-hour ambulatory blood pressure from baseline|Titer of IgG specific for angiotensin II|Amount of RAS-Biomarkers (plasma renin concentration, angiotensin II, aldosterone)","http://ClinicalTrials.gov/show/NCT00701649",NA
"41465",41465,"NCT00709449","An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects","Completed","No Results Available","Macular Degeneration|Glaucoma|Regional Blood Flow","Drug: moxaverine|Drug: moxaverine|Drug: moxaverine","Medical University of Vienna","Both","Adult|Senior","Phase II|Phase III",60,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OPHT-011007","June 27, 2008","01/05/2008",2009-03-01,"November 30, 2009","01/11/2009","",2009-03-01,"Choroidal and optic nerve head blood flow|Retrobulbar flow velocities|Retinal blood flow velocity|Retinal venous and arterial diameters|Intraocular pressure|Systolic and diastolic blood pressure","http://ClinicalTrials.gov/show/NCT00709449",NA
"41469",41469,"NCT00706849","Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Subjects With Coronary Artery Disease","Completed","No Results Available","Heterozygous Familial Hypercholesterolemia|Coronary Artery Disease","Drug: mipomersen sodium (ISIS 301012)|Drug: placebo","Genzyme|Isis Pharmaceuticals","Both","Adult|Senior","Phase III",124,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","301012-CS7","June 26, 2008","01/08/2008",2010-05-01,"October 2, 2010","01/10/2010","RADICHOL II",2009-12-01,"Percent reduction in low-density lipoprotein cholesterol (LDL-C) from Baseline at Week 28|Percent reduction in apolipoprotein B (apoB) from Baseline at Week 28|Percent reduction in total cholesterol from Baseline at Week 28|Percent reduction in non-high-density lipoprotein cholesterol (non-HDL-C) from Baseline at Week 28|Percent reduction in Lipoprotein (a) (Lp(a)) from Baseline at Week 28","http://ClinicalTrials.gov/show/NCT00706849",NA
"41482",41482,"NCT00739349","NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye","Completed","No Results Available","Dry Eye","Drug: NOVA22007 ''Cyclosporine''|Drug: NOVA22007 ''Cyclosporine''|Drug: NOVA22007","Novagali Pharma","Both","Adult|Senior","Phase II",129,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NVG08B112","August 20, 2008","01/08/2008",2009-01-01,"July 15, 2010","01/07/2010","",2009-01-01,"Assess the safety and efficacy of two doses of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Emulsions","http://ClinicalTrials.gov/show/NCT00739349",NA
"41510",41510,"NCT00779649","MoviPrep?ó Versus HalfLytely?ó, Low-VolUme PEG Solutions for Colon Cleansing: An InvesTigator-blindEd, Randomized, Trial","Completed","No Results Available","Colonoscopy","Other: MoviPrep Kit|Other: HalfLytely and Bisacodyl Tablets Bowel Prep Kit","Research Associates of New York, LLP","Both","Adult|Senior","Phase IV",220,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Diagnostic","LUSTER","October 22, 2008","01/09/2008",2009-10-01,"October 29, 2009","01/10/2009","LUSTER",2009-08-01,"The primary endpoint of the study will be a comparison of mean overall colon cleansing scores for each treatment arm, determined by the ratings on the Physician Questionnaire.","http://ClinicalTrials.gov/show/NCT00779649",NA
"41529",41529,"NCT00808249","AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)","Completed","No Results Available","Anxiety Disorders","Drug: AZD7325|Drug: AZD7325|Drug: AZD7325|Drug: Placebo","AstraZeneca","Both","Adult","Phase II",725,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1140C00006","December 12, 2008","01/12/2008",2009-05-01,"September 9, 2009","01/09/2009","",2009-05-01,"To give evidence of an effect of AZD7325 versus placebo by change in the HAM-A total score from randomization to day 28.|To evaluate the efficacy of AZD7325 versus placebo by change in the HADS-A, HAM-A psychic cluster and HAM-A somatic cluster score from randomization to each assessment time point.|To assess the safety of the treatment with AZD7325 by incidence of AEs, vital signs, changes in laboratory evaluations etc.|To evaluate the effect of AZD7325 versus placebo on the health-related quality of life by assessment of change in SDS.","http://ClinicalTrials.gov/show/NCT00808249",NA
"41536",41536,"NCT00823849","Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker","Completed","No Results Available","Type 2 Diabetes Mellitus|Arteriosclerosis Obliterans","Drug: Cilostazol|Drug: Probucol|Drug: Cilostazol+Probucol|Other: Control Group","Otsuka Beijing Research Institute","Both","Adult|Senior","Phase IV",200,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","246-08-802-01","January 14, 2009","01/10/2008",2010-03-01,"April 21, 2010","01/04/2010","",2009-08-01,"Primary Efficacy Evaluation: Comparing with the basic line information, the change value of arteriosclerosis related biomarker in 4 groups after 12 weeks of treatment.","http://ClinicalTrials.gov/show/NCT00823849",NA
"41593",41593,"NCT00917449","Prevention of Type 2 Diabetes Mellitus by L-Arginine in Patients With Metabolic Syndrome","Completed","No Results Available","Metabolic Syndrome|Impaired Glucose Tolerance|Insulin Resistance|Endothelial Dysfunction","Drug: L-arginine|Drug: Placebo","IRCCS San Raffaele","Both","Adult|Senior","Phase III",142,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","2005-004639-24","June 9, 2009","01/12/2005",2009-06-01,"June 9, 2009","01/06/2009","L-arginine",2009-06-01,"To evaluate the efficacy of long term (18 months) L-Arginine therapy in preventing or delaying clinical onset of type 2 diabetes mellitus in subjects with impaired glucose tolerance (IGT) and Metabolic Syndrome.|Define if the treatment with L-arginine can ameliorate insulin sensitivity and endothelial dysfunction and find new risk profiles and candidate genes able to characterize the sub-group of patients at higher risk to develop type 2 diabetes mellitus.","http://ClinicalTrials.gov/show/NCT00917449",NA
"41596",41596,"NCT00921349","A Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis","Completed","No Results Available","Variceal Bleeding|Cirrhosis","Procedure: Ligation of varices|Drug: Nadolol","National Science Council, Taiwan","Both","Adult|Senior","Phase IV",140,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","EVL+Nadolol","June 3, 2009","01/12/2004",2009-05-01,"June 15, 2009","01/06/2009","",2009-05-01,"The primary end points of the study were the first episode of variceal bleeding.|The secondary end points were adverse events related to treatment and death of any cause.","http://ClinicalTrials.gov/show/NCT00921349",NA
"41598",41598,"NCT00918749","Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women","Completed","No Results Available","Healthy","Drug: risedronate IR tablet","Warner Chilcott","Female","Adult|Senior","Phase II",204,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2009003","June 10, 2009","01/05/2009",2009-10-01,"June 7, 2010","01/07/2009","",2009-10-01,"Serum type-1 collagen C-telopeptide (CTX) 75mg DR tablet compared with 150 mg IR tablet|Serum CTX 100 mg DR tablet compared with 150 mg IR tablet|Serum bone specific alkaline phosphatase (BAP) and urinary type-1 collagen N-telopeptide (NTX) of risedronate 150 mg IR tablet compared with 75 mg DR tablet ministered immediately after breakfast|Serum BAP and urinary NTX of risedronate 150 mg IR tablet compared with 100 mg DR tablet administered immediately after breakfast|Safety and tolerability of the 75 and 100 mg DR tablets|Relative bioavailability based on Ae (cumulative amount of risedronate recovered in urine) and A'e(% ) [percentage of dose recovered in urine] of the 75 & 100 mg DR tablets compared to 150 mg IR tablet","http://ClinicalTrials.gov/show/NCT00918749",NA
"41623",41623,"NCT00956449","Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects","Completed","No Results Available","Influenza|Seasonal Influenza","Biological: Seasonal Influenza Vaccine","Novartis|Novartis Vaccines","Both","Adult|Senior","Phase II",126,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","V78_07S|2009-011004-33","August 8, 2009","01/06/2009",2009-07-01,"August 10, 2009","01/08/2009","",2009-07-01,"Immunogenicity and tolerability of the Flu vaccines is being measured|To evaluate safety of a single IM (intramuscular) dose of the subunit vaccine of Influenza Vaccine Surface Antigen, Inactivated of Influenza Vaccine","http://ClinicalTrials.gov/show/NCT00956449",NA
"41624",41624,"NCT00959049","A Study to Determine the Immunogenicity and Safety of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population","Completed","No Results Available","Influenza","Biological: CSL's Influenza Virus Vaccine (Afluria)|Biological: Influenza Virus Vaccine (Fluzone)","CSL Limited","Both","Child","Phase III",1474,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CSLCT-USF-07-36","August 12, 2009","01/09/2009",2010-05-01,"May 24, 2010","01/05/2010","",2009-12-01,"Geometric mean titer and seroconversion rate for each strain contained within the vaccines|Frequency, duration and intensity of local and systemic solicited symptoms|Frequency, duration and intensity of unsolicited adverse events|Frequency, duration and intensity of serious adverse events|New onset of chronic illnesses","http://ClinicalTrials.gov/show/NCT00959049",NA
"41667",41667,"NCT01025349","Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer","Drug: Bevacizumab, docetaxel, cisplatin","Taipei Medical University Hospital","Female","Adult","Phase II",20,"Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TMUH-01-09-09","December 1, 2009","01/01/2005",2009-09-01,"December 2, 2009","01/12/2009","",2009-09-01,"Response Rate|Time to Progression(TTP), Progression free survival, overall survival, safety, Quality of Life","http://ClinicalTrials.gov/show/NCT01025349",NA
"41714",41714,"NCT01105949","An Evaluation of Two Novel Nasal Strip Prototypes on Nasal Patency","Completed","No Results Available","Healthy Volunteer","Device: Marketed nasal strip|Device: NexGen JB Organic PET/PE|Device: NexGen AB 2R11","GlaxoSmithKline","Both","Adult|Senior","Phase II",50,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","B3560645","April 15, 2010","01/09/2009",2009-10-01,"April 15, 2010","01/04/2010","",2009-10-01,"Change from baseline in minimum cross sectional area (second restriction) of the nasal valve using acoustic rhinometry|Change from baseline in total nasal volume of the nose using acoustic rhinometry|Nasal airway breathing as measured by Posterior Rhinomanometry|Nasal airway breathing as measured by Peak Nasal Inspiratory Flow (PNIF)|Subjective perceptions of airway breathing","http://ClinicalTrials.gov/show/NCT01105949",NA
"41795",41795,"NCT01229449","Ibuprofen/Acetaminophen Versus Nurofen Plus?ó and Panadeine?ó Extra Dental Pain Study","Completed","No Results Available","Post-operative Pain","Drug: Ibuprofen/acetaminophen|Drug: Ibuprofen/acetaminophen (higher dose)|Drug: Nurofen Plus?ó|Drug: Panadeine?ó Extra|Drug: Placebo","Reckitt Benckiser Inc.|Worldwide Clinical Trials Ltd.|Premier Research Group plc|ACM Laboratories|Aptuit Inc.|Clearcut Clinical Consulting","Both","Child|Adult|Senior","Phase III",678,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NL0811","October 26, 2010","01/01/2009",2009-09-01,"October 26, 2010","01/10/2010","",2009-09-01,"SPRID (the sum of the pain intensity difference (PID) and the pain relief (PR) score)|SPID (Sum of Pain Intensity Difference)|SPRID|TOTPAR (Total Pain Relief)","http://ClinicalTrials.gov/show/NCT01229449",NA
"41806",41806,"NCT01250249","A Study of Comparing Safety and Reactogenicity, of Lyophilized BCG Vaccine IP of Green Signal Bio Pharma Private Limited, India With BCG Vaccine of Serum Institute of India Limited in 120 Healthy Children.","Completed","No Results Available","Healthy","Biological: BCG Vaccine IP - Serum Institute of India","Green Signal Biopharma Private Limited","Both","Child","Phase III",120,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","BCGV/034/08","November 26, 2010","01/11/2008",2009-06-01,"November 29, 2010","01/11/2010","",2009-06-01,"","http://ClinicalTrials.gov/show/NCT01250249",NA
"41865",41865,"NCT00005850","Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer","Completed","No Results Available","Anxiety Disorder|Depression|Fatigue|Lung Cancer","Drug: cisplatin|Drug: fluoxetine|Drug: gemcitabine hydrochloride","Cancer and Leukemia Group B|National Cancer Institute (NCI)","Both","Child|Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067871|CLB-119802","June 2, 2000","01/08/2001",NA,"September 10, 2009","01/08/2003","",2009-08-01,"","http://ClinicalTrials.gov/show/NCT00005850",NA
"41914",41914,"NCT00072150","Bortezomib in Treating Patients With Advanced Transitional Cell Carcinoma of the Urothelium","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: bortezomib","Cancer and Leukemia Group B|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000335517|CALGB-90207","November 4, 2003","01/10/2003",NA,"October 1, 2009","01/11/2004","",2009-08-01,"","http://ClinicalTrials.gov/show/NCT00072150",NA
"41929",41929,"NCT00108550","Chronic Low Back Pain Research Project","Completed","No Results Available","Chronic Low Back Pain","Drug: gabapentin|Drug: Inert placebo","Department of Veterans Affairs","Both","Adult|Senior","Phase II",115,"U.S. Fed","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLNA-013-04S","April 15, 2005","01/10/2004",2009-09-01,"December 8, 2010","01/12/2010","",2009-07-01,"Mean pain intensity (Descriptor Differential Scale) at exit|Oswestry Disability Index|SF-36|Quality of Well-Being","http://ClinicalTrials.gov/show/NCT00108550",NA
"42043",42043,"NCT00273650","Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism","Completed","No Results Available","Autistic Disorder","Drug: methylcobalamin|Other: saline placebo","University of California, Davis","Both","Child","Phase II|Phase III",35,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","MB12-AUT","January 6, 2006","01/07/2005",2009-08-01,"January 19, 2010","01/01/2010","",2009-06-01,"Primary measure is the Clinical Global Impression Scale -Improvement supplemented by videos taken at all visits and rated blindly to measure executive function, speech, and language, and socio-economic development.|Secondary measures:NEPSY, ABC, PPVT, SB:V, PDRF, MCDI, PIA-CV, and CARS.","http://ClinicalTrials.gov/show/NCT00273650",NA
"42066",42066,"NCT00304850","Polyamine-free Diet to Prevent Post Surgery Hyperalgesia","Completed","No Results Available","Breast Cancer|Surgery","Behavioral: polyamine-free diet|Drug: Ketamine or placebo","University Hospital, Bordeaux|Ministry of Health, France|Insurance CNP foundation","Female","Adult|Senior","Phase II",160,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","9258-03|2002-004","March 17, 2006","01/03/2006",2009-05-01,"December 24, 2009","01/12/2009","PoLyDOL",2009-04-01,"Morphine requirement|Pain intensity for the 4 days (and possibly at 7th day if the patient is still hospitalized) after surgery|Allodynia measurements|Hyperesthesia measurements|Chronic pain incidence|Late allodynia and/or hyperesthesia|safety of treatment","http://ClinicalTrials.gov/show/NCT00304850",NA
"42067",42067,"NCT00307450","Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease","Completed","No Results Available","Parkinson's Disease","Drug: Levetiracetam","Dresden University of Technology|UCB GmbH, Huettenstrasse 205, 50170 Kerpen, Germany","Both","Adult|Senior","Phase IV",34,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TUD-LELEDY-007|Ethic board no.: EK10012006|EUDRAC no.: 2005-005940-18","March 27, 2006","01/03/2006",2009-07-01,"July 31, 2009","01/07/2009","LeLeDys",2009-03-01,"Modified AIMS|UPDRS items 32 & 33|UPDRS|Schwab & England scale|Hoehn & Yahr scale|GCI|Patient day record|Epsworth sleep scale|Levodopa challenge test|Safety measures","http://ClinicalTrials.gov/show/NCT00307450",NA
"42068",42068,"NCT00308750","First Line Chemotherapy Treatment of Advanced NSCLC","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: enzastaurin|Drug: pemetrexed|Drug: docetaxel|Drug: carboplatin","Eli Lilly and Company","Both","Adult|Senior","Phase II",217,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10651|H6Q-US-S004","March 28, 2006","01/03/2006",2009-07-01,"May 27, 2010","01/05/2010","",2009-07-01,"Time to progressive disease|Assessment of biomarkers relevant to pemetrexed, carboplatin, enzastaurin, and disease state, and their correlation to clinical outcome|Assessment of smoking history and hormone replacement therapy and the correlation to clinical outcome|Comparisons of safety between each treatment arm|Comparisons of patient reported outcomes using the FACT-Lung and FACT-Taxane|Overall survival|Duration of response|Time to treatment failure","http://ClinicalTrials.gov/show/NCT00308750",NA
"42073",42073,"NCT00313950","Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine","Completed","No Results Available","Measles|Mumps|Rubella|Hepatitis A","Biological: Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|Biological: Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|Biological: Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella","Sanofi-Aventis","Both","Child","Phase IV",470,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","HAF65","April 11, 2006","01/09/2006",2010-04-01,"April 8, 2010","01/04/2010","",2009-12-01,"To provide information concerning the immunogenicity of Hepatitis A Vaccine in subjects receiving Pediatric vaccines.","http://ClinicalTrials.gov/show/NCT00313950",NA
"42117",42117,"NCT00368550","Sertraline Pharmacotherapy for Alcoholism Subtypes","Completed","Has Results","Alcoholism","Drug: Sertraline|Drug: Placebo","University of Connecticut Health Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","Both","Adult","Phase IV",134,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","03-225-2|R01AA013631","August 22, 2006","01/02/2004",2009-12-01,"January 3, 2011","01/01/2011","",2009-06-01,"Number of Days on Which Subjects Drank|Number of Days of Heavy Drinking (Defined as Days on Which Women Drank >= 4 Drinks and Men Drank >= 5 Drinks)|Change in the Level of Alcohol-related Problems","http://ClinicalTrials.gov/show/NCT00368550",NA
"42150",42150,"NCT00425750","Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: bortezomib|Drug: docetaxel|Other: laboratory biomarker analysis|Other: pharmacological study","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",25,"Other|NIH","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000525999|P30CA068485|VU-VICC-HN-0501|MILLENIUM-X05170|VU-VICC-IRB-050183","January 19, 2007","01/08/2005",2009-06-01,"November 25, 2010","01/11/2010","",2009-06-01,"Response data by RECIST criteria|Overall survival|Progression-free survival","http://ClinicalTrials.gov/show/NCT00425750",NA
"42162",42162,"NCT00440050","DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease","Completed","Has Results","Alzheimer's Disease","Drug: DHA (Docosahexaenoic Acid)|Drug: Placebo","Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)|Martek Biosciences Corporation","Both","Adult|Senior","Phase III",402,"Other|NIH|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0099|1RC2AG036535|ADC-027-DHA","February 22, 2007","01/02/2007",2009-05-01,"August 27, 2010","01/08/2010","DHA",2009-05-01,"Rate of Change on the ADAS-Cog 11.|Rate of Change on CDR-SOB|ADCS-ADL|Neuropsychiatric Inventory (NPI)","http://ClinicalTrials.gov/show/NCT00440050",NA
"42164",42164,"NCT00446550","A Study of Oral AT2101 in Treatment-naive Patients With Gaucher Disease","Completed","No Results Available","Gaucher Disease, Type 1","Drug: AT2101","Amicus Therapeutics","Both","Adult|Senior","Phase II",16,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GAU-CL-202","March 9, 2007","01/12/2007",2009-08-01,"September 10, 2009","01/09/2009","",2009-08-01,"The primary objective of this study is to evaluate the safety and tolerability of AT2101.|The secondary objective of the study is to evaluate the pharmacodynamic effects of AT2101.","http://ClinicalTrials.gov/show/NCT00446550",NA
"42178",42178,"NCT00469950","The Effect of Training on Endothelial Function, Progression of Disease,Inflammation, Heart Rate Variability and Mental Health After Percutaneous Coronary Intervention","Completed","No Results Available","Coronary Artery Disease","Behavioral: exercise training","Helse Stavanger HF","Both","Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3.2005.1437","May 4, 2007","01/01/2006",2009-02-01,"February 3, 2009","01/02/2009","EFECTOR",2009-02-01,"flow mediated dilation, serum concentrations of biomarkers, restenosis-rate/ late luminal loss, heart rate variability in SDNN|Oxygen uptake capacity (mg/kg/min), Sf36 scores","http://ClinicalTrials.gov/show/NCT00469950",NA
"42194",42194,"NCT00498550","Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual","Completed","No Results Available","Schizophrenia|Dual Diagnosis|Schizoaffective Disorder|Psychotic Disorder|Cannabis Abuse","Drug: Clozapine|Drug: Treatment as usual","National Institute on Drug Abuse (NIDA)|Dartmouth-Hitchcock Medical Center|University of Missouri, Kansas City|VA Medical Center-West Los Angeles|University of South Carolina","Both","Adult","Phase IV",35,"NIH|Other|U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","R01 DA013196|DPMCDA","July 6, 2007","01/10/2000",2009-03-01,"April 15, 2009","01/04/2009","",2009-03-01,"Days of cannabis use as measured by the Timeline Followback|To begin to investigate the process by which Clozapine produces its affects on cannabis use through the study of negative symptoms using the Scale for the Assessment of Negative Symptoms.","http://ClinicalTrials.gov/show/NCT00498550",NA
"42203",42203,"NCT00506350","Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults","Completed","No Results Available","Pandemic Flu","Biological: Pandemic influenza candidate vaccine (GSK1562902A)","GlaxoSmithKline","Both","Adult","Phase II",350,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","109817","July 24, 2007","01/08/2007",2009-10-01,"January 14, 2010","01/01/2010","",2009-10-01,"Humoral immune response in terms of anti-HA antibodies (adjuvanted groups): Geometric mean titres|Humoral immune response in terms of anti-HA antibodies (adjuvanted groups): Seroconversion rates|Humoral immune response in terms of anti-HA antibodies (adjuvanted groups): Seroconversion factors|Humoral immune response in terms of anti-HA antibodies (adjuvanted groups): Seroprotection rates|Humoral immune response in terms of anti-HA antibodies and neutralising antibodies (all groups): Geometric mean titres|Humoral immune response in terms of anti-HA antibodies and neutralising antibodies (all groups): Seroconversion rates|Humoral immune response in terms of anti-HA antibodies and neutralising antibodies (all groups): Seroconversion factors|Humoral immune response in terms of anti-HA antibodies and neutralising antibodies (all groups): Seroprotection rates|Cell-mediated immunity (groups 1, 5 and 9): Frequency of antigen-specific CD4/CD8 cells per 10E6 in tests identified as producing at least two out of four different cytokines","http://ClinicalTrials.gov/show/NCT00506350",NA
"42208",42208,"NCT00520650","Health Evaluation of Abilify Long-term Therapy","Completed","No Results Available","Schizophrenia|Schizoaffective Disorder","Drug: Aripiprazole","Taiwan Otsuka Pharm. Co., Ltd","Both","Adult","Phase IV",245,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","31-06-P01","August 23, 2007","01/08/2006",2009-04-01,"December 15, 2009","01/12/2009","HEALTH",2009-04-01,"Change from baseline in Clinical Global Impression-Severity (CGI-S) scale after 52 weeks treatment.|Change from baseline in CGI-S scale at each visit during the first 39 weeks treatment.|Change from baseline in total score on the Brief Psychiatric Rating Scale (BPRS) at each visit during the treatment period.|Change from baseline in total score on WHOQOL-BREF questionnaire at each visit during the treatment period.|Change from baseline in total score on PANSS (optional) questionnaire at each visit during the treatment period.|Change from baseline in total score on SFS (optional) questionnaire at 12 and 52 weeks treatment.|Change from Visit 2 on POM questionnaire at each visit during the 12-week switching period.|CGI-I scores after 12, 26, 39, and 52 weeks of treatment.","http://ClinicalTrials.gov/show/NCT00520650",NA
"42229",42229,"NCT00550550","Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (Study P05239AM3)(COMPLETED)","Completed","No Results Available","Rhinoconjunctivitis|Rhinitis|Conjunctivitis|Allergy|Immunotherapy","Drug: Placebo|Biological: SCH 697243","Schering-Plough","Both","Child","Phase III",450,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05239|3733251","October 29, 2007","01/11/2007",2009-09-01,"October 22, 2009","01/10/2009","",2009-09-01,"The combined (sum of) rhinoconjunctivitis daily symptom score (DSS) and rhinoconjunctivitis daily medication score (DMS) averaged over the entire grass pollen season (GPS).|The average rhinoconjunctivitis DSS for the entire grass pollen season (GPS).|The average rhinoconjunctivitis DMS for the entire GPS.","http://ClinicalTrials.gov/show/NCT00550550",NA
"42264",42264,"NCT00601250","Efficacy and Safety of B I1356 vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: BI 1356|Drug: Placebo","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",702,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1218.17|EudraCT No.: 2007-002457-24","January 15, 2008","01/01/2008",NA,"May 28, 2009","01/05/2009","",2009-05-01,"The primary endpoint in this study is the change from baseline in HbA1c (HbA1c after 24 weeks of treatment).|change from baseline in HbA1c, change from baseline in FPG, Change from baseline in Postprandial glucose","http://ClinicalTrials.gov/show/NCT00601250",NA
"42268",42268,"NCT00614250","Evaluation of the Effect of AVE0657 on Obstructive Sleep Apnea","Completed","No Results Available","Sleep Apnea, Obstructive","Drug: AVE0657|Drug: placebo","Sanofi-Aventis","Both","Adult|Senior","Phase II",38,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT6796|EudraCT 2007-002174-58","January 31, 2008","01/01/2008",2009-01-01,"July 17, 2009","01/07/2009","",2009-01-01,"Change in Apnea Hypopnea Index (AHI)|Safety and tolerability","http://ClinicalTrials.gov/show/NCT00614250",NA
"42285",42285,"NCT00640250","Clinical Evaluation of T.R.U.E. TEST?ó Panel 3.2 Allergens: Dose Response","Completed","No Results Available","Contact Dermatitis","Biological: T.R.U.E. TEST?ó Skin Patch Test: Dose Response Allergens","Allerderm","Both","Adult|Senior","Phase II",48,"Industry","Interventional","Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","Mekos 07 2P3.2 201|2007-007130-19|WIRB Pr. No.: 20072233","March 3, 2008","01/04/2008",2009-09-01,"May 13, 2010","01/05/2010","",2009-03-01,"Determination of optimal test concentration for Disperse Blue 106 and Bronopol as the lowest concentration eliciting either +1 or +2 positive reactions in 70-90% of sensitive subjects.|Frequency of irritation, late/persistent reactions, tape reactions, subject-reported itching or burning, and adverse events for each allergen and concentration.","http://ClinicalTrials.gov/show/NCT00640250",NA
"42289",42289,"NCT00642850","STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients","Completed","No Results Available","Anemia","Drug: methoxy polyethylene glycol-epoetin beta [Mircera]","Hoffmann-La Roche","Both","Adult|Senior","Phase III",187,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21040","March 19, 2008","",2009-09-01,"December 15, 2009","01/12/2009","",2009-09-01,"% patients maintaining average Hb conc. within the target range during the Efficacy Evaluation Period (EEP)|Change in Hb conc.|% patients maintaining Hb within target range|% patients requiring dose adjustments; incidence of RBC transfusions|AEs, lab parameters","http://ClinicalTrials.gov/show/NCT00642850",NA
"42324",42324,"NCT00707850","Pegasys?ó Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C|Thalassemia","Drug: PEGASYS?ó (Peginterferon Alfa-2a (40KD)) Plus COPEGUS?ó (Ribavirin)","Baqiyatallah Medical Sciences University|Baqiyatallah Research Center for Gastroenterology and Liver Diseases|Tehran Hepatitis Center|Guilan Research Center for Gastroenterology and Liver Diseases|Tabriz Research Center for Gastroenterology and Liver Diseases","Both","Child|Adult|Senior","Phase IV",300,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BRCGL-08-06","June 26, 2008","01/05/2007",2009-09-01,"August 30, 2010","01/09/2009","",2009-09-01,"Early Virologic Response|End of Treatment Response|Sustained Virologic Response|Rapid Virologic Response|Tolerability of drugs for whole therapy period|Biochemical response (ALT)|Laboratory Parameters","http://ClinicalTrials.gov/show/NCT00707850",NA
"42338",42338,"NCT00657150","Dabigatran Etexilate Compared With Enoxaparin in Prevention of VTE Following Total Hip Arthroplasty","Completed","Has Results","Venous Thromboembolism","Drug: Dabigatran etexilate|Drug: Enoxaparin","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",2055,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","1160.64","March 27, 2008","01/03/2008",NA,"November 18, 2010","01/10/2010","",2009-09-01,"Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period|Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period|Proximal Deep Vein Thrombosis During Treatment Period|Total Deep Vein Thrombosis During Treatment Period|Symptomatic Deep Vein Thrombosis During Treatment Period|Pulmonary Embolism During Treatment Period|Death During Treatment Period|Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period|Major Bleeding Events During Treatment Period","http://ClinicalTrials.gov/show/NCT00657150",NA
"42347",42347,"NCT00702650","A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations","Completed","Has Results","Hypogonadism","Drug: Testosterone MD-Lotion","Eli Lilly and Company","Male","Adult|Senior","Phase III",155,"Industry","Interventional","Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14272|MTE08|I5E-MC-TSAH","June 19, 2008","01/06/2008",2009-07-01,"January 5, 2011","01/01/2011","",2009-07-01,"Percentage of Participants With 24-Hour Average Concentration [Cavg(0-24h)] Total Testosterone Within Normal Range at Day 120|Percentage of Participants With Maximum Serum Concentration (Cmax) >1500 ng/dL|Percentage of Participants With Cmax Between 1800 and 2500 ng/dL|Percentage of Participants With Cmax >2500 ng/dL|Percentage of Participants With Minimum Concentration (Cmin) <300 ng/dL|Change From Baseline to Endpoint in Psychosexual Daily Questionnaire|Change From Baseline to Endpoint in the 36-Item Short-Form Health Survey (SF-36)|Change From Baseline to Endpoint in Fasting Insulin|Change From Baseline to Endpoint in Fasting Glucose|Change From Baseline to Endpoint in Prostate Specific Antigen (PSA)|Change From Baseline to Endpoint in Luetinizing Hormone (LH) and Follicle Stimulating Hormone (FSH)|Change From Baseline to Endpoint in Estradiol|Change From Baseline to Endpoint in Haemoglobin|Change From Baseline to Endpoint in Haematocrit|Change From Baseline to Endpoint in Draize Score","http://ClinicalTrials.gov/show/NCT00702650",NA
"42359",42359,"NCT00761150","Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP).","Completed","No Results Available","Chronic Low Back Pain","Drug: ABT-712|Drug: ABT-712 placebo","Abbott","Both","Adult|Senior","Phase III",310,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-385","September 25, 2008","01/08/2008",NA,"December 30, 2010","01/12/2010","",2009-03-01,"Visual Analog Scale (VAS) for pain intensity|Chronic Pain Sleep Inventory (CPSI)","http://ClinicalTrials.gov/show/NCT00761150",NA
"42370",42370,"NCT00775450","Influenza Vaccine Revaccination in Ambulatory Elderly Subjects","Completed","No Results Available","Influenza|Orthomyxovirus Infection|Myxovirus Infection","Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B","Sanofi-Aventis","Both","Adult|Senior","Phase II",807,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","FID21","October 16, 2008","01/10/2008",2009-07-01,"March 31, 2010","01/03/2010","",2009-06-01,"Safety: To provide information concerning the safety after revaccination with influenza vaccine|Immunogenicity: To provide information concerning the immune response of Influenza vaccine","http://ClinicalTrials.gov/show/NCT00775450",NA
"42375",42375,"NCT00787150","A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation","Completed","No Results Available","Atrial Fibrillation","Drug: Apixaban|Drug: Apixaban|Drug: Warfarin sodium","Pfizer|Bristol-Myers Squibb","Both","Adult|Senior","Phase II",222,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","B0661003","November 5, 2008","01/06/2008",2009-09-01,"October 3, 2009","01/10/2009","",2009-09-01,"Incidence of adjudicated major or clinically relevant non-major bleeding during the treatment period|Incidence of adjudicated myocardial infarction or all-cause death during the treatment period|Incidence of major bleeding during the treatment period|Other safety outcome measures will also be assessed, including serious and non-serious AEs and changes in standard clinical laboratory test results|Incidence of adjudicated stroke or systemic embolism during the treatment period|Incidence of adjudicated stroke, systemic embolism or all-cause death during the treatment period|Incidence of total bleeding (major bleeding, clinically relevant non-major bleeding, and minor bleeding) during the treatment period","http://ClinicalTrials.gov/show/NCT00787150",NA
"42385",42385,"NCT00805350","Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties","Completed","No Results Available","Primary Insomnia","Drug: Eplivanserin (SR46349)|Drug: Placebo","Sanofi-Aventis","Both","Adult|Senior","Phase III",637,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC10844|EudraCT 2008-003791-22","December 4, 2008","01/12/2008",2009-06-01,"November 29, 2010","01/11/2010","ECLIPSE",2009-06-01,"Change from baseline of mean PSG-WASO on N41/N42|Change from baseline of mean PSG-NAW on N41/N42|Other PSG sleep parameters: PSG-TST, PSG-SE (TST/Time in Bed), PSG-LPS; sleep architecture: percentage of time spent in each sleep stage (1, 2, 3-4/SWS, REM), shift to stage 1, shift to wake, stage 1 + WASO, [stages 3&4]/[stage 1 + WASO]).|Patient-reported sleep parameters measured on patient sleep questionnaire: pr-WASO, pr-NAW, pr-TST, QoS, RQoS.|Residual effects measured by psychometric tests DSST & RAVLT in the morning and evening following nights in sleep lab, and reported by patients on sleep questionnaires (morning sleepiness, ability to concentrate in the morning).","http://ClinicalTrials.gov/show/NCT00805350",NA
"42390",42390,"NCT00784550","A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS 250/50mcg Plus SPIRIVA HANDIHALER Versus SPIRIVA HANDIHALER Plus Placebo DISKUS in Subjects With Chronic Obstructive Pulmonary Disease (COPD). SPIRIVA and HANDIHALER Are Trade Marks of Boehringer Ingelheim","Completed","Has Results","Pulmonary Disease, Chronic Obstructive","Drug: Tiotropium Bromide|Drug: FLuticasone Propionate/Salmeterol","GlaxoSmithKline","Both","Adult|Senior","Phase IV",342,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","111114","October 31, 2008","01/12/2008",2009-12-01,"January 6, 2011","01/01/2011","ADC111114",2009-12-01,"Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Expiratory Volume in One Second (FEV1) at Endpoint|Mean Change From Baseline in 2 Hour Post-dose FEV1 at Endpoint|Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Vital Capacity (FVC) at Endpoint|Mean Change From Baseline in 2 Hour Post-dose FVC at Endpoint|Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-Dose Inspiratory Capacity (IC) at Endpoint|Mean Change From Baseline in Scores on the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) at Endpoint","http://ClinicalTrials.gov/show/NCT00784550",NA
"42398",42398,"NCT00820950","A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis","Completed","No Results Available","Plaque Psoriasis","Drug: INCB018424 phosphate cream|Drug: Vehicle (placebo) cream","Incyte Corporation","Both","Adult|Senior","Phase II",29,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","INCB 18424-201","January 8, 2009","01/05/2007",2009-04-01,"June 17, 2010","01/06/2010","",2009-01-01,"The safety, tolerability (assessed by local irritation, adverse experiences, vital signs, ECGs, and clinical labs) and pharmacokinetics (plasma concentrations) of INCB018424 cream formulations when applied once or twice daily to patients.|Efficacy endpoints will include: Change in target lesion scores including total score and each component analyzed separately. Change in target lesion area","http://ClinicalTrials.gov/show/NCT00820950",NA
"42405",42405,"NCT00833950","Phase Out in Tinnitus Patients","Completed","No Results Available","Tinnitus","Device: Phase Out treatment in pure tone tinnitus patients","University Hospital, Antwerp","Both","Adult|Senior","Phase IV",40,"Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","08/02/2012","January 30, 2009","01/03/2008",NA,"March 2, 2009","01/12/2008","",2009-03-01,"Visual Analogue Scale|Score on Tinnitus Questionnaire","http://ClinicalTrials.gov/show/NCT00833950",NA
"42461",42461,"NCT00924950","Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis","Completed","No Results Available","Plaque Psoriasis|Psoriasis Vulgaris","Drug: Taclonex Ointment and Hydrogel Patch|Drug: Taclonex Ointment","University of California, San Francisco","Both","Adult|Senior","Phase IV",35,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H5939-31328-02","June 17, 2009","01/06/2009",2009-12-01,"January 15, 2010","01/01/2010","",2009-12-01,"Difference in change between baseline and Week 4 modified PASI scores in targeted plaques treated with Taclonex under occlusive dressing versus Taclonex alone.|To determine the change in modified PASI scores between Week 4 and Week 6 during the follow-up period. This is to determine whether there is further improvement of psoriasis after the cessation of occlusion.","http://ClinicalTrials.gov/show/NCT00924950",NA
"42484",42484,"NCT00958750","Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia","Completed","No Results Available","Androgenetic Alopecia|Female Pattern Hair Loss","Drug: minoxidil","Charite University, Berlin, Germany","Female","Adult|Senior","Phase III",113,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","CRC-AGA01|EudraCT: 2008-001770-33","August 12, 2009","01/06/2008",2009-02-01,"August 12, 2009","01/08/2009","",2009-02-01,"Change of target area non-vellus hair count (TAHC) [n/cm??] after 24 weeks|Assessing the investigational products safety by means of clinical examination (local intolerance, facial hypertrichosis, AE, SAE) and blood Minoxidil level (baseline + week 24)|Change of cumulative hair width in non-vellus hair (TAHW) after 24 weeks|Global expert panel rating of change in scalp coverage via assessment of global photographs|Volunteer questionnaire rating for administration and contentment of the study product","http://ClinicalTrials.gov/show/NCT00958750",NA
"42502",42502,"NCT00980850","Swine Flu (Novel Influenza A H1N1) Vaccine Study","Completed","No Results Available","Influenza","Biological: Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Biological: GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine","University of Oxford","Both","Child","Phase II",1000,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","2009/08 H1N1","September 18, 2009","01/09/2009",2009-12-01,"February 2, 2010","01/02/2010","",2009-12-01,"Percentage of subjects with a 4 fold rise in MN titre between the pre-vaccination sample and sample taken 3 weeks after the second dose|Percentage of participants experiencing each of fever (??­ 38??C per axilla), local tenderness, local swelling or local erythema within the 7 days following each immunisation with the study vaccines|Percentage of subjects with an HAI titre ??­ 1 in 32|Percentage of subjects with a 4 fold rise in HAI titre between the pre-vaccination sample and sample taken 3 weeks after the second dose|The geometric mean fold rises in HAI titres from baseline to after three weeks after 2 doses of the Baxter H1N1 vaccine and the GSK H1N1 vaccine.|The geometric mean fold rises in MN titres from baseline to three weeks after 2 doses of the Baxter H1N1 vaccine and the GSK H1N1 vaccine.|The geometric mean HAI and MN titres three weeks after 2 doses of the Baxter H1N1 vaccine and the GSK H1N1 vaccine.|Percentage of participants experiencing each of: reduced feeding, reduced activity, irritability, persistent crying, vomiting or diarrhoea, receiving medication for pain or temperature (6 month to 5 year olds).|Percentage of participants experiencing each of: malaise, headache, nausea/ vomiting, diarrhoea, reduced appetite, muscle pain or joint pain, receiving analgesic/ antipyretic medication (5 to 12 year olds).|The effect of genetic polymorphisms on the immunogenicity and reactogenicity of the H1N1 vaccines.","http://ClinicalTrials.gov/show/NCT00980850",NA
"42534",42534,"NCT01034150","Effects of Home-based Neurostimulation Associated With Motor Training in Chronic Stroke Patients","Completed","No Results Available","Stroke","Device: Relief band (Somatosensory stimulation)|Device: Placebo stimulation","University of Sao Paulo General Hospital|Funda????o de Amparo ?? Pesquisa do Estado de S??o Paulo|Conselho Nacional de Desenvolvimento Cient?¦fico e Tecnol??gico","Both","Adult|Senior","Phase I|Phase II",20,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","1309-06|477916/06-6","December 11, 2009","01/12/2007",2009-11-01,"December 16, 2009","01/11/2009","",2009-09-01,"the improvement in upper extremity performance assessed using Jebsen-Taylor test|Compliance with the interventions, assessed through a daily written log, and oral reports of the patients|Adverse events","http://ClinicalTrials.gov/show/NCT01034150",NA
"42550",42550,"NCT01061450","Simvastatin and Diastolic Dysfunction","Completed","No Results Available","Diastolic Dysfunction|Hypertension","Drug: Simvastatin|Drug: Placebo","Brasilia Heart Study Group|Funda????o de Amparo a Pesquisa do Distrito Federal|Coordena????o de Aperfei??oamento de Pessoal de N?¦vel Superior.","Both","Adult","Phase IV",55,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Statin_DD","February 2, 2010","01/11/2006",2009-08-01,"February 2, 2010","01/02/2010","",2009-07-01,"Changes in E/A ratio and e' wave velocity|Changes in left atrium volume.|Changes in left ventricular mass.|Changes in e??/a?? waves ratio.|Changes in mitral deceleration time.|Changes in the ratio of mitral inflow velocity to annular relaxation velocity.|Changes in mitral annulus systolic velocity|Diastolic function reserve index measured at peak stress with dobutamine","http://ClinicalTrials.gov/show/NCT01061450",NA
"42555",42555,"NCT01073150","Tea Tree Oil in the Treatment of Chronic Blepharitis","Completed","No Results Available","Blepharitis","Drug: Tea Tree Oil","Federal University of S??o Paulo","Both","Adult|Senior","Phase II",34,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","Nahin Geha","February 19, 2010","01/04/2009",2009-11-01,"February 19, 2010","01/02/2010","",2009-08-01,"","http://ClinicalTrials.gov/show/NCT01073150",NA
"42589",42589,"NCT01139450","Study of 0417 Ointment in the Treatment of Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Drug: 0417|Drug: Vehicle of 0417 test product|Drug: Tacrolimus Ointment 0.03%","Nycomed US Inc.","Both","Child|Adult|Senior","Phase III",900,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","417","June 7, 2010","01/01/2008",2009-08-01,"June 7, 2010","01/06/2010","",2009-08-01,"Incidence of success based on the investigator's global evaluation at the end of treatment|The mean change from baseline in the total individual clinical signs and symptoms per body region|The mean change from baseline in pruritus|The mean change from baseline in the percentage total body surface affected (%BSA)","http://ClinicalTrials.gov/show/NCT01139450",NA
"42682",42682,"NCT00001151","Studies With Vitamin D","Completed","No Results Available","Hypocalcemia|Rickets","Drug: 1,25-Dihydroxycholecalciferol","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Child|Adult|Senior","Phase II",200,"NIH","Interventional","Primary Purpose: Treatment","760081|76-DK-0081","November 3, 1999","01/03/1976",2009-10-01,"July 29, 2010","01/10/2009","",2009-10-01,"Normal serum calcium concentration.","http://ClinicalTrials.gov/show/NCT00001151",NA
"42735",42735,"NCT00028951","Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva","Completed","No Results Available","Lymphedema|Perioperative/Postoperative Complications|Vulvar Cancer","Drug: fibrin sealant|Procedure: surgical wound closure","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Adult|Senior","Phase III",NA,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Supportive Care","CDR0000069149|GOG-0195|NCI-P01-0201","January 4, 2002","01/01/2003",NA,"May 9, 2009","01/12/2005","",2009-01-01,"Incidence of lymphedema of the lower extremity at 1 week, 6 weeks, 3 months, and 6 months postoperatively|Frequency of surgical complications at 1 week, 6 weeks, 3 months, and 6 months postoperatively","http://ClinicalTrials.gov/show/NCT00028951",NA
"42805",42805,"NCT00144651","Study of MRA in Patients With Rheumatoid Arthritis (RA)","Completed","No Results Available","Rheumatoid Arthritis","Drug: MRA(Tocilizumab)","Chugai Pharmaceutical","Both","Adult|Senior","Phase II",135,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MRA010JP","September 2, 2005","01/08/2001",2009-06-01,"December 21, 2009","01/12/2009","",2009-06-01,"ACR 20% responder rate compared to the pre-treatment in the preceding study|Frequency and severity of adverse events and adverse drug reactions|Time course of DAS28,compared to the pre-treatment in the preceding study|Time course of the ACR 20%, 50%, and 70% responder rates compared to the pre-treatment in the preceding study|ACR N AUC compared to the pre-treatment in the preceding study|Time course of the ACR core set variables compared to the pre-treatment in the preceding study","http://ClinicalTrials.gov/show/NCT00144651",NA
"42844",42844,"NCT00205751","Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy","Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide/Dexamethasone vs Melphalan/Prednisone","Austrian Forum Against Cancer","Both","Adult|Senior","Phase II|Phase III",350,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","01-002-0601","September 12, 2005","01/08/2001",2009-10-01,"July 22, 2010","01/07/2010","",2009-10-01,"Time to progression|Response rate|Survival|Time to response|Toxicity|Quality of life","http://ClinicalTrials.gov/show/NCT00205751",NA
"42910",42910,"NCT00304551","A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)","Completed","No Results Available","Liver Cirrhosis|Chronic Hepatitis C","Drug: peginterferon alfa-2a 180??g|Drug: peginterferon alfa-2a 90??g|Drug: ribavirin","Chugai Pharmaceutical","Both","Adult|Senior","Phase III",180,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JV19595","March 5, 2006","01/06/2006",2010-06-01,"June 1, 2010","01/06/2010","",2009-12-01,"Sustained virological response, defined as undetectable hepatitis C virus (HCV)-RNA (< 50 IU per milliliter [IU/mL])|Biochemical response (normalization of serum alanine aminotransferase activity)|Virological response (HCV-RNA < 50 IU per milliliter)","http://ClinicalTrials.gov/show/NCT00304551",NA
"42911",42911,"NCT00303251","Safety of TKI258 in Advanced/Metastatic Melanoma Subjects","Completed","No Results Available","Melanoma","Drug: TKI258","Novartis Pharmaceuticals","Both","Adult|Senior","Phase I|Phase II",47,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CTKI258A2105","March 14, 2006","01/04/2006",NA,"November 20, 2009","01/11/2009","",2009-09-01,"Dose Expansion: Determine the maximum tolerated dose based on dose limiting toxicity of TKI258|Dose Expansion: Determine the plasma and whole blood pharmacokinetics of orally administered TKI258|Dose Escalation: Assess tumor response according to RECIST as measured by response rate and lack of early progressive disease (<=2 months)|Assess the safety profile of TKI258 in this patient population|Assess the effect of TKI258 on biomarkers in the blood|Assess biomarker changes in tumor/nevi biopsies and archival tumor tissues where accessible, pre- and post-treatment|Assess changes in tumor glucose metabolism/cell viability between pre- and post-treatment using [18F]-FDG-PET|Assess anti-angiogenic effects of TKI258 using DCE-MRI pre- and post-treatment","http://ClinicalTrials.gov/show/NCT00303251",NA
"42959",42959,"NCT00376051","Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia","Completed","No Results Available","Frontotemporal Dementia","Drug: Citalopram","Sunnybrook Health Sciences Centre|Alzheimer Society of Canada","Both","Adult|Senior","Phase IV",22,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","218-2006|07-48","September 13, 2006","01/09/2006",2009-09-01,"November 20, 2009","01/11/2009","",2009-07-01,"Neuropsychiatric Inventory (NPI)|Frontal Behavioural Inventory (FBI)|Clinical Global Impression (CGI)|Cornell Scale for Depression in Dementia|Disability Assessment for Dementia Scale (DAD)|Functional Assessment Staging (FAST)","http://ClinicalTrials.gov/show/NCT00376051",NA
"42982",42982,"NCT00418951","Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections","Completed","No Results Available","Acute Myelogenous Leukemia|Myelodysplastic Syndrome","Drug: Voriconazole|Drug: Liposomal amphotericin B|Drug: Liposomal amphotericin B","M.D. Anderson Cancer Center","Both","Adult|Senior","Phase II",120,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","2006-0536","January 3, 2007","01/11/2006",2009-10-01,"December 14, 2009","01/12/2009","",2009-10-01,"Infection Rate|Toxicity Rate","http://ClinicalTrials.gov/show/NCT00418951",NA
"42984",42984,"NCT00425451","The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis","Completed","No Results Available","Periodontitis","Drug: flurbiprofen/chlorhexidine","Dexcel Pharma Technologies Ltd.","Both","Adult|Senior","Phase II",80,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CLI/006P","January 21, 2007","01/08/2008",2009-03-01,"December 28, 2009","01/08/2008","",2009-01-01,"At 24 weeks, relative to baseline, the mean reductions in probing pocket depth (PPD) will be used as primary efficacy endpoint. Additional primary endpoints are clinical attachment levels (CAL) and bleeding on probing (BOP) in the target pockets selected|PPD measurements at 6, 12 and 18 weeks will be used as secondary endpoints. Additional secondary endpoints are clinical attachment levels (CAL) and bleeding on probing (BOP) in the target pockets selected at screening, measured at weeks 6, 12 and 18.","http://ClinicalTrials.gov/show/NCT00425451",NA
"42985",42985,"NCT00424151","Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy","Completed","No Results Available","Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy","Drug: Rituximab","Silkiss, Rona Z., M.D., FACS|Lauer, Simeon, M.D.|Reier, Alice M.D.|Coleman, Morton M.D.","Both","Adult|Senior","Phase I|Phase II",12,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","U4126s","January 17, 2007","01/12/2006",2009-03-01,"October 4, 2010","01/10/2010","",2009-03-01,"Clinical response to treatment, alteration in immunoglobulin levels|To assess the safety and tolerability of Rituximab in Graves' dysthyroid disease up to 24 weeks. Adverse and serious adverse events during the study period, reasonably or probably related to Rituximab, will be assessed at each study visit up to 12 month|Efficacy:|A significant (25%) reduction in progression of Thyroid Associated Ophthalmopathy or disease activity as measured by the thyroid associated ophthalmopathy scale (University of British Columbia Thyroid Orbitopathy Inflammatory Score) up to 24 weeks.|To evaluate for a reduction in disease activity as measured by:|Reduction (25%) of elevated antibody levels- serum thyroid stimulating immunoglobulin (TSI), antithyroidperoxidase antibody (TPO) or antithyroglobulin levels at 24 weeks.|MRI of the orbit with coronal and axial views to evaluate evidence of optic nerve crowding, muscle size reduction or decreased proptosis during treatment and follow up interval at 24 weeks.","http://ClinicalTrials.gov/show/NCT00424151",NA
"42990",42990,"NCT00411151","Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer","Completed","Has Results","Adenocarcinoma of Stomach|Barrett Esophagus","Drug: Sunitinib-Malate","Johannes Gutenberg University Mainz|Pfizer","Both","Adult|Senior","Phase II",52,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GC-SU-2006|KKS 2005-015","December 11, 2006","01/12/2006",2009-08-01,"December 15, 2010","01/11/2010","",2009-07-01,"Objective Response Rate (ORR)|Progression-Free Survival (PFS)|Overall Survival (OS)|One-Year Survival|Adverse Events|Safety and Tolerability: Serious Adverse Events|Safety and Tolerability: Adverse Events in ??­10% of Patients","http://ClinicalTrials.gov/show/NCT00411151",NA
"43023",43023,"NCT00473551","Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies","Completed","No Results Available","Leukemia|Lymphoma|Myeloma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Mesna|Radiation: Radiation Treatment|Procedure: Stem Cell Transplantation (SCT)|Drug: Sirolimus|Procedure: Anti-third Party Cytolytic T-lymphocytes (CTL)","M.D. Anderson Cancer Center","Both","Adult|Senior","Phase I|Phase II",4,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0682","May 11, 2007","01/05/2007",2009-11-01,"December 7, 2009","01/12/2009","",2009-11-01,"Maximally Tolerated Dose of antithird party cytolytic T-lymphocytes (CTLs)","http://ClinicalTrials.gov/show/NCT00473551",NA
"43027",43027,"NCT00485251","Prospective Randomized Trial of Hand-assisted Laparoscopic Right Hemicolectomy vs Total Laparoscopic Right Hemicolectomy","Completed","No Results Available","Operation Time|Pain Score|Recurrence|Survival","Procedure: hand-assisted laparoscopic right hemicolectomy|Procedure: total laparoscopic right hemicolectomy|Procedure: hand-assisted right hemicolectomy|Procedure: laparoscopic right hemicolectomy","Pamela Youde Nethersole Eastern Hospital","Both","Adult|Senior","Phase IV",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","CShan","June 11, 2007","01/02/2007",2009-09-01,"November 23, 2009","01/11/2009","",2009-09-01,"operation time|pain score, recurrence","http://ClinicalTrials.gov/show/NCT00485251",NA
"43035",43035,"NCT00493051","Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities","Completed","No Results Available","Diabetic Foot","Biological: GAM501|Biological: Placebo|Other: Standard of care","Tissue Repair Company|Cardium Therapeutics","Both","Adult|Senior","Phase II",124,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SWHI-03","June 25, 2007","01/11/2007",2009-12-01,"February 8, 2010","01/02/2010","MATRIX",2009-12-01,"Effect of GAM501 on the incidence of complete ulcer closure|Time to complete ulcer closure|The absolute change and percent change in ulcer area|The durability of ulcer closure|Ulcer healing trajectories will be assessed by plots of percentage of ulcer closure versus time|Safety and tolerance","http://ClinicalTrials.gov/show/NCT00493051",NA
"43059",43059,"NCT00545051","A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.","Completed","No Results Available","Post-Menopausal Osteoporosis","Drug: ibandronate [Bonviva/Boniva]|Drug: Placebo","Hoffmann-La Roche|GlaxoSmithKline","Female","Adult|Senior","Phase IV",140,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ML20088","October 16, 2007","",2009-05-01,"December 15, 2009","01/12/2009","",2009-05-01,"Percentage change from baseline in mean lumbar spine (L1-L4) BMD|Change in mean lumbar spine BMD|Change in total hip BMD|Change in bone turnover markers|Withdrawal rates due to worsening BMD|AEs, clinical fractures, laboratory parameters","http://ClinicalTrials.gov/show/NCT00545051",NA
"43098",43098,"NCT00615251","A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization","Completed","No Results Available","Infertility","Drug: DR-2011|Drug: Crinone 8%","Duramed Research","Female","Adult","Phase III",1300,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","DR-PGN-302","February 4, 2008","01/02/2008",2009-08-01,"January 8, 2010","01/01/2010","",2009-08-01,"Clinical pregnancy rate at 8 weeks and 12 weeks of pregnancy|Secondary outcome measures will include: live birth rate, cycle cancellation rate, rate of spontaneous abortion, rate of biochemical pregnancy, rate of ectopic pregnancy|Adverse events","http://ClinicalTrials.gov/show/NCT00615251",NA
"43103",43103,"NCT00561951","Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.","Completed","Has Results","Overactive Bladder","Drug: fesoterodine fumarate|Drug: Placebo|Drug: fesoterodine fumarate","Pfizer","Both","Adult|Senior","Phase II",951,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A0221005","November 19, 2007","01/11/2007",2009-01-01,"August 18, 2010","01/08/2010","",2009-01-01,"Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12.|Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.|Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12.|Change From Baseline in Mean Number of Micturitions Per 24 Hours at Weeks 2, 4, 8, and 12.|Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12.|Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.|Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12.|Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.|Change From Baseline in Mean Number of Night-Time Micturitions Per 24 Hours at Week 12.|Change From Baseline in Mean Number of Night-Time Micturitions Per 24 Hours at Weeks 2, 4, 8, and 12.|Change From Baseline in Mean Voided Volume Per Micturition at Week 12.|Change From Baseline in Mean Voided Volume Per Micturition at Weeks 2, 4, 8, and 12.|Change From Baseline in Each Domain Scores of King's Health Questionnaire (KHQ).|Change From Baseline in Each Domain Scores of Overactive Bladder Questionnaire (OAB-q) at Week 12.|Change From Baseline for Patient Perception of Bladder Condition (PPBC) at Week 12.|The Number of Patients With \Severe Problems","http://ClinicalTrials.gov/show/NCT00561951",NA
"43106",43106,"NCT00620451","Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate (AT-1001) in Active Celiac Disease","Completed","No Results Available","Celiac Disease","Drug: larazotide acetate (AT-1001)|Drug: larazotide acetate (AT-1001)|Drug: placebo","Alba Therapeutics","Both","Adult|Senior","Phase II",105,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AT1001-011","February 7, 2008","01/02/2008",2009-12-01,"January 18, 2010","01/01/2010","",2009-07-01,"Villous Height to Crypt Depth (Vh:Cd) ratio|To assess the safety and tolerability of larazotide acetate (AT-1001)","http://ClinicalTrials.gov/show/NCT00620451",NA
"43109",43109,"NCT00629551","An Eight-Week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder","Completed","No Results Available","Depressive Disorder, Major","Drug: saredutant (SR48968)|Drug: paroxetine|Drug: placebo","Sanofi-Aventis","Both","Adult","Phase III",820,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC10438|EudraCT 2007-003863-31","February 26, 2008","01/02/2008",2009-02-01,"March 19, 2009","01/03/2009","COMPASS",2009-02-01,"Change from baseline in Hamilton Depression Rating Scale total score|Change from baseline in the Changes in Sexual Functioning Questionnaire total score|Change from baseline in the Clinical Global Impression severity of illness score","http://ClinicalTrials.gov/show/NCT00629551",NA
"43110",43110,"NCT00624351","Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease","Completed","No Results Available","Systemic Lupus Erythematosus","Biological: Epratuzumab|Other: Placebo","UCB, Inc.","Both","Adult|Senior","Phase II",227,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SL0007|EudraCT Number: 2007-002566-35","February 15, 2008","01/01/2008",2009-08-01,"November 22, 2010","01/11/2010","",2009-08-01,"Efficacy as measured by the responder rate according to a combined response index evaluated at week 12 (visit 10) incorporating BILAG assessment, SLEDAI, a physician's global assessment and treatment failure status.|The combined response index analysis described for the primary endpoint.|The combined response index including an additional criteria involving the SF-36 response.|Number and percent of patients with BILAG improvement.|Change from baseline in total BILAG score.|Change from baseline in SLEDAI.|Change from baseline in physician and patient global assessments.|Percentage of patients achieving SF-36 response from baseline.|EQ-5D results at weeks 12.|Time to first sustained BILAG response|Time to enhanced BILAG response.|Proportion of patients meeting treatment failure.|Endpoints relating to use of steroids over treatment period.|Safety outcome measures include adverse events (including infusion reactions), vital signs and clinical safety laboratory assessments.|Immunogenicity as measured from baseline by human anti-human antibodies (HAHA)|Assessment of changes from baseline in levels of circulating B and T cells","http://ClinicalTrials.gov/show/NCT00624351",NA
"43126",43126,"NCT00643851","An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets","Completed","No Results Available","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Metformin XR","Bristol-Myers Squibb|AstraZeneca","Both","Adult|Senior","Phase III",600,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MB102-021","March 20, 2008","01/06/2008",2009-08-01,"September 10, 2010","01/08/2010","",2009-08-01,"Change from baseline in hemoglobin A1C|Change from baseline in fasting plasma glucose achieved with Dapagliflozin in Combination with Metformin compared to Dapagliflozin Monotherapy and compared to Metformin Monotherapy|Proportion of subjects achieving a therapeutic glycemic response, defined as A1C < 7.0%|Change from baseline in total body weight|Change from baseline in A1C (A1C category ??­9.0%)|Change from baseline in total body weight (baseline BMI category ??­27 kg/m2)","http://ClinicalTrials.gov/show/NCT00643851",NA
"43147",43147,"NCT00655551","Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures","Completed","Has Results","Partial Epilepsies|Partial Onset Seizures","Drug: lacosamide|Drug: lacosamide|Drug: lacosamide","UCB, Inc.","Both","Child|Adult","Phase III",100,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SP925","March 26, 2008","01/04/2008",2009-09-01,"November 15, 2010","01/11/2010","",2009-09-01,"Number of Subjects With at Least One Adverse Event During the Treatment Period (up to 7 Days)|Number of Subjects Who Withdrew From the Trial Due to an Adverse Event|Number of Subjects With at Least One Adverse Event With an Onset Within 4 Hours of Start of Infusion","http://ClinicalTrials.gov/show/NCT00655551",NA
"43175",43175,"NCT00743951","A Feasibility Study to Test if Adding Patient Decision Aids to Screening for Eligibility for Surgery Decreases Unnecessary Referrals for Total Joint Replacement","Completed","No Results Available","Joint Replacement","Behavioral: Patient decision aid and referral onward.|Behavioral: Patient education and referral onward","Ottawa Hospital Research Institute|The Ottawa Hospital|University of Ottawa|University of Toronto","Both","Child|Adult|Senior","Phase III",142,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Health Services Research","OHREB 2006724-01H","July 25, 2007","01/01/2007",2009-04-01,"June 2, 2009","01/05/2009","",2009-04-01,"Feasibility of participant recruitment, intervention provision, and data collection; sample size needed to detect differences in the rates of unnecessary referral|Decision quality|Satisfaction with preparation for decision making|Proportion of unnecessary surgical referrals","http://ClinicalTrials.gov/show/NCT00743951",NA
"43176",43176,"NCT00741351","Anesthesiological Strategies in Elective Craniotomy","Completed","No Results Available","Anesthesia|Craniotomy|Neurosurgery","Drug: Sevoflurane + Fentanyl|Drug: Sevoflurane + Remifentanyl|Drug: Propofol + Remifentanyl","Azienda Ospedaliera San Gerardo di Monza","Both","Adult|Senior","Phase III",411,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","EudraCT number 2007-005279-32|AIFA FARM6FKJKK","August 22, 2008","01/12/2007",2009-12-01,"May 26, 2010","01/05/2010","Neuromorfeo",2009-03-01,"Post-anesthesia awaking time, assessed as the interval (min:sec)required to reach an ALDRETE score ??­ 9|Neurovegetative stress|Intraoperative and post-operative adverse events assessment|Brain relaxation evaluated by a blinded neurosurgeon|Patient's satisfaction|Costs of the three strategies","http://ClinicalTrials.gov/show/NCT00741351",NA
"43188",43188,"NCT00729651","Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis","Completed","Has Results","Osteoporosis Postmenopausal","Drug: alendronate sodium (+) cholecalciferol|Drug: Comparator: Alendronate sodium (Fosamax)|Dietary Supplement: Comparator: Calcium","Merck","Female","Adult|Senior","Phase IV",343,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008_015|MK0217A-263","August 5, 2008","01/03/2008",2009-04-01,"April 6, 2010","01/04/2010","",2009-04-01,"Patients With Serum 25 OHD (Serum 25-hydroxyvitamin D) Below the Deficiency Level (Less Than 15 ng/ml) at 16 Weeks of Treatment|Serum PTH (Parathyroid Hormone) Percentage Changes From Baseline to 16 Weeks of Treatment","http://ClinicalTrials.gov/show/NCT00729651",NA
"43206",43206,"NCT00795951","Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents","Completed","No Results Available","Dermatitis, Contact","Biological: T.R.U.E. Test|Biological: TRUE TEST Diagnostic Patch Test","Allerderm","Both","Child|Adult","Phase IV",102,"Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","MEKOS 07 29P1/2/3/401","November 20, 2008","01/11/2008",2009-11-01,"May 13, 2010","01/05/2010","",2009-10-01,"Frequency and characterization of positive reactions per allergen.|Prevalence of late or persistent reactions, irritation, adhesion, subject-reported itching or burning, and adverse events","http://ClinicalTrials.gov/show/NCT00795951",NA
"43209",43209,"NCT00790751","Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED","Completed","No Results Available","Erectile Dysfunction","Drug: placebo|Drug: avanafil","VIVUS, Inc.|Quintiles","Male","Adult|Senior","Phase III",646,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TA-301","November 10, 2008","01/11/2008",2009-08-01,"November 9, 2010","01/11/2010","REVIVE-G",2009-08-01,"The change in percent of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourse.|The change in percent of sexual attempts in which subjects are able to insert the penis into the partner's vagina.|The change in score on the erectile function (EF) domain of the IIEF questionnaire.|The change in response to individual questions and for other domains (orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction) from the IIEF|Responses to secondary subject diary questions|The response to the Global Assessment Question on treatment effect and the Future Use Question.","http://ClinicalTrials.gov/show/NCT00790751",NA
"43230",43230,"NCT00831051","Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients","Completed","No Results Available","Postoperative Pain","Drug: Q8003|Drug: Morphine sulfate|Drug: Oxycodone HCl|Drug: Q8003|Drug: Morphine sulfate|Drug: Oxycodone HCl 4mg","QRxPharma Inc.","Both","Adult|Senior","Phase II",197,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Q8003-021","January 27, 2009","01/12/2008",2009-02-01,"August 30, 2010","01/08/2010","",2009-01-01,"Difference in pain intensity scores from baseline|Safety: adverse events","http://ClinicalTrials.gov/show/NCT00831051",NA
"43235",43235,"NCT00842751","Oral T-7 Oral Androgens in Man-7","Completed","No Results Available","Healthy Males","Drug: Acyline|Drug: Testosterone Undecanoate|Drug: Finasteride 0.5 mg|Drug: Finasteride 1 mg","University of Washington|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Male","Adult","Phase II",12,"Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","35724-W|1K23HD045386|5U54HD042454","February 10, 2009","01/07/2009",2009-12-01,"April 21, 2010","01/04/2010","Oral T-7",2009-11-01,"To determine what dose of Finasteride, when combined with Oral TU, will yield an average serum testosterone over 24 hours in the eugonadal range while at the same time maintaining serum DHT concentrations within the normal range.","http://ClinicalTrials.gov/show/NCT00842751",NA
"43245",43245,"NCT00860951","P300 Brain Computer Interface Keyboard to Operate Assistive Technology","Completed","No Results Available","Healthy","Device: Brain Computer Interface Keyboard","University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Adult|Senior","Phase I|Phase II",158,"Other|NIH","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research","H0002 - AT P300 Keyboard Study","March 11, 2009","01/09/2008",2009-05-01,"January 14, 2010","01/01/2010","",2009-05-01,"Accuracy of typing with BCI keyboard.","http://ClinicalTrials.gov/show/NCT00860951",NA
"43246",43246,"NCT00863551","Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial","Completed","No Results Available","Elderly|Pharmacokinetics|Overactive Bladder","Drug: Trospium Chloride","Allergan","Both","Adult|Senior","Phase IV",12,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MA-SXR-09-001|SMART Trial","March 16, 2009","01/04/2009",2009-08-01,"September 16, 2010","01/09/2010","",2009-08-01,"Mean concentration of trospium in cerebral spinal fluid at day 10, hour 5|The proportion of study subjects with no clinically significant effect on neurocognitive function as measured by the Hopkins Verbal Learning test-Revised|The proportion of study subjects with no clinically significant effect on neurocognitive function as measured by the Brief Visuospatial Memory Test-Revised","http://ClinicalTrials.gov/show/NCT00863551",NA
"43265",43265,"NCT00689351","Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea","Completed","Has Results","Vaccines|Pneumococcal Conjugate Vaccine","Biological: 13-valent pneumococcal conjugate vaccine|Biological: 7-valent pneumococcal conjugate vaccine","Wyeth","Both","Child","Phase II",180,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Investigator)|Primary Purpose: Prevention","6096A1-010|B1851001","May 29, 2008","01/06/2008",2009-12-01,"December 10, 2010","01/12/2010","",2009-12-01,"Percentage of Participants Achieving a Serotype-specific Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (??­) 0.35 Micrograms Per Milliliter (Mcg/mL) Measured 1 Month After the Infant Series|Percentage of Participants Achieving a Serotype-specific IgG Antibody Level ??­0.35 Mcg/mL Measured 1 Month After the Toddler Dose","http://ClinicalTrials.gov/show/NCT00689351",NA
"43268",43268,"NCT00906451","Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction","Completed","No Results Available","Myocardial Infarction|Inflammation|Endothelial Dysfunction","Drug: Simvastatin","Brasilia Heart Study Group","Both","Adult|Senior","Phase IV",58,"Other","Interventional","Allocation: Non-Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","Simvastatin Post-MI","May 19, 2009","01/11/2008",2009-05-01,"May 20, 2009","01/05/2009","",2009-05-01,"Elevation of plasma C reactive protein|Brachial Artery Endothelial function","http://ClinicalTrials.gov/show/NCT00906451",NA
"43272",43272,"NCT00915551","A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","Completed","No Results Available","Actinic Keratosis","Drug: PEP005 Gel|Drug: Vehicle Gel","Peplin","Both","Adult|Senior","Phase III",278,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","PEP005-025","June 4, 2009","01/06/2009",2009-09-01,"October 6, 2010","01/10/2010","",2009-09-01,"Efficacy (complete and partial clearance of AK lesions)|Safety (Incidence of treatment related AEs, local skin reactions and pigmentation and scarring)","http://ClinicalTrials.gov/show/NCT00915551",NA
"43285",43285,"NCT00927251","Model 4296 Left Ventricular (LV) Lead Study","Completed","Has Results","Heart Failure","Device: Pacing Lead (Model 4296 LV Lead)","Medtronic Cardiac Rhythm Disease Management","Both","Child|Adult|Senior","Phase II",90,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4296","June 23, 2009","01/06/2009",2010-02-01,"December 1, 2010","01/06/2010","4296",2009-12-01,"Number of Participants With Left Ventricular (LV)Lead Related Complications","http://ClinicalTrials.gov/show/NCT00927251",NA
"43286",43286,"NCT00938951","Evaluate the Ability of Systane Ultra to Improve Subjective Symptoms of Ocular Irritation Post 60 Min. Athletic Performance.","Completed","No Results Available","Dry Eye Symptoms|Visual Performance","Drug: Systane?ó Ultra","Alcon Research","Both","Adult|Senior","Phase IV",60,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","SMA-09-22","July 13, 2009","01/06/2009",NA,"February 8, 2010","01/02/2010","",2009-07-01,"Effectiveness of eye drop basd on athlete's opinion/experience during a one hour practice session","http://ClinicalTrials.gov/show/NCT00938951",NA
"43308",43308,"NCT00976651","Low Dose Human Chorionic Gonadotropin: Influence on the Endometrium","Completed","No Results Available","Infertility","Drug: human menopausal gonadotropin","Universitair Ziekenhuis Brussel","Female","Adult","Phase IV",30,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","CBLD2","September 11, 2009","01/01/2009",2009-12-01,"March 24, 2010","01/09/2009","",2009-11-01,"number of oocytes","http://ClinicalTrials.gov/show/NCT00976651",NA
"43360",43360,"NCT01054651","A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni","Completed","No Results Available","Schistosoma Mansoni","Drug: Artesunate+Sulfamethoxypyrazine/pyrimethamine|Drug: Praziquantel","Kenya Medical Research Institute|Dafra Pharma","Both","Child","Phase III",212,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KEMRI SSC 1582|DRD140 - S6.2008","January 21, 2010","01/10/2009",2009-12-01,"January 21, 2010","01/01/2010","",2009-12-01,"Compare the cure rate between the two treatment arms|Compare the proportion of children excreting schistosoma eggs between the two treatment arms|Compare the amount of eggs produced between the two arms|Compare the incidence of clinical and biological adverse events","http://ClinicalTrials.gov/show/NCT01054651",NA
"43491",43491,"NCT01271751","Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity","Completed","No Results Available","Atherogenic Dyslipidaemia|Abdominal Obesity","Drug: GFT505 80mg|Drug: Placebo","Genfit","Both","Adult|Senior","Phase II",96,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GFT505-208-3|2008-005779-86","January 6, 2011","01/01/2009",2009-11-01,"January 6, 2011","01/01/2011","",2009-09-01,"Decrease in serum Triglycerides (TG) level|Increase in serum High Density Lipoprotein Cholesterol (HDL-C) level|Decrease in Low Density Lipoprotein Cholesterol (LDL-C) levels|Decrease in non-HDL-C (High Density Lipoprotein Cholesterol) levels","http://ClinicalTrials.gov/show/NCT01271751",NA
"43569",43569,"NCT00059852","Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane","Completed","No Results Available","Breast Cancer","Drug: erlotinib hydrochloride|Drug: gemcitabine hydrochloride","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000298778|NCCTG-N0234","May 6, 2003","01/06/2003",NA,"February 4, 2009","01/09/2004","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00059852",NA
"43668",43668,"NCT00174252","Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age","Completed","Has Results","Fetal Growth Retardation","Drug: Genotonorm (Somatropin)","Pfizer","Both","Child","Phase III",57,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6281234","September 9, 2005","01/02/2005",2009-04-01,"June 10, 2010","01/06/2009","",2009-04-01,"Percentage of Children With Insulin Growth Factor-1 (IGF-1) > 2 Standard Deviation (SD) at 9 and 12 Months|Change in Height SD Chronological Age (CA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months|Change in Height SD CA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months|Change in Height SD CA From Baseline at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months|Change in Height SD Bone Age (BA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months|Change in Height SD BA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months|Change in Height SD BA From Baseline at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months|Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months|Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months|Summary of Growth Rate SD (BA) at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months|Summary of Growth Rate SD (BA) at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months|Summary of Growth Rate SD (BA) at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months|Analysis of Covariance (ANCOVA) for Height SD CA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months|ANCOVA for Height SD CA at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months|ANCOVA for Height SD BA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months|ANCOVA for Height SD BA at 24 Months in Children With IGF-1 <= 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months|Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months|Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months|IGF-1/Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months|IGF-1/IGFBP-3 Ratio at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months","http://ClinicalTrials.gov/show/NCT00174252",NA
"43670",43670,"NCT00223652","Telephone Administered Psychotherapy for the Treatment of Depression for Veterans in Rural Areas","Completed","No Results Available","Depressive Disorder|Depression","Behavioral: Telephone-administered Cognitive-Behavioral Therapy (T-CBT)","Department of Veterans Affairs","Both","Adult|Senior","Phase II",85,"U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","IIR 03-069","September 20, 2005","01/03/2006",2010-04-01,"November 29, 2010","01/11/2010","",2009-12-01,"Reduction in severity of depression; scores on depression rating scales.|Maintenance of treatment gains.","http://ClinicalTrials.gov/show/NCT00223652",NA
"43734",43734,"NCT00312052","Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease","Completed","No Results Available","Coronary Artery Disease","Drug: E5555|Drug: E5555|Drug: E5555|Drug: Placebo","Eisai Inc.","Both","Adult|Senior","Phase II",600,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E5555-G000-201","April 5, 2006","01/09/2007",2009-09-01,"September 1, 2009","01/09/2009","",2009-02-01,"Safety and tolerability - especially the risk of bleeding|Incidence of major adverse cardiovascular events; the effect on platelet aggregation inhibition. Exploratory Outcome Measure: effects on endovascular inflammatory processes","http://ClinicalTrials.gov/show/NCT00312052",NA
"43761",43761,"NCT00362752","A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome","Completed","No Results Available","Hepatopulmonary Syndrome","Drug: Norfloxacin|Drug: Placebo","St. Michael's Hospital, Toronto|University of Toronto","Both","Adult|Senior","Phase II",20,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","02-120","August 8, 2006","01/10/2006",2009-12-01,"January 26, 2010","01/01/2010","",2009-01-01,"- Primary endpoint: A-a gradient|paO2,|exhaled NO|DLCO|6MWD|CO|TPR|PAP (on echocardiogram)|endotoxin levels|ET-1 levels|MELD score|bilirubin and INR|BDI|TDI|CRQ","http://ClinicalTrials.gov/show/NCT00362752",NA
"43769",43769,"NCT00370552","A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer","Drug: Ixabepilone|Drug: Ixabepilone|Drug: Bevacizumab|Drug: Bevacizumab|Drug: Paclitaxel|Drug: Bevacizumab","Bristol-Myers Squibb","Both","Adult|Senior","Phase II",123,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA163-115","August 30, 2006","01/03/2007",2009-11-01,"July 26, 2010","01/12/2009","",2009-11-01,"Response Rate|duration of response|time to response|week 24 PFS (progression free survival)|PFS and OS (overall survival)","http://ClinicalTrials.gov/show/NCT00370552",NA
"43778",43778,"NCT00384852","A Study of rhBMP-2/CPM in Closed Fractures of the Humerus","Completed","No Results Available","Fractures","Drug: rhBMP-2/CPM","Wyeth","Both","Adult|Senior","Phase II",139,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","3100N7-212","October 3, 2006","01/11/2006",2010-02-01,"April 12, 2010","01/04/2010","",2009-02-01,"The primary efficacy variable in this study is radiographic union.","http://ClinicalTrials.gov/show/NCT00384852",NA
"43781",43781,"NCT00343252","Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis","Completed","Has Results","Osteoporosis, Postmenopausal|Back Pain|Spinal Fracture","Drug: teriparatide|Drug: risedronate|Drug: placebo|Drug: placebo","Eli Lilly and Company","Female","Adult|Senior","Phase III",712,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","9041|B3D-MC-GHCY","June 20, 2006","01/06/2006",2010-06-01,"August 12, 2010","01/08/2010","",2009-06-01,"Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 6-Month Endpoint|Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 12-Month Endpoint|Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 6-Month Endpoint|Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 12-Month Endpoint|Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 6 Months|Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 12 Months|Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 6 Months|Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 12 Months|Change From Baseline to 3-Month Endpoint in the Roland-Morris Disability Questionnaire.|Change From Baseline to 6-Month Endpoint in the Roland-Morris Disability Questionnaire.|Change From Baseline to 12-Month Endpoint in the Roland-Morris Disability Questionnaire.|Change From Baseline to 6-Month Endpoint, European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO)|Change From Baseline to 12-Month Endpoint, European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO)|Safety|Safety|Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 18-Month Endpoint|Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 18-Month Endpoint|Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 18 Months|Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 18 Months|Change From Baseline to 18-Month Endpoint in the Roland-Morris Disability Questionnaire.|Change From Baseline to 18-Month Endpoint in European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO)","http://ClinicalTrials.gov/show/NCT00343252",NA
"43803",43803,"NCT00419952","A Comparison of SYMBICORT pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.","Completed","No Results Available","Asthma","Drug: Budesonide/formoterol (SYMBICORT) pMDI|Drug: Budesonide HFA pMDI","AstraZeneca","Both","Child|Adult|Senior","Phase III",720,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","D5896C00022","January 5, 2007","01/02/2007",2009-11-01,"April 23, 2010","01/04/2010","",2009-11-01,"To assess the long-term safety profile of SYMBICORT pMDI 160/4.5 ??g x 2 actuations twice daily compared to budesonide HFA pMDI 160 ??g x 2 actuations twice daily, in African American subjects with moderate to severe asthma, over a 52-week treatment perio|Patient reported outcome variables over a 52-week treatment period collected using Onset of Effect Questionnaire to assess pre-dose FEV1 and morning peak expiratory flow (AM PEF)|To collect a blood sample for pharmacogenetic analyses in all subjects","http://ClinicalTrials.gov/show/NCT00419952",NA
"43821",43821,"NCT00451152","Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma","Completed","No Results Available","Open-Angle Glaucoma","Drug: Anecortave Acetate","Alcon Research","Both","Adult|Senior","Phase II",81,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","C-06-19","March 21, 2007","01/03/2007",NA,"September 10, 2009","01/09/2009","",2009-08-01,"Mean IOP|Percentage of patients declared treatment failures","http://ClinicalTrials.gov/show/NCT00451152",NA
"43822",43822,"NCT00448552","Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: capecitabine|Drug: oxaliplatin","University of Miami Sylvester Comprehensive Cancer Center","Both","Adult|Senior","Phase II",30,"Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","EPROST-20030243|SCCC-2003050|WIRB-20060071","March 15, 2007","01/02/2004",2009-06-01,"April 7, 2010","01/01/2010","",2009-06-01,"Objective response rate (complete response and partial response)|Toxicity as measured by NCI CTC|Survival","http://ClinicalTrials.gov/show/NCT00448552",NA
"43831",43831,"NCT00465452","Impact of Switching to Continuous Release Dopamine Agonists","Completed","No Results Available","Parkinson Disease","Drug: Continuous Release Dopamine Agonists","University of Toledo Health Science Campus","Both","Adult|Senior","Phase III",15,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MUO-04","April 24, 2007","01/01/2007",2009-03-01,"March 18, 2009","01/03/2009","",2009-03-01,"Equal or improved motor scores as measured by the Unified Parkinson's Disease Rating Scale (UPDRS), parts 3 (motor performance) and 4 (disability).|A significant improvement in somnolence as measured by the Epworth Sleepiness Scale (ESS).|A significant stabilization or improvement in the cognitive/mood battery of the Mini-Mental Status Exam (MMSE), the Clock Drawing Test (CDT), the Patient Health Questionnaire (PHQ-9) and the Neuropsychiatric Inventory Questionnaire (NPI-Q).|An improvement in peripheral edema, as measured by quantitative assessment of ankle and calf edema.|Increased patient satisfaction/preference (Patient Satisfaction Questionnaire - PS) scores.|Improvement in quality of life (Parkinson's Disease Questionnaire - PDQ-39).","http://ClinicalTrials.gov/show/NCT00465452",NA
"43869",43869,"NCT00335452","Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS","Completed","Has Results","Acute Coronary Disease|Angina Unstable","Drug: Clopidogrel|Drug: acetylsalicyclic acid (ASA)","Sanofi-Aventis|Bristol-Myers Squibb","Both","Adult|Senior","Phase III",25086,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC5965|EUDRACT: 2006-000313-38","June 8, 2006","01/06/2006",2009-09-01,"November 9, 2010","01/11/2010","CURRENT/OASIS7",2009-09-01,"First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison|First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison|First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level|First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup|Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison|Occurrence of Major Bleeding - ASA Dose Level Comparison","http://ClinicalTrials.gov/show/NCT00335452",NA
"43875",43875,"NCT00535652","Concentration of Ertapenem in Colorectal Tissue","Completed","No Results Available","Diverticulosis, Colonic|Rectal Neoplasms|Colonic Neoplasms","Drug: Ertapenem","University of Ulm","Both","Adult|Senior","Phase IV",23,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-Jul","September 24, 2007","01/09/2007",2009-12-01,"April 5, 2010","01/02/2009","",2009-12-01,"Concentration of ertapenem in colorectal tissue in mg/kg 3 to 6 hours after a single dose of 1 gram ertapenem I.V..|safety assessment","http://ClinicalTrials.gov/show/NCT00535652",NA
"43890",43890,"NCT00559052","An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)","Completed","No Results Available","Exocrine Pancreatic Insufficiency","Drug: VIOKASE 16","Axcan Pharma|AAIPharma|Mayo Clinical Services|City Hospital Laboratory Birmingham","Both","Adult|Senior","Phase II",22,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic","VIO16IP07-01","November 14, 2007","01/03/2008",2009-02-01,"February 9, 2010","01/02/2010","",2009-02-01,"Evaluation of the Intraduodenal Lipase activity following single dose administration of VIOKASE16 tablets in EPI after a liquid meal.|Evaluation of the Intraduodenal protease and amylase activities following administration of VIOKASE16 tablets in EPI after a liquid meal.","http://ClinicalTrials.gov/show/NCT00559052",NA
"43908",43908,"NCT00578552","Gabapentin for Smoking Cessation","Completed","Has Results","Cigarette Smoking|Tobacco Use","Drug: Placebo|Drug: Gabapentin - 1800 mg/day|Drug: Gabapentin - 2700 mg/day","Mayo Clinic","Both","Adult","Phase II",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","06-005262|07-000700","December 19, 2007","01/10/2007",2009-05-01,"December 1, 2010","01/12/2010","",2009-02-01,"Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco","http://ClinicalTrials.gov/show/NCT00578552",NA
"43913",43913,"NCT00595452","Study Comparing Satisfaction and Perceptions for Two Different Delivery Mechanisms for Rheumatoid Arthritis Patients Administered Etanercept","Completed","No Results Available","Active Rheumatoid Arthritis","Device: Etanercept Prefilled Syringe|Device: Etanercept Autoinjector","Wyeth","Both","Adult|Senior","Phase III",264,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0881K1-3329","December 20, 2007","01/11/2007",2009-09-01,"February 23, 2010","01/02/2010","",2009-04-01,"Perception and satisfaction","http://ClinicalTrials.gov/show/NCT00595452",NA
"43932",43932,"NCT00626652","Study of K201 Injection on Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation","Completed","No Results Available","Atrial Fibrillation","Drug: K201 Injection","Sequel Pharmaceuticals, Inc","Both","Adult|Senior","Phase II",153,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CJI-201","February 18, 2008","01/03/2008",2009-12-01,"January 7, 2010","01/01/2010","RESTORATION",2009-12-01,"Restoration of sinus rhythm","http://ClinicalTrials.gov/show/NCT00626652",NA
"43961",43961,"NCT00624052","26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension","Completed","Has Results","Hypertension","Drug: fixed-dose combination of telmisartan 40mg+amlodipine 10mg|Drug: fixed-dose combination of telmisartan 80mg+amlodipine10mg","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",838,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","1235.8","February 5, 2008","01/03/2008",NA,"September 1, 2010","01/09/2010","",2009-06-01,"Trough Seated Diastolic Blood Pressure (DBP) Control|Trough Seated Systolic Blood Pressure (SBP) Control|Change From Baseline to End of Study in Trough Seated Diastolic Blood Pressure|Change in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052|Change From Baseline to End of Study in Trough Seated Systolic Blood Pressure|Change in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052|Trough Seated DBP Response|Trough Seated SBP Response|Trough BP Normality Classes|Time to First Additional Antihypertensive|Number of Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control|Additional Reduction in DBP by Use of Additional Antihypertensive Therapy|Additional Reduction in SBP by Use of Additional Antihypertensive Therapy|Trough DBP Control Pre- and Post- Uptitration","http://ClinicalTrials.gov/show/NCT00624052",NA
"43965",43965,"NCT00681252","Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer","Completed","No Results Available","Gastric Cancer","Biological: URLC10, VEGFR1 and VEGFR2","Tokyo University|Human Genome Center, Institute of Medical Science, University of Tokyo","Both","Adult|Senior","Phase I|Phase II",14,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMS-MKA0201","May 19, 2008","01/05/2008",2009-04-01,"November 18, 2009","01/11/2009","",2009-04-01,"safety (Phase I: toxicities as assessed by NCI CTCAE version 3) and efficacy (Phase II: Feasibility as evaluated by RECIST)|To evaluate immunological responses","http://ClinicalTrials.gov/show/NCT00681252",NA
"43967",43967,"NCT00683852","A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy","Completed","No Results Available","Major Depressive Disorder","Drug: Aripiprazole|Drug: Aripiprazole|Drug: Placebo","Massachusetts General Hospital|Bristol-Myers Squibb","Both","Adult","Phase III",224,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BMS - 2008A053242","May 22, 2008","01/07/2008",2009-09-01,"August 11, 2010","01/08/2010","",2009-09-01,"The primary outcome will be the difference in rate of response (decrease in MADRS total score of at least 50%) between patients treated with adjunctive aripiprazole 2 mg and adjunctive placebo using the sequential parallel comparison design.|To document the safety and tolerability of low doses of aripiprazole augmentation","http://ClinicalTrials.gov/show/NCT00683852",NA
"43983",43983,"NCT00709852","Safety and Efficacy of Gadobutrol 1.0 Molar (Gadovist?ó) in Patients for Central Nervous System (CNS) Imaging","Completed","No Results Available","Diagnostic Imaging|Central Nervous System Diseases","Drug: Gadobutrol (Gadovist, BAY86-4875)|Drug: Gadoteridol (ProHance)","Bayer","Both","Adult|Senior","Phase III",402,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","91681|EudraCT: 2007-004746-33|310123","July 1, 2008","01/06/2008",2009-05-01,"November 18, 2010","01/11/2010","",2009-05-01,"To demonstrate superiority of combined unenhanced and gadobutrol-enhanced magnetic resonance imaging (MRI).|To demonstrate noninferiority of combined unenhanced and gadobutrol-enhanced magnetic resonance imaging (MRI).|To demonstrate noninferiority of gadobutrol compared to gadoteridol for: degree of contrast enhancement, border delineation, internal morphology, total number of lesions|Demonstrate improvement of gadobutrol-enhanced MRI to unenhanced MRI and noninferiority to gadoteridol-enhanced MRI for: exact match of the MR diagnoses with the final clinical diagnosis|Assess the safety profile of gadobutrol compared to gadoteridol after intravenous (IV) administration","http://ClinicalTrials.gov/show/NCT00709852",NA
"43988",43988,"NCT00718952","The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension","Completed","No Results Available","Pulmonary Hypertension","Drug: Vardenafil|Drug: Placebo|Drug: Vardenafil","Tongji University","Both","Child|Adult","Phase III",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","EVALUATION-01","July 18, 2008","01/07/2008",2010-02-01,"February 11, 2010","01/02/2010","EVALUATION",2009-12-01,"The change in exercise capacity, as measured by the total distance walked in six minutes|The reduction of mean pulmonary-artery pressure(mPAP)and pulmonary vascular resistance(PVR)|The increase of cardiac output(CO)|The increase of Peripheral Saturation of oxygen(SPO2)|The change in the Borg dyspnea index(a measure of perceived breathlessness on a scale of 0 to 10, with higher values indicating more severe dyspnea)|The change in World Health Organization (WHO) functional classification of pulmonary arterial hypertension (an adaptation of the New York Heart Association classification)|Time from randomization to clinical worsening(defined as death, transplantation,hospitalization for PAH and worse right heart failure,acute heart failure,or vardenafil allergy,or worsening leading to discontinuation,need for epoprostenol or bosentan)","http://ClinicalTrials.gov/show/NCT00718952",NA
"43989",43989,"NCT00722852","Study of Safety and Efficacy of Diractin?ó for the Treatment of Osteoarthritis (OA) of the Knee","Completed","No Results Available","Osteoarthritis of the Knee","Drug: ketoprofen in Diractin?ó|Drug: Placebo","IDEA AG","Both","Adult|Senior","Phase III",555,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CL-033-III-06","July 24, 2008","01/06/2008",2009-04-01,"October 2, 2009","01/10/2009","",2009-02-01,"pain subscale of the WOMAC|Patient global assessment of response to therapy|function subscale of the WOMAC","http://ClinicalTrials.gov/show/NCT00722852",NA
"43998",43998,"NCT00673452","A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia","Completed","Has Results","Fibromyalgia","Drug: duloxetine hydrochloride|Drug: placebo","Eli Lilly and Company|Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase IV",530,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12220|F1J-US-HMGB","May 5, 2008","01/06/2008",2009-07-01,"May 28, 2010","01/05/2010","",2009-04-01,"Patient's Global Impressions of Improvement (PGI-I) at Week 12|Change From Baseline in Brief Pain Inventory (BPI) (Modified Short Form) at 12 Week Endpoint|Change From Baseline in Multidimensional Fatigue Inventory (MFI) at 12 Week Endpoint|Change From Baseline in Beck Depression Inventory-II (BDI-II) at 12 Week Endpoint|Change From Baseline in Clinical Global Impressions of Severity (CGI-S) at 12 Week Endpoint|Change From Baseline in Beck Anxiety Inventory (BAI) at 12 Week Endpoint|Change From Baseline in 36-Item Short-form Health Survey (SF-36) at 12 Weeks|Change From Baseline in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score at 12 Week Endpoint|Change From Baseline in the Mood, Anxiety, Pain, Sleep, and Stiffness Likert Scale at 12 Week Endpoint|Number of Responders: 30% Improvement in Brief Pain Inventory Average Pain at 12 Week Endpoint|Number of Responders: 50% Improvement in Brief Pain Inventory Average Pain Score at 12 Week Endpoint|Change From Baseline in Blood Pressure at 12 Week Endpoint|Change From Baseline in Heart Rate at 12 Week Endpoint|Number of Patients With Columbia Suicide Severity Rating Scale (CSSR-S) Events (Behaviors, Ideations, Acts)|Change From Baseline in Weight at 12 Week Endpoint","http://ClinicalTrials.gov/show/NCT00673452",NA
"44004",44004,"NCT00750152","Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris","Completed","No Results Available","Tinea Cruris|Jock Itch","Drug: NAFT-500|Drug: Placebo","Merz Pharmaceuticals, LLC","Both","Child|Adult|Senior","Phase III",334,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MRZ 90200/FI/3001","September 9, 2008","01/09/2008",2010-02-01,"August 20, 2010","01/08/2010","",2009-08-01,"the percentage of subjects at the 2 week time point post treatment with complete cure defined as negative mycology results from the central laboratory (dermatophyte culture, KOH and Physicians Global Evaluation score of 1).|Mycological Cure;Clinical Cure;Clinical Success;Physicians Global Evaluation; Subject Satisfaction Assessment","http://ClinicalTrials.gov/show/NCT00750152",NA
"44033",44033,"NCT00799552","Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye","Completed","No Results Available","Dry Eye Syndrome","Drug: RX-10045|Drug: Placebo","Resolvyx Pharmaceuticals, Inc","Both","Adult|Senior","Phase II",232,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","08-004-03","November 26, 2008","01/11/2008",2009-06-01,"September 20, 2010","01/09/2010","",2009-05-01,"Corneal fluorescein staining and integrated subject diary data|Changes in dry eye signs and symptoms","http://ClinicalTrials.gov/show/NCT00799552",NA
"44044",44044,"NCT00826852","Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-Tax","Completed","No Results Available","Lung Neoplasms","Drug: docetaxel and carboplatin","Sanofi-Aventis","Both","Child|Adult|Senior","Phase II",49,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976B_6020","October 13, 2008","01/10/2003",2009-07-01,"July 26, 2010","01/07/2010","",2009-07-01,"Efficacy by response rate|Adverse events|Efficacy by time to progression|Overall survival","http://ClinicalTrials.gov/show/NCT00826852",NA
"44095",44095,"NCT00889252","Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers","Completed","Has Results","Allergic Conjunctivitis","Device: contact lens with ketotifen|Device: contact lens","Vistakon Pharmaceuticals","Both","Child|Adult|Senior","Phase III",250,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CR-4539","April 24, 2009","01/04/2009",NA,"October 26, 2010","01/10/2010","",2009-07-01,"Lid and Lid Margin Erythema, Change From Baseline|Lid and Lid Margin Swelling, Change From Baseline|Conjunctival Redness, Change From Baseline|Conjunctival Chemosis, Change From Baseline|Corneal Edema, Change From Baseline|Corneal Erosion, Change From Baseline|Corneal Endothelial, Change From Baseline|Lens Pathology, Change From Baseline|Flare in Anterior Chamber, Change From Baseline|Cells in Anterior Chamber, Change From Baseline|Corneal Staining - Nasal, Change From Baseline|Corneal Staining - Temporal, Change From Baseline|Corneal Staining - Inferior, Change From Baseline|Corneal Staining - Superior, Change From Baseline|Corneal Staining - Central, Change From Baseline|Intraocular Pressure - Change From Baseline|Dilated Ophthalmoscopy - Fundus, Change From Baseline|Dilated Ophthalmoscopy - Vitreous, Change From Baseline|Visual Acuity Assessment","http://ClinicalTrials.gov/show/NCT00889252",NA
"44113",44113,"NCT00947752","Safety of New Formulation of Glatiramer Acetate","Completed","No Results Available","Relapsing Remitting Multiple Sclerosis (RRMS)","Drug: Glaterimer Acetate|Drug: Glaterimer acetate (GA)","Teva Pharmaceutical Industries","Both","Adult|Senior","Phase III",132,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","PM033","July 25, 2009","01/07/2009",2009-11-01,"April 27, 2010","01/04/2010","Song",2009-09-01,"To compare subject-reported pain associated with injections of a 20mg/1.0mL formulation of GA (F1) versus 20mg/0.5mL formulation of GA (F2) occurring immediately after injection|To compare subject-reported pain with injections F1 versus F2 five mins following injection and subject-reported LISR and degree of severity with injections occurring within 5 mins an within 24 hours","http://ClinicalTrials.gov/show/NCT00947752",NA
"44125",44125,"NCT00969852","Pharmacokinetics and Pharmacodynamics of Sertraline After Low Dose Administration","Completed","No Results Available","Healthy","Drug: Sertraline","Seoul National University Hospital|Ministry of Health, Welfare and Family Affairs|Korea National Enterprise for Clinical Trials","Male","Adult","Phase IV",10,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SNUCPT09_Sertraline","August 29, 2009","01/07/2009",2010-03-01,"January 9, 2011","01/01/2011","",2009-08-01,"Serotonin receptor occupancy|Plasma concentration of sertraline","http://ClinicalTrials.gov/show/NCT00969852",NA
"44140",44140,"NCT00993252","Canadian Computed Tomography (CT) Head Rule Study","Completed","No Results Available","Head Injury","Procedure: CT Scan","Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR)","Both","Child|Adult|Senior","Phase III",4531,"Other","Interventional","Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","42521|2003165-01H","April 21, 2008","01/09/2003",2009-03-01,"October 13, 2010","01/10/2010","",2009-01-01,"Computed tomography ordering proportions|Number of missed CTs|Number of serious adverse outcomes|Length of stay in emergency department (ED)|Patient satisfaction|Sustainability of the intervention|Performance of the Canadian CT Head Rule|Economic evaluation measures","http://ClinicalTrials.gov/show/NCT00993252",NA
"44219",44219,"NCT01115452","Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity","Completed","No Results Available","Dentin Sensitivity","Drug: Higher level potassium nitrate solution|Drug: Lower level pottassium nitrate solution|Other: Sterile water","GlaxoSmithKline","Both","Adult","Phase II",32,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","Z3770633","April 30, 2010","01/09/2009",2009-10-01,"May 20, 2010","01/05/2010","",2009-10-01,"Change from baseline dentinal hypersensitivity after post evaporative (air) stimulus|Change from baseline dentinal hypersensitivity after post evaporative (air) stimulus","http://ClinicalTrials.gov/show/NCT01115452",NA
"44314",44314,"NCT01270152","Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter","Completed","No Results Available","Occluded Totally Implanted Central Venous Catheter","Drug: Ascorbic Acid","University of Sao Paulo","Both","Adult|Senior","Phase II",21,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","0925-0586","January 4, 2011","01/10/2008",2010-07-01,"January 4, 2011","01/01/2011","",2009-12-01,"Restore patency|Eosinophil count","http://ClinicalTrials.gov/show/NCT01270152",NA
"44417",44417,"NCT00094653","MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma","Completed","No Results Available","Melanoma|Metastases","Drug: MDX-010 (anti-CTLA4) monoclonal antibody|Biological: MDX-1379 Melanoma Peptide Vaccine","Bristol-Myers Squibb","Both","Adult|Senior","Phase III",676,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","MDX010-20|CA184-002","October 21, 2004","01/09/2004",2009-10-01,"September 10, 2010","01/04/2010","",2009-08-01,"Comparison of overall survival of patients administered MDX-010 in combination with gp 100 melanoma peptide vaccine versus those administered gp 100 melanoma peptide vaccine alone|Determination of Best overall response rate (BORR)|Major durable response rate|duration of response|progression free survival|time to progression|health-related Quality of Life|Comparison of overall survial of patients administered MDX-010 in combination with gp100 melanoma vaccine vs MDX-010 monotherapy and patients administered vaccine monotherapy vs MDX-010 monotherpay","http://ClinicalTrials.gov/show/NCT00094653",NA
"44465",44465,"NCT00179153","Improving The Nutritional Status Of The Malnourished Chronic Hemodialysis Patients In The State Of Tennessee","Completed","No Results Available","End Stage Renal Disease","Dietary Supplement: Nepro nutritional supplement","Vanderbilt University","Both","Adult|Senior","Phase II",352,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","40345","September 13, 2005","01/02/2005",2009-05-01,"September 23, 2010","01/09/2010","",2009-05-01,"increase in serum albumin","http://ClinicalTrials.gov/show/NCT00179153",NA
"44476",44476,"NCT00193453","Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: Gemcitabine|Drug: Docetaxel|Drug: Cetuximab","Sarah Cannon Research Institute|Bristol-Myers Squibb","Both","Adult|Senior","Phase II",69,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI LUN 92|CA225 117","September 12, 2005","01/07/2005",2009-12-01,"November 2, 2010","01/11/2010","",2009-02-01,"Overall clinical response rate|Progression free survival|Toxicity of drug combination","http://ClinicalTrials.gov/show/NCT00193453",NA
"44496",44496,"NCT00222053","IFM 99-02 Thalidomide in Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide|Drug: Biphosphonates","University Hospital, Toulouse","Both","Adult","Phase III",800,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PHRC 98-45-N","September 15, 2005","01/04/2000",2009-12-01,"April 1, 2010","01/04/2010","",2009-09-01,"Duration of response|Survival|Toxicity","http://ClinicalTrials.gov/show/NCT00222053",NA
"44572",44572,"NCT00337753","Cognitive Behavioral Therapy for Pathological Gambling","Completed","No Results Available","Pathological Gambling","Behavioral: Cognitive Behavioral Therapy|Behavioral: Wait-list","University of Minnesota - Clinical and Translational Science Institute|National Institute of Mental Health (NIMH)","Both","Adult|Senior","Phase II",76,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0503M68191|K23MH069754-01A1","June 14, 2006","01/06/2006",2009-06-01,"January 4, 2010","01/01/2010","",2009-06-01,"PG-YBOCS|Time spent gambling","http://ClinicalTrials.gov/show/NCT00337753",NA
"44580",44580,"NCT00350753","Avastin and Tarceva for Upper Gastrointestinal Cancers","Completed","No Results Available","Cholangiocarcinoma|Gallbladder Cancer","Drug: Erlotinib and bevacizumab","Rigshospitalet, Denmark|Morten Ladekarl, MD, DMSc.,Dept. of Oncology, ??rhus University Hospital, Denmark","Both","Child|Adult|Senior","Phase II",126,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EB-UGI-01|2006-001308-35","July 10, 2006","01/06/2006",2009-06-01,"July 14, 2009","01/07/2009","",2009-06-01,"Objective response by RECIST criteria|Time to progression|Toxicity evaluated by NCI-CTCae version 3.0|Survival|Biomarkers","http://ClinicalTrials.gov/show/NCT00350753",NA
"44587",44587,"NCT00365053","PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery","Completed","No Results Available","Malignant Mesothelioma","Drug: belinostat|Genetic: reverse transcriptase-polymerase chain reaction|Other: laboratory biomarker analysis","California Cancer Consortium|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",37,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000489194|U01CA062505|CCC-PHII-67|NCI-7255","August 16, 2006","01/06/2006",NA,"October 11, 2010","01/10/2010","",2009-03-01,"Objective tumor response rate as measured by RECIST criteria|Overall survival by Kaplan-Meier|Time to progression by Kaplan-Meier|Toxicity profile|Effect of PXD101 on apoptosis and histone acetylation as measured by TUNEL assay, immunohistochemistry, and western blot","http://ClinicalTrials.gov/show/NCT00365053",NA
"44591",44591,"NCT00368953","YUKON Choice Versus TAXUS Libert?¢ in Diabetes Mellitus","Completed","No Results Available","Coronary Arteriosclerosis","Device: Yukon Choice stent system|Device: Taxus Libert?¢ stent system","University of Leipzig|Translumina GmbH","Both","Adult|Senior","Phase IV",240,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","Lipsia-Yukon-DM","August 28, 2006","01/09/2006",2009-12-01,"February 1, 2010","01/01/2010","",2009-12-01,"\In-stent late lumen loss\"" at follow-up-angiography (9 months)|Binary restenosis|Target vessel revascularisation rate|Target lesion revascularisation rate|Late loss (in-segment)|MLD und diameter of stenosis (%)|Death|Success rate index procedure (residual diameter stenosis < 30%)|Combined MACE (cardiac death","http://ClinicalTrials.gov/show/NCT00368953",NA
"44593",44593,"NCT00371553","Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer","Completed","No Results Available","Relapsed or Cisplatin-Refractory Germ Cell Cancer","Drug: SU011248 (Sunitinib)","British Columbia Cancer Agency|Canadian Urologic Oncology Group|NCIC Testis Group|German Testicular Cancer Study Group (GTSCG)","Male","Adult|Senior","Phase II",33,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Testis protocol Version 003|CUOG-TE 05/OZM-007","September 1, 2006","01/11/2006",2009-06-01,"July 7, 2009","01/07/2009","",2009-06-01,"Response Rate|Rate and duration of stable disease|Time to progression.|Median and 1 yr survival|Safety and tolerability of SU011248","http://ClinicalTrials.gov/show/NCT00371553",NA
"44607",44607,"NCT00394953","A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.","Completed","No Results Available","Anemia","Drug: methoxy polyethylene glycol-epoetin beta [Mircera]|Drug: Darbepoetin alfa","Hoffmann-La Roche","Both","Adult|Senior","Phase III",490,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BH17847","November 1, 2006","",2009-03-01,"July 15, 2009","01/07/2009","",2009-03-01,"Percentage of patients with average Hb decrease from baseline <=1.0g/dL, and an average Hb >=10.5g/dL|Change in dose over time|AEs, laboratory parameters, vital signs","http://ClinicalTrials.gov/show/NCT00394953",NA
"44611",44611,"NCT00398853","Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes","Completed","No Results Available","Type 2 Diabetes","Dietary Supplement: chromium picolinate 1000 mcg daily vs placebo","Pennington Biomedical Research Center","Both","Adult|Senior","Phase IV",100,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R01 DK060126","November 9, 2006","01/10/2003",2009-06-01,"January 25, 2010","01/04/2009","",2009-04-01,"Insulin Sensitivity as assessed with hyperinsulinemic-euglycemic clamps|glucose control|body weight and fat distribution, myocellular and intrahepatic lipid content as assessed with MRS scans","http://ClinicalTrials.gov/show/NCT00398853",NA
"44635",44635,"NCT00435253","US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study","Completed","No Results Available","Pulmonary Emphysema","Biological: BLVR Treatment","Aeris Therapeutics","Both","Adult|Senior","Phase II",20,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-C06-003","February 7, 2007","01/02/2007",2009-06-01,"January 14, 2010","01/01/2010","",2009-06-01,"Reduction in gas trapping|SAEs - Safety of treatment and the procedure|Improvement in vital capacity|Improvement in expiratory flow|Improvement in inspiratory flow|Improvement in dyspnea symptoms (breathlessness)|Improvement in exercise capacity|Improvement in respiratory quality of life","http://ClinicalTrials.gov/show/NCT00435253",NA
"44637",44637,"NCT00436553","Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization","Completed","No Results Available","Macular Degeneration|Choroidal Neovascularization","Drug: Verteporfin for injection, Ranibizumab injection|Drug: ranibizumab","Novartis","Both","Adult|Senior","Phase II|Phase III",321,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CBPD952A2308","February 16, 2007","01/02/2007",NA,"May 10, 2010","01/05/2010","",2009-10-01,"Change from baseline in Best-Corrected Visual Acuity (BCVA) (letters) at Month 12 and Treatment-free interval of at least 3 months duration until Month 12|Retreatment pattern of combination therapy until Month 12/24 based on the time to first retreatment, the number of retreatment, and the proportion of patients with a treatment-free interval of at least 3 months duration until Month 24|Safety of combination therapy and monotherapy over 24 months|Changes in Best Corrected Visual Acuity from baseline over 24 months|Angiographic and optical coherence tomography (OCT) outcomes from baseline over 24 months|Onset of effect assessed by change from baseline in BCVA at Months 1, 2 and 3","http://ClinicalTrials.gov/show/NCT00436553",NA
"44649",44649,"NCT00443053","Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)","Completed","Has Results","Thrombosis, Venous|Superficial Thrombophlebitis","Drug: Fondaparinux 2.5mg or placebo","GlaxoSmithKline","Both","Adult|Senior","Phase III",3002,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ART108053|EudraCT number 2006-004774-27","March 2, 2007","01/03/2007",2009-07-01,"November 24, 2010","01/11/2010","",2009-07-01,"Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47|Number of Participants With at Least One Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 77|Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77|Number of Participants Who Required Surgery to Treat Superficial Vein Thrombosis Recurrence at Days 47 and 77|Number of Adjudicated Major Bleeding Events and Deaths at Days 47 and 77|Number of Adjudicated Non-Major Bleeding Events at Days 47 and 77|Number of Any Adjudicated Bleeding Events at Days 47 and 77","http://ClinicalTrials.gov/show/NCT00443053",NA
"44713",44713,"NCT00531453","A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma","Completed","Has Results","Multiple Myeloma","Drug: bortezomib, dexamethasone, and thalidomide|Drug: bortezomib, dexamethasone, thalidomide, and cyclophosphamide","Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult|Senior","Phase II",98,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","26866138-MMY-2043","September 14, 2007","01/10/2007",2009-05-01,"June 4, 2010","01/06/2010","",2009-04-01,"Percent of Particpants Achieving Overall Combined Complete Response (CR) Following Induction|Percent of Participants Achieving Overall Combined Complete Response (CR) Following High-dose Chemotherapy (HDT)/Stem Cell Transplantation (SCT)","http://ClinicalTrials.gov/show/NCT00531453",NA
"44719",44719,"NCT00565253","Inhaled Nitric Oxide in Pulmonary Embolism","Completed","No Results Available","Pulmonary Embolism","Drug: Inhaled nitric oxide (NO)","Medical University of Vienna","Both","Adult|Senior","Phase II",30,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3052001","November 28, 2007","01/03/2005",2009-12-01,"June 22, 2010","01/06/2010","",2009-07-01,"right ventricular size and arterial oxygenation|blood pressure, central venous pressure, right ventricular function, pulmonary artery pressure","http://ClinicalTrials.gov/show/NCT00565253",NA
"44739",44739,"NCT00597753","Hematide?ºÑ Injection for Anemia in Chronic Hemodialysis (HD) Patients","Completed","No Results Available","Chronic Renal Failure|Chronic Kidney Disease|Anemia","Drug: Hematide?ºÑ|Drug: Epoetin Alfa","Affymax","Both","Adult|Senior","Phase III",803,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AFX01-12","January 10, 2008","01/09/2007",2010-01-01,"October 7, 2010","01/10/2010","EMERALD 1",2009-07-01,"Mean change in Hgb between baseline and the Evaluation Period|Proportion of patients who receive red blood cell (RBC) transfusions during the Titration and Evaluation Periods.|Proportion of patients whose mean Hgb level during the Evaluation Period is within the target range of 10.0 - 12.0 g/dL.","http://ClinicalTrials.gov/show/NCT00597753",NA
"44740",44740,"NCT00592553","Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (DMD/BMD)","Completed","No Results Available","Duchenne Muscular Dystrophy|Becker Muscular Dystrophy","Drug: PTC124|Drug: PTC124|Drug: PTC124","PTC Therapeutics","Male","Child|Adult|Senior","Phase II|Phase III",165,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTC124-GD-007-DMD","January 1, 2008","01/02/2008",2009-12-01,"March 3, 2010","01/03/2010","",2009-12-01,"To determine the effect of PTC124 on ambulation in subjects with nonsense-mutation-mediated DMD/BMD (as assessed by changes in the distance walked during a 6-minute walk test)|Activity in the community setting|Proximal muscle function|Muscle strength|Muscle fragility|Biceps muscle dystrophin expression|Quality of Life|Cognitive ability|Cardiac function|Frequency of accidental falls during ambulation|Treatment satisfaction|Safety|Compliance with treatment|PTC124 pharmacokinetics","http://ClinicalTrials.gov/show/NCT00592553",NA
"44744",44744,"NCT00591253","Efficacy and Safety of Azilsartan Medoxomil in African American Subjects With Essential Hypertension","Completed","No Results Available","Essential Hypertension","Drug: Azilsartan medoxomil|Drug: Azilsartan medoxomil|Drug: Placebo","Takeda Global Research & Development Center, Inc.","Both","Adult|Senior","Phase III",413,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01-06-TL-491-011|U1111-1113-8925","December 27, 2007","01/10/2007",2009-04-01,"July 14, 2010","01/07/2010","",2009-04-01,"Change from baseline to Week 6 in the 24-hour mean systolic blood pressure by ambulatory blood pressure monitor.|Change from baseline to Week 6 in trough clinic sitting systolic blood pressure.|Change from baseline to Week 6 in the 24-hour mean diastolic blood pressure by ambulatory blood pressure monitor.|Change from baseline to Week 6 in trough clinic sitting diastolic blood pressure.|Change from baseline for daytime mean (6am to 10pm) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for daytime mean (6am to 10pm) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) diastolic blood pressure by ambulatory blood pressure monitor|Proportion of subjects who achieve a Clinic Diastolic Blood Pressure Response, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg|Proportion of subjects who achieve a Clinic Systolic Blood Pressure Response, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg|Proportion of subjects who achieve both a clinic Diastolic and Systolic Blood Pressure Response","http://ClinicalTrials.gov/show/NCT00591253",NA
"44748",44748,"NCT00605553","Study to Evaluate SYN115 in Parkinson's Disease","Completed","No Results Available","Parkinson's Disease","Drug: Placebo|Drug: SYN115","Synosia Therapeutics, Inc.","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SYN115-CL01","January 15, 2008","01/04/2008",NA,"December 3, 2009","01/12/2009","",2009-05-01,"This is an exploratory study to evaluate effects of SYN115 in patients with PD, as determined by clinical and fMRI evaluation. The results of this initial study will help determine the range to be used in subsequent studies.|Pittsburgh side effect scale|VAS for overall well being, dizziness/light-headedness, nausea/vomiting, mood anxiety|Measurement of motor symptoms of Parkinson's disease and tapping speed","http://ClinicalTrials.gov/show/NCT00605553",NA
"44759",44759,"NCT00621153","Candesartan Effect in Second Stage Arterial Hypertension","Completed","Has Results","Stage II Hypertension","Drug: Candesartan Cilexetil|Drug: Hydrochlorothiazide|Drug: Candesartan Cilexetil","AstraZeneca","Both","Adult|Senior","Phase IV",214,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D2452L00016","January 24, 2008","01/02/2008",2009-03-01,"February 24, 2010","01/04/2009","CAESAR",2009-03-01,"Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy|Changes in Mean Sitting SBP From Baseline After 4 Weeks of Therapy|Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (<90 mmHg, But <80 mmHg for DM & Chronic Kidney Disease) and SBP (<140 mmHg, But <130 mmHg for DM & Chronic Kidney Disease) After 4 Weeks of Therapy|Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (<90 mmHg, But <80 mmHg for DM & Chronic Kidney Disease) and SBP (<140 mmHg, But <130 mmHg for DM & Chronic Kidney Disease) After 8 Weeks of Therapy|Changes in Mean Sitting SBP From Baseline After 8 Weeks of Therapy|Changes in Hs-CRP Level From Baseline After 8 Weeks of Therapy|Occurrence of Adverse Events (AE) and Discontinuation of Study Medication Due to AE's From Baseline (Randomisation) to the End of the Study (8 Weeks)|Compliance Levels at 4 Weeks and 8 Weeks of Therapy","http://ClinicalTrials.gov/show/NCT00621153",NA
"44767",44767,"NCT00645853","Long-Term Safety in Atrial Fibrillation Patients","Completed","No Results Available","Paroxysmal|Persistent or Permanent Nonvalvular Atrial Fibrillation","Drug: AZD0837|Drug: Vitamin-K Antagonists (warfarin)","AstraZeneca","Both","Adult|Senior","Phase II",523,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","D1250C00042","March 19, 2008","01/10/2007",2009-05-01,"June 11, 2009","01/06/2009","",2009-05-01,"To evaluate safety and tolerability of long-term treatment with AZD0837 compared to Vitamin-K Antagonist (VKA) in Atrial Fibrillation patients with a moderate to high risk of stroke and systemic embolic events.|To evaluate the PK of AZD0837 and metabolites; To evaluate the effect of AZD0837 on PD markers and coagulation assays in Atrial Fibrillation patients with a moderate to high risk of stroke and systemic embolic events.","http://ClinicalTrials.gov/show/NCT00645853",NA
"44775",44775,"NCT00654953","Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-dependent Humans","Completed","No Results Available","Cocaine Dependence|Depressive Symptoms","Drug: sertraline|Drug: Placebo|Drug: gabapentin","National Institute on Drug Abuse (NIDA)","Both","Adult","Phase II",105,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P50-DA018197|P50-DA018197|DPMCDA","April 4, 2008","01/01/2006",2009-05-01,"December 15, 2010","01/12/2010","",2009-05-01,"Urine toxicology results for cocaine/metabolite or other illicit drugs|scores on Ham-D","http://ClinicalTrials.gov/show/NCT00654953",NA
"44776",44776,"NCT00657553","Pre-Emptive Strike With Bortezomib in Multiple Myeloma Patients","Completed","No Results Available","Multiple Myeloma","Drug: Bortezomib","University of Arkansas","Both","Adult|Senior","Phase III",10,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","100241","April 9, 2008","01/02/2008",2009-01-01,"May 12, 2009","01/05/2009","2007-77",2009-01-01,"The amount of patients on Bortezomib that have maintained event-free survival will be compared to the patients on observation.|To determine if there is any increase in the amount of positive response when given Bortezomib alone.|To determine if Bortezomib will cause the reduction in MRI-defined focal lesions.|To evaluate whether Bortezomib will induce bone formation.","http://ClinicalTrials.gov/show/NCT00657553",NA
"44801",44801,"NCT00687453","Insulin Glargine Versus Twice-Daily NPH","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Insulin glargine at bedtime instead of NPH|Drug: NPH twice-daily","Charles Drew University of Medicine and Science|National Institutes of Health (NIH)","Both","Adult|Senior","Phase IV",27,"Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","03-02-519|U54RR014616","May 27, 2008","01/02/2003",2009-08-01,"September 15, 2010","01/09/2010","",2009-08-01,"Hemoglobin A1c Change From Baseline|Frequency of Pre-supper Glucose Readings 120 mg/dL or Less|Frequency of Total Hypoglycemic Reactions|Frequency of Severe Hypoglycemic Reactions|Body Mass Index Change From Baseline|Total Daily Insulin Dose|Any Adverse Event Other Than Hypoglycemia","http://ClinicalTrials.gov/show/NCT00687453",NA
"44803",44803,"NCT00704353","Safety and Tolerability of a Single Dose of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia","Completed","No Results Available","Anemia","Drug: Ferric Carboxymaltose|Drug: Ferrous Sulfate","Luitpold Pharmaceuticals","Both","Adult|Senior","Phase III",526,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1VIT08021","June 20, 2008","01/06/2008",NA,"August 30, 2010","01/08/2010","",2009-07-01,"Safety and Tolerability","http://ClinicalTrials.gov/show/NCT00704353",NA
"44813",44813,"NCT00699153","Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery","Completed","Has Results","Ocular Inflammation","Drug: Loteprednol Etabonate|Drug: Vehicle of Ophthalmic Loteprednol Etabonate","Bausch & Lomb, Inc.","Both","Adult|Senior","Phase III",400,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","526","June 13, 2008","01/06/2008",2009-06-01,"September 1, 2010","01/09/2010","",2009-05-01,"Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0|Participants With Grade 0 (no) Pain|Participants With Complete Resolution of Anterior Chamber Cells and Flare, at Each Visit.|Mean Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare","http://ClinicalTrials.gov/show/NCT00699153",NA
"44815",44815,"NCT00719953","Study to Assess the Efficacy of Cognitex","Completed","Has Results","Elderly|Memory Impairment","Dietary Supplement: Cognitex","Tel-Aviv Sourasky Medical Center|Enzymotec","Both","Adult|Senior","Phase IV",30,"Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TASMC-08-NV-305-CTIL|0305-08-TLV","July 21, 2008","01/08/2008",2009-08-01,"April 18, 2010","01/07/2008","Cognitex001",2009-03-01,"Improvement of Cognitive Performance (Change From Baseline in Neuropsychological Computerized Test)","http://ClinicalTrials.gov/show/NCT00719953",NA
"44840",44840,"NCT00758953","Pain Associated With Endometriosis","Completed","No Results Available","Endometriosis","Drug: Danazol Once Weekly|Drug: Danazol Twice Weekly|Drug: Placebo Once Weekly|Drug: Placebo Twice Weekly","KV Pharmaceutical Company","Female","Adult","Phase II",66,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DZ2-201-601-725036","September 23, 2008","01/02/2007",2009-01-01,"January 11, 2010","01/01/2010","",2009-01-01,"Pain associated with endometriosis","http://ClinicalTrials.gov/show/NCT00758953",NA
"44842",44842,"NCT00755053","Comparative Efficacy of Ovule vs Tablet","Completed","No Results Available","Clotrimazole|Ovulen|Vulvovaginal Candidiasis","Drug: Clotrimazole, vaginal ovule|Drug: Clotrimazole, vaginal tablet","Bayer","Female","Child|Adult","Phase III",465,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","13071|EudraCT Nr: 2008-000718-63","September 17, 2008","01/09/2008",2009-05-01,"June 29, 2009","01/06/2009","",2009-04-01,"Subjects with mycological and clinical cure|Subjects with mycological and clinical cure|Clinical cure|Clinical cure|Mycological cure|Mycological cure","http://ClinicalTrials.gov/show/NCT00755053",NA
"44845",44845,"NCT00703053","H5N1 Priming and Boosting Strategies","Completed","Has Results","Influenza","Biological: A/Vietnam/1203/04|Biological: A/Indonesia/05/05","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","Phase II",505,"NIH","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","07-0019|N01AI80003C","June 19, 2008","01/09/2008",2009-11-01,"November 11, 2010","01/09/2009","",2009-07-01,"Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen|Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen|Number of Subjects Achieving a 4-fold or Greater HAI Antibody Titer Increase Against A/Vietnam/04 Antigen|Number of Subjects Achieving a 4-fold or Greater HAI Antibody Titer Increase Against A/Indonesia/05 Antigen|Number of Subjects Achieving a HAI Antibody Titer of 1:40 or Greater Against A/Vietnam/04 Antigen|Number of Subjects Achieving a HAI Antibody Titer of 1:40 or Greater Against A/Indonesia/05 Antigen|Number of Serious Adverse Events|Number of Subjects Reporting Solicited Symptoms Within 7 Days of First Vaccination|Number of Subjects Reporting Solicited Symptoms Within 7 Days of Second Vaccination|Neutralizing Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen|Neutralizing Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen|Number of Subjects Achieving a 4-fold or Greater Neutralizing Antibody Titer Increase Against A/Vietnam/04 Antigen|Number of Subjects Achieving a 4-fold or Greater Neutralizing Antibody Titer Increase Against A/Indonesia/05 Antigen|Number of Subjects Achieving Neutralizing Antibody Titer of 1:40 or Greater Against A/Vietnam/04 Antigen|Number of Subjects Achieving Neutralizing Antibody Titer of 1:40 or Greater Against A/Indonesia/05 Antigen|Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 6 Months Post Last Vaccination|Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen at 6 Months Post Last Vaccination|Neutralizing Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 6 Months Post Last Vaccination|Neutralizing Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen at 6 Months Post Last Vaccination|Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 1, 2, 3 and 4 Weeks After 2 Doses","http://ClinicalTrials.gov/show/NCT00703053",NA
"44864",44864,"NCT00797953","Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina","Completed","No Results Available","Angina Pectoris","Drug: T89","Tasly Pharmaceuticals, Inc.","Both","Adult|Senior","Phase II",108,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","T89-005-0003-US","November 24, 2008","01/02/2007",2010-01-01,"January 13, 2010","01/01/2010","T89 phase 2",2009-12-01,"Total Exercise Duration (TED) change from screen baseline value in Exercise Tolerance Test (ETT) on Standard Bruce Protocol at trough drug levels at the end of the 4th and 8th week of treatment compared to placebo.|Frequency of weekly angina episodes","http://ClinicalTrials.gov/show/NCT00797953",NA
"44885",44885,"NCT00831753","Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix?óHexa in Healthy Peruvian Infants","Completed","No Results Available","Diphtheria|Tetanus|Pertussis|Haemophilus Influenzae Type B|Hepatitis B","Biological: DTaP IPV HB PRP~T vaccine|Biological: DTaP-HB-IPV and Haemophilus influenzae type b","Sanofi-Aventis","Both","Child","Phase III",266,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","A3L17","January 27, 2009","01/05/2008",2009-11-01,"January 20, 2010","01/01/2010","",2009-05-01,"To provide information concerning the immunogenicity of DTaP-IPV-Hep B-PRP~T vaccine.|To provide information concerning the safety of DTaP-IPV-Hep B-PRP~T vaccine.","http://ClinicalTrials.gov/show/NCT00831753",NA
"44894",44894,"NCT00770653","Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.","Completed","Has Results","Diabetes Mellitus|Dyslipidemias","Drug: Pioglitazone and Metformin|Drug: Glimepiride and Metformin","Takeda Pharma GmbH","Both","Adult|Senior","Phase III",305,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ATS K024|2006-004455-37|D-PIO-114|U1111-1114-1678","October 9, 2008","01/04/2007",2009-05-01,"September 13, 2010","01/09/2010","",2009-05-01,"The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.|Change From Baseline in High-Density Lipoprotein Cholesterol.|Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.|Change From Baseline in Triglycerides.|Change From Baseline in Low-Density Lipoprotein Subfractions.|Change From Baseline in Low-Density Lipoprotein Cholesterol.|Change From Baseline in Glycosylated Hemoglobin.|Change From Baseline in Fasting Intact Proinsulin.|Change From Baseline in Fasting Glucose.|Change From Baseline in Adiponectin.|Change From Baseline in High Sensitivity C-reactive Protein (Original).|Change From Baseline in High Sensitivity C-reactive Protein (??? 10 mg/L).|Change From Baseline in Systolic Blood Pressure.|Change From Baseline in Diastolic Blood Pressure.|Intake of Study Medication Greater Than 80% and Less Than 120%.|Change From Baseline in Nitrotyrosine.|Change From Baseline in Soluble CD40 Ligand.|Change From Baseline in Matrix Metallo Proteinase-9.|Change From Baseline in Soluble Intracellular Adhesion Molecule.|Change From Baseline in Soluble Vascular Cell Adhesion Molecule.|Change From Baseline in Thromboxane B2.|Change From Baseline in Platelet Function.|Change From Baseline in E-Selectin.|Change From Baseline in Von-Willebrand Factor.|Change From Baseline in Erythrocyte Deformability (0.30%).|Change From Baseline in Erythrocyte Deformability (0.60%)|Change From Baseline in Erythrocyte Deformability (1.20).|Change From Baseline in Erythrocyte Deformability (3.00).|Change From Baseline in Erythrocyte Deformability (6.00).|Change From Baseline in Erythrocyte Deformability (12.00).|Change From Baseline in Erythrocyte Deformability (30.00).|Change From Baseline in Erythrocyte Deformability (60.00).","http://ClinicalTrials.gov/show/NCT00770653",NA
"44929",44929,"NCT00913653","Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure","Completed","No Results Available","Heart Failure","Drug: LCZ696","Novartis Pharmaceuticals","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLCZ696A2117","June 2, 2009","01/05/2009",NA,"December 21, 2009","01/12/2009","",2009-07-01,"Safety (including blood pressure, renal function and serum electrolytes) and tolerability of LCZ696|Pharmacokinetics of LCZ696 and its metabolites|Pharmacodynamics of LCZ696","http://ClinicalTrials.gov/show/NCT00913653",NA
"44951",44951,"NCT00944853","Effects of Liquid Zinc Supplementation and Dispersible Zinc Tablets on Plasma Zinc Concentration","Completed","No Results Available","Zinc Deficiency","Dietary Supplement: Liquid zinc supplement|Dietary Supplement: Zinc tablet|Dietary Supplement: Liquid placebo supplement","University of California, Davis|Institut de Recherche en Sciences de la Sant?¢, Bobo-Dioulasso|Helen Keller International|Nutriset S.A.S.","Both","Child","Phase IV",462,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","200917272|ZincTab","July 21, 2009","01/08/2009",2010-02-01,"February 18, 2010","01/02/2010","",2009-12-01,"Plasma zinc concentration","http://ClinicalTrials.gov/show/NCT00944853",NA
"44986",44986,"NCT00992953","Virtual Reality (VR) Therapy for Post-Traumatic Stress Disorder (PTSD)","Completed","No Results Available","Post-Traumatic Stress Disorder","Behavioral: Treatment as Usual|Behavioral: Virtual Reality Exposure with Stimulus Control","Office of Naval Research|Naval Hospital Camp Pendleton|Virtual Reality Medical Center|United States Naval Medical Center, San Diego","Both","Adult","Phase I|Phase II",136,"Other|U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","S-05-005","October 8, 2009","01/01/2005",2009-10-01,"October 8, 2009","01/10/2009","",2009-10-01,"","http://ClinicalTrials.gov/show/NCT00992953",NA
"45040",45040,"NCT01091753","Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers","Completed","No Results Available","Hypertension","Drug: Valsaltan, amlodipine","Yonsei University","Both","Adult|Senior","Phase IV",28,"Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","4-2007-0440","March 23, 2010","01/03/2008",2009-09-01,"October 7, 2010","01/10/2010","",2009-05-01,"IMT(intima media thickness) Measure data(Sono)|IMT(intima media thickness) Measure data(Sono)","http://ClinicalTrials.gov/show/NCT01091753",NA
"45061",45061,"NCT01124253","Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: recombinant human endostatin","Shanghai Jiao Tong University School of Medicine|Shanghai Municipal Science and Technology Commission|Shanghai Chest Hospital|Simcere Pharmaceutical Co., Ltd","Both","Adult|Senior","Phase III",250,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","endo001","May 6, 2010","01/07/2007",2009-10-01,"May 14, 2010","01/10/2009","Dengshan",2009-10-01,"overall survival(OS)|disease-free survival(DFS)|the toxicity and safety","http://ClinicalTrials.gov/show/NCT01124253",NA
"45253",45253,"NCT00069654","Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease","Completed","No Results Available","Coronary Arteriosclerosis","Procedure: Forearm blood flow study|Procedure: Brachial artery reactivity study|Procedure: Treadmill exercise test","National Heart, Lung, and Blood Institute (NHLBI)","Both","Adult|Senior","Phase II",42,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","030312|03-H-0312","September 29, 2003","01/09/2003",NA,"June 17, 2010","01/05/2009","",2009-05-01,"Comparison of forearm blood flow during exercise after 3 days of the nitrate-nitrite-enriched diet to forearm blood flow during exercise after 3 days of the nitrate/nitrite-restricted diet.|Comparison of effects of high versus low nitrate/nitrite diets on exercise forearm blood flow between the two cohorts of patients.","http://ClinicalTrials.gov/show/NCT00069654",NA
"45264",45264,"NCT00089154","Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Completed","No Results Available","Leukemia|Lymphoma","Biological: apolizumab","Chronic Lymphocytic Leukemia Research Consortium|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000378072|CLLRC-OSU-0410|NCI-6257|OSU-0410","August 4, 2004","01/08/2004",NA,"February 6, 2010","01/09/2005","",2009-09-01,"Overall response rate (compete and partial response)|Safety and toxicity as assessed by NCI CTCAE v3.0|Time to progression|Disease-free survival|Correlation of pharmacokinetic clearance and 1D10 antigen density with leukemic or lymphoma cells, clinical response, and frequency and severity of observed toxicities|Correlation of presence of reactive oxygen species and specific signaling pathways' promotion of drug-mediated apoptosis in vitro and in vivo in primary leukemic or lymphoma cells with clinical response|Cellular properties that convey resistance in vivo|Spontaneous and apolizumab-induced apoptosis|Bcl-2 and superoxide dismutase|Lysis sensitivity","http://ClinicalTrials.gov/show/NCT00089154",NA
"45306",45306,"NCT00148954","RIGHT: Rhythm ID Going Head-to-Head Trial","Completed","No Results Available","Tachycardia","Device: Implantable Cardioverter Defibrillator","Boston Scientific Corporation","Both","Adult|Senior","Phase IV",2000,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CR-CA-032105-T|RIGHT","September 6, 2005","01/07/2005",2010-07-01,"August 17, 2010","01/08/2010","",2009-03-01,"Time to first inappropriate ventricular tachycardia (VT)/ventricular fibrillation (VF) therapy (shock or antitachycardia pacing [ATP]) after the Pre-Discharge visit|Time to first inappropriate shock using Guidant and competitive ICDs|Positive predictive value (PPV) of VT/VF discrimination algorithms found in Guidant and competitive ICDs|Time to first inappropriate therapy for which the discrimination algorithm found in Guidant and competitive ICDs inappropriately classified the episode","http://ClinicalTrials.gov/show/NCT00148954",NA
"45375",45375,"NCT00259454","Project COPE:Managing Dementia at Home","Completed","No Results Available","Dementia, Alzheimer Type","Behavioral: In-home intervention","Thomas Jefferson University|Pennsylvania Department of Health","Both","Adult|Senior","Phase III",278,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Single Group Assignment|Masking: Open Label","SAP 4100027298","November 28, 2005","01/06/2005",2009-07-01,"March 15, 2010","01/03/2010","",2009-04-01,"ADL/IADL|Caregiver upset|Caregiver confidence|Behaviors","http://ClinicalTrials.gov/show/NCT00259454",NA
"45381",45381,"NCT00265954","Internet Assisted Obesity Treatment","Completed","No Results Available","Overweight|Obesity","Behavioral: internet, in-person and internet+in-person","University of Vermont|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Arkansas","Both","Adult|Senior","Phase III",488,"Other|NIH","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DK56746|R01DK056746","December 14, 2005","01/02/2006",2009-10-01,"January 21, 2010","01/01/2010","iReach",2009-10-01,"Body Mass Index or body weight change|Social support, diet, exercise, adherence to treatment components","http://ClinicalTrials.gov/show/NCT00265954",NA
"45393",45393,"NCT00284154","Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Small Cell|Lung Cancer","Drug: Vinflunine","Sarah Cannon Research Institute|Bristol-Myers Squibb","Both","Adult|Senior","Phase II",41,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI LUN 122|CA183017","January 27, 2006","01/01/2006",2009-11-01,"November 1, 2010","01/11/2010","",2009-05-01,"Overall response rate|Duration of response|Overall survival|Progression free survival","http://ClinicalTrials.gov/show/NCT00284154",NA
"45420",45420,"NCT00319254","Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer","Completed","No Results Available","Breast Neoplasms|Neoplasm Metastasis","Drug: SKI-606 (Bosutinib)","Wyeth","Female","Adult|Senior","Phase II",75,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3160A2-201|B1871014","April 24, 2006","01/04/2006",2009-02-01,"November 29, 2010","01/11/2010","",2009-02-01,"Rate of progression free survival (PFS) at 16 weeks.|Safety profile of 400mg/day|Rate of objective response within 1 year after beginning treatment.|Survival rate at 3 years after beginning treatment.|Pharmacokinetics (PK) of SKI-606 (Bosutinib) in this patient population.","http://ClinicalTrials.gov/show/NCT00319254",NA
"45488",45488,"NCT00425854","An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer","Completed","No Results Available","Breast Neoplasms","Drug: BIBW 2992","Boehringer Ingelheim Pharmaceuticals","Female","Adult|Senior","Phase II",50,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","1200.10|Eudract 2006-002018-36","January 22, 2007","01/11/2006",NA,"September 24, 2010","01/09/2010","",2009-05-01,"Objective response|Clinical benefit|time to objective response|duration of objective response|time to tumour progression|overall survival|safety, changes in cardiac LVEF|pharmacokinetics|progression free survival","http://ClinicalTrials.gov/show/NCT00425854",NA
"45505",45505,"NCT00321854","Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease","Completed","Has Results","Parkinson Disease","Drug: pramipexole","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase IV",535,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","248.595","May 3, 2006","01/05/2006",NA,"September 1, 2010","01/09/2010","",2009-04-01,"Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Total Score at Month 9|Change From Baseline in the Investigator Rated UPDRS Total Score at Month 6|Change From Baseline in the Investigator Rated UPDRS Total Score at Month 3|Change From Baseline in the Blinded Rater UPDRS Parts II+III Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 9|Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 6|Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 3|Change From Baseline in the Blinded Rater UPDRS Part III Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 9|Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 6|Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 3|Change From Baseline in the Blinded Rater UPDRS Part II Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 9|Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 6|Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 3|Change From Baseline in the Blinded Rater UPDRS Part I Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 9|Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 6|Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 3|Number of Responders Using the Blinded Rater Assessment of Clinical Global Impressions of Global Improvement (CGI-I) Score at Month 15|Change From Baseline in Blinded Rater Assessment of Clinical Global Impressions of Severity of Illness (CGI-S) Category at Month 15|Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 15|Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 9|Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 6|Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 3|Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 15|Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 9|Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 15|Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 9|Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 15|Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 9|Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 1|Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 6|Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 9|Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 12|Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 15|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 1|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 6|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 9|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 12|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 15|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 1|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 6|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 9|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 12|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 15|Percentage Change From Baseline in the Striatum Uptake at Month 15","http://ClinicalTrials.gov/show/NCT00321854",NA
"45510",45510,"NCT00434954","Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide twice daily (BID)|Drug: premixed insulin aspart twice daily (BID)","Amylin Pharmaceuticals, Inc.|Eli Lilly and Company","Both","Adult|Senior","Phase III",494,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H8O-SB-GWBN","February 12, 2007","01/02/2007",2009-06-01,"July 30, 2010","01/07/2010","",2009-06-01,"Change in Glycosylated Hemoglobin (HbA1c)|Incidence of Hypoglycemia (Percentage of Participants With at Least One Hypoglycemic Episode)|Percentage of Subjects Achieving HbA1c Target of < 6.5%|Percentage of Subjects Achieving HbA1c Target of < 7.0%|Incidence of Hypoglycemic Episodes [Blood Glucose <= 3.0 mmol/L or Severe] (Percentage of Subjects Who Experienced at Least One Treatment-emergent Hypoglycemic Episode During the 26-week Treatment Period)|Incidence of Nocturnal Hypoglycemia (Percentage of Subjects Who Experienced at Least One Episode of Nocturnal Hypoglycemia During the 26 Week Treatment Period)|7 Point Self-monitored Blood Glucose (SMBG) Profiles|Blood Lipid Levels|Change in Body Weight|Change in Body Mass Index (BMI)|Patient Reported Outcomes: Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Patient Reported Outcomes: Quality of Life (SF-12)","http://ClinicalTrials.gov/show/NCT00434954",NA
"45521",45521,"NCT00406354","Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany","Completed","Has Results","Attention Deficit Hyperactivity Disorder|Oppositional Defiant Disorder","Drug: Atomoxetine|Drug: Placebo","Eli Lilly and Company","Both","Child","Phase IV",181,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11149|B4Z-SB-LYDW","November 29, 2006","01/11/2006",2009-01-01,"February 19, 2010","01/02/2010","",2009-01-01,"Swanson, Nolan and Pelham Rating Scale Revised (SNAP-IV) Oppositional Defiant Disorder: (ODD) Score|Swanson, Nolan & Pelham Rating Scale - Revised (SNAP-IV): ADHD Combined Score|Swanson, Nolan & Pelham Rating Scale - Revised (SNAP-IV): ADHD Inattention Score|Swanson, Nolan & Pelham Rating Scale - Revised (SNAP-IV): Hyperactivity/Impulsivity Score|Parent-Rated Attention-Deficit Scale (FBB-HKS), Total Score: Severity|Parent-Rated Oppositional Defiant/Conduct Disorders Scale (FBB-SSV): Total Score, Severity|Investigator-Rated Individual Target Behaviors (ITB-Inv): Intensity Score|Investigator-Rated Individual Target Behaviors (ITB-Inv): Frequency Score|Impact on Family Scale (FaBel), Total Impact Score|Clinical Global Impressions - Severity (CGI-S): ADHD Score|Clinical Global Impressions - Severity (CGI-S): ODD Score|Clinical Global Impressions - Severity (CGI-S): Combined ADHD and ODD Scores|German Revised Children's Quality of Life Questionnaire (KINDL-R): Total Quality of Life Score|German Revised Children's Quality of Life Questionnaire (KINDL-R): Physical Well-Being Score|German Revised Children's Quality of Life Questionnaire (KINDL-R): Emotional Well-Being Score|German Revised Children's Quality of Life Questionnaire (KINDL-R): Self Esteem Score|German Revised Children's Quality of Life Questionnaire (KINDL-R): Family Score|German Revised Children's Quality of Life Questionnaire (KINDL-R): Friends Score|German Revised Children's Quality of Life Questionnaire (KINDL-R): School Score|Number of Participants Discontinuing Treatment|Number of Patients Who Experienced Clinically Relevant Categories of Adverse Events During Initial Three Weeks of Study Treatment|Number of Patients Who Experienced Clinically Relevant Categories of Adverse Events During Nine-Week Study Treatment Period","http://ClinicalTrials.gov/show/NCT00406354",NA
"45595",45595,"NCT00546754","BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy","Completed","Has Results","Hypertension","Drug: losartan potassium (+) hydrochlorothiazide|Drug: Comparator: Valsartan (+) Hydrochlorothiazide","Merck","Both","Adult|Senior","Phase III",808,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2007_031|MK0954A-333","October 17, 2007","01/05/2007",2009-05-01,"April 20, 2010","01/04/2010","EASE",2009-04-01,"Change in Systolic Blood Pressure From Baseline to Week 12|Change in Diastolic Blood Pressure From Baseline to Week 12|Change in Systolic Blood Pressure From Baseline to Week 6|Change in Diastolic Blood Pressure From Baseline to Week 6|Number of Patients Achieving Target Blood Pressure at Week 6|Number of Patients Achieving Target Blood Pressure at Week 12|Time to Achieve Target Blood Pressure|Change in Uric Acid From Baseline to Week 6|Change in Uric Acid From Baseline to Week 12|Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 6|Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 12|Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 6|Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 12","http://ClinicalTrials.gov/show/NCT00546754",NA
"45608",45608,"NCT00623454","Non Cardiac Chest Pain and Benign Palpitations","Completed","No Results Available","Anxiety/Depression in Cardiological Unit","Behavioral: Cognitive behaviour therapy","Norwegian University of Science and Technology","Both","Adult","Phase IV",40,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4.2006.1110 (REK)","February 14, 2008","01/03/2007",2009-04-01,"August 4, 2009","01/08/2009","",2009-04-01,"Body sensation questionnaire (BSQ)|Beck Depression Inventory (BDI)","http://ClinicalTrials.gov/show/NCT00623454",NA
"45639",45639,"NCT00635154","Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma","Completed","Has Results","Multiple Myeloma and Plasma Cell Neoplasm","Biological: Anakinra (IL-1Ra)|Drug: Dexamethasone acetate","Mayo Clinic|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",55,"Other|NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000583300|P30CA015083|MC0282|1316-02","March 12, 2008","01/12/2002",2010-11-01,"December 17, 2010","01/12/2010","",2009-12-01,"Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months of Treatment With Anakinra Alone|Number of Patients With Response to Treatment With Dexamethasone and Anakinra|Number of Patients Who Are Progression-free and Alive at 6 Months|Number of Patients With Severe Non-hematological Adverse Events in Patients Receiving Anakinra Alone or in Combination With Dexamethasone.|Progression Free Survival (PFS) in Patients Treated With Anakinra Alone or in Combination With Dexamethasone|Number of Patients With Severe Non-hematological Adverse Events in Participants Receiving Anakinra in Combination With Dexamethasone|Duration of Response","http://ClinicalTrials.gov/show/NCT00635154",NA
"45658",45658,"NCT00707954","Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: TA-7284|Drug: Placebo of TA-7284","Mitsubishi Tanabe Pharma Corporation","Both","Adult","Phase I|Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TA-7284-02","June 27, 2008","01/06/2008",2009-02-01,"June 29, 2009","01/06/2009","",2009-02-01,"Safety: Adverse events, adverse drug reactions|Pharmacokinetics- 1)Plasma Concentration of TA-7284: Tmax,Cmax, AUC, etc.; and 2)Urinary Excretion of TA-7284: Ae, Ae%, CLr|Pharmacodynamics- 1)Urinary Glucose excretion; 2)Plasma Glucose concentration; 3)Insulin concentration in plasma; 4)Insulinogenic Index;and 5)Hemoglobin A1c and Glycoalbumin","http://ClinicalTrials.gov/show/NCT00707954",NA
"45693",45693,"NCT00769054","Local Infiltration Analgesia With Ropivacaine in Posterior Vaginal Wall Prolapse:a Randomized, Double-Blind Study","Completed","No Results Available","Vaginal Prolapse","Drug: Ropivacaine|Drug: Isotonic NaCl","Hvidovre University Hospital","Female","Adult|Senior","Phase IV",48,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","H-C-2008-035","October 7, 2008","01/10/2008",2009-10-01,"July 8, 2010","01/10/2008","",2009-10-01,"Postoperative Pain during rest, coughing and ambulation|Postoperative Nausea and Vomitus","http://ClinicalTrials.gov/show/NCT00769054",NA
"45707",45707,"NCT00787254","Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs","Completed","No Results Available","Stomach Ulcer|Duodenal Ulcer","Drug: Lansoprazole|Drug: Gefarnate","Takeda Pharmaceutical Company Limited","Both","Adult|Senior","Phase III",366,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG-1749-CCT-352|CTI-070495(ja)|U1111-1114-2071","November 6, 2008","01/04/2007",2009-05-01,"April 20, 2010","01/04/2010","",2009-05-01,"Rate of onset of gastric ulcer and/or duodenal ulcer.|Rate of onset of gastric and duodenal mucosal injury, hemorrhagic lesions and gastrointestinal symptoms.|Adverse events.","http://ClinicalTrials.gov/show/NCT00787254",NA
"45711",45711,"NCT00789854","Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients","Completed","No Results Available","Major Depressive Disorder|Treatment Resistant Depression","Drug: Quetiapine XR|Drug: Lithium carbonate","AstraZeneca","Both","Adult","Phase III",600,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D1443L00044","November 11, 2008","01/11/2008",2009-08-01,"May 13, 2010","01/04/2010","RUBY",2009-08-01,"Change in depressive symptoms between randomisation and week 6 as measured by MADRS total score|Depression remission; MADRS ???10: Responder, CGI-I item 2, Response rate; MADRS score reduced > 50%, Change in CGI-S, Change in pain, measured by VAS, Response rate; MADRS score reduced > 50%, and Change in BDI: all patients|Depression remission; MADRS ???12, MADRS ???10, MADRS ???8, Response rate; MADRS score reduced > 50%, Responder: CGI-I item 2, Change in CGI-S and Change in BDI; patients with one previous treatment failure|Depression remission; MADRS ???12, MADRS ???10, MADRS ???8, Response rate; MADRS score reduced > 50%, Responder: CGI-I item 2, Change in CGI-S and Change in BDI; patients with two previous treatment failure|Change in pain measured by VAS, change anxiety measured by VAS and STAI, Change in sleep quality measured by MADRS item 4 and PSQI; all patients|Change in pain measured by VAS, change anxiety measured by VAS and STAI, Change in sleep quality measured by MADRS item 4 and PSQI; patients with one previous treatment failure|Change in pain measured by VAS, change anxiety measured by VAS and STAI, Change in sleep quality measured by MADRS item 4 and PSQI; patients with two previous treatment Sfailure|Change in quality of life measured by SF-36 with 2 component scores and 8 domains and EQ-5D as Utility and 5 domains, all patients|Change in quality of life measured by SF-36 with 2 component scores and 8 domains and EQ-5D as Utility and 5 domains, patients with one previous treatment failure|Change in quality of life measured by SF-36 with 2 component scores and 8 domains and EQ-5D as Utility and 5 domains, patients with two previous treatment failure|Change in WPAI:GH, all patients|Change in WPAI:GH, patients with one previous treatment failure|Change in WPAI:GH, patients with two previous treatment failure|Safety as Serious Adverse Events, Discontinuation due the adverse events and all non-serious adverse events|Change in CGI item 4 efficacy and safety combined","http://ClinicalTrials.gov/show/NCT00789854",NA
"45719",45719,"NCT00810654","Effect of Aspergillus Niger Prolyl Endoprotease (AN-PEP) Enzyme on the Effects of Gluten Ingestion in Patients With Coeliac Disease","Completed","No Results Available","Celiac Disease","Dietary Supplement: Aspergillus niger prolyl endoprotease|Dietary Supplement: Placebo","VU University Medical Center|DSM Food Specialties|Leiden University Medical Center","Both","Adult|Senior","Phase I|Phase II",14,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RD.0601.54|NTR1281","December 17, 2008","01/05/2008",2009-12-01,"January 18, 2011","01/05/2009","",2009-05-01,"Histopathological changes according to the Modified Marsh criteria|The presence of coeliac disease specific antibodies (EMA, tTGA, gliadin)|Presence and activity of gluten reactive Tcells isolated from biopsies and serum|Immunophenotype of lymphocytes isolated from biopsies|Clinical symptoms after gluten intake with and without AN-PEP","http://ClinicalTrials.gov/show/NCT00810654",NA
"45740",45740,"NCT00837954","Trial to Evaluate the Hemostatic Effect of Lyostypt?ó Versus Surgicel?ó in Arterial Bypass Anastomosis","Completed","No Results Available","Peripheral Vascular Diseases|Hemostasis","Device: Lyostypt?ó AND Surgicel?ó|Device: Lyostypt?ó|Procedure: Surgicel?ó","Aesculap AG","Both","Adult|Senior","Phase IV",32,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AAG-G-H-0803","February 5, 2009","01/02/2009",2010-04-01,"May 4, 2010","01/05/2010","COBBANA",2009-12-01,"Time to hemostasis|Number of Complications|Postoperative Mortality|Efficacy Rating of Study Device evaluated by Surgeon","http://ClinicalTrials.gov/show/NCT00837954",NA
"45748",45748,"NCT00818454","4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma","Completed","Has Results","Asthma","Drug: Combivent CFC MDI|Drug: Albuterol HFA MDI|Drug: Respimat Combivent","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",226,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment","1012.57|57948","January 6, 2009","01/12/2008",NA,"November 23, 2010","01/11/2010","",2009-09-01,"FEV1 AUC0-6 Response (Crossover Part of the Study)|Peak FEV1 Response (Crossover Part of the Study)|Mini Asthma Quality of Life Questionnaire (Crossover Part of the Study)|Asthma Control Questionnaire (Crossover Part of the Study)|Puffs Study Medication Used During Day (Crossover Part of the Study)|Puffs Study Medication Used During Night (Crossover Part of the Study)|Puffs Open-label Albuterol Used During Day (Crossover Part of the Study)|Puffs Open-label Albuterol Used During Night (Crossover Part of the Study)|FEV1 AUC0-6 Response (Parallel Part of the Study)|Peak FEV1 Response","http://ClinicalTrials.gov/show/NCT00818454",NA
"45766",45766,"NCT00857454","A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations","Completed","Has Results","Hypogonadism","Drug: Testosterone MD-Lotion","Eli Lilly and Company","Male","Adult|Senior","Phase III",71,"Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","14273|MTE09|I5E-MC-TSAI","March 4, 2009","01/10/2008",2009-08-01,"December 15, 2010","01/12/2010","",2009-08-01,"Change From Baseline MTE08 to MTE09 Endpoint in Draize Score|Change From Baseline MTE08 to MTE09 Follow-up in Fasting Insulin|Change From Baseline MTE08 to MTE09 Follow-up in Fasting Glucose|Change From Baseline MTE08 to MTE09 Follow-up in Prostatic Specific Antigen (PSA)|Change From Baseline MTE08 to MTE09 Follow-up in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH)|Change From Baseline MTE08 to MTE09 Follow-up in Estradiol|Change From Baseline MTE08 to MTE09 Follow-up in Hemoglobin|Change From Baseline MTE08 to MTE09 Follow-up in Hematocrit","http://ClinicalTrials.gov/show/NCT00857454",NA
"45823",45823,"NCT00970554","Effectiveness of Telescopic Magnification in the Treatment of Amblyopia","Completed","No Results Available","Amblyopia","Other: Patching|Other: Telescopic magnification","The Hospital for Sick Children","Both","Child","Phase I|Phase II",15,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1000011712","September 1, 2009","01/12/2007",2009-05-01,"September 2, 2009","01/09/2009","",2009-05-01,"The best corrected logMAR visual acuity score of the amblyopic eye.|Visual acuity of at least 0.2 logMAR (20/30) and/or improvement of at least 0.2 logMAR from baseline in the amblyopic eye.","http://ClinicalTrials.gov/show/NCT00970554",NA
"45846",45846,"NCT01003054","Autologous Transplantation for Chronic Myelogenous Leukemia","Completed","No Results Available","Chronic Myelogenous Leukemia","Drug: Busulfan|Drug: Cyclophosphamide|Drug: Imatinib Mesylate|Procedure: Autologous Stem Cell Transplantation","M.D. Anderson Cancer Center","Both","Child|Adult|Senior","Phase II",24,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-672","October 26, 2009","01/03/2005",2009-10-01,"October 27, 2009","01/10/2009","",2009-10-01,"Number of patients with CML alive in cytogenetic remission at one year following treatment","http://ClinicalTrials.gov/show/NCT01003054",NA
"45922",45922,"NCT01131754","Heparin 100U/L for Prevention of PVC Complications","Completed","No Results Available","Peripheral Venous Catheter Complications|Occlusion|Phlebitis|Ecchymosis","Other: heparin 100U/L flushes","IRCCS Policlinico S. Matteo","Both","Adult|Senior","Phase III",214,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","EPA 2007|2007-001347-21","May 26, 2010","01/06/2007",2009-09-01,"June 13, 2010","01/02/2007","",2009-08-01,"Phlebitis or Occlusion|Ecchymosis|Heparin induced thrombocytopenia","http://ClinicalTrials.gov/show/NCT01131754",NA
"45924",45924,"NCT01130454","A Study for Evaluating the SCIO Biofeedback Device's Ability to Increase Body Wellness After One 45-minute Session","Completed","No Results Available","Stress","Device: Universal Electrophysiological Biofeedback Treatment|Device: Universal Electrophysiological Biofeedback Treatment","Maitreya Kft.","Both","Adult","Phase II",151,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CT-103-01","May 10, 2010","01/09/2009",2010-04-01,"November 24, 2010","01/11/2010","",2009-11-01,"VARHOPE Score|Energy Index Factor|Strength Test|Anaerobic Oxygenation Test|Low Back Flexibility|Side to Side Flexibility|Neck Flexibility|Memory Test|pH Test|Quality of Life Questionnaire","http://ClinicalTrials.gov/show/NCT01130454",NA
"45930",45930,"NCT01147354","Effect of Selenium Supplement on Inflammatory,Oxidative and Nutritional Markers in Hemodialysis Patients","Completed","No Results Available","Inflammatory|Nutritional Status|Hemodialysis","Drug: selenium yeast|Drug: placebo capsules","Shiraz University of Medical Sciences","Both","Child|Adult|Senior","Phase III",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","88-4747","June 17, 2010","01/04/2009",2009-09-01,"June 17, 2010","01/07/2009","",2009-07-01,"serum malondialdehyde|serum parathyroid hormone|serum lipoproteins|serum calcium|serum phosphorus|serum c-reactive protein|interleukin-6|serum albumin|hemoglobin|subjective global assessment|quality of life|food intake","http://ClinicalTrials.gov/show/NCT01147354",NA
"45945",45945,"NCT01174654","Development of a Methamphetamine Early Intervention","Completed","No Results Available","HIV|Sexual Behavior|Methamphetamine|Behavioral Research","Behavioral: Contingency management|Behavioral: Referral to community resources","National Institute on Drug Abuse (NIDA)","Male","Adult|Senior","Phase I|Phase II",127,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","R21 DA019420-01A1","August 2, 2010","01/12/2006",2009-04-01,"August 2, 2010","01/08/2010","",2009-04-01,"Non-concordant unprotected anal intercourse|Number of non-concordant unprotected anal intercourse partners|Stimulant (methamphetamine and crack/cocaine) urinalyses|Self-reported methamphetamine use","http://ClinicalTrials.gov/show/NCT01174654",NA
"46100",46100,"NCT00094055","Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer","Completed","No Results Available","Thyroid Neoplasms","Drug: AG013736","Pfizer","Both","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A4061014","October 8, 2004","01/09/2004",2009-01-01,"September 24, 2009","01/09/2009","",2009-01-01,"Response rate of AG 013736 in patients with 131 I cancer|As measured by the overall response rate|As measured by the complete response (CR)|And as by partial response (PR) by RECIST|Time to completion is estimated at 12 months|Determine progression-free survival (PFS)|Determine duration of response|Determine overall survival, population pharmacokinetic analyses|Determine the safety profile of AG 013736|Explore relationships between clinical response and plasma soluble proteins","http://ClinicalTrials.gov/show/NCT00094055",NA
"46151",46151,"NCT00172055","Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy","Completed","No Results Available","Cancer Prostate","Drug: Zoledronic acid","Novartis Pharmaceuticals","Both","Adult|Senior","Phase III",300,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CZOL446GBE03","September 13, 2005","01/12/2004",NA,"September 2, 2010","01/09/2010","",2009-07-01,"To assess if and to what extent rising levels of the bone resorption marker CTX can be used as an indicator for the development of bone metastases, diagnosed via bone scintigraphy.|To assess if and to what extent rising levels of PSA can be used as an indicator for the development of bone metastases","http://ClinicalTrials.gov/show/NCT00172055",NA
"46193",46193,"NCT00226655","An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies","Completed","No Results Available","Brain Edema|Brain Tumor","Drug: hCRF [XERECEPT (corticorelin acetate injection)]","Celtic Pharma Development Services|Neurobiological Technologies","Both","Adult|Senior","Phase III",340,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NTI 0501","September 23, 2005","01/07/2005",2009-04-01,"April 28, 2009","01/04/2009","",2009-03-01,"The study will evaluate the overall long-term safety and tolerability of hCRF and steroid toxicities by monitoring dexamethasone dosing, laboratory values, adverse events,electrocardiograms and neurological and clinical status.","http://ClinicalTrials.gov/show/NCT00226655",NA
"46209",46209,"NCT00257855","A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis","Completed","No Results Available","Secondary Progressive Multiple Sclerosis","Drug: Lamotrigine","University College London Hospitals","Both","Adult","Phase II",120,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","2005-001949-42","November 22, 2005","01/11/2005",2009-02-01,"February 5, 2010","01/02/2009","",2009-01-01,"Change in central brain volume on MRI using the 'Loseff method'|Change in whole brain volume on MRI using Brain Boundary Shift Integral|Number and volume of new T2 high intensity lesion volume on T2 weighted MRI|Number and volume of new T1 low signal lesion volume on T1 weighted MRI|Ratio of new T1 to new T2 lesions on MRI|Change in magnetisation transfer ratio in normal MRI normal appearing white matter and normal appearing grey matter.|Change in upper cervical cord cross sectional area using the 'Loseff method' on MRI|Change in Kurtzke's Extended Disability Scaling Score.|Change in Multiple Sclerosis Functional Composite.|Change in Multiple Sclerosis Impact Scale.","http://ClinicalTrials.gov/show/NCT00257855",NA
"46235",46235,"NCT00290355","Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery","Completed","No Results Available","Non-Small-Cell Lung Cancer","Biological: GSK 249553 vaccine|Biological: Placebo","GlaxoSmithKline","Both","Adult|Senior","Phase II",134,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","249553/004","February 10, 2006","01/05/2002",2009-06-01,"November 5, 2009","01/11/2009","",2009-06-01,"Number of days from surgical resection to the recurrence of NSCLC (all types of recurrence will be included).|All serious adverse events|Haematological, biochemical and urinalysis parameters|Unsolicited non-serious adverse events|Recurrence|Disease-free survival|Time to death|Time to lung cancer death|Lung-cancer-related death.|Antibodies to MAGE-3 and protein D|In vitro cellular immune response|Serum level of Cyfra21.1 and CEA|Level of plasma DNA and molecular characterisation by loss of heterozygosity and microsatellite instability|Number of circulating tumour cells in the blood|MAGE-3 expression in circulating tumour cells in the blood|Gene expression profiles of primary and relapsed tumour samples|Proteomes of the patients' plasma|Solicited local and general signs and symptoms recorded by the patients on diary cards","http://ClinicalTrials.gov/show/NCT00290355",NA
"46251",46251,"NCT00320255","A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer","Completed","No Results Available","Thrombosis|Cancer|Pulmonary Embolism","Drug: Apixaban|Drug: Placebo","Bristol-Myers Squibb|Ontario Clinical Oncology Group","Both","Adult|Senior","Phase II",129,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","CV185-027","April 28, 2006","01/06/2006",2009-01-01,"January 6, 2011","01/05/2009","",2009-01-01,"The occurrence of either a major bleeding (fatal or non-fatal) event or a clinically relevant non-major bleeding event|Symptoms compatible with venous thromboembolism","http://ClinicalTrials.gov/show/NCT00320255",NA
"46279",46279,"NCT00354055","Chemotherapy Followed By Autologous Natural Killer Cells and Aldesleukin in Treating Patients With Metastatic Melanoma or Kidney Cancer","Completed","No Results Available","Kidney Cancer|Melanoma (Skin)","Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",58,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000486918|NCI-06-C-0169|NCI-P6950","July 19, 2006","01/05/2006",NA,"April 18, 2009","01/11/2008","",2009-03-01,"Tumor regression|Clinical response|Natural killer (NK) cell repopulation in the immune system|Toxicity","http://ClinicalTrials.gov/show/NCT00354055",NA
"46305",46305,"NCT00394355","Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418AM4)(COMPLETED)","Completed","No Results Available","Asthma","Drug: mometasone furoate dry powder inhaler|Drug: mometasone furoate dry powder inhaler|Drug: fluticasone propionate HFA|Drug: montelukast|Drug: montelukast","Schering-Plough","Both","Adult","Phase IV",560,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","P03418|Doc ID: 3387777;|EUDRACT No: 2004-002930-21;","October 31, 2006","01/11/2006",2009-09-01,"January 15, 2010","01/01/2010","",2009-09-01,"Mean % change in lumbar spine BMD from the averaged baseline value (average of two scan results prior to treatment) to the endpoint of treatment time point, ie, average of last two valid post Baseline BMD scans during treatment period carried forward|Mean percent change in the left total femur and femoral neck BMD from the averaged baseline value to the averaged value at the endpoint of treatment time point.|All BMD assessments.","http://ClinicalTrials.gov/show/NCT00394355",NA
"46315",46315,"NCT00411255","Brain Stimulation to Treat Blepharospasm or Meige Syndrome","Completed","No Results Available","Blepharospasm|Focal Dystonia","Procedure: repetitive transcranial magnetic stimulation (rTMS)","National Institute of Neurological Disorders and Stroke (NINDS)","Both","Adult|Senior","Phase II",22,"NIH","Interventional","Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","060192|06-N-0192","December 12, 2006","01/06/2006",2009-04-01,"February 20, 2010","01/02/2010","",2009-04-01,"Patient report the subject rating of their symptoms before and after intervention.","http://ClinicalTrials.gov/show/NCT00411255",NA
"46323",46323,"NCT00426855","Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)","Completed","No Results Available","Lymphoma, Non-Hodgkin","Drug: Bendamustine|Drug: Bortezomib","Kantonsspital Aarau","Both","Adult|Senior","Phase I|Phase II",12,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZOHT-01/07|26866138LYM1003","January 24, 2007","01/01/2007",2009-06-01,"November 5, 2009","01/11/2009","",2009-02-01,"Optimal dosage|Overall Response Rate|Progression-free Survival","http://ClinicalTrials.gov/show/NCT00426855",NA
"46327",46327,"NCT00432055","Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy","Completed","No Results Available","Cerebral Palsy","Drug: Botulinum toxin type A (Botox)|Drug: placebo (saline)","Sunnaas Rehabilitation Hospital|The Royal Norwegian Ministry of Health","Both","Adult","Phase IV",66,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20624503|EudraCTnumber: 2006-001427-19","February 5, 2007","01/01/2007",2009-01-01,"February 23, 2009","01/02/2009","",2009-01-01,"Ankle sagittal kinematic with corresponding knee and hip data (3D-gait analysis)|Summary measure of health related quality of life (SF-36)|Stiffness/spasticity according to VAS|Questionnaire gait function|Spasticity in ankle, knee and hip according to Modified Ashworth Scale|3D-gait data (Kinetics,Temporospatial (stride length, velocity)|Global Scale|Timed Up and Go|6 minutes walking test|Registrations of sample characteristics|Registration of adverse reactions|Pain according to VAS","http://ClinicalTrials.gov/show/NCT00432055",NA
"46329",46329,"NCT00434655","Laparoscopic Adjustable Gastric Banding Versus Laparoscopic Sleeve Gastrectomy","Completed","No Results Available","Morbid Obesity","Procedure: Laparoscopic restrictive procedure","North Texas Veterans Healthcare System","Both","Adult","Phase III",40,"U.S. Fed","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07-010","February 9, 2007","01/01/2008",2009-12-01,"December 14, 2009","01/12/2009","",2009-12-01,"Short and long term clinical outcomes|Metabolic outcomes|Esophago-gastric physiology|Hormonal physiology|Procedure costs","http://ClinicalTrials.gov/show/NCT00434655",NA
"46365",46365,"NCT00473655","Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients","Completed","Has Results","Hypertriglyceridemia|Hyperlipoproteinemia Type IV|Hyperlipoproteinemia Type V|Hyperlipoproteinemia Type IIb|Hyperlipidemia","Drug: rosuvastatin","AstraZeneca","Both","Adult|Senior","Phase IV",334,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","DM-CRESTOR-0002","May 14, 2007","01/01/2007",2009-02-01,"November 30, 2010","01/11/2010","",2009-02-01,"Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8)|Non-HDL-C Reduction|LDL-C Reduction|Total Cholesterol Reduction|HDL-C Increase|ApoA1 Levels|hsCRP Reduction|Adverse Events Reported|ApoB Levels","http://ClinicalTrials.gov/show/NCT00473655",NA
"46419",46419,"NCT00567255","A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Obesity","Completed","No Results Available","Obesity","Drug: naltrexone SR/bupropion SR","Orexigen Therapeutics, Inc","Both","Adult","Phase III",1500,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NB-303","November 30, 2007","01/11/2007",2009-05-01,"January 22, 2010","01/01/2010","",2009-05-01,"Co-primary outcome measures are the percentage of total body weight lost and the percentage of subjects who achieve a weight decrease of greater than or equal to 5%|Proportion of subjects achieving a weight loss of ??­10%; Waist circumference; Fasting triglyceride,insulin, blood glucose and HDL cholesterol; HOMA-IR:IW QOL-Lite score; SF-36; IDS-SR score; hs-CRP; systolic and diastolic blood pressure","http://ClinicalTrials.gov/show/NCT00567255",NA
"46420",46420,"NCT00571155","Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery","Completed","No Results Available","Primary Brain Tumor|Epilepsy","Drug: levetiracetam","University Hospital Tuebingen","Both","Adult|Senior","Phase IV",30,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HELLO-Study 2007|EudraCT Number: 2007-005063-96","December 10, 2007","01/12/2007",2009-08-01,"August 19, 2009","01/08/2009","",2009-08-01,"Feasibility of standardized treatment of patients with primary brain tumors and symptomatic epilepsy with levetiracetam in the period of neurosurgical intervention.|Efficacy, safety and tolerance of intravenous and oral levetiracetam in patients with primary brain tumors and symptomatic epilepsy in the period of neurosurgical intervention.","http://ClinicalTrials.gov/show/NCT00571155",NA
"46424",46424,"NCT00572455","Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.","Completed","No Results Available","Primary Open Angle Glaucoma|Ocular Hypertension","Drug: PF-04217329--High Dose|Drug: PF-04217329--Low Dose|Drug: PF-04217329--Medium Dose|Drug: Xalatan|Drug: vehicle|Drug: High Dose PF-04217329 and Xalatan|Drug: Low Dose PF-04217329 and Xalatan|Drug: Medium Dose PF-04217329 and Xalatan","Pfizer","Both","Adult|Senior","Phase II",318,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","A0191001","December 11, 2007","01/12/2007",2009-06-01,"January 3, 2011","01/01/2011","",2009-06-01,"Mean diurnal IOP (intraocular pressure) change from baseline in the study eye at the Day 14 Visit (Stage 1)|Evaluation of ocular and systemic safety assessments throughout the study period (Stage 1)|Mean diurnal IOP (intraocular pressure) change from baseline in the study eye at the Day 28 Visit (Stage 2)|Proportion of patients reaching a target IOP across study visits.|Mean IOP value and its change from baseline in the study eye across study visits.|Evaluation of ocular and systemic safety assessments throughout the study period (Stage 2)|Proportion of patients reaching a target IOP across study visits (Stage 2)|Mean IOP value and its change from baseline in the study eye across study visits.","http://ClinicalTrials.gov/show/NCT00572455",NA
"46425",46425,"NCT00581555","Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy","Completed","No Results Available","Psoriasis","Drug: Etanercept|Other: Placebo","Wyeth","Both","Adult|Senior","Phase IV",154,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","0881A6-410","December 21, 2007","01/10/2007",2009-11-01,"April 9, 2010","01/04/2010","",2009-11-01,"Evaluation of change in PASI score from randomization to week 24|PASI Area under the Curve between randomization and week 24|Change in PGA score|% Relapse and time to relapse|% Improvement in PASI score|Change in DLQI|Incidence of adverse events|Rebound effects (worsening of psoriasis)","http://ClinicalTrials.gov/show/NCT00581555",NA
"46461",46461,"NCT00621855","RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome","Completed","No Results Available","Coronary Disease","Drug: Dabigatran etexilate|Drug: Placebo","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",1878,"Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1160.67|RE-DEEM EUDRACT2007-004301-99","February 13, 2008","01/03/2008",NA,"October 12, 2009","01/10/2009","",2009-10-01,"The composite of major and clinically relevant minor bleeding events during six months of treatment|Indicators of efficacy and composite of cardiovascular death or all cause death with: non fatal MI and non haemorrhagic stroke during six months of treatment.","http://ClinicalTrials.gov/show/NCT00621855",NA
"46495",46495,"NCT00669955","Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy","Completed","Has Results","Helicobacter Infections","Drug: Omeprazole, amoxicillin, clarithromycin|Drug: Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole","Axcan Pharma","Both","Adult|Senior","Phase III",440,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PYLHp07-01","April 29, 2008","01/06/2008",2009-08-01,"August 3, 2010","01/08/2010","",2009-07-01,"Helicobacter Pylori Eradication Confirmed by Urea Breath Test|Number of Patients Experiencing Treatment Emergent Adverse Events.|H. Pylori Eradication and Presence or Past History of Peptic Ulcers|Clarithromycin Resistance|Metronidazole Resistance|Overall Compliance to Study Medications|Number of Patients With Bismuth Plasma Concentrations Above the Toxic Level","http://ClinicalTrials.gov/show/NCT00669955",NA
"46512",46512,"NCT00731055","Effects of Varenicline on Cigarette Self Administration","Completed","No Results Available","Nicotine Dependence","Drug: Varenicline","New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)","Both","Adult","Phase II",30,"Other|NIH","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NIDA-17572-4|R01DA017572|DPMCDA","August 6, 2008","01/02/2008",2009-05-01,"December 8, 2009","01/12/2009","",2009-05-01,"Cigarette Choice.","http://ClinicalTrials.gov/show/NCT00731055",NA
"46520",46520,"NCT00740155","Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Na??ve Adults","Completed","No Results Available","Dengue Virus|Dengue Fever|Dengue Hemorrhagic Fever|Dengue Diseases","Biological: Bivalent CYD-1,3 Dengue (Vero)|Biological: Bivalent CYD-2,4 Dengue (Vero)|Biological: Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)|Biological: Tetravalent CYD-1,2,3,4 Dengue (Vero)|Biological: Japanese encephalitis virus vaccine inactivated","Sanofi-Aventis","Both","Adult","Phase II",154,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CYD11","May 7, 2008","01/08/2008",2010-01-01,"March 8, 2010","01/03/2010","",2009-10-01,"Safety: To provide information concerning the safety of ChimeriVax?ºÑ Dengue Vaccine","http://ClinicalTrials.gov/show/NCT00740155",NA
"46523",46523,"NCT00750555","Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: Erlotinib","Geisinger Clinic|Genentech","Both","Adult|Senior","Phase II",42,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0153|OSI4178S","September 9, 2008","01/09/2008",2009-12-01,"July 9, 2010","01/07/2010","",2009-12-01,"One year disease free|Overall Survival","http://ClinicalTrials.gov/show/NCT00750555",NA
"46529",46529,"NCT00763555","Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis","Completed","No Results Available","Psoriasis","Drug: CD 2027|Drug: Vehicle (placebo)","Galderma","Both","Adult|Senior","Phase II",88,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RD.06.SPR.18119","September 30, 2008","01/09/2008",2009-03-01,"December 2, 2010","01/12/2010","",2009-01-01,"Success rates at Week 8|Change in Global Severity Score from Baseline at Week 8","http://ClinicalTrials.gov/show/NCT00763555",NA
"46547",46547,"NCT00780455","Rehabilitation Study in MS Patients","Completed","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Drug: Interferon beta-1b (Betaseron, BAY86-5046)|Drug: Interferon beta-1b (Betaseron, BAY86-5046)","Bayer","Both","Adult|Senior","Phase IV",4,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13089|EudraCT No 2006-006673-24|308083","May 28, 2008","01/10/2008",2009-09-01,"July 5, 2010","01/07/2010","",2009-09-01,"The principal evaluation criterion is the covered distance during a walking test of 6 minutes (6MWT).|Persistence of the effect on 6 minute walk test, isokinetics of the knee and posturography|Isokinetics of the knee (muscular strength)|Posturography|Fatigue using FSS questionaire|Quality of life using SEP 59 questionaire|Number of AEs and SAEs reported","http://ClinicalTrials.gov/show/NCT00780455",NA
"46563",46563,"NCT00812955","Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (\Bad Cholesterol\"") and Triglycerides""","Completed","No Results Available","Dyslipidemias|Hypercholesterolemia|Coronary Heart Disease|Hypertriglyceridemia","Drug: ABT-143|Drug: simvastatin","Abbott","Both","Adult|Senior","Phase III",474,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","M10-667","December 18, 2008","01/11/2008",2009-06-01,"September 13, 2010","01/09/2010","",2009-06-01,"Percent change in LDL-C with ABT-143 20/135 mg versus simvastatin 40 mg|LDL-C|Percent change in LDL-C, with ABT-143 (10/135 mg) versus simvastatin 40 mg|Percent change in LDL-C with ABT-143 (5/135 mg) versus simvastatin 40 mg","http://ClinicalTrials.gov/show/NCT00812955",NA
"46564",46564,"NCT00818155","Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females","Completed","No Results Available","Depression","Drug: desvenlafaxine succinate SR|Other: Placebo","Wyeth","Both","Adult","Phase IV",36,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","3151A1-197","December 23, 2008","01/01/2009",2009-02-01,"July 8, 2009","01/07/2009","",2009-02-01,"Safety and tolerability as evaluated from reported adverse events, scheduled physical examinations, vital sign measurements, cardiac rhythm monitoring, 12 lead ECG and clinical laboratory results.|Pharmacokinetics as evaluated from blood and urine concentrations of desvenlafaxine","http://ClinicalTrials.gov/show/NCT00818155",NA
"46627",46627,"NCT00928655","Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude","Completed","No Results Available","Obstructive Sleep Apnea Syndrome","Drug: acetazolamide|Procedure: nocturnal continuous positive airway pressure|Drug: placebo","University of Zurich","Both","Adult|Senior","Phase IV",52,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EK-1522A#1-4","June 22, 2009","01/06/2009",2009-11-01,"May 25, 2010","01/05/2010","",2009-11-01,"sleep disordered breathing and oxygenation|sleep quality, vigilance, acute mountain sickness, blood pressure","http://ClinicalTrials.gov/show/NCT00928655",NA
"46658",46658,"NCT00988455","Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma With 6 Months Follow-up","Completed","No Results Available","Basal Cell Carcinoma","Radiation: photodynamic therapy","Shaheed Beheshti Medical University","Both","Adult|Senior","Phase I|Phase II",28,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","pdt bcc 2|zthr","September 29, 2009","01/01/2008",2009-08-01,"October 1, 2009","01/10/2009","",2009-03-01,"response rate at the end of therapy protocol (regarding tumor diameter and/or pathologic examination)|recurrence rate(regarding clinical and/or pathological examination) after 6 months of follow up","http://ClinicalTrials.gov/show/NCT00988455",NA
"46665",46665,"NCT01004055","Efficacy Study of a Bioelectric Dressing to Treat Wounds Caused by Curettage and Electrodesiccation","Completed","No Results Available","Wound Healing|Wound Infection","Device: Procellera?ºÑ Antimicrobial Wound Dressing|Drug: ACTICOAT?ºÑ Antimicrobial Barrier Dressing|Drug: Mepilex?ó Ag Silver Foam Dressing","Vomaris Innovations","Both","Adult|Senior","Phase II",15,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XSMP-011","October 27, 2009","01/07/2008",2009-10-01,"October 28, 2009","01/10/2009","",2009-08-01,"Wound healing over time|Comparing three FDA cleared products for pain reduction and incidence of infection","http://ClinicalTrials.gov/show/NCT01004055",NA
"46764",46764,"NCT01171755","Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer","Completed","No Results Available","Biliary Tract Cancer","Drug: Gemcitabine TS-1","Samsung Medical Center","Both","Adult|Senior","Phase II",48,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-12-017|82-02-3410-0914","July 27, 2010","01/02/2008",2009-12-01,"July 27, 2010","01/07/2010","GetBil",2009-12-01,"Response rate","http://ClinicalTrials.gov/show/NCT01171755",NA
"46785",46785,"NCT01202955","Pilot Study of Tolcapone in Smokers","Completed","No Results Available","Nicotine Dependence","Drug: Tolcapone|Drug: Placebo","University of Pennsylvania","Both","Adult","Phase II",16,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","808250","August 19, 2010","01/07/2008",2009-06-01,"September 15, 2010","01/08/2010","",2009-05-01,"To assess the feasibility and safety of administering the Catechol-O-Methyl-Transferase (COMT) inhibitor, tolcapone, to smokers|To obtain preliminary data on the effects of tolcapone on abstinence-induced neurocognitive deficits in abstinent smokers with differing COMT genotypes.","http://ClinicalTrials.gov/show/NCT01202955",NA
"46849",46849,"NCT00002556","Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Previously Untreated Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: carmustine|Drug: cyclophosphamide|Drug: melphalan|Drug: prednisone|Drug: vincristine sulfate","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",289,"Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000063435|E-5A93","November 1, 1999","01/04/1994",NA,"May 29, 2009","01/06/2002","",2009-05-01,"","http://ClinicalTrials.gov/show/NCT00002556",NA
"46911",46911,"NCT00079456","CCI-779 in Treating Patients With Relapsed or Refractory Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: temsirolimus","Arthur G. James Cancer Hospital & Richard J. Solove Research Institute|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",25,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000355767|OSU-0347|NCI-6186|OSU-2003C0090","March 8, 2004","01/02/2004",NA,"February 20, 2010","01/08/2006","",2009-03-01,"Overall response rate|Progression-free survival|Toxicity|Incidence of PTEN mutation|Pharmacodynamics","http://ClinicalTrials.gov/show/NCT00079456",NA
"46916",46916,"NCT00088556","Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: TLK286|Drug: carboplatin|Drug: paclitaxel","Telik","Both","Adult|Senior","Phase I|Phase II",100,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Masking: Open Label|Primary Purpose: Treatment","TLK286.2023","July 29, 2004","01/08/2004",2009-05-01,"May 27, 2009","01/05/2009","",2009-05-01,"","http://ClinicalTrials.gov/show/NCT00088556",NA
"46919",46919,"NCT00084656","Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma","Completed","No Results Available","Intraocular Melanoma|Melanoma (Skin)","Biological: ipilimumab|Biological: Tyrosinase/gp100/MART-1 Peptides","Bristol-Myers Squibb|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",75,"Industry|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000365467|P30CA076292|P30CA014089|MCC-15241|MDX010-16|NCI-6446|CA184-016","June 10, 2004","01/05/2004",NA,"April 23, 2010","01/04/2010","",2009-10-01,"First part of study: To achieve at least a 40% immune-related adverse event rate defined by the induction of Grade 1, grade 2, or acceptable grade 3 drug-related immune-related adverse events|Second part of study: To determine the time to disease relapse and to determine the rate of acceptable immune-related Grade 1, grade 2, or acceptable grade 3 drug-related immune-related adverse events|Determine incidence of drug-related irAEs (1st & 2nd part) through clinical and laboratory assessment of immune-related adverse events|Determine time to disease relapse (1st part) through diagnostic imaging assessments, including brain MRI|Determine immunologic response (1st & 2nd part) through assay of peripheral blood samples|Evaluate toxicity profile (1st & 2nd part) through clinical and laboratory assessment of adverse events","http://ClinicalTrials.gov/show/NCT00084656",NA
"47008",47008,"NCT00221156","Acarbose and Secondary Prevention After Coronary Stenting","Completed","No Results Available","Glucose Metabolism Disorders|Coronary Artery Disease","Drug: Acarbose","Translational Research Informatics Center, Kobe, Hyogo, Japan|Institute of Biomedical Research and Innovation|Kobe City General Hospital","Both","Adult|Senior","Phase III",300,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","BRI_CAD_04-02","September 13, 2005","01/05/2005",2009-04-01,"June 23, 2009","01/06/2009","",2009-04-01,"Cardiovascular event free survival time|Conversion of abnormal glucose tolerance to type 2 diabetes|All causes of death|Occurrence of every cardiovascular event|Occurrence of in-stent restenosis|Change in fasting, 2-hour blood glucose and insulin level|Change in homeostasis model assessment of insulin resistance|Change in hemoglobin A1c (HbA1c)|Change in lipid profile","http://ClinicalTrials.gov/show/NCT00221156",NA
"47040",47040,"NCT00271856","Staying Well: A Clinical Trial of Mindfulness-Based Stress Reduction and Education Groups for HIV","Completed","No Results Available","HIV","Behavioral: Mindfulness-Based Stress Reduction (MBSR)|Behavioral: HIV-education and self-management workshop","University of California, San Francisco|National Center for Complementary and Alternative Medicine (NCCAM)","Both","Adult|Senior","Phase II",200,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P01 AT002024|P01AT002024","December 30, 2005","01/05/2005",2009-09-01,"December 15, 2010","01/12/2010","",2009-09-01,"CD4 T-cell count and HIV viral load ; perceived stress (Cohen's Perceived Stress Scale); depression (Beck Depression Inventory; Prime-MD) and positive affect (PANAS scale).|Quality of life (SF-36); cortisol (basal a.m. and diurnal change); T-cell activation (measured by CD38-cell surface marker) and NK cell number and function; autonomic activity (blood pressure, estimated systemic vascular resistance); cell aging","http://ClinicalTrials.gov/show/NCT00271856",NA
"47105",47105,"NCT00370656","Effects of Pregabalin, Duloxetine & Amitriptyline on Pain & Sleep","Completed","No Results Available","Diabetes Mellitus|Peripheral Neuropathies","Drug: Pregabalin|Drug: Duloxetine|Drug: Amitriptyline","University of Surrey","Both","Adult|Senior","Phase II|Phase III",90,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CRC 235","August 31, 2006","01/02/2007",2009-05-01,"November 16, 2009","01/11/2009","",2009-05-01,"Whether there is a reduction in subjective pain as assessed by the Brief Pain Inventory.|Whether there has been an improvement in sleep continuity and subjective sleep, morning after cognitive and psychomotor performance, and quality of life (QoL).","http://ClinicalTrials.gov/show/NCT00370656",NA
"47118",47118,"NCT00388856","Antioxidant Supplementation in Pregnant Women With Low Antioxidant Status","Completed","No Results Available","Preeclampsia","Drug: Vitamin C 1000mg and E 400IU","Showa University|Indonesia University","Female","Child|Adult","Phase II",400,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","17791137","October 16, 2006","01/10/2006",2010-02-01,"February 16, 2010","01/03/2007","",2009-11-01,"preeclampsia cases|adverse pregnancy outcome","http://ClinicalTrials.gov/show/NCT00388856",NA
"47121",47121,"NCT00394056","Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss.","Completed","No Results Available","Tinnitus","Drug: Vestipitant + Paroxetine|Other: Placebo|Drug: Vestipitant","GlaxoSmithKline","Both","Adult","Phase II",26,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NKP106254","October 27, 2006","01/12/2006",2009-08-01,"February 18, 2010","01/02/2010","",2009-08-01,"Visual Analog Scales (VAS) to measure the change in tinnitus loudness as perceived at the moment of the measurement at 2 hrs after dosing (or at any other time point vs. pre-dose baseline).|VAS to measure tinnitus pitch, distress and anxiety. Pure Tone Audiometry & Psychoacoustic assessment. Sleep & Tinnitus questionnaires. Safety, tolerability and pharmacokinetics of drug.","http://ClinicalTrials.gov/show/NCT00394056",NA
"47146",47146,"NCT00427856","Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)","Completed","No Results Available","Lymphoma, Follicular","Drug: Obatoclax mesylate (GX15-070MS)","Gemin X","Both","Adult|Senior","Phase II",7,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEM014","January 25, 2007","01/03/2007",2009-07-01,"September 14, 2010","01/09/2010","",2009-02-01,"Determine the response rate to obatoclax in combination with rituximab and characterize the safety profile.|Time to Tumor Progression.","http://ClinicalTrials.gov/show/NCT00427856",NA
"47149",47149,"NCT00429156","Non-invasive Ventilation Versus Sham Ventilation in Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Hypercapnic Respiratory Failure|Chronic Obstructive Pulmonary Disease","Device: Home non-invasive ventilation|Device: Home non-invasive ventilation (sham)","United Christian Hospital|Respironics|Hong Kong Lung Foundation","Both","Adult|Senior","Phase III",46,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KC/KE 06-0147/FR-1","January 30, 2007","01/01/2007",2009-02-01,"October 22, 2009","01/10/2009","",2009-02-01,"Time to first life-threatening event (recurrent AHRF and death) within the first year of hospital discharge, after an episode of AHRF treated by acute NIV.|Withdrawal from study|Number of readmissions|NIV use|Intubation|Hospitalised days|Blood gases levels in the first year after discharge","http://ClinicalTrials.gov/show/NCT00429156",NA
"47184",47184,"NCT00478556","Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT","Completed","Has Results","Healthy","Drug: Omnipaque|Drug: Gastroview","University of Alabama at Birmingham|GE Healthcare","Both","Adult|Senior","Phase IV",300,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Diagnostic","F070208011|Omnipaque vs Gastroview Oral","May 24, 2007","01/08/2007",2009-03-01,"May 19, 2010","01/05/2010","",2009-03-01,"Preferred Contrast Agent|Bowel Opacification Score","http://ClinicalTrials.gov/show/NCT00478556",NA
"47256",47256,"NCT00594256","Sodium Oxybate in Schizophrenia With Insomnia","Completed","No Results Available","Schizophrenia|Insomnia Associated to Schizophrenia","Drug: Sodium Oxybate","Nathan Kline Institute for Psychiatric Research|Jazz Pharmaceuticals","Both","Adult","Phase II",8,"Other|Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07I/C36-0","January 3, 2008","01/05/2008",2009-04-01,"November 30, 2009","01/11/2009","",2009-04-01,"Pittsburgh Sleep Quality Index|Epworth Sleepiness Scale|Positive and Negative Syndrome Scale (PANSS)|MATRICS+ neurocognitive battery|Polysomnographic Measures","http://ClinicalTrials.gov/show/NCT00594256",NA
"47263",47263,"NCT00600756","Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone","Completed","No Results Available","Schizophrenic Disorders","Drug: Quetiapine XR|Drug: Risperidone","AstraZeneca","Both","Adult","Phase III",798,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D1443L00039","January 9, 2008","01/01/2008",2009-10-01,"February 22, 2010","01/02/2010","RECOVER",2009-10-01,"The primary objective of this study is to demonstrate the non-inferiority of quetiapine XR to risperidone assessed at month 6 in terms of responder rate using the self-report instrument SWN-K.|Among other things a secondary objective of particular interest is to demonstrate the non-inferiority of quetiapine XR to risperidone assessed at month 12 by evaluating the change from baseline in SWN-K mean total score.","http://ClinicalTrials.gov/show/NCT00600756",NA
"47267",47267,"NCT00595556","Zonisamide vs. Placebo in the Treatment of Alcohol Dependence","Completed","Has Results","Alcoholism|Alcohol Abuse|Alcohol Dependence","Drug: zonisamide|Drug: Placebo","University of Connecticut Health Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Center for Research Resources (NCRR)","Both","Adult","Phase IV",40,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","06-113-1|P50 AA03510|M01RR006192","January 6, 2008","01/07/2006",2009-05-01,"September 28, 2010","01/09/2010","",2009-05-01,"Change in Number of Heavy Drinking Days (i.e., 5 or More Drinks Per Day for Men, and 4 or More Per Day for Women)Per Week, by Week|Weekly Rate of Change in Abstinent Days|Change in Number of Drinks Per Week by Week|Change in the Urge to Drink Alcohol as Measured by the Alcohol Urge Questionnaire (AUQ)|Change in Gamma-glutamyl Transferase (GGT) Concentration","http://ClinicalTrials.gov/show/NCT00595556",NA
"47271",47271,"NCT00612456","A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD","Completed","No Results Available","Macular Degeneration","Drug: Pazopanib","GlaxoSmithKline","Both","Adult|Senior","Phase II",70,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MD7108240","January 29, 2008","01/02/2008",2009-01-01,"April 22, 2010","01/04/2010","",2009-01-01,"central retinal thickness measured by OCT, an imaging technique|Clinical lab tests, ECG, vital signs, eye exam, visual acuity|Retinal morphology, neovascular size, and lesion size and characteristics|Plasma pharmacokinetics|Safety endpoints include complete ophthalmic examination, vital signs (heart rate and blood pressure), cardiac monitoring (electrocardiogram), clinical laboratory tests, clinical monitoring and adverse event reporting.|Change in visual acuity (number of letters read on standardized ETDRS charts).|Change in retinal morphology (i.e. CNV, intraretinal cysts, intraretinal fluid, subretinal fluid, and retinal pigment epithelial detachment) as determined by OCT.|Change in neovascular size, lesion size and characteristics (fibrosis, atrophy, blood) as measured by fluorescein angiography and fundus photography.|Cmax, tmax, and AUC(0-24) of plasma pazopanib, if data are sufficient.","http://ClinicalTrials.gov/show/NCT00612456",NA
"47282",47282,"NCT00630656","Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis","Completed","No Results Available","Severe Sepsis","Drug: Talactoferrin alfa|Drug: Placebo","Agennix","Both","Adult|Senior","Phase II",190,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","LF-0801|NIH grant 1R44GM077816-01A2","February 28, 2008","01/04/2008",2010-02-01,"August 25, 2010","01/08/2010","",2009-08-01,"All-cause mortality|All-cause mortality|All-cause mortality","http://ClinicalTrials.gov/show/NCT00630656",NA
"47283",47283,"NCT00638456","Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis","Completed","No Results Available","Eosinophilic Esophagitis","Drug: Budesonide plus Prevacid|Drug: placebo plus Prevacid","University of California, San Diego|Meritage Pharma, Inc.","Both","Child|Adult|Senior","Phase II",33,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VPI-106-01","March 12, 2008","01/02/2008",2009-09-01,"September 9, 2009","01/09/2009","",2009-09-01,"Histologic resolution of esophageal eosinophilia on repeat endoscopy.|Endoscopic resolution of esophagitis and improvement in EE symptom score as assessed by a pediatric EE questionnaire.|Open Label Budesonide given and measured through endoscopic resolution of esophagitis and improvement in EE symptoms","http://ClinicalTrials.gov/show/NCT00638456",NA
"47325",47325,"NCT00693056","Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)","Completed","No Results Available","Erectile Dysfunction (ED)","Drug: Placebo|Drug: RX-10100 5mg|Drug: RX-10100 10mg|Drug: RX-10100 15mg","Rexahn Pharmaceuticals, Inc.","Male","Adult","Phase II",40,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RX-10100-P2A-001","June 4, 2008","01/06/2008",2009-05-01,"May 4, 2009","01/05/2009","",2009-03-01,"Scores on IIEF-EF Questionnaires and on SEP Questions II and III|Scores on other domains of IIEF, other questions on Subject Diaries, RigiScan measurement, and ED-QoL questionnaires","http://ClinicalTrials.gov/show/NCT00693056",NA
"47335",47335,"NCT00709956","Iloprost Power 15 in Pulmonary Arterial Hypertension","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: iloprost power 15 ( Ventavis(R))|Drug: placebo","Actelion","Both","Adult|Senior","Phase III",70,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-063A301","July 1, 2008","01/06/2008",2009-09-01,"August 17, 2010","01/08/2010","PROWESS 15",2009-08-01,"6-minute-walk distance after a single dose of iloprost power 15 or placebo|Borg dyspnea score after a single dose of iloprost power 15 or placebo","http://ClinicalTrials.gov/show/NCT00709956",NA
"47348",47348,"NCT00735956","PARTNER Recruitment and Brief Intervention Pilot Study","Completed","No Results Available","Alcohol Abuse","Behavioral: Counseling","Duke University","Both","Child|Adult","Phase I|Phase II",300,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","Pro00006998","August 13, 2008","01/09/2008",2009-08-01,"August 19, 2010","01/08/2010","PARTNER",2009-02-01,"The trial will compare the effectiveness of using an onsite behavioral health specialist for screening, intervention and referral with basic written information and staff recommendations typically provided in primary care offices.|Assessments and early intervention of identifying alcohol abuse in minors.","http://ClinicalTrials.gov/show/NCT00735956",NA
"47367",47367,"NCT00764556","Phase II Study of Safety and Feasibility of Intensive Blood Glucose Control With Insulin on Acute Medical Wards","Completed","No Results Available","COPD|Hyperglycemia","Drug: Insulin","St George's, University of London","Both","Adult|Senior","Phase II",20,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SGH-ClinPharm-1|EudraCT 2007-004956-35|Ethics 07/H0715/93","October 1, 2008","01/05/2008",2009-05-01,"October 13, 2009","01/10/2009","IPS2008",2009-05-01,"The frequency of severe hypoglycaemia - Neuroglycopenic symptoms (other than mild agitation) responsive to administration of carbohydrate|The frequency of symptomatic hypoglycaemia (capillary glucose???3.3mM AND symptoms consistent with hypoglycaemia)|The frequency of asymptomatic hypoglycaemia (capillary glucose???3.3mM without any symptoms consistent with hypoglycaemia).|Mean 24 hour capillary glucose concentrations|Proportion of capillary glucose measurements in target range (4.4-6.5mM)|Comparison of capillary blood glucose measurements to those obtained from the Guardian REAL?ó-time continuous glucose monitoring system|Comparison of rates of detection of hypoglycaemia by capillary and continuous blood glucose monitoring|Quantification of acceptability of the study intervention to patients","http://ClinicalTrials.gov/show/NCT00764556",NA
"47370",47370,"NCT00730756","A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis","Completed","Has Results","Rhinitis, Allergic, Perennial|Irritant (Non-Allergic) Rhinitis","Drug: Fluticasone Furoate Nasal Spray|Other: Placebo Nasal Spray","GlaxoSmithKline","Both","Child|Adult|Senior","Phase II",102,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","FFR111158","February 27, 2008","01/03/2008",2009-02-01,"October 21, 2010","01/10/2010","",2009-02-01,"Mean Change From Baseline in Daily rTNSS Over the Entire Treatment Period (28 Days)|Mean Change From Baseline in AM rTNSS, PM rTNSS, and AM Pre-dose iTNSS Over the Entire Treatment Period (28 Days)|Mean Change From Baseline in Daily Reflective Individual Nasal Symptoms Score Over the Entire Treatment Period (28 Days)|Mean Change From Baseline in AM Pre-dose Instantaneous Individual Nasal Symptoms Over the Entire Treatment Period (28 Days)|Mean Change From Baseline in AM and PM Reflective Individual Nasal Symptoms Over the Entire Treatment Period (28 Days)|Mean Change From Baseline in Total Ocular Symptoms Over the Entire Treatment Period (28 Days)|Mean Change From Baseline in Daily Reflective Individual Ocular Symptoms Over the Entire Treatment Period (28 Days)|Mean Change From Baseline in AM Pre-dose Instantaneous Individual Ocular Symptoms Over the Entire Treatment Period (28 Days)|Mean Change From Baseline in AM and PM Reflective Individual Ocular Symptoms Over the Entire Treatment Period (28 Days)","http://ClinicalTrials.gov/show/NCT00730756",NA
"47390",47390,"NCT00799656","Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain","Completed","No Results Available","Pain","Drug: ataciguat (HMR1766)|Drug: placebo","Sanofi-Aventis","Both","Adult|Senior","Phase II",62,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","DFI10569|EudraCT 2008-001518-26","November 27, 2008","01/11/2008",2009-09-01,"June 15, 2010","01/06/2010","SERENEATI",2009-06-01,"Change in average daily pain intensity|Responder rate|Rescue medication intake|Change in Neuropathic Pain Symptom Inventory (NPSI)","http://ClinicalTrials.gov/show/NCT00799656",NA
"47396",47396,"NCT00803556","Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy","Completed","No Results Available","Solid Tumor|Breast Cancer","Drug: Alvespimycin|Drug: Trastuzumab|Drug: Paclitaxel","Bristol-Myers Squibb","Both","Adult|Senior","Phase I|Phase II",50,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA201-001|KDG 132","December 4, 2008","01/01/2006",2009-08-01,"November 4, 2009","01/11/2009","",2009-08-01,"No formal analysis of efficacy will occur. For patients with measurable disease, response will be assessed by RECIST criteria first after two cycles of therapy (8 weeks in patients having no delay in the schedule of administration)|Subsequent response evaluations will occur following every two cycles of treatment (8 weeks). All patients with responding tumors (CR or PR) must have the response confirmed 4 weeks after the first documentation of response, confirmed by CT|To evaluate the safety and cumulative toxicity of repeated dosing of KOS-1022 when administered in combination with trastuzumab or trastuzumab/paclitaxel|2. To determine the pharmacokinetics of KOS-1022 when delivered via weekly infusion when administered in combination with trastuzumab or trastuzumab/paclitaxel|To determine the effect of KOS-1022 on the expression of Hsp90-client proteins in peripheral blood lymphocytes|To describe any evidence of anti-tumor activity","http://ClinicalTrials.gov/show/NCT00803556",NA
"47457",47457,"NCT00915356","Intravenous Cardioversion of Atrial Fibrillation With AZD1305","Completed","No Results Available","Atrial Fibrillation","Drug: AZD1305|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase II",228,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","D3191C00009|2009-009862-15 (EudraCT No)","June 5, 2009","01/05/2009",2009-12-01,"October 4, 2010","01/10/2010","",2009-12-01,"QTcF interval|Heart rhythm (conversion of Atrial Fibrillation to Sinus Rhythm)|Safety and tolerability variables|Pharmacokinetic variables|Heart rhythm","http://ClinicalTrials.gov/show/NCT00915356",NA
"47485",47485,"NCT00954356","Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction","Completed","No Results Available","Dental Pain","Drug: XPF-001|Drug: placebo","Xenon Pharmaceuticals Inc.","Both","Adult","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XPF-001-201","July 22, 2009","01/09/2009",2009-12-01,"May 28, 2010","01/05/2010","",2009-11-01,"Total pain relief at 6 hours post dose (TOTPAR 6)|Summed Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at defined timepoints post dose|Time to first perceptible and first meaningful relief|Time to rescue medication|Adverse Events, ECGs, vital sign and laboratory measurements","http://ClinicalTrials.gov/show/NCT00954356",NA
"47514",47514,"NCT01006356","The Clinical Usefulness of Hydromorphone HCl ORal Osmotic System in the Reduction of Breakthrough Pain Medication Frequency","Completed","No Results Available","Pain","Drug: Hydromorphone HCl OROS","Janssen Korea, Ltd., Korea","Both","Adult|Senior","Phase IV",73,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR015694","October 29, 2009","01/10/2008",2009-09-01,"April 26, 2010","01/04/2010","",2009-09-01,"Change in medication frequency of immediate release analgesic for breakthrough pain treatment|Breakthrough pain frequency|Change in Korean-Brief Pain Inventory|Change in pain intensity (using numeric rating scale & Korean- Brief Pain Inventory)|Change in European Organization for Research and Treatment of Cancer Quality of Life -C30|Clinical Global Impression-Improvement (Clinical Global Improvement assesses the patient's improvement or worsening from baseline, which is usually the beginning of a clinical trial.)","http://ClinicalTrials.gov/show/NCT01006356",NA
"47550",47550,"NCT01067456","Diagnostic Value of Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Undifferentiated Acute Chest Pain","Completed","No Results Available","Acute Chest Pain","Radiation: Comprehensive Cardiothoracic DSCT arm","Massachusetts General Hospital|Bracco Diagnostics, Inc","Both","Adult|Senior","Phase II",59,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2008P000389","February 10, 2010","01/05/2008",2010-01-01,"February 10, 2010","01/02/2010","CAPTURE",2009-06-01,"To compare rate of discharge and length of hospital stay between comprehensive cardiothoracic DSCT and dedicated PE/ACS/AD CT Scan protocols|To compare the cost of care between the comprehensive cardiothoracic CT arm and the dedicated AD/ACS/PE CT protocol (standard of care) arm","http://ClinicalTrials.gov/show/NCT01067456",NA
"47555",47555,"NCT01075256","Dose Response of a Tubule Occlusion Agent","Completed","No Results Available","Dental Pain","Drug: Monographed toothpaste|Device: Occlusion Product 2|Device: Placebo|Other: Occlusion Product 1","GlaxoSmithKline","Both","Adult","Phase IV",195,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","Z3690607","February 23, 2010","01/12/2008",2009-03-01,"February 23, 2010","01/02/2010","",2009-03-01,"Change from baseline Evaporative Sensitivity Pain Response on a visual analogue scale (VAS) at week 2|Change from baseline Thermal Sensitivity Pain Response (VAS) at week 2|Oral tolerance adverse events","http://ClinicalTrials.gov/show/NCT01075256",NA
"47585",47585,"NCT01127256","Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation","Completed","No Results Available","Epilepsy","Drug: zonisamide|Drug: carbamazepine","Eisai Korea Inc.","Both","Child|Adult|Senior","Phase IV",200,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E2090-S082-405","May 19, 2010","01/05/2006",2009-07-01,"May 19, 2010","01/05/2010","",2009-05-01,"Seizure free rate|Quality of life assessment","http://ClinicalTrials.gov/show/NCT01127256",NA
"47631",47631,"NCT01200056","Virtual Histology Findings and Effects of Varying Doses of Atorvastatin Treatment","Completed","No Results Available","Coronary Disease|Ultrasonography, Interventional|Hydroxymethylglutaryl-CoA Reductase Inhibitors","Drug: Atorvastatin 10mg versus 40mg.","The University of Hong Kong|Queen Mary Hospital, Hong Kong|Pfizer","Both","Adult|Senior","Phase IV",40,"Other|Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UW 07-266 (IRB HKU)|HKCTR-517","September 9, 2010","01/08/2007",2010-06-01,"September 10, 2010","01/09/2010","VENUS",2009-11-01,"The primary endpoint would be the 6-month angiographic and VH-IVUS restudy findings.|The secondary endpoint would be the occurrence of any major adverse cardiac events at 6 months (including any death, myocardial infarction or need for revascularization) as routinely monitored after all percutaneous interventional procedures.","http://ClinicalTrials.gov/show/NCT01200056",NA
"47645",47645,"NCT01227356","A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia","Completed","No Results Available","Health Care Quality|Health Care Evaluation","Drug: imatinib and pegylated interferon","Uppsala University|Uppsala University Hospital|Karolinska University Hospital","Both","Adult|Senior","Phase II",112,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NordCML002","October 22, 2010","01/09/2004",2009-11-01,"October 22, 2010","01/10/2010","",2009-03-01,"Comparison of rate Major Molecular Response between treatment arms|Comparison of complete cytogenetic response between the treatment arms at 12 months|Comparison rate complete cytogenetic response between the treatment arms at 12 months","http://ClinicalTrials.gov/show/NCT01227356",NA
"47724",47724,"NCT00015457","Amlodipine Plus Botulinum Toxin for Focal Dystonia","Completed","No Results Available","Focal Dystonia","Drug: Amlodipine plus Botulinum toxin","National Institute of Neurological Disorders and Stroke (NINDS)","Both","Adult|Senior","Phase II",80,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","010147|01-N-0147","April 18, 2001","01/04/2001",NA,"January 28, 2010","01/04/2009","",2009-04-01,"Change in response to botulinum toxin injection.|Change in duration of response to bolulinum toxin injection.","http://ClinicalTrials.gov/show/NCT00015457",NA
"47738",47738,"NCT00038857","Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases","Completed","No Results Available","Leukemia|Lymphoma","Procedure: Megadose of CD34 Selected Progenitor Cells","M.D. Anderson Cancer Center","Both","Child|Adult","Phase II",29,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID01-220","June 5, 2002","01/09/2001",2009-06-01,"September 18, 2009","01/09/2009","",2009-06-01,"To learn if purified CD34 peripheral blood progenitor cell (PBPC) transplants are an effective treatment for patients with hematological malignant diseases.","http://ClinicalTrials.gov/show/NCT00038857",NA
"47755",47755,"NCT00058357","Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery","Completed","No Results Available","Pain|Unspecified Adult Solid Tumor, Protocol Specific","Drug: lidocaine","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",100,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care","CDR0000288824|NCCTG-N01CB","April 7, 2003","01/05/2004",NA,"November 24, 2009","01/06/2006","",2009-02-01,"Pain intensity rating (NRS)|Pain as assessed by the Brief Pain Inventory-Short Form, Neuropathy Pain Scale, Subject Global Impression of Change, Pain Catastrophizing Scale, Profile of Mood States Short Form, and NCCTG Quality of Life|Incidence of each toxicity reported in each treatment period|Maximum severity reported of each toxicity|Distribution of the overall toxicity score|Proportion of patients who report a preference for lidocaine patch or placebo at study completion|Proportion of patients who terminate treatment prematurely","http://ClinicalTrials.gov/show/NCT00058357",NA
"47778",47778,"NCT00111657","Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout","Completed","No Results Available","Gout","Biological: Pegloticase","Duke University|Savient Pharmaceuticals","Both","Adult|Senior","Phase II",30,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FD-R-02537","May 24, 2005","01/12/2004",2009-07-01,"October 7, 2010","01/10/2010","",2009-07-01,"Reduction in plasma uric acid to less than 6 mg/dL|Clinical response will be evaluated, including the frequency of gout flares, number and distribution of swollen/tender joints, change in size of tophi, change in functional status|In a subset of subjects who volunteer separately, change in uric acid pool size will be assessed by a method that involves infusion of uric acid labeled with N15, a stable (nonradioactive) isotope of nitrogen.|Reduction of the ratio of uric acid:creatinine in urine|Development of antibodies to PEG-uricase|Pharmacokinetics of PEG-uricase","http://ClinicalTrials.gov/show/NCT00111657",NA
"47783",47783,"NCT00116857","Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors","Completed","No Results Available","Cardiovascular Diseases|Depression|Heart Diseases|Myocardial Infarction|Angina, Unstable","Drug: Sertraline/omega-3|Drug: Sertraline/Corn Oil","National Heart, Lung, and Blood Institute (NHLBI)","Both","Adult|Senior","Phase III",122,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","186|R01 HL76808","June 30, 2005","01/02/2005",2009-11-01,"November 5, 2010","01/02/2009","",2009-06-01,"Depression interview and self-report inventory|Procoagulant and proinflammatory markers and plasma levels of sertraline and omega-3 from blood draws","http://ClinicalTrials.gov/show/NCT00116857",NA
"47811",47811,"NCT00157157","Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients","Completed","No Results Available","Hemophilia A","Drug: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM)|Drug: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM)|Drug: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM)","Baxter Healthcare Corporation","Both","Child","Phase III",50,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","60103","September 9, 2005","01/04/2004",2009-09-01,"September 16, 2009","01/09/2009","",2009-09-01,"To assess the immunogenicity of rAHF PFM by determining the risk of factor VIII inhibitor development|To assess in vivo incremental recovery of rAHF PFM|To evaluate the hemostatic efficacy of rAHF PFM in the management of acute bleeding events|To evaluate the hemostatic efficacy of rAHF PFM during surgical prophylaxis, if surgery is required|To assess the safety of rAHF-PFM","http://ClinicalTrials.gov/show/NCT00157157",NA
"47856",47856,"NCT00232557","Telecommunications System in Asthma","Completed","No Results Available","Asthma","Device: Telephone","Department of Veterans Affairs","Both","Adult|Senior","Phase III",170,"U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","IIR 01-054","September 30, 2005","01/08/2004",2009-12-01,"May 11, 2010","01/05/2010","",2009-07-01,"Unscheduled Asthma-related Visits|Oral Corticosteroid Use; Quality of Life; Medication Adherence","http://ClinicalTrials.gov/show/NCT00232557",NA
"47907",47907,"NCT00105157","Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies","Completed","Has Results","HIV Infections|Acquired Immunodeficiency Syndrome","Drug: Comparator: MK0518|Drug: MK0518|Drug: MK0518|Drug: Placebo","Merck","Both","Adult|Senior","Phase II",179,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2005_007|MK0518-005","March 8, 2005","01/03/2005",NA,"June 17, 2010","01/06/2010","",2009-07-01,"Change From Baseline in Plasma HIV RNA (log10 Copies/mL) at Week 24|Number of Patients With Virologic Responses at Week 24|Change From Baseline in CD4 Cell Count at Week 24|Number of Patients With Clinical Adverse Experiences (CAEs) at 48 Weeks|Number of Patients With Serious CAEs at 48 Weeks|Number of Patients With Drug-related CAEs at 48 Weeks|Number of Patients With Serious Drug-related CAEs at 48 Weeks|Number of Patients That Died by 48 Weeks|Number of Patients That Discontinued With CAEs at 48 Weeks|Number of Patients That Discontinued With Drug-related CAEs at 48 Weeks|Number of Patients That Discontinued With Serious CAEs at 48 Weeks|Number of Patients That Discontinued With Serious Drug-related CAEs at 48 Weeks|Number of Patients With Laboratory Adverse Experiences (LAEs) at 48 Weeks|Number of Patients With Drug-related LAEs at 48 Weeks|Number of Patients Discontinued With Laboratory Adverse Experiences (LAEs) at 48 Weeks|Number of Patients Discontinued With Drug-related LAEs at 48 Weeks|Number of Patients With Clinical Adverse Experiences (CAEs) at 96 Weeks|Number of Patients With Serious CAEs at 96 Weeks|Number of Patients With Drug-related CAEs at 96 Weeks|Number of Patients With Serious Drug-related CAEs at 96 Weeks|Number of Patients That Died by 96 Weeks|Number of Patients That Discontinued With CAEs at 96 Weeks|Number of Patients That Discontinued With Drug-related CAEs at 96 Weeks|Number of Patients That Discontinued With Serious CAEs at 96 Weeks|Number of Patients That Discontinued With Serious Drug-related CAEs at 96 Weeks|Number of Patients With Laboratory Adverse Experiences (LAEs) at 96 Weeks|Number of Patients With Drug-related LAEs at 96 Weeks|Number of Patients Discontinued With Laboratory Adverse Experiences (LAEs) at 96 Weeks|Number of Patients Discontinued With Drug-related LAEs at 96 Weeks|Number of Patients With Clinical Adverse Experiences (CAEs) at 168 Weeks|Number of Patients With Serious CAEs at 168 Weeks|Number of Patients With Drug-related CAEs at 168 Weeks|Number of Patients With Serious Drug-related CAEs at 168 Weeks|Number of Patients That Died by 168 Weeks|Number of Patients That Discontinued With CAEs at 168 Weeks|Number of Patients That Discontinued With Drug-related CAEs at 168 Weeks|Number of Patients That Discontinued With Serious CAEs at 168 Weeks|Number of Patients That Discontinued With Serious Drug-related CAEs at 168 Weeks|Number of Patients With Laboratory Adverse Experiences (LAEs) at 168 Weeks|Number of Patients With Serious LAEs at 168 Weeks|Number of Patients Discontinued With Drug-related LAEs at 168 Weeks|Number of Patients With Drug-related LAEs at 168 Weeks|Number of Patients With Serious Drug-related LAEs at 168 Weeks|Number of Patients Discontinued With LAEs at 168 Weeks","http://ClinicalTrials.gov/show/NCT00105157",NA
"47923",47923,"NCT00326157","PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation","Completed","No Results Available","Fungus Diseases","Drug: AmBisome","Gilead Sciences","Both","Adult|Senior","Phase II",34,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","GS-IT-131-0151","May 10, 2006","01/06/2006",2009-11-01,"February 11, 2010","01/02/2010","",2009-01-01,"Safety and tolerability profile will be obtained by considering: Number (%) of patients with adverse events (AEs)|Number (%) of patients with infusion related AE|Laboratory parameters (in particular renal toxicity, hepatotoxicity, hypokalaemia, hypomagnesaemia)|Overall adverse events|Number (%) of patients with probable or proven invasive fungal infection according to EORTC-MSG criteria within the 6 months following the initiation of prophylaxis treatment|Number (%) of patients with fever of unknown origin requiring empirical antifungal treatment within the 6 months following the initiation of prophylaxis treatment|Number (%) of patients with superficial fungal infections within the 6 months following the initiation of prophylaxis treatment|Number (%) of patients with evidence of colonization by fungal organisms observed within the 6 months following the initiation of prophylaxis treatment|Reasons for early study discontinuation|Survival rate and incidence of mortality related to fungal infection at the end of treatment and within 3, 6, and 12 months after the initiation of prophylaxis treatment|Time to probable or proven invasive fungal infection; fever of unknown origin requiring empirical antifungal treatment|Time to superficial fungal infections|Time to initiation of empirical antifungal treatment|Time to study discontinuation|Number of patients enrolled|Number of patients completing the study|Number of patients with early discontinuation|Number of patients classified by reason for discontinuing study drug (including the study completion)","http://ClinicalTrials.gov/show/NCT00326157",NA
"48008",48008,"NCT00467857","Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora Contamination","Completed","No Results Available","Skin Flora Contamination","Device: cyanoacrylate based microbial sealant|Other: Standard preoperative skin preparation","Kimberly-Clark Corporation","Both","Adult|Senior","Phase IV",310,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","IS 100-06-0001","April 27, 2007","01/04/2007",2009-03-01,"April 2, 2009","01/01/2009","",2009-03-01,"Qualitative reduction in skin flora at the end of surgery compared to the intact skin flora at the start of the surgery between two treatment groups.|Compare quantitative reduction in microbial count of skin flora at the end of surgery to intact skin at the beginning of surgery between two treatment groups.|Comparison of quantitative microbial counts at end of surgery between two treatment groups.|Comparison of qualitative reduction in skin flora immediately post incision to intact skin flora at beginning of surgery between two treatment groups.|Comparison of quantitative reduction in microbial count of skin flora immediately post-incision to intact skin flora at beginning of surgery between two treatment groups.|Comparison of quantitative microbial count of skin flora immediately post-incision between two treatment groups.|Evaluation of proportion of subjects with SSIs between two treatment groups.|Evaluation of other factors related to SSIs.","http://ClinicalTrials.gov/show/NCT00467857",NA
"48108",48108,"NCT00623857","Micronutrients and Child Health Study","Completed","No Results Available","Malaria","Dietary Supplement: Zinc|Dietary Supplement: Vitamins and minerals other than zinc|Dietary Supplement: Vitamins plus zinc and other minerals|Dietary Supplement: Placebo","Wageningen University|Kilimanjaro Christian Medical Centre, Tanzania","Both","Child","Phase III",612,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","WAO 93-442","February 14, 2008","01/03/2008",2009-03-01,"March 3, 2010","01/03/2010","MACH",2009-03-01,"Febrile malaria episodes|Haematologic and urinary indicators of micronutrient status|Anthropometric indices|T cell immune responses to in vitro stimulation with a crude Plasmodium falciparum lysate|Plasma immunoglobulin concentrations","http://ClinicalTrials.gov/show/NCT00623857",NA
"48112",48112,"NCT00631657","A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106)(P05701AM2)","Completed","No Results Available","Sleep Initiation and Maintenance Disorders|Mental Disorders|Dyssomnias|Sleep Disorders|Sleep Disorder, Intrinsic","Drug: Org 50081|Drug: Placebo","Schering-Plough","Both","Adult","Phase III",460,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21106|P05701","February 29, 2008","01/03/2008",2009-11-01,"December 3, 2009","01/12/2009","Aquamarine",2009-11-01,"Total Sleep Time as recorded daily in the sleep diary|To demonstrate the long-term efficacy in improving sleep latency|To investigate the long term efficacy on other sleep maintenance parameters and on sleep quality and satisfaction with sleep duration.|To investigate long-term safety and tolerability.|To investigate the effects of discontinuation after long-term treatment.|To explore the effect on functional and quality of life outcomes","http://ClinicalTrials.gov/show/NCT00631657",NA
"48128",48128,"NCT00656357","Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers","Completed","No Results Available","Cocaine Dependence","Drug: SYN117|Drug: SYN117","Synosia Therapeutics, Inc.|National Institute on Drug Abuse (NIDA)","Both","Adult","Phase I|Phase II",20,"Industry|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SYN117-CL01","April 4, 2008","01/06/2008",NA,"December 3, 2009","01/12/2009","",2009-05-01,"Determine the safety of treatment with SYN117 in cocaine-dependent volunteers by measuring hemodynamic and subjective effects of administration of ascending doses of cocaine(10mg, 20mg, 40mg)and placebo during treatment with ascending doses of SYN117.|Determine tolerability by measuring adverse events|Determine subjective effects produced by self administration of cocaine or placebo|Determine the effect of SYN117 of the pharmacokinetics of IV cocaine|Determine if any baseline measures of impulsivity or drug use severity predict efficacy of SYN117 in reducing subjective effects of cocaine","http://ClinicalTrials.gov/show/NCT00656357",NA
"48130",48130,"NCT00655057","Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression","Completed","No Results Available","Depression","Drug: S-citalopram|Behavioral: Cognitive behavioral therapy (CBT)|Procedure: TRODAT-1 single photon emission computed tomographic (SPECT) imaging","National Institute of Mental Health (NIMH)","Both","Adult","Phase II|Phase III",66,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Open Label","R34 MH070753|DATR A3-NSS","April 7, 2008","01/10/2005",2009-12-01,"April 23, 2010","01/03/2009","",2009-08-01,"Change in dopamine transporter binding","http://ClinicalTrials.gov/show/NCT00655057",NA
"48136",48136,"NCT00665457","Biomarkers in Women Receiving Chemotherapy and Celecoxib for Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: capecitabine|Drug: celecoxib|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Genetic: gene expression analysis|Genetic: polymorphism analysis|Genetic: protein expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: imaging biomarker analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacogenomic studies|Procedure: dynamic contrast-enhanced magnetic resonance imaging|Procedure: needle biopsy|Procedure: neoadjuvant therapy|Procedure: radiomammography|Procedure: ultrasound imaging","University of Nebraska|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",46,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000583473|UNMC-08504","April 22, 2008","01/04/2004",NA,"July 28, 2009","01/07/2009","",2009-07-01,"Safety|Efficacy in terms of pathologic complete response, progression-free and overall survival, and time to treatment failure|Determine mRNA and protein levels of TP, TS, COX-2, MMP-2, MDR-1, and VEGF before and after treatment|Correlate baseline expression of TS, TP, VEGF, MDR, COX-2 and MMP-2 to tumor response|Correlate specific molecule markers to clinical outcome","http://ClinicalTrials.gov/show/NCT00665457",NA
"48146",48146,"NCT00687557","Study of TAS-108 in Postmenopausal Patients With Locally Advanced Breast Carcinoma Following Standard First or Second Line Endocrine Therapy","Completed","No Results Available","Metastatic Breast Cancer","Drug: TAS-108","Taiho Pharma USA, Inc.|Quintiles","Female","Adult|Senior","Phase II",180,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TAS108-0004","May 28, 2008","01/10/2003",2009-06-01,"June 30, 2009","01/06/2009","",2009-06-01,"The primary efficacy endpoints for this study are the response rate of the tumor, namely CR and PR, and clinical benefit, namely CR, PR, or SD for 24 weeks.|To evaluate the safety of TAS-108 administered on this schedule|To investigate the comparative concentrations of TAS-108 and its metabolites in tumor tissue and blood at steady-state|To determine the time to progression of TAS-108 administered on this schedule|To investigate selective biomarker activity related to TAS-108 including ER??, progesterone receptor (PgR), phosphorylated ER?? (S118 and S167), estrogen receptor subtype (ER??), and coactivator of ER-mediated gene transcription (AIB1)","http://ClinicalTrials.gov/show/NCT00687557",NA
"48148",48148,"NCT00691457","Comparison of 3 Novel Contact Lens Solutions on the Basal Lamina","Completed","No Results Available","Contact Lens Solution","Other: Opti-Free contact lens solution|Other: ReNu Multiplus contact lens solution|Other: Clear Care contact lens solution","Alcon Research","Both","Adult|Senior","Phase IV",15,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","SMA-08-09","June 3, 2008","01/04/2008",2009-01-01,"June 4, 2009","01/06/2009","",2009-01-01,"Change from baseline in corneal fluorescein staining as evaluated at Day 30|Confocal evaluation variables as measured at Days 0, 14, and 30","http://ClinicalTrials.gov/show/NCT00691457",NA
"48150",48150,"NCT00683657","Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone","Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo","Bristol-Myers Squibb|AstraZeneca","Both","Adult|Senior","Phase III",93,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CV181-066|Eudract-2008-000976-26","May 21, 2008","01/07/2008",2009-02-01,"November 30, 2010","01/11/2010","",2009-02-01,"Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4|Change From Baseline in 4-Hour Mean Weighted Postprandial Plasma Glucose at Week 4|Change From Baseline in 2-Hour Postprandial Plasma Glucose After the Evening Meal at Week 4|Change From Baseline in Mean Daily Glucose at Week 4|Change From Baseline in 2-Day Average Fasting Plasma Glucose (FPG) at Week 4","http://ClinicalTrials.gov/show/NCT00683657",NA
"48153",48153,"NCT00696657","A Trial in Type 2 Diabetes Comparing NN9535 to Placebo and Liraglutide","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: NN9535|Drug: NN9535|Drug: NN9535|Drug: NN9535|Drug: NN9535|Drug: NN9535|Drug: placebo|Drug: placebo|Drug: placebo|Drug: placebo|Drug: placebo|Drug: placebo|Drug: liraglutide|Drug: liraglutide","Novo Nordisk","Both","Adult|Senior","Phase II",415,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NN9535-1821|EudraCT No: 2007-003956-12","June 11, 2008","01/06/2008",2009-02-01,"February 6, 2009","01/02/2009","",2009-02-01,"HbA1c|Safety|Antibodies","http://ClinicalTrials.gov/show/NCT00696657",NA
"48167",48167,"NCT00666757","A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression","Completed","Has Results","Depression","Drug: duloxetine|Drug: fluoxetine|Drug: citalopram|Drug: paroxetine|Drug: sertraline","Eli Lilly and Company|Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase IV",750,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11715|F1J-US-HMFT","April 23, 2008","01/05/2008",2009-03-01,"May 12, 2010","01/05/2010","TRY FIRST",2009-02-01,"Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint]|Change From Baseline in QIDS-SR Total Score at 12-Week Endpoint (Mood Measure)|Probability of Remission [17-item Hamilton Depression Rating Scale (HAMD-17) (Mood Measure) Less Than or Equal to 7 at 12-Week Endpoint]|Probability of Response [QIDS-SR Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]|Probability of Response [HAMD-17 Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]|Change From Baseline in HAMD-17 Total Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Maier Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Bech Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Retardation Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Sleep Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in Brief Pain Inventory (BPI) Average 24-hour Pain Score, in Particpants With a Baseline BPI Average 24-hour Pain Score of 3 or Greater, at 12-Week Endpoint (Pain Measure)|Change From Baseline in BPI Average 24 Hour Pain Score at 12-Week Endpoint (Pain Measure)|Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score at 12-Week Endpoint (Functional Outcome Measure)|Change From Baseline in SDS Work/School Item Score at 12-Week Endpoint (Functional Outcome Measure)|Change From Baseline in Sheehan Disability Scale (SDS) Family/Home Item Score at Week-12 Endpoint (Functional Outcome Measure)|Change From Baseline in SDS Social Item Score at 12-Week Endpoint (Functional Outcome Measure)|Change From Baseline in Systolic Blood Pressure at Week-12 Endpoint|Change From Baseline in Diastolic Blood Pressure at Week-12 Endpoint|Change From Baseline in Pulse Rate at Week-12 Endpoint|Change From Baseline in Weight at Week-12 Endpoint","http://ClinicalTrials.gov/show/NCT00666757",NA
"48175",48175,"NCT00736957","A Verification Study of a Long-term Use of JNS013 in Patients With Chronic Pain","Completed","No Results Available","Pain","Drug: JNS013","Janssen Pharmaceutical K.K.","Both","Adult|Senior","Phase III",190,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR015115|JNS013-JPN-05","August 14, 2008","01/04/2008",2009-10-01,"April 26, 2010","01/04/2010","",2009-10-01,"VAS24 changes and the time course changes, pain intensity difference (PID) and the time course, time course changes of pain relief rating (PAR), time course changes of sum of PID and PAR, overall pain relief rating, SF-36, etc.","http://ClinicalTrials.gov/show/NCT00736957",NA
"48209",48209,"NCT00794157","Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Indacaterol 150 ??g|Drug: Indacaterol 300 ??g|Drug: Placebo","Novartis Pharmaceuticals","Both","Adult|Senior","Phase III",336,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CQAB149B1302","November 17, 2008","01/11/2008",NA,"October 13, 2009","01/10/2009","",2009-10-01,"To demonstrate superiority of indacaterol (150 and 300 ??g o.d.) versus placebo with respect to 24 h post-dose trough forced expiratory volume in 1 second (FEV1)|To compare two doses of indacaterol (150 and 300 ??g o.d.) to placebo on trough FEV1|To assess the safety and tolerability of two doses of indacaterol (150 and 300 ??g o.d.) as compared with placebo","http://ClinicalTrials.gov/show/NCT00794157",NA
"48248",48248,"NCT00855257","Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome","Completed","No Results Available","Acute Coronary Syndrome (ACS)","Drug: Acid Nicotinique|Drug: Placebo","French Cardiology Society|Merck Serono International SA","Both","Adult|Senior","Phase III",93,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2005-07","March 2, 2009","01/06/2007",2009-05-01,"July 8, 2009","01/07/2009","EVANACS",2009-05-01,"Measure of endothelial function by high resolution echography in response to nitric agent|Measure of plasmatic CRP, cytokines, lipid level","http://ClinicalTrials.gov/show/NCT00855257",NA
"48249",48249,"NCT00857857","A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics","Completed","No Results Available","Mild Asthma","Drug: GW870086X|Drug: Placebo|Drug: FP","GlaxoSmithKline","Male","Adult","Phase II",24,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","110762","March 5, 2009","01/02/2009",2009-11-01,"December 3, 2009","01/12/2009","",2009-11-01,"Late asthmatic response|Early asthmatic response|Lung function as measured by FEV1|Assess safety and tolerability|Exhaled NO|Effect on bronchial hyperactivity as measured by methacholine challenge|Assessment of established markers of anti-inflammatory activity in sputum","http://ClinicalTrials.gov/show/NCT00857857",NA
"48263",48263,"NCT00882557","A Study to Evaluate Daptomycin Given During Dialysis and After Dialysis","Completed","No Results Available","End-Stage Renal Disease|Hemodialysis","Drug: daptomycin|Drug: daptomycin","Cubist Pharmaceuticals","Both","Adult|Senior","Phase IV",12,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","DAP-RENID-08-06","April 15, 2009","01/05/2009",2009-07-01,"September 20, 2010","01/09/2010","",2009-07-01,"Pharmacokinetic evaluation|Incidence of AEs, deaths, premature discontinuation due to an AE, clinical lab data, ECG results, Physical Exam Findings, and Concomitant medications and procedures.","http://ClinicalTrials.gov/show/NCT00882557",NA
"48265",48265,"NCT00885157","Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly","Completed","No Results Available","Poliomyelitis","Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens|Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens","Sanofi-Aventis","Both","Child","Phase II",225,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","IPV26","April 20, 2009","01/04/2009",2009-12-01,"March 19, 2010","01/03/2010","",2009-10-01,"Immunogenicity: To provide information concerning the immunogenicity of IPV vaccine administrated intradermally as a booster vaccination.|Safety: To provide information concerning the safety after booster intradermal administration of IPV vaccine","http://ClinicalTrials.gov/show/NCT00885157",NA
"48276",48276,"NCT00907257","A Study of Different Use Regimens Using Two Acne Treatments","Completed","No Results Available","Acne Vulgaris","Drug: benzoyl peroxide wash and tretinoin gel|Drug: benzoyl peroxide wash and tretinoin gel","Johnson & Johnson Consumer & Personal Products Worldwide","Both","Child|Adult|Senior","Phase IV",67,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","CA-P-6270","May 20, 2009","01/02/2009",2009-09-01,"November 30, 2009","01/11/2009","",2009-09-01,"Change from baseline in the total acne lesions count|Change from baseline and percent change from baseline in individual acne lesion counts|Measurement of success according to dichotomized IGA using criteria of improvement of 2 grades from baseline score or clear or almost clear grades (grades 0 or 1)|Change from baseline in Investigator's Global Assessment of Acne Severity (IGA) score","http://ClinicalTrials.gov/show/NCT00907257",NA
"48279",48279,"NCT00915057","Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.","Completed","No Results Available","Hepatitis, Viral, Human","Drug: NRL972","Norgine","Both","Adult","Phase II",100,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","NRL972-09/2008 (CHBC)","June 3, 2009","01/03/2009",2009-03-01,"December 21, 2009","01/12/2009","",2009-03-01,"Pharmacokinetics of NRL972","http://ClinicalTrials.gov/show/NCT00915057",NA
"48290",48290,"NCT00933257","Dermacyd PH_DESILSTY_FR (Lactic Acid) - Photo Evaluation - Stay on Frutal","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Both","Adult","Phase III",27,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LACAC_L_04808","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"Measure of the photo irritation test and the photosensitivity byusing UVA irradiation and evaluation according to International Contact Dermatitis Research Group (ICDRG) scale. Evaluation of the sensibility according to the skin type.","http://ClinicalTrials.gov/show/NCT00933257",NA
"48294",48294,"NCT00911157","The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","Completed","Has Results","Thrombosis, Venous|Acute Deep Vein Thrombosis","Drug: Fondaparinux sodium|Drug: unfractionated heparin (UFH)","GlaxoSmithKline","Both","Adult|Senior","Phase III",39,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","111436|AR3111436","May 28, 2009","01/06/2008",2009-11-01,"September 3, 2010","01/09/2010","",2009-11-01,"Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE)|Percentage of Participants With Recurrent or New Symptomatic/Asymptomatic VTE (by Type)|Percentage of Participants With Perfusion Lung Scan Results Scored as Improved, no Change, or Worse Compared to Baseline|Total Perfusion Score at Baseline and Mean Change From Baseline at Day 5-10|Percentage of Participants With a Bleeding Event","http://ClinicalTrials.gov/show/NCT00911157",NA
"48297",48297,"NCT00943657","Yearly Strain Variation Study, 2009/2010","Completed","No Results Available","Influenza|Seasonal Influenza","Biological: Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]","Baxter Healthcare Corporation","Both","Adult|Senior","Phase III",110,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","720901","July 21, 2009","01/06/2009",2009-07-01,"October 6, 2009","01/10/2009","",2009-07-01,"Number of subjects demonstrating seroconversion to each of the three antigens contained in the vaccine 21 days after vaccination","http://ClinicalTrials.gov/show/NCT00943657",NA
"48317",48317,"NCT00972257","24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination","Completed","No Results Available","Glaucoma","Drug: treatment with dorzolamide/timolol|Drug: treatment with brimonidine/timolol","Aristotle University Of Thessaloniki","Both","Adult|Senior","Phase IV",64,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","A5132","September 3, 2009","01/01/2009",2009-09-01,"September 29, 2010","01/09/2010","",2009-09-01,"To compare the quality of 24-hour IOP control after 2 months of chronic therapy with the Dorzolamide/Timolol fixed combination versus the Brimonidine/Timolol fixed combination in primary open-angle glaucoma.|Assess fluctuation of 24-hour pressure","http://ClinicalTrials.gov/show/NCT00972257",NA
"48354",48354,"NCT01026857","Propionyl-L-Carnitine in Ulcerative Colitis","Completed","No Results Available","Ulcerative Colitis","Drug: Propionyl-L-Carnitine|Drug: Propionyl-L-Carnitine|Drug: Placebo","sigma-tau i.f.r. S.p.A.","Both","Adult|Senior","Phase II",121,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","ST261 DM 01 004","December 4, 2009","01/05/2006",2009-12-01,"December 16, 2009","01/12/2009","",2009-04-01,"Disease Activity Index score|Adverse Events","http://ClinicalTrials.gov/show/NCT01026857",NA
"48469",48469,"NCT00444457","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants","Completed","Has Results","Vaccines, Pneumococcal","Biological: 13-valent Pneumococcal Conjugate Vaccine|Biological: 7vPnC","Wyeth","Both","Child","Phase III",1712,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","6096A1-3005","March 5, 2007","01/05/2007",2009-06-01,"November 9, 2010","01/11/2010","",2009-06-01,"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series|Percentage of Participants Achieving Predefined Antibody Level ??­0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series|Percentage of Participants Achieving Predefined Antibody Level ??­1:8 for Poliovirus in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series|Percentage of Participants Achieving Predefined Antibody Level ??­10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series|Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ??­0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Infant Series|Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ??­0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose|Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ??­1.00 Mcg/mL in the Combined 13vPnC Group 1 Month After the Infant Series|Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ??­1.00 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose|Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose","http://ClinicalTrials.gov/show/NCT00444457",NA
"48479",48479,"NCT01247857","Local Anesthetic Nebulization for Pain Control After Laparoscopic Cholecystectomy","Completed","No Results Available","Laparoscopic Cholecystectomy","Drug: Ropivacaine 30 mg|Drug: Ropivacaine 30 mg|Drug: Saline","San Gerardo Hospital|CHU de Hautepierre Strasbourg","Both","Adult|Senior","Phase III",90,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AR HSG 02-2008","November 23, 2010","01/04/2008",2009-03-01,"November 23, 2010","01/03/2008","",2009-03-01,"Postoperative Pain|Time of unassisted walking|Morphine consumption (mg)|Hospital morbidity|Time to hospital discharge","http://ClinicalTrials.gov/show/NCT01247857",NA
"48494",48494,"NCT01276457","The Upper Target Everolimus Randomized Study","Completed","No Results Available","Kidney Transplantation","Drug: Everolimus (the daily dose of EVE had to be adjusted to mantain a blood trough level (C0) of 10 ng/mL (8-12 ng/mL) until end of month 24|Drug: Everolimus (the daily dose of EVE had to be adjusted to mantain a blood trough level (C0) of 6 ng/mL (3-8 ng/mL) until end of month 24","Novartis Pharmaceuticals","Both","Adult","Phase III",223,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD001AIT02E1","January 12, 2011","01/05/2006",NA,"January 12, 2011","01/01/2011","EVEREST",2009-02-01,"Presence and the severity of acute rejection, chronic rejection, adverse events, malignancies or infections|To collect long-term safety, tolerability and efficacy data","http://ClinicalTrials.gov/show/NCT01276457",NA
"48556",48556,"NCT00024258","Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Kidney Cancer|Liver Cancer|Neuroblastoma|Ovarian Cancer|Retinoblastoma|Sarcoma","Drug: arsenic trioxide","Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",120,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068906|MSKCC-01042|CTI-1059|NCI-G01-2014","September 13, 2001","01/03/2001",NA,"July 22, 2009","01/07/2009","",2009-05-01,"Response rate after every 3 courses during treatment and then every 2-3 months for 1 year after completion of treatment|Toxicity after every course during treatment","http://ClinicalTrials.gov/show/NCT00024258",NA
"48611",48611,"NCT00115258","Nutrition Support in Pediatric Stem Cell Transplantation","Completed","No Results Available","Hematopoietic Stem Cell Transplantation","Drug: Parenteral Nutrition","Children's Hospital Boston|Massachusetts Vitamin Litigation Grant","Both","Child|Adult|Senior","Phase III",26,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","86483|03-11-192","June 21, 2005","01/01/2004",2009-07-01,"August 3, 2009","01/08/2009","",2009-07-01,"Changes in % body fat at baseline, day +30, and day +100.|Body composition measured by DXA, BIA, and 4-site skinfolds.|Changes in body composition from baseline to day +100.|Insulin resistance, defined by HOMA, at each time point.|Measured resting energy expenditure (REE) at each time point.|Changes in percent predicted REE between the two groups.|Correlation between body composition and measured REE.|Resumption of oral intake.","http://ClinicalTrials.gov/show/NCT00115258",NA
"48639",48639,"NCT00154258","A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Clozapine","Novartis","Both","Adult","Phase II",19,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLEX123J1202","September 8, 2005","01/01/2002",NA,"May 10, 2010","01/05/2010","",2009-12-01,"Adverse events during the long term treatment (until NDA approval)|Vital signs at every 4 weeks|Laboratory tests (hematology: at every 1 - 2 weeks, others: at every 4 weeks)|ECG at every 12 weeks|Echo cardiogram at every 24 weeks|Changes in the symptoms of psychosis at every 8 weeks up to 52 weeks of treatment, thereafter at every 16 weeks|Motor side effects at every 8 weeks up to 52 weeks of treatment, thereafter at every 16 weeks","http://ClinicalTrials.gov/show/NCT00154258",NA
"48658",48658,"NCT00184158","Treatment for Cubital Tunnel Syndrome","Completed","No Results Available","Cubital Tunnel Syndrome","Procedure: Conservative, simple decompression and nerve transfer","Norwegian University of Science and Technology","Both","Child|Adult|Senior","Phase II",81,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","056-02","September 12, 2005","01/01/2005",NA,"March 3, 2009","01/03/2009","",2009-01-01,"Reduction of symptoms: pain|paresthesia|weakness|and patient satisfaction with the treatment|Evaluation of the electroneurography (ENG) before and after the operation and to see if it is consistent with the patient evaluation.","http://ClinicalTrials.gov/show/NCT00184158",NA
"48716",48716,"NCT00272558","Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma","Completed","No Results Available","Malignant Pleural Mesothelioma","Drug: Carboplatin and Vinorelbine","Rigshospitalet, Denmark","Both","Adult|Senior","Phase II",40,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MPM phase II Carbo/VNB","January 3, 2006","01/09/2004",2009-09-01,"September 17, 2009","01/09/2009","",2009-09-01,"Response|Survival|Feasibility","http://ClinicalTrials.gov/show/NCT00272558",NA
"48768",48768,"NCT00354458","PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function","Completed","No Results Available","Heart Failure, Congestive","Drug: rolofylline|Drug: Comparator: Placebo (unspecified)","NovaCardia, Inc.|Merck","Both","Adult|Senior","Phase III",1102,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CKI-302|2007_804|MK7418-302","July 18, 2006","01/10/2006",2009-07-01,"October 8, 2009","01/10/2009","",2009-07-01,"effect on heart failure signs and symptoms|effect on renal function|safety|within trial medical costs compared to placebo","http://ClinicalTrials.gov/show/NCT00354458",NA
"48791",48791,"NCT00384358","Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures","Completed","No Results Available","Fractures","Drug: rhBMP-2/CPM|Drug: rhBMP-2/CPM|Other: surgical intervention alone","Wyeth","Both","Adult|Senior","Phase II",108,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","3100N7-211|B1921004","October 3, 2006","01/01/2007",2010-06-01,"September 14, 2010","01/09/2010","",2009-02-01,"The safety outcome is the incidence of secondary fracture displacement among subjects treated with rhBMP-2/CPM compared to those receiving standard surgical treatment (internal fixation) alone.|To establish a satisfactory method of administering rhBMP-2/CPM to implement in a phase 3 efficacy trial in this clinical indication.|To estimate the success and failure rates associated with key fracture outcomes.","http://ClinicalTrials.gov/show/NCT00384358",NA
"48834",48834,"NCT00441558","A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).","Completed","No Results Available","Sexual Dysfunctions, Psychological","Drug: Flibanserin","Boehringer Ingelheim Pharmaceuticals","Female","Adult","Phase III",1767,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","511.84","February 28, 2007","01/02/2007",NA,"August 20, 2009","01/08/2009","",2009-08-01,"The frequency of adverse events (side effects).|Clinically significant changes to physical exam, pelvic exam, vital signs, ECG, labs, eye exams, and overall patient status. Additionally, patients must complete questionnaires related to sexual health, depression and suicidal thoughts.","http://ClinicalTrials.gov/show/NCT00441558",NA
"48852",48852,"NCT00466258","LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)","Completed","No Results Available","HIV Infections|Diffuse Large B Cell Lymphoma","Drug: R-CHOP|Drug: Highly active antiretroviral therapy|Drug: Central nervous system (CNS) prophylaxis|Drug: Prophylaxis of opportunistic infections and support treatment","PETHEMA Foundation","Both","Adult|Senior","Phase IV",50,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-003750-23|LINFOTARGAM","April 25, 2007","01/10/2006",2009-11-01,"November 23, 2009","01/11/2009","LINFOTARGAM",2009-05-01,"treatment toxicity according to the CTC criteria (version 3.0) of the National Cancer Institute (NCI)|opportunistic and non-opportunistic infections rate after 6 cycles of treatment with R-CHOP administered every 14 days and HAART in patients with DLBCL and HIV infection|adherence to the treatment with 6 cycles of R-CHOP considering the delays in the administration of the cycles and the reductions in the doses of chemotherapy (planned dose administered in predicted term)|efficacy of the treatment in patients with DLBCL and HIV infection after 6 cycles of treatment with R-CHOP administered every 14 days|global response and complete remission rate|duration of the response|event-free survival probability in 5 years|global survival probability in 5 years|predictive factors of the response after 6 cycles of treatment with R-CHOP administered every 14 days in patients with DLBCL and HIV infection|impact of the therapeutic combination of R-CHOP and HAART in the parameters of the HIV infection (HIV viral load and CD4+ lymphocyte count)","http://ClinicalTrials.gov/show/NCT00466258",NA
"48861",48861,"NCT00474058","Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine","Completed","Has Results","Parkinson's Disease","Drug: Rotigotine|Other: Placebo","UCB, Inc.","Both","Adult|Senior","Phase III",287,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SP889|EudraCT No.: 2006-006752-35","May 14, 2007","01/05/2007",2009-03-01,"November 24, 2010","01/11/2010","RECOVER",2009-03-01,"Change in Early Morning UPDRS Part III Score|Change in Parkinson's Disease Sleep Scale (PDSS)|Change in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS)|Change in Number of Nocturias","http://ClinicalTrials.gov/show/NCT00474058",NA
"48912",48912,"NCT00565058","Combination of GTI 2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)","Completed","No Results Available","Acute Myeloid Leukemia","Biological: GTI-2040","Lorus Therapeutics|Ohio State University","Both","Adult","Phase II",60,"Industry|Other","Interventional","Allocation: Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2040AML201","November 27, 2007","01/08/2007",2010-02-01,"February 11, 2010","01/02/2010","",2009-09-01,"To determine the overall response rate of GTI-2040 combined with HiDAC in refractory or relapsed AML|To determine the influence of GTI-2040 treatment on pharmacologic activity in leukemic cells. To assess the activity and toxicity profile of the early and delayed GTI-2040 treatment","http://ClinicalTrials.gov/show/NCT00565058",NA
"48913",48913,"NCT00566358","Surgical Treatment of Non-obese Type 2 Diabetic Patients With Duodenal Exclusion","Completed","No Results Available","Diabetes Mellitus, Type 2","Procedure: Duodenal exclusion surgery","University of Campinas, Brazil|Ethicon Endo-Surgery","Both","Adult","Phase I|Phase II",18,"Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LIMED0002","November 30, 2007","01/01/2006",2009-06-01,"July 20, 2010","01/07/2010","",2009-06-01,"Improvement or reversal of type 2 diabetes mellitus|Changes in the secretion pattern of incretins, insulin and glucagon after intervention, as measured by standardized mixed meal tolerance test|Changes in body weight and fat distribution after intervention|Changes in seric free fatty acids and lipoproteins|Regression of carotid intima-media thickness","http://ClinicalTrials.gov/show/NCT00566358",NA
"48928",48928,"NCT00552058","Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease","Completed","Has Results","Crohn Disease","Biological: certolizumab pegol (CDP870, CZP)|Other: Placebo","UCB, Inc.","Both","Adult|Senior","Phase III",439,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C87085|2007-001913-41","October 18, 2007","01/03/2008",2009-11-01,"December 1, 2010","01/12/2010","",2009-10-01,"Percentage of Subjects in Clinical Remission at Week 6|Percentage of Subjects Achieving a Clinical Response at Week 6|Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 6|Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 6|Change in Harvey Bradshaw Index (HBI) Score From Week 0 to Week 6|Percentage of Subjects in Clinical Remission at Week 2|Percentage of Subjects in Clinical Remission at Week 4|Percentage of Subjects Achieving a Clinical Response at Week 2|Percentage of Subjects Achieving a Clinical Response at Week 4|Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 2|Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 4|Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 2|Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 4|Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6|Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6|Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6|Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6","http://ClinicalTrials.gov/show/NCT00552058",NA
"48938",48938,"NCT00607958","Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours","Completed","No Results Available","HIV Infections","Drug: tipranavir/ritonavir (dose reduction)","Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA","Both","Adult|Senior","Phase IV",15,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TPVRTV_500100_IQ","January 23, 2008","01/12/2007",2009-05-01,"July 14, 2009","01/07/2009","",2009-05-01,"Proportion of patients with viral load <50 copies/mL|Proportion of patients that show a tipranavir IQ >60 while treated with tipranavir/ritonavir 500/200 mg every 12 hours|Proportion of patients that maintain a tipranavir IQ >=40 while treated with tipranavir/ritonavir 500/100 mg every 12 hours|Change in CD4 lymphocytes count after 24 and 48 weeks' follow-up|Incidence and severity of adverse events after 24 and 48 weeks' follow-up|Change in lipid profile (total cholesterol, HDL-cholesterol. LDL-cholesterol and triglycerides) after 24 and 48 weeks' follow-up|Change in hepatic enzymes (AST, ALT and GGT) after 24 and 48 weeks' follow-up|In patients with virological failure, incidence of new mutations in the protease gene","http://ClinicalTrials.gov/show/NCT00607958",NA
"48940",48940,"NCT00615758","Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Erlotinib","Hellenic Oncology Research Group|University Hospital of Crete","Both","Adult|Senior","Phase II",50,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/06.03","February 1, 2008","01/10/2006",2009-11-01,"December 14, 2009","01/12/2009","",2009-11-01,"Overall Response Rate|Overall Survival|Time to Tumor Progression|Quality of life assessment|Toxicity assesment","http://ClinicalTrials.gov/show/NCT00615758",NA
"48946",48946,"NCT00624858","A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression","Completed","No Results Available","Depression","Drug: naltrexone SR 32 mg/ bupropion SR 360 mg daily","Orexigen Therapeutics, Inc","Both","Adult","Phase II",25,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NB-402","February 19, 2008","01/01/2008",2009-07-01,"July 10, 2009","01/07/2009","",2009-07-01,"To assess the change in depressive symptoms as measured by Montgomery-Asberg Depression Rating Scale (MADRS) total score at 12 weeks|To assess the percentage change from baseline in total body weight at 12 and 24 weeks.","http://ClinicalTrials.gov/show/NCT00624858",NA
"48958",48958,"NCT00631358","Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention","Completed","Has Results","Sjogren's Syndrome","Drug: Maxidex|Other: No treatment","Alcon Research","Both","Child|Adult|Senior","Phase IV",97,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ORE 14351","February 29, 2008","01/02/2008",NA,"March 29, 2010","01/03/2010","",2009-02-01,"Change in Levels of Biomarkers After Dosing With Maxidex|Correlation Between Biomarker Expression and Ocular Symptoms|Correlation Between Biomarker Expression and Tear Film Break up Time|Correlation Between Biomarker Expression and NaFl (Sodium Fluorescein) Staining|Correlation Between Biomarker Expression and the Schirmer Test","http://ClinicalTrials.gov/show/NCT00631358",NA
"48961",48961,"NCT00644358","A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)","Completed","No Results Available","Major Depressive Disorder","Drug: vilazodone","PGxHealth, LLC","Both","Adult|Senior","Phase III",616,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLDA-07-DP-04","March 20, 2008","01/12/2007",2009-05-01,"August 24, 2010","01/08/2010","",2009-05-01,"adverse events (AEs), laboratory parameters, physical examinations, vital signs, weight, ECGs, the CSFQ, ophthalmologic exams, the Columbia-Suicide Severity Rating Scale (C-SSRS).|The study will collect information on effectiveness of vilazodone therapy over the course of the treatment period using MADRS, CGI severity of illness and CGI improvement scales.","http://ClinicalTrials.gov/show/NCT00644358",NA
"48973",48973,"NCT00659958","ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs","Completed","No Results Available","Epilepsy","Drug: Zonisamide","Eisai Inc.|Eisai Farmaceutica, S.A.","Both","Adult","Phase IV",32,"Industry|Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E2090-E044-407","April 16, 2008","01/04/2008",2009-09-01,"March 10, 2010","01/03/2010","",2009-09-01,"Frequency of seizures.|Quality of life, tolerability.","http://ClinicalTrials.gov/show/NCT00659958",NA
"48982",48982,"NCT00663858","Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)","Completed","Has Results","Benign Prostatic Hypertrophy","Drug: Cetrorelix 78+78|Drug: Cetrorelix 78 + Placebo|Other: Placebo","AEterna Zentaris","Male","Adult|Senior","Phase III",420,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AEZS-102-036","April 17, 2008","01/03/2008",2010-01-01,"December 15, 2010","01/12/2010","",2009-09-01,"International Prostate Symptom Score (IPSS)","http://ClinicalTrials.gov/show/NCT00663858",NA
"48983",48983,"NCT00666458","18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)","Completed","Has Results","Type 2 Diabetes","Drug: saxagliptin|Drug: sitagliptin","AstraZeneca|Bristol-Myers Squibb","Both","Adult|Senior","Phase III",822,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1680C00002|EudraCT number 2007-006095-11","April 23, 2008","01/04/2008",2009-03-01,"March 5, 2010","01/03/2010","",2009-03-01,"Hemoglobin A1c (HbA1c) Change From Baseline to Week 18|Proportion of Patients Achieving Therapeutic Glycaemic Response Defined as HbA1c <= 6.5% at Week 18|Fasting Plasma Glucose Change From Baseline to Week 18 (mg/dL)|Fasting Plasma Glucose Change From Baseline to Week 18 (mmol/L)","http://ClinicalTrials.gov/show/NCT00666458",NA
"49015",49015,"NCT00722358","A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects","Completed","No Results Available","Chronic Hepatitis C","Drug: BMS-650032|Drug: Placebo","Bristol-Myers Squibb","Both","Adult","Phase II",15,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","AI447-004","July 23, 2008","01/12/2008",2009-12-01,"January 6, 2011","01/06/2010","",2009-12-01,"Antiviral activity will be assessed by the magnitude and rate of change in plasma HCV RNA levels from baseline. The primary endpoint for antiviral activity is decrease from baseline in plasma HCV RNA levels to Day 3/ or 5|PD-PK Relationship Measures: Asses relationship between antiviral activity and measures of exposure to BMS-650032|Safety Outcome Measures: Safety and tolerability assessments|Pharmacokinetic Measures: Pharmacokinetic assessments","http://ClinicalTrials.gov/show/NCT00722358",NA
"49025",49025,"NCT00741858","Duragen Versus Duraguard in Chiari Surgery","Completed","No Results Available","Chiari Malformation","Procedure: Duraplasty with Duragen|Procedure: Duraplasty with Duraguard","University of Illinois","Both","Adult|Senior","Phase III",34,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UIC 2002-0232","August 25, 2008","01/04/2003",2010-04-01,"August 17, 2010","01/08/2010","",2009-12-01,"Length of hospital stay; Duration of surgery; Rate of postoperative infections; Rate of postoperative CSF leaks; Rate of other complications; Patients' level of functioning and well being (based on SF-36 results)","http://ClinicalTrials.gov/show/NCT00741858",NA
"49037",49037,"NCT00758758","Performance of the Hedrocel(R) Cervical Fusion Device","Completed","No Results Available","Symptomatic Cervical Disc Disease","Device: Anterior Cervical Discectomy and Fusion|Device: Anterior Cervical Discectomy and Fusion|Device: Anterior Cervical Discectomy and Fusion","Zimmer, Inc.","Both","Adult|Senior","Phase III",231,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","IC 003-99","September 23, 2008","01/12/2001",2009-06-01,"June 11, 2009","01/06/2009","",2009-01-01,"Overall Clinical Success (NDI, Fusion, Additional Surgical Procedures)|SF-36","http://ClinicalTrials.gov/show/NCT00758758",NA
"49038",49038,"NCT00763958","Relapse Prevention to Reduce HIV Among Women Prisoners","Completed","No Results Available","Opioid Relapse","Drug: Suboxone","University of Alabama at Birmingham|National Institute on Drug Abuse (NIDA)","Female","Adult","Phase IV",50,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","R21DA019838|5R21DA019838-03|7R21DA019838-02","September 29, 2008","01/06/2006",2010-09-01,"November 22, 2010","01/11/2010","",2009-09-01,"acceptability and feasibility","http://ClinicalTrials.gov/show/NCT00763958",NA
"49045",49045,"NCT00771758","Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis","Completed","No Results Available","Back Pain","Drug: oxycodone IR|Drug: tapentadol IR|Drug: placebo","Ortho-McNeil Janssen Scientific Affairs, LLC|Gr??nenthal GmbH","Both","Adult|Senior","Phase III",108,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR015064|KF5503/40","October 10, 2008","01/08/2008",2009-12-01,"April 8, 2010","01/04/2010","",2009-12-01,"The primary endpoint is the sum of pain intensity difference over 72 hours|Secondary endpoints: 30% and 50% responder rate; total pain relief over 2, 3, 5, and 10 days; sum of pain intensity difference over 2, 5, and 10 days; sleep quality, patient satisfaction, functionality, and physical performance and adverse events","http://ClinicalTrials.gov/show/NCT00771758",NA
"49057",49057,"NCT00801658","Efficacy of SLT in Patients With Insufficient IOP Control Under Maximum Tolerated Drug Therapy (Eye Drops)","Completed","No Results Available","Glaucoma","Device: selective Laser Trabeculoplasty (SLT)","University of Zurich|Ellex Medical Pty, 82 Gilbert Str., Adelaide, SA 5000","Both","Adult|Senior","Phase IV",30,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FunkSLT","December 2, 2008","01/01/2008",2009-07-01,"December 3, 2008","01/12/2008","",2009-07-01,"IOP lowering effect of SLT in a special patient group","http://ClinicalTrials.gov/show/NCT00801658",NA
"49060",49060,"NCT00805558","Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole on Patients With Chronic Periodontitis","Completed","No Results Available","Chronic Periodontitis","Drug: moxifloxacin|Drug: Ciprofloxacin plus metronidazole","Facultad Nacional de Salud Publica|Universidad de Antioquia","Both","Adult|Senior","Phase IV",76,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ARD-0001-CM|CBEIH-SIU 08-44-203","December 8, 2008","01/02/2009",2010-04-01,"May 10, 2010","01/10/2009","",2009-12-01,"Probing Depth|Subjective perception of treatment outcome, attachment gain,bleeding on probing, and full mouth plaque score.|Microbial colonization dynamic","http://ClinicalTrials.gov/show/NCT00805558",NA
"49064",49064,"NCT00814658","The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life","Completed","No Results Available","Dementia","Drug: Galantamine; Nimodipine","Janssen-Cilag Farmaceutica Ltda.","Both","Adult|Senior","Phase IV",22,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","CR014938","December 24, 2008","01/05/2008",2009-10-01,"July 22, 2010","01/07/2010","",2009-10-01,"Change from baseline in CNTB scores. Change from baseline at QoL- AD scores|Change from baseline in ADAS-Cog scores. Change from baseline at the CGI. Change from baseline at the NPI.","http://ClinicalTrials.gov/show/NCT00814658",NA
"49138",49138,"NCT00927758","Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair","Completed","No Results Available","Asthma","Drug: ADVAIR (fluticasone propionate/salmeterol)","Sandoz Inc.","Both","Adult","Phase II",100,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CP-Sandoz-2009-PilotFP","June 23, 2009","01/06/2009",2009-12-01,"February 24, 2010","01/11/2009","",2009-12-01,"To examine the post-dose changes in eNO following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines","http://ClinicalTrials.gov/show/NCT00927758",NA
"49195",49195,"NCT00791258","A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure","Completed","Has Results","Hypertension","Drug: amlodipine and olmesartan medoxomil tablets|Drug: hydrochlorothiazide tablets","Daiichi Sankyo Inc.|Integrium","Both","Adult|Senior","Phase IV",999,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CS8663-404","November 13, 2008","01/11/2008",2009-09-01,"September 30, 2010","01/09/2010","BP CRUSH",2009-08-01,"The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks|The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks|The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks|Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks|Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks|Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks|Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks|Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks|Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks|Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks|Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values|Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values|Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks|Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks|Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks|Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks|Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks|Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks","http://ClinicalTrials.gov/show/NCT00791258",NA
"49282",49282,"NCT01169558","A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.","Completed","No Results Available","Colorectal Cancer","Drug: bevacizumab [Avastin]","Hoffmann-La Roche","Both","Adult|Senior","Phase III",163,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20552","July 22, 2010","01/05/2006",2009-12-01,"September 23, 2010","01/09/2010","",2009-12-01,"Safety: Serious and specific adverse events|Efficacy: Duration of survival|Efficacy: Time to disease progression","http://ClinicalTrials.gov/show/NCT01169558",NA
"49368",49368,"NCT00003659","Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate","Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",30,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000066752|MSKCC-98080|NCI-G98-1483","November 1, 1999","01/09/1998",NA,"June 6, 2009","01/06/2009","",2009-05-01,"","http://ClinicalTrials.gov/show/NCT00003659",NA
"49501",49501,"NCT00185159","Olmesartan Medoxomil in Diabetes Mellitus","Completed","No Results Available","Diabetes Mellitus, Type 2|Cardiovascular Disease|Kidney Disease","Drug: Olmesartan medoxomil|Drug: Placebo Tablets","Sankyo Pharma Gmbh","Both","Adult|Senior","Phase III",4449,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","SE-866/44","September 12, 2005","01/10/2004",2009-07-01,"January 19, 2010","01/01/2010","",2009-07-01,"Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urine|Incidence of cardiovascular mortality and morbidity|Incidence of renal disease, such as worsening of renal function as well as end-stage (dialysis)|Occurrence and progression of retinopathy|Treatment effects on a combined endpoint of cardiovascular mortality and morbidity and renal disease|Safety and tolerability","http://ClinicalTrials.gov/show/NCT00185159",NA
"49519",49519,"NCT00218959","Randomized Controlled Trial of Narrative Exposure Therapy Compared to Treatment as Usual for Traumatized Refugees","Completed","No Results Available","Posttraumatic Stress Disorder","Behavioral: Narrative Exposure Therapy","Norwegian University of Science and Technology|Vivo International|University of Konstanz|Centre on violence, traumatic stress and suicide prevention, Mid-Norway","Both","Adult|Senior","Phase III",80,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","4.2005.1100","September 20, 2005","01/09/2005",2009-08-01,"October 22, 2010","01/10/2010","",2009-08-01,"Clinician Administered PTSD Scale|Hamilton Depr. Scale","http://ClinicalTrials.gov/show/NCT00218959",NA
"49545",49545,"NCT00267059","Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)","Completed","No Results Available","Chronic Lymphocytic Leukemia|Leukemia","Drug: Lenalidomide","M.D. Anderson Cancer Center|Celgene Corporation","Both","Adult|Senior","Phase II",45,"Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0175","December 19, 2005","01/12/2005",2009-08-01,"September 4, 2009","01/09/2009","",2009-08-01,"Overall response (OR)","http://ClinicalTrials.gov/show/NCT00267059",NA
"49551",49551,"NCT00280059","Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy","Completed","No Results Available","Epilepsy, Partial","Drug: Pregabalin|Drug: Lamotrigine","Pfizer","Both","Child|Adult|Senior","Phase III",660,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","A0081046","January 18, 2006","01/08/2006",2010-04-01,"September 23, 2010","01/09/2010","",2009-12-01,"Proportion of patients seizure-free for 6 months during the efficacy assessment phase (excluding dose escalation phase).|Sleep Scale|Seizure freedom by month and by avg. daily dose|Anxiety and Depression Scale|Time to 6-month seizure-freedom|Time to 1st seizure|Time to exit due to adverse event, lack of efficacy, or any reason","http://ClinicalTrials.gov/show/NCT00280059",NA
"49559",49559,"NCT00285259","Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)","Completed","No Results Available","Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Myelodysplastic Syndrome","Biological: VCL-CB01|Other: PBS","Vical","Both","Adult","Phase II",240,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CB01-202","January 30, 2006","01/01/2006",2010-11-01,"December 15, 2010","01/07/2010","",2009-11-01,"Safety of CMV immunotherapeutic vaccine in donors and recipients undergoing HCT|occurrence rate of clinically significant CMV viremia in recipients receiving CMV immunotherapeutic vaccine.","http://ClinicalTrials.gov/show/NCT00285259",NA
"49586",49586,"NCT00090259","Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)(COMPLETED)","Completed","Has Results","Heart Failure","Drug: Losartan 50 mg|Drug: Losartan 150 mg","Merck","Both","Adult|Senior","Phase III",3834,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2004_004|MK0954-948","August 25, 2004","01/10/2001",2009-08-01,"October 21, 2010","01/10/2010","",2009-08-01,"Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure|Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization|Number of Participants That Died (Any Cause)|Number of Participants That Were Hospitalized for Heart Failure|Number of Participants That Experienced Cardiovascular Hospitalization","http://ClinicalTrials.gov/show/NCT00090259",NA
"49606",49606,"NCT00359359","A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Small Cell","Drug: Sagopilone (BAY86-5302, ZK 219477)","Bayer","Both","Adult|Senior","Phase II",26,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","91495|EudraCT: 2006-000067-29|310101","July 27, 2006","01/07/2006",2009-08-01,"September 17, 2009","01/09/2009","",2009-03-01,"Phase 1: Safety measure to establish the MTD or RPDII dose of Sagopilone used in combination with carboplatin and bevacizumab|Phase 2: Efficacy measure|Phase 1: PK of Sagopilone + Cisplatin|Phase 2: Duration of CR or PR|Phase 2: TTP|Phase 2: PFS|Phase 2: OS","http://ClinicalTrials.gov/show/NCT00359359",NA
"49619",49619,"NCT00377559","Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer|Neoplasm Metastasis","Drug: Non pegylated liposomal doxorubicin and docetaxel","Catharina Ziekenhuis Eindhoven|Cephalon|Sanofi-Aventis","Both","Adult|Senior","Phase II",70,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MYOTAX","September 15, 2006","01/05/2006",2009-11-01,"June 2, 2010","01/06/2010","MYOTAX",2009-11-01,"Cardiotoxicity (definite or probable cardiac death)|Signs or symptoms of congestive heart failure (CHF), New York Heart Association (NYHA) class III-IV|Decline in left ventricular ejection fraction (LVEF) of ??­ 5% to < 50% with mild signs or symptoms of CHF (NYHA class < III)|Decline in LVEF of ??­ 10% to < 50% without signs or symptoms of CHF|Frequency and severity of intercurrent events according to the National Cancer Institute - Common Terminology Criteria (NCI-CTC) classification|Response rate|Median time to progression|Progression free survival","http://ClinicalTrials.gov/show/NCT00377559",NA
"49634",49634,"NCT00403559","A 4 Week Study of Elidel for the Treatment of Seborrheic Dermatitis","Completed","No Results Available","Seborrheic Dermatitis","Drug: Elidel","Dermatology Specialists Research|Novartis","Both","Adult|Senior","Phase II",110,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","CASM981CUS37|SAIRB # 06-4893|IND 75,225","November 21, 2006","01/01/2007",2009-01-01,"March 31, 2009","01/10/2007","",2009-01-01,"The change of IGA from BL to wk 1 will be the primary efficacy variable|Key secondary efficacy will be the % of patients with facial clearance","http://ClinicalTrials.gov/show/NCT00403559",NA
"49645",49645,"NCT00419159","Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Chemotherapy","Completed","No Results Available","Colorectal Cancer","Drug: everolimus","Novartis Pharmaceuticals","Both","Adult|Senior","Phase II|Phase III",199,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD001C2241","January 4, 2007","01/12/2006",NA,"February 5, 2010","01/02/2010","",2009-03-01,"Disease control rate (DCR) and objective response rate (ORR) according to the response evaluation criteria in solid tumors (RECIST)|Progression-free survival|Overall survival|Safety profile of RAD001","http://ClinicalTrials.gov/show/NCT00419159",NA
"49655",49655,"NCT00436059","The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)","Completed","No Results Available","Multiple Myeloma","Drug: bortezomib","Vejle Hospital|Odense University Hospital","Both","Adult|Senior","Phase II",20,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006/175","February 15, 2007","01/02/2007",2009-07-01,"July 7, 2009","01/07/2009","",2009-07-01,"Changes in bone markers during treatment|Changes in osteolysis during treatment","http://ClinicalTrials.gov/show/NCT00436059",NA
"49678",49678,"NCT00467259","Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women","Completed","No Results Available","Hypoactive Sexual Desire Disorder","Drug: Testosterone Transdermal System|Drug: Placebo patch","Warner Chilcott","Female","Adult|Senior","Phase III",1271,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007004","April 27, 2007","01/04/2007",2009-01-01,"March 22, 2010","01/03/2010","",2009-01-01,"To estimate the incidence of endometrial hyperplasia associated with 300 mcg/day testosterone transdermal system therapy in naturally postmenopausal women with hypoactive sexual desire disorder who are not using concomitant estrogen.","http://ClinicalTrials.gov/show/NCT00467259",NA
"49688",49688,"NCT00488059","AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients.","Completed","No Results Available","HIV Infections","Drug: enfuvirtide [Fuzeon]|Drug: Optimized ARV background|Drug: Integrase inhibitor|Drug: enfuvirtide [Fuzeon]","Hoffmann-La Roche|Trimeris","Both","Adult|Senior","Phase IV",30,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20837","June 18, 2007","",2009-02-01,"May 13, 2009","01/05/2009","",2009-02-01,"Number and percentage of patients with HIV RNA <50 copies/mL|Mean change in HIV RNA and CD4 from baseline; number and percentage of patients with HIV RNA <=50 copies/mL and <400 copies/mL; number and percentage of patients with >=1 log decline in HIV RNA from baseline. SAEs, ISRs, laboratory parameters.","http://ClinicalTrials.gov/show/NCT00488059",NA
"49713",49713,"NCT00365859","Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)","Completed","Has Results","Autistic Disorder|Behavioral Symptoms","Drug: Aripiprazole","Bristol-Myers Squibb|Otsuka America Pharmaceutical","Both","Child","Phase III",330,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CN138-180","August 15, 2006","01/09/2006",2009-06-01,"June 28, 2010","01/06/2010","",2009-06-01,"Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome (EPS)-Related AEs|Mean Change From Baseline in Total Simpson-Angus Scale (SAS) At Week 8, Week 26, and Week 52|Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) At Week 8, Week 26, and Week 52|Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment at Week 8, Week 26, Week 52, and Endpoint|Number of Participants With Potentially Clinically Relevant Laboratory Metabolic Abnormalities|Number of Participants With Potentially Clinically Relevant Laboratory Hematology Abnormalities|Number of Participants With Potentially Clinically Relevant Laboratory Chemistry Abnormalities|Number of Participants With Potentially Clinically Relevant Eletrocardiograph (ECG) Abnormalities|Number of Potentially Clinically Relevant Vital Sign Abnormalities|Mean Change From Baseline in Patient Weight|Mean Change From Baseline by Time Period in Body Weight Z-Score|Mean Change From Baseline in Patient Body Mass Index (BMI)|Mean Change From Baseline By Time Period in BMI Z-Score|Mean Change From Baseline in Clinical Global Impression (CGI)-Severity Score at Week 52 (Endpoint, LOCF)|CGI-Improvement Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Hyperactivity Subscale Score at Week 52 (Endpoint, LOCF)|Change From Baseline in ABC Stereotypy Subscale Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Social Withdrawal Scale At Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Inappropriate Speech Subscale Score at Week 52 (Endpoint, LOCF)|Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Score at Week 52 (Endpoint, LOCF)","http://ClinicalTrials.gov/show/NCT00365859",NA
"49718",49718,"NCT00523159","IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease","Completed","No Results Available","Renal Cell Carcinoma","Drug: Endoxana, IMA901, Leukine|Drug: IMA901 and Leukine","immatics Biotechnologies GmbH","Both","Adult|Senior","Phase II",68,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT Nr: 2006-006370-25","August 30, 2007","01/05/2007",2009-08-01,"February 25, 2010","01/02/2010","IMA901-202",2009-08-01,"Disease control rate|Tumor response rates and SD rate|Duration of response|Time to response|TTP|PFS and OS|DCR|Immune response|Effect of cyclophosphamide pre-treatment on immune response|Safety","http://ClinicalTrials.gov/show/NCT00523159",NA
"49721",49721,"NCT00529659","Study The Safety and Efficacy of MK0773 in Women With Sarcopenia (Loss of Muscle Mass)","Completed","No Results Available","Sarcopenia","Drug: Comparator: MK0773|Drug: Comparator: Placebo","Merck","Female","Adult|Senior","Phase II",170,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2007_532|MK0773-005","September 11, 2007","01/10/2007",2009-10-01,"October 21, 2009","01/10/2009","",2009-10-01,"Effect of MK0773 on muscle strength (measured by leg press) and total lean body mass following 6 months of treatment|Physical performance following 6 months of treatment.","http://ClinicalTrials.gov/show/NCT00529659",NA
"49724",49724,"NCT00533559","Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl","Completed","No Results Available","Diabetes|Insulin Resistance","Drug: sodium phenylbutyrate|Drug: Placebo","University Health Network, Toronto","Male","Adult","Phase IV",10,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Health Services Research","07-0274-B|Canadian Diabetes Association","September 19, 2007","01/09/2007",2010-03-01,"June 24, 2010","01/08/2007","",2009-12-01,"we will measure insulin secretion, calculate disposition index and insulin clearance during a hyperglycemic clamp. We will also measure insulin sensitivity during a euglycemic hyperinsulinemic clamp|During the hyperglycemic clamp we will also measure Free Fatty Acid, C-peptide and triyglycerides. During the euglycemic hyperinsulinemic clamp we will determine the insulin sensitivity index and the disposition index.","http://ClinicalTrials.gov/show/NCT00533559",NA
"49731",49731,"NCT00550459","Effects of Titrated Oral Tolvaptan 15, 30, or 60 mg QD on Cognitive and Neurological Function in Elderly Hyponatremic Patients","Completed","No Results Available","Hyponatremia","Drug: Tolvaptan","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","Both","Adult|Senior","Phase III",57,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","156-04-246|INSIGHT","October 25, 2007","01/08/2007",2009-03-01,"February 24, 2010","01/09/2009","INSIGHT",2009-02-01,"Change from baseline in the variable of the sum of z-scores of individual cognitive variables under the domains of Reaction Time, Psychomotor Speed, and Processing Speed at Day 22|Safety endpoint: Adverse events, vital signs, ECGs, Clinical laboratory test.|Change from baseline: in the individual neurocognitive domains included in the primary endpoint (reaction time, psychomotor speed, and processing speed), in the overall Neurocognitive Composite Score, in Postural Stability, in serum sodium concentrations","http://ClinicalTrials.gov/show/NCT00550459",NA
"49743",49743,"NCT00562159","Efficacy and Safety of Grass Sublingual Tablet in Adults (Study P05238AM3)(COMPLETED)","Completed","No Results Available","Rhinoconjunctivitis|Rhinitis|Conjunctivitis|Allergy|Immunotherapy","Drug: Placebo|Biological: SCH 697243","Schering-Plough","Both","Adult","Phase III",450,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05238|3727105","November 20, 2007","01/11/2007",2009-09-01,"October 22, 2009","01/10/2009","",2009-09-01,"The combined (sum of) rhinoconjunctivitis daily symptom score (DSS) and rhinoconjunctivitis daily medication score (DMS) averaged over the entire grass pollen season (GPS).|The average rhinoconjunctivitis daily symptom score (DSS).|The average rhinoconjunctivitis daily medication score (DMS).|The average weekly rhinoconjunctivitis quality of life total score.","http://ClinicalTrials.gov/show/NCT00562159",NA
"49767",49767,"NCT00610259","Brief Behavioral Therapy for Insomnia (bBT-I) for Depressed Outpatients With Refractory Insomnia","Completed","No Results Available","Major Depressive Disorder","Behavioral: brief behavioral therapy for insomnia (bBT-I)|Other: Treatment as usual (TAU)","Nagoya City University|Kochi University","Both","Adult|Senior","Phase II|Phase III",40,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","NCUPsychiatry001|HLSRG (Ministry of Health)","January 16, 2008","01/01/2008",2009-08-01,"September 17, 2009","01/09/2009","",2009-07-01,"Changes in the total Insomnia Severity Index (ISI) score between the baseline and the 8-week assessment|\No clinically significant insomnia\"" at the 8-week assessment","http://ClinicalTrials.gov/show/NCT00610259",NA
"49769",49769,"NCT00615459","A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control","Completed","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Indacaterol 150 ??g|Drug: Indacaterol 300 ??g|Drug: Tiotropium (18 ??g)|Drug: Placebo","Novartis","Both","Adult|Senior","Phase III",169,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CQAB149B2331","February 1, 2008","01/02/2008",2009-01-01,"December 16, 2009","01/12/2009","",2009-01-01,"24-hour trough forced expiratory volume in 1 second (FEV1) after 14 days of treatment.|24 h post dose trough FEV1 after 14 days of treatment in each treatment period in patients with COPD.|safety of indacaterol in terms of vital signs, glucose and potassium, electrocardiogram (ECG) and adverse events.","http://ClinicalTrials.gov/show/NCT00615459",NA
"49777",49777,"NCT00624559","The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure","Completed","No Results Available","Healthy","Drug: celecoxib (Celebrex)|Drug: placebo","University of Delaware|Christiana Care Health Services","Both","Adult","Phase IV",32,"Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science","HS 08-054","February 15, 2008","01/02/2008",2009-01-01,"March 30, 2009","01/03/2009","",2009-01-01,"Blood Pressure|Urinary sodium excretion","http://ClinicalTrials.gov/show/NCT00624559",NA
"49810",49810,"NCT00672659","Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)","Completed","No Results Available","Depression","Drug: Citalopram + Pipamperone|Drug: Citalopram","PharmaNeuroBoost N.V.","Both","Adult","Phase II",165,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PNB/CPS 02 2007","May 2, 2008","01/02/2008",2009-01-01,"January 30, 2009","01/01/2009","",2009-01-01,"Change in Montgomery-Asberg Depression Rating Scale score|The number of patients showing evidence of onset of action defined as a 20% improvement from baseline MADRS","http://ClinicalTrials.gov/show/NCT00672659",NA
"49811",49811,"NCT00619359","Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule","Completed","Has Results","Chemotherapy-Induced Nausea and Vomiting (CINV)","Drug: Comparator: fosaprepitant dimeglumine|Drug: Comparator: Aprepitant|Drug: Dexamethasone|Drug: Dexamethasone|Drug: Ondansetron","Merck","Both","Adult|Senior","Phase III",2322,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2007_594|MK0517-017","January 28, 2008","01/02/2008",2009-06-01,"March 25, 2010","01/03/2010","EASE",2009-06-01,"A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).|A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).|No Vomiting Overall (in the 120 Hours Following Initiation of Cisplatin)","http://ClinicalTrials.gov/show/NCT00619359",NA
"49815",49815,"NCT00668759","A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation","Completed","No Results Available","Atrial Fibrillation","Drug: Vernakalant Injection|Drug: Amiodarone Injection:","Cardiome Pharma","Both","Adult|Senior","Phase III",254,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VERI-305-AMIO","April 25, 2008","01/04/2008",2009-11-01,"December 12, 2009","01/12/2009","AVRO",2009-10-01,"Proportion of subjects with conversion of atrial fibrillation to sinus rhythm within 90 minutes after the start of infusion.|Time to conversion within 90 minutes after the start of infusion.|Proportion of subjects with symptom relief at 90 minutes after the start of infusion.|EQ-5D quality of life assessment.|Monitoring of adverse events, vital signs, continuous telemetry monitoring, 12-lead Holter monitoring, 12-lead ECGs, and laboratory tests.","http://ClinicalTrials.gov/show/NCT00668759",NA
"49816",49816,"NCT00679159","A Study of MVA85A in Healthy Children and Infants","Completed","No Results Available","Tuberculosis","Biological: MVA85A|Biological: Prevenar","University of Oxford|University of Cape Town","Both","Child","Phase II",168,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","TB014|MCC: 20070156","April 2, 2008","01/02/2008",2009-12-01,"February 8, 2010","01/02/2010","",2009-12-01,"Safety of MVA85A. Both local and systemic adverse events will be monitored, including a daily diary card for the first week. Blood will be taken at day 7 and day 28 for biochemistry and haematology.|Immunogenicity of MVA85A","http://ClinicalTrials.gov/show/NCT00679159",NA
"49837",49837,"NCT00712959","Immune Responses in Adults to Revaccination With ADACEL?ó 10 Years After a Previous Dose","Completed","No Results Available","Pertussis|Tetanus|Diphtheria","Biological: Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL?ó)|Biological: Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL?ó)","Sanofi-Aventis","Both","Adult|Senior","Phase IV",857,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","TD526","July 7, 2008","01/06/2008",2009-12-01,"January 12, 2010","01/01/2010","",2009-09-01,"Immunogenicity: To provide information concerning immune response to Tdap after booster vaccination.","http://ClinicalTrials.gov/show/NCT00712959",NA
"49846",49846,"NCT00729859","CEP-1 Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men","Completed","No Results Available","Healthy","Drug: Acyline|Drug: Acyline + Testosterone gel|Drug: Acyline + testosterone gel + anastrozole","University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Male","Adult","Phase II",24,"Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","33853-A","August 5, 2008","01/12/2008",2009-12-01,"July 20, 2010","01/07/2010","CEP-1",2009-05-01,"To determine whether sex steroids influence EPC number and function in normal men|To determine whether T or Estradiol are primarily responsible for modulation of EPC number and to determine the impact sex steroids on HDL-C protein composition in healthy men","http://ClinicalTrials.gov/show/NCT00729859",NA
"49852",49852,"NCT00745459","Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy","Completed","No Results Available","Stomach Diseases","Drug: NPO-11","Nihon Pharmaceutical Co., Ltd","Both","Adult|Senior","Phase III",100,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NPO-11-01/S-01","September 1, 2008","01/09/2008",2009-08-01,"November 8, 2010","01/11/2010","",2009-04-01,"Presence or absence of gastric peristalsis (central evaluation by independent evaluator) No gastric peristalsis is defined as when patients have no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy.|Change in gastric peristalsis (central evaluation by independent evaluator) Difficulty level of intragastric observation (evaluation by investigator) Adverse events and ADRs observed between administration and 7 ?? 3 days after administration","http://ClinicalTrials.gov/show/NCT00745459",NA
"49853",49853,"NCT00742859","Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin","Completed","No Results Available","Atrial Fibrillation","Drug: betrixaban|Drug: Warfarin","Portola Pharmaceuticals","Both","Adult|Senior","Phase II",508,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","08-015","August 26, 2008","01/10/2008",2009-11-01,"January 19, 2010","01/01/2010","EXPLORE-Xa",2009-08-01,"The primary endpoint will be the occurrence of major or clinically relevant non-major bleeding.","http://ClinicalTrials.gov/show/NCT00742859",NA
"49854",49854,"NCT00716859","A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.","Completed","Has Results","Glaucoma","Drug: Timolol|Drug: latanoprost","Pfizer","Both","Child|Adult","Phase III",139,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A6111137","July 14, 2008","01/07/2008",2009-11-01,"November 1, 2010","01/11/2010","",2009-11-01,"Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)|Reduction From Baseline in Mean IOP at Week 1|Reduction From Baseline in Mean IOP at Week 4|Reduction From Baseline in Mean IOP at Week 12 (Observed)|Mean IOP at Baseline|Mean IOP at Week 1|Mean IOP at Week 4|Mean IOP at Week 12|Percentage of Participants With Greater Than or Equal to (??­) 15% IOP Reduction From Baseline at Both Weeks 4 and 12|Percentage of Participants Discontinuing Therapy Due to a Drug-related Adverse Experience","http://ClinicalTrials.gov/show/NCT00716859",NA
"49859",49859,"NCT00754559","A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.","Completed","No Results Available","Rheumatoid Arthritis","Drug: tocilizumab [RoActemra/Actemra]","Hoffmann-La Roche","Both","Adult|Senior","Phase III",332,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21469|2008-000105-11","September 17, 2008","",2009-11-01,"June 10, 2010","01/06/2010","",2009-11-01,"The rate of patients reaching DAS28 low disease (<=3.2)|Longitudinal analysis of DAS28; longitudinal analysis of ACR20, ACR50 and ACR70 responses.|Mean DAS28 reduction of <=1.2|Change in DAS28 from baseline; proportion of patients with DAS28 score of <2.6; proportion of patients with ACR20, ACR50 and ACR70 responses; HAQ-DI, SF-36, FACIT fatigue scale and TSQM scores.","http://ClinicalTrials.gov/show/NCT00754559",NA
"49862",49862,"NCT00758459","Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: AZD1236|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","D4260C00003","September 23, 2008","01/09/2008",2009-03-01,"July 24, 2009","01/07/2009","CERA",2009-03-01,"Nature and incidence of Adverse Events|Vital signs and laboratory safety assessments|Lung Function (Spirometry and PEF)Health status (COPD symptoms, rescue medication use, Clinical COPD questionnaire)|Systemic exposure of AZD1236|Biomarkers in blood and urine","http://ClinicalTrials.gov/show/NCT00758459",NA
"49880",49880,"NCT00785759","Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers","Completed","No Results Available","Alzheimer's Disease|Amnestic Mild Cognitive Impairment","Drug: AH110690 (18F) Injection","GE Healthcare|i3 Statprobe|Medpace, Inc.|Hvidovre Hospital Center Demark Danish Research Centre for Magnetic Resonance","Both","Adult|Senior","Phase II",78,"Industry|Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","ALZ201","November 4, 2008","01/09/2008",2009-12-01,"December 4, 2009","01/12/2009","ALZ201",2009-03-01,"Examine the efficacy and determine visual assessment of raised [18F] brain uptake for separating subjects with probable Alzheimer's Disease from healthy volunteers and assigning amnestic mild cognitive impairment cases to an AD or HV category.|Examine the efficacy and parameters of brain [18F] uptake for separating 25 subjects with probable AD from 25 HV, assigning 20 amnestic MCI cases to an AD or HV category by measuring ranges of regional cerebral to cerebellum tracer uptake ratios.","http://ClinicalTrials.gov/show/NCT00785759",NA
"49887",49887,"NCT00798759","Examination of Ocular Surface Effects With Administration of Travatan Z and Xalatan","Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: Xalatan|Drug: Travatan Z","Alcon Research","Both","Adult|Senior","Phase IV",216,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","C-08-050","November 24, 2008","01/12/2008",NA,"October 28, 2009","01/10/2009","",2009-05-01,"Mean change from baseline (Day 0) in Tear Film Break-Up Time (TFBUT)|Mean change from baseline (Day 0) in corneal fluorescein staining score","http://ClinicalTrials.gov/show/NCT00798759",NA
"49893",49893,"NCT00802659","A Phase I/II Dose Escalation Study Using Extracranial Stereotactic Radiosurgery to Control Pain","Completed","No Results Available","Metastases","Radiation: Stereotactic radiotherapy|Radiation: Stereotactic Radiosurgery|Radiation: Stereotactic Radiosurgery|Radiation: Group 4 Radiation Dose 1600 cGy","Washington University School of Medicine","Both","Adult|Senior","Phase I|Phase II",2,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-1149","December 4, 2008","01/12/2007",2009-09-01,"February 11, 2010","01/02/2010","",2009-09-01,"To determine the optimal dose of stereotactic spinal irradiation needed to obtain durable pain control at 4 weeks in a previously irradiated spine field.|To determine the duration of pain control for each dose level.|Determine the rate of radiation-induced myelopathy from stereotactic re-irradiation of the spinal metastases.|Determine the pattern of failure after stereotactic irradiation of spinal metastases.|Measure quality of life in patients treated with stereotactic radiotherapy (ESRT)","http://ClinicalTrials.gov/show/NCT00802659",NA
"49924",49924,"NCT00855959","Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients","Completed","No Results Available","Asthma","Drug: Budesonide|Drug: Pulmicort Turbuhaler","AstraZeneca","Both","Child|Adult|Senior","Phase III",113,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D5259C00001","March 4, 2009","01/02/2009",2009-08-01,"June 14, 2010","01/06/2010","",2009-08-01,"PEF (mPEF)|PEF (ePEF), Asthma symptom score - day, night and total, Use of rescue medication - day, night and total, Nighttime awakenings due to asthma symptoms|Forced expiratory volume in one second (FEV1.0), Forced vital capacity (FVC)","http://ClinicalTrials.gov/show/NCT00855959",NA
"49950",49950,"NCT00888459","A Pilot Study Evaluating Nicotine Lozenges and Self Help","Completed","Has Results","Smokeless Tobacco Use","Drug: nicotine replacement therapy|Drug: placebo NRT","Mayo Clinic|Oregon Research Institute","Male","Adult|Senior","Phase II",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","07-008574|CA121165","April 24, 2009","01/04/2008",2009-05-01,"November 29, 2010","01/11/2010","",2009-04-01,"Number of Participants With Tobacco Abstinence","http://ClinicalTrials.gov/show/NCT00888459",NA
"49970",49970,"NCT00933959","Pilot Study on Sleep Management for US Veterans","Completed","No Results Available","Insomnia","Behavioral: Mind-Body Bridging Program|Behavioral: Sleep Hygiene","University of Utah","Both","Adult|Senior","Phase I|Phase II",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","27522","June 18, 2009","01/03/2008",2009-03-01,"July 6, 2009","01/07/2009","",2009-03-01,"Medical Outcomes Study-Sleep Scale|Medical Outcomes Study Short Form-36 for Veterans|Center for Epidemiologic Studies Depression Scale|Five-factor Mindfulness Questionnaire|PTSD Check List-Military","http://ClinicalTrials.gov/show/NCT00933959",NA
"49975",49975,"NCT00940459","Subjective and Conjunctival Response to Edge Design of Different Silicone Hydrogels","Completed","No Results Available","Contact Lenses","Device: Acuvue Oasys (Vistakon)|Device: Biofinity (CooperVision)|Device: AirOptix (CibaVision|Device: PureVision (Bausch and Lomb)|Device: Acuvue 2 (Vistakon)","Alcon Research","Both","Adult|Senior","Phase IV",30,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","M-09-11","July 14, 2009","01/06/2009",NA,"February 15, 2010","01/02/2010","",2009-09-01,"Conjunctival staining","http://ClinicalTrials.gov/show/NCT00940459",NA
"49982",49982,"NCT00948259","Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer??s Disease","Completed","No Results Available","Alzheimer??s Disease","Drug: NP031112|Drug: Placebo","Noscira SA","Both","Adult|Senior","Phase I|Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NP031112-08B03 (CR080901)","July 27, 2009","01/12/2008",2009-11-01,"November 10, 2009","01/11/2009","",2009-11-01,"Incidence rates and severity of clinical adverse events and lab abnormalities for each dose level and placebo|Effect of treatment with four doses of NP031112 on cognition and depressive mood","http://ClinicalTrials.gov/show/NCT00948259",NA
"50018",50018,"NCT01013259","Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis","Completed","No Results Available","Rhinoconjunctivitis","Drug: Mutaflor|Drug: Placebo","Charite University, Berlin, Germany","Both","Adult","Phase II",34,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ecorhino","November 10, 2009","01/02/2009",2009-10-01,"November 12, 2009","01/11/2009","Ecorhino",2009-09-01,"symptom-medication score","http://ClinicalTrials.gov/show/NCT01013259",NA
"50030",50030,"NCT01026259","Local Warming of Surgical Incisions","Completed","No Results Available","Surgical Wound Infection","Other: Warming of surgical incision|Other: Warming dressing without actual warming","University of Washington","Both","Adult|Senior","Phase III",146,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","29991-A","December 2, 2009","01/10/2005",2009-11-01,"December 3, 2009","01/12/2009","",2009-11-01,"Surgical site infection|Wound tissue response","http://ClinicalTrials.gov/show/NCT01026259",NA
"50059",50059,"NCT01078259","Antimicrobial Response to Oral Vitamin D3 in Patients With Psoriasis","Completed","No Results Available","Atopic Dermatitis|Psoriasis","Drug: Vitamin D3|Drug: Placebo","National Institute of Allergy and Infectious Diseases (NIAID)|Food and Drug Administration (FDA)|University of California, San Diego","Both","Adult|Senior","Phase II",46,"NIH|U.S. Fed|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DAIT ADVN CATH 03-01","February 26, 2010","01/12/2008",2009-12-01,"February 26, 2010","01/02/2010","",2009-12-01,"Difference between the change in expression of AMP (hCAP18/LL-37, HBD3) from baseline to study day 21 in psoriatic subjects' lesional skin biopsies and the change in expression of AMP from baseline to study day 21 in their non-lesional skin biopsies.|Expression of antimicrobial peptides (hCAP18/LL-37, HBD3) at baseline and study day 21 in psoriatic subjects' saliva and lesional and non-lesional skin biopsies.|Bacterial colony counts (colony forming units) at baseline and study day 21 in AD, non-AD, and psoriatic subjects.|Change in bacterial colony counts (colony forming units) from baseline to study day 21 in AD, non-AD, and psoriatic subjects.|Expression of antimicrobial peptides (hCAP18/LL-37, HBD3) at baseline and study day 21 in psoriatic subjects' lesional and non-lesional skin tape strips.|Change in expression of TH2 cytokines IL-13 and IL-4 from baseline and study day 21 in psoriatic subjects' lesional and non-lesional skin biopsies.|Change in expression of serum total IgE and RAST from baseline and study day 21 in psoriatic subjects' serum.|Change in PASI score from baseline and study day 21 in psoriatic subjects.|Profile of bacteria present in lesional and non-lesional skin swabs at baseline and study day 21 in AD, non-AD, and psoriatic subjects.","http://ClinicalTrials.gov/show/NCT01078259",NA
"50190",50190,"NCT00002760","Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: ketoconazole|Drug: therapeutic hydrocortisone","Cancer and Leukemia Group B|National Cancer Institute (NCI)","Male","Child|Adult|Senior","Phase III",250,"Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064708|CLB-9583","November 1, 1999","01/08/1996",NA,"August 27, 2009","01/08/2009","",2009-08-01,"","http://ClinicalTrials.gov/show/NCT00002760",NA
"50236",50236,"NCT00027560","Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: alemtuzumab|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI)","Both","Child|Adult|Senior","Phase II",50,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069043|MSKCC-01092|NCI-G01-2028","December 7, 2001","01/07/2001",NA,"April 10, 2010","01/12/2009","",2009-04-01,"Durable hematopoietic reconstitution|Incidence and characteristics of peritransplantation morbidity and mortality|Incidence and severity of acute and chronic graft-versus-host disease|Overall and disease-free survival at 1, 3, 6, 12, and 24 months after transplantation|Quality of bone marrow and peripheral blood chimerism at 1, 3, 6, 12, and 24 months after transplantation|Kinetics of immune reconstitution","http://ClinicalTrials.gov/show/NCT00027560",NA
"50251",50251,"NCT00069160","Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer","Completed","No Results Available","Lung Neoplasms|Ovarian Neoplasms|Cervix Neoplasms|Renal Neoplasms","Drug: docetaxel|Drug: tariquidar","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",48,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","030284|03-C-0284","September 15, 2003","01/09/2003",2009-12-01,"January 11, 2011","01/09/2010","",2009-12-01,"Pharmacokinetics|Safety|Clinical response|Impact of tariquidar on technietium Tc 99m sestamibi uptake","http://ClinicalTrials.gov/show/NCT00069160",NA
"50295",50295,"NCT00113360","RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma","Completed","Has Results","Neuroendocrine Carcinoma|Islet Cell Carcinoma","Drug: RAD001|Drug: Octreotide Depot","M.D. Anderson Cancer Center|Novartis Pharmaceuticals","Both","Adult|Senior","Phase II",67,"Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-0597","June 7, 2005","01/01/2005",2009-07-01,"November 8, 2010","01/11/2010","",2009-07-01,"Progression Free Survival (PFS)","http://ClinicalTrials.gov/show/NCT00113360",NA
"50297",50297,"NCT00136760","Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia","Completed","No Results Available","Schizophrenia and Disorders With Psychotic Features|Tobacco Use Disorder","Drug: Bupropion|Drug: Contingent reinforcement plus placebo|Drug: non-contingent reinforcement plus bupropion|Drug: Non-contingent reinforcement plus placebo","National Institute on Drug Abuse (NIDA)|Brown University","Both","Adult|Senior","Phase II",57,"NIH|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","NIDA-17566-1|R01-17566-1","August 25, 2005","01/09/2003",2009-03-01,"October 1, 2010","01/10/2010","",2009-03-01,"Urinary cotinine|Cigarettes smoked per day|Withdrawal severity|Craving|Adverse events","http://ClinicalTrials.gov/show/NCT00136760",NA
"50340",50340,"NCT00205660","Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole","Completed","No Results Available","Schizophrenia|Type 2 Diabetes Mellitus","Drug: ziprasidone|Drug: risperidone|Drug: olanzapine|Drug: quetiapine|Drug: aripiprazole|Drug: aripiprazole|Drug: aripiprazole|Drug: aripiprazole","Washington University School of Medicine|Bristol-Myers Squibb","Both","Adult","Phase IV",78,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BMS #942370","September 12, 2005","01/02/2005",2009-08-01,"July 30, 2010","01/07/2010","",2009-08-01,"Improvement in Total Body Adiposity at 12 weeks|Improvement in high sensitivity C-reactive protein @ 12 wks|Improvement in glucose metabolism @ 12 wks|Improvement in lipid metabolism @ 12 wks","http://ClinicalTrials.gov/show/NCT00205660",NA
"50453",50453,"NCT00383760","E7389 as Second-Line Therapy in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: eribulin mesylate","Princess Margaret Hospital, Canada|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",37,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000502291|PMH-PHL-049","September 29, 2006","01/04/2006",NA,"October 7, 2009","01/07/2009","",2009-02-01,"Objective response (complete and partial)|Response or stable disease duration|Objective stable disease rate|Toxicity|Time to disease progression (median, 6 month, and 1 year)|Overall survival (median, 6 month, and 1 year)","http://ClinicalTrials.gov/show/NCT00383760",NA
"50469",50469,"NCT00378560","V501 Efficacy Study in Women Aged 18 to 26","Completed","Has Results","HPV Infections","Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Biological: Comparator: Placebo","Merck","Female","Adult","Phase II",1021,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2006_032|V501-027","September 18, 2006","01/06/2006",2009-09-01,"May 27, 2010","01/05/2010","",2009-09-01,"Combined Incidence of Persistent Human Papillomavirus (HPV) 6, 11, 16 and 18 Infection or HPV 6, 11, 16 and 18 Related-Disease as Determined by Clinical/Pathologic Criteria and Positive Polymerase Chain Reaction (PCR) Assay for Virus Subtype|Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 6)|Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 11)|Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 16)|Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 18)","http://ClinicalTrials.gov/show/NCT00378560",NA
"50485",50485,"NCT00377260","Acute Otitis Media (AOM) Therapy Trial in Young Children","Completed","Has Results","Acute Otitis Media","Drug: Amoxicillin-clavulanate|Drug: Placebo","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Child","Phase IV",291,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","05-0142","September 14, 2006","01/11/2006",2009-04-01,"January 6, 2011","01/04/2010","",2009-04-01,"The Time to Resolution of Symptoms, Defined as Acute Otitis Media-Severity of Symptoms (AOM-SOS) Score of 0 or 1, According to Treatment Assignment|The Time to Resolution of Symptoms, Defined as Acute Otitis Media-Severity of Symptoms (AOM-SOS) Score of 0 or 1 on Two Consecutive Occasions, According to Treatment Assignment|The Distribution of Clinical Failures by the On-therapy Visit According to Treatment Assignment|The Distribution of Clinical Failures by the End-of-therapy Visit According to Treatment Assignment|The Mean Acute Otitis Media - Severity of Symptom (AOM-SOS) Score, Post-enrollment, Over the First 7 Days of Therapy According to Treatment Assignment|The Distribution of Children Developing Worsening Symptoms Prior to Receiving 72 Hours of Study Medication According to Treatment Assignment|The Mean Number of Times Analgesic Medication Was Administered to the Child According to Treatment Assignment|The Distribution of Children With Observed or Parent Reported Adverse Events or Complications According to Treatment Assignment|The Distribution of Children With Nasopharyngeal (NP) Colonization With AOM Pathogens at the End-of-therapy Visit According to Treatment Assignment|The Distribution of Children With Nasopharyngeal (NP) Colonization With Penicillin-susceptible Streptococcus Pneumoniae (S. pn) at the End-of-therapy Visit According to Treatment Assignment|The Distribution of Children With Nasopharyngeal (NP) Colonization With AOM Pathogens at the Follow-up Visit According to Treatment Assignment|The Distribution of Children With Nasopharyngeal (NP) Colonization With Penicillin-susceptible Streptococcus Pneumoniae (S. pn) at the Follow-up Visit|The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the On-therapy Visit According to Treatment Assignment|The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the End-of-therapy Visit According to Treatment Assignment|The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the Follow-up Visit According to Treatment Assignment|The Mean Number of Visits to a Primary Care Provider (PCP) According to Treatment Assignment|The Mean Number of Emergency Room Visits According to Treatment Assignment|The Mean Number of Antibiotic Prescriptions, Exclusive of Study Medication, According to Treatment Assignment|The Total Number of Visits, Summed Across All Participants, at Which a Family Member Reported Having Missed Work According to Treatment Assignment|The Total Number of Visits, Summed Across All Participants, at Which a Family Member Reported Making Special Daycare Arrangements According to Treatment Assignment|The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the On-therapy Visit According to Treatment Assignment|The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the End-of-therapy Visit According to Treatment Assignment|The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the Follow-up Visit According to Treatment Assignment","http://ClinicalTrials.gov/show/NCT00377260",NA
"50528",50528,"NCT00498160","Bone Marrow Transplant to Induce Tolerance in Kidney Transplant Recipients","Completed","No Results Available","Deceased Donor Kidney Transplant","Procedure: Bone marrow transplant","University of Louisville|National Institutes of Health (NIH)|Department of Defense|Jewish Hospital and St. Mary's Healthcare","Both","Adult","Phase I|Phase II",38,"Other|NIH|U.S. Fed","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20031154","July 6, 2007","01/01/2005",2009-10-01,"November 23, 2010","01/11/2010","",2009-10-01,"Safety of bone marrow transplant|Tolerance induction","http://ClinicalTrials.gov/show/NCT00498160",NA
"50559",50559,"NCT00535860","Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis","Completed","No Results Available","Osteoporosis","Drug: Teriparatide","TransPharma Medical|Eli Lilly and Company","Female","Adult|Senior","Phase II",104,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CS 82-000-04|I2Y-MC-GHFE","September 25, 2007","01/04/2008",2009-03-01,"July 9, 2009","01/07/2009","",2009-03-01,"Change from baseline to endpoint 96 days in procollagen 1 N-terminal propeptide (P1NP)|Change from baseline in C-terminal telopeptide of type I collagen (CTX-1.)|hPTH (1-34) Pharmacokinetic AUC of ViaDerm-hPTH (1-34) and teriparatide SC.|Ratio of hPTH (1-34) AUC of transdermal treatment and subcutaneous injection|Ratio of hPTH (1-34) Cmax of transdermal treatment and subcutaneous injection|hPTH (1-34) Pharmacokinetic Cmax of ViaDerm-hPTH (1-34) and teriparatide SC.|Percentage of patients with serum total calcium above the upper limit of normal range|Percentage of patients with serum total calcium more than 1 mg/dl above the upper limit of normal range|Number of participants with hPTH (1-34) specific antibody immune response|Draize score for erythema and edema|Visual Analog Scale (VAS) pain assessment","http://ClinicalTrials.gov/show/NCT00535860",NA
"50562",50562,"NCT00548860","Study to Investigate the Safety of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients","Completed","No Results Available","Anemia","Drug: Ferric Carboxymaltose","Luitpold Pharmaceuticals","Female","Child|Adult|Senior","Phase III",NA,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1VIT07017","October 22, 2007","01/10/2007",2009-04-01,"June 5, 2009","01/06/2009","",2009-04-01,"safety and tolerability","http://ClinicalTrials.gov/show/NCT00548860",NA
"50613",50613,"NCT00617760","Safety and Immunogencitiy Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar?ó)","Completed","No Results Available","Neisseria Meningitidis (Bacterial Meningitis)|Invasive Pneumococcal Disease (IPD)","Biological: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|Biological: 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|Biological: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)","Baxter Healthcare Corporation","Both","Child","Phase III",330,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","670701","February 6, 2008","01/03/2008",2009-12-01,"January 4, 2010","01/01/2010","",2009-08-01,"Number of subjects achieving PCV7-specific (elicited by each vaccine pneumococcal serotype) antibody concentrations of at least 0.2 mg/mL 1 month after a booster vaccination with PCV7|Number of subjects achieving sero-protective levels of meningococcal serogroup C (MenC) specific serum bactericidal activity (SBA), defined as titer >=1:8, 1 month after administration of MenC-TT vaccine","http://ClinicalTrials.gov/show/NCT00617760",NA
"50626",50626,"NCT00635960","Growth Hormone in Amyotrophic Lateral Sclerosis","Completed","No Results Available","Amyotrophic Lateral Sclerosis","Drug: Growth Hormone (Somatropin)|Drug: Placebo","Federico II University|Istituto Biostrutture e Immagini, CNR Naples|Agenzia Italiana del Farmaco","Both","Adult|Senior","Phase II",40,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SLA_GH_1","March 3, 2008","01/03/2007",2010-05-01,"May 25, 2010","01/05/2010","",2009-07-01,"Primary endpoint is the N-acetylaspartate/Creatine ratio in the motor cortex assessed with magnetic resonance spectroscopy.|Difference in mortality between groups|Difference in the ALS-FRS score (motor function scale)|Difference in the SF-36 score (quality of life )|Safety and tolerability","http://ClinicalTrials.gov/show/NCT00635960",NA
"50628",50628,"NCT00639860","Clinical and Histological Evaluation of OSSIX-Plus Resorbable Collagen Membranes for Alveolar Ridge Preservation Following Exodontia","Completed","No Results Available","Tooth Extractions","Device: OSSIX-Plus","University of Michigan|Johnson & Johnson|OraPharma","Both","Adult|Senior","Phase I|Phase II",10,"Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-01","March 14, 2008","01/03/2008",2009-03-01,"May 20, 2009","01/05/2009","OSSIX",2009-03-01,"bone gain or loss in millimeters, radiographic bone changes, and percentage of new bone formation in the alveolar bone core biopsies|soft tissue wound healing","http://ClinicalTrials.gov/show/NCT00639860",NA
"50650",50650,"NCT00643760","A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)","Completed","No Results Available","Neuropathic Pain From Peripheral Diabetic Neuropathy|Neuropathy, Diabetic","Drug: XP13512/GSK1838262","GlaxoSmithKline","Both","Adult|Senior","Phase II",421,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","110448","February 19, 2008","01/03/2008",2009-02-01,"November 4, 2010","01/11/2010","",2009-02-01,"Change from baseline to end of treatment with respect to the mean 24-hour average pain intensity score based on an 11-point PI-NRS|24-hour average pain intensity score.|Percent of subjects achieving various levels of reduction in 24 hour average pain intensity score (derived from primary endpoint)|Time to onset of sustained improvement in the 24-hour average pain intensity score (sustained improvement is defined as a reduction of ??­ 2 points from baseline for ??­ 2 consecutive days).|Day-time average pain intensity score recorded in the evening before bedtime. Day-time is defined as the time between rising in the morning and going to bed at night.|Night-time average pain intensity score recorded in the morning upon awakening. Night-time is defined as the time between going to bed at night and rising in the morning.|Current pain intensity score recorded in the morning upon awakening and in the evening before bedtime.|Day-time worst pain intensity score recorded in the evening before bedtime. Day-time is defined as the time between rising in the morning and going to bed at night.|Night-time worst pain intensity score recorded in the morning upon awakening. Night-time is defined as the time between going to bed at night and rising in the morning.|Sleep interference score recorded in the morning upon awakening. The sleep interference score is the subject's assessment of sleep interference due to pain.|Pain quality (completed in physician's office)|Patient global impression of change (completed in physician's office)|Pre and post 50 foot (15 meter) walk. The pain intensity before and after walking 50 feet.|Rescue analgesic use recorded in the evening before bedtime|Physical functioning (completed in physician's office)|Quality of life (completed in physician's office)|Emotional functioning (completed in physician's office)|Clinician global impression of change (completed in physician's office)","http://ClinicalTrials.gov/show/NCT00643760",NA
"50669",50669,"NCT00704860","Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","Completed","No Results Available","Major Depression","Other: Open label pharmacotherapy","University of Ottawa","Both","Adult","Phase IV",27,"Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","REB- 200506","June 18, 2008","01/02/2005",2010-12-01,"January 18, 2011","01/02/2009","",2009-11-01,"Sustained Remission from Depression and Hippocampal Atrophy|5-HT1a Genetic Markers","http://ClinicalTrials.gov/show/NCT00704860",NA
"50670",50670,"NCT00689260","Easypod United States User Trial","Completed","Has Results","Growth Hormone Deficiency","Device: easypod|Device: easypod","EMD Serono","Both","Child|Adult","Phase IV",42,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)","28358","May 22, 2008","01/03/2008",2009-10-01,"October 29, 2010","01/10/2010","",2009-05-01,"Percent rhGH Injections Missed During the Treatment Period (Based on the Easypod?ºÑ Injection Log)|Subjects Perception of Easypod Ease of Use Compared to Two Other rhGH Pen Injection Devices|Subject Perceptions of Easypod: Storage Convenience Compared to Two Other rhGH Pen Injection Devices.|Subject Perceptions of Easypod: Preference to Use Easypod Over Two Other rhGH Pen Injection Devices.","http://ClinicalTrials.gov/show/NCT00689260",NA
"50682",50682,"NCT00721760","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery","Completed","No Results Available","Venous Thromboembolism","Drug: Enoxaparin|Drug: Semuloparin sodium (AVE5026)|Drug: Placebo","Sanofi-Aventis","Both","Adult|Senior","Phase III",1003,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","EFC10343|2007-007945-11","July 22, 2008","01/07/2008",2009-10-01,"December 20, 2010","01/12/2010","SAVE-HIP2",2009-09-01,"Occurence of the composite endpoint of any VTE confirmed by a blinded Central Independent Adjudication Committee (CIAC) and deaths from any cause|Occurence of the composite endpoint of any proximal Deep Vein Thrombosis (DVT), symptomatic distal DVT, nonfatal Pulmonary Embolism (PE), and all cause deaths|Number of patients with major bleedings and clinically relevant non-major bleedings as confirmed by the CIAC","http://ClinicalTrials.gov/show/NCT00721760",NA
"50707",50707,"NCT00772460","Comparison of a New Patient Warming System Using Polymer Conductive Warming With Forced Air Warming During Surgery","Completed","No Results Available","Hypothermia","Device: Patient Warming with conductive / convective warming","Medical University of Vienna","Both","Adult|Senior","Phase III",80,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","HotDogVienna","October 14, 2008","01/10/2008",2009-06-01,"September 18, 2009","01/09/2009","HDV",2009-06-01,"Area under the standardized \core temperature * time\"" curve|Area under \""mean skin temperature * time\"" curve""","http://ClinicalTrials.gov/show/NCT00772460",NA
"50715",50715,"NCT00790660","A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: ASP1941|Drug: Placebo","Astellas Pharma Inc","Both","Adult|Senior","Phase II",61,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","1941-CL-0016","November 11, 2008","01/10/2008",2009-02-01,"February 26, 2010","01/02/2010","",2009-02-01,"Evaluation of safety through clinical safety labs and adverse events|Evaluation of routine PK and PD parameters","http://ClinicalTrials.gov/show/NCT00790660",NA
"50720",50720,"NCT00794560","Self-management of Low Molecular Weight Heparin Therapy","Completed","No Results Available","Thromboembolism","Behavioral: patient education","University Hospital, Basel, Switzerland|Pfizer|Investigator Initiated Research Grant","Both","Adult|Senior","Phase IV",147,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","NRA 630 00 23|EKBB 95/07","November 18, 2008","01/06/2007",2009-08-01,"October 4, 2010","01/10/2010","",2009-08-01,"drug use problems|compliance|patient satisfaction","http://ClinicalTrials.gov/show/NCT00794560",NA
"50725",50725,"NCT00802360","MENOPUR?ó Versus FOLLISTIM?ó","Completed","No Results Available","Infertility","Drug: Menopur?ó|Drug: Endometrin?ó|Drug: Follistim Pen?ó|Drug: Progesterone in oil","Ferring Pharmaceuticals","Female","Adult","Phase IV",173,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-04","December 3, 2008","01/12/2008",2010-01-01,"May 5, 2010","01/05/2010","",2009-11-01,"Ongoing Pregnancy Rate|Number of Follicles|Number of oocytes retrieved|Fertilization rate|Embryo quality|Number of embryos frozen|Cycle cancellation rate|Implantation rate|Biochemical pregnancy rate|Clinical pregnancy rate|Adverse events, including ovarian hyperstimulation syndrome (OHSS)|Live birth rate","http://ClinicalTrials.gov/show/NCT00802360",NA
"50727",50727,"NCT00806260","A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.","Completed","No Results Available","Overweight|Obesity","Drug: VI-0521|Drug: Placebo|Other: Alcohol or fruit juice","VIVUS, Inc.|MDS Pharma Services","Both","Adult","Phase II",80,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","OB-205","December 9, 2008","01/12/2008",2009-05-01,"November 20, 2009","01/11/2009","",2009-05-01,"Measure of psychomotor function using speed and coordination on the CogScreen Pathfinder Number Test, assessed by reaction time for correct responses and coordination error, in subjects treated with VI-0521 compared to placebo.|Additional measures of psychomotor function supporting the primary endpoint including: Reaction time, attention, and information processing speed","http://ClinicalTrials.gov/show/NCT00806260",NA
"50741",50741,"NCT00824460","Study of Phosphate Levels in Patients With Chronic Kidney Disease","Completed","No Results Available","Chronic Kidney Disease","Drug: PA21|Drug: Renagel","Vifor Inc.","Both","Adult|Senior","Phase II",252,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PA-CL-03A|75610","January 9, 2009","01/12/2008",2010-03-01,"April 12, 2010","01/03/2010","PA21",2009-10-01,"Change from baseline in serum-phosphate levels at the end of treatment.|Change from baseline in serum-phosphate levels at week 2|Change from baseline in serum-phosphate levels at week 4|Change from baseline in serum-phosphate levels at week 5","http://ClinicalTrials.gov/show/NCT00824460",NA
"50745",50745,"NCT00833560","Study on the Reduction of Tumor Cell Burden With Bortezomib (Vel), Cyclophosphamide (C) and Dexamethasone (D) Before Stem Cell Transplantation (So-called Induction Therapy) in Patients With Multiple Myeloma Aged 60 Years or Less.","Completed","No Results Available","Multiple Myeloma|Remission Induction|Stem Cell Transplantation","Drug: Cyclophosphamide (Cy)|Drug: Bortezomib (Btz)|Drug: Dexamethasone (D)","Janssen-Cilag G.m.b.H","Both","Adult","Phase II|Phase III",401,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR005242","January 23, 2009","01/03/2006",2009-06-01,"July 15, 2010","01/07/2010","",2009-06-01,"Efficacy (Response)|Tolerability and comparison of response rates in different cytogenetic risk groups","http://ClinicalTrials.gov/show/NCT00833560",NA
"50759",50759,"NCT00854360","Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR","Completed","No Results Available","Seasonal Allergic Rhinitis|Hayfever","Drug: Beclomethasone dipropionate HFA Nasal Aerosol|Drug: Placebo","Teva Branded Pharmaceutical Products, R&D Inc.","Both","Child|Adult|Senior","Phase II",480,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BDP-AR-201","March 2, 2009","01/02/2009",2009-05-01,"July 22, 2009","01/07/2009","",2009-05-01,"Average of the AM and PM patient-reported reflective Total Nasal Symptom Score (TNSS) over the two-week Treatment Period.|Average of AM and PM patient-reported instantaneous TNSS over the two week treatment period|AM patient-reported instantaneous TNSS over the two-week Treatment Period|Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at Endpoint in patients with impaired quality of life at Baseline as defined by a RQLQ score at the Randomization Visit (TV0) of 3.0 or greater|AM patient-reported 24-hour reflective ocular symptom score over the two-week Treatment Period in patients with adequate symptoms during the Run-in period|AM patient-reported 24-hour reflective non-nasal symptom score over the two-week Treatment Period in patients with adequate symptoms during the Run-in period","http://ClinicalTrials.gov/show/NCT00854360",NA
"50779",50779,"NCT00886860","The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol","Completed","No Results Available","Cervical Ripening|Labor Induction","Drug: misoprostol|Drug: misoprostol","Mahidol University","Female","Adult","Phase IV",64,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","091/2552(EC2)","April 22, 2009","01/05/2009",2010-03-01,"July 12, 2010","01/07/2010","",2009-12-01,"success rate of cervical ripening in labor induction|number of vaginal delivery","http://ClinicalTrials.gov/show/NCT00886860",NA
"50838",50838,"NCT00992160","Vestipitant 28-day Tolerance Study","Completed","No Results Available","Primary Insomnia","Drug: GW597599|Drug: Placebo","GlaxoSmithKline","Both","Adult","Phase II",161,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","111364","July 16, 2009","01/05/2009",2009-09-01,"January 28, 2010","01/01/2010","",2009-09-01,"Nocturnal polysomngraphy|Subjective sleep assessments as performed by Post-Sleep Questionnaires and subject -rated Insomnia Severity Index|Motor and cognitive functioning assessed by neurological tests (Romberg and Hee-to-toe) and Cognitive tests (Digit Symbol Substitution test and verbal Learning Memory test)","http://ClinicalTrials.gov/show/NCT00992160",NA
"50906",50906,"NCT01118260","Total Intravenous Anaesthesia (TIVA) Versus Spinal Anaesthesia in Patients Undergoing Transurethral Prostate Resection","Completed","No Results Available","Prostate|Hyperplasia","Procedure: total intravenous anaesthesia|Procedure: spinal anaesthesia","Asker & Baerum Hospital","Male","Adult|Senior","Phase IV",101,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-002672-42","April 7, 2010","01/01/2006",2009-05-01,"May 5, 2010","01/05/2010","TURPS",2009-05-01,"patient satisfaction|time in PACU","http://ClinicalTrials.gov/show/NCT01118260",NA
"51054",51054,"NCT00006461","Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child","Phase III",65,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068269|COG-P9934|POG-P9934","November 6, 2000","01/10/2000",NA,"November 20, 2010","01/11/2010","",2009-01-01,"Event-free survival rate at 1 year|Feasibility and safety|Toxicity|Neuropsychological and neuroendocrine effects|Incidence of atypical teratoid and/or rhabdoid tumor","http://ClinicalTrials.gov/show/NCT00006461",NA
"51120",51120,"NCT00124761","A Trial Comparing Radiosurgery With Surgery for Solitary Brain Metastases","Completed","No Results Available","Neoplasm Metastasis|Brain Neoplasm","Procedure: Surgery + WBRT|Radiation: Radiosurgery + WBRT","Royal Adelaide Hospital","Both","Adult|Senior","Phase III",22,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","21108","July 27, 2005","01/12/2002",2009-05-01,"September 2, 2010","01/09/2010","",2009-04-01,"Overall survival and Quality of life|Local and distant recurrence|Failure free survival|Acute and late toxicities","http://ClinicalTrials.gov/show/NCT00124761",NA
"51214",51214,"NCT00276861","Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer","Completed","No Results Available","Colorectal Cancer","Drug: gemcitabine hydrochloride|Drug: oxaliplatin","University of Miami Sylvester Comprehensive Cancer Center","Both","Adult|Senior","Phase II",27,"Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","EPROST-20030655|SCCC-2003110|WIRB-20050993","January 12, 2006","01/09/2005",NA,"January 11, 2010","01/01/2010","",2009-06-01,"Response rate as measured by RECIST criteria|Time to progression as measured by the Kaplan Meyer curve at completion of study treatment","http://ClinicalTrials.gov/show/NCT00276861",NA
"51259",51259,"NCT00324961","Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B","Completed","Has Results","Chronic Hepatitis B","Drug: adefovir dipivoxil tablets","GlaxoSmithKline","Both","Adult","Phase IV",533,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ADF106632","May 9, 2006","01/01/2006",2009-01-01,"October 26, 2009","01/10/2009","",2009-01-01,"Number of Participants Achieving HBV DNA ???300 Copies/mL at Week 104|Number of Participants Achieving Histological Improvement After the 104-week Treatment|Liver Histology Scores in HBeAg Negative Participants With Two Sequential Liver Biopsies During the Period of 104 Weeks|Change From Baseline in Median Serum HBV DNA Over Time|Number of Participants Achieving ALT Normalization at Week 104|Number of Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 104|Number of Participants With ADV-associated Resistance at Week 104|Number of Participants Achieving HBV DNA ???300 Copies/mL Over Time|Number of Participants Achieving Complete Response at Week 104|Time to Protocol-defined Complete Response Over a 104-week Treatment Period","http://ClinicalTrials.gov/show/NCT00324961",NA
"51276",51276,"NCT00365261","Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer","Completed","No Results Available","Sleep Initiation and Maintenance Disorders","Drug: eszopiclone","University of California, San Diego","Both","Adult|Senior","Phase IV",50,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","UCSD 060340|ESRC 054","August 15, 2006","01/09/2006",2009-12-01,"June 24, 2010","01/06/2010","",2009-12-01,"Patient Self-report data on sleep, pain, and fatigue|Opiate dosing from patient controlled analgesia","http://ClinicalTrials.gov/show/NCT00365261",NA
"51279",51279,"NCT00371761","PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (Study P04498)(COMPLETED)","Completed","Has Results","Hepatitis B, Chronic (CHB)","Drug: Pegylated interferon alfa-2b (PegIntron)|Drug: Adefovir dipivoxil (adefovir)","Schering-Plough","Both","Adult|Senior","Phase III",25,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P04498","August 31, 2006","01/09/2006",2009-02-01,"November 18, 2010","01/11/2010","",2009-02-01,"Number of Participants With a Combined Response Consisting of All Three Responses - (a) Serological Response, (b) Virological Response, and (c) Biochemical Response","http://ClinicalTrials.gov/show/NCT00371761",NA
"51282",51282,"NCT00380861","Does Implant Design Improve Postoperative Flexion?","Completed","No Results Available","Arthritis","Device: Total Knee Arthroplasty","DePuy Orthopaedics","Both","Adult|Senior","Phase IV",186,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","4092","September 26, 2006","01/03/2006",2009-12-01,"January 19, 2010","01/01/2010","",2009-12-01,"Flexion at 6 and 12 months after total knee arthroplasty in a series of simultaneous bilateral knees where 1 implant design is in the left knee and a 2nd design is in the right knee.|Range of motion (ROM) over time|Effect of subject demographics and anthropometrics on ROM|AKS Score|KOOS score|Knee pain|Ability to perform activities|Crepitus|Subject satisfaction|Rate of adverse events","http://ClinicalTrials.gov/show/NCT00380861",NA
"51321",51321,"NCT00431561","Phase IIb Clinical Trial With TGF-??2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma","Completed","No Results Available","Glioblastoma|Anaplastic Astrocytoma","Drug: AP 12009 10 ??M|Drug: AP 12009 80 ??M|Drug: temozolomide or PCV|Device: Drug delivery system for administration of AP 12009|Procedure: Placement of Drug Delivery System","Antisense Pharma","Both","Adult|Senior","Phase II",141,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AP 12009-G004","February 5, 2007","01/04/2003",2009-03-01,"December 3, 2009","01/12/2009","",2009-03-01,"Overall response rate of two AP 12009 dose groups and control group assessed by the evaluation of tumor size on brain MRI scans|Overall survival|Overall survival|Response rates|Progression-free survival|Time to progression|Time to response|Best of all response rates assessed by survival status and variation of tumor size on brain MRI|Change of quality of life and Karnofsky Performance Status (KPS)|Best of all response rates|Safety and tolerability","http://ClinicalTrials.gov/show/NCT00431561",NA
"51432",51432,"NCT00620061","Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone","Completed","No Results Available","Opioid-Induced Bowel Dysfunction","Drug: Lubiprostone","Sucampo Pharmaceuticals, Inc.|Takeda Pharmaceutical Company Limited","Both","Adult|Senior","Phase III",440,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OBD06S1","February 11, 2008","01/11/2007",2009-09-01,"December 10, 2009","01/12/2009","",2009-09-01,"Evaluation of overall safety, including AEs; clinical laboratory evaluations; vital signs; 12-lead resting electrocardiograms; and physical examination results.|Change from baseline in spontaneous bowel movement (SBM) and bowel movement (BM) frequency|Frequency of SBMs and BMs|Responder rates|Mean change from baseline in straining associated with SBMs; stool consistency of SBMs; constipation severity; treatment effectiveness; abdominal bloating; abdominal discomfort; and bowel habit regularity.","http://ClinicalTrials.gov/show/NCT00620061",NA
"51436",51436,"NCT00617461","A Clinical Study Of XP13512/GSK1838262 In Subjects With Neuropathic Pain From Post-Herpetic Neuralgia (PHN) Who Have Had An Inadequate Response To Gabapentin Treatment","Completed","No Results Available","Neuralgia, Postherpetic|Pain Associated With Post-Herpetic Neuralgia","Drug: XP13512/GSK1838262","GlaxoSmithKline","Both","Adult|Senior","Phase II",96,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","110527","February 6, 2008","01/03/2008",2009-07-01,"September 17, 2010","01/09/2010","",2009-07-01,"the mean daily average pain intensity score for the last week of each treatment period based on an 11-point PI-NRS (0 = \no pain\"" and 10 = \""pain as bad as you can imagine\"").|24-hour","http://ClinicalTrials.gov/show/NCT00617461",NA
"51474",51474,"NCT00678561","Topical CP-690,550 For Chronic Plaque Psoriasis","Completed","No Results Available","Psoriasis","Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: Placebo Vehicle|Drug: Placebo Vehicle","Pfizer","Both","Adult|Senior","Phase II",81,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A3921038","May 13, 2008","01/10/2008",2009-07-01,"November 12, 2010","01/11/2010","",2009-07-01,"target plaque severity score|local toleration|safety laboratory assays|blood levels of drug|physician's global assessment of target lesion","http://ClinicalTrials.gov/show/NCT00678561",NA
"51490",51490,"NCT00701961","Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy","Completed","No Results Available","Plasmodium Falciparum Malaria","Drug: Mefloquine-artesunate","Institute of Tropical Medicine, Belgium|Centre Muraz|Liverpool School of Tropical Medicine","Female","Adult","Phase II|Phase III",48,"Other","Interventional","Control: Active Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ITMP0208","June 18, 2008","01/10/2008",2009-07-01,"September 12, 2010","01/09/2010","",2009-07-01,"To estimate the pharmacokinetic of MQ-AS for treatment of P. falciparum or mixed infection in pregnant compared to non-pregnant women.|The proportion of women in each treatment group with parasitological cure at 63 days, corrected by PCR for re-infection.","http://ClinicalTrials.gov/show/NCT00701961",NA
"51494",51494,"NCT00704561","Six-month Coverage and Vessel Wall Response of the Zotarolimus Drug-eluting Stent Implanted in AMI Assessed by Optical Coherence Tomography","Completed","No Results Available","Acute Myocardial Infarction","Device: ENDEAVOR?ó drug-eluting stent (Medtronic, Santa Rosa, CA)|Device: DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|Device: Coronary stent implantation|Device: Bare Metal Coronary Stent","Ospedali Riuniti di Bergamo|Case Western Reserve University|Medtronic","Both","Adult|Senior","Phase III",44,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","457/2008","June 24, 2008","01/04/2008",2009-10-01,"February 9, 2010","01/03/2009","OCTAMI",2009-04-01,"Non inferiority OCT Number of uncovered Stent struts for Endeavor drug eluting stent vs Driver BMSbare metal stent|number of well apposed stent struts without neointima|number of malapposed stent struts without neointima|number of sections with > 30% uncovered struts/total struts|Number of sections with incomplete strut apposition|Adjudicated MACE(Death, re-MI, TLR) rate at 30 days and 6 months (non inferiority)|In segment OCT neontimal volume","http://ClinicalTrials.gov/show/NCT00704561",NA
"51502",51502,"NCT00717561","A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia","Completed","No Results Available","Pneumonia","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin","Bayer","Both","Adult|Senior","Phase III",60,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12669|EudraCT: 2007-001320-12","July 16, 2008","01/02/2008",2009-06-01,"July 16, 2010","01/07/2010","",2009-05-01,"Clinical response 20 days after completion of study treatment (Test-of-Cure visit)|Clinical and bacteriological response on the day of switch from IV to oral therapy|Clinical and bacteriological response on treatment Day 3-5 (if the day of switch is different from Day 3, 4 or 5)|Bacteriological response at TOC|Clinical and bacteriological response at the end of treatment|Mortality attributable to pneumonia at the Test-of-Cure visit","http://ClinicalTrials.gov/show/NCT00717561",NA
"51536",51536,"NCT00770861","A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients","Completed","No Results Available","Hypertension","Drug: Nebivolol|Drug: Placebo","Forest Laboratories","Both","Adult|Senior","Phase IV",277,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NEB-MD-16","October 9, 2008","01/09/2008",NA,"March 9, 2010","01/03/2010","",2009-11-01,"Mean seated trough Diastolic Blood Pressure|Mean seated trough Systolic Blood Pressure","http://ClinicalTrials.gov/show/NCT00770861",NA
"51541",51541,"NCT00774761","A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: fluticasone propionate/formoterol fumarate|Drug: fluticasone propionate|Drug: formoterol fumarate","Dey","Both","Adult|Senior","Phase II",97,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","191-087","October 16, 2008","01/11/2008",2009-05-01,"September 22, 2009","01/09/2009","",2009-04-01,"Plasma AUC(0-t) after 1 week of dosing|FEV1","http://ClinicalTrials.gov/show/NCT00774761",NA
"51582",51582,"NCT00842361","Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: NN5401|Drug: biphasic insulin aspart 30","Novo Nordisk","Both","Adult|Senior","Phase II",65,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NN5401-3570|JAPIC: JapicCTI-090712","February 11, 2009","01/01/2009",2009-06-01,"November 9, 2009","01/07/2009","",2009-06-01,"The incidence of hypoglycaemic episodes|All adverse events|Change in 12-lead ECG|Change in body weight|Change in blood pressure","http://ClinicalTrials.gov/show/NCT00842361",NA
"51593",51593,"NCT00852761","A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis","Completed","No Results Available","Plaque-Type Psoriasis","Drug: Clobetasol propionate formulation A|Drug: clobetasol propionate formulation B","Stiefel, a GSK Company","Both","Adult|Senior","Phase IV",32,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","U0280-402","February 25, 2009","01/01/2009",2009-08-01,"August 19, 2009","01/08/2009","",2009-06-01,"Primary Outcome will be measured using the Psoriasis Grading Scale for Target Lesion from baseline to day 15 of the study|Proportion of subjects who achieve treatment success at day 7. Change in the psoriasis assessment from baseline to days 7 and 15. Proportion of subjects who achieve treatment success as evaluated by the subject from visit 1 to days 7 and 15","http://ClinicalTrials.gov/show/NCT00852761",NA
"51645",51645,"NCT00942461","Inflammatory Response in Laparoscopic and Open Colectomy","Completed","No Results Available","Colorectal Cancer","Procedure: Laparoscopic colectomy|Procedure: Open colectomy","G. Hatzikosta General Hospital|University of Ioannina","Both","Child|Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)","GH-1948-04|GHDS-12345-4","July 20, 2009","01/10/2008",NA,"July 20, 2009","01/07/2009","",2009-06-01,"Inflammatory reaction of the patients organism in laparoscopic vs open colorectal surgery for cancer","http://ClinicalTrials.gov/show/NCT00942461",NA
"51652",51652,"NCT00956761","Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010","Completed","No Results Available","Seasonal Influenza","Biological: Seasonal Influenza Vaccine (MF59C.1)","Novartis|Novartis Vaccines","Both","Adult|Senior","Phase II",63,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","V70_09S|2009-010586-23","August 8, 2009","01/06/2009",2009-07-01,"August 10, 2009","01/08/2009","",2009-07-01,"To evaluate the antibody response to each flu vaccine antigen, as measured by SRH at 21 days post-immunization in elderly subjects in compliance with the requirements of the EU recommendations for clin. trials related to yearly licensing of flu vaccines|To evaluate the safety of a IM injection of an MF59 -adjuvanted seasonal flu vaccine in elderly subjects in compliance with the requirements of the current EU recommendations for clinical trials related to yearly licensing of influenza vaccines","http://ClinicalTrials.gov/show/NCT00956761",NA
"51667",51667,"NCT00978861","Clinical Study to Evaluate of The Whitening Efficacy and Safety of REMEWHITE","Completed","No Results Available","Tooth Whitening","Drug: Hydrogen Peroxide","JDC Tech","Both","Adult|Senior","Phase III",70,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RE5","August 31, 2009","01/10/2008",2009-08-01,"September 16, 2009","01/09/2009","REMEWHITE",2009-06-01,"colorimeter|colorimeter","http://ClinicalTrials.gov/show/NCT00978861",NA
"51695",51695,"NCT01021761","A Comparison of PGE2 Indibition of Acuvail, Xibrom and Nevanac in Patients Undergoing Phacoemulsification","Completed","No Results Available","Cataracts","Drug: Ketorolac Tromethamine|Drug: Bromfenac|Drug: neppafenac","Bucci Laser Vision Institute|Allergan","Both","Adult|Senior","Phase IV",120,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","2009 0199","November 25, 2009","01/10/2009",2010-01-01,"August 16, 2010","01/08/2010","",2009-12-01,"Aqueous PGE2 levels","http://ClinicalTrials.gov/show/NCT01021761",NA
"51884",51884,"NCT00003162","Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer","Completed","No Results Available","Breast Cancer|Metastatic Cancer|Pain|Prostate Cancer","Procedure: pain therapy|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group","Both","Adult|Senior","Phase III",938,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Supportive Care","CDR0000065957|RTOG-9714|NCCTG-R9714|NCI-P97-0124","November 1, 1999","01/02/1998",NA,"July 29, 2009","01/04/2002","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00003162",NA
"52066",52066,"NCT00258362","Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer","Completed","Has Results","Endometrial Cancer","Drug: carboplatin|Drug: docetaxel|Radiation: radiation therapy","Masonic Cancer Center, University of Minnesota|Sanofi-Aventis","Female","Adult|Senior","Phase II",41,"Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004LS021|UMN-WCC-38|13062","November 22, 2005","01/07/2005",2009-12-01,"November 10, 2010","01/11/2010","",2009-12-01,"Percent of Patients Estimated to be Progression-Free and Alive|Percent of Patients Estimated to be Alive","http://ClinicalTrials.gov/show/NCT00258362",NA
"52088",52088,"NCT00294762","Tarceva as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Tarceva|Drug: Tarceva + carboplatin/paclitaxel","OSI Pharmaceuticals","Both","Adult|Senior","Phase II",140,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OSI-774-203","February 17, 2006","01/01/2006",2009-04-01,"June 29, 2010","01/05/2009","",2009-04-01,"Progression Free Survival|Estimates, overall survival, tumor response, Safety","http://ClinicalTrials.gov/show/NCT00294762",NA
"52175",52175,"NCT00435162","Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure","Completed","No Results Available","Hypertension","Drug: Valsartan","Novartis Pharmaceuticals","Both","Child","Phase III",75,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CVAL489K2303","February 13, 2007","01/03/2007",2009-01-01,"February 6, 2010","01/02/2010","",2009-01-01,"Change in mean sitting systolic blood pressure (MSSBP)|safety and tolerability of valsartan measured by frequency of adverse events, laboratory values, pulse, standing blood pressure, body weight|Change in mean sitting systolic blood pressure (MSSBP) at end of placebo-controlled withdrawal period|Change in mean sitting diastolic blood pressure (MSDBP)|Change in mean sitting diastolic blood pressure (MSDBP) at end of placebo-controlled withdrawal period","http://ClinicalTrials.gov/show/NCT00435162",NA
"52296",52296,"NCT00628862","Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Formoterol Turbuhaler 4.5mg|Drug: Formoterol Turbuhaler 9 mg|Drug: Turbuhaler placebo","AstraZeneca","Both","Adult|Senior","Phase III",613,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","D5122C00001|EudraCT no 2007-003999-19","January 24, 2008","01/12/2007",2009-04-01,"May 4, 2009","01/05/2009","OCEAN",2009-04-01,"To show that formoterol 4.5 ??g and 9 ??g twice daily are superior to placebo in Japanese and European COPD patients treated for 12 weeks by evaluation of FEV1 60 minutes post-dose as the primary outcome variable.|Evaluate the onset of action of formoterol 4.5 ??g and 9 ??g using placebo as a control, by evaluation of FEV1 as the primary objective|Compare the effect of formoterol 4.5 ??g twice daily to that of formoterol 9 ??g twice daily by evaluation of the same primary and secondary variables as for the primary objective|Evaluate the safety of formoterol 4.5 ??g and 9 ??g twice daily for 12 weeks in terms of: - Adverse events, laboratory variables, 12-lead ECG, blood pressure and pulse rate","http://ClinicalTrials.gov/show/NCT00628862",NA
"52315",52315,"NCT00661362","Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes","Completed","No Results Available","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo|Drug: Metformin","AstraZeneca|Bristol-Myers Squibb","Both","Adult|Senior","Phase III",530,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","D1680C00006","April 17, 2008","01/05/2008",2009-09-01,"November 1, 2009","01/11/2009","",2009-09-01,"Absolute change from baseline in glycosylated haemoglobin A1c (HbA1c) after 24 weeks oral administration|Compare the effects of Saxagliptin versus placebo given as add on therapy to metformin during 24 weeks.","http://ClinicalTrials.gov/show/NCT00661362",NA
"52329",52329,"NCT00683462","An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)","Completed","No Results Available","ADHD","Drug: Placebo|Drug: AZD3480|Drug: AZD3480","AstraZeneca|Targacept Inc.","Both","Adult","Phase II",24,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TC-1734-226-CRD-005","May 21, 2008","01/05/2008",2009-07-01,"October 29, 2009","01/10/2009","",2009-07-01,"The Total Symptoms Scale Score (of ADHD) of the Connors Adult ADHD Rating Scale-Investigator Rating (CAARS-INV).|Clinical Global Impressions Scales (NIMH 1985)|CDR computerized cognitive battery|CNRU computerized cognitive battery","http://ClinicalTrials.gov/show/NCT00683462",NA
"52340",52340,"NCT00548262","This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis","Completed","Has Results","Candidemia|Invasive Candidiasis","Drug: Anidulafungin|Drug: Voriconazole","Pfizer","Both","Adult|Senior","Phase IV",54,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A8851015","October 19, 2007","01/02/2008",2009-10-01,"December 15, 2010","01/12/2010","",2009-10-01,"Number of Participants for Global Response (Based on Clinical and Microbiological Success or Failure) at End of Treatment|Number of Participants for Global Response (Based on Clinical and Microbiological Success or Failure)|Number of Participants for Global Response Per Type of Candida Species Isolated at Baseline: EIVT|Number of Participants for Global Response Per Type of Candida Species Isolated at Baseline: EOT|Number of Participants for Global Response Per Type of Candida Species Isolated at Baseline: Week 2 Follow-up|Number of Participants for Global Response for Pre-specified Baseline Risk Factors Subgroups of Interest: EOT|Number of Participants for Global Response for Baseline Risk Factors for Candidemia and Invasive Candidiasis: EIVT|Number of Participants for Global Response for Baseline Risk Factors for Candidemia and Invasive Candidiasis: Week 2 Follow-up|Number of Participants for Global Response by Acute Physiological Assessment and Chronic Health Evaluation II (APACHE II) Score|Number of Participants Per Survival Status (Alive or Dead) on Day 30|Number of Participants With Death Attributable (Yes or No) to Candidemia or Invasive Candidiasis|Time to Negative Blood, Specimen, or Tissue Culture|Duration of Exposure to Intravenous Anidulafungin Prior to Switch to Oral Voriconazole Treatment|Length of Hospital Stay|Length of Stay in Intensive Care Unit (ICU)|Change From Baseline in Vital Signs: Supine Blood Pressure|Change From Baseline in Vital Signs: Supine Heart Rate|Change From Baseline in Vital Signs: Weight|Change From Baseline in Vital Signs: Temperature|Change From Baseline in Vital Signs: Respiration Rate|Change From Baseline in Chemistry Laboratory Test Data (Measured as mg/dL)|Change From Baseline in Chemistry Laboratory Test Data (Measured as IU/L)","http://ClinicalTrials.gov/show/NCT00548262",NA
"52342",52342,"NCT00701662","A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)","Completed","No Results Available","Multifocal Motor Neuropathy (MMN)","Biological: Human Normal Immunoglobulin","CSL Behring","Both","Adult|Senior","Phase II",8,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1464|ZLB06_006CR|2007-000710-37","June 18, 2008","01/11/2007",2009-01-01,"October 7, 2010","01/10/2010","",2009-01-01,"Muscle strength of the patients measured using a modified Medical Research Council (MRC) scale|Disability, scored using modified Guy's Neurological Disability Scale|Individual Functional Test of four common daily tasks (motor function)|Quality of Life (QoL), using an adapted QoL questionnaire","http://ClinicalTrials.gov/show/NCT00701662",NA
"52348",52348,"NCT00704262","Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds","Completed","No Results Available","Psoriasis Vulgaris","Drug: Calcipotriol plus hydrocortisone (LEO 80190)","LEO Pharma","Both","Adult|Senior","Phase II",33,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LEO 80190-O23","June 23, 2008","01/05/2008",2009-12-01,"December 14, 2009","01/12/2009","",2009-12-01,"Effect on the hypothalamic-pituitary-adrenal axis and effect on the calcium metabolism|Overall disease severity of the face and intertriginous areas according to the investigator??s global assessment of disease severity.","http://ClinicalTrials.gov/show/NCT00704262",NA
"52368",52368,"NCT00735462","Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts","Completed","No Results Available","External Genital Warts|Perianal Warts|Condylomata Acuminata","Drug: imiquimod cream A|Drug: imiquimod cream B|Drug: placebo","Graceway Pharmaceuticals, LLC","Both","Child|Adult|Senior","Phase III",450,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GW01-0805","August 14, 2008","01/08/2008",2009-07-01,"January 26, 2010","01/01/2010","",2009-07-01,"The primary efficacy endpoint is the proportion of subjects achieving complete clearance of all warts (baseline and new) at the end of study.|Safety variables include adverse reactions (AEs), local skin reactions (LSRs), and number and duration of rest periods during the Treatment Period","http://ClinicalTrials.gov/show/NCT00735462",NA
"52374",52374,"NCT00747162","Muscle Oxygenation and Skin Pigmentation","Completed","No Results Available","Muscle Oxygenation|Skin Pigmentation","Device: Measure of muscle oxygenation|Device: Skin pigmentation determination","Emory University","Both","Adult|Senior","Phase IV",500,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","9004","August 27, 2008","01/08/2008",2009-01-01,"January 29, 2009","01/01/2009","",2009-01-01,"Measure from The INVOS cerebral oximeter and DermaSpectrometer","http://ClinicalTrials.gov/show/NCT00747162",NA
"52383",52383,"NCT00758862","The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo","Completed","No Results Available","Secondarily Infected Traumatic Lesions (SITL)|Impetigo","Drug: 2% TD1414 Cream","LEO Pharma","Both","Adult","Phase II",20,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TD1414-C22","September 23, 2008","01/12/2008",2009-02-01,"August 11, 2009","01/08/2009","",2009-02-01,"To determine the pharmacokinetic profile of TD1414 after repeated topical administration of 2% TD1414 cream for the treatment of SITL or impetigo in adult patients|To determine the safety of 2% TD1414 cream in the treatment of SITL or impetigo in adult patients","http://ClinicalTrials.gov/show/NCT00758862",NA
"52468",52468,"NCT00891462","Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Aclidinium bromide|Drug: Aclidinium bromide|Drug: Placebo","Forest Laboratories|Almirall, S.A.","Both","Adult|Senior","Phase III",561,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAS-MD-33|ACCORD COPD I","April 30, 2009","01/04/2009",2009-11-01,"February 23, 2010","01/02/2010","",2009-11-01,"Morning Pre-dose Forced Expiratory Volume in 1 Second|Peak Forced Expiratory Volume in 1 Second","http://ClinicalTrials.gov/show/NCT00891462",NA
"52483",52483,"NCT00860262","Telmisartan and Amlodipine Fixed Dose Combination Trial for the Treatment of Severe Hypertension","Completed","Has Results","Hypertension","Drug: amlodipine|Drug: telmisartan|Drug: telmisartan and amlodipine","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",860,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","1235.20|2008-000873-40","March 11, 2009","01/03/2009",NA,"December 10, 2010","01/12/2010","",2009-12-01,"Change From Baseline in Trough Seated Systolic Blood Pressure at Week 8|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 8|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1|Patients Achieving Diastolic Blood Pressure Control at Week 1|Patients Achieving Diastolic Blood Pressure Control at Week 2|Patients Achieving Blood Pressure Control at Week 1|Patients Achieving Blood Pressure Control at Week 2|Patients Achieving Diastolic Blood Pressure Response at Week 1|Patients Achieving Diastolic Blood Pressure Response at Week 2|Patients Achieving Systolic Blood Pressure Response at Week 1|Patients Achieving Systolic Blood Pressure Response at Week 2|Patients Achieving Normal Blood Pressure Response at Week 1|Patients Achieving Normal Blood Pressure Response at Week 2|Patients Achieving Diastolic Blood Pressure Control at Week 4|Patients Achieving Diastolic Blood Pressure Control at Week 6|Patients Achieving Diastolic Blood Pressure Control at Week 8|Patients Achieving Blood Pressure Control at Week 4|Patients Achieving Blood Pressure Control at Week 6|Patients Achieving Blood Pressure Control at Week 8|Patients Achieving Diastolic Blood Pressure Response at Week 4|Patients Achieving Diastolic Blood Pressure Response at Week 6|Patients Achieving Diastolic Blood Pressure Response at Week 8|Patients Achieving Systolic Blood Pressure Response at Week 4|Patients Achieving Systolic Blood Pressure Response at Week 6|Patients Achieving Systolic Blood Pressure Response at Week 8|Patients Achieving Normal Blood Pressure Response at Week 4|Patients Achieving Normal Blood Pressure Response at Week 6|Patients Achieving Normal Blood Pressure Response at Week 8","http://ClinicalTrials.gov/show/NCT00860262",NA
"52492",52492,"NCT00930462","Evaluation of the Use of Cap in Improving the Performance of Colonoscopy","Completed","No Results Available","Colonoscopy","Device: Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)","Royal Prince Alfred Hospital, Sydney, Australia","Both","Adult|Senior","Phase IV",400,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","CAPCOLON|X07-0107","June 26, 2009","01/03/2008",2009-02-01,"June 29, 2009","01/06/2009","",2009-02-01,"Time to cecum|Polyp detection rate","http://ClinicalTrials.gov/show/NCT00930462",NA
"52538",52538,"NCT00994162","Evaluation of the Use of EZCare??? in the Management of Acute and Chronic Wounds","Completed","No Results Available","Wounds","Device: EZCARE Negative Pressure Wound Therapy System","Smith & Nephew Wound Management Inc","Both","Adult|Senior","Phase IV",131,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CIME 012","October 9, 2009","01/04/2008",2009-07-01,"November 19, 2009","01/11/2009","EZCARE-CIME",2009-01-01,"The performance of EZCare??? in terms of wound progress towards closure in wounds deemed suitable for treatment with negative pressure wound therapy|General performance characteristics.|Wound pain over the treatment period including pain upon application and removal of the dressing and therapy.|Wound odor over the treatment period.|All adverse events and product complaints throughout the evaluation.","http://ClinicalTrials.gov/show/NCT00994162",NA
"52582",52582,"NCT01070862","Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.","Completed","No Results Available","Multiple Myeloma de Novo Treatment","Drug: Thalidomide, Dexamethasone|Drug: Vincristin , Adriamycin, Dexamethasone = VAD|Drug: Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Drug: melphalan, endoxan, dexamethasone (MCDex)|Drug: Thalidomide, Dexamethasone","University Hospital, Caen|Laphal","Both","Adult|Senior","Phase III",NA,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20879","February 17, 2010","01/05/2003",2009-12-01,"February 17, 2010","01/02/2010","MAG 2002",2009-12-01,"very good partial response rate (monclonal protein decrease of 90 % or more)at the end induction phase (MY-TAG and MY-DECT), progression free survival during consolidation/maintenance treatment (MY-PLAT)|partial response rate (> or = 50%), PFS and OS since diagnosis, safety thalidomide + chemotherapy","http://ClinicalTrials.gov/show/NCT01070862",NA
"52607",52607,"NCT01116362","Comparing Primary With Secondary Repair of Based on Electrodiagnostic Assessment and Clinical Examination","Completed","No Results Available","Peripheral Nerve Injury","Procedure: primary repair|Procedure: secondary repair","Isfahan University of Medical Sciences","Both","Child|Adult|Senior","Phase II",46,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","ASD-1213-2","May 3, 2010","01/03/2008",2009-12-01,"May 19, 2010","01/03/2008","",2009-12-01,"motor function|sensory recovery|nerve conduction velocity|electromyography","http://ClinicalTrials.gov/show/NCT01116362",NA
"52717",52717,"NCT00001563","EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma","Completed","No Results Available","AIDS Related Lymphoma|Non Hodgkin's Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: EPOCH regimen|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",39,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","970040|97-C-0040","November 3, 1999","01/12/1996",2009-06-01,"September 17, 2010","01/03/2010","",2009-06-01,"Toxicity and activity of EPOCH during and at the completion of study treatment|Molecular markers of drug resistance and lymphomagenesis in tumor tissue at the beginning of study treatment","http://ClinicalTrials.gov/show/NCT00001563",NA
"52747",52747,"NCT00005963","Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: carboplatin|Drug: docetaxel","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067945|NCCTG-N9932","July 5, 2000","01/11/2000",NA,"January 31, 2009","01/05/2006","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00005963",NA
"52816",52816,"NCT00095563","Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers","Completed","No Results Available","Head and Neck Cancer","Drug: lapatinib ditosylate","Princess Margaret Hospital, Canada|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000394174|PMH-PHL-028|NCI-6701","November 5, 2004","01/11/2004",NA,"December 1, 2009","01/01/2006","",2009-06-01,"Objective response rate (complete response and partial response)|Objective response duration|Stable disease rate|Stable disease duration|Progression-free survival at 6 months and 1 year|Overall survival at 6 months and 1 year|Median survival|Safety and tolerability","http://ClinicalTrials.gov/show/NCT00095563",NA
"52864",52864,"NCT00176163","Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain","Completed","No Results Available","Fibromyalgia|Back Pain","Behavioral: Operant behavioral treatment; Drug: THC","University of Heidelberg|Central Institute of Mental Health, Mannheim|University of Mannheim|Academic City Hospital, Germany|BG-clinics Ludwigshafen Germany","Both","Adult|Senior","Phase II",240,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double-Blind|Primary Purpose: Treatment","kfg107","September 13, 2005","01/08/2005",2009-05-01,"February 1, 2010","01/09/2005","",2009-05-01,"Impairment by pain|Pain intensity|physical function and emotional state assessed by questionnaires|number of serious adverse events|subjective rating of improvement by therapy|subjective rating of therapy effectiveness|therapy satisfaction rated by patient","http://ClinicalTrials.gov/show/NCT00176163",NA
"52960",52960,"NCT00316563","Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study","Completed","No Results Available","Cancer|Anorexia|Taste Disorders|Olfactory Disorders","Drug: Marinol (Dronabinol)|Other: Placebo","Alberta Health Services|University of Alberta","Both","Adult|Senior","Phase II",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PS-8-0008","April 19, 2006","01/08/2006",2009-11-01,"February 8, 2010","01/11/2007","",2009-11-01,"Total caloric intake|self-perceived chemosensory ability|palatable food intake|self-perceived appetite|changes in nausea|safety and tolerability","http://ClinicalTrials.gov/show/NCT00316563",NA
"53026",53026,"NCT00417963","ViVEXX Carotid Revascularization Trial (VIVA)","Completed","No Results Available","Extracranial Carotid Artery Stenosis","Device: Carotid Artery Stenting","C. R. Bard","Both","Adult|Senior","Phase III",407,"Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BPV-VX-1502","January 2, 2007","01/10/2005",2010-03-01,"August 9, 2010","01/08/2010","",2009-01-01,"MACE","http://ClinicalTrials.gov/show/NCT00417963",NA
"53135",53135,"NCT00585663","Accuracy of Radiolabeled Fatty Acid Analog, BMIPP, in the Late Detection of Decreased Blood Flow to the Heart","Completed","No Results Available","Coronary Artery Disease|Acute Coronary Syndrome|Ischemic Heart Disease","Radiation: Iodofiltic acid I-125","Yale University|Molecular Insight Pharmaceuticals, Inc.","Both","Adult|Senior","Phase II",600,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","BMIPP|MIP-BP23","December 25, 2007","01/08/2007",2009-02-01,"March 25, 2009","01/03/2009","ZEUSS-ACS",2009-02-01,"Evaluation of sensitivity and specificity of BMIPP for the detection of coronary artery disease using cardiac catheterization or SPECT perfusion imaging with tetrofosmin or sestamibi as the gold standard|Evaluate for adverse events associated with administration of BMIPP in patients with suspected acute coronary syndromes","http://ClinicalTrials.gov/show/NCT00585663",NA
"53137",53137,"NCT00590863","Combining Medications to Enhance Depression Outcomes","Completed","No Results Available","Major Depressive Disorder","Drug: One of the following: bupropion, escitalopram, mirtazapine, or venlafaxine|Drug: Two of the following: bupropion, escitalopram, mirtazapine or venlafaxine","National Institute of Mental Health (NIMH)","Both","Adult|Senior","Phase IV",665,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","N01 MH090003-02|DSIR AT","December 26, 2007","01/03/2008",2009-09-01,"February 19, 2010","01/04/2009","CO-MED",2009-09-01,"Remission rates in patients with chronic and/or recurrent major depression.|Anxiety, social functioning, quality of life, cognitive and physical well being, treatment emergent psychiatric symptoms, and side-effect burden","http://ClinicalTrials.gov/show/NCT00590863",NA
"53141",53141,"NCT00536263","PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (Study P05170Am2)(COMPLETED)","Completed","Has Results","Hepatitis B, Chronic","Drug: pegylated interferon alpha-2b|Drug: pegylated interferon alpha-2b|Drug: pegylated interferon alpha-2b","Schering-Plough","Both","Adult","Phase III",671,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P05170","September 26, 2007","01/09/2007",2009-11-01,"November 23, 2010","01/11/2010","",2009-11-01,"Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss|Number of Participants With HBeAg Loss|HBe Seroconversion|Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL|Number of Participants With HBV-DNA < 200 IU/mL|Number of Participants With HBV-DNA Undetectable|Number of Participants With Biochemical Response|Number of Participants With Combined Response|Hepatitis B Surface Antigen (HBsAg) Loss|Hepatitis B Surface Antigen (HBs) Seroconversion|Change From Baseline in Liver Biopsy Score","http://ClinicalTrials.gov/show/NCT00536263",NA
"53182",53182,"NCT00655863","Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.","Completed","No Results Available","Diabetes Mellitus","Drug: Alogliptin and Pioglitazone|Drug: Alogliptin|Drug: Pioglitazone","Takeda Global Research & Development Centre (Europe) Ltd.","Both","Adult|Senior","Phase III",71,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SYR-322_301|2007-000486-38|U1111-1113-2081","April 4, 2008","01/08/2007",2009-12-01,"June 2, 2010","01/06/2010","",2009-12-01,"Change in postprandial incremental area under the curve for triglycerides.|Postprandial incremental area under the curve changes for triglycerides.|Postprandial incremental area under the curve changes for lipid parameters.|Postprandial incremental area under the curve changes for lipoprotein parameters.|Postprandial changes over time in glucagon-like peptide-1, glucose, insulin, and glucagon.|Fasting plasma glucose.|C-peptide.|High-sensitive C-reactive protein.|Adiponectin.|Glycosylated hemoglobin.|Insulin.|Proinsulin.|Anti-Vascular Cell Adhesion Molecule.|Anti-Intercellular Adhesion Molecule.|e-Selectin.|Endothelial function (pulse wave tonometry).","http://ClinicalTrials.gov/show/NCT00655863",NA
"53206",53206,"NCT00698763","Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables","Completed","No Results Available","Transient Ischemic Attack|Stroke","Drug: Levosimendan|Drug: Placebo","Orion Corporation, Orion Pharma","Both","Adult|Senior","Phase II",32,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3001088","June 12, 2008","01/08/2008",2009-09-01,"November 23, 2009","01/11/2009","Electro",2009-04-01,"24-h Holter reporting","http://ClinicalTrials.gov/show/NCT00698763",NA
"53208",53208,"NCT00703963","Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care","Completed","No Results Available","INR Patient Self Testing.|Usual Care.","Device: INRatio monitor by Hemosense","Mayo Clinic|Sorin Group","Both","Adult|Senior","Phase IV",200,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Diagnostic","07-001398","June 10, 2008","01/03/2007",2009-03-01,"October 22, 2010","01/10/2010","",2009-03-01,"To compare time in therapeutic range between patients that are self-testing, and patients that are being tested in the usual manner by their primary care provider.","http://ClinicalTrials.gov/show/NCT00703963",NA
"53248",53248,"NCT00759863","LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia","Completed","Has Results","Alzheimer's Disease|Dementia","Behavioral: Lifezig","Photozig, Inc.","Both","Adult|Senior","Phase II",242,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","Pz-A102b|R44AG022261","September 23, 2008","01/08/2006",2009-04-01,"February 22, 2010","01/02/2010","Lifezig",2009-04-01,"Multidimensional Observation Scale for Elderly Subject|Revised Memory and Behavior Problems Checklist|Center for Epidemiologic Studies Depression Scale","http://ClinicalTrials.gov/show/NCT00759863",NA
"53264",53264,"NCT00749463","Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette?ó Gum and Patch Treatment","Completed","Has Results","Tobacco Dependence","Drug: Nicotine Gum|Drug: Nicotine Patch","Johnson & Johnson Consumer & Personal Products Worldwide","Both","Adult|Senior","Phase IV",300,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NICTDP4009","September 8, 2008","01/02/2009",2009-11-01,"September 30, 2010","01/09/2010","",2009-11-01,"Treatment-Related Adverse Events|Self-Reported Smoking Reduction|Smoking Abstinence|Carbon Monoxide (CO)-Verified Smoking Reduction|Smoking Consumption Per Day|Smoking Consumption Per Week|Point Prevalence Smoking Abstinence (PPSA)","http://ClinicalTrials.gov/show/NCT00749463",NA
"53268",53268,"NCT00785863","Modulation of Remifentanil-Induced Postinfusion Hyperalgesia","Completed","No Results Available","Hyperalgesia, Secondary","Other: Placebo|Drug: Remifentanil|Drug: Ketorolac and remifentanil|Drug: Parecoxib and remifentanil","Ullevaal University Hospital|University of Oslo|Rikshospitalet University Hospital","Male","Adult|Senior","Phase IV",16,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science","2008-000904-10","November 4, 2008","01/12/2008",2009-04-01,"April 20, 2009","01/11/2008","",2009-04-01,"H0 : Parecoxib prevents remifentanil postinfusion secondary hyperalgesi. Ketorolac does not prevent remifentanil postinfusion secondary hyperalgesi.|HA : Parecoxib and ketorolac prevent remifentanil postinfusion secondary hyperalgesi.","http://ClinicalTrials.gov/show/NCT00785863",NA
"53289",53289,"NCT00818363","A Safety and Effectiveness Study of SABER?ºÑ-Bupivacaine for Pain Following Shoulder Surgery","Completed","No Results Available","Postoperative Pain","Drug: SABER?ºÑ-Bupivacaine|Drug: SABER?ºÑ-Placebo","Durect|Nycomed","Both","Adult","Phase II",60,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C803-017","January 5, 2009","01/12/2008",2009-10-01,"February 4, 2010","01/02/2010","",2009-10-01,"Pain Intensity|Supplemental opioid use|Frequency of opioid related side effects|Pain Intensity|Supplemental opioid use|Time-to-first use of opioid supplemental pain medication|Severity of opioid-related side effects","http://ClinicalTrials.gov/show/NCT00818363",NA
"53296",53296,"NCT00826163","Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Budesonide","Mahidol University|National Science and Technology Development Agency, Thailand","Both","Adult|Senior","Phase III",20,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BT-B-01-MG-14-5114","December 16, 2008","01/01/2009",2009-12-01,"March 12, 2010","01/03/2010","",2009-11-01,"Sputum IL-8, IL-17|The expression of NF-kappa B in sputum macrophages","http://ClinicalTrials.gov/show/NCT00826163",NA
"53303",53303,"NCT00841763","Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects","Completed","No Results Available","Pandemic Influenza Disease","Biological: Interpandemic adjuvanted trivalent influenza vaccine|Biological: Investigational adjuvanted monovalent influenza vaccine","Novartis|Novartis Vaccines","Both","Adult|Senior","Phase III",3647,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","V87P13|2008-003871-32","February 10, 2009","01/10/2008",2009-11-01,"January 7, 2010","01/01/2010","",2009-04-01,"To assess the safety and tolerability profile of two doses of adjuvanted monovalent influenza vaccine; To contribute to integrate the safety database detecting rare adverse events in adult subjects and uncommon adverse events in elderly subjects.|to evaluate safety and tolerability of adjuvanted monovalent influenza vaccine compared with an adjuvanted interpandemic trivalent influenza vaccine.|to evaluate the immunogenicity of two doses of adjuvanted monovalent influenza vaccine in a subgroup of adult and elderly subjects.","http://ClinicalTrials.gov/show/NCT00841763",NA
"53319",53319,"NCT00869063","Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion","Completed","No Results Available","Acute Pain","Drug: Diclofenac Sodium Patch|Drug: Matching Placebo Patch","Cerimon Pharmaceuticals|PPD","Both","Child|Adult|Senior","Phase III",214,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DCF-005","March 24, 2009","01/02/2009",2009-09-01,"January 26, 2010","01/01/2010","WIND",2009-07-01,"Change in average pain during daily activity|Change in average pain during daily activity","http://ClinicalTrials.gov/show/NCT00869063",NA
"53348",53348,"NCT00919763","Efficacy and Safety Study of CD2027 Ointment 3 Mcg/g Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Drug: CD 2027|Drug: CD 2027 Vehicle","Galderma","Both","Adult|Senior","Phase II",100,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RD.06.SPR.18158","June 9, 2009","01/05/2009",2009-11-01,"November 23, 2010","01/11/2010","",2009-10-01,"Total sum score (TSS)of target lesion|Percent change in TSS","http://ClinicalTrials.gov/show/NCT00919763",NA
"53366",53366,"NCT00945763","Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery","Completed","No Results Available","Dental Pain","Drug: N1539|Drug: placebo|Drug: N1539|Drug: N1539|Drug: ibuprofen","Elan Drug Delivery Inc","Both","Adult|Senior","Phase II",230,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","N1539-02","July 23, 2009","01/07/2009",2009-11-01,"August 19, 2010","01/08/2010","",2009-11-01,"Pain Intensity Difference at End of Study|Onset of action","http://ClinicalTrials.gov/show/NCT00945763",NA
"53402",53402,"NCT01008163","A Dose-Finding, Efficacy and Safety Study of YY-351 in Patients With Type 2 Diabetes","Completed","No Results Available","Diabetes","Drug: YY-351/Placebo|Drug: YY-351/Placebo|Drug: YY-351|Drug: Placebo","Yuyu Pharma, Inc.","Both","Adult|Senior","Phase II",72,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","YY351-1|YY-351-4","October 20, 2008","01/01/2008",2009-06-01,"November 3, 2009","01/11/2009","",2009-06-01,"Change from baseline in the fasting plasma glucose and postprandial glucose [after 2 hours, oral glucose tolerance test (OGTT) (75 g)] and HbA1c|Subjects achieving a glycemic response defined as ??? 7.0%|Decrease of HbA1c > 0.5%|Biomarkers [liver function tests (LFT), high-sensitivity C-reactive protein (hsCRP), adiponectin]|Body weight (or body composition)|Waist girth|Homeostasis model assessment (HOMA)|Lipid profile","http://ClinicalTrials.gov/show/NCT01008163",NA
"53403",53403,"NCT01006863","Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study","Completed","No Results Available","Hypotension|Valve Surgery","Drug: Ephedrine|Drug: Placebo|Drug: Phenylephrine","King Faisal University|Mansoura University","Both","Adult","Phase II",150,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Outcomes Assessor)|Primary Purpose: Prevention","28/2004","October 30, 2009","01/03/2004",2010-03-01,"May 26, 2010","01/05/2010","",2009-06-01,"Primary outcome variables include the changes in hemodynamic variables namely; MAP, SVRI, CI, HR, LVSWI, and ST segment changes.|Secondary outcome variables were outcome data, troponin I changes, and the need for vasoactive drugs.","http://ClinicalTrials.gov/show/NCT01006863",NA
"53613",53613,"NCT00023764","Bortezomib in Treating Patients With Lymphoproliferative Disorders","Completed","No Results Available","Lymphoma","Drug: bortezomib","Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",105,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000068860|MSKCC-01049|NCI-2795|CWRU-MSKCC-1Y02|UNMC-03903","September 13, 2001","01/06/2001",NA,"February 26, 2010","01/12/2009","",2009-03-01,"Frequency and duration of complete and partial response rates|Mean and median duration of response, progression-free survival, and overall survival|Probability of polymerase chain reaction (PCR) negativity after completion of study treatment","http://ClinicalTrials.gov/show/NCT00023764",NA
"53641",53641,"NCT00062764","Treating Nonalcoholic Steatohepatitis With Pioglitazone","Completed","No Results Available","Hepatitis","Drug: Actos (Pioglitazone)","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Adult|Senior","Phase II",30,"NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","030212|03-DK-0212","June 12, 2003","01/06/2003",NA,"January 28, 2010","01/02/2009","",2009-02-01,"Improvement in liver histology|Insulin sensitivity, reduction in visceral fat, liver volune and liver tests.","http://ClinicalTrials.gov/show/NCT00062764",NA
"53712",53712,"NCT00178464","Aspirin Prophylaxis in Sickle Cell Disease","Completed","No Results Available","Sickle Cell Disease","Drug: aspirin","University of Rochester|University of Miami|Bayer|National Institute of Neurological Disorders and Stroke (NINDS)","Both","Child","Phase I|Phase II",9,"Other|Industry|NIH","Interventional","Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09661|5R01NS045948-03","September 13, 2005","01/03/2005",2009-11-01,"February 25, 2010","01/02/2010","START",2009-04-01,"Ability to complete the trial on the originally assigned dosage of study medication with or without dosage modification or suspension; Occurrence of individual adverse events, intracranial hemorrhage &/or Reyes syndrome|# of subjects recruited over time, screening failures, withdrawal rates;Compliance (pill counts & labs);Changes in performance on neurocognitive tests; Changes in MRI/MRA; Changes in TCD;Incidences of stroke, acute chest crises, and pain crises","http://ClinicalTrials.gov/show/NCT00178464",NA
"53727",53727,"NCT00196664","Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin","Completed","No Results Available","Chronic Hepatitis C","Drug: Paroxetine","French National Agency for Research on AIDS and Viral Hepatitis","Both","Adult|Senior","Phase III",144,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","2004-004102-24|ANRS HC18 PAROPEG","September 13, 2005","01/10/2005",2009-02-01,"May 12, 2009","01/05/2009","",2009-02-01,"Incidence of depression based on MINI International Neuropsychiatric Interview (MINI, DSM IV)from D0 to W74|Evolution of depression score (MADRS and BDI scales) to W74,Quality of life (HQL questionnaire), Fatigue, Compliance to PEG-interferon and ribavirin, Virological response at W74 ,Safety","http://ClinicalTrials.gov/show/NCT00196664",NA
"53733",53733,"NCT00205764","Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy","Completed","No Results Available","Multiple Myeloma","Drug: Melphalan","Austrian Forum Against Cancer","Both","Adult|Senior","Phase III",212,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Mar-99","September 12, 2005","01/03/1999",2009-10-01,"July 22, 2010","01/07/2010","",2009-10-01,"Time to treatment failure|Response rate|Time to response|Tolerance of treatment|Quality of life|Overall survival","http://ClinicalTrials.gov/show/NCT00205764",NA
"53824",53824,"NCT00355264","Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency","Completed","No Results Available","Tetrahydrobiopterin Deficiencies|Hyperphenylalaninemia, Non-Phenylketonuric","Drug: Phenoptin","BioMarin Pharmaceutical","Both","Child|Adult|Senior","Phase II",12,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PKU-007","July 19, 2006","01/08/2006",2009-06-01,"June 7, 2010","01/06/2010","",2009-06-01,"control of blood phenylalanine levels, as measured by the proportion of subjects|whose blood Phe level at Week 10 is < 360 mmol/L;|the mean blood Phe level at Week 10 among all subjects.","http://ClinicalTrials.gov/show/NCT00355264",NA
"53874",53874,"NCT00431964","Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Who Are Not Infected With P. Aeruginosa","Completed","No Results Available","Cystic Fibrosis","Drug: azithromycin 250 mg tablets|Drug: placebo tablets","CF Therapeutics Development Network Coordinating Center|Cystic Fibrosis Foundation","Both","Child|Adult","Phase IV",263,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AZ0004","February 2, 2007","01/02/2007",2009-11-01,"October 7, 2010","01/10/2010","",2009-07-01,"Change in FEV1 from baseline to end of treatment|Safety, frequency of pulmonary exacerbations, changes in other measures of lung function, treatment emergent pathogens, weight, and serum inflammatory markers","http://ClinicalTrials.gov/show/NCT00431964",NA
"53927",53927,"NCT00522964","Educational Intervention on Weight Management in Chinese-American Children","Completed","No Results Available","Overweight","Behavioral: behavioral intervention","University of California, San Francisco","Both","Child","Phase III",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","KL2RR024130|NIH KL2 RR024130","August 28, 2007","01/05/2006",2009-04-01,"August 16, 2009","01/08/2009","ABC",2009-04-01,"health behaviors, psychosocial function, and anthropometrics of Chinese-American children|insulin, cholesterol, high-density lipoproteins (HDLs), low-density lipoproteins (LDLs), and triglycerides (TGs)","http://ClinicalTrials.gov/show/NCT00522964",NA
"53934",53934,"NCT00533364","Effect of SBG in Patients With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: SBG (Soluble beta-glucan)","Biotec Pharmacon ASA","Female","Adult|Senior","Phase I|Phase II",11,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SBG-2-01","September 20, 2007","01/01/2007",2010-01-01,"February 17, 2010","01/02/2010","",2009-08-01,"Asess the safety of SBG in combination with standard antibody and chemotherapy treatment","http://ClinicalTrials.gov/show/NCT00533364",NA
"53953",53953,"NCT00559364","Safety and Efficacy Study of VIOKASE 16 for the Correction of Steatorrhea","Completed","No Results Available","Exocrine Pancreatic Insufficiency|Chronic Pancreatitis","Drug: VIOKASE 16|Drug: Placebo","Axcan Pharma|i3 Statprobe|Quintiles|Mayo Clinical Trial Services|Laboratoire Marcel Merieux|City Hospital Laboratory Birmingham","Both","Adult|Senior","Phase III",60,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","VIO16EPI07-01","November 14, 2007","01/11/2007",2009-08-01,"May 4, 2010","01/05/2010","",2009-08-01,"Efficacy of VIOKASE 16 for the correction of steatorrhea (malabsorption of dietary fats). The efficacy will be based on a comparison of the Coefficient of Fecal Fat Absorption (CFA%) between VIOKASE 16 and placebo.|Effect of VIOKASE 16 on stool frequency and stool characteristics. Evaluate the safety of VIOKASE 16 used for the correction of steatorrhea using laboratory analyses and adverse events.","http://ClinicalTrials.gov/show/NCT00559364",NA
"53961",53961,"NCT00567164","Efficacy and Safety of Two Extended Regimens (Yaz Flex) in Comparison With the Conventional Regimen of YAZ","Completed","No Results Available","Contraception|Ovulation Inhibition|Contraceptives, Oral","Drug: Yaz (SH T00186D)|Drug: SH T00186D|Drug: SH T00189D, SH T470PD + Placebo","Bayer","Female","Adult","Phase III",1885,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","91698|311642","December 3, 2007","01/10/2007",2009-11-01,"December 8, 2010","01/12/2010","",2009-10-01,"Number of observed unintended pregnancies (evaluated using the Pearl Index)|Number of bleeding and spotting days|Number of intracyclic bleeding days, including and excluding spotting","http://ClinicalTrials.gov/show/NCT00567164",NA
"53970",53970,"NCT00587964","Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases","Completed","No Results Available","Brain Metastasis|Bladder Cancer|Breast Cancer|Cervical Cancer|Colon Cancer|HEENT Cancer|Lung Cancer|Melanoma|Pancreatic Cancer|Prostate Cancer|Rectal Cancer|Sarcoma|Testicular Cancer","Radiation: Stereotactic Radiosurgery","Memorial Sloan-Kettering Cancer Center","Both","Adult|Senior","Phase II",50,"Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-061","December 26, 2007","01/06/2004",2009-01-01,"March 20, 2009","01/03/2009","",2009-01-01,"To determine the local control following a combination of stereotactic radiosurgery and surgical resection for brain metastases; to determine the incidence of the brain injury following the combination therapy","http://ClinicalTrials.gov/show/NCT00587964",NA
"53986",53986,"NCT00616564","Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma","Completed","No Results Available","Malignant Melanoma","Drug: GM-CSF","Mt. Sinai Medical Center, Miami|Bayer|Chiron Corporation","Both","Child|Adult|Senior","Phase II",35,"Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MEL0105","February 4, 2008","01/02/2006",2009-09-01,"September 17, 2009","01/09/2009","",2009-09-01,"","http://ClinicalTrials.gov/show/NCT00616564",NA
"53989",53989,"NCT00612664","Phase II, 2nd Line Melanoma - RAND Monotherapy","Completed","No Results Available","Melanoma","Drug: Anti-CD137 (4-1BB) (BMS-663513)","Bristol-Myers Squibb","Both","Adult|Senior","Phase II",158,"Industry","Interventional","Allocation: Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA186-006","January 30, 2008","01/03/2008",2009-10-01,"January 6, 2011","01/01/2010","",2009-10-01,"Radiographic imaging, photographic and clinical evaluation will be used for tumor assessment to determine 6-month progression-free survival rate|Safety profiles|Disease response rate|Disease control rate|1-year survival|Pharmacokinetics|Pharmacodynamics|Biomarkers","http://ClinicalTrials.gov/show/NCT00612664",NA
"53991",53991,"NCT00619164","A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome","Completed","No Results Available","Acute Coronary Syndrome","Drug: E5555|Drug: E5555|Drug: E5555|Drug: Placebo","Eisai Limited","Both","Adult|Senior","Phase II",240,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E5555-J081-207","December 5, 2007","01/11/2007",NA,"February 17, 2010","01/02/2010","",2009-09-01,"Safety and tolerability: Adverse events, bleeding events, clinical laboratory tests, Coagulation tests, vital signs and 12-lead ECG.|Major cardiac adverse events, biomarkers, platelet aggregation inhibition, plasma concentration.","http://ClinicalTrials.gov/show/NCT00619164",NA
"53999",53999,"NCT00630864","The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis","Completed","No Results Available","Transthyretin-associated Amyloidosis With Polyneuropathy","Drug: Fx-1006A","FoldRx Pharmaceuticals","Both","Adult|Senior","Phase II",24,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Fx1A-201","February 27, 2008","01/06/2008",2010-02-01,"February 23, 2010","01/02/2010","",2009-03-01,"TTR stabilization|Incidence of patients experiencing treatment-emergent adverse events|Incidence of patients experiencing treatment-emergent >/= Grade 3 adverse events|Incidence of patients with treatment-emergent echocardiography findings considered by the Investigator to be clinically significant|Incidence of patients with treatment-emergent electrocardiogram (ECG) findings considered by the Investigator to be clinically significant|Incidence of patients with treatment-emergent Holter monitoring findings considered by the Investigator to be clinically significant|Incidence of patients discontinuing from the study because of clinical or laboratory adverse events|Change from Baseline in the Neuropathy Impairment Score (NIS) and NIS-Lower Limb (LL) scores|Response to treatment (change from Baseline in the NIS-LL of < 2)|Change from Baseline in the total quality of life and five individual domain scores of the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN)|Change from Baseline in nerve conduction studies (NCS)|Change from Baseline in heart rate response to deep breathing (HRDB)|Change from Baseline in modified body mass index (mBMI)|Change from Baseline in overall quality of life and individual domains of the SF-36|Change from Baseline in echocardiography parameters|Change from Baseline in NT-pro-BNP and troponin I levels|Change from Baseline in Karnofsky score","http://ClinicalTrials.gov/show/NCT00630864",NA
"54004",54004,"NCT00620464","A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(COMPLETED)(P05720)","Completed","Has Results","Contraception","Drug: Radiopaque Implanon|Drug: Implanon (etonogestrel implant)","Schering-Plough","Female","Adult","Phase III",108,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","34528|P05720","February 11, 2008","01/05/2005",2009-02-01,"September 23, 2010","01/09/2010","",2009-02-01,"Bioequivalence of Implanon?ó and Radiopaque Implanon.|Bioequivalence of Implanon?ó and Radiopaque Implanon","http://ClinicalTrials.gov/show/NCT00620464",NA
"54030",54030,"NCT00691964","Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","Completed","No Results Available","Plaque Psoriasis","Biological: ABT-874|Biological: etanercept|Drug: placebo","Abbott|Paragon Biomedical","Both","Adult|Senior","Phase III",347,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","M10-114","June 4, 2008","01/06/2008",NA,"November 1, 2010","01/09/2010","",2009-03-01,"Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12","http://ClinicalTrials.gov/show/NCT00691964",NA
"54035",54035,"NCT00669864","Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: biphasic insulin aspart 30|Drug: metformin","Novo Nordisk","Both","Adult|Senior","Phase IV",293,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BIASP-1960","April 29, 2008","01/11/2007",2009-04-01,"June 4, 2010","01/06/2010","",2009-04-01,"Change in HbA1c (Glycosylated Haemoglobin A1c)|Change in 8-point Plasma Glucose Profile|Percentage of Subjects Achieving HbA1c Less Than 7.0%|Percentage of Subjects Achieving HbA1c Below or Equal to 6.5%|Hypoglycaemic Episodes|Hypoglycaemic Episodes, Diurnal/Nocturnal","http://ClinicalTrials.gov/show/NCT00669864",NA
"54036",54036,"NCT00688064","Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris","Completed","Has Results","Severe Acne Vulgaris","Drug: Adapalene BPO Gel associated with Doxycyline Hyclate|Drug: Vehicle Gel associated with Doxycycline Hyclate","Galderma","Both","Child|Adult","Phase III",459,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RD.03.SPR.29074","May 28, 2008","01/08/2008",2009-02-01,"March 31, 2010","01/03/2010","ACCESS I",2009-02-01,"Percent Change From Baseline in Total Lesion Counts at Week 12.|Percent Change From Baseline in Inflammatory Lesion Counts at Week 12.|Percent Change From Baseline in Non-inflammatory Lesion Counts at Week 12|Success Rate on the Investigator's Global Assessment|Percent of Subjects With Adverse Events","http://ClinicalTrials.gov/show/NCT00688064",NA
"54053",54053,"NCT00725764","Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck","Completed","No Results Available","Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck","Drug: GSK1363089 (foretinib)","GlaxoSmithKline","Both","Adult|Senior","Phase II",14,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MET111646","July 28, 2008","01/08/2007",2009-05-01,"March 25, 2010","01/03/2010","",2009-05-01,"To determine the best confirmed response rate of GSK1363089 treatment in subjects with SCCHN|To assess the progression-free survival, duration of response, and overall survival in subjects with SCCHN treated with GSK1363089.|To further characterize the pharmacokinetic (PK) parameters of GSK1363089 in subjects with SCCHN","http://ClinicalTrials.gov/show/NCT00725764",NA
"54054",54054,"NCT00730964","A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.","Completed","No Results Available","Echocardiography","Drug: Perflutren Protein-Type A Microspheres Injectable Suspension, USP","GE Healthcare","Both","Adult|Senior","Phase IV",1039,"Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label","GE-191-003","August 5, 2008","01/05/2008",2009-10-01,"February 4, 2010","01/02/2010","OSSAR",2009-10-01,"The frequency of serious adverse reactions (SAR's) among subjects who receive Optison during contrast enhanced echocardiography in routine clinical practice.|The frequency of overall serious adverse events (SAE's) among subjects who receive Optison during contrast enhanced echocardiography in routine clinical practice.","http://ClinicalTrials.gov/show/NCT00730964",NA
"54064",54064,"NCT00743964","Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)","Completed","No Results Available","Advanced Gastric Cancer","Drug: Epirubicin|Drug: Cisplatin, capecitabine","Samsung Medical Center","Both","Child|Adult|Senior","Phase II",91,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SMC IRB 2008-04-027|01-9-0804027","August 27, 2008","01/04/2008",2009-10-01,"January 13, 2010","01/01/2010","",2009-10-01,"Failure-free survival|progression-free survival","http://ClinicalTrials.gov/show/NCT00743964",NA
"54076",54076,"NCT00762164","Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol","Completed","No Results Available","Hypercholesterolemia","Drug: Vytorin|Drug: Simvastatin","Bronx VA Medical Center","Both","Adult|Senior","Phase IV",34,"U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VA---19-07-01","September 29, 2008","01/03/2007",2009-05-01,"August 12, 2009","01/08/2009","",2009-04-01,"LDL cholesterol|Total cholesterol","http://ClinicalTrials.gov/show/NCT00762164",NA
"54085",54085,"NCT00758264","Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration","Completed","No Results Available","Meningococcal Disease|Pneumococcal Disease.","Biological: Meningococcal vaccine GSK134612|Biological: Pneumococcal vaccine GSK1024850A","GlaxoSmithKline","Both","Child","Phase III",363,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","111393","September 23, 2008","01/10/2008",2009-06-01,"June 29, 2010","01/06/2010","",2009-06-01,"Anti-pneumococcal antibody concentrations in Groups A and B|Meningococcal serum bactericidal assay titres in Groups A and C.|Anti-PD antibody concentrations.|Meningococcal serum bactericidal assay titres.|Anti-meningococcal polysaccharide concentrations.|Anti-tetanus toxoid antibody concentrations.|Occurrence of solicited local and general symptoms (any and grade 3).|Occurrence of unsolicited symptoms.|Occurrence of serious adverse events.|Occurrence of specific adverse events of rash, new onset of chronic illness(es), conditions prompting emergency room visits and physician office visits not related to common illnesses and/or any event(s) related to lack of vaccine efficacy.|Anti-pneumococcal antibody concentrations.|Opsonophagocytic activity/titres against pneumococcal serotypes..","http://ClinicalTrials.gov/show/NCT00758264",NA
"54091",54091,"NCT00771264","Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms","Completed","Has Results","Overactive Bladder","Device: Urgent PC Neuromodulation System","Uroplasty, Inc","Both","Adult|Senior","Phase IV",220,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","UPC082008","October 9, 2008","01/09/2008",2009-06-01,"August 26, 2010","01/08/2010","SUmiT",2009-06-01,"The Global Response Assessment (GRA) for Overall Bladder Symptoms to Compare the Proportion of Subjects Reporting \Moderately\"" or \""Markedly Improved\"" Responses on the GRA After 12 Interventions of Randomized Therapy","http://ClinicalTrials.gov/show/NCT00771264",NA
"54095",54095,"NCT00793364","Effect of Plant Stanol Ester-Containing Spread on Estimated Cardiovascular Risk in Comparison to Mediterranean Diet","Completed","No Results Available","Hypercholesterolemia","Dietary Supplement: Stanol ester spread|Dietary Supplement: Placebo spread|Dietary Supplement: Mediterranean Diet","Hellenic Atherosclerosis Society|Minerva SA","Both","Adult|Senior","Phase IV",150,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","MINERVA 01|171108","November 17, 2008","01/11/2008",2009-04-01,"May 27, 2009","01/05/2009","",2009-03-01,"Primary endpoint: Change from baseline in cardiovascular (CVD) risk as assessed by the PROCAM and Framingham risk engines.|Change from baseline in major CVD risk factors [TC, LDL-C, HDL-C, TG, apoB], in an inflammatory marker [C-reactive protein], in hemostatic parameters (PAI-I, fibrinogen), liver function tests at the end of the study vs baseline.","http://ClinicalTrials.gov/show/NCT00793364",NA
"54133",54133,"NCT00828464","Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis","Completed","Has Results","Hand Dermatosis","Drug: clobetasol propionate","Stiefel, a GSK Company","Both","Adult|Senior","Phase IV",30,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","U0280-401","January 22, 2009","01/10/2008",2009-01-01,"September 7, 2010","01/09/2010","",2009-01-01,"Proportion of Subjects With at Least 1-grade Improvement From Baseline to Day 15 in Investigator's Static Global Assessment Score (ISGA) Score|Proportion of Subjects Who Achieve at Least a 1-grade Improvement Based on the ISGA at Day 8.|Change in Subject's Visual Analogue Assessment Scale|Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Finger Tips|Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Finger Tips|Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline - Fingers|Proportion of Subjects With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Fingers|Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Palm of Hands|Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Palm of Hands|Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Back of Hands|Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Back of Hands|Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Wrists|Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Wrists|Change in Subject's Visual Analogue Assessment Scale From Baseline to Day 15","http://ClinicalTrials.gov/show/NCT00828464",NA
"54161",54161,"NCT00902564","Efficacy and Safety of Escitalopram in Patients With Generalized Anxiety Disorder","Completed","No Results Available","Generalized Anxiety Disorder","Drug: Escitalopram","H. Lundbeck A/S","Both","Adult","Phase IV",30,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12132A","May 14, 2009","01/03/2009",2010-03-01,"March 30, 2010","01/03/2010","",2009-12-01,"Efficacy of escitalopram after 8 weeks of treatment in patients with GAD using Clinical Global Impression (CGI), Sheehan Disability Scale (SDS), and Hamilton Anxiety Scale (HAMA)|Evaluation of proportion of patients who responded to escitalopram during 8 weeks of treatment using the CGI-I definition|To evaluate safety in patients with GAD treated with escitalopram","http://ClinicalTrials.gov/show/NCT00902564",NA
"54220",54220,"NCT01005264","Removable Walker for Neuropathic Ulcers","Completed","No Results Available","Diabetic Foot","Device: non-removable fiberglass|Device: Stabil-D?ó","IRCCS Multimedica","Both","Adult|Senior","Phase III",48,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","05/2007cardiovascolare","October 19, 2009","01/02/2008",2009-03-01,"October 29, 2009","01/10/2009","",2009-03-01,"Decrease in ulcer size|Complete healing rate at the end of the study","http://ClinicalTrials.gov/show/NCT01005264",NA
"54254",54254,"NCT01065064","Visual Performance After RESTOR Implantation","Completed","No Results Available","Refractive Assessment","Procedure: RESTOR IOL","Hospital Oftalmologico de Brasilia","Both","Adult|Senior","Phase IV",50,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","HOB-01/09","February 8, 2010","01/01/2009",2009-12-01,"February 8, 2010","01/02/2010","",2009-02-01,"To evaluate distance, intermediate, and near vision after aspheric multifocal diffractive AcrySof?ó ReSTOR SN6AD1 intraocular lens (IOL) implantation.","http://ClinicalTrials.gov/show/NCT01065064",NA
"54339",54339,"NCT01187264","Dose Ranging Study to Compare the Efficacy and Safety of Methotrexate in Plaque Type Psoriasis","Completed","No Results Available","Psoriasis","Drug: Methotrexate","Postgraduate Institute of Medical Education and Research","Both","Adult","Phase IV",100,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7557/PG/2Trg/07","August 23, 2010","01/08/2008",2009-09-01,"August 24, 2010","01/09/2009","",2009-09-01,"change in Psoriasis Area and Severity Index (PASI) score between two groups from baseline to 12 weeks|time to achieve PASI 75|number of patients achieving PASI 90 and 100","http://ClinicalTrials.gov/show/NCT01187264",NA
"54536",54536,"NCT00148265","A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema","Completed","No Results Available","Diabetic Macular Oedema","Drug: Triamcinolone acetate","University of Sydney|The University of Western Australia|University of Melbourne|Marsden Eye Centre","Both","Adult|Senior","Phase II|Phase III",54,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NHMRC project 352312","September 6, 2005","01/04/2005",2009-05-01,"June 21, 2010","01/11/2005","",2009-05-01,"The proportion of eyes showing an improvement of visual acuity by 10 letters on a LogMAR chart compared with the pre-injection level 24 months after treatment|Number of laser treatments required for the treatment of macular oedema during the course of the study.|Change in retinal thickness demonstrated on optical coherence tomography (OCT)|The incidence of moderate or severe side effects related to the procedure of intravitreal injection or related to the drug","http://ClinicalTrials.gov/show/NCT00148265",NA
"54539",54539,"NCT00162565","Beta-Blocker Continuation Versus Interruption in Heart Failure Worsening","Completed","No Results Available","Heart Failure, Congestive","Drug: beta-blocker treatment","Assistance Publique - H??pitaux de Paris","Both","Adult|Senior","Phase IV",180,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P030414","September 9, 2005","01/11/2004",2009-02-01,"May 22, 2009","01/08/2005","BConvinced",2009-02-01,"Clinical status (questionnaire): the percentage (%) of patients with clinical improvement is the primary endpoint criterion.|Clinical status (evaluation by investigator and autoevaluation by patient)|BNP change|Mortality, hospital admission, % of patients with beta-blocker treatment","http://ClinicalTrials.gov/show/NCT00162565",NA
"54553",54553,"NCT00188565","Celebrex With Preoperative Chemoradiation - Rectal Cancer","Completed","No Results Available","Colorectal Neoplasms","Drug: Celecoxib","University Health Network, Toronto|Ontario Cancer Research Network|Princess Margaret Hospital, Canada","Both","Adult|Senior","Phase I|Phase II",39,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 02-0130-C|Ontario Cancer ResearchNetwork","September 12, 2005","01/03/2004",2009-03-01,"August 12, 2010","01/08/2010","",2009-03-01,"- To assess the safety of celecoxib at a maximum dose of 400 mg orally twice daily in combination with preop RT and continuous infusional 5-FU. Incidence of dose-limiting toxicity (DLT) will be determined.|- To determine the efficacy of celecoxib in combi","http://ClinicalTrials.gov/show/NCT00188565",NA
"54554",54554,"NCT00174265","6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)","Completed","Has Results","Schizophrenia","Drug: asenapine|Drug: olanzapine","Schering-Plough","Both","Adult|Senior","Phase III",196,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A7501014|Aphrodite;|P05772","September 9, 2005","01/07/2005",2009-05-01,"May 27, 2010","01/05/2010","",2009-05-01,"Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total Score|Change From Baseline in Quality of Life Measured by the Quality of Life Scale (QLS) Total Score","http://ClinicalTrials.gov/show/NCT00174265",NA
"54583",54583,"NCT00227565","Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: pemetrexed disodium","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",77,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000442866|NCCTG-N0423","September 26, 2005","01/02/2006",NA,"July 28, 2010","01/10/2009","",2009-10-01,"Proportion of confirmed-tumor response","http://ClinicalTrials.gov/show/NCT00227565",NA
"54584",54584,"NCT00218465","Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking","Completed","Has Results","Nicotine Dependence","Drug: GW468816|Drug: Placebo Comparator","Massachusetts General Hospital|National Institute on Drug Abuse (NIDA)|Mclean Hospital|GlaxoSmithKline","Female","Adult","Phase II",264,"Other|NIH|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NIDA-19378-2|U01DA019378|IND 74964","September 16, 2005","01/08/2006",2009-06-01,"November 23, 2010","01/11/2010","",2009-06-01,"Time to Relapse to Smoking in the 5-week Relapse Prevention Phase.|Number of Abstinent and Nonabstinent Participants at End of 5 Week Placebo-controlled Relapse Prevention Trial|Days to Relapse Within the 60 Days Following Randomization","http://ClinicalTrials.gov/show/NCT00218465",NA
"54657",54657,"NCT00322465","NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)","Completed","No Results Available","C Trachomatis|M Genitalium|Non-Gonococcal Urethritis|Urethritis|T Vaginalis","Drug: Azithromycin|Drug: Placebo|Drug: Tinidazole|Drug: Doxycycline","National Institute of Allergy and Infectious Diseases (NIAID)","Male","Child|Adult","Phase II",305,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","05-0120","May 4, 2006","01/11/2006",2009-04-01,"February 4, 2010","01/11/2009","",2009-04-01,"Evaluate the safety and tolerability of doxycycline/tinidazole and azithromycin/tinidazole in the treatment of NGU.|For the treatment of NGU, compare the clinical cure rates of doxycycline versus doxycycline with tinidazole; and azithromycin versus azithromycin with tinidazole.|Clinical cure rates, analysis will also include: (doxycycline plus doxycycline/tinidazole) versus (azithromycin plus azithromycin/tinidazole).|Collect specimens for future studies to determine the role of unique and novel pathogens in the etiology of non-gonococcal urethritis.|Evaluate microbiological cure of C. trachomatis, T. vaginalis, and M. genitalium in men treated with doxycycline versus doxycycline with tinidazole; and azithromycin versus azithromycin with tinidazole.|Prevalence of C. trachomatis, T. vaginalis, and M. genitalium in men with non-gonococcal urethritis; clinical, behavioral, and demographic predictors of C. trachomatis, T. vaginalis, and M. genitalium in men with non-gonococcal urethritis.","http://ClinicalTrials.gov/show/NCT00322465",NA
"54687",54687,"NCT00390065","Follow-Up at 6 Years of a Cohort of Children Born Very Prematurely","Completed","No Results Available","Premature Birth","Drug: Nitric Oxide","Maternite Regionale Universitaire","Both","Child","Phase IV",108,"Other","Interventional","Allocation: Non-Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","MRAP060308","October 17, 2006","01/10/2006",2009-06-01,"September 18, 2009","01/09/2009","",2009-06-01,"Pulmonary Function testing|Neurodevelopmental and Cognitive outcomes","http://ClinicalTrials.gov/show/NCT00390065",NA
"54697",54697,"NCT00405665","The Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis","Completed","No Results Available","Cystic Fibrosis","Drug: L-arginine|Drug: L-arginine","The Hospital for Sick Children|Irvin Foundation","Both","Child|Adult|Senior","Phase II",20,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","1000009282","November 28, 2006","01/11/2006",2009-06-01,"December 6, 2010","01/12/2010","",2009-06-01,"Change in FEV1 (in liters) from baseline|Adverse events such as gastrointestinal complaints, wheezing, hepatitis or shortness of breath|Change in FVC and change in FEV25-75 from baseline to completion of the 2 week treatment period.|Change in exhaled nitric oxide (FeNO)|Changes in inflammatory markers in sputum from baseline including neutrophils (sputum), neutrophil elastase (sputum) and interleukin (IL)-8 concentrations (sputum).|Changes in sputum concentrations of L-arginine metabolites","http://ClinicalTrials.gov/show/NCT00405665",NA
"54743",54743,"NCT00475865","Pilot Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Drug: teriflunomide (HMR1726)|Drug: Placebo","Sanofi-Aventis","Both","Adult","Phase II",120,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PDY6046|EUDRACT : 2006-004893-29|HMR1726D-2004|LTS6047","May 18, 2007","01/05/2007",2009-10-01,"December 18, 2009","01/12/2009","",2009-10-01,"Tolerability and safety data based on adverse event reports, physical examinations, laboratory evaluations, electrocardiograms and abdominal ultrasound of the pancreas.|Total number of gadolinium enhancing T1-lesions per MRI (Magnetic Resonance Imaging) scan, Percentage change from baseline in burden of disease (based on T2-lesions per MRI), Annualized relapse rate.","http://ClinicalTrials.gov/show/NCT00475865",NA
"54765",54765,"NCT00505765","A Multicenter Study of NAP (AL-108) in Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: AL-108|Drug: AL-108|Drug: placebo|Drug: placebo","University of California, Los Angeles|University of Maryland|Washington University School of Medicine|Massachusetts General Hospital|Nathan Kline Institute for Psychiatric Research|Columbia University|Duke University|Beth Israel Deaconess Medical Center","Both","Adult","Phase II",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TURNS03|HHSN 278200441003C","July 20, 2007","01/07/2007",2009-04-01,"January 13, 2010","01/01/2010","AL-108",2009-04-01,"Primary: MCCB: MATRICS Consensus Cognitive Battery|Secondary: UPSA: UCSD Performance-Based Skills Assessment; SCoRS: Schizophrenia Cognition Rating Scale","http://ClinicalTrials.gov/show/NCT00505765",NA
"54775",54775,"NCT00521365","Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.","Completed","No Results Available","Bipolar Disorder|Affective Psychosis, Bipolar|Mania|Manic Disorder|Manic State","Drug: quetiapine 300mg","AstraZeneca","Both","Child|Adult","Phase IV",100,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D1443L00017","August 24, 2007","01/05/2008",2009-08-01,"December 7, 2009","01/12/2009","EMMY",2009-08-01,"Change in YMRS total score from baseline to day 21 of treatment|To evaluate if Quetiapine improves health related quality of life of patients with Bipolar Mania|To evaluate the safety and tolerability of Quetiapine in the treatment of patients of Bipolar Mania","http://ClinicalTrials.gov/show/NCT00521365",NA
"54776",54776,"NCT00525265","A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","Completed","No Results Available","Cardiac Edema","Drug: OPC-41061(Tolvaptan)|Drug: Placebo","Otsuka Pharmaceutical Co., Ltd.","Both","Adult|Senior","Phase III",20,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","156-06-004","September 3, 2007","01/09/2007",2009-01-01,"December 11, 2009","01/12/2009","",2009-01-01,"Pharmacological Outcome Variables(Urine volume, fluid intake, urine osmolality, quantitative examination,biochemical examination of blood, plasma AVP)","http://ClinicalTrials.gov/show/NCT00525265",NA
"54782",54782,"NCT00523965","Combination Therapy in Indian Visceral Leishmaniasis","Completed","No Results Available","Leishmaniasis, Visceral","Drug: amphotericin B deoxycholate|Drug: Liposomal Amphotericin B with Miltefosine|Drug: Liposomal Amphotericin B and Paromomycin Sulfate|Drug: miltefosine + Paromomycin sulfate","Banaras Hindu University|Drugs for Neglected Diseases|Rajendra Memorial Research Institute of Medical Sciences","Both","Child|Adult","Phase III",624,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VLCombo 07","August 31, 2007","01/09/2007",2010-02-01,"May 25, 2010","01/01/2009","",2009-08-01,"Final cure at six month follow up|Cure at six month follow up|Initial cure at the end of treatment","http://ClinicalTrials.gov/show/NCT00523965",NA
"54791",54791,"NCT00418665","A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid","Completed","Has Results","Myelodysplastic Syndromes|Thrombocytopenia","Biological: AMG 531|Drug: Placebo","Amgen","Both","Adult|Senior","Phase II",39,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","20060102","January 4, 2007","01/12/2006",2010-10-01,"December 22, 2010","01/12/2010","",2009-03-01,"Occurrence of a Clinically Significant Thrombocytopenic Event|Lenalidomide Dose Reduction and Delay Due to Thrombocytopenia|Achieving an Overall Response (Complete Response (CR) or Partial Response (PR)) Determined by the Investigator Based on Modified International Working Group 2006 Response Criteria Guidelines|Platelet Transfusion","http://ClinicalTrials.gov/show/NCT00418665",NA
"54797",54797,"NCT00552565","Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)","Completed","No Results Available","Irritable Bowel Syndrome With Diarrhea","Drug: Rezular 15mg|Drug: Placebo|Drug: Rezular|Drug: Rezular","AGI Therapeutics, Inc.","Both","Adult|Senior","Phase III",711,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARDIS-1","October 31, 2007","01/09/2007",2009-06-01,"June 10, 2009","01/06/2009","ARDIS-1",2009-06-01,"Adequate Relief","http://ClinicalTrials.gov/show/NCT00552565",NA
"54838",54838,"NCT00625365","A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY?ó in Clinical Practice","Completed","Has Results","Cardiovascular Disease","Other: Perflutren Lipid Microspheres (DEFINITY?ó)","Lantheus Medical Imaging","Both","Adult|Senior","Phase IV",1060,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label","DMP 115-415","February 20, 2008","01/02/2008",2009-07-01,"December 17, 2010","01/12/2010","",2009-05-01,"The Number and Percentage of Patients With Death or Life Threatening Cardiopulmonary Events Occurring Following Definity Administration|Serious Adverse Events|Adverse Events","http://ClinicalTrials.gov/show/NCT00625365",NA
"54842",54842,"NCT00631865","Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin","Completed","No Results Available","Vitiligo","Biological: Melanocyte transplantation","Royan Institute","Both","Child|Adult","Phase I|Phase II",10,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Royan-skin-001","March 3, 2008","01/01/2008",2009-02-01,"February 21, 2009","01/02/2009","",2009-01-01,"percentage of repigmentation|stability of the achieved repigmentation","http://ClinicalTrials.gov/show/NCT00631865",NA
"54845",54845,"NCT00635765","Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients","Completed","No Results Available","Acromegaly","Drug: C2L-OCT-01 PR 30 mg","Ambrilia Biopharma, Inc.","Both","Adult","Phase III",63,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C2L-OCT-01 PR-302","March 11, 2008","01/10/2007",2009-06-01,"June 3, 2009","01/06/2009","",2009-06-01,"Assess, for up to an additional 96 weeks, the safety profile of C2L-OCT-01 PR administered intra muscularly every 6, 5 or 4 weeks in patients who have completed the C2L-OCT-01 PR-301 study.|To determine the percentage of patients who remain with controlled mean GH and normal (gender- and age-matched values) IGF-1 serum concentrations.|Compare plasma concentrations of C2L-OCT-01 PR.","http://ClinicalTrials.gov/show/NCT00635765",NA
"54847",54847,"NCT00638365","Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa","Completed","No Results Available","Cystic Fibrosis","Biological: KB001|Other: Placebo","KaloBios Pharmaceuticals","Both","Child|Adult|Senior","Phase I|Phase II",48,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KB001-03","March 12, 2008","01/03/2008",2009-04-01,"July 29, 2009","01/07/2009","",2009-03-01,"The safety and tolerability of a single-dose of KB001.|To measure to the pharmacodynamic effects of a single-dose of KB001 as determined by lung microbial ecology and lung function.","http://ClinicalTrials.gov/show/NCT00638365",NA
"54868",54868,"NCT00666965","A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients","Completed","No Results Available","Idiopathic Restless Legs Syndrome","Drug: SPM 962","Otsuka Pharmaceutical Co., Ltd.","Both","Adult|Senior","Phase II",180,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","243-07-003","April 23, 2008","01/06/2008",2009-08-01,"January 11, 2010","01/01/2010","",2009-08-01,"Change of IRLS sum score from the baseline to the end of titration/maintenance period|CGI severity|PGI improvement|PSQI|SF-36|IRLS each parameter","http://ClinicalTrials.gov/show/NCT00666965",NA
"54875",54875,"NCT00677365","Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients","Completed","No Results Available","Cystic Fibrosis","Drug: MP-376 (Levofloxacin solution for Inhalation)|Drug: Placebo","Mpex Pharmaceuticals","Both","Child|Adult|Senior","Phase II",151,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mpex-204","May 12, 2008","01/06/2008",2009-06-01,"August 17, 2009","01/05/2009","",2009-06-01,"Change in P. aeruginosa density from baseline to end of treatment|Changes in respiratory and other domains of CFQ-R from baseline to end of treatment|Time to administration of other anti-pseudomonal antimicrobials|Evaluate changes in FEV1 and FVC from baseline to end of treatment|Changes in bacterial load and susceptability patterns of isolated organisms from baseline to end of treatment|Evaluate the safety and tolerability of three dosage regimens of MP-376 administered over 28 days, compared to placebo","http://ClinicalTrials.gov/show/NCT00677365",NA
"54884",54884,"NCT00695565","Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy","Completed","No Results Available","Painful Diabetic Neuropathy","Drug: placebo|Drug: topical clonidine (ARC-4558)","Arcion Therapeutics Inc","Both","Adult|Senior","Phase II",170,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CLO-027","June 10, 2008","01/05/2008",2009-12-01,"January 22, 2010","01/01/2010","",2009-12-01,"mean change from Baseline in NPRS score|mean change from Baseline in NPRS score at each week|Percentage of subjects who experience at least 30% or at least 50% reduction in pain intensity from Baseline to each week of treatment","http://ClinicalTrials.gov/show/NCT00695565",NA
"54887",54887,"NCT00691665","Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Olopatadine HCL Nasal Spray, 0.6%|Drug: Fluticasone Propionate Nasal Spray, 50 mcg","Alcon Research","Both","Child|Adult|Senior","Phase IV",130,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","SMA-08-06","June 3, 2008","01/05/2008",NA,"March 23, 2010","01/03/2010","",2009-01-01,"Mean Percent Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline|Mean Percent Change in Instantaneous Total Nasal Symptom Score (iTNSS) From Baseline|Mean Percent Change in Reflective Total Ocular Symptom Scores (rTOSS) From Baseline|Mean Percent Change in Instantaneous Total Ocular Symptom Scores (iTOSS) From Baseline","http://ClinicalTrials.gov/show/NCT00691665",NA
"54901",54901,"NCT00709865","Phase 2b Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency","Completed","No Results Available","Congestive Heart Failure|Renal Insufficiency","Drug: tonapofylline|Drug: Placebo","Biogen Idec","Both","Adult|Senior","Phase II|Phase III",420,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","160HF301","July 1, 2008","01/07/2008",2009-12-01,"December 8, 2009","01/12/2009","TRIDENT-1",2009-10-01,"Assess the safety andtolerability of intravenous tonapofylline, when added to standard therapy in subjects hospitalized with ADHF and renal insufficiency.","http://ClinicalTrials.gov/show/NCT00709865",NA
"54934",54934,"NCT00776165","Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)","Completed","No Results Available","Chemotherapy-Induced Neutropenia","Biological: Recombinant Human GCSF (Shantha Biotechnics Limited)|Biological: Neupogen","Shantha Biotechnics Limited","Both","Adult|Senior","Phase III",126,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","SBL/GCSF/N/2007/0100","October 20, 2008","01/10/2007",2009-09-01,"February 1, 2010","01/02/2010","",2009-07-01,"Percentage of patients developing febrile neutropenia (defined as body temperature ??­ 38.2??C or developing a temperature of > 38??C twice in a 12-hour period and absolute neutrophil count < 0.5 x 10e9/L on the same day of the fever or the day after.|Percentage of patients developing adverse events and/ or changes in laboratory values.|Incidence of neutropenia defined as absolute neutrophil count < 0.5 x 10e9/L not associated with fever|Incidence of need for IV anti-infectives and days of admission, as a result of neutropenia","http://ClinicalTrials.gov/show/NCT00776165",NA
"54971",54971,"NCT00837265","Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel","Completed","No Results Available","Chemotherapy-Induced Neutropenia","Biological: Neugranin|Drug: Pegfilgrastim","Teva Pharmaceutical Industries","Both","Adult|Senior","Phase II|Phase III",334,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","NEUGR-002","February 4, 2009","01/08/2008",2010-07-01,"September 2, 2010","01/09/2010","NEUGR-002",2009-09-01,"Duration of severe neutropenia|Incidence of febrile neutropenia|Duration of severe neutropenia in cycles 2-4, ANC recovery in cycles 1-4","http://ClinicalTrials.gov/show/NCT00837265",NA
"55039",55039,"NCT00959465","A/H1N1 Immunogenicity and Safety in Adults","Completed","No Results Available","Influenza|Pandemic Influenza","Biological: H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)","Baxter Healthcare Corporation","Both","Adult|Senior","Phase I|Phase II",408,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","820902|EUDRACT Number 2009-013394-17","August 13, 2009","01/08/2009",2010-04-01,"July 8, 2010","01/07/2010","",2009-11-01,"Number of subjects achieving antibody levels to A/H1N1/California/07/2009 virus that meet the definition of seroprotection and seroconversion at 21 days after the second vaccination","http://ClinicalTrials.gov/show/NCT00959465",NA
"55040",55040,"NCT00962065","Study of LX4211 in Subjects With Type 2 Diabetes Mellitus","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: LX4211 Low Dose|Drug: LX4211 High Dose|Drug: Placebo","Lexicon Pharmaceuticals","Both","Adult","Phase II",36,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LX4211.1-201-DM|LX4211.201","August 10, 2009","01/08/2009",NA,"January 20, 2010","01/01/2010","",2009-12-01,"Safety and tolerability (physical examinations, monitoring of adverse events, clinical laboratory tests, vital signs measurements, and ECGs)|Efficacy (urinary glucose excretion, oral glucose tolerance testing, plasma glucose and fructosamine levels)","http://ClinicalTrials.gov/show/NCT00962065",NA
"55052",55052,"NCT00973765","Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses","Completed","Has Results","Abscesses","Drug: bactrim|Drug: placebo","Wilford Hall Medical Center|Emergency Medicine Foundation","Both","Child|Adult|Senior","Phase III",212,"U.S. Fed|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FWH20080055H_","September 8, 2009","01/11/2007",2009-08-01,"March 1, 2010","01/09/2009","",2009-08-01,"Treatment Failures at 7 Days","http://ClinicalTrials.gov/show/NCT00973765",NA
"55065",55065,"NCT01007565","Postoperative Pain After Volar Plating for Distal Radius Fractures","Completed","No Results Available","Distal Radius Fractures","Procedure: periarticular anesthetics injection","Seoul National University Hospital|Seoul National University Bundang Hospital","Both","Child|Adult|Senior","Phase II",44,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","B-0801/053-013","November 1, 2009","01/03/2008",2009-04-01,"November 3, 2009","01/11/2009","",2009-04-01,"postoperative pain level","http://ClinicalTrials.gov/show/NCT01007565",NA
"55072",55072,"NCT01019265","A Study Comparing Norspan Patch and Oral Tramadol","Completed","No Results Available","Osteoarthritis","Drug: Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg","Mundipharma Pte Ltd|Mundipharma YH (Korea) is the Sponsor|C&R Reaserch Inc. is the CRO","Both","Adult|Senior","Phase IV",170,"Industry|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","BUP07-KR-001","November 24, 2009","01/03/2008",2009-05-01,"November 24, 2009","01/11/2009","",2009-03-01,"Pain intensity - BS-11 pain scale|WOMAC score|Degree of sleep disturbance due to pain and improvement in quality of sleep|Incidence of early discontinuation due to lack of efficacy","http://ClinicalTrials.gov/show/NCT01019265",NA
"55084",55084,"NCT01043965","Myocardial Perfusion in Type 2 Diabetes","Completed","No Results Available","Type 2 Diabetes","Drug: Metformin","University of Sao Paulo General Hospital|Funda????o de Amparo ?? Pesquisa do Estado de S??o Paulo","Both","Adult","Phase I|Phase II",61,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Diagnostic","0925|nata925","January 6, 2010","01/08/2005",2009-08-01,"January 6, 2010","01/08/2005","",2009-08-01,"myocardial blood flow velocity, myocardial blood flow reserve","http://ClinicalTrials.gov/show/NCT01043965",NA
"55137",55137,"NCT01127165","Low and High Dose Zonisamide in Children as Monotherapy","Completed","No Results Available","Epilepsy","Drug: zonisamide","Eisai Korea Inc.","Both","Child","Phase IV",125,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E2090-S082-404","May 19, 2010","01/03/2006",2009-05-01,"June 4, 2010","01/05/2010","",2009-03-01,"Seizure free rate|Quality of life assessment|Cognitive assessment|Behavioral assessment","http://ClinicalTrials.gov/show/NCT01127165",NA
"55214",55214,"NCT01245465","Profermin?ó in Active Ulcerative Colitis","Completed","No Results Available","Ulcerative Colitis","Other: Profermin","Nordisk Rebalance A/S|Hvidovre University Hospital","Both","Adult","Phase I|Phase II",39,"Industry|Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-B-2008-FSP-20","November 18, 2010","01/01/2009",2009-11-01,"November 22, 2010","01/11/2010","CUPE-1",2009-11-01,"Our primary endpoint was to estimate the proportion of patients with a reduction in SCCAI ??­50%.|Our secondary endpoint was to estimate the proportion of patients in remission defined as SCCAI lower than or equal to 2.5","http://ClinicalTrials.gov/show/NCT01245465",NA
"55311",55311,"NCT00056966","Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases","Completed","No Results Available","Hematologic Malignancy","Drug: ANTI-CD45|Drug: CAMPATH-1H|Drug: FK506|Drug: Fludarabine|Radiation: Total Body Irradiation|Procedure: Stem cell infusion","Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine","Both","Child|Adult|Senior","Phase I|Phase II",40,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12472|ACHE","March 26, 2003","01/11/2002",2009-10-01,"December 2, 2009","01/10/2009","",2009-10-01,"Assess safety and feasibility of monoclonal abs directed to CD45 and CD52 antigens, Fludarabine and low dose TBI, as a non-myeloablative preparatory regimen for allo HSCT. This will be determined by 100d Non-relapse mortality and 100d Graft rejection|To obtain a preliminary estimate of the efficacy of this therapy as defined by: Complete remission at day 100 and One-year disease free survival.","http://ClinicalTrials.gov/show/NCT00056966",NA
"55312",55312,"NCT00066066","Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers","Completed","No Results Available","Periodontitis|Periodontal Diseases","Drug: Group 1: metronidazole|Drug: Group 2: metronidazole + amoxicillin + locally delivered|Drug: Tetracycline|Drug: Metronidazole","The Forsyth Institute|National Institute of Dental and Craniofacial Research (NIDCR)","Both","Adult|Senior","Phase II",216,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NIDCR-14242|R01DE014242","August 1, 2003","01/07/2003",2009-07-01,"November 8, 2010","01/11/2010","",2009-07-01,"Change in mean attachment level","http://ClinicalTrials.gov/show/NCT00066066",NA
"55322",55322,"NCT00079066","Cetuximab and Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Quality of Life","Biological: cetuximab|Procedure: quality-of-life assessment","NCIC Clinical Trials Group|Australasian Gastro-Intestinal Trials Group","Both","Child|Adult|Senior","Phase III",NA,"Other","Interventional","Allocation: Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment","CO17|CAN-NCIC-CO17|AGITG-CAN-NCIC-CO17|BMS-CA225-025|IMCL-CAN-NCIC-CO17|CDR0000353486","March 8, 2004","01/08/2003",2009-02-01,"November 7, 2010","01/03/2010","",2009-02-01,"Overall survival|Time to progression|Objective response rate|Quality of life by European Organization for Research of the Treatment of Cancer Quality of Life Questionnaire -C30 (EORTC QLQ-C30)|Health utilities by Health Utilities Index 13 (HU 13)|Economic evaluation|Safety profile","http://ClinicalTrials.gov/show/NCT00079066",NA
"55359",55359,"NCT00138866","Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury","Completed","No Results Available","Osteoporosis","Drug: Risedronate","Toronto Rehabilitation Institute|The Physicians' Services Incorporated Foundation|St. Joseph's Healthcare","Both","Adult|Senior","Phase III",46,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TRI REB #04-016|PSI #03-52","August 29, 2005","01/11/2004",2009-03-01,"October 12, 2010","01/07/2008","",2009-01-01,"Change in bone mineral density of the distal femur between baseline and 18-months|Change in bone mineral density of the hips and proximal tibia between baseline and 18-months|The change in biochemical bone markers of bone turnover between baseline and 18-months|The frequency and severity of adverse events","http://ClinicalTrials.gov/show/NCT00138866",NA
"55371",55371,"NCT00147966","Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)","Completed","Has Results","Rheumatoid Arthritis","Drug: rituximab","University of California, San Diego|Genentech","Both","Adult|Senior","Phase II",24,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","41569","September 2, 2005","01/06/2008",2009-12-01,"March 22, 2010","01/06/2008","",2009-12-01,"American College of Rheumatology (ACR) 20 at Week 12","http://ClinicalTrials.gov/show/NCT00147966",NA
"55381",55381,"NCT00162266","CTLA4IG With Methotrexate- Phase IIB - Long Term","Completed","No Results Available","Rheumatoid Arthritis","Drug: Abatacept|Drug: Abatacept|Drug: Placebo","Bristol-Myers Squibb","Both","Adult|Senior","Phase II",219,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","IM101-100","September 9, 2005","01/10/2000",2009-09-01,"May 26, 2010","01/05/2010","",2009-09-01,"Abatacept combined with methotrexate will have greater clinical efficacy than the use of methotrexate alone in subjects with active rheumatoid arthritis|ACR 50 and 70 will be evaluated","http://ClinicalTrials.gov/show/NCT00162266",NA
"55467",55467,"NCT00298766","Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis","Completed","Has Results","Amyloidosis","Drug: VELCADE","Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult|Senior","Phase I|Phase II",70,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","26866138-CAN-2007","March 1, 2006","01/06/2005",2009-09-01,"September 24, 2010","01/09/2010","",2009-07-01,"Maximum Tolerated Dose|Subjects With Treatment Emergent Adverse Events|Subjects With Serious Treatment Emergent Adverse Events|Subjects Grade 3/4/5 Treatment Emergent Adverse Events|Subjects With Treatment Emergent Adverse Events Leading to Treatment Termination|Best Confirmed Hematologic Responders","http://ClinicalTrials.gov/show/NCT00298766",NA
"55493",55493,"NCT00349466","Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca","Completed","No Results Available","Keratoconjunctivitis Sicca","Drug: CF101|Drug: Placebo","Can-Fite BioPharma","Both","Adult|Senior","Phase II",50,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CF101-201KCS","July 6, 2006","01/01/2007",2009-05-01,"September 8, 2009","01/09/2009","",2009-05-01,"Teat Meniscus Height|Tear Break-Up Time|Fluorescein Staining for superficial punctate keratitis|Schirmer Test|Dry Eye Symptom Score","http://ClinicalTrials.gov/show/NCT00349466",NA
"55533",55533,"NCT00407966","Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","Completed","No Results Available","Leukemia","Drug: alvocidib|Drug: cytarabine|Drug: mitoxantrone hydrochloride","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",25,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000518322|U01CA070095|P30CA006973|JHOC-J0669","December 4, 2006","01/10/2006",NA,"March 18, 2010","01/03/2010","",2009-11-01,"Complete response|Toxicity","http://ClinicalTrials.gov/show/NCT00407966",NA
"55542",55542,"NCT00419666","A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis","Completed","No Results Available","Chronic Plaque Psoriasis","Drug: Calcitriol","Galderma","Both","Child","Phase II",25,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RD.06.SPR.18102","January 5, 2007","01/08/2006",2009-11-01,"April 19, 2010","01/04/2010","",2009-09-01,"PK|PD","http://ClinicalTrials.gov/show/NCT00419666",NA
"55554",55554,"NCT00440466","PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients","Completed","No Results Available","Anemia|Renal Diseases","Drug: epoetin alfa|Drug: epoetin alfa|Drug: epoetin alfa","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult|Senior","Phase III",400,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR010414|EPOAKD3002","February 26, 2007","01/05/2007",2009-03-01,"April 30, 2009","01/04/2009","",2009-03-01,"The primary measure of effectiveness in the study is the change in hemoglobin value from baseline to end of study|The secondary efficacy endpoint is the proportion of weeks the hemoglobin value remains within the treatment target range.","http://ClinicalTrials.gov/show/NCT00440466",NA
"55556",55556,"NCT00446966","Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery","Completed","No Results Available","Atrial Fibrillation","Drug: Omega Three Polyunsaturated fatty acids","University of Iowa|GlaxoSmithKline","Both","Adult|Senior","Phase IV",260,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1733860001","March 12, 2007","01/02/2007",2010-01-01,"May 10, 2010","01/02/2007","FISH",2009-12-01,"The primary endpoint is the development of postoperative atrial fibrillation or flutter after bypass surgery.|Time to post-operative atrial fibrillation.","http://ClinicalTrials.gov/show/NCT00446966",NA
"55589",55589,"NCT00500266","Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects","Completed","No Results Available","Pneumococcal Infections","Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)","Wyeth","Both","Senior","Phase III",1053,"Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","6115A1-3000","July 9, 2007","01/05/2008",2009-05-01,"March 2, 2010","01/06/2009","",2009-04-01,"Safety","http://ClinicalTrials.gov/show/NCT00500266",NA
"55591",55591,"NCT00504166","Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women","Completed","No Results Available","Osteopenia|Osteoporosis","Drug: alendronate","University of California, San Francisco|Merck","Female","Adult","Phase IV",44,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","M250","July 17, 2007","01/02/2006",2009-04-01,"April 16, 2009","01/01/2007","",2009-03-01,"Mean percent change from baseline in apparent trabecular number at the distal radius at 24 months of treatment with alendronate, 70 mg once a week as compared to placebo.","http://ClinicalTrials.gov/show/NCT00504166",NA
"55656",55656,"NCT00591266","Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Subjects With Essential Hypertension","Completed","No Results Available","Essential Hypertension","Drug: Azilsartan Medoxomil|Drug: Azilsartan Medoxomil|Drug: Amlodipine","Takeda Global Research & Development Center, Inc.","Both","Adult|Senior","Phase III",566,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01-05-TL-491-010|U1111-1113-9132","December 27, 2007","01/10/2007",2009-04-01,"April 9, 2010","01/04/2010","",2009-03-01,"Change from baseline to Week 6 in the 24-hour mean systolic blood pressure by ambulatory blood pressure monitor.|Change from baseline to Week 6 in trough clinic sitting systolic blood pressure.|Change from baseline to Week 6 in the 24-hour mean diastolic blood pressure by ambulatory blood pressure monitor.|Change from baseline to Week 6 in trough clinic sitting diastolic blood pressure.|Change from baseline for daytime mean (6am to 10pm) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for daytime mean (6am to 10pm) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) diastolic blood pressure by ambulatory blood pressure monitor|Proportion of subjects who achieve a Clinic Diastolic Blood Pressure Response, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg|Proportion of subjects who achieve a Clinic Systolic Blood Pressure Response, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg|Proportion of subjects who achieve both a Clinic Diastolic Blood Pressure < 90 mm Hg and/or reduction of ??­ 10 mm Hg from Baseline and a Systolic Blood Pressure < 140 mm Hg and/or reduction of ??­ 20 mm Hg from Baseline.","http://ClinicalTrials.gov/show/NCT00591266",NA
"55659",55659,"NCT00615966","Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients","Completed","No Results Available","Kidney Transplantation","Drug: Diannexin|Drug: Placebo|Drug: Diannexin","Alavita Pharmaceuticals Inc|CTI Clinical Trial and Consulting Services","Both","Adult|Senior","Phase I|Phase II",58,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DAV-CL002","February 1, 2008","01/02/2008",2010-02-01,"August 13, 2010","01/08/2010","",2009-01-01,"Safety assessments -- physical examinations, vital signs, clinical safety laboratory tests, ECGs, immunogenicity testing, adverse events|Population pharmacokinetics","http://ClinicalTrials.gov/show/NCT00615966",NA
"55663",55663,"NCT00621166","Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women","Completed","No Results Available","HIV Infections","Drug: generic lopinavir/ritonavir","The HIV Netherlands Australia Thailand Research Collaboration","Female","Adult","Phase II",20,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HIV-NAT 093|approved","February 12, 2008","01/06/2008",2009-12-01,"November 30, 2010","01/11/2010","",2009-12-01,"To evaluate the pharmacokinetic profile of generic lopinavir/ritonavir tablets 200/50 mg in pregnant Thai HIV-infected women|To determine the antiviral activity of generic lopinavir/ritonavir 400/100 mg BID in Thai pregnant women To determine the safety of generic lopinavir/ritonavir?ó 400/100 mg BID in Thai pregnant women Compare pharmacokinetics parameters before and after","http://ClinicalTrials.gov/show/NCT00621166",NA
"55697",55697,"NCT00670566","Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients","Completed","No Results Available","Hypertension","Drug: irbesartan/hydrochlorothiazide","Sanofi-Aventis","Both","Adult|Senior","Phase IV",503,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRBEH_L_03170","April 30, 2008","01/04/2008",NA,"September 14, 2009","01/09/2009","",2009-03-01,"Number of patients with controlled blood pressure|Adverse events|Systolic and Diastolic Blood Pressure","http://ClinicalTrials.gov/show/NCT00670566",NA
"55719",55719,"NCT00701766","BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia","Completed","No Results Available","Leukemia, Myeloid, Acute","Drug: BI 2536","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",70,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1216.20|EudraCT No:2006-000613-38","June 18, 2008","01/10/2006",NA,"December 1, 2009","01/12/2009","",2009-10-01,"Maximum tolerated dose Best objective response|Event free survival, Overall survival, Remission duration, BI 2536 plasma concentrations, Incidence and intensity of adverse events graded according to CTCAE, PD, Incidence of DLT","http://ClinicalTrials.gov/show/NCT00701766",NA
"55742",55742,"NCT00743366","Effect of Quetiapine on Marijuana Withdrawal and Relapse","Completed","No Results Available","Marijuana Smoking","Drug: Marijuana|Drug: Quetiapine","New York State Psychiatric Institute|Research Foundation for Mental Hygiene|National Institute on Drug Abuse (NIDA)","Both","Adult","Phase II",20,"Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Masking: Double-Blind|Primary Purpose: Treatment","5685","August 26, 2008","01/08/2008",2009-03-01,"September 22, 2009","01/09/2009","",2009-03-01,"Marijuana's direct effects|Marijuana withdrawal symptoms|Marijuana relapse","http://ClinicalTrials.gov/show/NCT00743366",NA
"55744",55744,"NCT00749866","Long Term Nebulised Gentamicin in Patients With Bronchiectasis","Completed","No Results Available","Bronchiectasis","Drug: Gentamicin|Drug: Saline","University of Edinburgh|NHS Lothian","Both","Adult|Senior","Phase IV",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","CZB/4/451","September 8, 2008","01/05/2007",2009-08-01,"August 9, 2010","01/08/2010","",2009-08-01,"Reduction in bacterial load|airways and systemic inflammation|Spirometry and exercise capacity|Exacerbation frequency|Health Related Quality of Life|Long term safety with nebulised Gentamicin","http://ClinicalTrials.gov/show/NCT00749866",NA
"55754",55754,"NCT00760266","Blood Pressure Lowering of Aliskiren HCTZ Compared HCTZ in Stage 2 Systolic Hypertension in Older Population","Completed","No Results Available","Hypertension","Drug: Aliskiren HCTZ|Drug: HCTZ","Novartis","Both","Adult|Senior","Phase IV",432,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CSPP100A2411","September 25, 2008","01/09/2008",NA,"May 5, 2009","01/05/2009","ACTION",2009-04-01,"Change in msSBP after 8 weeks of treatment|Change in msDBP after 8 weeks of treatment|Efficacy of regimens on msSBP and msDBP|Proportion of responders at week 4 and regimens at week 8|Proportion of patients achieving BP control at week 4 and regimens at week 8|Safety and tolerability of aliskiren HCTZ compared to HCTZ at week 4 and regimens at week 8","http://ClinicalTrials.gov/show/NCT00760266",NA
"55763",55763,"NCT00712166","Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa","Completed","Has Results","Cystic Fibrosis|Lung Infection|Pseudomonas Aeruginosa","Drug: AZLI 75 mg three times daily (TID)|Drug: Placebo three times daily (TID)","Gilead Sciences","Both","Child|Adult|Senior","Phase III",160,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-205-0117","July 7, 2008","01/05/2008",2009-08-01,"November 19, 2010","01/11/2010","AIR-CF4",2009-06-01,"Change From Baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS) Score at Day 28|Change From Baseline in CFQ-R RSS Score at Day 14|Change From Baseline in CFQ-R RSS Score at Day 42|Change From Baseline in CFQ-R Physical Functioning Domain Score|Number of Participants Using Additional (Nonprotocol-specified) Antipseudomonal Antibiotics During Study|Number of Participants Hospitalized During Study|Change From Baseline in Log10 Pseudomonas Aeruginosa (PA) Colony Forming Units (CFUs) in Sputum at Day 28|Relative Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted","http://ClinicalTrials.gov/show/NCT00712166",NA
"55783",55783,"NCT00805766","Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)","Completed","No Results Available","Crohn's Disease","Drug: TA-650","Mitsubishi Tanabe Pharma Corporation","Both","Child|Adult|Senior","Phase III",30,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TA-650-19","December 9, 2008","01/12/2008",2010-07-01,"September 21, 2010","01/09/2010","",2009-11-01,"Changes in Crohn's Disease Activity Index (CDAI) from baseline after 8 weeks administration of increased dose of TA-650|CDAI|CDAI remission rate|Changes in CDAI|Adverse event, Adverse drug Reaction|Serum Concentration of Infliximab|Antibody to Infliximab (ATI)","http://ClinicalTrials.gov/show/NCT00805766",NA
"55787",55787,"NCT00807066","Randomized Gefitinib Trial","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Gefitinib|Drug: Platinum","Fondazione Humanitas per la Ricerca","Both","Adult|Senior","Phase III",1,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ONC-2008-001","December 10, 2008","01/11/2008",2010-10-01,"October 14, 2010","01/10/2010","RANGE",2009-11-01,"Quality of life (FACT-L Total Score)|Time to disease progression (TTP), Objective Response Rate (ORR), overall survival (OS), and tolerability.","http://ClinicalTrials.gov/show/NCT00807066",NA
"55802",55802,"NCT00838266","Study of Growing Biofilm by an Antiplaque Mouthrinse","Completed","No Results Available","Dental Plaque","Drug: mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Other: mouthrinse containing non-active component","University Hospital, Bordeaux","Both","Adult","Phase III",50,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CHUBX 2008/05","February 5, 2009","01/02/2009",2009-03-01,"September 22, 2009","01/09/2009","Bain de bouche",2009-03-01,"Plaque index of Quickley-Hein modified by Tureski. Plaque deposits are scored on all natural teeth (except third molars) after staining.|Product tolerance|Product acceptability (oral sensation)","http://ClinicalTrials.gov/show/NCT00838266",NA
"55830",55830,"NCT00877266","Ultrasound Guidance Versus Electrical Stimulation for Perineural Catheter Insertion","Completed","No Results Available","Postoperative Pain","Procedure: perineural mepivicaine catheter placed via ultrasound or electrical stimulation","University of California, San Diego","Both","Adult|Senior","Phase IV",180,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","US vs. NS Perineural Catheter","April 3, 2009","01/08/2007",2009-02-01,"April 6, 2009","01/04/2009","",2009-02-01,"The primary outcome measurement will be the time of placement for a perineural catheter using either ultrasound-guided method or electrical stimulation method.|Pain and discomfort as assessed by a 0-10 scale (0=no pain/discomfort and 10=worst pain/discomfort imaginable) by the research coordinator.","http://ClinicalTrials.gov/show/NCT00877266",NA
"55832",55832,"NCT00882466","The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction","Completed","No Results Available","Acute Myocardial Infarction","Drug: human recombinant erythropoietin","Seoul National University Bundang Hospital","Both","Adult|Senior","Phase IV",58,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EPO in AMI","April 15, 2009","01/05/2008",2009-02-01,"April 16, 2009","01/04/2009","",2009-02-01,"Creatinine kinase (CK), creatinine kinase-MB (CK-MB)|Infarct size assessed by cardiac MRI","http://ClinicalTrials.gov/show/NCT00882466",NA
"55855",55855,"NCT00918866","A Study of Commercial DEFINITY?ó to Monitor the Effects of the Heart's Pulmonary Artery Pressure","Completed","No Results Available","Pulmonary Heart Disease","Drug: Definity","Lantheus Medical Imaging","Both","Adult|Senior","Phase IV",32,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","DMP 115-416","June 4, 2009","01/07/2009",2009-12-01,"November 10, 2010","01/11/2010","",2009-12-01,"Primary outcome is the evaluation of the effect of DEFINITY?ó on Pulmonary Artery Hemodynamics.","http://ClinicalTrials.gov/show/NCT00918866",NA
"55860",55860,"NCT00931866","Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)","Completed","No Results Available","Acute Pain|Soft Tissue Injury","Drug: Diclofenac Sodium|Drug: Matching Placebo Patch","Cerimon Pharmaceuticals|PPD","Both","Adult|Senior","Phase III",407,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DCF-006","June 29, 2009","01/04/2009",2009-12-01,"August 12, 2010","01/08/2010","",2009-09-01,"Change in average pain during daily activity at Day 7|Change in average pain during daily activity at Day 14","http://ClinicalTrials.gov/show/NCT00931866",NA
"55907",55907,"NCT01005966","In Situ Caries Model of Fluoride Toothpastes","Completed","No Results Available","Caries","Drug: 675 ppmf toothpaste|Drug: Sodium Fluoride Toothpaste|Drug: Amine Fluoride Toothpaste|Drug: Sodium monofluorophosphate/Sodium Fluoride Toothpaste|Drug: Placebo","GlaxoSmithKline","Both","Adult|Senior","Phase III",57,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","T3508605","October 15, 2009","01/11/2008",2009-03-01,"October 29, 2009","01/10/2009","",2009-03-01,"To use an in situ caries model to compare fluoride toothpastes with respect to enamel remineralisation potential|To use an in situ caries model to compare fluoride toothpastes with respect to enamel fluoride uptake","http://ClinicalTrials.gov/show/NCT01005966",NA
"55922",55922,"NCT01025466","Exelon Patch and Combination With Memantine Comparative Trial","Completed","No Results Available","Alzheimer's Disease","Drug: Rivastigmine transdermal patch (Exelon patch), memantine|Drug: Rivastigmine transdermal patch","Inha University Hospital","Both","Adult|Senior","Phase IV",206,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EXPECT","December 2, 2009","01/12/2008",2010-04-01,"May 18, 2010","01/05/2010","EXPECT",2009-11-01,"Retention rate at week 16 after randomization|Change from baseline at week 16 in Alzheimer's Disease Assessment Scale-Cognitive subscale|Change from baseline at week 16 in Mini-Mental State Examination|Change from baseline at week 16 in Frontal Assessment Battery|Change from baseline at week 16 in Alzheimer's Disease Cooperative Study - Activities of Daily Living|Change from baseline at week 16 in Caregiver-Administered Neuropsychiatric Inventory|Change from baseline at week 16 in Cohen Mansfield Agitation Inventory|Change from baseline at week 16 in Clinical Dementia Rating Scale-Sum of Boxes|Safety","http://ClinicalTrials.gov/show/NCT01025466",NA
"55937",55937,"NCT01056666","Conveen Optima Urisheaths With Collecting Bags Versus Absorbents on Men Suffering of Moderate to Severe Urinary Incontinence","Completed","No Results Available","Urinary Incontinence","Device: Conveen Optima is a urisheath to be used together with a collecting bag for urine|Device: absorbent protection","Coloplast A/S","Male","Adult|Senior","Phase IV",61,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","FR002CC","January 25, 2010","01/06/2007",2009-03-01,"April 8, 2010","01/04/2007","",2009-02-01,"Impact on quality of life|Efficacy (leakages)","http://ClinicalTrials.gov/show/NCT01056666",NA
"55953",55953,"NCT01087866","Metformin Versus Insulin in the Treatment of Gestational Diabetes Mellitus","Completed","No Results Available","Gestational Diabetes Mellitus","Drug: Metformin|Drug: Insulin","University of Oulu","Female","Adult","Phase II|Phase III",97,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","70471","March 15, 2010","01/06/2005",2009-10-01,"March 15, 2010","01/03/2010","",2009-08-01,"Percentage of fetal macrosomy","http://ClinicalTrials.gov/show/NCT01087866",NA
"55991",55991,"NCT01142466","A Phase IV Study of Rebif ?ó 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone","Completed","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Drug: Interferon beta-1a (Rebif)","Merck KGaA|GKM Gesellschaft f??r Therapieforschung GmbH","Both","Adult","Phase IV",30,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IMP 25874","June 10, 2010","01/12/2005",2010-01-01,"June 10, 2010","01/06/2010","REMAIN",2009-12-01,"Time to first relapse in subjects treated with Rebif 44 mcg tiw compared with subjects not treated over 96 weeks|Relapse-free subjects|Change of magnetic resonance imaging (MRI) criteria (T1, T1-Gd, T2) from baseline to relevant visits|Mean change in Expanded Disability Status Scale (EDSS) score from baseline to relevant visits|Change in multiples sclerosis functional composite (MSFC) from baseline to relevant visits|Safety","http://ClinicalTrials.gov/show/NCT01142466",NA
"56001",56001,"NCT01159366","Incidence of Occluded Culprit Arteries and Impact of Coronary Collaterals on Outcome in Patients With NSTEMI","Completed","No Results Available","NSTEMI","Procedure: percutaneous coronary intervention","University of Jena","Both","Adult|Senior","Phase IV",602,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","","July 8, 2010","01/07/2006",2010-01-01,"July 9, 2010","01/07/2010","",2009-12-01,"MACE|CK and CK-MB","http://ClinicalTrials.gov/show/NCT01159366",NA
"56121",56121,"NCT00009867","Arsenic Trioxide in Treating Patients With Recurrent Bladder or Urinary Tract Cancer","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: arsenic trioxide","Cancer and Leukemia Group B|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068419|CLB-99903","February 2, 2001","01/02/2001",NA,"October 15, 2009","01/10/2009","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT00009867",NA
"56185",56185,"NCT00125567","Stalevo in Early Wearing-Off Patients","Completed","No Results Available","Idiopathic Parkinson's Disease","Drug: Stalevo (levodopa/carbidopa/entacapone)|Drug: Levodopa/carbidopa","Orion Corporation, Orion Pharma","Both","Adult|Senior","Phase IV",223,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2939111|EudraCT number: 2004-005234-39","July 29, 2005","01/08/2005",2009-03-01,"June 19, 2009","01/06/2009","SEWOP",2009-03-01,"The time until a patient requires changes in antiparkinsonian therapy due to inadequately controlled parkinsonian symptoms|Unified Parkinson's Disease Rating Scale|Clinical Global Impression of Change (investigator)|Parkinson's Disease Questionnaire (PDQ-39)|Work Impairment Questionnaire","http://ClinicalTrials.gov/show/NCT00125567",NA
"56286",56286,"NCT00273767","Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB","Completed","No Results Available","Myocardial Ischemia","Drug: epoetin beta|Drug: placebo","University Hospital, Grenoble|Roche Pharma AG","Both","Adult|Senior","Phase II",50,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DCIC 05 04","January 6, 2006","01/01/2006",2009-11-01,"December 4, 2009","01/12/2009","EPOetCEC",2009-07-01,"Area under curve and maximal plasmatic level of troponin-T, NT-pro-BNP, and creatine kinase-MB (CK-MB) after cardiopulmonary bypass|Area under curve and maximal plasmatic level of protein S-100 after cardiopulmonary bypass|Blood level of erythropoietin","http://ClinicalTrials.gov/show/NCT00273767",NA
"56382",56382,"NCT00418067","Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions","Completed","No Results Available","Coronary Artery Disease","Device: Endeavor, Medtronic|Device: Cypher, Cordis|Device: Taxus Liberte, Boston Scientific","CardioVascular Research Foundation, Korea|Medtronic Vascular","Both","Adult|Senior","Phase IV",2645,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","2006-0136","January 3, 2007","01/10/2006",2009-01-01,"January 30, 2009","01/01/2009","ZEST",2009-01-01,"The composite of death (all cause-mortality), myocardial infarction, and ischemia-driven target vessel revascularization|All-cause Death|Cardiac death|Myocardial infarction|Target vessel revascularization (all and ischemia-driven)|Target lesion revascularization (all and ischemia-driven)|Stent thrombosis by definition of Academic Research Consortium (ARC)|Late luminal loss in both in-stent and in-segment|Binary restenosis in both in-stent and in-segment|Procedural success defined as achievement of a final diameter stenosis of <30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or urgent revascularization during the hospital stay.","http://ClinicalTrials.gov/show/NCT00418067",NA
"56390",56390,"NCT00431067","Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy","Completed","No Results Available","Breast Neoplasms","Drug: BIBW 2992","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",41,"Industry","Interventional","Primary Purpose: Treatment","1200.11|EUDRACT 2007-004805-80","February 2, 2007","01/09/2006",NA,"August 20, 2010","01/08/2010","",2009-08-01,"The primary endpoint of this trial is objective response (CR, PR) by RECIST criteria|Time to progression Progression free survival Overall survival Time to objective response Duration of objective response Occurrence and intensity of adverse events graded according to NCI CTCAE Version 3.0","http://ClinicalTrials.gov/show/NCT00431067",NA
"56393",56393,"NCT00442767","Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus","Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: Pramlintide acetate","Baylor College of Medicine|Amylin Pharmaceuticals, Inc.","Both","Child|Adult","Phase IV",8,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","H-18629|GCRC protocol #:0954","March 1, 2007","01/02/2007",2009-02-01,"November 30, 2010","01/11/2010","",2009-02-01,"Blood glucose level|Insulin levels|Glucagon levels","http://ClinicalTrials.gov/show/NCT00442767",NA
"56398",56398,"NCT00453167","Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: Paclitaxel|Drug: Gemcitabine","National Cancer Center, Korea","Both","Adult|Senior","Phase II",35,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-05-155","March 27, 2007","01/12/2005",2010-03-01,"July 9, 2010","01/07/2010","",2009-12-01,"To evaluate the response rate of paclitaxel plus gemcitabine|To access the toxicity|To estimate the time to progression|To examine the association between genotypes of paclitaxel biotransformation and the pharmacokinetics /|To estimate the overall survival","http://ClinicalTrials.gov/show/NCT00453167",NA
"56403",56403,"NCT00462267","Examining the Feasibility of Collaborative Care Treatment for Overweight Adolescents","Completed","No Results Available","Obesity|Overweight","Behavioral: Usual care control group|Behavioral: Enriched lifestyle intervention","Kaiser Permanente|Garfield Memorial Fund","Female","Child","Phase II",215,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","101-9295","April 17, 2007","01/01/2005",2009-12-01,"March 23, 2010","01/03/2010","SHINE-Garfield",2009-12-01,"BMI z-score|Quality of life (PedsQL 4.0)|Self esteem (RSE)|Depression (PHQ-A)|Unhealthy eating practices (QEWPR-A, TFEQ)|Weight and shape concerns (WCS)|Sociocultural attitudes toward appearance (SATAQ)|Participant satisfaction with the intervention|Dietary intake|Personal and family eating patterns|Physical activity|Sedentary behaviors|Personal and family physical activity patterns","http://ClinicalTrials.gov/show/NCT00462267",NA
"56410",56410,"NCT00423267","POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)","Completed","Has Results","Coccidioidomycosis","Drug: Posaconazole|Drug: Fluconazole","Schering-Plough","Both","Child|Adult|Senior","Phase III",16,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P04558","January 17, 2007","01/05/2007",2009-05-01,"August 12, 2010","01/08/2010","",2009-05-01,"Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) or Fluconazole (FLU) in Period A|Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) in Period B|Number of Participants With Treatment-emergent Adverse Events (TEAEs)That Occurred With POS or FLU in Period A|Number of Participants With Treatment-emergent Adverse Events (TEAEs) That Occurred With POS in Period B|Number of Participants With Laboratory Test Abnormalities (at Least a 1 Grade Shift From Baseline) That Occurred With POS or FLU in Period A|Number of Participants With Laboratory Abnormalities (at Least a 1 Grade Shift From Baseline) That Occurred With POS in Period B|Number of Participant Discontinuations Due to Adverse Events and/or Laboratory Evaluations of Safety in Period A|Number of Participant Discontinuations Due to Adverse Events and/or Laboratory Evaluations of Safety in Period B","http://ClinicalTrials.gov/show/NCT00423267",NA
"56484",56484,"NCT00593567","Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer","Completed","No Results Available","Diabetic Foot Ulcer","Drug: gentamicin-collagen sponge|Drug: Levofloxacin","Innocoll Technologies|Premier Research Group plc","Both","Adult|Senior","Phase II",70,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","INN-TOP-001","January 4, 2008","01/12/2007",2009-05-01,"July 22, 2010","01/07/2010","",2009-05-01,"Percent of patients with a clinical outcome of \clinical cure\"" in each treatment group|Percent of patients with a clinical outcome of \""clinical cure\"" in each treatment group|Percent of patients with pathogen eradication in each treatment group|Reduction (absolute and percent decrease","http://ClinicalTrials.gov/show/NCT00593567",NA
"56493",56493,"NCT00601367","Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desir Disorder","Completed","No Results Available","Sexual Dysfunctions, Psychological","Drug: BIMT 17 BS 25 mg|Drug: BIMT 17 BS 50 mg|Drug: BIMT 17 BS 100 mg","Boehringer Ingelheim Pharmaceuticals","Female","Adult|Senior","Phase III",483,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment","511.118","January 15, 2008","01/01/2008",NA,"November 23, 2009","01/11/2009","",2009-10-01,"Frequency of Adverse events|FSFI desire subscale, FSDS R, PGI Improvement, CGI Improvement, Patient Benefit Evaluation","http://ClinicalTrials.gov/show/NCT00601367",NA
"56499",56499,"NCT00558467","Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria","Completed","Has Results","Tourette Syndrome","Drug: pramipexole IR|Drug: Placebo","Boehringer Ingelheim Pharmaceuticals","Both","Child","Phase II",63,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","248.644","November 14, 2007","01/01/2008",NA,"October 4, 2010","01/10/2010","",2009-06-01,"Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale|Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 1|Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 2|Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 3|Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 4|Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 6|Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 1|Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 2|Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 3|Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 4|Clinical Global Impressions - Improvement at 1 Week|Clinical Global Impressions - Improvement at Week 2|Clinical Global Impressions - Improvement at Week 3|Clinical Global Impressions - Improvement at Week 4|Clinical Global Impressions - Improvement at Week 6|Clinical Global Impressions - Severity of Illness at Week 1|Clinical Global Impressions - Severity of Illness at Week 2|Clinical Global Impressions - Severity of Illness at Week 3|Clinical Global Impressions - Severity of Illness at Week 4|Clinical Global Impressions - Severity of Illness at Week 6|Patient Global Impression at Week 1|Patient Global Impression at Week 2|Patient Global Impression at Week 3|Patient Global Impression at Week 4|Patient Global Impression at Week 6","http://ClinicalTrials.gov/show/NCT00558467",NA
"56520",56520,"NCT00648167","A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)","Completed","No Results Available","Hyperphosphatemia|End-Stage Renal Disease","Drug: ferric citrate","Keryx Biopharmaceuticals","Both","Adult|Senior","Phase II",24,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KRX-0502-201","March 27, 2008","01/03/2008",2009-01-01,"January 5, 2009","01/01/2009","",2009-01-01,"This study is exploratory in nature and is intended to assess the tolerability and safety of Zerenex.|Serum phosphorus levels will be monitored prior to study drug titration.","http://ClinicalTrials.gov/show/NCT00648167",NA
"56522",56522,"NCT00650767","Orally Active, Small Molecule Inhibitor of MEK1 and MEK2 in Patients With Active Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: ARRY-438162|Other: Placebo","Array BioPharma","Both","Adult|Senior","Phase II",200,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARRAY-162-201","March 31, 2008","01/03/2008",2009-07-01,"December 9, 2009","01/12/2009","",2009-07-01,"To compare the efficacy of 3 dose levels of ARRY-438162 (10 mg BID, 40 mg QD, and 20 mg BID) versus placebo, administered over 12 weeks for the treatment of the signs and symptoms of patients with Rheumatoid Arthritis on stable doses of methotrexate.|To determine the American College of Rheumatology 20% (ACR20) best response rate at week 12 of patients treated with any well-tolerated dose.|To evaluate the safety and tolerability of ARRY-438162 in patients with active Rheumatoid Arthritis on stable doses of methotrexate (> 10 mg <25 mg) for > 6 weeks.|To evaluate the pharmacokinetic profiles of multiple doses of ARRY-438162 administered for 12 weeks to patients with active Rheumatoid Arthritis on stable doses of methotrexate.|To evaluate the dose-and concentration- response of ARRY-438162 against measures of disease activity through 12 weeks of treatment","http://ClinicalTrials.gov/show/NCT00650767",NA
"56529",56529,"NCT00658567","A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","Completed","No Results Available","Parkinson's Disease Psychosis","Drug: Pimavanserin tartrate (ACP-103)|Drug: Pimavanserin tartrate (ACP-103)|Drug: Pimavanserin tartrate (ACP-103)","ACADIA Pharmaceuticals Inc.","Both","Adult|Senior","Phase III",240,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACP-103-014","April 10, 2008","01/03/2008",NA,"August 4, 2010","01/08/2010","",2009-12-01,"Antipsychotic efficacy will be assessed using the scale for the assessment of Positive Symptoms (SAPS)","http://ClinicalTrials.gov/show/NCT00658567",NA
"56533",56533,"NCT00667667","Effects of Whole Body Vibration on Postmenopausal Risk-factors in Elderly Women","Completed","No Results Available","Postmenopausal","Device: vertical vibration device (Vibrafit whole body vibration platform)|Device: side alternating vibration device (Board 3000 whole body vibration platform)|Behavioral: stretching and wellness (control group)","University of Erlangen-N??rnberg Medical School|Elsbeth-Bonhoff-Stiftung, Berlin","Female","Adult|Senior","Phase III",108,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","OFZ-Elvis-II","April 24, 2008","01/04/2008",2009-11-01,"December 3, 2009","01/12/2009","",2009-06-01,"Bone Mineral Density|muscle strength|Quality of life|falls","http://ClinicalTrials.gov/show/NCT00667667",NA
"56535",56535,"NCT00670267","Oral Nadolol for the Treatment of Adults With Mild Asthma","Completed","No Results Available","Asthma","Drug: nadolol","Inverseon, Inc.|University of Houston|Sandler Program for Asthma Research|Baylor College of Medicine","Both","Adult","Phase I|Phase II",10,"Industry|Other","Interventional","Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAND1002","April 29, 2008","01/01/2007",2009-06-01,"February 2, 2010","01/02/2010","",2009-05-01,"safety|Airway hyper-responsiveness","http://ClinicalTrials.gov/show/NCT00670267",NA
"56536",56536,"NCT00609167","Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","Completed","Has Results","Multiple Myeloma and Plasma Cell Neoplasm","Drug: bortezomib|Drug: cyclophosphamide|Drug: dexamethasone","Mayo Clinic|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",63,"Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000583225|P30CA015083|MC0686|06-002613|NCI-2010-02147","January 31, 2008","01/12/2006",2010-11-01,"December 14, 2010","01/12/2010","",2009-01-01,"Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment|Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants Who Responded to Treatment (Complete Response,CR; Near Complete Response, nCR; Very Good Partial Response, VGPR; or Partial Response, PR) After 4 Cycles|Duration of Response|Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 8 Cycles|Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 12 Cycles|Number of Participants With Severe Adverse Events|Participants Who Successfully Completed Collection of Peripheral Blood Stem Cells for Transplant","http://ClinicalTrials.gov/show/NCT00609167",NA
"56547",56547,"NCT00688467","Efficacy and Safety of SCH 527123 in Subjects With Allergen-Induced Asthma (Study P05363)(COMPLETED)","Completed","No Results Available","Asthma","Drug: SCH 527123|Drug: SCH 527123","Schering-Plough","Both","Adult","Phase II",18,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","P05363","May 29, 2008","01/06/2008",2009-02-01,"October 16, 2009","01/10/2009","",2009-02-01,"LAR area under the curve from 3 to 7 hours (AUC(3-7 hr)) expressed as % change in FEV1 from the prechallenge value of FEV1 taken from 3 to 7 hours postallergen challenge, following 9 days pretreatment with SCH 527123.|Maximum percent fall in FEV1 during the late response following 9 days of pretreatment with SCH 527123.|LAR AUC(3-7 hr), expressed as actual change in FEV1 from preallergen FEV1 taken from 3 to 7 hours postallergen challenge, following 9 days of pretreatment with SCH 527123.|Changes in airway responsiveness as measured by methacholine PC20 24 hours postallergen challenge.|Reduction in sputum neutrophils and eosinophils at 7 and 24 hours postallergen challenge.|Attenuation of EAR (maximum percent fall in FEV1 from preallergen FEV1 0-2 hours postchallenge) and EAR UC(0-2 hr) following 9 days of pretreatment with SCH 527123.|Changes in interleukin 8 (IL-8), myeloperoxidase (MPO), neutrophil elastase, and eosinophil cationic protein (ECP) levels in sputum at 7 and 24 hours postallergen challenge.|Safety and tolerability as measured by peripheral neutrophil counts, asthma symptoms, frequency of use of rescue medication, PFTs, ECGs, labs, and AEs.","http://ClinicalTrials.gov/show/NCT00688467",NA
"56561",56561,"NCT00707967","Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.","Completed","No Results Available","Tuberculosis (TB)","Biological: GSK's candidate Mycobacterium tuberculosis vaccine 692342|Biological: Control vaccine with the adjuvant system.|Biological: Control vaccine with physiological saline","GlaxoSmithKline","Both","Adult","Phase II",37,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","111517","June 27, 2008","01/06/2008",2009-05-01,"September 3, 2009","01/09/2009","",2009-05-01,"Occurrence, intensity and relationship to vaccination of solicited local and general adverse events|Occurrence, intensity and relationship to vaccination of unsolicited adverse events.|Occurrence and relationship to vaccination of serious adverse events|Haematological and biochemical levels|Analysis of cytokine/activation marker expression by antigen-specific CD4+/CD8+ T cells by means of in vitro flow cytometry.|Antigen-specific antibody titres as measured by ELISA.","http://ClinicalTrials.gov/show/NCT00707967",NA
"56602",56602,"NCT00770367","Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes","Completed","Has Results","Diabetes","Drug: Pioglitazone then Placebo|Drug: Placebo then Pioglitazone","Medical University of South Carolina|Takeda Global Research & Development Center, Inc.","Both","Adult|Senior","Phase IV",36,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Takeda 07-060|18379","October 9, 2008","01/10/2008",2010-06-01,"October 21, 2010","01/10/2010","",2009-12-01,"Asymmetric Dimethylarginine (ADMA) Level|NOx f2-isoprostanes","http://ClinicalTrials.gov/show/NCT00770367",NA
"56634",56634,"NCT00818467","UVB Light and Sunscreen","Completed","No Results Available","Vitamin D Status","Other: Tanning spray|Other: UVB","Creighton University|UV Foundation","Both","Adult","Phase IV",50,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Creighton 7","January 6, 2009","01/05/2008",2009-02-01,"November 27, 2009","01/11/2009","Sunscreen",2009-02-01,"To measure the response of 25(OH)D to 40 milliJoules of UV-B light in white Caucasians with melanoidins-sunscreen from 3% DHA in comparison to the response of control subjects who have not used 3% DHA.","http://ClinicalTrials.gov/show/NCT00818467",NA
"56636",56636,"NCT00819767","Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise","Completed","No Results Available","Hypertension","Drug: Aliskiren|Drug: Valsartan","Novartis","Both","Adult|Senior","Phase II",68,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CSPP100A2406","January 7, 2009","01/02/2009",NA,"June 2, 2010","01/06/2010","",2009-10-01,"Change from baseline in systolic blood pressure at peak exercise (85% of the maximal predicted heart rate)|Change in systolic blood pressure at peak exercise (85% of the maximal predicted heart rate) from baseline to end of active treatment|Change in systolic blood pressure during the treadmill exercise test assessed at each of the stages of the Bruce Protocol comparing: 1) study baseline to the end of active treatment; 2) study baseline and the end of active treatment.|Overall safety and tolerability of aliskiren 300 mg compared to valsartan 320 mg monotherapies","http://ClinicalTrials.gov/show/NCT00819767",NA
"56648",56648,"NCT00837967","Study to Investigate the Safety and Efficacy of High Dose of Symbicort SMART in Japanese Patients","Completed","No Results Available","Asthma","Drug: Symbicort Turbuhaler|Drug: Terbutaline Turbuhaler","AstraZeneca","Both","Child|Adult","Phase III",25,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D589LC00003","February 5, 2009","01/01/2009",2009-07-01,"September 9, 2009","01/09/2009","",2009-07-01,"Adverse events, Clinical laboratory tests, ECG, Vital signs (blood pressure, pulse rate, body temperature)","http://ClinicalTrials.gov/show/NCT00837967",NA
"56699",56699,"NCT00926367","Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications","Completed","No Results Available","Acne Vulgaris","Drug: topical antibiotic and benzoyl peroxide gel|Drug: benzoyl peroxide 2.5% and adapalene 0.1% gel","Stiefel, a GSK Company","Both","Adult","Phase IV",52,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","C0000-405","June 21, 2009","01/05/2009",2009-07-01,"April 21, 2010","01/04/2010","",2009-06-01,"To determine and compare the tolerance and irritation potential of a topical antibiotic and benzoyl peroxide gel to benzoyl peroxide and adapalene gel using visual assessments by an independent blinded grader|Outcome Measure: To assess skin moisture and hydration and to assess subject tolerability through a skin assessment questionnaire","http://ClinicalTrials.gov/show/NCT00926367",NA
"56749",56749,"NCT01000467","Pharmacokinetics Study for Probucol","Completed","No Results Available","Healthy","Drug: probucol|Drug: probucol|Drug: probucol","Korea Otsuka Pharmaceutical Co.,Ltd.","Male","Adult","Phase IV",30,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","009-KOB-0801i","October 18, 2009","01/02/2009",2009-09-01,"October 21, 2009","01/10/2009","",2009-08-01,"Plasma pharmacokinetic (PK) parameters: Auc, Cmax etc.","http://ClinicalTrials.gov/show/NCT01000467",NA
"56758",56758,"NCT01017367","Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)","Completed","No Results Available","Rheumatoid Arthritis","Drug: MDX-1100|Drug: Placebo","Bristol-Myers Squibb","Both","Adult|Senior","Phase II",70,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MDX1100-04|IM129-003","November 16, 2009","01/02/2008",2009-05-01,"April 22, 2010","01/04/2010","MDX1100-04",2009-01-01,"ACR 20 Response rate|Safety and tolerability will be monitored by physical exam, laboratory tests, electrocardiograms, chest x-ray and adverse events experienced and reported by the patient","http://ClinicalTrials.gov/show/NCT01017367",NA
"56769",56769,"NCT01032967","Surgery or Chemoradiation for Esophageal Cancer","Completed","No Results Available","Esophageal Cancers","Procedure: Esophagectomy|Radiation: Definitive chemoradiation","Chinese University of Hong Kong","Both","Adult|Senior","Phase III",40,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Surgery or CRT Ca Esophagus","December 15, 2009","01/07/2000",2009-06-01,"December 15, 2009","01/12/2009","",2009-06-01,"Overall survival and disease-free survival|Quality of life and function outcomes","http://ClinicalTrials.gov/show/NCT01032967",NA
"56811",56811,"NCT01107067","Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism","Completed","No Results Available","Hypogonadism","Drug: Sustanon","Gulhane School of Medicine","Male","Adult","Phase IV",32,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","aa001","April 19, 2010","01/06/2008",2009-12-01,"April 19, 2010","01/05/2008","",2009-12-01,"paraoxonase level after testosterone treatment","http://ClinicalTrials.gov/show/NCT01107067",NA
"56816",56816,"NCT01112267","Efficacy and Safety of Extended Release Tramadol HCl/Acetaminophen for the Treatment of Chronic Low-back Pain","Completed","No Results Available","Low Back Pain","Drug: Placebo|Drug: Tramadol HCl/acetaminophen Extended Release|Drug: Placebo|Drug: Tramadol HCl/acetaminophen Extended Release","Janssen Korea, Ltd., Korea","Both","Adult|Senior","Phase III",222,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CR016222|ULTER-KOR-3003","April 1, 2010","01/05/2009",2009-10-01,"August 5, 2010","01/08/2010","",2009-10-01,"Difference in pain intensity intensity as measured on the Visual Analog Scale (VAS)|Changes in Pain Relief Rating Score|Changes in Korean Short Form-36 score (Health-Related Quality of Life)|Changes in Korean version of ODI total score (Oswestry Disability Index)|Investigator's Global Impression of Change|Subject's Global Impression of Change","http://ClinicalTrials.gov/show/NCT01112267",NA
"56927",56927,"NCT00002868","Interferon-Alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: busulfan|Drug: cytarabine|Drug: etoposide|Drug: hydroxyurea|Drug: idarubicin|Procedure: peripheral blood stem cell transplantation","Medical Research Council|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Both","Child|Adult","Phase III",744,"Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065146|MRC-LEUK-CML-2000|ECOG-E7995|MRC-LEUK-CML-IV|MRC-LEUK-CML-IVa|EU-96029","November 1, 1999","01/01/1996",NA,"February 4, 2009","01/06/2005","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00002868",NA
"56968",56968,"NCT00031668","Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation","Completed","No Results Available","Lymphoma","Radiation: radiation therapy","NCIC Clinical Trials Group","Both","Adult|Senior","Phase III",NA,"Other","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","LY8|CAN-NCIC-LY8|CDR0000069214","March 8, 2002","01/01/2001",2009-02-01,"November 7, 2010","01/03/2010","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00031668",NA
"56982",56982,"NCT00048568","A Phase III Study of BMS-188667 in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","Completed","No Results Available","Rheumatoid Arthritis","Drug: BMS-188667|Drug: Methotrexate|Drug: Placebo|Drug: BMS-188667|Drug: Methotrexate","Bristol-Myers Squibb","Both","Adult|Senior","Phase III",656,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","IM101-102","November 2, 2002","01/12/2002",2009-10-01,"November 30, 2009","01/11/2009","",2009-10-01,"Compare the clinical efficacy of BMS-188667 used in combination with methotrexate versus methotrexate alone on: Symptomatic relief as measured by ACR20 following 6 months of treatment|Compare the clinical efficacy of BMS-188667 used in combination with methotrexate versus methotrexate alone on: Physical function as measured by the disability index of the HAQ at 12 months|Compare the clinical efficacy of BMS-188667 used in combination with methotrexate versus methotrexate alone on: Structural damage as assessed by erosion scores using a Genant-modified method at 12 months of treatment|The primary objective of long term extension is to assess the safety and long term tolerability of BMS-188667 in subjects who have completed the initial 12-month double-blind treatment period|Determine the effect of BMS-188667 in combination with methotrexate on structural damage as assessed by total and joint space narrowing score using a Genant-modified Sharp method at 12 months of treatment|Compare ACR 50 and ACR 70|Assessed ACR 20, ACR 50, and ACR 70|Determine the proportion of subjects receiving BMS-188667 in combination with methotrexate who achieve a major clinical response (continuous ACR 70)|Assess disease activity as measured by Disease Activity Score-28 (DAS-28)|Assess the safety of chronic use of BMS-188667 in combination with methotrexate|Assess the discontinuation rate in subjects receiving BMS-188667 in combination with methotrexate|Assess the incidence of new tender and swollen joints and 100% reduction in joint counts|Assess the immunogenicity of BMS-188667 in combination with methotrexate|Assess changes of surrogate markers (RF, CRP, ESR, IL2-r) in subjects receiving BMS-188667 in combination with methotrexate|Assess the changes of functional status as measured by the disability index and individual components of the HAQ in subjects receiving BMS-188667 in combination with methotrexate|Assess the change of subject's health-related quality of life, as measured by the SF-36 questionnaire in subjects receiving BMS-188667 in combination with methotrexate|Assess the pharmacokinetics of BMS-188667|Determine the effect of BMS-188667 in combination with methotrexate on structural damage as assessed by x-ray evaluation in subjects with RA after two years of treatment|Assess chx of functional status measured by disability index & individual components of HAQ in subjects receiving BMS-188667 in combination with methotrexate to determine if any improvement in HAQ associated with BMS-188667 treatment - long-term adm|Assess ACR 20, ACR 50, and ACR 70|Determine the proportion of subjects receiving BMS-188667 in combination with methotrexate who achieve a major clinical response (continuous ACR 70 for six months)|Assess disease activity as measured by Disease Activity Score-28 (DAS-28), at each quarterly visit|Assess the immunogenicity of BMS-188667 in combination with methotrexate|Assess changes of surrogate markers (RF, CRP, ESR, IL-6, MMP-3) in subjects receiving BMS-188667 in combination with methotrexate|Assess the change of subject's health-related quality of life, as measured by the SF-36 questionnaire in subjects receiving BMS-188667 in combination with methotrexate","http://ClinicalTrials.gov/show/NCT00048568",NA
"56983",56983,"NCT00052468","Carboplatin and Paclitaxel With or Without Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer","Drug: carboplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Procedure: adjuvant therapy|Procedure: conventional surgery","AGO Ovarian Cancer Study Group|Nordic Society for Gynaecologic Oncology|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","Female","Adult|Senior","Phase III",NA,"Other","Interventional","Allocation: Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment","CDR0000258429|AGO-OVAR-9|NORDIC-AGO-OVAR-9|GERCOR-AGO-OVAR-9|EU-20241","January 24, 2003","01/08/2002",NA,"October 9, 2010","01/10/2010","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT00052468",NA
"56988",56988,"NCT00051168","A Long-term Safety Study of Once-daily Travatan","Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Travatan","Alcon Research","Both","Adult|Senior","Phase III",502,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C-02-20","January 3, 2003","01/01/2006",NA,"April 9, 2010","01/04/2010","",2009-03-01,"Mean Intraocular Pressure","http://ClinicalTrials.gov/show/NCT00051168",NA
"57050",57050,"NCT00113568","Safety Study of XP12B in Women With Menorrhagia","Completed","Has Results","Menorrhagia|Heavy Menstrual Bleeding","Drug: Tranexamic acid tablets (XP12B)","Ferring Pharmaceuticals","Female","Adult","Phase III",784,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XP12B-MR-302","June 8, 2005","01/06/2005",2009-05-01,"June 9, 2010","01/06/2010","",2009-05-01,"Number of Subjects With at Least One Adverse Event During the Study|Number of Subjects With at Least One Possibly Treatment-Related Adverse Event During the Study|Number of Subjects With at Least One Probably Treatment-Related Adverse Event During the Study|Number of Subjects With at Least One Definitely Treatment-Related Adverse Event During the Study|Number of Subjects With at Least One Serious Adverse Event During the Study|Number of Subjects With at Least One Life-Threatening Adverse Event During the Study|Number of Subjects With Adverse Events That Led to Discontinuation From the Study|Number of Subjects With Any Thrombotic or Thromboembolic Adverse Event During the Study|Number of Subjects Who Died During the Study","http://ClinicalTrials.gov/show/NCT00113568",NA
"57117",57117,"NCT00238368","Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: busulfan|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: methylprednisolone|Drug: prednisone|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: positron emission tomography|Radiation: fludeoxyglucose F 18|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",55,"Other|NIH","Interventional","Primary Purpose: Diagnostic","CDR0000445618|P30CA006973|JHOC-J0348|JHOC-03082605","October 12, 2005","01/02/2004",NA,"March 16, 2010","01/03/2010","",2009-02-01,"2-year event free survival|Overall survival|Predictive value of early negative fludeoxyglucose F 18 positron emission tomography (FDG-PET)|Correlation of International Prognostic Index risk category with FDG-PET results and overall outcome","http://ClinicalTrials.gov/show/NCT00238368",NA
"57125",57125,"NCT00274768","Capecitabine in Treating Patients With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: capecitabine","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",45,"Other|NIH","Interventional","Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0425 CDR0000446286|P30CA006973|JHOC-J0425|JHOC-SKCCC-J0425|JHOC-IRB-04032502","January 10, 2006","01/04/2004",NA,"August 6, 2010","01/08/2010","",2009-12-01,"Response rate|Clinical benefit, time to treatment failure, safety and toxicity|Pharmacokinetic and pharmacodynamic effects|Patient adherence and compliance to oral treatment","http://ClinicalTrials.gov/show/NCT00274768",NA
"57137",57137,"NCT00300768","Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection","Completed","No Results Available","Onchocerciasis","Drug: moxidectin|Drug: ivermectin","Wyeth|World Health Organization","Both","Adult","Phase II",172,"Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3110A1-200|B1751004","March 7, 2006","01/09/2006",2009-11-01,"September 20, 2010","01/09/2010","",2009-11-01,"Incidence of clinical adverse events and clinically significant laboratory test results|Skin mf counts at day 8 and months 1, 2, 3, 6 and 12|Nodulectomy at 18 months|Pharmacokinetics (PKs) at days 1, 2, 4, 13, and 18 and months 1, 2, 3, 6 and 12","http://ClinicalTrials.gov/show/NCT00300768",NA
"57182",57182,"NCT00376168","A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease","Completed","No Results Available","Gaucher Disease","Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)|Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)","Protalix","Both","Adult|Senior","Phase III",32,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PB-06-001","September 12, 2006","01/08/2007",2009-10-01,"October 6, 2009","01/10/2009","",2009-09-01,"Change from baseline in spleen volume measured by MRI.|Change from baseline in: Liver volume, Hemoglobin measurement, Platelet count, Biomarkers (chitotriosidase and pulmonary and activation-regulated chemokine (PARC/ CCL18)","http://ClinicalTrials.gov/show/NCT00376168",NA
"57189",57189,"NCT00390468","Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases","Completed","No Results Available","Metastatic Cancer|Pain|Prostate Cancer","Drug: Tandutinib","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Male","Adult|Senior","Phase II",18,"Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0717|P30CA016672|MDA-2005-0717|NCI-7409|CDR0000504104","October 18, 2006","01/10/2006",2009-11-01,"September 23, 2010","01/09/2010","",2009-11-01,"Time to Progression","http://ClinicalTrials.gov/show/NCT00390468",NA
"57209",57209,"NCT00419068","Trial of Adjunctive Vitamin D in Tuberculosis Treatment","Completed","No Results Available","Tuberculosis, Pulmonary","Drug: Cholecalciferol|Drug: Migliol Placebo Oil","Barts & The London NHS Trust|British Lung Foundation","Both","Adult|Senior","Phase III",146,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","2005??Ê003562??Ê42|EudraCT no: 2005??Ê003562??Ê42|REC ref: 06/Q0605/83","January 5, 2007","01/01/2007",2009-09-01,"September 29, 2009","01/09/2009","",2009-09-01,"Time to sputum culture conversion|Rate of bacillary kill|2-month culture conversion rate|Time to sputum smear conversion|Weight change|Radiographic response","http://ClinicalTrials.gov/show/NCT00419068",NA
"57214",57214,"NCT00422968","Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease","Completed","No Results Available","Coronary Artery Disease","Device: Cypher, Cordis","CardioVascular Research Foundation, Korea","Both","Adult|Senior","Phase III",600,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0012","January 16, 2007","01/03/2005",2009-09-01,"August 17, 2010","01/06/2010","PRECOMBAT",2009-09-01,"Major cardiac and cerebrovascular event (MACCE): the composite of death, myocardial infarction, stroke, and ischemica-driven target vessel revascularization|All-cause mortality|Cardiac death|Myocardial infarction|Cerebrovascular accident|Target vessel revascularization (all and ischemia-driven)|Target lesion revascularization (all and ischemia-driven)|Stent thrombosis in the PCI group|Binary restenosis in both in-stent and in-segment|Graft patency and reocclusion rate|Late luminal loss in both in-stent and in-segment","http://ClinicalTrials.gov/show/NCT00422968",NA
"57218",57218,"NCT00415168","Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer","Completed","Has Results","Gastric Cancer","Drug: pemetrexed|Drug: cisplatin","Eli Lilly and Company","Both","Adult|Senior","Phase II",53,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10874|H3E-MW-S108","December 20, 2006","01/12/2006",2009-07-01,"August 11, 2010","01/08/2010","",2009-07-01,"Percentage of Participants With Objective Response (Objective Response Rate)|Duration of Response|Progression Free Survival (PFS)|Overall Survival|Number of Participants With Pharmacology Toxicity - Grade 3 or 4 Laboratory Toxicity Possibly Related to Study Therapy|Number of Participants With Pharmacology Toxicity - Grade 3 or 4 Non-Laboratory Toxicity Possibly Related to Study Therapy|Number of Participants Who Died During the Study","http://ClinicalTrials.gov/show/NCT00415168",NA
"57228",57228,"NCT00437268","A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumor","Drug: enzastaurin|Drug: irinotecan|Drug: cetuximab","Eli Lilly and Company","Both","Adult|Senior","Phase II",26,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10538|H6Q-MC-S018","February 16, 2007","01/03/2007",2009-05-01,"April 16, 2010","01/04/2010","",2009-05-01,"Progression-free survival (PFS) rate|Tumor response rate|Duration of response|Overall survival|Safety and adverse events","http://ClinicalTrials.gov/show/NCT00437268",NA
"57316",57316,"NCT00577668","A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)","Completed","No Results Available","Multiple Myeloma","Drug: Melphalan, Velcade, Thalidomide, Dexamethasone","University of Arkansas","Both","Adult|Senior","Phase II",75,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","2007-01","December 18, 2007","01/04/2007",2009-04-01,"October 20, 2009","01/04/2009","",2009-04-01,"To find out if using the VTD regimen, along with higher doses melphalan, in subjects who have relapsed or progressed after previous transplant(s), can be given safely to subjects who have failed previous transplant(s).","http://ClinicalTrials.gov/show/NCT00577668",NA
"57325",57325,"NCT00604968","Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059 AM2)(COMPLETED)","Completed","No Results Available","Breast Neoplasms","Drug: Caelyx (pegylated liposomal doxorubicin; SCH 200746)","Schering-Plough","Female","Adult|Senior","Phase IV",40,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P05059","January 21, 2008","01/02/2007",2009-10-01,"January 14, 2010","01/01/2010","",2009-10-01,"Time to treatment failure. Treatment failure is defined as progression of disease (according to the RECIST or WHO criteria) or unacceptable toxicity leading to discontinuation of treatment or death.|Safety, response rate, time to progression, survival, symptom control measured by patient assessment, quality of life, and analysis of treatment predictive factors in tumor tissue and angiogenetic factors, proteomics and snp-analysis in serum/plasma.","http://ClinicalTrials.gov/show/NCT00604968",NA
"57326",57326,"NCT00608868","SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients","Completed","No Results Available","Non Small Cell Lung Carcinoma","Drug: Gefitinib","AstraZeneca","Both","Adult|Senior","Phase IV",156,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D7913L00067","January 23, 2008","01/01/2007",2009-01-01,"February 26, 2009","01/02/2009","SELINE",2009-01-01,"To evaluate Objective Response Rate of gefitinib as a second-line therapy for NSCLC patients based on RECIST and check up ORR difference by EGFR mutation, gender, smoking history, and type of tumor|PFS (Progression-Free survivals), Assessment of symptom improvement and Quality of Life by FACT-L, Overall Survival","http://ClinicalTrials.gov/show/NCT00608868",NA
"57338",57338,"NCT00621868","A Phase 2 Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus","Completed","No Results Available","Diabetes Mellitus","Drug: ASP1941|Drug: Placebo","Astellas Pharma Inc","Both","Adult|Senior","Phase II",361,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1941-CL-0103","February 13, 2008","01/02/2008",2009-03-01,"April 7, 2009","01/04/2009","",2009-03-01,"HbA1c level|Blood glucose level|Safety","http://ClinicalTrials.gov/show/NCT00621868",NA
"57381",57381,"NCT00686868","Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients","Completed","No Results Available","Rheumatoid Arthritis","Drug: ofatumumab|Other: placebo","GlaxoSmithKline","Both","Adult|Senior","Phase II",35,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","OFA110867","May 28, 2008","01/06/2008",2009-11-01,"March 31, 2010","01/03/2010","",2009-11-01,"Safety and tolerability as described by the incidence and severity of adverse events [AEs], clinical laboratory parameters and vital signs.|Requirement for the use of pre-medication, including the timing, type and dose required.|Pharmacodynamics (B-cell depletion and re-population) as measured by CD-19 peripheral blood B- lymphocyte count via routine fluorescent activated cell sorting (FACS) analysis.|PK/PD parameters including estimation of time to re-population of CD-19 peripheral blood B-cells to above LLQ (and/or <95% depletion) following single subcutaneous dose of Ofatumumab.|Immunogenicity as measured by the incidence, titre and type of human anti-human antibody (HAHA) immune response.|Other pharmacodynamic/biomarkers of disease activity and immune status may include high sensitivity C-reactive protein (hsCRP), Erythrocyte Sedimentation Rate (ESR), B-Lymphocyte Stimulator (BLyS/BAFF), B-Lymphocyte Chemokine (BLC), IL-6,|Immunoglobulins (IgA, IgG, IgM), Complement (CH50, C3, C4), IgM Rheumatoid Factor (IgM-RF), IgA-RF and IgG-RF, anti-cyclic citrullinated peptide antibody (aCCP),|serum amyloid A (SAA), CD-3+, CD-4+ and CD-8+ lymphocytes or other biomarkers, as data permit.|Pharmacodynamics (B-cell depletion and re-population) as measured by CD-19 peripheral blood B- lymphocyte count via routine FACS analysis.Other Secondary Endpoints","http://ClinicalTrials.gov/show/NCT00686868",NA
"57384",57384,"NCT00702468","Evaluate the Maintenance of Effect After Long-term Treatment With Sativex?ó in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis","Completed","No Results Available","Spasticity|Multiple Sclerosis","Drug: Sativex|Drug: Placebo","GW Pharmaceuticals Ltd.","Both","Adult|Senior","Phase III",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","GWSP0702","June 19, 2008","01/11/2007",2009-01-01,"March 1, 2010","01/03/2010","",2009-01-01,"The time to treatment failure in the randomised-withdrawal period.|Average daily spasticity severity as measured on a spasticity severity 0-10 Numerical rating scale (NRS).|Modified Ashworth Scale.|Motricity Index|Timed 10-metre walk.|Daily sleep disruption NRS|Carer, Physician and Subject global impressions of change.|Carer global impressions of change for ease of transfer.|Adverse events|Clinical laboratory tests|Vital signs|Oral Examination","http://ClinicalTrials.gov/show/NCT00702468",NA
"57396",57396,"NCT00718068","Safety of Continuous Potassium Chloride Infusion in Critical Care","Completed","No Results Available","Hypokalemia|Arrhythmias, Cardiac","Drug: Sterile Potassium Chloride Concentrate|Drug: Sterile Potassium Chloride Concentrate","The Queen Elizabeth Hospital","Both","Adult|Senior","Phase IV",160,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2007185","July 16, 2008","01/10/2008",2009-10-01,"July 26, 2010","01/11/2009","ASPIC",2009-09-01,"Adherence to a potassium level 4.0 - 4.5mmol/L|Total quantity of potassium administered|Incidence of potassium level < 3.0mmol/L and > 5.5mmol/L|Incidence of arrhythmia|Number of arterial blood gases taken","http://ClinicalTrials.gov/show/NCT00718068",NA
"57430",57430,"NCT00760968","Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis","Completed","No Results Available","Arthritis, Rheumatoid","Drug: TAK-783 and methotrexate|Drug: Methotrexate","Takeda Global Research & Development Centre (Europe) Ltd.","Both","Adult|Senior","Phase II",224,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-783-EC201|2006-003054-26|U1111-1114-0266","September 24, 2008","01/08/2007",2009-02-01,"June 9, 2010","01/06/2010","",2009-02-01,"Percent of subjects with greater than or equal to 20% improvement in Arthritis Signs and Symptoms according to the American College of Rheumatology|Change from Baseline in Treatment-emergent adverse events.|Change from Baseline in Vital signs.|Change from Baseline in Electrocardiogram findings.|Change from Baseline in Spirometry tests.|Change from Baseline in Hematology Laboratory tests.|Change from Baseline in Chemistry Laboratory tests.|Change from Baseline in Urinalysis Laboratory tests.|Percent of subjects with greater than or equal to 50% improvement in Arthritis Signs and Symptoms according to the American College of Rheumatology|Percent of subjects with greater than or equal to 70% improvement in Arthritis Signs and Symptoms according to the American College of Rheumatology|Change from Baseline in individual Arthritis Signs and Symptoms according to the American College of Rheumatology.|Percent change from Baseline in the disability index of the Heath Assessment Questionnaire, based on the American College of Rheumatology criteria.|Percent Change from Baseline in 36-Item Short-Form Quality of Life Assessments|Change from Baseline in Swollen Joint Counts.|Change from Baseline in Tender Joint Counts.|Change from Baseline in Patient's Assessment of Pain.|Change from Baseline in Patient's Global Assessment of Disease Activity.|Change from Baseline in Physician's Global Assessment of Disease Activity.|Change from Baseline in Health Assessment Questionnaire.|Change from Baseline in Erythrocyte Sedimentation rate|Change from Baseline in C-reactive Protein","http://ClinicalTrials.gov/show/NCT00760968",NA
"57432",57432,"NCT00777868","A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis","Completed","No Results Available","Onychomycosis","Drug: Low Strength IDP-108|Drug: High Strength IDP-108|Drug: High Strength IDP-108 under occlusion|Drug: Vehicle","Dow Pharmaceutical Sciences","Both","Adult","Phase II",135,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","DPSI-IDP-108-P2-01","October 20, 2008","01/10/2007",2009-04-01,"May 22, 2009","01/05/2009","",2009-04-01,"Change from baseline in area of infected nail|Change from baseline in mycological results","http://ClinicalTrials.gov/show/NCT00777868",NA
"57439",57439,"NCT00784368","A Pharmacokinetics Study of JK1211, Itraconazole Oral Solution, in Patients With Deep Mycosis and Those With Febrile Neutropenia Due to a Suspected Fungal Infection.","Completed","No Results Available","Mycoses|Candidiasis|Aspergillosis|Cryptococcosis|Blastomycosis|Histoplasmosis|Neutropenia)","Drug: itraconazole (IV)|Drug: JK1211","Janssen Pharmaceutical K.K.","Both","Adult|Senior","Phase III",63,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR014299|JK1211-JPN-07","October 23, 2008","01/01/2008",2009-05-01,"April 26, 2010","01/04/2010","",2009-04-01,"Pharmacokinetic parameters through 12 weeks|Effectiveness assessments through 12 weeks including improvement of clinical symptoms, mycological efficacy, serologic efficacy against fungi and improvement of endoscopy/diagnostic imaging; Safety assessments throughout the study.","http://ClinicalTrials.gov/show/NCT00784368",NA
"57453",57453,"NCT00809068","High-density Lipoprotein (HDL) Cholesterol in Women Taking Tibolone","Completed","No Results Available","HDL Cholesterol","Drug: fenofibrate and tibolone|Drug: tibolone","Keogh Institute for Medical Research","Female","Adult|Senior","Phase IV",20,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","ID: 2005-001|SCGH Research Grant","June 10, 2008","01/08/2005",2009-10-01,"January 31, 2010","01/01/2010","TibFen",2009-08-01,"HDL subpopulation analysis|Increase in HDL subpopulations","http://ClinicalTrials.gov/show/NCT00809068",NA
"57468",57468,"NCT00832468","The Complementary Effect of Ear Acupressure on Older Patients With Chronic Insomnia","Completed","No Results Available","Insomnia","Other: ear acupressure|Other: sham ear acupressure","National Yang Ming University","Both","Adult|Senior","Phase II",72,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","97032R","January 29, 2009","01/12/2008",2009-12-01,"December 7, 2009","01/12/2009","",2009-11-01,"polysomnography|Pittsburgh sleep quality index, Heart rate variability, SF-36","http://ClinicalTrials.gov/show/NCT00832468",NA
"57474",57474,"NCT00840268","A Study of Hydroxypropyl Guar Galactomannan 0.25% (HPGG) Versus Vehicle in Dry Eye Patients","Completed","No Results Available","Dry Eye","Drug: HPGG 0.25% or HPGG Vehicle","Alcon Research","Both","Adult|Senior","Phase II",427,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","C-08-34","February 6, 2009","01/02/2009",NA,"September 8, 2009","01/09/2009","",2009-08-01,"Mean change from baseline in sodium fluorescein corneal staining score|Mean change from baseline in Dry Eye Symptom Questionnaire score","http://ClinicalTrials.gov/show/NCT00840268",NA
"57476",57476,"NCT00828568","A Therapeutic Equivalence Study of Two Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis","Completed","Has Results","Actinic Keratosis","Drug: Imiquimod 5% manufactured by Taro|Drug: Aldara - Imiquimod 5%|Drug: Imiquimod Vehicle manufactured by Taro","Taro Pharmaceuticals USA","Both","Adult|Senior","Phase III",425,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MIQ-0403","January 22, 2009","01/06/2008",2009-05-01,"November 30, 2009","01/11/2009","",2009-03-01,"Number of Participants With 100% Clearance of Actinic Keratosis Lesions: Comparison of Taro Imiquimod 5% and Aldara-Imiquimod 5%|Number of Participants in Intention-to-treat (ITT)Population With 100% Clearance of Actinic Keratosis (AK) Lesions Identified at Baseline|Patients Reporting at Least One Adverse Event","http://ClinicalTrials.gov/show/NCT00828568",NA
"57477",57477,"NCT00846768","BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: BI 1744 CL","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",47,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment","1222.26|EudtaCT No: 2008-006334-10","February 18, 2009","01/02/2009",NA,"August 4, 2009","01/08/2009","",2009-07-01,"The primary efficacy variable will be (FEV1). The coprimary efficacy endpoints are FEV1 AUC 0 to 12 and FEV1 AUC 12 to 24 after 3 weeks of treatment.|Efficacy endpoints Efficacy after 3 weeks of treatment: FEV1 and FVC AUC 0 to 24, peak FEV1and FVC and trough FEV1 and FVC;individual FEV1 and FVC measurements at each time point over 24 hours. Safety: AE, vital signs, lab, ECG pK plasma and urine","http://ClinicalTrials.gov/show/NCT00846768",NA
"57503",57503,"NCT00883168","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Placebo|Drug: azelastine hydrochloride|Drug: fluticasone propionate|Drug: azelastine hydrochloride/fluticasone propionate formulated product","Meda Pharmaceuticals","Both","Child|Adult|Senior","Phase III",1800,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP4006","April 16, 2009","01/04/2009",2009-07-01,"November 25, 2009","01/11/2009","",2009-07-01,"Change from baseline in 12 hour Reflective Total Nasal Symptom Score|Change from baseline in 12 hour Instantaneous Total Nasal Symptom Score|Onset of action|Change from baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)|Nasal Examinations","http://ClinicalTrials.gov/show/NCT00883168",NA
"57506",57506,"NCT00890968","Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis","Completed","No Results Available","Hand Dermatoses","Drug: Triamcinolone Acetonide (TAC) DuraPeel|Drug: Placebo DuraPeel","ZARS Pharma Inc.","Both","Adult|Senior","Phase II",56,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TAC-202","April 28, 2009","01/04/2009",2009-08-01,"November 16, 2009","01/11/2009","TAC-202",2009-06-01,"Response as assessed by Investigator Global Assessment (IGA)|Subject's Global Impression of Change (SGIC)|Individual Primary Parameters of Hand Dermatitis|Signs or symptoms of hand dermatitis|Subject's self-assessment of overall hand disease|Study medication assessment","http://ClinicalTrials.gov/show/NCT00890968",NA
"57515",57515,"NCT00881868","Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp","Completed","Has Results","Scalp Psoriasis","Drug: clobetasol propionate spray 0.05%|Drug: Vehicle spray","Galderma Laboratories, L.P.","Both","Adult|Senior","Phase IV",81,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","US10118","April 13, 2009","01/04/2009",2009-12-01,"January 7, 2011","01/01/2011","",2009-12-01,"Number of Participants Who Were a Success or Failure Based on the Global Severity Score (GSS) of Scalp Psoriasis From Baseline to End of Treatment (Week 4 or Week 2 if Clear)|Number of Participants in Each Category of the Scalp Psoriasis Individual Sign Scores (Scaling, Erythema and Plaque Elevation) at Baseline and Week 4|Number of Participants in Each Category of the Extent of Scalp Involvement Index at Baseline and Week 4|Number of Participants in Each Category of Pruritus at Baseline and Week 4","http://ClinicalTrials.gov/show/NCT00881868",NA
"57523",57523,"NCT00918268","Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects","Completed","No Results Available","Influenza Disease","Biological: Influenza vaccine","Novartis|Novartis Vaccines","Both","Adult|Senior","Phase II",130,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","V71_10S|2009??Ê010598??Ê19","June 9, 2009","01/06/2009",2009-07-01,"January 5, 2010","01/01/2010","",2009-07-01,"Evaluation of the antibody response to each influenza vaccine antigen, as measured by Single Radial Hemolysis (SRH) at 21 days post-immunization in non-elderly adult and elderly subjects|Evaluation of safety of a single intramuscular injection of influenza vaccine in non elderly adult and elderly subjects","http://ClinicalTrials.gov/show/NCT00918268",NA
"57540",57540,"NCT00948168","Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: exenatide (Byetta)","Cliniques universitaires Saint-Luc- Universit?¢ Catholique de Louvain","Both","Adult|Senior","Phase IV",34,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCL-DIAB-01","July 27, 2009","01/07/2008",2009-07-01,"July 30, 2009","01/07/2009","",2009-07-01,"Improvement in HbA1c|Non-invasive modeling of glucose homeostasis determinants, including insulin sensitivity","http://ClinicalTrials.gov/show/NCT00948168",NA
"57541",57541,"NCT00950768","Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients","Completed","No Results Available","Multiple Myeloma|Diagnosis","Procedure: Autologous transplantation","Azienda Ospedaliera San Giovanni Battista","Both","Adult","Phase III",298,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GISMM2001","July 31, 2009","01/02/2002",2009-06-01,"July 31, 2009","01/07/2009","",2009-05-01,"Primary endpoints of the study were Overall Survival defined as the time from diagnosis until death from any cause; Progression Free Survival defined as the time from diagnosis until death from any cause or date of first relapse or progression.|Secondary endpoint was time to progression (TTP) defined as the time from the date of diagnosis to relapse or death from progression.","http://ClinicalTrials.gov/show/NCT00950768",NA
"57559",57559,"NCT00976768","Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin","Completed","No Results Available","Advanced Gastric Cancer","Drug: oxaliplatin, 5-fluorouracil","Asan Medical Center","Both","Adult|Senior","Phase II",44,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-0402","September 11, 2009","01/10/2004",2009-12-01,"February 11, 2010","01/02/2010","",2009-12-01,"Progression-free survival|Overall survival|Toxicity profile (according to National Cancer Institute Common Terminology Criteria for Adverse Event [NCI CTC AE] version 3.0)|Response rate","http://ClinicalTrials.gov/show/NCT00976768",NA
"57580",57580,"NCT01004068","Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS)","Completed","No Results Available","Polycystic Ovary Syndrome|Anovulation","Other: SET-diet plus clomiphene|Drug: Clomiphene citrate|Behavioral: Structured exercise program plus hypocaloric diet","University Magna Graecia","Female","Adult","Phase IV",96,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Jun-09","July 15, 2009","01/02/2008",2009-10-01,"November 2, 2010","01/11/2009","",2009-10-01,"Ovulation rate|Clinical data|Metabolic data","http://ClinicalTrials.gov/show/NCT01004068",NA
"57597",57597,"NCT01033968","Pain Perception at Laser Treatment","Completed","No Results Available","Laser Therapy, Low-Level","Procedure: retina photocoagulation","University of Campinas, Brazil","Both","Adult|Senior","Phase IV",30,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","Lira-001","December 16, 2009","01/01/2009",2010-05-01,"May 19, 2010","01/05/2010","",2009-12-01,"Although the treatment of peripheral retinal degenerations with infrared laser to be well tolerated by the majority of the patients, it is more painful than with green wavelength.","http://ClinicalTrials.gov/show/NCT01033968",NA
"57598",57598,"NCT01032668","The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance","Completed","No Results Available","Coronary Artery Disease","Drug: Clopidogrel","Bursa Postgraduate Hospital","Both","Adult|Senior","Phase III",192,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BY??EAH2","December 14, 2009","01/09/2008",2009-12-01,"December 14, 2009","01/08/2008","EFFICIENT",2009-07-01,"Death, MI, TVR revascularization, stroke (MACCE) within 30 days and 6 moths|Major or minor bleeding according to TIMI criteria 30 days and 6 months To evaluate the clinical effect of VerifyNow which use as a clopidogrel resistance kit 30 days and 6 months.","http://ClinicalTrials.gov/show/NCT01032668",NA
"57608",57608,"NCT01046968","Lepticore in Metabolic Syndrome and Weight Loss","Completed","No Results Available","Obesity|Hyperlipidemia|Hyperglycemia","Dietary Supplement: Lepticore","University of Yaounde 1|Cameroon Nutritional Science Society","Both","Adult","Phase I|Phase II",92,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Basic Science","LNNB232","January 11, 2010","01/08/2009",2009-11-01,"January 11, 2010","01/07/2009","",2009-11-01,"Improvement of symptoms of metabolic syndrome|Change in weight","http://ClinicalTrials.gov/show/NCT01046968",NA
"57818",57818,"NCT00066469","Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation","Completed","No Results Available","Lymphoproliferative Disorder","Biological: rituximab|Drug: cyclophosphamide|Drug: methylprednisolone|Drug: prednisone","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",60,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000316241|COG-ANHL0221","August 6, 2003","01/04/2004",NA,"November 20, 2010","01/11/2010","",2009-10-01,"Event-free survival at 2 years","http://ClinicalTrials.gov/show/NCT00066469",NA
"57845",57845,"NCT00113269","Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients","Completed","No Results Available","Kidney Transplantation","Drug: basiliximab|Drug: rabbit anti-thymocyte globulin|Drug: tacrolimus|Drug: alemtuzumab","Astellas Pharma Inc","Both","Adult|Senior","Phase IV",502,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20-04-003","June 7, 2005","01/05/2005",2009-03-01,"April 17, 2009","01/04/2009","INTAC",2009-03-01,"The incidence of biopsy-confirmed acute rejection|Patient and graft survival rates","http://ClinicalTrials.gov/show/NCT00113269",NA
"57878",57878,"NCT00160069","Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-Small-Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non Small Cell Lung","Drug: Sagopilone (BAY86-5302, ZK 219477)|Drug: Sagopilone (BAY86-5302, ZK 219477)|Drug: Sagopilone (BAY86-5302, ZK 219477)","Bayer","Both","Adult|Senior","Phase II",127,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","91374|EudraCT: 2005-000586-19|307971","September 8, 2005","01/08/2005",2009-04-01,"May 6, 2009","01/05/2009","",2009-03-01,"The primary efficacy variable is defined as Proportion of patients with either CR or PR as 'best overall response'. Tumor assessment is performed according to RECIST criteria.|Secondary objectives : investigate the safety and tolerability of ZK 219477","http://ClinicalTrials.gov/show/NCT00160069",NA
"57892",57892,"NCT00183469","Maintenance Treatment of Bipolar Depression","Completed","No Results Available","Bipolar Disorder|Depression","Drug: Lamotrigine (LAM)|Drug: Divalproex (DIV)|Drug: Placebo","National Institute of Mental Health (NIMH)","Both","Adult|Senior","Phase IV",170,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P20 MH68662|DSIR 83-ATSO","September 13, 2005","01/12/2004",2009-04-01,"June 30, 2009","01/06/2009","",2009-02-01,"Rates of response to treatment regimen","http://ClinicalTrials.gov/show/NCT00183469",NA
"57984",57984,"NCT00326469","Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours","Completed","No Results Available","Neuroendocrine Tumours","Drug: lanreotide (Autogel formulation)","Ipsen","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A-92-52030-166","May 15, 2006","01/05/2006",2009-11-01,"November 30, 2010","01/11/2010","",2009-11-01,"Time to disease progression (appearance of 1+ new lesions or increase >or= to 20% of sum of the longest diameters of target lesions compared to the lower sum of maximum diameters recorded since the start of the study).|To evaluate efficacy related to tumour's partial or total response, biological disease markers response, symptomatic control, effect of treatment on patient's quality of life|Identify tumour growth stabilization predictive factors under treatment with lanreotide Autogel|Tolerance","http://ClinicalTrials.gov/show/NCT00326469",NA
"57988",57988,"NCT00330369","DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension","Completed","No Results Available","Hypertension","Drug: darusentan (LU 135252) and placebo","Gilead Sciences","Both","Adult|Senior","Phase III",352,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DAR-311","May 24, 2006","01/06/2006",2009-01-01,"October 2, 2009","01/10/2009","",2009-01-01,"The co-primary efficacy measures are change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry|Secondary efficacy measurements are (i) change from baseline in mean 24-hour systolic and diastolic ambulatory blood pressure, (ii) percent of subjects to reach systolic blood pressure goal, and (iii) change from baseline in eGFR","http://ClinicalTrials.gov/show/NCT00330369",NA
"58050",58050,"NCT00431769","Bortezomib Retreatment in Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Bortezomib","Janssen-Cilag International NV","Both","Adult|Senior","Phase II",130,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR010519","February 2, 2007","01/05/2006",2010-01-01,"February 25, 2010","01/02/2010","",2009-02-01,"Determine best response to bortezomib re-treatment. Response will be evaluated according to the European Bone Marrow Transplant group's criteria at least every two treatment cycles (Cycle 1, Cycle 3, Cycle 5, Cycle 7, End of Treatment).|Incidence of Serious Adverse Events, Grade 3 and 4 AEs,and all grades of neuropathy since signature of informed consent to at least 30 days last dose; best confirmed M-protein response (at least every 2 cycles); Duration Of Response; Time To Progression","http://ClinicalTrials.gov/show/NCT00431769",NA
"58101",58101,"NCT00485069","REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study","Completed","Has Results","Parkinson Disease|Parkinson's Disease","Drug: ROP|Drug: ROP+L-Dopa","GlaxoSmithKline","Both","Adult|Senior","Phase IV",123,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","108862","June 11, 2007","01/06/2007",2009-12-01,"November 18, 2010","01/11/2010","",2009-12-01,"Mean Change From Baseline in the Japanese Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score (in \On\"" State for the ROP+L-Dopa Group) at Week 52 and Final Assessment Point (FAP)|Mean Change From Baseline in the Japanese UPDRS Part I Total Score at Week 52 and FAP|Mean Change From Baseline in the Japanese UPDRS Part II Total Score at Week 52 and FAP by \""On\""/\""Off\"" State in the ROP+L-Dopa Group|Mean Change From Baseline in the Japanese UPDRS Part II Total Score at Week 52 and FAP in the ROP Group|Mean Change From Baseline in the Japanese UPDRS Part IV Total Score at Week 52 and FAP|Japanese UPDRS Part I Mean Total Score at Baseline","http://ClinicalTrials.gov/show/NCT00485069",NA
"58105",58105,"NCT00522769","Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents","Completed","No Results Available","Bulimia Nervosa","Behavioral: Cognitive Behavioral Therapy","Kaiser Permanente","Female","Child|Adult","Phase I|Phase II",26,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","5 R34 MH073796","August 29, 2007","01/09/2005",2009-05-01,"February 12, 2010","01/02/2010","claire",2009-05-01,"Recovery from ED (abstinence of all binging and purging during past 28 indices of binge eating, purging, and scores on the EDE-Q5 scale).|: changes in other psychiatric symptomatology and|associated adaptive functioning and eating concerns","http://ClinicalTrials.gov/show/NCT00522769",NA
"58119",58119,"NCT00544869","A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)","Completed","No Results Available","Cardiac Edema","Drug: OPC-41061 ???Tolvaptan)","Otsuka Pharmaceutical Co., Ltd.","Both","Adult|Senior","Phase III",50,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","156-06-006","October 15, 2007","01/10/2007",2009-02-01,"December 11, 2009","01/12/2009","",2009-02-01,"Change value of body weight","http://ClinicalTrials.gov/show/NCT00544869",NA
"58181",58181,"NCT00631969","Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction","Completed","No Results Available","Erectile Dysfunction","Drug: Vardenafil (BAY 38-9456)|Drug: Placebo","Bayer|GlaxoSmithKline|Schering-Plough","Male","Adult|Senior","Phase III",362,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","12093|Eudra CT- 2008-000536-40","February 29, 2008","01/04/2008",2009-01-01,"February 8, 2010","01/02/2010","",2009-01-01,"International Index of Erectile Function IIEF - EF Domain score at visit 4 (week 12) or LOCF (Last Observation Carried Forward)|Sexual Encounter Profile, Question 2 (SEP 2) (success rates of penetration) at Visit 4 (Week 12) overall|SEP 3 (maintenance of erection) at Visit 4 (Week 12) overall|Percentage of subjects achieving \back to normal\"" erectile function (IIEF-EF > / = 26) at visit 4 (week 12) or LOCF;|All diary questions other than SEP 2 and 3 concerning erectile function administered over the entire treatment period;|Number of sexual attempts under medication till first successful attempt (SEP 3)|Treatment Satisfaction Scale (TSS) to be administered at the randomization visit and the final visit (or at Premature Discontinuation).|A Global Assessment Question (GAQ) concerning the overall effect on erectile function to be administered at the final visit only.|Safety laboratory examinations","http://ClinicalTrials.gov/show/NCT00631969",NA
"58195",58195,"NCT00663169","Efficacy and Safety of a Single Dose of ACZ885 in Hospitalized Patients With Acute Gout","Completed","No Results Available","Arthritis, Gouty","Biological: ACZ885|Biological: ACZ885","Novartis","Both","Adult|Senior","Phase II",6,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CACZ885A2212","April 18, 2008","01/04/2008",NA,"September 21, 2010","01/09/2010","",2009-10-01,"Self-assessed response to treatment at 72 hours post-dose.|non-inferiority of a single dose of ACZ885 compared to the active comparator during treatment period|safety, tolerability and immunogenicity following administration of ACZ885 to patients with acute gout during treatment period|time to walk independently and time to recurrence of the symptoms of acute gout (if applicable) during treatment period|change in C-reactive protein (CRP) and serum amyloid A protein (SAA) from baseline to last visit|pharmacokinetics (PK) of ACZ885 during treatment period|change in pain following ACZ885 administration via a 0-100 mm Visual Analog Scale during treatment period","http://ClinicalTrials.gov/show/NCT00663169",NA
"58211",58211,"NCT00680069","H5N1 (Clade 2) Vaccination of Adults and Elderly","Completed","No Results Available","Influenza","Biological: Inactivated Influenza A/H5N1/Indonesia/05/05 (clade 2)","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult|Senior","Phase I|Phase II",517,"NIH","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","07-0022|N01AI80008C","May 15, 2008","01/11/2008",2009-11-01,"January 13, 2011","01/11/2009","",2009-05-01,"Immune responses approximately 28 days after one dose of an H5N1 clade 2 vaccine.|Immunologic outcomes include antibodies generated against strains other than A/Indonesia/05/05.|Safety outcomes include frequencies and severities of adverse events (AEs) in the high- and low-dose groups in aggregate, and in other strata previously identified.","http://ClinicalTrials.gov/show/NCT00680069",NA
"58213",58213,"NCT00695669","A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64","Completed","No Results Available","Influenza Disease","Biological: GSK influenza virus H5N1 vaccine 1557484A","GlaxoSmithKline","Both","Adult","Phase II",312,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","111626","June 10, 2008","01/06/2008",2009-01-01,"September 28, 2009","01/09/2009","",2009-01-01,"Antibody response after 2 vaccine doses, assessed by: Seroconversion rates (SCR), Seroprotection rates (SPR)|Antibody response, assessed by: SCR, SPR, GMTs|Antibody response, assessed by: SCR, SPR, GMTs|Solicited AEs, unsolicited AEs, SAEs, and medically-attended events.","http://ClinicalTrials.gov/show/NCT00695669",NA
"58226",58226,"NCT00717769","A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Drug: SUN13834|Drug: Placebo","Asubio Pharmaceuticals, Inc.","Both","Adult","Phase II",270,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASBI 404","July 16, 2008","01/07/2008",2009-04-01,"May 21, 2009","01/05/2009","",2009-04-01,"Eczema Area and Severity Index (EASI) Score measured throughout the study|Investigator's Global Assessment measured throughout the study|Pruritis score measured throughout the study|Insomnia evaluation measured throughout the study|Safety and tolerability data as measured by adverse events, electrocardiograms, serum biomarkers, clinical laboratory tests, and vital signs","http://ClinicalTrials.gov/show/NCT00717769",NA
"58230",58230,"NCT00725569","Homeopathy for Post-operative (C. Section) Recovery","Completed","No Results Available","Cesarean Section","Drug: Bellis perennis and Staphysagria (C6)|Drug: Bellis perennis and Staphysagria (C30)|Drug: Placebo","Shaare Zedek Medical Center","Female","Adult|Senior","Phase II|Phase III",90,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","POR2008","July 29, 2008","01/08/2008",2009-04-01,"October 18, 2009","01/10/2008","",2009-04-01,"pain, to be evaluated using a numerical rating score (NRS) on a 100mm scale (0= no pain whatsoever, 100 = unbearable pain).|Analgesic Use|Duration of Hospital Stay|Time from Surgery to First Bowel Movement|Blood Loss|Post-operative Complications the following complications will be noted: Nausea, vomiting, abdominal distension, fever, urinary tract infection, thrombophlebitis, wound infection, wound hematoma, ileus, vaginal bleeding.|Quality of Life Assessment|Adverse Effects of Treatment","http://ClinicalTrials.gov/show/NCT00725569",NA
"58234",58234,"NCT00729469","Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity","Completed","No Results Available","Atrophy|Vaginal Diseases","Drug: Ospemifene|Drug: Placebo","QuatRx Pharmaceuticals Company","Female","Adult|Senior","Phase III",750,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","15-50821","August 4, 2008","01/07/2008",2009-08-01,"February 2, 2010","01/02/2010","",2009-08-01,"Change from baseline to week 12 in percentage of parabasal cells in the maturation index of the vaginal smear|Change from baseline to week 12 in percentage of superficial cells in the maturation index of the vaginal smear|Change from baseline to week 12 in vaginal pH.|Change from baseline to week 12 in severity of the most bothersome symptom of vaginal dryness and vaginal pain associated with sexual activity.|Change from baseline in percentage of parabasal cells in the maturation index|Change from baseline in percentage of superficial cells in the maturation index|Change from baseline in vaginal pH|Change from baseline in severity of most bothersome symptom of vaginal dryness and vaginal pain associated with sexual activity","http://ClinicalTrials.gov/show/NCT00729469",NA
"58268",58268,"NCT00797069","Comparison of Nutritional Products for People With Type 2 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type 2","Other: standard nutritional product (medical food)|Other: nutritional product for diabetes (medical food)|Other: diabetes specific experimental nutritional product (medical food)","Abbott Nutrition","Both","Adult|Senior","Phase III",58,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BK20","November 23, 2008","01/11/2008",2009-07-01,"July 29, 2010","01/03/2010","",2009-02-01,"To compare the postprandial glycemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.|To compare the postprandial insulinemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.","http://ClinicalTrials.gov/show/NCT00797069",NA
"58270",58270,"NCT00798369","Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients","Completed","No Results Available","Acute Gout","Drug: ACZ885|Drug: ACZ885|Drug: ACZ885|Drug: ACZ885|Drug: ACZ885|Drug: Triamcinolone acetonide","Novartis","Both","Adult|Senior","Phase II",200,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CACZ885H2255|EudraCT 2008-004666-61","November 25, 2008","01/11/2008",NA,"September 23, 2009","01/09/2009","",2009-08-01,"The dose of ACZ885 for treatment of acute flares in gout patients that leads to the same efficacy as triamcinolone acetonide with respect to pain intensity on a 0-100 mm VAS|The change in pain intensity in the target joint following ACZ885 administration compared to triamcinolone acetonide on Visual Analog Scale and via a 5-point Likert scale|The efficacy of ACZ885 as compare to triamcinolone acetonide with regards to the patient`s global assessment of response to treatment|The efficacy of ACZ885 as compare to triamcinolone acetonide with regards to the time to 50% reduction of baseline pain intensity in the target joint|The efficacy of ACZ885 as compare to triamcinolone acetonide with regards to the high sensitivity C-reactive protein and serum amyloid protein levels|The efficacy of ACZ885 as compare to triamcinolone acetonide with regards to the amount of rescue medication taken","http://ClinicalTrials.gov/show/NCT00798369",NA
"58273",58273,"NCT00795769","Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","Completed","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With T(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With T(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|De Novo Myelodysplastic Syndromes|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Poor Prognosis Metastatic Gestational Trophoblastic Tumor|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Neuroblastoma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage II Ovarian Epithelial Cancer|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Ovarian Epithelial Cancer|Stage III Small Lymphocytic Lymphoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Breast Cancer|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Ovarian Epithelial Cancer|Stage IV Small Lymphocytic Lymphoma","Drug: ondansetron|Other: survey administration|Procedure: management of therapy complications","Fred Hutchinson Cancer Research Center","Both","Adult|Senior","Phase II",50,"Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2247.00|NCI-2010-00325","November 20, 2008","01/08/2008",NA,"August 26, 2010","01/08/2010","",2009-09-01,"Reduction in rates of nausea or vomiting after ondansetron (compared to historical rates)","http://ClinicalTrials.gov/show/NCT00795769",NA
"58282",58282,"NCT00820469","Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab","Completed","No Results Available","Humoral Acute Refection of Renal Transplant|Autoimmune Diseases","Drug: Rituximab 375|Drug: rituximab 1000","University Hospital, Toulouse","Both","Adult|Senior","Phase IV",20,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label","714003","January 9, 2009","01/09/2008",2010-01-01,"March 4, 2010","01/03/2010","PK-rituximab",2009-11-01,"Comparison of the total AUC levels between 2 arms : patients treated by rituximab alone or patients treated by rituximab and plasma exchange|Determination of amount rituximab eliminated during a plasma exchange|Evaluation of the efficacy of the treatment by CD19+B Cell count","http://ClinicalTrials.gov/show/NCT00820469",NA
"58324",58324,"NCT00884169","Study to Investigate the Efficacy and the Safety of M518101 in Psoriasis Patients","Completed","No Results Available","Plaque Psoriasis","Drug: M518101|Drug: placebo","Maruho Co., Ltd.","Both","Adult","Phase II",NA,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind","M518101-EU03","April 17, 2009","01/07/2009",2009-12-01,"November 2, 2010","01/11/2010","",2009-12-01,"Severity of plaque psoriasis|Investigator and Patient overall assessment","http://ClinicalTrials.gov/show/NCT00884169",NA
"58328",58328,"NCT00888069","Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects","Completed","No Results Available","Chronic Kidney Disease|Secondary Hyperparathyroidism|Chronic Renal Insufficiency|Chronic Renal Failure","Drug: CTAP101|Drug: CTAP101|Drug: CTAP101","Cytochroma Inc.","Both","Adult|Senior","Phase I|Phase II",92,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTAP101-CL-2004","April 23, 2009","01/05/2009",2009-12-01,"February 24, 2010","01/02/2010","",2009-11-01,"To assess the PK and bioavailability of CTAP101 in Stage 3 and 4 CKD subjects with vitamin D insufficiency and SHPT|To assess the safety and tolerability of CTAP101 capsules and injection|To assess the pharmacodynamics of single dose CTAP101 in Stage 3 and Stage 4 CKD subjects with vitamin D insufficiency and SHPT.","http://ClinicalTrials.gov/show/NCT00888069",NA
"58351",58351,"NCT00933569","Dermacyd Silver Floral (Lactic Acid) - Acceptability.","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Female","Adult","Phase III",31,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","LACAC_L_04838","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"Evaluation of the absence of irritation and the good acceptability by using one specific scale which describes the intensity of the reaction.","http://ClinicalTrials.gov/show/NCT00933569",NA
"58392",58392,"NCT01001169","Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children","Completed","No Results Available","Influenza Infection","Biological: GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)","GlaxoSmithKline","Both","Child","Phase II",60,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","113847","October 22, 2009","01/10/2009",2009-12-01,"July 2, 2010","01/07/2010","",2009-12-01,"Humoral immune response in terms of haemagglutination inhibition (HI) antibodies|Humoral immune response in terms of haemagglutination inhibition (HI) antibodies (will also be performed in each age stratum)|Humoral immune response in terms of neutralizing antibodies|Occurrence of solicited local and general signs and symptoms|Occurrence of unsolicited adverse events|Occurrence of Medically attended events, Potential immune mediated disorders and Serious adverse events|Biochemical and haematological abnormal parameters","http://ClinicalTrials.gov/show/NCT01001169",NA
"58408",58408,"NCT01024569","Randomized Controlled Trial of Wellness Recovery Action Planning","Completed","No Results Available","Mental Disorders","Behavioral: Wellness Recovery Action Planning (WRAP)","University of Illinois|U.S. Department of Education|Substance Abuse and Mental Health Services Administration (SAMHSA)","Both","Adult|Senior","Phase I|Phase II",550,"Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Health Services Research","H133B050003|UIC WRAP Study","December 2, 2009","01/12/2007",2009-10-01,"December 2, 2009","01/12/2009","WRAP RCT",2009-09-01,"Psychiatric Symptoms Recovery using the Brief Symptoms Inventory (BSI)|Personal Empowerment, measured using the Boston University Empowerment Scale (Rogers et al.)","http://ClinicalTrials.gov/show/NCT01024569",NA
"58438",58438,"NCT01073969","Study to Determine the Digestive and Physiological Effects of an Extract From Bran in Healthy Men and Women","Completed","No Results Available","Healthy","Other: wheat bran extract|Other: control wheat bran extract","Kellogg Company|Provident Clinical Research|Tufts University|University of Toronto|University of Reading|University of Saskatchewan","Both","Adult|Senior","Phase IV",65,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","PRV-08011","February 19, 2010","01/03/2009",2009-08-01,"February 22, 2010","01/02/2010","",2009-07-01,"The primary outcome variable will be the difference between treatments in bifidobacteria counts per g of feces, expressed as log10 cells per g feces (dry weight)|Other fecal bacterial counts|laxation|fecal pH|fecal moisture|stool consistency|blood glucose|Blood insulin|plasma lipid profiles|serum free fatty acids|fecal short chain fatty acids|fecal ammonia|urinary para-cresol|urinary phenol (total)|urinary isoprostanes|oxidized low density lipoprotein (TBARS, conjugated dienes)|Urinary F2alpha-isoprostanes|Plasma antioxidant capacity (ORAC, FRAP)|serum amyloid A|hs-CRP|IL-6|TNF-alpha|gastrointestinal symptom survey|stool consistency (Bristol stool scale)|Quality of Life questionaire (Quality Metrics SF-36)","http://ClinicalTrials.gov/show/NCT01073969",NA
"58542",58542,"NCT01275469","Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.","Completed","No Results Available","Impaired Glucose Tolerance|Abdominal Obesity","Drug: GFT505 80mg|Drug: Placebo","Genfit","Both","Adult|Senior","Phase II",47,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GFT505-209-4|2009-011003-23","January 10, 2011","01/06/2009",2010-01-01,"January 11, 2011","01/01/2011","",2009-12-01,"Oral Glucose test Tolerance (OGTT)|Volume oxygen maximal (VO2max)|Respiratory parameters measured during the physical exercise test|Fasting Glycemia and Insulinemia|HOMA index (Homeostasis Model Assessment)|Lipids","http://ClinicalTrials.gov/show/NCT01275469",NA
"58562",58562,"NCT00002570","Immediate Compared With Delayed Chemotherapy in Treating Patients With Advanced Colorectal Cancer Without Signs or Symptoms of Disease","Completed","No Results Available","Colorectal Cancer","Drug: fluorouracil|Drug: leucovorin calcium","NCIC Clinical Trials Group|North Central Cancer Treatment Group","Both","Adult|Senior","Phase III",144,"Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CO10|CAN-NCIC-CO10|NCCTG-JCO10|NCCTG-JCO.10|NCI-V94-0463|CDR0000063607","November 1, 1999","01/07/1994",2009-02-01,"November 7, 2010","01/11/2010","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00002570",NA
"58611",58611,"NCT00055770","Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: docetaxel|Drug: erlotinib hydrochloride","Arthur G. James Cancer Hospital & Richard J. Solove Research Institute|National Cancer Institute (NCI)","Both","Adult|Senior","Phase I|Phase II",45,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000271197|OSU-02H0084|OSU-0213|NCI-5393","March 6, 2003","01/02/2003",NA,"February 6, 2010","01/12/2006","",2009-02-01,"Maximum tolerated dose of erlotinib and docetaxel (Phase I)|Objective response (Phase II)|Response rate as measured by RECIST criteria (Phase II)|Time to tumor progression (Phase II)|Median survival (Phase II)","http://ClinicalTrials.gov/show/NCT00055770",NA
"58614",58614,"NCT00068770","Celecoxib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Who Are Receiving Anticonvulsant Drugs and Undergoing Radiation Therapy","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: celecoxib|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","NABTT-2100 CDR0000328117|U01CA062475|NABTT-2100|JHOC-NABTT-2100","September 10, 2003","01/10/2003",NA,"October 1, 2010","01/10/2010","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00068770",NA
"58635",58635,"NCT00096070","Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: oxaliplatin|Radiation: radiation therapy","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",50,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000391191|NCCTG-N0349","November 9, 2004","01/12/2004",NA,"March 10, 2009","01/03/2009","",2009-03-01,"Overall survival at 6 and 12 months|Survival time|Confirmed tumor response (complete and partial response)|Time to disease progression|Duration of response|Time to treatment failure","http://ClinicalTrials.gov/show/NCT00096070",NA
"58792",58792,"NCT00343070","Functional Neuroimaging in Depression","Completed","No Results Available","Major Depression","Drug: Oral administration of escitalopram during 8 weeks","University Hospital, Ghent|Fund for Scientific Research, Flanders, Belgium|H. Lundbeck A/S","Both","Adult","Phase II",40,"Other|Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006/176","June 19, 2006","01/03/2007",2009-10-01,"August 30, 2010","01/08/2010","",2009-10-01,"Brain metabolism|Cognitive functions|Efficacy scales (mood, anxiety, anger and hopelessness)","http://ClinicalTrials.gov/show/NCT00343070",NA
"58823",58823,"NCT00380770","HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT","Completed","No Results Available","HIV|AIDS|Kaposi's Sarcoma|Human Herpesvirus 8","Drug: Generic HAART Triomune : d4T, 3TC, NVP|Drug: Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV","University of KwaZulu|AIDS Care Research in Africa|National Research Foundation, Singapore|AIDS Malignancy Consortium|Cipla Medpro|Dermatological Society of South Africa","Both","Adult|Senior","Phase IV",112,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H029/02","September 25, 2006","01/01/2003",2009-03-01,"July 20, 2010","01/03/2009","KAART",2009-02-01,"Clinical response of KS|Skin: tumour measurements of 5 indicator skin lesions. Assessment of KS as per AMC RKS 02 (www.amc.uab.edu)|photography of indicator lesions with metric tape in frame|Visceral: chest radiograph and endoscopy, where necessary, bronchoscopy|Safety and toxicity by DAIDS Toxicity criteria|Immunological and virological response to HAART as measured by CD4 and HIV-viral load|QOL by EORTC QLQ C30|Adherence","http://ClinicalTrials.gov/show/NCT00380770",NA
"58883",58883,"NCT00467870","Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men","Completed","No Results Available","Hypogonadism|Primary Hypogonadism|Secondary Hypogonadism","Drug: Testosterone Undecanoate","Endo Pharmaceuticals Solutions Inc.","Male","Adult|Senior","Phase III",500,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IP157-001","April 27, 2007","01/03/2006",2009-07-01,"September 21, 2010","01/09/2010","TU",2009-07-01,"To evaluate the pharmacokinetics of TU|To compare serum levels of DHT, E2, and SHBG to simultaneous levels of serum total testosterone at steady state","http://ClinicalTrials.gov/show/NCT00467870",NA
"58891",58891,"NCT00474370","Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)","Completed","No Results Available","HIV Infections|Acquired Immunodeficiency Syndrome","Drug: Vicriviroc|Drug: Placebo","Schering-Plough","Both","Child|Adult|Senior","Phase III",375,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P04889|3547030","May 15, 2007","01/05/2007",2010-10-01,"November 18, 2010","01/11/2010","",2009-08-01,"Proportion of subjects with undetectable plasma HIV-1 RNA (<50 copies/mL)|Mean change from baseline in plasma HIV-1 RNA (log10 copies/mL); Proportion of subjects with <400 copies/mL of plasma HIV-1 RNA; Proportion of subjects with at least 2log10 reduction from baseline in plasma HIV-1 RNA","http://ClinicalTrials.gov/show/NCT00474370",NA
"58894",58894,"NCT00482170","Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept","Completed","No Results Available","Psoriasis","Device: Enbrel (etanercept)|Device: Etanercept","Wyeth","Both","Adult|Senior","Phase III",524,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0881A6-3326","June 1, 2007","01/09/2007",2009-09-01,"February 23, 2010","01/02/2010","",2009-04-01,"Compare patient satisfaction with 2 injection devices (PFS - AutoInjector) will be measured by asking patients: \How satisfied are you with your injection device?\"": using a 10 point scale|Device attributes and patient perception : Ease of use and convenience of injection device operation Confidence in the device -Presence or absence of fear of the device-Device characteristics -Side effects related to administration- Anxiety measure""","http://ClinicalTrials.gov/show/NCT00482170",NA
"58921",58921,"NCT00528970","A Study Evaluating IV MOA-728 for the Treatment of POI In Subjects After Ventral Hernia Repair","Completed","No Results Available","Ileus","Drug: MOA-728|Other: placebo","Wyeth|Progenics Pharmaceuticals, Inc.","Both","Adult|Senior","Phase III",500,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double-Blind|Primary Purpose: Treatment","3200L2-301","September 11, 2007","01/08/2007",2009-02-01,"February 5, 2010","01/07/2009","",2009-02-01,"Primary: The effect of the interventional treatment will be measured by the time to bowel movement.","http://ClinicalTrials.gov/show/NCT00528970",NA
"58925",58925,"NCT00540670","A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease","Completed","No Results Available","Coronary Artery Disease","Drug: E5555 50 mg|Drug: E5555 100 mg|Drug: E5555 200 mg|Drug: Placebo","Eisai Limited","Both","Adult|Senior","Phase II",240,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E5555-J081-206","October 4, 2007","01/10/2007",NA,"February 17, 2010","01/02/2010","",2009-03-01,"Safety and tolerability: Adverse events, bleeding events, clinical laboratory tests, Coagulation tests, vital signs and 12-lead ECG|Major cardiac adverse events, biomarkers, platelet aggregation inhibition, plasma concentration.","http://ClinicalTrials.gov/show/NCT00540670",NA
"58927",58927,"NCT00543270","Powerlink Bifurcated Stent Graft Long-Term Follow-up Study","Completed","No Results Available","Abdominal Aortic Aneurysm","Device: Powerlink infrarenal bifurcated stent graft delivery system|Procedure: Open Surgery","Endologix","Both","Adult|Senior","Phase II|Phase III",231,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TP00-005/CP04-001","October 10, 2007","01/10/2005",2009-11-01,"February 22, 2010","01/02/2010","",2009-11-01,"Safety: Major adverse events. Effectiveness: Stent graft patency, aneurysm exclusion, aneurysm related mortality, and all-cause mortality.","http://ClinicalTrials.gov/show/NCT00543270",NA
"58943",58943,"NCT00565370","Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC)","Completed","No Results Available","Advanced Gastric Cancer","Drug: Capecitabine, Cisplatin, Sorafenib","Asan Medical Center","Both","Adult|Senior","Phase I|Phase II",21,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-0701","November 28, 2007","01/11/2007",2009-12-01,"February 11, 2010","01/02/2010","",2009-12-01,"Maximum tolerated dose for phase I portion|Progression-free survival for phase II portion|Response rate|Overall survival|Toxicity profile (according to National Cancer Institute Common Terminology Criteria for Adverse Event version 3.0)","http://ClinicalTrials.gov/show/NCT00565370",NA
"58945",58945,"NCT00569270","Dynamic Hyperinflation and Tiotropium","Completed","No Results Available","COPD","Drug: tiotropium|Drug: placebo|Drug: tiotropium","Gelb, Arthur F., M.D.|Boehringer Ingelheim Pharmaceuticals|Pfizer","Both","Adult|Senior","Phase IV",40,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20061693|IIS Boehringer-Ingelheim|IIS Pfizer","December 6, 2007","01/10/2006",2009-03-01,"June 19, 2009","01/06/2009","",2009-02-01,"Measurement of inspiratory capacity|measurement of spirometry, lung volumes, airway resistance","http://ClinicalTrials.gov/show/NCT00569270",NA
"58949",58949,"NCT00577070","Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression","Completed","No Results Available","Major Depression","Device: TMS","BeerYaakov Mental Health Center","Both","Adult","Phase II",40,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TMS-204CTIL","December 18, 2007","01/01/2008",2009-10-01,"October 5, 2009","01/01/2009","",2009-10-01,"Treatment response defined as at least a 50% decrease in Hamilton Depression Rating Scale (HAM-D24). Remission is defined as below 8 in Hamilton Depression Rating Scale (HAM-D24)","http://ClinicalTrials.gov/show/NCT00577070",NA
"58961",58961,"NCT00595270","Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51","Completed","No Results Available","Japanese Encephalitis","Biological: Japanese Encephalitis purified inactivated vaccine","Intercell AG","Both","Adult|Senior","Phase III",357,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Prevention","IC51-305","January 4, 2008","01/10/2005",2009-04-01,"August 24, 2010","01/03/2006","",2009-04-01,"Long term immunogenicity of IC51 vaccine 24 months after the primary vaccination|Immunogenicity of IC51 vaccine 6 and 12 months after the primary vaccination","http://ClinicalTrials.gov/show/NCT00595270",NA
"58975",58975,"NCT00612170","A 14-Week, Multi-Center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.","Completed","No Results Available","Fibromyalgia","Drug: [S,S]-Reboxetine|Drug: Placebo|Drug: [S,S]-Reboxetine|Drug: [S,S]-Reboxetine","Pfizer","Both","Adult|Senior","Phase III",1129,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A6061043|A6061043","January 29, 2008","01/12/2007",2009-05-01,"July 9, 2009","01/07/2009","",2009-05-01,"Change from baseline in the endpoint mean pain score|Fibromyalgia Impact Questionnaire|Change from baseline in the endpoint mean sleep interference score|Patient Global Impression of Change|Multidimensional Assessment of Fatigue|Hospital Anxiety and Depression Scale|Short Form 36|Sheehan Disability Score|Pain Visual Analogue Scale","http://ClinicalTrials.gov/show/NCT00612170",NA
"58977",58977,"NCT00621270","Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety","Completed","No Results Available","Major Depressive Disorder|Anxiety","Drug: BCI-540","BrainCells Inc.","Both","Adult","Phase II",90,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BCI-540-CL-001","February 11, 2008","01/01/2008",2009-10-01,"October 23, 2009","01/10/2009","",2009-10-01,"Co-primary outcome measures will be the change from Baseline to Week 6 on the total score of the Inventory of Depressive Symptomatology-Clinician Version (IDS-C30) and the Hamilton Rating Scale for Anxiety (HAM-A).|The safety, tolerability and side effect profile of BCI-540 will also be measured by adverse events, clinical laboratory values, electrocardiograms, vital signs, and the Physician Withdrawal Checklist (PWC).","http://ClinicalTrials.gov/show/NCT00621270",NA
"58985",58985,"NCT00573170","TREXIMET?ó Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults","Completed","Has Results","Migraine Disorders|Migraine, Acute","Drug: TREXIMET?ó|Drug: Butalbital-containing Combination Medications (BCM)|Drug: placebo","GlaxoSmithKline","Both","Adult","Phase III",375,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TRX109011/TRX109013","December 12, 2007","01/02/2008",2009-08-01,"November 30, 2010","01/11/2010","",2009-08-01,"Number of Participants With a Sustained Pain-free (SPF) Response From 2 to 24 Hours Post-dose|Number of Participants With a Pain-free Response From 2 to 48 Hours Post-dose|Number of Participants Using Rescue Medication Within 48 Hours Post Dose|Mean Time to First Use of Rescue Medication for the First Attack Treated With Study Medication (Attack 1)|Mean Time to First Use of Rescue Medication for the Second Attack Treated With Study Medication (Attack 2)|Mean Time to First Use of Rescue Medication for the Third Attack Treated With Study Medication (Attack 3)|Number of Participants With a Migraine-free Response 2-48 Hours After Dosing|Number of Participants With Pain-freedom and Relief of Nausea at 2, 4, 6, 8, 24 and 48 Post-dose Time Points|Number of Participants With Pain-freedom and Relief of Photophobia at 2, 4, 6, 8, 24 and 48 Post-dose Time Points|Number of Participants With Pain-freedom and Relief of Phonophobia at 2, 4, 6, 8, 24 and 48 Post-dose Time Points|Number of Participants With Pain-freedom and Relief of Vomiting at 2, 4, 6, 8, 24 and 48 Hours Post-dose|Number of Participants With Relief From Sinus/Facial Pain at 2, 4, 6, 8, 24 and 48 Hours After Dosing in Those Who Also Had the Symptom at Dosing|Number of Participants With Relief From Neck Pain at 2, 4, 6, 8, 24 and 48 Hours After Dosing Who Also Had the Symptom at Baseline|Number of Participants With Pain Relief at 2, 4, 6, 8, 24 and 48 Hours After Dosing Moderate or Severe Baseline Pain|Number of Participants Who Reported a Complete Symptom-Free Response at 2, 4, 6, 8, 24 and 48 Hours After Dosing|Mean Performance Index (PI) Scores at Time of Dosing and at 2, 4, 6, 8, 24 and 48 Hours After Dosing|Mean Stanford Sleepiness (SS) Scale Scores at Time of Dosing and at 2, 4, 6, 8, 24 and 48 Hours After Dosing|Efficacy Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Treating a Migraine|Functionality Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication|Ease-of-Use Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication|Bothersomeness-of-side Effect Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication|Total PPMQ-R Score as Measured With the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication|Numbers of Participants Able to \Engage in Normal Activities Not Impaired\"" at Time of Dosing and 2","http://ClinicalTrials.gov/show/NCT00573170",NA
"59025",59025,"NCT00688870","Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan","Completed","No Results Available","Vaccines, Pneumococcal Conjugate Vaccine","Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)|Biological: 7-valent pneumococcal conjugate vaccine (7vPnC)","Wyeth","Both","Child","Phase III",168,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","6096A1-3004","May 29, 2008","01/06/2008",2009-11-01,"February 1, 2010","01/02/2010","",2009-11-01,"To assess the pneumococcal immune responses induced by 13vPnC relative to those induced by 7vPnC when measured 1 month after the infant series; and to assess safety by incidence rates of injections site reactions, systemic events and adverse events|To assess the pneumococcal immune responses induced by 13vPnC relative to those induced by 7vPnC when measured 1 month after the toddler dose","http://ClinicalTrials.gov/show/NCT00688870",NA
"59031",59031,"NCT00647270","Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing","Completed","Has Results","Rheumatoid Arthritis","Drug: adalimumab|Drug: Placebo|Drug: adalimumab","Abbott","Both","Adult|Senior","Phase III",420,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-261","March 27, 2008","01/12/2007",2009-04-01,"November 4, 2010","01/09/2010","",2009-04-01,"The Number of Responders According to the American College of Rheumatology (ACR) 20 Response Criteria at Week 12 Involving the Comparison of Adalimumab 80 mg Monthly Dose Versus Placebo and Adalimumab 40 mg Every Other Week (Eow)|Within Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)|Within Group Mean Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])|Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)|Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])","http://ClinicalTrials.gov/show/NCT00647270",NA
"59047",59047,"NCT00723970","Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression","Completed","No Results Available","Major Depressive Disorder|Insomnia|Hot Flashes","Drug: Quetiapine Extended Release","McMaster University","Female","Adult","Phase IV",40,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","D1443C00008","July 25, 2008","01/06/2007",2009-05-01,"July 22, 2009","01/07/2009","",2009-05-01,"Changes in depressive scores (MADRS) from baseline (after a 2-week lead-in phase) to study end|Changes in Menopause-related scores, based on the Greene Climacteric Scale (GCS) and Hot Flash Related daily interference Scale (HFRDIS)","http://ClinicalTrials.gov/show/NCT00723970",NA
"59131",59131,"NCT00852670","ACT-128800 in Psoriasis","Completed","No Results Available","Plaque Psoriasis","Drug: ACT-128800|Drug: Placebo","Actelion","Both","Adult","Phase II",66,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-058A200","February 26, 2009","01/10/2008",2009-09-01,"November 11, 2009","01/11/2009","",2009-07-01,"Psoriasis Area and Severity Index (PASI) percent change relative to baseline at Week 6 visit.|\Clear - almost clear\"" Physician Global Assessment (PGA) at Week 6 visit.""","http://ClinicalTrials.gov/show/NCT00852670",NA
"59140",59140,"NCT00866970","Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia","Completed","No Results Available","NSCLC|Fatigue|Cachexia","Biological: ALD518|Biological: ALD518|Biological: ALD518|Biological: Infusion of 0.9% Saline without ALD518","Alder Biopharmaceuticals, Inc.","Both","Adult|Senior","Phase II",124,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALD518-CLIN-004","March 20, 2009","01/09/2008",2009-12-01,"September 10, 2010","01/09/2010","",2009-08-01,"Change in Safety parameters.|Time to symptomatic progressions at Weeks 12 and 24","http://ClinicalTrials.gov/show/NCT00866970",NA
"59145",59145,"NCT00881270","Dermacyd Infantile - Acceptability.","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Both","Child","Phase IV",31,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","LACAC_L_04678","April 10, 2009","01/03/2009",2009-03-01,"September 25, 2009","01/09/2009","",2009-03-01,"The absence of irritation and the good acceptability will be evaluated using one specific scale which describes the intensity of the reaction.","http://ClinicalTrials.gov/show/NCT00881270",NA
"59156",59156,"NCT00894270","Comparison of Vehicle Delivery Depth Using the NovoFine?ó 5 mm Needle With or Without a Skin Fold and Inserted at Either 45 or 90 Degrees","Completed","No Results Available","Diabetes Mellitus","Procedure: Sterile air injection|Procedure: Placebo injection|Device: Novofine needle","Liggins Institute|Novo Nordisk","Both","Child|Adult|Senior","Phase IV",240,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Novofine002","May 5, 2009","01/11/2008",2009-05-01,"May 7, 2009","01/05/2009","",2009-05-01,"Assess the safety and effectiveness of 5 mm needles using either thigh or abdomen and either a pinched or unpinched skin fold.|Examine leakage of placebo medium from thigh or abdomen.|Examine pain/discomfort of injections using the different techniques and the different injection sites.","http://ClinicalTrials.gov/show/NCT00894270",NA
"59160",59160,"NCT00904670","NWP06 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)","Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Drug: NWP06|Drug: Placebo","NextWave Pharmaceuticals","Both","Child","Phase III",45,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NWP06-ADD-100","May 18, 2009","01/05/2009",2009-08-01,"August 19, 2009","01/08/2009","",2009-08-01,"SKAMP|PERMP","http://ClinicalTrials.gov/show/NCT00904670",NA
"59172",59172,"NCT00921570","The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension","Completed","No Results Available","Diabetes|Hypertension|Proteinuria","Drug: Amlodipine|Drug: Valsartan","Gulhane School of Medicine","Both","Adult|Senior","Phase IV",105,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","GATA VALAMEX study","June 15, 2009","01/02/2008",2009-05-01,"June 16, 2009","01/06/2009","",2009-05-01,"Flow mediated dilatation|TWEAK, PTX-3, Systolic Blood Pressure and Diastolic Blood Pressure","http://ClinicalTrials.gov/show/NCT00921570",NA
"59206",59206,"NCT00983970","Effects of Interactive Video Game Cycling on Obese Adolescent Health","Completed","No Results Available","Overweight With Comorbidity|Obesity","Behavioral: Interactive video game cycling|Behavioral: Cycling to Music","Children's Hospital of Eastern Ontario|Canadian Diabetes Association","Both","Child","Phase IV",30,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GA-2-06-2106-GG|CDA-GG-2-06-2106-GG","September 23, 2009","01/05/2007",2009-03-01,"September 23, 2009","01/09/2009","",2009-03-01,"Energy Expenditure (kilocalories)|Aerobic fitness","http://ClinicalTrials.gov/show/NCT00983970",NA
"59226",59226,"NCT01024270","Cervical Priming With Misoprostol Prior to Operative Hysteroscopy","Completed","No Results Available","Cervical Ripening","Drug: Misoprostol","Samsung Medical Center","Female","Adult","Phase III",141,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Masking: Single Blind (Caregiver)","2008-06-035","November 12, 2009","01/07/2008",2009-07-01,"November 30, 2009","01/07/2009","",2009-07-01,"The primary outcome measure in this study was the preoperative cervical width after misoprostol administration.|Duration of cervical dilatation, up to Hegar number 10.|Complications during cervical dilation.|Misoprostol associated side effects.|Complications during the hysteroscopy.","http://ClinicalTrials.gov/show/NCT01024270",NA
"59234",59234,"NCT01038570","Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo","Completed","No Results Available","Prader Willi Syndrome","Drug: Syntocinon?ó/- Spray|Drug: Physiological serum (Sodium chloride)","University Hospital, Toulouse","Both","Adult|Senior","Phase II",24,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","09 071 03","November 16, 2009","01/06/2009",2009-09-01,"January 6, 2010","01/01/2010","",2009-09-01,"Result scores at Psychological tests : \Reading the mind in the eyes\"" (RMET)","http://ClinicalTrials.gov/show/NCT01038570",NA
"59274",59274,"NCT01097070","A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days","Completed","No Results Available","HIV-1 Infection","Drug: Bevirimat","Myrexis Inc.","Both","Adult|Senior","Phase II",35,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Bevirimat Study 206","March 23, 2010","01/11/2008",2009-01-01,"March 30, 2010","01/03/2010","",2009-01-01,"Measure bevirimat blood plasma concentrations to calculate the pharmacokinetic parameters of AUC, Cmax, Cmin, and half-life when bevirimat is administered as 2 x 100 mg tablets BID, 3 X 100 mg tablets QD, 4 X 100 mg tablets QD for 15 days|Measure bevirimat blood plasma concentrations following the administration of bevirimat 2 X 100 mg, 3 x 100 mg, or 4 x 100 mg tablets after a standardized meal. The pharmacokinetic parameters of AUC, Cmax, Cmin, and half-life will be calculated.","http://ClinicalTrials.gov/show/NCT01097070",NA
"59422",59422,"NCT00005971","Flavopiridol in Treating Patients With Metastatic Malignant Melanoma","Completed","No Results Available","Melanoma (Skin)","Drug: alvocidib","NCIC Clinical Trials Group","Both","Adult|Senior","Phase II",NA,"Other","Interventional","Primary Purpose: Treatment","I137|CAN-NCIC-IND137|NCI-NCIC-137|CDR0000067955","July 5, 2000","01/07/2000",2009-12-01,"November 7, 2010","01/03/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00005971",NA
"59503",59503,"NCT00147771","Imiquimod in Children With Plaque Morphea","Completed","No Results Available","Scleroderma, Localized","Drug: Imiquimod 5% cream","The Hospital for Sick Children","Both","Child|Adult","Phase III",10,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1000007595","September 2, 2005","01/09/2005",2009-09-01,"April 14, 2010","01/09/2009","",2009-09-01,"Percent improvement in the thickness of the skin|Frequency of side-effects","http://ClinicalTrials.gov/show/NCT00147771",NA
"59546",59546,"NCT00216671","Long-acting Injectable Risperidone in Post-acute Schizophrenia","Completed","No Results Available","Schizophrenia|Psychotic Disorders","Drug: risperidone","Janssen Pharmaceutica N.V., Belgium","Both","Adult","Phase IV",220,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR002257","September 13, 2005","01/11/2005",2009-12-01,"October 28, 2010","01/10/2010","",2009-12-01,"Positive And Negative Syndrome Scale (PANSS) at baseline and Week 26.|Positive And Negative Syndrome Scale (PANSS) at baseline and Weeks 6, 12, and 26. Clinical Global Impression - Severity (CGI-S), Global Assessment of Functioning (GAF), and Quality of Life Questionnaire SF-12 at baseline, Weeks 6, 12, and 26.","http://ClinicalTrials.gov/show/NCT00216671",NA
"59586",59586,"NCT00275171","rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter","Completed","No Results Available","Nodular Goiter","Drug: Recombinant human thyrotropin (Thyrogen)|Drug: recombinant human TSH|Other: isotonic saline = placebo","Odense University Hospital","Both","Adult|Senior","Phase II",90,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19","January 9, 2006","01/02/2006",2009-09-01,"December 27, 2010","01/04/2009","",2009-04-01,"An intra-individual comparison of the thyroid 131I-uptake before and after stimulation with rhTSH /placebo|An inter-individual comparison of the thyroid 131I uptake between those who receive placebo and those who receive rhTSH|An estimation of which time-interval, injecting rhTSH, that is more favourable before 131I therapy (24 hours, 48 hours or 72 hours)|A comparison of the degree of goiter reduction when patients are prestimulated with rhTSH and receive a thyroid 131I dose of 50 Gy or when receiving conventional 131I, receiving a thyroid dose of 100 Gy|A registration of adverse effects following rhTSH/placebo|Patient satisfaction (Visual Analogue Scale) before, 3 months post 131I therapy, and at the end of follow-up (1 year).|Development of TPOab or TSHRab|Thyroid function","http://ClinicalTrials.gov/show/NCT00275171",NA
"59667",59667,"NCT00392171","The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601AM1)(COMPLETED)","Completed","Has Results","Glioma|Astrocytoma|Oligodendroglioma|Glioblastoma","Drug: Temozolomide","Schering-Plough","Both","Adult|Senior","Phase II",120,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P04601","October 24, 2006","01/06/2006",2009-09-01,"June 3, 2010","01/06/2010","",2009-09-01,"Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression.","http://ClinicalTrials.gov/show/NCT00392171",NA
"59731",59731,"NCT00494871","Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation","Completed","No Results Available","Atrial Fibrillation","Drug: Xarelto (Rivaroxaban, BAY59-7939)|Drug: Warfarin","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult|Senior","Phase III",1280,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","12620","June 29, 2007","01/06/2007",2010-01-01,"February 19, 2010","01/02/2010","",2009-12-01,"(Safety)The composite of major and non-major clinically relevant bleeding events|(Efficacy)The composite of stroke and non-CNS systemic embolism|Each category of bleeding events, and adverse event|The composite of stroke, non-CNS systemic embolism, and vascular death","http://ClinicalTrials.gov/show/NCT00494871",NA
"59738",59738,"NCT00514371","A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: tanespimycin and bortezomib","Bristol-Myers Squibb","Both","Adult|Senior","Phase II|Phase III",0,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA200-003|KAG-302","August 8, 2007","01/08/2007",2009-02-01,"September 15, 2010","01/11/2009","TIME-2",2009-02-01,"Objective Response Rate|Response rate between treatment arms and time-to-event endpoints.","http://ClinicalTrials.gov/show/NCT00514371",NA
"59756",59756,"NCT00545571","MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.","Completed","No Results Available","Anemia","Drug: methoxy polyethylene glycol-epoetin beta [Mircera]","Hoffmann-La Roche","Both","Adult|Senior","Phase III",91,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20826","October 16, 2007","",2009-11-01,"February 15, 2010","01/02/2010","",2009-11-01,"Percentage of patients maintaining average Hb concentration within country-specific target range (11-13g/dL for Switzerland and 10-12g/dL for Austria) OR +/- 1g/dL of reference Hb concentration during evaluation period.|Change in Hb concentration between reference and evaluation period|Mean time spent in country-specific target range; percentage of patients maintaining Hb within target range; dose adjustments; RBC transfusions.|AEs, laboratory parameters, vital signs","http://ClinicalTrials.gov/show/NCT00545571",NA
"59757",59757,"NCT00546871","Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in PID Subjects","Completed","No Results Available","Primary Immunodeficiency (PID)","Drug: Immune Globulin Intravenous (Human), 10%","Baxter Healthcare Corporation","Both","Child|Adult|Senior","Phase II|Phase III",45,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","160601","October 18, 2007","01/10/2007",2009-09-01,"July 27, 2010","01/07/2010","",2009-07-01,"Subjects aged 12 years or older: Bioavailability of IgG after administration of IGIV, 10%, either IV, SC or SC at an adapted dose, as measured by area under the curve IgG concentration versus time curve (AUC) per week.|Subjects aged >2 to <12 years: Bioavailability of IgG after administration of IGIV, 10%, either IV, SC or SC at an adapted dose, as measured by trough levels of IgG.","http://ClinicalTrials.gov/show/NCT00546871",NA
"59769",59769,"NCT00559871","Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease","Completed","No Results Available","Parkinson's Disease","Drug: fipamezole","Juvantia Pharma Ltd|Santhera Pharmaceuticals","Both","Adult|Senior","Phase II",180,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SNT-II-004","November 15, 2007","01/10/2007",2009-05-01,"June 2, 2009","01/06/2009","Fjord",2009-05-01,"To compare the efficacy of 3 different doses of fipamezole with that of placebo on dyskinesia as assessed by a dyskinesia assessment scale.|To compare efficacy of 3 different doses of fipamezole with that of placebo on the mean daily 'Off' time, as recorded in the patient diary.","http://ClinicalTrials.gov/show/NCT00559871",NA
"59776",59776,"NCT00574171","Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: lapatinib|Drug: Capecitabine","University of Wisconsin, Madison|GlaxoSmithKline","Both","Adult|Senior","Phase II",29,"Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CO07201 (LAP109859)","December 13, 2007","01/09/2007",2009-08-01,"October 15, 2010","01/10/2010","",2009-08-01,"response to therapy|toxicity and tolerability of the lapatinib/capecitabine combination in this patient population","http://ClinicalTrials.gov/show/NCT00574171",NA
"59823",59823,"NCT00385671","An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain","Completed","Has Results","Diabetic Neuropathy, Painful","Drug: duloxetine hydrochloride|Drug: pregabalin|Drug: gabapentin","Eli Lilly and Company|Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase IV",407,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10822|F1J-US-HMEZ","October 6, 2006","01/09/2006",2009-11-01,"October 1, 2010","01/10/2010","",2009-08-01,"Mean Change From Baseline to 12 Weeks in Weekly Mean of Daily 24 Hour Average Pain Score, Pregabalin Compared With Duloxetine|Mean Change From Baseline to 12 Weeks in Weekly Mean of Daily 24 Hour Average Pain Score, Duloxetine Compared With Duloxetine+Gabapentin|Mean Change From Baseline to 12 Weeks in Weekly Mean of Nighttime Pain Severity|Mean Change From Baseline to 12 Weeks in Weekly Mean of the Daily Worst Pain Severity Score|Mean Change From Baseline to 12 Weeks in Clinical Global Impression of Severity Scale (CGI Severity)|Patient's Global Impression of Improvement Scale (PGI - Improvement) at 12 Weeks|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: 24-hour Average Pain|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: Worst Pain|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: Least Pain|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: Pain Right Now|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference: With General Activity|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Mood|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Walking Ability|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Normal Work|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Relations With Other People|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Sleep|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Enjoyment of Life|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Mean Interference Score|Number of Participants With ??­ 30% Reduction in the Weekly Mean 24 Hour Average Pain Score at 12 Weeks|Number of Patients With a Reduction of ??­ 50% in Weekly Mean of 24 Hour Average Pain Score|Number of Participants With a ??­ 2-points Reduction on the Weekly Average of the Daily 24-hour Average Pain Scale at 12 Weeks|Mean Change From Baseline to 12 Weeks in Leeds Sleep Evaluation Questionnaire (LSEQ) Subscales of Ease of Going to Sleep (GTS), Awakening (AFS), and Behaviour Following Wakefulness (BFW), Quality of Sleep (QOS)|Mean Change From Baseline to 12 Weeks in Sheehan Disability Scale (SDS) - Total Score and Scores for Items 1 to 3|Summary of Adverse Events and Serious Adverse Events Leading to Discontinuation|Mean Change From Baseline to 12 Weeks in Sexual Functioning Questionnaire (CSFQ) Total Score and Subscale Scores|Categorical Change From Baseline to 12 Weeks in Sexual Functioning Questionnaire (CSFQ) Total Score and Subscale Scores|Mean Change From Baseline to 12 Weeks in Portland Neurotoxicity Scale - Total Score and Subscale Scores|Categorial Change From Baseline to 12 Weeks in Portland Neurotoxicity Scale - Total Score and Subscale Scores|Path Analysis of Improvement in Pain Through Improvement in Depressive Symptoms|Mean Change From Baseline to 12 Weeks in Beck Depression Inventory II (BDI-II) Total Score|Categorical Change From Baseline to 12 Weeks in Number of Patients Using Health Care as Measured by the Resource Utilization Scale|Summary of Number of Participants Who Discontinued|Time to First ??­ 30% Reduction in Weekly Mean 24 Hour Average Pain Score|Time to First ??­ 50 % Reduction in Weekly Mean 24 Hour Average Pain Score|Time to First Sustained Response in Weekly Mean 24 Hour Average Pain Score|Time to First ??­ 2 Points Reduction in Weekly Mean 24 Hour Average Pain Score|Weekly Mean Change in 24 Hour Average Pain Severity +/- Generalized Anxiety Disorer (GAD)|Weekly Mean Change From Baseline to 12 Weeks in 24 Hour Average Pain Severity - Only Participants Who Adhered to Key Protocol Requirements (Per-Protocol Population)|Weekly Mean Change in 24 Hour Average Pain Severity by Week by Gabapentin Exposure Subgroup (de Novo Versus Prior Use)|Discontinuations for Abnormal Laboratory Analytes, Vital Signs, Overall and for Each Measure|Mean Change From Baseline to 12 Weeks in Blood Pressure|Mean Change From Baseline to 12 Weeks in Heart Rate|Mean Change From Baseline to 12 Weeks in Body Weight|Number of Participants With Treatment-emergent Elevated Blood Pressure|Number of Participants With Treatment-Emergent Elevated Heart Rate|Number of Participants With Treatment-Emergent Changes in Body Weight|Mean Change From Baseline to 12 Weeks in Hepatic Enzyme Serum Levels|Mean Change From Baseline to 12 Weeks in Total Bilirubin|Mean Change From Baseline to 12 Weeks in Fasting Plasma Glucose|Mean Change From Baseline to 12 Weeks in Hemoglobin A1C|Number of Patients With Treatment-Emergent Elevated Laboratory Analytes","http://ClinicalTrials.gov/show/NCT00385671",NA
"59827",59827,"NCT00645671","Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery","Completed","Has Results","Ocular Inflammation","Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment|Drug: Vehicle of Loteprednol Etabonate Ophthalmic Ointment","Bausch & Lomb, Inc.","Both","Adult|Senior","Phase III",400,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","525","March 13, 2008","01/03/2008",2009-03-01,"September 1, 2010","01/06/2010","",2009-03-01,"Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.|Grade 0 for Pain|Subjects With Complete Resolution of Anterior Chamber Cells and Flare. At Each Follow-up Visit.|Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare","http://ClinicalTrials.gov/show/NCT00645671",NA
"59843",59843,"NCT00687271","A Study of MK6213 Co-Administered With Atorvastatin in Patients With Hypercholesterolemia","Completed","No Results Available","High Cholesterol","Drug: MK6213|Drug: Comparator: atorvastatin calcium|Drug: Comparator: placebo (unspecified)","Merck","Both","Adult|Senior","Phase II",330,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2007_514|MK6213-006","May 27, 2008","01/06/2008",NA,"February 5, 2009","01/02/2009","",2009-01-01,"Evaluate the efficacy of MK6213 co-administered with atorvastatin compared to atorvastatin monotherapy in lowering LDL-C|Evaluate the safety and tolerability of MK6213","http://ClinicalTrials.gov/show/NCT00687271",NA
"59847",59847,"NCT00693771","Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Insulin Glargine","Sanofi-Aventis","Both","Adult|Senior","Phase IV",313,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LANTU_L_02756","June 5, 2008","01/04/2008",2009-07-01,"September 14, 2009","01/09/2009","OPTIMIZATION",2009-07-01,"HbA1c values|Adverse events including hypoglycemia","http://ClinicalTrials.gov/show/NCT00693771",NA
"59857",59857,"NCT00709371","Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity","Completed","No Results Available","Obesity","Drug: Zonisamide SR placebo plus bupropion SR placebo|Drug: Zonisamide SR placebo plus bupropion SR 360 mg/day|Drug: Zonisamide SR 120 mg/day plus bupropion SR placebo|Drug: Zonisamide SR 360 mg/day plus bupropion SR placebo|Drug: Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day|Drug: Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day","Orexigen Therapeutics, Inc","Both","Adult","Phase II",600,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ZB-202","June 29, 2008","01/07/2008",2009-07-01,"February 4, 2010","01/02/2010","",2009-04-01,"Percentage change in total body weight","http://ClinicalTrials.gov/show/NCT00709371",NA
"59871",59871,"NCT00732771","Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism","Completed","No Results Available","Primary Hyperaldosteronism","Drug: LCI699","Novartis","Both","Adult|Senior","Phase II",12,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","CLCI699A2206","August 5, 2008","01/06/2008",NA,"August 25, 2009","01/08/2009","",2009-05-01,"Systolic blood pressure over a 7-week forced titration treatment period|Plasma and urine hormone levels and electrolytes, diastolic blood pressure and drug pharmacokinetics over a 7-week forced titration treatment period","http://ClinicalTrials.gov/show/NCT00732771",NA
"59878",59878,"NCT00734071","An Efficacy and Safety Study of Lu AA21004 in Treating Generalized Anxiety Disorder","Completed","No Results Available","Generalized Anxiety Disorder","Drug: Lu AA21004|Drug: Placebo","Takeda Global Research & Development Center, Inc.|H. Lundbeck A/S","Both","Adult|Senior","Phase III",309,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","LuAA21004_310|U1111-1114-4876","August 11, 2008","01/06/2008",2009-02-01,"June 17, 2010","01/06/2010","",2009-01-01,"The least squares mean change from Baseline in the Hamilton Anxiety Scale total score after 8 weeks of treatment.|The least squares mean change from Baseline in Hamilton Anxiety Scale total score at each week assessed.|Response rates at Week 8, with response defined as a ??­50% decrease in the HAM-A total score from Baseline.|Remission rates at Week 8, with remission defined as a Hamilton Anxiety Scale total score ???7.|The least squares mean change from Baseline in Clinical Global Impression Scale-Severity of Illness and Hospital Anxiety and Depression anxiety subscale.|The least squares mean change from Baseline in Clinical Global Impression Scale-Global Improvement.|Sheehan Disability Scale.|Medical Outcomes Study 36-Item Short-Form Health Survey.|Health care resource utilization as assessed by the Health Economic Assessment Questionnaire","http://ClinicalTrials.gov/show/NCT00734071",NA
"59888",59888,"NCT00735371","Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)","Completed","Has Results","ADHD","Drug: LDX 30 mg|Drug: LDX 50 mg|Drug: LDX 70 mg|Drug: Placebo","Shire Pharmaceutical Development","Both","Child","Phase III",314,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPD489-305","August 12, 2008","01/10/2008",2009-04-01,"April 29, 2010","01/04/2010","",2009-04-01,"Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks|Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores|Youth Quality of Life-Research Version (YQOL-R) Total Score","http://ClinicalTrials.gov/show/NCT00735371",NA
"59918",59918,"NCT00804271","Memantine and Validation of a New Alzheimer's Disease Scale","Completed","No Results Available","Alzheimer's Disease","Drug: memantine","Merz Pharmaceuticals GmbH","Both","Adult|Senior","Phase III",487,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label","MRZ 90001/AD/3001|EudraCT No. 2008-005144-16","December 5, 2008","01/12/2008",2009-11-01,"November 18, 2009","01/11/2009","",2009-11-01,"Validation of new scale regarding content, reliability and responsiveness for DAT symptoms|Assessment of treatment response and correlation of new scale against ADAScog, SIB, NPI, DAD.","http://ClinicalTrials.gov/show/NCT00804271",NA
"59929",59929,"NCT00818571","Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients","Completed","No Results Available","Renal Impairment|Diabetes","Drug: Vildagliptin|Drug: Vildagliptin|Drug: Vildagliptin|Drug: Vildagliptin","Novartis Pharmaceuticals","Both","Adult|Senior","Phase I|Phase II",96,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLAF237B2202|2008-004565-25","January 6, 2009","01/12/2008",NA,"September 23, 2010","01/09/2010","",2009-05-01,"Measure: pharmacokinetics of vildagliptin and its metabolites|Measure: safety assessments will include vital signs, electrocardiograms and adverse events","http://ClinicalTrials.gov/show/NCT00818571",NA
"59937",59937,"NCT00828971","A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs","Completed","No Results Available","Infectious Diseases","Drug: Avelox (Moxifloxacin, BAY12-8039)|Drug: Amoxicilline/clavulanic","Bayer","Both","Adult|Senior","Phase III",898,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12670|2007-001491-36","January 23, 2009","01/11/2008",2009-10-01,"May 3, 2010","01/05/2010","MERAK",2009-10-01,"Clinical response up to 14-21 days after the completion of study drug therapy (Test-of-Cure visit [TOC]).|Clinical response assessed by the investigator on treatment Day 3-5|Clinical response assessed by the investigator at the end-of-therapy (EOT).|Time to switch from oral to IV therapy|Bacteriological response (for microbiologically valid population) at the EOT and TOC","http://ClinicalTrials.gov/show/NCT00828971",NA
"60022",60022,"NCT00997971","Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein","Completed","No Results Available","Growth|Allergy","Other: Modilac Rose 1","Sodilac","Both","Child","Phase III",86,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","ROS-CL3-001","September 14, 2009","01/09/2007",2009-08-01,"October 19, 2009","01/10/2009","Rose",2009-08-01,"Growth parameters|Clinical Tolerance|Atopic diseases (eczema atopic, asthma)","http://ClinicalTrials.gov/show/NCT00997971",NA
"60083",60083,"NCT01098071","Nasonex in Adenoids Hypertrophy in Children (P04367)","Completed","No Results Available","Adenoids","Drug: mometasone furoate nasal spray","Schering-Plough","Both","Child","Phase IV",34,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P04367 - Lebanon","April 1, 2010","01/08/2008",2010-09-01,"November 18, 2010","01/11/2010","NAHCh",2009-09-01,"Measurement of post choana obstruction as proved by endoscopy grading, the total clinical score & the nasal obstruction severity allergy symptom scores.|Portion of patients who needed to refer to surgery within one year","http://ClinicalTrials.gov/show/NCT01098071",NA
"60215",60215,"NCT00003372","Topotecan in Treating Patients With Recurrent Brain Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: topotecan hydrochloride","NCIC Clinical Trials Group","Both","Adult|Senior","Phase II",30,"Other","Interventional","Primary Purpose: Treatment","I109|CAN-NCIC-IND109|CDR0000066362","November 1, 1999","01/12/1997",2009-12-01,"November 7, 2010","01/11/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00003372",NA
"60244",60244,"NCT00027872","Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","Completed","No Results Available","Leukemia","Drug: tipifarnib","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000069089, J0255|U01CA069854|P30CA006973|JHOC-J0255|MSGCC-U5400|MSGCC-0116|NCI-1754","December 7, 2001","01/12/2001",NA,"March 9, 2010","01/03/2010","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00027872",NA
"60279",60279,"NCT00087672","A Phase II Study of CC-5013 in Myelofibrosis","Completed","No Results Available","Myelofibrosis","Drug: CC-5013","M.D. Anderson Cancer Center|Celgene Corporation","Both","Child|Adult|Senior","Phase II",41,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0648","July 12, 2004","01/07/2004",2009-02-01,"August 31, 2009","01/08/2009","",2009-02-01,"Efficacy of CC-5013 in myelofibrosis.","http://ClinicalTrials.gov/show/NCT00087672",NA
"60284",60284,"NCT00094172","Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Drug: Atorvastatin|Drug: Placebo","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network","Both","Adult","Phase II",83,"NIH|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DAIT ITN020AI","October 14, 2004","01/05/2005",2009-05-01,"August 23, 2010","01/01/2008","STAYCIS",2009-05-01,"The proportion of participants who develop at least three new T2 lesions with or without Gd+ enhancement (in any combination), or one clinical exacerbation, at anytime during the 12-month treatment phase compared to baseline|Incidence of adverse events|Proportion of participants who are diagnosed with MS according to the McDonald criteria during treatment phase|Proportion of participants who are diagnosed with MS according to the McDonald criteria through end of follow-up phase","http://ClinicalTrials.gov/show/NCT00094172",NA
"60340",60340,"NCT00174772","Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Lung Neoplasms","Drug: docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|Drug: docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin","Sanofi-Aventis","Both","Adult|Senior","Phase II",72,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976B_2505","September 12, 2005","01/03/2004",2009-02-01,"February 15, 2010","01/02/2010","",2009-02-01,"anti-tumor activity including overall response rate|all treatment related acute and chronic toxicity assessed according to the NCI-CTC scale|other adverse events not reported in the NCI-CTI scale|hematological and non-hematological toxicities","http://ClinicalTrials.gov/show/NCT00174772",NA
"60449",60449,"NCT00350272","Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects","Completed","No Results Available","HIV Infections","Drug: elvucitabine","Achillion Pharmaceuticals","Both","Adult","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","ACH443-015","July 6, 2006","01/04/2006",2009-07-01,"August 18, 2009","01/08/2009","",2009-07-01,"Primary:|Determination of the proportion of subjects having achieved a virologic response for 10 mg/day elvucitabine in combination with efavirenz and tenofovir in human immunodeficiency virus type 1 (HIV-1)-infected subjects by 12 weeks compared with the propor|Determination of the safety profile of elvucitabine.|Secondary:|Determination of the pharmacokinetics (PK) of 10-mg/day elvucitabine over 12 weeks as measured by concentrations of elvucitabine in plasma and of elvucitabine triphosphate in peripheral blood mononuclear cells|Determination of the efficacy of the study treatment regimen compared with the standard regimen, as measured by the change in HIV 1?? RNA and helper T cell (CD4) count.","http://ClinicalTrials.gov/show/NCT00350272",NA
"60455",60455,"NCT00361972","Elucidation of Acid-Induced Pulmonary Inflammation","Completed","No Results Available","Gastroesophageal Reflux|Asthma","Drug: lansoprazole|Drug: placebo","University of Utah","Both","Adult","Phase II|Phase III",36,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","15444|IRB #15444","August 8, 2006","01/08/2006",2009-04-01,"April 22, 2009","01/04/2009","",2009-04-01,"To determine whether treatment of asthmatics with gastric acid suppressing medication will decrease bronchial inflammation and bronchoreactivity in asthmatics. We will demonstrate a decrease in specific cytokine expression and inflammatory infiltrate in|To determine whether reduction in inflammation in pulmonary biopsies (as defined by reduction in specific cytokines or cellular infiltrate) correlates with improvement in pulmonary symptoms as defined by use of rescue inhalers or validated asthma quality","http://ClinicalTrials.gov/show/NCT00361972",NA
"60482",60482,"NCT00393172","Women in Steady Exercise Research [Formerly Women, Oxidative Stress, Exercise and Estrogens (WOSEE)]","Completed","No Results Available","Breast Cancer|Obesity","Behavioral: exercise","University of Minnesota - Clinical and Translational Science Institute|National Cancer Institute (NCI)","Female","Adult","Phase II|Phase III",400,"Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CDR0000511819|U54CA116849|UMN-0505M69867","October 25, 2006","01/05/2006",2010-03-01,"November 8, 2010","01/11/2010","WISER",2009-09-01,"Changes in urine levels of F2-isoprostanes|Changes in levels of IGF-axis proteins|Changes in insulin and glucose|Changes in estrogen metabolites|Changes in body composition","http://ClinicalTrials.gov/show/NCT00393172",NA
"60486",60486,"NCT00391872","A Comparison of AZD6140 and Clopidogrel in Patients With Acute Coronary Syndrome","Completed","No Results Available","Acute Coronary Syndrome","Drug: AZD6140|Drug: Clopidogrel","AstraZeneca","Both","Adult|Senior","Phase III",18000,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5130C05262|PLATO","October 23, 2006","01/10/2006",2009-03-01,"April 21, 2009","01/04/2009","PLATO",2009-03-01,"The primary outcome measure will be the reduction in the relative risk of vascular death, nonfatal myocardial infarction, or nonfatal stroke (composite primary endpoint), comparing AZD6140 to clopidogrel in patients with non-ST or ST elevation ACS.|Secondary outcomes will include the individual event categories from the primary composite endpoint, a variety of other important clinical outcomes related to ACS, and assessment of the overall safety and tolerability of AZD6140 compared to clopidogrel.","http://ClinicalTrials.gov/show/NCT00391872",NA
"60504",60504,"NCT00434772","Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers","Completed","No Results Available","Hypoglycemia","Drug: glucagon","Shaare Zedek Medical Center","Both","Child","Phase II",NA,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","bisseliches-glucagon-ctil","February 11, 2007","01/12/2007",2009-05-01,"May 27, 2009","01/05/2009","",2009-05-01,"glucose|hospitalisation days","http://ClinicalTrials.gov/show/NCT00434772",NA
"60535",60535,"NCT00477672","A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","Completed","No Results Available","Parkinson's Disease Psychosis","Drug: pimavanserin tartrate (ACP-103)|Drug: ACP-103|Drug: Placebo","ACADIA Pharmaceuticals Inc.","Both","Adult|Senior","Phase III",240,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACP-103-012","May 22, 2007","01/06/2007",NA,"August 4, 2010","01/08/2010","",2009-06-01,"Antipsychotic efficacy will be assessed using the scale for the assessment of Positive Symptoms (SAPS)","http://ClinicalTrials.gov/show/NCT00477672",NA
"60566",60566,"NCT00527072","PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept","Completed","Has Results","Psoriasis","Biological: infliximab","Centocor Ortho Biotech Services, L.L.C.","Both","Adult|Senior","Phase III",217,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR014500|C0168Z04","September 6, 2007","01/07/2007",2009-10-01,"May 28, 2010","01/05/2010","",2009-05-01,"Number (Percent) of Patients Who Achieve a Physician Global Assessment (PGA) Score of Minimal (1) or Clear (0)|Number (Percent) of Patients Achieved Psoriasis Area Activity Index (PASI) 50 Response|Number (Percent) of Patients Achieved Psoriasis Area Activity Index (PASI) 50 Response","http://ClinicalTrials.gov/show/NCT00527072",NA
"60570",60570,"NCT00528372","A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise","Completed","No Results Available","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin matching Placebo|Drug: Metformin|Drug: Metformin (as needed for rescue based on protocol specific criteria)","Bristol-Myers Squibb|AstraZeneca","Both","Adult|Senior","Phase III",560,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MB102-013","September 11, 2007","01/09/2007",2010-07-01,"December 15, 2010","01/12/2010","",2009-02-01,"Change from baseline in hemoglobin A1C|Change from baseline in fasting plasma glucose for each dose of dapagliflozin vs placebo|Proportion of subjects achieving a therapeutic glycemic response, defined as AIC < 7.0%|Change from baseline in total body weight|Change from baseline in fasting plasma glucose","http://ClinicalTrials.gov/show/NCT00528372",NA
"60573",60573,"NCT00541372","Needle Length In Obese Insulin-Using Diabetic Subjects","Completed","No Results Available","Diabetes Mellitus","Device: insulin injection needle size","University Medical Centre Groningen|Martini Hospital Groningen","Both","Adult|Senior","Phase IV",130,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Supportive Care","BWO-07001","October 9, 2007","01/09/2007",2009-03-01,"March 13, 2009","01/03/2009","INOBESE",2009-03-01,"Preference of the patient and amount of experienced hypoglycaemic events, bruises, backflow of insulin, bleeding and pain (VAS-scale)|HbA1c levels 1,5 anhydroglucitol and fructosamine levels Insulin dose","http://ClinicalTrials.gov/show/NCT00541372",NA
"60581",60581,"NCT00520572","A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)","Completed","Has Results","Rheumatoid Arthritis","Drug: AZD9056|Drug: Etanercept|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase II",385,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","D1520C00001","August 22, 2007","01/08/2007",2009-03-01,"December 2, 2010","01/12/2010","",2009-03-01,"American College of Rheumatology 20 Response (ACR20) at 6 Months|American College of Rheumatology 50 Response (ACR50) at 6 Months|American College of Rheumatology 70 Response (ACR70) at 6 Months|Disease Activity Score (Based on 28 Joint Count) (DAS28) at 6 Months.|Health Assessment Questionnaire - Disability Index (HAQ-DI) at 6 Months.","http://ClinicalTrials.gov/show/NCT00520572",NA
"60602",60602,"NCT00590772","The Role of Montelukast in Rhinitis and Sleep","Completed","No Results Available","Perennial Allergic Rhinitis","Drug: montelukast|Drug: placebo","Penn State University|Merck","Both","Child|Adult","Phase IV",50,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB 2003-114|Merck Grant #IISP ID# 20030","December 26, 2007","01/05/2003",2009-01-01,"February 5, 2009","01/02/2009","",2009-01-01,"The primary outcome will be improvement of fatigue and daytime sleepiness","http://ClinicalTrials.gov/show/NCT00590772",NA
"60616",60616,"NCT00602472","BI 1356 in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: BI 1356|Drug: Placebo","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",1058,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1218.18|EudraCT Number: 2007-002450-28","January 15, 2008","01/02/2008",NA,"June 24, 2009","01/06/2009","",2009-05-01,"The primary endpoint in this study is the change from baseline in HbA1c after 24 weeks of treatment. Throughout the study protocol, the term \baseline\"" refers to the last observation prior to the treatment phase.|occurrence of a treat to target response","http://ClinicalTrials.gov/show/NCT00602472",NA
"60617",60617,"NCT00601172","A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.","Completed","No Results Available","Nausea and Vomiting|Nausea and Vomiting, Chemotherapy-Induced","Drug: Casopitant|Drug: Dexamethasone and Ondansetron|Drug: Placebo","GlaxoSmithKline","Both","Adult|Senior","Phase III",710,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","NKV110721|NKV110721","January 15, 2008","01/03/2008",2009-04-01,"October 14, 2010","01/10/2010","",2009-04-01,"Complete response (no vomiting and no use of rescue medication) assessed via subject diary completed during cycle 1, that records vomiting and the use of rescue medication.|Complete response during cycle 2.|The proportion of subjects who achieve a complete response in the acute and delayed phases of Cycle 1.|Assessed in the overall, acute and delayed phases of Cycle 1:|Maximum nausea score, assessed by a Visual Analogue Scale (VAS). ??Ñ The proportion of subjects who receive rescue medication. ??Ñ The proportion of subjects who vomit/retch.|The proportion of subjects reporting significant nausea, defined as a maximum nausea score ??­ 25 mm on the VAS. ??Ñ The proportion of subjects reporting nausea, defined as a maximum nausea score ??­ 5 mm on the VAS.|The proportion of subjects achieving complete protection, defined as complete responders who had no significant nausea.|The proportion of subjects achieving total control, defined as complete responders who had no nausea. ??Ñ Time to first anti-emetic rescue medication. ??Ñ Time to first emetic event.|Time to event is defined as the time elapsed from the start of the oxaliplatin infusion to the first event.|If a subject withdraws prematurely or dies during the first 120 hours, then the time of withdrawal or death will be considered to be their time to first event, and will be censored.|Health Outcomes Endpoints assessed in Cycle 1: ??Ñ The impact on subjects' daily life activities in the overall phase, as assessed by the FLIE questionnaire.|Severity of nausea in the overall, acute, and delayed phases assessed by a categorical scale.|PK Endpoints assessed in Cycle 1 (subset of subjects only)|Single-dose pharmacokinetic parameters: AUC(0-???), AUC(0-t), Cmax, tmax, t1/2 for casopitant and metabolites GSK525060, GSK517142 and GSK631832; and CL and Vdss for casopitant only.","http://ClinicalTrials.gov/show/NCT00601172",NA
"60664",60664,"NCT00629772","Safety and Efficacy of Infliximab in Palmoplantar Psoriasis","Completed","Has Results","Palmoplantar Psoriasis","Drug: Placebo|Drug: Infliximab","Innovaderm Research Inc.|Schering-Plough","Both","Adult|Senior","Phase III",24,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Inno-6003|P-05121","February 27, 2008","01/03/2007",2009-07-01,"November 10, 2010","01/11/2010","",2009-02-01,"75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0|Number of Adverse Events at Week 14|Mean Dermatology Life Quality Index (DLQI) at Week 14|Mean Percent Palmoplantar Psoriasis Surface Area (PPSA) at Week 14|Mean Physician's Global Assessment (PGA) at Week 14|Mean Percent Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) at Week 26|Mean Percent Improvement in Dermatology Life Quality Index (DLQI) at Week 26|Mean Percent Improvement in Physician's Global Assessment (PGA) at Week 26|Mean Percent Improvement in Palmoplantar Psoriasis Surface Area (PPSA) at Week 26","http://ClinicalTrials.gov/show/NCT00629772",NA
"60677",60677,"NCT00710372","Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension","Completed","No Results Available","Mild Essential Hypertension|Moderate Essential Hypertension","Biological: CYT006-AngQb","Cytos Biotechnology AG","Both","Adult|Senior","Phase II",83,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CYT006-AngQb 03|EudraCT No.: 2007-007516-28","July 3, 2008","01/06/2008",2010-11-01,"November 11, 2010","01/11/2010","",2009-07-01,"Adverse events: quality, quantity, severity|Change in daytime, nighttime and 24h ambulatory blood pressure from baseline|anti-Angio II IgG antibody titer|Level of RAS Biomarkers (concentrations of plasma renin, angiotensinII and aldosterone)","http://ClinicalTrials.gov/show/NCT00710372",NA
"60678",60678,"NCT00707772","Pegasys?ó Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C|Hemophilia","Drug: PEGASYS?ó (Peginterferon Alfa-2a (40KD)) Plus COPEGUS?ó (Ribavirin)|Drug: PEGASYS?ó (Peginterferon Alfa-2a (40KD)) Plus COPEGUS?ó (Ribavirin)","Baqiyatallah Medical Sciences University|Baqiyatallah Research Center for Gastroenterology and Liver Diseases|Tehran Hepatitis Center|Guilan Research Center for Gastroenterology and Liver Diseases|Tabriz Research Center for Gastroenterology and Liver Diseases|Research Center for Gastroenterology and Liver Disease, Shaheed Beheshti University of Medical Sciences|Research Center for Gastroenterology and Liver Disease, Iran University of Medical Sciences, Firoozgar Hospital","Both","Child|Adult|Senior","Phase IV",400,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BRCGL-07-03|BRCGL-07-03","June 26, 2008","01/03/2007",2009-09-01,"September 16, 2009","01/09/2009","",2009-09-01,"Early Virologic Response|End of Treatment Response|Sustained Virologic Response|Rapid Virologic Response|Tolerability of drugs for whole therapy period|Biochemical response (ALT)|Laboratory Parameters","http://ClinicalTrials.gov/show/NCT00707772",NA
"60681",60681,"NCT00720772","Intravenous Sodium Thiosulfate on Coronary Calcification in Patients on Hemodialysis","Completed","No Results Available","Coronary Calcification|Vascular Calcification","Drug: 25% intravenous (IV) sodium thiosulfate","Ramathibodi Hospital","Both","Adult|Senior","Phase II",50,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","ID 02-51-31","July 21, 2008","01/07/2008",2009-11-01,"December 16, 2009","01/12/2009","",2009-05-01,"CAC score|Bone mineral density, calcium removal","http://ClinicalTrials.gov/show/NCT00720772",NA
"60687",60687,"NCT00729872","A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis","Completed","No Results Available","Moderately Active Ulcerative Colitis","Biological: AG011|Other: Placebo","ActoGeniX N.V.","Both","Adult|Senior","Phase I|Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG011-MDUC-201","August 4, 2008","01/07/2008",2009-09-01,"September 9, 2009","01/09/2009","",2009-09-01,"SAFETY: Adverse Events|SAFETY: Physical Examination (complete or brief)|SAFETY: Vital signs|SAFETY: Clinical Laboratory Tests (hematology, serum chemistry, urinalysis)|SAFETY: Analysis of hIL-10 (systemic exposure) and anti-hIL-10 antibodies (immunogenicity) in plasma|SAFETY: Stool Diary|SAFETY: Other Safety Measures (Stool samples for culture, ova and parasite evaluation and Clostridium difficile assay.|BIOLOGICAL CONTAINMENT: Evaluation of living, genetically modified micro-organisms in stool samples|PHARMACODYNAMICS: Biomarkers in blood and colon biopsy samples|EFFICACY: Flexible sigmoidoscopy (assessment of inflammation)|EFFICACY: Histological assessment of inflammation (biopsy samples)|EFFICACY: Disease activity assessments (MCDAS, UCCS, Investigator and Subject Global Ratings)|EFFICACY: Laboratory assessments (CRP and fecal calprotectin)","http://ClinicalTrials.gov/show/NCT00729872",NA
"60690",60690,"NCT00736372","A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer","Completed","No Results Available","Metastatic Cancer|Advanced Cancer","Drug: PX-12","Oncothyreon Inc.","Both","Adult|Senior","Phase I|Phase II",14,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PX-12-004","August 13, 2008","01/06/2008",2009-08-01,"February 3, 2010","01/02/2010","",2009-08-01,"To determine the MTD of PX-12 delivered as a 72-hour infusion over days 1, 2, and 3 of a 21-day cycle|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Evaluate the safety profile of PX-12|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Assess the pharmacodynamics of PX-12 using surrogate tissues obtained pre- and post-drug treatment|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Assess pharmacokinetic profiles of PX-12 in plasma samples|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Identify any antitumor activity of PX-12 in this patient population","http://ClinicalTrials.gov/show/NCT00736372",NA
"60693",60693,"NCT00732472","A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive|Chronic Obstructive Pulmonary Disease","Drug: GSK573719","GlaxoSmithKline","Both","Adult|Senior","Phase II",36,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","105211","August 11, 2008","01/10/2008",2009-08-01,"January 6, 2011","01/01/2011","",2009-08-01,"AEs, BP, heart rate, 12-lead ECG,24h Holter monitoring,lung function (FEV1), rescue medication usage(total number of salbutamol doses taken over the 7-day study period) and clinical laboratory safety tests during 12 day study|??Ñ Plasma concentrations of GSK573719 throughout days 1 and 7. Also collected at follow up??Ñ Urine concentrations of GSK573719 throughout days 1 and 7. Also collected at follow up","http://ClinicalTrials.gov/show/NCT00732472",NA
"60699",60699,"NCT00748072","1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy","Completed","No Results Available","Kidney Failure","Drug: DDAVP|Drug: placebo","University of Bari","Both","Child|Adult|Senior","Phase IV",162,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DDAVP 01","September 5, 2008","01/08/2008",2009-12-01,"January 19, 2010","01/12/2009","",2009-08-01,"presence/absence of haematoma","http://ClinicalTrials.gov/show/NCT00748072",NA
"60729",60729,"NCT00789672","Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia","Completed","No Results Available","Amblyopia","Drug: levodopa/carbidopa|Device: patching|Drug: levodopa/carbidopa","Jaeb Center for Health Research|National Eye Institute (NEI)","Both","Child","Phase II|Phase III",33,"Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NEI-141|2U10EY011751","October 27, 2008","01/01/2009",2009-12-01,"February 26, 2010","01/01/2010","ATS14",2009-09-01,"Tolerability of levodopa by adverse events reported and symptom survey|Visual acuity","http://ClinicalTrials.gov/show/NCT00789672",NA
"60757",60757,"NCT00841672","Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension","Completed","No Results Available","Moderate to Severe Hypertension","Drug: Aliskiren/Amlodipine|Drug: Amlodipine","Novartis","Both","Adult|Senior","Phase III",485,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CSPA100A2306","February 10, 2009","01/01/2009",NA,"June 2, 2010","01/06/2010","",2009-09-01,"Change from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment|Change from baseline in mean sitting diastolic blood pressure (msDBP) after 8 weeks of treatment.|The proportion of patients achieving blood pressure control (msSBP < 140 mmHg and msDBP < 90 mmHg), in both study arms, after 8 weeks of treatment.|The proportion of patients achieving the systolic blood pressure response (msSBP < 140 mmHg or a reduction ??­ 20 mmHg from the baseline), in both study arms, after 8 weeks of treatment.|The proportion of patients achieving the diastolic blood pressure response (msDBP < 90 mmHg or a reduction ??­10 mmHg from the baseline), in both study arms, after 8 weeks of treatment|Reduction in amlodipine-induced edema","http://ClinicalTrials.gov/show/NCT00841672",NA
"60770",60770,"NCT00859872","Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: risperidone oral solution|Drug: haloperidol","Central South University|Wuhan Mental Health Institute|Beijing Anding Hospital, Affiliate of Capital University of Medical Sciences|Shanghai Mental Health Center|Guangzhou Mental Hospital|Chongqing Mental Hospital","Both","Adult","Phase IV",198,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","IIS-0801","March 10, 2009","01/08/2008",2009-03-01,"July 31, 2009","01/07/2009","",2009-03-01,"the change of PANSS-EC scores|response rate based on the PANSS","http://ClinicalTrials.gov/show/NCT00859872",NA
"60775",60775,"NCT00857272","F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects","Completed","Has Results","Colonoscopy","Drug: PEG electrolyte lavage solution + bisacodyl - reformulation|Drug: PEG electrolyte lavage solution + bisacodyl","Braintree Laboratories","Both","Adult|Senior","Phase IV",308,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","F38-27","March 5, 2009","01/02/2009",NA,"September 29, 2010","01/09/2010","",2009-05-01,"Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale","http://ClinicalTrials.gov/show/NCT00857272",NA
"60808",60808,"NCT00931372","Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Lixisenatide (AVE0010)|Drug: Placebo","Sanofi-Aventis|Profil GmbH, Neuss, Germany","Both","Adult","Phase I|Phase II",22,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PDY10433|EudraCT:2008-003242-28","June 30, 2009","01/06/2009",2009-08-01,"June 15, 2010","01/06/2010","RESTORE",2009-08-01,"Area under the insulin secretion curve|Area under the insulin secretion curve","http://ClinicalTrials.gov/show/NCT00931372",NA
"60818",60818,"NCT00940472","Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients","Completed","No Results Available","Diabetes Type 2","Drug: DMMET-01|Drug: Metformin Hydrochloride","Laboratorios Silanes S.A. de C.V.","Both","Adult","Phase II|Phase III",20,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SIL-0790/2009|SIL-DMMET080609","July 14, 2009","01/03/2009",NA,"May 17, 2010","01/05/2010","DMMET2",2009-12-01,"Metabolic Control (Fasting glucose, postprandial glucose, HbA1C)|Lipid Profile (Total cholesterol, HDL, LDL, triglycerides)|Adverse Events","http://ClinicalTrials.gov/show/NCT00940472",NA
"60825",60825,"NCT00952172","Stair Stepping Exercise Training in Patients With Obstructive Sleep Apnea Syndrome","Completed","No Results Available","Sleep Apnea Syndrome","Behavioral: stair stepping exercise","Chang Gung Memorial Hospital|National Science Council, Taiwan","Both","Adult","Phase II",47,"Other","Interventional","Allocation: Randomized|Control: Historical Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","95-2314-B-182-032-MY3|CGMH-IRB-94-935B","August 3, 2009","01/08/2006",2009-07-01,"August 4, 2009","01/08/2009","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT00952172",NA
"60838",60838,"NCT00978172","Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria","Completed","No Results Available","Malaria","Drug: artesunate and mefloquine","Mepha Ltd.|Centre M??re et Enfant, Fondation Chantal Biya","Both","Child|Adult|Senior","Phase IV",220,"Industry|Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ART-P 001-2007","September 10, 2009","01/12/2007",2009-03-01,"September 15, 2009","01/09/2009","",2009-03-01,"To assess the neuropsychiatric and neurological safety of a fixed-dose combination of artesunate and mefloquine (Artequin Paediatric) in the treatment of children (>=10kg to <=20kg body weight) with uncomplicated P. falciparum malaria|To determine further safety and effectiveness parameters of Artequin Paediatric","http://ClinicalTrials.gov/show/NCT00978172",NA
"60840",60840,"NCT00975572","Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older","Completed","No Results Available","Virus Diseases|Respiratory Tract Diseases|Respiratory Tract Infections|Influenza|Orthomyxoviridae Infections","Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 ??g|Biological: Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 ??g|Biological: Experimental: split-virion, adjuvanted H1N1 vaccine of 15 ??g|Biological: Experimental: split-virion, adjuvanted H1N1 vaccine of 30 ??g|Biological: Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 ??g|Biological: Placebo Comparator: Placebo control","Jiangsu Province Centers for Disease Control and Prevention|Hualan Biological Bacterin Co. Ltd","Both","Child|Adult|Senior","Phase II",2200,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","JSVCT001","September 8, 2009","01/07/2009",2010-02-01,"September 16, 2010","01/09/2009","",2009-09-01,"Hemagglutination inhibition antibody titer|local and systemic adverse reaction after vaccination","http://ClinicalTrials.gov/show/NCT00975572",NA
"60842",60842,"NCT00987272","Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects","Completed","No Results Available","Allergic Conjunctivitis","Drug: Olopatadine 0.2% + Olopatadine 0.2% vehicle|Drug: Olopatadine 0.1% + Olopatadine 0.1% Vehicle","Alcon Research","Both","Adult|Senior","Phase III",200,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-09-044","September 28, 2009","01/09/2009",NA,"January 4, 2010","01/01/2010","",2009-11-01,"Ocular itching|Total redness|Ocular itching","http://ClinicalTrials.gov/show/NCT00987272",NA
"60927",60927,"NCT01128972","Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental Erosion","Completed","No Results Available","Tooth Erosion","Drug: Test fluoride toothpaste and test fluoride rinse|Drug: Marketed fluoride toothpaste and water rinse|Drug: Placebo toothpaste and test fluoride rinse|Drug: Test fluoride toothpaste and water rinse|Drug: Placebo toothpaste and water rinse","GlaxoSmithKline","Both","Adult","Phase II",36,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","Z3480664","April 30, 2010","01/08/2009",2009-10-01,"June 15, 2010","01/06/2010","",2009-10-01,"Change from baseline in percent net erosion resistance (%NER)|Change from baseline in percent surface microhardness recovery (%SMHR)","http://ClinicalTrials.gov/show/NCT01128972",NA
"60979",60979,"NCT01214772","The Effect of Heparin in Treatment IVF-ET Failure","Completed","No Results Available","Pregnancy|Thrombophilia","Drug: heparin","Yazd Medical University|Yazd Research & Clinical Center for Infertility","Female","Adult","Phase IV",86,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","1378","September 28, 2010","01/05/2009",2010-06-01,"October 1, 2010","01/10/2010","",2009-09-01,"chemical pregnancy rate|clinical pregnancy rate","http://ClinicalTrials.gov/show/NCT01214772",NA
"61100",61100,"NCT00061373","Adjunctive Drug Treatment for Ischemic Stroke Patients","Completed","No Results Available","Cerebrovascular Accident","Drug: Eptifibatide in combination w Aspirin, Tinzaparin sodium","National Institute of Neurological Disorders and Stroke (NINDS)","Both","Adult|Senior","Phase II",18,"NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","030171|03-N-0171","May 23, 2003","01/05/2003",2009-12-01,"September 17, 2010","01/12/2009","",2009-12-01,"Symptomatic ICH, major systemic hemorrhage, or other serious adverse event related to study drug administration, including death, occurring after study drug initiation and prior to the 72-hour safety head CT.|Secondary safety outcomes will be all ICH types (fatal, symptomatic, asymptomatic), all bleeding (major, minor, insignificant), deaths, serious adverse events at 72 hrs, 5 days, and 30 days. Reperfusion on MRI and clinical improvements are also ...","http://ClinicalTrials.gov/show/NCT00061373",NA
"61110",61110,"NCT00087373","Vaccine Therapy in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)","Biological: recombinant fowlpox-TRICOM vaccine","University of Chicago|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",28,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000374979|UCCRC-12759A|NCI-6038","July 8, 2004","01/06/2004",NA,"March 13, 2010","01/08/2006","",2009-06-01,"Safety and tolerability|Local response rate (complete or partial response, stable or progressive disease)|Overall clinical response as measured by RECIST criteria|Change in mRNA expression of B7-1, LFA-3, and/or ICAM-1in the tumor microenvironment and correlate with response|Change in tumor-associated T cells and correlate with response|Time to tumor progression","http://ClinicalTrials.gov/show/NCT00087373",NA
"61126",61126,"NCT00109473","Trial of Growth Hormone Therapy in Pediatric Crohn's Disease","Completed","No Results Available","Crohn's Disease","Drug: Somatropin, E-coli Derived","Children's Hospital Medical Center, Cincinnati|Genentech","Both","Child|Adult|Senior","Phase II",22,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CCHMC IRB #: 04-12-06|FDA IND#: 71344","April 28, 2005","01/04/2005",2009-08-01,"August 10, 2010","01/08/2010","",2009-07-01,"The primary endpoint will be the CD histologic index of severity (CDHIS)|Serum IGF-1|Colon crypt epithelial cell (CEC) proliferation labeling index|IMPACT III|Pediatric Crohn's disease Activity Index|Total corticosteroid use|Intra-abdominal fat|Height velocity|Fecal Calprotectin","http://ClinicalTrials.gov/show/NCT00109473",NA
"61195",61195,"NCT00219973","CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)","Completed","No Results Available","Cancer|Venous Thromboembolism","Drug: Bemiparin","Rovi Pharmaceuticals Laboratories","Both","Adult|Senior","Phase III",526,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","ROV-BEM-2003-02","September 19, 2005","01/05/2005",2009-04-01,"April 27, 2010","01/04/2010","",2009-04-01,"EFFICACY: Combined incidence (from day 1 to day 20??2 after the randomisation): total DVT + non-fatal PE + all-cause mortality.|SAFETY: incidence of major bleeding (from day 1 to day 20??2 after the randomisation).|EFFICACY: combined and isolated incidence of DVT (Total, proximal and distal), non-fatal PE, deaths related and not related with VTE.|SAFETY: incidence of major bleeding (from day 1 to day 82??8 after the randomisation) and incidence of minor bleeding (from day 1 to day 20??2 and to day 82??8 after the randomisation).|EXPLORATORY ANALYSES: Biological markers, tumour evolution and survival at 6 months.","http://ClinicalTrials.gov/show/NCT00219973",NA
"61215",61215,"NCT00252473","S-Frame CT Immobilization Masks For Patients Undergoing Radiation Therapy For Head and Neck Cancer","Completed","No Results Available","Head and Neck Neoplasms","Device: MedTec S-frame Immobilization Masks","University Health Network, Toronto|Princess Margaret Hospital, Canada","Both","Adult|Senior","Phase II",30,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 02-0832-C","November 9, 2005","01/01/2005",2009-06-01,"August 12, 2010","01/08/2010","",2009-06-01,"Measurement of the accuracy of MedTec S-frame head and neck immobilization system (isocentre set-up accuracy, patient movement margins and movement of the normal tissue critical structures and planning target volumes)","http://ClinicalTrials.gov/show/NCT00252473",NA
"61269",61269,"NCT00316173","Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer","Completed","Has Results","Ovarian Cancer","Drug: topotecan|Drug: CARBOPLATIN","GlaxoSmithKline","Female","Adult|Senior","Phase II",77,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","104864/902","April 19, 2006","01/03/2005",2009-03-01,"December 17, 2009","01/12/2009","",2009-01-01,"Number of Participants With the Indicated Response|Time to Response|Duration of Response|Progression-free Survival|Number of Participants Who Died From the Start of Treatment to Follow-up|The Number of Participants Classified as Responders in Cancer Antigen 125 (CA-125)|Time to Disease Progression","http://ClinicalTrials.gov/show/NCT00316173",NA
"61293",61293,"NCT00369473","Long-Term Assessment of Safety and Physical Function With AMG 108 in RA","Completed","No Results Available","Rheumatoid Arthritis","Drug: AMG 108|Drug: AMG 108","Amgen","Both","Adult|Senior","Phase II",690,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060119","August 24, 2006","01/09/2006",2009-01-01,"April 9, 2009","01/04/2009","",2009-01-01,"To assess long-term safety of AMG 108 SC in subjects with RA previously enrolled in study 20050168|To determine whether long-term use of AMG 108 improves function in subjects with RA","http://ClinicalTrials.gov/show/NCT00369473",NA
"61295",61295,"NCT00373373","Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML","Completed","No Results Available","Acute Myeloid Leukemia","Drug: Sorafenib|Drug: Placebo","University Hospital Muenster|Bayer","Both","Adult|Senior","Phase II",200,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KKS/INNERE_A/AML2006|EudraCT Number: 2005-005966-35|Sorafenib in AML","September 6, 2006","01/09/2006",2009-07-01,"August 18, 2009","01/08/2009","",2009-07-01,"Median Event Free Survival of all AML patients|Median Event Free Survival of AML patients with Flt3-ITD mutations|Median Event Free Survival of the patients in each of the four strata (Flt3 Non-ITD/NPM1 WT, Flt3 Non-ITD/NPM1 mut, Flt3 ITD/NPM1 WT, Flt3 ITD/NPM1 mut)|Median Overall Survival of AML patients with Flt3-ITD mutations|Median Overall Survival of all AML patients|Rate of Complete Remission in all AML patients|Rate of Molecular Remission in all AML patients|Toxicity|Evidence of Minimal Residual Disease in all AML patients|Development of Biomarkers indicating the course of disease","http://ClinicalTrials.gov/show/NCT00373373",NA
"61317",61317,"NCT00403273","Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Joint","Completed","No Results Available","Arthroplasty, Replacement, Knee","Drug: Botulinum toxin A|Drug: Normal Saline","Minneapolis Veterans Affairs Medical Center|University of Minnesota - Clinical and Translational Science Institute|Arthritis Foundation","Both","Child|Adult|Senior","Phase II",50,"U.S. Fed|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1-singh","November 21, 2006","01/07/2006",2009-01-01,"April 6, 2009","01/04/2009","",2009-01-01,"proportion with clinically meaningful Change in Pain Severity (0-10)|Patient global assessment of response to treatment|Physician global assessment of response to treatment|Improvement in Physical Function subscale of the WOMAC and WOMAC total|Time to Onset of Pain Relief and duration of pain relief|Change in joint function as measured by active and passive range of motion, and Time to perform sit to stand 10 times without using arms to push up (Timed Stands Test) and Timed up-and-go (TUG) tests|QOL: SF-36 scores, a generic health status measure|Clinical assessment of joint erythema, warmth, swelling and tenderness|Manual muscle strength testing of flexion and extension.|Proportion with Minimal Clinically Important Improvement (MCII) on VAS pain, WOMAC pain, physical function, stiffness subscales and total scores|correlation of Baseline Serum and Joint Fluid Cytokine Levels with baseline pain and function|Correlation of Change in Serum and Joint Fluid Cytokine Levels with improvement in pain and function|McGill Sensory pain, affective pain and total score","http://ClinicalTrials.gov/show/NCT00403273",NA
"61336",61336,"NCT00434473","IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome","Completed","No Results Available","Sickle Cell Disease|Vaso-occlusive Crisis|Acute Chest Syndrome","Drug: A-001|Other: Placebo","Anthera Pharmaceuticals","Both","Child|Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AN-SCD1121","February 9, 2007","01/12/2006",2009-12-01,"April 28, 2010","01/04/2010","",2009-08-01,"To determine the safety and tolerability of different doses of A 001 therapy when administered as a 2-day continuous infusion to sickle cell disease (SCD) patients at-risk for the acute chest syndrome (ACS).|To determine the pharmacokinetic profile of A-001 in SCD patients|To confirm the ability of A-001 infusion to suppress serum sPLA2 activity in SCD patients with elevated serum sPLA2|To determine the efficacy of A-001 infusion in preventing ACS in SCD patients with the combination of vaso-occlusive crisis (VOC), fever, and elevated serum sPLA2","http://ClinicalTrials.gov/show/NCT00434473",NA
"61342",61342,"NCT00249873","Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)","Completed","Has Results","Atrial Fibrillation|Vascular Risk","Drug: clopidogrel (SR25990C)|Drug: placebo","Sanofi-Aventis|Bristol-Myers Squibb","Both","Adult|Senior","Phase III",7554,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","EFC4912 A","November 4, 2005","01/06/2003",2009-03-01,"March 31, 2010","01/03/2010","",2009-03-01,"First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication|Occurrence of Stroke|Death From Any Cause (Cardiovascular and Noncardiovascular)|Adjudicated Major Bleedings","http://ClinicalTrials.gov/show/NCT00249873",NA
"61367",61367,"NCT00468273","A Clinical Study of the PK, Efficacy and Safety of Omr-IgG-am IGIV in Subjects With Primary Immune Deficiency Diseases","Completed","No Results Available","Immunologic Deficiency Syndromes","Drug: Intravenous Immune Globulin","FFF Enterprises","Both","Child|Adult|Senior","Phase III",57,"Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","GAM-PID-03-US","May 1, 2007","01/11/2006",2009-08-01,"July 6, 2010","01/07/2010","",2009-05-01,"Incidence of acute serious bacterial infections|IgG pharmacokinetics|Incidence of adverse events that occur during or within 1 hour, 24 hours and 72 hours following infusion|The number of hospitalizations and days of hospitalization per subject per year for PID related infections|The incidence of infections other than acute serious bacterial infections|The number of days lost from work/school/usual activities|The number of days of antibiotic therapy (prophylactic and treatment)|Pharmacokinetic parameters of IgG subclasses and specific antibodies will be determined in at least 20 patients: AUC0-t, Cmax, Tmax, t1/2, Vd and elimination rate constants.|Trough levels of IgG subclasses and specific antibodies will be estimated for each subject in the pharmacokinetic study at defined intervals.|The number of patients whose trough IgG levels fall below the target of 500 mg/dL at any time will be recorded.|All adverse events that occur during the study regardless of the investigator's assessment of the relationship to the investigational product.|Laboratory assessments on blood and urine samples including direct antiglobulin (Coomb's) tests.|Markers of blood borne virus infections at baseline and up to 3 months after the last infusion i.e. HIV (serology), HCV (serology and NAT), HBV (HbsAg).","http://ClinicalTrials.gov/show/NCT00468273",NA
"61368",61368,"NCT00478673","Post-Approval Study of the NexStent Carotid Stent System and the FilterWire EZ Embolic Protection System: SONOMA","Completed","No Results Available","Extracranial Carotid Artery Stenosis","Device: NexStent Carotid Stent System (Monorail Delivery System)|Device: FilterWire EZ?ºÑ Embolic Protection System","Boston Scientific Corporation","Both","Adult|Senior","Phase IV",298,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S2042|SONOMA","May 24, 2007","01/05/2007",2009-07-01,"September 3, 2009","01/09/2009","SONOMA",2009-07-01,"30-day rate of major adverse events (MAE); 12-month composite rate of major adverse events (MAE) and ipsilateral stroke events that occur within 31-365 days for all subjects.","http://ClinicalTrials.gov/show/NCT00478673",NA
"61370",61370,"NCT00486473","Multihance Versus Magnevist in Breast MRI","Completed","No Results Available","Breast Cancer","Drug: Multihance|Drug: Magnevist","Bracco Diagnostics, Inc","Female","Adult|Senior","Phase III",130,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","MH 131","June 13, 2007","01/07/2007",2009-12-01,"July 14, 2010","01/07/2010","DETECT",2009-12-01,"Sensitivity in diagnosing breast lesions compared to histopathology results|Sensitivity, specificity, accuracy, PPV and NPV at region, breast and patient levels","http://ClinicalTrials.gov/show/NCT00486473",NA
"61395",61395,"NCT00522873","Endometrial Safety Study","Completed","No Results Available","Postmenopause","Drug: SH K 04739 B|Drug: SH K 04739 E","Bayer|Laboratorium f??r Klinische Forschung|Diagnostic Cytology Laboratory|University of California, San Francisco","Female","Adult","Phase III",662,"Industry|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91508|EudraCT No. 2006-006199-39|310523","August 29, 2007","01/08/2007",2009-08-01,"September 21, 2010","01/09/2010","",2009-08-01,"The proportion of subjects with an assessment of endometrial hyperplasia or worse during or after one year of treatment.|The incidence of amenorrhea (no bleeding or spotting) during months 1-3 and 10-12 of treatment.","http://ClinicalTrials.gov/show/NCT00522873",NA
"61397",61397,"NCT00534573","Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation","Completed","No Results Available","Clozapine-induced Hypersalivation","Drug: Amisulpride, Moclobemide","Beersheva Mental Health Center|Tirat Carmel Mental Health Center","Both","Adult","Phase III",54,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","LCK4569|ISRCTN4569|ISRCTN4569","September 24, 2007","01/11/2008",2009-01-01,"June 28, 2010","01/11/2009","CIH",2009-01-01,"Hypersalivation will be assessed by subjective and objective tools. Clinical global impression (CGI) patient's self assessment will be taken as subjective tool and NHRS as an objective assessment tool.|CGI, NHRS","http://ClinicalTrials.gov/show/NCT00534573",NA
"61399",61399,"NCT00528073","Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease","Completed","No Results Available","Crohn's Disease","Drug: Rifaximin-EIR","Alfa Wassermann S.p.A.","Both","Adult|Senior","Phase II",410,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RETIC/03/06|EudraCT: 2007-001014-17","September 10, 2007","01/09/2007",2009-10-01,"February 19, 2010","01/02/2010","",2009-03-01,"Clinical remission (Crohn's Disease Activity Index < 150 points)|Clinical response (reduction of baseline CDAI score by 100 points or more)|Clinical response (reduction of baseline CDAI by 70 points or more)|Time to obtain clinical response and remission|Maintenance of clinical remission|Maintenance of clinical remission|Number of treatment failures|Definition of therapeutic dose to be used in subsequent phase III trials.|Adverse events","http://ClinicalTrials.gov/show/NCT00528073",NA
"61414",61414,"NCT00557973","A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury","Completed","No Results Available","Muscle Spasticity","Drug: XP19986, 10 mg BID|Drug: XP19986, 20 mg BID|Drug: XP19986, 30 mg BID","XenoPort, Inc.","Both","Adult","Phase II",37,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XP-B-065","November 12, 2007","01/12/2007",2009-04-01,"September 10, 2010","01/09/2010","",2009-04-01,"Assessment of muscle tone|Severity and pain associated with muscle spasms; muscle strength and tendon reflexes; sleep symptoms","http://ClinicalTrials.gov/show/NCT00557973",NA
"61425",61425,"NCT00578773","A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea","Completed","No Results Available","Acute Otitis Media","Drug: AL-15469A|Drug: AL-38905","Alcon Research","Both","Child","Phase III",300,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","C-05-38","December 19, 2007","01/11/2007",2009-01-01,"May 7, 2009","01/05/2009","",2009-01-01,"Time to cessation of otorrhea as recorded by the parent or guardian via a patient diary|Clinical cures at each visit|Absence of otorrhea at each visit","http://ClinicalTrials.gov/show/NCT00578773",NA
"61428",61428,"NCT00580073","Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum","Completed","No Results Available","Rectal Cancer","Drug: FOLFOX4|Drug: Cetuximab","University of Wisconsin, Madison|Sanofi-Aventis|Bristol-Myers Squibb|ImClone LLC","Both","Adult|Senior","Phase II",6,"Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-0197 (CO06207)","December 17, 2007","01/12/2007",2009-11-01,"October 15, 2010","01/10/2010","",2009-11-01,"response to therapy","http://ClinicalTrials.gov/show/NCT00580073",NA
"61431",61431,"NCT00586573","Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS","Completed","No Results Available","ADHD|ADHD NOS","Drug: memantine hydrochloride","Massachusetts General Hospital","Both","Adult","Phase IV",20,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-P-000067","December 28, 2007","01/03/2007",2009-10-01,"June 21, 2010","01/06/2010","",2009-10-01,"DSM-IV ADHD Rating Scale|BRIEF-A|CANTAB","http://ClinicalTrials.gov/show/NCT00586573",NA
"61444",61444,"NCT00598273","Safety & Efficacy of Hematide?ºÑ for the Correction of Anemia in Patients With Chronic Renal Failure","Completed","No Results Available","Chronic Renal Failure|Anemia","Drug: Hematide?ºÑ|Drug: Hematide?ºÑ|Drug: Darbepoetin Alfa","Affymax","Both","Adult|Senior","Phase III",490,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AFX01-11","January 10, 2008","01/10/2007",2009-12-01,"October 7, 2010","01/10/2010","PEARL 1",2009-12-01,"Mean change in Hgb between baseline and the Evaluation Period.|Proportion of patients who received RBC transfusions during the Correction and Evaluation Periods.|Proportion of patients achieving Hgb response during the Correction and Evaluation Periods.","http://ClinicalTrials.gov/show/NCT00598273",NA
"61445",61445,"NCT00603473","A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures","Completed","No Results Available","Epilepsies, Partial","Drug: gabapentin","Pfizer","Both","Child","Phase III",92,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A9451162","January 16, 2008","01/01/2008",2009-12-01,"January 26, 2010","01/01/2010","",2009-12-01,"To confirm Response Ratio of Gabapentin in Japanese pediatric patients with partial seizures|Responder Rate, Percent change in seizure frequency, Pharmacokinetics|Safety","http://ClinicalTrials.gov/show/NCT00603473",NA
"61446",61446,"NCT00591773","Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Subjects With Essential Hypertension","Completed","No Results Available","Essential Hypertension","Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and chlorthalidone|Drug: Chlorthalidone","Takeda Global Research & Development Center, Inc.","Both","Adult|Senior","Phase III",551,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01-05-TL-491-009|U1111-1113-9040","December 27, 2007","01/09/2007",2009-03-01,"July 14, 2010","01/07/2010","",2009-03-01,"Change from baseline to Week 6 in the 24-hour mean systolic blood pressure by ambulatory blood pressure monitor.|Change from baseline to Week 6 in trough clinic sitting systolic blood pressure.|Change from baseline to Week 6 in the 24-hour mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline to Week 6 in trough clinic sitting diastolic blood pressure.|Change from baseline for daytime mean (6am to 10pm) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for daytime mean (6am to 10pm) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) diastolic blood pressure by ambulatory blood pressure monitor|Proportion of subjects who achieve a Clinic Diastolic Blood Pressure Response, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg|Proportion of subjects who achieve a Clinic Systolic Blood Pressure Response, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg|Proportion of subjects who achieve both a clinic Diastolic and Systolic Blood Pressure Response","http://ClinicalTrials.gov/show/NCT00591773",NA
"61449",61449,"NCT00607373","Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia","Completed","No Results Available","Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders","Drug: ISIS 301012 (mipomersen sodium)|Drug: Placebo","Genzyme|Isis Pharmaceuticals","Both","Child|Adult|Senior","Phase III",51,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","301012-CS5|2005-003449-15","January 22, 2008","01/09/2007",2009-04-01,"October 2, 2010","01/10/2010","RADICHOL 1",2009-03-01,"To evaluate the LDL-C lowering efficacy of ISIS 301012 (mipomersen) in subjects with homozygous familial hypercholesterolemia on lipid-lowering therapy|To evaluate the incremental apoB-lowering efficacy of ISIS 301012 (mipomersen)|To assess the incremental total cholesterol-lowering efficacy of ISIS 301012 (mipomersen)|To assess the incremental non-HDL-C-lowering efficacy of ISIS 301012 (mipomersen)|To evaluate the incremental effects of ISIS 301012 (mipomersen) on triglycerides, VLDL-C, HDL-C, apoA-1, Lp(a), lipoprotein subclasses, and hsCRP","http://ClinicalTrials.gov/show/NCT00607373",NA
"61461",61461,"NCT00625573","Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)","Completed","No Results Available","Colorectal Cancer","Drug: Abraxane","Mt. Sinai Medical Center, Miami|Abraxis BioScience, LLC.","Both","Adult|Senior","Phase II",29,"Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COL-01","February 19, 2008","01/09/2007",2009-03-01,"September 17, 2009","01/09/2009","ABX067",2009-02-01,"To evaluate the efficacy by means of response rate of Abraxane and capecitabine in combination, in the treatment of patients with colorectal cancer in the 2nd or 3rd line metastatic setting following failure of irinotecan or oxaliplatin based therapy|To evaluate overall survival, time to progression, response duration, time to response and safety of this combination","http://ClinicalTrials.gov/show/NCT00625573",NA
"61469",61469,"NCT00642473","MATER Study: A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: erlotinib [Tarceva]|Drug: metronidazole actavis 1% topical cream","Hoffmann-La Roche","Both","Adult|Senior","Phase II",34,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21308|2007-002895-32","March 19, 2008","",2009-03-01,"June 16, 2009","01/06/2009","",2009-03-01,"Frequency and intensity of Tarceva-associated rash (CTC AE v3.0)|Adverse events","http://ClinicalTrials.gov/show/NCT00642473",NA
"61492",61492,"NCT00671073","Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: Oglemilast|Drug: Placebo|Drug: Oglemilast|Drug: Oglemilast","Forest Laboratories","Both","Adult|Senior","Phase II",400,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","GRC-MD-50","April 29, 2008","01/04/2008",NA,"May 27, 2009","01/05/2009","",2009-05-01,"Pre-bronchodilator morning (trough) forced expiratory volume in 1 second (FEV1)|Pre-bronchodilator forced vital capacity (FVC)","http://ClinicalTrials.gov/show/NCT00671073",NA
"61498",61498,"NCT00687973","Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5mg","Completed","No Results Available","Hypertension","Drug: Amlodipine/Valsartan|Drug: Amlodipine","Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",474,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CVAA489AFR02","March 20, 2008","01/01/2008",NA,"May 19, 2009","01/05/2009","",2009-01-01,"central SBP measured at carotid artery level ( assessed with Sphygmocor system, Atcor Medical, Sydney, Australia) : difference in reduction of central SBP at baseline and at 24 weeks between the two arms|central pressure assessed with Sphygmocor system (Atcor Medical, Sydney, Australia)","http://ClinicalTrials.gov/show/NCT00687973",NA
"61513",61513,"NCT00703573","Phase IIa Safety and Efficacy of S-777469 in Patients With Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Drug: S-777469|Drug: S-777469|Drug: Placebo","Shionogi USA, Inc.","Both","Adult","Phase II",209,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0721D1424","June 20, 2008","01/05/2008",2009-12-01,"February 3, 2010","01/02/2010","POC",2009-05-01,"Physician Global Assessment (PGA)|Itch Numerical Rating Score (NRS)|Itch Behavioral Rating Score (BRS)|Eczema Area and Severity Index (EASI)|Digital Photography with IPR|Thymus Activation-Regulated Chemokine (TARC)|Skindex-16 Quality of Life Determination","http://ClinicalTrials.gov/show/NCT00703573",NA
"61528",61528,"NCT00733473","Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing","Completed","No Results Available","Asthma|Acute Asthma","Drug: Budesonide 0.5 mg/ml nebules|Drug: % 0.9 Saline solution","Kecioren Education and Training Hospital","Both","Child","Phase IV",100,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B.10.0.??EG.0.11.00.01-3246","August 12, 2008","01/09/2007",2010-01-01,"February 22, 2010","01/09/2009","",2009-12-01,"Time to discharge from the hospital to home|Pulmonary index score|Respiratory rate|Oxygen saturation|Adverse reactions.","http://ClinicalTrials.gov/show/NCT00733473",NA
"61531",61531,"NCT00739973","Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension","Completed","No Results Available","Hypertension","Drug: Aliskiren|Drug: Aliskiren|Drug: Amlodipine|Drug: Amlodipine|Drug: Aliskiren/amlodipine|Drug: Aliskiren/amlodipine|Drug: Aliskiren/amlodipine|Drug: Aliskiren/amlodipine|Drug: Placebo","Novartis","Both","Adult|Senior","Phase III",1688,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CSPA100A2305","August 20, 2008","01/09/2008",NA,"October 16, 2009","01/10/2009","",2009-05-01,"Vital signs at every visit|Vital signs at every visit|Adverse events at every visit|24-hour blood pressure profile of in a subset of patients at Day 1 and Day 56 (end of study)|Biomarker assessments (PRA, PRC) at Day 1 and Day 56 in subset of patients.","http://ClinicalTrials.gov/show/NCT00739973",NA
"61573",61573,"NCT00812773","Study to Evaluate GSK2190915 in Subjects With Mild Asthma","Completed","No Results Available","Mild Asthma","Drug: GSK2190915","GlaxoSmithKline","Both","Adult","Phase II",17,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","112356","December 8, 2008","01/12/2008",2009-07-01,"September 3, 2009","01/09/2009","",2009-07-01,"Early Asthmatic Response|Lung function as measured by FEV1|Assess safety and tolerability","http://ClinicalTrials.gov/show/NCT00812773",NA
"61592",61592,"NCT00824473","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Placebo|Drug: 0.15% azelastine hydrochloride","Meda Pharmaceuticals","Both","Child|Adult|Senior","Phase III",506,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP443","January 14, 2009","01/12/2008",2009-02-01,"February 19, 2010","01/02/2010","",2009-02-01,"Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days|Mean Change From Baseline in Instantaneous Total Nasal Symptom Sscore (AM) for the Entire 14-day Study Period Compared to Placebo|Change From Baseline in Instantaneous Total Nasal Symptom Score for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)|Change From Baseline in 12-hour Reflective Total Ocular Symptom Score and Instantaneous Total Ocular Symptom Score for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)|Change From Baseline to Visit 4 in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Compared to Placebo in Subjects 18 Years of Age and Older|Change From Baseline on Direct Visual Nasal Exams to 14 Days","http://ClinicalTrials.gov/show/NCT00824473",NA
"61605",61605,"NCT00866073","Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia","Completed","No Results Available","Acute Myeloid Leukemia","Drug: Decitabine 15 mg/m2 i.v.","University Hospital Freiburg","Both","Adult|Senior","Phase II",238,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","331","March 19, 2009","01/04/2003",2009-03-01,"March 19, 2009","01/03/2009","",2009-02-01,"response rate (complete and partial remissions, antileukemic effect)|overall survival|progression-free survival time|toxicity of Decitabine (alone and in combination with all-trans retinoic acid)","http://ClinicalTrials.gov/show/NCT00866073",NA
"61620",61620,"NCT00889473","Study of the Efficacy of AT1001 (Larazotide Acetate) to Treat Celiac Disease","Completed","No Results Available","Celiac Disease","Drug: Larazotide acetate (AT1001)|Drug: Placebo","Alba Therapeutics","Both","Adult|Senior","Phase II",42,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLIN1001-006 Part B","April 27, 2009","01/04/2009",2010-04-01,"August 12, 2010","01/01/2010","",2009-11-01,"Response to gluten|Anti-transglutaminase","http://ClinicalTrials.gov/show/NCT00889473",NA
"61636",61636,"NCT00912873","Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks","Completed","No Results Available","Hip Arthroplasty|Hip Pain","Drug: ropivicaine (Psoas compartment block)","University of California, San Diego","Both","Adult|Senior","Phase IV",50,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","Hip Concentration Study","June 1, 2009","01/05/2008",2009-06-01,"January 13, 2010","01/06/2009","",2009-06-01,"Quadriceps femoris muscle strength, by measuring the maximum voluntary isometric contraction (MVIC). The difference in MVIC on POD1 compared with the preoperative MVIC, expressed as a percentage of the preoperative MVIC.|Hip adductor strength, evaluated in sitting position using the same technique as described for the primary outcome measure.|Hip flexor strength, evaluated in the supine position using the same technique as described for the primary outcome measure.|Sensory level, evaluated in the seated position, the current through TES is increased from 0mV until the patient describes mild discomfort and the current is then recorded.|Ambulatory ability, evaluated using the 100-foot walk test and the six minute walk test. Afer patients walk 100 feet, they will continue to walk for six minutes and the total distance will be recorded.|Range of motion, evaluated using a standard goniometer for hip flexion within precaution limits.|Weight bearing, evaluated using a standard scale to demonstrate the correct amount of weight to place on an operative extremity.|Pain, evaluated using a verbal rating scale of 0-10, where 0=no pain and 10=worst imaginable pain.|Sample size estimation, as centered around our primary null hypothesis that differing the concentration but providing an equal total dose of ropivicaine has no impact on the percentage drop in quadriceps muscle strength.","http://ClinicalTrials.gov/show/NCT00912873",NA
"61708",61708,"NCT01035073","Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome","Completed","No Results Available","Major Depressive Disorder|Soft Tissue Discomfort Syndrome|Pain","Drug: Duloxetine","University of Pennsylvania|Eli Lilly and Company","Both","Adult|Senior","Phase IV",22,"Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","F1J-US-X018","December 17, 2009","01/04/2006",2009-05-01,"December 17, 2009","01/12/2009","",2009-05-01,"24-hour activity level|Functional Symptom Questionnaire","http://ClinicalTrials.gov/show/NCT01035073",NA
"61751",61751,"NCT01120873","The Effect of Metamin 3D on the Lipid and Glucose in Subjects With Metabolic Syndrome","Completed","No Results Available","Metabolic Syndrome","Drug: Metamin 3D","Taichung Veterans General Hospital","Both","Adult|Senior","Phase III",110,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","S06203","May 5, 2010","01/03/2007",2009-06-01,"May 10, 2010","01/05/2010","",2009-06-01,"Total cholesterol|Total cholesterol|Triglycerides|Low-density lipoprotein cholesterol|The plasma insulin by meal tolerant test|Glycosylated hemoglobin|Fasting plasma glucose|Systolic and diastolic blood pressure|Triglycerides|The plasma glucose by meal tolerant test|Glycosylated hemoglobin|Fasting plasma glucose|Aspartate aminotransferase|Alanine aminotransferase|Creatinine","http://ClinicalTrials.gov/show/NCT01120873",NA
"61766",61766,"NCT01150773","Study Using Gentamicin Sponge in Surgical Subjects at Higher Risk for Wound Infection","Completed","No Results Available","Surgical Wound Infections","Other: collatamp-G sponge","University of South Alabama","Both","Adult|Senior","Phase III",10,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","INN-SWI-002","June 23, 2010","01/03/2008",2009-08-01,"June 24, 2010","01/06/2010","",2009-08-01,"Efficacy will be evaluated by a comparison between 2 study groups of the incidence of surgical wound infections that occur within the period from surgery through post-op day 60.","http://ClinicalTrials.gov/show/NCT01150773",NA
"61791",61791,"NCT01189773","Combined Analgesia to Control Pain in Children Seen in Emergency Department (ED) for a Trauma of a Limb","Completed","No Results Available","Trauma","Drug: ibuprofen and codeine","St. Justine's Hospital","Both","Child|Adult","Phase IV",200,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2633","May 11, 2010","01/02/2008",2009-10-01,"August 26, 2010","01/05/2010","",2009-10-01,"pain level on Verbal Analogue Scale (VAS) 60 minutes post administration of meds|pain level on Verbal Analogue Scale (VAS) 120 minutes post study meds|side-effects of study meds","http://ClinicalTrials.gov/show/NCT01189773",NA
"61845",61845,"NCT01279473","Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)","Completed","No Results Available","Chronic Myelogenous Leukemia|Acute Lymphoblastic Leukemia","Drug: Nilotinib","Novartis Pharmaceuticals","Both","Adult|Senior","Phase I|Phase II",42,"Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CAMN107A1101E1|TAS-3-01","December 2, 2010","01/08/2005",NA,"January 18, 2011","01/01/2011","",2009-12-01,"Number of Adverse Events|Best hematologic response rate and Best cytogenetic response rate.|Percentage of BCR-ABL genes transcript and mutation status of BCR-ABL","http://ClinicalTrials.gov/show/NCT01279473",NA
"61906",61906,"NCT00028574","Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer","Completed","No Results Available","Hot Flashes|Prostate Cancer","Drug: gabapentin","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Male","Adult|Senior","Phase III",220,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care","CDR0000069107|NCCTG-N00CB|NCI-P01-0199","January 4, 2002","01/12/2001",NA,"July 20, 2010","01/12/2006","",2009-11-01,"Hot flash reduction by diary scores at 4 weeks|Toxicity by questionnaires at 4 weeks","http://ClinicalTrials.gov/show/NCT00028574",NA
"61938",61938,"NCT00088374","17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease","Completed","No Results Available","Hippel-Lindau Disease|Kidney Cancer","Drug: 17 allylamino-17-demethoxygeldanamycin|Drug: 18 FDG|Drug: [15-O] H2O|Drug: EPL diluent","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",9,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","040238|04-C-0238","July 23, 2004","01/07/2004",2009-01-01,"December 23, 2010","01/12/2010","",2009-01-01,"Response of renal tumors after 3 courses of study therapy.|Effect of 17-N-allylamino-17-demethoxygeldanamycin (17AAG) on nonrenal tumors.","http://ClinicalTrials.gov/show/NCT00088374",NA
"62006",62006,"NCT00183274","Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR","Completed","No Results Available","Anxiety Disorders","Drug: Venlafaxine XR|Drug: Placebo","National Institute of Mental Health (NIMH)","Both","Adult|Senior","Phase IV",330,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01 MH65963|DSIR 83-ATAS","September 12, 2005","01/01/2004",2009-09-01,"October 12, 2010","01/09/2008","",2009-09-01,"Relapse of GAD|Anxiety, depression, and GAD symptoms","http://ClinicalTrials.gov/show/NCT00183274",NA
"62010",62010,"NCT00193674","Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage","Completed","No Results Available","Recurrent Miscarriage","Drug: Dydrogesterone|Drug: Placebo","Solvay Pharmaceuticals","Female","Adult","Phase III",77,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S102.3.116","September 11, 2005","01/09/2003",2009-09-01,"September 24, 2009","01/09/2009","",2009-09-01,"Cytokine ratio IFN/IL-10|Exploratory analysis of pregnancy outcome by monitoring biochemical and clinical pregnancy parameters, weekly evaluation of serum progesterone","http://ClinicalTrials.gov/show/NCT00193674",NA
"62018",62018,"NCT00205374","Use of Cidofovir for Recurrent Respiratory Papillomatosis","Completed","No Results Available","Recurrent Respiratory Papillomatosis","Drug: Cidofovir|Drug: Placebo","University of Wisconsin, Madison","Both","Child|Adult|Senior","Phase IV",19,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","1999-196","September 13, 2005","01/11/1999",2009-12-01,"June 24, 2010","01/06/2010","",2009-12-01,"Reduction in papilloma severity|There are no secondary outcome measures","http://ClinicalTrials.gov/show/NCT00205374",NA
"62090",62090,"NCT00306774","Vitamin D to Slow Progression of Knee Osteoarthritis","Completed","No Results Available","Osteoarthritis, Knee","Dietary Supplement: Vitamin D (cholecalciferol)|Dietary Supplement: Placebo","National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Office of Dietary Supplements (ODS)","Both","Adult|Senior","Phase II",146,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01 AR051361|R01 AR51361","March 22, 2006","01/03/2006",2009-06-01,"July 12, 2010","01/07/2010","",2009-06-01,"Cartilage volume loss (MRI)|Knee symptoms (WOMAC questionnaire)|Physical function|Quality of life|Pathological (MRI) severity global score","http://ClinicalTrials.gov/show/NCT00306774",NA
"62098",62098,"NCT00314574","A Study of Xolair in Subjects With Moderate to Severe Persistent Asthma (EXTRA)","Completed","No Results Available","Asthma","Drug: omalizumab|Drug: placebo|Drug: corticosteroids|Drug: long-acting beta-agonists","Genentech","Both","Child|Adult|Senior","Phase III",860,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","Q3662g","April 12, 2006","01/04/2006",NA,"January 14, 2010","01/01/2010","",2009-09-01,"Rate of asthma exacerbations|The change in overall asthma-related quality of life|The change in nocturnal and daytime asthma symptom scores|The change in the number of puffs per day of beta agonist rescue medication|Frequency and severity of treatment-emergent adverse events","http://ClinicalTrials.gov/show/NCT00314574",NA
"62121",62121,"NCT00363974","Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML","Completed","No Results Available","Leukemia, Myelomonocytic, Acute","Drug: XIAP antisense","Aegera Therapeutics","Both","Adult|Senior","Phase I|Phase II",54,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AEG35156-103|MDA 2005-0384|PMH 05-0452-C","August 10, 2006","01/10/2005",2009-03-01,"November 30, 2009","01/11/2009","",2009-03-01,"Dose at which AEG35156 when combined with fixed doses of ara-C and idarubicin, produces acceptable CR and toxicity rates as defined and observed at 30 days post-last dose|Effects of AEG35156 on XIAP mRNA and protein expression and plasma pharmacokinetic profile of AEG35156.","http://ClinicalTrials.gov/show/NCT00363974",NA
"62132",62132,"NCT00296374","Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease","Completed","Has Results","Diabetes Mellitus","Drug: Rosuvastatin|Drug: Rosuvastatin|Drug: Atorvastatin","AstraZeneca","Both","Adult|Senior","Phase II",353,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D3569C00007|PLANET 1","February 23, 2006","01/02/2006",2009-03-01,"November 30, 2010","01/11/2010","PLANET 1",2009-03-01,"Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.|Urinary Protein/Creatinine Ratio at Week 26.|Urinary Albumin/Creatinine Ratio at Week 26|Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]|Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26|Change From Baseline in eGFR at Week 52 [LOCF]|Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and TC|Relationship Between Renal Effects and Lipid Changes: eGFR and TC|Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and TG|Relationship Between Renal Effects and Lipid Changes: eGFR and TG|Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio","http://ClinicalTrials.gov/show/NCT00296374",NA
"62143",62143,"NCT00397774","Physical Activity and Functioning in Palliative Cancer Patients - a Clinical Randomised Trial","Completed","No Results Available","Palliative Care|Cancer|Physical Exercise|Physical Function","Behavioral: Physical exercise|Behavioral: physiacl exercise vs treatment as usual","Norwegian University of Science and Technology","Both","Child|Adult|Senior","Phase III",160,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","4.2006.2179","November 9, 2006","01/10/2006",2009-06-01,"November 19, 2009","01/11/2009","",2009-06-01,"Fatigue|Health related quality of life and physical functioning","http://ClinicalTrials.gov/show/NCT00397774",NA
"62167",62167,"NCT00428974","Safety and Efficacy Study of CF101 to Treat Psoriasis","Completed","No Results Available","Plaque Psoriasis","Drug: CF101|Drug: CF101|Drug: CF101|Drug: Placebo","Can-Fite BioPharma","Both","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CF101-201PS","January 29, 2007","01/06/2007",2009-09-01,"September 8, 2009","01/09/2009","",2009-09-01,"Change from Baseline (CFB) in PASI Score, Percent Change from Baseline (PCFB) in PASI Score, PASI 50, and PASI 75|Safety of oral CF101|the proportion of patients who achieve a score of \almost clear\"" or \""clear\"" by PGA|individual PASI components redness","http://ClinicalTrials.gov/show/NCT00428974",NA
"62169",62169,"NCT00435474","Malignant Wounds, Wound Treatment, Psycho-Social Support and Relaxation Therapy","Completed","No Results Available","Cancer|Malignant Wounds","Procedure: Wound treatment|Procedure: wound treatment|Other: psycho-social support|Other: relaxation therapy","Rigshospitalet, Denmark","Both","Adult|Senior","Phase III",70,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","kf 0102006-5491","February 14, 2007","01/04/2007",2009-05-01,"June 8, 2009","01/06/2009","",2009-05-01,"Wound size|Wound odor. Wound infection. Wound exudate. Wound pain. Anxiety and depression. Body-Image.Sexuality.Quality of life.","http://ClinicalTrials.gov/show/NCT00435474",NA
"62200",62200,"NCT00483574","Study of the Safety of Menactra?ó Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers","Completed","No Results Available","Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella","Biological: Menactra?ó: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|Biological: Routine pediatric vaccines","Sanofi-Aventis","Both","Child","Phase III",1378,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","MTA48","June 6, 2007","01/05/2007",2009-04-01,"March 31, 2010","01/03/2010","",2009-01-01,"To provide information concerning the safety of Menactra after vaccination.","http://ClinicalTrials.gov/show/NCT00483574",NA
"62225",62225,"NCT00525174","Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children","Completed","No Results Available","Amblyopia","Device: Bangerter filters|Device: Patching|Procedure: Near activities","Jaeb Center for Health Research|National Eye Institute (NEI)","Both","Child","Phase III",186,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NEI-136|2U10EY011751","August 31, 2007","01/11/2007",2009-01-01,"March 23, 2010","01/08/2009","ATS10",2009-01-01,"Amblyopic and sound eye visual acuity|Time course of visual improvement with Bangerter filter treatment|Compare patient quality of life between patients treated with patching vs Bangerter filters|Determine in the Bangerter filter group whether the degree of blurring of sound eye visual acuity relative to the amblyopic eye visual acuity predicts improvement in acuity|Determine in the Bangerter filter group whether fixation preference is predictive of improvement in visual acuity","http://ClinicalTrials.gov/show/NCT00525174",NA
"62228",62228,"NCT00530374","Impact of Sprinkles on Infectious Morbidity When Moderate to Severe Pediatric Malnutrition Is Highly Prevalent","Completed","No Results Available","Malnutrition|Iron Deficiency","Dietary Supplement: Oral Iron Supplement|Dietary Supplement: Placebo","The Hospital for Sick Children|Bangladesh Rural Advancement Committee|International Centre for Diarrhoeal Disease Research, Bangladesh","Both","Child","Phase III",268,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1000009576","September 13, 2007","01/11/2007",2009-04-01,"May 25, 2009","01/05/2009","",2009-01-01,"A composite score based on the sum of all distinct episodes of diarrhea, dysentery and lower respiratory tract infections|Incidence of death and fever without a source [Safety]|Change in haemoglobin concentration after Sprinkles supplementation [Efficacy]","http://ClinicalTrials.gov/show/NCT00530374",NA
"62237",62237,"NCT00543374","Extended Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease","Completed","No Results Available","Crohn's Disease","Drug: adult human mesenchymal stem cells|Drug: adult human mesenchymal stem cells","Osiris Therapeutics","Both","Adult|Senior","Phase III",200,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Osiris 610","October 11, 2007","01/10/2007",2009-07-01,"July 23, 2010","01/07/2010","",2009-07-01,"Duration of clinical benefit|Re-induction of clinical benefit|Improvement in quality of life","http://ClinicalTrials.gov/show/NCT00543374",NA
"62246",62246,"NCT00555074","Sodium Tungstate in Obesity","Completed","No Results Available","Obesity","Drug: Sodium Tungstate|Drug: Placebo","Hospital Clinic of Barcelona|Fundacio Clinic","Both","Adult","Phase II",44,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TROTA-1|EudraCT: 2006-000567-28","November 6, 2007","01/11/2007",2009-05-01,"March 30, 2010","01/05/2008","TROTA-1",2009-05-01,"weight loss|changes in lipids|changes in caloric intake and in hungry sensation|resting metabolic rate|changes in body composition|adverse events|changes in hormonal parameters","http://ClinicalTrials.gov/show/NCT00555074",NA
"62267",62267,"NCT00584974","A Safety, Efficacy and Tolerability Study of SEP-225289","Completed","No Results Available","Depressive Disorder, Major","Drug: SEP-225289|Drug: SEP-225289|Drug: Venlafaxine|Drug: placebo","Sunovion","Both","Adult","Phase II",523,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","360-029","December 21, 2007","01/12/2007",2009-05-01,"November 1, 2010","01/11/2010","",2009-05-01,"To assess the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder (MDD)|To examine the response to SEP-225289 in MDD subjects meeting DSM_IV criteria for atypical and melancholic features","http://ClinicalTrials.gov/show/NCT00584974",NA
"62294",62294,"NCT00618774","An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination","Completed","Has Results","Hypertension","Drug: telmisartan40/amlodipine5|Drug: telmisartan80/amlodipine5","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",259,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1235.16","February 8, 2008","01/01/2008",NA,"March 2, 2010","01/03/2010","",2009-10-01,"Percentage of Participants Who Experienced Adverse Events|Change From Baseline in Seated Diastolic Blood Pressure at Week 8|Change From Baseline in Seated Systolic Blood Pressure at Week 8|Change From Baseline in Seated Diastolic Blood Pressure at Week 48|Change From Baseline in Seated Systolic Blood Pressure at Week 48","http://ClinicalTrials.gov/show/NCT00618774",NA
"62315",62315,"NCT00660374","Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: insulin NPH|Drug: EX1000","Novo Nordisk","Both","Adult|Senior","Phase II",402,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EX1000-1865","February 28, 2008","01/02/2008",2009-03-01,"November 2, 2010","01/11/2010","",2009-03-01,"HbA1c|Fructosamine|FPG|4-point SMPG profiles|Incidence of hypoglycaemic episodes|Frequency and severity of adverse events (including injection site reactions)|Laboratory safety parameters (haematology, biochemistry and lipids)|Physical examination and vital signs|HbA1c","http://ClinicalTrials.gov/show/NCT00660374",NA
"62324",62324,"NCT00672074","Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus","Completed","No Results Available","Ileus","Drug: Ipamorelin|Drug: placebo","Helsinn Therapeutics (U.S.), Inc","Both","Adult|Senior","Phase II",117,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ST-IPAM-201","May 2, 2008","01/04/2008",2009-12-01,"September 1, 2010","01/09/2010","",2009-12-01,"Recovery of GI function","http://ClinicalTrials.gov/show/NCT00672074",NA
"62334",62334,"NCT00642174","Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)","Completed","Has Results","Diabetes Mellitus|Coronary Artery Disease","Drug: prasugrel|Drug: Clopidogrel","Eli Lilly and Company|Daiichi Sankyo Inc.","Both","Adult|Senior","Phase II",35,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11241|H7T-MC-TACA","March 21, 2008","01/04/2008",2009-01-01,"February 19, 2010","01/02/2010","OPTIMUS-3",2009-01-01,"Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow?ºÑ P2Y12 Assay|Inhibition of Platelet Aggregation at 1- and 24-Hours After Loading Dose (LD) and 24-Hours After Last Maintenance Dose (LMD) Assessed by Accumetrics VerifyNow?ºÑ P2Y12 Assay|Maximum Platelet Aggregation (MPA) as Assessed by Light Transmittance Aggregometry (LTA)|Platelet Reactivity Index (PRI)|Inhibition of Platelet Function as Measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate","http://ClinicalTrials.gov/show/NCT00642174",NA
"62379",62379,"NCT00764374","A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia","Completed","No Results Available","Dyspepsia|Functional Dyspepsia","Drug: YM443","Astellas Pharma Inc","Both","Adult|Senior","Phase III",412,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","443-CL-501","September 30, 2008","01/08/2008",2009-12-01,"March 15, 2010","01/03/2010","",2009-12-01,"Subject's global assessment|Disappearance rate of symptoms|Laboratory tests, resting|12-lead ECG|Adverse events","http://ClinicalTrials.gov/show/NCT00764374",NA
"62381",62381,"NCT00765674","Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-Severe Hypertension","Completed","No Results Available","Hypertension","Drug: Aliskiren 150/Amlodipine 5 mg, 300/10 mg|Drug: Aliskiren 150/Hydrochlorothiazide 12.5 mg, 300/25 mg|Drug: Amlodipine 150/Hydrochlorothiazide 12.5 mg, 10/25 mg|Drug: Aliskiren 150/Amlodipine 5/Hydrochlorothiazide 12.5 mg, 300/10/25 mg","Novartis","Both","Adult|Senior","Phase III",1160,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CSAH100A2302","October 2, 2008","01/09/2008",NA,"March 12, 2010","01/03/2010","",2009-08-01,"Vital signs at every visit|Vital signs at every visit|Adverse events at every visit|24-hour ambulatory blood pressure measurement of a subset of patients at Day 1 and Day 56 (end of study)|Pharmacokinetics","http://ClinicalTrials.gov/show/NCT00765674",NA
"62383",62383,"NCT00768274","Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol","Completed","No Results Available","Dyslipidemia|Atherosclerosis|Acute Coronary Syndrome|Cardiovascular Disease","Drug: RVX000222 (common name RVX-208)","Resverlogix Corp","Both","Adult","Phase I|Phase II",72,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RVX222-CS-003","October 7, 2008","01/09/2008",NA,"January 27, 2010","01/01/2010","",2009-08-01,"Safety, pharmacokinetics and changes in lipid parameters from baseline and placebo.","http://ClinicalTrials.gov/show/NCT00768274",NA
"62386",62386,"NCT00755274","Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone?ó","Completed","Has Results","Influenza|Orthomyxoviridae Infections","Biological: Influenza Virus Vaccine No Preservative: Pediatric Dose|Biological: Influenza Virus Vaccine No Preservative: Pediatric Dose","Sanofi-Aventis","Both","Child","Phase IV",32,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","GRC40","September 16, 2008","01/09/2008",2009-01-01,"March 10, 2010","01/03/2010","",2009-01-01,"Number of Participants With Solicited Local and Systemic Reactions After Fluzone?ó Vaccination 1|Number of Participants With Solicited Local and Systemic Reactions After Fluzone?ó Vaccination 2","http://ClinicalTrials.gov/show/NCT00755274",NA
"62387",62387,"NCT00696774","Switching to Duloxetine in Patients With Depression","Completed","Has Results","Depressive Disorder, Major","Drug: Duloxetine","Eli Lilly and Company","Both","Adult|Senior","Phase IV",242,"Industry","Interventional","Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12349|F1J-CR-S022","June 11, 2008","01/06/2008",2009-07-01,"September 2, 2010","01/09/2010","ARDENT",2009-07-01,"Change From Baseline in Brief Pain Inventory-Modified Short Form (BPI-SF) Interference Score Between Responder and Non-Responder Participants at 4 Weeks|Percentage of Participants Meeting Criteria for Response on the 17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Subscale at 4 and 8 Weeks|Change From Baseline HAMD-17 Total Score at 8 Weeks|Change From Baseline HAMD-17 Core Subscale at 8 Weeks|Change From Baseline HAMD-17 Maier Subscale at 8 Weeks|Change From Baseline HAMD-17 Anxiety/Somatization Subscale at 8 Weeks|Change From Baseline HAMD-17 Retardation/Somatization Subscale at 8 Weeks|Change From Baseline HAMD-17 Sleep Subscale at 8 Weeks|Change From Baseline in the Hamilton Anxiety Rating Scale (HAMA) at 8 Weeks|Change From Baseline in the Clinical Global Impression - Severity (CGI-Severity) Scale at 8 Weeks|Change From Baseline in the Brief Pain Inventory - Modified Short Form (BPI-SF) Average Pain Score at 8 Weeks|Change From Baseline in Patient Global Impression - Improvement (PGI-I) Scale Score at 8 Weeks|Change From Baseline in the Sexual Functioning Questionnaire Clinical Version (CSFQ) at 4 and 8 Weeks|Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM) at 4 and 8 Weeks|Change From Baseline in the Sheehan Disability Scale (SDS) at 4 and 8 Weeks","http://ClinicalTrials.gov/show/NCT00696774",NA
"62397",62397,"NCT00789074","Use of Varenicline for 4-weeks Prior to Quitting","Completed","No Results Available","Tobacco Dependence|Smoking Cessation","Drug: Varenicline|Drug: Placebo","Queen Mary University of London","Both","Adult|Senior","Phase III",101,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","qmul120508","November 7, 2008","01/07/2009",2010-03-01,"November 24, 2010","01/06/2010","",2009-12-01,"Rating of urges to smoke 24 hours and one week after the target quit date assessed by Mood and Physical Symptoms Scale|Change in pre-quit end-expired carbon monoxide reading (CO)|Change in pre-quit cotinine levels|Change in pre-quit ratings of cigarette satisfaction|Change in pre-quit cigarette consumption|Change in MPSS scores of urges to smoke and cigarette withdrawal symptoms throughout the first four weeks of abstinence","http://ClinicalTrials.gov/show/NCT00789074",NA
"62405",62405,"NCT00739674","SAALT: Subtracting Salt and Adding Losartan Trial (0954-335)(COMPLETED)","Completed","Has Results","Hypertension","Drug: losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])|Behavioral: Low Salt Diet","Merck","Both","Adult|Senior","Phase III",992,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MK0954A-335|2008_022","August 20, 2008","01/02/2008",2010-01-01,"November 4, 2010","01/11/2010","",2009-07-01,"Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline|Change in Systolic Blood Pressure From Baseline to Week 14|Change in Diastolic Blood Pressure From Baseline to Week 14|Number of Patients Achieving Target Blood Pressure at Week 6 From Baseline|Number of Patients Achieving Target Blood Pressure at Week 10 From Baseline|Number of Patients Achieving Target Blood Pressure at Week 40 From Baseline|Change in Systolic Blood Pressure From Baseline to Week 6|Change in Diastolic Blood Pressure From Baseline to Week 6|Change in Systolic Blood Pressure From Baseline to Week 10|Change in Diastolic Blood Pressure From Baseline to Week 10|Time to Achieve the Target Blood Pressure From Baseline","http://ClinicalTrials.gov/show/NCT00739674",NA
"62453",62453,"NCT00881374","Dermacyd Infantile (Lactic Acid)- Compatibility.","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Both","Adult","Phase IV",50,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","LACAC_L_04679","April 10, 2009","01/02/2009",2009-03-01,"April 14, 2009","01/04/2009","",2009-03-01,"The absence of primary and accumulated dermic irritability and dermic sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.","http://ClinicalTrials.gov/show/NCT00881374",NA
"62457",62457,"NCT00878774","Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis","Completed","No Results Available","Allergy","Biological: ToleroMune Ragweed|Biological: Placebo","Circassia Limited|Adiga Life Sciences","Both","Adult","Phase II",50,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","TR001","April 8, 2009","01/04/2009",2009-11-01,"November 9, 2010","01/11/2010","",2009-11-01,"Safety and tolerability of multiple intradermal injections of ToleroMune Ragweed in ragweed allergic subjects with allergic rhinoconjunctivitis|Mean change from baseline in area of the LPSR 8 hours after intradermal challenge with whole ragweed allergen at PTC after ToleroMune Ragweed injection compared to placebo|Mean change from baseline in area of the EPSR 15 minutes after intradermal challenge with whole ragweed allergen at PTC after ToleroMune Ragweed injection compared to placebo|Mean change from baseline in CPT score at PTC after ToleroMune Ragweed injection compared to placebo|Mean change from baseline in concentration of ragweed specific IgE at PTC after ToleroMune Ragweed injection compared to placebo","http://ClinicalTrials.gov/show/NCT00878774",NA
"62462",62462,"NCT00891774","Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI","Completed","No Results Available","Non Therapeutic Body Modification","Device: EVOLENCE?ó","Johnson & Johnson Consumer & Personal Products Worldwide","Both","Adult|Senior","Phase IV",172,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DP101 US-04","April 30, 2009","01/12/2008",2009-11-01,"December 31, 2009","01/12/2009","",2009-11-01,"Local and systemic adverse events, including pigmentation changes and keloid formation|Reduction in wrinkle severity score|Investigator's satisfaction of the overall treatment|Subject's satisfaction of the overall treatment","http://ClinicalTrials.gov/show/NCT00891774",NA
"62490",62490,"NCT00920374","A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW?ó 2009/2010 in Adults","Completed","Has Results","Seasonal Influenza","Biological: FluarixTM/Influsplit SSW?ó","GlaxoSmithKline","Both","Adult|Senior","Phase III",118,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","113018","June 12, 2009","01/06/2009",2009-07-01,"June 29, 2010","01/06/2010","",2009-07-01,"Hemagglutination Inhibition (HI) Antibody Titer|Number of Subjects With HI Antibody Titer Above the Cut-off Value|Number of Seroprotected Subjects|Number of Seroconverted Subjects|Seroconversion Factor|Seroprotection Power|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Number of Subjects Reporting Serious Adverse Events (SAE)","http://ClinicalTrials.gov/show/NCT00920374",NA
"62523",62523,"NCT00994474","Comparison of Outcome Parameters in Laser Rhytide Treatment","Completed","No Results Available","Skin Aging","Procedure: Fractional carbon dioxide laser treatment|Procedure: Fractional Er:YAG laser treatment","Laserklinik Karlsruhe","Both","Adult","Phase IV",28,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","LK_06_2009","October 13, 2009","01/08/2008",2009-03-01,"October 13, 2009","01/10/2009","",2009-03-01,"Quantitative measurement of wrinkle depth|Fitzpatrick wrinkle score|Patient benefit index (PBI)|Patient satisfaction","http://ClinicalTrials.gov/show/NCT00994474",NA
"62571",62571,"NCT01073774","Side by Side - Prediction of Couples' Adjustment to Breast or Gynecological Cancer","Completed","No Results Available","Enhancing Couples Coping","Behavioral: Side by side|Behavioral: couples control condition","Technical University of Braunschweig|German Research Foundation","Both","Adult|Senior","Phase II",NA,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Crossover Assignment|Masking: Open Label","He61491994|DFG He61481994","February 22, 2010","01/02/2006",2009-12-01,"February 22, 2010","01/02/2010","Side by Side",2009-12-01,"","http://ClinicalTrials.gov/show/NCT01073774",NA
"62592",62592,"NCT01107574","Fibromyalgia Treatment Trial With Gabapentin and Osteopathic Manipulative Medicine","Completed","No Results Available","Fibromyalgia","Drug: Gabapentin|Procedure: Osteopathic Manipulative Medicine|Other: Gabapentin and Osteopathic Manipulative Medicine","Good Samaritan Regional Medical Center, Oregon","Both","Adult","Phase III",41,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","04/01/2004","April 19, 2010","01/04/2004",2010-04-01,"April 20, 2010","01/04/2010","FTTGO",2009-12-01,"Outcomes of Efficacy and Tolerability by measure of scored visual tools|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","http://ClinicalTrials.gov/show/NCT01107574",NA
"62658",62658,"NCT01221974","Use of Essure?ó Micro-inserts in Women With Hydrosalpinx Prior to In Vitro Fertilization: A Prospective, Multicenter, International Feasibility Study","Completed","No Results Available","Women Who Suffer From Hydrosalpinx That is Causing Infertility and Whom Want a Safer Way of Treamtent","Device: Essure Micro Insert","Reproductive Science Center|Shady Grove Fertility","Female","Adult","Phase I|Phase II",NA,"Industry|Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","IVF1","October 4, 2010","01/07/2008",NA,"October 15, 2010","01/10/2010","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT01221974",NA
"62688",62688,"NCT01273974","The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients","Completed","No Results Available","Hemodialysis Patients","Biological: intradermal influenza vaccine|Biological: intramuscular influenza vaccine","Shiraz University of Medical Sciences","Both","Adult|Senior","Phase II|Phase III",130,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","89-5905","January 10, 2011","01/10/2009",2010-02-01,"January 10, 2011","01/08/2010","",2009-11-01,"vaccine effectiveness","http://ClinicalTrials.gov/show/NCT01273974",NA
"62712",62712,"NCT00002975","Photodynamic Therapy in Treating Patients With Skin Cancer","Completed","No Results Available","Non-melanomatous Skin Cancer|Precancerous Condition","Drug: aminolevulinic acid","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Both","Child|Adult|Senior","Phase II",175,"Other|NIH","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000065494|RPCI-DS-96-55|NCI-G97-1224","November 1, 1999","01/02/1997",2010-04-01,"September 15, 2010","01/09/2010","",2009-04-01,"Efficacy|Range of biological variations in PpIX levels and distributions within lesions and skin|Range of biological variations in the rate and extent of treatment-induced photobleaching of the PpIX and recovery from photobleaching|Range of biological variations in photodynamic therapy (PDT)-induced clinical epidermal toxicity|Range of biological variations in PDT-induced tissue damage and host responses on a microscopic level|Range of biological variations in the rate and extent of treatment-induced photobleaching within lesions and skin","http://ClinicalTrials.gov/show/NCT00002975",NA
"62751",62751,"NCT00025675","Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: gefitinib","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","NABTC-0001 CDR0000068984|U01CA062399|ABTC-0001|NABTC-0001","October 11, 2001","01/01/2002",NA,"October 1, 2010","01/10/2010","",2009-06-01,"Progression-free survival at 6 months","http://ClinicalTrials.gov/show/NCT00025675",NA
"62754",62754,"NCT00030875","Bortezomib in Treating Patients With Mantle Cell Lymphoma","Completed","No Results Available","Lymphoma","Drug: bortezomib","NCIC Clinical Trials Group","Both","Adult|Senior","Phase II",NA,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Primary Purpose: Treatment","I150|CAN-NCIC-IND150|CDR0000069207","February 14, 2002","01/07/2002",2009-12-01,"November 7, 2010","01/03/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00030875",NA
"62766",62766,"NCT00049075","Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Drug: fludarabine phosphate","NCIC Clinical Trials Group","Both","Child|Adult|Senior","Phase II",NA,"Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CL2|CAN-NCIC-CL2|BRLX-304160|CDR0000257836","November 12, 2002","01/08/2002",2009-12-01,"November 7, 2010","01/03/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00049075",NA
"62811",62811,"NCT00125775","Does Extra-High Dose Hepatitis B Vaccination Confer Longer Serological Protection in Peritoneal Dialysis Patients?","Completed","No Results Available","Peritoneal Dialysis|Renal Disease, End-Stage","Biological: Engerix-B","Chinese University of Hong Kong","Both","Adult|Senior","Phase IV",130,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CRE-2005.134","August 1, 2005","01/05/2005",2009-12-01,"January 6, 2010","01/07/2009","",2009-12-01,"hepatitis B surface antibody anti-HBs level ??­ 10 IU/L 3 months after completion of the third dose and the persistence of protective anti-HBs 12 months after completion of the third dose of Engerix-B vaccine","http://ClinicalTrials.gov/show/NCT00125775",NA
"62814",62814,"NCT00129675","Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty","Completed","No Results Available","Parkinsonian Syndrome","Procedure: [123I]?È CIT and SPECT imaging","Institute for Neurodegenerative Disorders|Molecular NeuroImaging","Both","Adult|Senior","Phase II",169,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","Query-PD Study","August 11, 2005","01/02/2003",2009-05-01,"August 27, 2009","01/08/2009","",2009-05-01,"Comparison of the imaging diagnosis, based on visual analysis and quantitative analysis, to the clinical diagnosis of the investigator blinded to the imaging results|Comparison of the DAT imaging diagnosis, initial diagnosis by the movement disorder experts and referral neurologist diagnosis to the 'gold standard' diagnosis","http://ClinicalTrials.gov/show/NCT00129675",NA
"62890",62890,"NCT00250575","A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Clozapine","Novartis","Both","Adult","Phase III",43,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLEX123J1301","November 7, 2005","01/11/2005",NA,"May 10, 2010","01/05/2010","",2009-12-01,"Values of hematological tests during the 24 week treatment|Incidence of hematological adverse events during the 24 week treatment|Compliance to Clozapine Patient Monitoring System during the 24 week treatment|Changes in the symptoms of psychosis every 4 weeks up to week 24|Global change in severity of psychosis at baseline and week 12|Global impression of change in the condition of patients at week 12 and 24","http://ClinicalTrials.gov/show/NCT00250575",NA
"62919",62919,"NCT00190775","A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","Completed","Has Results","Attention Deficit Hyperactivity Disorder","Drug: Atomoxetine Hydrochloride|Drug: Placebo","Eli Lilly and Company","Both","Adult|Senior","Phase IV",502,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","9043|B4Z-US-LYCW","September 12, 2005","01/09/2004",2009-10-01,"October 4, 2010","01/10/2010","",2009-07-01,"Change From Baseline to 24 Weeks in the Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scale - Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptoms Score|Change From Baseline to 12 Weeks in the Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scale - Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptoms Score|Change From Baseline to 8 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Participant|Change From Baseline to 24 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Participant|Change From Baseline to 8 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Spouse/Significant Other|Change From Baseline to 24 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Spouse/Significant Other|Change From Baseline to 8 Weeks in the Dyadic Adjustment Scale (DAS) - Participant|Change From Baseline to 24 Weeks in the Dyadic Adjustment Scale (DAS) - Participant|Change From Baseline to 8 Weeks in the Dyadic Adjustment Scale (DAS) - Spouse/Significant Other|Change From Baseline to 24 Weeks in the Dyadic Adjustment Scale (DAS) - Spouse/Significant Other|Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Total Stress and Life Stress|Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Parent Domains|Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Child Domains|Change From Baseline to 24 Weeks in the Parenting Stress Index (PSI) Score - Total Stress and Life Stress|Change From Baseline to 24 Weeks in the Parenting Stress Index (PSI) Score - Parent Domains|Change From Baseline to 24 Weeks in the Parenting Stress Index (PSI) Score - Child Domains|Change From Baseline to 12 Weeks in the Alabama Parenting Questionnaire (APQ) Parent Form|Change From Baseline to 24 Weeks in the Alabama Parenting Questionnaire (APQ) Parent Form|Change From Baseline to 12 Weeks in the Alabama Parenting Questionnaire (APQ) Child Form|Change From Baseline to 24 Weeks in the Alabama Parenting Questionnaire (APQ) Child Form|Mean Change From Baseline to 24 Weeks in the Child Disruptive Behavior Rating Scale (CDBRS) Parent Form|Mean Change From Baseline to 24 Weeks in the Child Disruptive Behavior Rating Scale (CDBRS) Parent Form Oppositional Defiant Disorder (ODD) and Conduct Disorder Flags|Change From Baseline to 8 Weeks in the Parenting Sense of Competence (PSOC) Scale|Change From Baseline to 24 Weeks in the Parenting Sense of Competence (PSOC) Scale|Change From Baseline to 12 and 24 Weeks in the Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale Total and Subscale Scores|Change From Baseline to 8 and 24 Weeks in the Clinical Global Improvement Attention Deficit Hyperactivity Disorder Severity (CGI-ADHD-S)|Change From Baseline to 12 and 24 Weeks in the Montgomery-Asberg Depression Rating Scale Total Score (MADRS)|Change From Baseline to 12 and 24 Weeks in the State-Trait Anxiety Inventories (STAI)|Change From Baseline to 1 Week of Titration in the CAARS-Inv:SV Total Attention Deficit Hyperactivity Disorder (ADHD) Symptoms and Subscale Scores|Change From Baseline to 2 Weeks of Titration in the CAARS-Inv:SV Total Attention Deficit Hyperactivity Disorder (ADHD) Symptoms and Subscale Scores|Change From Baseline to After a 2-Week Titration Period Beginning at Week 24 and Ending at Week 26 in the CAARS-Inv:SV Total Attention Deficit Hyperactivity Disorder (ADHD) Symptoms and Subscale Scores: Dosing Titration Strategy After Placebo","http://ClinicalTrials.gov/show/NCT00190775",NA
"62964",62964,"NCT00372775","Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Sunitinib","Pfizer","Both","Adult|Senior","Phase II",66,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181092","September 5, 2006","01/03/2007",2009-12-01,"August 13, 2010","01/08/2010","",2009-12-01,"Radiographic progression of disease|Radiographic progression of intracranial disease, overall objective disease response, safety evaluated by adverse events and standard laboratory assessments, survival at 1 year, pharmacokinetics, biomarkers and patient reported outcomes.","http://ClinicalTrials.gov/show/NCT00372775",NA
"62974",62974,"NCT00337675","Intermittent and Daily Dosing for Episodic (Periodic) Asthma","Completed","Has Results","Asthma","Drug: montelukast sodium|Drug: Comparator: Placebo (unspecified)|Drug: montelukast sodium","Merck","Both","Child","Phase III",1771,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2006_015|MK0476-302","June 14, 2006","01/10/2006",2009-08-01,"April 20, 2010","01/04/2010","",2009-08-01,"Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period|Daily Average of Wheeze and Difficulty Breathing in the 3 Days Prior to Start of an Asthma Attack Within an Asthma Episode|Daily Average of the Mean Symptom Scores (Wheeze, Difficulty Breathing, Interference With Activity, and Daytime Cough) Assessed Over the 12-day Treatment Period of Asthma Episodes","http://ClinicalTrials.gov/show/NCT00337675",NA
"62990",62990,"NCT00402675","Randomized Trial of Immediate Versus Early and Selective Invasive Percutaneous Coronary Intervention in NSTEMI","Completed","No Results Available","Myocardial Infarction","Procedure: Timing of percutaneous coronary intervention","University of Leipzig","Both","Adult|Senior","Phase IV",600,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Leipzig-4","November 20, 2006","01/07/2006",2010-01-01,"January 4, 2010","01/11/2006","LIPSIA-NSTEMI",2009-12-01,"peak creatine kinase- MB level|Major bleeding complications (GUSTO definition)|Composite: death, re-myocardial infarction, recurrent unstable angina","http://ClinicalTrials.gov/show/NCT00402675",NA
"62994",62994,"NCT00409175","Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis","Completed","No Results Available","Familial Amyloid Polyneuropathy","Drug: Fx-1006A","FoldRx Pharmaceuticals|FDA Office of Orphan Products Development","Both","Adult|Senior","Phase II|Phase III",127,"Industry|U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Fx-005","December 6, 2006","01/12/2006",2009-06-01,"March 9, 2010","01/03/2010","",2009-05-01,"Response to treatment at Month 18 as measured by the Neurologic Impairment Score - Lower Limb (NIS-LL)|Change from Baseline to 18 months in the Total Quality of Life (TQOL) score, as measured by the Norfolk QOL-DN.|Change from Baseline through Month 18 in \+7 composite score\"" as measured by nerve conduction studies (NCS)","http://ClinicalTrials.gov/show/NCT00409175",NA
"63012",63012,"NCT00436475","Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes","Completed","No Results Available","Glucose Intolerance|Type 2 Diabetes Mellitus|Metabolic Syndrome","Drug: Vitamin D3 2,000 IU orally once daily|Drug: Calcium Carbonate 400 mg orally twice daily|Drug: Vitamin D3-Placebo|Drug: Calcium-Placebo","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Office of Dietary Supplements (ODS)|Tufts Medical Center","Both","Adult|Senior","Phase I|Phase II",112,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DK76092 (completed)|DK76092","February 16, 2007","01/09/2007",2009-11-01,"June 13, 2010","01/06/2010","CaDDM",2009-11-01,"Insulin sensitivity, Insulin secretion and Disposition Index|glucose tolerance (fasting, after OGTT), systemic inflammation, lipoprotein profile, blood pressure, body weight and body composition|Genetic studies on Vitamin D related genes and risk of type 2 diabetes and cardiometabolic outcomes|To collect and archive biological specimens (serum, plasma, DNA) so that they can be used for testing of new hypotheses either within the parent stud or through future ancillary studies.","http://ClinicalTrials.gov/show/NCT00436475",NA
"63080",63080,"NCT00522275","Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures","Completed","Has Results","Partial Epilepsies","Drug: lacosamide","UCB, Inc.","Both","Child|Adult|Senior","Phase III",308,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SP756","August 27, 2007","01/10/2004",2009-10-01,"November 23, 2010","01/11/2010","",2009-10-01,"Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (Maximum 6 Years)|Number of Subjects Prematurely Discontinuing Due to a Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (Maximum 6 Years)|Number of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (Maximum 6 Years)|Median Percentage Change From Baseline in 28-day Seizure Frequency During the Treatment Period (Maximum 6 Years)|Percentage of at Least 50% Responders During the Treatment Period (Maximum 6 Years)","http://ClinicalTrials.gov/show/NCT00522275",NA
"63108",63108,"NCT00598975","A Phase 2a/2b Multicenter, Open-Label Study to Evaluate NKTR 102 (PEG-Irinotecan) in Combination With Cetuximab Versus Irinotecan in Combination With Cetuximab in Second Line Colorectal Cancer Patients","Completed","No Results Available","Tumor|Colorectal Cancer","Drug: NKTR-102 + Cetuximab","Nektar Therapeutics","Both","Adult|Senior","Phase II",18,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-PIR-02","January 11, 2008","01/01/2008",NA,"November 11, 2009","01/11/2009","",2009-05-01,"Establish the recommended Phase 2a dose (RPTD) of the combination of NKTR-102 and cetuximab|Safety, pharmacokinetics, and tumor response of NKTR-102 in combination with cetuximab.","http://ClinicalTrials.gov/show/NCT00598975",NA
"63117",63117,"NCT00610675","Fifty Two Week Extension Trial of Org 50081 in the Treatment of Insomnia (176004)(P05708)(COMPLETED)","Completed","No Results Available","Insomnia","Drug: Org 50081","Schering-Plough","Both","Adult","Phase III",309,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","176004|P05708","January 9, 2008","01/12/2006",2009-08-01,"January 14, 2010","01/01/2010","",2009-08-01,"To investigate long term safety with regard to laboratory values and side effect profile of long-term treatment with Org 50081 in adult patients with chronic primary insomnia.|To collect exploratory efficacy data of long-term treatment with Org 50081 in adult patients with chronic primary insomnia.","http://ClinicalTrials.gov/show/NCT00610675",NA
"63122",63122,"NCT00578175","Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad?ó in Children 12-14 Months of Age","Completed","Has Results","Measles-Mumps-Rubella-Varicella Vaccine|Diseases Caused by Measles, Mumps, Rubella and Varicella Viruses.","Biological: Priorix-Tetra?ºÑ (MMRV vaccine 208136)|Biological: ProQuad?ó|Biological: Havrix?ó|Biological: Prevnar?ó","GlaxoSmithKline","Both","Child","Phase II",1851,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","110058","December 20, 2007","01/11/2007",2009-02-01,"December 2, 2010","01/12/2010","",2009-02-01,"Number of Subjects With Seroresponse for Antibodies to Varicella Virus (VZV)|Concentration of Antibodies to Varicella Virus (VZV)|Number of Subjects With Seroresponse for Antibodies to Mumps Virus|Number of Subjects With Seroresponse for Antibodies to Measles Virus|Number of Subjects With Seroresponse for Antibodies to Rubella Virus|Concentration of Antibodies to Hepatitis A Virus (HAV)|Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F|Antibody Titers to Mumps Virus|Concentration of Antibodies to Measles Virus|Concentration of Antibodies to Rubella Virus|Number of Subjects With Vaccine Response to Havrix?ó|Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value|Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value|Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value|Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Fever ??­ 38.0??C/100.4??F and > 39.5??C/103.1??F During the 15-day Follow up Period After Vaccination|Number of Subjects Reporting Fever ??­ 38.0??C/100.4??F and > 39.5??C/103.1??F During the 43-day Follow-up Period After Vaccination|Number of Subjects Reporting Investigator-confirmed Measles/Rubella-like Rash|Number of Subjects Reporting Investigator-confirmed Varicella-like Rash|Number of Subjects Reporting Investigator-confirmed Parotid/Salivary Gland Swelling|Number of Subjects Reporting Unsolicited Adverse Events and Medically-attended Adverse Events (Excluding Rash and Parotid/Salivary Gland Swelling)|Number of Subjects Reporting New Onset Chronic Illnesses and Conditions Prompting Emergency Room Visits|Number of Subjects Reporting Serious Adverse Events","http://ClinicalTrials.gov/show/NCT00578175",NA
"63127",63127,"NCT00552175","A Study for the Treatment of Diabetic Peripheral Neuropathic Pain","Completed","Has Results","Diabetic Neuropathies","Drug: Duloxetine hydrochloride - 40 mg|Drug: placebo|Drug: Duloxetine hydrochloride - 60 mg","Eli Lilly and Company|Shionogi","Both","Adult|Senior","Phase III",339,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12191|0715N0831|F1J-JE-HMFX","October 31, 2007","01/11/2007",2009-03-01,"March 26, 2010","01/03/2010","",2009-03-01,"Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg)|Change From Baseline at Week 12 in Average Pain Severity Rating Score Using Diaries|Change From Baseline at Week 12 in Worst Pain Severity Score and Night Pain Severity Score Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg)|Change From Baseline at Week 12 in Worst Pain Severity Score and Night Pain Severity Score Using Diaries|Patient Global Impression of Improvement Scale at Week 12 in Combined Duloxetine Arms (40 mg + 60 mg)|Patient Global Impression of Improvement Scale at Week 12|Change From Baseline in Brief Pain Inventory Severity Scores at Week 12 for the Combined Duloxetine Arms (40 mg + 60 mg)|Change From Baseline in Brief Pain Inventory Severity Scores at Week 12|Change From Baseline in Brief Pain Inventory Interference Scores at Week 12 for the Combined Duloxetine Arms (40 mg + 60 mg)|Change From Baseline in Brief Pain Inventory Interference Scores at Week 12|Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score at Week 12 for the Combined Duloxetine Arms (40 mg + 60 mg)|Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score at Week 12","http://ClinicalTrials.gov/show/NCT00552175",NA
"63128",63128,"NCT00553475","Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy","Completed","Has Results","Diabetic Neuropathy, Painful","Drug: placebo|Drug: pregabalin|Drug: pregabalin","Pfizer","Both","Adult|Senior","Phase III",314,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A0081163","November 2, 2007","01/10/2007",2009-03-01,"July 16, 2010","01/07/2010","",2009-03-01,"Change From Baseline to Study Endpoint in Mean Weekly Pain Scores|Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations|Number of Responders|Change From Baseline at Week 1 in Mean Weekly Pain Scores|Change From Baseline at Week 2 in Mean Weekly Pain Scores|Change From Baseline at Week 3 in Mean Weekly Pain Scores|Change From Baseline at Week 4 in Mean Weekly Pain Scores|Change From Baseline at Week 5 in Mean Weekly Pain Scores|Change From Baseline at Week 6 in Mean Weekly Pain Scores|Change From Baseline at Week 7 in Mean Weekly Pain Scores|Change From Baseline at Week 8 in Mean Weekly Pain Scores|Change From Baseline at Week 9 in Mean Weekly Pain Scores|Change From Baseline at Week 10 in Mean Weekly Pain Scores|Change From Baseline at Week 11 in Mean Weekly Pain Scores|Change From Baseline at Week 12 in Mean Weekly Pain Scores|Change From Baseline at Week 13 in Mean Weekly Pain Scores|Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning|Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical|Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain|Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception|Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning|Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional|Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality|Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health|Change From Baseline in Mean Sleep Interference Scores|Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores|Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores|Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores|Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores|Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores|Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance|Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring|Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache|Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep|Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy|Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence|Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index|Clinical Global Impression of Change|Patient Global Impression of Change","http://ClinicalTrials.gov/show/NCT00553475",NA
"63132",63132,"NCT00634075","Clinical Assessment of Fish Oil-based Lipid Emulsion Infusions in Critical Patients With Severe Sepsis","Completed","No Results Available","Severe Sepsis","Drug: omega-3-fatty acids (Omegaven)|Drug: placebo","Li Shin Hospital","Both","Child|Adult|Senior","Phase IV",100,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-08-01","March 4, 2008","01/03/2008",2009-08-01,"August 12, 2009","01/08/2009","",2009-08-01,"All cause mortality|Lengths of ICU and hospital stay. Duration of mechanic ventilator requirement. Serial changing APACHE II and SOFA score. Changing of TNF-??, IL- 1??, IL-6, IL-8, and IL-10 levels. Incidence of hospital-acquired infection.","http://ClinicalTrials.gov/show/NCT00634075",NA
"63151",63151,"NCT00658775","Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)","Completed","No Results Available","Gastroesophageal Reflux Disease (GERD)","Drug: Rabeprazole sodium|Drug: Esomeprazole","Eisai Inc.","Both","Adult|Senior","Phase III",1060,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E3810-G000-302","April 9, 2008","01/02/2008",2010-01-01,"March 16, 2010","01/03/2010","",2009-09-01,"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and Investigator's assessment.|Adverse events, electrocardiograms (ECGs), lab evaluations (hematology, blood chemistry, urinalysis, serum gastrin), physical exams, vital signs.","http://ClinicalTrials.gov/show/NCT00658775",NA
"63155",63155,"NCT00670475","Comparative Study of Olive Oil With Piroxicam Gel in Osteoarthritis of the Knee","Completed","No Results Available","Osteoarthritis of the Knee","Drug: Piroxicam|Dietary Supplement: Olive Oil","Ardabil University of Medical Sciences","Both","Adult|Senior","Phase II",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1/86010","April 29, 2008","01/04/2008",2010-04-01,"April 28, 2010","01/04/2010","",2009-05-01,"The primary outcome measures is defined as the change from baseline to final assessment of the study knee in the 3 core continuous variables pain and physical function, assessing using the WOMAC subscales, and patient global assessment (PGA).|The primary outcome measures is defined as the change from baseline to final assessment of the study knee in the 3 core continuous variables pain and physical function, assessing using the WOMAC subscales, and patient global assessment (PGA).|The primary outcome measures is defined as the change from baseline to final assessment of the study knee in the 3 core continuous variables pain and physical function, assessing using the WOMAC subscales, and patient global assessment (PGA).|The primary outcome measures is defined as the change from baseline to final assessment of the study knee in the 3 core continuous variables pain and physical function, assessing using the WOMAC subscales, and patient global assessment (PGA).|the secondary measure will be changes in stiffness|the secondary measure will be changes in stiffness|the secondary measure will be changes in stiffness|the secondary measure will be changes in stiffness","http://ClinicalTrials.gov/show/NCT00670475",NA
"63161",63161,"NCT00662675","A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency","Completed","Has Results","Exocrine Pancreatic Insufficiency|Steatorrhea|Malabsorption Syndromes|Cystic Fibrosis","Drug: Pancrease MT 10.5, or MT 21|Drug: Placebo for Pancrease MT 10.5 or MT 21","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Child|Adult","Phase III",40,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR014719","April 17, 2008","01/08/2008",2009-02-01,"September 23, 2010","01/09/2010","",2009-02-01,"Change in the Coefficient of Fat Absorption (COA-fat Percent)|Change in Percent COA-Protein (Nitrogen)|Percent of Patients Reporting Clinical Signs and Symptoms of Exocrine Pancreatic Insufficiency (EPI) During the Double-Blind Phase","http://ClinicalTrials.gov/show/NCT00662675",NA
"63168",63168,"NCT00673075","The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease","Completed","Has Results","Hypertension|Coronary Artery Disease","Drug: Nebivolol|Drug: Carvedilol","Forest Laboratories","Both","Adult|Senior","Phase IV",39,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NEB-MD-06","April 29, 2008","01/05/2008",NA,"September 2, 2010","01/09/2010","",2009-09-01,"Peripheral Diastolic Blood Pressure (DBP)|Peripheral Systolic Blood Pressure (SBP)|Proportion of Patients With Peripheral SBP <140 mm Hg and DBP <90 mm Hg at Week 18|Left Ventricular Ejection Fraction (LVEF) (%) at Week 18","http://ClinicalTrials.gov/show/NCT00673075",NA
"63171",63171,"NCT00696475","Diazoxide Choline in Hypertriglyceridemia","Completed","No Results Available","Hypertriglyceridemia","Drug: Diazoxide choline|Drug: Diazoxide choline|Drug: Diazoxide choline|Drug: Placebo","Essentialis, Inc.|Medpace, Inc.","Both","Adult|Senior","Phase II",80,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PC007","June 10, 2008","01/06/2008",2009-03-01,"November 4, 2010","01/11/2010","",2009-01-01,"To assess the effect on triglycerides of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects|To assess the effect on other lipid parameters (LDL, HDL, VLDL, and non-HDL cholesterol), insulin, glucose and weight of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects|To assess the safety and tolerability of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects","http://ClinicalTrials.gov/show/NCT00696475",NA
"63177",63177,"NCT00705575","Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension","Completed","No Results Available","Hypertension","Drug: Aliskiren / HCTZ (300/25 mg)|Drug: Aliskiren","Novartis","Both","Adult|Senior","Phase III",688,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CSPP100A2353","June 23, 2008","01/06/2008",NA,"January 19, 2010","01/01/2010","ACQUIRE",2009-04-01,"Change from baseline in mean sitting systolic blood pressure (msSBP) after 12-weeks of treatment.|Change from baseline in msSBP (after 8 weeks of treatment) and in msDBP ( after 12 and 8 weeks of treatment)for aliskiren / HCTZ (300/25 mg) combination vs. aliskiren (300 mg) monotherapy|Change from baseline in msSBP and msDBP after 12 and 8 weeks of treatment with aliskiren / HCTZ (300/25 mg) combination|Change from baseline in msSBP and msDBP after 12 and 8 weeks of aliskiren (300 mg) monotherapy.|Proportion of patients achieving the target blood pressure (msSBP < 140 mmHg and msDBP < 90 mmHg, and msSBP < 130 mmHg and msDBP < 80 mmHg for diabetics), in both study arms, after 12 and 8 weeks of treatment.|Safety and tolerability of aliskiren / HCTZ (300/25 mg) combination compared to aliskiren (300 mg) monotherapy regimen in patients with Stage II hypertension.","http://ClinicalTrials.gov/show/NCT00705575",NA
"63195",63195,"NCT00735475","A Study to Determine the Immunogenicity and Safety of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine","Completed","No Results Available","Influenza","Biological: CSL Limited Influenza Virus Vaccine|Biological: US Licensed Influenza Virus Vaccine","CSL Limited","Both","Adult|Senior","Phase IV",1268,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","CSLCT-USF-07-41","August 13, 2008","01/10/2008",2009-06-01,"November 5, 2009","01/11/2009","",2009-01-01,"Geometric mean titer and seroconversion rate for each strain contained within the vaccines|Frequency, duration and intensity of local and systemic solicited symptoms, unsolicited adverse events, serious adverse events and new onset of chronic illnesses","http://ClinicalTrials.gov/show/NCT00735475",NA
"63213",63213,"NCT00766675","This Open-label Study Will Evaluate the Analgesic Effectiveness and Safety Measurement of Tramadol HCl/Acetaminophen in the Treatment of Pain for Fibromyalgia.","Completed","No Results Available","Pain|Fibromyalgia","Drug: Ultracet (tramadol HCL/acetaminophen)","Johnson & Johnson Taiwan Ltd","Both","Adult|Senior","Phase IV",82,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR015319","October 3, 2008","01/05/2008",2009-03-01,"April 22, 2010","01/04/2010","",2009-03-01,"Difference of the Pain Visual Analog Scale (VAS) at day 1, 14, 28 and 56.|The number of discontinuations due to lack of efficacy after the sixth day of the Treatment Phase; Pain Assessments (pain relief scores and tender-point evaluation/myalgic scores); and safety at Day 1, 14, 28 and 56.","http://ClinicalTrials.gov/show/NCT00766675",NA
"63251",63251,"NCT00823875","Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject","Completed","No Results Available","Atherosclerosis Cerebral Infarction","Drug: Cilostazol group|Drug: Probucol group|Drug: Cilostazol + Probucol group|Drug: control group","Otsuka Beijing Research Institute","Both","Adult|Senior","Phase IV",200,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","260-08-803-01","January 15, 2009","01/03/2009",2010-07-01,"November 30, 2010","01/01/2010","",2009-12-01,"After 12 weeks of treatment, the change difference of arteriosclerosis related biomarker between 4 modality groups.","http://ClinicalTrials.gov/show/NCT00823875",NA
"63264",63264,"NCT00851175","Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?","Completed","No Results Available","Atherosclerosis|Cardiovascular Disease","Drug: rosuvastatin|Drug: caffeine","Radboud University","Both","Adult","Phase IV",8,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","rosucaff2","February 24, 2009","01/03/2009",2009-09-01,"September 30, 2009","01/03/2009","",2009-08-01,"Forearm blood flow (FBF)after 2, 5, and 13 minutes of forearm ischemia","http://ClinicalTrials.gov/show/NCT00851175",NA
"63280",63280,"NCT00877175","Comparison of Instillation and Packing in Mydriasis for Premature Infants","Completed","No Results Available","Preterm Infants","Drug: 1% tropicamide and 2.5% phenylephrine","Khon Kaen University","Both","Child","Phase IV",25,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","I50221|HE480729","April 6, 2009","01/03/2009",2009-06-01,"July 2, 2009","01/07/2009","",2009-05-01,"The primary outcome measure was the horizontal pupil diameter measured with a ruler in millimeters","http://ClinicalTrials.gov/show/NCT00877175",NA
"63283",63283,"NCT00879775","Efficacy of Caffeine Injection as an Adjuvant to Opioid Therapy in Cancer Pain","Completed","No Results Available","Cancer|Pain","Drug: Caffeine|Drug: Normal saline","Korea Research Foundation|Korea University Guro Hospital","Both","Adult|Senior","Phase II",50,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","E00058|GR0857-006|SuYeon2009-08","April 9, 2009","01/04/2009",2009-09-01,"September 17, 2009","01/09/2009","",2009-07-01,"Numeric rating of scale (from 0 to 10) of pain and side effects (drowsiness, confusion, nausea, sleep disturbance) of opioids|Degree of fatigue at the point of time with visual analogue scale from 0 to 10|Health-related quality of life with visual analogue scale from 0 to 10|Impact of symptom burden to daily life (by MD Anderson Symptom Inventory-Korean)","http://ClinicalTrials.gov/show/NCT00879775",NA
"63313",63313,"NCT00933075","Dermacyd Silver Frutal (Lactic Acid) - Photo Evaluation.","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Both","Adult","Phase III",27,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LACAC_L_04843","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"Measure of the photo irritation test and the photosensitivity by using UVA irradiation and evaluation according to International Contact Dermatitis Research Group (ICDRG) scale. Evaluation of the sensibility according to the skin type.","http://ClinicalTrials.gov/show/NCT00933075",NA
"63318",63318,"NCT00943475","Assessment of Hemodynamic Response in Surgery of Circumcision in Children","Completed","No Results Available","Children Who Need Circumcision","Procedure: circumcision","Federal University of Juiz de Fora","Male","Child","Phase IV",40,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","CAAE:0101.0.180.000-08","July 21, 2009","01/03/2009",2009-06-01,"July 21, 2009","01/03/2009","",2009-03-01,"local anesthesia relieve the circumcision pain|local anesthesia relieve the circumcision pos-operatory pain","http://ClinicalTrials.gov/show/NCT00943475",NA
"63363",63363,"NCT01001975","Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(COMPLETED)","Completed","Has Results","Sun Protection","Drug: Sunscreen Test Code: V53-028|Drug: Sunscreen Test Code: V53-030|Drug: Standard SPF 4 Sunscreen","Schering-Plough","Both","Adult|Senior","Phase III",10,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","SR09-15","October 23, 2009","01/07/2009",2009-08-01,"November 4, 2010","01/11/2010","PFA and SPF",2009-08-01,"Determination of Sunscreen Protection Factor (SPF)|Determination of Ultraviolet Light A Protection Factor (PFA)","http://ClinicalTrials.gov/show/NCT01001975",NA
"63588",63588,"NCT00030576","Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: erlotinib hydrochloride","University Health Network, Toronto|National Cancer Institute (NCI)","Both","Adult|Senior","Phase I|Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069178|PMH-PHL-002|NCI-5380|CAN-NCIC-IND157","February 14, 2002","01/11/2001",2009-12-01,"March 30, 2010","01/10/2004","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00030576",NA
"63610",63610,"NCT00057876","Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: gemcitabine hydrochloride|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Radiation Therapy Oncology Group","Both","Adult|Senior","Phase III",NA,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000278947|ECOG-E4201|RTOG-ECOG-E4201","April 7, 2003","01/04/2003",NA,"May 29, 2009","01/01/2006","",2009-05-01,"Overall survival at 13, 20, 26, and 36 months|Objective response rate|Progression-free survival|Toxicity as measured by NCI CTC v2.0|Quality of life as measured by Functional Assessment of Cancer Treatment-Hepatobiliary Symptom Index at baseline, 6, 15, and 16 weeks, and at 9 months","http://ClinicalTrials.gov/show/NCT00057876",NA
"63622",63622,"NCT00095576","Investigation of V520 in an HIV Vaccine Proof-of-Concept Study","Completed","No Results Available","AIDS|HIV Infections","Biological: Comparator: V520|Drug: Comparator: placebo","Merck|HIV Vaccine Trials Network","Both","Adult","Phase II",3000,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2004_091|V520-023/V520-030","November 5, 2004","01/11/2004",2009-12-01,"January 21, 2010","01/01/2010","",2009-12-01,"(1) General safety and tolerability|Acquisition of HIV-1 infection|HIV-1 viral load|To demonstrate a favorable effect on disease progression measured by a durable suppression of HIV-1 plasma viral RNA and a lack of decline (preservation) of CD4 cell count","http://ClinicalTrials.gov/show/NCT00095576",NA
"63625",63625,"NCT00094276","Intervention for Improving Asthma Care for Minority Children in Head Start","Completed","No Results Available","Asthma|Lung Diseases","Behavioral: Facilitated Asthma Communication Intervention (FACI)|Behavioral: Breathmobile intervention","National Heart, Lung, and Blood Institute (NHLBI)","Both","Child","Phase III",336,"NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Prevention","168|R01 HL73833","October 15, 2004","01/09/2004",2009-06-01,"July 14, 2009","01/07/2009","",2009-06-01,"Symptom-free days|Health care utilization (i.e., emergency department visits, hospitalizations, and primary care visits)|Asthma medications|Parent asthma-related quality of life|Parent asthma management practices|Cost-effectiveness","http://ClinicalTrials.gov/show/NCT00094276",NA
"63716",63716,"NCT00195676","Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis","Completed","Has Results","Psoriasis","Drug: adalimumab","Abbott","Both","Adult|Senior","Phase III",1469,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M03-658|2005-000095-41","September 13, 2005","01/05/2004",2009-10-01,"December 13, 2010","01/12/2010","",2009-10-01,"Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R","http://ClinicalTrials.gov/show/NCT00195676",NA
"63790",63790,"NCT00360776","Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia","Completed","No Results Available","Anemia|Leukemia|Neutropenia","Drug: tipifarnib|Genetic: mutation analysis|Other: laboratory biomarker analysis","The Cleveland Clinic|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",56,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CASE-4202|P30CA043703|CASE-4202|NCI-6823|CASE-RDN-5402","August 3, 2006","01/06/2006",NA,"May 12, 2010","01/06/2009","",2009-06-01,"Complete response rate, partial response rate, and overall response rate|Toxicity of treatment|Mechanism of treatment response as measured by biomarkers in peripheral blood at baseline and at the end of 4 and 8 courses of treatment","http://ClinicalTrials.gov/show/NCT00360776",NA
"63831",63831,"NCT00424476","A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)","Completed","No Results Available","Systemic Lupus Erythematosus","Drug: belimumab|Drug: belimumab|Drug: Placebo","Human Genome Sciences|GlaxoSmithKline","Both","Adult|Senior","Phase III",867,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","HGS1006-C1057|BLISS-52","January 17, 2007","01/05/2007",2009-07-01,"September 22, 2009","01/09/2009","BLISS-52",2009-07-01,"At Wk52, the percent of subjects with ??­ 4 point reduction from baseline in SELENA SLEDAI score and no worsening in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline at the time of assessment.|Percent of subjects with 4 points reduction from baseline in SELENA SLEDAI score at Wk 52.|Mean change in PGA at Wk 24.|Mean change in SF-36 Health Survey physical component summary score (PCS) at Wk 24.|Percent of subjects whose average prednisone dose has been reduced by ??­ 25% from baseline to ??? 7.5 mg/day during Weeks 40 through 52","http://ClinicalTrials.gov/show/NCT00424476",NA
"63837",63837,"NCT00434876","The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence","Completed","No Results Available","Alcoholism|Sleep Initiation and Maintenance Disorders","Drug: Quetiapine XR|Drug: Placebo.","Department of Veterans Affairs","Both","Adult","Phase III",24,"U.S. Fed","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","101206","February 12, 2007","01/08/2007",2009-12-01,"February 8, 2010","01/02/2010","",2009-11-01,"Sleep Efficiency (from an in-laboratory polysomnogram)|Objective sleep-wake recordings using actigraphy.|Pittsburgh Sleep Quality Index, Insomnia Severity Index and Epworth Sleepiness Scale.|Time Line Followback, Penn Alcohol craving scale.|PHQ-9, Beck's Anxiety Rating Scale","http://ClinicalTrials.gov/show/NCT00434876",NA
"63845",63845,"NCT00432276","Efficacy of SYR-322 and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","Completed","No Results Available","Diabetes Mellitus","Drug: Alogliptin and pioglitazone and metformin|Drug: Pioglitazone and metformin","Takeda Global Research & Development Center, Inc.","Both","Adult|Senior","Phase III",821,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01-06-TL-322OPI-004|2006-006025-73|U1111-1112-3363","February 5, 2007","01/12/2006",2009-06-01,"April 8, 2010","01/04/2010","",2009-05-01,"Change from Baseline in Glycosylated Hemoglobin.|Glycosylated Hemoglobin|Fasting Plasma Glucose|Proinsulin|Insulin|Proinsulin/Insulin ratio|C-peptide|Serum Lipids|Nuclear magnetic resonance Lipid Fractionation|Free Fatty Acids|Apolipoprotein A-I|Apolipoprotein A-II|Apolipoprotein B|Apolipoprotein C-III|Plasminogen activator inhibitor-1|High-sensitivity C-reactive protein|Adiponectin|Body weight|Change from Baseline in calculated HOMA insulin resistance|Change from Baseline in calculated HOMA beta-cell function|Incidence of Marked Hyperglycemia (fasting plasma glucose greater than or equal to 200 mg/dL) (11.10 mmol/L).|Incidence of Rescue.|Incidence of Glycosylated Hemoglobin less than or equal to 6.5%|Incidence of Glycosylated Hemoglobin less than or equal to 7.0%|Incidence of Glycosylated Hemoglobin less than or equal to 7.5%|Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 0.5%|Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 1.0%|Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 1.5%|Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 2.0%","http://ClinicalTrials.gov/show/NCT00432276",NA
"63848",63848,"NCT00447876","Study to Assess the Efficacy and Safety of Dysport?ó in the Treatment of Chronic Plantar Fasciitis","Completed","No Results Available","Chronic Plantar Fasciitis","Drug: Botulinum type A toxin (Dysport?ó)","Ipsen","Both","Adult|Senior","Phase II|Phase III",40,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A-94-52120-100","March 13, 2007","01/07/2005",2009-04-01,"October 20, 2009","01/10/2009","",2009-01-01,"Improvement of score value on the visual analogue scale for pain during weight-bearing in the last 48 hours in week 6. \Responder\"" is defined as a reduction in score value of ??­ 50%|Gerbershagen Score|Pain intensity on the Visual Analogue Scale|Measurement of pressure pain with algorimeter: most severe pain experienced on the medial hindfoot|Force measurement by Brunner (Grade 0-5)|Global assessment by the investigator and the patient|Tolerance of study drug (recording of drug side-effects)|Adverse events""","http://ClinicalTrials.gov/show/NCT00447876",NA
"63870",63870,"NCT00481676","Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria Who Exhibit IgE Against Thyreoperoxidase","Completed","No Results Available","Chronic Urticaria","Drug: Omalizumab|Drug: placebo","Novartis","Both","Adult|Senior","Phase IV",51,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIGE025ADE05","June 1, 2007","01/05/2007",NA,"May 12, 2009","01/05/2009","",2009-05-01,"Urticaria activity score (UAS) after 24 weeks of treatment in adult patients|Use of concomitant and rescue medication while in treatment phase|Dermatology Life Quality Index (DLQI) at visit 2 and visit 8|Patient's quality of life using the Skindex at visit 2 and visit 8|Patient's quality of life using the chronic urticaria quality of life index|Investigator and Patient Global Assessment of Efficacy at visit 2 and visit 8","http://ClinicalTrials.gov/show/NCT00481676",NA
"63878",63878,"NCT00490776","Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma","Completed","No Results Available","Cutaneous T-Cell Lymphoma","Drug: LBH589","Novartis Pharmaceuticals","Both","Adult|Senior","Phase II|Phase III",9,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLBH589B2212","June 21, 2007","01/06/2007",NA,"February 16, 2010","01/02/2010","",2009-09-01,"To determine the overall response rate of patients treated with LBH589 by using the modified Severity-Weighted Assessment Tool to assess skin disease and the evaluation of disease in the viscera, lymph nodes, and blood (circulation SS cells)|To determine the response rate using the Physicians Global Assessment of Clinical Condition(PGA)of patients with resistant CTCL|To determine the response rate using Modified Severity Weighted Assessment (mSWAT) skin score of patients with resistant CTCL|Responses in index lesions by lesion measurements with photographic supporting documentation|Overall response rate of patients with resistant CTCL treated with oral LBH589 by using the modified Physician's Global Assessment (PGA) to assess skin disease and the evaluation of disease in the viscera, lymph nodes and blood (circulating SS cells).|Duration of response","http://ClinicalTrials.gov/show/NCT00490776",NA
"63884",63884,"NCT00505076","Treatment Study for Cognitive Deficits in Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: MK-0777|Drug: MK-0777|Drug: placebo","University of California, Los Angeles|University of Maryland|Washington University School of Medicine|Massachusetts General Hospital|Nathan Kline Institute for Psychiatric Research|Columbia University|Duke University|Beth Israel Deaconess Medical Center","Both","Adult","Phase II",90,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TURNS02|HHSN 278200441003C","July 19, 2007","01/07/2007",2009-09-01,"January 13, 2010","01/01/2010","TURNS",2009-09-01,"Primary: MCCB: MATRICS Consensus Cognitive Battery|Secondary: UPSA: UCSD Performance-Based Skills Assessment; SCoRS: Schizophrenia Cognition Rating Scale","http://ClinicalTrials.gov/show/NCT00505076",NA
"63900",63900,"NCT00540176","The Safety and Efficacy of DCA for the Treatment of Brain Cancer","Completed","No Results Available","Malignant Gliomas, Glioblastoma Multiforme","Drug: Dichloroacetate (DCA)","University of Alberta|Capital Health, Canada","Both","Adult|Senior","Phase II",50,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DCA 10002","October 4, 2007","01/10/2007",2009-08-01,"February 5, 2010","01/02/2010","",2009-08-01,"To determine the therapeutic response to oral Dichloroacetate (DCA) in patients with malignant gliomas, utilizing standard criteria for the objective response of tumor size to treatment (CT and/or MRI).|To evaluate the safety and tolerability of oral (DCA) in patients with gliomas.|To determine the progression-free survival (PFS) and overall survival achieved with oral DCA in patients with gliomas.|??Ñ To evaluate the in vitro effects of DCA on cell proliferation/apoptosis and mitochondrial function in malignant glioma tissues taken from enrolled patients at the time of surgery and correlate them with clinical data.|??Ñ To evaluate glucose uptake using 18F-FDG Positron Emission Tomography (PET) scanning as a biological marker for predicting subsequent therapeutic response to oral DCA in patients with malignant gliomas.","http://ClinicalTrials.gov/show/NCT00540176",NA
"63904",63904,"NCT00550576","Antibodies to Digoxin for Bipolar Disorder","Completed","No Results Available","Bipolar Disorder","Drug: Digibind (Fab)","Rambam Health Care Campus","Both","Adult","Phase II",20,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","IRB2142_CTIL","October 29, 2007","01/10/2007",2009-02-01,"February 15, 2009","01/02/2009","",2009-02-01,"improvement","http://ClinicalTrials.gov/show/NCT00550576",NA
"63905",63905,"NCT00547976","PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis","Completed","No Results Available","Atherosclerosis|Healthy","Drug: [C-11]PBR28","National Institute of Mental Health (NIMH)","Both","Adult|Senior","Phase I|Phase II",5,"NIH","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","080006|08-M-0006","October 20, 2007","01/10/2007",2009-08-01,"May 11, 2010","01/05/2010","",2009-08-01,"Binding of [11C]PBR28 at peripheral benzodiazepine receptor|PET [F-18]FDG uptake","http://ClinicalTrials.gov/show/NCT00547976",NA
"63914",63914,"NCT00562276","Immediate Versus Delayed Intrauterine Device (IUD) Insertion Following First Trimester Suction Aspiration Procedures","Completed","No Results Available","Contraception","Procedure: Immediate IUD insertion","Oregon Health and Science University","Female","Adult|Senior","Phase IV",578,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","OHSU FAMPLAN 2535","November 21, 2007","01/05/2007",2009-06-01,"August 21, 2009","01/08/2009","PAIR",2009-06-01,"IUD expulsion|IUD continuation","http://ClinicalTrials.gov/show/NCT00562276",NA
"63929",63929,"NCT00510276","Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes","Completed","Has Results","Attention Deficit Hyperactivity Disorder","Drug: Atomoxetine hydrochloride|Drug: Placebo","Eli Lilly and Company","Both","Adult","Phase IV",445,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10803|B4Z-US-LYDZ","July 30, 2007","01/08/2007",2009-02-01,"April 7, 2010","01/04/2010","",2009-02-01,"Mean Change in the Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptom Score From Baseline to 12 Week Endpoint|Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Total Score|Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Relationship Subscale|Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Life Productivity Subscale|Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Psychological Health Subscale|Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Life Outlook Subscale|Mean Change From Baseline to 12 Week Endpoint in Clinical Global Impression-ADHD- Severity (CGI-ADHD-S)|Mean Change From Baseline to 12 Week Endpoint in CAARS Self Report (CAARS-S:SV) Total Score|Endpoint Scores in Patient Global Impression - Improvement (PGI-I)|Mean Change From Baseline to 12 Week Endpoint on the Montgomery Asberg Depression Rating Scale (MADRS)|Mean Change From Baseline to 12 Week Endpoint on the Beck Anxiety Inventory (BAI)|Correlation of Mean Changes From Baseline to 12 Week on the Adult ADHD Quality of Life-29 Total Score and of Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated:Screening Version Total Score|Mean Change From Baseline to 12 Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Alcohol|Mean Change From Baseline to 12-Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Caffeine|Mean Change From Baseline to 12-Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Drugs|Mean Change From Baseline to 12-Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Nicotine|Mean Change From Baseline to 12 Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Marijuana|Mean Change From Baseline to 12 Week Endpoint on the Fagerstrom Test for Nicotine Dependence (FTND)|Mean Change From Baseline to 12 Week Endpoint on the Social Adaptation Self-Evaluation Scale (SASS)|Mean Change From Baseline to 12-Week Endpoint on the Driving Behavior Survey Self-Report|Mean Change From Baseline to 12-Week Endpoint on the Driving Behavior Survey-Other Report|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Behavioral Regulation Section Score|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Emotional Control Section Score|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - GEC Section Score|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Inconsistency Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Infrequency Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Inhibit Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Initiate Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Metacognition Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Negativity Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Organization of Materials Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Plan/Organize Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - SHIFT Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Self Monitor Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Task Monitor Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Working Memory Section|Mean Change From Baseline to 12-Week Endpoint on the Epworth Sleepiness Scale (ESS)|Responders by Baseline Smoking Status|Strong Responders by Baseline Smoking Status","http://ClinicalTrials.gov/show/NCT00510276",NA
"63933",63933,"NCT00598676","3 Limus Agent Eluting Stents With Different Polymer Coating","Completed","No Results Available","Coronary Heart Disease","Device: biodegradable polymer Rapamycin-eluting stent|Device: permanent polymer rapamycin-eluting stent (Cypher)|Device: permanent polymer everolimus-eluting stent (Xience, Promus)","Deutsches Herzzentrum Muenchen","Both","Adult|Senior","Phase IV",2600,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GE IDE No. S02607","January 10, 2008","01/09/2007",2009-04-01,"March 12, 2010","01/03/2010","ISAR-TEST-4",2009-03-01,"The primary end point of the study is a combined endpoint of cardiac death, myocardial infarction related to the target vessel or revascularization related to the target lesion.|In-segment binary restenosis at follow-up angiography|Late Lumen Loss at follow-up angiography|All cause mortality.|Incidence of stent thrombosis (by ARC definition)","http://ClinicalTrials.gov/show/NCT00598676",NA
"63954",63954,"NCT00619476","A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)","Completed","No Results Available","Neuropathic Pain Associated With Post-Herpetic Neuralgia","Drug: XP13512/GSK1838262","GlaxoSmithKline","Both","Adult|Senior","Phase II",376,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","110748","February 7, 2008","01/02/2008",2009-07-01,"February 18, 2010","01/02/2010","",2009-07-01,"The change from baseline to end of treatment with respect to the mean 24-hour average pain intensity score based on an 11-point PI-NRS (0 = \no pain\"" and10 = \""pain as bad as you can imagine\"").|24-hour","http://ClinicalTrials.gov/show/NCT00619476",NA
"63971",63971,"NCT00658476","Omega-3 Fatty Acids for Treatment of Depression in Adolescents","Completed","No Results Available","Depression","Dietary Supplement: Fish Oil|Behavioral: Cognitive Behavior Therapy|Drug: Placebo","Cedars-Sinai Medical Center|National Alliance for Research on Schizophrenia and Depression","Both","Child|Adult","Phase III",40,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","9407","April 8, 2008","01/11/2006",2009-04-01,"November 19, 2009","01/11/2009","PUFA",2009-04-01,"Child Depression Inventory - CDI|Ham-D","http://ClinicalTrials.gov/show/NCT00658476",NA
"63994",63994,"NCT00688376","Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment","Completed","No Results Available","Attention Impairment","Drug: Donepezil hydrochloride|Drug: Placebo","Eisai Inc.|Eisai Limited","Both","Child","Phase III",300,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E2020-G000-333","May 28, 2008","01/08/2008",2009-09-01,"September 22, 2009","01/09/2009","",2009-06-01,"Change in the TOVA-CPT (Test of Variables in Attention - Continuous Performance Test) reaction time variability measure (administered to subjects).|Paired Assoc. Learning Test, Woodcock Johnson Decision Speed Test, Woodcock Johnson Mathematics Fluency; Go/No-Go Task (for subjects); Conners' Parent Rating Scale-Revised (S); Behavioral Rating Inventory of Executive Functioning (parent/legal guardian).","http://ClinicalTrials.gov/show/NCT00688376",NA
"63996",63996,"NCT00697476","Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent Small Cell Lung Cancer (SCLC)","Completed","No Results Available","Small Cell Lung Cancer","Drug: topotecan, vorinostat","Istituto Clinico Humanitas","Both","Adult|Senior","Phase I|Phase II",78,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ONC-2007-002|EUDRACT","June 11, 2008","01/01/2009",2010-01-01,"January 21, 2010","01/01/2010","",2009-09-01,"Maximum tolerated dose of the combination as the recommended dose for phase II trial [Phase I]; objective response rate of the combination [Phase II]; toxicity and safety profile of the combination [Phase II]|To assess the antitumor activity of the combination in terms of time to progression (TTP) and overall survival (OS) [Phase II]","http://ClinicalTrials.gov/show/NCT00697476",NA
"64012",64012,"NCT00722176","Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020","Completed","No Results Available","Schizophrenia","Drug: BL-1020|Drug: BL-1020 10-30 mg|Drug: risperidone","BioLineRx, Ltd.","Both","Adult","Phase II",220,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BL-1020 IIb (Extension)","July 23, 2008","01/06/2008",2009-12-01,"June 27, 2010","01/06/2010","",2009-07-01,"changes from baseline in vital signs, laboratory and ECG evaluations, physical/neurological examination, Extrapyramidal Symptom Rating Scale (ESRS), and incidence of adverse events (AEs) and adverse drop-outs (ADOs).|Comparisons between each of the BL-1020 treatment groups and the risperidone group","http://ClinicalTrials.gov/show/NCT00722176",NA
"64013",64013,"NCT00667576","Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis","Completed","Has Results","Chronic Kidney Disease on Hemodialysis|Secondary Hyperparathyroidism","Drug: Maxacalcitol|Drug: Paricalcitol","Abbott|Abbott Japan Co.,Ltd","Both","Adult|Senior","Phase II",153,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","M10-309","April 24, 2008","01/04/2008",2009-03-01,"April 6, 2010","01/04/2010","",2009-03-01,"Percentage of Subjects With ??­ 50% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Serum Level|Mean Change From Baseline in Intact Parathyroid Hormone (iPTH) Level|Percentage of Subjects With Intact Parathyroid Hormone (iPTH) ??? 180 Picograms/Milliliter (pg/mL)|Percentage of Subjects With 2 or More Decreases of ??­ 50% From Baseline in Intact Parathyroid Hormone (iPTH) Level|Duration of 2 Consecutive Decreases of ??­ 50% From Baseline in Intact Parathyroid Hormone (iPTH) Values|Duration of 2 Consecutive Intact Parathyroid Hormone (iPTH) Values ??? 180 pg/mL","http://ClinicalTrials.gov/show/NCT00667576",NA
"64028",64028,"NCT00742976","Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients","Completed","No Results Available","Diabetes Type 2|Weight Gain","Drug: Insulin Detemir; Insulin Insulatard|Drug: Insulin Detemir, Insulin Insulatard","Rigshospitalet, Denmark","Both","Adult|Senior","Phase IV",24,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Basic Science","EudraCT 2008-001602-16","August 27, 2008","01/06/2008",2009-12-01,"January 19, 2010","01/06/2008","Le-Na",2009-12-01,"change in weight; change in extracellular volume|sodium excretion in urine, 24 hour blood pressure, body composition change,urine osmolality, urine albumin excretion, GFR, HbA1c, Blood lipid profile, NT-proBNP, plasma Albumin, Plasma metanephrines, aldosterone, active renin, angiotensin II","http://ClinicalTrials.gov/show/NCT00742976",NA
"64031",64031,"NCT00744276","A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease","Completed","No Results Available","Fibrocystic Disease of Breast","Drug: danazol|Drug: Placebo","FemmePharma Global Healthcare, Inc.","Female","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FP1198-001","August 28, 2008","01/01/2007",2009-06-01,"May 25, 2010","01/05/2010","FP1198-001",2009-04-01,"Subject reported breast pain as measured using a visual analog scale on the subject daily diary|Physician assessment of breast nodularity at each treatment cycle visit","http://ClinicalTrials.gov/show/NCT00744276",NA
"64034",64034,"NCT00749476","Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX","Completed","Has Results","Hemophilia B","Biological: Factor IX recovery","Wyeth","Male","Child|Adult|Senior","Phase IV",1,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","3090X1-4405","September 8, 2008","01/04/2008",2009-01-01,"May 26, 2010","01/05/2010","",2009-01-01,"Number of Subjects Reporting Efficacy","http://ClinicalTrials.gov/show/NCT00749476",NA
"64043",64043,"NCT00765076","Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older","Completed","No Results Available","Influenza Infection","Biological: GSK Biologicals' Fluarix|Biological: GSK Biologicals' influenza vaccine GSK2186877A","GlaxoSmithKline","Both","Adult|Senior","Phase III",192,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","112147","October 1, 2008","01/10/2008",2009-11-01,"July 2, 2010","01/07/2010","",2009-11-01,"The frequency of influenza-specific CD4 T-cells per 10E6 CD4+ T-cells identified after in vitro stimulation with pooled vaccine strains as producing at least two different markers (CD40L, IL-2, TNF-??, IFN-??) in the elderly vaccine groups|Frequency of influenza-specific CD4 T-cells per 10E6 CD4+ T-cells identified after in vitro stimulation with pooled vaccine strains and with each vaccine strain separately as producing at least two different markers in each vaccine group.|For pooled vaccine strains and for each vaccine strain separately, frequency of influenza-specific CD4 T-cells per 10E6 CD4+ T-cells defined on the expression profile of each of the immune markers plus another immune marker in each vaccine group.|Serum haemagglutination-inhibition (HI) antibody titers|Occurrence, intensity, duration of solicited local Adverse Events (AEs).|Occurrence, intensity, duration and relationship to vaccination of solicited general AEs.|Occurrence, intensity and relationship to vaccination of unsolicited AEs.|Occurrence, intensity and relationship to vaccination of AEs with a medically attended visit.|Occurrence and relationship to vaccination of serious AEs (SAEs) and AEs of specific interest including autoimmune diseases.","http://ClinicalTrials.gov/show/NCT00765076",NA
"64056",64056,"NCT00794976","Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral Epicondylitis","Completed","No Results Available","Lateral Epicondylitis|(Tennis Elbow)","Drug: Dexamethasone Iontophoretic Patch (low dose)|Drug: Dexamethasone Iontophoretic Patch (high dose)|Drug: Dexamethasone Passive Patch|Drug: Placebo Patch","Travanti Pharma Inc.|ResearchPoint","Both","Adult|Senior","Phase II",200,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","1779","November 20, 2008","01/10/2008",2009-05-01,"May 19, 2009","01/05/2009","",2009-05-01,"Pain severity assessed by VAS (Visual Analog Scale)|Safety","http://ClinicalTrials.gov/show/NCT00794976",NA
"64079",64079,"NCT00815776","Treatment Outcomes for Temporomandibular Disorders (TMD) Via the Clayton Intra-aural Device (CID) Clinical Trial","Completed","Has Results","Temporomandibular Disorders","Device: Clayton Intra-aural Device (CID)|Device: Mouth Splint|Other: Exercise Group","Ascentia Health, Inc.","Both","Child|Adult|Senior","Phase I|Phase II",152,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CID2007","December 29, 2008","01/04/2008",2009-01-01,"August 16, 2010","01/08/2010","",2009-01-01,"Change From Baseline In Craniomandibular Index (CMI) Scores At 3 Months (In A Scale)|Number of Subjects With Adverse Events|Change From Baseline In Craniomandibular Index (CMI) Scores At 3 Months (In A Scale)","http://ClinicalTrials.gov/show/NCT00815776",NA
"64082",64082,"NCT00839176","Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)","Completed","No Results Available","Major Depressive Disorder (MDD)","Drug: RX-10100","Rexahn Pharmaceuticals, Inc.","Both","Adult","Phase II",72,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RX-10100-P2A-002","February 5, 2009","01/01/2009",2009-10-01,"December 4, 2009","01/12/2009","",2009-09-01,"Change from baseline at 8 weeks on the Montgomery-Asberg Depression Rating Scale (MADRS)|Changes from baseline on the HAM-D|Changes from baseline on the QIDS-SR|CGI-I scale at the end of treatment,|Side effects during and immediately following the treatment period","http://ClinicalTrials.gov/show/NCT00839176",NA
"64120",64120,"NCT00910676","Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor (EGF-R) Inhibitors","Completed","No Results Available","Metastatic Colorectal Cancer|Non-Small-Cell Lung Carcinoma","Drug: Diprosone","Centre Oscar Lambret|Roche Pharma AG","Both","Adult|Senior","Phase II",30,"Other|Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","2007-002913-38","May 29, 2009","01/10/2007",2009-03-01,"May 29, 2009","01/05/2009","DIPROCOL",2009-03-01,"To reduce by 30 % the frequency of folliculitis by a local corticotherapy beginning at the same time that the treatment by EGF-R inhibitors began|To assess the frequency of grade I, II and III folliculitis under Cetuximab and under Erlotinib|To list the cutaneous side effects of the EGF-R inhibitors|To assess the patient quality of life with the DLQI questionnaire","http://ClinicalTrials.gov/show/NCT00910676",NA
"64146",64146,"NCT00945776","Weekly Phone Calls Versus Brief Patient Education to Improve Continuous Positive Airway Pressure (CPAP) Compliance","Completed","No Results Available","Obstructive Sleep Apnea (OSA)","Behavioral: Weekly phone calls|Behavioral: Frequently asked questions|Behavioral: Usual care","CAMC Health System","Both","Adult|Senior","Phase II",128,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","08/04/2047","July 23, 2009","01/04/2008",2009-06-01,"July 23, 2009","01/07/2009","",2009-06-01,"To determine which intervention will improve CPAP compliance in sleep apnea|To try to identify which individual characteristics within a group may require a specific intervention","http://ClinicalTrials.gov/show/NCT00945776",NA
"64168",64168,"NCT00987376","Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE Collaboration","Completed","No Results Available","Prostate Cancer","Device: Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy","Mayo Clinic|National Cancer Institute (NCI)","Male","Adult|Senior","Phase I|Phase II",8,"Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","8-03|CA91956-02","December 20, 2007","01/11/2003",2009-09-01,"September 29, 2009","01/09/2009","",2009-09-01,"Test accuracy|Test comparative accuracy of PET and MRI","http://ClinicalTrials.gov/show/NCT00987376",NA
"64169",64169,"NCT00986076","Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery","Completed","No Results Available","Inflammation","Drug: Enoxaparin|Drug: Balanced Salt Solution","Iladevi Cataract and IOL Research Center","Both","Child","Phase IV",23,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","08-010","September 26, 2009","01/03/2008",2009-09-01,"September 28, 2009","01/09/2009","",2009-04-01,"Anterior Segment Inflammation|Anterior Segment inflammation","http://ClinicalTrials.gov/show/NCT00986076",NA
"64183",64183,"NCT01010776","Evaluating Patient Satisfaction and Quality of Life When Switching From Risperidone to Paliperidone ER (Extended Release) in Stable But Symptomatic Outpatients With Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: paliperidone","Janssen-Cilag Farmaceutica Ltda.","Both","Adult","Phase IV",220,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR013744","November 5, 2009","01/01/2008",2009-12-01,"February 18, 2010","01/02/2010","",2009-12-01,"To explore the effectiveness, based on total Positive and Negative Syndrome Scale (PANSS) score, of flexibly dosed paliperidone ER in patients with schizophrenia previously unsuccessfully treated with risperidone.|To explore the tolerability and safety of flexibly dosed paliperidone ER in patients with schizophrenia previously unsuccessfully treated with a risperidone|To explore the characteristics of response of the transition from previous risperidone to flexibly dosed paliperidone ER. This will be done by assessing study scales","http://ClinicalTrials.gov/show/NCT01010776",NA
"64211",64211,"NCT01054976","The Efficacy of Galantamine Treatment on Attention","Completed","No Results Available","Alzheimer Disease","Drug: galantamine","Janssen Korea, Ltd., Korea","Both","Adult|Senior","Phase IV",94,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR015850|GAL-KOR-21","January 21, 2010","01/10/2006",2009-02-01,"January 25, 2010","01/01/2010","",2009-02-01,"The change in computerized attention test score from baseline at 12 weeks.|The improvement in Alzheimer's Disease Assessment Scale - cognitive subscale 11 (ADAS-cog11)|Seoul- Instrumental Activities of daily livings (S-IADL)","http://ClinicalTrials.gov/show/NCT01054976",NA
"64234",64234,"NCT01077076","Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (Study CL2008-16) (COMPLETED)","Completed","Has Results","Intragastric Acidity","Drug: Zegerid|Drug: Prilosec OTC?ºÑ Tablets|Other: Placebo","Schering-Plough","Both","Adult","Phase III",30,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Open Label","CL2008-16","February 25, 2010","01/12/2008",2009-03-01,"April 15, 2010","01/04/2010","",2009-03-01,"Percent Time With Intragastric pH>4 During the First 4 Hours Following Administration on Day 4 of Treatment","http://ClinicalTrials.gov/show/NCT01077076",NA
"64379",64379,"NCT00003377","Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: paclitaxel|Radiation: brachytherapy|Radiation: radiation therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Adult|Senior","Phase I|Phase II",40,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066371|GOG-9804","November 1, 1999","01/11/1999",NA,"October 15, 2009","01/05/2006","",2009-07-01,"Maximum tolerated dose (MTD) as assessed by CTC 3.0 after 6 weeks of treatment|Toxicity of the MTD as assessed by CTC 3.0 after 6 weeks of treatment|Disease-free survival at 2 years|Overall survival at 2 years","http://ClinicalTrials.gov/show/NCT00003377",NA
"64497",64497,"NCT00152477","A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer","Completed","No Results Available","Carcinoma|Non-Squamous Non-Small-Cell Lung Cancer","Drug: Carboplatin|Drug: Paclitaxel|Drug: CDP791 10mg/kg|Drug: CDP791 20mg/kg","UCB, Inc.","Both","Adult|Senior","Phase II",165,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C79102|EudraCT 2005-001731-30","September 6, 2005","01/08/2005",2009-06-01,"July 30, 2009","01/07/2009","",2009-06-01,"Tumour response rate at 18 weeks.|Safety and Tolerability|Progression free survival|Time to treatment failure|Overall survival|Safety and Tolerability|Quality of life","http://ClinicalTrials.gov/show/NCT00152477",NA
"64506",64506,"NCT00171977","Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)","Completed","No Results Available","Gastrointestinal Stromal Tumors","Drug: Imatinib Mesylate","Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",64,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CSTI571BJP07","September 13, 2005","01/07/2004",NA,"April 13, 2010","01/04/2010","",2009-04-01,"To evaluate the relapse-free survival (RFS) in patients receiving postoperative adjuvant therapy|To evaluate overall survival, relapse free|Safety","http://ClinicalTrials.gov/show/NCT00171977",NA
"64563",64563,"NCT00251277","Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura","Completed","No Results Available","Thrombotic Thrombocytopenic Purpura","Drug: Rituximab","Weill Medical College of Cornell University|Genentech","Both","Child|Adult|Senior","Phase I|Phase II",12,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","409007463","November 7, 2005","01/11/2005",2009-04-01,"September 28, 2010","01/09/2010","",2009-04-01,"Failure to maintain the complete response until day 120; Non-protocol treatment for TTP, such as other immunosuppressive agents or splenectomy, reinstitution of plasma exchange within the first 90 days","http://ClinicalTrials.gov/show/NCT00251277",NA
"64571",64571,"NCT00266877","Study Evaluating the Safety of HKI-272 in Subjects With Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung|Lung Neoplasms","Drug: HKI-272","Wyeth","Both","Adult|Senior","Phase II",167,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3144A1-200","December 16, 2005","01/11/2005",2009-01-01,"June 17, 2010","01/06/2010","",2009-01-01,"Radiographic tumor assessments will be used to assess outcome.","http://ClinicalTrials.gov/show/NCT00266877",NA
"64591",64591,"NCT00287677","Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients","Completed","No Results Available","HIV Infections","Biological: recombinant human Growth Hormone|Biological: Vaccination|Drug: HAART","Germans Trias i Pujol Hospital|Hospital Clinic of Barcelona|Hospital General Universitario Gregorio Mara??on|Carlos III Health Institute","Both","Adult","Phase IV",33,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VIHCREC01","February 6, 2006","01/01/2006",2009-07-01,"November 3, 2009","01/11/2009","",2009-07-01,"Proportion of patients HIV+ that recover the immunospecific responses against tetanus toxoid and Hepatitis A at 24 weeks of rhGH administration (time of treatment interruption).|The rhGH activates the thymic function.|This effect is lasting once the rhGH administration is interrupted.","http://ClinicalTrials.gov/show/NCT00287677",NA
"64602",64602,"NCT00314977","Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.","Completed","No Results Available","Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel","Radboud University|Sanofi-Aventis|Amgen","Female","Adult|Senior","Phase III",200,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IKO 2005-01 / BOOG 2007-02","April 14, 2006","01/02/2006",NA,"March 17, 2010","01/03/2010","INTENS",2009-04-01,"The pathologic complete response rate to neoadjuvant chemotherapy.|The delivered chemotherapy dose and dose-intensity of both chemotherapy regimens|The tolerability (grade 3/4 CTC toxicities) of both chemotherapy regimens.|The clinical responses of neoadjuvant chemotherapy correlated to pathological responses after neoadjuvant chemotherapy.|The value of breast MRI in evaluating response to neoadjuvant chemotherapy as compared to clinical palpation, ultrasound techniques and histo-pathological outcome.|The false-negative rate of the sentinel node biopsy after neoadjuvant chemotherapy.|The disease-free and overall survival after 3 and 5 years follow-up.|The relation between pCR and DFS/OS.|The feasibility of the criteria for reporting pathological tumour response in surgical breast and axillary node resection specimens.|The prognostic and predictive value of tumour- and molecular markers, including ER, PgR, c-erbB2, microarray and other tumour characteristic analyses.","http://ClinicalTrials.gov/show/NCT00314977",NA
"64636",64636,"NCT00351377","Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate","Completed","Has Results","Autoimmune Disease","Drug: Enteric-coated Mycophenolate sodium (EC-MPS)","Novartis Pharmaceuticals","Both","Adult|Senior","Phase III",111,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CERL080ADE08","July 10, 2006","01/06/2006",2009-06-01,"December 14, 2010","01/12/2010","",2009-06-01,"Changes in GI Symptom Severity After Conversion From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium|Changes in the GI Symptom Severity Subscales After Conversion to Enteric-coated Mycophenolate Sodium.|Changes in GI-related Quality of Life, After Patients Are Converted From MMF to Enteric-coated Mycophenolate Sodium.|Changes in the GI-related Quality of Life Subscales After Conversion to Enteric-coated Mycophenolate Sodium.|Changes in Psychological General Well-Being Index (PGWB) After Conversion to Enteric-coated Mycophenolate Sodium.|Changes in Psychological General Well-Being Index (PGWB) Subscales After Conversion to Enteric-coated Mycophenolate Sodium.|Overall Treatment Effects for GI Symptoms Assessed by the Physician|Overall Treatment Effects for GI Symptoms Assessed by the Patient.|Overall Treatment Effects for for Health-related Quality of Life Assessed by the Patient.","http://ClinicalTrials.gov/show/NCT00351377",NA
"64695",64695,"NCT00394277","A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C","Completed","Has Results","Hepatitis C, Chronic","Drug: peginterferon alfa-2a|Drug: Ribavirin|Drug: peginterferon alfa-2a|Drug: Ribavirin","Hoffmann-La Roche","Both","Adult|Senior","Phase IV",1175,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NV18210","October 30, 2006","01/02/2007",2009-04-01,"July 30, 2010","01/07/2010","",2009-04-01,"Sustained Virological Response (SVR)-24 (Scheduled Treatment Period)|SVR-24 (Actual Treatment Period)|SVR-12 (Scheduled Treatment Period)|SVR-12 (Actual Treatment Period)","http://ClinicalTrials.gov/show/NCT00394277",NA
"64728",64728,"NCT00515177","Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study","Completed","No Results Available","Chronic Insomnia|Primary Insomnia","Behavioral: Mindfulness-Based Stress Reduction|Drug: eszopiclone","University of Minnesota - Clinical and Translational Science Institute|Hennepin County Medical Center, Minneapolis","Both","Adult","Phase II|Phase III",40,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","0705M09301","August 10, 2007","01/08/2007",2009-06-01,"November 1, 2010","01/11/2010","MVP#1",2009-06-01,"Pittsburgh Sleep Quality Index (PSQI)|Insomnia Severity Index|Actigraphy|State-Trait Anxiety Inventory (STAI)|Center for Epidemiological Studies Depression Scale (CES-D)|Medical Outcome Study Short Form (SF-12)","http://ClinicalTrials.gov/show/NCT00515177",NA
"64735",64735,"NCT00499577","Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: CMV pp65 peptide|Biological: hTERT I540/R572Y/D988Y multipeptide vaccine|Biological: pneumococcal polyvalent vaccine|Biological: survivin Sur1M2 peptide vaccine","University of Maryland Greenebaum Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase I|Phase II",56,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000552988|MSGCC-0610-GCC|UPCC-0610-GCC","July 10, 2007","01/12/2006",NA,"November 3, 2010","01/08/2009","",2009-02-01,"Toxicity at 21 and 28 days post-transplant|T-cell responses against the hTERT vaccine as measured by tetramer assays at 100 days post-transplant|Paraprotein levels in the blood or urine and serum free light chain analyses at 60 days and at 6 months post-transplant|Cytotoxic T-cell responses against autologous myeloma cell at day 100 post-transplant via chromium-51 release or flow-based assays|Maximum clinical response|1 and 2-year event-free survival|Overall survival rates|CD4 and CD8 T-cell responses against cytomegalovirus (CMV) at days 60 and 100 post-transplantation by CFSE dye dilution assays|Composite binding antibody responses at days 60 and day 100 post-transplant by ELISA","http://ClinicalTrials.gov/show/NCT00499577",NA
"64737",64737,"NCT00526877","A Study of the Effectiveness and Safety of Long Acting Risperidone in Patients With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment","Completed","No Results Available","Risperdal Consta|Schizophrenia|Schizoaffective Disorders","Drug: Risperidone","Johnson & Johnson Taiwan Ltd","Both","Adult|Senior","Phase IV",27,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR013873","September 6, 2007","01/05/2007",2009-01-01,"April 26, 2010","01/04/2010","",2009-01-01,"The mean change in total PANSS (Positive and Negative Syndrome Scale score) at endpoint versus baseline.|Compare the PSP (Personal and Social Performance) score, CGI (Clinical Global Impression) score and SQLS (Quality of Life) at endpoint versus the baseline and pre-risperidone long acting period.","http://ClinicalTrials.gov/show/NCT00526877",NA
"64755",64755,"NCT00537277","Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: biphasic insulin aspart","Novo Nordisk","Both","Adult|Senior","Phase IV",161,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BIASP-1849","September 28, 2007","01/10/2007",2009-01-01,"July 19, 2010","01/07/2010","IMPROVE",2009-01-01,"Percentage of Subjects Achieving the Treatment Target of Glycosylated Haemoglobin (HbA1c) Below 7.0%|Percentage of Trial Completers Achieving the Treatment Target of Glycosylated Haemoglobin (HbA1c) Below 7.0%|Number of Hypoglycaemic Episodes|Number of Diurnal Hypoglycaemic Episodes|Number of Nocturnal Hypoglycaemic Episodes|Number of Treatment Emergent Serious Adverse Events (SAEs)","http://ClinicalTrials.gov/show/NCT00537277",NA
"64778",64778,"NCT00589277","Message Framing for Telephone Quitline Callers","Completed","No Results Available","Smoking|Nicotine Dependence","Behavioral: \Yale coaching\""|Behavioral: Standard care""","Yale University|National Cancer Institute (NCI)","Both","Adult|Senior","Phase I|Phase II",2032,"Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","NCI R21 CA127818|0705002661","January 3, 2008","01/08/2007",2009-05-01,"June 3, 2010","01/06/2010","",2009-05-01,"Efficacy data from the clinical trial will be used to determine effect size estimates for both 1-week and 3-month self-reported point prevalence abstinence rates.|To examine mediators of message framing effects.","http://ClinicalTrials.gov/show/NCT00589277",NA
"64814",64814,"NCT00645177","Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer","Drug: ABT-869|Drug: paclitaxel|Drug: Placebo for ABT-869","Abbott|Genentech","Female","Adult|Senior","Phase II",10,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","M10-265|EudraCT 2007-005949-38","March 24, 2008","01/07/2008",NA,"November 2, 2010","01/09/2010","",2009-12-01,"Progression-free survival|Overall survival","http://ClinicalTrials.gov/show/NCT00645177",NA
"64824",64824,"NCT00659477","Comparison Safety and Efficacy of Basal Insulin Lantus?ó (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: insulin glargine","Sanofi-Aventis","Both","Adult|Senior","Phase IV",117,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LANTU_L_02673|EudraCT #: 2007-003393-25","April 10, 2008","01/03/2008",2009-06-01,"July 29, 2010","01/07/2010","COBIN 2",2009-06-01,"The change in blood glucose variability|Occurrence of adverse events|Development of diabetes compensation - fastig blood glucose and HbA1|Development of weight of patients|Comparison of dose of insulins NPH vs Lantus","http://ClinicalTrials.gov/show/NCT00659477",NA
"64841",64841,"NCT00681577","Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer","Completed","No Results Available","Gastric Cancer","Biological: URLC10, KOC1, VEGFR1 and VEGFR2","Tokyo University|Human Genome Center, Institute of Medical Science, University of Tokyo","Both","Adult|Senior","Phase I|Phase II",14,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMS-MKA2402","May 19, 2008","01/05/2008",2009-10-01,"November 18, 2009","01/11/2009","",2009-10-01,"safety (Phase I: toxicities as assessed by NCI CTCAE version 3) and efficacy (Phase II: Feasibility as evaluated by RECIST)|To evaluate immunological responses","http://ClinicalTrials.gov/show/NCT00681577",NA
"64855",64855,"NCT00684177","Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)","Completed","Has Results","Secondarily-infected Abrasions|Secondarily-infected Lacerations|Secondarily-infected Sutured Wounds|Secondarily-infected Traumatic Lesions|Skin Diseases, Bacterial","Drug: Retapamulin Ointment, 1%|Drug: Placebo ointment","GlaxoSmithKline","Both","Child|Adult|Senior","Phase III",508,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TOC110977","May 22, 2008","01/05/2008",2009-10-01,"January 6, 2011","01/01/2011","",2009-10-01,"Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Primary Efficacy Population|Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Intent-to-Treat Bacteriology (ITTB) Subset of the Primary Efficacy Population|Number of Participants With Microbiological Success and Failure at Follow-up (7-9 Days Post Therapy)|Number of Participants With the Indicated Clinical Outcome at End of Therapy (2-4 Days Post Therapy)|Number of Baseline Pathogens With the Indicated Microbiological Outcome at End of Therapy (2-4 Days Post Therapy)|Number of Participants With Therapeutic Success and Failure at Follow-up (7-9 Days Post Therapy)","http://ClinicalTrials.gov/show/NCT00684177",NA
"64884",64884,"NCT00751777","Traveler's Diarrhea (TD) Automated Process","Completed","No Results Available","Prevention of Travelers' Diarrhea","Biological: heat-labile enterotoxin of E. coli (LT)|Biological: Placebo","Intercell USA, Inc.","Both","Adult","Phase II",120,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ELT207","September 11, 2008","01/09/2008",2009-11-01,"August 12, 2010","01/08/2010","",2009-11-01,"Evaluation of immunogenicity of LT vaccine patch after first and second vaccination and comparison against placebo|Evaluation of safety of LT vaccine patch after first and second vaccination compared to placebo patch|Evaluation of residual LT in the patch and on the skin at the patch site post-wear|Evaluation of duration of LT-specific immune responses one-year after original treatment regimen in LT patch group","http://ClinicalTrials.gov/show/NCT00751777",NA
"64887",64887,"NCT00758277","Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients","Completed","No Results Available","Prevention|Alcohol Dependence|Relapse","Drug: levetiracetam (Keppra)|Drug: Placebo","Charite University, Berlin, Germany|UCB, Inc.","Both","Adult|Senior","Phase III",190,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","Kep-F10.2.01","September 23, 2008","01/05/2007",2009-12-01,"August 5, 2009","01/08/2009","Keppra-2",2009-07-01,"Comparison alcohol free \surviving \""(heavy alcohol relapse) between experimental therapy (Keppra?ó) and a group of placebos|1 Time up to first drinking|2 cumulative Time of do not drinking over the study duration|3 Frequency of Lapses|Tolerability of the study medication|Drop Out rate|Side effects|Changes with the neuropsychological testing","http://ClinicalTrials.gov/show/NCT00758277",NA
"64901",64901,"NCT00772577","Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ??­ 30) With Stage 2 Hypertension","Completed","No Results Available","Hypertension","Drug: Aliskiren Hydrochlorothiazide|Drug: Ramipril:","Novartis","Both","Adult|Senior","Phase IV",386,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CSPP100AUS07","October 10, 2008","01/08/2008",NA,"May 14, 2009","01/05/2009","ATTAIN",2009-05-01,"Change in from baseline in mean sitting systolic blood pressure (MSSBP) after|Change from baseline in mean sitting diastolic blood pressure (MSDBP)|Change from baseline in mean sitting pulse pressure|Proportion of responders (MSSBP <140 mmHg or a > 20 mmHg decrease from baseline in MSSBP)|Proportion of patients achieving BP control (BP <140/90 mmHg)|Safety and tolerability","http://ClinicalTrials.gov/show/NCT00772577",NA
"64907",64907,"NCT00784277","A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease","Completed","No Results Available","Joint Disease|Arthritis|Osteoarthritis","Drug: Tapentadol IR (CG5503)|Drug: Tapentadol IR (CG5503)|Drug: Tapentadol ER(CG5503)|Drug: Placebo|Drug: oxycodone IR|Drug: Placebo|Drug: oxycodone CR","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Gr??nenthal GmbH","Both","Adult|Senior","Phase III",597,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR014326|KF5503/41","October 31, 2008","01/10/2008",2009-07-01,"September 4, 2009","01/09/2009","",2009-07-01,"The primary endpoints are the 5-day Sum of Pain Intensity Difference (SPID) and the Number of Spontaneous Bowel Movements per Week.|The secondary endpoints are derived pain severity and relief measures and the severity of constipation associated bowel symptoms.","http://ClinicalTrials.gov/show/NCT00784277",NA
"64918",64918,"NCT00798577","Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment","Completed","Has Results","Bacterial Conjunctivitis","Drug: Vigamox Ophthalmic Solution|Drug: BSS placebo","Alcon Research|Topical Solutions Ltd.","Both","Child|Adult|Senior","Phase IV",24,"Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SMA-08-03","November 25, 2008","01/10/2008",2009-02-01,"March 30, 2010","01/03/2010","",2009-02-01,"Exploratory Outcomes From Digital Photography|Exploratory Evaluation of Changes in Ocular Signs and Symptoms|Microbiological Culture Evaluation/Eradication Percent - Enterobacter Faecalis and Candida Albicans|Microbiological Culture Evaluation/Eradication Percent - Eradication of All Other Isolates and Corynform-like|Microbiological Culture Evaluation/Eradication Percent - Staphylococcus Aureus, Steptococcus Pneumoniae, and Enterobacter Cloacae","http://ClinicalTrials.gov/show/NCT00798577",NA
"64928",64928,"NCT00814177","Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients","Completed","Has Results","Atrial Fibrillation|Venous Thromboembolism|Ischemic Stroke|Myocardial Infarction","Drug: warfarin|Drug: warfarin","Hamilton Health Sciences Corporation","Both","Adult|Senior","Phase II",160,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HRC060425","December 23, 2008","01/07/2006",2009-04-01,"February 26, 2010","01/11/2009","FORESPEAK-0",2009-01-01,"Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks","http://ClinicalTrials.gov/show/NCT00814177",NA
"64931",64931,"NCT00828477","Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)","Completed","No Results Available","Intraocular Pressure","Drug: Xibrom|Drug: Nevanac","Bp Consulting, Inc","Both","Adult|Senior","Phase IV",25,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0144","January 14, 2009","01/01/2009",2009-06-01,"June 8, 2009","01/06/2009","",2009-06-01,"Tolerability of study medication|Intraocular pressure changes|Visual Acuity","http://ClinicalTrials.gov/show/NCT00828477",NA
"64940",64940,"NCT00837577","MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (0431-104)(COMPLETED)","Completed","No Results Available","Diabetes Mellitus, Non-Insulin-Dependent","Drug: sitagliptin|Drug: Comparator: Placebo|Drug: Voglibose|Drug: sitagliptin","Merck","Both","Adult|Senior","Phase III",130,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2009_535|MK0431-104","February 3, 2009","01/02/2009",2010-08-01,"November 2, 2010","01/11/2010","",2009-11-01,"HbA1c, Safety and Tolerability|2-hour postmeal glucose and fasting plasma glucose","http://ClinicalTrials.gov/show/NCT00837577",NA
"64944",64944,"NCT00846677","Study Comparing Two Vitamin D Supplements for Infants: Liquid Versus D-Strips","Completed","No Results Available","Healthy","Dietary Supplement: Vitamin D, cholecalciferol|Dietary Supplement: Vitamin D, cholecalciferol","McGill University","Both","Child","Phase IV",50,"Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label","PLB-D301","February 17, 2009","01/01/2009",2009-09-01,"November 13, 2009","01/11/2009","",2009-09-01,"Parental and infant preference for a new vitamin D delivery system over the standard of care supplement in syrup form.|Barriers to either supplement delivery system being given during infancy.","http://ClinicalTrials.gov/show/NCT00846677",NA
"64959",64959,"NCT00868777","The Influence of Dimensional Anatomic Variables on the Outcomes of Maxillary Sinus Grafting Procedures","Completed","No Results Available","Edentulism|Alveolar Bone Atrophy|Sinus Pneumatization","Procedure: Sinus grafting using allogenic bone","University of Michigan|BioHorizons, Inc.","Both","Adult|Senior","Phase IV",25,"Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HUM00017520","March 24, 2009","01/01/2008",2009-03-01,"September 24, 2009","01/03/2009","",2009-02-01,"Histomorphometric proportion of vital bone","http://ClinicalTrials.gov/show/NCT00868777",NA
"64965",64965,"NCT00875277","A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products","Completed","No Results Available","Psoriasis Vulgaris","Drug: LEO 29102 cream and combination products","LEO Pharma","Both","Adult|Senior","Phase II",24,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)","PLQ-003","April 2, 2009","01/04/2009",2009-07-01,"August 11, 2009","01/08/2009","",2009-05-01,"Total Clinical Score of the clinical symptoms|Clinical scores, lesions thickness, histology and immunohistochemistry measurements","http://ClinicalTrials.gov/show/NCT00875277",NA
"64972",64972,"NCT00884377","Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis","Completed","No Results Available","Cutaneous Leishmaniasis","Drug: Sodium stibogluconate (Pentostam)|Device: ThermoMed","U.S. Army Medical Research and Materiel Command|Walter Reed Army Medical Center","Both","Adult","Phase II",60,"U.S. Fed","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A-12364","April 17, 2009","01/02/2004",2009-03-01,"April 17, 2009","01/04/2009","",2009-01-01,"The primary objective is to assess if local heat treatment with the ThermoMed device is equivalent in efficacy to 10 days of parenteral sodium stibogluconate|Determine efficacy of heat vs SSG for all lesions at 12 mos after treatment start.|Compare the toxicity profiles of heat versus parenteral SSG therapy|Evaluate the immune response to leishmania before, and on day 10 and 6 months following treatment|Establish the feasibility of a L. major species specific polymerase chain reaction as a rapid diagnostic device in the context of a treatment trial.","http://ClinicalTrials.gov/show/NCT00884377",NA
"64985",64985,"NCT00907777","Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23?ºÑ","Completed","No Results Available","Haemophilus Influenzae Infections|Pneumococcal Disease","Biological: Pneumococcal conjugate vaccine GSK 1024850A|Biological: Pneumococcal conjugate vaccine Prevenar?ºÑ (Wyeth Lederle's)","GlaxoSmithKline","Both","Child","Phase III",52,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","112807","May 21, 2009","01/06/2009",2009-10-01,"December 23, 2009","01/12/2009","",2009-10-01,"Immune response to components of the investigational pneumococcal conjugate vaccine|Immune response to components of the investigational pneumococcal conjugate vaccine for additional parameters|Immune response to components of the investigational pneumococcal conjugate vaccine|Occurrence of serious adverse events|Occurrence of solicited local and general adverse events.|Occurrence of unsolicited adverse events.","http://ClinicalTrials.gov/show/NCT00907777",NA
"64987",64987,"NCT00914277","SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction","Completed","No Results Available","Erectile Dysfunction","Drug: SAR407899|Drug: Placebo|Drug: Sildenafil","Sanofi-Aventis","Male","Adult","Phase II",24,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT10775|EudraCT:2009-009936-56","June 2, 2009","01/05/2009",2009-10-01,"May 11, 2010","01/05/2010","RHOKET",2009-09-01,"Duration of penile rigidity during sexual stimulation|Time to onset of penile rigidity|Blood pressure","http://ClinicalTrials.gov/show/NCT00914277",NA
"65005",65005,"NCT00946777","Barrier Function Measurement in Dry Eye Patients After Using Systane Ultra for 30 Days","Completed","No Results Available","Dry Eye","Drug: Systane?ó Ultra","Alcon Research","Both","Adult|Senior","Phase IV",20,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SMA-09-04","July 24, 2009","01/07/2009",NA,"January 27, 2010","01/01/2010","",2009-09-01,"Percent change from baseline of corneal fluorescein|Adverse event occurence","http://ClinicalTrials.gov/show/NCT00946777",NA
"65036",65036,"NCT00987077","Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy","Completed","No Results Available","Central Serous Chorioretinopathy|Selective Retina Therapy","Device: Selective Retina Therapy (SRT)","University of Kiel|Medical Laser Center L??beck, L??beck, Germany|Institute for Medical Informaties and Statistics Kiel, Germany","Both","Child|Adult|Senior","Phase II",30,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","SRT_CSC_Kiel","September 29, 2009","01/04/2007",2009-01-01,"September 29, 2009","01/09/2009","",2009-01-01,"Serial changes in ETDRS letterscore|The maximum distance between the RPE and the outer neurosensory retina in the area of Subretinal fluid accumulation","http://ClinicalTrials.gov/show/NCT00987077",NA
"65089",65089,"NCT01076777","Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial","Completed","No Results Available","Panic Disorder","Behavioral: Physical exercise|Behavioral: Cognitive-behavioral therapy","University of Bergen|Norwegian Department of Health and Social Affairs","Both","Adult","Phase II",36,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3.2007.499 (REK)","February 25, 2010","01/05/2007",2009-12-01,"February 25, 2010","01/02/2010","",2009-12-01,"Mobility Inventory (MI) - Alone & Accompanied|Agoraphobic Cognitions Questionnaire (ACQ)|Body Sensations Questionnaire|Panic frequency - Self-report & Clinician-rating|Panic distress/disability - Self-report & Clinician-rating|Beck Anxiety Inventory (BAI)|State-Trait Anxiety Inventory - State & Trait (STAI S/T)|Beck Depression Inventory II (BDI-II)|Quality of Life Inventory (QoLI)","http://ClinicalTrials.gov/show/NCT01076777",NA
"65092",65092,"NCT01080677","Caffeine/Propranolol Acute Migraine","Completed","No Results Available","Migraine Disorders","Drug: caffeine propranolol combination","Stanford University","Both","Adult","Phase II",60,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SU-02112010-4963|7011","March 2, 2010","01/01/2007",2009-12-01,"March 2, 2010","01/03/2010","",2009-09-01,"Pain-relief at 2 hrs post first administration of caffeine/propranolol (defined as a decrease in headache pain intensity from severe or moderate headache pain at baseline to mild or no pain at 2 hrs)|Pain free at 2 hrs post first administration of caffeine/propranolol|Relief of associated symptoms such as nausea, and photophobia and phonophobia at 2 hours|Safety and tolerability|Subject treatment satisfaction|Lack of need for rescue medication","http://ClinicalTrials.gov/show/NCT01080677",NA
"65226",65226,"NCT00002678","Combination Chemotherapy in Treating Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: dexamethasone|Drug: melphalan|Drug: prednisone","NCIC Clinical Trials Group","Both","Adult|Senior","Phase III",600,"Other","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","MY7|CAN-NCIC-MY7|NCI-V95-0713|CDR0000064328","November 1, 1999","01/05/1995",2009-12-01,"November 7, 2010","01/11/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00002678",NA
"65229",65229,"NCT00003078","Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: fluorouracil|Radiation: brachytherapy|Radiation: radiation therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child|Adult|Senior","Phase III",870,"Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065771|GOG-0165","November 1, 1999","01/10/1997",NA,"February 27, 2010","01/02/2010","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00003078",NA
"65373",65373,"NCT00176878","Stem Cell Transplant for Bone Marrow Failure Syndromes","Completed","Has Results","Diamond-Blackfan Anemia|Kostmann's Neutropenia|Shwachman-Diamond Syndrome","Procedure: Stem cell transplant|Drug: Fludarabine monophosphate|Procedure: Total lymphoid irradiation|Drug: Busulfan|Biological: anti-thymocyte globulin","Masonic Cancer Center, University of Minnesota","Both","Child|Adult","Phase II|Phase III",10,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MT2000-18|9504M09637","September 12, 2005","01/06/2000",2009-03-01,"September 30, 2010","01/09/2010","",2009-03-01,"Number of Patients Alive (Survival) at 2 Years|Number of Patients Alive at Three Years (Survival)|Number of Patients With Succcessful Engraftment After Transplantation|Number of Patients With Grade 2-4 Acute Graft Versus Host Disease|Number of Patients With Chronic Graft Versus Host Disease|Number of Patients With Disease Recurrence","http://ClinicalTrials.gov/show/NCT00176878",NA
"65422",65422,"NCT00260078","Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children","Completed","No Results Available","HIV Infections","Drug: Atazanavir|Drug: Darunavir|Drug: Efavirenz|Drug: Nevirapine|Drug: Ritonavir|Drug: Tenofovir disoproxil fumarate|Procedure: Pharmacokinetic Study","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Child","Phase I|Phase II",64,"NIH","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IMPAACT P1058|PACTG 1058","November 29, 2005","01/02/2006",2009-04-01,"October 19, 2010","01/04/2009","",2009-04-01,"Predosage concentration (C0 and C12) and area under the concentration-time curve (AUC)","http://ClinicalTrials.gov/show/NCT00260078",NA
"65427",65427,"NCT00274378","Allomatrix Injectable Putty in Distal Radius Fractures","Completed","No Results Available","Radius Fractures","Device: ALLOMATRIX injectable putty in distal radius fractures","Universit?¢ Catholique de Louvain|Wright Medical Technology","Both","Adult|Senior","Phase IV",50,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","Allomatrix radius UCL","January 6, 2006","01/06/2005",2009-05-01,"July 29, 2009","01/07/2009","",2009-05-01,"Hand ability: self-assesment questionnaire ABILHAND and DASH|Bone mineral density|Radiological evaluation|Hand impairment (strength, sensibilty, mobility)","http://ClinicalTrials.gov/show/NCT00274378",NA
"65428",65428,"NCT00275678","Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies","Completed","No Results Available","Blood Stem Cell Transplant","Procedure: Blood stem cell versus bone marrow transplant","Mayo Clinic|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|National Marrow Donor Program|University of Minnesota - Clinical and Translational Science Institute|University of Florida|Duke University|Children's Memorial Hospital","Both","Adult|Senior","Phase III",15,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2158-03","January 10, 2006","01/11/2003",NA,"June 2, 2010","01/06/2010","",2009-09-01,"Two-year survival|Two-year survival|Neutrophil Engraftment > 500/mcl|Primary graft failure|Platelet engraftment > 20,000 and 50,000/mcl transfusion independent|Acute GVHD of grades II-IV and III-IV","http://ClinicalTrials.gov/show/NCT00275678",NA
"65436",65436,"NCT00284778","Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Alimta?ó|Drug: Taxotere?ó","University Hospital, Limoges|Groupe Francais De Pneumo-Cancerologie","Both","Adult|Senior","Phase III",150,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","I05026","January 31, 2006","01/02/2006",2009-12-01,"March 26, 2010","01/03/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00284778",NA
"65446",65446,"NCT00289978","Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Drug: Fingolimod|Drug: Fingolimod|Drug: Fingolimod matching placbeo","Novartis","Both","Adult","Phase III",1272,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CFTY720D2301","February 9, 2006","01/01/2006",NA,"December 4, 2009","01/12/2009","FREEDOMS",2009-07-01,"Annualized relapse rate in patients with RRMS treated up to 24 months|Time to 3-month confirmed disability progression measured by EDSS|Safety and tolerability of FTY720 in patients treated up to 24 months|Time to the first relapse and proportion of relapse-free patients|Time to 6-month confirmed disability progression|MRI parameters to measure inflammatory disease activity and burden of disease.","http://ClinicalTrials.gov/show/NCT00289978",NA
"65458",65458,"NCT00317278","Effects of Massage on the Immune System of Preterm Infants","Completed","No Results Available","Premature Birth|Stress","Other: massage therapy|Other: Sham","National Center for Complementary and Alternative Medicine (NCCAM)","Both","Child","Phase I|Phase II",120,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","R21 AT001872-01A2","April 20, 2006","01/10/2005",2009-07-01,"December 4, 2009","01/12/2009","",2009-02-01,"NK cell numbers|Cellular immune function","http://ClinicalTrials.gov/show/NCT00317278",NA
"65480",65480,"NCT00349778","High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: cyclophosphamide|Drug: etoposide|Drug: BCNU Melphalan","Stanford University","Both","Adult|Senior","Phase I|Phase II",49,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT183|97115|BMT183","July 5, 2006","01/08/2006",2010-04-01,"October 7, 2010","01/10/2010","",2009-04-01,"Evaluate the risk of interstitial pneumonitis with the current dosing of BCNU and melphalan|Remission rate, event-free survival, overall survival and relapse","http://ClinicalTrials.gov/show/NCT00349778",NA
"65524",65524,"NCT00409578","Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome","Completed","No Results Available","Post Acute Coronary Syndrome|Myocardial Ischemia","Drug: Aliskiren/Valsartan|Drug: Aliskiren/Valsartan|Drug: Placebo","Novartis|The TIMI Study Group","Both","Adult|Senior","Phase II",1100,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CSPP100A2347","December 7, 2006","01/04/2007",NA,"August 31, 2009","01/08/2009","",2009-05-01,"Reduction of the NT-proBNP levels for valsartan and aliskiren compared to placebo|Reduction of NT-proBNP levels for valsartan/aliskiren combination compared to each individual monotherapy and placebo|Reduction of adverse cardiac events rate (death, recurrent myocardial infarction, or hospitalization for congestive heart failure) as compared to placebo|Explore if the combination of aliskiren or valsartan reduces the rate of adverse cardiac events (death, recurrent myocardial infarction, or hospitalization for congestive heart failure) as compared to each individual monotherapy and placebo|Reduction of NT-proBNP levels for valsartan or aliskiren compared to placebo|Reduction of NT-proBNP levels for aliskiren or valsartan compared to placebo|Reduction of levels of key biomarkers of cardiovascular risk (e.g, hsCRP, PRA) for aliskiren and valsartan combination or individual monotherapies","http://ClinicalTrials.gov/show/NCT00409578",NA
"65535",65535,"NCT00423878","Comparison of Antipsychotics for Metabolic Problems in the Treatment of People With Schizophrenia or Schizoaffective Disorder","Completed","No Results Available","Schizophrenia|Schizoaffective Disorder","Drug: Risperidone|Drug: Olanzapine|Drug: Quetiapine|Drug: Aripiprazole|Behavioral: Intervention used to control diet and modify activity level","National Institute of Mental Health (NIMH)","Both","Adult","Phase IV",215,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","STROUP06STN0|DSIR AT-AP","January 16, 2007","01/01/2007",2010-03-01,"November 12, 2010","01/11/2010","CAMP",2009-10-01,"Mean difference in non-HDL cholesterol level changes between patients assigned to stay compared to patients assigned to switch at the last observation|Efficacy failure, defined as psychiatric hospitalization, a 25 percent increase from baseline on the Positive and Negative Syndrome Scale or substantial clinical deterioration on the Clinical Global Impressions-Change (CGI-C)","http://ClinicalTrials.gov/show/NCT00423878",NA
"65559",65559,"NCT00464178","A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: bevacizumab","Hackensack University Medical Center|Genentech","Both","Adult|Senior","Phase II",30,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AV3502s|Protocol no. AVF3502s|WIRB no. 20070359","April 19, 2007","01/04/2007",2009-02-01,"October 20, 2010","01/10/2010","",2009-02-01,"Time to Tumor Progression (TTP)|TTP is calculated at the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Blad?¢ et al (Appendix F). If disease progression is based on increasing monoclonal parap|Overall Survival (OS)|Overall survival is calculated at the time of the screening evaluation to death from any cause.","http://ClinicalTrials.gov/show/NCT00464178",NA
"65562",65562,"NCT00475878","SSRI and Buprenorphine","Completed","No Results Available","Opiate Dependence|Depression","Drug: escitalopram|Drug: placebo","Butler Hospital","Both","Adult|Senior","Phase III",147,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","DA022207|0807-002","May 18, 2007","01/12/2006",2009-09-01,"September 30, 2009","01/08/2006","",2009-09-01,"buprenorphine adherence|mood symptoms","http://ClinicalTrials.gov/show/NCT00475878",NA
"65564",65564,"NCT00469378","Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis","Completed","No Results Available","Relapsing Forms of Multiple Sclerosis","Drug: firategrast","GlaxoSmithKline","Both","Adult","Phase II",46,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A4M108119","May 2, 2007","01/07/2007",2010-02-01,"May 14, 2010","01/05/2010","",2009-05-01,"Number and change in number of total leukocytes, total lymphocytes and lymphocyte subsets and the CD4:CD8 ratio in the CSF and blood|Number and change in number of CD34+ cells in the blood|Safety and tolerability of firategrast given for up to 24 weeks|The relationship between systemic exposure (pharmacokinetics) and leukocyte counts and pharmacogenetics.","http://ClinicalTrials.gov/show/NCT00469378",NA
"65583",65583,"NCT00500578","Intermittent Use of Aerosolized Ribavirin for Treatment of RSV","Completed","Has Results","Hematological Malignancies","Drug: Ribavirin|Drug: Ribavirin","M.D. Anderson Cancer Center|ICN Pharmaceuticals","Both","Child|Adult|Senior","Phase IV",51,"Other|Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ID03-0010","July 10, 2007","01/02/2003",2009-01-01,"October 18, 2010","01/10/2010","",2009-01-01,"Occurrences of Pneumonia","http://ClinicalTrials.gov/show/NCT00500578",NA
"65603",65603,"NCT00447278","A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents","Completed","Has Results","Attention Deficit Hyperactivity Disorder","Drug: Atomoxetine|Drug: Other standard therapy for ADHD","Eli Lilly and Company","Both","Child","Phase III",399,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11576|B4Z-EW-LYDY","March 12, 2007","01/03/2007",2009-07-01,"April 22, 2010","01/04/2010","ADHD LIFE",2009-03-01,"Change From Baseline to 6 Month Endpoint in Child Health and Illness Profile - Child Edition, Parent Report Form (CHIP-CE PRF), Achievement Domain|Change From Baseline to 4 Month and 12 Month Endpoints in CHIP-CE PRF, Achievement Domain|Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in the CHIP-CE PRF Domain Scores (Satisfaction, Comfort, Resilience and Risk Avoidance)|Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P)|Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in Attention-Deficit/Hyperactivity Disorder Rating Scale - Parent Version: Investigator Adminitered and Scored (ADHD-RS-IV Parent:Inv)|Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in Clinical Global Impression Attention-Deficit/Hyperactivity Disorder - Severity (CGI-ADHD-S)|Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in the CHIP-CE CRF for Children (6-11 Years)|Change From Baseline to 4 Month, 6 Month, and 12 Month Endpoints in the CHIP-Adolescent Edition (AE) for Adolescents (>11-17 Years)|Correlation Between CHIP-CE Parent Rated and Pooled CHIP-CE Child Rated and CHIP AE Adolescent Rated T-Scores","http://ClinicalTrials.gov/show/NCT00447278",NA
"65613",65613,"NCT00556478","Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation","Completed","No Results Available","Premature Ejaculation","Drug: PSD502, contains a mixture of lidocaine and prilocaine|Drug: PSD502 Placebo","Plethora Solutions Ltd|Shionogi Pharma, Inc.","Male","Adult|Senior","Phase II|Phase III",256,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PSD502-PE-002","November 9, 2007","01/10/2007",2009-10-01,"July 14, 2010","01/07/2010","PSD502-PE-002",2009-10-01,"To evaluate efficacy of treatment with PSD502 compared with placebo in subjects with PE as measured by: ??Ñ changes in mean IELT from baseline to during 3 month double-blind treatment ??Ñ changes in all 3 IPE domains from baseline to month 3|Proportion of subjects with short mean IELT during double-blind treatment; Change in mean IELT from Baseline; Subject & Partner PEP scores; Evaluation of safety and tolerability measured by Adverse Event data","http://ClinicalTrials.gov/show/NCT00556478",NA
"65615",65615,"NCT00565578","Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload","Completed","No Results Available","Transfusion-Dependent Iron Overload","Drug: Deferasirox","Novartis Pharmaceuticals","Both","Child|Adult|Senior","Phase III",185,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CICL670A2409E1","November 29, 2007","01/07/2006",NA,"January 17, 2011","01/01/2011","",2009-05-01,"To Evaluate if fixed starting dose of ICL670, based on transfusional history and subsequent dose titration can provide clinically acceptable chelation as measured by serum ferritin|Safety assessed by serum Ferritin Tolerability assessed by safety profile Evaluate the relationship between serum ferritin and potential surrogate markers","http://ClinicalTrials.gov/show/NCT00565578",NA
"65633",65633,"NCT00592878","Screening and Brief Advice to Reduce Teen Substance Use Czech Collaboration","Completed","No Results Available","Substance-Related Disorders","Behavioral: Computerized Screening and Physician Brief Advice","Children's Hospital Boston|The Centre for the Evaluation, Prevention, and Research of Substance Abuse","Both","Child|Adult","Phase II",589,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","R01 DA018848-03S1|R01 DA018848-03S1","January 3, 2008","01/09/2006",2009-08-01,"June 15, 2010","01/06/2010","",2009-04-01,"Percentage days abstinent of substance use|Rate of cessations of substance use|Rate of initiation of substance use|Driving under the influence or riding with a driver under the influence","http://ClinicalTrials.gov/show/NCT00592878",NA
"65642",65642,"NCT00591578","Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Subjects With Essential Hypertension","Completed","No Results Available","Essential Hypertension","Drug: Azilsartan Medoxomil|Drug: Azilsartan Medoxomil|Drug: Valsartan","Takeda Global Research & Development Center, Inc.","Both","Adult|Senior","Phase III",984,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-491_301|U1111-1113-9238","December 27, 2007","01/12/2007",2010-03-01,"March 25, 2010","01/03/2010","",2009-09-01,"Change from Baseline in the 24-hour mean Systolic Blood Pressure by ambulatory blood pressure monitor.|Change from Baseline in trough sitting clinic Systolic Blood Pressure|Change from Baseline for 24-hour mean Diastolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline in trough sitting clinic Diastolic Blood Pressure|Change from Baseline for daytime mean (6am to 10pm) Systolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for daytime mean (6am to 10pm) Diastolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for nighttime mean (12am to 6am) Systolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for nighttime mean (12am to 6am) Diastolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for 0-12-hr mean Systolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for 0-12-hr mean Diastolic Blood Pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) Systolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for trough mean (22-24-hr) Diastolic Blood Pressure by ambulatory blood pressure monitor|Percentage of subjects who achieve a clinic Diastolic Blood Pressure < 90 mm Hg and/or reduction of ??­10 mm Hg from baseline|Percentage of subjects who achieve a clinic Systolic Blood Pressure < 140 mm Hg and/or reduction of ??­20 mm Hg from baseline|Proportion of subjects who achieve both clinic Diastolic and Systolic Blood Pressure Response","http://ClinicalTrials.gov/show/NCT00591578",NA
"65653",65653,"NCT00546078","Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America","Completed","Has Results","Human Papillomavirus (HPV) Infection|Papillomavirus Vaccines","Biological: Cervarix?ºÑ","GlaxoSmithKline","Female","Child|Adult","Phase II",116,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","109628","October 17, 2007","01/01/2008",2009-11-01,"December 2, 2010","01/12/2010","",2009-11-01,"Number of Subjects With Anti-human Papilloma Virus-16 (Anti-HPV-16) and Anti-HPV-18 Antibody Titers Greater Than or Equal to Pre-defined Cut-off Values|Anti-HPV-16 and Anti-HPV-18 Antibody Titers|Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Greater Than or Equal to Pre-defined Cut-off Values|Anti-HPV-16 and Anti-HPV-18 Antibody Titers|Number of Subjects With Antibody Titers Against Other Oncogenic HPV Types (HPV-31 & HPV-45) Greater Than or Equal to 59 EL.U/mL|Anti-HPV-31 and Anti-HPV-45 Antibody Titers|Number of Subjects With Cluster of Differentiation 4 (CD4) T Cell-mediated Immune Responses Specific to Defined Oncogenic HPV Types|Number of Subjects With Cluster of Differentiation 8 (CD8) T Cell-mediated Immune Responses Specific to Defined Oncogenic HPV Types|Number of Subjects With B Cell-mediated Immune Responses Specific to Defined Oncogenic HPV Types|Number of Subjects Seropositive for Anti-HPV-16 and Anti-HPV-18 Antibodies in Cervico-vaginal Secretion Samples|Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Cervico-vaginal Secretion Samples|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Outcome of Any Reported Pregnancies|Number of Subjects With New Onset of Chronic Diseases (NOCDs), New Onset of Autoimmune Diseases (NOADs) and Medically Significant Conditions (MSCs)|Number of Subjects Reporting Serious Adverse Events (SAEs)","http://ClinicalTrials.gov/show/NCT00546078",NA
"65665",65665,"NCT00638378","Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer","Completed","No Results Available","Metastatic Prostate Cancer","Drug: INCB018424","Incyte Corporation","Male","Adult|Senior","Phase II",41,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INCB 18424-254","March 12, 2008","01/02/2008",2009-01-01,"June 17, 2010","01/06/2010","",2009-01-01,"PSA50 response rate of oral INCB018424 as monotherapy in the treatment of metastatic, androgen-independent prostate cancer and safety and tolerability of oral INCB018424 in patients with metastatic prostate cancer|Median time to progression in patients with metastatic androgen-independent prostate cancer and response rate according to RECIST criteria in patients with measurable metastatic prostate cancer who are treated with INCB018424.","http://ClinicalTrials.gov/show/NCT00638378",NA
"65674",65674,"NCT00642278","An Efficacy, Safety, and Tolerability Study for JNJ-28431754 in Patients With Type 2 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type II|Diabetes Mellitus, Non Insulin Dependent","Drug: JNJ-28431754|Drug: JNJ-28431754|Drug: Sitagliptin|Drug: JNJ-28431754|Drug: Placebo|Drug: JNJ-28431754|Drug: JNJ-28431754","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult","Phase II",451,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR014587","March 21, 2008","01/04/2008",2009-01-01,"September 23, 2010","01/09/2010","",2009-01-01,"The change in hemoglobin A1c (A1C) from baseline through Week 12.|The change in A1C from baseline to Weeks 6, 9, and 12;|The proportion of subjects with A1C of <6.5% and <7.0%|The change in 7-point self-monitored blood glucose profiles from baseline to Week 6 and 12","http://ClinicalTrials.gov/show/NCT00642278",NA
"65676",65676,"NCT00650078","Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra?ó) Therapy in Patients With Active Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: MR tablet formulation of prednisone|Drug: Placebo","Nitec Pharma AG","Both","Adult|Senior","Phase III",294,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NP01-007|EudraCT-Number: 2007-003508-36","March 28, 2008","01/03/2008",2009-07-01,"July 17, 2009","01/07/2009","CAPRA-2",2009-07-01,"ACR 20 response rate|Relative reduction of morning stiffness","http://ClinicalTrials.gov/show/NCT00650078",NA
"65692",65692,"NCT00673478","Tiotropium and Salmeterol PK Study in COPD Patients","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: Tiotropium+Salmeterol|Drug: Salmeterol|Drug: Tiotropium","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",50,"Industry","Interventional","Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment","1184.24|EudraCT 2007-000207-15","May 6, 2008","01/05/2008",NA,"July 22, 2009","01/07/2009","",2009-06-01,"Pharmacokinetics of tiotropium and salmeterol.|1) Pharmacokinetics 2) Safety and tolerability 3) Efficacy","http://ClinicalTrials.gov/show/NCT00673478",NA
"65704",65704,"NCT00696878","Org 36286 in Patients Undergoing Repeated Controlled Ovarian Stimulation Cycles Using a Multiple Dose GnRH Antagonist Protocol (Study 38825)(P05714)(COMPLETED)","Completed","No Results Available","In Vitro Fertilization","Drug: Org 36286, corifollitropin alfa","Schering-Plough","Female","Adult","Phase III",681,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","38825|P05714","June 11, 2008","01/09/2006",2009-04-01,"October 2, 2009","01/10/2009","Trust",2009-04-01,"Main safety parameters: anti-Org 36286 antibodies, local tolerance, occurrence of (S)AEs and occurrence of moderate to severe OHSS.|Amount of (rec)FSH needed from stimulation day 8 onwards to reach the criterion for administration of (rec)hCG|Number and size distribution of follicles (>= 11 mm, >= 15 mm, and >= 17 mm) as documented by ultrasonography from stimulation day 1 up to and including the day of (rec)hCG administration; Number and quality of oocytes retrieved|Number of fertilized oocytes obtained, frozen and used for embryo development; Fertilization rate, defined as the ratio of the number of fertilized 2PN oocytes obtained and the number of oocytes incubated (IVF or ICSI)|Implantation rate for subjects with ET (defined as 100 times the number of gestational sacs as assessed by the first USS after ET divided by the number of embryos transferred for each subject)|Biochemical pregnancy, ectopic pregnancy, clinical pregnancy, vital pregnancy, (singleton and multiple) ongoing pregnancy and miscarriage; Outcome of FTET cycles; Cumulative ongoing pregnancy rate.|Number and quality of embryos obtained, transferred and frozen|Endocrinological parameters (FSH, LH, E2, P, inhibin-B) as determined by central lab, during stimulation and including the day of (rec)hCG administration, at embryo transfer and 2 weeks after embryo transfer","http://ClinicalTrials.gov/show/NCT00696878",NA
"65711",65711,"NCT00708578","Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: Glimepiride|Drug: Metformin|Drug: Insulin Glargine","Sanofi-Aventis","Both","Adult|Senior","Phase IV",99,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LANTU_L_02670","June 27, 2008","01/05/2008",2009-12-01,"February 5, 2010","01/02/2010","",2009-12-01,"HbA1c values|Hypoglycemia events|Percentage of patients with HbA1c < 7%|Fasting Blood Glucose level","http://ClinicalTrials.gov/show/NCT00708578",NA
"65730",65730,"NCT00746278","A Random Clinical Trial (RCT) of the Impact of Electrocoagulation on Ovarian Reserve","Completed","No Results Available","Ovarian Cyst","Procedure: Laparoscopic ovarian cystectomy using bipolar|Procedure: Laparoscopic ovarian cystectomy using ultrasonic scalpel|Procedure: Laparoscopic ovarian cystectomy using suture","Shandong Provincial Hospital|Shandong University","Female","Adult","Phase IV",180,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SPH-CL-080512","August 29, 2008","01/09/2008",2010-02-01,"February 25, 2010","01/05/2008","",2009-09-01,"Serum FSH and inhibin-B and Anti-Mullerian hormone(AMH) assays|Transvaginal ultrasound examinations for basal antral follicle number, mean ovarian diameter and peak systolic velocity","http://ClinicalTrials.gov/show/NCT00746278",NA
"65738",65738,"NCT00760578","A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: Placebo|Drug: Pioglitazone|Drug: MSDC-0160 1|Drug: MSDC-0160 2","Metabolic Solutions Development Company","Both","Adult|Senior","Phase II",110,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSDC-C003","September 25, 2008","01/09/2008",2009-02-01,"May 11, 2009","01/05/2009","",2009-01-01,"Post Prandial Blood Glucose|Characterize pharmacokinetics and pharmacodynamics of MSDC-0160 and identify potential biomarkers","http://ClinicalTrials.gov/show/NCT00760578",NA
"65753",65753,"NCT00734578","Efficacy and Safety of SPD503 in Combination With Psychostimulants","Completed","Has Results","ADHD","Drug: SPD503-AM|Drug: SPD503-PM|Drug: Placebo","Shire Pharmaceutical Development","Both","Child","Phase III",461,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPD503-313","August 12, 2008","01/09/2008",2009-12-01,"December 6, 2010","01/12/2010","",2009-12-01,"Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 8 - Last Observation Carried Forward (LOCF)|Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 8 - LOCF|Assessment of Clinical Global Impression-Severity of Illness (CGI-S) at Week 8 - LOCF|Change From Baseline in Conners' Global Index - Parent (CGI-P) Total Score at Week 8 - LOCF: Morning Assessment (Before School)|Change From Baseline in Conners' Global Index - Parent (CGI-P) Total Score at Week 8 - LOCF: Evening Assessment (Before Bedtime)|Percentage of Participants With Improvement on Parent Global Assessment (PGA) at Week 8 - LOCF|Change From Baseline in the Oppositional Subscale of the Conners' Parent Rating Scale-Revised Long Form (CPRS-R:L) Score at Week 8 - LOCF|Change From Baseline in Before School Functioning Questionnaire (BSFQ) at Week 8 - LOCF|Post Sleep Questionnaire (PSQ) Quality of Sleep at Week 8 - LOCF","http://ClinicalTrials.gov/show/NCT00734578",NA
"65765",65765,"NCT00817778","Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin","Completed","No Results Available","Type 2 Diabetes","Drug: AZD1656|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase II",20,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","D1020C00019","January 5, 2009","01/01/2009",2009-07-01,"July 27, 2009","01/07/2009","",2009-07-01,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG)|Pharmacokinetic variables (Area under the plasma conc vs. time curve (AUC), maximum plasma conc (Cmax), Plasma conc immediately before the next dose (Ctrough), time to reach maximum plasma conc, terminal elimination half-life and apparent oral clearance|Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide)","http://ClinicalTrials.gov/show/NCT00817778",NA
"65789",65789,"NCT00854178","Toxicogenomic and Immunocytotoxic Effects of Propofol and Isoflurane Anesthetics in Patients Undergoing Elective Surgery","Completed","No Results Available","Patients in Good Health|Types of General Anesthesia|DNA Damage","Drug: Comparison of two anesthetic drugs","UPECLIN HC FM Botucatu Unesp|Funda????o de Amparo ?? Pesquisa do Estado de S??o Paulo","Both","Adult","Phase IV",26,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","upeclin/HC/FMB-Unesp-20","March 2, 2009","01/03/2008",2009-12-01,"January 5, 2010","01/01/2010","",2009-12-01,"Evaluation of genotoxicity, gene expression, apoptosis and cytokines profile","http://ClinicalTrials.gov/show/NCT00854178",NA
"65837",65837,"NCT00941278","An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis","Completed","No Results Available","Psoriasis","Drug: PH-10 (0.001% Rose Bengal)","Provectus Pharmaceuticals","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PH-10-PS-22","July 15, 2009","01/07/2009",2010-04-01,"July 2, 2010","01/07/2010","",2009-12-01,"The primary efficacy endpoint is \Treatment Success","http://ClinicalTrials.gov/show/NCT00941278",NA
"65851",65851,"NCT00968578","Effects of Methylprednisolone After Total Knee Arthroplasty","Completed","No Results Available","Postoperative Pain|Postoperative Nausea and Vomiting|Sleeping Quality|Fatigue|Inflammatory Response","Drug: Methylprednisolone|Drug: Placebo","Hvidovre University Hospital|Lundbeck Foundation","Both","Adult|Senior","Phase IV",48,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","H-C-2008-134|2009-41-3786","August 28, 2009","01/08/2009",2009-12-01,"December 31, 2009","01/12/2009","",2009-12-01,"Postoperative pain|Postoperative nausea and vomiting (PONV)|Sleeping quality|Inflammatory response|Additional analgetics, antinausea agents and sleeping medicine|Time in hospital|Fatigue","http://ClinicalTrials.gov/show/NCT00968578",NA
"65876",65876,"NCT01010178","Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Macrolid, Theophylline, Inhaler Corticosteroids","Baqiyatallah Medical Sciences University","Both","Adult|Senior","Phase IV",64,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","BMT-1388-2","November 6, 2009","01/02/2008",2009-07-01,"November 6, 2009","01/11/2009","",2009-04-01,"15% increasing in forced expiratory volume in 1 second","http://ClinicalTrials.gov/show/NCT01010178",NA
"65903",65903,"NCT01051778","Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome","Completed","No Results Available","Recurrent Abortion","Drug: enoxaparin 40mg plus low dose aspirin|Drug: Heparin calcium5,000 U twice daily plus low dose aspirin","Cairo University|Ahmed Elgazzar hospital","Female","Adult","Phase II",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Aps/UFH/enox40","January 19, 2010","01/06/2006",2009-12-01,"January 19, 2010","01/01/2010","",2009-11-01,"Live birth rate|Minor and major bleeding|Thrombocytopenia|Preeclampsia|IUFD|Preterm delivery|Spontaneous osteoporotic fractures","http://ClinicalTrials.gov/show/NCT01051778",NA
"65917",65917,"NCT01076478","Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines","Completed","No Results Available","Polyneuropathy","Drug: Cilostazol","Otsuka Pharmaceutical, Inc., Philippines","Both","Adult|Senior","Phase IV",47,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","PLT-004-01","February 24, 2010","01/03/2004",2009-11-01,"February 25, 2010","01/02/2010","ASCEND",2009-11-01,"Subjective neuropathy assessment by NSS (Neuropathy Symptom Scores)from Baseline (BS) to week 12 (W12) after Cilostazol therapy of the three (3) arms of the study.|Objective neuropathy assessment by NIS (Neuropathy Impairment Scores)from Baseline (BS) to week 12 (W12) after Cilostazol therapy of the three (3) arms of the study.|Electrophysiologic assessment by NCS (Nerve Conduction Studies) from Baseline (BS) to week 12 (W12) after Cilostazol therapy of the three (3) arms of the study.|To determine the relationship of peripheral neuropathy with peripheral vascular disease using the WIQ and the ABI from baseline to W12.|To determine if there is improvement in subjective parameters of neuropathy as assessed by NSS and NSC (Neuropathy Symptoms and Change Questionnaire) from baseline to week 4 (W4), week 8 (W8) and week 12 (W12) after Cilostazol therapy.|To determine if there is improvement in objective parameters using NIS and NCS from baseline to W4, W8 and W12 after Cilostazol therapy.|To compare the effectivity of low dose (100mg) and high dose (200mg) Cilostazol based on subjective (NSS, NSC) and objective parameters (NIS, NCS) from baseline, to W4, W8 and W12.|To assess the safety of Cilostazol therapy.","http://ClinicalTrials.gov/show/NCT01076478",NA
"65931",65931,"NCT01099878","Cycling Exercise With Functional Electrical Stimulation Improves Postural Control in Stroke Patients","Completed","No Results Available","Postural Control","Device: Cycling Exercise with Functional Electrical Stimulation|Device: cycling exercise","Chung Shan Medical University","Both","Adult|Senior","Phase I|Phase II",20,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","CS07136","April 6, 2010","01/01/2009",2009-12-01,"April 6, 2010","01/04/2010","",2009-04-01,"","http://ClinicalTrials.gov/show/NCT01099878",NA
"66044",66044,"NCT00000479","Women's Health Study (WHS): A Randomized Trial of Low-Dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer","Completed","No Results Available","Cardiovascular Diseases|Cerebrovascular Disorders|Coronary Disease|Heart Diseases|Myocardial Infarction|Myocardial Ischemia|Vascular Diseases","Drug: Aspirin|Drug: Vitamin E|Behavioral: Placebo","National Heart, Lung, and Blood Institute (NHLBI)","Female","Adult|Senior","Phase III",39876,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","69|HL043851|CA047988","October 27, 1999","01/09/1991",2009-03-01,"May 1, 2009","01/05/2009","WHS",2009-03-01,"Reduction of the risk of all important vascular events (a combined endpoint of nonfatal myocardial infarction, nonfatal stroke, and total cardiovascular death) and a decrease in the incidence of total malignant neoplasms of epithelial cell origin","http://ClinicalTrials.gov/show/NCT00000479",NA
"66101",66101,"NCT00047879","Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas","Completed","No Results Available","Glioma","Biological: PEG-interferon alfa-2b|Drug: Thalidomide|Procedure: Adjuvant Therapy","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",7,"NIH","Interventional","Control: Active Control|Primary Purpose: Treatment","030002|03-C-0002","June 19, 2006","01/10/2002",2009-06-01,"December 3, 2010","01/11/2010","",2009-06-01,"Progression-free survival at 6-months|Response (complete and partial response)","http://ClinicalTrials.gov/show/NCT00047879",NA
"66121",66121,"NCT00079079","Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor","Completed","No Results Available","Head and Neck Cancer","Drug: carboplatin|Drug: cisplatin|Drug: gemcitabine hydrochloride","NCIC Clinical Trials Group","Both","Adult|Senior","Phase II",34,"Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","HN4|CAN-NCIC-HN4|LILLY-CAN-NCIC-HN4|CDR0000353487","March 8, 2004","01/10/2003",2009-02-01,"November 7, 2010","01/03/2010","",2009-02-01,"Objective response measured by RECIST criteria after accrual of 11 evaluable patients|Toxicity assessed by NCI CTC v2.0|Overall survival","http://ClinicalTrials.gov/show/NCT00079079",NA
"66131",66131,"NCT00095979","Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer","Completed","No Results Available","Endometrial Cancer","Drug: ixabepilone","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child|Adult|Senior","Phase II",51,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000391849|GOG-0129P","November 9, 2004","01/05/2005",NA,"August 8, 2009","01/12/2007","",2009-07-01,"Frequency and duration of objective response|Frequency and severity of observed adverse effects|Survival time|Duration of progression-free survival","http://ClinicalTrials.gov/show/NCT00095979",NA
"66196",66196,"NCT00185679","Haploid Allogeneic Transplant Using the CliniMACS System","Completed","No Results Available","Leukemia|Lymphoma","Procedure: Haploidentical allogeneic hematopoietic cell transplantation","Stanford University|National Institutes of Health (NIH)","Both","Adult","Phase II",30,"Other|NIH","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT123|77453|BMT123","September 12, 2005","01/11/2001",2010-02-01,"August 9, 2010","01/08/2010","",2009-10-01,"Donor neutrophil engraftment|Incidence of acute GvHD (grade II-IV)|Platelet engraftment|Incidence of graft failure and chronic GvHD|Overall and disease free survival|Clinical safety and device performance","http://ClinicalTrials.gov/show/NCT00185679",NA
"66202",66202,"NCT00205179","Alzheimer's Disease: Potential Benefit of Isoflavones","Completed","No Results Available","Alzheimer's Disease","Drug: Novasoy|Drug: Placebo","University of Wisconsin, Madison|National Institutes of Health (NIH)","Both","Adult|Senior","Phase II",60,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2003-0048|5K23AG024302-03","September 13, 2005","01/01/2005",2009-12-01,"September 27, 2010","01/09/2010","",2009-12-01,"Cognitive Data|biological assays of isoflavones and hormones","http://ClinicalTrials.gov/show/NCT00205179",NA
"66237",66237,"NCT00254579","Study of CP-675,206 in Refractory Melanoma","Completed","No Results Available","Refractory Melanoma","Drug: CP-675,206","Pfizer","Both","Adult|Senior","Phase II",251,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A3671008","November 14, 2005","01/12/2005",2009-12-01,"October 21, 2010","01/10/2010","",2009-12-01,"To assess the anti-tumor efficacy, as determined by objective response rate, of intravenous CP-675,206 administered at a dose of 15 mg/kg every 90 days to patients with relapsed or refractory advanced melanoma|Safety, PK, Survival, health-related QoL","http://ClinicalTrials.gov/show/NCT00254579",NA
"66243",66243,"NCT00266279","Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies","Completed","No Results Available","Head & Neck Cancer","Drug: Oxaliplatin, Capecitabine","James Graham Brown Cancer Center|University of Louisville","Both","Adult|Senior","Phase II",13,"Other","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","153.05","December 15, 2005","01/04/2005",2009-10-01,"November 2, 2009","01/11/2009","",2009-10-01,"","http://ClinicalTrials.gov/show/NCT00266279",NA
"66302",66302,"NCT00358579","Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest","Completed","No Results Available","Cardiac Arrest","Drug: Vasopressin|Drug: Adrenaline","Singapore General Hospital|National Medical Research Council (NMRC), Singapore|Alexandra Hospital, Singapore|National University Hospital, Singapore|Changi General Hospital","Both","Child|Adult|Senior","Phase III",720,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SQCA01","July 30, 2006","01/03/2006",2010-01-01,"March 23, 2010","01/02/2010","",2009-01-01,"Survival to hospital discharge|Neurological status on discharge or at 30 days post arrest, if not discharged|Neurological status at 1 year|Return of spontaneous circulation|Survival to admission","http://ClinicalTrials.gov/show/NCT00358579",NA
"66327",66327,"NCT00392379","Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction","Completed","Has Results","Smokeless Tobacco Use","Drug: Nicotine Lozenges|Drug: Placebo lozenge","Mayo Clinic|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",270,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06-003091|R01 CA121165","October 24, 2006","01/01/2007",2009-03-01,"August 9, 2010","01/08/2010","",2009-03-01,"Prolonged Smokeless Tobacco Abstinence at 3 Months|Self-reported Point Prevalence All Tobacco Abstinence at 3 Months|Prolonged Smokeless Tobacco Abstinence at 6 Months","http://ClinicalTrials.gov/show/NCT00392379",NA
"66328",66328,"NCT00389779","DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension","Completed","No Results Available","Hypertension","Drug: darusentan (LU 135252), guanfacine, and placebo","Gilead Sciences","Both","Adult|Senior","Phase III",849,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Protocol DAR-312","October 17, 2006","01/09/2006",2009-08-01,"October 2, 2009","01/10/2009","Darusentan",2009-08-01,"Co-primary efficacy measures: changes from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry|Secondary efficacy measures: 1) change from baseline in mean 24-hour systolic and diastolic blood pressure measured by ABPM; 2) percent of subjects reaching systolic blood pressure goal after 14 weeks of treatment; 3) change from baseline in eGFR.","http://ClinicalTrials.gov/show/NCT00389779",NA
"66330",66330,"NCT00393679","Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children","Completed","No Results Available","Fever|Malaria","Drug: amodiaquine-artesunate (ASAQ)|Drug: dihydroartemisinin-piperaquine (DHAPQ)|Drug: artemether-lumefantrine (AL)|Drug: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)","Institute of Tropical Medicine, Belgium|Liverpool School of Tropical Medicine|East African Network for Monitoring Antimalarial Treatment|Centre Muraz|University of Calabar|Tropical Diseases Research Centre, Zambia|University Hospital Tuebingen|Albert Schweitzer Hospital|Uganda Malaria Surveillance Project|Mbarara University of Science and Technology|Programme National Lutte contre le Paludisme,Kigali,Rwanda|University of Barcelona|Manhica Research Centre, Mozambique","Both","Child","Phase III",4112,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4 ABC|IRB Antwerp: 6/40/187","October 27, 2006","01/07/2007",2009-12-01,"September 12, 2010","01/09/2010","",2009-12-01,"PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.|PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.|PCR unadjusted treatment failure up to day 63 (TF63U): TF28U plus all cases of recurrent parasitaemia (symptomatic or asymptomatic) detected between day 29 and day 63 by passive follow up, regardless of genotyping|PCR adjusted treatment failure for the whole period of passive surveillance (TFAPS): TF28A plus all episodes of recurrent parasitaemia identified as recrudescence by genotyping.|Fever clearance time.|Asexual parasite clearance time.|Gametocytaemia (prevalence and density) at day 7, 14, 21 and 28 after treatment (for both active follow-ups);|Hb changes day 3, 7, 14 and 28 (first and second follow up);|Clinical malaria after first active follow-up;|Clinical malaria after second active follow-up;|TF second clinical episode (D28 and D63);|Changes in the frequency of mutations in the dihydrofolate reductase (DHFR) gene at day 0 first follow-up and day re-appearance of parasitaemia (for patients treated with CDA - NOTE that CDA arm was discontinued on 17.02.2008).|Safety profiles including significant changes in relevant laboratory values.","http://ClinicalTrials.gov/show/NCT00393679",NA
"66352",66352,"NCT00435279","A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia","Completed","No Results Available","Major Depressive Disorder|Insomnia","Drug: Eszopiclone|Drug: Placebo|Drug: Venlafaxine","Sunovion","Both","Adult","Phase III",678,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","190-062","February 12, 2007","01/06/2007",2009-07-01,"November 1, 2010","01/11/2010","",2009-07-01,"The primary endpoint is the change from baseline in HAM-D-17 total score at Week 8.|The key secondary endpoint is the change from baseline in the mean subjective Total Sleep Time (TST) during Week 1.","http://ClinicalTrials.gov/show/NCT00435279",NA
"66354",66354,"NCT00443079","A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)","Completed","No Results Available","Fatty Liver","Drug: IdB 1016 (Siliphos)","University of California, San Diego|American College of Gastroenterology","Both","Adult|Senior","Phase II",10,"Other","Interventional","Allocation: Non-Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","51117","March 2, 2007","01/03/2007",2009-12-01,"June 24, 2010","01/06/2008","",2009-12-01,"Safety, as determined by laboratory and clinical assessment, during and after treatment|Tolerability, as determined by clinical assessment of side effects, during and after treatment|Efficacy, determined by serial measurement of serum aminotransferase levels before, during, and after treatment","http://ClinicalTrials.gov/show/NCT00443079",NA
"66387",66387,"NCT00483379","Dose and Dose Interval Study of Alglucosidase Alfa","Completed","No Results Available","Pompe Disease|Glycogen Storage Disease Type II (GSD-II)|Glycogenesis 2 Acid Maltase Deficiency","Biological: alglucosidase alfa","Genzyme","Both","Child|Adult|Senior","Phase IV",13,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AGLU03306","June 6, 2007","01/05/2007",2010-07-01,"December 25, 2010","01/12/2010","",2009-12-01,"Evaluate the safety and efficacy of alternate alglucosidase alfa dosing regimens|Evaluate difference in efficacy in 2 dosing arms|Evaluate effect of increases in alglucosidase alfa dose or dose frequency on cardiac pathophysiology|Evaluate effect of increases in alglucosidase alfa dose or dose frequency on respiratory function|Evaluate effect of increases in alglucosidase alfa dose or dose frequency on proximal and distal muscle strength|Evaluate effect of increases in alglucosidase alfa dose or dose frequency on gross motor function|Evaluate effect of increases in alglucosidase alfa dose or dose frequency on functional status and health-related quality of life","http://ClinicalTrials.gov/show/NCT00483379",NA
"66388",66388,"NCT00417079","XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer","Completed","Has Results","Neoplasms|Prostatic Neoplasms","Drug: cabazitaxel (XRP6258) (RPR116258)|Drug: mitoxantrone|Drug: prednisone","Sanofi-Aventis","Male","Adult|Senior","Phase III",755,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC6193","December 28, 2006","01/01/2007",2009-09-01,"December 22, 2010","01/12/2010","TROPIC",2009-09-01,"Overall Survival|Time to Progression Free Survival (PFS)|Overall Tumor Response|Time to Tumor Progression|Time to Prostatic Specific Antigen (PSA) Progression|PSA (Prostate-Specific Antigen) Response|Time to Pain Progression|Pain Response","http://ClinicalTrials.gov/show/NCT00417079",NA
"66414",66414,"NCT00534079","Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis","Completed","No Results Available","Cystic Fibrosis|Rhinosinusitis","Drug: Dornase alfa (Pulmozyme)","University of Jena","Both","Child|Adult|Senior","Phase III",15,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","pulmozyme-nasal-cf","September 21, 2007","01/09/2007",2009-02-01,"November 25, 2009","01/11/2009","",2009-02-01,"Variations in the Sino-nasal-outcome test SNOT-20 adapt CF (primary nasal parameters: obstruction of nasal breathing, sneeze stimulus, permanent nose running, thick-mucous nasal discharge, earaches)|Variations in the Sino-nasal-outcome test SNOT-20 adapt CF (secondary nasal parameters, general quality of live parameters and total SNOT 20 adapt. CF score)|Changes of pathological alterations visible in MRT images of nose and paranasal sinuses (in selected patients)|Changes in the nasal lavage fluid and in the serological markers of inflammation|Changes in rhinoscopic findings|Changes in rhinomanometric findings|Incidence of rhinosinusitic and pulmonary exacerbations during therapy|Need for decongestants or nasal lavage during treatment","http://ClinicalTrials.gov/show/NCT00534079",NA
"66418",66418,"NCT00532779","A Study of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Obese Subjects","Completed","No Results Available","Obesity","Drug: naltrexone SR/bupropion SR","Orexigen Therapeutics, Inc","Both","Adult","Phase III",1650,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NB-301","September 19, 2007","01/09/2007",2009-05-01,"February 4, 2010","01/02/2010","",2009-05-01,"Co-primary outcome measures are the percentage of total body weight lost and the percentage of subjects who achieve a weight decrease of ??­ 5%.|Proportion of subjects achieving ??­10% weight loss; Waist circumference; Fasting triglyceride, HDL cholesterol, insulin and glucose","http://ClinicalTrials.gov/show/NCT00532779",NA
"66444",66444,"NCT00578279","EUS-CPN in Unresectable Pancreatic Cancer: a Pilot Study","Completed","No Results Available","Pancreatic Cancer","Drug: dehydrated alcohol","Indiana University","Both","Adult|Senior","Phase IV",20,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","0702-25|IRB # 0702-25|Clarian Values Grant: vfr-262","December 19, 2007","01/03/2007",2009-06-01,"September 15, 2010","01/06/2010","",2009-06-01,"Increased amounts of alcohol used in EUS-CPN is more efficacious in improving pain relief in patients with locally advanced or unresectable pancreatic adenocarcinoma.|Increased amounts of alcohol used in EUS-CPN is safe in improving pain relief in patients with locally advanced or unresectable pancreatic adenocarcinoma.|Effective pain relief obtained from EUS-CPN will be related to better QOL","http://ClinicalTrials.gov/show/NCT00578279",NA
"66461",66461,"NCT00552279","Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age","Completed","Has Results","HPV-16/18 Infections and Cervical Neoplasia","Biological: Cervarix TM|Biological: Cervarix TM","GlaxoSmithKline","Female","Child|Adult","Phase III",805,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","109179","October 30, 2007","01/11/2007",2009-02-01,"July 15, 2010","01/07/2010","",2009-02-01,"Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies|Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies|Number of Subjects Seroconverted for Anti-HPV-16 and Anti-HPV-18 Antibodies|Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs), New Onset Autoimmune Diseases (NOADs), Serious Adverse Events (SAEs), and Medically Significant Conditions (MSCs)|Number of Subjects With Pregnancies and Their Outcomes|Number of Subjects Completing the 3-dose Vaccination Schedule","http://ClinicalTrials.gov/show/NCT00552279",NA
"66462",66462,"NCT00604279","Comparative Study of Paliperidone Palmitate (50, 100, 150 mg eq) and Risperidone LAI (Long Acting Injection )(25, 37.5, or 50 mg) in Patients With Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Risperidone LAI","Xian-Janssen Pharmaceutical Ltd.","Both","Adult|Senior","Phase III",453,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR013150|R092670PSY3008","January 17, 2008","01/01/2008",2009-01-01,"January 7, 2011","01/01/2011","",2009-01-01,"The primary endpoint is the change from baseline to endpoint in the total PANSS score.|Change from baseline to endpoint in CGI-S,PSP,sleep VAS, responder rate will be analyzed.The safety and tolerability of paliperidone palmitate will also be assessed.","http://ClinicalTrials.gov/show/NCT00604279",NA
"66496",66496,"NCT00661479","An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa","Completed","No Results Available","Retinitis Pigmentosa","Drug: Brimonidine Tartrate|Drug: Brimonidine Tartrate|Drug: Brimonidine Tartrate|Drug: Brimonidine Tartrate","Allergan","Both","Adult|Senior","Phase I|Phase II",25,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","190342-028D","October 29, 2007","01/07/2008",2010-06-01,"September 8, 2010","01/09/2010","",2009-12-01,"Change in Visual Acuity|Contrast sensitivity|Patient questionnaires","http://ClinicalTrials.gov/show/NCT00661479",NA
"66501",66501,"NCT00671879","Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back","Completed","No Results Available","Lower Back Pain","Drug: Carisoprodol SR 700 mg|Drug: Carisoprodol SR 500 mg|Drug: Placebo","Meda Pharmaceuticals","Both","Adult|Senior","Phase III",840,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP511","May 1, 2008","01/04/2008",2009-03-01,"April 30, 2009","01/04/2009","",2009-03-01,"Subject rating of pain on a 100-point visual analog scale|Subject functional assessment based on the Roland-Morris Disability Questionnaire (RMDQ)|Adverse events assessment","http://ClinicalTrials.gov/show/NCT00671879",NA
"66507",66507,"NCT00678379","Pediatric Tonsillectomy Pain Reduction Study","Completed","No Results Available","Postoperative Pain","Drug: lidocaine + bupivacaine|Drug: normal saline|Drug: lidocaine + bupivacaine + clonidine","Vanderbilt University","Both","Child","Phase III",120,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","80127","May 8, 2008","01/04/2008",2009-11-01,"December 10, 2009","01/12/2009","",2009-11-01,"Total number of post-operative doses of analgesics.|Mean number of pain medication doses per day.|Total time until discharge from hospital.|Mean visual analog scale pain number.|Type of diet patient is able to tolerate.","http://ClinicalTrials.gov/show/NCT00678379",NA
"66520",66520,"NCT00666679","Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma","Completed","Has Results","Asthma","Drug: Comparator: mometasone|Drug: Comparator: montelukast|Drug: Comparator: placebo (unspecified)","Merck","Both","Child|Adult|Senior","Phase II",134,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2007_654|MK0476-386","April 23, 2008","01/05/2008",2009-02-01,"April 20, 2010","01/04/2010","",2009-02-01,"Change From Baseline in FEV1 (Forced Expiratory Volume; Volume of Air That is Exhaled During the First Second of a Forced Exhalation)|Change From Baseline in Daytime Asthma Symptom Score|Change From Baseline in Nighttime Asthma Symptom Score","http://ClinicalTrials.gov/show/NCT00666679",NA
"66539",66539,"NCT00731679","Rifaximin TID for Non-constipation Irritable Bowel Syndrome (IBS)","Completed","No Results Available","Non-constipation Irritable Bowel Syndrome","Drug: Rifaximin|Drug: Placebo","Salix Pharmaceuticals","Both","Adult|Senior","Phase III",600,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RFIB3007","July 16, 2008","01/07/2008",2009-09-01,"December 21, 2009","01/12/2009","TARGET 1",2009-08-01,"Proportion of subjects achieving adequate of IBS symptoms.","http://ClinicalTrials.gov/show/NCT00731679",NA
"66540",66540,"NCT00736879","Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: Dapagliflozin|Drug: Placebo","Bristol-Myers Squibb|AstraZeneca","Both","Adult|Senior","Phase III",280,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MB102-032","August 15, 2008","01/09/2008",2009-12-01,"January 6, 2011","01/02/2010","",2009-12-01,"Change from baseline in hemoglobin A1C|Change from baseline in: total body weight; FPG; 2-hour post liquid meal glucose and waist circumference|Proportion of subjects achieving a therapeutic glycemic response, defined as AIC<7.0%","http://ClinicalTrials.gov/show/NCT00736879",NA
"66543",66543,"NCT00740779","Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.","Completed","No Results Available","Chronic Abacterial Prostatitis","Drug: Silodosin 8 mg|Drug: Placebo|Drug: Silodosin 4 mg","Watson Pharmaceuticals","Male","Adult|Senior","Phase II",153,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SI08001","August 21, 2008","01/09/2008",2009-10-01,"October 30, 2009","01/10/2009","",2009-10-01,"National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) total score.|NIH-CPSI pain score|NIH-CPSI urinary symptoms score|Short Form Health Survey (SF-12)","http://ClinicalTrials.gov/show/NCT00740779",NA
"66555",66555,"NCT00751179","Reversal With Sugammadex in Short Procedures in Out-patient Surgicenters as Compared to Succinylcholine Alone (19.4.319)(P05700)(COMPLETED)","Completed","No Results Available","Neuromuscular Blockade","Drug: rocuronium|Drug: sugammadex|Drug: succinylcholine","Schering-Plough","Both","Adult|Senior","Phase III",140,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","19.4.319|P05700","September 10, 2008","01/11/2008",2009-12-01,"February 3, 2010","01/02/2010","",2009-12-01,"To evaluate changes in plasma potassium levels after treatment with rocuronium, sugammadex, and succinylcholine in adult subjects scheduled for short surgical procedures in out-patient surgicenters.|To evaluate the safety of the combination of rocuronium and a single dose of 4.0 mg.kg-1 sugammadex for reversal as compared to the use of 1.0 mg.kg-1 succinylcholine in adult subjects scheduled for short surgical procedures in out-patient surgicenters|To evaluate the efficacy of reversal with 4.0 mg.kg-1 of sugammadex after neuromuscular blockade induced by rocuronium|To evaluate spontaneous recovery after neuromuscular block induced by succinylcholine.","http://ClinicalTrials.gov/show/NCT00751179",NA
"66568",66568,"NCT00773279","Efficacy, Safety and Preference Study of a Comparator Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics","Completed","No Results Available","Diabetes Mellitus","Device: PDS290|Device: Novo Nordisk marketed insulin pen","Novo Nordisk","Both","Adult|Senior","Phase III",255,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","PDS290-1971","October 14, 2008","01/09/2008",2009-06-01,"November 9, 2009","01/09/2009","",2009-06-01,"HbA1c|Clinical technical complains|Compare the effectiveness of PDS290 vs a Novo Nordisk marketed insulin pen using questionnaires|Hypoglycaemic episodes|Adverse events and adverse device effects","http://ClinicalTrials.gov/show/NCT00773279",NA
"66575",66575,"NCT00779779","Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix?ºÑ (Human Rotavirus Vaccine) in Infants","Completed","Has Results","Rotavirus Gastroenteritis|Rotavirus Vaccines","Biological: Rotarix?ºÑ","GlaxoSmithKline","Both","Child","Phase IV",522,"Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","111664","October 23, 2008","01/11/2008",2009-08-01,"November 24, 2010","01/11/2010","",2009-08-01,"Number of Subjects With at Least One >= Grade \2\"" Fever","http://ClinicalTrials.gov/show/NCT00779779",NA
"66590",66590,"NCT00810979","Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia","Completed","No Results Available","Hyperlipidemia","Drug: SLx-4090|Drug: SLx-4090|Other: Placebo","Surface Logix","Both","Adult","Phase II",133,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SLx-4090-08-06","December 17, 2008","01/01/2009",2009-09-01,"December 14, 2009","01/03/2009","",2009-09-01,"Reduction in LDL-C|Adverse events","http://ClinicalTrials.gov/show/NCT00810979",NA
"66596",66596,"NCT00820079","ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)","Completed","No Results Available","Gastroesophageal Reflux","Drug: ADX10059|Drug: ADX10059 Matching Placebo","Addex Pharma S.A.","Both","Adult|Senior","Phase II",120,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ADX10059-204|2008-005104-10","January 8, 2009","01/12/2008",NA,"December 23, 2009","01/12/2009","",2009-10-01,"Number of GERD symptom free days in week 2 of study medication treatment|GERD symptoms|Sleep disturbance|Use of antacid rescue medication|Global assessment of GERD|Effect on lower oesophageal sphincter and reflux episodes","http://ClinicalTrials.gov/show/NCT00820079",NA
"66599",66599,"NCT00825279","A Trial Comparing a Paclitaxel Eluting Stent With Biodegradable Polymer Versus a Bare Metal Stent","Completed","No Results Available","Coronary Artery Disease","Device: Bare Metal Stent|Device: Drug Eluting Stent","Centro de estudios en Cardiologia Intervencionista|Eucatech AG","Both","Adult|Senior","Phase IV",300,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","02-CECI|02-CECI|IMA 01","January 20, 2009","01/08/2007",2009-08-01,"May 27, 2010","01/05/2010","EUCATAX",2009-08-01,"Target Vessel Failure|Stent thrombosis|Paclitaxel allergy|Cost-effectiveness|Quantitative Coronary Angiography","http://ClinicalTrials.gov/show/NCT00825279",NA
"66622",66622,"NCT00857779","Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients","Completed","No Results Available","Rhinitis|Conjunctivitis|Asthma","Biological: subcutaneous immunotherapy","ALK-Abell?? A/S","Both","Adult","Phase II",473,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AF-H-01","March 5, 2009","01/02/2009",2009-10-01,"August 16, 2010","01/08/2010","",2009-08-01,"IgE-blocking factor|Tolerability of two different updosing schedules","http://ClinicalTrials.gov/show/NCT00857779",NA
"66629",66629,"NCT00855179","Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous Insufficiency","Completed","No Results Available","Venous Insufficiency","Drug: Red vine leaf extract (AS 195)|Drug: Placebo","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",250,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","1138.11","March 3, 2009","01/03/2009",NA,"February 18, 2010","01/02/2010","",2009-11-01,"Change from baseline in limb volume determination at day 84 (water displacement method)|Change from baseline in limb volume determination at day 21 and 42 (water displacement method)|Change from baseline in the calf circumference at day 21, 42 and 84, change from baseline in the subjective symptoms of CVI (tired, heavy legs, sensation of tension in the legs, pain in the legs) measured vy Visual Analgue Scales (VAS)|Adverse events, vital signs (PR, BP), serum laboratory parameters, global assessment of tolerability by the patient at day 84, global assessment of tolerability by the investigator at day 84|Global assessment of efficacy by the patient at day 84, global assessment of efficacy by the investigator at day 84, time to improvement in symptoms","http://ClinicalTrials.gov/show/NCT00855179",NA
"66639",66639,"NCT00886379","Blue Sky Study: Impact of Milk and Vitamin D for Child Growth and Health","Completed","No Results Available","Vitamin D Deficiency","Dietary Supplement: Mongolian milk without vitamin D|Dietary Supplement: Mongolian milk with vitamin D|Dietary Supplement: UHT milk|Dietary Supplement: Milk Substitute|Dietary Supplement: Seasonal D supplement|Dietary Supplement: Daily D supplement","Brigham and Women's Hospital","Both","Child","Phase II",744,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Prevention","BSS-103306","April 20, 2009","01/01/2009",2009-03-01,"April 21, 2009","01/04/2009","BSS",2009-03-01,"","http://ClinicalTrials.gov/show/NCT00886379",NA
"66664",66664,"NCT00929279","Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time","Completed","No Results Available","Acute Coronary Syndrome","Drug: bolus+infusion|Drug: abciximab bolus only regimen","Universitaria di Ferrara","Both","Adult|Senior","Phase IV",73,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FAS-07-I","June 26, 2009","01/11/2008",2009-05-01,"June 26, 2009","01/06/2009","FABOLUS",2009-05-01,"In responders to clopidogrel: Inhibition of platelet aggregation at peak 4h after administration of study drugs measured by LTA (stimulated with 20micromolar ADP)|In all patients treated and in the responders to clopidogrel: ??Ñ Inhibition of platelet aggregation in the two study groups at time points different from 4 hours after abciximab bolus measured by LTA|MACE rate|Bleeding rates|Thrombocytopenia","http://ClinicalTrials.gov/show/NCT00929279",NA
"66673",66673,"NCT00946179","Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation","Completed","No Results Available","Influenza","Biological: Influenza virus (split virion, inactivated) vaccine","Sanofi-Aventis","Both","Adult|Senior","Phase II",130,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","GRT86","July 22, 2009","01/05/2009",2009-07-01,"July 23, 2009","01/07/2009","",2009-06-01,"To provide information concerning the immunogenicity of intramuscular (IM) Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation.|To provide information concerning the safety of intramuscular (IM) Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation","http://ClinicalTrials.gov/show/NCT00946179",NA
"66700",66700,"NCT00992979","Therapeutic Massage to Manage Withdrawal Related Anxiety","Completed","No Results Available","Substance Withdrawal Syndrome|Drug Withdrawal Symptoms|Anxiety","Procedure: Therapeutic Massage|Procedure: Relaxation Control","Dalhousie University|Holistic Health Research Foundation of Canada","Both","Adult","Phase II",80,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DAL09-01|HHRFC #2007-06","October 1, 2009","01/06/2008",2009-01-01,"October 8, 2009","01/01/2009","",2009-01-01,"State and Trait Anxiety (Spielberger State Trait Anxiety Inventory of Adults (Y1 and Y2))|Heart Rate and Blood Pressure|Sleep Quality","http://ClinicalTrials.gov/show/NCT00992979",NA
"66704",66704,"NCT01000779","Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH)","Completed","No Results Available","Non Cirrhotic Portal Hypertension","Drug: Propranolol|Device: multi band ligator for esophageal varices","Govind Ballabh Pant Hospital","Both","Child|Adult|Senior","Phase III",100,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","NG001","October 22, 2009","01/01/2005",2009-10-01,"December 21, 2010","01/10/2009","",2009-10-01,"Rebleed, death|Adverse effects of EVL or drug therapy, variceal eradication on EVL, variceal recurrence after eradication on EVL, decrease in variceal grade in the propranolol limb","http://ClinicalTrials.gov/show/NCT01000779",NA
"66715",66715,"NCT01021579","Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study","Completed","No Results Available","Polycystic Ovary Syndrome","Drug: Metformin plus Placebo|Drug: Metfomin plus Simvastatin","Fasa University of Medical Sciences|Shiraz University of Medical Sciences","Female","Child|Adult","Phase IV",84,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","SUMS 84-258","November 23, 2009","01/01/2008",2009-11-01,"November 27, 2009","01/11/2009","",2009-03-01,"Serum total testosterone|Lipid profile BMI (kg/m2) Total Chol. (mg/dl) HDL (mg/dl) LDL (mg/dl) TG (mg/dl) Testosterone (ng/ml) LH (mIU/ml) FSH (mIU/ml) LH/FSH DHEAS (microgr/dL) Hirsutism score Prolactin (ng/dL) FBS (mg/dL) Fasting Insulin (??U/ml) QUICKI index","http://ClinicalTrials.gov/show/NCT01021579",NA
"66741",66741,"NCT01068379","Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation","Completed","No Results Available","Rhegmatogenous Retinal Detachment","Procedure: criopexy|Procedure: laser","University of Campinas, Brazil","Both","Child|Adult|Senior","Phase III",86,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","cryo laser","February 11, 2010","01/07/2006",NA,"May 24, 2010","01/05/2010","",2009-01-01,"The primary outcome was one week reattachment rate","http://ClinicalTrials.gov/show/NCT01068379",NA
"66788",66788,"NCT01151579","Effect of Nebulized Bronchodilators on Heart Rate","Completed","No Results Available","COPD|CABG Surgery|Sepsis|Shock|Ventilators, Mechanical","Drug: Levalbuterol|Drug: Albuterol","Genesys Regional Medical Center","Both","Adult|Senior","Phase IV",70,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care","ME 07-0011","June 24, 2010","01/12/2008",2009-11-01,"July 14, 2010","01/05/2010","",2009-11-01,"Average difference in Heart rate between pre and post breathing treatments|Arrhythmias|Total number arrhythmias","http://ClinicalTrials.gov/show/NCT01151579",NA
"66917",66917,"NCT00016380","Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen","Completed","No Results Available","Cancer","Drug: dexamethasone|Drug: ondansetron|Procedure: quality-of-life assessment","NCIC Clinical Trials Group","Both","Child|Adult|Senior","Phase III",NA,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care","SC19|CAN-NCIC-SC19|CDR0000068627","May 6, 2001","01/02/2001",2009-02-01,"November 7, 2010","01/03/2010","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00016380",NA
"66975",66975,"NCT00112580","MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Pancreatic Cancer","Biological: ipilimumab","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",82,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000430666|NCI-05-C-0141|NCI-P6557|MDX-010-24","June 2, 2005","01/07/2005",NA,"September 21, 2010","01/08/2009","",2009-08-01,"Clinical response (complete and partial)|Incidence of autoimmunity","http://ClinicalTrials.gov/show/NCT00112580",NA
"67072",67072,"NCT00258180","Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy","Completed","No Results Available","Diarrhea|Gastrointestinal Complications|Unspecified Childhood Solid Tumor, Protocol Specific","Biological: filgrastim|Drug: cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",11,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Supportive Care","J0326, CDR0000441133|P30CA006973|JHOC-J0326|JHOC-03070804","November 22, 2005","01/06/2005",2009-01-01,"September 21, 2010","01/09/2010","",2009-01-01,"Treatment-free remission at 1 year after study completion|Toxicities during study treatment|Effect of treatment on anti-enterocyte antibody titers at 1 year after study completion","http://ClinicalTrials.gov/show/NCT00258180",NA
"67078",67078,"NCT00276380","A Study on the Use of Tanakan?ó for Recovery of Neurological Impairment Following Ischaemic Stroke","Completed","No Results Available","Stroke, Acute|Neurological Impairment","Drug: EGb761 (Tanakan) and acetylsalicylic acid|Drug: Placebo and acetylsalicylic acid","Ipsen","Both","Adult|Senior","Phase III",204,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A-38-00240-704","January 12, 2006","01/02/2003",2009-03-01,"July 23, 2009","01/07/2009","",2009-03-01,"Patients with Modified Rankin score 0 or 1 or 2 at the end of study period.|Evolution of the following scores and scales: Barthel index, Modified Rankin score, National Institutes of Health Score Scale, Sandoz Scale, Mini Mental State","http://ClinicalTrials.gov/show/NCT00276380",NA
"67193",67193,"NCT00453180","A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders","Completed","No Results Available","Autistic Disorder|Asperger Syndrome|Child Development Disorders, Pervasive","Drug: N-acetylcysteine|Drug: Placebo","Indiana University School of Medicine|National Alliance for Autism Research","Both","Child","Phase II",32,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","0611-10","March 27, 2007","01/03/2007",2009-11-01,"August 23, 2010","01/08/2010","",2009-08-01,"Clinical Global Impression - Severity done at Screen, Baseline, and at the end of week 12 of treatment|Clinical Global Impression - Improvement done at the end of weeks 4, 8, and 12 of treatment|Aberrant Behavior Checklist done at Baseline and end of weeks 4, 8, and 12|Social Responsiveness Scale done at Baseline and end of weeks 4, 8, and 12|Pervasive Developmental Disorder Behavior Index done at Baseline and end of week 12|Vineland Adaptive Behavior Scales done at Baseline and end of week 12","http://ClinicalTrials.gov/show/NCT00453180",NA
"67221",67221,"NCT00493480","Danish Carvedilol Study in Portal Hypertension","Completed","No Results Available","Cirrhosis|Portal Hypertension","Drug: carvedilol|Drug: propranolol","Hvidovre University Hospital","Both","Adult|Senior","Phase III",40,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","KF-02-049/03","June 27, 2007","01/09/2003",2009-08-01,"August 7, 2009","01/08/2009","DACAPO",2009-08-01,"If carvedilol is better than propranolol in lowering portal pressure after 3 months of treatment|If the effect of a single dose of propranolol can predict the long term effect of propranolol or carvedilol","http://ClinicalTrials.gov/show/NCT00493480",NA
"67236",67236,"NCT00523380","Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer","Completed","No Results Available","Ovarian Cancer|Cancer","Drug: recombinant interleukin-21|Drug: Caelyx (Pegylated liposomal doxorubicin)","Novo Nordisk","Female","Adult|Senior","Phase II",10,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NN028-1802|EudraCT No: 2007-001506-25","August 30, 2007","01/10/2007",2009-01-01,"November 9, 2009","01/07/2009","",2009-01-01,"Efficacy of treatment assessed by overall response rate (RR). RR measured and recorded using imaging techniques, CA-125 blood samples and pelvic examination.|Pharmacokinetics|IL-21 antibody formation|Progression free survival|Patient reported outcomes|Biomarker assessments CA-125","http://ClinicalTrials.gov/show/NCT00523380",NA
"67237",67237,"NCT00520780","Ferinject?ó Assessment in Patients With IRon Deficiency and Chronic Heart Failure (FAIR-HF)","Completed","No Results Available","Chronic Heart Failure|Iron Deficiency|Iron Deficiency Anemia|Anaemia","Drug: Ferinject ?ó (Ferric carboxymaltose)|Drug: Normal saline (0.9%)","Vifor Inc.|Kendle International|ClinStar","Both","Adult|Senior","Phase III",456,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FER-CARS-02","August 24, 2007","01/04/2007",2009-09-01,"October 15, 2009","01/10/2009","FAIR-HF",2009-07-01,"Self-reported patient global assessment (PGA) and NYHA functional status 24 weeks after initiation of therapy|Key secondary objectives (efficacy): Exercise tolerance (6-minute walk test distance). Further secondary objectives(efficacy): Health related quality of life, resource use and costs associated with the treatment, safety and tolerability","http://ClinicalTrials.gov/show/NCT00520780",NA
"67244",67244,"NCT00537680","Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia","Completed","No Results Available","Friedreich's Ataxia","Drug: Idebenone|Drug: Idebenone|Drug: Placebo","Santhera Pharmaceuticals","Both","Child","Phase III",70,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SNT-III-002","September 7, 2007","01/12/2007",2009-04-01,"May 28, 2009","01/05/2009","IONIA",2009-04-01,"ICARS|FARS|ADL of FARS|FACT","http://ClinicalTrials.gov/show/NCT00537680",NA
"67248",67248,"NCT00538980","Dasatinib in Polycythemia Vera","Completed","No Results Available","Polycythemia Vera","Drug: Dasatinib","Weill Medical College of Cornell University|Bristol-Myers Squibb","Both","Adult|Senior","Phase II",24,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA180-104|0701008940","October 2, 2007","01/04/2007",NA,"October 20, 2009","01/10/2009","",2009-10-01,"To evaluate the effect of dasatinib on the platelet count and the stabilization of hematocrit when restored by phlebotomy to normal range (HCT <45% for men, <42% for women).|To determine change in performance status and development of side effects and complications in patients treated under this protocol.|To determine changes in marrow cellularity, reticulin and fibrous content.|To determine change in cytogenetics if initially abnormal.|To determine if quantitative change in JAK2 expression occurs as measured by quantitative pyrosequencing.","http://ClinicalTrials.gov/show/NCT00538980",NA
"67251",67251,"NCT00536380","Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849AM4)(COMPLETED)","Completed","Has Results","Chronic Idiopathic Urticaria","Drug: 5-mg Desloratadine|Drug: 10-mg Desloratadine|Drug: 20-mg Desloratadine","Schering-Plough","Both","Adult|Senior","Phase IV",314,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P04849","September 26, 2007","01/09/2007",2009-04-01,"April 8, 2010","01/04/2010","",2009-04-01,"Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mg","http://ClinicalTrials.gov/show/NCT00536380",NA
"67254",67254,"NCT00545480","SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.","Completed","No Results Available","Post-Menopausal Osteoporosis","Drug: ibandronate [Bonviva/Boniva]|Drug: ibandronate [Bonviva/Boniva]","Hoffmann-La Roche|GlaxoSmithKline","Female","Adult|Senior","Phase IV",596,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML19358","October 16, 2007","",2009-03-01,"October 15, 2009","01/10/2009","",2009-03-01,"Comparison of percentage of patients with persistence to >=10/12 administrations of Bonviva in feedback and no feedback group|Differences between groups in persistence|QoL and patient satisfaction","http://ClinicalTrials.gov/show/NCT00545480",NA
"67255",67255,"NCT00551980","The Efficacy of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in a Working Community","Completed","No Results Available","Migraine|Tension Type Headache|Cervical Pain","Behavioral: Cognitive, Relaxation, Exercise Therapy","University of Turin, Italy|Compagnia di San Paolo|Comune di Torino|CPO Piemonte|Regione Piemonte","Both","Child|Adult|Senior","Phase III",2895,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1130SD2006.1911","October 31, 2007","01/10/2007",2009-11-01,"November 12, 2009","01/11/2009","",2009-06-01,"Reduction in number of days per month with headache and shoulders pain after 6 months.Proportion of subjects with more than 4 days with headache and shoulder pain at the baseline that will have reduction in pain frequency of more than 50%, after 6 months|Headache index (Intensity x Frequency) after 6 and 12 months. Frequency of analgesic drug consumption after 6 and 12 months Frequency of headache and shoulder pain after 12 months","http://ClinicalTrials.gov/show/NCT00551980",NA
"67256",67256,"NCT00550680","A Study of Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia.","Completed","No Results Available","Anemia","Drug: methoxy polyethylene glycol-epoetin beta [Mircera]","Hoffmann-La Roche","Both","Adult|Senior","Phase III",189,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20952","October 29, 2007","",2009-11-01,"March 25, 2010","01/03/2010","",2009-11-01,"Percentage of patients maintaining average Hb concentration within target range of 10.5-12.5g/dL during evaluation period.|Change in Hb concentration and percentage of patients maintaining Hb concentration in target range throughout evaluation period.|Mean time in Hb target range; percentage of patients needing dose adjustments; incidence of RBC transfusions","http://ClinicalTrials.gov/show/NCT00550680",NA
"67261",67261,"NCT00561080","Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Subjects ??­ 70 Years","Completed","No Results Available","Prevention of : Herpes-Zoster","Biological: Zostavax|Biological: Zostavax|Biological: Zostavax","Sanofi Pasteur MSD","Both","Senior","Phase III",750,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","X06-Z-305","November 19, 2007","01/10/2007",2009-09-01,"September 17, 2009","01/09/2009","",2009-09-01,"The 4 weeks post-dose 1 and 4 weeks post-dose 2 VZV antibody titres in group 2 and in group 3|The 4 weeks post-dose 1 VZV antibody titres in group 1|The VZV antibody titres individual fold rise from pre-vaccination to 4 weeks post-dose 1 in all groups and 4 weeks post-dose 2 in group 2 and in group 3|The 12 months post-dose 1 VZV antibody titres in group 1 and the 12 months post-dose 2 VZV antibody titres in group 2 and in group 3|The VZV antibody titres individual fold rise from pre-vaccination to 12 months post-dose 1 in group 1 and from pre-vaccination to 12 months post-dose 2 in group 2 and in group 3|The 24 and 36 months post-dose 1 VZV antibody titres in group 1 and the 24 and 36 months post-dose 2 VZV antibody titres in group 2 and in group 3|The VZV antibody titres individual fold rise from pre-vaccination to 24 and 36 months post-dose 1 in group 1 and from pre-vaccination to 24 and 36 months post-dose 2 in group 2 and in group 3|Injection site erythema; Injection site swelling; Injection site pain|Unsolicited injection-site adverse reactions; Herpes zoster/ varicella/ zoster-like rash/ varicella-like rash; Other systemic adverse events; Any serious adverse events|Deaths; Vaccine-related serious adverse events; Herpes zoster/ zoster-like rash","http://ClinicalTrials.gov/show/NCT00561080",NA
"67277",67277,"NCT00584480","Pilot Study of the Effect of Hyperbaric Oxygen Treatment on Behavioral and Biomarker Measures in Children With Autism","Completed","No Results Available","Autism","Other: HBOT","University of California, San Francisco|University of California, Davis","Both","Child","Phase III",10,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200715202-1","December 22, 2007","01/09/2007",2009-03-01,"November 16, 2010","01/11/2010","HBOT",2009-03-01,"Clinical Global Impression Scale - Improvement (CGI-I)","http://ClinicalTrials.gov/show/NCT00584480",NA
"67304",67304,"NCT00627380","Yoga for the Management of HIV-Metabolic Syndromes","Completed","No Results Available","HIV Infections|HIV Metabolic Cardiovascular Syndrome|HIV Lipodystrophy|HIV Metabolic Syndromes|Hypertension","Behavioral: Yoga lifestyle intervention|Other: Standard of care","Washington University School of Medicine|National Center for Complementary and Alternative Medicine (NCCAM)","Both","Adult|Senior","Phase IV",60,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","R21 AT003083|R21AT003083|WU187","February 28, 2008","01/11/2005",2009-06-01,"July 23, 2010","01/07/2010","",2009-06-01,"The primary efficacy outcome is a metabolic parameter: insulin integrated area under the curve (AUC) during the oral glucose tolerance test.|Fasting lipid/lipoprotein levels.|Body composition: visceral and subcutaneous adipose tissue areas (VAT, SAT), trunk/limb adipose ratio.|Cardiovascular disease risk: Framingham 10-yr CVD risk calculation|Quality of life: SF36 MOS|Safety: CD4 count and plasma HIV RNA","http://ClinicalTrials.gov/show/NCT00627380",NA
"67309",67309,"NCT00633880","Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)","Completed","No Results Available","Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency","Drug: Placebo|Drug: Droxidopa","Chelsea Therapeutics|Chiltern International Inc.","Both","Adult|Senior","Phase III",118,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Droxidopa NOH302","March 5, 2008","01/01/2008",2009-09-01,"July 30, 2010","01/07/2010","302NOH",2009-08-01,"To evaluate the efficacy of droxidopa in patients with symptomatic NOH as measured by the relative change in mean score of Item 1 of the (OHSA) 14 days following randomization to continued therapy with droxidopa or placebo.|Evaluate efficacy of droxidopa as measured by changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements 3 minutes post standing;|Evaluate efficacy of droxidopa by global assessment evaluations using the clinician-recorded and patient-recorded Clinical Global Impressions-Severity (CGI-S) and Clinical Global Impressions-Improvement (CGI-I) scales;|Evaluate efficacy of droxidopa by symptom and activity measurements using the composite scores of OHSA, OHDAS (the two subcomponents of the Orthostatic Hypotension Questionnaire (OHQ))|Evaluate the safety of droxidopa based on the occurence of treatment-emergent adverse events and specific evaluation of blood pressure, heart rate, ECG, and laboratory findings across the study","http://ClinicalTrials.gov/show/NCT00633880",NA
"67333",67333,"NCT00614380","Open Label Study Telmisartan and Amlodipine in Hypertension","Completed","Has Results","Hypertension","Drug: telmisartan/amlodipine 40/5 mg fixed combination|Drug: telmisartan/amlodipine 80/5 mg fixed combination","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",976,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","1235.7|EUDRACT2007-002410-19","January 28, 2008","01/01/2008",NA,"September 1, 2010","01/09/2010","",2009-03-01,"Trough Seated Diastolic Blood Pressure (DBP) Control|Trough Seated Systolic Blood Pressure (SBP) Control|Change From Baseline in Trough Seated Diastolic Blood Pressure|Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7|Change From Baseline in Trough Seated Systolic Blood Pressure|Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7|Trough Seated DBP Response|Trough Seated SBP Response|Trough Blood Pressure (BP) Normality Classes|Time to First Additional Antihypertensive|Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control|Additional Reduction in DBP by Use of Additional Antihypertensive Therapy|Additional Reduction in SBP by Use of Additional Antihypertensive Therapy|Trough DBP Control Pre- and Post- Uptitration","http://ClinicalTrials.gov/show/NCT00614380",NA
"67336",67336,"NCT00671580","Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection","Completed","No Results Available","Skin Infections","Drug: PZ-601|Drug: PZ-601|Drug: Standard of Care","Protez Pharmaceuticals, Inc.","Both","Adult|Senior","Phase II",99,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","PZ-601-02","May 1, 2008","01/05/2008",2009-02-01,"June 2, 2009","01/06/2009","",2009-02-01,"The primary efficacy parameter is the proportion of patients experiencing clinical response based on improvement or resolution of clinical signs and symptoms of infection in the Clinically Evaluable population at the Test of Cure visit.|Clinical Response in the Clinically Evaluable (CE) population at the End of Treatment (EOT) visit|Clinical Response in the Intent-to-Treat (ITT), Microbiological ITT (mITT), and Microbiologically Evaluable (ME) populations at the Test of Cure (TOC) visit|Clinical Response in the Intent-to-Treat (ITT), Microbiological ITT (mITT), and Microbiologically Evaluable (ME) populations at the End of Treatment (EOT) visit|By-pathogen and by-patient Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the Test of Cure (TOC) visit|By-pathogen and by-patient Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the End of Treatment (EOT) visit|Overall combined Clinical and Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the Test of Cure (TOC) visit|Overall combined Clinical and Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the End of Therapy (EOT) visit","http://ClinicalTrials.gov/show/NCT00671580",NA
"67341",67341,"NCT00688480","Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?","Completed","No Results Available","Kidney Disease|Left Ventricular Hypertrophy","Drug: Placebo|Drug: Allopurinol","University of Dundee","Both","Adult|Senior","Phase IV",67,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MK001","May 29, 2008","01/01/2008",2010-02-01,"June 24, 2010","01/05/2008","",2009-08-01,"Primary objective is to see if Allopurinol reduces left ventricular hypertrophy (LVH) in this group of CKD patients|Secondary objective is to see if Allopurinol reduces endothelial dysfunction in this group of CKD patients","http://ClinicalTrials.gov/show/NCT00688480",NA
"67359",67359,"NCT00710580","Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","Completed","No Results Available","Moderate to Severe Plaque Psoriasis","Biological: ABT-874|Biological: etanercept|Drug: placebo","Abbott|Paragon Biomedical","Both","Adult|Senior","Phase III",350,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","M10-315","July 2, 2008","01/07/2008",NA,"November 1, 2010","01/09/2010","",2009-04-01,"Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12","http://ClinicalTrials.gov/show/NCT00710580",NA
"67410",67410,"NCT00789880","Analysis of the Response of Subjects With Atopic Dermatitis to Oral Vitamin D3 by Measurement of Antimicrobial Peptide Expression in Skin and Saliva","Completed","No Results Available","Atopic Dermatitis","Drug: Vitamin D3|Drug: Placebo","National Institute of Allergy and Infectious Diseases (NIAID)|Food and Drug Administration (FDA)|National Jewish Health|University of California, San Diego|Oregon Health and Science University","Both","Adult|Senior","Phase II",60,"NIH|U.S. Fed|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DAIT ADVN CATH 03|Contract No. HHSN266200400029C","November 11, 2008","01/12/2008",2009-12-01,"February 23, 2010","01/02/2010","",2009-12-01,"Difference in change in expression of AMP (hCAP18/LL-37, HBD3) from baseline to study day 21 in AD lesional skin biopsies compared to change in expression of AMP from baseline to study day 21 in AD non-lesional skin biopsies.|Expression of antimicrobial peptides (hCAP18/LL-37, HBD3) at baseline and study day 21 in AD subjects' lesional and non-lesional skin biopsies.|Expression of antimicrobial peptides (hCAP18/LL-37, HBD3) at baseline and study day 21 in non-AD subjects' skin biopsies.|Change in expression of systemic antimicrobial peptides (hCAP18/LL-37, HBD3) from baseline to study day 21 in AD and non-AD subjects' saliva.|Change in expression of TH2 cytokines IL-13 and IL-4 from baseline and study day 21 in AD subjects' lesional and non-lesional skin biopsies.|Change in expression of TH2 cytokines IL-13 and IL-4 from baseline and study day 21 in non-AD subjects' skin biopsies.|Change in expression of serum total IgE and RAST from baseline and study day 21 in AD and non-AD serum.|Change in EASI score from baseline and study day 21 in AD subjects.|The proportion of subjects in each arm who experience any Grade 3 or higher adverse events over the duration of follow-up in this trial.","http://ClinicalTrials.gov/show/NCT00789880",NA
"67437",67437,"NCT00840580","Effect on Wound Healing of Vigamox Versus Cravit","Completed","No Results Available","Cataract Extraction","Drug: Vigamox or Cravit","Alcon Research","Both","Adult|Senior","Phase IV",50,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","SMA-08-22","February 9, 2009","01/01/2009",NA,"January 7, 2010","01/01/2010","",2009-09-01,"Definite healing time after surgery.|Wound leak post operation; Width of corneal defect (optional); Punctate corneal epitheliopathy during postoperative day 1-4; Corneal epithelial defect persisting after post operative day 4; Cornea staining score; Visual acuity","http://ClinicalTrials.gov/show/NCT00840580",NA
"67440",67440,"NCT00841880","China Medical University Hospital (CMUH) Triapin Listing","Completed","No Results Available","Hypertension","Drug: Ramipril + Felodipine|Drug: Ramipril|Drug: Ramipril","Sanofi-Aventis","Both","Adult|Senior","Phase IV",49,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RAMFE_L_03420","February 10, 2009","01/01/2009",2009-09-01,"August 26, 2010","01/08/2010","",2009-09-01,"Seated SBP at office|Seated DBP at office|Seated SBP at office|Response rate|BP controlled rate","http://ClinicalTrials.gov/show/NCT00841880",NA
"67443",67443,"NCT00845780","Withdrawal Versus Continuation of Amiodarone in Successfully Treated Patients With Persistent Atrial Fibrillation","Completed","No Results Available","Persistent Atrial Fibrillation","Drug: withdrawal or continuation of amiodarone therapy","University Medical Centre Groningen","Both","Adult|Senior","Phase IV",37,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T377","February 17, 2009","01/08/2000",2009-06-01,"June 23, 2009","01/06/2009","WISDOM",2009-06-01,"occurrence of late relapse of persistent atrial fibrillation|difference in occurrence of adverse events (amiodarone and atrial fibrillation/underlying heart disease related) between both strategies","http://ClinicalTrials.gov/show/NCT00845780",NA
"67458",67458,"NCT00869180","Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain","Completed","No Results Available","Acute Pain|Ankle Sprain","Drug: Diclofenac Sodium|Drug: Matching Placebo Patch","Cerimon Pharmaceuticals|PPD","Both","Child|Adult|Senior","Phase III",219,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DCF-004","March 24, 2009","01/02/2009",2009-08-01,"January 26, 2010","01/01/2010","SUPPORT 2",2009-06-01,"Change in average pain during daily activity at Day 3|Change in average pain during daily activity at Day 7","http://ClinicalTrials.gov/show/NCT00869180",NA
"67482",67482,"NCT00905580","Perioperative Administration of Pregabalin for Pain After Robot-assisted Endoscopic Thyroidectomy","Completed","Has Results","Pain, Postoperative","Drug: Pregabalin|Drug: Vitamin Complex (placebo)","Severance Hospital","Both","Adult","Phase IV",99,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","IRB 4-2009-0070","May 18, 2009","01/05/2009",2009-09-01,"January 15, 2010","01/10/2009","",2009-09-01,"Pain Scores (VNRS) at 1, 6, 24, 48 Hours Postoperatively.|The Number of Participants With the Indicated Side Effects - Nausea & Vomiting, Sedation, Headache, Dizziness Etc.|Number of Patients Who Required Additional Analgesics During the First 48 Hours Postoperatively|Number of Patients With Hypoesthesia in the Anterior Chest at 3 Months After Operation.","http://ClinicalTrials.gov/show/NCT00905580",NA
"67486",67486,"NCT00922480","Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients","Completed","No Results Available","Hypertension","Drug: Fimasartan|Drug: Losartan (Control)","Boryung Pharmaceutical Co., Ltd|Seoul National University Hospital|The Catholic University of Korea|Kangbuk Samsung Hospital|Konkuk University Medical Center|Konyang University Hospital|Keimyung University|Korea University|Korea University Guro Hospital|DongGuk University|Seoul National University Bundang Hospital|Samsung Medical Center|Asan Medical Center|Severance Hospital|Ajou University|Yonsei University|Yeungnam University|Inha University Hospital|Chonbuk National University Hospital|Cheil General Hospital|Chungnam National University|Chungbuk National University|Hanyang University","Both","Adult|Senior","Phase III",506,"Industry|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A657-BR-CT-301","June 16, 2009","01/12/2008",2009-09-01,"October 7, 2009","01/10/2009","",2009-07-01,"Diastolic Blood Pressure|Diastolic Blood Pressure","http://ClinicalTrials.gov/show/NCT00922480",NA
"67519",67519,"NCT00969280","Acupuncture for Dry Eye Syndrome","Completed","Has Results","Dry Eye Syndromes","Device: Standardized Acupuncture|Device: Non-acupuncture point shallow penetration acupuncture","Korea Institute of Oriental Medicine","Both","Adult","Phase III",42,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","KI0906","August 31, 2009","01/09/2009",2009-12-01,"December 17, 2010","01/09/2010","",2009-12-01,"Ocular Surface Disease Index : OSDI|Visual Analogue Scale of Self Symptoms|Schirmer 1 Test|Tear Film Break-up Time : BUT|Medication Quantification Scale (MQS)|General Assessment","http://ClinicalTrials.gov/show/NCT00969280",NA
"67547",67547,"NCT01017380","Preemptive Analgesia in Cruciate Reconstruction","Completed","No Results Available","Anterior Cruciate Ligament Injury","Drug: Celecoxib|Drug: etoricoxib","Prince of Songkla University","Both","Child|Adult","Phase III",30,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","EC50/369-007","November 17, 2009","01/01/2008",2009-06-01,"November 19, 2009","01/11/2009","",2009-01-01,"VAS score|number of analgesic used","http://ClinicalTrials.gov/show/NCT01017380",NA
"67555",67555,"NCT01030380","Determination of the Efficacy of Slendertone?ó Face to Tone the Muscles of the Face and Reduce the Signs of Facial Aging","Completed","No Results Available","Facial Muscle Toning","Device: Slendertone Face","Bio-Medical Research, Ltd.","Female","Adult","Phase III",108,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","BMR-09-2009","December 9, 2009","01/02/2009",2009-05-01,"December 10, 2009","01/12/2009","Face",2009-05-01,"Ultrasound measurements of the zygomaticus major muscle|Increased psychometric assessments of improvements among the characteristics of facial appearance: firming; tone; lift; radiance and complexion|Ease of Use and Overall Acceptance of the Slendertone Face device","http://ClinicalTrials.gov/show/NCT01030380",NA
"67609",67609,"NCT01127880","Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax","Completed","No Results Available","Hemopneumothorax|Pneumothorax","Drug: Ancef or Clindamycin|Drug: Placebo","St. Luke's Hospital, Pennsylvania","Both","Child|Adult|Senior","Phase II|Phase III",50,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SLHN 2005-34","May 19, 2010","01/07/2005",2009-12-01,"May 20, 2010","01/02/2009","",2009-12-01,"efficacy of prophylactic antibiotics in reduction of empyema|Incidence of Pneumonia and/or development of resistant microorganisms","http://ClinicalTrials.gov/show/NCT01127880",NA
"67616",67616,"NCT01138280","Heat Disinfection of HD Water Treatment System in Hemodialysis Patients","Completed","No Results Available","All Cause Mortality","Device: CWP 103H (Gambro, Sweden): a heat disinfection device","Taipei Veterans General Hospital,Taiwan|National Science Council, Taiwan","Both","Adult|Senior","Phase IV",540,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","VGHIRB 96-12-21A|VGHUST97-P1-01","May 25, 2010","01/03/2005",2010-03-01,"June 4, 2010","01/01/2005","",2009-12-01,"CV events, CV|all-cause mortality|biofilm formation|endotoxin level of dialysis water|pro-inflammatory cytokine levels in serum","http://ClinicalTrials.gov/show/NCT01138280",NA
"67774",67774,"NCT00048581","Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.","Completed","No Results Available","Rheumatoid Arthritis","Drug: Abatacept|Drug: Placebo|Drug: Abatacept","Bristol-Myers Squibb","Both","Adult|Senior","Phase III",393,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","IM101-029","November 2, 2002","01/12/2002",2009-09-01,"July 28, 2010","01/09/2009","",2009-09-01,"The clinical efficacy of a fixed dose of abatacept with placebo as assessed by the ACR 20 response rate in subjects with active RA on a background of DMARDs who have failed any anti-TNF therapy|Compare ACR 50 and ACR 70 response rates|compare ACR 20, ACR 50 and ACR 70 response rates|Assess the long-term safety and tolerability of abatacept|Assess the efficacy, pharmacodynamic marker activity and immunogenicity of abatacept in combination with background non-biologic DMARDs","http://ClinicalTrials.gov/show/NCT00048581",NA
"67775",67775,"NCT00053781","Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma","Completed","No Results Available","Melanoma (Skin)","Drug: perifosine","NCIC Clinical Trials Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","I156|CAN-NCIC-IND156|CDR0000269475","February 5, 2003","01/06/2003",2009-12-01,"November 7, 2010","01/03/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00053781",NA
"67785",67785,"NCT00066781","Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary","Completed","No Results Available","Carcinoma of Unknown Primary","Drug: gemcitabine hydrochloride|Drug: irinotecan hydrochloride","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",42,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000318830|NCCTG-N004E","August 6, 2003","01/02/2004",NA,"April 14, 2009","01/03/2009","",2009-03-01,"Confirmed response rate (partial or complete response for 2 consecutive evaluations at least 4 weeks apart) as measured by RECIST criteria|Overall survival periodically for up to 2 years from registration|Time to disease progression periodically for up to 2 years from registration|Adverse event rates assessed by NCI common toxicity criteria for adverse events (CTCAE v3.0) at all courses|Relationship between genetic variations and the clinical outcomes of response, adverse events, survival, and time to progression at baseline","http://ClinicalTrials.gov/show/NCT00066781",NA
"67794",67794,"NCT00071981","Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)","Biological: incomplete Freund's adjuvant|Biological: melanoma helper peptide vaccine|Biological: multi-epitope melanoma peptide vaccine|Biological: sargramostim|Biological: tetanus peptide melanoma vaccine","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",169,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000335055|ECOG-E1602","November 4, 2003","01/03/2005",NA,"July 29, 2009","01/03/2009","",2009-03-01,"Immune response as measured by amount of peripheral blood T-cell lymphocytes present over the first 6 weeks|Clinical response as measured by amount of helper T-cells present at week 8","http://ClinicalTrials.gov/show/NCT00071981",NA
"67897",67897,"NCT00240981","TOM: Testosterone in Older Men With Sarcopenia","Completed","No Results Available","Sarcopenia|Hypogonadism|Muscular Diseases","Drug: Topical testosterone gel 1% (active formulation)|Drug: Topical gel (placebo formulation)","Boston Medical Center|National Institute on Aging (NIA)","Male","Adult|Senior","Phase IV",210,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG0057|U01AG014369|2U01AG14369-06","October 14, 2005","01/01/2005",2009-12-01,"April 2, 2010","01/03/2010","",2009-12-01,"Changes in physical performance measured by an exercise testing regimen|Changes in disability, fatigue, affect, and sense of well being assessed by validated questionnaires","http://ClinicalTrials.gov/show/NCT00240981",NA
"67903",67903,"NCT00248781","Home-based Exercise Via a Telecommunications System","Completed","No Results Available","Functional Limitation","Device: Telecommunications system","Department of Veterans Affairs","Both","Adult|Senior","Phase III",398,"U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","E2777R","November 2, 2005","01/09/2003",2009-11-01,"November 13, 2009","01/11/2009","",2009-04-01,"Muscle strength and physical performance|Durability of benefits","http://ClinicalTrials.gov/show/NCT00248781",NA
"67995",67995,"NCT00122681","Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18","Completed","Has Results","Human Papillomavirus (HPV) Infection|Papillomavirus Vaccines|Cervical Neoplasia","Biological: Cervarix?ºÑ|Biological: Havrix?ºÑ-based investigational formulation","GlaxoSmithKline","Female","Child|Adult","Phase III",18729,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","580299/008","July 20, 2005","01/05/2004",2009-11-01,"January 6, 2011","01/01/2011","",2009-11-01,"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection|Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection|Number of Subjects Reporting Solicited Local and General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events|Number of Subjects Reporting Serious Adverse Events (SAEs)|Number of Subjects Reporting New Onset of Chronic Disease (NOCDs)|Number of Subjects Reporting Medically Significant Conditions|Number of Subjects With Outcome of Pregnancies, Overall and Stratified by Initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus|Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18|Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18|Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types|Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types|Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Subjects Reporting Persistent Infection (12-month Definition) With HPV-16 or HPV-18|Number of Subjects Reporting Persistent Infection (12-month Definition) With HPV-16 or HPV-18|Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Seropositive Subjects for Anti-HPV-16 and Anti-HPV-18 Antibody Titers by ELISA in the Immunogenicity Subset, According to Initial (Month 0) HPV-16 or HPV-18 Serostatus|Anti-HPV-16 and Anti-HPV-18 ELISA Titers in the Immunogenicity Subset|HPV-16 and HPV-18 Seroconversion (V5/J4 Monoclonal Inhibition Test)|HPV-16 and HPV-18 Geometric Mean Titers (GMT) (V5/J4 Monoclonal Inhibition Test)|Number of Subjects Seropositive for Anti-HPV-16 and Anti-HPV-18 Antibodies Using Pseudovirion Based Neutralizing Assay (PBNA)|Titers for Anti-HPV-16 and Anti-HPV-18 Antibodies Using Pseudovirion Based Neutralizing Assay (PBNA)","http://ClinicalTrials.gov/show/NCT00122681",NA
"68001",68001,"NCT00399581","Comparison of Two Methods of High Frequency Oscillatory Ventilation in Individuals With Acute Respiratory Distress Syndrome","Completed","No Results Available","Respiratory Distress Syndrome, Adult","Procedure: High Frequency Oscillatory Ventilation-Hi|Procedure: High Frequency Oscillatory Ventilation-Lo","National Heart, Lung, and Blood Institute (NHLBI)","Both","Adult|Senior","Phase II",100,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","471|P50 HL073994","November 14, 2006","01/11/2006",2009-06-01,"July 10, 2009","01/07/2009","",2009-05-01,"Number of ventilator free days|Changes in plasma concentration of IL-6|Number of intensive care unit free days|Mortality|Number of hospital free days|Changes in plasma IL1ra|Changes in plasma IL-1|Changes in plasma IL-10|Changes in plasma surfactant protein D|Changes in plasma von Willebrand factor","http://ClinicalTrials.gov/show/NCT00399581",NA
"68033",68033,"NCT00445081","Prednisolone vs. Ciclosporine in Severe Atopic Eczema","Completed","No Results Available","Atopic Dermatitis","Drug: Prednisolone|Drug: Ciclosporine A","Dresden University of Technology","Both","Adult","Phase IV",66,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","TUD_PROVE_001|EudraCT-Nr:2006-003667-31","March 7, 2007","01/03/2007",2010-01-01,"October 28, 2010","01/10/2010","PROVE",2009-09-01,"stable remission in both treatment groups|response rate in both treatment groups|relapse rate in both treatment groups|mean change in objective SCORAD in both treatment groups|mean change in HRQL (DLQI) in both treatment groups|change in disease symptoms (POEM)in both treatment groups|Cost-effectiveness of both treatments|Tolerability and Safety|change in presenteeism in both treatment groups|patient satisfaction","http://ClinicalTrials.gov/show/NCT00445081",NA
"68037",68037,"NCT00443781","Study Of Disc Anaesthesia For The Preoperative Diagnosis Of Chronic Lower Back Pain","Completed","Has Results","Low Back Pain","Procedure: functional anaesthetic discography|Procedure: provocative discography","Medtronic Spine LLC","Both","Adult|Senior","Phase IV",62,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","SP0603","March 2, 2007","01/03/2007",2009-06-01,"September 8, 2010","01/09/2010","SODA",2009-06-01,"Difference in Number of Magnetic Resonance Imaging (MRI)-Positive Discs Diagnosed Positive by Provocative Discography (PD) and Functional Anesthetic Discography (F.A.D.)|Proportion of Subjects in Whom a Device-related Serious Adverse Event Occurs During or After PD/F.A.D.|Change in Self-rated Numerical Rating Scale (NRS) Back Pain and Oswestry Disability Index (ODI) at Six Months After Institution of Selected Treatment.|Individual Subject Success.|Work Status|Change in Medication Usage","http://ClinicalTrials.gov/show/NCT00443781",NA
"68045",68045,"NCT00454181","Treatment of Oral Warts in HIV+ Patients","Completed","Has Results","Papillomatosis|HIV Infections","Drug: Interferon-alpha|Other: placebo","Amarillo Biosciences, Inc.","Both","Adult|Senior","Phase II",59,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","03HUHI19","March 29, 2007","01/02/2007",2009-10-01,"January 13, 2011","01/01/2011","",2009-09-01,"Change in Total Oral Mucosal Area Covered by Warts.|Total Surface Area of the Lips Covered by Warts|Subject Questionnaire Regarding Changes in Warts|Subject Questionnaire Regarding Global Oral Changes|Investigator Assessment Regarding Changes in Warts|Investigator Assessment Regarding Global Oral Changes.","http://ClinicalTrials.gov/show/NCT00454181",NA
"68056",68056,"NCT00481481","Conversion Study From Cyclosporine to FK506MR Based Immunosuppression in Kidney Transplant Subjects","Completed","No Results Available","Transplantation","Drug: tacrolimus","Astellas Pharma Inc","Both","Adult|Senior","Phase III",346,"Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PMR-EC-1209","May 30, 2007","01/04/2007",2009-03-01,"May 12, 2009","01/05/2009","CONCERTO",2009-03-01,"Change in creatinine clearance, calculated according to Cockcroft and Gault formula.|Change in creatinine clearance, calculated according to Cockcroft and Gault formula, between Baseline (Day 1) and week 24 (End of Study) overall|Rating of subjects according to reason for conversion: Changes in mean lipid levels (total cholesterol)","http://ClinicalTrials.gov/show/NCT00481481",NA
"68073",68073,"NCT00512681","A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer","Completed","No Results Available","Stomach Neoplasms","Drug: Irinotecan, Oxaliplatin, TS-1","National Cancer Center, Korea","Both","Adult|Senior","Phase II",44,"Other","Interventional","Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-07-264","August 7, 2007","01/07/2007",2009-07-01,"September 17, 2009","01/09/2009","TIROX2",2009-07-01,"Maximal overall response rate|Progression-free survival,Overall survival,Toxicity assessment,&genetic polymorphism and association with chemical outcomes","http://ClinicalTrials.gov/show/NCT00512681",NA
"68078",68078,"NCT00517881","A Study of Subcutaneous Mircera for the Maintenance Treatment of Pre-Dialysis Patients With Chronic Renal Anemia.","Completed","No Results Available","Anemia","Drug: methoxy polyethylene glycol-epoetin beta [Mircera]","Hoffmann-La Roche","Both","Adult|Senior","Phase III",39,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20944","August 16, 2007","",2009-11-01,"November 19, 2010","01/11/2010","",2009-11-01,"Percentage of patients maintaining average Hb concentration in target range during evaluation period|Change in Hb concentration and percentage of patients maintaining Hb concentration in target range during evaluation period|Mean time spent in target range; percentage of patients needing dose adjustments; incidence of RBC transfusions|AEs, laboratory parameters","http://ClinicalTrials.gov/show/NCT00517881",NA
"68082",68082,"NCT00524381","Etanercept Treatment in the Early Course of Polymyalgia Rheumatica","Completed","No Results Available","Polymyalgia Rheumatica","Drug: Etanercept (Enbrel)|Drug: Sodium chloride (placebo)","Bispebjerg Hospital","Both","Adult|Senior","Phase III",40,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PMR-ENBREL-1","August 30, 2007","01/08/2007",2009-09-01,"February 22, 2010","01/02/2010","",2009-07-01,"Polymyalgia rheumatica activity score (PMR-AS)|Plasma concentrations of various cytokines, chemokines, and adipokines|Quantitative use of analgesics|Insulin sensitivity (HOMA)","http://ClinicalTrials.gov/show/NCT00524381",NA
"68093",68093,"NCT00537381","A Study of the Safety and Effectiveness of CNTO 95 in Patients Wih Metastatic Hormone Refractory Prostate Cancer","Completed","No Results Available","Prostate Cancer","Biological: CNTO 95, docetaxel, prednisone|Drug: Placebo, docetaxel, prednisone","Centocor, Inc.","Male","Adult|Senior","Phase II",131,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR013249|C1034T08","September 27, 2007","01/05/2007",2009-11-01,"October 18, 2010","01/10/2010","",2009-11-01,"Progression-free survival (PFS), defined as the time from the date of randomization until the first documented sign of disease progression or death throughout the course of the trial.|Tumor and PSA response rate","http://ClinicalTrials.gov/show/NCT00537381",NA
"68111",68111,"NCT00558181","High-dose Methylprednisolone and Rituximab in High Risk B-CLL","Completed","No Results Available","Chronic B-Lymphocytic Leukemia","Drug: rituximab, methylprednisolone","Vilnius University","Both","Adult|Senior","Phase II",29,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LT-CLL-001","November 13, 2007","01/09/2007",2009-12-01,"February 22, 2010","01/02/2010","LT-CLL-001",2009-01-01,"Primary endpoint will be the ORR defined as the proportion of patients achieving CR, CR with MRD negativity (Complete Flow Cytometric Remission), nPR and PR.|PFS defined as time from the first day of treatment to the day the subject progresses or dies of any cause. OS defined as time from the first day of treatment to the day the subject dies of any cause.","http://ClinicalTrials.gov/show/NCT00558181",NA
"68120",68120,"NCT00573781","Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism","Completed","No Results Available","Metabolic Syndrome|Obesity|Impaired Glucose Tolerance|Impaired Fasting Glucose","Dietary Supplement: Diet with increased intake of rye bread, berries and fish|Dietary Supplement: Increased intake of whole grain and rye bread|Dietary Supplement: Control diet with decreased intake of rye bread, berries and fish","University of Eastern Finland|VTT Technical Research Centre, Espoo, Finland|Wageningen University","Both","Adult","Phase II",106,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","56/2007|117844 by Finnish Academy","December 13, 2007","01/09/2007",2009-06-01,"September 13, 2010","01/09/2010","Sysdimet",2009-06-01,"Changes in glucose metabolism, changes in transcriptomic and metabolomic profiles|Interaction between the diet and genetic factors within treatment groups","http://ClinicalTrials.gov/show/NCT00573781",NA
"68182",68182,"NCT00673881","ABT-355 Reverse Cholesterol Transport (RCT) Study","Completed","No Results Available","Dyslipidemia","Drug: ABT-335","Radiant Research","Both","Adult|Senior","Phase I|Phase II",25,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ABT-335-001","May 5, 2008","01/03/2008",2009-05-01,"October 8, 2009","01/10/2009","",2009-05-01,"The outcome will measure the rate of appearance (Ra) of plasma cholesterol (cholesterol efflux (mg/kg/hr), cholesterol excretion (%/day), RCT efflux (mg/kg/day) and de novo cholesterol synthesis (%).","http://ClinicalTrials.gov/show/NCT00673881",NA
"68198",68198,"NCT00699881","Study of Cetuximab to Treat Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: cetuximab","Fudan University","Both","Adult|Senior","Phase II",61,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62202- 806","June 17, 2008","01/05/2008",2009-10-01,"December 21, 2009","01/06/2008","STAGE",2009-10-01,"time to progression|toxicity","http://ClinicalTrials.gov/show/NCT00699881",NA
"68212",68212,"NCT00718081","A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 in Patients Undergoing Major Abdominal Surgery","Completed","No Results Available","Major Upper or Lower Abdominal Surgery","Drug: Oral sufentanil|Drug: Placebo","AcelRx Pharmaceuticals, Inc.","Both","Adult|Senior","Phase II",94,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARX-C-005","July 16, 2008","01/08/2008",2009-03-01,"March 9, 2009","01/07/2008","",2009-03-01,"To determine how effective different dosages of ARX-F01 is in the treatment of moderate to severe post-operative pain compared to placebo, as determined by the difference between pain intensity scores over the 12-hour study period.|To assess how effective ARX-F01 is for post-operative pain relief using categorical subject ratings as well as time to perceived pain relief and to meaningful pain relief.","http://ClinicalTrials.gov/show/NCT00718081",NA
"68252",68252,"NCT00790881","Artemether/Lumefantrine and Nevirapine Interaction Study in HIV-infected Adults","Completed","No Results Available","Malaria|HIV","Drug: Artemether/Lumefantrine|Drug: Artemether/ lumefantrine","University of Cape Town|London School of Hygiene and Tropical Medicine","Both","Adult|Senior","Phase IV",36,"Other","Interventional","Control: Active Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SEACAT 2.4.1|DOH-27-0807-2012","November 13, 2008","01/10/2008",2009-12-01,"June 25, 2010","01/06/2010","",2009-08-01,"Lumefantrine plasma concentration|Point estimates and 90% confidence intervals for the mean ratios of the lumefantrine, artemether and DHA log-transformed Cmax, AUC0-t, AUC0 ??? , t?¥,z, tmax and MRT with/without NVP","http://ClinicalTrials.gov/show/NCT00790881",NA
"68268",68268,"NCT00812981","A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.","Completed","No Results Available","Pandemic Influenza","Biological: GSK1562902A|Biological: GSK1562902A","GlaxoSmithKline","Both","Adult","Phase III",320,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","111954","December 18, 2008","01/11/2008",2009-06-01,"September 9, 2009","01/09/2009","",2009-06-01,"Serum HI antibody titres|Geometric mean titres (GMTs) of HI antibody titres|Serum HI antibody titres|GMTs of HI antibody titres|Seropositivity of HI antibody titres|Seroconversion rates for HI antibodies|Seroconversion factors for HI antibodies|Seroprotection rates for HI antibodies|Serum neutralising antibody titres|GMTs of neutralising antibody titres|Seroconversion rates for neutralising antibodies|Percentage, intensity, and relationship to vaccination of solicited local and general signs and symptoms|Percentage, intensity and relationship to vaccination of unsolicited local and general signs and symptoms|Occurrence of unsolicited adverse events|Occurrence of adverse events of specific interest|Occurrence of serious adverse events","http://ClinicalTrials.gov/show/NCT00812981",NA
"68283",68283,"NCT00845481","A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris","Completed","No Results Available","Psoriasis Vulgaris","Drug: Daivobet?ó ointment","LEO Pharma","Both","Adult|Senior","Phase II",24,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)","PLQ-002","February 16, 2009","01/01/2009",2009-05-01,"August 13, 2009","01/08/2009","",2009-03-01,"The primary objective of the study is to compare the anti-psoriatic effect of marketed products by evaluation of the clinical scoring and ultrasound skin echography of lesion thickness of psoriasis plaques","http://ClinicalTrials.gov/show/NCT00845481",NA
"68304",68304,"NCT00876681","Ultrasound Guidance Versus Electrical Stimulation for Continuous Popliteal-Sciatic Nerve Blocks","Completed","No Results Available","Postoperative Pain|Foot Numbness","Procedure: Popliteal catheter placed via ultrasound or electrical stimulation","University of California, San Diego","Both","Adult|Senior","Phase IV",80,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Popliteal Catheter: US vs. NS","April 3, 2009","01/04/2008",2009-04-01,"October 7, 2009","01/10/2009","",2009-04-01,"The primary outcome measurement will be the average pain in the three hours previous to a phone call the day following surgery as measured on a numeric rating scale (NRS, 0-10, 0=no pain, 10=worst imaginable pain).|Sensory deficit in the operative limb the day following surgery as measured with a simple 0-10 scale (0=no numbness; 10=completely insensate) of the part of the foot with the greatest sensory deficit at time of the data collection phone call.|Time for catheter placement. Time will begin when probe is placed on skin for the ultrasound-guidance method and when the nerve stimulation needle is placed on the skin for the electrical stimulation method.|Catheter placement success rate as assessed by attending physician who will test for sensory deficit.|Worst pain experienced since the surgery in the surgical limb as measured on the 0-10 NRS as assessed by the research staff when they call the patient the day following surgery.","http://ClinicalTrials.gov/show/NCT00876681",NA
"68310",68310,"NCT00888381","A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira?ó Vaccine in Healthy Volunteers","Completed","No Results Available","Influenza","Biological: Inactivated Influenza Vaccine (2009 / 2010 formulation)","CSL Limited","Both","Adult|Senior","Phase IV",120,"Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","CSLCT-NHF-09-57|EUDRACT number: 2009-011450-18","April 24, 2009","01/05/2009",2009-05-01,"June 18, 2009","01/06/2009","",2009-05-01,"Immunogenicity of Enzira?ó vaccine according to the criteria specified in the CPMP/BWP/214/96 Note for Guidance on Harmonisation of Requirements for Influenza Vaccines.|The frequency of solicited local reactions|The frequency of solicited systemic symptoms|The incidence of unsolicited adverse events","http://ClinicalTrials.gov/show/NCT00888381",NA
"68316",68316,"NCT00901381","Granulocyte-Colony Stimulating Factor for Stem Cells Therapy for Acute Ischemic Stroke","Completed","No Results Available","Ischemic Stroke","Drug: Filgrastim","Clinical Institute of the Brain, Russia|Institute of Medical Cells Technologies|City Clinical Hospital #40","Both","Adult|Senior","Phase II",20,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GKSF-8","May 12, 2009","01/06/2007",2009-02-01,"May 12, 2009","01/05/2009","STEMTHER",2009-02-01,"Dependence assessed by the modified Rankin scale|Impairment assessed by the Medical Research Consul scale and National Institutes of Health Stroke Scale|Disability assessed by the Barthel Index and Glasgow Outcome Scale|Infarct size assessed by the magneto-resonance imaging|Safety was assessed as mortality, incidence of hemorrhagic transformation and serious adverse events","http://ClinicalTrials.gov/show/NCT00901381",NA
"68317",68317,"NCT00903981","Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil","Completed","No Results Available","Erectile Dysfunction","Drug: Avanafil|Drug: Avanafil|Drug: Placebo","ChoongWae Pharma Corporation","Male","Adult|Senior","Phase III",208,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CWP-AVA-301","May 18, 2009","01/03/2009",2009-11-01,"April 22, 2010","01/02/2009","ALERT",2009-10-01,"Change of EF domain score in the IIEF(The International Index of Erectile Function)|Change of successful rate in SEPQ2,Q3,Q4,Q5 Change of score in other domains of IIEF Change of IIEF Q3 and Q4 score GEAQ The rate of normal erectile function","http://ClinicalTrials.gov/show/NCT00903981",NA
"68320",68320,"NCT00848081","A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers","Completed","Has Results","Benign Prostatic Hyperplasia","Drug: Tadalafil|Drug: Placebo","Eli Lilly and Company","Male","Adult|Senior","Phase III",318,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","11668|H6D-MC-LVHS","February 19, 2009","01/03/2009",2009-12-01,"August 16, 2010","01/08/2010","",2009-12-01,"Number of Men With Treatment-emergent Dizziness|Number of Participants With Positive Orthostatic Vital Signs Test; Shift From Any Pre-Randomization to Any Post-Randomization Visit|International Prostate Symptom Score (IPSS) Change From Baseline|Postvoid Residual Volume (PVR) Change From Baseline|Uroflowmetry (Qmax) Change From Baseline","http://ClinicalTrials.gov/show/NCT00848081",NA
"68323",68323,"NCT00892281","ORCA - Oracea?ó for Rosacea: A Community-based Assessment","Completed","Has Results","Rosacea","Drug: doxycycline (Oracea?ó) 40 mg modified release as monotherapy|Drug: doxycycline (Oracea?ó) 40 mg modified release as add-on therapy","Galderma Laboratories, L.P.","Both","Adult|Senior","Phase IV",1421,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","US10120","April 30, 2009","01/04/2009",2009-10-01,"December 16, 2010","01/12/2010","",2009-10-01,"Change in Investigator's Global Assessment (IGA) Score From Baseline to Endpoint|Change in Clinician's Erythema Assessment Scale (CEA) Score From Baseline to Endpoint|Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear)","http://ClinicalTrials.gov/show/NCT00892281",NA
"68326",68326,"NCT00916981","Treatment of Atrophic Nonunion by Preosteoblast Cells","Completed","No Results Available","Pseudarthrosis|Fractures, Ununited","Procedure: percutaneous autologous preosteoblast cells implantation","University Hospital of Liege","Both","Adult|Senior","Phase I|Phase II",15,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ref:2006-73","June 3, 2009","01/11/2008",2009-06-01,"June 15, 2009","01/06/2009","",2009-06-01,"radiological progression of bone fusion|reduction of pain using VAS","http://ClinicalTrials.gov/show/NCT00916981",NA
"68344",68344,"NCT00941681","Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure","Completed","Has Results","Heart Failure","Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452","Cytokinetics","Both","Adult|Senior","Phase II",35,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CY 1021","July 15, 2009","01/04/2009",2009-10-01,"January 6, 2011","01/01/2011","",2009-10-01,"C Max (Day 1, Dose 1)|T Max (Day 1, Dose 1)|AUC (Day 1, Dose 1)|C Max (Day 10)|T Max (Day 10)|AUC (Day 10)|Evaluate the Safety and Tolerability of Oral Formulations of CK-1827452 When Dosed to Steady-state in Patients With Stable Heart Failure.","http://ClinicalTrials.gov/show/NCT00941681",NA
"68364",68364,"NCT00981981","Effect of the Molecular Weight of Oat ??-glucan on Its Ability to Lower Serum Cholesterol","Completed","No Results Available","Hypercholesterolemia","Dietary Supplement: Wheat bran|Dietary Supplement: 3g high MW|Dietary Supplement: 4g medium MW|Dietary Supplement: 3g medium MW|Dietary Supplement: 4g low MW","Glycemic Index Laboratories, Inc|CreaNutrition, AG|University of Guelph|University of Sydney|Laval University|Reading Scientific Services, Ltd.|University of Toronto|Agriculture and Agri-Foods Canada","Both","Adult|Senior","Phase II",367,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GIL8034","September 18, 2009","01/11/2008",2009-08-01,"October 9, 2009","01/10/2009","Bluebird",2009-07-01,"Serum LDL-cholesterol lowering effect of 3g high MW beta-glucan|Correlation between serum LDL-cholesterol lowering and log(MW*C)|Total cholesterol|Serum triglycerides|Serum HDL cholesterol|Fasting serum glucose|Serum aspartate transaminase|serum c-reactive protein|Serum urea|Serum creatinine|Time course of changes in blood lipids|Blood pressure|Macronutrient composition of diet|Symptoms questionnaire|apolipoprotein B|Serum markers of cholesterol absorption and synthesis","http://ClinicalTrials.gov/show/NCT00981981",NA
"68386",68386,"NCT01027481","Ranibizumab in Patients With Branch Retinal Vein Occlusion","Completed","No Results Available","Retinal Vein Occlusion","Drug: Lucentis","Medical University of Vienna","Both","Adult|Senior","Phase IV",30,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","V1","December 7, 2009","01/12/2007",2009-12-01,"December 7, 2009","01/11/2007","",2009-11-01,"Main outcome measure: Retinal vessel diameters|Secondary outcome measures: Retrobulbar flow velocities, best-corrected visual acuity, macular sensitivity, objective functional response, anatomic changes in the macula region, angiographical outcomes.","http://ClinicalTrials.gov/show/NCT01027481",NA
"68476",68476,"NCT01186081","Comparison of Preoperative and Postoperative Radiotherapy and Capecitabine in Locally Advanced Rectal Cancer","Completed","No Results Available","Rectal Cancer","Radiation: Preoperative chemoradiotherapy|Radiation: Postoperative chemoradiotherapy","Asan Medical Center","Both","Adult|Senior","Phase III",240,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC Rectal Pre Vs Post 2004","August 18, 2010","01/03/2004",2009-08-01,"August 20, 2010","01/08/2010","",2009-04-01,"Disease-free survival|Overall survival|Local relapse-free survival|Sphincter preservation rate|Treatment related toxicities","http://ClinicalTrials.gov/show/NCT01186081",NA
"68482",68482,"NCT01195181","Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.","Completed","No Results Available","Hepatitis C Virus|Chronic Liver Disease|Viral Hepatitis|Therapeutic Uses|Antiviral Agents","Drug: peginterferon plus ribavirin","Azienda Ospedaliera di Padova|Regione Veneto|University of Padua","Both","Adult","Phase IV",506,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HEPCOVE protocol|DRG N.2920/2002","August 31, 2010","01/09/2005",2010-08-01,"September 3, 2010","01/09/2010","",2009-12-01,"Evaluation of real dose drugs intake in relation to sustained virological response (SVR).|Description of the profile of the virus decay during antiviral therapy in relation to virological response.","http://ClinicalTrials.gov/show/NCT01195181",NA
"68620",68620,"NCT00079482","Study of CEP-701 in Patients With Acute Myeloid Leukemia (AML)","Completed","No Results Available","Acute Myeloid Leukemia","Drug: lestaurtinib|Drug: lestaurtinib","Cephalon","Both","Adult|Senior","Phase II",224,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C701a/204/ON/US","March 8, 2004","01/10/2003",2010-01-01,"April 29, 2010","01/04/2010","",2009-03-01,"Determine whether CEP-701 given in sequence with induction chemotherapy increases the proportion of patients with relapsed AML who achieve a second complete remission or a complete remission with incomplete platelet count recovery.|- overall survival - event-free survival - remission duration - safety and tolerability of CEP-701 - pharmacokinetics of CEP-701 - CEP-701 inhibitory activity","http://ClinicalTrials.gov/show/NCT00079482",NA
"68639",68639,"NCT00096382","Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)","Biological: aldesleukin|Biological: filgrastim|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",116,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000393480|NCI-04-C-0288|NCI-7025|NCI-PRMC-P6273","November 9, 2004","01/09/2004",NA,"February 6, 2009","01/01/2007","",2009-01-01,"Complete clinical tumor regression|Safety|Survival","http://ClinicalTrials.gov/show/NCT00096382",NA
"68657",68657,"NCT00124982","Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy","Completed","No Results Available","Rheumatoid Arthritis","Drug: Abatacept","Bristol-Myers Squibb","Both","Adult|Senior","Phase III",535,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IM101-064","June 30, 2005","01/10/2005",2009-08-01,"July 28, 2010","01/06/2010","",2009-08-01,"Assess the long term safety and tolerability of abatacept in subjects who have completed the initial 6 month open label treatment period|Assess efficacy and immunogenicity of abatacept in combination with non-biologic DMARDs|Assess maintenance of response in subjects who eliminate or reduce their dose of concomitant non-biologic background DMARD therapy","http://ClinicalTrials.gov/show/NCT00124982",NA
"68735",68735,"NCT00240682","Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR","Completed","No Results Available","Skin Diseases|Carcinoma, Squamous Cell","Drug: cetuximab","Centre Hospitalier of Chartres|Hospital of Chartres- France","Both","Adult|Senior","Phase II",37,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-001098-82","October 17, 2005","01/10/2005",2009-06-01,"August 27, 2009","01/08/2009","CTXSCC",2009-04-01,"Disease control rate assessed by CT or MRI|Safety profile.|Time to disease progression.|Overall survival.|Duration of response in responder patients at 6 weeks.","http://ClinicalTrials.gov/show/NCT00240682",NA
"68755",68755,"NCT00282282","Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation","Completed","No Results Available","Graft Versus Host Disease|GVHD","Drug: tacrolimus|Drug: sirolimus|Drug: fludarabine|Drug: busulfex","Dana-Farber Cancer Institute|Brigham and Women's Hospital","Both","Adult|Senior","Phase II",30,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-362","January 24, 2006","01/01/2006",2009-07-01,"January 4, 2010","01/01/2010","",2009-01-01,"To assess the incidence and severity of grade II-IV acute GvHD developing by day 100 following non-myeloablative PBSC transplantation using tacrolimus and sirolimus.|To assess donor stem cell engraftment, including donor-host hematopoietic chimerism studies post transplant|to assess disease response.","http://ClinicalTrials.gov/show/NCT00282282",NA
"68764",68764,"NCT00297882","Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon","Completed","No Results Available","Malaria","Drug: Artemether-Lumefantrine , Amodiaquine-Artesunate","Gates Malaria Partnership|University of Yaounde|Health Board, Cameroon Baptist Convention, Cameroon","Both","Child","Phase III",900,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","ITCRVG46","February 28, 2006","01/07/2006",2009-07-01,"March 3, 2010","01/03/2010","",2009-04-01,"Cure rate on Day 28|Cure rate on Day 14|Adverse Events by Day 28","http://ClinicalTrials.gov/show/NCT00297882",NA
"68781",68781,"NCT00323882","Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer","Completed","No Results Available","Prostate Cancer|Neoplasm Metastasis","Drug: MDX-010","Bristol-Myers Squibb","Male","Adult|Senior","Phase I|Phase II",66,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MDX010-21|CA184-017","May 8, 2006","01/02/2005",2009-09-01,"April 23, 2010","01/04/2010","MDX010-21",2009-09-01,"The primary objective of the study is to determine the safety profile|Provide a preliminary assessment of clinical antitumor activity, including an assessment of prostate-specific antigen (PSA) responses and metabolic bone activity.","http://ClinicalTrials.gov/show/NCT00323882",NA
"68826",68826,"NCT00395382","Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease","Completed","No Results Available","Vascular Calcification|Arteriosclerosis","Drug: Alendronate|Drug: Placebo","Monash University","Both","Adult|Senior","Phase IV",50,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HREC 06099C","November 1, 2006","01/01/2007",2009-09-01,"February 8, 2010","01/02/2010","",2009-09-01,"Change in degree of arterial stiffness measured by pulse wave velocity|Changes in vascular calcification on CT scans of superficial femoral artery and aorta|Changes in bone mineral density|Changes in serum calcium and phosphate levels|Cardiovascular events including myocardial ischaemia, myocardial infarction, cardiac failure, stroke, PVD|Incidence of fractures|Symptoms and severity of side effects from alendronate|Episodes of hypocalcemia (serum corrected calcium <2.10mmol/L)","http://ClinicalTrials.gov/show/NCT00395382",NA
"68929",68929,"NCT00555282","Rate of Catheter Colonization and Risk of Bloodstream Infection During Use of Two Different Central Venous Catheters (CVC)","Completed","No Results Available","Bacteriaemia|Catheter Related Bloodstream Infection","Device: central venous catheter|Device: central venous catheter","B. Braun Melsungen AG","Both","Adult|Senior","Phase IV",680,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HC-G-H-0507","November 7, 2007","01/11/2005",2009-07-01,"February 4, 2010","01/02/2010","",2009-07-01,"Incidence of catheter colonization|Incidence of bloodstream infection|Safety of catheter: complications related to the catheter and adverse events in general, clinical therapy, TISS-Score, ICU stay, infection markers|Safety of catheter: central venous catheter variables, time of catheter insertion and removal, kind of colonization","http://ClinicalTrials.gov/show/NCT00555282",NA
"68930",68930,"NCT00552682","Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+","Completed","No Results Available","Fibromyalgia|HIV-1 Infection","Drug: Duloxetine 60 mg, QD","Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA","Both","Adult|Senior","Phase III",10,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FIBROHIV","October 31, 2007","01/01/2007",2009-07-01,"July 20, 2009","01/07/2009","",2009-07-01,"Variation in pain measured using the Brief Pain Inventory questionnaire in both branches of the study|Assess differences in Short-Form 36 Health Survey (SF-36) questionnaire scale score.|Assess differences in Beck Depression Inventory (BDI) questionnaire scale score.|Assess differences in Profile of Mood States - Forma A (POMS-A) questionnaire scale score.|Assess the percentage of patients that leave duloxetine due to intolerance or toxicity.|Assess, if possible, pharmacokinetic profile of duloxetine and determine interaction with antiretroviral drugs.","http://ClinicalTrials.gov/show/NCT00552682",NA
"68936",68936,"NCT00566982","A Clinical Study to Evaluate the Safety of Ospemifene","Completed","No Results Available","Atrophy|Vaginal Diseases","Drug: Ospemifene (orally dosed once daily for 52 weeks)|Drug: Placebo","QuatRx Pharmaceuticals Company|Hormos Medical Ltd.","Female","Adult|Senior","Phase III",350,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15-50718","November 30, 2007","01/10/2007",2009-07-01,"July 10, 2009","01/07/2009","",2009-07-01,"Mean change from baseline in percentage of parabasal cells in maturation index of vaginal smear|Mean change in percentage of superficial cells in maturation index of vaginal smear|Mean change from baseline in vaginal pH|Change from baseline in serum hormone levels|Change from baseline in visual evaluation of the vagina","http://ClinicalTrials.gov/show/NCT00566982",NA
"68951",68951,"NCT00596882","Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study","Completed","No Results Available","Smoking Cessation","Other: Message Prime|Other: Message Prime","University of Pennsylvania|Pennsylvania Department of Health|Pfizer","Both","Adult","Phase IV",100,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","806910","January 8, 2008","01/02/2008",2009-06-01,"December 1, 2009","01/12/2009","",2009-06-01,"The primary outcome variables are:(1)Attendance to the intake evaluation & enrollment in the smoking cessation program; (2)7-day point prevalence abstinence(3)Self-reported cigarette consumption","http://ClinicalTrials.gov/show/NCT00596882",NA
"68982",68982,"NCT00635882","Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)","Completed","No Results Available","Asthma|Airway Inflammation","Drug: mometasone furoate/formoterol 100/10 mcg|Drug: mometasone furoate/formoterol 200/10 mcg|Drug: mometasone furoate/formoterol 400/10 mcg|Drug: MF DPI 200 mcg|Drug: MF MDI 200 mcg|Drug: Placebo","Schering-Plough","Both","Child|Adult|Senior","Phase II",90,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","P05122","January 21, 2008","01/02/2008",2009-06-01,"September 30, 2009","01/09/2009","",2009-06-01,"Percent change from Baseline to Day 14 eNO.|Percent change from Baseline to Day 7 in eNO.|Percent change from Baseline to Day 14 in sputum eosinophil count.|Change from Baseline to Day 15 in PD15 of mannitol challenge.|Change from Baseline AM and PM asthma symptoms at Days 1-15.|Change from Baseline AM and PM PEF at Days 1-15.","http://ClinicalTrials.gov/show/NCT00635882",NA
"69011",69011,"NCT00686582","An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees","Completed","No Results Available","Smallpox","Biological: IMVAMUNE|Biological: IMVAMUNE|Procedure: Blood Draw Only","Bavarian Nordic|National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","Phase II",304,"Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","POX-MVA-023|EudraCT-No.2007-006297-28|DMID 08-0018","May 27, 2008","01/08/2008",2009-10-01,"May 21, 2010","01/05/2010","",2009-07-01,"Percentage of subjects with appearance (initially seronegative subjects) or increase (compared to baseline by pre-existing titers) of antibody titers in a vaccinia-specific IgG ELISA derived from individual peak responses.","http://ClinicalTrials.gov/show/NCT00686582",NA
"69045",69045,"NCT00748982","Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction","Completed","No Results Available","Left Ventricle Function","Drug: AZD1305|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase II",16,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","D3190C00013|2008-001254-41","September 5, 2008","01/08/2008",2009-07-01,"August 27, 2009","01/08/2009","",2009-07-01,"Pharmacodynamic variables including QT interval and echocardiographic variables|Pharmacokinetic variables|Adverse events, ECG, safety laboratory, vital signs, physical examination","http://ClinicalTrials.gov/show/NCT00748982",NA
"69059",69059,"NCT00765882","Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation","Completed","No Results Available","Chronic Constipation","Drug: Linaclotide 300 micrograms|Drug: Linaclotide 150 micrograms|Drug: Placebo","Forest Laboratories|Ironwood Pharmaceuticals, Inc.","Both","Adult|Senior","Phase III",600,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LIN-MD-01","October 1, 2008","01/09/2008",2009-07-01,"January 20, 2010","01/01/2010","",2009-07-01,"Complete Spontaneous Bowel Movement (CSBM) Overall Responder|Change from Baseline in 12-week CSBM Frequency","http://ClinicalTrials.gov/show/NCT00765882",NA
"69076",69076,"NCT00794482","Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.","Completed","No Results Available","Hepatic Cirrhosis","Drug: NRL972","Norgine","Both","Adult|Senior","Phase III",1200,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","NRL972-03/2006 (CIR)","November 19, 2008","01/03/2008",2009-06-01,"October 7, 2009","01/10/2009","",2009-06-01,"Influence of CTP staging on the pharmacokinetics of NRL972 in patients with cirrhosis.|Inter-subject relationship between the pharmacokinetics of NRL972 and other parameters used to define the severity of hepatic cirrhosis|To assess the safety and tolerability of 2mg NRL972 administered by intravenous injection to patients with hepatic cirrhosis","http://ClinicalTrials.gov/show/NCT00794482",NA
"69090",69090,"NCT00820482","Comparing Highly Purified hMG With Recombinant FSH + Recombinant LH in Women Undergoing Intrauterine Insemination.","Completed","No Results Available","Ovarian Stimulation Preceding Intrauterine Insemination","Drug: Menopur?ó, Ferring|Drug: rFSH (Gonal?ó,","Instituto Valenciano de Infertilidad, Spain","Female","Adult","Phase IV",80,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VLC- EL-0106-307-9","January 8, 2009","01/01/2009",2009-05-01,"September 17, 2009","01/09/2009","",2009-05-01,"The present study aims to elucidate if the FSH and LH activity contained in hMG preparations is comparable to the recombinant FSH and LH administration in proporci??n 1:1. Mean outcome: - Ovarian response according to the protocol used.|Secondary outcomes: - Days of stimulation - Total doses of gonadotrophins administrated - Clinical pregnancy , ongoing pregnancy and miscarriage rate - Cancellation rate","http://ClinicalTrials.gov/show/NCT00820482",NA
"69095",69095,"NCT00825682","The Effect of Reflexology on Radiation-Related Fatigue in Breast Cancer Patients","Completed","No Results Available","Radiation Related Fatigue","Other: Reflexology treatment.","Sheba Medical Center","Female","Adult|Senior","Phase I|Phase II",40,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SHEBA-07-4923-DG-CTIL","January 19, 2009","01/05/2008",2009-05-01,"July 2, 2009","01/07/2009","",2009-02-01,"Lee fatigue scale|Multidimensional Quality of Life Scale (MQOLS-CA)|General Sleep Disturbance Scale","http://ClinicalTrials.gov/show/NCT00825682",NA
"69125",69125,"NCT00864682","Preventing Propofol-Associated Injection Pain","Completed","Has Results","Pain","Drug: Saline|Drug: Lidocaine / propofol admixture|Drug: lidocaine pretreatment","Benaroya Research Institute","Both","Adult|Senior","Phase IV",156,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","06091|373","March 16, 2009","01/01/2008",2009-04-01,"June 15, 2009","01/06/2009","",2009-03-01,"Verbal Pain Score|Complete Alleviation of Injection Pain|Satisfaction With Anesthetic Technique","http://ClinicalTrials.gov/show/NCT00864682",NA
"69129",69129,"NCT00871182","Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Inhaled PT001|Drug: Inhaled Placebo|Drug: tiotropium","Pearl Therapeutics, Inc.","Both","Adult|Senior","Phase I|Phase II",33,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PT0010801","March 26, 2009","01/03/2009",2009-09-01,"October 5, 2010","01/10/2010","",2009-09-01,"Peak improvement in forced expiratory volume in one second (FEV1)|Time to onset of action (>10% improvement in FEV1 from baseline)|Time to peak FEV1|FEV1 area under the curve (AUC) from 0 to 24 hours|FEV1 AUC from 0 to 12 hours|Trough FEV1 at 12 and 24 hours|Peak Improvement in inspiratory capacity (IC)","http://ClinicalTrials.gov/show/NCT00871182",NA
"69138",69138,"NCT00890682","Study of Postoperative Analgesia in Bunionectomy","Completed","No Results Available","Bunion|Hallux Valgus","Drug: SKY0402|Drug: NaCl","Pacira Pharmaceuticals, Inc","Both","Adult|Senior","Phase III",193,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","SKY0402C317","April 28, 2009","01/04/2009",2009-11-01,"August 31, 2010","01/08/2010","",2009-11-01,"The area under the curve (AUC0-24) of the numeric rating scale (NRS) pain intensity scores through 24 hours for subjects receiving SKY0402 vs. placebo","http://ClinicalTrials.gov/show/NCT00890682",NA
"69140",69140,"NCT00891982","A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash","Completed","No Results Available","Acne Vulgaris","Drug: CTGel|Drug: Soap Free Cleanser and CTGel","Stiefel, a GSK Company","Both","Child|Adult","Phase III",61,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","W0265-306","April 29, 2009","01/04/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-06-01,"Local tolerability - Skin Dryness|Local Tolerability - Skin scaling|Local tolerability - Erythema (redness)|Subject Assessment of Burning/Stinging and Itching","http://ClinicalTrials.gov/show/NCT00891982",NA
"69171",69171,"NCT00945282","Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.","Completed","No Results Available","Infection, Human Immunodeficiency Virus|HIV-1 Infection","Drug: GSK2248761|Drug: Lopinavir/ritonavir|Drug: HAART|Drug: Placebo|Drug: GSK2248761","GlaxoSmithKline","Both","Adult","Phase II",8,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","113020|SGN113020","July 23, 2009","01/10/2009",2009-12-01,"November 2, 2010","01/11/2010","",2009-12-01,"Safety and tolerability parameters, including adverse event, clinical laboratory, electrocardiogram (EGC) and vital sign assesssments.|Change from baseline through Day 8 in plasma HIV-1 RNA.|GSK2248761 PK parameters following dose administration on Day 1 and Day 7.|Change from baseline in reverse transcriptase sequences of HIV-1 at Day 8.|Change from baseline CD4+ and CD8+ T-Lymphocyte cell count and percentages at Day 8.|GSK2248761 PK parameters on Day 2 through Day 7.|Day 1 and Day 7 PK data at different doses for the assessment of dose proportionality.","http://ClinicalTrials.gov/show/NCT00945282",NA
"69186",69186,"NCT00971282","Adjunctive Usage of a Moisturizing Lotion (Cetaphil?ó Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-Up of a Treatment by Topical Retinoid (Differin?ó Gel 0,1%) in Healthy Subjects of Chinese Origins","Completed","No Results Available","Healthy Skin","Drug: adapalen 0.1% and Cetaphil?ó","Galderma","Both","Adult|Senior","Phase IV",30,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","RD.03.SPR.29076","September 2, 2009","01/12/2008",2009-05-01,"September 2, 2009","01/09/2009","",2009-04-01,"Assessment of the local tolerability on the face : erythema, scaling, dryness, stinging/burning and pruritus,using a scale from none (0) to severe (3)","http://ClinicalTrials.gov/show/NCT00971282",NA
"69216",69216,"NCT01016782","Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea","Completed","No Results Available","Inflammatory Rosacea","Drug: 0444","Nycomed US Inc.","Both","Adult|Senior","Phase III",867,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","444","November 17, 2009","01/01/2008",2009-07-01,"November 18, 2009","01/11/2009","",2009-07-01,"Reduction in the number of papules and pustules from Baseline to End of Treatment|Reduction in the Investigator's Global Evaluation, Clear or Almost Clear","http://ClinicalTrials.gov/show/NCT01016782",NA
"69232",69232,"NCT01046682","Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults","Completed","No Results Available","HIV|Endothelial Dysfunction|Inflammation|Insulin Resistance","Drug: Salsalate","University Hospitals of Cleveland|Bristol-Myers Squibb","Both","Adult|Senior","Phase II",40,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","02/08/2002","January 11, 2010","01/01/2009",2009-07-01,"January 11, 2010","01/01/2010","Salsalate",2009-07-01,"Flow mediated dilation of the brachial artery measured by ultrasound|Insulin resistance, measured by fasting glucose and insulin","http://ClinicalTrials.gov/show/NCT01046682",NA
"69322",69322,"NCT01203982","Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT)","Completed","No Results Available","ST-segment Elevation Myocardial Infarction|Subclinical Carotid Atherosclerosis","Drug: Rosuvastatin|Drug: Rosuvastatin","Odense University Hospital","Both","Adult|Senior","Phase IV",87,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","VF-20060060","September 15, 2010","01/11/2007",2009-06-01,"September 16, 2010","01/09/2010","",2009-06-01,"change from baseline in mean CIMT|changes from baseline in max CIMT|change from baseline in mean common CIMT|change from baseline in max common CIMT|change from baseline in mean bulbus CIMT|change from baseline in max bulbus CIMT|change from baseline in lipid values|correlation between CIMT measurements and lipid values|correlation between CIMT measurements and plaque components evaluated by IVUS-VH","http://ClinicalTrials.gov/show/NCT01203982",NA
"69388",69388,"NCT00002583","Vinorelbine Plus Cisplatin or No Further Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Surgically Removed","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: vinorelbine ditartrate","NCIC Clinical Trials Group|National Cancer Institute (NCI)|Southwest Oncology Group|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B","Both","Adult|Senior","Phase III",450,"Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","BR10|CAN-NCIC-BR10|CLB-9795|E-JBR10|SWOG-JBR10|GW-565/040|NCI-V94-0492|CDR0000063698","November 1, 1999","01/07/1994",2009-12-01,"November 7, 2010","01/11/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00002583",NA
"69412",69412,"NCT00020683","COL-3 in Treating Patients With HIV-Related Kaposi's Sarcoma","Completed","No Results Available","Sarcoma","Drug: incyclinide","AIDS Malignancy Clinical Trials Consortium|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment","CDR0000068703|U01CA070019|AMC-027","July 11, 2001","01/04/2001",NA,"November 3, 2010","01/11/2010","",2009-11-01,"","http://ClinicalTrials.gov/show/NCT00020683",NA
"69475",69475,"NCT00107783","Long-Term Study of Nitisinone to Treat Alkaptonuria","Completed","Has Results","Alkaptonuria","Drug: Nitisinone (NTBC)","National Human Genome Research Institute (NHGRI)","Both","Adult|Senior","Phase II",40,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","050076|05-HG-0076","April 7, 2005","01/01/2005",2009-04-01,"December 20, 2010","01/12/2010","",2009-04-01,"Change in Total ROM Worse Hip.|Change in Schober's Test|Change in Functional Reach Assessment|Change in Timed Get up and go|Change in 6 Minute Walk Test (6MWT)","http://ClinicalTrials.gov/show/NCT00107783",NA
"69517",69517,"NCT00181883","Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar Disorder","Completed","No Results Available","Bipolar Disorder|Mania","Drug: quetiapine (Seroquel)","Massachusetts General Hospital","Both","Child","Phase IV",20,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-P-001509","September 13, 2005","01/02/2005",2009-04-01,"June 18, 2010","01/06/2010","",2009-04-01,"reductions in symptoms measured by|Young-Mania Rating Scale (Y-MRS)|Mania Symptom Checklist","http://ClinicalTrials.gov/show/NCT00181883",NA
"69527",69527,"NCT00201383","Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients","Completed","No Results Available","Oral Cavity|Squamous Cell Carcinoma","Drug: cisplatin","National Health Research Institutes, Taiwan|National Taiwan University Hospital|Changhua Christian Hospital|China Medical University Hospital|Buddhist Tzu Chi General Hospital|Mackay Memorial Hospital|Sun Yat-sen University|Chi Mei Medical Hospital|Kaohsiung Veterans General Hospital.","Both","Child|Adult|Senior","Phase III",161,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T2399","September 13, 2005","01/10/1999",2009-08-01,"September 13, 2005","01/01/2005","",2009-08-01,"RT versus RT plus CT in effect on local control and survival of patients of oral cavity cancer after curative operation.|the acute and chronic toxicity of RT versus RT plus CT in patients of oral cavity cancer after curative operation.","http://ClinicalTrials.gov/show/NCT00201383",NA
"69552",69552,"NCT00246883","Effect of Regular Exercise on Vascular Function and Cardiovascular Risk in a Sedentary Work Force","Completed","No Results Available","Vascular Formation","Procedure: Exercise","National Heart, Lung, and Blood Institute (NHLBI)","Both","Child|Adult|Senior","Phase II",120,"NIH","Interventional","Primary Purpose: Treatment","060018|06-H-0018","October 29, 2005","01/10/2005",2009-04-01,"April 16, 2009","01/04/2009","",2009-04-01,"Improvement in brachial artery dilator responsiveness to shear stress as a bioassay for endothelium-dependent nitric oxide bioavailability following 3 months participation in the Keep the Beat program as compared with baseline measuraements.","http://ClinicalTrials.gov/show/NCT00246883",NA
"69576",69576,"NCT00287183","6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria","Completed","No Results Available","Diabetic Nephropathy","Drug: PF-04494700 (TTP488)|Other: Placebo","Pfizer","Both","Adult|Senior","Phase II",110,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","B0341001|TTP488-202","January 20, 2006","01/02/2006",2009-08-01,"September 30, 2009","01/09/2009","",2009-08-01,"Primary endpoint of efficacy will be assessed by comparing the treatment groups based on the change in urinary albumin-creatinine ratio (UACR)|To evaluate treatment on estimated GFR and serum creatinine|To evaluate the effects of TTP488 on other relevant biomarkers|To evaluate the safety of TTP488|To evaluate the PK profile of oral TTP488.|To evaluate the effect of treatment with TTP488 on UACR","http://ClinicalTrials.gov/show/NCT00287183",NA
"69577",69577,"NCT00215683","An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer","Completed","Has Results","Prostate Cancer","Drug: Degarelix","Ferring Pharmaceuticals","Male","Adult|Senior","Phase II|Phase III",137,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FE200486 CS12A","September 20, 2005","01/02/2005",2009-11-01,"November 12, 2010","01/11/2010","",2009-10-01,"Participants With Markedly Abnormal Change in Vital Signs and Body Weight|Liver Function Tests","http://ClinicalTrials.gov/show/NCT00215683",NA
"69652",69652,"NCT00402883","Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: Bevacizumab|Drug: Pemetrexed|Procedure: Radiation therapy","Sarah Cannon Research Institute|Genentech|Eli Lilly and Company","Both","Adult|Senior","Phase II",50,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI LUN 134|AVF3793s|H3E-US-1019","November 21, 2006","01/11/2006",2009-01-01,"November 1, 2010","01/11/2010","",2009-01-01,"Time to progression|To evaluate the objective response rates|Overall survival","http://ClinicalTrials.gov/show/NCT00402883",NA
"69707",69707,"NCT00488683","B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants","Completed","No Results Available","Meningococcal Disease","Biological: Meningococcal ACWY Conjugate Vaccine","Novartis|Novartis Vaccines","Both","Child","Phase II",216,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","V59P16|2006-003476-35","June 19, 2007","01/05/2007",2009-12-01,"April 16, 2010","01/04/2010","",2009-05-01,"Whether the frequency of meningococcal serogroup A, C, W-135 and Y specific memory B Cells predicts the specific serum bactericidal activity using human complement of (respectively) serogroup A, C, W-135 and Y at 12 months of age|The safety and tolerability of Novartis MenACWY vaccine concomitantly with a combined diphtheria, tetanus toxoid, acellular pertussis, Haemophilus influenzae type B and inactivated polio vaccine and a heptavalent PCV.|Whether the frequency of meningococcal serogroup A, C, W-135 and Y specific memory B Cells predicts the concentration of (respectively) serogroup A, C, W-135 and Y specific IgG and memory B-cells at 12 months of age|Whether the frequency of meningococcal serogroup A,C,W-135 and Y specific memory B Cells predicts serogroup A,C,W-135 and Y specific memory B-cells and IgG concentrations and hSBA titers 1 month after a booster of MenACWY administered at 12 months of age|Whether the frequency of meningococcal serogroup A,C,W-135,Y specific B Cells predicts the rise from prebooster levels in serogroup A,C,W-135,Y specific IgG and B-cell conc. and hSBA titers 1 month after a booster of MenACWY admin. at 12 months of age|Whether the frequency of meningococcal serogroup A,C,W135,Y specific B Cells predicts the conc. of serogroup A,C,W135,Y specific plasma cells and B-cells and specific IgG and hSBA titers in the week after a booster of MenACWY admin. at 12months of age|Whether the frequency of CRM197 specific memory B Cells predicts the concentration of CRM197 specific IgG and memory B Cells at 12 months of age and one month following a booster dose of MenACWY administered at 12 months of age","http://ClinicalTrials.gov/show/NCT00488683",NA
"69721",69721,"NCT00512083","Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia","Completed","No Results Available","Leukemia, Myeloid","Drug: AS1411","Antisoma Research","Both","Adult|Senior","Phase II",70,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AS1411-C-201","August 6, 2007","01/07/2007",NA,"September 24, 2009","01/09/2009","",2009-04-01,"The prorportion of patients achieving a completel response (CR) after the first cycle of treatment in each treatment group","http://ClinicalTrials.gov/show/NCT00512083",NA
"69782",69782,"NCT00612183","Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma","Completed","No Results Available","Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma","Drug: bendamustine hydrochloride","SymBio Pharmaceuticals","Both","Adult|Senior","Phase II",56,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007002","January 28, 2008","01/12/2007",2009-09-01,"July 21, 2010","01/05/2010","",2009-09-01,"Overall response rate based on [Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas]|CR rate of overall results based on [Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas]","http://ClinicalTrials.gov/show/NCT00612183",NA
"69793",69793,"NCT00634283","Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects","Completed","No Results Available","Depression","Drug: venlafaxine","University of California, Los Angeles","Both","Adult|Senior","Phase IV",7,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver)","07-10-051|07-10-051","March 6, 2008","01/02/2008",2009-02-01,"August 6, 2009","01/08/2009","",2009-02-01,"Whether short-term antidepressant exposure results in long-term changes in resting brain function, as measured using QEEG cordance.","http://ClinicalTrials.gov/show/NCT00634283",NA
"69801",69801,"NCT00643383","A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain","Completed","No Results Available","Acute Low Back Pain","Drug: Combination drug (Acetaminophen + Tramadol)|Drug: Placebo","Labopharm Inc.","Both","Adult|Senior","Phase III",250,"Industry","Interventional","Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","06CCL3-001","March 20, 2008","01/03/2008",2009-02-01,"January 12, 2010","01/01/2010","",2009-01-01,"Pain Intensity change from Baseline|Overall satisfaction with the study medication|Safety evaluation","http://ClinicalTrials.gov/show/NCT00643383",NA
"69840",69840,"NCT00691483","Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date","Completed","Has Results","Smoking Cessation","Drug: placebo|Drug: varenicline","Pfizer","Both","Adult|Senior","Phase IV",659,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","A3051095","June 3, 2008","01/09/2008",2009-12-01,"November 19, 2010","01/11/2010","",2009-09-01,"Percentage of Participants With 4-week Continuous Abstinence (CA)|Percentage of Participants With Continuous Abstinence (CA) From Smoking Weeks 9-24|Percentage of Participants With Long Term Quit Through Week 24|Percentage of Participants With 7-day Point Prevalence of Nonsmoking (Smoking Cessation)|Percentage of Participants With 4-week Point Prevalence of Nonsmoking","http://ClinicalTrials.gov/show/NCT00691483",NA
"69861",69861,"NCT00743483","Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency","Completed","No Results Available","Cystic Fibrosis|Exocrine Pancreatic Insufficiency","Drug: Bucelipase alfa (INN)","Biovitrum","Both","Adult|Senior","Phase II",15,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BVT.BSSL-002|EudraCT Number: 2007-004063-21","August 26, 2008","01/08/2008",2009-06-01,"August 4, 2009","01/08/2009","",2009-06-01,"Coefficient of fat absorption measured in stool collected for a 72-hour period during the final 3 days of each period","http://ClinicalTrials.gov/show/NCT00743483",NA
"69871",69871,"NCT00742183","Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex?ó Ag Versus Silvadene?ó","Completed","Has Results","Second Degree Burn","Device: Mepilex|Device: Silvadene","Molnlycke Health Care AB","Both","Child|Adult|Senior","Phase IV",100,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","PUMA 415","August 19, 2008","01/08/2008",2009-11-01,"October 11, 2010","01/10/2010","",2009-10-01,"Compare the Costs of Using the Interventions (Direct and Indirect)","http://ClinicalTrials.gov/show/NCT00742183",NA
"69885",69885,"NCT00785083","A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma","Completed","No Results Available","Asthma","Drug: FTY720|Drug: Placebo","Novartis","Both","Adult","Phase II",36,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CFTY720D2102","November 4, 2008","01/09/2008",NA,"May 8, 2009","01/05/2009","",2009-02-01,"Change from baseline in Pulmonary function tests (particularly Forced Expiratory Volume at 1 sec (FEV1) at Day 10|Safety of FTY720|Use of short acting beta agonists during treatment compared to pre-treatment|Pharmacokinetics of FTY720 and FTY720-P","http://ClinicalTrials.gov/show/NCT00785083",NA
"69922",69922,"NCT00818883","Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Subjects With Moderate to Severe Hypertension","Completed","No Results Available","Essential Hypertension","Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and hydrochlorothiazide","Takeda Global Research & Development Center, Inc.","Both","Adult|Senior","Phase III",609,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-491CLD_306|U1111-1112-7119","January 7, 2009","01/02/2009",2009-11-01,"July 15, 2010","01/07/2010","",2009-11-01,"Change from Baseline in trough, sitting, Clinic Systolic Blood Pressure|Change from Baseline in trough, sitting, Clinic Diastolic Blood Pressure|Change from Baseline in mean trough Systolic Blood Pressure (22 to 24 hours after dosing) per ambulatory blood pressure monitoring.|Change from Baseline in mean trough Diastolic Blood Pressure (22 to 24 hours after dosing) per ambulatory blood pressure monitoring.|Change from Baseline in 24-hour mean Systolic Blood Pressure per ambulatory blood pressure monitoring.|Change from Baseline in 24-hour mean Diastolic Blood Pressure per ambulatory blood pressure monitoring.|Change from Baseline in the mean daytime (6 AM to 10 PM) Systolic Blood Pressure per ambulatory blood pressure monitoring.|Change from Baseline in the mean daytime (6 AM to 10 PM) Diastolic Blood Pressure per ambulatory blood pressure monitoring.|Change from baseline in the mean nighttime (12 AM to 6 AM) Systolic Blood Pressure per ambulatory blood pressure monitoring.|Change from baseline in the mean nighttime (12 AM to 6 AM) Diastolic Blood Pressure per ambulatory blood pressure monitoring.|Change from baseline in the mean Systolic Blood Pressure at 0 to 12 hours after dosing per ambulatory blood pressure monitoring|Change from baseline in the mean Diastolic Blood Pressure at 0 to 12 hours after dosing per ambulatory blood pressure monitoring.|Proportion of subjects who reached their trough, sitting, clinic Systolic and Diastolic blood pressure targets, defined as <140/90 mm Hg without diabetes or chronic kidney disease or <130/80 mm Hg with diabetes or chronic kidney disease|Proportion of subjects who reached their trough, sitting, clinic Systolic blood pressure targets, defined as <140 mm Hg for subjects without diabetes or chronic kidney disease or <130 mm Hg for subjects with diabetes or chronic kidney disease|Proportion of subjects who reached their trough, sitting, clinic Diastolic blood pressure targets, defined as <90 mm Hg for subjects without diabetes or chronic kidney disease or <80 mm Hg for subjects with diabetes or chronic kidney disease","http://ClinicalTrials.gov/show/NCT00818883",NA
"69950",69950,"NCT00890383","Colloids in Severe Trauma","Completed","No Results Available","Abdominal Hypertension|Abdominal Compartment Syndrome|Severe Trauma","Drug: tetrastarch (Voluven)","University of the Philippines|Fresenius Kabi","Both","Adult","Phase IV",50,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","GCS Sur 2007-030","April 28, 2009","01/05/2009",2009-11-01,"November 23, 2009","01/11/2009","CIST",2009-11-01,"Intraabdominal hypertension|abdominal compartment syndrome","http://ClinicalTrials.gov/show/NCT00890383",NA
"69957",69957,"NCT00891683","Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy","Completed","No Results Available","Diabetic Peripheral Neuropathy|Chronic Pain","Drug: AEG33773 oral dosing","Aegera Therapeutics","Both","Adult|Senior","Phase II",128,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AEG33773-201","April 30, 2009","01/03/2009",2010-02-01,"May 28, 2010","01/05/2010","",2009-12-01,"To evaluate the potential efficacy of AEG33773 in reducing chronic pain due to DPN|To evaluate a range of AEG33773 doses that provide efficacy|To determine a minimally effective dose of AEG33773|To determine a maximally tolerated dose of AEG33773|To evaluate the safety and tolerability of AEG33773|To explore AEG33773-dependent pharmacodynamic (PD) effects in blood of patients","http://ClinicalTrials.gov/show/NCT00891683",NA
"70006",70006,"NCT00978783","Speech Effects of a Speaking Valve Versus External Positive End-expiratory Pressure (PEEP) in Tracheostomized Ventilator-Dependent Neuromuscular Patients","Completed","No Results Available","Tracheostomy|Mechanical Ventilation","Device: Passy Muir Valve|Device: Positive end expiratory pressure","University of Versailles","Both","Adult|Senior","Phase II|Phase III",10,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","PMV vs PEEP","September 8, 2009","01/12/2008",2009-04-01,"September 16, 2009","01/09/2009","",2009-04-01,"text reading duration|respiratory comfort|speech comfort|Dragon NaturallySpeaking 10?ó system ability to recognise the speech|Sustained [a] duration|perceptual score and intelligibility score determined by 2 blinded speech therapists","http://ClinicalTrials.gov/show/NCT00978783",NA
"70020",70020,"NCT01003483","Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients","Completed","No Results Available","Obesity","Drug: orlistat","Yazd Research & Clinical Center for Infertility|Yazd Medical University","Female","Child|Adult","Phase II",80,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","616","October 27, 2009","01/11/2008",2009-10-01,"October 27, 2009","01/10/2009","",2009-08-01,"Body Mass Index (BMI)|Ovulatory","http://ClinicalTrials.gov/show/NCT01003483",NA
"70100",70100,"NCT01137383","Pegaferon and Ribavirin for Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: Pegaferon (pegylated interferon alpha 2a) + ribavirin","Tehran University of Medical Sciences|Pars No Tarkib Co","Both","Child|Adult","Phase III",108,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DDRC.86.90","June 3, 2010","01/12/2007",2010-02-01,"June 28, 2010","01/06/2010","",2009-12-01,"Sustained viral response|Adverse drug events","http://ClinicalTrials.gov/show/NCT01137383",NA
"70324",70324,"NCT00158184","Prescription Opioid Effects in Abusers Versus Non-Abusers","Completed","No Results Available","Opioid-Related Disorders|Substance-Related Disorders","Drug: oxycodone","National Institute on Drug Abuse (NIDA)","Both","Adult","Phase II",96,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Basic Science","NIDA-16759-1|R01 DA16759-01|DPMC","September 8, 2005","01/06/2004",2009-06-01,"July 15, 2009","01/07/2009","",2009-06-01,"Progressive ratio breakpoint value","http://ClinicalTrials.gov/show/NCT00158184",NA
"70399",70399,"NCT00273884","Amonafide in Combination With Cytarabine in Secondary AML","Completed","No Results Available","Acute Myeloid Leukemia","Drug: Amonafide L-Malate|Drug: Cytarabine","Xanthus Pharmaceuticals, Inc.","Both","Adult|Senior","Phase II",80,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0001A3-200-GL","January 5, 2006","01/08/2005",2009-04-01,"February 16, 2007","01/02/2007","",2009-04-01,"- To determine the rate of complete remission with or without complete hematopoietic recovery (CR + CRi).|Determine the median duration of complete remission with or without complete hematopoietic recovery (CR or CRi)|Determine the proportion of subjects ","http://ClinicalTrials.gov/show/NCT00273884",NA
"70413",70413,"NCT00190684","Long-Term, Open Label Atomoxetine Study","Completed","Has Results","Attention Deficit Hyperactivity Disorder","Drug: atomoxetine","Eli Lilly and Company","Both","Child|Adult","Phase III",1553,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4331|B4Z-MC-LYAI","September 12, 2005","01/08/2000",2009-10-01,"December 15, 2010","01/12/2010","",2009-10-01,"Categorical Changes in Vital Signs (Blood Pressure [BP], Pulse, Weight, Temperature) During the Study|Change From Baseline to 5 Year Endpoint in BP|Change From Baseline to 5 Year Endpoint in Pulse|Change From Baseline to 5 Year Endpoint in Body Weight|Change From Baseline to 5 Year Endpoint in Height|Change From Baseline to 5 Year Endpoint in Weight, Height, and Body Mass Index (BMI) Percentile Stratified by Baseline Quartile|Change From Baseline to 5 Year Endpoint in Electrocardiogram (ECG)|Change From Baseline to 5 Year Endpoint in Heart Rate|Number of Patients Meeting Committee for Proprietary Medicinal Products (CPMP) Categorical QTc Interval Criteria Part I (Numerical Increase)|Number of Patients Meeting CPMP Categorical QTc Interval Criteria Part II (Interpretation at Baseline and Endpoint)|Number of Participants With Abnormal Laboratory Analytes During the Study|Number of Participants in Each Tanner Stage (Pubic Hair) by Age Group|Change From Baseline to 5 Year Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score and Subscale Scores|Change From Baseline to 5 Year Endpoint in Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity (CGI-ADHD-S) Score|Change From Baseline to 5 Year Endpoint in Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S) Subscale Scores|Change From Baseline to 5 Year Endpoint in the Stroop Word Color Test","http://ClinicalTrials.gov/show/NCT00190684",NA
"70428",70428,"NCT00311584","Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: irinotecan hydrochloride|Drug: temozolomide","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",50,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000465487|COG-ANBL0421","April 5, 2006","01/04/2006",NA,"January 15, 2011","01/11/2010","",2009-04-01,"Overall response (complete and partial response)","http://ClinicalTrials.gov/show/NCT00311584",NA
"70440",70440,"NCT00338884","Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer","Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sunitinib malate","Pfizer","Both","Adult|Senior","Phase II",120,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181110","June 16, 2006","01/09/2006",2009-04-01,"May 21, 2009","01/05/2009","",2009-04-01,"To evaluate the anti-tumor activity of sunitinib malate in first-line metastatic RCC when administered in a continuous treatment regimen|To evaluate patient reported outcomes (PROs)|To explore the correlations of potential biomarkers with clinical outcomes|To evaluate the safety and tolerability of sunitinib malate administered in a continuous treatment regimen|To evaluate time-to-tumor-progression (TTP), progression-free survival (PFS), duration of response, and the proportion of subjects alive one year after starting treatment.|To evaluate sunitinib malate and SU012662 trough concentrations (Ctrough ) and to correlate these plasma concentrations with efficacy and safety parameters","http://ClinicalTrials.gov/show/NCT00338884",NA
"70444",70444,"NCT00336284","TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up","Completed","Has Results","Patient Indicated for an ICD","Other: Home Monitoring|Other: In-Office Conventional Follow-up","Biotronik, Inc.","Both","Adult|Senior","Phase IV",1450,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20052069","June 9, 2006","01/11/2005",2009-06-01,"July 28, 2010","01/07/2010","TRUST",2009-06-01,"Home Monitoring Effectiveness|Percent of Participants Experiencing Death, Incidence of Stroke, or Event Requiring Surgical Intervention.|Early Detection of Cardiac Events|Patient Initiated Follow-up","http://ClinicalTrials.gov/show/NCT00336284",NA
"70473",70473,"NCT00392184","Partial Breast Irradiation With Multi-Catheter Brachytherapy for pT1-2pN0 Breast Cancer After Breast Conserving Surgery","Completed","No Results Available","Breast Cancer","Procedure: Accelerated partial breast irradiation","University of Erlangen-N??rnberg Medical School","Female","Adult|Senior","Phase II",NA,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","German-Austrian APBI Trial","October 24, 2006","01/11/2000",2010-10-01,"February 17, 2009","01/02/2009","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00392184",NA
"70490",70490,"NCT00410384","A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)","Completed","No Results Available","Systemic Lupus Erythematosus","Drug: belimumab|Drug: belimumab|Drug: Placebo","Human Genome Sciences|GlaxoSmithKline","Both","Adult|Senior","Phase III",819,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","HGS1006-C1056|BLISS-76","December 8, 2006","01/12/2006",2010-10-01,"October 21, 2010","01/10/2010","",2009-09-01,"At Wk 52 the % of subjects with great than or equal to 4 point reduction from baseline in SELENA SLEDAI score & no worsening in PGA & no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline at the time of assessment.|At Wk 76, % of subjects with great than or equal to 4 point reduction from baseline in SELENA SLEDAI score & no worsening in (PGA) and no new BILAG organ domain score or 2 new BILAG organ domain scores compared with baseline at the time of assessment.|Percent of subjects with great than or equal to 4 point reduction from baseline in SELENA SLEDAI score at Wk 52.|Mean change in PGA at Wk 24.|Mean change in SF-36 Health Survey physical component summary score (PCS) at Wk 24.|Percent of subjects whose average prednisone dose has been reduced by greater than or equal to 25% from baseline to less than or equal to 7.5 mg/day during Weeks 40 through 52","http://ClinicalTrials.gov/show/NCT00410384",NA
"70492",70492,"NCT00420784","A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: Telaprevir|Drug: Ribavirin|Drug: Peg-interferon Alfa-2a","Vertex Pharmaceuticals Incorporated","Both","Adult|Senior","Phase II",440,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VX06-950-106","January 8, 2007","01/01/2007",2009-04-01,"May 8, 2009","01/05/2009","",2009-04-01,"Undetectable HCV RNA|Undetectable HCV RNA|Undetectable HCV RNA|Adverse events and clinical laboratory assessments, including ALT and other liver function tests.|Genotypic and phenotypic analyses of the NS3??Ñ4A HCV region.|Pharmacokinetic assessments of telaprevir, Peg-IFN-a-2a, and RBV.","http://ClinicalTrials.gov/show/NCT00420784",NA
"70500",70500,"NCT00435084","A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL","Completed","No Results Available","B-Cell Chronic Lymphocytic Leukemia","Drug: APO866","TopoTarget A/S","Both","Adult|Senior","Phase I|Phase II",10,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AP3005|EudraCT number 2006-002850-31","February 13, 2007","01/12/2006",2009-01-01,"March 12, 2009","01/06/2007","",2009-01-01,"Safety and tolerability of APO866 in patients with refractory B-CLL not amenable to allogeneic HSCT|To determine the effect on the number of circulating leukemic after treatment as compared to baseline|To determine the effect on the number of CD38+ after treatment as compared to baseline|Correlative analysis on in vivo and in vitro sensitivity of leukemic cells, CD38 expression of leukemic cells and clinical outcome, immunophenotype and clinical outcome","http://ClinicalTrials.gov/show/NCT00435084",NA
"70569",70569,"NCT00545584","Addition Of Januvia Improves Glycemic Control In Patient In Adequately Controlled By Metformin","Completed","No Results Available","Diabetes Mellitus, Non-Insulin-Dependent","Drug: sitagliptin phosphate|Behavioral: Comparator: Diet|Behavioral: Comparator: Physical Activity","Merck","Both","Adult|Senior","Phase III",1435,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2007_023|MK0431-078","October 16, 2007","01/04/2007",2009-11-01,"November 30, 2009","01/11/2009","",2009-11-01,"Efficacy measurements will include, hba1c,fasting plasma glucose (FPG), and body weight","http://ClinicalTrials.gov/show/NCT00545584",NA
"70580",70580,"NCT00562484","A Study of the Efficacy, Safety and Tolerability of CSL Limited's Influenza Virus Vaccine Administered Intramuscularly in Healthy Adults","Completed","No Results Available","Influenza","Biological: CSL Limited Influenza Vaccine|Biological: Placebo","CSL Limited","Both","Adult","Phase IV",7500,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CSLCT-USF-06-28","November 20, 2007","01/03/2008",2010-01-01,"May 23, 2010","01/05/2010","",2009-11-01,"Incidence of Laboratory Confirmed Influenza A/B infection|Incidence of Influenza Like Illness, Immune response, Safety","http://ClinicalTrials.gov/show/NCT00562484",NA
"70581",70581,"NCT00492284","Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)","Completed","Has Results","Choroidal Neovascularization|Macular Degeneration","Drug: verteporfin|Drug: verteporfin|Drug: ranibizumab|Drug: dexamethasone","QLT Inc","Both","Adult|Senior","Phase II",162,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","BPD OCR 022","June 25, 2007","01/07/2007",2010-05-01,"June 22, 2010","01/06/2010","RADICAL",2009-05-01,"Mean Number of Retreatments (Day 0 Excluded)|Mean Change From Baseline in Study Eye Best-corrected VA Score (ETDRS Chart)|Percentage of Subjects With >=15 Letters of Visual Acuity Gained From Baseline|Percentage of Subjects With >=0 Letter Gain of Visual Acuity From Baseline|Percentage of Subjects With >=15 Letters of Visual Acuity Lost From Baseline|Mean Change From Baseline in Central Retinal Thickness|Mean Change From Baseline in Lesion Size","http://ClinicalTrials.gov/show/NCT00492284",NA
"70584",70584,"NCT00566384","Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido","Completed","No Results Available","Decreased Libido","Drug: Dehydroepiandrosterone, BAY86-5314|Drug: Placebo","Bayer","Female","Adult","Phase II",100,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","91692|310741|EudraCT No 2006-004397-27","November 29, 2007","01/11/2007",2009-04-01,"April 13, 2010","01/04/2010","",2009-03-01,"FSDS questionnaire (sexual desire and arousal component scores)|Change from baseline period to cycle 6 in the number of satisfactory sexual events|FSFI questionnaire (absolute values and change from baseline) - All domains|FSDS-R questionnaire results|FSEP questionnaire results|PGWBI questionnaire results|Serum hormone levels (SHBG, T, DHEA, DHEA-S)|Vaginal pH","http://ClinicalTrials.gov/show/NCT00566384",NA
"70602",70602,"NCT00600184","Clinic-Based AMES Treatment of Stroke","Completed","No Results Available","Stroke|Cerebrovascular Accident","Device: The AMES device","AMES Technology|Oregon Health and Science University","Both","Adult|Senior","Phase I|Phase II",2,"Industry|Other","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT002|IRB00004005","December 31, 2007","01/01/2008",2009-11-01,"December 15, 2009","01/12/2009","AMES",2009-11-01,"Fugl-Meyer Assessment of the Lower Extremity|Gait Assessment|Stroke Impact Scale|Spasticity (Modified Ashworth) Scale|Biodex Isokinetic Strength Measurements|Strength Test|Joint Position Test|Passive Motion Test","http://ClinicalTrials.gov/show/NCT00600184",NA
"70605",70605,"NCT00597584","Hematide?ºÑ Injection for Anemia in Chronic Hemodialysis (HD) Patients","Completed","No Results Available","Chronic Renal Failure|Chronic Kidney Disease|Anemia","Drug: Hematide?ºÑ|Drug: Epoetin","Affymax","Both","Adult|Senior","Phase III",823,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AFX01-14","January 10, 2008","01/10/2007",2010-01-01,"October 7, 2010","01/10/2010","EMERALD 2",2009-07-01,"Mean change in Hgb between baseline and the Evaluation Period|Proportion of patients who received red blood cell (RBC) transfusions during the Titration and Evaluation Periods.|Proportion of patients whose mean Hgb level during the Evaluation Period is within the target range of 10.0 - 12.0 g/dL.","http://ClinicalTrials.gov/show/NCT00597584",NA
"70606",70606,"NCT00601484","An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis","Completed","No Results Available","Cystitis, Interstitial","Drug: PF-04383119|Drug: Placebo","Pfizer","Both","Adult|Senior","Phase II",65,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A4091010","January 15, 2008","01/03/2008",2009-04-01,"January 4, 2011","01/01/2011","",2009-04-01,"Change in average daily pain|Change in O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) score|Change in Pelvic Pain and Urgency/Frequency (PUF) symptom score|Change in O'Leary-Sant Interstitial Cystitis Problem Index (ICPI) score|Global response assessment|Patient-reported treatment impact assessment|Treatment failures|Biomarkers|Safety endpoints|Pharmacokinetic measures|Change in average daily pain|Change in micturition variables including frequency, nocturnal frequency, incontinence episode frequency, mean volume voided per micturition, mean interstitial cystitis pain severity, urinary urgency episodes, average sleep disturbance score,....","http://ClinicalTrials.gov/show/NCT00601484",NA
"70647",70647,"NCT00663884","Glufast On Insulin Glargine Trial in Type 2 DM","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Mitiglinide|Drug: Voglibose","ChoongWae Pharma Corporation","Both","Adult|Senior","Phase IV",167,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CWP-KAD-402","April 18, 2008","01/02/2008",2009-09-01,"October 18, 2010","01/10/2010","GLORIA",2009-07-01,"Change of HbA1c before and after administration of test drug|Change of self-monitoring of blood glucose before and after administration of test drug|Change of insulin dose before and after administration of test drug|Achievement rate of HbA1c target level (rate of the patients whose HbA1c were improved under 6.5% after administration)|Change of CRP, 8-OHdG and Nitrotyrosine before and after administration of test drug","http://ClinicalTrials.gov/show/NCT00663884",NA
"70664",70664,"NCT00696384","A Safety and Tolerability Study of Azilsartan Medoxomil in Subjects With Essential Hypertension","Completed","No Results Available","Essential Hypertension","Drug: Azilsartan medoxomil|Drug: Placebo","Takeda Global Research & Development Center, Inc.","Both","Adult|Senior","Phase III",418,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01-06-TL-491-016|U1111-1113-9088","June 10, 2008","01/06/2007",2009-04-01,"July 14, 2010","01/07/2010","",2009-04-01,"Change from Baseline in sitting clinic diastolic blood pressure.|Change from Baseline in sitting clinic systolic blood pressure.","http://ClinicalTrials.gov/show/NCT00696384",NA
"70673",70673,"NCT00709384","Prevention of Atrial Tachycardia After a Right Atriotomy II","Completed","No Results Available","Atrial Flutter","Procedure: Prophylactic surgical lesion","Skejby Hospital|Danish Heart Foundation","Both","Adult|Senior","Phase II",14,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20030198B","July 1, 2008","01/01/2006",2009-03-01,"September 18, 2009","01/09/2009","",2009-03-01,"completeness of the lines of block|safety","http://ClinicalTrials.gov/show/NCT00709384",NA
"70693",70693,"NCT00740584","Retention and Duration of Activity of SPL7013 (VivaGel?ó) After Vaginal Dosing.","Completed","No Results Available","HIV Infections|HSV-2 Genital Herpes","Drug: 3% SPL7013 Gel (VivaGel)","Starpharma Pty Ltd|National Institute of Allergy and Infectious Diseases (NIAID)","Female","Adult","Phase I|Phase II",12,"Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SPL7013-003|NIH contract HHSN266200500042C|DAIDS ES number 10730","August 21, 2008","01/08/2008",2009-03-01,"June 4, 2009","01/06/2009","",2009-03-01,"HIV and HSV-2 Antiviral activity and amount of SPL7013|Incidence of Adverse Experiences","http://ClinicalTrials.gov/show/NCT00740584",NA
"70700",70700,"NCT00756184","Value of an Intervention to Enhance Adherence in Glaucoma Patients","Completed","No Results Available","Glaucoma","Device: TDA monitor for adherence, travoprost therapy|Device: TDA and travoprost monotherapy","Aristotle University Of Thessaloniki|Alcon Research","Both","Adult|Senior","Phase IV",107,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","A5133","September 19, 2008","01/09/2007",2009-09-01,"September 16, 2009","01/09/2009","",2009-07-01,"Comparison between IOP control in the adherence intervention group compared to the control group(attention placebo) Rate of adherence between the two groups measured by the TDA","http://ClinicalTrials.gov/show/NCT00756184",NA
"70704",70704,"NCT00658684","Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.","Completed","Has Results","Overactive Bladder","Drug: fesoterodine fumarate","Pfizer","Both","Adult|Senior","Phase III",153,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A0221006|A0221006","April 9, 2008","01/02/2008",2009-08-01,"October 5, 2010","01/10/2010","",2009-08-01,"Safety Measurement Based on Adverse Events (AEs), Vital Signs, Clinical Laboratory Test, 12-lead ECG and Residual Urine Volume|Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4, 8, 28 and 52|Change From Baseline in Mean Number of Micturitions at Week 4, 8, 28 and 52|Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 4, 8, 28 and 52|Change From Baseline in Mean Incontinence Episodes Per 24 Hours at Week 4, 8, 28 and 52|Change From Baseline in Number of Nighttime Micturitions Per 24 Hours at Week 4, 8, 28 and 52|Change From Baseline in Mean Voided Volume Per Micturition at Week 4, 8, 28 and 52|Change From Baseline in Score of King's Health Questionnaire (KHQ) at Week 28 and 52|Change From Baseline in Score of Overactive Bladder Questionnaire (OAB-q) at Week 28 and 52|The Number of Subjects Shifted in Patient Perception of Bladder Condition (PPBC) Responses From Baseilne to Week 28 and 52 Assessment and Its Percentage|Change From Baseline in Grade of PPBC at Week 28 and 52","http://ClinicalTrials.gov/show/NCT00658684",NA
"70728",70728,"NCT00801684","A Study of TrIP Administered to Subjects With COPD","Completed","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Placebo|Drug: TrIP-B|Drug: TrIP-C|Drug: TrIP-D|Drug: TrIP-E","Alkermes","Both","Adult|Senior","Phase II",24,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALK27-001","December 2, 2008","01/02/2009",2009-07-01,"August 5, 2009","01/08/2009","",2009-04-01,"Spirometry parameters, including peak FEV1, FEV1/FVC ratio, time to onset of response, and rescue medication use|Blood pressure and heart rate measurements|Maximum plasma concentration of TrIP|Area under the plasma concentration curve (AUC)","http://ClinicalTrials.gov/show/NCT00801684",NA
"70757",70757,"NCT00852384","Non Invasive Pressure Support Ventilation (NIPPV) Versus Recruitment Maneuver (RM) and Preoxygenation","Completed","No Results Available","Obesity","Procedure: NIPPV and IRM","University Hospital, Clermont-Ferrand","Both","Adult|Senior","Phase IV",60,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)","CHU-0046","February 26, 2009","01/02/2009",2009-08-01,"August 27, 2009","01/08/2009","",2009-08-01,"Oxygenation (PaO2) measured 5min after the onset of mechanical ventilation|- FRC after tracheal intubation and after 5 min of mechanical ventilation","http://ClinicalTrials.gov/show/NCT00852384",NA
"70770",70770,"NCT00848484","Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)","Completed","Has Results","Schizophrenia","Drug: MK5757|Drug: Comparator: Placebo","Merck","Male","Adult","Phase II",54,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MK-5757-005|2007_603","February 19, 2009","01/10/2008",2009-06-01,"November 17, 2010","01/11/2010","",2009-06-01,"Mean Change From Baseline in the Composite Score From the Brief Assessment of Cognition in Schizophrenia (BACS) Battery After 2 Weeks of Treatment|Mean Change From Baseline After 2 Weeks of Treatment in the CogState Composite Score|Mean Change From Baseline After 2 Weeks of Treatment in the Executive Functioning Composite Score|Mean Change From Baseline After 2 Weeks of Treatment in the Episodic Memory Composite Score|Mean Change From Baseline After 2 Weeks of Treatment in the Working Memory Composite Score|Mean Change From Baseline After 2 Weeks of Treatment in the Attention/Processing Speed Composite Score","http://ClinicalTrials.gov/show/NCT00848484",NA
"70783",70783,"NCT00887484","A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne","Completed","No Results Available","Acne Vulgaris","Drug: BENZOYL PEROXIDE/ CLINDAMYCIN|Drug: BENZOYL PEROXIDE/ ADAPALENE","Stiefel, a GSK Company","Both","Adult|Senior","Phase IV",50,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","C0000-401","April 23, 2009","01/02/2009",2009-07-01,"December 22, 2009","01/12/2009","",2009-06-01,"Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)|Efficacy parameters ISGA, lesion counts, and Subject Global Change Assessment at each visit will be assessed, quality of life (SKINDEX-29) and product acceptability","http://ClinicalTrials.gov/show/NCT00887484",NA
"70805",70805,"NCT00932984","Dermacyd Silver Floral (Lactic Acid) - Photo Evaluation","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Both","Adult","Phase III",27,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LACAC_L_04840","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"Measure of the photo irritation test and the photosensitivity by using UVA irradiation and evaluation according International Contact Dermatitis Research Group (ICDRG) scale. Evaluation of the sensibility according to the skin type.","http://ClinicalTrials.gov/show/NCT00932984",NA
"70972",70972,"NCT01205984","Systemic Methylprednisolone in Chronic Rhinosinusitis","Completed","No Results Available","Chronic Rhinosinusitis|Children","Drug: methylprednisolone","Ondokuz May??s University","Both","Child","Phase IV",48,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRS-0655-IF","September 20, 2010","01/07/2007",2010-04-01,"September 20, 2010","01/09/2010","",2009-09-01,"Mean change in total symptom score and coronal CT score after treatment|mean changes in individual symptom scores after treatment|relapse rate|tolerability of oral methylprednisolone tablet","http://ClinicalTrials.gov/show/NCT01205984",NA
"71042",71042,"NCT00003685","Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer","Completed","No Results Available","Fatigue|Lung Cancer|Nausea and Vomiting|Pain|Pulmonary Complications|Quality of Life","Procedure: fatigue assessment and management|Procedure: nausea and vomiting therapy|Procedure: pain therapy|Procedure: quality-of-life assessment|Radiation: radiation therapy","NCIC Clinical Trials Group","Both","Child|Adult|Senior","Phase III",210,"Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","SC15|CAN-NCIC-SC15|CDR0000066787","November 1, 1999","01/12/1998",2009-02-01,"November 7, 2010","01/03/2010","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00003685",NA
"71112",71112,"NCT00088985","Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: therapeutic autologous dendritic cells|Biological: trastuzumab|Drug: vinorelbine ditartrate","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",37,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000377732|UNC-LCCC-0310|UNC-GCRC-2102-ORC","August 4, 2004","01/01/2004",NA,"April 18, 2009","01/04/2009","",2009-04-01,"Response rate by RECIST criteria at 6 months following treatment|Immune response by ELISPOT tetramer at 3 months following treatment","http://ClinicalTrials.gov/show/NCT00088985",NA
"71242",71242,"NCT00289185","Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants","Completed","No Results Available","Plasmodium Falciparum|Malaria","Biological: Engerix-B|Biological: TETRActHib|Biological: GSK Malaria vaccine 257049 vaccine","GlaxoSmithKline","Both","Child","Phase II",340,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","104298","February 8, 2006","01/09/2006",2009-01-01,"September 3, 2009","01/09/2009","",2009-01-01,"Occurrence of SAEs|Anti-Hepatitis B surface agent (HBs) antibody titers: difference between groups in percent seroprotection.|Anti-diphtheria antibody titers: difference between groups in percent seroprotection|Anti-tetanus antibody titers: difference between groups in percent seroprotection|Anti- polyribosyl-ribitol-phosphate (anti-PRP) antibody titers: difference between groups in percent seroprotection.|Anti-pertussis antibody titers: GMT ratio between groups|Occurrence of unsolicited AEs.|Occurrence of solicited general and local reactions.|Anti HBs antibody titers.|Anti-tetanus antibody titers measured by ELISA|Anti-pertussis antibody titers measured by ELISA|Anti-PRP antibody titers measured by ELISA.|First malaria infection (first recording of infection of asexual stage falciparum parasites detected by the active detection of infection surveillance).|The asexual P. falciparum parasitemia (prevalence and density).|Antibody titers to the P. falciparum circumsporozoite (CS) repeat|Anti-diphtheria antibody titers measured by ELISA.","http://ClinicalTrials.gov/show/NCT00289185",NA
"71273",71273,"NCT00335985","Efficacy and Safety Study of GB-0998 for Treatment of Steroid-Resistant Polymyositis and Dermatomyositis (PM/DM)","Completed","No Results Available","Polymyositis|Dermatomyositis","Drug: GB-0998|Drug: Placebo of GB-0998","Mitsubishi Tanabe Pharma Corporation|Benesis Corporation","Both","Child|Adult|Senior","Phase III",20,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0998-12","June 8, 2006","01/06/2006",2009-03-01,"July 7, 2009","01/07/2009","",2009-03-01,"Changes in manual muscle strength (MMT) scores|Changes in the serum levels of creatine kinase (CK) and total scores of activities of daily living (ADL)|Adverse events and laboratory tests","http://ClinicalTrials.gov/show/NCT00335985",NA
"71290",71290,"NCT00359385","The Effects of Alendronate After Cure of Primary Hyperparathyroidism","Completed","No Results Available","Hyperparathyroidism","Drug: Alendronate 70mg weekly","Columbia University|Merck","Both","Adult|Senior","Phase IV",40,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","AAAB8202","August 1, 2006","01/07/2006",2009-09-01,"August 10, 2010","01/08/2010","AlenPostPara",2009-09-01,"To investigate the effects of alendronate on bone mineral density using data on changes at the lumbar spine, the hip and distal 1/3 radius. The rate of change in BMD at these sites will also be determined by BMD.|We also intend to determine whether alendronate alters bone turnover to maximize the augmented window defined by a rapid fall in bone resorption and a slower fall in bone formation.","http://ClinicalTrials.gov/show/NCT00359385",NA
"71309",71309,"NCT00389285","Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma","Completed","No Results Available","Carcinoma, Renal Cell","Drug: rIL-21 only|Drug: rIL-21 + sorafenib","ZymoGenetics","Both","Adult|Senior","Phase I|Phase II",52,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","494F01","October 16, 2006","01/10/2006",2009-05-01,"May 26, 2009","01/05/2009","",2009-05-01,"Safety profile, including incidence and severity of adverse events|Objective response rate at recommended dose of rIL-21|Progression-free survival at recommended dose of rIL-21|Pharmacokinetic profiles of rIL-21 and sorafenib","http://ClinicalTrials.gov/show/NCT00389285",NA
"71333",71333,"NCT00423085","Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: rivastigmine transdermal patch|Drug: Placebo","Novartis|Ono Pharma","Both","Adult|Senior","Phase III",859,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CENA713D1301","January 11, 2007","01/01/2007",NA,"May 18, 2009","01/05/2009","",2009-03-01,"Change from baseline in the Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog)|Change from baseline in the Clinician's Interview-Based Impression of Change plus - Japan (CIBIC plus-J)|Change from baseline in CIBIC plus-J score (Disability Assessment for Dementia [DAD], Behavioral Pathology in Alzheimer's Disease Rating Scale [Behave-AD], the Mental Function Impairment Scale [MENFIS ])|Change from baseline in MMSE","http://ClinicalTrials.gov/show/NCT00423085",NA
"71349",71349,"NCT00445185","Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix?ºÑ","Completed","No Results Available","Hepatitis B","Biological: Henogen HB vaccine|Biological: Fendrix vaccine","Henogen","Both","Child|Adult|Senior","Phase III",102,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","HN015/HBV-EXT001","March 7, 2007","01/03/2007",2009-11-01,"November 18, 2009","01/11/2009","",2009-07-01,"Anti-HBs antibody concentrations|Quality of immune response|SAEs retrospective reporting|RF-1 like antibody concentrations in the subset of subjects for whom this analysis was done at the primary study (HN014/HBV-001).","http://ClinicalTrials.gov/show/NCT00445185",NA
"71387",71387,"NCT00512785","Long-Term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder","Completed","No Results Available","Overactive Bladder","Drug: imidafenacin, KRP-197/ONO-8025|Drug: imidafenacin, KRP-197/ONO-8025","Ono Pharma|Kyorin Pharmaceutical Co.,Ltd","Both","Adult|Senior","Phase III",435,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KRP197-T301/ONO-8025-12","August 7, 2007","01/08/2007",NA,"June 18, 2009","01/06/2009","",2009-05-01,"Safety Measures: adverse events, laboratory tests, 12-lead ECG, vital signs, post-void residual volume|Efficacy measures: number of urgency incontinence episodes per week, number of incontinence episodes per week, number of micturitions per day, number of urgency episodes per day, severity of urgency, urine volume voided per micturition, Quality of Life","http://ClinicalTrials.gov/show/NCT00512785",NA
"71398",71398,"NCT00503685","Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Patients With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFr Therapy","Completed","No Results Available","Colorectal Cancer","Biological: IMC-A12|Biological: cetuximab","ImClone LLC","Both","Adult|Senior","Phase II",65,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13936|CP02-0657|CP13-0605","July 17, 2007","01/06/2007",2009-12-01,"October 12, 2010","01/10/2010","",2009-02-01,"Objective response rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)|Duration of stable disease (SD)|Duration of Overall response|Summary Listing of Participants Reporting Treatment-Emergent Adverse Events (AEs)|Summary Listing of Participants Reporting Treatment-Emergent Severe Adverse Events (SAEs)|Maximum concentration (Cmax)|Minimum concentration (Cmin)|Area under Serum Concentration (AUC)|Potential associations between KRAS mutations and response rate (cetuximab)|Evaluate tumors for expression of Type I IGF receptors (IGF-IR), IGF binding proteins (IGFBP2, IGFBP3), and related signaling molecules, and potential association|Evaluate tumors for expression of Type I IGF receptors (IGF-IR), IGF binding proteins (IGFBP2, IGFBP3), and related signaling molecules, and assess potential association","http://ClinicalTrials.gov/show/NCT00503685",NA
"71419",71419,"NCT00546585","Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults","Completed","No Results Available","Influenza","Biological: Influenza A/H7N7 Vaccine|Drug: Placebo","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","Phase I|Phase II",126,"NIH","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","07-0023|N01AI30039C","October 18, 2007","01/03/2008",2009-02-01,"January 13, 2011","01/01/2010","",2009-02-01,"Adverse event (AE) or serious adverse event (SAE) information (solicited in-clinic and via memory aids, concomitant medications, and periodic targeted physical assessment).|Geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing antibody titers in each group and serum hemagglutination inhibition (HAI) antibody titers in each group.|Proportion of subjects in each dose group achieving a serum neutralizing antibody titer of greater than or equal to 40 against the influenza A/H7N7 virus.","http://ClinicalTrials.gov/show/NCT00546585",NA
"71421",71421,"NCT00562185","Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer","Completed","No Results Available","Ovarian Cancer","Drug: carboplatin|Drug: doxorubicin hydrochloride","Simmons Cancer Center","Female","Adult|Senior","Phase I|Phase II",61,"Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000574034|SCCC-04E07|SCCC-062007-043|ORTHO-SCCC-04E07","November 20, 2007","01/05/2008",NA,"March 19, 2009","01/03/2009","",2009-03-01,"Acute toxicity|Maximum tolerated dose of intraperitoneal carboplatin when given in combination with IV doxorubicin hydrochloride (phase I)|Primary efficacy and safety (phase II)","http://ClinicalTrials.gov/show/NCT00562185",NA
"71458",71458,"NCT00608985","Almorexant in Adult Subjects With Chronic Primary Insomnia","Completed","No Results Available","Chronic Primary Insomnia","Drug: almorexant|Drug: almorexant|Drug: Placebo|Drug: zolpidem","Actelion","Both","Adult","Phase III",709,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-057A301","January 11, 2008","01/03/2008",2009-11-01,"February 3, 2010","01/02/2010","RESTORA 1",2009-09-01,"Change from Baseline to Day 1&2 in WASO|Change from Baseline to Day 15&16 in WASO|Change from Baseline to Week 1&2 in the self-reported WASO.|Change from Baseline to Day 1&2 in LPS|Change from Baseline to Day 15&16 in LPS|Change from Baseline to Week 1&2 in sLSO","http://ClinicalTrials.gov/show/NCT00608985",NA
"71460",71460,"NCT00618085","Motor Imagery Practice in Neurological Rehabilitation","Completed","No Results Available","Stroke|Brain Injury|Multiple Sclerosis","Behavioral: Motor imagery practice|Other: Standard physiotherapy and occupational therapy","Nuffield Orthopaedic Centre NHS Trust|Oxford Brookes University","Both","Adult|Senior","Phase II",50,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","07/H0605/84NOC|07/H0605/84","February 5, 2008","01/02/2008",2009-04-01,"May 1, 2009","01/05/2009","",2009-04-01,"Goal Attainment Scaling|Motor imagery questionnaire|Timed up and go|Action research arm test","http://ClinicalTrials.gov/show/NCT00618085",NA
"71463",71463,"NCT00621985","Dexamethasone Treatment of Congenital Adrenal Hyperplasia","Completed","No Results Available","Adrenal Hyperplasia, Congenital","Drug: dexamethasone","Children's Hospital Boston","Both","Child","Phase II",5,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","08-01-0025","February 11, 2008","01/02/2008",2009-06-01,"August 3, 2009","01/08/2009","",2009-06-01,"Area under the curve of 17 hydroxyprogesterone as measured via frequent lab draws in a 24 hour period.|Area under the curve of ACTH and Androstenedione as measured via frequent lab draws during a 24 hour period","http://ClinicalTrials.gov/show/NCT00621985",NA
"71543",71543,"NCT00742885","Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine","Completed","No Results Available","Pandemic Influenza","Biological: (Pre-) pandemic influenza vaccine GSK1557484A","GlaxoSmithKline","Both","Adult","Phase II",100,"Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","111756","August 27, 2008","01/09/2008",2009-03-01,"September 28, 2009","01/09/2009","",2009-03-01,"Geometric mean titers (GMTs) of hemagglutination inhibition (HI) antibody against the H5N1 vaccine strain|Seroconversion Rates (SCR)|Seroprotection Rates (SPR)|Seroconversion Factors (SCF)|Percentage, intensity and relationship to vaccination of unsolicited local and general signs and symptoms|Occurrence of serious adverse events|Medically-attended visits|Geometric mean titers (GMTs) of hemagglutination inhibition (HI) antibody against the H5N1 vaccine strain|Percentage, intensity and relationship to vaccination of solicited local and general signs and symptoms|Seroconversion Rates (SCR)|Seroprotection Rates (SPR)|Seroconversion Factors (SCF)|Geometric mean titers (GMTs) of serum anti-H5N1 neutralising antibodies against the H5N1 vaccine strain|Seroconversion Rates (SCR)|The number and percentage of subjects with normal or abnormal haematological and biochemical values|The number and percentage of subjects with normal or abnormal urine values","http://ClinicalTrials.gov/show/NCT00742885",NA
"71550",71550,"NCT00758485","Comparing 4.0 mg.Kg-1 Sugammadex With Placebo During Profound Neuromuscular Blockade (19.4.316)(P05767)(COMPLETED)","Completed","No Results Available","Anesthesia, General|Neuromuscular Relaxation","Drug: Sugammadex|Drug: 0.9% NaCl","Schering-Plough","Both","Adult|Senior","Phase III",140,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","19.4.316|EudraCT #: 2008-002518-23;|P05767","September 23, 2008","01/12/2008",2009-06-01,"October 2, 2009","01/10/2009","",2009-06-01,"Time from start of administration of IMP to recovery of the T4/T1 ratio to 0.9|Time from start of administration of IMP to recovery of the T4/T1 ratio to 0.7|Time from start of administration of IMP to recovery of the T4/T1 ratio to 0.8","http://ClinicalTrials.gov/show/NCT00758485",NA
"71584",71584,"NCT00810485","ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)","Completed","No Results Available","Gastroesophageal Reflux","Drug: ADX10059|Drug: ADX10059|Drug: ADX10059|Drug: ADX10059 Matching Placebo","Addex Pharma S.A.","Both","Adult|Senior","Phase II",320,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ADX10059-205|2008-005105-18","December 17, 2008","01/12/2008",NA,"December 23, 2009","01/12/2009","",2009-12-01,"Number of GERD symptom free days in week 4 of study medication treatment|GERD symptoms|Sleep disturbance|Use of antacid medications|Global assessment of GERD|Safety and tolerability assessments","http://ClinicalTrials.gov/show/NCT00810485",NA
"71585",71585,"NCT00807885","Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase","Completed","No Results Available","Dehydration","Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase","Baxter Healthcare Corporation|Halozyme Therapeutics","Both","Adult","Phase IV",100,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1838-007","December 10, 2008","01/12/2008",2009-01-01,"April 28, 2010","01/04/2010","INFUSE-AT",2009-01-01,"Technical challenges (tube kinks, catheter dislodgement, catheter pull-out, infusion pump beeping, other pump failure, intervention to maintain infusion, other technical challenges) during infusion|Multiple ease-of-use measures|Safety and tolerability (catheter placement-associated pain, infusion site reactions, other adverse events)","http://ClinicalTrials.gov/show/NCT00807885",NA
"71604",71604,"NCT00836485","Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis","Completed","No Results Available","Allergic Conjunctivitis","Drug: Ketotifen 4.0% Patch|Drug: Placebo|Drug: Olopatadine 0.2%|Drug: Artificial tears","Senju USA, Inc.","Both","Adult|Senior","Phase II",120,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SNJ-ALK201/08-003-11","February 2, 2009","01/02/2009",2009-03-01,"May 15, 2009","01/05/2009","",2009-03-01,"Ocular itching and bulbar conjunctival redness|Ocular: Ciliary, episcleral, and inferior palpebral conjunctival redness; chemosis; lid swelling; tearing; ocular mucous discharge|Nasal: Rhinorrhea; ear or palate pruritis; nasal pruritis; nasal congestion; and a composite score of all nasal symptoms","http://ClinicalTrials.gov/show/NCT00836485",NA
"71616",71616,"NCT00854685","Dose Optimisation Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate","Completed","No Results Available","Rheumatoid Arthritis","Drug: ART621|Drug: ART621|Drug: ART621|Drug: ART621|Drug: Placebo|Drug: Placebo","Arana Therapeutics Ltd|Trident Clinical Research Pty Ltd","Both","Adult|Senior","Phase II",27,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ART621-223","March 1, 2009","01/02/2009",2010-01-01,"January 4, 2010","01/03/2009","",2009-12-01,"Safety and tolerability of subcutaneous injections of ART621 (preceded by a single i.v. loading dose) at different dose frequencies","http://ClinicalTrials.gov/show/NCT00854685",NA
"71618",71618,"NCT00861185","Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma","Completed","No Results Available","Exercise Induced Asthma","Drug: senicapoc|Drug: Placebo","Icagen","Both","Adult","Phase II",69,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ICA-17043-18","March 12, 2009","01/03/2009",2009-09-01,"November 13, 2009","01/11/2009","",2009-07-01,"The change from baseline in the maximal percentage decrease in forced expiratory volume in one second (FEV1) after exercise|- Area under the curve (AUC) for FEV1 after exercise challenge, - the length of time for recovery of FEV1 after exercise challenge, - changes in non-challenge pulmonary function tests, and an asthma control questionnaire.","http://ClinicalTrials.gov/show/NCT00861185",NA
"71620",71620,"NCT00863785","Treatment of Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone","Completed","No Results Available","Alcoholic Hepatitis","Drug: Corticoids plus N Acetyl Cysteine","Centre Hospitalier Universitaire, Amiens","Both","Adult","Phase III",174,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","PHRC R04 - Dr NGUYEN-KHAC|AFSSAPS 040276","March 17, 2009","01/04/2004",2009-09-01,"October 19, 2009","01/10/2009","HAA-NAC",2009-08-01,"Survival at one, three and six months|bilirubin decrease at day seven survival at one and three months nac tolerance side effects","http://ClinicalTrials.gov/show/NCT00863785",NA
"71629",71629,"NCT00872885","Bunionectomy Trial With GRT6005","Completed","No Results Available","Post Operative Pain","Drug: GRT6005|Drug: Morphine|Drug: Placebo","Gr??nenthal GmbH","Both","Adult|Senior","Phase II",258,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","425965","March 24, 2009","01/03/2009",2009-10-01,"June 21, 2010","01/06/2010","",2009-08-01,"Sum of pain intensity 2-10 hours after Investigational medicinal product intake. Pain assessments|Amount of rescue medication|Adverse events|Time to first rescue medication|Patient Global Impression of Change","http://ClinicalTrials.gov/show/NCT00872885",NA
"71664",71664,"NCT00928785","Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults","Completed","No Results Available","Healthy","Biological: REPEVAX|Biological: Monovalent Tetanus vaccine","Sanofi Pasteur MSD","Both","Adult|Senior","Phase III",456,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","RPV02C","June 25, 2009","01/07/2009",2009-12-01,"December 3, 2009","01/12/2009","",2009-12-01,"Anti-tetanus seroprotection rate (defined as the percentage of subjects with anti-tetanus antibody titre (ELISA) ??­ 0.1 IU/mL)|Geometric Mean Titre (GMT) for tetanus antibodies in both groups|The anti-tetanus seroprotection rate (antibody titre ??­ 0.1 IU/mL in ELISA)|Percentage of subjects with immediate reactions, solicited injection-site reactions, systemic reactions and unsolicited adverse events|Percentage of subjects with serious adverse events","http://ClinicalTrials.gov/show/NCT00928785",NA
"71668",71668,"NCT00941785","Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso","Completed","No Results Available","Malaria","Drug: DHA-PQ|Drug: SP-AQ","London School of Hygiene and Tropical Medicine|BEIJING HOLLEY-COTEC PHARMACEUTICALS CO. LTD.","Both","Child","Phase II|Phase III",1500,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","EC5550","June 18, 2009","01/07/2009",2009-12-01,"May 25, 2010","01/05/2010","",2009-12-01,"Efficacy against clinical malaria|Incidence of adverse events|Pharmacokinetics of piperaquie: the oral clearance (CL/F), AUC, steady state volume of distribution(s) (Vss/F), inter-compartment clearance(s) (Q/F) and absorption rate (ka) will be estimated.","http://ClinicalTrials.gov/show/NCT00941785",NA
"71681",71681,"NCT00958685","Safety Study of Feeding With Ginger Extract in Acute Respiratory Distress Syndrome","Completed","No Results Available","Acute Respiratory Distress Syndrome","Dietary Supplement: ginger|Dietary Supplement: placebo","Shahid Beheshti University","Both","Adult|Senior","Phase II",32,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INFI-112","August 3, 2009","01/01/2007",2009-01-01,"August 12, 2009","01/08/2009","",2009-01-01,"changes in oxygenation, respiratory mechanics and serum inflammatory factors|oxygenation|the number of organ failure free days, the occurrence of barotraumas, the number of ventilator free days, the number of ICU free days and ICU mortality.","http://ClinicalTrials.gov/show/NCT00958685",NA
"71777",71777,"NCT01122485","Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis","Completed","No Results Available","Osteoarthritis of the Knee","Other: PG201|Other: Placebo","ViroMed Co., Ltd.","Both","Adult|Senior","Phase II",82,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","PG201-PT-001","May 6, 2010","01/12/2006",2009-09-01,"May 10, 2010","01/05/2010","",2009-09-01,"The change in the WOMAC-Pain VAS total score from baseline to the end of the study|The changes in the WOMAC sub-scale score and the WOMAC total score|The responder index (RI)|The change in the quality of life score (SF36)|The change in the patient self-assessed overall symptom scores|The change in the investigator-assessed overall symptom scores|Adverse event, and the presence and incidence of abnormal laboratory","http://ClinicalTrials.gov/show/NCT01122485",NA
"71917",71917,"NCT00015886","Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery","Completed","No Results Available","Breast Cancer","Drug: docetaxel|Drug: fluorouracil|Drug: leucovorin calcium","Wake Forest University|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068567|CCCWFU-74896|NCI-3137","May 6, 2001","01/05/2001",NA,"September 18, 2009","01/09/2009","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT00015886",NA
"71968",71968,"NCT00097786","Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: nateglinide|Drug: valsartan","Novartis Pharmaceuticals","Both","Adult|Senior","Phase III",9518,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","CDJN608B2302","November 30, 2004","01/01/2002",2009-10-01,"June 23, 2010","01/06/2010","Navigator",2009-10-01,"Time to having a cardiovascular or neurologic event, including: death from a cardiovascular event, heart attack, stroke, hospitalization for chest pain or heart failure, or procedure to open a blockage in an arterial blood vessel.|Risk of developing diabetes|Time to having a cardiovascular or neurologic event, including: death from a cardiovascular event, heart attack, stroke, or hospitalization for heart failure.","http://ClinicalTrials.gov/show/NCT00097786",NA
"71984",71984,"NCT00113386","Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Biological: filgrastim|Biological: pegfilgrastim|Drug: cisplatin|Drug: docetaxel|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group","Both","Adult|Senior","Phase III",574,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000429479|RTOG-0412|SWOG-S0332|CALGB-RTOG-0412|ECOG-RTOG-0412|NCCTG-RTOG-0412","June 7, 2005","01/04/2005",NA,"December 26, 2009","01/02/2009","",2009-02-01,"Comparison of overall survival|Comparison of progression-free survival|Comparison of median survival time|Comparison of treatment toxicity rates|Comparison of clinical and pathologic response rates|Comparison of overall survival and progression-free survival between patients with and without pathologic complete response|Association of molecular markers and overall survival, progression-free survival and response|Change in patient-reported functional status","http://ClinicalTrials.gov/show/NCT00113386",NA
"71998",71998,"NCT00138086","Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma","Completed","No Results Available","B-Cell Lymphoma","Drug: Zevalin plus BEAM","Groupe d'Etudes de Lymphomes de L'Adulte","Both","Adult","Phase II",75,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Z-BEAM","August 29, 2005","01/03/2005",2009-03-01,"September 6, 2006","01/09/2006","",2009-03-01,"EFS (event free survival)|Overall response rate (ORR)|Toxicities, transplant related mortality at 1 and 2 years|Hematological reconstitution after ASCT and 1 year|Time to progression or relapse, disease free survival for complete responders after ASCT, overall survival","http://ClinicalTrials.gov/show/NCT00138086",NA
"72001",72001,"NCT00117286","Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer","Completed","Has Results","Prostate Cancer","Drug: Degarelix","Ferring Pharmaceuticals","Male","Adult|Senior","Phase II|Phase III",57,"Industry","Interventional","Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FE200486 CS14A","June 30, 2005","01/03/2005",2009-11-01,"September 29, 2010","01/09/2010","",2009-09-01,"Participants With Markedly Abnormal Change in Vital Signs and Body Weight|Liver Function Tests","http://ClinicalTrials.gov/show/NCT00117286",NA
"72046",72046,"NCT00191386","Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)","Completed","Has Results","Attention Deficit Hyperactivity Disorder","Drug: Atomoxetine hydrochloride","Eli Lilly and Company","Both","Child","Phase III",228,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9315|B4Z-JE-LYDA","September 12, 2005","01/05/2005",2009-08-01,"December 14, 2010","01/12/2010","",2009-08-01,"Number of Participants With Adverse Events for Long Term Safety and Tolerability|Change From Baseline at Various Timepoints in Attention Deficit Hyperactivity Disorder Rating Scale-IV-Translated in Japanese Parent Version: Investigator Administered and Scored (ADHDRS-IV-J:I) Total Score|Change From Baseline at Various Timepoints in the Clinical Global Impressions-Attention Deficit Hyperactivity Disorder-Severity (CGI-ADHD-S)|Cytochrome P450 2D6 (CYP2D6) Phenotype Status","http://ClinicalTrials.gov/show/NCT00191386",NA
"72074",72074,"NCT00255086","The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients","Completed","No Results Available","Alzheimer Disease","Drug: Memantine","Stanford University|Palo Alto Institute for Research and Education, Inc|Forest Laboratories","Both","Adult|Senior","Phase III",17,"Other|Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","95722","November 15, 2005","01/05/2005",2010-02-01,"October 14, 2010","01/10/2010","",2009-06-01,"NAA/Cr ratio|Progression as measured by performance on the ADAS-Cog and caregiver and clinician ratings.","http://ClinicalTrials.gov/show/NCT00255086",NA
"72145",72145,"NCT00356486","Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin ?? in Patients Coinfected HCV/HIV","Completed","No Results Available","HIV Infections","Drug: Peginterferon alfa-2a, Ribavirin, epoetin-??|Drug: Peginterferon alfa-2a + Ribavirin for 12 weeks","Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA","Both","Adult|Senior","Phase IV",74,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CORAL-2|2004 - 000907 -16","July 25, 2006","01/10/2005",2009-03-01,"September 2, 2009","01/09/2009","",2009-03-01,"Percentage of patients with undetectable RNA-HCV|Variations of the levels of RNA-HCV|Percentage of patients with undetectable HCV RNA|Levels of ALT|Percentage of patients that must reduce the dose of peginterferon alpha-2a (40 KD) and ribavirin.|Percentage of patients that drop out of the study for adverse effects or intolerance|Variations in levels of haemoglobin, neutrophil, and platelet count|AIDS-defining events or death|Changes in the CD4/CD8 cell count","http://ClinicalTrials.gov/show/NCT00356486",NA
"72151",72151,"NCT00362986","Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer","Completed","No Results Available","Dermatologic Complications|Unspecified Adult Solid Tumor, Protocol Specific","Biological: cetuximab|Biological: matuzumab|Biological: panitumumab|Drug: canertinib dihydrochloride|Drug: erlotinib hydrochloride|Drug: gefitinib|Drug: titanium dioxide/zinc oxide sunscreen cream SPF 60","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",110,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care","CDR0000492254|NCCTG-N05C4","August 10, 2006","01/10/2006",NA,"September 1, 2010","01/10/2009","",2009-10-01,"Incidence and severity of rash development by Skindex questionnaire|Toxicity by NCI CTCAE v3.0|Rash incidence at 4 and 8 weeks","http://ClinicalTrials.gov/show/NCT00362986",NA
"72157",72157,"NCT00383786","Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder","Completed","No Results Available","PTSD","Drug: NK1 Antagoist (GR205171)|Procedure: Psychophysiology (Trauma Script)|Procedure: Psychophysiology (Verbal Threat)|Procedure: Psychophysiology (Fear Conditioning)|Procedure: Psychophysiology (Affective Modulation)|Procedure: Psychophysiology (Heart rate variability)|Procedure: Lumbar Puncture|Procedure: 24-hour plasma sampling|Procedure: MRI|Device: GR205171","National Institute of Mental Health (NIMH)","Both","Adult","Phase II",52,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Treatment","060253|06-M-0253","October 3, 2006","01/09/2006",2009-06-01,"September 16, 2009","01/09/2009","",2009-06-01,"Changes in CAPS scores.|Able to identify biological markers that predict response to treatment.","http://ClinicalTrials.gov/show/NCT00383786",NA
"72239",72239,"NCT00515086","Study of Everolimus in Patients With Recurrent Glioblastoma Multiforme","Completed","No Results Available","Glioblastoma Multiforme","Drug: everolimus","Novartis Pharmaceuticals","Both","Adult|Senior","Phase II",41,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD001C2410","August 10, 2007","01/10/2006",NA,"June 21, 2010","01/06/2010","",2009-12-01,"Arm 1: To explore the biological effectiveness of 2 doses of RAD001 measured by inhibition of S6 phosphokinase in GBM tumor cells.|Arm 2: To determine the efficacy of RAD001 in patients with recurrent GBM as measured by the objective response rate.|Arm 1: To determine blood and brain tissue levels of RAD001|Arm 1: To measure time to progression after salvage surgery while receiving treatment with a fixed dose of daily RAD001|Arm 1: To define the safety profile of daily RAD001 administration in patients with recurrent GBM.|Arm 2: To correlate response with biomarkers for the PTEN and EGFR pathways|Arm 2: To determine the progression free survival at 3 months post-treatment in patients with recurrent GBM receiving RAD001.","http://ClinicalTrials.gov/show/NCT00515086",NA
"72243",72243,"NCT00518986","Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Comorbid Major Depressive Disorder or Dysthymic Disorder","Completed","No Results Available","Sleep Disorders|Obstructive Sleep Apnea|Major Depressive Disorder|Dysthymic Disorder","Drug: armodafinil|Drug: placebo","Cephalon","Both","Adult","Phase IV",250,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","C10953/4024/ES/US","August 17, 2007","01/10/2007",2009-03-01,"May 8, 2009","01/05/2009","",2009-03-01,"MWT mean sleep latency assessed at week 12 (or last postbaseline observation) and CGI-C ratings assessed at week 12 (or last postbaseline observation).|ESS assessed at week 12 (or last postbaseline observation).","http://ClinicalTrials.gov/show/NCT00518986",NA
"72255",72255,"NCT00498186","Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)","Completed","Has Results","Restless Legs Syndrome","Drug: Rotigotine","UCB, Inc.","Both","Adult|Senior","Phase II",295,"Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SP710","July 6, 2007","01/07/2003",2009-04-01,"December 14, 2010","01/12/2010","",2009-04-01,"Number of Subjects With at Least One Adverse Event, as Reported Spontaneously by the Subject or Observed by the Investigator, During the 5-year Open-label Extension.|Number of Subjects Who Withdrew From the Trial Due to an Adverse Event During the 5-year Open Label Extension","http://ClinicalTrials.gov/show/NCT00498186",NA
"72256",72256,"NCT00538486","A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients","Completed","No Results Available","Hypertension|Obesity","Drug: Telmisartan plus Metformin|Drug: Telmisartan|Drug: Candesartan|Drug: Candesartan plus Metformin|Drug: Amlodipine|Drug: Amlodipine plus Metformin","Third Military Medical University","Both","Adult|Senior","Phase IV",360,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HOT-ACME 1","October 1, 2007","01/02/2008",2009-06-01,"July 7, 2009","01/07/2009","HOT-ACME",2009-06-01,"Blood Pressure|Metabolic profiles, including lipid profile and blood glucose|Abdominal fat assessed by CT|Obesity parameters, including waist circumference (WC) and body mass index (BMI)|Insulin resistance assessed by fasting serum insulin and HOMA-IR|Incidents of side effects between groups","http://ClinicalTrials.gov/show/NCT00538486",NA
"72257",72257,"NCT00543686","Leukotriene Receptor Antagonists or Steroids in Pre-School Asthma","Completed","No Results Available","Asthma","Drug: Montelukast|Drug: Fluticasone","Johann Wolfgang Goethe University Hospitals","Both","Child","Phase II",100,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","165/07/FFM","October 11, 2007","01/08/2007",2009-02-01,"February 3, 2009","01/02/2009","LOS",2009-01-01,"The primary efficacy variable is the number of responders with a very good asthma symptom control defined as requiring no rapid acting beta agonist (RABA) between the 2. and 6th week of intervention (end of trial)|the number of patients requiring at least five times RABA between the 2. and 6th week, the number of patients with an increase of FEV1 7.5%, the symptom score, symptom free days, rescue medication, presence of allergy RAST > 2, concentration of eNO, PD20","http://ClinicalTrials.gov/show/NCT00543686",NA
"72261",72261,"NCT00542386","A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia","Completed","No Results Available","Chronic Kidney Disease|Dialysis|Hyperphosphatemia|Dyslipidemia","Drug: MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE?ó)|Drug: Placebo","Mitsubishi Tanabe Pharma Corporation","Both","Adult|Senior","Phase III",642,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MCI-196-E08","October 10, 2007","01/12/2007",2009-11-01,"June 27, 2010","01/06/2010","",2009-11-01,"The change in serum phosphorus for MCI-196 and placebo|The change in LDL-cholesterol for MCI-196 and placebo|The change in Total-cholesterol|The change in HDL-cholesterol|The change in Triglycerides|The change in PTH|The change in Ca|The change in Ca x P ion product|The incidence of adverse events","http://ClinicalTrials.gov/show/NCT00542386",NA
"72279",72279,"NCT00570986","A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","Completed","No Results Available","Plaque Psoriasis","Drug: Placebo|Biological: ABT-874|Biological: ABT-874","Abbott","Both","Adult|Senior","Phase III",1465,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M06-890","December 7, 2007","01/12/2007",NA,"November 2, 2010","01/09/2010","",2009-06-01,"PGA|PASI|PGA|DLQI|NAPSI|PASI|Safety parameters","http://ClinicalTrials.gov/show/NCT00570986",NA
"72313",72313,"NCT00626886","Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy","Completed","No Results Available","Herniorrhaphy|Postoperative Pain|Inguinal Hernia","Drug: Bupivacaine Collagen Sponge|Drug: placebo collagen sponge","Innocoll Technologies|Premier Research Group plc","Male","Adult|Senior","Phase II",53,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","INN-CB-003","February 20, 2008","01/01/2008",2009-01-01,"March 19, 2009","01/03/2009","",2009-01-01,"Total use of opioid rescue analgesia|Total use of opioid rescue analgesia|Total use of opioid rescue analgesia|Pain intensity on the VAS at rest and after aggravated movement (cough)|Pain intensity rating on a 4-point Likert scale at rest and after aggravated movement (cough)|Pain relief rating on a 5-point Likert scale at rest and after aggravated movement (cough)|Patient's global evaluation of the study treatment on a 5 point Likert scale|Time to first use of opioid rescue analgesia|Pharmacokinetic parameters|Treatment emergent adverse events|Vital signs (heart rate, respiratory rate, systolic and diastolic blood pressure and body temperature)","http://ClinicalTrials.gov/show/NCT00626886",NA
"72333",72333,"NCT00658086","Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)","Completed","No Results Available","Respiratory Syncytial Virus Infections","Drug: ALN-RSV01|Drug: normal saline","Alnylam Pharmaceuticals","Both","Adult|Senior","Phase II",24,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALN-RSV01-106","April 9, 2008","01/04/2008",2009-06-01,"June 15, 2009","01/06/2009","",2009-04-01,"Assess safety and tolerability of aerosolized ALN-RSV01 versus placebo in lung transplant patients infected with RSV|Evaluate effects of ALN-RSV01 on clinical and virologic endpoints","http://ClinicalTrials.gov/show/NCT00658086",NA
"72335",72335,"NCT00661986","Effect of Different Dosages of Dark Chocolate on Arterial Blood Pressure in Cardiovascular High-risk Patients","Completed","No Results Available","Hypertension","Dietary Supplement: dark chocolate 6 g/day|Dietary Supplement: dark chocolate 25 g/day","University of Leipzig","Both","Adult|Senior","Phase IV",102,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","Leipzig chocolate","April 17, 2008","01/02/2008",2009-05-01,"February 1, 2010","01/01/2010","",2009-05-01,"change in mean ambulatory arterial blood pressure|change in weight and BMI|change in various lab parameters","http://ClinicalTrials.gov/show/NCT00661986",NA
"72355",72355,"NCT00686686","Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)","Completed","No Results Available","Psoriasis","Biological: Infliximab","Schering-Plough|Centocor, Inc.","Both","Adult|Senior","Phase III",32,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P04555","May 27, 2008","01/12/2007",2009-04-01,"October 7, 2010","01/10/2010","TIPS",2009-02-01,"Percentage of subjects who achieve more than 75% of improvement in Palmoplantar Psoriasis Activity Severity Index (PPPASI) after 3 infusions.|Percentage of subjects who achieve a moderate response.|Percentage of subjects who maintain the initial clearance at Weeks 12 and 18.|Percentage of subjects who respond to the fourth infusion.|Dermatology Life Quality Index|Unexpected SAEs","http://ClinicalTrials.gov/show/NCT00686686",NA
"72360",72360,"NCT00693186","A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC?ó or INFANRIX?ó-HEXA","Completed","No Results Available","Hepatitis B","Biological: HBVaxPRO?ó 5 ??g / 0.5 mL|Biological: Engerix B?ó 10 ??g / 0.5 mL","Sanofi Pasteur MSD","Both","Child","Phase III",410,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","HXV01C","June 4, 2008","01/10/2008",2010-03-01,"November 17, 2010","01/11/2010","",2009-12-01,"Percentage of subjects with anti-HBs antibody titres >=10 mIU/mL measured at 1 month post-booster dose","http://ClinicalTrials.gov/show/NCT00693186",NA
"72377",72377,"NCT00710086","Intravenous Remifentanil for Labor Analgesia","Completed","No Results Available","Labor Pain","Drug: Hydromorphone|Drug: Remifentanil","Nanjing Medical University|HRSA/Maternal and Child Health Bureau","Female","Adult","Phase IV",1000,"Other|U.S. Fed","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NJFY-08021MZ|NSR083","July 2, 2008","01/07/2008",2009-09-01,"September 17, 2009","01/09/2009","IRELAN",2009-09-01,"Maternal Visual Analog Scale (VAS) rating of pain|Rate of cesarean delivery|Rate of instrument-assisted delivery|Indications of cesarean delivery|Duration of analgesia|Maternal satisfaction with analgesia|Maternal oral temperature|Use of oxytocin after analgesia|Maximal oxytocin dose|Breastfeeding success at 6 weeks after vaginal delivery|Neonatal one-minute Apgar scale|Neonatal five-minute Apgar scale|Umbilical-cord gases analysis|Neonatal sepsis evaluation|Neonatal antibiotic treatment|Incidence of maternal side effects","http://ClinicalTrials.gov/show/NCT00710086",NA
"72425",72425,"NCT00803686","A Crossover Study of Oral Calcitonin Given at Night to Normal, Healthy, Postmenopausal Women","Completed","No Results Available","Osteoporosis, Postmenopausal","Drug: Recombinant Salmon Calcitonin","Unigene Laboratories Inc.","Female","Adult|Senior","Phase II",12,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","UGL-OR0803|Bio-Kinetic No.: 13808","December 4, 2008","01/12/2008",2009-01-01,"February 17, 2009","01/02/2009","",2009-01-01,"CTx-1","http://ClinicalTrials.gov/show/NCT00803686",NA
"72436",72436,"NCT00817986","A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms","Completed","No Results Available","Back Spasms","Drug: Arbaclofen placarbil, 20 mg BID|Drug: Placebo|Drug: Arbaclofen placarbil, 30 mg BID|Drug: Arbaclofen placarbil, 40 mg BID","XenoPort, Inc.","Both","Adult","Phase II",161,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","XP-B-083","January 6, 2009","01/12/2008",2009-07-01,"September 14, 2010","01/09/2010","",2009-07-01,"Incidence of treatment-emergent adverse events|Change in pain severity score using the VAS","http://ClinicalTrials.gov/show/NCT00817986",NA
"72471",72471,"NCT00869986","A Study for Patients With Relapsing Remitting Multiple Sclerosis","Completed","No Results Available","Relapsing Remitting Multiple Sclerosis","Drug: dirucotide|Drug: placebo","Eli Lilly and Company|BioMS Technology Corp.","Both","Adult","Phase II|Phase III",218,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12791|I3E-BM-MSAE|2006-001947-70|MBP8298-RR01","March 24, 2009","01/11/2006",2009-09-01,"September 7, 2010","01/09/2010","MINDSET01",2009-09-01,"Annualized relapse rate|Time to confirmed worsening of disability by Expanded Disability Status Scale (EDSS)|Time to confirmed worsening of disability by Multiple Sclerosis Functional Composite (MSFC)|Proportion of patients relapse-free|Activity analysis of T2 and Gadolinium enhancing lesions","http://ClinicalTrials.gov/show/NCT00869986",NA
"72492",72492,"NCT00911586","Pharmacokinetic Study to Determine Time to Steady-state","Completed","No Results Available","Male Hypogonadism|Primary Hypogonadism|Secondary Hypogonadism","Drug: Testosterone undecanoate","Clarus Therapeutics, Inc.","Male","Adult|Senior","Phase II",15,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLAR-09009","May 29, 2009","01/07/2009",2010-01-01,"August 17, 2010","01/08/2010","",2009-09-01,"Confirmation of time to reach steady-state when oral testosterone undecanoate is administered twice daily.","http://ClinicalTrials.gov/show/NCT00911586",NA
"72495",72495,"NCT00925886","Use of Toric Intraocular Lens to Neutralize Keratometric Astigmatism","Completed","No Results Available","Cataract|Astigmatism","Procedure: Acrysof Toric one-piece intraocular lens","Asociaci??n para Evitar la Ceguera en M?¢xico","Both","Adult|Senior","Phase IV",50,"Other","Interventional","Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-Jan","June 18, 2009","01/07/2007",2009-03-01,"June 19, 2009","01/06/2009","",2009-03-01,"Neutralization of Astigmatism","http://ClinicalTrials.gov/show/NCT00925886",NA
"72510",72510,"NCT00953186","Hyperbaric Oxygen Therapy as Adjunctive Treatment of Chronic Diabetic Foot Ulcers","Completed","No Results Available","Diabetes|Foot Ulcer|Healing","Device: hyperbaric air|Device: HBOT","Mrs. Thelma Zoegas Foundation|Faculty of Medicine Lund University Lund Sweden|Region Sk?­ne Sweden|Gorthons Foundation Helsingborg Sweden","Both","Adult|Senior","Phase IV",94,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Z012094","July 28, 2009","01/06/2002",2009-06-01,"August 5, 2009","01/08/2009","HODFU",2009-05-01,"Ulcer healing|Amputationrate|time to ulcer healing|QoL","http://ClinicalTrials.gov/show/NCT00953186",NA
"72540",72540,"NCT00999986","Low Dose Cyclophosphamide Treats Genital Warts","Completed","No Results Available","Genital Wart","Drug: cyclophosphamide","Huazhong University of Science and Technology","Both","Adult","Phase III",104,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","Sheng-Qi-An","October 21, 2009","01/01/2007",2009-08-01,"November 24, 2009","01/11/2009","",2009-06-01,"low-dose cyclophosphamide effectively prevents the recurrence of large genital warts after laser therapy","http://ClinicalTrials.gov/show/NCT00999986",NA
"72577",72577,"NCT01068886","External Pancreatic Duct Stent After Pancreaticoduodenectomy","Completed","No Results Available","Pancreatic Fistula","Procedure: External pancreatic stent","University Hospital, Angers","Both","Adult|Senior","Phase III",150,"Other","Interventional","Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PHRC 04-04","September 14, 2005","01/01/2006",2009-12-01,"February 12, 2010","01/02/2010","",2009-04-01,"pancreatic fistula|overall morbidity","http://ClinicalTrials.gov/show/NCT01068886",NA
"72622",72622,"NCT01150786","Effect of Selenium on Serum Adiponectin, Homocystein and Malnutrition-inflammation Complex Syndrome in Hemodialysis Patients","Completed","No Results Available","Oxidative Stress|Inflammation|Nutrition","Dietary Supplement: Selenium Supplement|Other: starch","Shiraz University of Medical Sciences","Both","Adult|Senior","Phase III",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment","884746","June 22, 2010","01/04/2009",2009-09-01,"June 24, 2010","01/09/2009","",2009-07-01,"adiponectin|homocystein|hs-CRP|nutritional status|quality of life|albumin|ferritin|transferrin","http://ClinicalTrials.gov/show/NCT01150786",NA
"72729",72729,"NCT00003687","Treatment for Chronic Pain in Patients With Advanced Cancer","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Pain|Precancerous/Nonmalignant Condition|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: dextromethorphan hydrobromide|Drug: morphine sulfate","NCIC Clinical Trials Group","Both","Child|Adult|Senior","Phase III",NA,"Other","Interventional","Allocation: Randomized|Control: Active Control|Masking: Double-Blind|Primary Purpose: Supportive Care","SC17|CAN-NCIC-SC17|CDR0000066789","November 1, 1999","01/12/1998",2009-02-01,"November 7, 2010","01/03/2010","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00003687",NA
"72803",72803,"NCT00090987","Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma","Completed","No Results Available","Sarcoma","Drug: imatinib mesylate","AIDS Associated Malignancies Clinical Trials Consortium|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",30,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000380955|AMC-042","September 7, 2004","01/06/2005",NA,"December 5, 2009","01/10/2007","",2009-12-01,"Clinical response|Inhibition of platelet-derived growth factor-receptor as assessed by immunohistochemistry|Cytokine profiles before and after imatinib therapy|Pharmacokinetic profile of imatinib and antiretrovirals|Mechanisms of primary and secondary resistance to imatinib therapy|Viral transcription profile of Kaposi's sarcoma-associated herpesvirus","http://ClinicalTrials.gov/show/NCT00090987",NA
"72865",72865,"NCT00184587","Prophylactic Treatment of Episodic Cluster Headache","Completed","No Results Available","Cluster Headache","Drug: candesartan cilexetil (angiotensin II receptor blocker)","Norwegian University of Science and Technology|AstraZeneca","Both","Adult|Senior","Phase II",64,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","D2452L0004|EudraCT nr. 2004-002737-39|Nr. 045-04|NSD 10815","September 13, 2005","01/03/2005",2009-12-01,"September 1, 2010","01/09/2010","",2009-12-01,"frequency of attacks per week|level of disability|duration of attacks|hours with cluster headache|days with cluster headache|hours with headache|days with headache|occurrence of autonomic symptoms|number of attacks treated with sumatriptan or oxygen|doses of sumatriptan|acceptability of treatment|comparison between the last two weeks on medication and yhe week with headache diary only|days with sick leave|headache severity index|doses of analgesics|candesartan-responders|placebo-responders","http://ClinicalTrials.gov/show/NCT00184587",NA
"72878",72878,"NCT00202787","Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: FOLFOX-4+cetuximab|Drug: FOLFOX-4","Spanish Cooperative Group for Gastrointestinal Tumour Therapy|Merck","Both","Adult|Senior","Phase II",136,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-04-02|eudract-number: 2004-001700-12","September 12, 2005","01/02/2005",2009-02-01,"February 18, 2010","01/02/2010","",2009-02-01,"Determine confirmed objective response rate|Determine safety of combination, surgical resectability and R0 resections, clinical benefit, time to disease progression, time to onset of response, duration of response, time to treatment failure, overall survival time|determination of polymorphisms of the intron 1 of the EGFR gene, TS, XRCC1, XPD, serum levels of EGFR and ATP7A and ATP7B, n?? of copies of EGFR gene, the levels of PTEN, EGFR, AKT y MAPK proteins, and mutations at EGFR, PI3KCA, K-RAS y B-RAF genes","http://ClinicalTrials.gov/show/NCT00202787",NA
"72972",72972,"NCT00349687","Practicing Self-Control Lowers the Risk of Smoking Lapse","Completed","No Results Available","Behavior, Addictive|Cigarette Smoking","Behavioral: self-control practice","National Institute on Drug Abuse (NIDA)","Both","Adult","Phase I|Phase II",120,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","DA016131","July 6, 2006","01/05/2004",2009-03-01,"December 11, 2009","01/12/2009","",2009-03-01,"smoking cesssation","http://ClinicalTrials.gov/show/NCT00349687",NA
"72978",72978,"NCT00354887","Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater","Completed","No Results Available","Gastrointestinal Cancer","Drug: Capecitabine|Drug: Oxaliplatin","M.D. Anderson Cancer Center|Sanofi-Synthelabo","Both","Adult|Senior","Phase II",31,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0827","July 18, 2006","01/11/2004",2009-11-01,"November 3, 2010","01/11/2010","",2009-11-01,"Number of Patients with Response (Complete Response or Partial Response)","http://ClinicalTrials.gov/show/NCT00354887",NA
"72991",72991,"NCT00373087","COMT Polymorphism and Entacapone Efficacy","Completed","No Results Available","Parkinson's Disease","Drug: entacapone|Drug: l dopa versus placebo","Assistance Publique - H??pitaux de Paris","Both","Adult|Senior","Phase IV",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","P051034","September 6, 2006","01/10/2006",2009-11-01,"April 28, 2010","01/07/2007","COMT",2009-11-01,"L-dopa efficacy duration on UPDRS motor scale during an acute L-dopa test|Pharmacokinetics of L-dopa and its metabolites","http://ClinicalTrials.gov/show/NCT00373087",NA
"73024",73024,"NCT00417287","Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer","Completed","No Results Available","Pancreatic Neoplasms","Drug: PX-12","Oncothyreon Inc.|National Cancer Institute (NCI)|Translational Genomics Research Institute, Phoenix, Arizona.","Both","Adult|Senior","Phase II",80,"Industry|NIH|Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PX-12-II-01|P01 CA109552","December 29, 2006","01/12/2006",2009-04-01,"February 3, 2010","01/02/2010","",2009-04-01,"Progression free survival and overall survival (percentage of patients alive at 6 months)|Determine if there is a difference in effect on circulating Trx-1 protein levels between two dose levels of PX-12|Determine which of two dose levels of PX-12 causes the greatest effect on three surrogate markers of clinical activity|Determine effects of two different dose levels on overall clinical response|Further evaluate safety profile of PX-12|Assess the effects of metabolic excretion of PX-12","http://ClinicalTrials.gov/show/NCT00417287",NA
"73038",73038,"NCT00447187","Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk","Completed","No Results Available","Corneal Diseases|Cornea Transplant","Drug: LX201","Lux Biosciences, Inc.","Both","Adult|Senior","Phase III",175,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","LX201-01","March 12, 2007","01/03/2007",2009-09-01,"November 3, 2009","01/11/2009","",2009-09-01,"immunological rejection|graft loss|vision|quality of life","http://ClinicalTrials.gov/show/NCT00447187",NA
"73056",73056,"NCT00477087","Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer","Completed","No Results Available","Prostatic Neoplasms","Drug: Mitoxantrone|Drug: GM-CSF","Stanford University|Bayer","Male","Adult|Senior","Phase II",20,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PROS0017|96817|PROS0017","May 18, 2007","01/07/2006",2010-07-01,"September 10, 2010","01/09/2010","",2009-01-01,"Time to Progression - 1st study drug dose to observation of disease progression (increase >25% over baseline PSA on 2 consecutive measurements 2 weeks apart, need for palliative therapy, formation/progression of new bone lesions, or decline of >20% KPS)|PSA response, defined as the first evidence of a total serum PSA decline of >50% from baseline maintained for at least 28 days and confirmed with two consecutive measurements taken two weeks apart|Time to sustained biochemical response, defined as the time from first administration of drug to first evidence of sustained response|Duration of sustained response, defined as time from PSA decrease of >50% from baseline to the first evidence of disease progression","http://ClinicalTrials.gov/show/NCT00477087",NA
"73057",73057,"NCT00479687","SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder","Completed","No Results Available","Glenohumeral Osteoarthritis of the Shoulder","Device: SUPARTZ|Device: Saline","Smith & Nephew, Inc.|Seikagaku Corporation","Both","Adult|Senior","Phase III",300,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SHO-0106","May 24, 2007","01/05/2007",2009-10-01,"October 27, 2010","01/10/2010","",2009-10-01,"Improvement in shoulder pain compared to subjects treated with placebo|Characteristic effects of pain improvement over a period of 26 weeks.","http://ClinicalTrials.gov/show/NCT00479687",NA
"73065",73065,"NCT00491387","Sympathetic Nervous System Modulation in Hypertension","Completed","No Results Available","Hypertension","Drug: Sustained release metoprolol","University of Cincinnati","Both","Adult|Senior","Phase IV",24,"Other","Interventional","Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","#07-01-12-01","June 21, 2007","01/08/2007",2009-01-01,"September 28, 2010","01/09/2010","",2009-01-01,"Improved left ventricular diastolic function|Improved sympathetic cardiac innervation.","http://ClinicalTrials.gov/show/NCT00491387",NA
"73067",73067,"NCT00493987","The Role of 5-alpha Reductase in Mediating Testosterone Actions","Completed","No Results Available","Healthy","Drug: Testosterone Enanthate|Drug: Dutasteride","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Male","Adult","Phase IV",184,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01HD043348|R01HD043348","June 28, 2007","01/11/2002",2010-03-01,"May 12, 2010","01/01/2009","5aR",2009-12-01,"Change from baseline in fat-free mass, measured by DEXA scanning|Body composition by Deuterium dilution method|Maximal voluntary strength in the leg press and chest press exercises.|Upper and lower extremity muscle power|Muscle volume by MRI scan|Prostate volume by MRI Scan|International Index of Erectile Function|Men's Sexual Health Questionnaire|Davidson Sexual Encounter Profile|Nocturnal penile tumescence and penile rigidity measures|Prostate specific antigen|Hematocrit|Fasting lipid profile / atherogenic markers","http://ClinicalTrials.gov/show/NCT00493987",NA
"73103",73103,"NCT00548587","Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome","Completed","No Results Available","Acute Coronary Syndrome","Drug: E5555|Drug: E5555|Drug: E5555|Drug: Placebo","Eisai Inc.","Both","Adult|Senior","Phase II",600,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","E5555-G000-202","October 22, 2007","01/10/2007",2009-08-01,"September 2, 2009","01/09/2009","",2009-04-01,"Safety and tolerability|Incidence of Major Adverse Cardiovascular Events; Platelet Aggregation Inhibition; Holter Monitoring. Exploratory Outcome Measure: effects on endovascular inflammatory processes","http://ClinicalTrials.gov/show/NCT00548587",NA
"73105",73105,"NCT00553787","Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions","Completed","No Results Available","Obesity|Type 2 Diabetes","Drug: VI-0521|Drug: VI-0521|Drug: VI-0521","VIVUS, Inc.|Medpace, Inc.","Both","Adult|Senior","Phase III",2487,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VIVUS OB-303","November 3, 2007","01/11/2007",2009-06-01,"November 30, 2009","01/11/2009","",2009-06-01,"Demonstrate an improvement over placebo in mean percent loss of baseline body weight and percent of subjects with at least 5% weight loss|Demonstrate improvements in HgbA1c and other obesity-associated comorbidities|Demonstrate an improvement over placebo in absolute weight loss and reduction in waist circumference|Demonstrate an improvement in quality of life","http://ClinicalTrials.gov/show/NCT00553787",NA
"73106",73106,"NCT00551187","A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL","Completed","No Results Available","Cervical Cancer|Vulvar Cancer|Vaginal Cancer|Genital Warts|Human Papillomavirus Infection","Biological: V504|Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Biological: Comparator: Placebo (unspecified)","Merck","Female","Child|Adult","Phase II",620,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","2007_566|V504-001","October 29, 2007","01/10/2007",2009-08-01,"October 27, 2009","01/10/2009","",2009-05-01,"Geometric mean titers (GMTs) to HPV types contained in the administered vaccines|Seroconversion percentages to HPV types contained in the administered vaccines","http://ClinicalTrials.gov/show/NCT00551187",NA
"73116",73116,"NCT00568087","N-acetylcysteine in Alcohol Dependence","Completed","No Results Available","Alcoholism","Drug: N-acetylcysteine|Drug: Placebo","Minneapolis Veterans Affairs Medical Center|Minnesota Veterans Research Institute","Both","Adult","Phase I|Phase II",60,"U.S. Fed|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Protocol #3852-B","December 4, 2007","01/12/2007",2009-08-01,"September 24, 2009","01/09/2009","",2009-08-01,"Alcohol consumption|Liver function tests","http://ClinicalTrials.gov/show/NCT00568087",NA
"73118",73118,"NCT00570687","A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Technosphere Insulin","Mannkind Corporation","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","MKC-TI-118","December 7, 2007","01/09/2007",2009-01-01,"October 23, 2009","01/10/2009","",2009-01-01,"To assess endogenous glucose production (EGP)","http://ClinicalTrials.gov/show/NCT00570687",NA
"73137",73137,"NCT00596687","Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery","Completed","No Results Available","Type 2 Diabetes|Inpatient Hyperglycemia","Drug: Insulin glargine and insulin glulisine|Drug: Regular insulin","Emory University|Sanofi-Aventis","Both","Adult|Senior","Phase IV",282,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","e5062|e5062","January 8, 2008","01/12/2007",2009-12-01,"April 9, 2010","01/04/2010","RABBIT 2-SX",2009-12-01,"To determine differences in glycemic control as measured by mean daily blood glucose concentration between insulin glargine once daily plus supplemental glulisine insulin versus sliding scale regular insulin in surgical patients with type 2 diabetes.|To determine differences between treatment arms in: # of hypoglycemic events, # of episodes of severe hyperglycemia, LOS,rate of post-op complications, and/or need for ICU admission","http://ClinicalTrials.gov/show/NCT00596687",NA
"73153",73153,"NCT00618787","Prospective Randomized Double Blind Clinical Trial of Polyhexamethylene Biguanide Impregnated Foam Dressing","Completed","Has Results","Wounds","Device: COPA AMD (note: name is not an acronym)|Device: COPA (note: name is not an acronym)","Tyco Healthcare Group","Both","Adult|Senior","Phase II",45,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","360.18","January 10, 2008","01/02/2008",2009-04-01,"April 9, 2010","01/04/2010","",2009-04-01,"Prevalence of Signs of Critical Colonization, Deep Infection, and Wound Healing Between the Two Groups|Percentage Change in Wound Surface Area (cm2) at Week 4 Compared to Week 0.|Pain","http://ClinicalTrials.gov/show/NCT00618787",NA
"73162",73162,"NCT00607087","Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Insulin glulisine|Drug: Insulin lispro|Drug: Insulin aspart","Sanofi-Aventis","Both","Adult|Senior","Phase IV",289,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","APIDR_C_02083|2007-003579-38","January 23, 2008","01/01/2008",2009-06-01,"August 26, 2010","01/08/2010","PUMP",2009-06-01,"Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion|Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion|Percentage of Patients With at Least One Unexplained Hyperglycemia|Monthly Rate of Unexplained Hyperglycemia|Percentage of Patients With at Least One Confirmed Infusion Set Occlusion|Monthly Rate of Confirmed Infusion Set Occlusion|Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis|Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis|Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ??? 70 mg/dL Per Patient-year|Rate of Severe Symptomatic Hypoglycemia Per Patient-year|Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ???70 mg/dL Per Patient-year|Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site|Time Interval Between Infusion Set Changes: All Changes|Time Interval Between Infusion Set Changes in Routine|Glycosylated Hemoglobin: HbA1c|Total Daily Basal Insulin Infusion|Total Daily Bolus Insulin Dose","http://ClinicalTrials.gov/show/NCT00607087",NA
"73193",73193,"NCT00691587","Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa","Completed","No Results Available","Pseudomonas Aeruginosa|Ventilator Associated Pneumonia","Biological: KB001|Biological: KB001|Biological: Placebo","KaloBios Pharmaceuticals","Both","Adult|Senior","Phase I|Phase II",36,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","KB001-04","June 3, 2008","01/04/2008",2009-04-01,"July 29, 2009","01/07/2009","",2009-03-01,"The safety and tolerability of a single dose of KB001.|To measure the pharmacodynamic effects of a single-dose of KB001.","http://ClinicalTrials.gov/show/NCT00691587",NA
"73212",73212,"NCT00726687","Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors","Completed","No Results Available","Advanced Solid Tumors","Drug: indibulin|Drug: capecitabine","ZIOPHARM","Both","Adult|Senior","Phase I|Phase II",30,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IBL1005","July 29, 2008","01/06/2008",2009-02-01,"October 12, 2010","01/10/2010","",2009-02-01,"toxicities|pharmacokinetics","http://ClinicalTrials.gov/show/NCT00726687",NA
"73235",73235,"NCT00764387","Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.","Completed","No Results Available","Neoplastic CNS Lesions","Drug: Gadovist?ó (Gadobutrol, BAY86-4875)|Drug: Dotarem","Bayer","Both","Adult|Senior","Phase IV",166,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","91780|EudraCT 2007-005693-31|312021","July 3, 2008","01/03/2008",2009-05-01,"October 12, 2009","01/10/2009","",2009-05-01,"The primary analysis will be the comparison of the enhancements characteristics of Gadobutrol and Gd-TOTA on a lesion per lesion basis.","http://ClinicalTrials.gov/show/NCT00764387",NA
"73237",73237,"NCT00772187","Intraoperative and Postoperative Analgesia for Laparoscopic Surgery.","Completed","No Results Available","Analgesia","Drug: morphine|Drug: intrathecal analgesia (morphine)|Drug: general anesthesia (fentanyl)","Rambam Health Care Campus","Both","Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","Rambam2690CTIL","May 21, 2008","01/10/2007",2009-09-01,"September 21, 2010","01/07/2010","",2009-09-01,"Good analgesic method with minimal side effect.","http://ClinicalTrials.gov/show/NCT00772187",NA
"73247",73247,"NCT00735787","Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet","Completed","Has Results","Psoriasis","Biological: Placebo|Biological: Adalimumab","Abbott","Both","Adult|Senior","Phase IV",81,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","M10-405","August 13, 2008","01/08/2008",2009-09-01,"October 11, 2010","01/10/2010","",2009-09-01,"Number of Subjects With Physician's Global Assessment of Psoriasis (PGA) of Clear or Almost Clear at Week 16|Mean Change From Baseline in Erythema, Scaling, Induration, and Fissuring (ESIF)|Mean Change From Baseline in ESIF for Palms|Mean Change From Baseline in ESIF for Soles|Number of Subjects With Moderate Improvement in ESIF From Baseline|Number of Subjects With Marked Improvement in ESIF From Baseline|Mean Change From Baseline in Nail Psoriasis Severity Index (NAPSI)|Number of Subjects With Physicians Global Assessment of Psoriasis (PGA) of Clear, Almost Clear, or Mild|Number of Subjects With PGA of Clear or Almost Clear|Number of Subjects With PGA of Clear|Number of Subjects With Psoriasis Area and Severity Index (PASI) 50|Number of Subjects With PASI 75|Number of Subjects With PASI 90|Number of Subjects With PASI 100|Mean Change From Baseline in Dermatology Life Quality Index (DLQI)|Number of Subjects Achieving a DLQI of 0|Mean Change From Baseline in Visual Analog Scale (VAS) for Psoriasis and Psoriatic Arthritis Pain|Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO)|Mean Change From Baseline in Patient Health Questionnaire (PHQ-9)|Number of Subjects With Difficulties According to PHQ-9","http://ClinicalTrials.gov/show/NCT00735787",NA
"73256",73256,"NCT00804687","Safety and Efficacy of JNJ-39220675 in Participants With Allergic Rhinitis","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: JNJ-39220675; Pseudoephedrine; Placebo","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult","Phase II",53,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind|Primary Purpose: Treatment","CR015709","December 8, 2008","01/11/2008",2009-02-01,"April 26, 2010","01/04/2010","",2009-02-01,"To evaluate the efficacy of JNJ 39220675 and pseudoephedrine compared to placebo by evaluating nasal congestion using acoustic rhinometry (AcR) before and after treatment|Evaluation of the Total Nasal Symptom Scores (TNSS), a scale participants complete to assess their nasal symptoms","http://ClinicalTrials.gov/show/NCT00804687",NA
"73278",73278,"NCT00841087","Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: insulin aspart|Drug: NN1250|Drug: insulin detemir","Novo Nordisk","Both","Adult|Senior","Phase II",65,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NN1250-3569|JAPIC: JapicCTI-090711","February 10, 2009","01/01/2009",2009-05-01,"November 9, 2009","01/10/2009","",2009-05-01,"The incidence of hypoglycaemic episodes during the 6 weeks of treatment|Adverse events|body weight|12-lead ECG|Blood pressure","http://ClinicalTrials.gov/show/NCT00841087",NA
"73304",73304,"NCT00882687","Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis","Completed","No Results Available","Allergic Conjunctivitis","Drug: SAR 1118|Other: Placebo","SARcode Corporation","Both","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1118-ACJ-100","April 15, 2009","01/04/2009",2009-05-01,"May 12, 2009","01/05/2009","",2009-05-01,"Ocular itching and conjunctival redness at defined timepoints.|Safety and tolerability in subjects with allergic conjunctivitis.","http://ClinicalTrials.gov/show/NCT00882687",NA
"73320",73320,"NCT00907387","Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","Completed","No Results Available","Lateral Canthal Lines","Drug: RT001|Drug: RT001|Other: Placebo","Revance Therapeutics, Inc.","Both","Adult","Phase II|Phase III",72,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","RT001-CL010LCL","May 20, 2009","01/04/2009",2009-10-01,"September 28, 2010","01/09/2010","",2009-10-01,"The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Rest from Baseline (Day 0) to Day 28|Incidence of treatment-emergent adverse events","http://ClinicalTrials.gov/show/NCT00907387",NA
"73330",73330,"NCT00799487","CONCERTA Lab School Study on Older Children With ADHD","Completed","Has Results","Attention Deficit Hyperactivity Disorder","Drug: CONCERTA (methylphenidate HCl)|Drug: Placebo","Ortho-McNeil Janssen Scientific Affairs, LLC","Both","Child","Phase IV",89,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CR015118","November 26, 2008","01/11/2008",2009-06-01,"November 8, 2010","01/11/2010","ABC",2009-06-01,"Hour 4 Permanent Product Math Test Attempted Score (PERMP-Attempted)|Hour 4 Permanent Product Math Test Correct Score (PERMP-Correct)|Hour 4 Swanson, Kotkin, Alger, M-Flynn and Pelham Scale for Deportment (SKAMP-Deportment)|Hour 4 Swanson, Kotkin, Alger, M-Flynn and Pelham Scale for Attention (SKAMP-Attention)|Hour 4 Swanson, Kotkin, Alger, M-Flynn and Pelham Scale for Composite (SKAMP-Composite)|Hour 5.5 Test of Variables of Attention (TOVA) ADHD Score|Hour 5.5 Test of Variables of Attention (TOVA) Reaction Time (Msec)|Hour 5.5 Test of Variables of Attention(TOVA) Reaction Time Variability (Standard Deviation in Milliseconds (Msecs))|Hour 5.5 Wide Range Assessment of Memory and Learning (WRAML-2) Finger Windows Backwards|Hour 5.5 Wide Range Assessment of Memory and Learning (WRAML-2) Finger Windows Forwards|Hour 5.5 Test of Variables of Attention (TOVA) Commissions|Hour 5.5 Wechsler Intelligence Scale for Children - 3rd ed. (WISC-III-PI) Digit Span Backwards|Hour 8.75 Gray Silent Reading Test (GSRT)|Hour 7.5 Test of Handwriting Skills (Revised) (THS-R)|Hour 3.5 Dynamic Indicators of Basic Early Literacy Skills (DIBELS)|Hour 5.5 Wechsler Intelligence Scale for Children - 3rd ed. (WISC-III-PI) Digit Span Forwards|Hour 5.5 Test of Variables of Attention (TOVA) Omissions|Hour 3.0 Grammar Task|Hour 8.75 Packet Activity - Short Story With Questions for Comprehension|Hour 8.75 Packet Activity - Identiy Root Word|Hour 8.75 Packet Activity - Alphabetize List of Words|Hour 8.75 Packet Activity - Identify Multiple Meanings for Words|Hour 8.75 Packet Activity - Complete Sentences Using Words Provided|Hour 8.75 Packet Activity - Word Search|Hour 8.75 Packet Activity - Decode the Mystery Sentence","http://ClinicalTrials.gov/show/NCT00799487",NA
"73358",73358,"NCT00967187","Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.","Completed","No Results Available","HIV Infections","Drug: bevirimat dimeglumine|Drug: bevirimat dimeglumine","Myrexis Inc.","Both","Adult|Senior","Phase II",32,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MPC-4326-204|BVM Study 204","August 25, 2009","01/05/2008",2009-12-01,"January 4, 2010","01/01/2010","",2009-11-01,"Change in HIV-1 viral load from baseline to day 15|To evaluate safety and tolerability","http://ClinicalTrials.gov/show/NCT00967187",NA
"73373",73373,"NCT00987987","Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion","Completed","No Results Available","Hematological Malignancy|Relapse","Procedure: donor lymphocyte infusion","Assistance Publique - H??pitaux de Paris|Universit?¢ Paris XII|Universit?¢ Paris VI","Both","Adult|Senior","Phase I|Phase II",21,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P040441","September 30, 2009","01/12/2005",2009-12-01,"January 5, 2010","01/09/2009","ILD-Treg",2009-12-01,"Incidence of \severe\"" GHVD (grade >II) following dDLI should be inferior to 40%.|The incidence of GVHD of any grade after dDLI|The anti-tumoral efficiency of dDLI to treat the relapse of the hematological malignancy|The survival and the survival without disease after dDLI""","http://ClinicalTrials.gov/show/NCT00987987",NA
"73572",73572,"NCT00004888","Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: docetaxel|Drug: pegylated liposomal doxorubicin hydrochloride","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Female","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067564|ECOG-3198","March 7, 2000","01/10/2000",NA,"May 29, 2009","01/04/2004","",2009-05-01,"","http://ClinicalTrials.gov/show/NCT00004888",NA
"73699",73699,"NCT00185588","Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: PTK787/ZK 222584|Drug: Gemcitabine","Stanford University|Novartis","Both","Adult|Senior","Phase I|Phase II",32,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PANC0002|95533|CPTK787AUS08|PANC0002","September 12, 2005","01/10/2004",2009-12-01,"June 18, 2010","01/06/2010","",2009-01-01,"Optimal safe and tolerable dose (MTD) of gemcitabine in combination with the 1250 mg continuous once daily dose of PTK/ZK.|Efficacy, as reflected in objective response rate, of the PTK/ZK and gemcitabine combination in patients with advanced pancreatic cancer.|Efficacy, as reflected in time to progression, of the PTK/ZK and gemcitabine combination in patients with advanced pancreatic cancer.|Efficacy, as reflected in overall survival, of the PTK/ZK and gemcitabine combination in patients with advanced pancreatic cancer.|Effect of the PTK/ZK and gemcitabine combination on DCE-MRI determinants of tumor perfusion.","http://ClinicalTrials.gov/show/NCT00185588",NA
"73737",73737,"NCT00259688","Prevalence Study of Sleep Apnea in Women With Preeclampsia","Completed","No Results Available","Preeclampsia","Device: CPAP therapy for subjects diagnosed with sleep apnea","University of Saskatchewan|Saskatchewan Health Research Foundation","Female","Adult|Senior","Phase II",60,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","BIO-REB 05-110","November 28, 2005","01/02/2006",2009-11-01,"January 7, 2010","01/01/2010","",2009-10-01,"Determine the prevalence of sleep apnea in preeclampsia and pregnancy.|For those subjects diagnoses with sleep apnea: Improvement in blood pressure and electronic fetal monitoring during with use of CPAP.","http://ClinicalTrials.gov/show/NCT00259688",NA
"73747",73747,"NCT00272688","Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit","Completed","No Results Available","Parkinson Disease","Drug: Levodopa (drug), intraduodenal administration","University Hospital, Akershus|Solvay Pharmaceuticals","Both","Child|Adult|Senior","Phase IV",10,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Duo-HRQoL-2","January 6, 2006","01/01/2006",2009-05-01,"July 31, 2009","01/07/2009","",2009-05-01,"Marginal cost per QALY of replacing conventional treatment with intraduodenal levodopa|Quality of life at three, six, nine and twelve months(Assessed by Nottingham Health Profile (NHP), Parkinson Disease Questionnaire (PDQ39), 15D Quality of life)|Parkinson related function at three, six, nine and twelve months(UPDRS, Hoehn and Yahr scores, Schwab and England)","http://ClinicalTrials.gov/show/NCT00272688",NA
"73764",73764,"NCT00299988","Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: Intravenous Immunoglobulin","Weill Medical College of Cornell University|Baxter BioScience|National Institutes of Health (NIH)","Both","Adult|Senior","Phase II",24,"Other|Industry|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","512008265","March 3, 2006","01/02/2006",2010-04-01,"November 8, 2010","01/11/2010","",2009-01-01,"ADAS-Cog|ADCS-CGIC|3MS|ADCS-ADL|NPI|GDS|QOL|ADCS Pharmacoeconomic Assessment|Plasma and CSF anti-amyloid antibody titers|Plasma and CSF beta amyloid levels|FDG Cerebral Glucose Utilization|PIB Cerebral Amyloid Distribution (PET)|PK11195 Microglial Activation (PET)|Adverse Event Frequency and Severity","http://ClinicalTrials.gov/show/NCT00299988",NA
"73765",73765,"NCT00305188","Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.","Completed","No Results Available","Metastases|Colorectal Neoplasms|Colorectal Carcinoma","Drug: xaliproden (SR57746A)|Drug: Placebo|Drug: oxaliplatin","Sanofi-Aventis","Both","Adult|Senior","Phase III",879,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","EFC5505|EUDRACT : 2005-002570-30","March 20, 2006","01/12/2005",2009-10-01,"December 16, 2010","01/12/2010","",2009-10-01,"Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment|Main: response rate using RECIST criteria|Other: nerve conduction studies|Other: progression free survival and survival","http://ClinicalTrials.gov/show/NCT00305188",NA
"73769",73769,"NCT00312988","Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy","Completed","No Results Available","Ovarian Cancer","Drug: Hycamtin|Drug: Gemcitabine","North Eastern Germany Society of Gynaecologic Oncology","Female","Adult|Senior","Phase III",450,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","031000|Topo Phase III","September 9, 2005","01/01/2000",2009-12-01,"April 10, 2006","01/09/2005","",2009-12-01,"overall survival|time to progression|determining adverse effects|quality of life","http://ClinicalTrials.gov/show/NCT00312988",NA
"73794",73794,"NCT00338988","Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma","Completed","Has Results","Cancer of the Gallbladder|Cancer of the Biliary Tract","Drug: Capecitabine|Drug: Oxaliplatin","M.D. Anderson Cancer Center|Sanofi-Synthelabo","Both","Adult|Senior","Phase II",44,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0340","June 16, 2006","01/08/2003",2009-05-01,"November 3, 2010","01/11/2010","",2009-05-01,"Number of Patients With Objective Response|Patient Toxicity","http://ClinicalTrials.gov/show/NCT00338988",NA
"73807",73807,"NCT00381888","Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer","Completed","Has Results","Cervical Cancer|Endometrial Cancer|Fallopian Tube Cancer|Ovarian Cancer|Sarcoma|Thromboembolism|Vaginal Cancer|Vulvar Cancer","Drug: fondaparinux sodium","Masonic Cancer Center, University of Minnesota","Female","Adult|Senior","Phase II",44,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000503985|UMN-2006LS009|UMN-0603M82707","September 26, 2006","01/01/2007",2009-01-01,"January 26, 2010","01/01/2010","",2009-01-01,"Number of Patients With Venous Thromboembolism at Week 4|Number of Patients Who Achieved Thromboembolism Prophylaxis at Week 4.","http://ClinicalTrials.gov/show/NCT00381888",NA
"73848",73848,"NCT00449488","Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction","Completed","No Results Available","Myocardial Infarction","Drug: epoetin alfa","University Medical Centre Groningen|The Interuniversity Cardiology Institute of the Netherlands|Janssen-Cilag Ltd.","Both","Adult|Senior","Phase II",529,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","B213|ISRCTN46528154","March 18, 2007","01/01/2007",2009-10-01,"December 14, 2009","01/12/2009","HEBEIII",2009-10-01,"Left ventricular ejection fraction 6 weeks after primary PCI, measured with planar radionuclide ventriculography|Safety, myocardial infarct size, and cardiovascular events at 6 weeks after a single bolus of EPO","http://ClinicalTrials.gov/show/NCT00449488",NA
"73852",73852,"NCT00445588","Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: erlotinib hydrochloride|Drug: sorafenib tosylate|Genetic: gene expression analysis|Genetic: mutation analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: mass spectrometry|Other: pharmacological study|Procedure: biopsy","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",56,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000531731|NABTT-0502","March 7, 2007","01/01/2007",NA,"August 27, 2009","01/10/2008","",2009-08-01,"Overall survival|Six-month progression-free survival|Tumor response rate|Toxicity as measured by CTCAE v 3.0|Pharmacokinetics of erlotinib hydrochloride and sorafenib tosylate|Relationship between tumor and blood biomarkers and clinical outcome","http://ClinicalTrials.gov/show/NCT00445588",NA
"73853",73853,"NCT00459888","Cryoplasty CLIMB-registry","Completed","No Results Available","Critical Limb Ischemia|Peripheral Arterial Occlusive Disease","Device: PolarCath Peripheral Dilatation System (Boston Scientific)","Flanders Medical Research Program","Both","Child|Adult|Senior","Phase IV",100,"Other","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FMRP-001","April 12, 2007","01/05/2007",2009-05-01,"July 2, 2010","01/07/2010","CLIMB",2009-05-01,"Clinical patency|Technical success|angiographic outcomes for the subgroup of patients in which made available.|Primary patency rate|Limb-salvage rate|Serious adverse events|Clinical success (improvement of Rutherford classification)|Health Economics assessment","http://ClinicalTrials.gov/show/NCT00459888",NA
"73855",73855,"NCT00462488","Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ","Completed","No Results Available","Urinary Bladder Cancer|Bladder Cancer|Bladder Neoplasms|Bladder Tumors","Drug: Vicinium","Viventia Biotech","Both","Adult|Senior","Phase II",46,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VB4-845-02-IIA","April 17, 2007","01/03/2007",2009-10-01,"December 2, 2009","01/12/2009","",2009-10-01,"Treatment Schedule A: 12-Week Efficacy, Treatment Schedule B: 13-Week Efficacy","http://ClinicalTrials.gov/show/NCT00462488",NA
"73864",73864,"NCT00387088","Tiotropium / Respimat One Year Study in COPD.","Completed","Has Results","Pulmonary Disease, Chronic Obstructive","Device: Respimat|Drug: Tiotropium","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",3991,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","205.372|2006-001009-27","October 11, 2006","01/09/2006",NA,"September 1, 2010","01/09/2010","",2009-01-01,"Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337|Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation|Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29|Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 169|Number of COPD Exacerbations Per Patient - Exposure Adjusted|Number of COPD Exacerbations Per Patient - na??ve Estimate|Number of Patients With at Least One COPD Exacerbation|Time to First Hospitalisation for COPD Exacerbation|Number of Hospitalisations for COPD Exacerbations Per Patient - Exposure Adjusted|Number of Hospitalisations for COPD Exacerbations Per Patient - na??ve Estimate|Number of Patients With at Least One Hospitalisation for a COPD Exacerbation|Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 337|Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 169|Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 29|Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 169|Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 337","http://ClinicalTrials.gov/show/NCT00387088",NA
"73888",73888,"NCT00515788","DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis","Completed","No Results Available","Neoplastic Meningitis","Drug: DepoCyt|Drug: Temozolomide","M.D. Anderson Cancer Center|Enzon Pharmaceuticals, Inc.|Schering-Plough","Both","Adult|Senior","Phase I|Phase II",11,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0135","August 13, 2007","01/02/2006",2009-06-01,"June 30, 2009","01/06/2009","",2009-06-01,"Maximum Tolerated Dose","http://ClinicalTrials.gov/show/NCT00515788",NA
"73894",73894,"NCT00523588","Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser","Completed","No Results Available","Cutaneous Lupus Erythematosus","Procedure: laser treatment (Candela Vbeam Perfecta?ºÑ)","University of Pennsylvania","Both","Adult|Senior","Phase II",10,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","805209","August 30, 2007","01/03/2007",2010-01-01,"June 24, 2010","01/01/2010","",2009-02-01,"Comparison of laser treated CLE skin lesions with a non-treated control CLE lesion of the same patient evaluated by the CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) and the M-CLASI (Modified CLASI).|Pain and itch relief compared to baseline and between the treated and untreated lesion|Reduction or increase in CLASI and MCLASI scores compared to baseline, and adverse events","http://ClinicalTrials.gov/show/NCT00523588",NA
"73911",73911,"NCT00527488","Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.","Completed","Has Results","BPH","Drug: Degarelix|Drug: Degarelix|Drug: Degarelix|Drug: Degarelix","Ferring Pharmaceuticals","Male","Adult|Senior","Phase II",52,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FE200486 CS25|EudraCT Number: 2007-003578-04","September 10, 2007","01/10/2007",2009-05-01,"October 27, 2010","01/10/2010","",2009-03-01,"Testosterone Area Below Baseline Interval|Time of Testosterone Concentration Below Baseline Interval|Minimal Value of Testosterone (Cnadir)|Time of Minimal Value of Testosterone (Tnadir)|Duration of Testosterone Concentration Below 0.5 ng/mL|Number of Subjects With Testosterone Concentration ???0.5 ng/mL|Number of Subjects With Testosterone Concentration at or Above the Baseline Interval Concentration|Prostate Specific Antigen (PSA) Concentration|Prostate Volume|Maximal Urinary Flow|Post-void Residual Urine Volume|International Prostate Specific Symptom (IPSS) Score|IPSS Global Quality of Life|Interntional Iindes of Erectile Function (IIEF) Score: Overall Satisfaction|Pharmacokinetic Parameters of Degarelix: AUCt|Pharmacokinetic Parameters of Degarelix: Cmax|Pharmacokinetic Parameters of Degarelix: Tmax","http://ClinicalTrials.gov/show/NCT00527488",NA
"73912",73912,"NCT00552188","Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event","Completed","No Results Available","Acute Coronary Syndrome","Drug: VIA-2291|Drug: Placebo","VIA Pharmaceuticals|Massachusetts General Hospital|Mount Sinai School of Medicine|University of Massachusetts, Worcester|Winthrop University Hospital|Montreal Heart Institute","Both","Adult|Senior","Phase II",52,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VIA-2291-03","October 31, 2007","01/10/2007",2009-11-01,"December 15, 2009","01/12/2009","",2009-10-01,"Change from baseline in plaque imaging|Change from baseline in plaque imaging","http://ClinicalTrials.gov/show/NCT00552188",NA
"73938",73938,"NCT00592488","Acetyl-L-Carnitine in the Treatment of Septic Shock","Completed","No Results Available","Septic Shock","Drug: Acetyl-L-Carnitine","Vanderbilt University","Both","Adult|Senior","Phase I|Phase II",16,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","50730","January 2, 2008","01/08/2006",2009-09-01,"January 13, 2010","01/01/2010","ALC",2009-08-01,"mean arterial blood pressure|vasopressor dose|serum lactate","http://ClinicalTrials.gov/show/NCT00592488",NA
"73945",73945,"NCT00562588","EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA","Completed","Has Results","Cerebrovascular Accident","Drug: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)|Drug: ASA 100 mg qd","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase IV",551,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","9.182","July 6, 2007","01/07/2007",NA,"July 1, 2010","01/07/2010","",2009-02-01,"Telephone Modified Rankin Scale (Centralised, Blinded Assessment)|Change From Baseline in NIHSS (National Institutes of Health Stroke Scale)|Patients With Relevant Event (Death, Non-fatal Stroke, Transient Ischaemic Attack (TIA), Myocardial Infarction (MI), Bleeding)","http://ClinicalTrials.gov/show/NCT00562588",NA
"73961",73961,"NCT00575588","52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea","Completed","Has Results","Type 2 Diabetes","Drug: Metformin|Drug: Sulphonylurea|Drug: Saxagliptin","AstraZeneca|Bristol-Myers Squibb","Both","Adult|Senior","Phase III",891,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","D1680C00001|EudraCT number 2007-003998-55","December 14, 2007","01/12/2007",2010-08-01,"November 5, 2010","01/11/2010","",2009-08-01,"Hemoglobin A1c (HbA1c) Change From Baseline to Week 52|Proportion of Participants Reporting at Least One Episode of Any Hypoglycaemic Event Over 52 Weeks|Body Weight Change From Baseline to Week 52 (LOCF)|Mean Slope of the Regressions of Change From Week 24 to Week 52 in HbA1c","http://ClinicalTrials.gov/show/NCT00575588",NA
"73965",73965,"NCT00631488","A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: MK0893|Drug: Comparator: sitagliptin phosphate|Drug: Comparator: Metformin hydrochloride|Drug: Comparator: Placebo (Unspecified)","Merck","Both","Adult","Phase II",126,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2007_646|MK0893-015","February 21, 2008","01/02/2008",2009-01-01,"February 5, 2009","01/02/2009","",2009-01-01,"The effect of treatment of MK0893 in combination with sitagliptin or with metformin compared to the combination of sitagliptin and metformin on 24-hour weighted mean glucose levels after 4 weeks|To assess the safety and tolerability of MK0893 after 4 weeks","http://ClinicalTrials.gov/show/NCT00631488",NA
"73983",73983,"NCT00658788","Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis","Completed","No Results Available","Psoriasis","Drug: clobetasol propionate spray 0.05%|Drug: calcitriol ointment","Galderma Laboratories, L.P.","Both","Adult|Senior","Phase III",305,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","US10085","March 4, 2008","01/03/2008",2009-01-01,"August 31, 2009","01/08/2009","",2009-01-01,"Percent of Subjects with an improvement from baseline in Overall Disease Severity score|Efficacy - Percent of Subjects with an improvement from baseline in Overall Disease Severity score|Efficacy - Overall Disease Severity, Global Improvement Score, Signs of Psoriasis, Percent change from baseline in Body Surface Area|Efficacy - Koo-Menter Psoriasis Qualify of Life Questionnaire; Subject Satisfaction Survey|Safety - Tolerability, adverse events","http://ClinicalTrials.gov/show/NCT00658788",NA
"73997",73997,"NCT00686088","An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy","Completed","No Results Available","Locally Recurrent Prostate Cancer","Drug: PRX302","Protox Therapeutics","Male","Adult|Senior","Phase II",30,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PRX302-1-02","May 26, 2008","01/02/2008",2009-09-01,"October 27, 2009","01/09/2009","",2009-09-01,"PSA levels, PSA doubling time, PSA velocity and tumor burden assessment by biopsy compared to screening.|Safety and tolerability of PRX302.","http://ClinicalTrials.gov/show/NCT00686088",NA
"74037",74037,"NCT00714688","A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder","Completed","Has Results","Attention Deficit/ Hyperactivity Disorder","Drug: prolonged release (PR) OROS methylphenidate 54 mg|Drug: prolonged release (PR) OROS methylphenidate 72 mg|Drug: Placebo","Janssen-Cilag International NV","Both","Adult","Phase III",279,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR014566|42603ATT3013","July 10, 2008","01/01/2008",2009-04-01,"July 13, 2010","01/07/2010","",2009-04-01,"Attention Deficit/Hyperactivity Disorder (ADHD) Symptoms Total Score of the Conners Adult ADHD Rating Scale (CAARS)|Change in Clinical Global Impression-Severity (CGI-S) From Baseline to End of Treatment|Clinical Global Impression-Change (CGI-C)|Change in Conners Adult ADHD Rating Scale Self Report Short Version (CAARS-S:S) Total Score","http://ClinicalTrials.gov/show/NCT00714688",NA
"74050",74050,"NCT00765388","A Randomised Cross-over Study With Two 1-piece Urostomy Bags.","Completed","No Results Available","Urologic Surgical Procedures","Device: SenSura Uro|Device: Hollister","Coloplast A/S","Both","Adult|Senior","Phase IV",30,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label","DK188OS","October 1, 2008","01/10/2008",2009-05-01,"November 27, 2009","01/11/2009","DK188OS",2009-05-01,"Preference|Awareness","http://ClinicalTrials.gov/show/NCT00765388",NA
"74065",74065,"NCT00786188","Eight-Week Efficacy & Safety Study of Mesafem in the Treatment of VMS Associated With Menopause","Completed","No Results Available","Hot Flashes","Drug: Mesafem|Drug: Sugar pill","Noven Therapeutics","Female","Adult|Senior","Phase II",103,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","N30-002","November 4, 2008","01/11/2008",2009-06-01,"December 30, 2010","01/12/2010","",2009-06-01,"Mean change in frequency of moderate to severe VMS from baseline to Week 4 and Week 8|Change from baseline in climacteric symptoms at Week 8.","http://ClinicalTrials.gov/show/NCT00786188",NA
"74069",74069,"NCT00793988","Vibration-Assisted Anaesthesia","Completed","No Results Available","Dermatochalasis|Blepharoptosis","Procedure: Vibration-assisted anaesthesia|Procedure: Switched-off vibrating device","University of British Columbia","Both","Child|Adult|Senior","Phase IV",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H08-02244","November 18, 2008","01/10/2008",2009-04-01,"April 2, 2009","01/04/2009","",2009-04-01,"Patients' verbal pain scores will be elicited and documented immediately by the oculoplastic fellow.","http://ClinicalTrials.gov/show/NCT00793988",NA
"74089",74089,"NCT00831688","Efficacy of Local Overpressure Treatment for Meniere's Disease","Completed","No Results Available","Meniere's Disease","Device: Meniett(C) device by MedTronic|Device: placebo treatment","Klinikum der Universitaet Muenchen, Grosshadern","Both","Adult|Senior","Phase IV",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","Meniere trial 037/05","January 28, 2009","01/08/2005",2009-04-01,"April 20, 2009","01/04/2009","",2009-04-01,"Change in vertigo score from pre-therapy to post-therapy. (Vertigo score = summation of daily vertigo severity over 4 weeks. Daily vertigo score = a number between = and 4.)|Pure tone audiometric thresholds|Speech recognition hearing levels|Horizontal semicircular canal paresis|Subjective Daily Activity levels (Number between 0 and 4)","http://ClinicalTrials.gov/show/NCT00831688",NA
"74116",74116,"NCT00871988","Nasolabial Fold Filler Study for People of Color","Completed","No Results Available","Bilateral Wrinkles in the Nasolabial Area","Drug: EVOLENCE","DeNova Research|Johnson & Johnson","Both","Adult|Senior","Phase IV",30,"Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DP101-US-04","March 27, 2009","01/11/2008",2009-11-01,"October 19, 2010","01/10/2010","",2009-11-01,"To assess the safety EVOLENCE?ó in subjects with Fitzpatrick Skin Color Types IV, V, and VI seeking correction of facial wrinkles in accordance with the approved device labeling including for example correction of the nasolabial wrinkle /folds.|To assess the device effectiveness in skin types IV, V, and VI","http://ClinicalTrials.gov/show/NCT00871988",NA
"74132",74132,"NCT00905788","Embryo Transfer: Embryo Expulsion and Outcome","Completed","No Results Available","Infertility","Procedure: prevention of embryo expulsion","Royan Institute","Female","Adult","Phase I|Phase II",134,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Royan-Emb-001","May 20, 2009","01/02/2008",2009-12-01,"April 17, 2010","01/04/2010","",2009-07-01,"Clinical pregnancy|Implantation rate","http://ClinicalTrials.gov/show/NCT00905788",NA
"74154",74154,"NCT00939588","Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients","Completed","No Results Available","Hypertension","Drug: Aliskiren/ Valsartan|Drug: Telmisartan/ Ramipril","Novartis Pharmaceuticals","Both","Adult","Phase II",88,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CSPV100A2225","July 9, 2009","01/07/2009",NA,"February 15, 2010","01/02/2010","",2009-12-01,"Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on 24-hour urinary aldosterone|Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on Plasma Renin Activity (PRA)and angiotensin II|Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on mean sitting systolic and diastolic blood pressure|Assess safety and tolerability of aliskiren + valsartan and ramipril + telmisartan","http://ClinicalTrials.gov/show/NCT00939588",NA
"74159",74159,"NCT00813488","Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain","Completed","Has Results","Chronic Pain","Drug: Fentanyl Buccal Tablet|Drug: Immediate release oxycodone","Cephalon","Both","Adult|Senior","Phase III",213,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C25608/3056/BP/US","December 19, 2008","01/12/2008",2010-01-01,"January 15, 2011","01/01/2011","",2009-11-01,"Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15)|Pain Intensity Difference (PID) at 5 Minutes Post-treatment|Pain Intensity Difference (PID) at 10 Minutes Post-treatment|Pain Intensity Difference (PID) at 30 Minutes Post-treatment|Pain Intensity Difference (PID) at 45 Minutes Post-treatment|Pain Intensity Difference (PID) at 60 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 5 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 10 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 15 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 30 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 45 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 60 Minutes Post-treatment|Sum of Pain Intensity Difference at 30 Minutes Post-treatment (SPID30)|Sum of Pain Intensity Difference at 60 Minutes Post-treatment (SPID60)|Pain Relief (PR) Score at 5 Minutes Post-treatment|Pain Relief Score at 10 Minutes Post-treatment|Pain Relief Score at 15 Minutes Post-treatment|Pain Relief Score at 30 Minutes Post-treatment|Pain Relief Score at 45 Minutes Post-treatment|Pain Relief Score at 60 Minutes Post-treatment|Total Pain Relief at 60 Minutes (TOTPAR60)|Percent Total Pain Relief at 60 Minutes Posttreatment (%TOTPAR)|Time to Any Pain Relief (APR) by Treatment - <= 5 Minutes|Time to Any Pain Relief (APR) by Treatment <=10 Minutes|Time to Any Pain Relief (APR) by Treatment <=15 Minutes|Time to Any Pain Relief (APR) by Treatment <=30 Minutes|Time to Any Pain Relief (APR) by Treatment <=45 Minutes|Time to Any Pain Relief (APR) by Treatment <=60 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment - <= 5 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=10 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=15 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=30 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=45 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=60 Minutes|Use of Standard Rescue Medication|Medication Performance Assessment 30 Minutes Post-treatment|Medication Performance Assessment 60 Minutes Post-treatment|Breakthrough Pain Preference Questionnaire|Patient Global Impression of Change (PGIC) at Visit 7- 1 Month After Open Label Treatment|Patient Global Impression of Change (PGIC) at Visit 8- 2 Months After Open Label Treatment|Patient Global Impression of Change (PGIC) at Visit 9- 3 Months After Open Label Treatment|Patient Global Impression of Change (PGIC) Endpoint|Clinician Global Impression of Change at Visit 7- 1 Month After Open Label Treatment|Clinician Global Impression of Change (CGIC) at Visit 8- 2 Months After Open Label Treatment|Clinician Global Impression of Change (CGIC) at Visit 9- 3 Months After Open Label Treatment|Clinician Global Impression of Change (CGIC)Endpoint","http://ClinicalTrials.gov/show/NCT00813488",NA
"74198",74198,"NCT00998088","Blood Management in Orthopedic Surgery","Completed","No Results Available","Osteoarthritis","Other: erythropoietin and cell saver|Drug: erythropoietin|Device: OrthoPAT|Device: Post-operative drain device|Other: Erythropoietin and OrthoPAT|Other: Erythropoietin and drain device|Device: OrthoPAT","Sanquin Research & Blood Bank Divisions|ZonMw: The Netherlands Organisation for Health Research and Development|Roche BV Netherlands|Haemonetics Corporation","Both","Adult|Senior","Phase IV",2598,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","ISRCTN96327523|ISRCTN96327523|NTR303|ZonMW945-06-601|Sanquin PPOC-03-002","October 19, 2009","01/05/2004",2009-09-01,"October 19, 2009","01/10/2009","TOMaat",2009-09-01,"Number of allogeneic red blood cell (RBC) transfusions.|Peri- and post-operative complications during hospitalization|Rehabilitation time|Hb/Ht post-operative|Quality of life|Transfusion reactions|Harris hip / knee society score (for determination of the mobility of the operated joint)|Cost analysis|Length of hospital stay","http://ClinicalTrials.gov/show/NCT00998088",NA
"74298",74298,"NCT01157988","90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma","Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: ibritumomab tiuxetan (Zevalin)","Chonnam National University Hospital|Samsung Medical Center|Asan Medical Center|Chonbuk National University Hospital|Dong-A University Hospital|Pusan National University Hospital|Severance Hospital","Both","Adult|Senior","Phase II",20,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CISL-2007","July 6, 2010","01/01/2007",NA,"July 7, 2010","01/04/2006","",2009-01-01,"Objective response|Safety and toxicity|Progression-free survival","http://ClinicalTrials.gov/show/NCT01157988",NA
"74320",74320,"NCT01191788","Building Recovery By Improving Goals, Habits, and Thoughts","Completed","No Results Available","Depression|Substance Use","Behavioral: Group Cognitive Behavioral Therapy|Behavioral: Group CBT for Depression","RAND|Behavioral Health Services, Inc.","Both","Adult|Senior","Phase II|Phase III",299,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","R01AA014699-03|R01AA014699","June 29, 2010","01/08/2006",2010-03-01,"January 18, 2011","01/06/2010","BRIGHT",2009-07-01,"Depressive symptoms as measured by the Beck Depression Inventory II|Improved mental health functioning as measured by SF-12 and reduced negative consequences from substance use as measured by the Shortened Inventory of Problems","http://ClinicalTrials.gov/show/NCT01191788",NA
"74447",74447,"NCT00048789","Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease","Completed","No Results Available","Graft vs Host Disease","Procedure: Extracorporeal Photopheresis","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Child|Adult|Senior","Phase II",25,"NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","030025|03-I-0025","November 7, 2002","01/11/2002",2009-01-01,"January 30, 2009","01/01/2009","",2009-01-01,"Determination of response rate including degree of improvement; steroid sparing effect; types of cGVHD problems which respond to this therapy; assessment of problems or side effects or adverse events associated with the procedure.","http://ClinicalTrials.gov/show/NCT00048789",NA
"74503",74503,"NCT00134589","CHOICE: Communicating Health Options Through Information and Cancer Education","Completed","No Results Available","Colorectal Neoplasms","Behavioral: Academic Detailing (Medical Practices)+Decision Aids (Patients)","Centers for Disease Control and Prevention|University of North Carolina|Aetna, Inc.","Both","Adult|Senior","Phase IV",450,"U.S. Fed|Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind","CDC-NCCDPHP-R-01-PH-000018","August 23, 2005","01/04/2005",2009-04-01,"August 3, 2009","01/07/2007","",2009-04-01,"Completion of colorectal cancer screening|Patient's intention to ask/patient asking medical provider for colorectal cancer screening","http://ClinicalTrials.gov/show/NCT00134589",NA
"74534",74534,"NCT00180089","Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation","Completed","No Results Available","Leukemia|Graft-Versus-Host Disease","Drug: Budesonide","Dresden University of Technology|Dr. Falk Pharma GmbH","Both","Child|Adult","Phase III",242,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","PROGAST","September 9, 2005","01/01/2004",2010-01-01,"March 29, 2010","01/03/2010","",2009-03-01,"incidence of acute gastrointestinal (GI) GVHD in the active group versus placebo group|safety|grade of acute GI GVHD|incidence of chronic GI GVHD|incidence of infectious complications|overall and disease-free survival 1 yr after transplant","http://ClinicalTrials.gov/show/NCT00180089",NA
"74538",74538,"NCT00187889","EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia","Completed","No Results Available","Ischemic Heart Disease","Drug: eplerenone","University of Florida|National Heart, Lung, and Blood Institute (NHLBI)|Pfizer","Female","Adult|Senior","Phase IV",53,"Other|NIH|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","EWISE|R01 H267173-01","September 10, 2005","01/08/2004",2009-02-01,"August 26, 2010","01/08/2010","",2009-02-01,"Epicardial coronary artery endothelial function (adjusted) at Week 16 comparing the eplerenone group to the placebo group|Microvascular coronary endothelial function (adjusted) at Week 16 comparing the eplerenone group to the placebo group","http://ClinicalTrials.gov/show/NCT00187889",NA
"74557",74557,"NCT00191789","Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer","Completed","Has Results","Breast Cancer","Drug: gemcitabine|Drug: doxorubicin|Drug: cisplatin|Procedure: surgery","Eli Lilly and Company","Female","Adult|Senior","Phase II",65,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","7117|B9E-MC-S329","September 12, 2005","01/02/2003",2009-04-01,"July 21, 2010","01/07/2010","",2009-04-01,"Number of Patients With Pathological Complete Response (Pathological Complete Response Rate)|Summary of Deaths During Study|Progression Free Survival (PFS)|Overall Survival|Time to Treatment Failure|Number of Patients Eligible for Breast Conservation Surgery at Baseline and Number of Patients Undergoing Breast Conservation Surgery","http://ClinicalTrials.gov/show/NCT00191789",NA
"74602",74602,"NCT00284089","Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration","Completed","No Results Available","Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)","Drug: Ranibizumab","Novartis","Both","Adult|Senior","Phase I|Phase II",88,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRFB002A1201","January 30, 2006","01/04/2005",NA,"July 14, 2010","01/07/2010","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00284089",NA
"74611",74611,"NCT00297089","A Phase 2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","Non-Small-Cell Lung Cancer|Lung Cancer|NSCLC","Drug: ABT-751|Drug: pemetrexed|Drug: placebo","Abbott","Both","Adult|Senior","Phase I|Phase II",165,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M05-780","February 27, 2006","01/11/2006",NA,"November 10, 2010","01/09/2010","",2009-01-01,"Progression-free Survival|Overall Survival|Response Rate|Time-to-Progression (TTP)","http://ClinicalTrials.gov/show/NCT00297089",NA
"74622",74622,"NCT00316589","Safety and Immunogenicity of IMVAMUNE?ó (MVA-BN?ó) Smallpox Vaccine in HIV Infected Patients","Completed","No Results Available","HIV Infections","Biological: IMVAMUNE (MVA-BN)|Biological: IMVAMUNE|Biological: IMVAMUNE","Bavarian Nordic|National Institutes of Health (NIH)","Both","Adult","Phase II",581,"Industry|NIH","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","POX-MVA-011","April 19, 2006","01/06/2006",2009-10-01,"May 21, 2010","01/05/2010","",2009-03-01,"Occurrence, relationship and intensity of any serious and/or unexpected adverse reaction at any time during the study|Neutralisation assay specific seroconversion rates and geometric mean titres (at all blood sampling time points);|ELISA specific seroconversion rates and geometric mean titres (at all blood sampling time points)","http://ClinicalTrials.gov/show/NCT00316589",NA
"74633",74633,"NCT00332189","Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006","Completed","No Results Available","Phenylketonuria","Drug: sapropterin dihydrochloride","BioMarin Pharmaceutical","Both","Child|Adult|Senior","Phase III",128,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PKU-008","May 30, 2006","01/07/2006",2009-08-01,"June 2, 2010","01/06/2010","",2009-08-01,"Tabulating the incidence and frequency of all AEs and SAEs that occur throughout the study.|Following blood Phe levels.","http://ClinicalTrials.gov/show/NCT00332189",NA
"74658",74658,"NCT00320489","Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia","Completed","Has Results","Schizophrenia","Drug: olanzapine|Drug: olanzapine pamoate depot","Eli Lilly and Company","Both","Adult","Phase III",524,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","6390|F1D-MC-HGLQ","April 28, 2006","01/04/2006",2009-09-01,"October 25, 2010","01/10/2010","",2009-09-01,"Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision)|Change From Baseline in Heinrich-Carpenter Quality of Life in Schizophrenia Scale (QLS) Total Score at 104 Weeks|Change From Baseline in 36-Item Short Form Health Survey (SF-36) at 104 Weeks, All Domains and Summary Scores|Change From Baseline in Overall Health Status Assessment Using the EuroQol: 5 Dimensions Questionnaire (EQ-5D) at 104 Weeks|Change From Baseline in Burden Assessment Scale (BAS) Total Score at 104 Weeks|Resource Utilization: Number of Outpatient Physician Visits During the Study|Resource Utilization: Days of Unpaid Care, Days of Workdays Missed, Days of Paid Care Per Week During the Study|Number of Hospitalization Days|Change From Baseline in Scale to Assess Unawareness of Mental Disorder (SUMD) Total Score at 104 Weeks|Change From Baseline in Working Alliance Inventory (WAI) Total Score at 104 Weeks|Change From Baseline in Schizophrenia Objective Functioning Instrument (SOFI) Global Score at 104 Weeks|Patient Satisfaction With Medication Questionnaire-Modified (PSMQ) at 104 Weeks (All Items)|Patient Attitude Toward Treatment Using the Drug Attitude Inventory (DAI) Scale Total Score at 104 Weeks|Number of Participants With All-Cause Discontinuations (Excluding Sponsor Decision)|Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Scale Scores at 104 Weeks|Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total and Subscale Scores at 104 Weeks|Median Time to Relapse|Number of Participants Experiencing Relapse|Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Score at 104 Weeks|Resource Utilization: Number of Outpatient Surgeries During the Study, 24 Months After Randomization|Change From Baseline in Weight at 104 Weeks|Participants With Potentially Clinically Significant (PCS) Weight Gain at 104 Weeks|Participants With Normal to High Fasting Glucose, Fasting Total Cholesterol, and Fasting Triglycerides|Participants With Treatment-Emergent Abnormal High Prolactin at 104 Weeks|Participants With Treatment-Emergent High Alanine Transaminase (ALT), Aspartate Transaminase (AST), and Total Bilirubin|Participants Discontinuing Because of an Adverse Event (AE) or Death","http://ClinicalTrials.gov/show/NCT00320489",NA
"74694",74694,"NCT00432289","Acupuncture for Treatment of Acute Spinal Cord Injury: an Exploratory/Developmental Study","Completed","No Results Available","Spinal Cord Injury","Procedure: Acupuncture","Craig Hospital","Both","Child|Adult|Senior","Phase I|Phase II",30,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","R21AT002763","February 5, 2007","01/11/2006",2009-06-01,"June 10, 2010","01/06/2010","",2009-06-01,"ASIA Standards for Neurological Classification of SCI","http://ClinicalTrials.gov/show/NCT00432289",NA
"74699",74699,"NCT00440089","Effects of Hands-on-Healing vs. Touch for Fatigued Breast Cancer Survivors","Completed","No Results Available","Breast Cancer","Behavioral: Hands-on-Healing","University of California, San Diego|National Center for Complementary and Alternative Medicine (NCCAM)","Female","Adult|Senior","Phase II|Phase III",76,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","F31 AT003021|F31AT003021","February 23, 2007","01/10/2005",2009-09-01,"May 24, 2010","01/11/2009","",2009-09-01,"Multiple Fatigue Symptom Inventory|Inflammatory Immune Markers|Diurnal Cortisol Variability","http://ClinicalTrials.gov/show/NCT00440089",NA
"74735",74735,"NCT00489489","Pilot Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Drug: teriflunomide (HMR1726)|Drug: placebo","Sanofi-Aventis","Both","Adult","Phase II",116,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","PDY6045|2006-003134-14|HMR1726D-2003","June 20, 2007","01/06/2007",2009-06-01,"October 27, 2010","01/09/2010","",2009-02-01,"Number of patients with adverse events|Number of patients with clinically significant abnormalities|Total number of gadolinium enhancing T1-lesions per Magnetic Resonance Imaging (MRI) scan|Burden of disease|Annualized relapse rate (number of relapses per subject-year)","http://ClinicalTrials.gov/show/NCT00489489",NA
"74738",74738,"NCT00499889","Imatinib Mesylate, Busulfan, Fludarabine, and ATG for CML Patients","Completed","No Results Available","Leukemia","Drug: Imatinib Mesylate|Drug: Fludarabine|Drug: Busulfan|Drug: ATG","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","Child|Adult|Senior","Phase II",42,"Other|NIH","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-901","July 10, 2007","01/02/2003",2009-11-01,"July 26, 2010","01/07/2010","",2009-11-01,"Number of Patients with Molecular Complete Remission at 1 year","http://ClinicalTrials.gov/show/NCT00499889",NA
"74749",74749,"NCT00518089","A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis","Completed","No Results Available","Bacterial Conjunctivitis","Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops","Allergan","Both","Child|Adult|Senior","Phase III",859,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","198782-005","August 16, 2007","01/02/2008",2009-01-01,"November 30, 2009","01/11/2009","",2009-01-01,"Proportion of patients with clearing of conjunctival hyperemia and conjunctival discharge|Microbiological cure|Clinical improvement of ocular signs|Clinical improvement of ocular symptoms","http://ClinicalTrials.gov/show/NCT00518089",NA
"74776",74776,"NCT00542789","Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID","Completed","Has Results","Gastric Ulcer|Duodenal Ulcer|Rheumatoid Arthritis|Osteoarthritis|Lumbago","Drug: Esomeprazole|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase III",343,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D961HC00001","October 11, 2007","01/08/2007",2009-02-01,"May 10, 2010","01/05/2010","",2009-02-01,"Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period|Absence of Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment|Absence of Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment","http://ClinicalTrials.gov/show/NCT00542789",NA
"74779",74779,"NCT00557089","The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis","Completed","No Results Available","Cystic Fibrosis","Drug: rhDNAse|Other: Placebo","The Hospital for Sick Children","Both","Child|Adult","Phase IV",17,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1000010903","November 9, 2007","01/01/2008",2009-06-01,"November 10, 2010","01/11/2010","",2009-06-01,"The change in LCI from baseline to end of treatment in rhDnase treated patients versus patients receiving placebo|Change in FEV1 % predicted|Change in FVC (in litres)|Change in FVC % predicted|Change in FEF25-75 (liters/sec)|Change in FEF25-75 % predicted|Change in exhaled nitric oxide concentrations|Incidence of adverse events and serious adverse events","http://ClinicalTrials.gov/show/NCT00557089",NA
"74785",74785,"NCT00570089","Microvascular Coronary Disease In Women: Impact Of Ranolazine","Completed","No Results Available","Myocardial Ischemia","Drug: Ranolazine|Drug: Placebo","Cedars-Sinai Medical Center|CV Therapeutics","Female","Child|Adult|Senior","Phase II",20,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","IRB 10465","December 7, 2007","01/04/2007",2009-12-01,"March 23, 2010","01/03/2010","",2009-12-01,"CMRs (CMR 1 and CMR 2) end of the 4th week of treatment 1 and treatment 2 respectively, 4 hours after the morning dose of study drug|Questionnaires will be completed (SAQ, WISE angina frequency, DASI and SF-36)","http://ClinicalTrials.gov/show/NCT00570089",NA
"74790",74790,"NCT00579189","Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes","Completed","No Results Available","Acute Otitis Media With Tympanostomy Tubes","Drug: AL-15469A / AL-38905","Alcon Research","Both","Child","Phase III",660,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-05-36","December 19, 2007","01/01/2006",2009-01-01,"May 7, 2009","01/05/2009","",2009-01-01,"Time to cessation of otorrhea as recorded by the parent or guardian via a patient diary|Clinical cure rate|Microbiological outcome|Treatment failures","http://ClinicalTrials.gov/show/NCT00579189",NA
"74800",74800,"NCT00598689","GenTeal in Perioperative Treatment of LASIK Patients","Completed","No Results Available","Refractive Surgical Procedures","Drug: 0.3% hypromellose|Other: No Artificial Tears|Drug: 0.3% hypromellose","Medical College of Georgia","Both","Adult","Phase IV",80,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","07-09-052","January 10, 2008","01/10/2007",2009-10-01,"September 23, 2010","01/09/2010","",2009-10-01,"Assess whether preoperative GenTeal Gel enhances epithelial healing after LASIK surgery within the first post-operative week, compared to control (no preoperative lubricant).|Assess whether preoperative GenTeal Gel alleviates post operative pain in LASIK surgery patients compared to control (no preoperative lubricant).","http://ClinicalTrials.gov/show/NCT00598689",NA
"74809",74809,"NCT00606489","Efficacy and Safety Study of Caldolor in Hospitalized Adult and Pediatric Burn Patients","Completed","No Results Available","Burns","Drug: Caldolor|Drug: Placebo","Cumberland Pharmaceuticals","Both","Child|Adult|Senior","Phase III",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CPI-CL-010","January 22, 2008","01/11/2007",2009-05-01,"April 8, 2010","01/04/2010","",2009-05-01,"To evaluate the efficacy of Caldolor compared to placebo when administered every 6 hours for 24 hours on reducing fever","http://ClinicalTrials.gov/show/NCT00606489",NA
"74811",74811,"NCT00607789","A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder","Completed","No Results Available","Binge Eating|Depression","Drug: duloxetine|Drug: placebo","University of Cincinnati","Both","Adult","Phase IV",40,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","Nelson #2","January 23, 2008","01/10/2006",2009-10-01,"October 9, 2009","01/10/2009","",2009-10-01,"The specific aim of this study is to assess the efficacy, tolerability, and safety of duloxetine compared with placebo in outpatients with binge eating disorder and a comorbid depressive disorder.","http://ClinicalTrials.gov/show/NCT00607789",NA
"74859",74859,"NCT00671489","Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-01 Study","Completed","No Results Available","Trauma|Posttraumatic Stress Disorder","Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid","Japan Science and Technology Agency|University of Toyama|Chiba University","Both","Adult|Senior","Phase I|Phase II",15,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","NDMC-TPOP-01","April 23, 2008","01/05/2008",2009-02-01,"June 4, 2010","01/05/2009","",2009-02-01,"Total score of Clinician-Administrated PTSD Scale (CAPS)|Incidence of diagnosis of PTSD (including partial PTSD)|Total score of Montgomery Asberg Depression Rating Scale (MADRAS)|Incidence of depression evaluated by Mini-International Neuropsychiatric Interview (MINI)|Autonomic response measured before, during and after script driven imagery and acoustic stimulation|Score of Impact of Event Scale revised (IES-R)|Score of Hospital Anxiety and Depression scale (HADS)|Score of health related Quality of Life scale, SF-36|Score of Conner-Davidson Resilience Scale (CD-RISC)|Brain-derived neurotrophic factor (BDNF) in serum|Number of days of leave taken from the time of injury|Buss-Perry Aggression Questionnaire (BAQ)|Total score of Clinician-Administrated PTSD Scale (CAPS)|DHEA: dehydroepiandrosterone|NPY: neuropeptide Y|IL-1 beta: interleukin 1 beta|IL-6: interleukin 6|TNF alpha: tumor necrosis factor alpha|D-serine|L-serine|DL-serine|Activin","http://ClinicalTrials.gov/show/NCT00671489",NA
"74873",74873,"NCT00715689","Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083","Completed","No Results Available","Growth Hormone Deficiency, Adults (GHDA)","Drug: NNC126-0083|Drug: NNC126-0083|Drug: NNC126-0083|Drug: NNC126-0083|Drug: placebo|Drug: placebo|Drug: placebo|Drug: placebo","Novo Nordisk","Both","Adult","Phase II",33,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NN8630-1823|EudraCT No: 2008-001061-29","July 14, 2008","01/07/2008",2009-03-01,"October 26, 2009","01/04/2009","",2009-03-01,"Safety and tolerability (adverse events, local tolerability, physical examination)|Cmax, maximum concentration of IGF-I","http://ClinicalTrials.gov/show/NCT00715689",NA
"74884",74884,"NCT00649389","Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension","Completed","Has Results","Hypertension","Drug: Olmesartan medoxomil|Drug: Amlodipine|Drug: Hydrochlorothiazide","Daiichi Sankyo Inc.","Both","Adult|Senior","Phase III",2500,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CS8635-A-U301","March 28, 2008","01/05/2008",2009-12-01,"August 31, 2010","01/08/2010","",2009-04-01,"Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).|Percentage of Subjects Who Reached Blood Pressure Goal (<140/90 mmHg; <130/80 mmHg for Subjects With Diabetes, Chronic Renal Disease, or Chronic Cardiovascular Disease)by 12 Weeks|Change in Mean 24-hour Ambulatory Blood Pressure From Baseline to Week 12 or Early Termination|Change in Seated Systolic Blood Pressure From Baseline to Week 12","http://ClinicalTrials.gov/show/NCT00649389",NA
"74899",74899,"NCT00758589","One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids","Completed","No Results Available","Asthma","Drug: AZD1981|Drug: AZD1981|Drug: AZD1981|Drug: Placebo","AstraZeneca","Both","Adult|Senior","Phase II",510,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D9830C00004","September 23, 2008","01/09/2008",2009-07-01,"August 12, 2009","01/08/2009","OLIVE",2009-07-01,"Peak expiratory flow|Asthma symptom score|Use of reliever medication|FEV1","http://ClinicalTrials.gov/show/NCT00758589",NA
"74908",74908,"NCT00772889","Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly","Completed","No Results Available","Influenza Infection","Biological: GSK Biologicals' Fluarix?ºÑ|Biological: Influenza vaccine GSK2186877A","GlaxoSmithKline","Both","Adult|Senior","Phase III",974,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","111738","October 10, 2008","01/10/2008",2009-12-01,"July 2, 2010","01/07/2010","",2009-12-01,"Occurrence, intensity and duration of solicited local symptoms|Occurrence, intensity, duration and relationship to vaccination of solicited general symptoms|Occurrence, intensity and relationship to vaccination of adverse events of specific interest including autoimmune diseases|Occurrence and relationship to vaccination of serious adverse events|Occurrence, intensity and relationship to vaccination of adverse events with medically attended visit|Occurrence, intensity and relationship to vaccination of adverse events of specific interest including autoimmune diseases|Occurrence and relationship to vaccination of serious adverse events|Haemagglutination-inhibition (HI) antibody titres","http://ClinicalTrials.gov/show/NCT00772889",NA
"74915",74915,"NCT00783289","A Phase 2a Study to Evaluate the Safety and Tolerability of MEDI-563 in Adults With Asthma","Completed","No Results Available","Asthma","Biological: MEDI-563|Other: Placebo","MedImmune LLC","Both","Adult|Senior","Phase II",24,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MI-CP197","October 30, 2008","01/11/2008",2009-12-01,"July 20, 2010","01/07/2010","MEDI-563",2009-11-01,"Summarizing AEs and SAEs.|To assess the PK and IM of MEDI-563","http://ClinicalTrials.gov/show/NCT00783289",NA
"74923",74923,"NCT00796289","Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females","Completed","No Results Available","Infertility","Drug: GnRH iontophoretic transdermal Lutrepatch|Drug: GnRH iontophoretic transdermal Lutrepatch|Drug: GnRH iontophoretic transdermal Lutrepatch|Drug: clomiphene citrate|Drug: placebo clomiphene citrate|Drug: placebo GnRH patch","Ferring Pharmaceuticals","Female","Adult","Phase II",350,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2008-03","November 20, 2008","01/02/2009",2010-01-01,"December 16, 2010","01/12/2010","",2009-12-01,"Ovulation rate|Pregnancy rate|Incidence of Ovarian Hyperstimulation Syndrome (OHSS)|Incidence of skin irritation","http://ClinicalTrials.gov/show/NCT00796289",NA
"75054",75054,"NCT01019889","Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection","Completed","No Results Available","Upper Respiratory Tract Infections","Drug: SCRT|Drug: YPS|Drug: Placebo","Korea Health Industry Development Institute","Both","Adult","Phase III",480,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","B070029","November 23, 2009","01/09/2008",2009-07-01,"November 23, 2009","01/11/2009","ESYUI",2009-06-01,"Changes of score daily measured by WURSS-K before, during and after treatment|Time of symptom disappearance|Changes of score daily measured by WURSS-K before, during and after treatment in pattern identification","http://ClinicalTrials.gov/show/NCT01019889",NA
"75312",75312,"NCT00084890","Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix","Completed","No Results Available","Cervical Cancer","Drug: carboplatin|Drug: docetaxel","Wake Forest University|National Cancer Institute (NCI)","Female","Adult|Senior","Phase I|Phase II",64,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000366942|CCCWFU-30102B|NCI-6949","June 10, 2004","01/05/2004",NA,"June 26, 2009","01/04/2007","",2009-06-01,"Maximum tolerated dose of docetaxel|Response rate|Time to progression|Toxicity|Quality of life","http://ClinicalTrials.gov/show/NCT00084890",NA
"75350",75350,"NCT00125190","Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency","Completed","Has Results","Insulin-Like Growth Factor-1 Deficiency|Growth Disorders","Drug: rhIGF-1 (mecasermin) for a period of 86 weeks","Ipsen","Both","Child|Adult|Senior","Phase II|Phase III",45,"Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MS308","July 27, 2005","01/07/2005",2009-01-01,"September 14, 2010","01/09/2010","",2009-01-01,"Height Velocity Over the Study Period 0 - 34 Weeks [Intent to Treat Population]|Height Velocity Over the Study Period 34 - 86 Weeks [Intent to Treat Population]|Changes in Height Standard Deviation (SD) Score Over the Study Period 0 - 34 Weeks [Intent to Treat Population]|Changes in Height Standard Deviation (SD) Score Over the Study Period 34 - 86 Weeks|Bone Age - Change From Pretreatment Minus Change in Chronological Age Over the Study Period 0 - 86 Weeks [Intent to Treat Population]|Percent Changes in Serum Concentration of Insulin-like Growth Factor Binding-1 (IGFBP-1) From Baseline to Week 86|Percent Changes in Serum Concentration of Insulin-like Growth Factor Binding-2 (IGFBP-2) From Baseline to Week 86|Percent Changes in Serum Concentration of Insulin-like Growth Factor Binding-3 (IGFBP-3) From Baseline to Week 86|Percent Changes in Serum Concentration of Acid Labile Subunit (ALS) From Baseline to Week 86|rhIGF-1 Doses Required to Achieve the Serum IGF-1 Targets With Measures Taken at Each Study Visit","http://ClinicalTrials.gov/show/NCT00125190",NA
"75356",75356,"NCT00149890","Efficacy and Safety of Basiliximab, Ciclosporin/Ciclosporin Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids","Completed","No Results Available","Liver Transplantation|Infection","Drug: Basiliximab|Drug: Ciclosporin/ciclosporin microemulsion","Novartis","Both","Child","Phase IV",71,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CCHI621ADE04","September 6, 2005","01/03/2004",2009-02-01,"February 3, 2010","01/02/2010","",2009-02-01,"Incidence of at least one biopsy proven acute rejection episode, graft loss or death within the first three months post-transplantation|Incidence of biopsy proven acute rejection episodes within the first three months|Incidence of steroid resistant rejection episodes within three and six months|Death or graft loss (defined as being listed for a retransplantation) within three and six months after transplantation|Incidence of bacterial, viral and fungal infections during six months|Time of onset of a first biopsy proven acute rejection","http://ClinicalTrials.gov/show/NCT00149890",NA
"75394",75394,"NCT00209690","Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.","Completed","No Results Available","Esophageal Cancer","Drug: Taxotere|Drug: 5-FU|Drug: Briplatin","Hokkaido Gastrointestinal Cancer Study Group|Hokkaido University Hospital","Both","Adult|Senior","Phase I|Phase II",30,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HGCSG0305-1|TPF","September 13, 2005","01/10/2003",2010-04-01,"May 24, 2010","01/05/2010","",2009-12-01,"Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.|Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.","http://ClinicalTrials.gov/show/NCT00209690",NA
"75520",75520,"NCT00403390","Generic vs. Name-Brand Levothyroxine","Completed","No Results Available","Congenital Hypothyroidism|Hypothyroidism","Drug: Levothyroxine versus Levothyroxine","Children's Hospital Boston","Both","Child|Adult","Phase III",34,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","05-11-146","November 21, 2006","01/11/2006",2010-03-01,"December 2, 2010","01/12/2010","",2009-12-01,"Thyroid Stimulating Hormone Measure","http://ClinicalTrials.gov/show/NCT00403390",NA
"75538",75538,"NCT00425490","Effect of Januvia on Beta Cell Function in Patients With Diabetes Mellitus","Completed","No Results Available","Diabetes Mellitus Type 2","Drug: sitagliptin","Sheba Medical Center","Both","Adult","Phase III",30,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","SHEBA-06-4373-OC-CTIL","January 22, 2007","01/01/2007",2009-07-01,"September 22, 2009","01/09/2009","",2009-07-01,"FPG,|HbA1c,|??-cell Function Parameters(??s, ??d, ??b, ??, ??ob, T), Insulin Secretion Rate (determined from C-peptide deconvolution), 1st and 2nd phase insulin secretion, Insulin response after arginine injection, Insulin sensitivity index, glucose, insulin,|C-peptide total and incremental area under the curve.","http://ClinicalTrials.gov/show/NCT00425490",NA
"75550",75550,"NCT00443690","Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy","Completed","No Results Available","Heart Failure, Congestive","Drug: rolofylline|Drug: Comparator: Placebo (unspecified)","NovaCardia, Inc.|Merck","Both","Adult|Senior","Phase III",480,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CKI-303|2007_805|MK7418-303","March 2, 2007","01/08/2007",2009-01-01,"February 19, 2009","01/02/2009","REACH UP",2009-01-01,"Effect on heart failure signs and symptoms|Effect on renal function","http://ClinicalTrials.gov/show/NCT00443690",NA
"75643",75643,"NCT00585390","Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia","Completed","No Results Available","Schizophrenia, Fatty Acid, Deficiency","Dietary Supplement: Omega-3 Fatty Acids|Other: Olive oil placebo","University of Cincinnati","Both","Child|Adult","Phase II|Phase III",80,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","Richtand #1","December 28, 2007","01/01/2008",2009-11-01,"April 2, 2010","01/04/2010","",2009-11-01,"Determine positive symptom treatment response in omega-3 fatty acid deficient first-episode schizophrenia patients augmented with omega-3 fatty acid supplementation vs. placebo.|Determine negative and cognitive symptom treatment response in omega-3 fatty acid deficient first-episode schizophrenia patients augmented with omega-3 supplementation vs. placebo.","http://ClinicalTrials.gov/show/NCT00585390",NA
"75645",75645,"NCT00590590","Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort","Completed","No Results Available","Vulvodynia","Drug: Lidocaine/Diphenhydramine|Drug: lidocaine|Drug: placebo","KV Pharmaceutical Company","Female","Adult","Phase II",140,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LDC-201-601-669020","December 26, 2007","01/10/2007",2009-07-01,"July 21, 2009","01/07/2009","",2009-06-01,"The primary outcome measure of the study will be measurement of a woman's ability to have vaginal intercourse.|Important secondary outcome measures include change in discomfort.","http://ClinicalTrials.gov/show/NCT00590590",NA
"75653",75653,"NCT00452790","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India","Completed","Has Results","Pneumococcal Infections","Biological: 13-valent Pneumococcal Conjugate Vaccine|Biological: 7 valent pneumococcal conjugate vaccine","Wyeth","Both","Child","Phase III",708,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","6096A1-011","March 23, 2007","01/06/2007",2010-02-01,"October 13, 2010","01/10/2010","",2009-10-01,"Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (Mcg)/mL, 1 Month After the Infant Series.|Percentage of Participants Achieving a Predefined Antibody Level for Concomitant Vaccine Pertussis Antigens (Pertussis Toxoid [PT], Filamentous Hemagglutinin [FHA], Pertactin [PRN]), 1 Month After the Infant Series.|Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Mcg/mL, 1 Month After the Toddler Dose.","http://ClinicalTrials.gov/show/NCT00452790",NA
"75668",75668,"NCT00620490","Paravertebral Analgesia Associated With Intravenous Morphine PCA After Thoracotomy","Completed","No Results Available","Pain","Drug: ropivacaine|Other: nacl 0,9%","University Hospital, Strasbourg, France","Both","Adult|Senior","Phase III",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","4068","February 7, 2008","01/03/2008",2009-03-01,"June 25, 2010","01/03/2008","",2009-02-01,"Pain|?? Total dosis of morphine consumption, side effects nausea, vomiting,pruritus,Urinary retention, respiratory rate and sedation, ?? heart rate, blood pressure and peripheral saturation","http://ClinicalTrials.gov/show/NCT00620490",NA
"75688",75688,"NCT00656890","A Study of MDX-1100 in Subjects With Active Ulcerative Colitis","Completed","No Results Available","Ulcerative Colitis","Biological: sterile saline for injection|Biological: MDX-1100","Bristol-Myers Squibb","Both","Adult|Senior","Phase II",110,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","MDX1100-06|IM129-004","April 4, 2008","01/04/2008",2009-09-01,"April 22, 2010","01/04/2010","MDX1100-06",2009-09-01,"Change in Mayo score at Day 57 compared with Screening|the remission rate","http://ClinicalTrials.gov/show/NCT00656890",NA
"75695",75695,"NCT00672490","Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder","Completed","No Results Available","Acute Mania in Bipolar Disorder","Drug: Quetiapine Fumarate|Drug: Lithium","AstraZeneca","Both","Adult","Phase IV",370,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D1443L00023","May 2, 2008","01/04/2008",2009-07-01,"February 11, 2010","01/02/2010","MANIA",2009-07-01,"To compare the efficacy of quetiapine fumarate used as mono-therapy and adjunct therapy to lithium in the treatment of patient with acute mania in bipolar disorder by evaluation of change from baseline in the YMRS tot","http://ClinicalTrials.gov/show/NCT00672490",NA
"75707",75707,"NCT00690690","No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV Risks","Completed","No Results Available","HIV Infections","Behavioral: Video (group-delivered video-based intervention)|Behavioral: HCT","Centers for Disease Control and Prevention|Education Development Center, Inc.|Callen-Lorde Community Health Center|Hispanic AIDS Forum, Inc.","Male","Adult","Phase II|Phase III",370,"U.S. Fed|Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CDC-NCHHSTP-5142","June 3, 2008","01/06/2008",2009-11-01,"March 8, 2010","01/03/2010","",2009-11-01,"Sexual risk behavior","http://ClinicalTrials.gov/show/NCT00690690",NA
"75715",75715,"NCT00699790","Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: CCR2 Antagonist|Drug: Placebo","Bristol-Myers Squibb","Both","Adult|Senior","Phase II",58,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MB114-005","June 17, 2008","01/02/2009",2009-12-01,"January 6, 2011","01/06/2010","",2009-12-01,"Change in HbA1c|Other glycemic, atherosclerosis, lipid and mechanism-based biomarkers will be measured","http://ClinicalTrials.gov/show/NCT00699790",NA
"75717",75717,"NCT00704990","Combination Natural Health Product in Children With Attention Deficit/Hyperactivity Disorder (ADHD)","Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Dietary Supplement: Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)","The Canadian College of Naturopathic Medicine|University of Toronto|Centre for Addiction and Mental Health","Both","Child","Phase II|Phase III",28,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCNM-083-ADHD","June 20, 2008","01/09/2008",2009-12-01,"December 13, 2010","01/12/2010","",2009-12-01,"Connors-3 Parent Rating Scale|Nutritional status of zinc and magnesium|Adverse events|SNAP-IV Parent ADHD questionnaire","http://ClinicalTrials.gov/show/NCT00704990",NA
"75720",75720,"NCT00686790","Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603AM3)(COMPLETED)","Completed","Has Results","Hepatitis D, Chronic|Hepatitis B, Chronic","Biological: Peginterferon alfa-2b (PegIntron, SCH 54031)","Schering-Plough","Both","Adult","Phase III",68,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P04603","May 27, 2008","01/12/2005",2009-05-01,"December 21, 2010","01/12/2010","",2009-05-01,"Number of Participants With a Virological Response|Number of Participants With a Biochemical Response|Number of Participants With a Combined Response|Number of Participants With HBV Replication Response (HBV Response)|Number of Participants With a Liver Histology Response","http://ClinicalTrials.gov/show/NCT00686790",NA
"75727",75727,"NCT00701090","A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)","Completed","Has Results","Type 2 Diabetes Mellitus, Non Insulin Dependent.|Diabetes Mellitus, Non-Insulin-Dependent","Drug: sitagliptin|Drug: Comparator: glimepiride|Drug: open-label metformin","Merck","Both","Adult|Senior","Phase III",1035,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","MK-0431-803|2008_503","June 17, 2008","01/05/2008",2009-10-01,"December 17, 2010","01/12/2010","",2009-10-01,"Change From Baseline in HbA1c at Week 30|Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30|Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30|Change From Baseline in Body Weight at Week 30|Percent of Patients With A1C <7.0% at Week 30|Percent of Patients With A1C <6.5% at Week 30","http://ClinicalTrials.gov/show/NCT00701090",NA
"75749",75749,"NCT00745290","A Phase 3 Study to Evaluate the Safety and Efficacy for Prolonged Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty","Completed","No Results Available","Total Knee Arthroplasty|Postoperative Pain","Drug: Bupivacaine HCl|Drug: SKY0402","Pacira Pharmaceuticals, Inc","Both","Adult|Senior","Phase III",251,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","SIMPLE TKA 311","August 29, 2008","01/08/2008",2009-02-01,"August 27, 2010","01/08/2010","TKA",2009-01-01,"Area under the curve (AUC) of pain scores with activity, using the NRS-A|Total postoperative consumption with and without supplemental opioid pain medication","http://ClinicalTrials.gov/show/NCT00745290",NA
"75758",75758,"NCT00749190","BI 10773 add-on to Metformin in Patients With Type 2 Diabetes","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: BI 10773|Drug: placebo|Drug: sitagliptin","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",495,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1245.10|EudraCT 2008-000641-54","September 8, 2008","01/08/2008",NA,"November 24, 2009","01/11/2009","",2009-10-01,"The primary endpoint is the HbA1c change from baseline after 12 weeks of treatment.|Change in fasting plasma glucose Change in HbA1c over time The proportion of patients with HbA1c <=7.0%, HbA1c lowering >0.5% Change in fasting plasma insulin Change in HOMA indices Change in body weight Pharmacokinetics of BI 10773","http://ClinicalTrials.gov/show/NCT00749190",NA
"75759",75759,"NCT00766090","Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma","Completed","No Results Available","Asthma","Drug: GW685698X","GlaxoSmithKline","Both","Child|Adult|Senior","Phase II",190,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","112202","October 2, 2008","01/10/2008",2009-03-01,"February 5, 2010","01/02/2010","",2009-03-01,"safety and efficacy","http://ClinicalTrials.gov/show/NCT00766090",NA
"75814",75814,"NCT00764790","Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children.","Completed","Has Results","Influenza|Influenza Vaccines","Biological: Fluarix|Biological: Fluzone","GlaxoSmithKline","Both","Child","Phase III",3317,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Outcomes Assessor)|Primary Purpose: Prevention","111751","October 1, 2008","01/10/2008",2009-03-01,"November 24, 2010","01/11/2010","",2009-03-01,"Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains|Number of Subjects Who Seroconverted|Number of Seroprotected Subjects|Seroconversion Factor|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)|Number of Subjects Reporting Rare Serious Events","http://ClinicalTrials.gov/show/NCT00764790",NA
"75817",75817,"NCT00851890","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","Completed","No Results Available","HCV Infection","Drug: ABT-333|Drug: Placebo|Drug: peginterferon alfa-2a|Drug: Ribavirin","Abbott","Both","Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)","M10-380","February 24, 2009","01/04/2009",NA,"October 19, 2010","01/09/2010","",2009-07-01,"Analysis of pharmacokinetic variables and antiviral activity in treatment-na??ve HCV-infected subjects.|Analysis of safety measures including but not limited to tabulation of adverse events, physical exam, clinical lab results (include chemistry, hematology and urine) and vital signs.|Assess emergence of resistant virus in conjunction with kinetics of viral load decay and rebound in treatment-na??ve HCV-infected subjects.","http://ClinicalTrials.gov/show/NCT00851890",NA
"75822",75822,"NCT00867490","Safety and Efficacy of Aliskiren + Hydrochlorothiazide in Patients With Moderate Hypertension","Completed","No Results Available","Hypertension","Drug: Aliskiren /hydrochlorothiazide","Novartis","Both","Adult|Senior","Phase IV",123,"Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CSPH100ADE01","March 20, 2009","01/03/2009",NA,"June 2, 2010","01/06/2010","AMAZING",2009-08-01,"Mean diastolic blood pressure reduction|Mean systolic blood pressure reduction|Responder rate for blood pressure|Normalization rate for blood pressure|Safety and tolerability (e.g. AEs, laboratory, physical examinations)|Changes in heart rate","http://ClinicalTrials.gov/show/NCT00867490",NA
"75823",75823,"NCT00849290","Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)","Completed","Has Results","Metastatic Androgen Independent Prostate Cancer","Biological: APC8015F","Dendreon","Male","Adult|Senior","Phase II",113,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PB01","February 19, 2009","01/04/2004",2009-04-01,"October 8, 2010","01/10/2010","",2009-01-01,"Safety of APC8015F by Review of Reported Adverse Events|To Evaluate the Efficacy of APC8015F in Delaying Prostate Specific Antigen Doubling Time and on Overall Clinical Response","http://ClinicalTrials.gov/show/NCT00849290",NA
"75833",75833,"NCT00880490","Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Inhaled PT005|Drug: Inhaled PT005|Drug: Inhaled PT005|Drug: Inhaled placebo|Drug: Formoterol Fumarate 12 mcg (Foradil Aerolizer)","Pearl Therapeutics, Inc.","Both","Adult|Senior","Phase I|Phase II",34,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PT0050801","April 9, 2009","01/11/2008",2009-05-01,"October 11, 2010","01/10/2010","",2009-05-01,"Change in forced expiratory volume in one second (FEV1) area under the curve from 0 to 12 hours [AUC(0-12)] from test day baseline across the three doses of inhaled PT005 compared with placebo.|Time to onset of action (>10% improvement in FEV1 from baseline)|Peak FEV1|Trough FEV1|Peak inspiratory capacity (IC)|Peak expiratory flow rate (PEFR)|Forced vital capacity (FVC)","http://ClinicalTrials.gov/show/NCT00880490",NA
"75883",75883,"NCT00968890","Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix?ºÑ Vaccine When Co-administered in Elderly","Completed","No Results Available","Influenza Infection","Biological: Placebo|Biological: Influenza vaccine GSK2340272A|Biological: Fluarix?ºÑ","GlaxoSmithKline","Both","Adult|Senior","Phase II",168,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","113525","August 27, 2009","01/09/2009",2009-11-01,"July 2, 2010","01/07/2010","",2009-11-01,"Humoral immune response in terms of vaccine Haemagglutination Inhibition (HI) antibodies|Humoral immune response in terms of vaccine HI antibodies on secondary read-outs|Solicited local and general symptoms|Unsolicited adverse events|Serious adverse events and adverse events of specific interest","http://ClinicalTrials.gov/show/NCT00968890",NA
"76052",76052,"NCT01231490","Acute Osteoarthritis Experimental Model Study.","Completed","No Results Available","Osteoarthritis","Drug: Placebo|Drug: Naproxen","GlaxoSmithKline","Both","Child|Adult|Senior","Phase II",53,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)","111293","October 28, 2010","01/09/2008",2009-03-01,"November 11, 2010","01/11/2010","",2009-01-01,"Change from baseline in the time to ascend and descend 11 stairs|Pain intensity difference as measured on numerical rating scales (NRS) after ascending and descending 11 stairs.|Change from baseline in the time to walk 20, 40 and 100m.|Pain intensity difference as measured on a numerical rating scales (NRS) after: 100m walk|Pain intensity difference as measured on a numerical rating scales (NRS) after: resting|Change from baseline in WOMAC scores|Patient Global Impression of Change (PGIC).","http://ClinicalTrials.gov/show/NCT01231490",NA
"76106",76106,"NCT00003691","Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","Completed","No Results Available","Endometrial Cancer","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: paclitaxel","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Adult|Senior","Phase III",240,"Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066794|GOG-0177","November 1, 1999","01/12/1998",NA,"September 10, 2010","01/09/2010","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00003691",NA
"76317",76317,"NCT00317291","Acupuncture/Moxibustion for Peripheral Neuropathy in HIV","Completed","No Results Available","Peripheral Neuropathies|HIV Infections","Procedure: Acupuncture/Moxibustion","National Center for Complementary and Alternative Medicine (NCCAM)","Both","Adult|Senior","Phase II",50,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","R21 AT003092|AAAB4122","April 20, 2006","01/11/2005",2009-01-01,"September 16, 2009","01/09/2009","",2009-01-01,"Symptom diary|Gracely Pain Scale|Subjective Peripheral Neuropathy Scale|Clinical Global Impression Scale|Neurological Assessment Form","http://ClinicalTrials.gov/show/NCT00317291",NA
"76319",76319,"NCT00318591","Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections","Completed","No Results Available","Urinary Tract Infections","Device: Intermittent catheter|Device: intermittent catheter","Coloplast A/S","Both","Adult|Senior","Phase IV",226,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","DK046CC","April 26, 2006","01/04/2006",2009-10-01,"January 19, 2010","01/01/2010","",2009-10-01,"Occurrence of symptomatic urinary tract infections (UTIs)|Symptomatic UTIs where antibiotic treatment has been prescribed|Symptomatic UTIs that meet protocol definition and antibiotic treatment has been prescribed|Bacteriuria, urine leucocytes and erythrocytes|Nurse evaluation of catheters ans overall satisfaction|Patient or caregiver's evaluation of catheters and overall satisfaction|Nurse time spent on catheterization procedure|Health economic measures|Adverse events","http://ClinicalTrials.gov/show/NCT00318591",NA
"76351",76351,"NCT00371891","Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)","Completed","No Results Available","Coronary Arteriosclerosis|Cardiomyopathies|Heart Defects, Congenital|Heart Valve Diseases","Procedure: Multidetector Computed Tomography Coronary Angiography","St. Joseph's Healthcare Hamilton","Both","Adult|Senior","Phase IV",168,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","HTA007-0603-01","September 1, 2006","01/09/2006",2009-06-01,"November 24, 2010","01/11/2010","",2009-06-01,"Sensitivity and specificity of MDCTCA as compared to CICA|Descriptive statistics (rates and proportions) will be calculated for the number of \avoidable\"" diagnostic cardiac catheterizations.|The accuracy of MDCTCA to CICA will be compared in categorizing patients inot single","http://ClinicalTrials.gov/show/NCT00371891",NA
"76352",76352,"NCT00289991","Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)","Completed","Has Results","Antifungal Prophylaxis of Invasive Fungal Infections","Drug: Itraconazole|Drug: Vfend - voriconazole","Pfizer","Both","Child|Adult|Senior","Phase III",489,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","A1501073","February 9, 2006","01/03/2006",2009-02-01,"March 26, 2010","01/03/2010","IMPROVIT",2009-02-01,"Success at Day 180: Percent of Responders (Randomization Strata)|Success at Day 100: Percent of Responders (Randomization Strata)|Time to Breakthrough Invasive Fungal Infection (IFI)|Percent of Subjects With Occurrence of Breakthrough IFI|Survival: Percent of Subjects Who Died at or Before Day 180|Time to Discontinuation of Study Treatment|Survival: Percent of Subjects Who Died Within 1 Year|Duration of Treatment|Percent of Subjects With Use of Other Systemic Antifungal Agents as Empirical or Therapeutic Treatment","http://ClinicalTrials.gov/show/NCT00289991",NA
"76386",76386,"NCT00418691","Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning","Completed","No Results Available","Brain Tumor","Drug: IR Methylphenidate|Drug: Modafinil|Drug: SR Methylphenidate","M.D. Anderson Cancer Center","Both","Adult|Senior","Phase III",34,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0925","January 3, 2007","01/02/2004",2009-11-01,"December 28, 2009","01/12/2009","",2009-11-01,"Patient Cognitive Test Scores at End of Treatment Period","http://ClinicalTrials.gov/show/NCT00418691",NA
"76394",76394,"NCT00427791","Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Drug: Etoposide|Radiation: Total Body Irradiation|Drug: Rituximab","M.D. Anderson Cancer Center","Both","Child|Adult","Phase II",23,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-0989","January 25, 2007","01/07/2005",2009-10-01,"October 29, 2009","01/10/2009","",2009-10-01,"To find out if giving rituximab with etoposide and total body irradiation (TBI) will help to control ALL in patients scheduled to receive an allogeneic hematopoietic stem cell transplantation (SCT).|To find the effect of this treatment on the occurrence of graft versus host disease (GVHD) in study participants.","http://ClinicalTrials.gov/show/NCT00427791",NA
"76459",76459,"NCT00538291","Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment","Completed","No Results Available","Colorectal Cancer","Biological: cetuximab|Drug: capecitabine|Genetic: gene expression analysis|Genetic: microarray analysis|Genetic: polymorphism analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: immunohistochemistry staining method","City of Hope Medical Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",13,"Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000567432|P30CA033572|CHNMC-05033","October 1, 2007","01/08/2005",NA,"December 22, 2009","01/12/2009","",2009-02-01,"Response rate|Overall survival|Progression-free survival|Duration of overall survival (median and 1-year rate)|Progression-free survival (median)|Safety|Tolerance to therapy","http://ClinicalTrials.gov/show/NCT00538291",NA
"76463",76463,"NCT00548691","Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients","Completed","No Results Available","Anemia","Drug: Ferric Carboxymaltose","Luitpold Pharmaceuticals","Both","Adult|Senior","Phase III",NA,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1VIT07018","October 22, 2007","01/10/2007",2009-04-01,"June 5, 2009","01/06/2009","",2009-04-01,"Safety and Tolerability","http://ClinicalTrials.gov/show/NCT00548691",NA
"76466",76466,"NCT00551291","A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.","Completed","No Results Available","Myelodysplastic Syndromes","Drug: epoetin beta [NeoRecormon]|Drug: CellCept|Drug: Prednisone","Hoffmann-La Roche","Both","Adult|Senior","Phase II",10,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20559","October 29, 2007","",2009-06-01,"September 16, 2009","01/09/2009","",2009-06-01,"Incidence of complete remission (transfusions, hematology parameters, bone marrow aspirates)|Cytogenesis assessments of bone marrow|AEs, laboratory parameters, vital signs.","http://ClinicalTrials.gov/show/NCT00551291",NA
"76499",76499,"NCT00604591","Effects of Tolcapone on Frontotemporal Dementia","Completed","No Results Available","Frontotemporal Lobar Degeneration","Drug: Tolcapone","National Institute of Neurological Disorders and Stroke (NINDS)","Both","Adult|Senior","Phase II",9,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","080045|08-N-0045","January 19, 2008","01/01/2008",2009-10-01,"August 25, 2010","01/09/2009","",2009-10-01,"Reaction time on the most difficult N-back condition that the patients can succesfully perform.|A difference in the normalized BOLD signal intensity between subjects on placebo vs. tolcapone.","http://ClinicalTrials.gov/show/NCT00604591",NA
"76514",76514,"NCT00625391","Green Tea and Tai Chi for Bone Health","Completed","No Results Available","Osteoporosis","Other: placebo|Dietary Supplement: GTP|Behavioral: Placebo plus Tai Chi|Other: GTP plus Tai Chi","Texas Tech University Health Sciences Center|National Center for Complementary and Alternative Medicine (NCCAM)","Female","Child|Adult|Senior","Phase I|Phase II",200,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","R21 AT003735-01A1|R21AT003735-01A1","February 26, 2008","01/02/2008",2009-08-01,"March 17, 2010","01/03/2010","GTP-TC-Bone",2009-08-01,"attrition rate, compliance|bone turnover biomarkers, oxidative stress damage biomarker, biomechanical response","http://ClinicalTrials.gov/show/NCT00625391",NA
"76546",76546,"NCT00678691","An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue","Completed","No Results Available","Fibromyalgia, Primary","Drug: armodafinil|Drug: placebo","State University of New York - Upstate Medical University","Both","Adult","Phase IV",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","ArmoFibro-001","May 13, 2008","01/08/2007",2009-12-01,"August 4, 2010","01/08/2010","",2009-06-01,"Brief Fatigue Inventory","http://ClinicalTrials.gov/show/NCT00678691",NA
"76548",76548,"NCT00685191","HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain","Completed","No Results Available","HIV Infections","Drug: Salvage antiretroviral therapy including raltegravir","Germans Trias i Pujol Hospital","Both","Adult|Senior","Phase IV",15,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ITHACA","May 23, 2008","01/06/2008",2009-10-01,"November 6, 2009","01/11/2009","",2009-04-01,"Change in viral load from day 0 to 7|Intracellular levels of HIV-1 proviral DNA and LTR circles","http://ClinicalTrials.gov/show/NCT00685191",NA
"76569",76569,"NCT00722891","Ocular Responses to Short and Long-term Lens Wear","Completed","No Results Available","Ametropia","Device: Balafilcon A Lenses with ReNu Multiplus|Device: Balafilcon A Lenses with Optifree RepleniSH","Bausch & Lomb, Inc.","Both","Child|Adult|Senior","Phase IV",30,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science","P/289/07/B","July 24, 2008","01/07/2008",2009-09-01,"November 12, 2010","01/11/2010","",2009-06-01,"Quantify the ocular response to acute and chronic lens wear using slit lamp examination, tear assay and corneal sensitivity.","http://ClinicalTrials.gov/show/NCT00722891",NA
"76580",76580,"NCT00730691","Efficacy and Safety of Lu AA21004 in Treating Generalized Anxiety Disorder","Completed","No Results Available","Generalized Anxiety Disorder","Drug: Lu AA21004|Drug: Lu AA21004|Drug: Lu AA21004|Drug: Placebo|Drug: Duloxetine","Takeda Global Research & Development Center, Inc.|H. Lundbeck A/S","Both","Adult","Phase III",781,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","LuAA21004_308|U1111-1114-3966","August 6, 2008","01/06/2008",2009-02-01,"June 17, 2010","01/06/2010","",2009-02-01,"The least squares mean change from Baseline in the Hamilton Anxiety Scale total score.|The least squares mean change from Baseline in the Hamilton Anxiety Scale total score at each week assessed.|Response rates at Week 8, with response defined as a ??­50% decrease in the Hamilton Anxiety Scale total score from Baseline.|Remission rates at Week 8, with remission defined as a Hamilton Anxiety Scale total score ???7.|The least squares mean change from Baseline in Clinical Global Impression Scale-Global Improvement.|The least squares mean change from Baseline in Clinical Global Impression Scale-Severity of Illness.|The least squares mean change from Baseline in Hospital Anxiety and Depression Scale.|Sheehan Disability Scale.|Healthcare resource utilization as assessed by the Health Economic Assessment Questionnaire.","http://ClinicalTrials.gov/show/NCT00730691",NA
"76583",76583,"NCT00742391","A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","Completed","No Results Available","Actinic Keratoses","Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel","Peplin","Both","Adult|Senior","Phase III",255,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","PEP005-014","August 25, 2008","01/08/2008",2009-02-01,"July 15, 2010","01/07/2010","",2009-02-01,"Efficacy (complete clearance of AKs)|Efficacy (partial clearance of AKs)","http://ClinicalTrials.gov/show/NCT00742391",NA
"76613",76613,"NCT00798291","Evaluation of AN777 in Elderly Subjects","Completed","No Results Available","Aged","Other: Ad lib diet and Control placebo|Other: Ad lib diet and An 777|Other: Ad lib diet/ placebo/ exercise|Other: Ad lib diet; AN 777; exercise","Abbott Nutrition","Both","Adult|Senior","Phase II|Phase III",108,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BK32","November 25, 2008","01/10/2008",2010-01-01,"March 19, 2010","01/03/2010","",2009-12-01,"The primary objective is to evaluate the effect of AN777 on muscle mass change in an elderly population while on an adequate protein intake.|The secondary objective is to measure the effects of AN777 on body composition, functional outcomes, strength, and quality of life.","http://ClinicalTrials.gov/show/NCT00798291",NA
"76635",76635,"NCT00789191","Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: insulin detemir|Drug: sitagliptin|Drug: metformin|Drug: sulphonylurea","Novo Nordisk","Both","Adult|Senior","Phase III",222,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NN304-3511|2008-001050-40","November 10, 2008","01/11/2008",2009-08-01,"January 10, 2011","01/01/2011","",2009-08-01,"HbA1c (Glycosylated Haemoglobin A1c)|Number of Subjects Achieving HbA1c Less Than or Equal to 7.0%|Number of Subjects Achieving HbA1c Less Than or Equal to 7.0% Without Symptomatic Hypoglycaemia|Number of Subjects Achieving HbA1c Less Than or Equal to 6.5%|Number of Subjects Achieving HbA1c Less Than or Equal to 6.5% Without Symptomatic Hypoglycaemia|Change in BMI (Body Mass Index)|Change in Body Weight|FPG (Fasting Plasma Glucose)|Hypoglycemic Episodes|Hypoglycemic Episodes: Day Time|Hypoglycemic Episodes: Night Time|Self-measured 9-point Plasma Glucose Profile","http://ClinicalTrials.gov/show/NCT00789191",NA
"76639",76639,"NCT00832091","Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers","Completed","Has Results","Venous Stasis Ulcers","Drug: Thymosin Beta 4|Drug: Placebo","RegeneRx Biopharmaceuticals, Inc.|sigma-tau i.f.r. S.p.A.","Both","Adult|Senior","Phase II",72,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SSVS","January 28, 2009","01/07/2006",2009-01-01,"March 24, 2010","01/03/2010","SSVS",2009-01-01,"Safety and Tolerability of Thymosin Beta 4 (T??4) Applied to Patients With Venous Stasis (VS) Ulcers for up to 84 Days|Wound Healing (Wound Closure Without Drainage) by Applying T??4 Gel Once Daily for up to 84 Days to Patients With Venous Stasis (VS) Ulcers","http://ClinicalTrials.gov/show/NCT00832091",NA
"76640",76640,"NCT00676091","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil","Completed","Has Results","Vaccines, Pneumococcal Conjugate Vaccine","Biological: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|Biological: 7-Valent Pneumococcal Conjugate Vaccine (7vPnc)","Wyeth","Both","Child","Phase III",354,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","6096A1-012","April 8, 2008","01/04/2008",2009-09-01,"October 20, 2010","01/10/2010","",2009-09-01,"Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ??­0.35 Micrograms Per Milliliter (Mcg/mL) in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series|Percentage of Participants Achieving Antibody Level ??­5 Enzyme-linked Immunosorbent Assay (ELISA) Units Per mL (EU/mL) for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series|Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ??­0.35 Mcg/mL in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose|Percentage of Participants Achieving Antibody Level ??­5 EU/mL for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose","http://ClinicalTrials.gov/show/NCT00676091",NA
"76652",76652,"NCT00846391","A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (8245-005)","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: MK8245 5 mg (twice a day) b.i.d.|Drug: MK8245 50 mg b.i.d.|Drug: Placebo","Merck","Both","Adult","Phase II",14,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2009_541|MK8245-005","February 17, 2009","01/12/2008",2009-08-01,"August 26, 2010","01/08/2010","",2009-08-01,"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4","http://ClinicalTrials.gov/show/NCT00846391",NA
"76656",76656,"NCT00868491","Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: docetaxel, cisplatin, 5-fluorouracil|Radiation: radiotherapy|Drug: cetuximab, cisplatin","Institute of Oncology Ljubljana","Both","Adult|Senior","Phase II",30,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR-62202-717","March 24, 2009","01/03/2008",2010-04-01,"November 19, 2010","01/04/2010","",2009-12-01,"locoregional control|feasibility (toxicity profile) of the proposed regimen|complete response rate|disease free survival|overall survival|late toxicity including thyroid function","http://ClinicalTrials.gov/show/NCT00868491",NA
"76657",76657,"NCT00869791","A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa","Completed","No Results Available","Parkinson's Disease","Drug: IPX066|Drug: CD-LD","IMPAX Laboratories, Inc.","Both","Adult|Senior","Phase I|Phase II",27,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","IPX066-B08-11","March 24, 2009","01/02/2009",2009-08-01,"October 29, 2010","01/10/2010","",2009-06-01,"Pharmacokinetics: CD and LD Cmax, Tmax, AUC, half-life|Safety (electrocardiogram, clinical laboratory tests, vital signs, AEs) and Pharmacodynamics (finger tapping, walking, UPDRS)","http://ClinicalTrials.gov/show/NCT00869791",NA
"76681",76681,"NCT00824291","Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","Completed","Has Results","Depressive Disorder, Major","Drug: desvenlafaxine succinate sustained release|Genetic: Genotyping","Wyeth","Both","Adult|Senior","Phase III",437,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3151A1-4415|B2061006","January 14, 2009","01/02/2009",2009-11-01,"November 30, 2010","01/11/2010","",2009-10-01,"Change From Baseline in Hamilton Depression Scale (HAM-D) at Week 12|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 12|Clinical Global Impression Scale - Improvement (CGI- I) Score at Week 12|Clinical Global Impressions Scale - Severity of Illness (CGI-S) at Week 12|Change From Baseline on Work and Activities Item of HAM-D17 at Week 12|Change From Baseline in Adjusted Mean on Montgomery-Asberg Depression Rating Scale (MADRS) at Week 12|Change From Baseline on Worry Anxiety Tension Scale (WATS) at Week 12|Change From Baseline on Stress and Social Support Scales at Week 12","http://ClinicalTrials.gov/show/NCT00824291",NA
"76682",76682,"NCT00919191","Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face","Completed","Has Results","Acne Vulgaris","Drug: Tretinoin gel|Drug: Adapalene and Benzoyl peroxide","Johnson & Johnson Consumer & Personal Products Worldwide","Female","Adult","Phase IV",26,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","CA-P-6805","June 10, 2009","01/04/2009",2009-05-01,"March 9, 2010","01/03/2010","",2009-05-01,"Comparative Assessment of Facial Irritation and Cutaneous Effects.|Self Assessment of Burning/Stinging and Itching","http://ClinicalTrials.gov/show/NCT00919191",NA
"76697",76697,"NCT00942591","Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b","Completed","No Results Available","Multiple Sclerosis","Drug: Interferon beta 1b|Drug: Atorvastatin","University Hospital Inselspital, Berne|CRO: PharmaPart AG, Bahnhofstrasse 20, P.O. Box 173, CH-8800 Thalwil|Laboratory: Viollier AG Spalenring 145 / 147 Postfach 4002 Basel","Both","Adult","Phase II",77,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","17/05|CWCNS01","July 17, 2009","01/05/2005",2009-05-01,"July 20, 2009","01/07/2009","SWABIMS",2009-04-01,"Proportion of patients with new T2 lesions on MRI.|Gd-enhancing lesion on T1-weighted images|Clinical disease progression|Time to first relapse|Cortical atrophy","http://ClinicalTrials.gov/show/NCT00942591",NA
"76750",76750,"NCT01024491","Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation","Completed","No Results Available","Premature Ejaculation","Drug: paroxetine|Drug: paroxetine|Drug: placebo","MorePharma Corporation","Male","Adult|Senior","Phase III",174,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MPEP-01","November 30, 2009","01/08/2008",2009-04-01,"December 1, 2009","01/12/2009","",2009-03-01,"Intravaginal Ejaculatory Latency Time (IELT)|Score of the control domain of the Index of Premature Ejaculation|Score of the sexual satisfaction domain of the Index of Premature Ejaculation|Score of the distress with ejaculation domain of the Index of Premature Ejaculation|Erectile function domain of the International Index of Erectile Function|Sexual desire domain of the International Index of Erectile Function","http://ClinicalTrials.gov/show/NCT01024491",NA
"76757",76757,"NCT01028391","30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.|Drug: Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Drug: Metformin","Merck","Both","Adult|Senior","Phase III",317,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2009_003|MK0431-064-10","December 8, 2009","01/09/2007",2009-01-01,"April 21, 2010","01/04/2010","",2009-01-01,"Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54|Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Fasting Plasma Glucose (FPG) at Week 54","http://ClinicalTrials.gov/show/NCT01028391",NA
"76778",76778,"NCT01076491","High Dose Inhaled Mannitol Study","Completed","No Results Available","Bronchiectasis","Drug: mannitol","Pharmaxis","Both","Adult|Senior","Phase I|Phase II",10,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label","DPM-DEV-102b|DPM-DEV-102b","November 11, 2009","01/01/2009",2009-04-01,"February 24, 2010","01/02/2010","",2009-03-01,"emitted dose","http://ClinicalTrials.gov/show/NCT01076491",NA
"76815",76815,"NCT01132391","Perianal Versus Endoanal Application of Glyceryl Trinitrate 0.4% Ointment for Chronic Anal Fissure","Completed","No Results Available","Chronic Anal Fissure","Drug: Rectogesic?ó (glyceryl trinitrate 0.4% ointment)","Hospital General Universitario Elche","Both","Adult|Senior","Phase III",60,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FAC","September 8, 2009","01/01/2009",2009-06-01,"May 27, 2010","01/09/2009","",2009-04-01,"Headache (during eights weeks of treatment)|Recurrence or persistence anal fissure (six month)","http://ClinicalTrials.gov/show/NCT01132391",NA
"76837",76837,"NCT01173991","Carbohydrate Counting in Adults With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion","Completed","No Results Available","Diabetes Mellitus, Type 1|Insulin Pump, Programmable","Behavioral: Carbohydrate counting training","IRCCS San Raffaele","Both","Adult","Phase III",61,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GIOCAR","July 26, 2010","01/10/2008",2010-01-01,"August 2, 2010","01/07/2010","GIOCAR",2009-09-01,"Glycated haemoglobin (HbA1c)|Fasting glucose|Glycemic variability (mean, sd, min, max, variability range, BG in target range, LBGI, HBGI) based on capillary glucose data|Daily insulin requirement (basal daily requirement, bolus daily requirement, total daily requirement)|Body Mass Index (BMI)|Waist circumference|Quality of life by Diabetes Specific Quality of Life Scale (DSQOLS) questionnaire|Hypoglycemia (capillary glucose<50 mg/dl)","http://ClinicalTrials.gov/show/NCT01173991",NA
"76932",76932,"NCT00003892","ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer","Completed","No Results Available","Ovarian Cancer","Drug: ISIS 5132","NCIC Clinical Trials Group","Female","Adult|Senior","Phase II",30,"Other","Interventional","Primary Purpose: Treatment","I116|CAN-NCIC-IND116|CDR0000067061","November 1, 1999","01/02/1999",2009-12-01,"November 7, 2010","01/03/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00003892",NA
"77045",77045,"NCT00167492","Enteric Coated Myfortic for Liver Transplant Recipients","Completed","No Results Available","Liver Transplantation","Drug: Myfortic","The University of Texas Health Science Center, Houston|Novartis","Both","Adult|Senior","Phase IV",50,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HSC-MS-05-0197|Novartis Pharmaceuticals|CERL080A-US11","September 9, 2005","01/09/2005",2009-02-01,"May 14, 2009","01/05/2009","",2009-02-01,"Rate of rejection|Rate of gastrointestinal side-effects|Levels of calcineurin inhibitors|Renal function|Relationship of dose to biologic monitoring of immunosuppression","http://ClinicalTrials.gov/show/NCT00167492",NA
"77060",77060,"NCT00151892","Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis","Completed","Has Results","Colitis, Ulcerative","Drug: SPD476|Drug: Asacol","Shire Pharmaceutical Development","Both","Adult|Senior","Phase III",829,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPD476-304","September 7, 2005","01/11/2007",2009-10-01,"September 24, 2010","01/09/2010","",2009-09-01,"Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months|Withdrawal Due to Relapse of UC|Endoscopic Remission of UC With No or Mild Symptoms at 6 Months|Change From Baseline in Modified Ulcerative Colitis Disease Activity Index (UCDAI) Score at 6 Months|Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Total Score","http://ClinicalTrials.gov/show/NCT00151892",NA
"77068",77068,"NCT00197392","Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System","Completed","No Results Available","Intraventricular Hemorrhage|Subarachnoid Hemorrhage","Device: Bactiseal TM EVD","Codman & Shurtleff","Both","Adult|Senior","Phase IV",515,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BAC-IN02-002","September 13, 2005","01/11/2004",2010-01-01,"December 6, 2010","01/12/2010","",2009-12-01,"The rate of infection for the Codman B-EVD in comparison to the conventional EVD catheter (ventriculostomy-related infections) throughout the duration of the implanted EVD systems and for a 2-week period post-explant.|The time to infection|The class of bacteria|The rate and extent of intraluminal bacterial colonization in EVD catheter systems|Device related adverse events|Influence of number of days with indwelling catheter|Subject age and diagnosis (reasons for catheter placement) on infection rates|Procedural differences and techniques|The influence of concurrent systemic antibiotics on infection rates|Health economic inferences.","http://ClinicalTrials.gov/show/NCT00197392",NA
"77127",77127,"NCT00294892","Pharmacokinetics Study on Nevirapine Resistance in Tanzania","Completed","No Results Available","HIV Infections","Drug: carbamazepine and nevirapine|Drug: Nevirapine","Radboud University","Female","Adult","Phase II",144,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VITA1","February 21, 2006","01/02/2006",2010-06-01,"July 6, 2010","01/07/2010","",2009-09-01,"Cord blood will be taken less than 30 minutes after delivery|Blood samples from mother will be taken less than 30 minutes after delivery to measure viral load and CD4 count.|Blood samples will be drawn from mother and child at week 1 (day 6-8), week 2 (day 13-15) and week 3 (day 20-22)|From all samples plasma nevirapine and if applicable carbamazepine levels will be determined in women and newborns.","http://ClinicalTrials.gov/show/NCT00294892",NA
"77138",77138,"NCT00310492","Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Biological: ALK-depot SQ mites","ALK-Abell?? A/S","Both","Adult","Phase III",154,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SHX0556","April 2, 2006","01/04/2006",2009-11-01,"August 17, 2010","01/08/2010","",2009-05-01,"Recording of symptoms and medication|Quality of life and adverse events","http://ClinicalTrials.gov/show/NCT00310492",NA
"77151",77151,"NCT00328692","PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function","Completed","No Results Available","Heart Failure, Congestive","Drug: rolofylline|Drug: Comparator: Placebo (unspecified)","NovaCardia, Inc.|Merck","Both","Adult|Senior","Phase III",932,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CKI-301|2007_803|MK7418-301","May 19, 2006","01/08/2006",2009-07-01,"October 8, 2009","01/10/2009","",2009-07-01,"effect on heart failure signs and symptoms|effect on renal function|safety|within trial medical costs compared to placebo","http://ClinicalTrials.gov/show/NCT00328692",NA
"77152",77152,"NCT00329992","Brief Eclectic Psychotherapy for PTSD - a Randomized Controlled Trial","Completed","No Results Available","Chronic Posttraumatic Stress Disorder","Behavioral: Brief Eclectic Psychotherapy for PTSD","University of Zurich|Swiss National Science Foundation|Herrmann-Klaus-Stiftung, Switzerland|Olga Mayenfisch Stiftung, Zurich, Switzerland|Jubil??umsspende f??r die Universit??t Z??rich, Switzerland","Both","Adult|Senior","Phase III",30,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","3200BO-102204","May 23, 2006","01/04/2004",2009-12-01,"January 19, 2010","01/01/2010","",2009-05-01,"PTSD symptom severity (CAPS, Blake et al. 1998; Post-therapy / post-waitlist comparison, controlled for baseline scores|Ability to work and use of health care facilities|Comorbidity: Structured Clinical Interview for DSM-IV SCID I (First et al. 1996); Hospital Anxiety and Depression Scale HADS (Zigmond and Snaith 1983)|Questions on Life Satisfaction FLZ (Henrich and Herschbach 2000)|Posttraumatic Cognitions Inventory PTCI (Foa et al. 1999)|Posttraumatic Growth Inventory PGI (Tedeschi and Calhoun 1996)|EEG, event-related potentials: P300|Post-therapy / post-waitlist comparison, follow-up at 6month post therapy","http://ClinicalTrials.gov/show/NCT00329992",NA
"77154",77154,"NCT00336492","A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Subjects With Moderately to SeverelyActive Ulcerative Colitis","Completed","No Results Available","Ulcerative Colitis","Biological: infliximab|Biological: infliximab","Centocor, Inc.","Both","Child","Phase III",60,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR012388|C0168T72","June 9, 2006","01/09/2006",2010-04-01,"October 18, 2010","01/10/2010","",2009-05-01,"The primary objectives of this study are to evaluatethe efficacy of infliximab in inducing a clinical response at week 8 inpediatric patients with UC and to evaluate the safety profile of infliximabduring induction and maintenance treatment.|The secondary objectives of this study are to evaluatethe efficacy of infliximab in inducing clinical remission and mucosal healing at week 8; Compare two dosing regimens in maintaining clinical response and remission at week 54","http://ClinicalTrials.gov/show/NCT00336492",NA
"77165",77165,"NCT00268892","Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer","Completed","Has Results","Prostate Cancer","Drug: Degarelix|Drug: Degarelix|Drug: Degarelix","Ferring Pharmaceuticals","Male","Adult|Senior","Phase II|Phase III",278,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FE200486 CS15A","December 21, 2005","01/01/2006",2009-12-01,"December 8, 2010","01/12/2010","",2009-09-01,"Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight|Liver Function Tests","http://ClinicalTrials.gov/show/NCT00268892",NA
"77203",77203,"NCT00409292","RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: RAD001","Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Novartis","Both","Adult|Senior","Phase II",35,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-197","December 6, 2006","01/01/2007",2009-05-01,"October 30, 2009","01/10/2009","",2009-01-01,"To assess progression-free survival of RAD001 at two months in patients with metastatic pancreatic cancer whose disease has progressed on gemcitabine chemotherapy.|To assess the safety of RAD001 in patients with metastatic pancreatic cancer|to assess response rate and overall survival associated with RAD001 in this patient population.","http://ClinicalTrials.gov/show/NCT00409292",NA
"77216",77216,"NCT00427492","Effect of Postoperative Laxative on Bowel Function After Colonic Surgery","Completed","No Results Available","Colonic Cancer","Drug: Magnesia|Drug: Placebo","Hvidovre University Hospital","Both","Adult|Senior","Phase IV",56,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care","02 290964","January 26, 2007","01/01/2007",2009-01-01,"February 10, 2009","01/02/2009","",2009-01-01,"Time to defecation after colonic resection","http://ClinicalTrials.gov/show/NCT00427492",NA
"77218",77218,"NCT00422292","Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra?ó in Healthy Toddlers","Completed","No Results Available","Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella","Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|Biological: Measles, Mumps, Rubella and Varicella","Sanofi-Aventis","Both","Child","Phase III",1664,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention","MTA37","January 12, 2007","01/12/2006",2009-04-01,"March 31, 2010","01/03/2010","",2009-01-01,"To provide information concerning the immune response of MMRV, Hib, and PCV after vaccination.","http://ClinicalTrials.gov/show/NCT00422292",NA
"77234",77234,"NCT00452192","Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome","Completed","No Results Available","Metabolic Syndrome","Drug: Telmisartan","University of Erlangen-N??rnberg Medical School","Male","Adult","Phase III",30,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","SFB 423-TP B5 Niere MRT","March 26, 2007","01/11/2006",2009-12-01,"February 1, 2010","01/02/2010","",2009-12-01,"Change in RPF to L-NMMA at baseline and after telmisartan (MRI)","http://ClinicalTrials.gov/show/NCT00452192",NA
"77236",77236,"NCT00456092","Phase II Study With CC-10004 in Psoriatic Arthritis","Completed","No Results Available","Psoriatic Arthritis","Drug: CC-10004","Celgene Corporation","Both","Adult|Senior","Phase II",204,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PsA-001","April 2, 2007","01/01/2009",2009-05-01,"February 1, 2010","01/02/2010","",2009-05-01,"Proportion of subjects in each treatment group who achieve ACR criteria for 20% improvement at Day 85/Early termination visit compared with baseline|Type, frequency, severity and relationship of adverse events to CC-10004;|Number of subjects who prematurely discontinue study medication due to any adverse event;|Frequency of clinically significant changes in physical examination, vital signs, ECG and/or laboratory findings|Frequency of subjects unable to withstand dose titration|Frequency of subjects who discontinue participation in the treatment phase due to inability to withstand over adverse effects of the study medication;|Proportion of subjects in each treatment group who meet PsARC at Day 85/Day 169/early termination|Proportion of subjects in each treatment group who achieve an ACR 50 and ACR 70 at Day 85/Day 169/early termination|Change in DAS of subjects in each treatment group at D85/Day 169/early termination|Change in PASI score at Day 85/Day 89/ET|Proportion of subjects in each treatment group who achieve >= PASI 50 at D85/Day 169/ET|Maximal ACR response during treatment|Maximal PASI response during treatment|Time to achieve ACR 20/50/70|Time to achieve PASI 50|Change in dactylitis severity score in subjects in each treatment group at D85/Day 169/ET|Proportion of subjects with and without enthesitis in each treatment group at D85/Day 169/ET|Time to relapse of psoriasis during observational follow up|Time to relapse of psoriatic arthritis during observational follow up|Proportion of subjects who relapse during observational follow up|Change from baseline in QOL assessment scores at D85/Day 169/ET|Change in peripheral blood T cell, B cell and NK cell subsets|Change in synovitis and change in inflammatory markers in synovial tissue at D85/ET|Change in epidermal thickness and change in inflammatory markers in psoriatic skin biopsies at D85/ET|Pharmacokinetic profile including AUC, Cmax, Tmax and relationship of PK to PD and clinical outcomes","http://ClinicalTrials.gov/show/NCT00456092",NA
"77245",77245,"NCT00462592","Comparison of Combination Therapy: Montelukast and Inhaled Steroid on Exercise Induced Bronchoconstriction","Completed","No Results Available","Asthma","Drug: budesonide|Drug: montelukast|Other: placebo","Hamilton Health Sciences Corporation|Merck","Both","Child|Adult","Phase III",18,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","monbud8035","April 18, 2007","01/03/2007",2009-06-01,"October 20, 2009","01/10/2009","",2009-06-01,"The magnitude of protection and the number of subjects with ??­50% protection (considered to be clinically relevant) following treatment|Change in sputum cell counts and fluid phase inflammatory mediators|Change in baseline exhaled nitric oxide (eNO) and response to exercise challenge|Change in EBC (exhaled breath condensate) inflammatory mediators from baseline|The change in exercise induced maximal percent fall in FEV1 (maxFEV1%) and area under the curve (AUC0-30) relative to pre-exercise FEV1 up to 30 minutes following exercise challenge","http://ClinicalTrials.gov/show/NCT00462592",NA
"77265",77265,"NCT00501592","Study of INT-747 in Patients With Diabetes and Presumed NAFLD","Completed","No Results Available","Diabetes Mellitus, Type II|Fatty Liver","Drug: INT-747","Intercept Pharmaceuticals","Both","Adult|Senior","Phase II",45,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","747-203","July 13, 2007","01/07/2007",2009-04-01,"April 7, 2009","01/04/2009","",2009-02-01,"The primary objective of assessing changes in insulin resistance and glucose homeostasis will be attained by performing a euglycemic clamp procedure at baseline (Day 0) and at the end of 6 weeks of treatment (Day 43).","http://ClinicalTrials.gov/show/NCT00501592",NA
"77268",77268,"NCT00506792","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis","Completed","No Results Available","Cystic Fibrosis","Drug: QAU145|Drug: Placebo","Novartis","Both","Adult","Phase II",9,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CQAU145A2201","July 22, 2007","01/07/2007",NA,"April 30, 2009","01/04/2009","",2009-04-01,"Pharmacodynamic response to single intranasal doses of QAU145 in cystic fibrosis patients using nasal potential difference measurements up to 6 hours post-dose.|Safety and tolerability of single ascending doses assessed by nasal examinations, adverse events, medications, and a nasal symptom questionnaire. Pharmacokinetics up to 6 hours post-dose","http://ClinicalTrials.gov/show/NCT00506792",NA
"77338",77338,"NCT00621192","Pharmacokinetic and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections","Completed","No Results Available","Necrotizing Enterocolitis|Intra-abdominal Infection","Drug: meropenem|Drug: meropenem|Drug: meropenem","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Child","Phase I|Phase II",200,"NIH","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HHSN267200700051C|HHSN267200700051C","February 20, 2008","01/06/2008",2009-10-01,"May 12, 2010","01/05/2009","Meropenem PK",2009-10-01,"Pharmacokinetics|seizure frequency","http://ClinicalTrials.gov/show/NCT00621192",NA
"77344",77344,"NCT00634192","Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin","Completed","No Results Available","Pseudomonas Infections","Drug: tobramycin|Drug: tobramycin","Novartis","Both","Child|Adult|Senior","Phase III",50,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","CTBM100DDE01","March 4, 2008","01/02/2008",2009-08-01,"August 31, 2010","01/08/2010","",2009-02-01,"To evaluate the serum pharmacokinetics (PK) of inhaled tobramycin (AUC 0-90') of continuous daily dosing regimens with 2x300mg/d Tobramycin Nebuliser Solution (=TNS) inhaled with the PARI eFlow?ó rapid in Cystic Fibrosis (CF) subjects|Serum PK of inhaled tobramycin (AUC 0-90') of continuous daily dosing regimens with 1 x 300mg/d tobramycin nebulized solution (= TNS) inhaled with the PARI eFlow rapid in cystic fibrosis subjects.|Compare serum PK of inhaled tobramycin (trough-/peak-level)of both dosing regimens in CF-subjects with a FEV1??­80% vs. CF-Subjects with a FEV1<80%.|Change of MIC of P. aeruginosa during a continuous treatment with 1 x 300 mg/d and 2 x 300 mg/d TNS.|Assess safety of a continuous daily dosing regimen with 1 x 300 mg/d and 2 x 300 mg/d TNS over 8 weeks, compared to historic safety data of the 4 week on/off dosing regimen with 2 x 300 mg/d.","http://ClinicalTrials.gov/show/NCT00634192",NA
"77365",77365,"NCT00667992","Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma","Completed","No Results Available","Asthma","Drug: Budesonide HFA|Drug: Budesonide CFC","AstraZeneca","Both","Adult","Phase IV",60,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","D5252C00008","April 23, 2008","01/04/2008",2009-05-01,"November 12, 2009","01/11/2009","",2009-05-01,"Change from pooled baseline (i.e., post run-in or washout periods) in methacholine airway responsiveness measured as the provocative concentration of methacholine (PC20) that causes a 20% drop in FEV1 for each treatment|Change from pooled baseline in PEF, FEV1 and Forced Expiratory Flow (FEF25-75) for each treatment|Change from pooled baseline in exhaled NO for each treatment|Asthma symptom scores (day, night and total) and rescue use consumption (day, night and total) for each treatment.|Change in pooled baseline for morning PEF","http://ClinicalTrials.gov/show/NCT00667992",NA
"77370",77370,"NCT00662792","Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: Tiotropium plus Salmeterol|Drug: Tiotropium|Drug: Salmeterol","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",147,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment","1184.13|n.a.","April 17, 2008","01/04/2008",NA,"October 12, 2009","01/10/2009","",2009-08-01,"FEV1 (AUC0 to 12h, AUC12 to 24h, peak and trough)|FEV1 (AUC0 to 24h; FVC (peak, trough, AUC0 to 12 h, AUC0 to 24h, AUC12 to 24h), twice daily PEFs and FEV1 recorded by the patients at home, daily rescue salbutamol use, COPD related night time awakenings","http://ClinicalTrials.gov/show/NCT00662792",NA
"77386",77386,"NCT00699192","Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension","Completed","No Results Available","Hypertension","Drug: Amlodipine/Valsartan|Drug: Amlodipine","Novartis Pharmaceuticals","Both","Adult|Senior","Phase III",670,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CVAA489A2318","June 9, 2008","01/05/2008",2009-06-01,"February 6, 2010","01/02/2010","",2009-06-01,"The overall reporting of adverse events, serious adverse events (SAEs) including death, discontinuation due to adverse events, and notable laboratory abnormalities.|To evaluate: aml/val 5/80mg compared to aml 5 mg monotherapy,|To evaluate aml/val 5/40mg to aml 5 mg monotherapy|To evaluate blood pressure lowering effects|To evaluate changes in orthostatic blood pressure, sitting and standing pulse, and laboratory data","http://ClinicalTrials.gov/show/NCT00699192",NA
"77394",77394,"NCT00683592","Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)","Completed","Has Results","Major Depressive Disorder","Drug: vilazodone|Drug: placebo","PGxHealth, LLC","Both","Adult|Senior","Phase III",481,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLDA-07-DP-02","May 21, 2008","01/03/2008",2009-03-01,"October 5, 2010","01/10/2010","",2009-02-01,"Change From Baseline to Week 8 in the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score.|Change From Baseline to Week 8 in the HAM-D 17 (17-Item Hamilton Rating Scale for Depression) Total Score|The CGI-I (Clinician's Global Impression of Improvement) Score at Week 8|Change From Baseline to Week 8 in the HAM-A ( Hamilton Anxiety Rating Scale) Total Score|MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate at Week 8|MADRS (Montgomery-Asberg Depression Rating Scale) Remission Rate at Week 8","http://ClinicalTrials.gov/show/NCT00683592",NA
"77409",77409,"NCT00738192","Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia","Completed","No Results Available","Postoperative Pain","Drug: Fentanyl citrate|Drug: Sufentanil citrate|Drug: Butorphanol tartrate","Nanjing Medical University","Female","Adult","Phase IV",150,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NMU-FY2008-311|NJFY0807311M","August 18, 2008","01/07/2008",2009-03-01,"March 10, 2009","01/03/2009","CARAN",2009-03-01,"VAS ratings of pain|Hemodynamics of patients|Sedative ratings with VAS system|Overall VAS satisfaction ratings|Blood cortisol and ??-endorphin levels|Side effects","http://ClinicalTrials.gov/show/NCT00738192",NA
"77456",77456,"NCT00807092","Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Type 2 Diabetics","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: biphasic insulin aspart 30|Drug: biphasic human insulin 30|Drug: metformin","Novo Nordisk","Both","Adult|Senior","Phase IV",145,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BIASP-3681","December 10, 2008","01/12/2008",2009-10-01,"December 3, 2009","01/12/2009","",2009-10-01,"Mean IAUC for postprandial glucose (0-4 hours) over 3 main meals assessed by CGMS|IAUC for postprandial glucose (0-4 hours) after each meal (breakfast, lunch, dinner) assessed by CGMS|FBG (Fasting blood glucose) assessed by CGMS (continuous glucose monitoring system )|FPG (Fasting plasma glucose) assessed by local laboratories|8-point SMBG (self-monitored blood glucose) profiles|MAGE (mean amplitude of glycaemic excursions) assessed by CGMS|GA (Glycated albumin) assessed by central laboratory|HbA1c assessed by central laboratory|Safety profiles during treatment period","http://ClinicalTrials.gov/show/NCT00807092",NA
"77457",77457,"NCT00808392","Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b","Completed","No Results Available","Haemophilus Influenzae Type B","Biological: Haemophilus influenzae type b vaccine|Biological: Commercial Haemophilus influenzae type b vaccine","Novartis|Novartis Vaccines","Both","Child","Phase III",900,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","M37P2","December 12, 2008","01/11/2008",NA,"November 4, 2009","01/11/2009","",2009-02-01,"Immunogenic response measured by detection of anti-PRP antibodies by IgG enzyme linked immunosorbent assay (ELISA).|Rates of local and systemic reactions, adverse events (AEs), and serious adverse events (SAEs) after each single vaccination dose will be evaluated.","http://ClinicalTrials.gov/show/NCT00808392",NA
"77493",77493,"NCT00862992","Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: Cariprazine low dose|Drug: Cariprazine medium dose|Drug: Cariprazine high dose","Mitsubishi Tanabe Pharma Corporation","Both","Adult","Phase II",30,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A002-A3","March 15, 2009","01/04/2008",2009-09-01,"September 8, 2009","01/09/2009","",2009-09-01,"Safety: Adverse event, Adverse drug Reaction|Pharmacokinetics: Plasma concentration|Efficacy: PANSS total score, CGI-S and CGI-I","http://ClinicalTrials.gov/show/NCT00862992",NA
"77540",77540,"NCT00938392","Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly","Completed","No Results Available","Influenza Infection","Biological: GSK investigational vaccine GSK2186877A, different formulations","GlaxoSmithKline","Both","Adult|Senior","Phase III",726,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","112662","July 9, 2009","01/07/2009",2009-10-01,"March 25, 2010","01/03/2010","",2009-10-01,"Humoral immune response in terms of HI antibodies|Humoral immune response in terms of HI antibodies (on secondary readouts)|Occurrence of solicited general signs and symptoms|Occurrence of solicited local signs and symptoms|Occurrence of unsolicited AEs|Occurrence of SAEs and AEs of specific interest including autoimmune diseases (AID)","http://ClinicalTrials.gov/show/NCT00938392",NA
"77596",77596,"NCT01041092","Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women","Completed","No Results Available","Schizophrenia","Drug: raloxifene","Fundaci?? Sant Joan de D?¢u","Female","Adult|Senior","Phase IV",34,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","04T-504","December 30, 2009","01/06/2004",2009-12-01,"December 30, 2009","01/12/2009","",2009-12-01,"The primary efficacy end-point will be the change in the score of the PANSS negative subscale from baseline to follow-up assessment.|Patients social and neuropsychological functioning will be evaluated, comparing baseline ratings to end-point.","http://ClinicalTrials.gov/show/NCT01041092",NA
"77651",77651,"NCT01129492","Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis","Completed","No Results Available","Autoimmune Thyroiditis","Device: Low-level Laser therapy","University of Sao Paulo General Hospital|Funda????o de Amparo ?? Pesquisa do Estado de S??o Paulo|Conselho Nacional de Desenvolvimento Cient?¦fico e Tecnol??gico|Coordena????o de Aperfei??oamento de Pessoal de N?¦vel Superior.","Both","Adult","Phase II",43,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","CAPPesq 375/05","May 14, 2010","01/03/2006",2009-03-01,"May 21, 2010","01/04/2009","",2009-03-01,"The main outcome measure was to gauge the effectiveness of applying LLLT in patients with hypothyroidism caused by CAT evaluated by a significant reduction of the levothyroxine (LT4) mean dose (??/day) 9 months post-LT4 withdrawal.|Evaluate the LLLT efficacy in reducing thyroid autoantibodies concentrations.|Evaluate the LLLT efficacy by quantitative and qualitative ultrasonography parameters.","http://ClinicalTrials.gov/show/NCT01129492",NA
"77734",77734,"NCT01269892","Early Administration of Lactose-free Milk in Children Presenting With Acute Diarrhea","Completed","No Results Available","Acute Diarrhea","Dietary Supplement: lactose-free milk|Dietary Supplement: conventional milk","Isfahan University of Medical Sciences","Both","Child","Phase II",74,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","ASD-1213-9","January 3, 2011","01/01/2009",2009-08-01,"January 3, 2011","01/01/2009","",2009-08-01,"duration of diarrhea|changes in weight gaining","http://ClinicalTrials.gov/show/NCT01269892",NA
"77790",77790,"NCT00009893","Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer","Completed","No Results Available","Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer","Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium","North Central Cancer Treatment Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068421|NCCTG-N0042","February 2, 2001","01/05/2001",NA,"October 16, 2009","01/10/2009","",2009-10-01,"","http://ClinicalTrials.gov/show/NCT00009893",NA
"77832",77832,"NCT00061893","Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors","Completed","No Results Available","Sarcoma","Drug: celecoxib|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vinblastine sulfate|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase II",36,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000302409|COG-AEWS02P1","June 5, 2003","01/04/2004",NA,"November 20, 2010","01/11/2010","",2009-05-01,"Feasibility as measured by toxicity at study completion|Event-free survival at 1 to 2 years following study completion","http://ClinicalTrials.gov/show/NCT00061893",NA
"77857",77857,"NCT00091793","Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis","Completed","Has Results","Postmenopausal Osteoporosis","Drug: AMG 162|Drug: Placebo","Amgen","Female","Child|Adult|Senior","Phase III",332,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20040132","September 17, 2004","01/08/2004",2009-03-01,"December 22, 2010","01/12/2010","",2009-02-01,"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24|Total Hip Bone Mineral Density Percent Change From Baseline at Month 24|Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24|Trochanter Bone Mineral Density Percent Change From Baseline at Month 24|Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24|Total Body (Without Head) Bone Mineral Density Percent Change From Baseline at Month 24|Distal Radius Trabecular Volumetric Bone Mineral Density Percent Change From Baseline at Month 24|Distal Radius Cortical Volumetric Bone Mineral Density Percent Change From Baseline at Month 24|Distal Radius Total Volumetric Bone Mineral Density Percent Change From Baseline at Month 24","http://ClinicalTrials.gov/show/NCT00091793",NA
"77903",77903,"NCT00200993","Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE I)","Completed","No Results Available","Cardiovascular Diseases|Heart Diseases|Obesity|Hyperlipidemia|Insulin Resistance|Metabolic Syndrome X","Behavioral: physical activity","National Heart, Lung, and Blood Institute (NHLBI)","Both","Adult|Senior","Phase II",NA,"NIH","Interventional","Allocation: Randomized|Primary Purpose: Prevention","268","September 12, 2005","01/09/1998",2009-04-01,"April 13, 2009","01/04/2009","",2009-04-01,"","http://ClinicalTrials.gov/show/NCT00200993",NA
"77904",77904,"NCT00163293","Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 y) (BY9010/CA-101)","Completed","Has Results","Asthma","Drug: Ciclesonide|Drug: Ciclesonide|Drug: Placebo","ALTANA Pharma","Both","Child","Phase III",240,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","BY9010/CA-101","September 12, 2005","01/01/2005",2010-04-01,"December 1, 2010","01/12/2010","POPCICLE",2009-06-01,"Time to First Exacerbation|Exacerbations (Post-hoc Analysis of Annual Rates)|Growth Velocity as Assessed by Stadiometric Height Measurement|Mean Rate of Asthma Exacerbations Per Year|Duration of Exacerbations|Number of Exacerbations|Drop-out Rate Due to Asthma Exacerbation|Change in FEV1 as Percent Predicted and Absolute Values|Morning and Evening PEF Measurements by Diary Entries|Variation in PEF by Diary Entries|Diurnal PEF Fluctuation|Total Symptom Score by Diary Entries|Percent Nights With Nocturnal Awakenings Due to Asthma Symptoms|Rescue Medication Use by Diary Entries|Number of Rescue Medication Free Days by Diary Entries|Number of Symptom Free Days by Diary Entries|Quality of Life Assessments as Per Pediatric Asthma Quality of Life Questionnaires PAQLQ(S) and PACQLQ|Physical Examination and Vital Signs|Laboratory Work-up.","http://ClinicalTrials.gov/show/NCT00163293",NA
"77942",77942,"NCT00265993","Enoxaparin in Acute Venous Thromboembolic Disease","Completed","No Results Available","Venous Thrombosis","Drug: enoxaparin","Sanofi-Aventis","Both","Adult|Senior","Phase IV",251,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP4563A_4001","December 14, 2005","01/12/2004",2009-01-01,"February 2, 2010","01/02/2010","",2009-01-01,"Frequency of bleeding emerged during the study drug administration; Frequency of bleeding emerged during 3 months of monitorization when the patient is on oral anticoagulants.","http://ClinicalTrials.gov/show/NCT00265993",NA
"77958",77958,"NCT00286793","Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: AT-101|Drug: Docetaxel|Drug: Prednisone","Ascenta Therapeutics","Male","Adult|Senior","Phase I|Phase II",75,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AT-101-CS-202","February 3, 2006","01/02/2006",2009-11-01,"February 2, 2010","01/02/2010","",2009-11-01,"Safety of AT-101 in combination with docetaxel and prednisone|Preliminary efficacy of AT-101 in combination with docetaxel and prednisone","http://ClinicalTrials.gov/show/NCT00286793",NA
"77968",77968,"NCT00128193","Leprosy Skin Test Antigens Trial","Completed","Has Results","Leprosy","Drug: MLSA-LAM|Drug: MLCwA|Drug: RT-23|Drug: Placebo|Drug: Tuberculin, Purified Protein Derivative (Tubersol?ó)","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","Phase II",260,"NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic","00-002","August 5, 2005","01/04/2002",2009-10-01,"December 2, 2010","01/08/2010","",2009-10-01,"Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram|Number of Participants With the Reaction of Itching to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram|Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Microgram|Number of Participants With the Reaction of Itching to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Microgram|Number of Participants With Reactions to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Microgram|Number of Participants With Reaction of Itching to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Microgram|Number of Participants With Reactions to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Microgram|Number of Participants With the Reaction of Itching to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Microgram|Number of Participants With Reactions to the Antigen Purified Protein Derivative (PPD)|Number of Participants With the Reaction of Itching to the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Erythema at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 0.1 Microgram.|Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 1.0 Microgram.|Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 0.1 Microgram.|Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 1.0 Microgram.|Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen PPD.|Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 0.1 Microgram|Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 1.0 Microgram|Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 0.1 Microgram|Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 1.0 Microgram|Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen PPD","http://ClinicalTrials.gov/show/NCT00128193",NA
"78045",78045,"NCT00416793","Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: Bortezomib|Drug: Carboplatin","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",9,"Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MDA-2006-0079|P30CA016672|MDA-2006-0079|CDR0000522739","December 27, 2006","01/12/2006",2009-10-01,"September 7, 2010","01/09/2010","",2009-10-01,"Overall survival at 6 months|Overall response rate|Overall survival","http://ClinicalTrials.gov/show/NCT00416793",NA
"78074",78074,"NCT00316693","Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine","Completed","Has Results","Human Papillomavirus (HPV) Infection|Cervical Neoplasia","Biological: HPV-16/18 vaccine (Cervarix?ºÑ)|Biological: Aimmugen?ºÑ","GlaxoSmithKline","Female","Adult","Phase II",1046,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","104798","April 19, 2006","01/04/2006",2009-02-01,"February 12, 2010","01/02/2010","",2009-02-01,"Number of Subjects With Persistent Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18)|Number of Subjects With Incident Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18)|Number of Subjects With Cytologically-confirmed Abnormalities Concurrently Associated With Human Papillomavirus 16 (HPV-16) and/or Human Papillomavirus 18 (HPV-18) Cervical Infection|Number of Subjects With Histopathologically-confirmed Lesions Concurrently Associated With Human Papillomavirus 16 (HPV-16) and/or Human Papillomavirus (HPV-18) Cervical Infection|Number of Subjects With Incident Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Types|Number of Subjects With Persistent Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Types|Number of Subjects With Cytologically-confirmed Abnormalities Concurrently Associated With Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Type|Number of Subjects With Histopathologically Confirmed Lesions Concurrently Associated With Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Type|Number of Subjects With Anti-human Papillomavirus 16 and 18 (Anti-HPV-16 and Anti-HPV-18) Antibody Titers Above the Cut-off Value|Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies|Number of Subjects Reporting Solicited Local and General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Number of Subjects Reporting Serious Adverse Events (SAE)|Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Other Medically Significant Conditions (MSCs)|Outcome of Any Reported Pregnancies|Number of Subjects Reporting Clinically Relevant Abnormalities in Hematological Parameters|Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical Parameters|Number of Subjects Reporting Abnormal Biochemical Parameters in Urine Samples","http://ClinicalTrials.gov/show/NCT00316693",NA
"78076",78076,"NCT00468793","Traditional Versus ScvO2 Guided Perioperative Fluid Therapy","Completed","No Results Available","Perioperative Care","Procedure: Intravenous fluid","Haukeland University Hospital","Both","Adult|Senior","Phase IV",240,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","16312","May 2, 2007","01/04/2007",2009-05-01,"June 5, 2009","01/05/2009","",2009-05-01,"Postoperative morbidity|serum creatinine","http://ClinicalTrials.gov/show/NCT00468793",NA
"78092",78092,"NCT00485693","Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty","Completed","No Results Available","Postoperative Pain","Drug: Bupivacaine HCl|Drug: SKY0402","Pacira Pharmaceuticals, Inc","Both","Adult|Senior","Phase II",138,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SKY0402C208","June 11, 2007","01/06/2007",2009-08-01,"September 1, 2010","01/09/2010","TKA",2009-08-01,"AUC of the NRS pain scores from 0 through 72 hours|AUC of the NRS pain scores from 0 through intervening timepoints 24, 36, 48, and 60 hours","http://ClinicalTrials.gov/show/NCT00485693",NA
"78113",78113,"NCT00501293","Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD","Completed","Has Results","Attention Deficit Hyperactivity Disorder","Drug: Methylphenidate Transdermal System","Shire Pharmaceutical Development","Both","Child","Phase III",163,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SPD485-410","July 12, 2007","01/08/2007",2009-02-01,"January 3, 2011","01/01/2011","",2009-02-01,"Systolic Blood Pressure|Diastolic Blood Pressure|Pulse Rate|Electrocardiogram Results (QTcF Interval)|Post Sleep Questionnaire (PSQ) Quality of Sleep|Weight|Dermal Reactions|Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Scores at 6 Months|Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) at 6 Months|Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores|Number of Participants With Improvement on Parent Global Assessment (PGA) Scores.|Change From Baseline in Youth Quality of Life-research Version (YQOL-R) Total Score at 6 Months","http://ClinicalTrials.gov/show/NCT00501293",NA
"78143",78143,"NCT00574093","Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD","Completed","No Results Available","Neovascular Age Related Macular Degeneration","Drug: Ranibizumab; Verteporfin","Fondazione G.B. Bietti, IRCCS","Both","Adult|Senior","Phase II",15,"Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CBPD952AIT03","December 13, 2007","01/01/2008",2009-10-01,"October 29, 2009","01/10/2009","Luvi",2009-06-01,"the mean change from baseline in BCVA letters with ETDRS at Month 3,6,12. -the number of retreatments, the treatment-free interval and the % of retreated patients at month 3, 6, 12. -the mean retinal thickness change from baseline at month 3, 6 and 12.|% of patients that gain ??­5, ??­10, ??­15 letters BCVA; % of patients that lose <15 letters; Mean BCVA change and mean change of the total area of the lesion from baseline; Change of FA leakage; Mean retinal sensitivity change at month 3, 6 and 12","http://ClinicalTrials.gov/show/NCT00574093",NA
"78168",78168,"NCT00615693","Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis","Completed","No Results Available","Uveitis|Posterior Uveitis|Panuveitis","Drug: AEB071","Novartis","Both","Adult|Senior","Phase II",13,"Industry","Interventional","Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CAEB071A2211","February 1, 2008","01/07/2008",NA,"July 19, 2010","01/07/2010","",2009-10-01,"Safety and tolerability of AEB071|Change in the degree of inflammation in the study eye|Change in the visual acuity of the study eye|Change in macular edema in the study eye","http://ClinicalTrials.gov/show/NCT00615693",NA
"78172",78172,"NCT00620893","Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).","Completed","No Results Available","Dry Eye Syndromes","Drug: PEG- 400 based artificial tear|Drug: Systane","Bp Consulting, Inc","Both","Adult|Senior","Phase IV",100,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","5339","February 11, 2008","01/02/2008",2009-05-01,"September 17, 2009","01/09/2009","",2009-05-01,"dry eye signs|refractive regression","http://ClinicalTrials.gov/show/NCT00620893",NA
"78174",78174,"NCT00622193","Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: anamorelin HCl|Drug: anamorelin HCl|Drug: placebo","Helsinn Therapeutics (U.S.), Inc","Both","Adult|Senior","Phase II",228,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ST-ANAM-207","February 12, 2008","01/03/2008",2009-12-01,"April 20, 2010","01/04/2010","",2009-12-01,"Hand grip strength and body weight|Quality of Life and Biomarker","http://ClinicalTrials.gov/show/NCT00622193",NA
"78187",78187,"NCT00642993","Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Subjects (Study P05483)(COMPLETED)","Completed","No Results Available","Obesity|Overweight|Body Weight","Drug: SCH 497079|Drug: Placebo","Schering-Plough","Both","Adult|Senior","Phase II",300,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05483","March 21, 2008","01/06/2008",2009-01-01,"September 30, 2009","01/09/2009","",2009-01-01,"Mean change in body weight from Baseline|Percent of responders demonstrating a weight loss ??­5% or ??­10% from Baseline.|Mean change in waist circumference from Baseline.|Mean change in BMI from Baseline.","http://ClinicalTrials.gov/show/NCT00642993",NA
"78244",78244,"NCT00717093","Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use","Completed","Has Results","Tobacco Use Cessation","Drug: Varenicline Tartrate|Drug: Placebo","Pfizer","Both","Adult|Senior","Phase IV",432,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","A3051104","July 15, 2008","01/08/2008",2009-07-01,"July 13, 2010","01/07/2010","",2009-04-01,"Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco|Number of Subjects With Continuous Abstinence (CA) of Smokeless Tobacco Use|Number of Subjects With Long Term Quit Rate (LTQR) of Smokeless Tobacco|Number of Subjects With 7-day Point Prevalence (PP) of Abstinence at the End of Treatment (Week 12) and at the End of Study (Week 26)","http://ClinicalTrials.gov/show/NCT00717093",NA
"78279",78279,"NCT00785993","Egg-Banking and Ovo-donation","Completed","No Results Available","Egg Banking","Other: Vitrification of oocytes for IVF treatment|Other: Protocolary IVF treatment with fresh donor oocytes","Instituto Valenciano de Infertilidad, Spain","Female","Adult","Phase IV",320,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","0703-C-017-AC","November 4, 2008","01/11/2008",2009-10-01,"October 1, 2009","01/10/2009","",2009-09-01,"To evaluate the clinical outcome in an ovum donation program conducted with egg-banking.","http://ClinicalTrials.gov/show/NCT00785993",NA
"78284",78284,"NCT00788593","Randomized Double-Blind Placebo Crossover Study to Evaluate Safety/Efficacy of Two Doses in CP Patients With EPI","Completed","No Results Available","Chronic Pancreatitis|Exocrine Pancreatic Insufficiency","Drug: Placebo|Drug: EUR-1008 high dose|Drug: EUR-1008 low dose","Eurand S.p.A.","Both","Adult|Senior","Phase III",78,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","PR-002","November 10, 2008","01/01/2008",2009-03-01,"March 12, 2009","01/03/2009","",2009-03-01,"The primary analysis conducted on all patients who complete both the high dose and low dose. An additional analysis will be conducted to calculate the difference between the mean CFA after administration of doses after administration.|Calculation of the differences in CFA of patients on high dose EUR-1008 vs. CFA at placebo baseline and patients on low dose EUR-1008 vs. CFA at placebo baseline. Change in the CNA from baseline. Change in weight and BMI from baseline","http://ClinicalTrials.gov/show/NCT00788593",NA
"78300",78300,"NCT00818493","Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty","Completed","No Results Available","Postoperative Pain","Drug: Q8003 (morphine sulfate and oxycodone hydrochloride)|Drug: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|Drug: Percocet (oxycodone and acetaminophen)","QRxPharma Inc.","Both","Adult|Senior","Phase II",44,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Q8003-020","January 6, 2009","01/02/2009",2009-07-01,"August 30, 2010","01/08/2010","",2009-07-01,"Difference in pain intensity scores from baseline|Safety: adverse events","http://ClinicalTrials.gov/show/NCT00818493",NA
"78308",78308,"NCT00821093","Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Indacaterol 150 ??g|Drug: Salmeterol 50 ??g","Novartis Pharmaceuticals","Both","Adult|Senior","Phase III",1084,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CQAB149B2349|2008-005146-23","January 9, 2009","01/01/2009",NA,"November 30, 2009","01/11/2009","INSIST",2009-10-01,"12 hr Area Under the Curve (AUC) forced expiratory volume in 1 second (FEV1)|Change from baseline to 24 hr post-dose of (trough) forced expiratory volume in 1 second (FEV1)","http://ClinicalTrials.gov/show/NCT00821093",NA
"78325",78325,"NCT00856193","A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Placebo|Drug: NVA237","Novartis","Both","Adult|Senior","Phase II|Phase III",33,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CNVA237A2207|2008-006849-28","March 4, 2009","01/02/2009",NA,"September 20, 2010","01/09/2010","",2009-05-01,"Measure: To investigate the bronchodilatory efficacy of 50 ??g NVA237 as measured by spirometry assessments|Measure: To investigate the peak bronchodilatory effect of NVA237 as measured by spirometry|Measure: To investigate the trough bronchodilatory effect at the end of the 24 hour assessment interval as measured by spirometry.|Measure: To investigate the bronchodilator effect on the first and second portion of the 24 hour assessment interval (0 hour - 12 hour and 12 hour - 24 hour after 14 days dosing) as measured by spirometry.|Measure: To investigate the bronchodilator effects of NVA237 on Day 7 as measured by spirometry.|Measure: To investigate the safety and tolerability of 50 ??g NVA237 in COPD patients","http://ClinicalTrials.gov/show/NCT00856193",NA
"78372",78372,"NCT00926393","Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression","Completed","No Results Available","Bipolar Depression","Drug: Quetiapine Immediate Release|Drug: Quetiapine Extended Release","AstraZeneca","Both","Adult","Phase IV",128,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","D1443C00040","June 19, 2009","01/06/2009",2009-08-01,"August 25, 2009","01/08/2009","",2009-08-01,"Visual Analog Scale|Safety and Tolerability during initial titration period","http://ClinicalTrials.gov/show/NCT00926393",NA
"78379",78379,"NCT00938093","Treatment of Late-life Anxiety in Primary Care Settings","Completed","No Results Available","Generalized Anxiety Disorder|Panic Disorder|Anxiety Disorder Not Otherwise Specified","Behavioral: Cognitive behavioral therapy|Behavioral: Enhanced usual care","Wake Forest University Baptist Medical Center|National Institute of Mental Health (NIMH)","Both","Adult|Senior","Phase II|Phase III",60,"Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","MH65281|MH65281","July 10, 2009","01/03/2006",2009-02-01,"July 10, 2009","01/07/2009","",2009-02-01,"","http://ClinicalTrials.gov/show/NCT00938093",NA
"78417",78417,"NCT00996593","Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab","Completed","No Results Available","Non-Hodgkin's Lymphoma","Biological: Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)","GlaxoSmithKline","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","104507|CP-97-012","October 8, 2009","01/07/1998",2010-04-01,"August 12, 2010","01/08/2010","",2009-08-01,"To determine the response rate, complete response rate, duration of response, and time to progression or death based on both MIRROR panel and the Investigators.|To determine the safety and survival of Iodine-131 Anti-B1 Antibody therapy based on the Investigators' assessment of patients who have been previously treated with rituximab.","http://ClinicalTrials.gov/show/NCT00996593",NA
"78428",78428,"NCT01012193","Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism","Completed","No Results Available","Coronary Artery Disease|Percutaneous Coronary Intervention","Drug: cilostazol 100mg bid or clopidogrel 150-mg daily","Gyeongsang National University Hospital","Both","Adult|Senior","Phase IV",134,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","GNUHIRB-2009-24","November 10, 2009","01/01/2008",2009-09-01,"November 10, 2009","01/11/2009","ACCEL-2C19",2009-07-01,"Reduction of maximal platelet aggregation according to CYP 2C19 polymorphism|Reduction of late platelet aggregation, reduction of P2Y12 reaction unit, and the rate of high post-clopidogrel platelet reactivity according to CYP 2C19 polymorphism","http://ClinicalTrials.gov/show/NCT01012193",NA
"78572",78572,"NCT01247493","Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)","Completed","No Results Available","Acute Myeloid Leukemia","Drug: induction chemotherapy (fludarabine, cytarabine, idarubicin)","Seoul National University Hospital","Both","Adult|Senior","Phase II",108,"Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-0704-029-205","November 17, 2010","01/06/2007",2010-07-01,"November 23, 2010","01/11/2010","m-FLAI",2009-06-01,"Complete remission rate|Rate of serious adverse events (SAE)|Event Free Survival|overall survival|Predictive factors for Complete remission","http://ClinicalTrials.gov/show/NCT01247493",NA
"78747",78747,"NCT00183794","Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma","Completed","No Results Available","Ovarian Carcinoma|Peritoneal Neoplasms","Drug: Docetaxel and Gemcitabine","USC/Norris Comprehensive Cancer Center","Female","Adult|Senior","Phase II",20,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","5GYN-02-2","September 9, 2005","01/11/2002",2009-05-01,"November 3, 2010","01/11/2010","",2009-05-01,"The percent of patients who experience a response to docetaxel + gemcitabine","http://ClinicalTrials.gov/show/NCT00183794",NA
"78783",78783,"NCT00243594","Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection","Completed","No Results Available","Melanoma Stage III or IV","Biological: Peptide-pulsed dendritic cells","Radboud University|Dutch Cancer Society","Both","Adult|Senior","Phase I|Phase II",40,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-3126|2004-3126|KUN99-1950","October 21, 2005","01/09/1999",NA,"February 18, 2009","01/02/2009","",2009-01-01,"Immune response|Migration efficacy|Clinical response","http://ClinicalTrials.gov/show/NCT00243594",NA
"78820",78820,"NCT00289094","Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKA","Completed","Has Results","Osteoarthritis|Rheumatoid Arthritis|Avascular Necrosis of Bone","Device: Total Knee Arthroplasty|Device: Total knee replacement","DePuy Orthopaedics","Both","Adult|Senior","Phase IV",99,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","SRP-2","February 7, 2006","01/05/2001",2009-09-01,"December 10, 2010","01/12/2010","",2009-09-01,"Knee Society Scores|Complications/Revisions|Medical Imaging|SF-12 Patient Outcomes","http://ClinicalTrials.gov/show/NCT00289094",NA
"78821",78821,"NCT00296894","Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints","Completed","No Results Available","Erosive Osteo-Arthritis","Drug: Adalimumab (40 mg sc every other week)|Drug: Placebo","University Hospital, Ghent","Both","Adult|Senior","Phase II",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2006/072","February 24, 2006","01/05/2006",2009-02-01,"February 6, 2009","01/02/2009","",2009-01-01,"Evaluation of x-rays|Evaluation of clinical parameters (pain, daily functioning, etc.)","http://ClinicalTrials.gov/show/NCT00296894",NA
"78884",78884,"NCT00395694","Clinical Evaluation of BW430C in Epilepsy","Completed","No Results Available","Epilepsy","Drug: lamictal","GlaxoSmithKline","Both","Child|Adult","Phase III",96,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LAM107844","November 2, 2006","01/08/2006",2009-03-01,"December 3, 2009","01/12/2009","",2009-03-01,"Incidence of rash in the first 8 weeks of treatment, in Japanese patients with epilepsy when administered at the same starting doses with the same dose escalation method as recommended Global Data Sheet for patients taking Valproic acid.|Efficacy of BW430C for prevention of seizures in Japanese patients with epilepsy when administered at the same starting doses and then maintained at an optimal maintenance dose.","http://ClinicalTrials.gov/show/NCT00395694",NA
"78895",78895,"NCT00413894","A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.","Completed","No Results Available","Anemia","Drug: methoxy polyethylene glycol-epoetin beta [Mircera]","Hoffmann-La Roche","Both","Adult|Senior","Phase III",661,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20572","December 19, 2006","",2009-04-01,"July 15, 2009","01/07/2009","",2009-04-01,"Percentage of patients in a defined Hb range and percentage of patients with or without dose adjustments, during evaluation period.|Percentage of patients in a defined Hb range, and percentage of patients with or without dose adjustments.|Incidence of RBC transfusions|AEs, laboratory parameters, vital signs.","http://ClinicalTrials.gov/show/NCT00413894",NA
"78912",78912,"NCT00419094","Conversion to Monotherapy Study With Keppra XR for Partial Seizures","Completed","Has Results","Epilepsy","Drug: Keppra XR|Drug: Keppra XR","UCB, Inc.","Both","Child|Adult|Senior","Phase III",228,"Industry","Interventional","Allocation: Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","N01280","January 4, 2007","01/08/2007",2009-09-01,"January 4, 2011","01/01/2011","",2009-09-01,"The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase|The Cumulative Rate of Exit Events, Which Include Discontinuation Due to Exit Criteria, Withdrawal Due to Adverse Events (AE) and Withdrawal Due to Lack of Efficacy, at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase|The Cumulative Rate of Exit Events Due to Any Reasons at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase|The Cumulative Exit Rate at 112 Days for the Keppra XR 1000 mg Group After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase","http://ClinicalTrials.gov/show/NCT00419094",NA
"78919",78919,"NCT00447694","Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment","Completed","No Results Available","Beta-Thalassemia|Iron Overload","Drug: Deferasirox","Novartis","Both","Child|Adult|Senior","Phase II",30,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CICL670AUS04","March 13, 2007","01/02/2006",2009-11-01,"November 18, 2009","01/11/2009","",2009-11-01,"Cardiac Iron in B thalassemia patients|Safety and tolerabilty of deferasirox|Changes in liver iron concentration (LIC)|Changes in ventricular ejection fraction|Ferritin, NTBI (LPI and DCI)& iron metabolism parameters|Compliance with deferasirox","http://ClinicalTrials.gov/show/NCT00447694",NA
"78980",78980,"NCT00556894","Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients","Completed","No Results Available","Rheumatoid Arthritis","Drug: CF101","Can-Fite BioPharma","Both","Adult|Senior","Phase II",230,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CF101-203RA","November 8, 2007","01/02/2008",2009-04-01,"November 26, 2009","01/11/2009","",2009-03-01,"ACR20|ACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change from baseline at each visit in the efficacy parameters","http://ClinicalTrials.gov/show/NCT00556894",NA
"78983",78983,"NCT00560794","Phase II Study of the BiTE?ó Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute ALL","Completed","No Results Available","Acute Lymphoblastic Leukemia","Drug: Blinatumomab (MT103)","Micromet AG","Both","Adult|Senior","Phase II",21,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MT103-202","November 19, 2007","01/10/2007",NA,"January 18, 2010","01/01/2010","",2009-12-01,"MRD response rate defined by the incidence of MRD negativity|Time to hematological relapse|Change in MRD level|Time to molecular relapse|Incidence and severity of adverse events|Quantification and characterization of peripheral blood lymphocytes|Cytokine serum concentrations|Pharmacokinetic parameters","http://ClinicalTrials.gov/show/NCT00560794",NA
"78989",78989,"NCT00568594","Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)","Completed","No Results Available","Coronary Heart Disease","Drug: APL180|Drug: Placebo","Novartis","Both","Adult|Senior","Phase I|Phase II",176,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science","CAPL180A2201","December 5, 2007","01/11/2007",NA,"October 2, 2009","01/10/2009","",2009-09-01,"Safety and tolerability, pharmacokinetics and effects on biomarkers of HDL function of APL180 after a single and 7-daily infusions in healthy volunteers (HV) and in patients with coronary heart disease (CHD)|Pharmacokinetic/pharmacodynamic relationship after a single and 7 daily infusions in CHD patients","http://ClinicalTrials.gov/show/NCT00568594",NA
"79013",79013,"NCT00608894","LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis","Completed","No Results Available","Autoimmune Hepatitis","Drug: LCP-Tacro (tacrolimus)|Drug: Azathioprine","LifeCycle Pharma A/S","Both","Adult|Senior","Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LCP-Tacro Study 2016","January 23, 2008","01/12/2007",2009-07-01,"October 21, 2009","01/10/2009","",2009-02-01,"Percent of patients that achieve biochemical remission of (AIH) at Month 6 during treatment with LCP-Tacro + prednisone or azathioprine + prednisone. Biochemical remission is defined as ALT, total bilirubin and gamma globulin within normal limits.|Percent of patients who achieve biochemical remission by Month 3 during treatment with LCP-Tacro + prednisone or azathioprine + prednisone.|Percents of patients in each treatment group classified as either in remission, having an incomplete response, a treatment failure, or a case of relapse. Each patient will be classified as being one of the four states at Month 6.","http://ClinicalTrials.gov/show/NCT00608894",NA
"79018",79018,"NCT00617994","Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis","Completed","No Results Available","Plaque Psoriasis","Drug: INCB018424","Incyte Corporation","Both","Adult","Phase II",25,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INCB 18424-202","January 21, 2008","01/08/2007",2009-05-01,"June 28, 2010","01/06/2010","",2009-04-01,"Safety and tolerability will be assessed by signs and symptoms of adverse experiences, measuring VS and ECGs, clinical laboratory blood and urine samples. The PK endpoints are planned to determine the INCB018424 plasma concentrations.|Pharmacodynamics and preliminary efficacy","http://ClinicalTrials.gov/show/NCT00617994",NA
"79022",79022,"NCT00623194","Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: insulin detemir|Drug: insulin aspart","Novo Nordisk","Both","Child","Phase III",146,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NN304-1690|EudraCT No: 2006-002478-23","February 14, 2008","01/02/2008",2009-09-01,"October 20, 2009","01/10/2009","",2009-09-01,"To study the development of insulin detemir-insulin aspart cross-reacting antibodies|To study the development of insulin detemir specific antibodies and insulin aspart specific antibodies|To follow the glycaemic control, measured as HbA1c, of insulin detemir|Fasting plasma glucose values|Incidence of hypoglycaemic episodes (mild, moderate, severe and biochemical) overall, daytime and night-time|BMI and SD-score (z-score) for weight|Incidence of adverse events|Incidence of diabetic ketoacidosis requiring hospitalisation|Insulin dose|Laboratory safety parameters (haematology and biochemistry) and fundoscopy/fundus photography|Vital signs","http://ClinicalTrials.gov/show/NCT00623194",NA
"79062",79062,"NCT00690794","Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension","Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: Travatan 0.004%, BAC Free","Alcon Research","Both","Adult|Senior","Phase III",700,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","C-08-03","June 3, 2008","01/07/2008",NA,"July 6, 2009","01/07/2009","",2009-06-01,"Ocular Surface Disease index questionnaire at 3 months|Corneal fluorescein staining at 3 months","http://ClinicalTrials.gov/show/NCT00690794",NA
"79094",79094,"NCT00737594","Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension","Completed","No Results Available","Portal Hypertension","Drug: Placebo|Drug: Cobiprostone|Drug: Cobiprostone","Sucampo Pharmaceuticals, Inc.","Both","Adult|Senior","Phase II",9,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SPH0721","August 15, 2008","01/07/2008",2009-03-01,"July 10, 2009","01/07/2009","",2009-02-01,"Change from baseline in hepatic venous pressure gradient (HVPG)|Acute changes from baseline in HVPG following administration of a single oral dose of cobiprostone|Change from baseline in total bilirubin|Change from baseline in ascites grade|Change from baseline in Child-Pugh score|Proportion of treatment responders|Change from baseline in quality of life","http://ClinicalTrials.gov/show/NCT00737594",NA
"79162",79162,"NCT00862394","A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma","Completed","No Results Available","Asthma","Drug: BDP/Formoterol Next DPI|Drug: Foster|Drug: BDP/Formoterol Next DPI|Drug: Foster","Chiesi Farmaceutici S.p.A.","Both","Child|Adult|Senior","Phase III",831,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CCD-0705-PR-0027","March 13, 2009","01/02/2009",2010-01-01,"December 22, 2010","01/10/2009","",2009-10-01,"Change from baseline measured at clinic to the end of treatment period in pre-dose morning FEV1 (L) measured at clinic|Pre-dose FEV1|Post-dose FEV1 AUC 0-8 h|FVC and FEF 25-75%|PEF|Morning and evening asthma clinical symptoms scores|Moderate and severe exacerbations|Rescue medication|Sputum","http://ClinicalTrials.gov/show/NCT00862394",NA
"79169",79169,"NCT00874094","Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds","Completed","No Results Available","Nasolabial Folds","Biological: Autologous platelet rich fibrin matrix","The New York Eye & Ear Infirmary","Female","Adult|Senior","Phase I|Phase II",15,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","8.01","April 1, 2009","01/04/2008",2009-07-01,"August 10, 2009","01/06/2009","",2009-06-01,"Improvement in nasolabial folds (laugh lines) from pre-treatment.","http://ClinicalTrials.gov/show/NCT00874094",NA
"79192",79192,"NCT00783094","Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension","Completed","Has Results","Benign Prostatic Hyperplasia","Drug: Tadalafil 2.5 mg|Drug: Tadalafil 5 mg|Drug: Placebo","Eli Lilly and Company","Male","Adult|Senior","Phase II",422,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12757|H6D-JE-LVIA","October 30, 2008","01/11/2008",2010-04-01,"June 25, 2010","01/06/2010","",2009-06-01,"Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint|Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12-Week Endpoint|Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12-Week Endpoint|Change From Baseline in IPSS Quality of Life (QoL) Index at 12-Week Endpoint|Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 12-Week Endpoint|Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12-Week Endpoint|Tadalafil Pharmacokinetics in Japanese Men: Plasma Concentration Measurement|Adverse Events During 12 Weeks of the Study|Change From Baseline in Blood Pressure at 12-Week Endpoint|Change From Baseline in Sitting Heart Rate at 12-Week Endpoint|Change From Baseline in Postvoid Residual Volume (PVR) at 12-Week Endpoint|Change From Baseline in Prostate Specific Antigen (PSA) at 12-Week Endpoint|Change From Baseline in the International Prostate Symptom Score (IPSS) Total Score at 54-Week Endpoint|Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 54-Week Endpoint|Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 54-Week Endpoint|Change From Baseline in IPSS Quality of Life (QoL) Index at 54-Week Endpoint|Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 54-Week Endpoint|Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 54-Week Endpoint|Adverse Events During 54 Weeks of the Study|Change From Baseline in Blood Pressure During at 54-Week Endpoint|Change From Baseline in Sitting Heart Rate at 54-Week Endpoint|Change From Baseline in Prostate Specific Antigen (PSA) at 54-Week Endpoint|Change From Baseline in Postvoid Residual Volume (PVR) at 54-Week Endpoint","http://ClinicalTrials.gov/show/NCT00783094",NA
"79207",79207,"NCT00935194","Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study","Completed","No Results Available","Influenza","Drug: oseltamivir|Other: blank|Drug: chinese medicinal herbs|Drug: oseltamivir and chinese medicinal herbs","Capital Medical University","Both","Child|Adult|Senior","Phase IV",102,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Z09000700090903","July 7, 2009","01/07/2009",2009-11-01,"November 30, 2009","01/11/2009","",2009-11-01,"time to resolution of fever (the period from start of study-drug to relief of fever)|time to resolution of respiratory symptoms(defined as the period from start of study-drug to relief of symptoms)|virus shedding time","http://ClinicalTrials.gov/show/NCT00935194",NA
"79267",79267,"NCT01030094","Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Women With Epilepsy","Completed","No Results Available","Seizures|Convulsions|Epilepsy|Osteopenia|Osteoporosis","Drug: Topiramate; Carbamazepine; Valproic Acid","Janssen Korea, Ltd., Korea","Female","Adult","Phase IV",142,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR015856|TOP-KOR-31","December 10, 2009","01/12/2006",2009-04-01,"April 26, 2010","01/04/2010","",2009-04-01,"To compare the difference in bone and mineral metabolism markers between Topiramate, Carbamazepine and Valproic acid monotherapy groups|To compare and analyze the following items of Topiramate, Carbamazepine, and Valproic acid monotherapy groups: Bone density, Osteopenia and osteoporosis, several markers in 24h urine such as clacium, phosphorus, sodium and creatinine","http://ClinicalTrials.gov/show/NCT01030094",NA
"79294",79294,"NCT01070394","Effectiveness and Duration of Effect of Open Treatment in Adult Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate- LDX (Vyvanse)","Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Drug: Lisdexamfetamine Dimesylate-LDX","New York University School of Medicine|Shire Pharmaceutical Development","Both","Adult","Phase IV",NA,"Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","909","February 16, 2010","01/10/2007",2009-07-01,"February 17, 2010","01/02/2010","",2009-07-01,"","http://ClinicalTrials.gov/show/NCT01070394",NA
"79398",79398,"NCT01245894","Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment","Completed","No Results Available","Myocardial Infarction [C14.907.585.500]","Drug: Low-dose Rosuvastatin|Drug: High-dose Rosuvastatin","Odense University Hospital","Both","Adult|Senior","Phase IV",87,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","VF-20060","November 22, 2010","01/11/2007",2010-06-01,"November 22, 2010","01/11/2007","",2009-06-01,"The primary endpoint was the change from baseline in Index of microcirculatory resistance(IMR).|The secondary endpoints were the changes from baseline in Fractional Flow Reserve (FFR) and lipid values.","http://ClinicalTrials.gov/show/NCT01245894",NA
"79402",79402,"NCT01254994","The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure","Completed","No Results Available","Liver Failure","Drug: entecavir|Drug: Traditional comprehensive medical treatment","Sun Yat-sen University","Both","Adult|Senior","Phase II",108,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Entecavir","December 6, 2010","01/08/2007",2010-12-01,"December 6, 2010","01/08/2007","",2009-07-01,"HBV DNA level and liver function|Symptoms,signs and mortality","http://ClinicalTrials.gov/show/NCT01254994",NA
"79469",79469,"NCT00014495","Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: filgrastim|Drug: cytarabine|Radiation: bismuth Bi213 monoclonal antibody M195","Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI)","Both","Child|Adult|Senior","Phase I|Phase II",39,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068549|MSKCC-00117|NCI-H01-0071","April 10, 2001","01/11/2000",NA,"April 10, 2010","01/10/2008","",2009-12-01,"Maximum tolerated dose|Antileukemic effects|Toxicity|Pharmacology, biodistribution, and dosimetry","http://ClinicalTrials.gov/show/NCT00014495",NA
"79485",79485,"NCT00045695","Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia","Completed","No Results Available","Lymphoma","Drug: bortezomib","NCIC Clinical Trials Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Both","Adult|Senior","Phase II",NA,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","I152|CAN-NCIC-IND152|ECOG-JI152|NCI-NCIC-152|CDR0000257042","September 6, 2002","01/08/2002",2009-12-01,"November 7, 2010","01/03/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00045695",NA
"79503",79503,"NCT00069095","A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: capecitabine [Xeloda]|Drug: Oxaliplatin|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5 FU|Drug: Avastin|Drug: Avastin","Hoffmann-La Roche","Both","Adult|Senior","Phase III",2035,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","NO16966","September 15, 2003","",2009-11-01,"February 15, 2010","01/02/2010","",2009-11-01,"Non-inferiority of XELOX vs FOLFOX, with respect to time to progression or death, and superiority of Avastin vs placebo.|Overall survival, overall response rate, time to response, duration of response, time to treatment failure.|AEs, laboratory tests.","http://ClinicalTrials.gov/show/NCT00069095",NA
"79548",79548,"NCT00140595","ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-Cell Lymphoma and Age-Adjusted IPI of 1","Completed","No Results Available","Diffuse Large-Cell Lymphoma","Drug: rituximab|Drug: doxorubicin|Drug: cyclophosphamide","Groupe d'Etudes de Lymphomes de L'Adulte","Both","Adult","Phase III",380,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LNH03-2B","August 31, 2005","01/12/2003",2009-01-01,"January 27, 2009","01/01/2009","",2009-01-01,"Event-free survival (EFS), events defined as death from any cause, relapse for complete responders (CR) and unconfirmed complete responders (CRu), progression during or after treatment, changes of therapy during allocated treatment.|Response rate at the end of the treatment, progression rate, relapse rate, disease-free survival for complete responders, overall survival, neuromeningeal relapse rate and additional toxicities with ACVBP+rituximab combination","http://ClinicalTrials.gov/show/NCT00140595",NA
"79638",79638,"NCT00283595","Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa","Completed","No Results Available","Anorexia Nervosa|Osteopenia|Osteoporosis|Eating Disorders","Drug: Recombinant Human Growth Hormone|Drug: Placebo for Recombinant Human Growth Hormone","Massachusetts General Hospital|Genentech","Female","Child|Adult","Phase II",21,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","2005-P-001443/3; MGH","January 27, 2006","01/01/2006",2009-02-01,"April 13, 2009","01/04/2009","",2009-02-01,"Bone Metabolism|IGF-1","http://ClinicalTrials.gov/show/NCT00283595",NA
"79653",79653,"NCT00309595","The Study to Compare SMART Nitinol Stent and Balloon Angioplasty","Completed","No Results Available","Superficial Femoral Artery Occlusions","Device: stent|Device: balloon","Cordis Corporation","Both","Adult|Senior","Phase IV",50,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EE04-03","March 31, 2006","01/12/2005",2009-05-01,"June 10, 2009","01/06/2009","SIT-UP",2009-05-01,"Binary restenosis by Duplex Ultrasound.|Technical success defined as a successful access and deployment of the device with recanalization.|Procedural complications.|Procedural success as defined by successful recanalization, without the occurence of a Serious Adverse Event (SAE).|Occurrence of Adverse events (AE) and Serious Adverse Events (SAE) in-hospital.|Ankle Brachial Index (ABI).|Restenosis measured by Duplex sonography.|Target Lesion revascularisation (TLR).|Target Vessel revascularisation (TVR).|Target Limb revascularisation.|The number of revascularisations in both limbs.|Clinical categorization of chronic limb ischemia by means of the Rutherford classification.|Pain free and absolute walking distance (treadmill testing) as compared to baseline testing.|Amputation of the index limb.|Cardiovascular events (ACS, TIA, stroke, vascular death).","http://ClinicalTrials.gov/show/NCT00309595",NA
"79705",79705,"NCT00394095","Pilot Study of Topiramate and Olanzapine in the Prevention of Weight Gain in Children and Adolescents With Bipolar Disorder","Completed","No Results Available","Bipolar Disorder|Weight Gain","Drug: olanzapine/topiramate|Drug: olanzapine/placebo","University of Cincinnati","Both","Child|Adult","Phase IV",30,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","F1D-MC-X304","October 27, 2006","01/12/2006",2009-09-01,"October 9, 2009","01/10/2009","",2009-08-01,"To examine the efficacy of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder.|To examine the tolerability of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder.","http://ClinicalTrials.gov/show/NCT00394095",NA
"79711",79711,"NCT00407095","An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.","Completed","No Results Available","Advanced Stage Parkinson's Disease","Drug: Pardoprunox","Solvay Pharmaceuticals","Both","Adult|Senior","Phase III",140,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S308.3.007|2006-005183-91|00407095","November 30, 2006","01/08/2007",2009-05-01,"September 10, 2010","01/09/2010","",2009-05-01,"Safety: laboratory data, adverse events, vital signs, ECG|On' and 'off' time recording, UPDRS parts 1-4, CGI-improvement, PDQ-39 total score: all change from baseline","http://ClinicalTrials.gov/show/NCT00407095",NA
"79725",79725,"NCT00430495","A Phase II Dose-finding Study of Atacicept in Rheumatoid Arthritis (RA)","Completed","No Results Available","Rheumatoid Arthritis","Drug: Atacicept","EMD Serono|ZymoGenetics","Both","Adult|Senior","Phase II",288,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","27298","January 30, 2007","01/12/2006",NA,"November 16, 2010","01/12/2009","August I",2009-09-01,"Primary is functional status or ACR 20 at week 26. Interval measurments are performed at monthly visits.|Proportions of subjects achieving: ACR50 and ACR70 responses, a DAS 28 of 3.2 or less, or subjects with an improvement in the HAQ Disability Index of at least 0.3 from baseline","http://ClinicalTrials.gov/show/NCT00430495",NA
"79754",79754,"NCT00474695","Study Evaluating Genotypes Using Lucentis","Completed","No Results Available","Age-Related Maculopathy","Drug: Lucentis","University of Utah|Genentech","Both","Adult|Senior","Phase IV",65,"Other|Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","21441|SEAGUL","May 15, 2007","01/05/2007",2009-12-01,"October 15, 2010","01/10/2010","SEAGUL",2009-06-01,"To determine the VEGF and HTRA1 genotypes associated with improvement in visual acuity|Determine VEGF and HTRA1 genotypes associated with change or no change in visual acuity","http://ClinicalTrials.gov/show/NCT00474695",NA
"79772",79772,"NCT00495495","Healozone Study to Evaluate the Safety and Efficacy of the Use of Ozone for Management of Dental Caries","Completed","Has Results","Dental Caries","Device: Ozone treatment|Device: Placebo treatment","Indiana University School of Dentistry|Tufts University|State University of New York at Buffalo","Both","Child|Adult","Phase II|Phase III",394,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention","07-D-187|IDE G50008|Clinical Trials. gov","July 1, 2007","01/02/2007",2009-12-01,"January 5, 2011","01/01/2011","",2009-05-01,"ICDAS Severity Value|Change in Caries Lesion Activity|Progression of Radiographic Scores at 12 Months|Laser Fluorescence Progression-12 Month (Increase From <=20 to >=30)|Laser Fluorescence Progression-12 Month (Increase at Least 10)","http://ClinicalTrials.gov/show/NCT00495495",NA
"79795",79795,"NCT00533195","Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis","Completed","No Results Available","Atopic Dermatitis","Drug: 5-Methoxypsoralen|Device: UVA1 phototherapy","Medical University of Vienna","Both","Adult|Senior","Phase III",20,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","03/01/07|EudraCT-Nr.: 2006-00698217","September 19, 2007","01/10/2007",2009-01-01,"January 13, 2009","01/01/2009","",2009-01-01,"remission duration after UVA1 phototherapy and after 5-MOP UVA photochemotherapy|SCORAD Score at the end of therapy and at 1,3,6 and 12 months after therapy; total IgE and ECP values at the beginning and the end of therapy; cumulative UVA doses; side effects","http://ClinicalTrials.gov/show/NCT00533195",NA
"79813",79813,"NCT00564395","Detemir: Role in Type 1 Diabetes","Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: insulin detemir","Baylor College of Medicine","Both","Child|Adult","Phase IV",20,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","H-16541","November 27, 2007","01/08/2007",2010-05-01,"August 23, 2010","01/10/2009","",2009-12-01,"Blood sugars patterns","http://ClinicalTrials.gov/show/NCT00564395",NA
"79814",79814,"NCT00249795","Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)","Completed","Has Results","Atrial Fibrillation|Cardiovascular Disease","Drug: Irbesartan|Drug: placebo","Sanofi-Aventis|Bristol-Myers Squibb","Both","Adult|Senior","Phase III",9016,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","EFC4912 I|Clopidogrel (SR25990)","November 4, 2005","01/06/2003",2009-08-01,"September 29, 2010","01/09/2010","ACTIVE I",2009-08-01,"First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke or Vascular Death as Per Adjudication|First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke, Vascular Death or Hospitalization for Heart Failure as Per Adjudication|First Occurrence of Stroke|Death From Any Cause|First Occurrence of Any Heart Failure (HF) Episode|First Hospitalisation for Heart Failure (HF)|First Hospitalisation for Other Cardiovascular (CV) Cause","http://ClinicalTrials.gov/show/NCT00249795",NA
"79846",79846,"NCT00613795","Lactobacillus GG in the Prophylaxis of Ventilator Associated Pneumonia","Completed","No Results Available","Pneumonia|Ventilator Associated Pneumonia","Dietary Supplement: Lactobacillus GG|Dietary Supplement: placebo","Creighton University","Both","Adult|Senior","Phase III",125,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention","03-13013","January 31, 2008","01/08/2004",2009-11-01,"March 17, 2010","01/03/2010","",2009-08-01,"To determine whether patients given oral Lactobacillus GG will have a smaller increase in the density of pathogenic bacterial in cultures from oral swabs, nasogastric aspirates, and minimally invasive bronchoalveolar lavage samples.|To assess whether administration of Lactobacillus GG to intubated patients reduces clinically diagnosed VAP,reduces microbiologically diagnosed VAP, affects mortality and duration of mechanical ventilation, and total antibiotic consumption.","http://ClinicalTrials.gov/show/NCT00613795",NA
"79852",79852,"NCT00626795","Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)","Completed","No Results Available","Impetigo|Secondarily Infected Traumatic Lesions","Drug: TD1414 2% cream|Drug: TD1414 2% cream|Drug: Bactroban?ó (mupirocin) 2% cream","LEO Pharma","Both","Child|Adult|Senior","Phase II",682,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","TD1414-C21","February 21, 2008","01/02/2008",2009-06-01,"March 5, 2010","01/03/2010","",2009-03-01,"Clinical cure at end of treatment according to investigator's assessment|Clinical cure at follow-up according to investigator's assessment. Clinical cure at end of treatment and follow-up according to investigator's assessment. Bacteriological cure at end of treatment and follow-up.","http://ClinicalTrials.gov/show/NCT00626795",NA
"79854",79854,"NCT00628095","Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate","Completed","No Results Available","Arthritis, Rheumatoid","Drug: CE-224,535|Drug: Placebo","Pfizer","Both","Adult|Senior","Phase II|Phase III",100,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A6341009","February 25, 2008","01/03/2008",2009-02-01,"October 7, 2009","01/10/2009","",2009-02-01,"ACR 20|DAS 28(3) crp|pharmacokinetics|adverse events|ACR 50 and 70|components of ACR responses","http://ClinicalTrials.gov/show/NCT00628095",NA
"79862",79862,"NCT00638495","Phase II Study of TRK-820 Soft Capsules ??© Intractable Pruritus in Patients With Chronic Liver Disease ??©","Completed","No Results Available","Pruritus With Chronic Liver Disease","Drug: Nalfurafine Hydrochloride (TRK-820)|Drug: Placebo","Toray Industries, Inc","Both","Adult|Senior","Phase II",120,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","820HPC01","March 12, 2008","01/03/2008",2009-12-01,"January 28, 2010","01/01/2010","",2009-12-01,"Change in VAS value (based on morning or evening scores, whichever larger, during the treatment period [4th week])","http://ClinicalTrials.gov/show/NCT00638495",NA
"79873",79873,"NCT00656695","Comparison Between Clinical and Paraclinical Effect of Iminoral Versus Neoral in Prevention of Acute Rejection in Renal Transplantation","Completed","No Results Available","End Stage Renal Disease|Kidney Transplantation","Drug: Iminoral|Drug: Neoral","Imam Khomeini Hospital","Both","Adult|Senior","Phase IV",208,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Outcomes Assessor)|Primary Purpose: Treatment","iminoral","April 7, 2008","01/04/2008",2009-10-01,"October 28, 2009","01/10/2009","",2009-04-01,"transplanted kidney acute rejection|cyclosporine side effects","http://ClinicalTrials.gov/show/NCT00656695",NA
"79875",79875,"NCT00648895","A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients","Completed","Has Results","Hypertension","Drug: Nebivolol|Drug: Metoprolol ER (TM)","Forest Laboratories","Both","Adult|Senior","Phase III",12,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","NEB-MD-08","March 28, 2008","01/11/2007",NA,"August 30, 2010","01/08/2010","",2009-07-01,"Percentage Change From Baseline to End of Treatment for the Difference Between the Post-ischemia and Pre-ischemia Forearm Vascular Resistance (FVR).","http://ClinicalTrials.gov/show/NCT00648895",NA
"79878",79878,"NCT00654095","Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)(COMPLETED)","Completed","Has Results","Hypercholesterolemia","Drug: Ezetimibe|Drug: atorvastatin","Schering-Plough","Both","Adult|Senior","Phase III",146,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P05456","April 1, 2008","01/12/2007",2009-06-01,"November 18, 2010","01/11/2010","",2009-06-01,"Number of Participants With Adverse Events and Adverse Reactions","http://ClinicalTrials.gov/show/NCT00654095",NA
"79880",79880,"NCT00661895","Black Education and Treatment of Hypertension (BEAT HTN)","Completed","No Results Available","Hypertension","Drug: Hydrochlorothiazide|Drug: Lisinopril|Drug: Lisinopril and Hydrochlorothiazide|Drug: Nifedipine XL|Drug: Metoprolol tartrate|Drug: Atenolol|Drug: Valsartan|Drug: Doxazosin|Drug: Clonidine|Drug: Hydralazine|Drug: Metoprolol succinate|Drug: Amlodipine","Creighton University","Both","Adult|Senior","Phase IV",160,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","05-13859|05-13589","December 28, 2007","01/08/2005",2009-11-01,"November 27, 2009","01/11/2009","BEAT",2009-08-01,"The primary study endpoint will be the percentage of subjects achieving blood pressure goals (< 140/90 mmHg for non-diabetic subjects and < 130/80 mmHg in diabetic subjects) in the usual care and intervention subject groups|New onset diabetes mellitus","http://ClinicalTrials.gov/show/NCT00661895",NA
"79898",79898,"NCT00686595","A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)(COMPLETED)","Completed","No Results Available","Psoriasis","Biological: Infliximab","Schering-Plough|Centocor, Inc.","Both","Adult|Senior","Phase IV",100,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P05133","May 27, 2008","01/11/2007",2009-10-01,"December 23, 2009","01/12/2009","TANGO",2009-10-01,"Psoriasis Area and Severity Index (PASI 75) response rate (PASI 75 is defined as the proportion of subjects achieving a >=75% improvement in PASI from Baseline value) at Visit 5 (Week 10).|PASI 75 response rate at Weeks 18 and 24|Rate of body surface area (BSA) affected from Baseline to Weeks 18 and 24.","http://ClinicalTrials.gov/show/NCT00686595",NA
"79904",79904,"NCT00637195","Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)","Completed","Has Results","Cervical Intraepithelial Neoplasia|Hepatitis B|Human Papillomavirus Infection","Biological: Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix?ºÑ)|Biological: Engerix?ºÑ","GlaxoSmithKline","Female","Adult","Phase III",152,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","111567","February 28, 2008","01/03/2008",2009-06-01,"June 29, 2010","01/06/2010","",2009-06-01,"Number of Subjects Seroprotected Against Hepatitis B Following 3 Doses of Engerix|Anti-hepatitis B Surface Antigen (HBs) Antibody Titers Following 3 Doses of Engerix|Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 and 18 (Anti-HPV-16 and Anti-HPV-18) Antibodies|Anti-HPV-16/18 Antibody Titers|Number of Subjects Seroconverted for Anti-hepatitis B (HBs) Antibodies|Number of Subjects Seroprotected Against Anti-Hepatitis B (HBs) Antibodies Following 2 Doses of Engerix and After Completing the 4-dose Engerix Vaccination Course|Anti-HBs Antibody Titers Following 2 Doses of Engerix and After Completing the 4-dose Engerix Vaccination Course|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events|Number of Subjects Reporting Unsolicited Adverse Events|Number of Subjects Reporting Serious Adverse Events (SAE)|Number of Subjects Reporting Medically Significant Conditions","http://ClinicalTrials.gov/show/NCT00637195",NA
"79911",79911,"NCT00721695","Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.","Completed","No Results Available","Cataract Extraction","Drug: OMS302|Drug: OMS302-PE|Drug: Vehicle","Omeros Corporation","Both","Adult|Senior","Phase I|Phase II",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","C07-005","July 22, 2008","01/05/2008",2009-02-01,"April 28, 2010","01/04/2010","",2009-02-01,"Pupil diameter|Pain and other measures of ocular discomfort|Degree of inflammation in the anterior chamber|Ocular safety and changes in visual activity and intraocular pressure|General measures of safety","http://ClinicalTrials.gov/show/NCT00721695",NA
"79917",79917,"NCT00711295","Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups","Completed","No Results Available","Influenza","Biological: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Biological: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted","Baxter Healthcare Corporation","Both","Adult|Senior","Phase III",3583,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","810705","July 2, 2008","01/08/2008",2010-10-01,"November 26, 2010","01/11/2010","",2009-07-01,"Frequency and severity of systemic reactions until 21 days after the first and second vaccinations|Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by microneutralization (MN) assay >= 1:20.|Antibody response 21 days after the second vaccination as measured by MN assay;|Frequency and severity of injection site reactions until 21 days after the first and second vaccinations|Number of subjects with fever, malaise or shivering with onset within 7 days after the first and second vaccinations|Frequency and severity of adverse events observed during the entire study period|Number of subjects with antibody response associated with protection 21 days after the first and second vaccinations defined as Hemagglutination Inhibition Antibody (HIA) titer >= 1:40 or Single Radial Hemolysis (SRH) area >= 25 mm2|Number of subjects with antibody response associated with protection 21 days after the second vaccination defined as titer measured by MN assay >=1:40, >= 1:80, >=1:160|Antibody response 21 days after the first and second vaccinations as measured by HI and SRH assays|Fold increase of antibody response 21 days after the first and second vaccinations as compared to baseline as measured by MN, HI and SRH assays|Number of subjects with seroconversion (MN/HI: min.4-fold titer increase vs baseline;SRH:post-vacc. hemolysis area >=25mm2 or increased by >=50% for pre-vacc. sample <=4mm2 and >4mm2, resp., 21 days after 1st and 2nd vaccinations, measured by MN,HI,SRH|Number of subjects with antibody response associated with protection 201 days after the first vaccination as measured by MN, HI and SRH assays|Antibody response 201 days after the first vaccination as measured by MN, HI and SRH assays|Fold increase of antibody response 201 days after the first vaccination as compared to baseline as measured by MN, HI and SRH assays|Number of subjects in the subset included in the assessment of antibody kinetics with antibody response associated with protection 28, 35 and 90 days after the first vaccination as measured by MN, HI and SRH assays|Antibody response in the subset of subjects included in the assessment of antibody kinetics 28, 35 and 90 days after the first vaccination as measured by MN, HI and SRH assays|Fold increase of antibody response in the subset of subjects included in the assessment of antibody kinetics 28, 35 and 90 days after the first vaccination as compared to baseline as measured by MN, HI and SRH assays|Number of subjects in subset for antibody kinetics evaluation with seroconversion (see definitions above) 28, 35, 90 days after 1st vaccination, measured by MN, HI, SRH|T-cell response in the subset of subjects included in the evaluation of cellular immunity after each vaccination as determined by the frequency of cytokine producing T-cells induced by influenza virus antigens|Increase in frequency of cytokine producing T-cells induced by influenza virus antigens after each vaccination as compared to baseline|Number of subjects with antibody response associated with protection 21 days after the first vaccination defined as titer measured by MN assay >=1:20, >=1:40, >=1:80, >=1:160|Antibody response 21 days after the first vaccination as measured by MN assay","http://ClinicalTrials.gov/show/NCT00711295",NA
"79924",79924,"NCT00738595","Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.","Completed","No Results Available","Smoking Cessation","Drug: EVT 302|Drug: Placebo|Drug: EVT 302 plus open label Nicotine replacement|Drug: Placebo plus open label Nicotine Replacement","Evotec Neurosciences GmbH|PRA International|Clinpharm International Management Holding GmbH","Both","Adult|Senior","Phase II",400,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EVT 302/3009|EUDRACT No.: 2008-002472-99","August 18, 2008","01/08/2008",2009-05-01,"May 28, 2009","01/05/2009","",2009-03-01,"The four-week continuous quit rate over the last four weeks of treatment|7 -week abstinence|7-day point prevalence quit rate|Daily cigarettes smoked|Change from baseline in the number of cigarettes smoked|Minnesota Nicotine Withdrawal Scale|Brief Questionnaire of Smoking Urges|Modified Cigarette Evaluation Questionnaire|Adverse Events|Laboratory investigations (Haematology & biochemistry)|ECGs","http://ClinicalTrials.gov/show/NCT00738595",NA
"79937",79937,"NCT00752895","American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Dietary Supplement: American ginseng|Other: placebo","Wake Forest University|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",336,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care","CDR0000614076|CCCWFU-98308","September 13, 2008","01/09/2008",NA,"July 3, 2010","01/01/2009","",2009-06-01,"Number of acute respiratory infection (ARI) days during a fixed 3-month period|Safety according to NCI CTCAE v3.0|Number of antibiotic use days|Rate of all infections|Duration and severity of each ARI episode|Incidence of major infections|Incidence of herpes zoster|Chronic lymphocytic leukemia disease activity|Incidence and type of ARI in untreated cohort|Incidence of confirmed influenza and respiratory syncytial virus by a physician","http://ClinicalTrials.gov/show/NCT00752895",NA
"79953",79953,"NCT00778895","Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip?ó as the Control","Completed","No Results Available","Influenza Virus","Biological: GSK Biologicals' influenza vaccine GSK1557482A|Biological: Vaxigrip","GlaxoSmithKline","Both","Child","Phase II",403,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","111635","October 23, 2008","01/11/2008",2009-08-01,"October 22, 2009","01/10/2009","",2009-08-01,"Evaluation of the humoral immune response for HI antibodies by calculating the post vaccination geometric mean titer (GMT) with 95% Confidence Intervals (CIs) after completion of the vaccine regimen for Groups A and B|Occurrence, intensity and investigator's assessment of relationship to vaccine of solicited local and general symptoms for Groups A and B.|Occurrence, intensity, and investigator's assessment of relationship to vaccine of unsolicited local and general symptoms for Groups A and B.|Occurrence, intensity and investigator's assessment of relationship to vaccine of medically-attended AEs and SAEs reported for Groups A and B.|GMTs calculated at pre-vaccination and after completion of the vaccine regimen with 95% Confidence Intervals (CIs) for all groups|Seroconversion Rates (SCR) calculated with 95% Confidence Intervals (CIs) for all groups|Seroprotection Rates (SPR) calculated with 95% Confidence Intervals (CIs) for all groups|Seroconversion Factors (SCF) calculated with 95% Confidence Intervals (CIs) for all groups|Occurrence, intensity and investigator's assessment of relationship to vaccine of solicited local and general symptoms for Group C|Occurrence, intensity, and investigator's assessment of relationship to vaccine of unsolicited local and general symptoms for Group C|Occurrence, intensity and investigator's assessment of relationship to vaccine of SAEs and medically-attended visits for Group C.","http://ClinicalTrials.gov/show/NCT00778895",NA
"79964",79964,"NCT00803595","A Multinational Phase III Study of CS-8958 (MARVEL)","Completed","No Results Available","Influenza, Human","Drug: CS-8958|Drug: CS-8958|Drug: oseltamivir phosphate","Daiichi Sankyo Co., Ltd.","Both","Adult|Senior","Phase III",900,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CS8958-A-J301","December 4, 2008","01/11/2008",2009-06-01,"July 16, 2009","01/07/2009","MARVEL",2009-03-01,"Time to alleviation of influenza illness|Time for body temperature to return to normal","http://ClinicalTrials.gov/show/NCT00803595",NA
"79971",79971,"NCT00804895","Cluster Headache Cortivazol Injection (CHCI)","Completed","No Results Available","Cluster Headache","Drug: ALTIM, cortivazol injections greater occipital nerve injection|Drug: PROAMP, subcutaneous serum physiological saline|Drug: Verapamil","Assistance Publique - H??pitaux de Paris","Both","Adult","Phase II|Phase III",43,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","P080602","December 8, 2008","01/12/2008",2009-10-01,"September 30, 2010","01/07/2010","CHCI",2009-10-01,"Number of patients with a daily attack frequency equal or inferior to two for the period going from two days after third injection to four days after the third injection|total number of attacks on the J1-J15 period|percentage of patients with a 50% or more decrease in attacks frequency at J15|percentage of patients reaching a remission at J30 defined as an absence of attacks for seven days or more|interval between the first injection and appearance of a remission|percentage of patients suffering from chronic CH, having reached a daily attack frequency equal or inferior to two, presenting a recurrence of attacks after J15, defined as more than two attacks per day|number of patients (episodic or chronic) presenting a daily attack frequency equal or inferior to two at J30|number of chronic patients presenting a daily attack frequency equal or inferior to two at J90|HIT-6 scores, comparison between groups at J0 and J30|tolerance of treatment : percentage of patients showing side effects|safety of treatment: percentage of patients with serious adverse events","http://ClinicalTrials.gov/show/NCT00804895",NA
"79987",79987,"NCT00833495","Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation","Completed","No Results Available","Allergic Conjunctivitis","Drug: Prednisolone Acetate 0.12% (Pred Mild?ó)|Drug: FOV1101-00|Drug: Prednisolone Acetate 1% (Pred Forte?ó)|Drug: Placebo","Fovea Pharmaceuticals SA","Both","Adult|Senior","Phase II",90,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","08-003-27","January 30, 2009","01/01/2009",2009-03-01,"September 28, 2010","01/09/2010","",2009-03-01,"Ocular Allergic signs and symptoms Diary Scores|Various ocular and nasal allergic diary scores","http://ClinicalTrials.gov/show/NCT00833495",NA
"79990",79990,"NCT00842595","Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas","Completed","No Results Available","B-cell Diffuse Large Cell Non Hodgkin's Lymphoma","Drug: rituximab|Drug: navelbine|Drug: ifosfamide|Drug: Mitoxantrone|Drug: Prednisone","Groupe Ouest Est d'Etude des Leuc?¢mies et Autres Maladies du Sang GOELAMS","Both","Adult|Senior","Phase II",50,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","R NIMP","February 11, 2009","01/12/2003",2010-05-01,"July 12, 2010","01/07/2010","",2009-11-01,"Complete remission rate|overall remission rate|Toxicity|Pharmacoeconomy","http://ClinicalTrials.gov/show/NCT00842595",NA
"79995",79995,"NCT00845195","Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Olopatadine HCl Nasal Spray, 0.6%|Drug: Azelastine HCl Nasal Spray, 0.1%","Alcon Research","Both","Child|Adult|Senior","Phase IV",150,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","SMA-08-23","February 13, 2009","01/03/2009",NA,"April 22, 2010","01/04/2010","",2009-05-01,"Mean Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline|Mean Change in Reflective Total Ocular Symptom Scores (rTOSS) From Baseline|Mean Change in Instantaneous Total Nasal Symptom Scores (iTNSS) From Baseline|Mean Change in Instantaneous Total Ocular Symptom Scores (iTOSS) From Baseline","http://ClinicalTrials.gov/show/NCT00845195",NA
"79996",79996,"NCT00855595","Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea","Completed","No Results Available","Papulopustular Rosacea","Drug: azelaic acid gel plus 40 mg doxycycline|Drug: metronidazole plus doxycycline","Intendis GmbH","Both","Adult|Senior","Phase IV",200,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","1402604|Project number: 256-0024","March 3, 2009","01/02/2009",2009-10-01,"August 23, 2010","01/08/2010","",2009-04-01,"Change in inflammatory lesion count from baseline|Rapidity of improvement","http://ClinicalTrials.gov/show/NCT00855595",NA
"80003",80003,"NCT00867295","Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device","Completed","No Results Available","Solid Tumor","Drug: cefazolin Sodium|Drug: placebo","Istanbul University","Both","Adult|Senior","Phase III",150,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2009/22","March 20, 2009","01/09/2008",2010-03-01,"June 1, 2010","01/03/2009","TIVAD",2009-12-01,"infectious complication","http://ClinicalTrials.gov/show/NCT00867295",NA
"80049",80049,"NCT00932295","Evaluating the Acute Effects of Electronic Nicotine Delivery Devices Marketed to Smokers.","Completed","No Results Available","No Conditions: This is Not a Treatment Study.|Focus is on Cigarette Smokers.","Other: OB|Other: Sham smoking|Other: CROWN SEVEN|Other: NJOY","National Cancer Institute (NCI)|National Institute on Drug Abuse (NIDA)","Both","Adult","Phase I|Phase II",32,"NIH","Interventional","Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Basic Science","HM11820|R01CA103827|R01CA120142","July 2, 2009","01/02/2009",2009-10-01,"November 3, 2009","01/11/2009","",2009-10-01,"Plasma nicotine concentration (ng/ml)|Heart rate|Withdrawal suppression (subjective measure)","http://ClinicalTrials.gov/show/NCT00932295",NA
"80058",80058,"NCT00950495","Oral Appliance Therapy in Obstructive Sleep Apnea","Completed","No Results Available","Obstructive Sleep Apnea","Device: Mandibular Advancement Device (MAD)|Device: nasal Continuous Positive Airway Pressure (nCPAP)|Device: intra-oral placebo appliance","VU University of Amsterdam","Both","Adult|Senior","Phase II",64,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","U/1731/0326","July 30, 2009","01/10/2003",2009-07-01,"July 30, 2009","01/07/2009","",2009-07-01,"apnea-hypopnea index (AHI)|other respiratory variables (apnea-hypopnea index during different sleep stages and positions);sleep variables (sleep stages and arousals);excessive daytime sleepiness;health perception;compliance;snoring reports; side-effects","http://ClinicalTrials.gov/show/NCT00950495",NA
"80096",80096,"NCT01018095","Trichomonas Vaginalis Recurrence Among HIV+ Women","Completed","No Results Available","Trichomonas Infections|HIV Infections","Drug: Metronidazole","Tulane University Health Sciences Center|National Institute of Allergy and Infectious Diseases (NIAID)","Female","Adult|Senior","Phase IV",270,"Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","543793|U19AI061972","November 20, 2009","01/05/2005",2009-08-01,"November 20, 2009","01/11/2009","",2009-07-01,"TV culture results|TV culture results","http://ClinicalTrials.gov/show/NCT01018095",NA
"80103",80103,"NCT01027195","Evaluation of the Efficacy of the Bipolar Sealer Aquamantys 6.0 in Patients Undergoing Total Hip Arthroplasty","Completed","No Results Available","Hip Arthritis","Device: Aquamantys 6.0|Device: Standard Bovie Electric Caudery","The Cleveland Clinic|Salient Surgical Technologies","Both","Adult|Senior","Phase IV",140,"Other|Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","06-615","December 3, 2009","01/08/2006",2009-06-01,"December 4, 2009","01/12/2009","Hip",2009-04-01,"Hemoglobin drop","http://ClinicalTrials.gov/show/NCT01027195",NA
"80137",80137,"NCT01081795","A Dose-finding Study of Topiramate in Migraine Patients","Completed","No Results Available","Migraine","Drug: Topiramate 100 mg|Drug: Topiramate 50 mg|Drug: Placebo","Janssen Pharmaceutical K.K.","Both","Adult","Phase II",474,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CR013681","March 4, 2010","01/04/2007",2009-01-01,"March 4, 2010","01/03/2010","",2009-01-01,"Change in the average monthly migraine period rate in double-blind phase compared with baseline determination period (24-hour rule)|Change in the average number of monthly rescue medication use in days in double-blind phase compared with baseline determination period|Percentage of responders to treatment (patients who had a 50% or more reduction in the frequency of migraine attacks are defined as responders)|Change in the average monthly headache days in double-blind phase compared with baseline determination period|Change in the average monthly migraine attacks rate [the diagnostic criteria of the International Headache Society (2nd Edition of the International Classification of Headache Disorders)] in double-blind phase compared with baseline determination period|Change in the average monthly migraine days in double-blind phase compared with baseline determination period","http://ClinicalTrials.gov/show/NCT01081795",NA
"80193",80193,"NCT01171495","Impact of Nutrition Intervention on HIV/AIDS Infected Patients","Completed","No Results Available","Human Immunodeficiency Virus (HIV)|Acquired Immune Deficiency Syndrome (AIDS)","Dietary Supplement: Theragran-M; Ensure Plus|Dietary Supplement: Theragran-M","Caribbean Health Research Council|The University of The West Indies","Both","Adult","Phase III",121,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CHRC 51016","July 27, 2010","01/04/2008",2009-08-01,"July 27, 2010","01/02/2010","INI",2009-08-01,"Effects of nutritional intervention on anthropometry in HIV infected individuals.|Effects of nutritional intervention on the clinical and immune status in HIV infected individuals.","http://ClinicalTrials.gov/show/NCT01171495",NA
"80200",80200,"NCT01185795","Efficacy of Cardioviva?ºÑ Probiotic Yogurt Formulation","Completed","No Results Available","Hypercholesterolemia","Dietary Supplement: Cardioviva?ºÑ yogurt|Dietary Supplement: Placebo yogurt","Micropharma Limited","Both","Adult|Senior","Phase II",159,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-001","August 18, 2010","01/09/2008",2009-04-01,"August 19, 2010","01/08/2010","",2009-01-01,"The primary outcome variable will be the percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C)","http://ClinicalTrials.gov/show/NCT01185795",NA
"80293",80293,"NCT00003896","Combination Chemotherapy in Treating Women With Stage III Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Drug: cisplatin|Drug: paclitaxel|Drug: pegylated liposomal doxorubicin hydrochloride|Procedure: adjuvant therapy","Southwest Oncology Group|National Cancer Institute (NCI)","Female","Child|Adult|Senior","Phase II",62,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000067066|SWOG-S9912","November 1, 1999","01/09/1999",NA,"June 10, 2009","01/09/2005","",2009-01-01,"Progression-free survival","http://ClinicalTrials.gov/show/NCT00003896",NA
"80345",80345,"NCT00073996","Tariquidar, Mitotane, Doxorubicin, Vincristine, and Etoposide Plus Surgery in Treating Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer","Completed","No Results Available","Adrenocortical Carcinoma","Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: mitotane|Drug: tariquidar|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",50,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000341556|NCI-04-C-0011","December 10, 2003","01/12/2004",NA,"November 26, 2009","01/04/2008","",2009-11-01,"Response rate (partial or complete)|Progression-free survival|Assessment of the extent of in vivo P-glycoprotein (Pgp) inhibition in CD56-positive cells as measured by CD56-positive cell assay with rhodamine|In vivo imaging with 99mTc-sestamibi and assessment of Pgp inhibition|Correlation of the pattern of gene expression found with the cDNA microarray with response and survival|Correlation of Pgp expression as measured by quantitative polymerase chain reaction and immunohistochemistry with response","http://ClinicalTrials.gov/show/NCT00073996",NA
"80364",80364,"NCT00102596","Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor","Completed","No Results Available","Essential Tremor","Drug: 1-Octanol","National Institute of Neurological Disorders and Stroke (NINDS)","Both","Adult|Senior","Phase II",50,"NIH","Interventional","Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","050092|05-N-0092","January 30, 2005","01/01/2005",2009-09-01,"May 29, 2010","01/09/2009","",2009-09-01,"1-octanol concentration-time data to determine pharmacokinetic. Assess bioequivalence between the two formulations based on the ratio of the peak concentrations and the ratio of the areas under the concentration-time curves for the 2 formulation...|Tremor severity based on accelerometric data will be assessed along with safety based on intoxication ratings and EKG monitoring.","http://ClinicalTrials.gov/show/NCT00102596",NA
"80414",80414,"NCT00184496","Switching From Morphine to Methadone. A Clinical, Pharmacological and Pharmacogenetic Study","Completed","No Results Available","Cancer","Drug: Methadone","Norwegian University of Science and Technology","Both","Adult|Senior","Phase III",50,"Other","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OPI 03/008","September 15, 2005","01/08/2004",2009-09-01,"July 22, 2010","01/07/2010","",2009-09-01,"The overall aim of the present study is to validate the switching procedure from morphine to methadone for patients with advanced cancer and a short life expectancy. More specifically, we will:|Collect blood samples for present and future genetic analyses in order to explore inter individual variations in methadone and morphine doses based upon possible polymorphisms.|Compare the QT-intervals on electrocardiograms obtained before and after start with methadone.","http://ClinicalTrials.gov/show/NCT00184496",NA
"80440",80440,"NCT00218296","Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use","Completed","No Results Available","Tobacco Use Disorder","Drug: Smokeless Tobacco Reduction Treatment|Drug: Standard Tobacco Cessation Treatment","National Institute on Drug Abuse (NIDA)","Both","Adult|Senior","Phase II",300,"NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NIDA-14404-4|R01-DA14404-4|DPMCDA","September 16, 2005","01/11/2006",2009-01-01,"October 21, 2009","01/10/2009","",2009-01-01,"Abstinence from tobacco|Duration of treatment|Reduction in ST use (measured at Month 6)","http://ClinicalTrials.gov/show/NCT00218296",NA
"80493",80493,"NCT00270296","Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV","Completed","No Results Available","HIV Infections","Drug: Trizivir|Drug: Lamivudine/Zidovudine|Drug: Lopinavir/Ritonavir|Drug: Nevirapine","National Institute of Allergy and Infectious Diseases (NIAID)|Harvard School of Public Health","Both","Child|Adult|Senior","Phase II",700,"NIH|Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Prevention","BHP 016|10430|U01 AI064002","December 22, 2005","01/06/2006",2009-05-01,"March 26, 2010","01/08/2008","",2009-03-01,"Virologic suppression|Infant's HIV status|HIV-1 RNA levels in plasma and breast milk|HIV-1 DNA levels in breast milk|Time from randomization to the first adverse event requiring discontinuation of any of the drugs that formed the initial regimen by treatment arm and compared to Mashi study|Time from randomization to the first Grade 3 or higher adverse event by treatment arm and compared to Mashi study|Occurrence of Grade 3 or higher adverse events by type, grade, body system, and association with study treatment compared to Mashi study|Premature birth and very premature birth, defined as 37 and 32 weeks gestation or less, respectively|Low birth weight and very low birth weight, defined as less than 2,500 g and less than 1,500 g, respectively|Growth and developmental delay, defined as standard norms and neurodevelopmental screening|Maternal mortality|Maternal morbidity, defined as occurrence of Grade 3 or 4 adverse events, hospitalizations, and AIDS-defining or AIDS-associated diagnoses|Change in maternal CD4 count from baseline over time|Infant mortality|Comparison of neurodevelopment at 2 years of age in the Mashi study and this study|Adherence, as measured by questionnaire and pill count|Occurrence of HIV-1 RNA genetic mutations associated with viral resistance in maternal plasma and breast milk and infant plasma among transmitting mother-infant pairs at the nearest time to transmission|Antiretroviral therapy (ARV) toxicities and viral load differences by maternal HLA type, for subset of up to 500 women with HLA-type available|ARV concentrations in breast milk and serum and in their infants' serum for all transmitting mother-infant pairs and a matched group of nontransmitting pairs","http://ClinicalTrials.gov/show/NCT00270296",NA
"80499",80499,"NCT00302796","Antibiotic Treatment to Patients With Low Back Pain","Completed","No Results Available","Back Pain","Drug: Bioclavid|Drug: Placebo","The Back Research Center, Denmark","Both","Adult","Phase IV",162,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2005-005500-17","March 14, 2006","01/03/2006",2009-10-01,"May 26, 2010","01/07/2009","",2009-10-01,"Low Back Pain Roland Morris Questionaire","http://ClinicalTrials.gov/show/NCT00302796","Denmark"
"80516",80516,"NCT00330096","Effects of Hesperidin on Bone Mineral Density and Bone Metabolism of Postmenopausal Women","Completed","No Results Available","Osteoporosis, Osteopenia","Drug: Hesperidin","Nestle Clinical Nutrition|Institut National de la Recherche Agronomique|Centre de Recherche en Nutrition Humaine. Clermont-Ferrand, France","Female","Adult","Phase III",110,"Industry|Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","05.12NRC","May 24, 2006","01/03/2006",2009-04-01,"October 8, 2009","01/10/2009","",2009-04-01,"Bone mineral density|Serum markers of bone resorption and bone formationChanges in body composition","http://ClinicalTrials.gov/show/NCT00330096","France"
"80526",80526,"NCT00348296","Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis","Completed","No Results Available","Scleroderma, Systemic","Drug: High-dose intravenous immunoglobulin (Venoglobulin-IH)","Benesis Corporation","Both","Child|Adult|Senior","Phase III",60,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","0998-A1","July 3, 2006","01/07/2006",2009-07-01,"July 28, 2010","01/07/2010","",2009-07-01,"Changes in TSS at 12 weeks|Changes in joint motion, oral aperture, active hand spread, fingertip-to-palm distance, health assessment questionnaire, histological analysis of dermal section at 12 weeks.; Adverse events and laboratory test.","http://ClinicalTrials.gov/show/NCT00348296","Japan"
"80530",80530,"NCT00358696","Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients","Completed","No Results Available","HIV|HIV Infections","Drug: tenofovir","University of British Columbia|Health Canada","Both","Adult|Senior","Phase IV",30,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C05-0218","July 28, 2006","01/07/2006",2009-10-01,"October 19, 2009","01/10/2009","",2009-10-01,"Virologic Suppression|HAART adherence, safety, CD4 cell count","http://ClinicalTrials.gov/show/NCT00358696","Canada"
"80537",80537,"NCT00357396","Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors","Completed","No Results Available","Sarcoma","Biological: graft versus host disease prophylaxis/therapy|Drug: busulfan|Drug: melphalan|Drug: thiotepa|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Memorial Sloan-Kettering Cancer Center","Both","Child|Adult","Phase II",30,"Other","Interventional","Primary Purpose: Treatment","CDR0000487592|MSKCC-05059","July 26, 2006","01/06/2005",NA,"November 10, 2009","01/11/2009","",2009-10-01,"Disease-free survival at 1 year|Overall survival|Morbidity and mortality|Incidence of acute and chronic graft-vs-host disease (GVHD)|Biologic response of minimal residual disease","http://ClinicalTrials.gov/show/NCT00357396","United States"
"80661",80661,"NCT00528996","An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: BEA 2180 BR|Drug: tiotropium","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",2080,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1205.14|2007-007946-42","September 12, 2007","01/09/2007",NA,"July 16, 2010","01/07/2010","",2009-05-01,"The primary endpoint in this study is trough FEV1 response after 24 weeks.|Trough FEV1 response after 1, 2, 4, 8, 12, and 18 weeks","http://ClinicalTrials.gov/show/NCT00528996","United States, &nbsp; Canada, &nbsp; Germany, &nbsp; Hungary, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Taiwan"
"80670",80670,"NCT00567996","Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control","Completed","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Indacaterol|Drug: placebo|Drug: Salmeterol","Novartis","Both","Adult|Senior","Phase III",1002,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CQAB149B2336","December 4, 2007","01/11/2007",NA,"January 13, 2010","01/01/2010","",2009-01-01,"Forced expiratory volume in 1 second (FEV???) after 12 weeks of treatment measured 24 hours after having taken medication|Effect of indacaterol on percentage of \days of poor control\"" of COPD over 26 weeks|Total score of St.George's Respiratory Questionnaire""","http://ClinicalTrials.gov/show/NCT00567996","Canada, &nbsp; Colombia, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; Iceland, &nbsp; India, &nbsp; Italy, &nbsp; Peru, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; Taiwan"
"80672",80672,"NCT00571896","The Use of SennaS for Prevention of Post-Operative Constipation After Urogynecologic Surgery","Completed","No Results Available","Constipation","Drug: Senna+ docusate|Drug: placebo","Hartford Hospital","Female","Adult|Senior","Phase II|Phase III",72,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PATE002472HE","December 10, 2007","01/01/2008",2009-06-01,"July 1, 2009","01/07/2009","",2009-06-01,"1. Time to first bowel movement after surgery. 2. Need for magnesium citrate or enemas in the immediate post-operative period.|Straining and pain with bowel movements in the immediate post-operative period","http://ClinicalTrials.gov/show/NCT00571896","United States"
"80700",80700,"NCT00621296","Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: MP-424","Mitsubishi Tanabe Pharma Corporation|Vertex Pharmaceuticals Incorporated","Both","Adult|Senior","Phase II",15,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","G060-A7","February 12, 2008","01/01/2008",2009-03-01,"August 31, 2009","01/08/2009","",2009-03-01,"HCV RNA kinetics and other viral characteristics|Safety","http://ClinicalTrials.gov/show/NCT00621296","Japan"
"80721",80721,"NCT00647296","Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)","Completed","No Results Available","Amyotrophic Lateral Sclerosis","Drug: KNS-760704","Knopp Neurosciences","Both","Adult|Senior","Phase II",102,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KNS-760704-CL201","March 26, 2008","01/03/2008",2009-10-01,"November 6, 2009","01/11/2009","CL201",2009-09-01,"To evaluate the safety and tolerability of oral administration of 3 dosage levels of KNS-760704 compared to placebo for 12 weeks in patients with ALS (Part 1)|To evaluate the long-term safety and tolerability of oral administration of 2 dosage levels of KNS 760704 in ALS patients (Part 2)|To evaluate the effects of KNS-760704 on measures of clinical function|To evaluate the reliability and clinical predictive value of upright and supine vital capacity|To evaluate the effects of KNS-760704 on selected protein levels in blood and cerebrospinal fluid","http://ClinicalTrials.gov/show/NCT00647296","United States"
"80770",80770,"NCT00718796","Naturopathic Treatment for the Prevention of Cardiovascular Disease","Completed","No Results Available","Cardiovascular Disease","Other: Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise|Other: Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)","The Canadian College of Naturopathic Medicine|Canada Post Corporation|Canadian Union of Postal Workers","Both","Adult","Phase III",300,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CP/CUPW4","April 25, 2008","01/04/2008",2009-10-01,"May 14, 2010","01/05/2010","Cardio pilot",2009-10-01,"Metabolic syndrome|General Cardiovascular Risk Profile: Framingham Heart Study|Adverse events|HbA1C|Compliance with naturopathic interventions|Quality of Life (Short-form 36)","http://ClinicalTrials.gov/show/NCT00718796","Canada"
"80782",80782,"NCT00746096","Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea","Completed","No Results Available","Dysmenorrhea","Drug: Norethindrone,Ethinyl Estrsdiol","Nobelpharma","Female","Child|Adult|Senior","Phase III",113,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","IKH-01-6","August 29, 2008","01/09/2008",2009-09-01,"May 21, 2010","01/05/2010","",2009-09-01,"patient response to treatment for primary dysmenorrhea ,as evaluated by VRS|change in the VAS of primary dysmenorrhea","http://ClinicalTrials.gov/show/NCT00746096","&nbsp;"
"80790",80790,"NCT00739596","Blood Pressure Lowering of Aliskiren HCTZ Versus Amlodipine in Stage 2 Hypertension in African Americans","Completed","Has Results","Hypertension","Drug: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Drug: Amlodipine: 8 weeks","Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",332,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CSPP100AUS03","August 21, 2008","01/07/2008",2009-03-01,"December 14, 2010","01/12/2010","ATLAAST",2009-03-01,"Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment|Change in Mean Sitting Diastolic Blood Pressure (MSDBP) After 8 Weeks of Treatment|Change in Mean Sitting Pulse Pressure (MSPP) After 8 Weeks of Treatment|Proportion of Responders After 8 Weeks of Treatment.|Proportion of Patients Achieving BP Control After 8 Weeks of Treatment","http://ClinicalTrials.gov/show/NCT00739596","United States"
"80804",80804,"NCT00781196","Folic Acid Supplementation in Phenytoin Induced Gingival Overgrowth","Completed","No Results Available","Gingival Overgrowth","Drug: folic acid|Drug: placebo","All India Institute of Medical Sciences, New Delhi","Both","Child","Phase III",120,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PIGO","October 27, 2008","01/05/2008",2009-07-01,"August 3, 2009","01/08/2009","PIGO",2009-01-01,"Occurrence of any grade of overgrowth in 2 groups after 6 mo of phenytoin therapy|Occurrence of grade > 2 hyperplasia at the end of 6 mo|Time to occurrence of grade > 2 overgrowth|Correlation between following and occurrence of grade > 2 overgrowth *phenytoin dose (in mg/kg/d) *serum phenytoin levels *plaque index","http://ClinicalTrials.gov/show/NCT00781196","India"
"80852",80852,"NCT00859196","Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Superficial Injuries","Completed","No Results Available","Wound Healing|Cell Proliferation|Gene Expression","Drug: Dexpanthenol (BAY81-2996)|Drug: Placebo","Bayer","Both","Adult","Phase IV",15,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science","13069|EudraCT: 2008-002069-30","March 9, 2009","01/02/2009",2009-02-01,"March 9, 2009","01/03/2009","",2009-02-01,"Investigation of gene expression in dermal fibroblasts and keratinocytes on a molecular level.","http://ClinicalTrials.gov/show/NCT00859196","Germany"
"80898",80898,"NCT00943696","Effects of White Wine vs. Tea Intake During and an Alcoholic Digestive Following a High Fat, High Calorie Cheese Fondue Meal on Gastric Emptying and Abdominal Symptoms in Healthy Volunteers","Completed","No Results Available","Healthy Participants","Dietary Supplement: Ingestion of white wine vs. tea during and an alco","University of Zurich|COOP","Both","Adult","Phase IV",12,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Health Services Research","Fonduestudie_EKGs","July 20, 2009","01/08/2009",2009-10-01,"June 24, 2010","01/06/2010","",2009-10-01,"Effect of white wine vs. tea on gastric emptying","http://ClinicalTrials.gov/show/NCT00943696","Switzerland"
"81025",81025,"NCT01180296","Oral Progesterone for Prevention of Preterm Birth","Completed","No Results Available","Preterm Birth","Drug: oral micronized progesterone|Drug: Identical Placebo tablet","Fetal Medicine Foundation","Female","Adult","Phase III",33,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MVH-MP-Pilot-RCT","August 10, 2010","01/11/2006",2009-01-01,"August 11, 2010","01/08/2010","",2009-01-01,"Rate of recurrent preterm birth|Serum Progesterone Levels","http://ClinicalTrials.gov/show/NCT01180296","United States"
"81059",81059,"NCT01233596","Monocanalicular Versus Bicanalicular Intubation in the Treatment of Congenital Nasolacrimal Duct Obstruction","Completed","No Results Available","Nasolacrimal Duct Obstruction","Device: Canalicular intubation","University Hospital Ostrava","Both","Child","Phase III",70,"Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ORL-FNO-2010","November 2, 2010","01/01/2006",2009-12-01,"November 2, 2010","01/11/2010","MCI_vs_BCI",2009-06-01,"Success rate and complications of monocanalicular and bicanalicular intubation in children","http://ClinicalTrials.gov/show/NCT01233596","Czech Republic"
"81062",81062,"NCT01237496","Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253","Completed","No Results Available","Hepatitis B, Chronic","Drug: peginterferon alfa-2a [Pegasys]","Hoffmann-La Roche","Both","Adult","Phase III",17,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18675","November 8, 2010","",2009-09-01,"November 8, 2010","01/11/2010","",2009-09-01,"CD4 and CD8 mediated immune response: Interferon-y (ELISPOT analysis, flow cytometry)|CD4 and CD8 mediated immune response: Interleukin-2 production (Flow cytometry)|CD4 and CD8 mediated immune response: Cytokine profile analysis by supernatant culture|CD4 and CD8 mediated immune response: Proliferative response upon T-cell stimulation|CD8 response in HLA-A2 positive patients|Profile of proinflammatory cytokines: analysis of cytokines in serum|HBV viremia (HBV RNA assessed by COBAS PaqMan HCV test)","http://ClinicalTrials.gov/show/NCT01237496","Italy"
"81168",81168,"NCT00058097","Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: tipifarnib|Radiation: radiation therapy","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000285732|NABTT-2200|JHOC-NABTT-2200","April 7, 2003","01/08/2003",NA,"April 24, 2009","01/04/2004","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00058097","United States"
"81186",81186,"NCT00091897","Rituximab to Treat Stiff Person Syndrome","Completed","No Results Available","Stiff Person Syndrome","Drug: Rituximab","National Institute of Neurological Disorders and Stroke (NINDS)","Both","Adult|Senior","Phase II",24,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","040287|04-N-0287","September 18, 2004","01/09/2004",NA,"January 28, 2010","01/05/2009","",2009-05-01,"To evaluate the efficacy, safety of the chimeric monoclonal antibody Rituximab to deplete B lymphocytes in patients with Stiff Person Syndrome with high anti-GAD antibodies.|The Heightened Sensitivity Scale will be used as a secondary outcome measure.","http://ClinicalTrials.gov/show/NCT00091897","United States"
"81238",81238,"NCT00171197","A 1-year Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Liver Iron Concentration of Deferasirox and Deferoxamine in Children and Adults With Sickle Cell Disease and Transfusional Hemosiderosis","Completed","No Results Available","Sickle Cell Disease","Drug: Deferasirox","Novartis Pharmaceuticals","Both","Child|Adult|Senior","Phase II",170,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CICL670A109E1","September 12, 2005","01/05/2004",NA,"December 9, 2010","01/12/2010","",2009-07-01,"Evaluate the long-term safety and tolerability profile of ICL670|Allow patients to continue iron chelation therapy|Estimate the absolute and relative change of liver iron content (LIC) and total body iron excretion (TBIE)|Evaluate the relationship between hepatic iron and potential surrogate markers","http://ClinicalTrials.gov/show/NCT00171197","United States, &nbsp; Canada, &nbsp; France, &nbsp; Italy, &nbsp; United Kingdom"
"81247",81247,"NCT00184197","Botulinum Toxin Injection in Neck Muscles in Cervicogenic Headache","Completed","No Results Available","Cervicogenic Headache","Drug: Botulinum toxin","Norwegian University of Science and Technology","Both","Adult|Senior","Phase II",30,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double-Blind|Primary Purpose: Treatment","2004-000724-32","September 12, 2005","01/05/2005",2009-12-01,"September 1, 2010","01/09/2010","",2009-12-01,"Number of days with headache from week 2 after injection to week 7.|No. of days until the patient has got > 50% of the pain level he or she had before the injection.|No. of drop-outs due to long-lasting improvement after first injection|No. of hours with headache from week 2 to week 7|Average headache intensity from week 2 to week 7.|Headache index (number of hours with headache times the number of pain intensity)|Number of days with neck pain from week 2 to week 7.|Number of days with shoulder or arm pain from week 2 to week 7.|Number of doses with analgesics from week 2 to week 7.|Number of days with sick-leave from week 2 to week 7.","http://ClinicalTrials.gov/show/NCT00184197","Norway"
"81319",81319,"NCT00298597","Influence of G-CSF and EPO on Associative Learning and Motor Skills","Completed","No Results Available","Chronic Stroke|Amyotrophic Lateral Sclerosis","Drug: granulocyte - colony stimulating factor (G-CSF)|Drug: erythropoetin (EPO)","University Hospital Muenster","Both","Adult|Senior","Phase II",180,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","GCSFEPO_01|EudraCT Number 2005-001113-18","March 1, 2006","01/03/2006",2009-03-01,"April 22, 2009","01/04/2007","",2009-03-01,"Learning success in a word learning model|Response time in motor function tests|Response time in a word learning model|Total time and number of keystrokes in motor function tests","http://ClinicalTrials.gov/show/NCT00298597","Germany"
"81370",81370,"NCT00373997","Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux","Completed","No Results Available","Larynx Disease|Gastroesophageal Reflux","Procedure: Esophageal and Laryngeal biopsies|Procedure: egd with biopsy","Vanderbilt University","Both","Adult|Senior","Phase IV",45,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Diagnostic","60725","September 5, 2006","01/09/2006",2009-12-01,"November 12, 2010","01/11/2010","biopsy I",2009-03-01,"Dilation of intracellular spaces at the beginning of the study","http://ClinicalTrials.gov/show/NCT00373997","United States"
"81412",81412,"NCT00441597","Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?","Completed","No Results Available","Ischemia Reperfusion Injury|Cardiovascular Disease","Drug: atorvastatin","Radboud University|Pfizer","Male","Adult","Phase IV",30,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","atorv01","February 28, 2007","01/02/2007",2009-03-01,"March 16, 2009","01/03/2009","",2009-02-01,"Annexin A 5 targeting in the non dominant thenar muscle after ischemic exercise, as a indicator for ischemia reperfusion injury.|workload during ischemic exercise|effect of 3-day treatment with atorvastatin 80mg daily on serum lipid levels","http://ClinicalTrials.gov/show/NCT00441597","Netherlands"
"81459",81459,"NCT00472797","Rebif New Formulation (RNF) Quality of Life (QOL) Study","Completed","Has Results","Relapsing Multiple Sclerosis","Drug: Rebif New Formulation Non Titrated|Drug: Rebif New Formulation Titrated","EMD Serono","Both","Adult","Phase III",232,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","27955","May 10, 2007","01/04/2007",2009-11-01,"August 17, 2010","01/08/2010","RebiQoL",2009-02-01,"Percent Change in Global Side Effects (GSE) on Multiple Sclerosis Treatment Concerns Quesionnaire (MSTCQ)|Total Score for Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)|Change in Score From Baseline to Week 12 for All Domains Other Than Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)|Total Score on Short-Form McGill Pain Questionnaire (SF-MPQ): Change in Baseline to Wk 12|Tolerability in Pain Using Visual Analog Scale (VAS)|Tolerability - Redness at Injection Site","http://ClinicalTrials.gov/show/NCT00472797","United States"
"81484",81484,"NCT00542997","Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy","Completed","No Results Available","Common Variable Immunodeficiency|X-linked Agammaglobulinemia","Biological: IgG with Proline (IgPro)","CSL Behring","Both","Child|Adult|Senior","Phase III",51,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1460|ZLB06_001CR","October 11, 2007","01/09/2007",2009-08-01,"February 4, 2010","01/02/2010","",2009-08-01,"Total serum IgG trough levels|Rate of clinically documented serious bacterial infections|Number of infection episodes|Use of antibiotics for infection prophylaxis and treatment|Adverse events","http://ClinicalTrials.gov/show/NCT00542997","France, &nbsp; Germany, &nbsp; Italy, &nbsp; Poland, &nbsp; Romania, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; United Kingdom"
"81500",81500,"NCT00574197","Enteric-coated Mycophenolate Sodium (Myfortic?ó) in Heart Transplant Recipients","Completed","No Results Available","Gastrointestinal Symptoms|Heart Transplantation","Drug: Mycophenolate Sodium","Cedars-Sinai Medical Center|Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",11,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9810","December 13, 2007","01/06/2006",2009-12-01,"July 21, 2010","01/08/2009","",2009-12-01,"Side-effects using the GSRS (Gastrointestinal Symptoms Rating Scale), GI complications and GI adverse events|Incidence of biopsy proven acute rejection, graft loss, and death","http://ClinicalTrials.gov/show/NCT00574197","United States"
"81524",81524,"NCT00511797","SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study","Completed","Has Results","Dysmenorrhea","Drug: SH T04740B|Drug: SH T00186DF|Drug: SH T04740F|Drug: Placebo","Bayer","Female","Adult|Senior","Phase II|Phase III",249,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","91615|310283","August 3, 2007","01/07/2007",2009-01-01,"November 5, 2010","01/11/2010","",2009-01-01,"Change From Baseline in Total Dysmenorrheal Score at Final Evaluation|Change From Baseline in Total Dysmenorrheal Score at Cycle 1 up to Cycle 4|Number of Participants With Severity of Lower Abdominal Pain During Menstruation at Cycle 4|Number of Pariticpants With Severity of Low Back Pain During Menstruation at Cycle 4|Number of Participants With Severity of Headache During Menstruation at Cycle 4|Number of Participants With Severity of Nausea or Vomiting During Menstruation at Cycle 4|Number of Participants With Total Pelvic Pain Score at Times Other Than During Menstruation at Cycle 4|Change From Baseline in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation at Cycle 4|Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation at Cycle 4|Change From Baseline in Endometrial Thickness After 4-cycle Treatment|Number of Bleeding / Spotting Episodes|Number of Bleeding / Spotting Days|Participants With Withdrawal Bleeding|Participants With Intracyclic Bleeding|Participants With Non-heavy Intracyclic Bleeding|Participants With Non-heavy Withdrawal Bleeding|Change From Baseline in Serum Carbohydrate Antigen-125 (CA125) After 4-cycle Treatment|Change From Baseline in Serum C-reactive Protein (CRP) After 4-cycle Treatment|Change From Baseline in Serum Estradiol Level After 4-cycle Treatment|Change From Baseline in Serum Progesterone Level at Cycle 4","http://ClinicalTrials.gov/show/NCT00511797","Japan"
"81525",81525,"NCT00617097","Paracervical Block in First Trimester Surgical Abortions","Completed","No Results Available","Pain|Abortion, Induced","Drug: lidocaine|Drug: ketorolac and lidocaine","Johns Hopkins University|Oregon Health and Science University","Female","Adult","Phase II|Phase III",50,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NA_00013075|SFP1-1","December 28, 2007","01/01/2008",2009-06-01,"June 8, 2009","01/06/2009","",2009-05-01,"The mean difference in distance (in millimeters) on a 100-mm Visual Analogue Scale (VAS) taken during specific time intervals throughout termination procedure.","http://ClinicalTrials.gov/show/NCT00617097","United States"
"81553",81553,"NCT00663897","Lansoprazole Versus Mosapride for Functional Dyspepsia","Completed","No Results Available","Functional Dyspepsia|Epigastric Pain Syndrome|Post Prandial Distress Syndrome","Drug: lansoprazole|Drug: mosapride","Lotung Poh-Ai Hospital|Tomorrow Medical Foundation","Both","Adult|Senior","Phase IV",329,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OMCP-97-007","April 21, 2008","01/05/2008",2009-09-01,"October 8, 2009","01/10/2009","",2009-07-01,"Improvement of dyspeptic symptoms as evaluated by validated questionnaire","http://ClinicalTrials.gov/show/NCT00663897","Taiwan"
"81585",81585,"NCT00526097","Dulcolax vs Placebo in Functional Constipation","Completed","Has Results","Constipation","Drug: Bisacodyl 10 mg|Drug: Placebo","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase III",368,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","122.56|EUDRACT 2007-001991-34","September 5, 2007","01/09/2007",NA,"September 1, 2010","01/09/2010","",2009-06-01,"Mean Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week Over the 4 Weeks Treatment Period|Number of CSBMs at Week 1|Number of CSBMs at Week 2|Number of CSBMs at Week 3|Number of CSBMs at Week 4|Mean Number of SBMs Per Week Over the 4 Weeks Treatment Period|Number of SBMs at Week 1|Number of SBMs at Week 2|Number of SBMs at Week 3|Number of SBMs at Week 4|Time to the First SBM Following the First Dose of Study Medication (SM)|Number of Participants With an Increase of at Least 1 in the Mean Number of CSBMs Per Week Over the 4 Weeks Treatment Period Compared to Baseline|Number of Participants With an Increase of at Least 1 CSBM at Week 1 Compared to Baseline|Number of Participants With an Increase of at Least 1 CSBM at Week 2 Compared to Baseline|Number of Participants With an Increase of at Least 1 CSBM at Week 3 Compared to Baseline|Number of Participants With an Increase of at Least 1 CSBM at Week 4 Compared to Baseline|Number of Participants With a Mean of at Least 1 CSBM a Day Over the 4 Weeks Treatment Period|Number of Participants With a Mean of at Least 3 CSBMs a Week Over the 4 Weeks Treatment Period|Number of Premature Withdrawals Over the 4 Weeks Treatment Period|Number of Premature Withdrawals at Week 1 in the Treatment Period|Number of Premature Withdrawals at Week 2 in the Treatment Period|Number of Premature Withdrawals at Week 3 in the Treatment Period|Number of Premature Withdrawals at Week 4 in the Treatment Period|Number of Participants Using Rescue Medication Over the 4 Weeks Treatment Period|Number of Participants Using Rescue Medication at Week 1 in the Treatment Period|Number of Participants Using Rescue Medication at Week 2 in the Treatment Period|Number of Participants Using Rescue Medication at Week 3 in the Treatment Period|Number of Participants Using Rescue Medication at Week 4 in the Treatment Period|Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 1|Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 2|Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 3|Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 4|Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 1|Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 2|Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 3|Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 4|Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 1|Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 2|Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 3|Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 4|Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 1|Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 2|Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 3|Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 4|Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 1|Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 2|Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 3|Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 4|Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 1 in the Treatment Period in Comparison to Baseline|Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 2 in the Treatment Period in Comparison to Baseline|Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 3 in the Treatment Period in Comparison to Baseline|Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 4 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 1 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 2 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 3 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 4 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 1 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 2 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 3 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 4 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 1 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 2 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 3 in the Treatment Period in Comparison to Baseline|Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 4 in the Treatment Period in Comparison to Baseline|Number of Participants With Respect to the Final Global Assessment of Efficacy by the Investigator|Number of Participants With Respect to the Final Global Assessment of Efficacy by the Patient|Number of Participants With Respect to the Final Global Assessment of Tolerability by the Investigator|Number of Participants With Respect to the Final Global Assessment of Tolerability by the Patient|Change From Baseline in the SF-36 Dimension 'Physical Functioning'|Change From Baseline in the SF-36 Dimension 'Role Limitation Due to Physical Problems'|Change From Baseline in the SF-36 Dimension 'Bodily Pain'|Change From Baseline in the SF-36 Dimension 'General Health'|Change From Baseline in the SF-36 Dimension 'Vitality'|Change From Baseline in the SF-36 Dimension 'Social Functioning'|Change From Baseline in the SF-36 Dimension 'Role Limitation Due to Emotional Problems'|Change From Baseline in the SF-36 Dimension 'Mental Health'|Change From Baseline in the SF-36 Mental Component Scale (MCS)|Change From Baseline in the SF-36 Physical Component Scale (PCS)|Change From Baseline in the PAC-QoL Subscale 'Worries and Concerns'|Change From Baseline in the PAC-QoL Subscale 'Physical Discomfort'|Change From Baseline in the PAC-QoL Subscale 'Psychosocial Discomfort'|Change From Baseline in the PAC-QoL Subscale 'Satisfaction'|Change From Baseline in the PAC-QoL Overall Score|Change From Baseline for Sodium (Normalized Value)|Change From Baseline for Potassium (Normalized Value)|Change From Baseline for Chloride (Normalized Value)","http://ClinicalTrials.gov/show/NCT00526097","United Kingdom"
"81589",81589,"NCT00706797","Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects","Completed","Has Results","Rheumatoid Arthritis","Drug: etanercept (EnbrelTM)|Drug: methotrexate","Wyeth","Both","Adult|Senior","Phase IV",141,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0881X1-4437","June 25, 2008","01/09/2008",2010-05-01,"December 22, 2010","01/12/2010","",2009-12-01,"Change From Baseline in Modified Total Sharp Score (TSS) at Week 52|Change From Baseline in Erosions at Week 52|Change From Baseline in Joint Space Narrowing at Week 52|Percentage of Participants Showing no Radiographic Progression (TSS Change <0.5) at Week 52|Percentage of Participants Achieving >1.2 Improvement in Disease Activity Score Based on a 28-joint Count (DAS28)|Percentage of Participants Achieving Remission (DAS28 <2.60)|Percentage of Participants Achieving Low Disease Activity (DAS28 ???3.20)|Percentage of Participants Achieving a >0.6 Disease Activity Score (DAS)28 Response|Percentage of Participants Achieving Moderate or Good Response on European League Against Rheumatism (EULAR) Response Criteria|Percentage of Participants With American College of Rheumatology 20% (ACR20) Response|Percentage of Participants With American College of Rheumatology 50% (ACR50) Response|Percentage of Participants With American College of Rheumatology 70% (ACR70) Response|Percentage of Participants With American College of Rheumatology 90% (ACR90) Response|Change From Baseline in Mean Daily Dose of Corticosteroids to Manage Flare-ups Across the 52-week Treatment Period|Percentage of Participants Achieving a Minimal Clinically Important Improvement (MCII)|Percentage of Participants Achieving a Patient Acceptable Symptom State (PASS)|Health Related Quality of Life: EuroQol-5D Health Index|Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS)","http://ClinicalTrials.gov/show/NCT00706797","Czech Republic, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; Italy, &nbsp; Poland, &nbsp; Spain, &nbsp; Turkey, &nbsp; United Kingdom"
"81613",81613,"NCT00760097","Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression","Completed","No Results Available","Depression","Device: Transcranial direct stimulation","University of California, Los Angeles","Both","Adult|Senior","Phase IV",18,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","aTDCS in MDD","September 24, 2008","01/09/2007",2009-05-01,"August 6, 2009","01/08/2009","aTDCS",2009-05-01,"To test our hypotheses, assessments of cognition, mood, and brain activity will be performed on three occasions|ADVERSE EVENT REPORTS Subjects will be asked about adverse events at the end of each treatment session","http://ClinicalTrials.gov/show/NCT00760097","United States"
"81633",81633,"NCT00797797","Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia","Completed","No Results Available","Fibromyalgia","Drug: pregabalin|Drug: milnacipran","Forest Laboratories","Both","Adult|Senior","Phase III",364,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MLN-MD-15","November 24, 2008","01/11/2008",2010-01-01,"April 29, 2010","01/04/2010","",2009-11-01,"PGIC responder rate at end of study|Change from baseline in VAS 1-week pain recall at end of study","http://ClinicalTrials.gov/show/NCT00797797","United States"
"81657",81657,"NCT00843297","COOL-Trial: Outcome With Invasive and Non-invasive Cooling After Cardiac Arrest","Completed","No Results Available","Cardiac Arrest|Hypothermia","Device: Coolgard|Device: ArcticSun|Other: Conventional treatment","University of Leipzig","Both","Child|Adult|Senior","Phase IV",120,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","COOL-Trial","February 12, 2009","01/04/2008",2010-01-01,"February 1, 2010","01/01/2010","COOL",2009-12-01,"Time to reach the target temperature|NSE as a parameter for cerebral damage|Neurologic outcome|Survival|Periprocedural complications","http://ClinicalTrials.gov/show/NCT00843297","Germany"
"81678",81678,"NCT00847197","A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)(Completed)","Completed","Has Results","Dyslipidemia","Drug: MK1903|Drug: Comparator: Placebo","Merck","Both","Adult|Senior","Phase II",191,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2009_542|MK1903-004","February 18, 2009","01/02/2009",2009-09-01,"August 27, 2010","01/08/2010","",2009-09-01,"Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) (mg/dL)|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) (mg/dL)|Percent Change From Baseline in Triglycerides (mg/dL)","http://ClinicalTrials.gov/show/NCT00847197","&nbsp;"
"81679",81679,"NCT00875797","Enteral Versus Parenteral Glutamine Supplement","Completed","No Results Available","Critically Ill","Dietary Supplement: enteral glutamine, parenteral glutamine","University Medical Centre Ljubljana","Both","Adult|Senior","Phase IV",72,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment","P4-0092: onko","April 2, 2009","01/10/2004",2009-03-01,"April 2, 2009","01/04/2009","",2009-01-01,"Measurement of intestinal permeability using lactulose-mannitol test|Infection rate and survival","http://ClinicalTrials.gov/show/NCT00875797","Slovenia"
"81723",81723,"NCT00940797","Effect of DMMET-01 on Insulin Sensitivity in Naive Type 2 Diabetes Patients (CLAMP)","Completed","No Results Available","Diabetes Type 2","Drug: DMMET-01|Drug: Placebo","Laboratorios Silanes S.A. de C.V.","Both","Adult","Phase II",20,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","SIL-1099/2008|SIL-DMMETClamp","July 14, 2009","01/07/2008",NA,"July 15, 2009","01/07/2009","DMMETclamp",2009-02-01,"Insulin sensitivity|Insulin, fasting glucose, HbA1c|Adverse Events|Creatinine, Total Cholesterol, HDL, Triglycerides, Uric acid, AST, ALT, FA, DHL","http://ClinicalTrials.gov/show/NCT00940797","Mexico"
"81743",81743,"NCT00970697","Becaplermin Gel for MARTORELL's Hypertensive Leg Ulcers","Completed","No Results Available","Martorell's Ulcer|Hypertensive Leg Ulcer|Necrotic Angiodermatitis","Drug: becaplermin gel|Drug: Duoderm Hydrogel?ºÑ","Assistance Publique - H??pitaux de Paris|French Society of Dermatology","Both","Adult|Senior","Phase III",64,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","P020706|Cochrane Skin Group:CSG27","September 1, 2009","01/01/2004",2009-06-01,"September 1, 2009","01/09/2009","ERAN",2009-05-01,"Complete wound closure rate at week 8 of treatment|Complete wound closure rate at week 12 of treatment|pain and quality of life evolution during the treatment( W4,8,10,12),|% of wound area reduction at week 8 and 12|safety of the treatment at week 4, 8 and 12","http://ClinicalTrials.gov/show/NCT00970697","France"
"81771",81771,"NCT01018797","Intrastromal Corneal Ring for High Astigmatism on Postkeratoplasty","Completed","No Results Available","Astigmatism","Procedure: INTRASTROMAL CORNEAL RING SEGMENT","Instituto de Olhos de Goiania","Both","Adult","Phase IV",18,"Other","Interventional","Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","BQ-1-09-ARVO","November 21, 2009","01/01/2007",2009-11-01,"November 23, 2009","01/11/2009","Anel",2009-07-01,"","http://ClinicalTrials.gov/show/NCT01018797","Brazil"
"81795",81795,"NCT01057797","Nurse Managed Upper Body Strength Training in Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Behavioral: Exercise-specific self-efficacy|Behavioral: Gentle chair exercise|Behavioral: upper body strength training","University of Illinois","Both","Adult|Senior","Phase II",208,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","NR08037","January 26, 2010","01/09/2003",2009-01-01,"January 26, 2010","01/01/2010","",2009-01-01,"Upper body strength|Dyspnea|Functional performance|Exercise adherence","http://ClinicalTrials.gov/show/NCT01057797","United States"
"82008",82008,"NCT00064298","Fruit and Vegetable Extracts in Treating Patients With Stage I, Stage II, Stage III, Stage IVA, or Stage IVB Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Dietary Supplement: fruit and vegetable extracts|Other: placebo","Wake Forest University|National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",200,"Other|NIH","Interventional","Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Treatment","CDR0000310184|CCCWFU-0112|CCCWFU-60A02|CCCWFU-BG03-161","July 8, 2003","01/01/2004",NA,"July 3, 2010","01/10/2008","",2009-01-01,"Expression of p27 cell cycle regulatory protein, associated with disease-free survival as measured by blood sample at baseline and week 12|Cell proliferation (Ki-67), DNA damage (strand breaks), and immune function (T-cell function) as measured by biopsy at baseline and week 12|Tobacco and alcohol use as measured by head and neck baseline questionnaire and food frequency questionnaire at baseline and week 12|Depression as measured by Center for Epidemiologic Depression scale and positive symptom subscale at baseline and week 12|Serum carotenoids and antioxidant levels (vitamins A, C, and E) as measured by blood tests at baseline and week 12","http://ClinicalTrials.gov/show/NCT00064298","United States"
"82027",82027,"NCT00085098","Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary CNS Germ Cell Tumor","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase III",225,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment","CDR0000367294|COG-ACNS0232","June 10, 2004","01/01/2007",NA,"November 20, 2010","01/11/2010","",2009-08-01,"Event-free survival|Response|Toxicity|Quality of life","http://ClinicalTrials.gov/show/NCT00085098","United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Puerto Rico"
"82050",82050,"NCT00130598","PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION","Completed","No Results Available","Kidney Failure, Acute","Drug: NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans?ó)","University Hospital, Basel, Switzerland|Swiss National Science Foundation","Both","Adult|Senior","Phase II|Phase III",258,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","PROVOCATION Trial|23.05|05.013|2005DR3170","August 12, 2005","01/06/2005",2009-12-01,"March 4, 2010","01/03/2010","",2009-12-01,"Decrease in glomerular filtration rate (GFR) within 48 hours. GFR is calculated using the abbreviated Modification of Diet in Renal Disease (MDRD) Study equation.|Development of contrast nephropathy, defined as an increase >=25% in the baseline serum creatinine concentration within 48 hours|Development of contrast nephropathy, defined as an increase >=44umol/l in serum creatinine concentration within 48 hours|Development of contrast nephropathy, defined as an increase >=25% in the baseline serum cystatin C concentration or an increase >=0.35mg/l in serum cystatin C concentration within 48 hours|Postcontrast increase in serum cystatin C at day 1 and 2|In-hospital morbidity (nonfatal myocardial infarction) and mortality|Dialysis dependency|Length of stay|Total costs of hospitalization|3-/12-month mortality|3-/12-month hospitalization for cardiac causes|GFR at 3 and 12 months","http://ClinicalTrials.gov/show/NCT00130598","Italy, &nbsp; Switzerland"
"82066",82066,"NCT00152698","Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia","Completed","No Results Available","Hypercholesterolemia","Drug: Irbesartan","University of Erlangen-N??rnberg Medical School|Bristol-Myers Squibb","Male","Adult","Phase III",80,"Other|Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double-Blind|Primary Purpose: Treatment","Retina-Irbesartan","September 8, 2005","01/11/2009",2009-12-01,"February 1, 2010","01/02/2010","",2009-12-01,"Comparison of retinal endothelial function between hypercholesterolemic patients and healthy control subjects|Effect of AT1-receptor blockade on retinal endothelial function in hypercholesterolemic patients","http://ClinicalTrials.gov/show/NCT00152698","Germany"
"82148",82148,"NCT00291798","Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane","Completed","No Results Available","Breast Cancer","Procedure: rate of remission","Austrian Breast & Colorectal Cancer Study Group|Pharmacia Austria GmbH","Female","Adult|Senior","Phase II",98,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG-17","February 14, 2006","01/09/2000",2009-03-01,"September 18, 2006","01/02/2006","",2009-03-01,"rate of remission|Toxicity (WHO-grading)|rate of mastectomy|response of tumor subject to HER2-status|collection of disease free survival and overall survival","http://ClinicalTrials.gov/show/NCT00291798","Austria"
"82155",82155,"NCT00259298","Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis","Completed","Has Results","Osteoporosis","Drug: teriparatide","Eli Lilly and Company","Female","Adult|Senior","Phase IV",12,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9917|B3D-US-GHCV","November 28, 2005","01/11/2005",2009-07-01,"July 14, 2010","01/07/2010","",2009-07-01,"Change From Baseline in Whole Skeleton Skeletal Plasma Clearance of 99m Technetium Methylene Diphosphonate (99m Tc-MDP) to 18 Months|Change in Skeletal Plasma Clearance of 99m Technetium Methylene Diphosphonate (99m Tc-MDP) in the Whole Skeleton, Skull, Mandible, Spine, Pelvis, Upper Extremities, and Lower Extremities|Change in Skeletal Uptake of 99m Technetium Methylene Diphosphonate (99m Tc-MDP) in the Whole Skeleton, Skull, Mandible, Spine, Pelvis, Upper Extremities, and Lower Extremities|Change in Qualitative Visual Scores of Focal Uptake of 99m Technetium Methylene Diphosphonate (99m Tc-MDP) in the Whole Skeleton|Number of Participants With Changes in Diffuse Uptake of 99m Tc-MDP - Qualitative Visual Assessment in the Whole Skeleton","http://ClinicalTrials.gov/show/NCT00259298","United Kingdom"
"82157",82157,"NCT00307398","Anecortave Acetate Risk-Reduction Trial (AART)","Completed","No Results Available","Dry AMD","Drug: Anecortave Acetate","Alcon Research","Both","Adult|Senior","Phase III",2500,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Treatment","C-02-60","March 24, 2006","01/03/2004",NA,"May 7, 2009","01/05/2009","",2009-01-01,"To demonstrate that anecortave acetate is safe and effective in arresting the progression of dry AMD to wet AMD in at-risk patients|Time to development of sight threatening CNV","http://ClinicalTrials.gov/show/NCT00307398","United States"
"82158",82158,"NCT00118898","Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","Completed","Has Results","HIV Infections","Drug: Abacavir/Lamivudine|Drug: Atazanavir|Drug: Efavirenz|Drug: Emtricitabine/Tenofovir disoproxil fumarate|Drug: Ritonavir|Drug: Abacavir/Lamivudine placebo|Drug: Emtricitabine/Tenofovir disoproxil fumarate placebo","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","Both","Child|Adult|Senior","Phase III",1864,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ACTG A5202|1U01AI068636|ACTG 5224s","July 7, 2005","01/09/2005",2009-11-01,"January 10, 2011","01/01/2011","",2009-11-01,"Time From Randomization to Virologic Failure|Time From Treatment Dispensation to a Grade 3/4 Safety Event|Time From Treatment Dispensation to Treatment Modification|Time From Treatment Dispensation to Regimen Failure (First Occurrence of Virologic Failure or Treatment Modification)|The Number of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL|Number of Participants With HIV-1 RNA Levels Less Than 200 Copies/mL|Change in CD4 Count (Cells/mm3) From Baseline|Number of Participants With Virologic Failure and Emergence of Major Resistance|Number of Participants Experiencing Certain Targeted Clinical Events, Including Death, AIDS-defining Illness, and HIV-1 Related Events.|Change in Fasting Total Cholesterol Level From Baseline|Change in Fasting High-density Lipoprotein (HDL) Cholesterol Level From Baseline|Change in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Level From Baseline|Change in Fasting Triglyceride Level From Baseline","http://ClinicalTrials.gov/show/NCT00118898","United States, &nbsp; Puerto Rico"
"82160",82160,"NCT00311298","Nutrition, Diabetes and Pulmonary TB/HIV","Completed","No Results Available","Tuberculosis|HIV|Diabetes","Dietary Supplement: Multimicronutrients|Dietary Supplement: Energy and proteins","University of Copenhagen|National Institute for Medical Research, Tanzania|The Danish Medical Research Council|Danish Council for Development Research","Both","Child|Adult|Senior","Phase III",1250,"Other","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NIMR-UC-2006-01","April 3, 2006","01/04/2006",2009-03-01,"August 3, 2009","01/08/2009","",2009-03-01,"Weight gain|Grip strength|Arm muscle and arm fat areas|Physical activity|HIV load|CD4 count|Serum acute phase reactants|Mortality","http://ClinicalTrials.gov/show/NCT00311298","Tanzania"
"82202",82202,"NCT00378898","Feasibility of Placing Bravo PH Capsule in Proximal Esophagus","Completed","No Results Available","Gastroesophageal Reflux Disease","Device: Bravo PH capsule|Procedure: Fluoroscopy","Vanderbilt University","Both","Adult|Senior","Phase III",25,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic","60724","September 20, 2006","01/09/2006",2009-07-01,"January 11, 2010","01/01/2010","bravo",2009-03-01,"Patient tolerance to a Bravo PH monitor in the proximal esophagus after 48 hours|Collection of and comparison of data between distal and proximal Bravo capsule","http://ClinicalTrials.gov/show/NCT00378898","United States"
"82234",82234,"NCT00423098","Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare","Completed","No Results Available","Lupus Nephritis","Drug: Mycophenolate sodium|Drug: Corticosteroids","Novartis Pharmaceuticals","Both","Adult|Senior","Phase II|Phase III",81,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CERL080A2420","January 16, 2007","01/02/2007",NA,"April 8, 2010","01/04/2010","",2009-11-01,"To demonstrate non-inferior efficacy (proportion of patients achieving complete remission of a lupus nephritis flare) of Myfortic with reduced corticosteroids regimen compared to Myfortic with standard corticosteroid regimen.|Assess proportion of pts complete remission at 12 wks. Assess proportion of pts with no therapeutic response at 12&24 wks. Assess CS use as cumulative dose until 12&24 wks as well as doses at baseline 12&24 wks.|Assess disease activity with(BILAG)(SLEDAI). Assess the proportion of patients with partial remission of lupus nephritis flares at week 12 and 24 weeks.","http://ClinicalTrials.gov/show/NCT00423098","Colombia, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Hungary, &nbsp; Italy, &nbsp; Spain, &nbsp; Taiwan, &nbsp; United Kingdom"
"82244",82244,"NCT00425698","Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation","Completed","Has Results","Kidney Transplantation","Drug: Recombinant erythropoietin alpha (rHuEPO alpha)|Drug: Placebo","Hannover Medical School","Both","Adult|Senior","Phase II|Phase III",88,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","MHH - EPONTX - 01/06","January 22, 2007","01/02/2007",2009-11-01,"September 23, 2010","01/09/2010","",2009-05-01,"Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)|Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)","http://ClinicalTrials.gov/show/NCT00425698","Germany"
"82250",82250,"NCT00441298","Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV","Completed","No Results Available","HIV Infections","Drug: Tenofovir gel|Drug: Placebo (Universal HEC placebo)","Centre for the AIDS Programme of Research in South Africa|Family Health International|United States Agency for International Development (USAID)|CONRAD","Female","Adult","Phase II",900,"Other|U.S. Fed","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention","CAPRISA 004|PHSC study #9946","February 27, 2007","01/05/2007",2010-03-01,"March 23, 2010","01/03/2010","",2009-12-01,"Comparison of HIV incidence rates in 2 arms (tenofovir vs placebo)|To assess the impact, if any, of tenofovir gel on the incidence rate of deep epithelial disruption|To assess the impact, if any, of tenofovir gel on viral load in women who become infected with HIV during the trial.|To assess tenofovir resistance in HIV seroconvertors in the trial|To ascertain the impact, if any, of tenofovir gel on pregnancy rates and outcomes|To assess the impact, if any, of product hold at study exit on HIV infection and tenofovir resistance","http://ClinicalTrials.gov/show/NCT00441298","South Africa"
"82260",82260,"NCT00455598","Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: ISIS 113715","Isis Pharmaceuticals","Both","Adult|Senior","Phase II",88,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","113715-CS14|EudraCT No: 2006-005718-11","April 2, 2007","01/02/2007",2009-05-01,"August 26, 2009","01/08/2009","",2009-03-01,"Change and % change from baseline HbA1c|Change and % change from baseline fasting glucose (serum and plasma)|Change and % change from baseline seven point glucose profile|Change and % change from baseline mean fasting and insulin c-peptide|Change and % change from baseline fasting proinsulin|Change and % change from baseline proinsulin / insulin ration|Change and % change from baseline lipid and lipoprotein values: TC, LDL, HDL, TG, VLDL, apoB-100|Change and % change from baseline Adiponectin|Adverse Events|Clinical laboratory tests|12 lead ECG|vital signs assessments, weight change, physical exams|concomitant medications","http://ClinicalTrials.gov/show/NCT00455598","Poland, &nbsp; Romania, &nbsp; Russian Federation"
"82268",82268,"NCT00476398","Evaluation of Patients With Non-cardiac Chest Pain","Completed","No Results Available","Non-Cardiac Chest Pain|Gastroesophageal Reflux Disease","Procedure: Capsule endoscopy","Brigham and Women's Hospital","Both","Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","2005P001321","May 21, 2007","01/01/2006",2009-06-01,"September 8, 2009","01/09/2009","",2009-06-01,"endoscopy for evaluating the prevalence of esophago-gastric lesions in patients","http://ClinicalTrials.gov/show/NCT00476398","&nbsp;"
"82278",82278,"NCT00484198","Randomized, Double-Blind Active Comparator-Controlled Study of Rivoglitazone in Type 2 Diabetes Mellitus","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: pioglitazone|Drug: placebo|Drug: rivoglitazone HCl|Drug: rivoglitazone HCl","Daiichi Sankyo Inc.","Both","Adult|Senior","Phase III",1820,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CS0011-A-U301","June 7, 2007","01/04/2007",2009-02-01,"February 1, 2010","01/02/2010","",2009-02-01,"Glycemic control - HbA1c|Glycemic control - FPG Responder rates - A1C Effects on lipid parameters","http://ClinicalTrials.gov/show/NCT00484198","United States, &nbsp; Argentina, &nbsp; Austria, &nbsp; Chile, &nbsp; Czech Republic, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Latvia, &nbsp; Mexico, &nbsp; Peru, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Serbia, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Ukraine, &nbsp; United Kingdom"
"82285",82285,"NCT00506298","Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes","Completed","No Results Available","Type 2 Diabetes","Drug: bezafibrate + diflunisal|Drug: bezafibrate + placebo","CombinatoRx","Both","Adult|Senior","Phase II",150,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CRx-401-001","July 20, 2007","01/07/2007",2009-05-01,"May 12, 2009","01/05/2009","",2009-04-01,"The primary efficacy endpoint will measure change in fasting plasma glucose from Baseline to Day 90|The exploratory efficacy endpoints will measure change in the following parameters: HOMA Index, HgbA1C, fructosamine, LDL, HDL, OGTT, triglycerides and total cholesterol from Baseline to Day 90","http://ClinicalTrials.gov/show/NCT00506298","Canada"
"82314",82314,"NCT00554398","Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression","Completed","No Results Available","HIV Infections","Drug: MK-0518 400mg twice a day","Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA","Both","Adult|Senior","Phase III",69,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","INTEGRAL","November 5, 2007","01/11/2007",2009-09-01,"November 12, 2009","01/11/2009","",2009-05-01,"Quantification of integrated and unintegrated viral HIV-1 DNA in PBMCs|Quantification of residual HIV-1 (using an ultrasensitive RT-PCR assay with a lower limit of quantification of 5 copies/mL)|Blips during the study (> 50 copies/mL, preceded and followed by determinations < 50 copies/mL in previous and posterior controls)|Lymphocyte activation marker CD8+HLADR+CD38+|Raltegravir plasma trough concentration.|Level of apoptosis in CD4 and CD8 T cells.","http://ClinicalTrials.gov/show/NCT00554398","Spain"
"82318",82318,"NCT00556998","A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents","Completed","No Results Available","Pharmacokinetics","Drug: Voriconazole","Pfizer","Both","Child","Phase I|Phase II",26,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","A1501081","November 9, 2007","01/06/2008",2009-12-01,"August 2, 2010","01/08/2010","",2009-12-01,"Pharmacokinetic parameters of voriconazole in adolescents compared to historical adult data.|Safety and tolerability of voriconazole in adolescents","http://ClinicalTrials.gov/show/NCT00556998","United States"
"82335",82335,"NCT00586898","Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle","Completed","No Results Available","Prostate|Cancer|Hormonal Cycling","Drug: GnRH|Drug: Ketoconazole|Drug: Bicalutamide|Drug: Testosterone transdermal gel|Drug: Estrogen transdermal patch","Memorial Sloan-Kettering Cancer Center","Male","Adult|Senior","Phase II",36,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-085","December 21, 2007","01/07/2001",2009-03-01,"July 9, 2009","01/07/2009","",2009-03-01,"To determine the response to rapid hormonal cycling in patients with non-castrate prostate cancer.","http://ClinicalTrials.gov/show/NCT00586898","United States"
"82347",82347,"NCT00549198","KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects","Completed","Has Results","Human Immunodeficiency Virus I Infection|HIV Infection","Drug: Abacavir/lamivudine and efavirenz|Drug: Tenofovir/Emtricitabine and efavirenz","GlaxoSmithKline","Both","Adult|Senior","Phase IV",392,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CNA109586","October 24, 2007","01/06/2007",2009-12-01,"January 6, 2011","01/01/2011","ASSERT",2009-12-01,"Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 48|Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 24|Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 96|Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 24|Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 48|Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 96|Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73 m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72 m^2, >=10%, and >=20% at Week 24|Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 48|Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 96|Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 24|Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 48|Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 96|Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24|Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24|Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48|Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48|Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96|Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96|Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 24|Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 48|Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 96|Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 24|Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 48|Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 96|Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 24|Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 48|Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 96|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 24|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 48|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 96|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 24|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 48|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 96|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 24|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 48|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 96|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 24|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 48|Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 96|Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 24|Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 48|Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 96|Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 24|Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 48|Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 96|Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 24|Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 48|Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 96|Number of Participants Classified as Protocol-defined Failures With Treatment-emergent Resistance to Study Drug in the Indicated Viruses at Week 96|Number of Participants Who Indicated \Yes\"" or \""No\"" to the Question of Whether Unplanned Healthcare Resources Were Utilized""","http://ClinicalTrials.gov/show/NCT00549198","Austria, &nbsp; Belgium, &nbsp; Denmark, &nbsp; France, &nbsp; Germany, &nbsp; Ireland, &nbsp; Italy, &nbsp; Latvia, &nbsp; Netherlands, &nbsp; Portugal, &nbsp; Spain, &nbsp; Switzerland, &nbsp; United Kingdom"
"82351",82351,"NCT00619398","A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf?ó in Stable Liver Transplantation Patients","Completed","No Results Available","Liver Transplantation","Drug: Prograf|Drug: FK506MR capsule","Astellas Pharma Inc","Both","Adult|Senior","Phase III",172,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MR4LTxCN02","January 23, 2008","01/01/2008",2009-03-01,"March 10, 2009","01/03/2009","",2009-03-01,"Event rate of patients with acute rejections|Incidence of and time to acute rejections|Overall frequency of acute rejections|Rate of patients and graft survival following transplantation|Incidence of adverse events including laboratory assessments","http://ClinicalTrials.gov/show/NCT00619398","China"
"82391",82391,"NCT00686998","Phase IIA Study in Patients With Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: AZD2624|Drug: Olanzapine|Drug: Placebo","AstraZeneca","Both","Adult","Phase II",110,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","D0970C00004","May 28, 2008","01/05/2008",2009-05-01,"August 18, 2009","01/08/2009","",2009-05-01,"Change in PANSS total score|Safety and Tolerability of AZD2624 vs Placebo|Pharmacokinetic evaluation","http://ClinicalTrials.gov/show/NCT00686998","United States"
"82392",82392,"NCT00685698","Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections","Completed","No Results Available","Diabetic Foot Infections","Drug: TG-873870 (Nemonoxacin)","TaiGen Biotechnology Co., Ltd.","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TG-873870-04","May 22, 2008","01/06/2008",2009-06-01,"January 18, 2010","01/01/2010","",2009-04-01,"Clinical Success|Safety Evaluation|Microbiological Success Rate|PK and PD Evaluation","http://ClinicalTrials.gov/show/NCT00685698","United States, &nbsp; South Africa, &nbsp; Taiwan, &nbsp; Thailand"
"82401",82401,"NCT00703898","Durability of Nevirapine-Based Antiretroviral Regimen","Completed","No Results Available","HIV Infections","Drug: nevirapine","Bamrasnaradura Infectious Diseases Institute","Both","Child|Adult|Senior","Phase IV",140,"Other","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0327/3619","June 20, 2008","01/11/2004",2010-04-01,"July 7, 2008","01/06/2008","",2009-12-01,"number of patients with undetectable plasma HIV-1 viral load","http://ClinicalTrials.gov/show/NCT00703898","Thailand"
"82407",82407,"NCT00709098","Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: iloprost|Drug: iloprost","Actelion","Both","Adult|Senior","Phase III",49,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-063A302","July 1, 2008","01/06/2008",2009-12-01,"April 30, 2010","01/04/2010","PROWESS 15 Ext",2009-11-01,"Treatment-emergent adverse events|Treatment-emergent serious adverse events|Adverse events leading to premature discontinuation of study drug|Treatment-emergent adverse events and serious adverse events leading to study drug discontinuation","http://ClinicalTrials.gov/show/NCT00709098","United States, &nbsp; Austria, &nbsp; Germany"
"82415",82415,"NCT00731198","Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)","Completed","Has Results","ERCP|Pancreatic Diseases|Bile Duct Diseases","Drug: Drotaverine hydrochloride|Drug: Hyoscine-N-butylbromide","Changhai Hospital","Both","Adult|Senior","Phase III",650,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention","Changhai-080615","August 6, 2008","01/08/2008",2009-07-01,"August 31, 2010","01/11/2009","",2009-03-01,"The Grades of the Number of Duodenal Contractions|Cannulation Time|Percentage of Successful Selective Cannulation|Frequency of Post-ERCP Complications|Side Effects","http://ClinicalTrials.gov/show/NCT00731198","China"
"82426",82426,"NCT00748098","Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in Restless Legs Syndrome (RLS) and Associated Sleep Disturbance","Completed","No Results Available","Restless Legs Syndrome (RLS)","Drug: GSK1838262 Extended Release Tablets|Drug: Placebo","GlaxoSmithKline","Both","Adult|Senior","Phase III",136,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RXP110908","September 5, 2008","01/10/2008",2009-07-01,"August 12, 2010","01/08/2010","",2009-07-01,"Change from baseline to end of each treatment period in Wake Time During Sleep (WTDS) measured by polysomnography|Change from baseline to end of each treatment period in Periodic Limb Movements associated with Arousal per hour (PLMAI) measured by polysomnography|Assess safety, tolerability, polysomnography efficacy measures, and patient reported outcomes.","http://ClinicalTrials.gov/show/NCT00748098","United States"
"82437",82437,"NCT00764998","Influenza Vaccine in HIV","Completed","No Results Available","Influenza|HIV","Biological: Fluviral","Ottawa Hospital Research Institute|Ontario HIV Treatment Network|Public Health Agency of Canada (PHAC)|Canadian HIV Trials Network","Both","Adult","Phase III",285,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention","CTN237","October 1, 2008","01/10/2008",2009-08-01,"August 19, 2010","01/08/2010","",2009-04-01,"Immunogenicity measured by haemagglutination inhibition (HI)|Frequencies of laboratory confirmed influenza and Frequencies clinical/respiratory illness","http://ClinicalTrials.gov/show/NCT00764998","Canada"
"82441",82441,"NCT00758498","Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder","Completed","Has Results","Excessive Sleepiness","Drug: armodafinil|Drug: armodafinil|Drug: placebo","Cephalon","Both","Adult","Phase III",427,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C10953/3065/ES/MN","September 23, 2008","01/09/2008",2009-02-01,"June 11, 2010","01/06/2010","",2009-02-01,"Multiple Sleep Latency Test (MSLT)|Patient Global Impression of Severity (PGI-S)|Karolinska Sleepiness Scale (KSS)|Multiple Sleep Latency Test (MSLT)|Patient Global Impression of Severity (PGI-S)","http://ClinicalTrials.gov/show/NCT00758498","United States"
"82447",82447,"NCT00784498","Procedural Sedation Using Propofol Versus Midazolam/Ketamine in the Adult Emergency Department","Completed","No Results Available","Procedural Sedation","Drug: Ketamine/Midazolam|Drug: Propofol","Tel-Aviv Sourasky Medical Center","Both","Adult","Phase IV",60,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","TASMC-08-PH-0272-CTIL|0272-08-TLV|Study Protocol [1] 2-Jul-08","November 2, 2008","01/11/2008",2009-09-01,"July 31, 2010","01/11/2008","",2009-09-01,"The effectiveness and safety profile of procedural sedation using propofol versus midazolam/ketamine.|The amnestic properties of procedural sedation with propofol versus midazolam/ketamine.","http://ClinicalTrials.gov/show/NCT00784498","Israel"
"82449",82449,"NCT00787098","Investigating Modes of Progressive Mobility","Completed","No Results Available","Critical Care|Mechanical Ventilation|Intensive Care|Muscular Atrophy","Other: ETM protocol","Hill-Rom","Both","Adult|Senior","Phase II",82,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","CR-0076","November 6, 2008","01/11/2007",2009-07-01,"July 2, 2009","01/07/2009","",2009-04-01,"Compare immediate molecular and physiological patient responses to activity with responses to an ETM protocol.|A secondary aim is to identify strategies and conditions that promote or prevent ETM.","http://ClinicalTrials.gov/show/NCT00787098","&nbsp;"
"82461",82461,"NCT00792298","Phase IIB 2-Period Crossover PSG Study in Patients With Primary Insomnia","Completed","No Results Available","Primary Insomnia","Drug: MK4305|Drug: Comparator: MK4305.|Drug: Comparator: MK4305,|Drug: Comparator: MK4305..","Merck","Both","Adult","Phase II",254,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","2008_583|MK4305-006","November 10, 2008","01/11/2008",2009-12-01,"May 25, 2010","01/05/2010","",2009-12-01,"Improvement in sleep efficiency as measured by polysomnography|Improvement in wake after sleep onset and latency to persistent sleep.","http://ClinicalTrials.gov/show/NCT00792298","&nbsp;"
"82486",82486,"NCT00846898","Is There a Metabolic Effect of Cinnamon on HbA1c, Blood Pressure and Serum Lipids in Type 2 Diabetes Mellitus?","Completed","No Results Available","Type 2 Diabetes Mellitus","Dietary Supplement: cinnamon 2g per day for 12 weeks","Thames Valley University|Wembley Health Care centre, NHS, UK.|Monks Park Primary care centre, NHS UK.|Willesden Health centre, NHS, UK.","Both","Adult|Senior","Phase II",58,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","07/H0717/47","February 18, 2009","01/03/2008",2009-02-01,"February 18, 2009","01/02/2009","cinnamon",2009-01-01,"HbA1c|Plasma glucose concentration Plasma lipid profiles (HDL, LDL, Triglycerides and total cholesterol) systolic and diastolic blood pressures. Body Mass Index. Waist circumference. Total calorie intake.","http://ClinicalTrials.gov/show/NCT00846898","United Kingdom"
"82487",82487,"NCT00813098","Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome","Completed","Has Results","Irritable Bowel Syndrome","Drug: LX1031 High Dose|Drug: LX1031 Low Dose|Drug: Placebo","Lexicon Pharmaceuticals","Both","Adult|Senior","Phase II",155,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Protocol LX1031.1-201-IBS|LX1031.201","December 19, 2008","01/12/2008",2010-08-01,"November 4, 2010","01/11/2010","",2009-07-01,"Subjects Who Experienced Relief of IBS Pain and Discomfort at Week 4|Change From Baseline at Week 4 in Proportion of Days Per Week When Experiencing Urgency to Defecate|Change From Baseline at Week 4 in Stool Consistency Scores|Change From Baseline at Week 4 in Stool Frequency|Change From Baseline at Week 4 on the Severity of Bloating|Change From Baseline at Week 4 on the Global Improvement Score.","http://ClinicalTrials.gov/show/NCT00813098","United States"
"82547",82547,"NCT00944398","Impact of Targeted Zinc Fortification Programs on Plasma Zinc Concentration","Completed","No Results Available","Zinc Deficiency","Dietary Supplement: Zinc fortified food|Dietary Supplement: Zinc supplement|Other: Placebo supplement|Dietary Supplement: Non-fortified food","University of California, Davis|Helen Keller International|Cheikh Anta Diop University, Senegal|Global Alliance for Improved Nutrition","Both","Child","Phase IV",98,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","200817275|107008","July 21, 2009","01/01/2009",2009-10-01,"February 18, 2010","01/02/2010","",2009-09-01,"Plasma zinc concentration","http://ClinicalTrials.gov/show/NCT00944398","Senegal"
"82560",82560,"NCT00959998","Acupressure for Post-Treatment Cancer Fatigue","Completed","No Results Available","Fatigue","Other: Self-administered Acupressure","University of Michigan|University of Michigan Cancer Center","Both","Adult|Senior","Phase II",43,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10915","August 14, 2009","01/09/2007",2009-07-01,"August 14, 2009","01/08/2009","",2009-07-01,"To examine the effect of two intensities of self-administered stimulating acupressure compared to self-administered relaxation acupressure on severity of chronic fatigue in people diagnosed with cancer who had completed all cancer therapies|Secondary objects were to evaluate the safety, tolerability, adherence, blinding and beliefs/expectation of participants of the three acupressure treatments","http://ClinicalTrials.gov/show/NCT00959998","United States"
"82565",82565,"NCT00972998","Study to Examine the Effect of Coated Phenylephrine Suppositories on Anal Pressure in Healthy Subjects","Completed","No Results Available","Incontinence","Drug: Phenyephrine","RDD Pharma Ltd","Both","Adult","Phase I|Phase II",8,"Industry","Interventional","Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","RDD 105","August 17, 2009","01/09/2009",2009-12-01,"December 28, 2009","01/12/2009","",2009-12-01,"The primary efficacy parameter is change in Resting Anal Pressure from baseline.|The ratio of change in anal pressure to plasma Phenylephrine level.|The ratio of change in anal pressure to change in blood pressure.|The ratio of change in anal pressure to change in heart rate.","http://ClinicalTrials.gov/show/NCT00972998","Israel"
"82602",82602,"NCT01031498","Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting","Completed","No Results Available","Acute Myelogenous Leukemia|Chemotherapy-Induced Nausea and Vomiting","Drug: Ondansetron|Drug: Palonosetron","M.D. Anderson Cancer Center|Eisai Inc.","Both","Adult|Senior","Phase II",150,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2005-0389","December 10, 2009","01/09/2005",2009-09-01,"December 11, 2009","01/12/2009","",2009-09-01,"Number of Emetic Episodes (with no use of rescue medication) During Chemotherapy Administration","http://ClinicalTrials.gov/show/NCT01031498","United States"
"82605",82605,"NCT01037998","UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer","Completed","No Results Available","Non-Small-Cell Lung Cancer","Drug: UFUR and Iressa","Taipei Veterans General Hospital,Taiwan","Both","Adult|Senior","Phase II",115,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","94-09-03","May 27, 2008","01/11/2005",2009-12-01,"December 22, 2009","01/12/2009","",2009-12-01,"To assess and compared the 6-month survival rate of these two arms of treatment.|To assess and compared the progression-free survival, overall survival, the response rate, and the toxicity profiles of these two arms of treatment.","http://ClinicalTrials.gov/show/NCT01037998","Taiwan"
"82688",82688,"NCT01187498","Behavioral Treatment of Overactive Bladder in Men","Completed","No Results Available","Overactive Bladder","Behavioral: Behavioral training|Drug: Oxybutynin chloride, extended release","Department of Veterans Affairs","Male","Adult|Senior","Phase III",143,"U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","B3083R","August 20, 2010","01/01/2005",2009-10-01,"August 20, 2010","01/08/2010","MOTIVE",2009-10-01,"24-hour voiding frequency|Urgency severity|Urge incontinence|Nocturia frequency|Patient satisfaction|Patient perception of improvement|American Urological Association (AUA) Symptom Index|Incontinence Impact Questionnaire|Patient global rating of bothersome symptoms|Patient global rating of activity restriction|Patient report of symptom distress|Patient desire for alternate treatment","http://ClinicalTrials.gov/show/NCT01187498","United States"
"82713",82713,"NCT01225198","Vitamin/Mineral Supplement for Children and Adults With Autism","Completed","No Results Available","Autism","Dietary Supplement: Multi-Vitamin/Mineral Supplement|Other: Liquid Placebo","Arizona State University|Autism Research Institute|Legacy Foundation","Both","Child|Adult","Phase II",143,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AutismVitaminStudy2008","September 14, 2010","01/05/2008",2009-02-01,"October 19, 2010","01/10/2010","",2009-02-01,"Oxidative Stress|Oxidative Stress|Parent Global Impressions - Revised","http://ClinicalTrials.gov/show/NCT01225198","United States"
"82769",82769,"NCT00003199","Combination Chemotherapy and Peripheral Stem Cell Transplantation Followed by Interleukin-2 and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: aldesleukin|Biological: sargramostim|Drug: busulfan|Drug: melphalan|Drug: tamoxifen citrate|Drug: thiotepa|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","Both","Adult","Phase II",70,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","1229.00|FHCRC-1229.00|PSOC-1605|NCI-G98-1399|CDR0000066035|IR-4559","November 1, 1999","01/11/1997",NA,"October 1, 2010","01/10/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00003199","United States"
"82831",82831,"NCT00080899","Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Na??ve Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: fenretinide","California Cancer Consortium|National Cancer Institute (NCI)","Male","Child|Adult|Senior","Phase II",37,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000357312|CCC-PHII-47|NCI-6168","April 7, 2004","01/06/2004",NA,"October 11, 2010","01/10/2010","",2009-01-01,"Prostate-specific antigen response|Time to clinical progression|Toxicity","http://ClinicalTrials.gov/show/NCT00080899","United States"
"82859",82859,"NCT00113399","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Head and Neck Cancer","Biological: filgrastim|Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Drug: paclitaxel|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",240,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000429480|RTOG-0421|ECOG-R0421","June 7, 2005","01/04/2005",NA,"February 24, 2009","01/02/2009","",2009-02-01,"Survival|Progression-free survival|Grade 5 toxicity rate|Quality of life as assessed by the immediate (acute) side effects of treatment at 3 months|Quality of life as assessed by the late side effects of treatment at 6, 12, 24, and 36 months|Quality-adjusted survival","http://ClinicalTrials.gov/show/NCT00113399","United States"
"82898",82898,"NCT00160199","Safety and Efficacy of PROMETRIUM?ó Capsules in Induction of Secretory Conversion","Completed","Has Results","Secondary Amenorrhea","Drug: PROMETRIUM?ó 300 mg|Drug: PROMETRIUM?ó 400 mg","Solvay Pharmaceuticals","Female","Adult","Phase IV",240,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","S168.4.002","September 8, 2005","01/11/2004",2009-02-01,"June 30, 2010","01/06/2010","",2009-02-01,"Secretory Conversion of the Endometrium|Number of Subjects With Withdrawal Bleeding|Maximum Intensity of Withdrawal Bleeding After Any Cycle|The Duration of Withdrawal Bleeding After the First Treatment Cycle|The Duration of Withdrawal Bleeding After Second Treatment Cycle|Time to Withdrawal Bleeding After First Treatment Cycle|Time to Withdrawal Bleeding After Second Treatment Cycle","http://ClinicalTrials.gov/show/NCT00160199","United States"
"82915",82915,"NCT00216099","Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: Pemetrexed|Dietary Supplement: Folic Acid|Dietary Supplement: Vitamin B12","Hoosier Oncology Group|Eli Lilly and Company|Walther Cancer Institute","Male","Adult|Senior","Phase II",43,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","HOG GU03-67","September 12, 2005","01/02/2005",2009-03-01,"April 29, 2009","01/04/2009","",2009-03-01,"?? To determine the rates of best overall PSA response (??­ 50% decline in PSA) at any time during the study with single agent pemetrexed in subjects with HRPC whose disease has progressed following one prior taxane based chemotherapy regimen for HRPC??|To determine time to disease progression, overall survival and duration of response (PSA criteria)|To determine OBJECTIVE response per RECIST|To determine the rate of clinical benefit (decreased pain, improved performance status)|To determine the safety and tolerability of pemetrexed in subjects with HRPC whose disease has progressed following one prior taxane-based chemotherapy regimen for HRPC|To explore whether polymorphisms of enzymes involved in pemetrexed metabolism impact its toxicity or efficacy profile","http://ClinicalTrials.gov/show/NCT00216099","United States"
"82916",82916,"NCT00221299","Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use","Completed","No Results Available","Glucocorticoid Induced Osteoporosis","Drug: Risedronate|Drug: Parathyroid Hormone","University of California, Davis|University of California, San Francisco","Both","Adult|Senior","Phase IV",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","200513216|RA-015865","September 14, 2005","01/09/2005",2009-05-01,"May 22, 2009","01/05/2009","",2009-03-01,"Bone Mineral Density (BMD): Examine the pattern and effect of BMD changes at hip and spine measured by DXA every 6 months.|Bone Turnover Markers : Evaluate the levels of bone biochemical markers serum total calcium and urinary excretion of calcium.|Incident Vertebral and non-Vertebral Fractures: Evaluate using Instant Vertebral Assessment (IVA) obtained at baseline and annually thereafter.","http://ClinicalTrials.gov/show/NCT00221299","United States"
"82963",82963,"NCT00291499","Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand","Completed","No Results Available","Osteoarthrosis","Drug: Chondroitin 4&6 sulfate (Condrosulf)|Other: Placebo","IBSA Institut Biochimique SA","Both","Adult|Senior","Phase IV",160,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","03CH/Ct06","February 13, 2006","01/06/2005",2010-08-01,"August 13, 2010","01/08/2010","",2009-12-01,"Intensity of global spontaneous pain for both hands is evaluated by the patient himself on a Huskisson's visual analogue scale (VAS) of 100 mm and the score of Dreiser's algo-functional index (FIHOA).|Global impression of efficacy.|Grip strength measured manometrically.|Morning stiffness duration|Consupmtion of paracetamol|Tolerability|Adverse events|Treatment compliance|Biological markers of arthritis","http://ClinicalTrials.gov/show/NCT00291499","&nbsp;"
"82979",82979,"NCT00320099","Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock","Completed","No Results Available","Septic Shock","Drug: recombinant human insulin|Drug: hydrocortisone|Drug: fludrocortisone|Drug: Hydrocortisone","University of Versailles|Assistance Publique - H??pitaux de Paris","Both","Adult|Senior","Phase III",508,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AOM04100|P040421","April 27, 2006","01/01/2006",2009-02-01,"April 5, 2010","01/04/2010","COIITSS",2009-01-01,"In-hospital mortality|Secondary outcomes :|90-day and 180-day mortality.|Duration of life-supporting treatments (i.e. vasopressors and mechanical ventilation)|Time to resolve multiple organ dysfunction, i.e. to obtain a SOFA score < 8|Hospital length of stay.|Number of hypoglycaemic events (blood glucose < 4 mmol/l) during insulin infusion|Muscle weakness at discharge from intensive care unit, 90-day and 180-day|Post traumatic stress disorders","http://ClinicalTrials.gov/show/NCT00320099","France"
"83009",83009,"NCT00374699","Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas","Completed","No Results Available","Peripheral T-Cell Lymphomas|Non-Hodgkin Lymphoma","Drug: Velcade","Samsung Medical Center|Janssen Medical Affairs","Both","Adult","Phase I|Phase II",55,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-07-021","September 7, 2006","01/04/2006",2009-10-01,"October 12, 2009","01/06/2007","",2009-09-01,"To define the dose-limiting toxicity and maximum tolerable dose|To evaluate the overall response rate|To evaluate the safety and tolerability of the treatment combination|To estimate the time to progression and the duration of overall response","http://ClinicalTrials.gov/show/NCT00374699","Korea, Republic of"
"83018",83018,"NCT00388999","Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant","Completed","No Results Available","Multiple Myeloma","Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)","Enzon Pharmaceuticals, Inc.","Both","Adult|Senior","Phase I|Phase II",50,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EZN-2232-01","October 13, 2006","01/09/2006",2009-05-01,"October 19, 2009","01/10/2009","",2009-02-01,"Safety and tolerability of rhMBL|Pharmacokinetic (PK) of rhMBL|Pharmacodynamics (PD) of rhMBL|Immunogenicity of rhMBL, incidence of infectious complications","http://ClinicalTrials.gov/show/NCT00388999","United States"
"83022",83022,"NCT00378599","Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","Completed","Has Results","Liver Transplantation|Hepatitis C, Chronic|Liver Cirrhosis","Drug: Combination of (a) pegylated interferon alfa-2b and (b) rebetol","Schering-Plough","Both","Adult|Senior","Phase III",125,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P04590","September 18, 2006","01/06/2006",2009-07-01,"September 14, 2010","01/09/2010","",2009-07-01,"A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment","http://ClinicalTrials.gov/show/NCT00378599","&nbsp;"
"83038",83038,"NCT00420199","A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","Completed","No Results Available","Rheumatoid Arthritis, NOS","Drug: Abatacept|Drug: placebo","Bristol-Myers Squibb","Both","Adult|Senior","Phase III",50,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","IM101-119|Eudract: 2006-003768-67","January 8, 2007","01/05/2007",2010-05-01,"November 9, 2010","01/06/2010","",2009-08-01,"Change in wrist Synovitis evaluated by gadolinium-enhanced Magnetic Resonance Imaging, using OMERACT 6 score|Assess change in bone lesions (i.e. bone edema, bone erosions), of hands (measured by gadolinium-enhanced Magnetic Resonance Imaging and using the OMERACT 6 RA MRI)|Assess changes in biochemical markers of bone, cartilage and synovial tissue metabolism|Assess safety and tolerability in both treatment arms","http://ClinicalTrials.gov/show/NCT00420199","Belgium, &nbsp; Germany, &nbsp; Netherlands, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom"
"83065",83065,"NCT00379899","ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis","Completed","Has Results","Chronic Kidney Disease|End Stage Renal Disease|Coronary Artery Calcification|Vascular Calcification|Calcification|Cardiovascular Disease|Chronic Renal Failure|Hyperparathyroidism|Kidney Disease|Nephrology|Secondary Hyperparathyroidism","Drug: cinacalcet","Amgen","Both","Adult|Senior","Phase IV",360,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20060111","September 21, 2006","01/09/2006",2009-11-01,"November 4, 2010","01/11/2010","",2009-05-01,"Percent Change From Baseline in CAC Score|Number of Participants Achieving > 15% Progression of CAC.|Absolute Change in PTH|Change From Baseline in AC Score|Change From Baseline of the Progression of AVC.|Percent Change in PTH|Absolute Change in Calcium|Percent Change in Calcium|Absolute Change in Phosphorus|Percent Change in Phosphorus|Absolute Change in Ca x P|Percent Change in Ca x P","http://ClinicalTrials.gov/show/NCT00379899","&nbsp;"
"83075",83075,"NCT00452699","A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg BID In Symptomatic Subjects With Asthma","Completed","Has Results","Asthma","Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Drug: Fluticasone propionate 250 mcg BID","GlaxoSmithKline","Both","Child|Adult|Senior","Phase IV",621,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADA109055|Fluticasone Propionate/salmete","March 26, 2007","01/05/2007",2009-05-01,"March 4, 2010","01/03/2010","",2009-05-01,"Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52|Mean Change From Baseline in AM PEF Over Weeks 1-52|Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52|Rate of Asthma Attacks Per Participant Per Year","http://ClinicalTrials.gov/show/NCT00452699","United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Canada, &nbsp; Philippines"
"83077",83077,"NCT00473499","PEPCAD III Substudy: Stem Cell Mobilization","Completed","No Results Available","Coronary Artery Disease","Device: DEBlue vs Cypher vs BMS","University Hospital, Saarland","Both","Adult|Senior","Phase I|Phase II",60,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment","BBM-VS54-HOM","May 14, 2007","01/07/2007",2009-11-01,"June 29, 2010","01/06/2010","PEPCADIIIsub",2009-03-01,"stem cell mobilization and differentiation|endothelial function|late lumen loss|MACE","http://ClinicalTrials.gov/show/NCT00473499","Germany"
"83089",83089,"NCT00494299","Phase III Study of BAY 43-9006 in Patients With Advanced Hepatocellular Carcinoma Treated After TACE","Completed","No Results Available","Carcinoma, Hepatocellular","Drug: Nexavar (Sorafenib, BAY43-9006)|Drug: Placebo","Bayer","Both","Adult|Senior","Phase III",457,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11721","June 28, 2007","01/04/2006",2010-11-01,"November 22, 2010","01/11/2010","",2009-07-01,"Time to Progression (TTP)|Overall Survial (OS)","http://ClinicalTrials.gov/show/NCT00494299","Japan, &nbsp; Korea, Republic of"
"83093",83093,"NCT00502099","Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4","Completed","No Results Available","Hepatitis C","Drug: Pegylated interferon alpha 2a|Drug: Ribavirin|Drug: Pegylated interferon alpha 2 b plus ribavirin","Ain Shams University|Al Mokhtabar Laboratories|Ain Shams Research Unit for Tropical Liver Diseases","Both","Adult","Phase IV",217,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LG161190-06","July 15, 2007","01/01/2006",2009-05-01,"July 23, 2010","01/02/2009","",2009-05-01,"SVR, defined as undetectable serum HCV RNA|histological response|biochemical response","http://ClinicalTrials.gov/show/NCT00502099","&nbsp;"
"83103",83103,"NCT00517699","A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.","Completed","No Results Available","Lymphoma","Drug: rituzimab [MabThera/Rituxan]|Drug: Methotrexate|Drug: Cytarabine","Hoffmann-La Roche","Both","Adult|Senior","Phase II",5,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML19652","August 16, 2007","",2009-05-01,"September 16, 2009","01/09/2009","",2009-05-01,"Complete response rate;overall response rate|Relapse rate; overall survival;PFS|AEs, laboratory parameters","http://ClinicalTrials.gov/show/NCT00517699","Canada"
"83118",83118,"NCT00521599","A Study of the Equivalent Effectiveness of 400 Mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)","Completed","Has Results","Asthma","Drug: Mometasone furoate dry powder inhaler|Drug: Placebo","Schering-Plough","Both","Adult|Senior","Phase IV",672,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","P04828","August 27, 2007","01/05/2007",2009-03-01,"July 2, 2010","01/07/2010","",2009-03-01,"Change From Baseline in the Average AM Peak Expiratory Flow (PEF) Over the 7 Days of Week 8.","http://ClinicalTrials.gov/show/NCT00521599","&nbsp;"
"83170",83170,"NCT00615199","A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease","Completed","No Results Available","Crohn's Disease","Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550","Pfizer","Both","Adult|Senior","Phase II",150,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A3921043","January 14, 2008","01/12/2007",2009-10-01,"November 23, 2009","01/11/2009","",2009-10-01,"Clinical response defined by a decrease in the Crohn's disease activity index (CDAI) score of at least 70 points from baseline|Percentage of subjects achieving clinical remission defined as a reduction of CDAI score below 150|Clinical response defined by a decrease in the CDAI score of at least 100 points from baseline|Clinical response defined by a decrease in the CDAI score of at least 70 points from baseline","http://ClinicalTrials.gov/show/NCT00615199","United States, &nbsp; Belgium, &nbsp; Czech Republic, &nbsp; France, &nbsp; Hungary, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; United Kingdom"
"83179",83179,"NCT00638599","Comparison of Laryngeal Mask Airway (LMA?ó) and Tracheal Tube in Modified Radical Mastectomy on Breast Cancer","Completed","No Results Available","Breast Cancer","Device: LMA?ó|Device: Endotracheal tube","Nanjing Medical University","Female","Adult|Senior","Phase IV",200,"Other","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","NMU-2579-7FW|NMU075451","March 4, 2008","01/01/2008",2009-07-01,"July 14, 2009","01/07/2009","LMATBBC",2009-07-01,"Circulatory Homeostasis|Airway pressure|Blood gas|Airway complications","http://ClinicalTrials.gov/show/NCT00638599","China"
"83191",83191,"NCT00656799","Dialysis of Sugammadex in Patients With Severe Renal Impairment (Study 19.4.333)(P05773)(COMPLETED)","Completed","No Results Available","Anesthesia, General","Drug: sugammadex","Schering-Plough","Both","Adult|Senior","Phase III",15,"Industry","Interventional","Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","19.4.333|P05773","April 7, 2008","01/04/2008",2009-07-01,"December 10, 2009","01/12/2009","",2009-07-01,"Blood and dialysate samples will be collected before, during and after hemodialysis/filtration, for calculation of clearance of sugammadexrocuronium complex|Pre-treatment events|(Serious) adverse events|Medical device (near) incidents|Vital signs|Physical examination|(Clinical evidence of) Reoccurrence of neuromuscular blockade|Events due to possible interaction|Pregnancy follow up|Time to TOF 0.9|Time to TOF 0.8|Time to TOF 0.7","http://ClinicalTrials.gov/show/NCT00656799","&nbsp;"
"83208",83208,"NCT00684099","Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Docetaxel|Drug: Pemetrexed","Hellenic Oncology Research Group|University Hospital of Crete","Both","Adult|Senior","Phase I|Phase II",70,"Other","Interventional","Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/05.18","May 22, 2008","01/05/2006",2009-05-01,"December 14, 2009","01/12/2009","",2009-05-01,"Evaluation of Dose Limited Toxicity and Maximum Tolerated Dose for the docetaxel/pemetrexed doublet|Response rate for the docetaxel/pemetrexed doublet","http://ClinicalTrials.gov/show/NCT00684099","Greece"
"83213",83213,"NCT00689299","Phase 2 Study in Adults Sensitized to Cat","Completed","No Results Available","Allergy to Cat Hair","Biological: SLIT","Antigen Laboratories, Inc.","Both","Adult","Phase II",167,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALI002-08","May 30, 2008","01/10/2008",2009-06-01,"October 14, 2009","01/10/2009","",2009-05-01,"Average of Total Symptom Scores","http://ClinicalTrials.gov/show/NCT00689299","United States"
"83218",83218,"NCT00697099","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery","Completed","No Results Available","Venous Thromboembolism","Drug: Semuloparin sodium (AVE5026)|Drug: Enoxaparin|Drug: Placebo","Sanofi-Aventis","Both","Adult|Senior","Phase III",2326,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","EFC10342|2007-007944-80","June 12, 2008","01/06/2008",2009-06-01,"December 20, 2010","01/12/2010","SAVE-HIP1",2009-05-01,"Occurence of the composite endpoint of any VTE confirmed by a blinded Central Independent Adjudication Committee (CIAC) and deaths from any cause|Occurence of the composite endpoint of any proximal Deep Vein Thrombosis (DVT), symptomatic distal DVT, nonfatal Pulmonary Embolism (PE), and all cause deaths|Number of patients with major bleedings and clinically relevant non-major bleedings as confirmed by the CIAC","http://ClinicalTrials.gov/show/NCT00697099","United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Belarus, &nbsp; Canada, &nbsp; Chile, &nbsp; Colombia, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Estonia, &nbsp; Finland, &nbsp; Germany, &nbsp; Greece, &nbsp; India, &nbsp; Italy, &nbsp; Mexico, &nbsp; Norway, &nbsp; Peru, &nbsp; Philippines, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Taiwan, &nbsp; Thailand, &nbsp; Turkey, &nbsp; Ukraine"
"83219",83219,"NCT00706199","The Expression of Antigens in Bone Marrow Samples From Volunteering Donors.","Completed","No Results Available","Antigen Expression in Bone Marrow From Donors","Procedure: Bone marrow aspiration","GlaxoSmithKline","Both","Adult|Senior","Phase II",48,"Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","111684","June 25, 2008","01/07/2008",2009-01-01,"October 1, 2009","01/10/2009","",2009-01-01,"Levels of antigen expression in bone marrow","http://ClinicalTrials.gov/show/NCT00706199","Belgium"
"83229",83229,"NCT00645099","A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia","Completed","Has Results","Schizophrenia","Drug: olanzapine|Drug: paliperidone ER","Janssen-Cilag International NV","Both","Adult","Phase III",462,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR013189|R076477SCH3020","March 24, 2008","01/08/2007",2009-04-01,"July 1, 2010","01/07/2010","",2009-04-01,"Change From Baseline to End Point in the Triglycerides (TG) to High Density Lipoprotein (HDL) Ratio (TG:HDL Ratio)|Change From Baseline to End Point in Triglycerides|Change From Baseline to End Point in High Density Lipoprotein|Change From Baseline to End Point in Total Cholesterol|Change From Baseline to End Point in Low Density Lipoprotein Cholesterol (Friedwald QT)|Change From Baseline to End Point in Converted Insulin|Change From Baseline to End Point in Fasting Glucose|Change From Baseline to End Point in Homeostatic Model Assessment of Beta-cell Function (HOMA-%B)|Change From Baseline to End Point in Homeastatic Model Assessment of Insulin Resistance (HOMA-IR)|Number of Patients Meeting the Criteria for Type 2 Diabetes Mellitus During Follow-up|Number of Patients With Onset of Impaired Glucose Tolerance|Number of Patients With Impaired Fasting Glucose|Change From Baseline at End Point of the Insulinogenic Index|Change From Baseline at End Point of Mari-Type Analysis of Glucose Sensitivity for Insulin|Change From Baseline at End Point in Body Weight|Change From Baseline at End Point in Body Mass Index (BMI)|Change From Baseline at End Point in Waist Circumference|Number of Patients First Meeting the NCEP/ATP III Criteria for Metabolic Syndrome During Follow-up|Change From Baseline to End Point in Total Positive and Negative Syndrome Scale Score (PANSS)","http://ClinicalTrials.gov/show/NCT00645099","&nbsp;"
"83231",83231,"NCT00720499","Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: BI1744/Tiotropium bromide","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",141,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment","1237.9|EudtaCT No: 2008-000562-23","July 21, 2008","01/07/2008",NA,"March 5, 2009","01/03/2009","",2009-02-01,"The primary efficacy variable will be forced expiratory volume in one second (FEV1). The primary endpoint is the trough FEV1 response [L] after four weeks of treatment.|FEV1 and FVC responses at different timepoints Weekly mean predose morning and evening PEF Weekly mean number of occations of rescue therapy used per day Patient's Global Rating scale Adverse events Laboratory and Vital signs","http://ClinicalTrials.gov/show/NCT00720499","United States, &nbsp; Belgium, &nbsp; Canada, &nbsp; Germany"
"83241",83241,"NCT00742599","Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy","Completed","No Results Available","Patients Undergoing Gastric Endoscopy","Drug: NPO-11|Drug: Placebo","Nihon Pharmaceutical Co., Ltd","Both","Adult|Senior","Phase III",80,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NPO-11-01/C-01","August 25, 2008","01/09/2008",2009-07-01,"November 8, 2010","01/11/2010","",2009-04-01,"Presence or absence of gastric peristalsis (central evaluation by independent evaluator) No gastric peristalsis is defined as when patients have no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy.|Change in gastric peristalsis|Difficulty level of intragastric observation (evaluation by investigator who performs endoscopy)|Adverse events and ADRs observed between administration and 7??3 days after administration","http://ClinicalTrials.gov/show/NCT00742599","Japan"
"83261",83261,"NCT00767299","A Study of Arzoxifene to Treat Korean Women With Osteoporosis","Completed","No Results Available","Osteoporosis","Drug: arzoxifene|Drug: Placebo","Eli Lilly and Company","Female","Adult|Senior","Phase II",91,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12185|H4Z-MC-GJAV","October 3, 2008","01/12/2008",2009-10-01,"December 14, 2009","01/12/2009","",2009-10-01,"Lumbar spine bone mineral density (BMD), by dual energy X-ray absorptiometry (DXA) analyses|Incidence of spontaneous vaginal bleeding.|Total hip BMD|Biochemical marker of bone metabolism (serum CTX and PINP)|Overall safety of arzoxifene administration in Korean postmenopausal women","http://ClinicalTrials.gov/show/NCT00767299","Korea, Republic of"
"83270",83270,"NCT00786799","Omega-3 Fatty Acids for Autism Treatment","Completed","No Results Available","Autism","Dietary Supplement: Omega-3 Fatty Acids|Dietary Supplement: Omega-3 Fatty Acids","University of California, San Francisco|Autism Speaks","Both","Child","Phase II",24,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","200816175-1","November 5, 2008","01/08/2008",2009-09-01,"November 18, 2010","01/11/2010","",2009-09-01,"Hyperactivity subscale of ABC|Secondary outcome measures include established measures of communication, social reciprocity, behavior, and changes in free fatty acids levels and markers of inflammation.","http://ClinicalTrials.gov/show/NCT00786799","United States"
"83289",83289,"NCT00811499","Treatment With ARRY-371797 in Patients With Active Ankylosing Spondylitis","Completed","No Results Available","Ankylosing Spondylitis","Drug: ARRY-371797|Drug: Placebo","Array BioPharma","Both","Adult|Senior","Phase II",25,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARRAY-797-201","December 17, 2008","01/12/2008",2009-09-01,"December 8, 2009","01/12/2009","",2009-09-01,"Efficacy of ARRY-371797 as measured by ASAS 20 (Assessments in Ankylosing Spondylitis 20% Working Group response criterion)|Safety of ARRY-371797 as measured by adverse events, findings on physical examinations, laboratory abnormalities, change from baseline in vital sign measurements, and change from baseline in 12-lead ECG parameters|Efficacy as measured by ASAS 20, ASAS 40, ASAS 5/6, BASDAI, BASFI, BASMI, EASMI, SPARCC Enthesitis Index, Nocturnal Back Pain, Total Back Pain, Patient's Global Assessment of Disease Activity, SF-36 Health Questionnaire V2 Acute, and CRP|Pharmacokinetics as measured by plasma concentrations of ARRY-371797 and a metabolite|Pharmacodynamics as measured by circulating levels of exploratory biomarkers of disease activity, and sacroiliac (SI) and spinal SPARCC MRI scores","http://ClinicalTrials.gov/show/NCT00811499","United States, &nbsp; Canada"
"83304",83304,"NCT00827099","UCB Transplant, Fludarabine, Melphalan, and ATG in Treating Patients With Hematologic Cancer","Completed","No Results Available","Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: fludarabine phosphate|Drug: melphalan|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation","Northside Hospital, Inc.","Both","Adult","Phase II",5,"Other","Interventional","Endpoint Classification: Safety Study|Masking: Open Label|Primary Purpose: Treatment","CDR0000632453|BMTGG-NSH-801","January 21, 2009","01/06/2006",2009-11-01,"March 10, 2010","01/03/2010","",2009-11-01,"Incidence of transplant-related mortality|Incidence of engraftment|Degree of donor-host chimerism|Incidence of acute and chronic graft-vs-host disease|Incidence of relapse|Survival","http://ClinicalTrials.gov/show/NCT00827099","United States"
"83306",83306,"NCT00845299","Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma","Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Latanoprost punctal plug|Drug: artificial tears preserved with Benzalkonium Chloride","QLT Plug Delivery, Inc.","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PPL GLAU 04","February 16, 2009","01/01/2009",2009-12-01,"February 2, 2010","01/02/2010","",2009-12-01,"IOP change from baseline","http://ClinicalTrials.gov/show/NCT00845299","United States"
"83309",83309,"NCT00847899","Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance","Completed","No Results Available","Hypertension|Impaired Glucose Tolerance","Drug: AR9281|Drug: AR9281|Drug: Placebo|Drug: Placebo","Arete Therapeutics","Both","Adult|Senior","Phase II",150,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","AR9281-CLN-003","February 17, 2009","01/01/2009",2009-11-01,"November 18, 2009","01/11/2009","",2009-10-01,"Systolic and Diastolic blood pressure|Glucose dynamics and insulin sensitivity","http://ClinicalTrials.gov/show/NCT00847899","United States"
"83330",83330,"NCT00877799","Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery","Completed","No Results Available","Acute Pain|Post-operative Pain","Drug: CR845","Cara Therapeutics, Inc.","Female","Adult","Phase II",114,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CR845-CLIN2001","April 6, 2009","01/03/2009",2010-01-01,"April 16, 2010","01/04/2010","",2009-12-01,"Analgesic efficacy measured by patient's self reported pain level at rest after surgery (after single dose administration).|Time to onset of analgesic efficacy|Time specific and total level of pain relief|Duration of analgesia|Time specific pain intensity difference from baseline and total level of pain relief|Time and requirement for rescue medication including survival curve of patients requesting rescue medication|Patient satisfaction with study medication with the patient Global evaluation scale|Vital signs, clinical laboratory parameters, ECG|Incidence of adverse events (AEs)|Sedation as measured by Ramsay sedation scale|Anti-inflammatory effects (measured by quantification of serum TNF alpha and serum IL-6","http://ClinicalTrials.gov/show/NCT00877799","United States"
"83338",83338,"NCT00894699","A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab?ºÑ in Patients Undergoing an Elective Abdominal Liposuction Procedure","Completed","No Results Available","Sedation|Anxiety|Pain","Drug: Sublingual Sufentanil/Triazolam NanoTab?ºÑ (ARX-F03)|Drug: Placebo NanoTab?ºÑ","AcelRx Pharmaceuticals, Inc.","Both","Adult","Phase II",40,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARX-C-007","May 5, 2009","01/06/2009",2009-09-01,"October 6, 2009","01/10/2009","",2009-09-01,"The primary objective is to evaluate the efficacy of ARX-F03 administered once as a single treatment in providing mild sedation compared to placebo in the procedural setting.|A secondary objective is to evaluate the efficacy of ARX-F03 in providing a reduction in anxiety and in pain intensity compared to placebo in the procedural setting.","http://ClinicalTrials.gov/show/NCT00894699","United States"
"83343",83343,"NCT00898599","Prebiotics and Immune Function in Middle Aged Humans","Completed","No Results Available","Immune Function","Dietary Supplement: Prebiotic|Dietary Supplement: Placebo","Southampton University Hospitals NHS Trust|University of Southampton","Both","Adult|Senior","Phase I|Phase II",49,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","RHMNUT0055","April 20, 2009","01/04/2009",2010-07-01,"July 28, 2010","01/07/2010","",2009-10-01,"Serum anti-vaccine antibody concentrations|Serum total antibody (IgG, IgA, IgM) concentrations|Innate immune responses - neutrophil and monocyte phagocytosis and respiratory burst|Ex vivo T lymphocyte responses to mitogen (activation, proliferation and cytokine production)|Ex vivo T lymphocyte responses to vaccine (activation, proliferation and cytokine production)|Ex vivo natural killer cell activity|Faecal microflora|Salivary IgA concentration","http://ClinicalTrials.gov/show/NCT00898599","United Kingdom"
"83363",83363,"NCT00933699","Dermacyd PH_DESILSTY_FL (Lactic Acid) - Acceptability - Stay on Floral.","Completed","No Results Available","Hygiene","Drug: LACTIC ACID(ND)","Sanofi-Aventis","Female","Adult","Phase III",32,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","LACAC_L_04803","July 3, 2009","01/06/2009",2009-07-01,"September 13, 2010","01/09/2010","",2009-07-01,"The absence of irritation and the good acceptability will be evaluated using one specific scale which describes the intensity of the reaction.","http://ClinicalTrials.gov/show/NCT00933699","Brazil"
"83415",83415,"NCT01014299","Recruitment Maneuver After Intubation","Completed","No Results Available","Hypoxemia","Other: Recruitment maneuver","University Hospital, Clermont-Ferrand","Both","Adult|Senior","Phase IV",40,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)","CHU-0061","November 13, 2009","01/12/2008",2009-11-01,"November 23, 2009","01/11/2009","",2009-11-01,"Oxygenation (PaO2) measured 5 min after the onset of mechanical ventilation|PaO2 at 30 min after intubation, hemodynamic and microbiologic safety, ICU length of stay, ICU mortality and mechanical ventilation duration.","http://ClinicalTrials.gov/show/NCT01014299","France"
"83542",83542,"NCT01210599","A Pilot Trial of IV Pamidronate for Low Back Pain","Completed","No Results Available","Chronic Low Back Pain","Drug: Pamidronate","Pappagallo, Marco, M.D.","Both","Adult|Senior","Phase I|Phase II",44,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06-0782","September 27, 2010","01/04/2004",2009-10-01,"October 12, 2010","01/09/2010","",2009-10-01,"","http://ClinicalTrials.gov/show/NCT01210599","United States"
